<SEC-DOCUMENT>0000885725-23-000008.txt : 20230223
<SEC-HEADER>0000885725-23-000008.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230223162014
ACCESSION NUMBER:		0000885725-23-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOSTON SCIENTIFIC CORP
		CENTRAL INDEX KEY:			0000885725
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042695240
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11083
		FILM NUMBER:		23659932

	BUSINESS ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
		BUSINESS PHONE:		508-683-4000

	MAIL ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bsx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4,d:0700a8f6ea1f4171b75e8081068a452b--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:bsx="http://www.bostonscientific.com/20221231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bsx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV8zLTEtMS0xLTExODgzMw_6c056f77-ab9c-469b-8068-274ce78db049">0000885725</ix:nonNumeric><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV80LTEtMS0xLTExODgzMw_297a38c8-9026-40a0-a124-65eddfe6525c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV81LTEtMS0xLTExODgzMw_d684aded-701d-4a0e-8f10-04a540dedeac">2022</ix:nonNumeric><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV82LTEtMS0xLTExODgzMw_6175f673-3dc4-412d-9317-ecb4151c1eee">FY</ix:nonNumeric><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV83LTEtMS0xLTExODgzMw_79bafe8c-990c-4ea4-9dcf-7166852a64a1">false</ix:nonNumeric><ix:nonNumeric contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da"></ix:nonNumeric><ix:nonNumeric contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602"></ix:nonNumeric><ix:nonNumeric contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bsx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1c201a7f894798953b951e25210181_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46385d71ef6d4d5d84809dc420bb3280_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i22375819fd604f498598a0c0ad1d2ecc_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768fc9449917456fa6ad3dc07b48a7de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1341e21d90443af90de6592dad0f9ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb83d68d15234b64aca503ff713f9dc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0b26deeb85428db3cd49a32a784be2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e82af43990a43a5806aec1a1b7cffc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a0e880d55a44638a412708352acd0fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c98902d1100477fb76e88964a02c7fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79dc2df78f7b482183a5fdbd827980dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a7639e46664d8fa457ee6d81350081_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da3f796ab7b4c4789b43fb01dbff97e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a848010fed34536975f3f72d972321b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987efda00d924bb3ac9171caadacb1a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icca748a50e2c4b028776ec23b7576190_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55cc43cb62e422cba78b408deb3fbe9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i910cb43c8c984811951e0a50cf31e4b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e78cc828ad64fd2a08ac51a9ab110e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11723763d0f4a7f9db1745ccb1925ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f33f8343cf341e081c829b309c949a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e12b27d5b94e89971f0a98991944b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0412e24c28c14e22992835fa7fabd269_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d8c8b108e34010b4bed817e2a890d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd9e2d2be054f858e0733f3f3365bbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5a34dafaee43739ad795081962c7a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8645703dda44b3d867bbb14b332875b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76729449762445b59ec9bcba12070a3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af7edc70c84446284ff6b173c1e6e62_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1ce07457004d06a149601f4c4f99ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0357c11625794ac7a3d84a5f74c260a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d6ae39de2543159b001084dffe037d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf5487b407e432ead1e4e694ed618be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f7478fc1994fa5ae2a4818204ac7c3_I20220615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i91739b0d9fae4d91a17da45404a70bd4_I20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:ApolloEndosurgeryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52eb55d7ac10453695894b8ed3be958c_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:ApolloEndosurgeryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d7591fa55b4499f8bcaade3bba40cff_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de90588254145949ff313db5ff70926_I20230220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AcotecScientificHoldingsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26a25d3f1534945a3bc82415ed7fc25_D20230101-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea77466150d48c9a38a34a0031f8c09_D20230101-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AcotecScientificHoldingsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76d0b974c2249e39200438329a79acb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c12e4b8e88946ea9f918f099eca4382_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a57f87953d04bcb90ea07b09c5d17be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if226113987c44049a2899b6e0639d557_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fae4e1ae03a42d985a17ed55da3dd73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bdd48bb3d8f42bda231800746b62182_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if611a01731ac40b8a3f718fdab5f1fef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683be7f8eded4529b408b52a5cef0564_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9244733cac7643bd91fbc8831f903805_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1450ea84df4039beb33b363a40d4ab_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0472293542444a397c435d4b743117f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9433d2d803b946a2a1c5f7f1eef556b3_D20210901-20210901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:DevoroMedicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-08</xbrli:startDate><xbrli:endDate>2021-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16dfec677c164b2db255f582287df56d_I20211108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:DevoroMedicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc362728b97e470189a743db7df633f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29dcadcc844744ce80267d06b1d1bee8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida522649c73f489991dc9d869ad4cb1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86cd5fe3fca484b870d2bca0d5beae5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb4a49895044b7f93b87f1125e9a416_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d216afbb77411a8e7a88fc901eb047_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1123ea65934f2e965ed236c8440439_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2d335c16564091877bbf5b8ea02230_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083186e7733646c894ee4a0c3759132d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8c96c67e8f436cbff8a3f7e7cf61ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e104fe52bd4eaf9ecabbd0966f5c0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8992dd65c54f5a8d206129a6e43300_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6bacafeb2c4ee19ca76f16ce8b05d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2f9147295b4342ae1ef9f9a08e5b1c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298875e7f6c14315a22aa84704cb2ce9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d8c251041c479c83a81894f74cb3a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bda1329ad5a4a2f81c742cf431791e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae118e7e63dd4c05b064ed16436ebc0b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1c3e36b9104f7d9dd2b0619383a285_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ad30b208f74b9dbc3abb41b51d5b1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id779a81f335b433c9e90f850b830d36d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36b821fcbadb4bd3aacf50d87394be76_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib279fd9ff9e24cabbeea019d2dce793a_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bsx:SpecialtyPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9e93fb57d049aba15e55858f4ab28e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c455c38cc5418c8c1d20f41ec12d1c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie352ea4b79494664ac3998f2352658f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc984d89ba45490889622ccc6fb20531_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic745df5cf86544beb987a6cdbf4ae321_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8236d39ea3a54b19b58c9057e3712dd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09fdfdce24574b16ae9fca57363d0048_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie344ff9d360c43ec88274800d50d23fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e5dd3a9e74146d9bdbd43b08724c65a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8770fe069a48c28a36571ec7f42a16_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea319dadfcac4428bed6eb3806fa0d6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60295929e3534f219e8dd476fdc06494_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b643ca1df374b79a206f73c4e819e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493e85aa50f24f0caa296c0a869c9130_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829f5796ec4446fda9daa222c9e48016_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb6963c5fa24817900cf506ab2e8417_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39aec4b0808e4322ac9eaa857e19619e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a09f7d28b7a4d58918c0fc8fd00608b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5be5738945b41cc9caa3ecef19ee3b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6476257158644418375f2f260ef1d9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia479b11e592d47a89236ff2bfeba753b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb9fb9238a440629faa09412375647f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc263f43956447489bf00cd95b47d45b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5e00fb04b14bd7be7b428099bd5934_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0460e71d5b418b813458aae9b11a82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie847a194b2334592ac9587e3029dbcd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2019AggregateOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i5f4f307170e14ffa98c3396e76d5b034_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:December2027NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07415990883e4ca3b5f954aa8871d444_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b264f96121f49c4947c5cebac003441_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ba4efd839e41a5a81e781338fa73f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if424464b0a3c4a39857873d850185168_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6d5b5ab6e344e9bf988dc3bff46611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b57c132f9d416694b1d85ee5e9c012_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefadff6b78cd431aa59e065d0ae8d019_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7034c0c152ad405b805f9b28b7b18795_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca004ff852f4e619fad9a26264773a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id838054c9b624ef88ede2a3ac03cca10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="units"><xbrli:measure>bsx:units</xbrli:measure></xbrli:unit><xbrli:context id="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775054b201874b0995c880d7f1742de0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc8106ccc3e4b4f8afb7eed48c9a6ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497eeb11153a4392b98631c49308f079_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e775c256acb4b869fa12bfa169522f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6965149134094476b73632a7c3d75d1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43976490229f4082a87ca1ad777107c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c931f3e9e82412985cdead08af7d632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b5902a38e94fb0bc7726cc131b7909_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0fbd55b32b490e9fdb76b959b0201f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf44831547f46288e08f02ae1ef637a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6b63466c604373ae38da6289aeb97b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e21397bfa8444b681ef8632f7075281_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9f9f3e82c944209c2e074ec8df6017_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c65a02c0b2346b8906129d0669bf500_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80d5979815640db88b06b04ebcb6895_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66ab9c892884deaade76365d66fd129_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7356fcfc65574de19d26d52fc3344322_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9d72a0fc2a4e5a95b3b411d70ff7cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023ada48280d48fbaabe57b9e17d60d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ada0ca796d42c992dc5e35b941a368_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3c5b387d0440dab8c546b5c1842949_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840959e741f54e53bcfa7cee090f415b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0f8ffbda174d938d2297ace40124d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14049c0347434075a00f370f84a4db4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b89ace1eaa46269adec5e0008ec73b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d5b145adac4671bb050182a0d509da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffcb904865b4d6580df24d96533c364_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee69410e5a5d4b89bc83f76bb50d6b38_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e9c8a5b25844acb555957ab3a50fda_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia769df42f17c44b6b313f45d148ee393_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5679aa760c46509687a1dde91bab70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306eeeee59414185854b583778c80597_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65715ea926ee481fb6c5149bad0221f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29915dcac5094d979b75f1f2f98cb3d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2194ed16e8554a818134176f669c6463_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c030aed5a44a2c9b75bda87f7ac3e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee8da85a7114dbf9b80f1b1ad1b7309_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af424844b524fbc975d6d2534326bb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i707b6e8943e4427a9a804100e6c467b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ab0e4e1b614daf98a769c6518ac202_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5897f9c4874d42b04253217254d1e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8cb2626e924fb8839e71109d5af54e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04324fd6d5b24d29b46e19849e7f37a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06c81ca089f4d1995643384dc902e2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2144f30d3644df97a834f3542eaa50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53531cf73b884a88961411dfb1a4df93_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2025NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02be01898d4d4188b550ce6554ad5461_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2025NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2025NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76f019bce26489da0bbcda06c714fcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2025NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2026NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b88044a72ca47a791ceb58f044afebf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2026NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96adf1f1d5d4c17ba33895d23e7b110_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:December2027NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0895858ef274288a9fce1cc6baf793d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864e95597acb4043a3697acb3ad55e62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a4d41448224bea93d0c944e7acd848_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe00cfc2a6d34b918d4ceff8a2a7df0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida72d7a38e1b45739fe07b735a844490_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018346feef584486b99651353c8ff6a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i682827fd95b7499d8506ecce105a57a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2030NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb00400334214dfba90153fcbfa6c190_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2030NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b7e8de32b04e2b9d457be393d35239_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2031NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a66dc38d4684266bdecece733ad71b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2031NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2034NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6171ca5966e144cda0bde8a3dec28ca5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2034NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2035NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e76a81818f4be58bec07896afe0da9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2035NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6bb195cd673465b82fb0f2af7d23b13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2039NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3999962f0a5340baaeffd9b46c41b048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2039NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:January2040NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1499dcaa0a4582b01d18fba8f0a457_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:January2040NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58dd8cfee9114b3094575d06ba47b061_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2049NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928315b0c4a64541aef04d53faebc49b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2049NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f56a60724c4866875a8a4eae6f3274_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32b67209ba7458d8464a71b457bf2e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b71607a73c4b9581145cffe097fb22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1115f7919aed4133876eff1699223515_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7989d8c3104e4c619e77b27f533f298b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa67b35af59447dbc5102119a3de9dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9cb66ce623493d8cf1bce6f5823751_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a25ee3da32a468a9bfc070a0c89a839_I20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bsx:The2018FacilityDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d77a9f992e540f08a1ba2d26480abde_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03e9205a64d476ab1ffbccbf9a5d6f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:ActualCovenantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423e15598ef9473093d58996221c5647_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementAsOfMarch312021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44684946d0c54e399e9c2de5643d2c10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a893ba0e00b4645b7c556abf4dec609_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb6963457e3481da9017401ed9b31fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ab63ee90e44984aa45a30f812a5e31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3172cf749dd40e98dad112948210e77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca8697fd7e248dbacff201a7b724e96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0251b7614994e199486b144a5575677_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:TheOfferingAggregatePrincipalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2025NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="iaf36b03a92634587a78fe98ecbda2739_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31b0bfab9628416589521c0cc6480c67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643af335931a4a30a480266df6ef95d9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98de3ef86645434aa333bc3813270c7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65dea5f8a5b4ac18eaa23709148f19b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce90adb5f284d558cee43d226b9984f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba3abf20e7914152b66511a2593d8f69_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife73119c01544765a2e816448d123ab4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33dfc13e3d6d4ae1bf1a49a51cf7ae03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9016a91a7f4898bd6a07d00738ca87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b9dfecd89c48c796f6821c64cd7270_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc10de8eb9b4b38a11dcc2d78d8200a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3c6f2ec1ae4c93b758ace41955b687_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5f7d93752e444488110da50a259559_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f29c696e3e14cde8b3aa694d11cc79f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic937ceba64df47d49bd0da69ef3f015d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7c693c1ad044d5b5d785d5431ee0a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1500544395e942a291c9853a03d49cd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5c980151684785bcfcbb6bbe9b77cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxAssetsDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2eb60a7197b4e5da1ffad49a2eee8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxAssetsDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cbe628c58a04e7ab7e6559ead7b48e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxLiabilitiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277df0ecaf304cf08357801c32ae2706_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxLiabilitiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2e7463fa724bcf9a0461181ceba4f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15f114eb8804a7c98bcd09d92bb0633_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>bsx:Unit</xbrli:measure></xbrli:unit><xbrli:context id="i3290f9f23eb24119a72f6930eead5d1f_D20220805-20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-05</xbrli:startDate><xbrli:endDate>2022-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62bc5e62d5db4d23866e0c44a56c5628_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if23c296459144875ad187e30e952915b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifada2c5db8c74b0f917945eda6797be6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6805ad1bd72431da0294f8b9f787280_D20230130-20230130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-30</xbrli:startDate><xbrli:endDate>2023-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bed8161679460e856d9920088ac04a_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf3f5d8a9e54dd79aaa2d19b5e4aff0_I20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182a1036891e4f75bb208c20f52223a2_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08365277a86440dab883742676202e25_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bsx:A2011LtipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65c415d7afe493a89650f841bc4bf30_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf9fcdaae944b3390aef4cad3b3d62a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia933afd979654f88afc557688fdca523_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaae3391a8f04f3aa64456d9284c46e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14bcf59fe7c34a8a94840e5aefc3a400_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3db7e9dbfd04e5087fede77d602a86d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0af4e13a75a42c69eb0c61842136ccd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ac253948f34ac7ab4ff32466a9dc4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7657382e881145e693f2f7a6e978a9cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabf66c1b2184034b2b380702d5950c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950414449291498aae88bf9cc6ecb151_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbed6b4234d64fd6a55a3d61b6c5cc7f_I20210217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2fdbe96ac342cfb2c6e55914689554_I20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2523c5f920482192b97a05b9cfd285_I20190221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d4b247dfcf42b18bdd3d7fc7fef232_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8687933af19a45e89f5ecbc7a113fc9c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040d7807c33b46a4b79cf78c184c0dd7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c56a446b7c417f8ba1d1a6f60d5e8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3043cc21b44462892099dc71ca5ae2f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e0030da7dd43208fdf78c181acd6b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5740688cc4a24abfa9eca604a6e8a9a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reportablesegments"><xbrli:measure>bsx:reportablesegments</xbrli:measure></xbrli:unit><xbrli:context id="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8209cc36f681456ca83869b5c6449383_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73aacf8162a94e5ca1cbfc7c3bbb8429_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4d1adfd5d54741badb3c93eae8f22f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8022cbc49a3d4c4fac891808fe3df6d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a81988fde44ba5b6bd50b742952a88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad42e640c3464b0da50b8fb06d89531e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828e9990d56940ce9f697d568f80f1ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ec3556bf5a454fa2bd44957535d39c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2bdc993f6049e2bd23b2de3c4d090c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282876cb44e2481c810f077edcb1f925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23150e692e7444a6b1096dff0b883677_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9912e3f7721e4f4eb02c8a146eb576ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff6c0b60ebb41109c5e430b7cf98bfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d25936d40ea49aab12bb59004cd2db9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6cf9fdde614399a2fe497025d3fd04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b22282599f043b7ac5083784fc608f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:ConsolidatedBSXDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b5c422cffd4ce5a6f4a90251a20608_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:ConsolidatedBSXDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56a78345d3145e2b9794e539a59c1d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4367e2317d04cf0b38cf472829367fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia714a3ddfec449b5b11c7aa4287614fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if045c803eadb4661aca54512d1bb0be2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2970551fa2429a88d913607880908f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95029382727473aaf7e493ea3baafeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7006856c9d44d2ab1e38d46423fd26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc270f01c02480db0f2bcec5a56070c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dca525960544c139044f842992c4cd1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac06cd2de024399894d3c6dfb28070e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e2ba9581ee4e218b8a89a221a0d400_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98056bb0e784957b5899a9e833f0fbf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2e323954f7444eafe535939a1c7edc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3945a09c204b04a2dbb81ac13ccf41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d43ae659ff4513bb97a8edea477a2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6ae61663a74c268cb97faeae2f6a45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfbdd903babe43e3990ab29bcbe6985e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5cf1f78e6445dcaf73a56694e9027e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b44455a502404199213289b929b707_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb65397f906401f908a347b4d777c0f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ede5593b494783a615d880fc8b78d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea5ae6a8a2245f1b71a59f4740ac05b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e19ddabb7c473ea576b951929e933d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7fe9c758704bc380ecdd891fe49855_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfe994c194b4ac8ae41f11a8e0cce7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d8cad94f45467790555d4a57825c01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief043d96b49f4090a6042a4c1e0f9605_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a88f9ce6ad4b2eb993d105654ed940_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59ce8cc839f4063a3e88b18ffbe49ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4d8cfc9f3949e0ab3d00ac9a41c0a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2111a536bd5a4796852fa7ccbf67dc68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd845dce72c499e927c52977b641d86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i266d7b2f5a4648a7aedcb54343a73155_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95007a0364764d788c9f338d90b37fa4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6658a131071b4edaa7cac05c6b6aca94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5309925cea74e63b88ce62afbe1270d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97bc9d7d5aef436ca66c436814c83b71_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea2540506a544eeb708632b6b53f89b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bc255eecd04f718e0dce31409bbb26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d0840a435a423cb7726c98d53dbb8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf111df6fc94178a8bb5ccf9404c15b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b14d4227e848e0add48cdc505946e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02edf62965645468d841ff2e20bd583_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ee3c0309a9465098537a7f86a5ed19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaaac1cd808c424895d59867a9db30ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3cec840750475fa319163520fd421c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if97a3d07e8ae412080d39dd505633b22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e2fdd1216d48ad9a132b46e9f04cc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c84859c22a480cb0e62d9cee342cf9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b43961f16149e79908d1ce39fcce65_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6511ff7f1ebd4c868948a72045ca4c95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2cccfcfa0da4d0ba64bd068cb216aaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ef965318ec475d8fe145a03272291f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f013c49cfa4e968944e9f014b68096_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84b586d1c33476cab5cd06fe83b53aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib63f895c42144907a76b542b549cfab7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c142c5abcd44f2097601e910946d27f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4badae83fb2143539a2f1dbc8f190c16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087cbed8b29e42feabd968d6ded400ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788426412f1a40f8ad96ce8056faccd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bff9d1f551440a688b46d38ff22c6f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3332eee0684d473898c31f79884ac25f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b385711e244459b5bc15b4489ddc67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c36f07461a4edb956649b1e7840283_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367ed0de181442618fa9e97ba29c26ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9d01f0516547888439cdac0d45255e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ee1376ff224dada10dcbfa895cde79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5934a9c4b546c8aa8a37ac4ff145ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9327fc2252e47e68dedb4bf033c1d99_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980a462ea63b44bfb0e472d26c91addf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f3dfdce6e044c1af8a7d768e300200_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5d84cf74294152822468efbefec311_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e041f4904a84a60b8108cc9c8334104_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050e41d3f89a4c0a99eec3c08767ddc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67b272c44934fe18e99394c9d6804bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270ce9e6a3b241c8adb7451d55aeab6e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581ceebdfc92445686149ad51b8ce5c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i299c0a24457a49c48fa0b7f8274dfbcc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a11a2bfead64c0d8b223433c88c9be4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d0aad282314e139497edd5e2dedbd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f4ab88945f40329c0a824cc3ac5fc8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c06369961704a7285b3ca38acb83219_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe90759eb8f424d8234de45b7a2a52f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907ac35c98df416294ddae9f68675c91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa4826270924bc38ed4e2b1152cc626_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a81b7be7914312a976ebf95b9963e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c43cfb6b094f59988dda6095180014_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49ee4af7f4d4a8687f9f49af6e015b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff090cbc1c5471fb8af72a026fedd32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c4af7a1ce94cab93068e8d456e80ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ce6d1a01654d339cdd042cff9f100c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcf6149b1404f96a68187ed3c062a35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9c77c73b8241e1a75da0171dba04aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6797d90a509d4ec8834a36e34146765f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242b0d85ba4e4a2fbe4aed3cf9b322a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05dda8644a90446b877b0a66f32d173a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f123aba421447aa9cfc9708023f08c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd26528424d45f2883dba765d3955d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd88a51eb14a4889becd9bf95a373936_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1f6bf8d3c34daab2415fdc9e3dd952_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210171398abc49e5804c051f9b9fc4cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d2ba2b1796414eb8143d8705a0465a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ab10efbdcf47528ab3d60926612e2f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5baeedb7124b2f84ddb781633016f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be1b83b1a924f748b1636472e5583be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b2f64263444c3080cc6d662586f06c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fe7e8d201c4c45ae3804080539f315_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85ad4347a4c4b54ae5c5fc3193a7800_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea4c3278ec34a698de1ffba66d08cf6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3c6b5d49ff44128141a1fbb83b6e1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12859b60da9b499db05018d9639782ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d5ab671eea46b3bff921eba5cde3cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb42a43becfb4015933cfee5cff72004_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51fd28aa8356476e99b8acb0eca6d645_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f7de2437fa49bfac860e607810e395_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa737befb7b447a8ba19436619112479_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifead762c7ade4e00b9129c72020dc3b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b812ed03474859ab0a0548820d732e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4fc248e09be4de88c3b1366bed3d1e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d8f6746e354f2e87c087199c9722d1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75aca95e90e14d6f8ad7d91562c55653_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0c54a79abb4963befbf39f66d3391e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7ba54afdd9452783afd6d19b9919ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0809617f4324434aaebbd5728f20d9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950de22b68424e98860e7337e3026204_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9523ca0ea2849a3ba7afdb3f792faac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12a969e10ec48b990fe38bdaab38a23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef567bf8d9645e88d19c89d931dc420_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="countries"><xbrli:measure>bsx:countries</xbrli:measure></xbrli:unit><xbrli:context id="i139d04cb2ec14e418ffc5d45192844cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:ExecutiveRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c3fb77fc3542338e354336e20bc3a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:InternationalRetirementPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie472ffec11ea4927bd1542ae98aa108f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:ExecutiveRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07418139cdce4f5c981ed2c683522433_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:InternationalRetirementPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398d31599a9a4c7a862b268487b31675_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:OtherInternationalPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a709d6c9a0b41feab31995bae094f9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:UKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:OtherInternationalPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05bd241aa7bc46a3bbc132eb60cc014c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec61999347b74ca9980b9262bc2473a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649253125d3e41ff83d40817dfc4b57c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81025787d2734b4085a77f222cdb83c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i464a3ab08a074038b0b11f145f5be6ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cf5d0c98a64efab2f25564d3cb8718_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6c0f8faf13418e93bbab3e1cdb4719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9720398bfd24fcaa4cd94ccacf55bfa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c80cf97e92455e89254f71abde961e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0700a8f6ea1f4171b75e8081068a452b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16.5pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA4_9787e394-bb7e-42b0-9f15-81145ec49039">10-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:3.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZTEzYzNiNDVjYmEwNDgyOTliYjU0NWRhNDA5OTlhYjgvdGFibGVyYW5nZTplMTNjM2I0NWNiYTA0ODI5OWJiNTQ1ZGE0MDk5OWFiOF8wLTAtMS0xLTExODgzMw_74573491-e445-42f6-8d43-1a2ac0843de4">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8xMTQ_16f1ceb8-4351-410f-b3a0-4488d0d2fd7b">December&#160;31, 2022</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:3.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OTY3YjMyYjg0NzkxNDQ0MTk2MDBjNmNlODcyYWNiNTgvdGFibGVyYW5nZTo5NjdiMzJiODQ3OTE0NDQxOTYwMGM2Y2U4NzJhY2I1OF8wLTAtMS0xLTExODgzMw_6999e608-8468-4b16-8e1b-c47e50c51a85">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA5_80418b68-43c9-41da-bbfe-d9152ea0fe58">1-11083</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEw_a12338bb-82e5-455a-b8d9-bc8ae77cf83f">BOSTON SCIENTIFIC CORPORATION</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:42.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6MmY3YjFjNWNiYWQ5NDkyZWI2ZjVjNDYyYWVkYjE1YmMvdGFibGVyYW5nZToyZjdiMWM1Y2JhZDk0OTJlYjZmNWM0NjJhZWRiMTViY18wLTAtMS0xLTExODgzMw_0cb326a3-326a-4975-8d01-6d35f4a6b59c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6MmY3YjFjNWNiYWQ5NDkyZWI2ZjVjNDYyYWVkYjE1YmMvdGFibGVyYW5nZToyZjdiMWM1Y2JhZDk0OTJlYjZmNWM0NjJhZWRiMTViY18wLTItMS0xLTExODgzMw_1801be3b-6328-47f2-a790-dbb34e167fbd">04-2695240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEx_3f8dc664-309c-49c0-96f6-7e79cb71be74">300 Boston Scientific Way</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEy_9cc03364-196a-413b-ab82-88389f15fdec">Marlborough</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEz_ec7cee86-3b75-4d4c-8c91-6f5a7cae0ac7">Massachusetts</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE0_fa217d3b-08ca-4dfc-be99-bff182e464e6">01752-1234</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Address of Principal Executive Offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  (Zip Code)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjAz_bbf65ac1-b427-42cf-aead-1e2df60c9f98">508</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA1_a6cdf955-5849-4220-b239-6de7eb536762">683-4000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:34.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTAtMS0xLTExODgzMw_97571bb9-ebb2-4b8a-8152-b4d01a4d8dc0">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTItMS0xLTExODgzMw_98f1b545-8eb4-4ed2-a22a-99b9203e7e38">BSX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTQtMS0xLTExODgzMw_d4bf4cdd-8fbe-45c4-9776-564301aa7493">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTAtMS0xLTExODgzMw_98344972-8737-4552-a243-4ed0c05b243e">0.625% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTItMS0xLTExODgzMw_171b90e3-7d40-4793-893c-b4cd68c4d558">BSX27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTQtMS0xLTExODgzMw_063b2521-b416-44d4-97d7-68c1857835d5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTAtMS0xLTExODgzMw_837f4c40-8623-4365-b360-e4d454c671ee">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTItMS0xLTExODgzMw_1e91adc7-89c6-49cf-82c4-2dce50017de0">BSX PR A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTQtMS0xLTExODgzMw_a54a391c-c16d-46d8-90a3-2ba3c285845c">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NONE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE1_60eb76ac-4805-4219-813a-0ba70bce8267">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act. Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA2_acbd7b01-ea80-4ce0-ad89-4d8a38c04fc7">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE2_65bed8e7-ab3a-40fc-9d8c-b051989561b4">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorted period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE3_d8ce1be0-5e4e-4c28-8903-ec8c716fa0b5">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:37.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8wLTAtMS0xLTExODgzMw_30851c90-e030-4047-ab2b-977a655a6bd4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8xLTMtMS0xLTExODgzMw_129aa1b1-2bb2-457c-a98e-f54c78c09997">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8yLTMtMS0xLTExODgzMw_6250a0ed-9a93-4011-a183-254b2f52b208">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA3_27f2f1e8-411c-4bb3-8323-883df44af767">&#9745;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE4_93c6d51a-d59e-49d9-b564-9d785c7738e5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="i46385d71ef6d4d5d84809dc420bb3280_I20210630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8yNjY2_d61662e8-f8d1-4812-b610-d351b9cead78">53.2</ix:nonFraction> billion based on the last reported sale price of $37.27 of the registrant&#8217;s common stock on the New York Stock Exchange on June&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter. (For this computation, the registrant has excluded the market value of all shares of common stock of the registrant reported as beneficially owned by executive officers, and directors of the registrant; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant.)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="dei:EntityListingParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zMjYw_f9f0e5ff-e263-4087-8c11-37d4c0bba2ef">0.01</ix:nonFraction> par value per share,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of January&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> was <ix:nonFraction unitRef="shares" contextRef="i22375819fd604f498598a0c0ad1d2ecc_I20230131" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zMzEx_914bd29d-776d-4d3a-bced-045e610fad1a">1,434,780,104</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Documents Incorporated by Reference</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed within 120 days of December&#160;31, 2022 with the Securities and Exchange Commission in connection with its 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_13">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_16">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_19">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_19">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_22">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_22">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_25">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_25">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_28">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_28">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_31">ITEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_31">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_34">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_34">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_37">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_37">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_40">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_40">RESERVED</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_40">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_43">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_43">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_70">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_70">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_70">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_76">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_76">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_76">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_166">ITEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_166">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_166">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_169">ITEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_169">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_169">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_172">ITEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_172">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_172">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_175">ITEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_175">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_175">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_178">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_178">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_181">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_181">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_181">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_184">ITEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_184">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_184">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_187">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_187">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_187">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_190">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_190">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_190">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_193">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_193">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_193">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_196">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_196">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_199">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_199">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_199">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_202">&#160;ITEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_202">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_202">135</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_205">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0700a8f6ea1f4171b75e8081068a452b_205">136</a></span></div></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:center"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients&#8217; quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate pursuant to five strategic imperatives. We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities. We believe that our execution of these strategic imperatives will help us deliver on our mission, drive innovation and increase value for our customers and employees, while strengthening our leadership position in the medical device industry and delivering profitable revenue growth. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to invest in our core franchises and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share, leverage our relationships with leading physicians and their clinical research programs, accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines. Our research and development efforts are focused largely on the development of next-generation and novel technology offerings across multiple programs and all divisions. In the past several years, we have completed numerous acquisitions in support of our growth strategy, both strengthening our core franchises and expanding into high growth adjacent markets. We continue to develop digital tools and technologies that enable us to compete more effectively and deliver first class remote physician education, drive deeper patient engagement and increase digitally-enabled sales force productivity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a firm commitment to corporate social responsibility and living our values as a global business and global corporate citizen. This includes taking actions to combat discrimination and advancing equality and diversity, including through financial support of racial equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly. Refer to discussion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Community Outreach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Sustainability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for additional information regarding measures we are undertaking.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Offerings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core businesses are organized into two reportable segments: MedSurg and Cardiovascular. The following describes our key product offerings and new product innovations by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedSurg</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Endoscopy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. Our product offerings include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Resolution 360&#8482; Clips and Resolution 360&#8482; ULTRA Clips, hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures, </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">WallFlex&#8482; Biliary Stent Systems, used for relieving biliary obstructions by providing bile drainage in both malignant and benign strictures,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AXIOS&#8482; Stents and Electrocautery Enhanced Delivery Systems, the first, and currently only stents systems in the U.S. indicated for endoscopic drainage of pancreatic pseudocysts,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SpyGlass&#8482; DS II Direct Visualization Systems and SpyGlass&#8482; Discover Digital Catheters, the first single-use scopes to enable physicians to take a single-stage approach to diagnostic and therapeutic procedures in the pancreaticobiliary system, including treating patients with bile duct stones,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EXALT&#8482; Model D Single-Use Duodenoscopes for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures, the first U.S. Food and Drug Administration (FDA)-cleared single-use (disposable) duodenoscopes on the market,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquire&#8482; Endoscopic Ultrasound Fine Needle Biopsy Devices, which are designed to obtain larger tissue specimens for histological assessment and diagnosis of diseases such as pancreatic cancer, liver cancer and stomach lesions and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our infection prevention portfolio, designed to minimize the risk of infection transmission and improve operational efficiencies by streamlining manual cleaning or eliminating the need for cleaning and tracking.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Urology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Urology business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Our product offerings include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a comprehensive line of stone management products, including ureteral stents, catheters, baskets, guidewires, sheaths and balloons,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LithoVue&#8482; Single-Use Digital Flexible Ureteroscopes, which deliver detailed high-resolution digital images for high-quality visualization and seamless navigation, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lumenis Pulse&#8482; Holmium Laser Systems with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MOSES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology, complemented by a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> full line of laser fibers and accessories used in urology and otolaryngology procedures,</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Prosthetic Urology portfolio, which includes AMS 700&#8482;, our penile implants to treat erectile dysfunction and AMS 800&#8482;, our urinary control systems to treat male urinary incontinence,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GreenLight XPS&#8482; Laser System, MoXy&#8482; Fiber, and Rez&#363;m&#8482; Systems for treatment of BPH and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SpaceOAR&#8482; Hydrogel Systems which help reduce side effects that men may experience after receiving radiotherapy to treat prostate cancer, together with our SpaceOAR VUE&#8482; Hydrogel, providing clinicians with enhanced product visualization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, we launched the Rez&#363;m&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Water Vapor Therapy System in Japan following regulatory approval from Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) and received approval of a new reimbursement category from Japan&#8217;s Central Social Insurance Medical Counsel (Chuikyo) for both the device and procedure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we received FDA clearance for and will begin a limited market release of our LithoVue&#8482; Elite Single-Use Digital Flexible Ureteroscope System, the first ureteroscope system with the ability to monitor intrarenal pressure in real-time during ureteroscopy procedures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neuromodulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Our product offerings include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Precision Montage&#8482; and WaveWriter Alpha&#8482;</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spinal Cord Stimulator (SCS)&#160;Systems, designed to provide improved pain relief to a wide range of patients who suffer from chronic pain, with proprietary features such as Multiple Independent Current Control, our Illumina 3D&#8482; Proprietary Programming Software and FAST&#8482; Therapy for profound parathesia-free pain relief in minutes, used by physicians to target specific areas of pain and customize stimulation of nerve fibers more precisely,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our G4&#8482; Generator and consumable portfolio in Radiofrequency Ablation (RFA) for pain management used by physicians to treat patients with chronic pain,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Cognita&#8482; Practice Optimization suite of tools designed to increase awareness, streamline patient management, and sustain long-term outcomes for patients,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vercise Gevia&#8482; and Vercise Genus&#8482; Deep Brain Stimulation (DBS) Systems for the treatment of Parkinson's disease, tremor, and intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Superion&#8482; Indirect Decompression Systems, minimally-invasive devices used to improve physical function and reduce pain in patients with moderate lumbar spinal stenosis (LSS).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vercise&#8482; DBS Systems are approved in the U.S. as an adjunctive therapy that aids in reducing some of the symptoms of moderate to advanced Parkinson&#8217;s disease as well as for patients diagnosed with essential tremor. The Vercise Genus&#8482; DBS platform features a full portfolio of primary cell and rechargeable MRI conditional systems with Bluetooth connectivity and the Cartesia&#8482; Directional Lead, providing multi-directional stimulation designed for greater precision, intended to minimize side effects for patients. In 2022, we further expanded our portfolio with Image Guided Programming with the US release of Stimview&#8482; XT, a proprietary DBS visualization software developed in collaboration with Brainlab AG, providing clinicians with real-time, 3D visualization and stimulation of brain anatomy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiovascular</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cardiology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interventional Cardiology Therapies (ICTx)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. Our product offerings include the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OptiCross&#8482; IVUS Imaging Catheters,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">iLab&#8482; Ultrasound Imaging Systems with Polaris Software, designed to enhance the diagnosis and treatment of blocked vessels and other heart disorders, compatible with our full line of imaging catheters,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AVVIGO&#8482; Guidance Systems and AVVIGO&#8482; Guidance System II, incorporating high-definition IVUS all in a mobile or integrated platform, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ROTAPRO&#8482; Rotational Atherectomy Systems, which regulate the flow of air to the advancer, controlling burr rotation speed, and also monitor and display burr rotation speed and rotational atherectomy procedural time,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SYNERGY&#8482;, SYNERGY MEGATRON&#8482; and SYNERGY&#8482; XD Everolimus-Eluting Platinum Chromium Coronary Stent Systems, featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safari2&#8482; Pre-Shaped Guidewires, intended to facilitate the introduction and placement of interventional devices within the heart,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ACURATE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">neo2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482; Aortic Valve Systems for use in transcatheter aortic valve replacement (TAVR) procedures and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SENTINEL&#8482; Cerebral Embolic Protection Systems, used to reduce the risk of stroke in TAVR procedures and is clinically proven to decrease cerebral embolization and its associated neurological effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Watchman</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our WATCHMAN FLX&#8482; Left Atrial Appendage Closure (LAAC) Devices are designed to close the left atrial appendage in patients with non-valvular atrial fibrillation who are at risk for ischemic stroke. WATCHMAN&#8482; is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiac Rhythm Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our product offerings include the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">the RESONATE&#8482; family of implantable cardioverter defibrillators (ICD) and implantable cardiac resynchronization therapy defibrillators (CRT-D), including our proprietary HeartLogic&#8482; Heart Failure (HF) Diagnostic and SmartCRT&#8482; Technology with Multisite pacing in CRT-D, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">EMBLEM&#8482; MRI S-ICD System, the world's first, and currently only, commercially available subcutaneous implantable cardiac defibrillators (S-ICD), which provides physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">ACCOLADE&#8482; family of pacemakers and implantable cardiac resynchronization therapy pacemakers (CRT-P),</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">ACUITY&#8482; X4 Quadripolar LV Leads, RELIANCE&#8482; family of ICD Leads and our INGEVITY&#8482; Pacing Leads,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">LATITUDE&#8482; Remote Patient Management Systems, which allow for more frequent monitoring and better guided treatment decisions by enabling physicians to monitor implantable system performance remotely,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) systems, long-term diagnostic devices implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">BodyGuardian&#8482; remote cardiac monitoring systems provide a full range of mobile health solutions and remote monitoring services, ranging from ambulatory cardiac monitors &#8211; including short and long-term holter monitors &#8211; to cardiac event monitors and mobile cardiac telemetry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our entire transvenous defibrillator portfolio leverages our EnduraLife&#8482; Battery Technology and has magnetic resonance imaging (MRI) conditional labeling when used with our current generation of leads.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Electrophysiology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab. Our product offerings include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Rhythmia&#8482; Mapping Systems, catheter-based, 3-D cardiac mapping and navigation solutions designed to help diagnose and guide treatment of a variety of arrhythmias,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">cardiac ablation catheters including the Blazer&#8482;, IntellaNav&#8482;, IntellaNav Stablepoint&#8482; and IntellaTip MiFi Open-Irrigated Ablation Catheter families, featuring a unique Total Tip Cooling&#8482; Design and DIRECTSENSE&#8482; Software for monitoring radiofrequency (RF) energy delivery during procedures, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">IntellaMap Orion&#8482; Mapping Catheters, for use with our Rhythmia Mapping System to provide high-density, high-resolution maps of the heart,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Farapulse&#8482; Pulsed Field Ablation (PFA) Systems for the treatment of atrial fibrillation (AF),</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">POLARx&#8482; Cryoablation Systems for the treatment of AF and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">intracardiac ultrasound catheters, delivery sheaths and other accessories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company, Inc (Baylis Medical), which has developed the radiofrequency (RF) NRG&#8482; and VersaCross&#8482; Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. In the second quarter of 2022, we received FDA 510(k) clearance for and launched the VersaCross Connect&#8482; LAAC Access Solution developed by Baylis Medical, providing safe and efficient access to the left side of the heart.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Peripheral Interventions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Our broad peripheral portfolio includes stent systems, balloon catheters, guidewires, atherectomy and thrombectomy systems, embolization devices, radioactive microspheres, radiofrequency and cryotherapy ablation systems, microcatheters and drainage catheters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our peripheral arterial product offerings include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EPIC&#8482; and Innova&#8482; Self-Expanding Stent Systems,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eluvia&#8482; Drug Eluting Vascular Stent Systems, innovative stents built on the Innova stent platform, designed to deliver a sustained dosage of paclitaxel during the time when restenosis is most likely to occur,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mustang&#8482;, Coyote&#8482; and Sterling&#8482; PTA Balloon Catheters designed for a wide variety of peripheral angioplasty procedures and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ranger&#8482; Drug-Coated Balloons, innovative balloons built on the Sterling balloon platform, featuring a low-dose of paclitaxel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, we launched an ELUVIA&#8482; line extension, introducing the longest-length available for treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery. We are also the first company to provide physicians with both a drug-eluting stent and drug-coated balloon option for the treatment of patients with PAD.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our venous disease product offerings include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AngioJet&#8482; Thrombectomy Systems, used in endovascular procedures to remove blood clots from blocked arteries and veins and our AngioJet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zelante DVT&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thrombectomy Catheters to treat deep vein thrombosis,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">WOLF Thrombectomy&#8482; Platform, which is designed to mechanically remove the clots without damaging blood vessels, while also minimizing blood loss,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EKOS&#8482; Ultrasound Assisted Thrombolysis systems used to treat pulmonary embolisms and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Varithena&#8482; Polidocanol Injectable Foam used to improve the symptoms of superficial venous incompetence and the appearance of visible varicosities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interventional oncology product offerings include the following:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TheraSphere&#8482; Y-90 radioactive glass microspheres used in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Renegade&#8482; HI-FLO&#8482; Fathom&#8482; Microcatheter and Guidewire System and Interlock&#8482; - 35 Fibered IDC&#8482; and 18 Fibered IDC&#8482; Occlusion System for peripheral embolization,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EMBOLD&#8482; Detachable Coil System, used for arterial and venous embolizations in the peripheral vasculature, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ICEFX&#8482; and Visual ICE&#8482; Cryoablation Systems for destruction of tissue, using image-guided needles to enable cryoablation visualization for optimal tumor coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encounter significant competition across our product lines and in each market in which we sell our products and solutions, some from companies that may have greater financial, sales and marketing resources than we do. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. In certain countries, and particularly in China, we also face competition from domestic medical device companies that may benefit from their status as local suppliers. We also face competition from non-medical device companies, which may offer alternative therapies for disease states that could also be treated using our products, or from companies offering technologies that could augment or replace procedures using our products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner. We also compete on ease of use, comparative effectiveness, reliability and physician familiarity. In the current environment of managed care, with economically motivated buyers, consolidation among healthcare providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price, value, reliability and efficiency. We believe the current global economic conditions and healthcare reform measures could continue to put additional competitive pressure on us, including on our average selling prices, overall procedure rates and addressable market sizes. We recognize that our continued competitive success will depend upon our ability to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer products and solutions that provide differentiated clinical and economic outcomes,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create or acquire innovative, scientifically advanced technologies,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">apply our technology and solutions cost-effectively and with superior quality across product lines and markets,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop or acquire proprietary products and solutions,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain qualified personnel, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent or other protection for our products,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required regulatory and reimbursement approvals,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continually provide quality products and enhance our quality systems, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply sufficient inventory at competitive prices to meet customer demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in research and development is critical to driving our future growth. Our investment in research and development supports the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal research and development programs, regulatory design and clinical science, as well as other programs obtained through our strategic acquisitions and alliances, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and next-generation products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have directed our development efforts toward innovative technologies designed to expand current markets or enter adjacent markets. We continue to transform how we conduct research and development by identifying best practices, driving efficiencies and optimizing our cost structure, which we believe will enable increased development activity and faster concept-to-market timelines. Focused, cross-functional teams take a formal approach to new product design and development, helping us to manufacture and offer innovative products consistently and efficiently. Involving cross-functional teams early in the process is the cornerstone of our product development cycle. We believe this collaboration allows our teams to concentrate resources on the most viable and clinically relevant new products and technologies and to maximize cost and time savings as we bring them to market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to internal development, we work with hundreds of leading research institutions, universities and clinicians around the world to develop, evaluate and clinically test our products. We continue to expand our collaborations to include research and development teams in our emerging market countries; these teams will focus on both global and local market requirements at a lower cost of development. We believe that these efforts will play a significant role in our future success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing and Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we marketed our products and solutions to approximately 36,000 hospitals, clinics, outpatient facilities and medical offices in 130 countries worldwide. Large group purchasing organizations, hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. Each of our businesses maintains dedicated sales forces and marketing teams focused on physicians who specialize in the diagnosis and treatment of different medical conditions, as well as on key hospital service line administrators. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our net sales are derived from countries in which we have direct sales organizations. We also have a network of distributors and dealers who offer our products in certain countries and markets. We expect to continue to leverage our infrastructure in markets where commercially appropriate and use third party distributors in those markets where it is not economical or strategic to establish or maintain a direct presence. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Resources</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing and Raw Materials</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on continuously improving our supply chain effectiveness, strengthening our manufacturing processes and increasing operational efficiencies within our organization worldwide. In doing so, we seek to focus our internal resources on the development and commercial launch of new products and the enhancement of existing products. We also drive continuous improvement in product quality through process controls and validations, supplier and distribution controls and training and tools for our operations team. In addition, we remain focused on examining our operations and general business activities to enhance our operational effectiveness by identifying cost-improvement opportunities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to maintaining appropriate investments to ensure supply chain stability. We have an ongoing supplier resiliency program which identifies and mitigates risk and have taken measures to mitigate the impact of challenges within the global supply chain, including those caused in part by the COVID-19 pandemic. We consistently monitor our inventory levels, manufacturing, sterilization and distribution capabilities and partnerships and maintain recovery plans to address potential disruptions. Many components used in the manufacturing of our products are readily fabricated from commonly available raw materials or off-the-shelf items available from multiple supply sources; however, certain items are custom made to meet our specifications. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an on-going basis, we track supplier status and inventory in risk areas and take action to prevent shortages, monitoring safety stock levels and building up product supplies as warranted, and mitigating risk of technology and material shortages by identifying new vendors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced increased levels of unpredictability in the supply of certain raw materials and components used in the manufacturing of our products. While we continue to believe we will have access to the raw materials and components that we need, these supply chain dynamics could result in increased costs to us or an inability to fully meet customer demand for certain of our products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary Rights and Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, trademarks, trade secrets and other forms of intellectual property to protect our proprietary rights. We generally file patent applications in the U.S. and other countries where patent protection for our technology is appropriate and available. We hold patents worldwide that cover various aspects of our technology. In addition, we hold exclusive and non-exclusive licenses to a variety of third-party technologies covered by patents and patent applications. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to our business as a whole.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry, particularly in the areas in which we compete. We continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others. Additionally, we may find it necessary to initiate litigation to enforce our patent rights, to protect our trade secrets or know-how and to determine the scope and validity of the proprietary rights of others. Accordingly, we may seek to settle some or all of our pending litigation, particularly to manage risk over time. Settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain insurance policies providing limited coverage against securities claims. We are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our 2022 consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for a discussion of intellectual property, product liability and other litigation and proceedings in which we are involved. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Device Regulatory Approvals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical devices that we manufacture, market and commercialize are subject to regulation by numerous worldwide regulatory bodies, including the U.S. FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution. Medical devices are also generally subject to varying levels of regulatory control based on risk level of the device. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., authorization to distribute a new device can generally be met in one of two ways. The first process requires that a premarket notification (510(k)) be made to the FDA to demonstrate that the device is as safe and effective as, or substantially equivalent to, a legally marketed device (the &#8220;predicate&#8221; device). Applicants must submit performance data to establish substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) premarket notification. If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption (IDE)&#160;regulations. The FDA must issue a decision finding substantial equivalence before commercial distribution can occur. Changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510(k) premarket notifications; otherwise, a new 510(k) is required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second process requires the submission of a premarket approval (PMA) application to the FDA to demonstrate that the device is safe and effective for its intended use. This approval process applies to most Class&#160;III devices and generally requires clinical data to support the safety and effectiveness of the device, obtained in adherence with IDE requirements. The FDA will approve the PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the Quality System Regulation (QSR). For novel technologies, the FDA may seek input from an advisory panel of medical experts and seek their views on the safety, effectiveness and benefit-risk of the device. The PMA process is generally more detailed, lengthier and more expensive than the 510(k) process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (EU), we are required to comply with the Medical Device Regulation (MDR or EU MDR) which became effective May 2021, superseding the existing Medical Device and Active Implantable Medical Device Directives. Medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021) can continue to be sold during the applicable transition period or until the CE Certificate expires, whichever comes first, providing there are no significant changes to the design or intended use. The CE Mark, which is required to sell medical devices in the EU is affixed following a Conformity Assessment and either approval from the appointed independent Notified Body or through self-certification by the manufacturer. The selected pathway to CE marking is based on device risk classification. CE marking indicates conformity to the applicable General Safety and Performance Requirements (GSPRs) for the MDR. The MDR changes multiple aspects of the regulatory framework for CE marking, such as increased clinical evidence requirements, changes to labelling, and new requirements, including Unique Device Identification (UDI), and many new post-market reporting obligations. MDR also modifies and increases the compliance requirements for the medical device industry and will continue to require significant investment over the next few years to transition all products. The CE mark continues to be a prerequisite for successful registration in many other global geographies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other EU countries continue to impose significant local registration requirements despite the implementation of MDR, and the United Kingdom has introduced new requirements following its exit from the EU.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market, including regulations that have been introduced in many countries in the Middle East and Southeast Asia that previously did not have medical device regulations, or had minimal regulations. In Japan we are required to comply with Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) regulations. In conjunction with the MHLW, the Pharmaceutical and Medical Device Agency is an independent agency that is responsible for reviewing drug and medical device applications and works with the MHLW to assess new product safety, develop comprehensive regulations, and monitor post-market safety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order recall or market withdrawal of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the Food, Drug and Cosmetic Act and the Safe Medical Devices Act, pertaining to medical devices, or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities in the countries where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with local laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality system is designed to enable us to satisfy various international quality system regulations, including those of the U.S. FDA with respect to products sold in the U.S. All of our medical device manufacturing facilities and distribution centers are certified under the ISO 13485 quality system standard, established by the International Standards Organization (ISO) for medical devices, which includes requirements for an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Policies and Reimbursement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political, economic and regulatory influences around the world continue to subject the healthcare industry to potential fundamental changes that could substantially affect our results of operations. We maintain a global Government Affairs presence, headquartered in Washington, D.C., to actively monitor and advocate on myriad legislation and policies that may potentially impact us, both on a domestic and an international front. The Government Affairs office works closely with members of Congress and committee staff, the White House and administration offices, state governors, legislatures and regulatory agencies, embassies and global governments on issues affecting our business. The Government Affairs office also advocates for public policy that benefits our employees and the patients we serve, and supports the communities in which we live. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs (e.g., Medicare and Medicaid in the U.S.) and private insurance payers, for the items and services provided to their patients. Government and private sector initiatives related to limiting the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness reviews of therapies, technology assessments, price transparency and healthcare delivery and payment structure reforms, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to place increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources necessary to demonstrate value to our customers, patients, payers and other stakeholders are significant and new therapies may take significantly longer periods of time to gain widespread adoption.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of cost containment initiatives and healthcare reforms in significant markets such as the U.S., China, Australia, and other markets may limit the price of, or the level at which reimbursement is provided for, our products or procedures using our products, which in turn may make it less likely that a hospital or physician will select our products to treat patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Regulation and Management</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various environmental laws, directives and regulations both in the U.S. and abroad. Our operations involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. We are focused on continuous improvement in environmental metrics with a goal of reducing pollution, minimizing depletion of natural resources and reducing our overall environmental footprint. Specifically, we are working to optimize energy and resource usage, ultimately reducing greenhouse gas emissions and waste. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Sustainability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Boston Scientific, our work is guided by core values that define our culture and empower our employees, including Caring, Diversity, Global Collaboration, High Performance, Meaningful Innovation and Winning Spirit. As of December&#160;31, 2022, we had approximately 45,000 employees, of which approximately 56 percent were outside the U.S. We believe the collective talent of our employees and our shared corporate culture and values give us a competitive advantage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hiring, developing and retaining talented employees are key parts of our strategy and are critical to our success, particularly in the current environment of labor shortages and unprecedented job market conditions. We strive to do this by fostering a diverse, equitable and inclusive workplace, providing competitive pay and benefits and flexible work conditions, offering ongoing employee growth and development opportunities and cultivating a culture that prioritizes employee health, safety and well-being.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do our best work to advance health care when we have a diverse range of perspectives and experience on our team. Innovation thrives in a culture of engagement, inclusion and equity. The society in which we live and the customers and patients we serve are diverse and our employees at all levels of the organization must reflect this. In recent years, we have made steady progress to increase the overall representation of employees who identify as women and as African American/Black, Asian, Hispanic/Latinx, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races (together, multicultural talent). As of December&#160;31, 2022, women represented 30 percent of our Board of Directors, and 49 percent of our employees. In addition, 36 percent of employees in the U.S. and Puerto Rico identified as multicultural. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to our goal of making further progress toward expanding our workforce diversity. In 2020, we set measurable Diversity, Equity &amp; Inclusion (DE&amp;I) goals with our &#8220;3UP by 2023&#8221; initiative, which included aspirations of a three percentage point increase in representation of both women and multicultural talent at the supervisor and manager level to 43 percent and 23 percent, respectively, by December&#160;31, 2022. As of December&#160;31, 2022, 42.6 percent of management roles were held by women and, within the U.S and Puerto Rico, 22.6 percent were held by multicultural employees. While we are making progress, our work is far from over. We are committed to intentional action to drive meaningful change. We listen to our employees and use that feedback to complement and expand our existing DE&amp;I programs to emphasize initiatives aimed at developing our pipeline of talent and fostering a psychologically safe and inclusive workplace for all. Additionally, our Executive Committee and our Board of Directors have oversight of employee diversity metrics and hiring trends. As evidence of our commitment to expand DE&amp;I, in 2021, we introduced an ESG scorecard, including DE&amp;I metrics, to our Annual Bonus Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ten Employee Resource Groups (ERGs) are at the heart of our DE&amp;I strategy. ERGs are voluntary, company-sponsored employee groups that foster and celebrate our diverse work environment. They provide forums for us to learn from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one another, celebrate our uniqueness and develop inclusive leadership skills. We support each ERG by designating global and local executive sponsors and providing financial resources. Our ERG chapters around the world collaborate across the business at all levels and are powerful voices for change in the company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our approach to supplier selection involves building DE&amp;I throughout the Boston Scientific supplier network. We are committed to the increased and sustained support of diverse businesses that share our dedication to improving the quality of patient care. As part of our strategy to combat racism, we have taken steps to further expand the number of Black-owned enterprises that provide supply chain services for our business in the U.S., and are also supporting small and diverse vendors by shortening our standard payment terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer competitive, performance-based compensation programs, recognizing that employee well-being, safety, culture, engagement and recognition are all critical to a healthy work environment and productive workforce. We offer programs that acknowledge, respect and support an individual&#8217;s life and work choices. Our holistic programs are guided by overall workforce health, focusing on physical, financial and emotional well-being as well as a healthy work environment. We believe that investing in employee well-being leads to improved performance for the individual and the organization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our broader rewards portfolio, we offer competitive pay and benefits that are flexible and affordable to meet the individual needs of our employees. In addition to cash-based salaries, our rewards portfolio includes cash bonus programs, sales incentives, stock awards, recognition awards, health insurance, paid time off and family leave, retirement savings plans, childcare and Employee Assistance Programs that encourage overall well-being, including help with finances, inclusive family planning and support, elder/child care, legal support and mental health resources.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equal pay for equal work is rooted in our values and foundational to fostering an inclusive environment. Pay equity is an important part of our long-standing global compensation planning practices. Sustaining pay equity requires constant measurement and attention, so we regularly conduct comprehensive audits, internal and external analyses and company-wide benchmarking of salaries to identify and eliminate disparities. In addition, we periodically contract with an independent, third party to assess pay equity across all positions. Our most recent pay equity study, completed in 2021, reported no statistically significant pay disparity for approximately 99 percent of our employees across gender globally and for multicultural talent in the U.S. and Puerto Rico. We continue to educate and train our people, update policies and expand benefits to decrease bias, increase gender and racial representation within our organization, and foster a culture where all employees feel valued and included.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Health and Safety</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a global approach to prioritizing and monitoring employee health and safety and we strive to foster a safety-oriented culture in all of our offices and facilities. We set health and safety goals which measure the number of injuries per 100 employees for the global organization. Our Employee Health &amp; Safety Global and Regional Councils review performance monthly to discuss trends and risks, as well as opportunities for improvement. We have obtained ISO 45001:2018 Occupational Health and Safety Management System at eight of our key global locations. This is a globally recognized standard for employee Occupational Health and Safety, established by the International Standards Organization, which provides a voluntary framework to identify key occupational health and safety aspects associated with our business helping to deliver continuous improvement. We have established a company-wide safety goal of 0.25 or fewer injuries per 100 employees by 2030, cutting our year-over-year incident rate by approximately 50 percent from a base year of 2019. As of December&#160;31, 2022, we have achieved a safety level of 0.28 per 100 employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Growth and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our people professionally is one of the most important things we do. We have robust succession planning to ensure our future leaders are ready to assume roles as they become available. At every level of the company, employees have access to training and tools they can use to advance their skills and expertise and create greater possibilities for their careers. We offer professional and technical courses, including on-the-job training, skills-based learning, mentoring opportunities and leadership development programs for high-potential employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek ongoing feedback from our employees to better understand what we are doing well and, conversely, how we can improve their experience. In addition to encouraging ongoing communication and feedback between employees and their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managers, we conduct periodic employee engagement surveys to ensure all employees have an opportunity to share their insights and we take appropriate action in response. As evidence of our commitment to foster employee engagement, we include these metrics within the ESG scorecard that forms part of our Annual Bonus Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Community Outreach</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are united by a goal to make a difference in the lives of the over 33&#160;million patients we serve annually. The Boston Scientific Caring value guides us in the work we do each day including how we invest in the well-being of communities. We work to advance possibilities in our three focus areas of health, STEM education and community. Our efforts evolve frequently as do the pressing needs of our communities. In 2022, we focused on supporting Ukrainian refugees, providing aid to those impacted by natural disasters and addressing the basic needs of underserved populations in communities where we live and work. In February 2023, we provided donations to charitable organizations providing earthquake relief efforts in T&#252;rkiye and Syria, including overnight stays, meals, hygiene items and critical emergency supplies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global community programs empowered employees to participate in and influence the way we care for local communities through volunteerism and personal donations. Many employees chose to support their communities through use of the Employee Matching Gifts program, which was doubled in 2022 on Giving Tuesday, the global day of giving that highlights the importance of supporting local communities around the world during the holiday season. Through employee contributions and the Boston Scientific match, a total of nearly $2&#160;million was donated in 2022. In February 2023, we launched an additional match campaign through our Employee Matching Gifts Program for aid to T&#252;rkiye and Syria and are also providing volunteer opportunities for our employees based in T&#252;rkiye to give back to their local communities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also collaborated with non-profit community organizations to decrease health disparities and reduce the risk for chronic disease for the underserved by increasing access to healthcare and screenings. Within many of the communities in which we operate, we have launched and funded a multi-year program to combat racism, inequity and injustice focused on five pillars: community, economic empowerment, education, healthcare disparities and government policies. We also continue our long-term Close the Gap initiative, which focuses on raising awareness and empowering healthcare providers to reach more patients of color, fight longstanding inequities, and address barriers to care. Through Close the Gap, hospitals and health systems are provided with zip code level data that highlight the disease prevalence and disparities occurring in their communities. The information, along with our health equity resources, allows health care administrators and providers to focus on improving care to underserved populations within their communities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also passionate about inspiring young learners to see themselves in a Science, Technology, Engineering and Math (STEM) roles in the future. Employees on our global STEM teams worldwide work with underrepresented K-12 students to share their passion for STEM by providing interactive product demos, development programs, and hands-on activities for young learners in their communities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net sales are influenced by many factors, including product launches, acquisitions, regulatory and reimbursement approvals, patient, physician and employee holiday schedules and other macro-economic conditions. While our consolidated net sales do not reflect any significant degree of seasonality, customer purchases of our medical devices have historically been lower in the first and third quarters of the year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available free of charge on our website (www.bostonscientific.com) as soon as reasonably practicable after we electronically file the material with or furnish it to the U.S. Securities and Exchange Commission (SEC). Additionally, the SEC maintains an internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Printed copies of these posted materials are also available free of charge to stockholders who request them in writing from Investor Relations, 300 Boston Scientific Way, Marlborough, MA 01752-1234. Information on our website or linked to our website is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Safe Harbor for Forward-Looking Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements that we may make from time to time, including statements contained in this Annual Report on Form 10-K and information incorporated by reference into this Annual Report on Form 10-K, constitute &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933 and Section&#160;21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;aim,&#8221; "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K are based on certain risks and uncertainties, including the risk factors described in Item&#160;1A under the heading &#8220;Risk Factors&#8221; and the specific risk factors discussed below and in connection with forward-looking statements throughout this Annual Report on Form 10-K, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Annual Report on Form 10-K.&#160;As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; the impact of the COVID-19 pandemic on our operations and financial results; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or may increase in significance or likelihood as a result of the COVID-19 pandemic.&#160;All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors&#160;contained within this Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A.&#160;Risk Factors&#160;in subsequent Quarterly Reports on Form 10-Q that we will file hereafter.&#160;We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.&#160;This cautionary statement is applicable to all forward-looking statements contained in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see Item 1A. Risk Factors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Businesses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The impact of the COVID-19 pandemic and economic conditions created in part by the pandemic on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Labor shortages and the impact of inflation on the cost of raw materials and direct labor,</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Risks associated with challenging or uncertain domestic and international economic conditions, including those related to rising interest rates, inflation, currency devaluations or economies entering into periods of recession,</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The impact of natural disasters, climate change, additional future public health crises and other catastrophic events on our ability to manufacture, distribute and sell our products,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variations in clinical results, reliability or product performance of our and our competitors' products, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effect of consolidation and competition in the markets in which we do business or plan to do business,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to attract and retain talent, including key personnel associated with recent acquisitions, and to maintain our robust corporate culture,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies, </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of potential goodwill and intangible asset impairment charges on our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Compliance, Litigation and Data Protection</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effect of global legal, regulatory or market responses to climate change, including increased compliance burdens and costs to meet regulatory obligations,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Costs and risks associated with current and future asserted litigation,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war, and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovation and Certain Growth Initiatives</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential failure to successfully integrate and realize the expected benefits, including cost synergies, from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in Emerging Markets such as Brazil, India and China,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">The impact of the Russia/Ukraine war and tension between China/Taiwan, and related, downstream effects thereof, including the impact of sanctions on U.S. manufacturers doing business in these regions,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protection of our intellectual property, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The impact of significant developments or uncertainties stemming from changes in the U.S. government following congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The possibility of counterparty default on our derivative financial instruments, and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost Reduction and Optimization Initiatives</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information contained in this Annual Report on Form 10-K and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. Our business, financial condition, cash flows or results of operations could be materially adversely affected by any of these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements set forth at the end of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K. The considerations and risks that follow are organized within relevant headings but may be relevant to other headings as well. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Challenging domestic and international economic conditions could adversely affect our business, financial condition, cash flows and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty around inflationary pressures, rising interest rates and monetary policy could potentially cause new, or exacerbate existing, economic challenges that we may face. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. If there were a general economic downturn, we may experience decreased customer spending or demand for our products and services, and our customers&#8217; ability to pay for our products on a timely basis, or at all, may be impacted. The same economic conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components, as well as the distributors and dealers who offer our products in certain countries and markets. Inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components. These adverse economic conditions or events could adversely affect our business, results of operations or financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, uncertainty about global economic conditions, including those resulting from credit and sovereign debt issues, has caused and may continue to cause disruption in the financial markets, including diminished liquidity and credit availability. These conditions may adversely affect our suppliers, leading them to experience financial difficulties or be unable to borrow money to fund their operations, which could cause disruptions in our ability to produce our products. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability or decision to purchase our products, particularly capital equipment, or to pay for our products that they purchase on a timely basis, if at all. In addition, we have accounts receivable factoring programs in certain European and Asian countries. Deterioration of the global economy or increase in sovereign debt issues may impact our ability to transfer receivables to third parties in certain of those countries. Third parties, such as banks, offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt. This could result in terminations of, or changes to the costs or credit limits of our existing factoring programs. Such terminations or changes could have a negative impact on our cash flow and days sales outstanding. Uncertain or challenging economic conditions could also lead to greater fluctuations in foreign currency exchange rates, which could adversely impact our results of operations and financial performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that there will not be further deterioration in the global economy. Accordingly, we cannot predict to what extent global economic conditions, including negative or uncertain economic conditions, sovereign debt issues and increased focus on healthcare systems and costs in the U.S. and abroad, may impact negatively our average selling prices, net sales and profit margins, operations, procedural volumes and reimbursement rates from third party payers. In addition, economic and financial market conditions, including rising interest rates, and other factors beyond our control may adversely affect our ability to borrow money in the credit markets, access the capital markets and obtain financing for mergers and acquisitions (M&amp;A) or other general purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device markets in which we participate are highly competitive. We encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies. Some of our competitors may have greater financial and marketing resources than we do, including as a result of consolidation among companies in our industry. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market segment or segments. We also face competition from non-medical device companies, including pharmaceutical companies and providers of various diagnostic tests, which may offer alternative therapies or diagnostics for disease states also amenable to treatment or diagnosis using our products. New competitors may emerge in the future, potentially including companies introducing new sales or distribution models to our industry or leveraging genomic robotic, navigation, and/or other automation technologies. Digital technologies have and may continue to increase in their applicability and importance to various aspects of our business, operating and competitive environments, R&amp;D pipeline and product portfolio. We believe we will need to develop new and enhanced digital capabilities and competences in order to remain competitive.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the medical device markets in which we participate are characterized by extensive research and development and rapid technological change. Developments by other companies of products and/or services, processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales. It is necessary for us to devote continued efforts and financial resources to the development or acquisition of scientifically advanced technologies and products. In addition, we will need to apply our technologies cost-effectively across product lines and markets, obtain patent and other protection for our technologies and products, obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards. If we fail to develop or acquire new products or enhance existing products, such failure could have a material adverse effect on our business, financial condition or results of operations. In addition, a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician confidence in, those products may result in declines in our market share and have an adverse impact on our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience declines in market size, average selling prices for our products, medical procedure volumes and our share of the markets in which we compete, which may materially adversely affect our results of operations and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to experience pressures across many of our businesses due to competitive activity, increased market power of our customers as the healthcare industry consolidates, national and regional government tenders, economic pressures experienced by our customers, staffing shortages within healthcare facilities that have and may continue to negatively impact demand for our products, public perception of our products, and the impact of managed care organizations and other third-party payers. These and other factors may adversely impact market sizes, as well as our share of the markets in which we compete, the average selling prices for our products or medical procedure volumes. There can be no assurance that the size of the markets in which we compete will increase, that we will be able to hold or gain market share or compete effectively on the basis of price or that the number of procedures in which our products are used will increase. Decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continued consolidation in the healthcare industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous initiatives and reforms by legislators, regulators and third-party payers to curb the rising cost of healthcare, and to increase access to care, have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products. Additionally, a growing number of countries have instituted or are contemplating introducing regional or national tender processes driven primarily by price. In some cases, such processes may favor local companies to multinational companies like Boston Scientific. In other instances, multinationals may be subject to a separate tender bidding process in which they compete only with each other and not with domestic companies. Further, in certain markets, the regulatory process through which new medical devices are approved may be faster and/or less burdensome for domestic companies compared to multinationals. As the healthcare industry consolidates, competition to provide products and services is expected to continue to intensify, resulting in pricing pressures, decreased average selling prices and the exclusion of certain suppliers from important market segments. We expect that market demand, government regulation, third-party coverage and reimbursement policies, government contracting requirements and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may increase competition, exert further downward pressure on the prices of our products and services and may adversely impact our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare cost containment pressures, government payment and delivery system reforms, changes in private payer policies, and marketplace consolidations could decrease the demand for our products, the prices which customers are willing to pay for those products and/or the number of procedures performed using our devices, which could have an adverse effect on our business, financial condition or results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs, authorities or agencies (e.g., Medicare and Medicaid in the U.S.) and private health plans, for the healthcare supplies and services provided to their patients. Governments and payers may institute changes in healthcare delivery or payment systems that may reduce funding for services or encourage greater scrutiny of healthcare costs. The ability of customers to obtain appropriate reimbursement for their products and services is critical to the success of medical technology companies because it affects which products customers purchase and the prices they are willing to pay. Reimbursement and funding vary by country and can significantly impact the acceptance of new products and technologies and the use of established products and technologies. We may find limited demand for otherwise promising new products unless reimbursement approval is obtained from private and governmental third-party payers. Further legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduce or eliminate reimbursement for procedures using our medical devices, including price regulation, site of service requirements, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, heightened clinical data requirements, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geopolitical Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International net sales accounted for 40 percent of our global net sales in 2022. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to our use of channel partners, go-to-market strategies, geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in healthcare financing and payment systems and healthcare delivery systems, local product preferences and requirements, including preferences for local manufacturers, workforce instability, weaker intellectual property protection in certain countries than exists in the U.S. and longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold. Most foreign countries have medical device regulations. Further, most countries outside of the U.S. require product approvals be renewed or re-certified on a regular basis in order to continue to be marketed and sold there. In addition, several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded, or plan to expand, existing regulations, including requiring local clinical data in addition to global clinical data. These factors have caused or may cause us to experience more uncertainty, risk, expense and delay in obtaining approvals and commercializing products in certain jurisdictions, which could adversely impact our net sales, market share and operating profits from our international operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, international markets are affected by economic pressure to contain healthcare costs, which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used. Governments and payers may also institute changes in healthcare delivery systems that may reduce funding for services, seek payback from market participants, or encourage greater scrutiny of healthcare costs. In addition, certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries. All of these types of changes may ultimately reduce selling prices of our products and/or reduce the number of procedures in which our products are used, which may adversely impact our net sales, market share and operating profits from our international operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their international operations. Any alleged or actual failure to comply with legal and regulatory requirements may subject us to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government scrutiny, civil and/or criminal proceedings, sanctions and other liabilities, which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The US-China relationship will continue to shape the geopolitical stage. Legislation aimed at boosting competitiveness of U.S. businesses may have unintended effects on our business. We may also face greater competition in China, among other countries, from domestic medical device companies that may benefit from their status as local manufacturers and suppliers. Ultimately, tariffs and other protectionist measures, as well as prolonged uncertainty, may have adverse effects on our ability to source and manufacture products in a timely and cost effective manner, thereby adversely affecting our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, sanctions and export restrictions are expected to continue to proliferate, leading to greater uncertainty in emerging and growth markets. Notably the Russia/Ukraine war has created barriers to doing business in Russia, and the tension between China/Taiwan has created geopolitical shifts in Asia. Any significant changes in the political, economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Financial Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our debt levels, maintain investment grade credit ratings at the three ratings agencies, or if we experience a disruption in our cash flows, it could have an adverse effect on our cost of borrowing, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy to maximize stockholder value, we use financial leverage to manage our cost of capital. Our outstanding debt balance was $8.935 billion as of December&#160;31, 2022. Although we currently have investment grade ratings at Moody's Investor Service, Standard &amp; Poor's Rating Service and Fitch Ratings, our inability to maintain investment grade credit ratings could increase our cost of borrowing funds in the future and reduce our access to liquidity. Uncertain or negative economic conditions, as well as rising interest rates, could also increase our cost of borrowing in the future or reduce our access to liquidity. Delays in our product development and new product launches could result in disruption in our cash flow or our ability to continue to effectively manage our debt levels, which could have an adverse effect on our cost of borrowing, financial condition or results of operations. In addition, our credit agreements contain a financial covenant that require us to maintain a minimum specified leverage ratio and place other limits on our business. If we are unable to satisfy this covenant, we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demand. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may record future intangible asset impairment charges related to one or more of our global reporting units, which could materially adversely impact our results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level. We also test our indefinite-lived intangible assets at least annually, or more frequently if impairment indicators are present, and we review intangible assets subject to amortization quarterly for impairment. In evaluating the potential for impairment, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and other intangible assets. Relatively small declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or small changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to integrate acquired businesses into our operations successfully could adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy to realign our business portfolio, we have completed multiple acquisitions in recent years and may pursue additional acquisitions in the future. Our integration of acquired businesses requires significant efforts, including corporate restructuring and the coordination of information technologies, research and development, sales and marketing, operations, regulatory, supply chain, manufacturing, quality systems and finance. These efforts result in additional expenses and involve significant management time. Some of the factors that could affect the success of our acquisitions include, among others, the effectiveness of our due diligence process, our ability to execute our business plan for the acquired companies, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strength of the acquired technology, results of clinical trials, regulatory approvals and reimbursement levels of the acquired products and related procedures, the continued performance of critical transition services, our ability to adequately fund acquired in-process research and development projects and retain key employees and our ability to achieve synergies with our acquired companies, such as increasing sales of our products, achieving cost savings and effectively combining technologies to develop new products. In addition, foreign acquisitions involve unique risks, including those related to integration of operations across different geographies, cultures and languages, currency risks and risks associated with the economic, political, legal and regulatory environment in specific countries. Our failure to manage successfully and coordinate the growth of the acquired companies could have an adverse impact on our business and our future growth. In addition, we cannot be certain that the businesses we acquire will become profitable or remain so, and if our acquisitions are not successful, we may record related asset impairment charges in the future or experience other negative consequences on our operating results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our strategy relating to future strategic acquisitions of, investments in, or alliances with, other companies and businesses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic acquisitions, investments and alliances are intended to further expand our ability to offer customers effective, high quality medical devices. We face competition for acquisitions from other healthcare and non-healthcare acquirers, financial sponsors, and from the market for Initial Public Offerings (IPOs). Some of our competitors in the medical device sector may have access to substantially greater amounts of cash than we do that could be deployed into M&amp;A or strategic investments if they so choose. The market for IPOs may also reduce the opportunities available to us for M&amp;A and/or cause us to need to pay higher prices. If we are unsuccessful in our acquisitions, investments and alliances, it may adversely impact our ability to grow our business. Any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing, depending on their size or nature. The success of our strategy relating to future acquisitions, investments or alliances will depend on a number of factors, including our ability to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify suitable opportunities for acquisition, investment or alliance, if at all,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage acquisition, investment or alliance opportunities within our capital capacity and prioritize those investments to execute on our strategy, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our due diligence process to uncover potential issues with targets,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">finance any future acquisition, investment or alliance on terms acceptable to us, if at all,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete acquisitions, investments or alliances in a timely manner on terms that are satisfactory to us, if at all, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully integrate and operate acquired businesses,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully identify and retain key target employees,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply with applicable laws and regulations, including foreign laws and regulations, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protect intellectual property and prevail in litigation related to newly acquired technologies.&#160;</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the expected benefits from our restructuring and optimization initiatives, our long-term cost savings programs may result in an increase in short-term expenses and our efforts may lead to unintended consequences. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the dynamics of the economy, the healthcare industry and the markets in which we compete, and assess opportunities for improved operational effectiveness and efficiency and to better align expenses with revenues, while preserving our ability to make investments in research and development projects, capital and our people, which we believe is important to our long-term success. As a result of these assessments, we have undertaken prior restructuring and optimization initiatives to enhance our growth potential and position us for long-term success. On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan) intended to support our efforts to expand operating performance and meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Restructuring Plan will </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further build on our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expanding operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">optimizing certain functional capabilities to better support business growth and achieve cost synergies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025. The 2023 Restructuring Plan is expected to result in total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million by the end of 2025 as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs. These measures could yield unintended consequences, such as distraction of our management and employees, reduced employee productivity, business disruption, and inability to attract or retain key personnel, which could negatively affect our business, sales, financial condition and results of operations. Moreover, our restructuring and optimization initiatives result in charges and expenses which impact </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operating results. We cannot guarantee that the activities under our restructuring plans or other optimization initiatives will result in the desired efficiencies and estimated cost savings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth is dependent upon the development of new products and enhancement of existing products, which requires significant research and development, clinical trials and regulatory approvals, all of which may be very expensive and time-consuming and may not result in commercially viable products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to develop new products and enhance existing products, we focus our research and development programs largely on the development of next-generation and novel technology offerings across multiple programs and businesses. The development of new products and enhancement of existing products requires significant investment in research and development, clinical trials and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and develop new products, complete clinical trials, obtain regulatory approvals and reimbursement in the U.S. and abroad, manufacture products in a cost-effective manner, obtain appropriate intellectual property protection for our products and gain and maintain market approval of our products. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products and enhanced products, our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted. Further, we are continuing to investigate and have completed several acquisitions that involve opportunities to further expand our presence in and diversify into, priority growth areas by accessing new products and technologies. There can be no assurance that our investments will be successful or that we will be able to access new products and technologies on terms favorable to us, or that these products and technologies will achieve commercial feasibility, obtain regulatory approval or gain market acceptance. A delay in the development or approval of new products and technologies or our decision to reduce or terminate our investments may adversely impact the contribution of these technologies to our future growth.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain products or groups of products, in particular new products or enhancements of existing products, may have a disproportionate impact on our business, financial condition and results of operations. Failure to meet growth projections, poor clinical outcomes, increasing regulatory requirements, launch delays and inability to effectively scale manufacturing and achieve targeted margins with respect to any of these products or groups of products in particular may materially adversely impact on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The global COVID-19 pandemic and related impacts have had, and could in the future have, an adverse effect on our operations, financial performance and cash flows. We are unable to predict the extent to which the pandemic or a similar health crisis and related impacts may adversely impact our business operations, financial performance, results of operations, financial position and the achievement of our strategic objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, financial performance and cash flows have been, and could in the future continue to be, negatively impacted by the COVID-19 pandemic and the risks and challenging macroeconomic conditions caused by the pandemic, including, but not limited to, disruptions in economic activity, global supply chains and labor markets, operational challenges such as site shutdowns, workplace disruptions or limited provider capacity to perform procedures using our products that were deferred as a result of the pandemic, volatile financial market dynamics and significant volatility in price and availability of goods and services. These and other risks and uncertainties related to the COVID-19 pandemic and its related impacts could adversely affect our business operations, financial position, results of operations and the achievement of strategic objectives. Because the severity, magnitude, and ultimate duration of the COVID-19 pandemic, or similar health crisis, and its economic consequences are uncertain, subject to rapid change, and difficult to predict, the pandemic&#8217;s future potential impact on our business, results of operations and financial performance remains uncertain and difficult to predict. Further, the ultimate impact of the COVID-19 pandemic or similar health crisis on our results of operations and financial performance depends on many factors that are not within our control, including, but not limited, to: governmental, business and individuals&#8217; actions that have been and in the future may be taken in response to the pandemic or similar public health crises, the impact of the pandemic and actions taken in response on global and regional economies, general economic uncertainty in key global markets and financial market volatility, global economic conditions and levels of economic growth; and any continuing economic effects of the COVID-19 pandemic even after it has subsided. The COVID-19 pandemic and related impacts may also have the effect of heightening many of the other risks described in the risk factors in this Annual Report on Form 10-K. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruption of our supply chain or manufacturing operations, including resulting from natural disasters, further public health crises and other catastrophic events or other events outside of our control, could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations. Factors such as a failure to follow specific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. In the event of an interruption in manufacturing, we may be unable to quickly move to alternate means of producing affected products or to meet customer demand. In the event of a significant interruption, for example, as a result of a failure to follow regulatory protocols and procedures, we may experience lengthy delays in resuming production of affected products due primarily to needs for regulatory approvals. As a result, we may experience loss of market share, which we may be unable to recapture and harm to our reputation, which could adversely affect our results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions in the supply of the materials and components used in manufacturing our products by third-party vendors or the sterilization of our products could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase the majority of the materials and components used in manufacturing our products from third-party vendors. Certain of these materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements. In certain cases, we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner, largely as a result of FDA regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors' manufacturing processes. Further, uncertain or negative economic conditions, including as a result of inflationary pressures, rising interest rates or impacts from the COVID-19 pandemic, could negatively affect our third-party vendors, which could lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components. A reduction or interruption in the supply of materials and components used in manufacturing our products, an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service. To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, we may be unable to transition to alternative internal or external resources or methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to attract or retain key talent, it could have an adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our industry, there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees. Our business depends to a significant extent on the continued service of senior management and other key personnel, the development of additional management personnel and the hiring of new qualified employees. There can be no assurance that we will be successful in retaining and developing existing personnel or recruiting new personnel. The loss of one or more key employees, our ability to attract or develop additional qualified employees or any delay in hiring key personnel could have material adverse effects on our business, financial condition or results of operations. Additionally, the COVID-19 pandemic has given rise to conditions that have created a highly competitive environment for talent. A shortage of skilled labor could also require higher wages that would increase labor costs. Our ability to attract and retain key talent at all levels of our organization has been and could continue to be challenged by these conditions, and inability to attract and retain talent could result in material adverse impacts to our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare policy changes may have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political, economic and policy influences are leading the healthcare industry to make substantial structural and financial changes that will continue affecting our results of operations. Government and private sector initiatives aimed at limiting the growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness of therapies, technology assessments, increasing price transparency and reforming healthcare delivery and payment structures, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to put increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources and evidence necessary to demonstrate value to our customers, patients, payers and other stakeholders may be significant, and it may take a significant period of time to gain widespread adoption. Moreover, there can be no assurance that our strategies will succeed for every product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the specific healthcare programs and regulations that will be ultimately implemented by various regional and national governments. However, any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes and/or increase cost containment pressures on us or others in the healthcare sector could adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive and dynamic medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act (FDC Act), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the FDC Act, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the EU, we are required to comply with the new Medical Device Regulation (MDR or EU MDR) effective May 2021 which supersedes the Medical Device Directives. Medical devices which have a valid CE Certificate to the current Directives (issued before May 2021) can continue to be sold until the earlier of May 2024 or when the CE Certificate expires, providing there are no significant changes to the design or intended use. Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). The CE Mark is applied following approval from an independent notified body or declaration of conformity. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products, or with respect to enhancements or modifications to existing products, could:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant period of time,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous pre-clinical and clinical testing, as well as increased post-market surveillance,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require changes to products and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in limitations on the indicated uses of products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country of origin or legal manufacturer first. Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every four to five years. The renewal or recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance. Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling our products in those countries. There can be no assurance that we will receive the required approvals for new products or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post-market study requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals, as well as the clinical and regulatory costs of supporting those approvals. Several countries that did not previously have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations. Certain regulators are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. While harmonization of global regulations has been pursued, requirements continue to differ significantly among countries. We expect this global regulatory environment will continue to evolve, which could impact our ability, or increase the time and cost, to obtain future approvals for our products. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices, recordkeeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA can take action against a company that promotes "off-label" uses. The FDA may also enjoin and restrain a company for certain violations of the FDC Act and other amending laws pertaining to medical devices, or initiate action for criminal prosecution of such violations. Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing and selling its products, may limit a company's ability to obtain future premarket clearances or approvals and could result in a substantial modification to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business practices and operations. International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations regarding the development, manufacture and sale of medical devices are evolving and subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Later discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. We may also initiate field actions as a result of a failure to strictly comply with our internal quality policies. The failure to receive product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are continually subject to clinical trials and other analyses conducted by us, our competitors or other third parties, the results of which may be unexpected, or perceived as unfavorable by the market, and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Unexpected or inconsistent clinical data from existing or future clinical trials or other analyses conducted by us, by our competitors or by third parties, including acquired businesses prior to acquisition by us, or the FDA's or the market's perception of this clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate and our business, financial condition, results of operations or future prospects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations, often involving marketing and other business practices or product quality issues including device recalls or advisories. These investigations could result in the commencement of civil and criminal proceedings; imposition of substantial fines, penalties and administrative remedies, including corporate integrity agreements, stipulated judgments or exclusion; diversion of our employees' and management's attention; imposition of administrative costs and have an adverse effect on our financial condition, results of operations and liquidity; and may lead to greater governmental regulation in the future.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. These authorities continue to closely scrutinize our industry. We have received and in the future may receive, subpoenas and other requests for information from Congress and state and federal governmental agencies, including, among others, the U.S. Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (HHS) and the Department of Defense, as well as from foreign governments and agencies. The requests and/or subpoenas we have received relate primarily to financial arrangements with healthcare providers, regulatory compliance and sale and/or product promotional practices. We have cooperated with these subpoenas and other requests for information and expect to continue to do so in the future. We cannot predict when a matter will be resolved, the outcome of the matter or its impact on us and cooperation may involve significant costs, including document production costs. An adverse outcome in any matter could include the commencement of an investigation, civil and criminal proceedings, substantial fines, penalties and administrative remedies, including exclusion from government reimbursement programs, entry into Corporate Integrity Agreements (CIAs) with governmental agencies and amendments to any existing CIAs. In addition, resolution of any matter could involve the imposition of additional and costly compliance obligations. Cooperation with requests and investigations from external agencies result in employee resource costs and diversion of employee focus. If any requests or investigations continue over a long period of time, they could divert the attention of management from the day-to-day operations of our business and impose significant additional administrative burdens on us. These potential consequences, as well as any adverse outcome from these requests or investigations, could have a material adverse effect on our financial condition, results of operations and liquidity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain foreign governments, state governments (including that of Massachusetts, where we are headquartered) and the U.S. federal government have enacted legislation aimed at increasing transparency of our interactions with healthcare providers. As an example, compliance with the U.S. Physician Payment Sunshine Act requires us by law to disclose payments and other transfers of value to all U.S. physicians and U.S. teaching hospitals at the U.S. federal level made after August 1, 2013. Any failure to comply with these legal and regulatory requirements could impact our business. In addition, we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure, policies, systems and processes to comply with enhanced legal and regulatory requirements, which may also impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal cost and exposure to litigation and have additional adverse effects on our operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes as well as non-income based taxes and tariffs, in the U.S. and numerous foreign jurisdictions. We are subject to ongoing tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under European Union state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws and regulations, or their interpretation and application, in the jurisdictions where we are subject to tax could materially impact our effective tax rate. The U.S. enacted the Tax Cuts and Jobs Act (TCJA) on December 22, 2017 and the Inflation Reduction Act on August 16, 2022. We expect the U.S. Treasury to issue future notices and regulations regarding the application and interpretation of these laws which could have a significant impact on our future results of operations as could interpretations made by the Company in the absence of regulatory guidance and judicial interpretations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group of Twenty (G20), the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD/G20 Inclusive Framework (IF) on base erosion and profit shifting (BEPS) includes actions intended to equip governments with domestic and international rules and instruments to address tax avoidance, ensuring that profits are taxed where economic activities generating the profits are performed and where value is created. The actions include a two-pillar solution to address the tax challenges of the digitalized economy. Pillar One focuses on how profits are allocated between taxing jurisdictions and Pillar Two creates a 15% global minimum tax.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2022 South Korea became the first country to enact Pillar Two into national law. On December 15, 2022, the Council of the (EU) European Union unanimously adopted a directive intended to provide EU member states a framework to implement the Pillar Two global minimum tax into their national laws by 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional countries including the United Kingdom and Japan are taking steps to implement Pillar Two into their national law. Currently, significant uncertainty exists regarding the detailed Pillar Two rules, whether such rules will be implemented consistently across taxing jurisdictions, how such rules interact with existing national tax laws and whether such rules are consistent with existing tax treaty obligations. Accordingly, the final adoption, implementation, and interpretation of Pillar Two across all jurisdictions where we do business could have a material adverse impact on our financial position, results of operations, and cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could have a material adverse effect on our business. Furthermore, changes in customs laws and regulations in the U.S. and various foreign jurisdictions could have a material impact on our results of operations or financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in Puerto Rico, Costa Rica and Malaysia presently benefit from various tax incentives and grants. Unless these incentives and grants are extended, they will expire between 2027 and 2034. If we are unable to renew, extend, or obtain new incentive and grants, the expiration of the existing incentives and grants could have a material impact on our financial results in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not effectively be able to protect our intellectual property or other sensitive data, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. Physician customers have historically moved quickly to new products and new technologies. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. However, intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court decisions. Furthermore, as our business increasingly relies on technology systems and infrastructure, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation. Finally, our ability to protect novel business models is uncertain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competing parties in our industry frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only of individual cases, but also of a series of pending and potentially related and unrelated cases. In addition, although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of third parties have asserted that our current and former product offerings infringe patents owned or licensed by them. We have similarly asserted that products sold by our competitors infringe patents owned or licensed by us. Adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions, or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition, results of operations or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are and will continue to be essential to our business, and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies. We rely upon trade secrets, know-how, continuing technological innovations, strategic alliances, and licensing opportunities to develop, maintain and strengthen our competitive position. We pursue a policy of generally obtaining patent protection in both the U.S. and abroad for patentable subject matter in our proprietary devices and attempt to review third-party patents and patent applications to the extent publicly available in order to develop an effective patent strategy, avoid infringement of third-party patents, identify licensing opportunities and monitor the patent claims of others. We own numerous U.S. and foreign patents and have numerous patent applications pending. We also are party to license agreements pursuant to which patent rights have been obtained or granted in consideration for cash, cross-licensing rights or royalty payments. No assurance can be made that any pending or future patent applications will result in the issuance of patents, that any current or future patents issued to, or licensed by, us will not be challenged or circumvented by our competitors, or that our patents will not be found invalid. In addition, we may have to take legal action in the future to protect our patents, trade secrets or know-how or to assert them against claimed infringement by others. Any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful. We are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual property-related actions. The invalidation of key patents or proprietary rights that we own, or an unsuccessful outcome in lawsuits to protect our intellectual property, could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the laws of certain countries in which we market and plan on manufacturing some of our products in the near future, do not protect our intellectual property rights to the same extent as the laws of the U.S. If we are unable to protect our intellectual property in these countries, it could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses and unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. While we have invested to protect our intellectual property, products and other data and continue to work diligently in this area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber-attacks or other events. Such events could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending and future intellectual property litigation could be costly and disruptive to us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an industry that is susceptible to significant intellectual property litigation and, in recent years, it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies. We are currently the subject of various patent litigation proceedings and other proceedings described in more detail under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intellectual property litigation is expensive, complex and lengthy and its outcome is difficult to predict. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial condition, results of operation or liquidity. Pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel. In the event that our right to market any of our products is successfully challenged, we may be required to obtain a license on terms which may not be favorable to us, if at all. If we fail to obtain a required license or are unable to design around a patent, our business, financial condition or results of operations could be materially adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending and future product liability claims and other litigation, including private securities litigation, stockholder derivative suits and contract litigation, may adversely affect our financial condition and results of operations or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, manufacturing and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims. Many of the medical devices that we manufacture and market are designed to be implanted in the human body for long periods of time or indefinitely. A number of factors could result in an unsafe condition or injury to, or death of, a patient with respect to these or other products that we manufacture or sell, including physician technique and experience in performing the surgical procedure, component failures, manufacturing flaws, design defects, off-label use or inadequate disclosure of product-related risks or product-related information. These factors could result in product liability claims, a recall of one or more of our products or a safety alert relating to one or more of our products. Product liability claims may be brought by individuals or by groups seeking to represent a class.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently the subject of product liability litigation proceedings and other proceedings described in more detail under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any future litigation may be significant. Product liability claims, securities and commercial litigation and other litigation in the future, regardless of the outcome, could have a material adverse effect on our financial condition, results of operations or liquidity. Additionally, we maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The fact that we do not maintain third-party insurance coverage for all categories of losses increases our exposure to unanticipated claims and adverse decisions and these losses could have a material adverse effect on our financial condition, results of operations or liquidity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a medical device manufacturer, we are required to register our establishments and list our devices with the FDA and are subject to periodic inspection by the FDA for compliance with its Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the Federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA which may result in observations on Form&#160;483 and in some cases warning letters that require corrective action. In the European Community, we are required to maintain certain International Standards Organization (ISO)&#160;certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Many other countries in which we do business have similar requirements and other foreign governments or agencies may subject us to periodic inspections.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our manufacturers, fail to adhere to quality system regulations or ISO requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology (IT) and operational technology (OT) systems, including technology from third party vendors, manufacture and ship our products, as well as to process, transmit and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our IT systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Various other factors may also cause system failures or security breaches, including power outages, natural disasters, inadequate or ineffective backups, issues with upgrading or creating new systems or platforms, vulnerabilities in third-party software or services, errors by our staff or third-party service providers, or breaches in the security of these technologies. Malicious actors may attempt to trick staff to disclose information to gain access to our systems and/or data. If our incident response, disaster </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recovery, and business continuity plans fail, they could result in adverse impacts to our business operations and our financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information and changing customer patterns. In addition, third parties have and may continue to attempt to hack into our products to obtain data relating to patients, or alter the intended functionality of our medical devices, or disrupt performance of our products, or access our proprietary information and the technology from third party vendors that we rely upon may have defects or vulnerabilities which, in turn, create vulnerabilities or disruptions in our system. Cyber-attacks continue to evolve in complexity and scope, and inherently may be difficult to detect. We have seen, and could continue to see, software and supply-chain vulnerabilities and malware, which could affect our systems and the systems of our third-party vendors and business partners</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure by us to maintain or protect our IT or OT systems, products and data integrity, including from cyber-attacks, intrusions or other breaches, could result in outages or unauthorized access to patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations, or, in the worst case, could result in harm to patients. In addition, such attackers may make demands for ransom, which could result in financial loss, or, if we determine not to pay such ransom, other harm, loss, or misappropriation of our data and assets. Such failure, or demonstration of vulnerability to such failure, may also result in additional regulatory scrutiny. We also grow our company through acquisitions and may face risks associated with defects and vulnerabilities in their systems as we work to integrate the acquisitions into our IT system. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state privacy and security laws require certain parts of our operations to protect the confidentiality of personal information including patient medical records and other health information, and to comply with other requirements with respect to personal data. In Europe, the Data Protection Directive requires us to manage individually identifiable information in the EU and, the General Data Protection Regulation (GDPR) may impose fines of up to four percent of our global revenue. Internationally, some countries have also passed laws that require individually identifiable data on their citizens to be maintained on local servers and that may restrict transfer or processing of that data. We strive to meet the expectations of applicable regulations, however, there is no guarantee that we will avoid enforcement actions by governmental bodies or civil actions based on this growing body of regulations. Enforcement actions could be costly and interrupt regular operations of our business. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other healthcare professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations are subject to risks related to climate change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, customers, and other business partners, which could cause disruption in our business and operations or increase costs to operate our business. Additionally, increased environmental regulation, including to address climate change, may result in increases in our costs to operate our business or restrict certain aspects of our activities. The extent and severity of climate change impacts are unknown, and therefore, the scope of potential impact on our business may be difficult to predict and it may be difficult to adequately prepare.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business could be negatively impacted by corporate social responsibility and sustainability matters.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, there has been an increased focus from certain investors, customers, employees, and other stakeholders concerning corporate social responsibility and sustainability matters. From time to time, we announce certain initiatives, including goals, regarding our focus areas, which include environmental matters, including carbon emissions and renewable energy goals, responsible sourcing, social investments and diversity, equity and inclusion. We may fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could fail in accurately reporting our progress on such initiatives and goals. Such failures could be due to changes in our business. Moreover, the standards by which corporate social responsibility and sustainability efforts and related matters are measured are developing and evolving, and certain areas are subject to assumptions that could change over time. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Any such matters, or related corporate social responsibility </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and sustainability matters, could have a material adverse impact on our future results of operations, financial position and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our world headquarters is located in the U.S, in Marlborough, Massachusetts, with principal regional headquarters located in Singapore and Voisins-le-Bretonneux, France. As of December&#160;31, 2022, we maintained 15 principal manufacturing facilities, including eight in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, and one in Brazil, as well as various distribution and technology centers around the world. Many of these facilities produce and manufacture products for more than one of our divisions, and also perform research activities. Our products are distributed worldwide from primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan. The following is a summary of our facilities as of December&#160;31, 2022 (in approximate square feet):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,043,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,467,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,065,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,532,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes our principal manufacturing facilities in Minnesota, Ireland, Puerto Rico and Coyol, Costa Rica, our manufacturing facility in Malaysia, our primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan, as well as our global headquarters located in Marlborough, Massachusetts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes our principal manufacturing facilities in California, Indiana, Brazil and Heredia, Costa Rica, as well as our regional headquarters located in Singapore and Voisins-le-Bretonneux, France.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_28"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-Kand incorporated herein by reference.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Market Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal market on which our common stock is traded is the New York Stock Exchange (NYSE)&#160;under the symbol &#8220;BSX.&#8221; </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Holders of Record</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 5,752 holders of record of our common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not pay a cash dividend in 2022, 2021 or 2020 on our common stock and currently we do not intend to pay cash dividends on our common stock. We may consider declaring and paying a cash dividend in the future; however, there can be no assurance that we will do so.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Item 12. "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" under Part III of this Annual Report on Form 10-K for information on where to find information required by Item 201(d) of Regulation S-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchases of Equity Securities by the Issuer and Affiliated Purchases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved, and we announced, a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock (2020 Share Repurchase Program). We made no share repurchases in 2022 or 2021 and, as of December&#160;31, 2022, had the full $1.000 billion remaining available under the 2020 Share Repurchase Program. Refer to Note J &#8211; Stockholders' Equity to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no purchases of equity securities by the issuer or affiliated purchases in the fourth quarter of 2022, required to be reported here.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the five-year total return to stockholders on our common stock with the return of the Standard &amp; Poor&#8217;s (S&amp;P) 500 Stock Index and the S&amp;P Healthcare Equipment Index. The graph assumes $100 was invested in our common stock and in each of the named indices on December&#160;31, 2017 and that any dividends were reinvested.</span></div><div style="margin-top:10pt;text-align:justify"><img src="bsx-20221231_g1.jpg" alt="bsx-20221231_g1.jpg" style="height:646px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note: The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. RESERVED </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Boston Scientific Corporation and its subsidiaries for the years ended December&#160;31, 2022 and 2021. For a full understanding of our financial condition and results of operations, this discussion should be read in conjunction with our consolidated financial statements and accompanying notes included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our financial condition and results of operations for the year ended December&#160;31, 2020, refer to our previously filed Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic Trends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty around inflationary pressures, rising interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, as well as the tension between China/Taiwan, may create economic, supply chain, energy, and other challenges, which impact, and may in the future negatively impact our business. In particular, international conflicts may result in sanctions, tariffs, and other measures that restrict international trade and negatively affect our business operations and results. In 2022, we experienced increases in cost and limited availability of raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. In 2023, we expect the impact of macroeconomic and supply chain conditions on our business to be similar to 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19, including all additional variations and strains thereof, a global pandemic (COVID-19 pandemic). Economic conditions created in part by the COVID-19 pandemic, have had, and may in the future have, a negative impact on our profitability. Further, the resurgence of COVID-19 infections and the emergence of new, more contagious variant strains of COVID-19, as well as staffing shortages within healthcare facilities, may negatively impact demand for our products, net sales, gross profit margin and operating expenses as a percentage of net sales. While the COVID-19 pandemic and related impacts may continue to negatively impact our performance to an extent, we continue to believe our long-term fundamentals remain strong and we intend to manage through these challenges with strategic focus and the winning spirit of our global team. </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Highlights and Trends</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we generated net sales of $12.682 billion, compared to $11.888 billion&#160;in 2021. This increase of $794 million, or 6.7 percent, included operational</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth of 11.1 percent and the negative impact of 440 basis points from foreign currency fluctuations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational net sales growth included organic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net sales growth of 8.7 percent in 2022 and the positive impact of 240 basis points from our acquisitions of Preventice Solutions, Inc. (Preventice), Farapulse, Inc. (Farapulse), the global surgical business of Lumenis, LTD (Lumenis) and Baylis Medical Company Inc. (Baylis Medical) for which there is less than a full period of comparable net sales. The increase in our net sales was primarily driven by recent acquisitions as well as the strength and diversity of our product portfolio coupled with growth in the underlying markets in which we compete and strong commercial execution. Refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business and Market Overview</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for further discussion of our net sales by global business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported net income available to common stockholders in 2022 was $642 million, or $0.45 per diluted share. Our reported results for 2022 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.816 billion (after-tax), or $1.26 per diluted share. Excluding these items, adjusted net income available to common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 2022 was $2.459 billion, or $1.71 per diluted share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported net income available to common stockholders in 2021 was $985 million, or $0.69 per diluted share. Our reported results for 2021 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.351 billion (after-tax), or $0.94 per diluted share. Excluding these items, adjusted net income available to common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 2021 was $2.336 billion, or $1.63 per diluted share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operational net sales growth rates, which exclude the impact of foreign currency fluctuations, and other adjusted measures, including organic net sales, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Additional Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for a discussion of management&#8217;s use of these non-GAAP financial measures. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of each reconciling item:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (Loss) Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Expense (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock Dividends</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income (Loss) Available to Common Stockholders</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impact per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reported</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition/divestiture-related net charges (credits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and restructuring-related net charges (credits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation-related net charges (credits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment portfolio net losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Union (EU) Medical device regulation (MDR) implementation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax expenses (benefits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discrete tax items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (Loss) Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Expense (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock Dividends</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income (Loss) Available to Common Stockholders</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impact per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reported</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition/divestiture-related net charges (credits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and restructuring-related net charges (credits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation-related net charges (credits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment portfolio net losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Union (EU) Medical device regulation (MDR) implementation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax expenses (benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discrete tax items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> For 2022 and 2021, the effect of assuming the conversion of our Series A 5.5% Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> and Adjusted net income were reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, as presented in our consolidated statements of operations, for purposes of calculating GAAP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income (loss) available to common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Market Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices into two reportable segments: MedSurg and Cardiovascular. Within the Cardiovascular segment, the newly formed Cardiology division represents the combined former Rhythm Management and Interventional Cardiology divisions. We have revised prior periods to conform to the current year presentation. The following section describes our results of operations by reportable segment and business unit. For additional information on our businesses and their product offerings, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedSurg</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Endoscopy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. Net sales of Endoscopy products of $2.221 billion represented 18 percent of our consolidated net sales in 2022. Endoscopy net sales increased&#160;$80 million, or 3.7 percent, in 2022 compared to 2021. This increase included operational net sales growth of 8.1 percent and the negative impact of 440 basis points from foreign currency fluctuations. These year-over-year changes were primarily driven by our biliary franchise led by our AXIOS&#8482; Stent and Delivery System and our single-use imaging franchise, including our EXALT&#8482; D Single-use Duodenoscope, as well as our infection prevention and hemostasis franchises. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Urology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Urology business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $1.773 billion represented 14 percent of our consolidated net sales in 2022. Urology net sales increased $190 million, or 12.0 percent, in 2022 compared to 2021. This increase included operational net sales growth of 14.9 percent and the negative impact of 290 basis points from foreign currency fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational net sales growth included organic net sales growth of 9.7 percent in 2022 and the positive impact of 530 basis points from our acquisition of Lumenis in the third quarter of 2021. Organic net sales growth was driven by our stone management franchise led by our LithoVue&#8482; System, our prosthetic urology franchise and our prostate health franchise led by our Rezum&#8482; System and SpaceOAR&#8482; Hydrogel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neuromodulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $917 million represented seven percent of our consolidated net sales in 2022. Neuromodulation net sales increased $8 million, or less than one percent, in 2022 compared to 2021. This increase included operational net sales growth of 3.5 percent and the negative impact of 260 basis points from foreign currency fluctuations. Operational net sales performance reflects growth within our spinal cord stimulation (SCS) franchise driven by our WaveWriter Alpha&#8482; SCS System, strong procedural volumes of our Vercise Genus&#8482; DBS systems as well as the recent launch of the Vercise&#8482; 2-in-1 lead extension, largely offset by the impact of reimbursement challenges in the U.S. related to our Vertiflex Superion&#8482; Indirect Decompression System.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiovascular</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cardiology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $5.932 billion represented 47 percent of our consolidated net sales in 2022. Cardiology net sales increased $510 million, or 9.4 percent, in 2022 compared to 2021. This increase included operational net sales growth of 14.5 percent and the negative impact of 510 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 10.4 percent in 2022 and the positive impact of 400 basis points from our acquisitions of Preventice, Farapulse and Baylis Medical in the first and third quarter of 2021 and the first quarter of 2022, respectively. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic sales growth was primarily driven by continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN&#8482; FLX LAAC Device, as well as performance of our cardiac diagnostics franchise, POLARx&#8482; and Farapulse&#8482; ablation systems and percutaneous coronary intervention guidance franchises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Peripheral Interventions </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $1.899 billion represented 15 percent of our consolidated net sales in 2022. Peripheral Interventions net sales increased $79 million, or 4.4 percent, in 2022 compared to 2021. This increase included operational net sales growth of 9.1 percent and the negative impact of 480 basis points from foreign currency fluctuations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational net sales growth was primarily driven by our Ranger&#8482; Drug-Coated Balloon and Eluvia&#8482; Drug-Eluting Stent System, as well as our interventional oncology franchise led by our Therasphere&#8482; Y-90 Radioactive Glass Microspheres.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategic imperative to drive global expansion, we seek to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#252;rkiye and Vietnam. Our Emerging Markets net sales represented 14 percent of our consolidated net sales in 2022 and 12 percent in 2021. In 2022, our Emerging Markets net sales grew 20.0 percent on a reported basis including operational net sales growth of 29.3 percent and the negative impact of 930 basis points from foreign currency fluctuations, compared to 2021. Operational net sales growth was driven primarily by growth in China and India as we continued to focus on globalization and execute new product launches.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Sales</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides our net sales by reportable segment and business unit, and the relative change in growth on a reported basis: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 versus 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 versus 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 22.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,694&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(+100.0)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.9)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, not allocated to reportable segments, which are being disputed in the Italian court system. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Summary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further discussion of our net sales and a comparison of our 2022 and 2021 net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we generated net sales of $11.888 billion compared to $9.913 billion in 2020. This increase of $1.975 billion, or 19.9 percent, included operational growth of 18.7 percent and the positive impact of 130 basis points from foreign currency fluctuations. Operational net sales included $212 million in 2021 associated with our acquisitions of Preventice, Farapulse and Lumenis, for which there was less than a full prior period of comparable net sales. Operational net sales also included $202 million in 2020 associated with our intrauterine health franchise and the Specialty Pharmaceuticals business, divested in the second quarter of 2020 and first quarter of 2021, respectively. The increase in our 2021 net sales was primarily driven by the recovery of elective and semi-emergent procedure volumes compared to 2020 when the COVID-19 pandemic had a more significant impact on our net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit was $8.727 billion in 2022 and $8.177 billion in 2021. As a percentage of net sales, our gross profit remained flat at 68.8 percent in 2022 compared to 2021. The following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit Margin</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.0%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales pricing, volume and mix</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abnormal production variances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOTUS Edge&#8482; discontinuation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact of foreign currency fluctuations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including other period expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and supply costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact of foreign currency fluctuations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales pricing, volume and mix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including other period expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.8%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin for 2022 was flat compared to 2021. Global supply chain disruption drove increased manufacturing and supply costs, including inflation on costs of certain raw materials and components, direct labor and freight, as well as inefficiencies in our manufacturing plants due to constraints in material availability. The negative impact on our gross profit margin due to global supply chain disruption was offset by foreign currency fluctuations that drove gains on our foreign currency hedging contracts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary factors contributing to the increase in our gross profit margin for 2021 compared to 2020 were higher sales volumes and favorable product mix associated with the resumption of the procedures using higher-margin products following reduced elective procedure volumes due to the COVID-19 pandemic. In addition, our gross profit margin in 2020 was negatively impacted by abnormal production variances attributable to manufacturing plant shut-downs, inventory charges related to the discontinuation of our LOTUS platform and sales return reserves due to our WATCHMAN FLX&#8482; consignment conversion. These improvements were partially offset by price declines related primarily to sales of our coronary drug-eluting stent systems and foreign currency fluctuations. In addition, macro-environment factors negatively impacted our gross profit margin, including the cost of operating manufacturing plants with COVID-19 specific health and safety measures and increases in costs of certain raw materials, direct labor and freight.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU MDR Implementation Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union Medical Device Regulation (EU MDR) replaced the existing European Medical Devices Directive (MDD) and Active Implantable Medical Device Directive (AIMDD) regulatory frameworks, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began our implementation efforts in late 2019 and have incurred cumulative expenses of $245 million through December 31, 2022, which are primarily being recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Cost of product sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to incur total expenses of approximately $400 million to $450 million over the transition period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our key operating expenses:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Net Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Net Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Net Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SG&amp;A expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $161 million, or 4 percent compared to 2021 and were 100 basis points lower as a percentage of net sales. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SG&amp;A expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was due primarily to higher selling costs driven by higher global net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SG&amp;A expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $572 million, or 15 percent compared to 2020 and were 150 basis points lower as a percentage of net sales. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SG&amp;A expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily due to higher selling costs driven by higher global net sales and the targeted lifting of spending controls implemented in 2020 in response to the then escalating COVID-19 pandemic. In addition, SG&amp;A expenses in 2021 were further impacted by higher restructuring-related spend and acquisition-related costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to advancing medical technologies and investing in meaningful research and development projects across our businesses. In 2022, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $119 million, or 10 percent compared to 2021, and were 30 basis points higher as a percentage of net sales as a result of targeted investments across our businesses. We expect to continue to make investments in clinical trials and innovative technologies to maintain a pipeline of new products that we believe will address unmet clinical needs and contribute to profitable sales growth. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $61 million, or 5 percent compared to 2020, and were 140 basis points lower as a percentage of sales, as a result of investments across our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a further description.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense relates to intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents. In 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $62 million, or 8 percent, as compared to 2021. The increase was driven by the addition of amortizable intangible assets associated with recent acquisitions. In 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased $48 million, or 6 percent, as compared to 2020. The decrease was driven by the divestiture of the Specialty Pharmaceuticals business, partially offset by the addition of amortizable intangible assets associated with recent acquisitions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Asset Impairment Charges</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $132 million in 2022 and $370 million in 2021. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management&#8217;s decision to discontinue commercialization of the VICI VENOUS STENT&#8482; System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&amp;D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&amp;D program due to the incremental time and cost required to complete the program and bring the technology to market. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of key assumptions used in our intangible asset impairment testing and future events that could have a negative impact on the recoverability of our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration Net Expense (Benefit)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $35 million in 2022 and net benefits of $136 million in 2021. In 2022, the net charges related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our 2021 acquisition of Farapulse. This increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned. In 2021, the net benefits related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&amp;D program. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details related to our contingent consideration arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Restructuring-related Net Charges </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2018, our Board of Directors approved, and we committed to, a global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan was intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we were appropriately structured and resourced to deliver sustainable value to patients and customers. Key activities under the 2019 Restructuring Plan included supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities to support business growth. These activities were initiated in 2019 and substantially completed in 2022, following a one-year extension and expansion approved by our Board of Directors on February 22, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of cumulative pre-tax charges associated with the 2019 Restructuring Plan, by major type of cost, of which approximately $404 million resulted in cash outlays:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Incurred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$73</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring-related expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$461</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consists primarily of consulting fees and costs associated with contractual cancellations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded restructuring charges pursuant to FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s related to the 2019 Restructuring Plan of $24 million in 2022, $38 million in 2021, and $32 million in 2020. In addition, we recorded restructuring-related charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold, Selling, general and administrative expenses, and Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $86 million in 2022, $134 million in 2021, and $84 million in 2020 associated with activities under the 2019 Restructuring Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program. For additional information, refer to &#8220;2023 Restructuring Plan&#8221; under the heading Liquidity and Capital Resources below.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LOTUS Discontinuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2020, we announced a global, voluntary recall of all unused inventory of our LOTUS Edge&#8482; Aortic Valve System, and our decision to retire the entire LOTUS&#8482; Valve platform. We recorded restructuring and restructuring-related net charges associated with the product discontinuation of $20 million in 2021 and $55 million in 2020. The restructuring activities were completed in 2021 and resulted in total pre-tax restructuring and restructuring-related net charges of approximately $75 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2020 we recorded $119 million of inventory charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $8 million of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated with the product discontinuation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related Net Charges (Credits)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded litigation-related net charges of $173 million in 2022 and $430 million in 2021, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit agreements. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional discussion of our material legal proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and average borrowing rate:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average borrowing rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense and our average borrowing rate increased in 2022, compared to the prior year, primarily due to $194 million of charges associated with the early extinguishment of $3.275&#160;billion of certain of our senior notes, including payment of tender premiums and the acceleration of unamortized debt issuance costs. As of December&#160;31, 2022, the weighted average borrowing rate associated with our outstanding senior notes was 2.6 percent. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note D &#8211; Hedging Activities and Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements contained in Item 8. of this Annual Report on Form 10-K for information regarding our debt obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, in connection with our acquisitions of Farapulse, Preventice and Devoro Medical, Inc. we remeasured the fair value of our previously-held interests in the acquired companies, which resulted in $475 million of gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we recorded a loss of $178 million in 2021 and a gain of $363 million in 2020 on our investment in Pulmonx </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporation (Pulmonx) presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated with the remeasurement of our investment to fair value based on observable market prices, as well as the disposition of our remaining ownership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains on previously held interests are included within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Acquisition/divestiture-related net charges (credits) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Pulmonx net gain (loss) is included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investment portfolio net losses (gains)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Summary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the reconciliation and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of management's use of non-GAAP financial measures.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_52"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our reported tax rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of certain receipts/charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These receipts/charges are taxed at different rates than our effective tax rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in our reported tax rate for 2022 compared to 2021, relates primarily to the jurisdictional mix of earnings and the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition/divestiture-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, debt extinguishment net charges, as well as certain discrete tax items primarily related to restructuring activities, and tax windfall benefits associated with share-based payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91&#160;million to release the reserves related to these years. We received a refund of $62&#160;million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 (Inflation Reduction Act) was enacted into law by the U.S. government and includes a new corporate alternative minimum tax of 15 percent on the adjusted financial statement income (AFSI) of corporations with average AFSI exceeding $1.0 billion over a three-year period. Additionally, the Inflation Reduction Act imposes a 1 percent excise tax on the fair market value of net corporate stock repurchases. These provisions are effective beginning in 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H &#8211; Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details on our tax rate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plan, we believe our existing balance of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future. Please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for additional details on our future payment obligations and commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $928 million of unrestricted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on hand, comprised of $673 million invested in money market funds and time deposits and $256 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility or our commercial paper program as of December&#160;31, 2022, resulting in an additional $2.220 billion of available liquidity. In anticipation of our purchase of a majority stake in Acotec Scientific Holdings Limited (Acotec), a Chinese medical technology company, which closed on February 20, 2023, we reserved approximately $530 million of our borrowing capacity under the 2021 Revolving Credit Facility in the fourth quarter of 2022 as proof of funds, as required by Hong Kong guidelines. We funded the acquisition using cash on hand and, as a result, have full borrowing capacity under the 2021 Revolving Credit Facility as of the date of filing of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details related to our debt obligations, including our financial covenant requirement, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K, which is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a summary and description of our net cash inflows (outflows):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used for) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used for) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used for) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, cash provided by (used for) operating activities decreased $344 million compared to 2021. This decrease was primarily due to changes in working capital, including higher levels of inventory and accounts receivable. In 2021, cash provided by operating activities increased $362 million compared to 2020. This increase was primarily due to comparatively higher net sales and operating income compared to the prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by (used for) operating activities included litigation-related payments of $282 million in 2022, $441 million in 2021 and $420 million in 2020, related primarily to transvaginal mesh litigation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, cash provided by (used for) investing activities primarily included net cash payments of $1.542 billion for the acquisitions of Baylis Medical and Obsidio, Inc, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchases of property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and internal use software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $588 million partially offset by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Proceeds from settlements of hedge contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $56 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $70 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, cash provided by (used for) investing activities primarily included payments of $2.258 billion for the acquisitions of Preventice, Lumenis, Farapulse and Devoro and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchases of property, plant and equipment and internal use software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $554 million, partially offset by proceeds of $826 million from the divestiture of the Specialty Pharmaceuticals business and net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from investments and acquisitions of certain technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $279 million primarily from the disposition of our shares in Pulmonx.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we completed a public offering (the Offering) of &#8364;3.000 billion in aggregate principal amount of euro-dominated senior notes. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275&#160;billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. For more information, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Cash provided by (used for) financing activities in 2022 also included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments of contingent consideration previously established in purchase accounting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $335 million as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments on short-term borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $250 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, cash provided by (used for) financing activities primarily included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $85 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash dividends paid on preferred stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $55 million, partially offset by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $110 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity plans are subject to a number of risks and uncertainties, including those described in Item 1A. Risk Factors of this Annual Report on Form 10-K, some of which are outside our control. Macroeconomic conditions, adverse tax and litigation matter outcomes and other risks and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the current and long-term portions of our total debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:61.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current debt obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:61.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed-rate debt instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate debt instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with the financial covenant required by the credit facilities described above. For additional details related to our debt obligations, including our financial covenant requirements, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 we received $136 million in proceeds from stock issuances related to our stock option and employee stock purchase plans, compared to $110 million in 2021. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of employees. Stock-based compensation expense related to our stock ownership plans was $220 million in 2022 and $194 million in 2021. Stock-based compensation expense varies from period to period based upon, among other factors, the timing, number and fair value of awards granted during the period, forfeiture levels related to unvested awards and employee contributions to our employee stock purchase plan, as well as the retirement eligibility of stock award recipients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 or 2021, and had the full amount available under the authorization as of December&#160;31, 2022. There were approximately 263 million shares in treasury as of December&#160;31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contractual Obligations and Commitments</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal reserves</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One-time transition tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,522</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   Debt obligations are comprised of our senior notes outstanding as of December&#160;31, 2022. This does not include unamortized debt issuance discounts, deferred financing costs and gain on fair value hedges or finance lease obligations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    In accordance with U.S. GAAP, these obligations relate primarily to expenses associated with future periods and, with the exception of accrued interest, are not reflected in our consolidated balance sheet as of December&#160;31, 2022. Interest payments included above are calculated based on rates and required fees applicable to our outstanding debt obligations as of December&#160;31, 2022 described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Interest payments above do not include interest on variable rate debt instruments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Timing of payment for our long-term liability for legal matters that are probable and estimable as of December&#160;31, 2022 is uncertain and as such it is excluded from the table above. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business. The table above does not include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any future obligations to make payments of contingent consideration pursuant to certain of our acquisition agreements, due to the exact amount and timing of payments being uncertain. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unrecognized tax benefits, accrued interest and penalties and other related items because the timing of their future cash settlement is uncertain. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H &#8211; Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired IPR&amp;D projects that require future funding to complete. We estimate that the total remaining cost to complete acquired IPR&amp;D projects is between $55 million and $65 million. Net cash inflows from the projects currently in development are expected to continue through 2039, following the respective launches of these technologies in the U.S. and Europe. Certain of our acquisitions also involve the potential payment of contingent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration, but the timing and amounts are uncertain. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information, </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holders of our MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations,</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The definitive agreement, entered into on June 15, 2022, with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech) for approximately $230 million, which we are working towards closing during the second quarter of 2023, and the definitive agreement, entered into on November 29, 2022, to acquire 100 percent of the fully diluted equity of Apollo Endosurgery, Inc. for approximately $615 million, which is expected to close during the first half of 2023, subject to customary closing conditions. Additionally, on February 20, 2023, we completed the acquisition of a majority stake in Acotec for approximately $520 million using cash on hand. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Restructuring Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan is intended to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Restructuring Plan will further build on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expand operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">optimizing certain functional capabilities to better support business growth and achieve cost synergies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in future cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million by the end of 2025 as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. The following table provides a summary of our estimates of total pre-tax charges associated with the 2023 Restructuring Plan by major type of cost:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Estimated Amount Expected to be Incurred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring-related expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$450</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$550 </span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consists primarily of consulting fees and costs associated with contractual cancellations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our material legal proceedings see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.</span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_61"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial results are affected by the selection and application of accounting policies and methods. We have adopted accounting policies to prepare our consolidated financial statements in conformity with U.S. GAAP. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, including our contingent liabilities, as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting periods. Our actual results may differ from these estimates. We consider estimates to be critical (i)&#160;if we are required to make assumptions about material matters that are uncertain at the time of estimation or (ii) if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management&#8217;s judgment: Revenue Recognition, Inventory Provisions, Valuation of Intangible Assets and Contingent Consideration Liability, Goodwill Valuation, Legal and Product Liability Accruals and Income Taxes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information related to our accounting policies and our consideration of these critical accounting areas. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE&#8482; Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. The use of alternative assumptions could impact the period over which revenue is recognized.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers and record these as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. We forward accrue the costs to provide these services at the time the devices are sold by estimating the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventory Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Valuation of Intangible Assets and Contingent Consideration Liability</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#8217;s best estimates of inputs and assumptions that a market participant would use. Further, for those arrangements that involve potential future contingent consideration, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. We re-measure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, useful life or probability of achieving clinical, regulatory or revenue-based milestones could result in different purchase price allocations and recognized amortization expense and contingent consideration expense or benefit in current and future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or adjustment to the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset is determined not recoverable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will write the carrying value down to fair value in the period the impairment is identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. The use of alternative assumptions, including estimated cash flows, discount rates and alternative estimated remaining useful lives could result in different calculations of impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we test our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets, or more frequently if indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 350)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to fair value. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Valuation</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing annual impairment assessments, when a quantitative test is performed, we typically use only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the income approach, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units&#8217; future expected cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests, these estimates are uncertain by nature and can vary from actual results. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels, </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully, </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative changes in one or more of these factors, among others, could result in future impairment charges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal and Product Liability Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Litigation and product liability matters are inherently uncertain, and the outcomes of individual matters are difficult to predict and quantify. As such, significant judgment is required in determining our legal and product liability accruals. Our estimates related to our legal and product liability accruals may change as additional information becomes available to us, including information related to the nature or existence of claims against us, trial court or appellate proceedings, and mediation, arbitration or settlement proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish reserves when we believe that certain positions are likely to be challenged despite our belief that our tax return positions are fully supportable. The calculation of our tax liabilities involves significant judgment based on individual facts, circumstances and information available in addition to applying complex tax regulations in various jurisdictions across our global operations. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must determine it is more likely than not the position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more than 50 percent likely to be realized upon resolution of the benefit. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, results of operations, financial position and/or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Tax Cut and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as a part of continuing operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note P &#8211; New Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information on standards implemented during 2022 and standards to be implemented in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Sustainability</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sustainable environmental, social and governance practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders &#8211; locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. These efforts are supported by our cross-functional Corporate Social Responsibility Steering Committee, our Corporate Social Responsibility Council, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs. In addition, our Executive Committee performance is measured, among other things, against global gender and U.S. (inclusive of Puerto Rico) multicultural goals and performance against annual renewable electricity and carbon emissions goals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also making measurable progress toward shaping a better future for our planet by proactively addressing energy consumption, carbon emissions and waste management. We have committed to a goal of carbon neutrality for Scope 1 and Scope 2 carbon emissions in our manufacturing and key distribution sites by 2030. Our Global Real Estate, Facilities, Environment, Health &amp; Safety function is responsible for rigorously measuring, assessing and reporting progress toward these goals globally. We are focused on a &#8220;C3&#8221; strategy: Cutting energy use, Converting to renewable energy sources and Compensating with carbon offset projects where needed. Our Global Headquarters and U.S. distribution center in Massachusetts, and our manufacturing plants in Dorado, Puerto Rico and Coyol, Costa Rica all utilize solar energy from on-site installations. Our goal is to fully source or generate electricity from renewable sources by 2024, and by 2027, our goal is that 90 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percent of all energy used across our manufacturing and key distribution sites, will be from renewable sources, representing an important milestone toward our 2030 carbon neutrality commitment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we obtained additional ISO 50001:2018 - Energy Management Systems certification for our manufacturing plants in Maple Grove and Arden Hills, Minnesota and in Dorado, Puerto Rico. This brings the total number of ISO 50001:2018 certified sites in our global network to twelve. We have also obtained ISO 14001:2015 - Environment Management Systems certification at our major manufacturing plants and Tier 1 distribution centers around the world, as well as our Global Headquarters. These are globally recognized standards for employee Energy and Environmental Management Systems, established by the International Standards Organization, which provides a voluntary framework to identify key energy and environmental aspects associated with our business. Using these management systems and the specific attributes of our certified locations, we continue to improve our energy and environmental performance. We also have 12 Leadership in Energy and Environmental Design (LEED) certified buildings on campuses in the U.S., Latin America, Europe and Asia. LEED is an internationally recognized certification program that seeks to ensure the mindful development, construction and maintenance of buildings in a way that benefits occupants and the environment by reducing waste and conserving resources.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cybersecurity</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues, including those involving vulnerabilities introduced by our use of third-party software, are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to our financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate.&#160;</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International conflicts, including, but not limited to the Russia/Ukraine war and tension between China/Taiwan, have heightened cybersecurity risks on a global basis. While there is significant uncertainty around implications of cybersecurity attacks resulting from such conflicts, we have taken steps to better understand our readiness, including the resilience of our critical business functions, with the goal of reducing the impact if such an event were to occur.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Non-GAAP Financial Measures</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income and GAAP net income available to common stockholders, which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GAAP financial measure most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis. </span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Annual Report on Form 10-K.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments&#8217; measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders adjusted net income (loss) per share, operational and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results &#8220;through the eyes&#8221; of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures as well as reasons for excluding each of these individual items. In each case, management has excluded the item for purposes of calculating the relevant non-GAAP financial measure to facilitate an evaluation of our current operating performance and a comparison to our past operating performance:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted Net Income (loss), Adjusted Net Income (loss) Available to Common Stockholders and Adjusted Net Income (loss) per Share</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Amortization expense&#160;- We record intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents at historical cost and amortize them over their estimated useful lives. Amortization expense is excluded from management's assessment of operating performance due to its non-cash nature and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Goodwill and other intangible asset impairment charges&#160;- These amounts represent write-downs of certain goodwill and/or other intangible asset balances. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment and test our goodwill and other indefinite-lived intangible assets at least annually for impairment. If we determine the carrying value of the amortizable intangible asset is not recoverable, goodwill of a reporting unit is impaired or it is more likely than not that the indefinite-lived asset is impaired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will write the carrying value down to fair value in the period identified. Impairment charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Acquisition/divestiture-related net charges (credits) - These adjustments may consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) due diligence, deal fees and other fees and costs related to our acquisition and divestiture transactions; (d) inventory step-up amortization and accelerated compensation expense; (e) integration and exit costs; and (f) separation costs and gains or losses primarily associated with the sale of a business or portion of a business. The contingent consideration fair value adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration. Gains on previously held investments, due diligence, deal fees and other fees and costs, inventory step-up amortization, accelerated compensation expense, and other expenses and gains or losses associated with divestitures or acquisitions can be highly variable and not representative of ongoing operations. Integration, separation and exit costs, include contract cancellations, severance and other compensation-related charges and costs, project management fees and costs, and other direct costs associated with the integration of our acquisitions or separation of our divested businesses. These integration, separation and exit activities take place over a defined timeframe and have distinct project timelines, are incremental to activities and costs that arise in the ordinary course </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our business and are not considered part of our core, ongoing operations. These acquisition/divestiture-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Restructuring and restructuring-related net charges (credits)&#160;- These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring initiatives take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring initiatives typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, during the fourth quarter of 2020 and first half of 2021, we incurred restructuring and restructuring-related net charges associated with management&#8217;s decision to retire the LOTUS platform. These restructuring plans are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Litigation-related net charges (credits) - These adjustments include certain significant product liability and other litigation-related charges and credits. We record these charges and credits, which we consider to be unusual or infrequent and significant, within the litigation-related charges line in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within selling general and administrative expenses. Certain litigation-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">EU MDR implementation costs - These adjustments represent certain incremental costs specific to complying with new regulatory requirements in the EU. EU MDR replaced the existing European Medical Devices Directive (MDD) regulatory framework, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). We expect to incur significant expenditures in connection with the adoption of the EU MDR requirements and we consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters. As such, certain of these costs are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Debt extinguishment net charges (credits) - These amounts relate to the early extinguishment of certain outstanding principal amounts of our senior notes. Certain debt extinguishment net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Investment portfolio net losses (gains) - These amounts represent write-downs or fair value remeasurement gains and losses related to our investment portfolio. Each reporting period, we evaluate our investments without a readily determinable fair value to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value and determine if the impairment is other-than-temporary, and recognize an impairment loss. In addition, for those investments accounted for under the measurement alternative method of accounting, we record gains and losses to remeasure the carrying value of the investments to their fair values based on observable market prices or implied market values. Investment impairment charges and fair value remeasurements can be highly variable dependent on external market factors and conditions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relative to the underlying investee, which are generally outside of the control of management, as such these amounts are excluded from management's assessment of performance.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Deferred tax expenses (benefits) - This adjustment relates to a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019 which resulted in our recording a $4.102 billion net deferred tax asset. The deferred tax benefit associated with the establishment of the net deferred tax asset as well as any deferred tax expense resulting from the reversal of the deferred tax asset are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Discrete tax items - These items represent adjustments of certain tax positions including those which a) are related to the finalization of the enactment date impact of the TCJA, or b) are related to the tax consequences of a non-GAAP adjustment item booked in a prior period. These discrete tax items are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. </span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operational Net Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The impact of foreign currency fluctuations is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign currency fluctuations for purposes of reviewing net sales and growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Net Sales</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rule&#160;10b5-1 Trading Plans by Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about our company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the management of Boston Scientific Corporation, we are responsible for establishing and maintaining adequate internal control over financial reporting. We designed our internal control process to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#8211;Integrated Framework (2013 framework). Based on our assessment, we believe that, as of December&#160;31, 2022, our internal control over financial reporting is effective at a reasonable assurance level based on these criteria.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the SEC Staff 's interpretive guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business's internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date. As such, we have excluded Baylis Medical Company Inc., acquired on February 14, 2022, from our annual assessment of internal controls over financial reporting as of December 31, 2022. This business represented less than one percent of total assets as of December 31, 2022 and approximately one percent of net sales for the year then ended.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, an independent registered public accounting firm, has issued an audit report on the effectiveness of our internal control over financial reporting. This report, in which they expressed an unqualified opinion, is included below.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.784%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael F. Mahoney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel J. Brennan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Mahoney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Brennan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief<br/>Financial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_67"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Boston Scientific Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Boston Scientific Corporation&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Boston Scientific Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Baylis Medical Company Inc., which is included in the 2022 consolidated financial statements of the Company and constituted less than 1% of total assets as of December 31, 2022 and approximately 1% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Baylis Medical Company Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2022 consolidated financial statements of the Company and our report dated February 23, 2023 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily manufacturing operations outside the U.S.) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $7.324 billion as of December&#160;31, 2022 and $8.381 billion as of December&#160;31, 2021. A ten percent appreciation in the U.S. dollar&#8217;s value relative to the hedged currencies would increase the derivative instruments&#8217; fair value by $208 million as of December&#160;31, 2022 compared to $298 million as of December&#160;31, 2021. A ten percent depreciation in the U.S. dollar&#8217;s value relative to the hedged currencies would decrease the derivative instruments&#8217; fair value by $254 million as of December&#160;31, 2022 compared to $364 million as of December&#160;31, 2021. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of December&#160;31, 2022 and December&#160;31, 2021. As of December&#160;31, 2022, $8.986&#160;billion in aggregate principal amount of our outstanding debt obligations were at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of December&#160;31, 2022, our outstanding debt obligations at fixed interest rates were comprised of senior notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for further information regarding our derivative financial instruments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Corporation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Boston Scientific Corporation (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 23, 2023 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.257%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations</span></div></td></tr><tr style="height:171pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note B to the consolidated financial statements, during 2022, the Company completed the acquisition of Baylis Medical Company Inc. for a purchase price of $1.46 billion, net of cash acquired. The transaction was accounted for as a business combination. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accounting for the acquisition was complex due to the significant estimation required by management to determine the fair value of identified intangible assets, which totaled $657 million and principally consisted of developed technology. A significant emphasis is placed on the appropriateness of the estimates used by management to determine the fair value of acquired intangible assets due to the sensitivity of the respective fair values to the underlying assumptions. The Company used an income approach to measure the technology-related intangible assets. The significant assumptions used to estimate the value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates, estimates of technological obsolescence, operating profit margin and market participant synergies. These significant assumptions are forward looking and could be affected by future economic and market conditions.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company&#8217;s accounting for acquisitions. For example, we tested controls over the identification and valuation of intangible assets, including the valuation models and underlying assumptions used to develop such estimates. We read the purchase agreement, evaluated the significant assumptions and methods used in developing the fair value estimates, and tested the recognition of (1) the tangible assets acquired and liabilities assumed at fair value; (2) the identifiable intangible assets acquired at fair value; and (3) goodwill measured as a residual.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company's use of the income approach and testing the significant assumptions used in the model, as described above. We evaluated the completeness and accuracy of the underlying data used in the analyses. For example, we compared the significant assumptions to current industry, market and economic trends, to the assumptions used to value similar assets in other acquisitions, to the historical results of the acquired business and to other guideline companies within the same industry. We involved our valuation professionals to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83My9mcmFnOjk3ZTk0YjFlZDhkMTQzMDg4NGUzY2I5NWViOWVlODMyL3RleHRyZWdpb246OTdlOTRiMWVkOGQxNDMwODg0ZTNjYjk1ZWI5ZWU4MzJfMzYzNA_f706f846-1439-4e98-9faf-27560938f3f7">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1992.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83My9mcmFnOjk3ZTk0YjFlZDhkMTQzMDg4NGUzY2I5NWViOWVlODMyL3RleHRyZWdpb246OTdlOTRiMWVkOGQxNDMwODg0ZTNjYjk1ZWI5ZWU4MzJfMzYzNg_728d86f4-af46-410e-9e87-a10602050ae9">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023 </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy0xLTEtMS0xMTg4MzM_af776dc2-c745-478e-8bcf-ae106299673a">12,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy0zLTEtMS0xMTg4MzM_849cb7de-2f18-4c43-8596-3a8224d66fb4">11,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy01LTEtMS0xMTg4MzM_9d662dfe-902e-4901-a1a5-a8aa5afeb3cc">9,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC0xLTEtMS0xMTg4MzM_b89f5f77-04ed-4fa9-965a-3e48ef2caccc">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC0zLTEtMS0xMTg4MzM_aa968464-3d53-4b13-959e-9d83d74e95ce">3,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC01LTEtMS0xMTg4MzM_c574ef45-eac7-4dd9-a939-255b19efb84a">3,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS0xLTEtMS0xMTg4MzM_3e8a4667-e4e5-46a6-bdca-b98c057f6879">8,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS0zLTEtMS0xMTg4MzM_aef286fe-e06d-47c4-94b7-a274314d3354">8,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS01LTEtMS0xMTg4MzM_bf9d5db5-3fc0-41ef-8d22-bd4e0343e178">6,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC0xLTEtMS0xMTg4MzM_e9226087-a425-4ca5-924a-17dd5b1cfaa6">4,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC0zLTEtMS0xMTg4MzM_5ee54169-4914-4153-9a9b-a2620c9f7fa7">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC01LTEtMS0xMTg4MzM_2a446d10-6d96-4c87-a6a1-5b668017171f">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS0xLTEtMS0xMTg4MzM_33b05680-58be-4803-9fd0-3d69e5abb67f">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS0zLTEtMS0xMTg4MzM_4fed18ef-064c-4cd8-b4e6-d0eee86775b5">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS01LTEtMS0xMTg4MzM_b781a29e-872c-44a5-ad06-a3652a9a214c">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtMS0xLTEtMTE4ODMz_83ef4104-fa46-4663-9493-13138c90531f">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtMy0xLTEtMTE4ODMz_9427448f-0a3b-4dcc-9d6f-1dda61c3f26e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtNS0xLTEtMTE4ODMz_561cfd29-7080-45d7-8898-b996014b1163">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtMS0xLTEtMTE4ODMz_50b21509-3986-49bd-a4b9-7d58c44fe3f0">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtMy0xLTEtMTE4ODMz_d77aeffe-010d-4a63-971a-d5ac1dae7ee6">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtNS0xLTEtMTE4ODMz_6c7c0c53-8135-42b8-90eb-d1aeb70f2d64">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItMS0xLTEtMTE4ODMz_ac526290-bfeb-4c2b-97a6-995aecdfffd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItMy0xLTEtMTE4ODMz_4592bd04-2711-4a4e-8b8a-b1c96dab7423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItNS0xLTEtMTE4ODMz_5aa45f01-b56e-4ed4-b7d2-22d88c6f687b">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtMS0xLTEtMTE4ODMz_f219adb4-5b19-4d2e-b864-135a0194f36e">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtMy0xLTEtMTE4ODMz_2dcd1bac-1faf-4729-80b4-c8f50dc2d77a">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtNS0xLTEtMTE4ODMz_15820e0a-d473-4b0c-9b19-f636679c02eb">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtMS0xLTEtMTE4ODMz_565f4534-3655-4c53-b078-a4ecd7c74514">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtMy0xLTEtMTE4ODMz_1f129adc-444e-4940-b87e-0d046c2728e7">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtNS0xLTEtMTE4ODMz_b2f8817f-8d1f-4067-b60c-9559d082f0da">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring net charges (credits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtMS0xLTEtMTE4ODMz_7a5ba2f6-b0cf-475a-bbd0-c098fb333e4c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtMy0xLTEtMTE4ODMz_3bc6e187-2f21-45a6-9c29-5496bd88ed55">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtNS0xLTEtMTE4ODMz_f3809505-bc6e-47fc-9f8d-8a882b8a8c2b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related net charges (credits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtMS0xLTEtMTE4ODMz_dfabb3d5-2e05-46a9-b4dc-e7e5de5cce81">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtMy0xLTEtMTE4ODMz_829e2a18-cd26-4fed-bb43-605f73a998ee">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtNS0xLTEtMTE4ODMz_05edd9e6-d2ca-4592-94cf-3e4067f055fa">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal of businesses and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctMS0xLTEtMTE4ODMz_48a791ac-7281-42d2-bcdd-b53b856513f4">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctMy0xLTEtMTE4ODMz_cad47bbc-87d0-4e01-a1e8-285d34744065">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctNS0xLTEtMTE4ODMz_e1a0b63c-11fa-4ba6-acd7-847227e3259e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtMS0xLTEtMTE4ODMz_79e1c2d2-3fed-4ed1-96a9-d8a99346f39a">7,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtMy0xLTEtMTE4ODMz_2b2a9ef4-243b-4f05-adbd-5018ae3c7f25">6,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtNS0xLTEtMTE4ODMz_d06c2393-6f4d-4475-8cd4-efa97efb9848">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktMS0xLTEtMTE4ODMz_4be11557-f172-443c-852f-883f43510dc4">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktMy0xLTEtMTE4ODMz_7d7caf0e-a6d5-4d37-a091-a956b4cbd360">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktNS0xLTEtMTE4ODMz_9dc87eff-cf2d-4907-8010-bba02eff3659">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItMS0xLTEtMTE4ODMz_16e2c289-46ff-4679-9288-2b4171753ce2">470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItMy0xLTEtMTE4ODMz_0e86498c-b97f-490d-89fb-d3850396d7d9">341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItNS0xLTEtMTE4ODMz_5ec15edc-024e-4438-b36c-a4051c865098">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtMS0xLTEtMTE4ODMz_b77dcb85-7f21-4191-9aea-d45d665a4ff4">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtMy0xLTEtMTE4ODMz_0a5a531d-f546-42a3-b217-1406d22f3477">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtNS0xLTEtMTE4ODMz_ab81265d-9b0e-4ff4-86bd-3cc689469f2d">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtMS0xLTEtMTE4ODMz_a8993706-e15c-45c0-a43a-a485751d3964">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtMy0xLTEtMTE4ODMz_bb7c55e9-157f-49b7-a845-f6861a17f3d5">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtNS0xLTEtMTE4ODMz_191adbc5-b5ff-4cd5-866a-14afa4958bf2">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtMS0xLTEtMTE4ODMz_263f4582-bfea-4bb0-b6ba-2d1feeeacfe9">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtMy0xLTEtMTE4ODMz_1a7f2f77-eb38-4944-be16-036e0b7fb95c">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtNS0xLTEtMTE4ODMz_180f71a4-6dfa-41ac-ac79-5cc1007bcd1a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtMS0xLTEtMTE4ODMz_940b54da-d15b-4c5f-b1a4-e7400f39e34f">698</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtMy0xLTEtMTE4ODMz_35f995b5-5d51-4fec-84dd-0f5811db5876">1,041</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtNS0xLTEtMTE4ODMz_34a0e93d-642a-49d4-a423-3d3d7d001c72">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividends</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DividendsPreferredStockStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctMS0xLTEtMTE4ODMz_204c78c5-cc8f-402f-a6a2-3196bd31514c">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DividendsPreferredStockStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctMy0xLTEtMTE4ODMz_6b819d76-fe3f-47d2-96d8-58856f10ef2a">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:DividendsPreferredStockStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctNS0xLTEtMTE4ODMz_bc5eb57a-2fd4-4b99-adb0-1186ca81d6b3">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtMS0xLTEtMTE4ODMz_a855516f-ffe6-4671-a693-20218fc6487c">642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtMy0xLTEtMTE4ODMz_19820d3f-d120-4091-8b90-c36e83bc7cfa">985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtNS0xLTEtMTE4ODMz_82b8c1da-600e-447d-8694-e5468dbe374d">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtMS0xLTEtMTE4ODMz_2d38e201-666e-4899-bdea-a70fed470bb5">0.45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtMy0xLTEtMTE4ODMz_52e371b4-696a-4295-bcb2-d6577db46d8e">0.69</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtNS0xLTEtMTE4ODMz_841c9654-b65a-4446-8b19-67c2815d921a">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share &#8212; assuming dilution</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtMS0xLTEtMTE4ODMz_03b11f7f-3ee3-4458-a136-5f2d330b13e6">0.45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtMy0xLTEtMTE4ODMz_aed6f052-5e77-4210-afe4-74a23de96135">0.69</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtNS0xLTEtMTE4ODMz_b4fd8cc0-52e4-48fa-b4e8-3fa887813a0e">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtMS0xLTEtMTE4ODMz_19a2ce74-86cf-4934-8993-d5792dac5a92">1,430.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtMy0xLTEtMTE4ODMz_6c11343d-18a3-4a09-b032-3158fc8cf67e">1,422.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtNS0xLTEtMTE4ODMz_cd18741d-b3b9-4b93-8c0a-f9b8983d9f7c">1,416.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtMS0xLTEtMTE4ODMz_1dfd270d-1828-4ccb-ad1a-935637892c29">1,439.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtMy0xLTEtMTE4ODMz_781a14e1-0780-4ee6-bbab-4af1e148e1e5">1,433.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtNS0xLTEtMTE4ODMz_18ba125e-99ad-4a71-a6e6-0036cac070f0">1,416.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi0xLTEtMS0xMTg4MzM_940b54da-d15b-4c5f-b1a4-e7400f39e34f">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi0zLTEtMS0xMTg4MzM_35f995b5-5d51-4fec-84dd-0f5811db5876">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi01LTEtMS0xMTg4MzM_34a0e93d-642a-49d4-a423-3d3d7d001c72">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC0xLTEtMS0xMTg4MzM_9657a9de-f7b1-4d13-b202-412d3d1eb7bf">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC0zLTEtMS0xMTg4MzM_6ed8290c-4833-40a8-9c9f-d8ce86905055">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC01LTEtMS0xMTg4MzM_227fad27-21d0-4d8f-8702-8c744912f409">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS0xLTEtMS0xMTg4MzM_3d67498f-d071-4a3e-b851-5f8483446d8e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS0zLTEtMS0xMTg4MzM_bc43e799-d385-4345-976a-f6ed3d371c2f">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS01LTEtMS0xMTg4MzM_b13ce5e9-50fb-4910-96c4-3e41601dfccf">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in defined benefit pensions and other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy0xLTEtMS0xMTg4MzM_2a723380-5b12-47dd-b722-10b822971698">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy0zLTEtMS0xMTg4MzM_5fc33b89-2869-410f-9cf5-926e5e1c9da6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy01LTEtMS0xMTg4MzM_40f3687b-f48c-409f-8f97-22bd94e2dc58">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC0xLTEtMS0xMTg4MzM_8a8c6338-aa31-4fa2-b1aa-ace393a7ab07">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC0zLTEtMS0xMTg4MzM_2188b743-3afc-4541-a822-dade4649802e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC01LTEtMS0xMTg4MzM_d29dae54-e728-4f70-9254-c3c78fd6f54d">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS0xLTEtMS0xMTg4MzM_3a9a4441-9db2-431e-9772-70521397506f">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS0zLTEtMS0xMTg4MzM_3e2ec739-d5b5-4fc6-b2d2-40bfef346ea4">1,096</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS01LTEtMS0xMTg4MzM_b8a9c9a1-733d-4763-8812-4beed5326184">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNC0xLTEtMS0xMTg4MzM_2adc141d-d958-4a16-b18b-3e2cc0192223">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNC0zLTEtMS0xMTg4MzM_295bfd6c-2340-4545-b9b7-c056c0cb8f76">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNS0xLTEtMS0xMTg4MzM_a758869b-9f11-4abd-8234-9f0dd795b1d3">1,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNS0zLTEtMS0xMTg4MzM_bd7e6f66-81a5-40f5-89e1-3cf94b1c6018">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNi0xLTEtMS0xMTg4MzM_c668f3e9-d00d-48c2-ad30-9290313377ba">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNi0zLTEtMS0xMTg4MzM_af2ebb34-2802-444f-88d1-8dec7a2ecdda">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNy0xLTEtMS0xMTg4MzM_3a6ce4c9-ef34-4041-84a4-c7f35bc8ca17">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNy0zLTEtMS0xMTg4MzM_c62293f7-b3fd-46f1-b610-684dcdc938f4">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfOS0xLTEtMS0xMTg4MzM_85891873-53da-44df-b940-833eef851fae">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfOS0zLTEtMS0xMTg4MzM_9a019931-ce80-444e-9564-0d2c2bbfe762">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTAtMS0xLTEtMTE4ODMz_45e8c302-c475-43b4-b1b6-ba83fd7c6d47">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTAtMy0xLTEtMTE4ODMz_06a83e07-f665-4b49-9271-166f75d31191">6,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTEtMS0xLTEtMTE4ODMz_161e7581-eb4e-47e5-8b98-7c83d9ea6005">2,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTEtMy0xLTEtMTE4ODMz_2d431a99-eb12-49aa-8e17-125dad6a87e9">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTItMS0xLTEtMTE4ODMz_b0099e53-f80a-4b78-9688-f9b7a387d42e">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTItMy0xLTEtMTE4ODMz_328a52a8-58de-4fd8-9608-ed45779091ad">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTMtMS0xLTEtMTE4ODMz_326c4346-966e-4b48-9386-514288f8c2ce">5,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTMtMy0xLTEtMTE4ODMz_9dab6693-8a67-46b4-820e-5cdf88e67f87">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTQtMS0xLTEtMTE4ODMz_e1f69a83-0c62-452d-8f13-ba2301bcc6bc">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTQtMy0xLTEtMTE4ODMz_352504c0-b484-4e0a-be2e-8b3449442fc5">4,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTUtMS0xLTEtMTE4ODMz_a3389488-6b98-4857-932b-2ddd1ae38cb1">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTUtMy0xLTEtMTE4ODMz_aca48e2a-0241-456f-bafa-7e43ff0aa222">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTYtMS0xLTEtMTE4ODMz_3f165a37-54c7-4e69-b090-f7391ed9635a">32,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTYtMy0xLTEtMTE4ODMz_682c90f7-734b-45ec-b7f9-3b750a80cf8a">32,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current debt obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjAtMS0xLTEtMTE4ODMz_d5e0237a-7342-4fcf-8d13-5c8adf0c74e6">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjAtMy0xLTEtMTE4ODMz_7c722033-a61e-49cc-92f2-c36d3ff8333f">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjEtMS0xLTEtMTE4ODMz_e3cc976f-81c8-4571-8433-13d82f2c541e">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjEtMy0xLTEtMTE4ODMz_e9c6d362-fdbf-4c78-96a5-f72135f57a02">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjItMS0xLTEtMTE4ODMz_5ec4266f-d79c-4386-83da-5702046ff11c">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjItMy0xLTEtMTE4ODMz_7b07ce03-2c82-44d5-8208-8d01a5168f60">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjMtMS0xLTEtMTE4ODMz_357e2541-0631-4077-ac2b-90f8dead9b48">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjMtMy0xLTEtMTE4ODMz_9f6ab0a5-ba56-49a8-b671-070b168c861d">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjQtMS0xLTEtMTE4ODMz_24cfac86-5081-4def-a141-0bf9b9e05973">3,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjQtMy0xLTEtMTE4ODMz_04df14f6-8fa8-4eb9-ab9a-cfb507a42e3c">4,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjUtMS0xLTEtMTE4ODMz_c141edf1-c84d-4279-a039-a764c5c17cf9">8,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjUtMy0xLTEtMTE4ODMz_79304af1-2577-40dd-8404-a4bf7608a468">8,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjYtMS0xLTEtMTE4ODMz_3442b55b-d42c-4868-b444-e042bef27e1f">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjYtMy0xLTEtMTE4ODMz_ae798504-abb5-43ff-a1e9-b61d849c4bf3">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjctMS0xLTEtMTE4ODMz_cc065951-ff6b-4373-b08b-c81940bbb4f0">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjctMy0xLTEtMTE4ODMz_4835beab-bc0b-40c4-a56b-d9e20a3da41e">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjktMS0xLTEtMTE4ODMz_2fa27480-a2fa-47e9-812f-f77544bfbf2e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjktMy0xLTEtMTE4ODMz_c21c1fcf-6c9a-4588-b705-6c9ba7199b79"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfMjE_0abbf763-3330-4aa0-ba37-d077d33db8a4"><ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfMjE_c2297788-0b71-4584-bb4e-baf139d11ec0">0.01</ix:nonFraction></ix:nonFraction> par value - authorized <ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNDc_237a50f2-fedd-4824-8c43-ddabbc888666"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNDc_9a3dd059-0012-47fc-a997-eb10cdd1cd2b">50,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNjU_37d4ddf7-a60b-4172-a23b-b93c2edf11e3"><ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNjU_cb80c136-9dab-493f-b78a-b709e448d517">10,062,500</ix:nonFraction></ix:nonFraction> shares as of December 31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMS0xLTEtMTE4ODMz_988c05ee-177c-4729-9bc2-2be8b499f061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMy0xLTEtMTE4ODMz_b6db1a25-56be-4a2c-8b17-4295e7c0d0f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTg_4d1c3860-7d70-4b64-afed-575a5aaf7421"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTg_9037d5c7-f83e-4f08-91ed-32c42c10cb9e">0.01</ix:nonFraction></ix:nonFraction> par value - authorized <ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNDQ_853bf742-1b75-418a-9458-873ce6f74a15"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNDQ_fb75b9fe-c0b3-4546-b8ed-4db64772eb6a">2,000,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNjI_85cd3bf1-e54f-4008-aea3-e52cefb97420">1,696,633,993</ix:nonFraction> shares as of December 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTAw_5bfce81a-ad6a-46ee-96c3-bd0206320b57">1,688,810,052</ix:nonFraction> shares as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMS0xLTEtMTE4ODMz_75365877-c6df-4682-9c9f-9d6675687538">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMy0xLTEtMTE4ODMz_0f5cfe53-4e4a-41fb-99e9-28d891f62a20">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost - <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246NDMwMTY0NzkzYjMwNDUyNjkzZGU4ZjhjYjA0NDNkN2JfMzA_08f5429c-fd7c-45f0-b0e3-5ffed7027ceb"><ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246NDMwMTY0NzkzYjMwNDUyNjkzZGU4ZjhjYjA0NDNkN2JfMzA_976cfdf8-309b-4199-aa50-65b8008914ed">263,289,848</ix:nonFraction></ix:nonFraction> shares as of December 31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMS0xLTEtMTE4ODMz_8a50f6e5-6ac5-43d4-9b1d-1d7d8ee1e388">2,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMy0xLTEtMTE4ODMz_673801a9-7f57-4d0b-8fd4-9675c9fda0d1">2,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzUtMS0xLTEtMTE4ODMz_8a2ed3d8-b77b-4f4c-ade3-63c905ed2072">20,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzUtMy0xLTEtMTE4ODMz_6d457a43-cd4d-451b-8ef6-952f3d9b3f69">19,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzYtMS0xLTEtMTE4ODMz_c4af3f7f-23aa-4d6a-b02d-1438e1c9b32e">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzYtMy0xLTEtMTE4ODMz_7919b762-c95b-41f1-a5cb-46679da7091c">1,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss), net of tax:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzctMS0xLTEtMTY1Njk1_25fadc24-36ad-4f99-98b8-94171cff0ae0">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzctMy0xLTEtMTY1NzAz_93f75916-0d63-42e3-847a-82bfbac8e3e6">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDItMS0xLTEtMTE4ODMz_9e2c578e-f114-443f-b238-bb8ae49099e9">17,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDItMy0xLTEtMTE4ODMz_13cafe52-80f6-4163-9dd0-70efdd9b0701">16,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDMtMS0xLTEtMTE4ODMz_d3a07631-3ac9-4e04-bb88-3427e935c05f">32,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDMtMy0xLTEtMTE4ODMz_328adf8c-b3bf-4515-aebd-8677ef6f759a">32,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred stock shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Beginning</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy0xLTEtMS0xMTg4MzM_14f59cf1-7ac2-4761-b700-3e4e031b7118">10,062,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy0zLTEtMS0xMTg4MzM_8d04ae46-b644-4338-9dd1-07e5d48df92f">10,062,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b0b26deeb85428db3cd49a32a784be2_I20191231" decimals="0" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy01LTEtMS0xMTg4MzM_6f588860-bb66-418b-8af2-e77650ee6add">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC0xLTEtMS0xMTg4MzM_c95cfbfb-38f1-4b1a-8119-7aa2b5195ff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC0zLTEtMS0xMTg4MzM_be55f86e-ada4-40de-a136-7c11ae3db116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC01LTEtMS0xMTg4MzM_73814b52-764b-43a8-8b56-bd333cad1d38">10,062,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Ending</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e82af43990a43a5806aec1a1b7cffc4_I20221231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS0xLTEtMS0xMTg4MzM_df47fdbc-c04b-4ede-affb-3e5fd1440284">10,062,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS0zLTEtMS0xMTg4MzM_6ed7b658-d33a-4459-b180-0256f8bdbb6a">10,062,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS01LTEtMS0xMTg4MzM_3a5f5e01-431c-40d8-a2f6-b67148fbee00">10,062,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Beginning</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy0xLTEtMS0xMTg4MzM_1de024b5-479b-494f-aeed-920cd12eb814">1,688,810,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy0zLTEtMS0xMTg4MzM_3d4238ca-1713-4efd-9027-4313f7ecbf1f">1,679,911,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79dc2df78f7b482183a5fdbd827980dc_I20191231" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy01LTEtMS0xMTg4MzM_8b9f94a8-8876-4cca-afb1-3da5671b9372">1,642,488,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC0xLTEtMS0xMTg4MzM_b13fd8fc-1123-4581-8cb1-3d11608bbb67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC0zLTEtMS0xMTg4MzM_951e85f3-2af9-483a-a55b-8c0bc6cfe3a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC01LTEtMS0xMTg4MzM_6c9cd968-6712-4758-b506-3d551949b47c">29,382,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS0xLTEtMS0xMTg4MzM_1293b227-2b10-4643-b7e9-508d5de04552">7,823,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS0zLTEtMS0xMTg4MzM_02bc4eb3-b7f9-425b-b107-8fd2e7ff4216">8,898,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS01LTEtMS0xMTg4MzM_0a379cdf-e29e-4c69-b360-9fdb2f5c6411">8,040,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Ending</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtMS0xLTEtMTE4ODMz_6a3b6890-49ce-4a33-8238-0c74ea0d4b1f">1,696,633,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtMy0xLTEtMTE4ODMz_a58763d7-660f-42fe-a2fa-4622f5d830f2">1,688,810,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtNS0xLTEtMTE4ODMz_3226d5af-fc21-45c5-8a70-db4d1d5fea1d">1,679,911,918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Beginning</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtMS0xLTEtMTE4ODMz_8cddecc9-b0b9-4c83-903b-58f8205b9298">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtMy0xLTEtMTE4ODMz_3e74b09e-7a9f-4868-9966-c0d6a2dcb39f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0b26deeb85428db3cd49a32a784be2_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtNS0xLTEtMTE4ODMz_a2dfbc8a-b22a-4925-84c1-22b32e7f9349">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtMS0xLTEtMTE4ODMz_672bf5fe-7929-4537-8287-690ca7135e6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtMy0xLTEtMTE4ODMz_bd43d3e1-4cc9-486c-b1a8-679739644c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtNS0xLTEtMTE4ODMz_6c860748-3ad9-4e13-86c5-df63db4993ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Ending</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e82af43990a43a5806aec1a1b7cffc4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtMS0xLTEtMTE4ODMz_f968c4be-afdd-487a-b656-e418e549202b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtMy0xLTEtMTE4ODMz_c7f3f3f2-bcaa-4979-9c64-df05407f7a33">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtNS0xLTEtMTE4ODMz_21ff7631-31e1-4dfc-8edd-4a9f5bdcdbd3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Beginning</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctMS0xLTEtMTE4ODMz_9274c3ad-86fc-4f8b-830a-d17711461104">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctMy0xLTEtMTE4ODMz_bd3d59a5-85a3-41a1-8480-8da673bd8fef">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dc2df78f7b482183a5fdbd827980dc_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctNS0xLTEtMTE4ODMz_01289517-1a91-4816-9236-f4dc20db8947">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtMS0xLTEtMTE4ODMz_79879507-1217-42a8-96ff-c325f293daf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtMy0xLTEtMTE4ODMz_aa520ec1-a8e8-4976-8cf3-589d91f7146b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtNS0xLTEtMTE4ODMz_0398ba54-f68c-4826-bf4d-3073cdecca80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktMS0xLTEtMTE4ODMz_094ad2cd-1fc8-418d-8568-1f2155aa61fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktMy0xLTEtMTE4ODMz_9b6e14ce-56de-4597-bf1a-06a915cf8177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktNS0xLTEtMTE4ODMz_ef1cadf9-8c44-445c-ab19-ee1972b935be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Ending</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da3f796ab7b4c4789b43fb01dbff97e_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtMS0xLTEtMTE4ODMz_ebaecd95-9f8d-4473-b1a0-7e45c24b4afc">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtMy0xLTEtMTE4ODMz_57959cd7-b1ef-4271-bbf0-0684724ade5a">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtNS0xLTEtMTE4ODMz_22d730ea-9a77-499e-b546-f13bfe4e5104">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a848010fed34536975f3f72d972321b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItMS0xLTEtMTE4ODMz_80d85a00-d68d-4d19-9f7e-b9eb12b06311">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i987efda00d924bb3ac9171caadacb1a4_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItMy0xLTEtMTE4ODMz_5b403ea6-4b87-4366-bc2b-243349a43275">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icca748a50e2c4b028776ec23b7576190_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItNS0xLTEtMTE4ODMz_8d124ed0-2c0a-4d79-8493-43c22af8990d">1,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55cc43cb62e422cba78b408deb3fbe9_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtMS0xLTEtMTE4ODMz_f200d165-ce27-44bc-8b59-489d8127a55e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910cb43c8c984811951e0a50cf31e4b8_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtMy0xLTEtMTE4ODMz_f581d98b-f410-4e57-8790-cd200cd50ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e78cc828ad64fd2a08ac51a9ab110e0_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtNS0xLTEtMTE4ODMz_e6e768ee-9630-48c3-9da5-3885a1b1529c">535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if11723763d0f4a7f9db1745ccb1925ad_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtMS0xLTEtMTE4ODMz_7628cddb-0e0a-4bc2-9ec9-97a7f9d862b0">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a848010fed34536975f3f72d972321b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtMy0xLTEtMTE4ODMz_49f2eb6a-d44d-4c25-98a8-9b466d925961">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i987efda00d924bb3ac9171caadacb1a4_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtNS0xLTEtMTE4ODMz_c5bd6e29-bb5c-42f3-8bce-a6ce3f393812">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f33f8343cf341e081c829b309c949a4_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtMS0xLTEtMTE4ODMz_1aa4a41f-80f1-4917-9b12-2e6a71e32ab6">19,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e12b27d5b94e89971f0a98991944b1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtMy0xLTEtMTE4ODMz_e7567ddf-8b83-4ba8-9716-3a3e2cfe838c">19,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0412e24c28c14e22992835fa7fabd269_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtNS0xLTEtMTE4ODMz_7f4e6d0e-5fc9-4335-be86-c135c34800e1">17,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctMS0xLTEtMTE4ODMz_5bea4cd8-dd0a-41ec-94dc-cdf5eb702a0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctMy0xLTEtMTE4ODMz_0f6ea933-6283-4557-828b-8b3ff8f8408c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctNS0xLTEtMTE4ODMz_c13e7bdf-0061-402e-9512-adeedc3acdb4">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtMS0xLTEtMTE4ODMz_6ae3f2a8-55fd-43c2-a583-deaa9a4d3f32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtMy0xLTEtMTE4ODMz_1b81dbab-ba4b-455c-9ba0-0d3c364cf08b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231" decimals="-6" name="bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtNS0xLTEtMTE4ODMz_3b9b9d2f-5dd9-4228-9d12-4765293d3a98">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktMS0xLTEtMTE4ODMz_f206943b-5d13-4a53-85ff-1de5c0fd4edf">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktMy0xLTEtMTE4ODMz_cd59d239-be8a-40fa-b77a-01dde297d67b">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231" decimals="-6" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktNS0xLTEtMTE4ODMz_a35ce84e-ceb2-4cee-a6f4-73967ee7d86d">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d8c8b108e34010b4bed817e2a890d0_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtMS0xLTEtMTE4ODMz_dcb13f40-b05c-4be2-bc83-54d6765ae026">20,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f33f8343cf341e081c829b309c949a4_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtMy0xLTEtMTE4ODMz_f50614ef-889c-41fb-a61b-765ae9639831">19,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e12b27d5b94e89971f0a98991944b1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtNS0xLTEtMTE4ODMz_b7d30679-5954-4da6-9a62-c508140d67af">19,732</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd9e2d2be054f858e0733f3f3365bbb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItMS0xLTEtMTE4ODMz_a585ac08-bdd6-49fe-a0b8-357fe40349af">1,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc5a34dafaee43739ad795081962c7a8_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItMy0xLTEtMTE4ODMz_d2572f84-4f70-440d-a401-c5d50e353778">2,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8645703dda44b3d867bbb14b332875b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItNS0xLTEtMTE4ODMz_f7b12280-0fb6-4b30-b6fb-fc40b626cf41">2,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtMS0xLTEtMTE4ODMz_4251e938-bd54-4fd6-9ee4-4e716194dc00">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtMy0xLTEtMTE4ODMz_f5b6e575-7105-4fd2-afa9-7f38b8e495f0">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtNS0xLTEtMTE4ODMz_1302648e-9244-428d-b071-53a1aa01a176">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231" decimals="-6" name="us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtMS0xLTEtMTE4ODMz_34b5dd56-5ed3-4d1c-a8fa-21aad67e5849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231" decimals="-6" name="us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtMy0xLTEtMTE4ODMz_fc8610e6-ad33-40c5-b9b6-a8d2a85efb59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtNS0xLTEtMTE4ODMz_e713e73f-7e37-4050-8aac-e3b140e52017">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtMS0xLTEtMTE4ODMz_68def251-3b1e-413c-a1dd-dcf7dbe3f504">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtMy0xLTEtMTE4ODMz_115e86ce-e617-444d-858e-acebfec96996">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtNS0xLTEtMTE4ODMz_dfba549a-8e70-4df8-9de1-b8bf16bbb8ea">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6af7edc70c84446284ff6b173c1e6e62_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtMS0xLTEtMTE4ODMz_db058d1b-60ef-4ceb-9b32-5357393115c3">750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd9e2d2be054f858e0733f3f3365bbb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtMy0xLTEtMTE4ODMz_d475420d-3fc2-448b-910b-5d7ab2c88521">1,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc5a34dafaee43739ad795081962c7a8_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtNS0xLTEtMTE4ODMz_29d38ad1-55fb-45d6-b84f-4eb279eb3d86">2,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss), Net of Tax </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1ce07457004d06a149601f4c4f99ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtMS0xLTEtMTE4ODMz_9ad65c6b-64e5-4977-93c7-f798538ba203">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtMy0xLTEtMTE4ODMz_72874a79-22e6-4ce5-9b6b-d97598ad55ed">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0357c11625794ac7a3d84a5f74c260a9_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtNS0xLTEtMTE4ODMz_a20111d7-67c3-422b-9ed7-9c3c664d59c4">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtMS0xLTEtMTE4ODMz_81ca5087-278e-4a81-b180-33cbfa763079">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtMy0xLTEtMTE4ODMz_70679c8a-6213-459e-8776-e551e2de8705">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtNS0xLTEtMTE4ODMz_0b63d534-faa1-4474-85da-f14f8aea7eca">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtMS0xLTEtMTE4ODMz_12c888b0-bb1f-4fdc-b96b-cb42b3f8a040">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtMy0xLTEtMTE4ODMz_2501a331-bf72-40cb-893e-ba7e990c6a3f">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtNS0xLTEtMTE4ODMz_56a84837-193c-4854-8736-f28331b28594">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined benefit pensions and other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItMS0xLTEtMTE4ODMz_6391e6fb-c8e0-43ea-b7d4-6c78598173ef">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItMy0xLTEtMTE4ODMz_88a3e58a-5a02-43f3-bdb3-f9e1162cc4ea">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItNS0xLTEtMTE4ODMz_bad6a78f-9b5e-4d93-a0d4-832d88a96ec8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d6ae39de2543159b001084dffe037d_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtMS0xLTEtMTE4ODMz_2261e0ba-bc04-4be2-ac6a-30d12a8615ad">269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1ce07457004d06a149601f4c4f99ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtMy0xLTEtMTE4ODMz_1406798a-ff9c-47f5-bd62-e5ebb0da087e">263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtNS0xLTEtMTE4ODMz_6f744bdb-7320-41b6-83f7-a2964f582c29">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtMS0xLTEtMTE4ODMz_200c801a-c673-4ab0-ac07-8a86122041d6">17,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtMy0xLTEtMTE4ODMz_8d6c2d60-7c99-4f1e-83db-8a994d999530">16,622</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtNS0xLTEtMTE4ODMz_3c8bbdce-102e-4286-838e-14b12739bce2">15,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy0xLTEtMS0xMTg4MzM_0c06fb88-28fa-42c2-8d97-f883df0f92fc">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy0zLTEtMS0xMTg4MzM_543326f0-5fc8-43fe-872e-811af5cd3154">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy01LTEtMS0xMTg4MzM_e9185411-baef-4b48-87c5-e2c6121f75b1">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposal of businesses and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS0xLTEtMS0xMTg4MzM_7d7ae3eb-414a-49e2-93e8-c43f6a7fc4ae">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS0zLTEtMS0xMTg4MzM_674c3e46-7c1e-40c3-ae28-db8f9a1fddb9">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS01LTEtMS0xMTg4MzM_d3266b80-e0a8-4094-875b-991a1e3a780b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy0xLTEtMS0xMTg4MzM_d4dbdc33-5988-421a-9530-8c119469c3cb">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy0zLTEtMS0xMTg4MzM_7533bab9-f977-4585-ae76-58a52755be68">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy01LTEtMS0xMTg4MzM_58b75126-b013-48e7-b768-1c7e3e55b58f">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred and prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC0xLTEtMS0xMTg4MzM_269f3940-6922-4164-a890-6f5da5670ee3">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC0zLTEtMS0xMTg4MzM_7a473b72-6f77-4ace-a1b8-895e94d79d72">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC01LTEtMS0xMTg4MzM_9357ef6c-09cb-4031-8e62-90b4a7a60201">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS0xLTEtMS0xMTg4MzM_83ac8a30-5257-4fe1-bf65-b24995399120">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS0zLTEtMS0xMTg4MzM_932b4cce-c538-4db7-8fc6-d7baa577b9f2">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS01LTEtMS0xMTg4MzM_3cf104dc-f1a0-4cc6-a8e2-7d21bcdb84fa">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangible asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtMS0xLTEtMTE4ODMz_7686862b-bece-4781-8c6c-61ca59804c5e">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtMy0xLTEtMTE4ODMz_627bac87-c07d-4939-b46f-e565e96f3624">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtNS0xLTEtMTE4ODMz_d831291f-996e-4928-be94-e574e5ab0226">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) on investments and notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItMS0xLTEtMTE4ODMz_96600354-7780-40f0-879c-6f81c6af743e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItMy0xLTEtMTE4ODMz_e3b4c881-1528-4068-9e71-b75521d729c9">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItNS0xLTEtMTE4ODMz_6c1dca5c-5e77-4165-9c15-f8ec2bba6b0c">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtMS0xLTEtMTE4ODMz_039ddf5c-1016-4ecc-908d-976bac32e502">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtMy0xLTEtMTE4ODMz_9d947c19-9c68-4786-9f8e-1e37abf98241">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtNS0xLTEtMTE4ODMz_622ce23f-d6ac-420a-9aa4-bdeca84fd44a">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory step-up amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:InventoryStepUpAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtMS0xLTEtMTE4ODMz_8aca7dca-18f3-4606-a265-6ec14b0cb475">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:InventoryStepUpAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtMy0xLTEtMTE4ODMz_ac29665e-6340-43b7-afae-730dd5a8efbd">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:InventoryStepUpAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtNS0xLTEtMTE4ODMz_6d7ab08f-1df6-4879-bef4-d4b19a23fd84">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="bsx:NetCurrencyExchangeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtMS0xLTEtMTE4ODMz_d0c25a23-fd7e-42c7-a4fc-97ba4996b4ff">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:NetCurrencyExchangeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtMy0xLTEtMTE4ODMz_eb231260-79c8-4a74-a35a-80c77c3659cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:NetCurrencyExchangeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtNS0xLTEtMTE4ODMz_2fcbefdf-b173-4316-b12c-3ab3891edcc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:OtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctMS0xLTEtMTE4ODMz_f247a153-170f-4883-960c-b97b36810632">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:OtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctMy0xLTEtMTE4ODMz_49818b3d-72a0-4821-bbf3-59d57394af38">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:OtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctNS0xLTEtMTE4ODMz_b70bb694-df00-4cfa-ae53-d808c632184c">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Increase (decrease) in operating assets and liabilities, excluding purchase accounting:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktMS0xLTEtMTE4ODMz_546c08ea-57dd-425a-894d-d120ceb8bf8c">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktMy0xLTEtMTE4ODMz_f6c39462-2eb7-4167-87d7-5034d56d9225">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktNS0xLTEtMTE4ODMz_a94aa688-d202-49fd-bdd0-66394fe0a085">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtMS0xLTEtMTE4ODMz_e5947468-c7ae-47ff-979f-e9a77f4347c7">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtMy0xLTEtMTE4ODMz_4b21f897-dac4-4706-88d4-b9891db15969">346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtNS0xLTEtMTE4ODMz_f841301d-52cf-44a8-b860-aa113f7f7c97">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtMS0xLTEtMTE4ODMz_b2af8c31-669d-4878-9f3c-a4aa6eaff371">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtMy0xLTEtMTE4ODMz_8346ae0a-2d38-44b7-92f8-028ce5c74d39">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtNS0xLTEtMTE4ODMz_758df244-b9e7-4040-83d5-afffcc7fe349">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItMS0xLTEtMTE4ODMz_1eb9bdc0-1024-4b2c-a4d5-27578c168922">255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItMy0xLTEtMTE4ODMz_966db5f3-73bc-459a-ba30-d6f344e5d0a3">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItNS0xLTEtMTE4ODMz_f077a4cd-d349-4028-bac4-32c9cdd2ef5b">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash provided by (used for) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtMS0xLTEtMTE4ODMz_447697a8-0a0c-45fc-a9ba-232e181213e2">1,526</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtMy0xLTEtMTE4ODMz_e92ffddf-81ee-4afa-8deb-2306d0e35f3e">1,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtNS0xLTEtMTE4ODMz_c8b5b3c8-0beb-478b-b218-51cfcbca00b1">1,508</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment and internal use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtMS0xLTEtMTE4ODMz_9b30f857-095e-4afb-92bb-8cba4250f5bd">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtMy0xLTEtMTE4ODMz_ed87b6a6-81b0-47f4-a33f-7696ee3aefca">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtNS0xLTEtMTE4ODMz_c461b262-fadd-476d-8c37-bad6262e321f">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctMS0xLTEtMTE4ODMz_4b86b82a-bdd8-4fee-b8fe-ebe839514ae9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctMy0xLTEtMTE4ODMz_e0adc42f-a012-4b4b-afee-7903cc709658">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctNS0xLTEtMTE4ODMz_8fe82922-22cf-48e3-83cd-e68c3d162e91">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtMS0xLTEtMTE4ODMz_ba41f49a-3d84-4c8f-9de1-3587cf7b1780">1,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtMy0xLTEtMTE4ODMz_df9026e9-766d-4945-8b63-0470871d0f9f">2,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtNS0xLTEtMTE4ODMz_e0a499a3-d918-447d-9c5b-943d6ec35c13">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from (payments for) investments and acquisitions of certain technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMS0xLTEtMTUwNDY0_bead5775-c7e4-4b7a-8a19-82a4a1d9e2f8">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMy0xLTEtMTUwNDY0_a990d84e-5c2d-4e25-b631-8729f2b42ab2">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktNS0xLTEtMTUwNDY0_a905ff6e-e8fe-45f2-a6bd-ca32ea06a92a">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of certain businesses and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMS0xLTEtMTE4ODMz_5236bba0-d2b9-4c6e-8cd7-edfede48319b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMy0xLTEtMTE4ODMz_e199ff6e-4f0f-4d33-95d5-48b5f437af9d">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktNS0xLTEtMTE4ODMz_96ca4bc2-f2a2-47ef-a243-36f9f4c581bd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtMS0xLTEtMTE4ODMz_36a42e8c-a4dc-4faa-9113-abb24447a800">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtMy0xLTEtMTE4ODMz_f31aad5c-f76a-4d9d-ae10-5c69e83aac39">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtNS0xLTEtMTE4ODMz_b44a7bbd-469e-4bbf-bfbc-5f2f4057503f">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from (payments for) settlements of hedge contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtMS0xLTEtMTE4ODMz_75ce2fa6-df00-43ea-8990-951ee349e36d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtMy0xLTEtMTE4ODMz_c6c4fa77-ccbe-44aa-a00c-41f8663d1f62">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtNS0xLTEtMTE4ODMz_dfcc74d7-8195-4b74-ab31-d99bba2c3fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash provided by (used for) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtMS0xLTEtMTE4ODMz_09eb00d0-27b0-45ec-a825-dfb825be599a">2,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtMy0xLTEtMTE4ODMz_19ecd4d7-975e-4150-b1b0-782ac89a9004">1,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtNS0xLTEtMTE4ODMz_f6fb33a4-189a-4cec-bdc5-1cd96ec7808c">411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent consideration previously established in purchase accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctMS0xLTEtMTE4ODMz_0d45de04-a615-4f07-9a64-d4dfe405f690">335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctMy0xLTEtMTE4ODMz_77cf0d62-a120-4c20-9604-8cb01005ff97">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctNS0xLTEtMTE4ODMz_a9fe5ebc-27f7-4c79-917e-96df4207039f">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:PaymentsForRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtMS0xLTEtMTE4ODMz_fd33ce7f-aaf9-47d1-a87e-38f2fefea5e6">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:PaymentsForRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtMy0xLTEtMTE4ODMz_2eca70ff-6d8d-4e8c-ace1-c1e8cf718db3">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:PaymentsForRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtNS0xLTEtMTE4ODMz_7e4b62bb-5d9c-4618-9a5b-ba4398466c48">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments on short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtMS0xLTEtMTE4ODMz_fd095333-06d6-420f-89f7-894ab19368c3">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtMy0xLTEtMTE4ODMz_5a89ea25-0203-468a-b531-77a8f8c92018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtNS0xLTEtMTE4ODMz_169a3f8a-d54e-4206-8309-28c9afb139e7">2,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings, net of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtMS0xLTEtMTE4ODMz_85b92412-041e-470f-b3b9-a0fca1d9505a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtMy0xLTEtMTE4ODMz_7bfbc7a7-e2d2-4765-b1e8-b2b1af150f0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtNS0xLTEtMTE4ODMz_19e0174c-14ad-4255-bec7-b853d2e54f33">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItMS0xLTEtMTE4ODMz_303a58f6-0abb-44f2-a239-a4e5446b7003">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItMy0xLTEtMTE4ODMz_2b149a2f-8084-4277-9a8f-c4f3835e9499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItNS0xLTEtMTE4ODMz_4ff33039-9eb4-49b3-acc0-ea27263397a6">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments on borrowings from credit facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtMS0xLTEtMTE4ODMz_3115e14d-cdba-454a-8a19-bb57aacf76f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtMy0xLTEtMTE4ODMz_393ac494-9bb5-4119-8ae9-867ead8bfe74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtNS0xLTEtMTE4ODMz_3b26e370-fd28-481c-b03e-673a6df2b2d4">1,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings on credit facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtMS0xLTEtMTE4ODMz_e87906a6-dbae-42d1-babd-b34757021110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtMy0xLTEtMTE4ODMz_f7817083-511f-40cb-98da-b3d077424744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtNS0xLTEtMTE4ODMz_d0c641a6-6bd8-4b33-869e-4ae8ab5d6d5e">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments on long-term borrowings and debt extinguishment costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtMS0xLTEtMTE4ODMz_056c8bac-9960-4f32-b149-8c2b7f101307">3,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtMy0xLTEtMTE4ODMz_92a368d5-71a1-45aa-8836-53f9373ac90d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtNS0xLTEtMTE4ODMz_add4c802-8085-49b6-b97f-7e476f85e66f">1,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from long-term borrowings, net of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtMS0xLTEtMTE4ODMz_f905a2d0-3b74-444f-a02c-6b50de3f2597">3,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtMy0xLTEtMTE4ODMz_42465cfd-a41a-4064-98b3-6f913400b89a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtNS0xLTEtMTE4ODMz_2e27c745-636e-4020-9919-46606cd46818">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends paid on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctMS0xLTEtMTE4ODMz_c89e4ba1-a2ef-4288-8a62-1e6c368b70a3">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctMy0xLTEtMTE4ODMz_5eeb4aaa-5e74-45a9-85e2-e6a9094ce2b9">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctNS0xLTEtMTE4ODMz_2da8e03d-0efa-4ca3-b1e6-4722fbbc11b9">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of preferred stock in connection with public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtMS0xLTEtMTE4ODMz_fc035360-6b22-444c-b477-c75b03ad54f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtMy0xLTEtMTE4ODMz_180ea527-dbd9-4716-bfbc-54a1da28c6c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtNS0xLTEtMTE4ODMz_178144e4-7706-4d64-8eb4-a7c39ea4a015">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock in connection with public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktMS0xLTEtMTE4ODMz_68df96b0-e82e-4845-a2c5-d72a8b2e635e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktMy0xLTEtMTE4ODMz_a71c8264-f44d-4112-b36f-d44548e73a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktNS0xLTEtMTE4ODMz_250037cc-2492-44df-a8d0-cfd85e91b6ee">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtMS0xLTEtMTE4ODMz_169a80d8-091e-4488-9c83-80ecca412616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtMy0xLTEtMTE4ODMz_cf28340b-110a-4f19-94e1-958baff280e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtNS0xLTEtMTE4ODMz_889f1c4e-a335-4620-922b-61130f23cdb6">535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used to net share settle employee equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:Paymenttonetsharesettleemployeeequityawards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtMS0xLTEtMTE4ODMz_cafd2acc-0737-4004-a1a5-b662da975f81">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:Paymenttonetsharesettleemployeeequityawards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtMy0xLTEtMTE4ODMz_6de568e2-b0ab-43ed-851d-5caa998b09c8">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:Paymenttonetsharesettleemployeeequityawards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtNS0xLTEtMTE4ODMz_e2ce0819-a664-43f7-81fc-d00e21deb937">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItMS0xLTEtMTE4ODMz_3ff8f48c-41b8-4519-bd52-ee9ada6cbd28">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItMy0xLTEtMTE4ODMz_8aabb1ea-6116-4ace-9505-270471d76f4f">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItNS0xLTEtMTE4ODMz_8b590c58-ec0a-4a3f-b9e8-12aef8032b25">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash provided by (used for) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtMS0xLTEtMTE4ODMz_ac03697a-588f-4110-b3d4-5d768a935ccf">548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtMy0xLTEtMTE4ODMz_afddc395-0434-4c95-a0aa-8c468f47cd51">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtNS0xLTEtMTE4ODMz_3553f10b-5f2d-4597-88b7-a971aff51a18">293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtMS0xLTEtMTE4ODMz_5eb9e67d-829e-4f4a-8a3d-1986d7eb58df">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtMy0xLTEtMTE4ODMz_6563e4bc-fd29-4424-bb41-2f0b19be9360">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtNS0xLTEtMTE4ODMz_2463501a-9f3a-4ea8-9857-8f215bf73588">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease)&#160;in cash, cash equivalents, restricted cash and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtMS0xLTEtMTE4ODMz_f6ff048b-9633-4abc-a355-2ea10e406be8">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtMy0xLTEtMTE4ODMz_e5648e96-9ba0-49f4-8f07-d76033e57981">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtNS0xLTEtMTE4ODMz_9d28d9ca-6ad4-4d6a-96ff-9c6729b03de3">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtMS0xLTEtMTE4ODMz_0b2b121b-c0d8-4a47-a1b4-fcf4a6403e3d">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtMy0xLTEtMTE4ODMz_01bc3d6c-bd47-45f5-9344-bf69844804f1">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtNS0xLTEtMTE4ODMz_0e328b4d-a889-4dfc-964f-00310c2fed44">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctMS0xLTEtMTE4ODMz_c361849a-434f-43b0-bfb6-ee9ed2e36d33">1,126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctMy0xLTEtMTE4ODMz_17054481-dc71-48da-adb2-7f75411cee05">2,168</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctNS0xLTEtMTE4ODMz_893a85df-054b-4386-b145-ce77f672ee56">1,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS (SUPPLEMENTAL INFORMATION)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash (received) paid for income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy0xLTEtMS0xMTg4MzM_3816988a-66d0-40e9-8811-361c94e733e0">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy0zLTEtMS0xMTg4MzM_47cfa8aa-bb95-46a2-8c0b-c4043b225c2c">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy01LTEtMS0xMTg4MzM_9dc3b01a-0628-442f-b32a-d47bf04fe2d1">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC0xLTEtMS0xMTg4MzM_f215f366-8fd0-44c5-8483-22b0dc44080a">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC0zLTEtMS0xMTg4MzM_4348ef50-9b2a-4928-b993-d53b41c39698">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC01LTEtMS0xMTg4MzM_7fbe558c-8548-429e-939e-a7cc2182d87d">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration recorded in purchase accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS0xLTEtMS0xMTg4MzM_9c38b7a7-ae32-4077-bc7e-d01d60445c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS0zLTEtMS0xMTg4MzM_e8db67f8-efa5-4291-b8a3-4b373a88b953">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS01LTEtMS0xMTg4MzM_a7e68917-35eb-4451-bedf-39e77f01beb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash impact of transferred royalty rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" sign="-" name="bsx:NonCashImpactOfTransferredRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi0xLTEtMS0xMTg4MzM_003208cc-15ec-40f0-937c-eb70393916f0">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" sign="-" name="bsx:NonCashImpactOfTransferredRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi0zLTEtMS0xMTg4MzM_ed0fa654-7b1a-49df-9ff3-37f91847a154">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" sign="-" name="bsx:NonCashImpactOfTransferredRoyaltyRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi01LTEtMS0xMTg4MzM_fa77f66f-f659-4062-a4a4-156f4f3a97ad">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation to amounts within the consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtMS0xLTEtMTE4ODMz_aec166f0-7495-4704-b1bc-cebefb57dade">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtMy0xLTEtMTE4ODMz_d0117375-0428-463a-8816-c3e097d03427">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtNS0xLTEtMTE4ODMz_c228ae1f-f774-4423-bdbc-34c387dee62f">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItMS0xLTEtMTE4ODMz_003211f4-fcc5-4bd2-8607-a44829b272af">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItMy0xLTEtMTE4ODMz_32b73cc0-6709-4312-a313-90d278ba93ef">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItNS0xLTEtMTE4ODMz_63c7c4c9-61e8-4f5c-9d83-63e9f47d506e">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash equivalents included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtMS0xLTEtMTE4ODMz_1d96370a-b3e6-4201-ba4a-d81641b90948">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtMy0xLTEtMTE4ODMz_dfeffcce-e858-4b10-9f65-79142a943943">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtNS0xLTEtMTE4ODMz_ffef3c01-899f-44a3-a048-c984ba8c1c1e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtMS0xLTEtMTE4ODMz_85a8f270-f0ac-44ce-915c-8e94f6d50cc9">1,126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtMy0xLTEtMTE4ODMz_0cf9c72e-929d-43de-aad7-7480a5b3a559">2,168</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtNS0xLTEtMTE4ODMz_97625789-7545-43a7-881d-55d36759263f">1,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_97"></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2MTA_53a36a52-45cf-4241-8ef2-07692b627caa" continuedAt="ib4c94d3034064d5583291d6baada5520" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A &#8211; SIGNIFICANT ACCOUNTING POLICIES</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2ODQ_05f0fe00-4c56-43e3-a04d-c7b1e566face" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity&#8217;s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation&#160;S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDM_383181d6-7a1c-424e-a422-d8830a86e9b6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NzU_567c1cde-267b-42d7-bdec-75df0060c203" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NTQ_601a1ea0-d75e-4772-862b-8ce4b5273749" continuedAt="i8f432ecfda7b4c159f61fc6ce6c943fe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib4c94d3034064d5583291d6baada5520" continuedAt="i45475489aa9943b3b914a2d62bb6d320"><ix:continuation id="i8f432ecfda7b4c159f61fc6ce6c943fe" continuedAt="i6c034592dd404399867f667dde33535a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i6c034592dd404399867f667dde33535a" continuedAt="i8bc5e0bada0a49e396d1eb95cb9ddb52"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bc5e0bada0a49e396d1eb95cb9ddb52">within our consolidated balance sheets are related to deferred compensation plans.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDQ_48a631cf-e2b5-4602-9aa7-5bb4cc082652" continuedAt="ied944525495846d6b8ddda4b9678ad4a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="ied944525495846d6b8ddda4b9678ad4a" continuedAt="i960256a4794844978809ba1f5676b349"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i960256a4794844978809ba1f5676b349"> is adequate as of December&#160;31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.</ix:continuation> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NDY_6b08227e-0993-4f0d-ade7-c00355cd8f24" continuedAt="ib3193546751e4b498ff1232ec23e6b19" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i45475489aa9943b3b914a2d62bb6d320" continuedAt="ic81031a9bb944372b87bdefdeca133c5"><ix:continuation id="ib3193546751e4b498ff1232ec23e6b19"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#8482; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:StandardProductWarrantyPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NjI_9df9e290-14d0-469b-b53b-5db8662e5d9a" continuedAt="ibf987f21963d48708ae63c232590b7b1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic81031a9bb944372b87bdefdeca133c5" continuedAt="i3f6f6c0e95f84118b733fc0ff0e0fdab"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf987f21963d48708ae63c232590b7b1">liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NDc_64e8f743-f5ca-4fdc-b5ac-8a5c9c2ac7a9" continuedAt="i7b5692b6420c4f068aba38245d3cb4c8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMTQ4NDg_1ebd1f65-267b-4278-b980-878b90304e38">149</ix:nonFraction>&#160;million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b5692b6420c4f068aba38245d3cb4c8">We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1ODg_2f99e962-e486-465e-86ed-2884a22c59d4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40&#160;years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2Mjc_4412441c-3032-4b80-9ebc-bd68499ab18f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#8217;s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1ODM_4e09066f-c2c5-426c-b273-bb4d972c5c57" continuedAt="id6ab297f99b84f09834bcd28def90322" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3f6f6c0e95f84118b733fc0ff0e0fdab" continuedAt="i743bd76c288b434a9f1e0b1703136f34"><ix:continuation id="id6ab297f99b84f09834bcd28def90322" continuedAt="i6bb855d0e8cc496b82a6c3ec377fe727"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects&#8217; stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bb855d0e8cc496b82a6c3ec377fe727">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2OTA_f278276a-04cc-4158-af14-7aabc7baed05" continuedAt="i808f0de750184546ac00d1458cfa7895" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20&#160;years; amortizable technology-related and customer relationships, five to 25&#160;years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i808f0de750184546ac00d1458cfa7895">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i743bd76c288b434a9f1e0b1703136f34" continuedAt="id014a4d8eb86428e904db6c725a3f733"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1MTk_ca70869c-b223-48b8-af6e-27104464ef5a" continuedAt="i2ff2369ef33a4bfa909fb7c2cc1cbc1d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i2ff2369ef33a4bfa909fb7c2cc1cbc1d" continuedAt="i8394ca6a41e844a79c18ebc7c6c28ce6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8394ca6a41e844a79c18ebc7c6c28ce6">, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2MjQ_8f675808-67d8-4073-9ae7-983db5be731e" continuedAt="icbad169bf88140df80b6413f1b66ce4b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50&#160;percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee&#8217;s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="icbad169bf88140df80b6413f1b66ce4b" continuedAt="if7567bbc7a2948ee85ddca0995a8edff"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7567bbc7a2948ee85ddca0995a8edff">in our consolidated statements of operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MTM_8dc96c53-a0cc-41a1-8257-2f112bbd2e9f" continuedAt="i1d51b7e6a4454433ac645ca54f72c8cb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id014a4d8eb86428e904db6c725a3f733" continuedAt="ie722ac4a897f4c19b3bb1d696eabc77a"><div style="text-align:justify"><ix:continuation id="i1d51b7e6a4454433ac645ca54f72c8cb"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H &#8211; Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2Njk_6b3d303f-73a4-4f74-9cb5-c8516622a78e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1MTA_643d3f14-4ddb-434f-8617-02848ed4283e" continuedAt="i915e882bfecf4bb8bdf64fe0c51d2500" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We record such costs into expense over the employee&#8217;s future service period, if any. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i915e882bfecf4bb8bdf64fe0c51d2500" continuedAt="i7c5653c6b98647b69481334e7bcccd3e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c5653c6b98647b69481334e7bcccd3e"> in our consolidated statements of operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NDE_11e03ba8-c2a3-48af-b567-b3dd1c852874" continuedAt="i8f685cf767b84e6f94968c59232f268e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i8f685cf767b84e6f94968c59232f268e" continuedAt="i135e32a8ca3043c8a97390e9d4d86c98"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i135e32a8ca3043c8a97390e9d4d86c98">in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.</ix:continuation> </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie722ac4a897f4c19b3bb1d696eabc77a"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NTA_b4095140-c9f3-4fe7-922a-80cc12339a01" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDU_8d6e4539-5da8-4c82-bfdf-c811c14ed1ee" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_100"></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjE3_95e61cba-b200-4388-a18b-9a2035e92ed6" continuedAt="ib00ae518c74c4ba9a0d87f655a73a03c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B &#8211; ACQUISITIONS AND STRATEGIC INVESTMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately <ix:nonFraction unitRef="number" contextRef="i39f7478fc1994fa5ae2a4818204ac7c3_I20220615" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc2MA_27bc329d-1e18-44f3-9a6e-e51fd6689898">64</ix:nonFraction> percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW <ix:nonFraction unitRef="krw" contextRef="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc3OA_a92dc058-62ac-4b45-858f-4c244a7f8357">291.2</ix:nonFraction>&#160;billion or approximately $<ix:nonFraction unitRef="usd" contextRef="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc5NA_f0d257bb-59f2-497f-850e-b916f7795e8c">230</ix:nonFraction> million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, we announced our entry into a definitive agreement to acquire <ix:nonFraction unitRef="number" contextRef="i91739b0d9fae4d91a17da45404a70bd4_I20221129" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI3NDg3NzkxMTA5ODM_23ef0403-a8a1-4f65-88d6-2d3a9a31c0bc">100</ix:nonFraction> percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i52eb55d7ac10453695894b8ed3be958c_D20221129-20221129" decimals="0" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgyNQ_94fc42e0-a629-4adb-b2ee-99d71d08a4b7">10.00</ix:nonFraction> per share, approximately $<ix:nonFraction unitRef="usd" contextRef="i2d7591fa55b4499f8bcaade3bba40cff_D20221129-20221129" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgxMw_025f2d98-eb52-41d0-9ba1-993420aca426">615</ix:nonFraction> million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately <ix:nonFraction unitRef="number" contextRef="i4de90588254145949ff313db5ff70926_I20230220" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg4MjQ_f355a9b2-5fff-4a69-9f91-eeba0179367f">65</ix:nonFraction> percent of the outstanding shares of Acotec, for an upfront cash payment of HK$<ix:nonFraction unitRef="krw" contextRef="if26a25d3f1534945a3bc82415ed7fc25_D20230101-20230223" decimals="0" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg3ODk_24c0a9bb-4f02-44f6-bc7a-f35695cc61d3">20.00</ix:nonFraction> per share, or approximately $<ix:nonFraction unitRef="usd" contextRef="ieea77466150d48c9a38a34a0031f8c09_D20230101-20230223" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg4MDg_a8e0167a-3fb0-4ff4-9e7a-78f69946e72b">520</ix:nonFraction> million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG&#8482; and VersaCross&#8482; Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgzMQ_9e4a46ea-761c-41ce-8b9a-523c3cae2cd4">1.463</ix:nonFraction> billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib00ae518c74c4ba9a0d87f655a73a03c" continuedAt="ia655af1a46b548c2bc95e68167599b48"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price was comprised of the amount presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIyOA_3fef7d8d-7dff-404a-bf1d-dfc9a50c2a51" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzEtMS0xLTEtMTQ5NTA4_3433c1f0-aa07-486d-8218-0e540c668437"><ix:nonFraction unitRef="usd" contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzEtMS0xLTEtMTQ5NTA4_cb4b3295-6c0c-489f-8eee-88ef7aee95ad">1,463</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzItMS0xLTEtMTUwMTcx_3433c1f0-aa07-486d-8218-0e540c668437"><ix:nonFraction unitRef="usd" contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzItMS0xLTEtMTUwMTcx_cb4b3295-6c0c-489f-8eee-88ef7aee95ad">1,463</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIyOQ_34006245-c62c-43ad-866b-54c1833b5c0c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:84.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzEtMS0xLTEtMTQ5NTA4_42b41253-328e-4f1c-8bd5-606572642f4d">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzItMS0xLTEtMTQ5NTA4_0d0f86b8-947c-45ef-bd2e-210e79616f04">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzQtMS0xLTEtMTQ5NTA4_df673c4a-d34f-4f2c-8523-9960e0b218a7">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzYtMS0xLTEtMTQ5NTA4_121565a3-2122-4d7f-87c6-9c22cf070dfe">287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzctMS0xLTEtMTQ5NTA4_a7f7025d-042b-4f06-9e1c-a51ced4e9fe2">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzgtMS0xLTEtMTQ5NTA4_815844ff-f2a9-49da-a0c1-d6cd8dceb318">1,463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIzMA_419e69dd-116c-4de6-bec6-53a51db567a0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c12e4b8e88946ea9f918f099eca4382_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtMS0xLTEtMTQ5NTA4_2f9f1cd1-1cd3-44dd-a545-ff7f646eb5b0">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a57f87953d04bcb90ea07b09c5d17be_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtMy0xLTEtMTQ5NTA4_f9938fe0-d00c-48c2-a3b2-8019dc9a6e76">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if226113987c44049a2899b6e0639d557_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzItNS0xLTMtMTcxMjY3_ba04a126-f2df-4a42-81c1-33fbbe43d221">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fae4e1ae03a42d985a17ed55da3dd73_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzUtMS0xLTEtMTQ5NTA4_ffbdf5d9-c180-4b0b-89d9-bfa92e69d345">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bdd48bb3d8f42bda231800746b62182_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzUtMy0xLTEtMTQ5NTA4_be959a4b-d6e8-4049-a0d3-92eaf17e1dac">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if611a01731ac40b8a3f718fdab5f1fef_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtNS0xLTMtMTcxMjY3_2bd23a3e-c1aa-4054-86a9-d630d630f7b5">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76d0b974c2249e39200438329a79acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzQtMS0xLTEtMTUwMjEy_7bd27c27-bde3-4dcb-82cc-62cde87188cf">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE0MDM_a250104c-b05d-449a-9767-db66f4f49764">925</ix:nonFraction> million and up to an additional $<ix:nonFraction unitRef="usd" contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301" decimals="-6" name="bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE0MzA_f8d2693a-4545-4951-af86-23cee63d9593">300</ix:nonFraction> million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately <ix:nonFraction unitRef="number" contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE1Njk_edfa30e2-9c2c-4bf3-907d-6fc53e1eeeb6">22</ix:nonFraction> percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE3ODc_aaa98c29-575d-440e-bd81-4d69de4f3de3">196</ix:nonFraction> million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE5MTE_69ca143a-8ba1-4281-802f-f7632c4e84a0">706</ix:nonFraction> million, net of cash acquired, and an additional revenue-based milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE5NjE_e8aab1ad-e096-4a73-801c-733862248f55">216</ix:nonFraction> million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia655af1a46b548c2bc95e68167599b48" continuedAt="iff90c47497c246d9bae2287ffa5a6f1c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzIzOTE_52ee6dad-8e13-4283-96a9-3741b43ba2dd">450</ix:nonFraction> million, up to $<ix:nonFraction unitRef="usd" contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806" decimals="-6" name="bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI0MDE_edbf7aaa-120f-462c-bf47-6441daf5fa6e">125</ix:nonFraction> million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next <ix:nonNumeric contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806" name="bsx:BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI1MTk_8fd15fde-baf4-4505-9fc2-7dae1a2eab68">three years</ix:nonNumeric>. We had been an investor in Farapulse since 2014 and held an equity stake of approximately <ix:nonFraction unitRef="number" contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI2MTM_af73eb84-d48e-434c-b009-d30016457626">27</ix:nonFraction> percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI4MzA_eb787d2f-6ecc-452b-90be-3a482b729cc9">222</ix:nonFraction> million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI5NTQ_9f405d11-5ae1-4340-a032-8ca6a77c2bce">268</ix:nonFraction> million, net of cash acquired, up to $<ix:nonFraction unitRef="usd" contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzMwMDQ_1fe2c4ac-8fc7-45dc-a2c3-55594e752dc1">92</ix:nonFraction> million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $<ix:nonFraction unitRef="usd" contextRef="ib0472293542444a397c435d4b743117f_D20220101-20221231" decimals="-6" name="bsx:PaymentOfContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI3NDg3NzkxMjI3NTY_c30aaa04-0586-45dd-aed4-0009872a5c31">114</ix:nonFraction> million to date. The Farapulse business is being integrated into our Cardiology division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i9433d2d803b946a2a1c5f7f1eef556b3_D20210901-20210901" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzM0ODE_57b8a31a-c971-4bd3-b424-4484035d4b0b">1.032</ix:nonFraction> billion, net of cash acquired. The Lumenis business is being integrated into our Urology division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy&#174; Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzM5OTA_ee707419-c3d5-4681-98fc-0b9515c4fe1c">320</ix:nonFraction> million and up to $<ix:nonFraction unitRef="usd" contextRef="i16dfec677c164b2db255f582287df56d_I20211108" decimals="-6" name="bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQwMDM_6383ed79-54f1-45f3-8ff8-2e2b26efbdd2">80</ix:nonFraction> million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately <ix:nonFraction unitRef="number" contextRef="i16dfec677c164b2db255f582287df56d_I20211108" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQxNjU_cccccace-1bfb-4697-9f8f-5cf7b43df1a8">16</ix:nonFraction> percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $<ix:nonFraction unitRef="usd" contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQzNDA_bd465acf-5b13-4898-a98b-dfe4fa9e185c">57</ix:nonFraction> million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQ0NjQ_e5fb3ab3-7445-4176-99bd-67058c115e2d">251</ix:nonFraction> million, net of cash acquired, and up to approximately $<ix:nonFraction unitRef="usd" contextRef="i16dfec677c164b2db255f582287df56d_I20211108" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQ1MTQ_4a1f1abb-6006-46cb-8ba1-3accff5c656a">67</ix:nonFraction> million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed <ix:nonNumeric contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjI0_465478c4-633e-4035-b959-92023dd19b6b" continuedAt="iae12769adda047d382621bd1584e3e68" escape="true">in accordance with Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification&#160;(ASC) Topic 805, </ix:nonNumeric></span><ix:continuation id="iae12769adda047d382621bd1584e3e68" continuedAt="ia4143b34b95043208d082f5bd6dc85e1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="ia4143b34b95043208d082f5bd6dc85e1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtMS0xLTEtMTE4ODMz_f1f5776b-0638-464a-a946-0727991f8cc7">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc362728b97e470189a743db7df633f8_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtMy0xLTEtMTE4ODMz_4210867f-b67b-41d1-b454-ed37c87b381a">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtNS0xLTEtMTE4ODMz_937038f4-e98f-47e0-b2ad-b570fdd96d21">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtNi0xLTEtMTE4ODMz_8f081a96-267a-41db-b546-80f0bd34e958">2,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItMS0xLTEtMTE4ODMz_4019e961-5768-4cad-a7ce-6afd7868f513">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItMy0xLTEtMTE4ODMz_45667216-580c-4af7-87fe-0870e102d365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItNS0xLTEtMTE4ODMz_125b86ca-66e6-4aba-b5e7-2129b8f409c5">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItNi0xLTEtMTE4ODMz_be9da697-a76f-4cc9-ad0a-62740b33fac5">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of prior interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtMS0xLTEtMTE4ODMz_dfafca01-8b7b-4dcc-bb73-1c03693d42af">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc362728b97e470189a743db7df633f8_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtMy0xLTEtMTE4ODMz_961380c5-15ec-436c-b3ae-802319ff08bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtNS0xLTEtMTE4ODMz_3f482eb7-8de5-49ac-8383-a1400ac73e1e">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtNi0xLTEtMTE4ODMz_95edc7a5-6178-4935-abb6-672d9f13d010">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtMS0xLTEtMTE4ODMz_a9ad6068-3fec-417e-9ee0-a96241fc545d">1,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtMy0xLTEtMTE4ODMz_7e1ed929-cc89-47c9-93ea-088e3d496aa8">1,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtNS0xLTEtMTE4ODMz_133b0bac-1203-4c0b-a496-1f66b0c0728d">1,025</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtNi0xLTEtMTE4ODMz_9f2a616d-8e43-4571-ae44-11b4f1332502">3,254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTkx_65668f03-1d03-4b18-9738-c57ec5c558c1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation for these acquisitions was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtMS0xLTEtMTE4ODMz_743a7468-ef54-45a6-b95d-023f39112583">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtMy0xLTEtMTE4ODMz_4aa6fa83-f689-4673-97de-e51800d3f468">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtNS0xLTEtMTE4ODMz_2bc43871-d56b-4733-85c9-27c7bcafeb9a">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtNi0xLTEtMTE4ODMz_c464b99e-160d-43d9-bbdc-67174ec8bd20">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItMS0xLTEtMTE4ODMz_4eab596e-363e-4955-8392-654b834e7592">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItMy0xLTEtMTE4ODMz_70625f16-071e-4770-a1c7-4d5cd1eab882">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItNS0xLTEtMTE4ODMz_7069aed0-31f5-4c90-85ea-79aaab8f8082">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItNi0xLTEtMTE4ODMz_003d1270-fa1b-4252-bc58-238f19f37a4e">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtMS0xLTEtMTE4ODMz_75d90a0b-dd95-4487-8724-31412743ded7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtMy0xLTEtMTE4ODMz_a4b8692e-c790-4128-844a-0ee469354849">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtNS0xLTEtMTE4ODMz_7abc98b2-7e02-4e2a-b796-a15d0f586a6f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtNi0xLTEtMTE4ODMz_7f73604c-cb9d-41cb-b345-f6098cda8d32">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtMS0xLTEtMTE4ODMz_91769143-c441-4871-9e0d-a4087117202a">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtMy0xLTEtMTE4ODMz_ba89cf38-271a-4a0e-8783-f48079d19604">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtNS0xLTEtMTE4ODMz_dbb0ccce-76d1-4e77-a826-82c0eac5c842">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtNi0xLTEtMTE4ODMz_4db99b66-945e-4d4d-988c-985dd02d1ca0">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtMS0xLTEtMTE4ODMz_1d73b952-d828-4863-87a9-b76367806c6d">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtMy0xLTEtMTE4ODMz_6374dc1b-5f3f-451f-ab15-2a65d1545926">282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtNS0xLTEtMTE4ODMz_d375497c-a080-4cf1-a3c4-a4de0288cb6e">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtNi0xLTEtMTE4ODMz_1ff230be-9f73-429c-bfc1-5c6a15edd8a5">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctMS0xLTEtMTE4ODMz_04b55d61-1320-4d0b-88a2-2fa3458cc266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctMy0xLTEtMTE4ODMz_9f7c2aad-87c8-4528-8d83-e284c1a5959d">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctNS0xLTEtMTE4ODMz_26565b4c-567e-411e-9e81-26a52fa15f3c">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctNi0xLTEtMTE4ODMz_a47e2b97-c649-406a-baf8-0909a8745fc8">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtMS0xLTEtMTE4ODMz_ed1df75b-4159-4e60-b43f-141f7d199dfd">1,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtMy0xLTEtMTE4ODMz_4d1bed1a-a99f-4ca3-a3dc-af507397b892">1,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtNS0xLTEtMTE4ODMz_432a49ba-3f1f-4c8a-bd25-6f6259cc709d">1,025</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtNi0xLTEtMTE4ODMz_e764c63b-76a5-4023-8395-3de09d502b3e">3,254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iff90c47497c246d9bae2287ffa5a6f1c" continuedAt="ibce15cdbcf724258aba3b0d75eaa6555"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzQzODc_32e51ffe-b732-450b-9555-929d3711aaf0">183</ix:nonFraction>&#160;million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $<ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzQzNjg_7ee9ca0b-f918-4a5a-ada7-b8dd3519c301">177</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding adjustments to the indemnification asset are being recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note G &#8211; Supplemental Balance Sheet Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding our indemnification asset.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjQz_c5f4fbdb-69d6-42d8-a4c9-2e0b6df71dda" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Preventice:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida522649c73f489991dc9d869ad4cb1f_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtMS0xLTEtMTE4ODMz_42378641-83b3-49d1-98b6-e7a904e3e40a">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if86cd5fe3fca484b870d2bca0d5beae5_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtMy0xLTEtMTE4ODMz_6bda4499-eeda-4857-810c-90e228d28531">9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ideb4a49895044b7f93b87f1125e9a416_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtNS0xLTEtMTE4ODMz_5d06fad8-5f93-425d-a920-9c7cde4c85d2">10</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d216afbb77411a8e7a88fc901eb047_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtMS0xLTEtMTE4ODMz_b8936d69-9584-4bab-81c9-ee721f305afe">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide1123ea65934f2e965ed236c8440439_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtMy0xLTEtMTE4ODMz_e212cec4-29e2-4c80-913f-1aea35d8db3b">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f2d335c16564091877bbf5b8ea02230_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtNS0xLTEtMTE4ODMz_097bd0c9-89d6-43d2-b5b8-1290f869a15c">10</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzgtMS0xLTEtMTE4ODMz_55f98049-7ce0-4b64-aaed-f7f7b70304f6">237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lumenis:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083186e7733646c894ee4a0c3759132d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTEtMS0xLTExODgzMw_4ba4420d-3349-4c04-b935-0384648cebdf">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a8c96c67e8f436cbff8a3f7e7cf61ed_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTMtMS0xLTExODgzMw_0f132df9-7616-4bd8-8893-a6c9d949fe30">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03e104fe52bd4eaf9ecabbd0966f5c0c_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTUtMS0zLTExODgzMw_8b832358-c1fb-45da-b089-fd11660e66c7">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8992dd65c54f5a8d206129a6e43300_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTEtMS0xLTExODgzMw_912505ee-367d-4b92-b41b-7e6d0f25bbeb">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf6bacafeb2c4ee19ca76f16ce8b05d5_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTMtMS0xLTExODgzMw_3ab28ccb-6ff3-4592-99db-6bee9af0a24c">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2f9147295b4342ae1ef9f9a08e5b1c_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTUtMS0zLTExODgzMw_3d698375-be22-4a0a-acfb-adb313db5b2f">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298875e7f6c14315a22aa84704cb2ce9_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE1LTEtMS0xLTExODgzMw_6e9148b1-3451-4d38-8b7f-fb45d406dd25">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0d8c251041c479c83a81894f74cb3a1_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE1LTUtMS0xLTExODgzMw_0366b2b2-da64-43ee-a67f-5fd433ee3b9c">12</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE2LTEtMS0xLTExODgzMw_e5ddabda-73e2-4010-b2d8-117fc3eba837">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">All Other:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bda1329ad5a4a2f81c742cf431791e3_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTEtMS0xLTExODgzMw_6cb98189-92e6-4220-b978-7301dae11b9f">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae118e7e63dd4c05b064ed16436ebc0b_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTMtMS0xLTExODgzMw_86c571ff-3517-4c70-8046-d97858a45f68">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d1c3e36b9104f7d9dd2b0619383a285_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTUtMS0xLTExODgzMw_7c395773-5516-4b88-959c-bb34170838d4">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad30b208f74b9dbc3abb41b51d5b1f_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTctMS0xLTExODgzMw_52e9f694-079a-4967-853c-385c52c86304">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id779a81f335b433c9e90f850b830d36d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzIzLTEtMS0xLTExODgzMw_c5900649-6776-495b-8f8c-d028f3de4a8a">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36b821fcbadb4bd3aacf50d87394be76_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzIzLTUtMS0xLTExODgzMw_9b1919c0-aade-4ca8-a1f8-3c90c0ce1393">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzI0LTEtMS0xLTExODgzMw_cf46c13d-5f70-425b-ac0c-bf10ea6581dc">508</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Divestiture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU4OTg_3536ecbc-cf39-4771-bef8-3928678dfbdd">800</ix:nonFraction> million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of <ix:nonFraction unitRef="usd" contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301" decimals="INF" name="bsx:DivestitureAgreementTransferOfFacilities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU5NDE_e2c1b182-3db1-4ba4-8116-080b197d229e">five</ix:nonFraction> facilities and approximately <ix:nonFraction unitRef="usd" contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301" decimals="INF" name="bsx:DivestitureAgreementTransferOfGlobalEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU5NzM_6b01f0ba-d28a-456d-986f-643c2af0b237">280</ix:nonFraction> employees globally. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzU1MTY_5aa45f01-b56e-4ed4-b7d2-22d88c6f687b">73</ix:nonFraction>&#160;million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibce15cdbcf724258aba3b0d75eaa6555" continuedAt="i071f4f62748140ccbb7b75d09c8ad0a2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjM0_5fcc4732-287f-44c2-ad02-4d490c92253e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzEtMS0xLTEtMTE4ODMz_3352a38f-c8f7-49bf-8f7e-1e16740f8c39">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzItMS0xLTEtMTQ5ODUz_ab4f531d-f91b-46f9-9fb5-da36dc9264ef">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzItMS0xLTEtMTE4ODMz_dc13b5dc-508a-45c1-ae9b-b4e9d5ccce4e">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:PaymentOfContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzMtMS0xLTEtMTE4ODMz_4ccd13c6-5078-4afd-868d-b3f79ddc1841">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzQtMS0xLTEtMTE4ODMz_d6a83912-fe2d-42e8-9bfc-b55f866d0703">486</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzYtMS0xLTEtMTE4ODMz_8210325a-d406-41de-b6c1-e1b282a0d628">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:PaymentOfContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzctMS0xLTEtMTE4ODMz_175cf0dc-8302-4653-8373-6aca43994ce7">371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzgtMS0xLTEtMTE4ODMz_db3e484d-54fe-4bf8-9981-21e778bff41c">149</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December&#160;31, 2022, the maximum amount of future contingent consideration (undiscounted)&#160;that we could be required to pay associated with our completed acquisitions was approximately $<ix:nonFraction unitRef="usd" contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNTEw_cfeecbea-808c-42b6-8747-f05cbf05748e">417</ix:nonFraction> million. The net expense of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNjUw_565f4534-3655-4c53-b078-a4ecd7c74514">35</ix:nonFraction> million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNjU3_1f129adc-444e-4940-b87e-0d046c2728e7">136</ix:nonFraction> million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&amp;D program. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTg4_d3fb7172-b362-4447-b8aa-d1e4946f2582" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibc9e93fb57d049aba15e55858f4ab28e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtMS0xLTEtMTE4ODMz_7fe9c011-cde4-44bd-a2f3-719f6fdeb8be">13</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9c455c38cc5418c8c1d20f41ec12d1c_D20220101-20221231" decimals="INF" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNC0xLTEtMTE4ODMz_0c3a00ba-b069-43bb-a095-d7188fca8aed">1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie352ea4b79494664ac3998f2352658f9_D20220101-20221231" decimals="INF" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNi0xLTEtMTE4ODMz_ee5bf024-5001-47b5-90b6-6e8927332ded">2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc984d89ba45490889622ccc6fb20531_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNy0xLTEtMTE4ODMz_0834a89c-cfa8-45ea-89c2-bd8a4e81e7cd">2</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic745df5cf86544beb987a6cdbf4ae321_I20221231" decimals="2" name="bsx:ContingentConsiderationLiabilityProbabilityOfPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNC0xLTEtMTE4ODMz_117b95ac-f817-48c9-ad39-036e68851721">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8236d39ea3a54b19b58c9057e3712dd5_I20221231" decimals="2" name="bsx:ContingentConsiderationLiabilityProbabilityOfPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNi0xLTEtMTE4ODMz_c57ae405-43c7-4608-a5c1-03fd5efd9237">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09fdfdce24574b16ae9fca57363d0048_I20221231" decimals="2" name="bsx:ContingentConsiderationLiabilityProbabilityOfPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNy0xLTEtMTE4ODMz_b8d1d428-adf7-4306-8609-4c842d204ec0">22</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie344ff9d360c43ec88274800d50d23fd_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtMS0xLTEtMTE4ODMz_002ad889-a9cf-4b7f-8f9a-f3a09fa34e70">136</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e5dd3a9e74146d9bdbd43b08724c65a_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNC0xLTEtMTE4ODMz_b06e4482-23a2-4765-891a-24a4bf12d8d4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b8770fe069a48c28a36571ec7f42a16_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNi0xLTEtMTE4ODMz_37c89962-0d77-4984-9619-895a28ae5e5e">14</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea319dadfcac4428bed6eb3806fa0d6a_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNy0xLTEtMTE4ODMz_91468d99-36f9-49e3-83be-29a04536c48e">7</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie344ff9d360c43ec88274800d50d23fd_I20221231" decimals="2" name="bsx:ContingentConsiderationLiabilityProbabilityOfPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzUtNC0xLTEtMTE4ODMz_e562b07f-6693-4201-97e8-ceab0be3da4a">100</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60295929e3534f219e8dd476fdc06494_I20221231" decimals="2" name="bsx:ContingentConsiderationLiabilityProbabilityOfPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzUtNy0xLTEtMTE4ODMz_38980167-9513-4b14-9a54-0e1857f91501">100</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to our R&amp;D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December&#160;31, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i071f4f62748140ccbb7b75d09c8ad0a2" continuedAt="i16ec35f9354f4d88b4a59f3f3278af0c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTg5_3dda468d-077c-40ff-ba58-3f3355cc7a06" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzItMS0xLTEtMTE4ODMz_9773943d-a104-431f-b1a8-d3f7c1f9a763">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzItMy0xLTEtMTE4ODMz_1163101f-353d-48ab-aad5-ebc0b972c2e3">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzMtMS0xLTEtMTE4ODMz_437906f0-3987-4552-b901-c4a819e0bf04">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzMtMy0xLTEtMTE4ODMz_08560ce0-3a30-4ba7-bd82-0a7e933c40aa">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzQtMS0xLTEtMTE4ODMz_a2d214c7-7b94-49a5-b614-be8933aaf945">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzQtMy0xLTEtMTE4ODMz_fa561cd8-35cf-4e1b-a0f8-97e439c09336">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzUtMS0xLTEtMTE4ODMz_77d9180c-442b-458e-989b-e2f522af2156">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzUtMy0xLTEtMTE4ODMz_2f6a1f3d-e32e-4452-8950-801ea1b5a067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzYtMS0xLTEtMTE4ODMz_de2fd2d8-5b94-4690-89c8-fcba53bde8c4">407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzYtMy0xLTEtMTE4ODMz_6dee8e37-a47d-4e5e-b8b1-8e1f6832c353">412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Publicly-held equity securities are measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i16ec35f9354f4d88b4a59f3f3278af0c" continuedAt="ib5eb409b9b834461978290191a736355"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE1Njc5_50f6edf5-be55-4ee7-91e1-861bdad9b696">178</ix:nonFraction> million loss on our investment in Pulmonx Corporation presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5eb409b9b834461978290191a736355"> associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December&#160;31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MDg4_f78b692a-9347-4fc5-afd6-e753048f1551">232</ix:nonFraction> million, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities.</ix:continuation> </span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_106"></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMDU_f312d928-3c2a-460b-a6b6-08442e388b33" continuedAt="i482e375393494f7dbd698dffc5ec0a2a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C &#8211; GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMTE_89608bc4-4b22-4f97-a8fc-732de7fd8236" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItMS0xLTEtMTE4ODMz_3d6456e8-7954-4350-a759-895f7947fcbe">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItMy0xLTEtMTE4ODMz_7fac5968-16b4-4038-a378-5ac222df586f">7,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b643ca1df374b79a206f73c4e819e2c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItNS0xLTEtMTE4ODMz_7d056e21-4d16-4d55-8b00-85df92418e04">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b643ca1df374b79a206f73c4e819e2c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItNy0xLTEtMTE4ODMz_6df01060-d884-4dbe-8838-0f21b2a3203e">6,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493e85aa50f24f0caa296c0a869c9130_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtMS0xLTEtMTE4ODMz_591b57c4-49f0-43ba-969e-2c4a1010c931">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i493e85aa50f24f0caa296c0a869c9130_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtMy0xLTEtMTE4ODMz_d48eed6b-c7c6-4903-98ed-3137a61638ac">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtNS0xLTEtMTE4ODMz_57499d46-662d-4c26-a64d-852239a3b13d">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtNy0xLTEtMTE4ODMz_a06e06d6-5c51-467d-aa7a-b106b947a98f">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i829f5796ec4446fda9daa222c9e48016_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtMS0xLTEtMTE4ODMz_08873390-b241-47e7-8c69-76b64cf454dd">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i829f5796ec4446fda9daa222c9e48016_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtMy0xLTEtMTE4ODMz_383d8c66-4f56-4b88-b0e4-148c50f151a9">1,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtNS0xLTEtMTE4ODMz_48c6abf9-c69b-4a44-863f-640024cd4bd3">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtNy0xLTEtMTE4ODMz_4b86c9de-bdab-4015-a0c0-cc74e9b9b5de">1,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtMS0xLTEtMTE4ODMz_97d58ca9-383b-424f-80a4-ab05d6063a4c">14,843</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtMy0xLTEtMTE4ODMz_f69e16e0-9dc5-4a42-8f7d-7858b9d6582c">9,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtNS0xLTEtMTE4ODMz_4c8eed7a-cf12-4fbb-a960-2247b9d34cbc">14,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtNy0xLTEtMTE4ODMz_a294e560-0cce-4ec0-9045-e49390724a1e">8,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctMS0xLTEtMTE4ODMz_2c3289b1-caa9-4073-ac14-62f13454752d">22,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctMy0xLTEtMTE4ODMz_56474836-2490-4395-a478-f5952492d9ba">9,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctNS0xLTEtMTE4ODMz_51178ba7-8cc7-4430-899d-e336821c75bc">21,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctNy0xLTEtMTE4ODMz_21688922-764a-4c6f-9560-a6d98e3bf18c">9,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb6963c5fa24817900cf506ab2e8417_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzktMS0xLTEtMTE4ODMz_23ef267b-eca0-4bb6-affa-68d366b5029f">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aec4b0808e4322ac9eaa857e19619e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzktNS0xLTEtMTE4ODMz_30b90567-e65c-4155-98cb-735007fc83f7">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a09f7d28b7a4d58918c0fc8fd00608b_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzEwLTEtMS0xLTExODgzMw_644d92b5-aaac-439b-981a-4b9369824808">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5be5738945b41cc9caa3ecef19ee3b3_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzEwLTUtMS0xLTExODgzMw_e4cf30bf-d068-4ca5-95bf-ea63ca726a26">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzExLTEtMS0xLTExODgzMw_009fb786-d912-4b75-b650-0c9c0abe301e">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzExLTUtMS0xLTExODgzMw_8f896f2c-4f46-4b20-98a5-8058ccec6751">246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc1OA_f219adb4-5b19-4d2e-b864-135a0194f36e">132</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc2OA_2dcd1bac-1faf-4729-80b4-c8f50dc2d77a">370</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc4MQ_15820e0a-d473-4b0c-9b19-f636679c02eb">460</ix:nonFraction> million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management&#8217;s decision </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i482e375393494f7dbd698dffc5ec0a2a" continuedAt="ie1e36e0dc7294c4ba8aaca081e8e86af"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to discontinue commercialization of the VICI VENOUS STENT&#8482; System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&amp;D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&amp;D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management&#8217;s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMzQ_f866aeaf-7241-404f-b75e-2d35664622b5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our goodwill balance by reportable segment.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:51.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6476257158644418375f2f260ef1d9c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtMS0xLTEtMTE4ODMz_2b7d455c-fde5-45b5-8320-04c107df6a6e">3,707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479b11e592d47a89236ff2bfeba753b_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtNS0xLTEtMTE4ODMz_946b005d-5284-4704-a818-562948973bb9">6,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtOS0xLTEtMTE4ODMz_1de3cd92-8342-42bc-a86a-8db57694906a">9,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtMS0xLTEtMTE4ODMz_57510838-c8a2-4795-93a4-6f6538d21ae8">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtNS0xLTEtMTE4ODMz_a2483f57-f979-4e98-a293-a13a8acb359d">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtOS0xLTEtMTE4ODMz_b83e5b11-ffa9-4a3b-a27c-5a8b7f3dffe3">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtMS0xLTEtMTE4ODMz_6d6f7d86-2b21-48b9-8efb-4cf051538326">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtNS0xLTEtMTE4ODMz_956bd47c-6a30-4fdd-8f63-8388a1d46377">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtOS0xLTEtMTE4ODMz_60f10a75-ef6a-4592-9d51-c3f24165f2ab">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc263f43956447489bf00cd95b47d45b_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtMS0xLTEtMTE4ODMz_52339acb-5d05-4440-a5d7-40dc89f243e7">4,246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a5e00fb04b14bd7be7b428099bd5934_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtNS0xLTEtMTE4ODMz_a317fa63-6966-4410-8411-ee74d19e4671">7,741</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtOS0xLTEtMTE4ODMz_c1fbc667-415f-4127-94de-1bc35aeaad4f">11,988</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTEtMS0xLTExODgzMw_4bf11454-1b6d-4c16-8bac-38cd338dc44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTUtMS0xLTExODgzMw_625dfd31-d409-4e23-8d22-8f00ee5e2f08">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTktMS0xLTExODgzMw_c0243194-0bc0-405e-97cf-fd93559f4632">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTEtMS0xLTExODgzMw_01841cd3-af92-4af9-acd1-f2395d3b236f">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTUtMS0xLTExODgzMw_e582b23a-34ea-4864-a151-6c2f1b2d2f4f">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTktMS0xLTExODgzMw_9164a2bf-ac04-4447-8605-5507d659e27b">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0460e71d5b418b813458aae9b11a82_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTEtMS0xLTExODgzMw_5366e5ae-819a-4571-a290-929c2bd1cd51">4,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie847a194b2334592ac9587e3029dbcd2_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTUtMS0xLTExODgzMw_3bd95c0a-6578-498d-a157-e0406ee9e933">8,684</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTktMS0xLTExODgzMw_7d5cc6fe-f1f0-499a-b513-a3274d2b15d2">12,920</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of our goodwill and intangible asset impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMzI_d2301c76-60ab-41d0-9a77-ba7ad8fb715f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December&#160;31, 2022 is as follows (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzItMS0xLTEtMTE4ODMz_41bf33a9-b7d3-4200-8e91-862d352a838a">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzMtMS0xLTEtMTE4ODMz_3d3cb992-d925-42a0-807e-6d0572905fa0">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzQtMS0xLTEtMTE4ODMz_d824b824-554f-4ec4-9d8f-79dca8d3e0f6">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzUtMS0xLTEtMTE4ODMz_09b0f356-457c-44cb-9769-820098a74624">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzYtMS0xLTEtMTE4ODMz_434186f2-70ba-46e9-ba90-a0ba143b4569">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1e36e0dc7294c4ba8aaca081e8e86af">These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December&#160;31, 2022.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE5MDAz_2fceb257-e0ab-4649-a85a-26ffeaa16dfa" continuedAt="ic878bc2096154ef3a3ff8f318352afae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D &#8211; HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Foreign currency translation adjustment (CTA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we reclassify amortization of the excluded component from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December&#160;31, 2022 and 2021, we designated as a net investment hedge our &#8364;<ix:nonFraction unitRef="eur" contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzQ3MDU_fb2eac35-de3c-4684-a322-01d1d960b4a0">900</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzQ3MDk_ed05bea9-4da9-4dfd-9a54-42c9e46c47af">0.625</ix:nonFraction>% senior notes issued in November 2019 and due in </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic878bc2096154ef3a3ff8f318352afae" continuedAt="i682e617bb1324c0789ca1f891726e7cd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reclassify these gains and losses to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December&#160;31, 2022, we had entered into $<ix:nonFraction unitRef="usd" contextRef="i07415990883e4ca3b5f954aa8871d444_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEwOTk1MTE2NDg1MjM_19c30975-7dd0-4577-959a-ea32db5d593f">228</ix:nonFraction> million in aggregate notional amount of these contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4Xzc5OTQ_3fd1a45d-af0c-4959-ad5a-2bb211684554">8</ix:nonFraction> million loss as of December&#160;31, 2022 and a $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzgwMTc_930ddcae-fc1f-4d3a-bb05-c8d862685c4e">24</ix:nonFraction> million loss as of December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as fair value hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which generally offset. </span></div><div style="text-align:justify"><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTE1_323cc7ea-c47b-4c51-8308-3bb347f861e2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b264f96121f49c4947c5cebac003441_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzItNC0xLTEtMTE4ODMz_a9395292-f201-40cd-9719-e3f83bd469ac">2,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ba4efd839e41a5a81e781338fa73f6_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzItNi0xLTEtMTE4ODMz_9e3c4598-1867-41fd-a4d0-75a6a9b42402">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if424464b0a3c4a39857873d850185168_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzMtNC0xLTEtMTE4ODMz_156ff6e0-b961-42bf-a9d4-c1d58fcdbe0e">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6d5b5ab6e344e9bf988dc3bff46611_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzMtNi0xLTEtMTE4ODMz_0ba60569-cd22-49fa-bbc4-e2a1ea9e8b5f">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b57c132f9d416694b1d85ee5e9c012_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzQtNC0xLTEtMTE4ODMz_ed1f50dc-d792-4884-b3d0-1d827e55f906">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefadff6b78cd431aa59e065d0ae8d019_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzQtNi0xLTEtMTE4ODMz_977958ab-612e-467f-b899-986ecba7137b">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7034c0c152ad405b805f9b28b7b18795_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzUtNC0xLTEtMTE4ODMz_93605465-76c5-4ae9-a5eb-7439f56f2ee1">4,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca004ff852f4e619fad9a26264773a5_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzUtNi0xLTEtMTE4ODMz_47d0a5ae-5f77-484d-bed4-bb25fe4008ef">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzctNC0xLTEtMTE4ODMz_94ce4853-e704-4b6f-ab20-6f19930e5e6c">8,321</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzctNi0xLTEtMTE4ODMz_a3817dbc-8580-4627-89f0-7948007534bd">9,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Foreign currency-denominated debt is the &#8364;<ix:nonFraction unitRef="eur" contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4Xzg5Nzg_fb2eac35-de3c-4684-a322-01d1d960b4a0">900</ix:nonFraction> million debt principal designated as a net investment hedge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining time to maturity as of December&#160;31, 2022 is within <ix:nonFraction unitRef="units" contextRef="id838054c9b624ef88ede2a3ac03cca10_I20221231" decimals="INF" name="bsx:ForwardCurrencyContractsTimetoMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzkwODU_16a28dd1-e45e-4807-8379-25dc52320673">48</ix:nonFraction>&#160;months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i682e617bb1324c0789ca1f891726e7cd" continuedAt="ic12a1be517be43ffbba0881c1f4f1ae4"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTU3_26ea5475-a073-4c9c-bd6a-a320a510ee36" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O &#8211; Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMS0xLTEtMTE4ODMz_13e3189b-18f8-435d-977c-9bcb847accde">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMi0xLTEtMTE4ODMz_84959653-2f39-49bb-a590-c3627dfcd4fe">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMy0xLTEtMTE4ODMz_992f1314-77d7-43d4-9d8b-1259cfecab8d">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtNi0xLTEtMTE4ODMz_b89f5f77-04ed-4fa9-965a-3e48ef2caccc">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtOC0xLTEtMTE4ODMz_67606590-4c8f-48c4-ba11-d541d18c189d">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtOS0xLTEtMTE4ODMz_127810de-f566-4c6d-8dde-ed273388073c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMTAtMS0xLTExODgzMw_f3137771-bce6-491a-bd77-8bc78363407f">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMS0xLTEtMTE4ODMz_4d28a80b-ce61-424e-81cf-d29f81ddc98e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMi0xLTEtMTE4ODMz_31fe2f9f-51f0-4838-8cf3-0483189817b6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMy0xLTEtMTE4ODMz_8aed8bf3-1a74-491f-bf7e-affd6659824e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtNi0xLTEtMTE4ODMz_3018eb11-8082-470c-a312-2632d1df2c09">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtOC0xLTEtMTE4ODMz_af1e4581-2b83-4596-b27a-c28f03580ea9">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtOS0xLTEtMTE4ODMz_c19b5f8b-5bed-4285-a5c3-aae7a0bde41e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMTAtMS0xLTExODgzMw_f5b0032e-209c-4844-8c4c-1da9a895ebe3">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMS0xLTEtMTE4ODMz_9644ce2e-7930-42a9-a5a6-b492cd02f5bf">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMi0xLTEtMTE4ODMz_0707a4f6-35b0-4980-b6fb-2d15e1ad5a41">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMy0xLTEtMTE4ODMz_7cb59d15-5c48-4581-9d4e-967914eedbca">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtNi0xLTEtMTE4ODMz_d661cbaf-c7e4-4459-9d93-0aa729543863">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtOC0xLTEtMTE4ODMz_fc4dc4fe-82fb-48da-89ef-504dbc2eec07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtOS0xLTEtMTE4ODMz_195054b4-8e18-4e54-8e07-1df6b997de84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMTAtMS0xLTExODgzMw_9c5c37ac-7f15-4372-ad33-1eedd9068476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTEtMS0xLTExODgzMw_cd82ee27-bf94-490f-b2a4-31609f15009b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTItMS0xLTExODgzMw_4edf956b-830f-432b-99d7-1d8cfd8e7a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTMtMS0xLTExODgzMw_c8b96275-5ec5-4a38-b87d-4e35f1548caa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTYtMS0xLTExODgzMw_3018eb11-8082-470c-a312-2632d1df2c09">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTgtMS0xLTExODgzMw_8313cd3f-97dc-41de-9013-d93960cfc5e7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTktMS0xLTExODgzMw_058b72c7-fd01-43d6-849b-50790060766e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTEwLTEtMS0xMTg4MzM_a2c47a86-b3b6-49f2-88b7-3b1ee6c49b70">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTEtMS0xLTExODgzMw_4c879923-b51c-42b7-885e-e0312f992e16">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTItMS0xLTExODgzMw_1dbf83e9-ffb7-4d55-8ab7-0730df06ff8a">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTMtMS0xLTExODgzMw_751b7b98-71f4-4661-b964-4b72f3a93b0c">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTYtMS0xLTExODgzMw_aa968464-3d53-4b13-959e-9d83d74e95ce">3,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTgtMS0xLTExODgzMw_6006e2a1-fc74-4532-9204-340bbbe5fbb1">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTktMS0xLTExODgzMw_2fd1d03a-b220-459d-9438-656993872f1c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTEwLTEtMS0xMTg4MzM_4881edb9-476a-465c-8866-fb4e837e6512">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTEtMS0xLTExODgzMw_36ea2b1e-fb5d-4605-ae0d-17c56579aae3">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTItMS0xLTExODgzMw_3a7719f3-bce5-4b90-9b79-eacdbe6d3025">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTMtMS0xLTExODgzMw_191408b2-816f-42d5-8404-2d3f7334968d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTYtMS0xLTExODgzMw_46c2b3aa-1065-4d6d-841e-e12cfa527d6e">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTgtMS0xLTExODgzMw_d511a69a-ff86-4904-9507-93c30b6b35e6">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTktMS0xLTExODgzMw_810ab373-7fd3-476e-94e4-3bea9ebcd2d4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTEwLTEtMS0xMTg4MzM_75f90d7c-ba79-4dac-80ec-23bea0008f56">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTEtMS0xLTExODgzMw_11f4b84b-00e5-4594-9021-94199cd1fe7e">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTItMS0xLTExODgzMw_393cb697-ca11-439e-a0b3-6c76d663004b">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTMtMS0xLTExODgzMw_82f9cb9a-e34a-480e-b7bf-6d1443503e25">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTYtMS0xLTExODgzMw_dc00bbe7-8fb4-4980-9e67-abe106e47e0e">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTgtMS0xLTExODgzMw_af2efb63-9cac-45d6-8bd8-141071c44028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTktMS0xLTExODgzMw_417ecf31-811d-4c38-904b-6ee817267acb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTEwLTEtMS0xMTg4MzM_102a81ca-7b20-4015-b8a9-69522f6ae94e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTEtMS0xLTExODgzMw_ca082669-81b6-4e81-8843-87ccee6b1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTItMS0xLTExODgzMw_21fba026-fa93-4f06-b1aa-769b7315873a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTMtMS0xLTExODgzMw_d9e23230-5c8a-4c88-ba7e-8636874228b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTYtMS0xLTExODgzMw_46c2b3aa-1065-4d6d-841e-e12cfa527d6e">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTgtMS0xLTExODgzMw_23560a85-98a9-4e25-a5c7-b9e0e3dc259c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTktMS0xLTExODgzMw_470a3e7b-38aa-45f1-9c2d-2c23521caa70">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTEwLTEtMS0xMTg4MzM_9d7d0b84-756a-4368-afdf-e574b4a7f4e1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTEtMS0xLTExODgzMw_8be8588b-057b-49c3-bbb7-fddfc5fe1272">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTItMS0xLTExODgzMw_18fc7bd1-ef14-496e-b68c-d1e1cd850f4b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTMtMS0xLTExODgzMw_5342c9bc-6f4b-4d31-a5b8-e5f65d4a3a60">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTYtMS0xLTExODgzMw_c574ef45-eac7-4dd9-a939-255b19efb84a">3,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTgtMS0xLTExODgzMw_28c1c586-3262-41e3-99c3-54d9b9fd7ff8">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTktMS0xLTExODgzMw_4d0be6bc-a6d7-431e-8ede-7e16eb5e4917">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTEwLTEtMS0xMTg4MzM_383925bc-de46-4c8c-9109-a5995455ec44">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTEtMS0xLTExODgzMw_09033882-0b73-4f76-b5be-e4433d098e64">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTItMS0xLTExODgzMw_9e9cf967-6ff5-428a-9d72-dcc9bd90c815">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTMtMS0xLTExODgzMw_a9ed8574-b5b5-49a6-a66b-08b2a288150c">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTYtMS0xLTExODgzMw_458a0696-728f-4a83-a7b6-34c8151087c8">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTgtMS0xLTExODgzMw_c2b694d8-dda4-4e7f-bd7e-097037b40eed">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTktMS0xLTExODgzMw_457bda19-1e55-4941-8c06-ef2a19022030">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTEwLTEtMS0xMTg4MzM_4b550557-2321-4c12-ac2f-365fb7e0cb06">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTEtMS0xLTExODgzMw_0ab2d807-37f3-4df9-bf86-664e4259a554">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTItMS0xLTExODgzMw_d6e809ae-cc33-43ca-8e75-b37773983aaf">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTMtMS0xLTExODgzMw_48cc6cd9-03ae-4816-bfa2-907e2019c33a">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTYtMS0xLTExODgzMw_483eec6f-da3a-4619-a431-ebe1df87d1b6">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTgtMS0xLTExODgzMw_96701c3e-74c2-40a1-8bb6-eae51101dea4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" name="bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTktMS0xLTExODgzMw_36874885-e5eb-4bee-b8f9-5b823ca256aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231" decimals="-6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTEwLTEtMS0xMTg4MzM_2492901e-cbca-484e-9496-4cc5e9b8682a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTEtMS0xLTExODgzMw_c3700a1e-6129-4221-9be3-97aa27dd608c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTItMS0xLTExODgzMw_7fbf5a44-c0c7-4f10-a010-5b4cc3cef5fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTMtMS0xLTExODgzMw_933b4b6e-c274-4b52-a7df-b3c9111f0d69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTYtMS0xLTExODgzMw_458a0696-728f-4a83-a7b6-34c8151087c8">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTgtMS0xLTExODgzMw_1f1e2e1e-268c-41a0-9a3c-9892e078f47f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTktMS0xLTExODgzMw_014354f0-f812-4269-8ecb-ed3c414d9e39">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTEwLTEtMS0xMTg4MzM_fd423629-3ed8-4cd1-83cd-98051956a66e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic12a1be517be43ffbba0881c1f4f1ae4" continuedAt="i5f7e06b8350f4eb8bbde77dbf2a3bdd7"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTIw_81ac0a7c-f5fb-4afc-a273-1ecce4baf698" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc8106ccc3e4b4f8afb7eed48c9a6ab_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzEtNi0xLTEtMTE4ODMz_ddd87c4f-d1c8-4c53-a889-ddcd5223cfa6">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497eeb11153a4392b98631c49308f079_I20221231" decimals="-6" name="bsx:DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzItNi0xLTEtMTE4ODMz_69b9d50d-4877-42bb-8b25-69574cc09a13">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e775c256acb4b869fa12bfa169522f7_I20221231" decimals="-6" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzMtNi0xLTEtMTE4ODMz_0a26ab98-e40f-484e-ba75-df1f8ed05c5a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTgw_5c50f9dc-f6ab-4eb4-bd3d-0fa80928b5de" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItNC0xLTEtMTE4ODMz_41bf979e-f207-498d-83d4-c48d64b6ef35">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItNi0xLTEtMTE4ODMz_5325faeb-1493-47b8-a370-7f8779b3c884">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItOC0xLTEtMTE4ODMz_d156dc0c-b0c7-4606-a0bf-961758df81a4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtNC0xLTEtMTE4ODMz_7bccf065-7f55-489c-bc86-d5aa4f1da62b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtNi0xLTEtMTE4ODMz_28bcaf7b-7db0-40cb-b362-b5746786f949">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtOC0xLTEtMTE4ODMz_a9f16ffa-427a-44d9-bac2-83992976a224">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231" decimals="-6" sign="-" name="bsx:NetCurrencyExchangeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtNC0xLTEtMTE4ODMz_f0549358-856a-4c38-9e9c-3dea55045818">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231" decimals="-6" sign="-" name="bsx:NetCurrencyExchangeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtNi0xLTEtMTE4ODMz_d0de3890-5a4b-4912-81f3-2a1e69dc9b7f">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231" decimals="-6" sign="-" name="bsx:NetCurrencyExchangeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtOC0xLTEtMTE4ODMz_cf01213c-0e99-4f65-9147-8da60f06bf7e">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5f7e06b8350f4eb8bbde77dbf2a3bdd7" continuedAt="ib0037bf64d434c219313ff16449480a4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTYx_08827868-a043-432d-99e1-0d80a681b8ea" continuedAt="ifabed2bbaa01414389040ea1dc1cc2a2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifabed2bbaa01414389040ea1dc1cc2a2">, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.</ix:continuation> <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTI4_46e84ef2-9d2e-44de-a611-e6e67af85a2c" continuedAt="iecbc742665864ec4b1ce79c274287142" escape="true">The following are the balances of our derivative and nonderivative assets and liabilities:</ix:nonNumeric></span></div><ix:continuation id="iecbc742665864ec4b1ce79c274287142"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43976490229f4082a87ca1ad777107c2_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzQtNC0xLTEtMTE4ODMz_e8899791-5303-4118-a4dd-107637e68644">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c931f3e9e82412985cdead08af7d632_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzQtNi0xLTEtMTE4ODMz_c1d9fb62-332c-4a57-a3f7-e2a8b597c88f">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b5902a38e94fb0bc7726cc131b7909_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzUtNC0xLTEtMTE4ODMz_e3e0aa64-6886-47e5-9f68-658449238f6e">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0fbd55b32b490e9fdb76b959b0201f_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzUtNi0xLTEtMTE4ODMz_073757d1-9446-48d0-ab1f-d306cc8deea8">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf44831547f46288e08f02ae1ef637a_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzYtNC0xLTEtMTE4ODMz_8e4d0625-9d19-4658-b008-176ae8dd13b0">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6b63466c604373ae38da6289aeb97b_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzYtNi0xLTEtMTE4ODMz_b840244b-aa1d-4af4-8166-21452cb47cf1">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21397bfa8444b681ef8632f7075281_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzgtNC0xLTEtMTE4ODMz_45503aa0-10e6-4fd9-9dfc-a371ea9237aa">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9f9f3e82c944209c2e074ec8df6017_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzgtNi0xLTEtMTE4ODMz_98171a63-aef4-4a7a-bb22-4f686c65aa38">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzktNC0xLTEtMTE4ODMz_f82656bc-5de3-4805-ae18-0e97feef94b9">381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzktNi0xLTEtMTE4ODMz_10b55e0a-ee4e-4d39-933f-08f6db4c614b">394</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c65a02c0b2346b8906129d0669bf500_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzEzLTQtMS0xLTExODgzMw_26d2780e-0b2a-476d-ba06-bd587d62b208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80d5979815640db88b06b04ebcb6895_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzEzLTYtMS0xLTExODgzMw_c51b8ffe-885e-44e7-9cf2-bb31bc625418">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66ab9c892884deaade76365d66fd129_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE0LTQtMS0xLTExODgzMw_12a6a126-2486-4f77-85b4-2f940e490a36">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7356fcfc65574de19d26d52fc3344322_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE0LTYtMS0xLTExODgzMw_1c19fa1e-a085-445f-a403-d9b93b4eca8b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9d72a0fc2a4e5a95b3b411d70ff7cf_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE1LTQtMS0xLTExODgzMw_9ac82ae2-f668-4a04-b20c-bbc63be8848a">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023ada48280d48fbaabe57b9e17d60d0_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE1LTYtMS0xLTExODgzMw_df71495e-3a3f-43a8-847a-d4f3230bafa4">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf44831547f46288e08f02ae1ef637a_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE3LTQtMS0xLTExODgzMw_960ae9b1-65d4-415d-8be7-91990711c463">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6b63466c604373ae38da6289aeb97b_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE3LTYtMS0xLTExODgzMw_fee9c6b5-6f73-42bf-b8fc-2081f5d1c558">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ada0ca796d42c992dc5e35b941a368_I20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE5LTQtMS0xLTExODgzMw_0776c476-e44b-44e1-8573-522d729d05f5">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3c5b387d0440dab8c546b5c1842949_I20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE5LTYtMS0xLTExODgzMw_a8cd9b3d-104b-4b67-b33f-3fdca711b09d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzIwLTQtMS0xLTExODgzMw_c79f3db2-f1d8-4777-a5d4-4039130a832f">1,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzIwLTYtMS0xLTExODgzMw_a077e514-2f17-4f3a-a35b-b11bd8435e81">1,071</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Foreign currency-denominated debt is the &#8364;<ix:nonFraction unitRef="eur" contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEyNTg4_fb2eac35-de3c-4684-a322-01d1d960b4a0">900</ix:nonFraction> million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Inputs to the valuation methodology are unobservable inputs based on management&#8217;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib0037bf64d434c219313ff16449480a4" continuedAt="ifc5aa468dcb44638baa5944fe8ba4e39"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTYy_a7bc3e71-46a9-4873-bd4b-1db88c23982c" continuedAt="i516927a03dd04fab8f163837c162757c" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:31.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMS0xLTEtMTE4ODMz_7a4db560-3a46-4bd0-9569-bb82994c796e">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMy0xLTEtMTE4ODMz_47c1673a-477f-4a29-8c2f-24e1bba74915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtNS0xLTEtMTE4ODMz_83eba745-8acb-4ce2-aadc-7d45bd603b00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtNy0xLTEtMTE4ODMz_c57c3097-d47d-47d4-8502-13e3b45b2582">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtOS0xLTEtMTE4ODMz_80244967-1cc6-431f-9302-f67b225a863b">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTEtMS0xLTExODgzMw_82a6fbbf-9bf3-47ba-a911-8a47a090c388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTMtMS0xLTExODgzMw_edb84046-4969-42f6-8cf4-b8a92167cd23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTUtMS0xLTExODgzMw_336c3a4a-972b-4489-ae20-da05361ee631">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMS0xLTEtMTE4ODMz_59ca5d67-cd85-4e76-b400-e6fae07117fd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMy0xLTEtMTE4ODMz_0cc33e12-b01c-453d-bff6-0912e8362f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtNS0xLTEtMTE4ODMz_cc260e7f-fc7a-46dd-b1f7-fcba7957d76e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtNy0xLTEtMTE4ODMz_adc8ac2d-9c48-476a-ba68-eb05d55f7d0f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtOS0xLTEtMTE4ODMz_c5dbd7db-9cfa-41aa-9b8d-d5860374f238">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTEtMS0xLTExODgzMw_cc7fa679-b83c-4623-b312-3af2094db44f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTMtMS0xLTExODgzMw_7ecaced6-8af6-49b5-807a-13c1a79c41c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTUtMS0xLTExODgzMw_66288285-5a06-4294-88ec-f58c44341fc7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMS0xLTEtMTE4ODMz_f01ada1d-92bd-404b-851b-638a6888f635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMy0xLTEtMTE4ODMz_64e68af3-905f-4456-aa9e-455e76321855">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtNS0xLTEtMTE4ODMz_8f6a2e78-e044-4682-aaa7-86bef4426667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtNy0xLTEtMTE4ODMz_508aa863-d020-4e72-92fd-54542e84489b">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtOS0xLTEtMTE4ODMz_5a3f70cf-9539-4171-a7b9-c0765edc3e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTEtMS0xLTExODgzMw_d59a2a8b-b780-4477-9ac2-e7c7359a3c49">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTMtMS0xLTExODgzMw_aa6aa0fa-242c-4143-8939-9eee5a0e2e41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTUtMS0xLTExODgzMw_4bb64ec3-800e-4bc4-a40c-2aae64fc57fb">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMS0xLTEtMTE4ODMz_1dd73d43-be11-4a1c-a2ce-ac352b7ce1f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMy0xLTEtMTE4ODMz_6587d4d4-5c83-42e9-b51e-fa0caac3a1ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctNS0xLTEtMTE4ODMz_c3cf6f88-57a2-4b01-ae11-73a1f16b210b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctNy0xLTEtMTE4ODMz_5ce94766-4601-4686-beec-c8b02980f31d">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctOS0xLTEtMTE4ODMz_9f46dbf9-ad92-4ace-847a-4febe19a35ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTEtMS0xLTExODgzMw_2298bef1-c414-4eae-9e00-dbf41635e530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTMtMS0xLTExODgzMw_ef4c47d4-b5b3-41bd-b6d8-8cea7e042bff">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTUtMS0xLTExODgzMw_ed325134-285f-4e1e-96d7-c6d2dbd78943">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMS0xLTEtMTE4ODMz_0021504c-db43-46cc-9caf-195649ca2a21">674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMy0xLTEtMTE4ODMz_224c7bab-29ab-483e-a79f-da93cb0c362c">381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtNS0xLTEtMTE4ODMz_6f27a1d4-c5ba-4779-8dbd-0bfb1f3db141">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtNy0xLTEtMTE4ODMz_2efb1b94-a908-4ba5-ab15-6826b468619c">1,182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtOS0xLTEtMTE4ODMz_61ec6824-6636-4c6e-8884-4fdc9ffe9fb4">1,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTEtMS0xLTExODgzMw_3ff1d45f-da0e-4552-8c84-3c07d6517255">394</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTMtMS0xLTExODgzMw_57338d7e-0ede-4461-adef-6e912286a1e4">246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTUtMS0xLTExODgzMw_829c3c28-e1e6-4f44-b19e-8b26f510ace3">2,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTEtMS0xLTExODgzMw_992d0332-2a5b-4c18-9a74-c1202bbdd036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTMtMS0xLTExODgzMw_7287c898-c78a-4ac1-b795-d6d18055aad1">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTUtMS0xLTExODgzMw_3eda3ede-b145-49bd-bf63-62718d003877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTctMS0xLTExODgzMw_24cb729c-2e81-4168-9aa1-bf2cab0c46ee">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTktMS0xLTExODgzMw_5b5a319d-98b5-4e6c-b1db-d48067cbcd9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTExLTEtMS0xMTg4MzM_92875a7f-e523-4bb3-926b-69ca150ac74c">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTEzLTEtMS0xMTg4MzM_87688b45-1227-4a77-a75e-06c374d6b52a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTE1LTEtMS0xMTg4MzM_9ddd1f2e-d1d3-486e-8073-4ab6ee548930">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTEtMS0xLTExODgzMw_1fd306e5-c4a6-4148-b28e-013ebcc945d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTMtMS0xLTExODgzMw_97afc279-b0f3-448b-ba1b-ae7e01a1699c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTUtMS0xLTExODgzMw_e1fe0272-748a-4d0b-9cac-8326931b8f83">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTctMS0xLTExODgzMw_1daa30da-1b99-4c76-bf21-88cb5d468073">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTktMS0xLTExODgzMw_19b025c3-a677-426f-a1a8-5fedb180066c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTExLTEtMS0xMTg4MzM_86ba664a-584c-4673-b04a-33ab627d60d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTEzLTEtMS0xMTg4MzM_a5cd7e47-6738-4f38-9083-be8a06ea8410">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTE1LTEtMS0xMTg4MzM_61abed93-eb27-479e-8571-22294b63ddde">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTEtMS0xLTExODgzMw_4911ae8a-7a5c-411f-bd4e-578ecbe78810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTMtMS0xLTExODgzMw_102157aa-fca1-4d40-a33c-de73427dc1dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTUtMS0xLTExODgzMw_e85e6738-4067-4e03-b3e3-ee54f56ca1df">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTctMS0xLTExODgzMw_00165eea-4cb2-4f1d-b839-3547a7cd277f">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTktMS0xLTExODgzMw_824a1d2a-86b4-464d-ac5a-9af458d09d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTExLTEtMS0xMTg4MzM_800c9991-15c2-4820-93a2-0151dcd269ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTEzLTEtMS0xMTg4MzM_9cc81f8c-565f-4dbd-9969-4df5e8347af9">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTE1LTEtMS0xMTg4MzM_6416836f-e306-4437-a8f8-d8974e35912b">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTEtMS0xLTExODgzMw_5faf5655-55ce-4caa-9ffe-fcd057e19423">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTMtMS0xLTExODgzMw_a80ce959-9de7-4b12-8c44-877eec8f6c5a">1,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTUtMS0xLTExODgzMw_c4cf90fe-3a4a-415b-af7e-a836e159e91c">308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTctMS0xLTExODgzMw_d7b32457-9fb5-4081-85a8-cf767819dcf5">1,313</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTktMS0xLTExODgzMw_3e788f38-b08d-48bd-879e-810009e02463">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTExLTEtMS0xMTg4MzM_fd28b7c2-4260-4e01-90a2-c65f5f9ce6ee">1,071</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTEzLTEtMS0xMTg4MzM_0e0c9c05-a639-4900-a81a-eb095419267d">767</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTE1LTEtMS0xMTg4MzM_78dfaa9f-188b-43d9-94e8-92c93cd4ed57">1,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $<ix:nonFraction unitRef="usd" contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0MzM5_7a4db560-3a46-4bd0-9569-bb82994c796e">673</ix:nonFraction> million invested in money market funds and time deposits as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i14049c0347434075a00f370f84a4db4e_I20211231" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NDA0_80244967-1cc6-431f-9302-f67b225a863b">1.632</ix:nonFraction> billion as of December&#160;31, 2021, we held $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NDI1_454070a0-b0d9-49fd-b60d-61154d934df6">256</ix:nonFraction> million in interest-bearing and non-interest-bearing bank accounts as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NTAw_ed53bf94-d152-49de-98e1-8a45f62e04b6">293</ix:nonFraction> million as of December&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the changes in the fair value of our contingent consideration liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga&#8482; Drug. We own the contractual right to receive 50 percent of the future Zytiga&#8482; Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from royalty rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and payments we remit to inventors reduce the fair value of the financial liability and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash impact of transferred royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December&#160;31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifc5aa468dcb44638baa5944fe8ba4e39"><ix:continuation id="i516927a03dd04fab8f163837c162757c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December&#160;31, 2022 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1ffcb904865b4d6580df24d96533c364_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtMS0xLTEtMTE4ODMz_e685c714-ec2a-4c4f-bfe1-f3d5ab9e75f3">127</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee69410e5a5d4b89bc83f76bb50d6b38_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtNC0xLTEtMTE4ODMz_cf503295-3add-46f2-becb-4f9defee1330">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2e9c8a5b25844acb555957ab3a50fda_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtNy0xLTEtMTE4ODMz_549e1a4a-8e3d-4eee-88e2-94fd3fa09046">15</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1ffcb904865b4d6580df24d96533c364_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtMS0xLTEtMTE4ODMz_515a760c-d5f5-417d-bc19-12335c01cb78">159</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia769df42f17c44b6b313f45d148ee393_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNC0xLTEtMTE4ODMz_25229b33-406e-4013-929e-1626e4783d4d">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd5679aa760c46509687a1dde91bab70_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNi0xLTEtMTE4ODMz_44910da7-ae07-4a82-a288-36b117498234">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i306eeeee59414185854b583778c80597_D20220101-20221231" decimals="2" name="bsx:DiscountRateFairValueInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNy0xLTEtMTE4ODMz_eba8edfc-782a-4b64-af2f-6dd4ec4d070d">13</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65715ea926ee481fb6c5149bad0221f8_I20201231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzEtMS0xLTEtMTE4ODMz_3f5effce-5b26-448a-b2ae-f3ca03fe60d5">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzItMS0xLTEtMTE4ODMz_00f102dc-5176-44a7-bd78-2d7036cd5154">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzMtMS0xLTEtMTE4ODMz_59b10a1c-4342-4dc8-a58d-e4c9eab4f281">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29915dcac5094d979b75f1f2f98cb3d8_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzQtMS0xLTEtMTE4ODMz_964b5fc6-565e-40e2-b1a4-6f1b2b2f0a73">246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2194ed16e8554a818134176f669c6463_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzUtMS0xLTEtMTE4ODMz_442b9e97-e090-4aee-a04f-855936710cf1">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2194ed16e8554a818134176f669c6463_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzYtMS0xLTEtMTE4ODMz_88181438-36d6-42a1-a10c-1c498170342a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c030aed5a44a2c9b75bda87f7ac3e7_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzctMS0xLTEtMTE4ODMz_11d73e08-a64b-4899-b44d-8a69544be0cb">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee8da85a7114dbf9b80f1b1ad1b7309_I20201231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzEtMS0xLTEtMTE4ODMz_11fd85b0-92ad-4f93-b605-163261f6be81">407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzItMS0xLTEtMTE4ODMz_c215dac1-98bb-46d9-bbe3-0ac4faee67cc">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzMtMS0xLTEtMTE4ODMz_54775849-3fee-47c2-972e-a046d80ef999">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af424844b524fbc975d6d2534326bb5_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzQtMS0xLTEtMTE4ODMz_11964e29-1062-40b2-b9f8-d7a8566a8722">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzUtMS0xLTEtMTE4ODMz_f8deb919-8316-441f-be4f-bdb90a036f41">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzYtMS0xLTEtMTE4ODMz_67e2d643-004e-4eba-8d86-f9f5fb90bd44">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707b6e8943e4427a9a804100e6c467b8_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzctMS0xLTEtMTE4ODMz_a3a93de0-2c58-4cdf-987b-c512dca6c7b7">159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations was $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4NDQx_b3f5a3b8-8143-486d-bf0f-ee7a8387d49d">8.203</ix:nonFraction> billion as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEwOTk1MTE2NDkzMjM_c80f367b-d8b3-4164-80d8-351f57c94d06">10.196</ix:nonFraction> billion as of December&#160;31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTYx_d7bbeb4c-a088-4ec5-9f1a-17da32e5f419" continuedAt="i259155ca1bf746e996491fd6a50ae165" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E &#8211; CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzgw_fac2d9e5-a7f2-499f-a65b-750f7fab4577">8.935</ix:nonFraction> billion as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzk2_498f5246-08b1-48a9-8bd5-0510ff3ed1f6">9.065</ix:nonFraction> billion as of December&#160;31, 2021, with current maturities of $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNg_d5e0237a-7342-4fcf-8d13-5c8adf0c74e6">20</ix:nonFraction> million as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzE1Mg_7c722033-a61e-49cc-92f2-c36d3ff8333f">261</ix:nonFraction> million as of December&#160;31, 2021. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNjA4_9a0dd8b8-212d-46d0-b2ae-79f897a8f911" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ab0e4e1b614daf98a769c6518ac202_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItNi0xLTEtMTE4ODMz_87b58c20-62af-4231-be58-adaef37bfaa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5897f9c4874d42b04253217254d1e9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItOC0xLTEtMTE4ODMz_558f6ecd-cc5a-4792-b3c0-b6e752a9f96c">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3ab0e4e1b614daf98a769c6518ac202_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItMTAtMS0xLTExODgzMw_764b2658-7ab9-4316-8bf5-3b4b69cfd4cd">4.125</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8cb2626e924fb8839e71109d5af54e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtNi0xLTEtMTE4ODMz_6671e119-2a9a-49c9-a505-7bb2b06ff6e7">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04324fd6d5b24d29b46e19849e7f37a2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtOC0xLTEtMTE4ODMz_57ae6820-380f-444b-90ed-63767a07b077">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf8cb2626e924fb8839e71109d5af54e_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtMTAtMS0xLTExODgzMw_fd491d8d-286e-40bd-a3be-19d33022c5f7">3.450</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06c81ca089f4d1995643384dc902e2d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtNi0xLTEtMTE4ODMz_cd70994c-f274-4dcb-9fee-47f7dfd51241">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2144f30d3644df97a834f3542eaa50_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtOC0xLTEtMTE4ODMz_7256a4d8-bd1a-405c-96e8-f489ca6bdc4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie06c81ca089f4d1995643384dc902e2d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtMTAtMS0xLTExODgzMw_bebcf8d9-472e-4a6d-b33d-fbd21d494863">0.750</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53531cf73b884a88961411dfb1a4df93_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtNi0xLTEtMTE4ODMz_adea30db-5db8-4433-b207-2694a8186bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02be01898d4d4188b550ce6554ad5461_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtOC0xLTEtMTE4ODMz_fb5ef362-bcba-40dc-a804-ceac01f7b996">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53531cf73b884a88961411dfb1a4df93_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtMTAtMS0xLTExODgzMw_f2e76f95-8420-4d41-99ea-6ac91dd45119">3.850</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtNi0xLTEtMTE4ODMz_acca3266-c700-4422-9c2c-80d76f681e34">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76f019bce26489da0bbcda06c714fcc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtOC0xLTEtMTE4ODMz_7ce40dba-c038-4d27-a38f-0877729091d5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtMTAtMS0xLTExODgzMw_07425366-fdeb-4f23-9d65-581416d269ec">1.900</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctNi0xLTEtMTE4ODMz_6472cdb1-946d-48b6-8ac5-af10a887059e">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88044a72ca47a791ceb58f044afebf_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctOC0xLTEtMTE4ODMz_90eb3169-0d9c-4cef-a155-2d6d5d864300">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctMTAtMS0xLTExODgzMw_955d7ad3-3513-42cf-82d3-26ce47171dba">3.750</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtNi0xLTEtMTE4ODMz_17f1206e-06bf-4fd5-9c90-72340c3a69f0">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96adf1f1d5d4c17ba33895d23e7b110_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtOC0xLTEtMTE4ODMz_54a113e0-8dd2-4e4b-9c63-67158842aead">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtMTAtMS0xLTExODgzMw_ed05bea9-4da9-4dfd-9a54-42c9e46c47af">0.625</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktNi0xLTEtMTQ2Mzk5_8758bb2a-b80e-468b-9ba1-d21899073923">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864e95597acb4043a3697acb3ad55e62_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktOC0xLTEtMTQ2Mzk5_f20ded2e-a525-45a4-af8a-8029c6280ea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktMTAtMS0xLTE0NjQwOQ_07708cdb-7973-451d-be29-11e17f29a0ca">1.375</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a4d41448224bea93d0c944e7acd848_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktNi0xLTEtMTE4ODMz_8f83511e-1c7e-4e31-9d03-da96c381a251">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe00cfc2a6d34b918d4ceff8a2a7df0f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktOC0xLTEtMTE4ODMz_be8fafe3-e660-422c-819c-6798d2c2c052">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a4d41448224bea93d0c944e7acd848_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktMTAtMS0xLTExODgzMw_e6e0ee47-45ba-4622-9be8-29bdc4c84d1c">4.000</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72d7a38e1b45739fe07b735a844490_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTYtMS0xLTExODgzMw_8959ce2a-a80c-415b-968e-be2003ec7c42">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018346feef584486b99651353c8ff6a2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTgtMS0xLTExODgzMw_c6a804e8-c628-4da3-83d4-4fc0966684ac">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida72d7a38e1b45739fe07b735a844490_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTEwLTEtMS0xMTg4MzM_024f7c14-116a-4ad3-8782-d2c21fc83efe">4.000</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i682827fd95b7499d8506ecce105a57a5_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTYtMS0xLTExODgzMw_0e0ab4fd-4222-4d02-bb8d-43797e964ea6">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb00400334214dfba90153fcbfa6c190_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTgtMS0xLTExODgzMw_74624b80-9e93-4f64-bdfe-0632c5285a56">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i682827fd95b7499d8506ecce105a57a5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTEwLTEtMS0xMTg4MzM_1064780c-79a7-4720-afbd-7211900a5e22">2.650</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTYtMS0xLTE0NjQyNQ_2ce48de3-682b-4578-9fb8-66704d3ab4ae">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a66dc38d4684266bdecece733ad71b1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTgtMS0xLTE0NjQyNQ_70993b91-f71e-4f10-9052-e5bf12e004ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTEwLTEtMS0xNDY0Mzk_eacd52ea-c639-401f-88e4-8dc2eb5ce81d">1.625</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTYtMS0xLTE0NjQyNQ_030b36d3-be09-494b-9c0a-a4b0e392989a">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6171ca5966e144cda0bde8a3dec28ca5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTgtMS0xLTE0NjQyNQ_70a4fda4-f08e-4376-ba36-9c2cb6915ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTEwLTEtMS0xNDY0Mzk_74bd3482-8e9f-4645-9929-d312dbd286c9">1.875</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTYtMS0xLTExODgzMw_2e96fbfa-76cd-4d49-968b-f292f6b2383f">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e76a81818f4be58bec07896afe0da9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTgtMS0xLTExODgzMw_775fec8a-1aca-4ca8-ab5d-de8d37938c7f">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTEwLTEtMS0xMTg4MzM_b19f8b3e-11ae-4ae9-ba2e-6a6efa7be144">6.750</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb195cd673465b82fb0f2af7d23b13_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTYtMS0xLTExODgzMw_9bf712f6-8ce9-43f2-8b77-f64972be99fb">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3999962f0a5340baaeffd9b46c41b048_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTgtMS0xLTExODgzMw_385ae416-58bc-484f-89d8-5005ea51eef0">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6bb195cd673465b82fb0f2af7d23b13_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTEwLTEtMS0xMTg4MzM_3db332f5-6c3b-4ddf-a0ce-e8773d06513d">4.550</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTYtMS0xLTExODgzMw_1fa39ec6-c14d-4f17-a934-e64fc3474e18">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1499dcaa0a4582b01d18fba8f0a457_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTgtMS0xLTExODgzMw_1f4f5ba1-fbeb-460b-97e9-c4af1aa2432f">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTEwLTEtMS0xMTg4MzM_19607ac3-1517-4ccb-b814-c22698972b5d">7.375</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58dd8cfee9114b3094575d06ba47b061_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTYtMS0xLTExODgzMw_b499dab7-101f-4098-a75a-f55ab5891824">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928315b0c4a64541aef04d53faebc49b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTgtMS0xLTExODgzMw_265920c0-f39e-4cb2-b3a2-33d17580c09c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58dd8cfee9114b3094575d06ba47b061_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTEwLTEtMS0xMTg4MzM_a9b2cdda-c69a-455c-8e2a-b04eae6f02bc">4.700</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f56a60724c4866875a8a4eae6f3274_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE2LTYtMS0xLTExODgzMw_965440d4-0cbe-4288-a35d-54a74f9bc930">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic32b67209ba7458d8464a71b457bf2e5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE2LTgtMS0xLTExODgzMw_2497569a-41d6-4961-ae04-0e666e073dbd">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Gain on Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b71607a73c4b9581145cffe097fb22_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE3LTYtMS0xLTExODgzMw_7f0a1f0b-7694-4170-99d0-e45c62475d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1115f7919aed4133876eff1699223515_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE3LTgtMS0xLTExODgzMw_bf256874-d76c-4fc1-87dd-18dd32a9906c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7989d8c3104e4c619e77b27f533f298b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE4LTYtMS0xLTExODgzMw_a3235516-5fb3-4972-bce3-4ac02c768749">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa67b35af59447dbc5102119a3de9dc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE4LTgtMS0xLTExODgzMw_fd203136-4972-4d15-a5ad-9fb75e735c8c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE5LTYtMS0xLTExODgzMw_565ea843-1c02-44f6-826b-c6b7d4fb2a63">8,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE5LTgtMS0xLTExODgzMw_530d18fb-a90f-411d-820a-1e38acc6300a">8,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November&#160;2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $<ix:nonFraction unitRef="usd" contextRef="icc9cb66ce623493d8cf1bce6f5823751_I20220331" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTY4NTk_bff1b764-b252-4ba5-86e4-91eba1435dff">250</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="icc9cb66ce623493d8cf1bce6f5823751_I20220331" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzU0OTc1NTg0MjE0MQ_bb1a45c5-3006-4ad5-8434-2b928bc000c1">3.375</ix:nonFraction>% May 2022 Senior Notes classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Current Debt Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December&#160;31, 2021.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i259155ca1bf746e996491fd6a50ae165" continuedAt="i558053ace65248de9c7b550faa257349"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzU0OTc1NTg0MjEzMw_6db4409d-2d7a-43f1-8f96-ea5f824ed70e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzItMS0xLTEtMTg4NjIz_f5c47829-e00e-4bd2-8c85-e8aa32ec8f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzItMS0xLTEtMTgxNTcx_6646d177-465d-463b-b478-2a9a331325ea">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzMtMS0xLTEtMTgxNTc1_f3a01bbe-ef7e-46a6-a1db-063580b253fc">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzQtMS0xLTEtMTgxNTc4_4d38ba2c-98b8-4784-961e-6082b320953b">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzUtMS0xLTEtMTgxNTgx_dce0de4d-c2c2-4424-b309-eb6259286d25">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzYtMS0xLTEtMTgxNTg0_07b4b178-ebc9-48e1-bec6-a9ad0697591a">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a new $<ix:nonFraction unitRef="usd" contextRef="i2a25ee3da32a468a9bfc070a0c89a839_I20210510" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzMjg_2f890a6f-ad63-4153-80cc-14ab7dc61a94">2.750</ix:nonFraction> billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTg3_656bfae2-9f40-4e6e-929e-9c2483907d39" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d77a9f992e540f08a1ba2d26480abde_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTowMGE0MzU5OTJhY2U0ODI1OGI0OGJjYmNmMjQ0MDkzNi90YWJsZXJhbmdlOjAwYTQzNTk5MmFjZTQ4MjU4YjQ4YmNiY2YyNDQwOTM2XzEtMS0xLTEtMTE4ODMz_713924c1-389d-4173-adf5-1f46891ab812">3.75</ix:nonFraction> times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03e9205a64d476ab1ffbccbf9a5d6f8_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTowMGE0MzU5OTJhY2U0ODI1OGI0OGJjYmNmMjQ0MDkzNi90YWJsZXJhbmdlOjAwYTQzNTk5MmFjZTQ4MjU4YjQ4YmNiY2YyNDQwOTM2XzEtMy0xLTEtMTE4ODMz_d4a9a76d-f08e-40b2-94b5-bcb8a6c300fd">2.57</ix:nonFraction> times</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of <ix:nonFraction unitRef="number" contextRef="i423e15598ef9473093d58996221c5647_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzYzNzA_48101e0c-ba64-47f8-a2a3-8232c8e44e99">3.75</ix:nonFraction> times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:DeemedConsolidatedEBITDA" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzY3Mzk_83b651f8-71f7-460a-889d-761412aacea2">1.000</ix:nonFraction> billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is <ix:nonFraction unitRef="number" contextRef="i44684946d0c54e399e9c2de5643d2c10_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzY5MzE_3d6fc05e-616b-4e38-bf56-6a6359e60fd2">4.75</ix:nonFraction> times. It steps down for the fifth, sixth and seventh succeeding quarters to <ix:nonFraction unitRef="number" contextRef="i5a893ba0e00b4645b7c556abf4dec609_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMDU_6d678ae2-fe99-4d99-be02-f25834babadf">4.50</ix:nonFraction> times, <ix:nonFraction unitRef="number" contextRef="i4cb6963457e3481da9017401ed9b31fa_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMDk_2e58221d-8fe2-477c-9daa-235567fb91e3">4.25</ix:nonFraction> times and <ix:nonFraction unitRef="number" contextRef="i09ab63ee90e44984aa45a30f812a5e31_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMTY_7a937fd7-8ec6-4f72-a375-d516c42f4085">4.00</ix:nonFraction> times, respectively. Thereafter, a maximum leverage ratio of <ix:nonFraction unitRef="number" contextRef="ib3172cf749dd40e98dad112948210e77_I20221231" decimals="2" name="bsx:MaximumLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwNzQ_7a3beb0b-513e-4cae-bb8a-cc05c1eca469">3.75</ix:nonFraction> times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:ExclusionFromEbitdaForRestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzczNDM_9638d6e2-459e-4c84-8b73-f592f21dbef4">500</ix:nonFraction> million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc0Nzc_3c885070-952a-452d-a165-7d8ed303a581">265</ix:nonFraction> million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:LitigationAndDebtExclusionFromEbitda" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc4MDk_efcb5784-a324-410d-a0c2-46ec2f71589e">1.455</ix:nonFraction> billion in the aggregate. As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc4NDc_f4aa7814-0626-4a1b-af8b-9de0a19f87b0">866</ix:nonFraction> million of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us.&#160;In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i558053ace65248de9c7b550faa257349" continuedAt="i1c756aa5d46d45bc96e0a470b2fa7cf9"><ix:nonNumeric contextRef="i9ca8697fd7e248dbacff201a7b724e96_D20220101-20221231" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTky_9f1a59af-0032-4267-b6d0-19c9ea196d5b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December&#160;31, 2022 and 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $<ix:nonFraction unitRef="usd" contextRef="i99f56a60724c4866875a8a4eae6f3274_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzkwNDM_f29dc940-9c56-4ffa-a529-90356de84980">8.986</ix:nonFraction> billion as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic32b67209ba7458d8464a71b457bf2e5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzkwNTk_29abfb8b-2513-444e-a29e-04e68a5da04f">9.121</ix:nonFraction> billion as of December&#160;31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of &#8364;<ix:nonFraction unitRef="eur" contextRef="id0251b7614994e199486b144a5575677_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5NjU_4fc86f23-f9f2-442e-bfdb-d039549d256b">3.000</ix:nonFraction> billion in aggregate principal amount of euro-dominated senior notes comprised of &#8364;<ix:nonFraction unitRef="eur" contextRef="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5NzI_b34f43e0-3384-4676-b94f-8e633065d773">1.000</ix:nonFraction> billion of <ix:nonFraction unitRef="rate" contextRef="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5ODE_7d283f29-9469-4f06-ab98-a9abe49735af">0.750</ix:nonFraction>% Senior Notes due 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5OTY_665b1967-18d2-464e-880f-777438aeea43">750</ix:nonFraction> million of <ix:nonFraction unitRef="rate" contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5OTA_e207e560-6614-4397-a904-309e635d671f">1.375</ix:nonFraction>% Senior Notes due 2028, &#8364;<ix:nonFraction unitRef="eur" contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMDU_b21cc03c-2214-4b9f-8538-fad4c936f0d0">750</ix:nonFraction> million of <ix:nonFraction unitRef="rate" contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMjE_add8f2be-bafb-4ec7-88cb-7dbf0dc88d93">1.625</ix:nonFraction>% Senior Notes due 2031 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMjU_a85776c1-0647-4e62-95b1-c13c23a3bf3a">500</ix:nonFraction> million of <ix:nonFraction unitRef="rate" contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMzU_9f55bddb-9cde-4c17-9293-12d6980600ba">1.875</ix:nonFraction>% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a &#8220;finance subsidiary&#8221; as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMzk_fdf4183c-b571-4ffa-8887-68d27008ee00">3.270</ix:nonFraction> billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="iaf36b03a92634587a78fe98ecbda2739_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwNTE_82aef472-993e-42bd-bf19-0a8805075e35">3.275</ix:nonFraction>&#160;billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $<ix:nonFraction unitRef="usd" contextRef="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwNTk_80fd473c-1741-4069-bc66-f02d8a7df8eb">194</ix:nonFraction> million during the first quarter of 2022 presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTkw_d35b8db3-3104-4d2f-8cc5-c5e3f48f4864" continuedAt="i262f8cda4d364151908031f420f7fef6" escape="true">Amounts de-recognized for accounts and notes receivable, which are excluded from </ix:nonNumeric></span><ix:continuation id="i262f8cda4d364151908031f420f7fef6" continuedAt="i54a73ad9fe334fe1ac17ef9f32db1e21"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i54a73ad9fe334fe1ac17ef9f32db1e21"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b0bfab9628416589521c0cc6480c67_I20221231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItMS0xLTEtMTE4ODMz_60b24c00-d74f-43ea-9e8e-884d4e06f0c5">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i643af335931a4a30a480266df6ef95d9_D20220101-20221231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItMy0xLTEtMTE4ODMz_758bb99d-ab4b-45fb-a889-9dec6ac12e34">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98de3ef86645434aa333bc3813270c7c_I20211231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItNS0xLTEtMTE4ODMz_88c783c1-01ca-4d98-a693-7c3950dc7d80">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id65dea5f8a5b4ac18eaa23709148f19b_D20210101-20211231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItNy0xLTEtMTE4ODMz_7a4982cc-bf4e-45e2-b776-c90d37a60767">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce90adb5f284d558cee43d226b9984f_I20221231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtMS0xLTEtMTE4ODMz_1b717105-9c99-4813-84af-12b16059ba9e">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba3abf20e7914152b66511a2593d8f69_D20220101-20221231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtMy0xLTEtMTE4ODMz_eaa2caae-173e-42f4-bbc7-b06d05c04fe8">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife73119c01544765a2e816448d123ab4_I20211231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtNS0xLTEtMTE4ODMz_9d2e61e3-6d08-48fa-833f-1b2f7e712ab3">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33dfc13e3d6d4ae1bf1a49a51cf7ae03_D20210101-20211231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtNy0xLTEtMTE4ODMz_b066d13d-6dee-4cf5-8fc0-40231d394e8e">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9016a91a7f4898bd6a07d00738ca87_I20221231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtMS0xLTEtMTE4ODMz_ee3e69c8-35d1-4ef2-b30e-8fc0876100e4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b9dfecd89c48c796f6821c64cd7270_D20220101-20221231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtMy0xLTEtMTE4ODMz_28599d10-dc83-4c67-ae8f-ee4c608a1392">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc10de8eb9b4b38a11dcc2d78d8200a_I20211231" decimals="-6" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtNS0xLTEtMTE4ODMz_a451162d-ad44-4967-9eb2-ccee7c8c7907">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a3c6f2ec1ae4c93b758ace41955b687_D20210101-20211231" decimals="3" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtNy0xLTEtMTE4ODMz_6327cb8b-b337-478f-8a30-9bf70f9cacd0">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEyOTcx_ad325840-6fcf-4913-8ac8-b177810dc43b">135</ix:nonFraction> million as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEyOTg3_95a1e5cf-6d60-4958-8564-ce4b3a78df13">134</ix:nonFraction> million as of December&#160;31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December&#160;31, 2022 and December&#160;31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1c756aa5d46d45bc96e0a470b2fa7cf9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December&#160;31, 2022 (in millions):</span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:LongTermPurchaseCommitmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNjEx_3f2bfc4c-4ab7-4df3-8388-9de2fe6b0494" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzEtMS0xLTEtMTE4ODMz_cf8a6de5-a00d-453f-8325-b992b049e4cc">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueInSecondYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzItMS0xLTEtMTE4ODMz_3be46f01-6480-4b63-aa87-875ce090d272">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueInThirdYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzMtMS0xLTEtMTE4ODMz_3a16647f-b568-4c89-b0ee-bc44a05ebcb5">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueInFourthYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzQtMS0xLTEtMTE4ODMz_f8d064b3-5f4e-4f4f-9a02-b8be13fbf46f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueInFifthYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzUtMS0xLTEtMTE4ODMz_f9618bf1-f63b-47c2-9cc1-370e0dfa870b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligationDueAfterFifthYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzYtMS0xLTEtMTE4ODMz_c953e7c0-12f3-480f-9d52-c7e852277fe0">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzctMS0xLTEtMTE4ODMz_cfccf8c7-6f4f-4a3e-b072-3423a260ed0c">1,021</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_118"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNDY_5a325064-1020-4c2f-a221-cd4040851cde" continuedAt="i63104348e75246d1985372a1e0960026" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F &#8211; LEASES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than <ix:nonNumeric contextRef="i5f5f7d93752e444488110da50a259559_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEyMzM_02df202d-843f-4061-930b-bc5fc8f229f9">1</ix:nonNumeric> year to approximately <ix:nonNumeric contextRef="i1f29c696e3e14cde8b3aa694d11cc79f_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEyNTM_f53bc01e-b4ff-44a2-9955-6d1abfc71a02">54</ix:nonNumeric> years, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231" name="bsx:LesseeOperatingAndFinanceLeasesOptionToExtend" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEzMjI_5c2ffef4-0787-4ad9-8297-a96fbfd43cfb">10</ix:nonNumeric> years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease right-of-use assets are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding liabilities are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding our finance leases. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNTM_d5b7f2d8-4df7-4635-a0ac-adfe941daef4" continuedAt="i32a3229272e74eaaa33ea17001b950c5" escape="true">The following table presents supplemental balance sheet information related to our operating leases:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i32a3229272e74eaaa33ea17001b950c5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzMtMS0xLTEtMTE4ODMz_3e5ee9a6-8c1e-40bb-883d-7a3cba1ecf7f">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzMtMy0xLTEtMTE4ODMz_9a84d3be-ef9c-45e0-9e30-3467e0506b53">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_81f8bbbf-aec6-4d61-9673-c05cd50e1871">61</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_d030d6ba-750f-441c-b420-f09e1215f100">71</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzYtMS0xLTEtMTE4ODMz_85a404a8-0f16-407b-8ccb-f7493b944626">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzYtMy0xLTEtMTE4ODMz_c7cab5b3-8c93-4925-95e3-1e7e9a7b604c">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i63104348e75246d1985372a1e0960026"><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNTQ_9b95134c-3cef-4f95-8966-95c9a5f645c5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzItMS0xLTEtMTE4ODMz_9261490d-f168-47ab-a35b-77597b9a53e1">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzItMy0xLTEtMTE4ODMz_9c105fcb-afbe-40fe-b634-303da38765d9">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzMtMS0xLTEtMTE4ODMz_86225b53-d7a8-48e0-a91c-b176348ab20b">3.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzMtMy0xLTEtMTE4ODMz_bf71ce01-b19c-441f-ace2-666e26094c58">2.6</ix:nonFraction>%</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost under FASB ASC Topic 842 was $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3NzE_3aa331d9-1cf1-4816-bea5-d59c5f6870d0">91</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3ODE_daf4db18-de78-495f-a3cf-4e9573e1fcbe">90</ix:nonFraction>&#160;million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3OTQ_a32e6f2f-1e79-48b6-8063-cd799464932d">92</ix:nonFraction>&#160;million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNjY_5c9047c1-1f6b-4ce8-90da-0155f96bb66b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTozNmM2ZWQyZDcxM2Q0Y2RlOTc5MzA1NTFlMWJiZDM2Yi90YWJsZXJhbmdlOjM2YzZlZDJkNzEzZDRjZGU5NzkzMDU1MWUxYmJkMzZiXzMtMS0xLTEtMTE4ODMz_f62578a8-4914-4065-9e9c-7c231fb14fb2">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTozNmM2ZWQyZDcxM2Q0Y2RlOTc5MzA1NTFlMWJiZDM2Yi90YWJsZXJhbmdlOjM2YzZlZDJkNzEzZDRjZGU5NzkzMDU1MWUxYmJkMzZiXzMtMy0xLTEtMTE4ODMz_537c10f2-0038-4d65-9c1f-65ac08e7e3b4">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligations were $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI5ODM_92341f6d-ed0e-4c20-a3e6-7a170e4c1fcc">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEwOTk1MTE2MzMxMzg_e36cfe40-0fdc-460a-aadb-affcc527693a">68</ix:nonFraction> million for the years ended December 31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:MaturitiesOfLeaseLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNjE_f9a78de2-e9b5-4f89-9903-2c88fce91bbd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December&#160;31, 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzEtMS0xLTEtMTE4ODMz_dd275732-56d1-48b6-8f46-ec4b74ce888c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzItMS0xLTEtMTE4ODMz_0b31a626-6517-4808-8100-a8f0aa10a26b">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzMtMS0xLTEtMTE4ODMz_547542c4-c307-4caf-b821-df3d0695cbd0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzQtMS0xLTEtMTE4ODMz_70efbfdf-9c8d-4daa-ae56-6c6a5e64ef61">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzUtMS0xLTEtMTE4ODMz_322838bb-870f-4a10-8485-3679c446770f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzYtMS0xLTEtMTE4ODMz_2e462d1f-e83d-4a31-bc11-83cf0bc5023c">214</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzctMS0xLTEtMTE4ODMz_670664f9-347f-41b5-80e4-7bb2e5df204c">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzgtMS0xLTEtMTE4ODMz_854671c3-5d4f-4af0-b984-d57dee57c3a7">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzktMS0xLTEtMTE4ODMz_070aee59-0559-467e-a1f0-408dd7e0d5b5">408</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2MQ_1ad93b6a-30f6-4a12-b2a0-3de39b71522a" continuedAt="i7f56461d484644ec8fe155e1e7af3063" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G &#8211; SUPPLEMENTAL BALANCE SHEET INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in our accompanying consolidated balance sheets are as follows:</span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk4MQ_d0b6bebd-f2db-40aa-9c31-58df7f9d43bb" continuedAt="i294bea1bad664441adf65fc8349f66ad" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzItMS0xLTEtMTE4ODMz_5251dfa9-2e10-4321-9381-bc97c9127449">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzItMy0xLTEtMTE4ODMz_eaddc108-80e9-451f-aaa6-55895f88b13d">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzMtMS0xLTEtMTE4ODMz_5b8c2b83-d259-4c6b-ad2d-ae9edc4ce430">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzMtMy0xLTEtMTE4ODMz_681a32bd-227d-4a13-ac0e-a9841a066c45">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzUtMS0xLTEtMTE4ODMz_3ba9866c-5f5b-45cb-a782-543d40d2ef18">1,970</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzUtMy0xLTEtMTE4ODMz_5a2b0d74-3533-4059-9bbb-ca89c91504ab">1,778</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItMS0xLTEtMTE4ODMz_d533ba51-f4a4-4eb8-aa0e-57997edd3cd6">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItMy0xLTEtMTE4ODMz_5054217a-1e55-461e-833c-1b975b82ddc5">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItNS0xLTEtMTE4ODMz_b87b0e88-6325-4836-8884-3b2be79da683">74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzMtNS0xLTEtMTQ2MTk3_041432f2-9ad9-44a9-acdd-d40ea3d51b2b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtMS0xLTEtMTE4ODMz_9b90e637-5fa1-477a-a730-527342de23c3">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtMy0xLTEtMTE4ODMz_659ff20d-f99f-4776-8aaa-bb3b02b3e76a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtNS0xLTEtMTE4ODMz_1275ac14-60c5-4959-9e58-efc1299e5932">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtMS0xLTEtMTE4ODMz_2e79dc4b-8274-4b06-b62f-dae94f01e08a">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtMy0xLTEtMTE4ODMz_5a53661a-af78-42ea-912b-d520e62a8505">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtNS0xLTEtMTE4ODMz_e33457ab-2063-42e3-833e-060815b2c0bb">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtMS0xLTEtMTE4ODMz_8eec1f0b-6fd5-46ad-b6d0-3222dfcbb09a">109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtMy0xLTEtMTE4ODMz_99f3c1bc-73ff-4e59-bad8-e5ebf9a7c2ed">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtNS0xLTEtMTE4ODMz_458df8f3-67ec-4d58-a8ea-efebb9007dbc">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i294bea1bad664441adf65fc8349f66ad">Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset&#8217;s contractual life.</ix:continuation> </span></div><div style="padding-left:18pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzEwMTA_e11a4de2-38b1-4481-becf-14d7fb14108d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzItMS0xLTEtMTE4ODMz_43ac89a7-1045-42f0-84f8-0d4eafe17bb0">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzItMy0xLTEtMTE4ODMz_0f4fdb96-0a36-4321-b44a-c9aee2274091">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzMtMS0xLTEtMTE4ODMz_b79f41be-c309-4d4e-9a73-03f9f520d6f6">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzMtMy0xLTEtMTE4ODMz_88a6d836-295a-419a-8664-0f0401ee9f70">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzQtMS0xLTEtMTE4ODMz_730f3804-3189-43f3-9192-8ac6e9dcab7f">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzQtMy0xLTEtMTE4ODMz_3fab1de5-0a75-453d-9115-07dbbaaf03bb">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzUtMS0xLTEtMTE4ODMz_178b9a60-a5c5-4c0f-b0b1-f6f82324a604">1,867</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzUtMy0xLTEtMTE4ODMz_f7a0b579-0917-407a-9144-38859f56e988">1,610</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="bsx:PercentOfFinishedGoodsAtConsignment" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzU0Mw_7581e6d2-f093-40e2-86a2-f7e8719bf5b4">27</ix:nonFraction> percent of our finished goods inventory as of December&#160;31, 2022 and approximately <ix:nonFraction unitRef="number" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="2" name="bsx:PercentOfFinishedGoodsAtConsignment" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzYwNQ_c923fb99-5769-4998-bf03-0b37047d06e3">30</ix:nonFraction> percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2NQ_b95c3fc8-310f-413f-a164-e6e1ec45e503" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzItMS0xLTEtMTE4ODMz_45242a57-89f8-4a58-b6fb-96720e507cd2">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzItMy0xLTEtMTE4ODMz_c9337927-57f8-4719-9acf-2ef00a660fa7">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzMtMS0xLTEtMTE4ODMz_c64e9757-ef0e-45a3-b48b-9e3fd6146a8d">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzMtMy0xLTEtMTE4ODMz_ba32aa32-df23-48f8-bb6d-738a17fb9f98">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:LicensingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzQtMS0xLTEtMTE4ODMz_6a087f6a-0cc9-488a-8323-2f14c99dcc35">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:LicensingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzQtMy0xLTEtMTE4ODMz_7b782c82-72ee-400d-8463-670a55e40a05">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzYtMS0xLTEtMTE4ODMz_c707d34b-497c-4d3b-b7ce-dc6a5716e93d">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzYtMy0xLTEtMTE4ODMz_05a5d839-59fd-4291-a713-6388e2482112">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzctMS0xLTEtMTE4ODMz_a1edd477-f791-4da4-a7e3-bb18f4bae2fc">731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzctMy0xLTEtMTE4ODMz_4f367ca1-f504-4dfb-8a08-ea433c0762b7">799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7f56461d484644ec8fe155e1e7af3063" continuedAt="i7a58da6ac0894424ab88cd91c5490549"><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk5Mw_4def8c70-8645-4dbb-a879-73cd1464b1d7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzItMS0xLTEtMTE4ODMz_9d447d79-9d78-4853-9ef9-c64c92dc711b">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzItMy0xLTEtMTE4ODMz_706426e9-6637-4feb-a319-aa9603354a31">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzMtMS0xLTEtMTE4ODMz_abf2ea4d-44ae-4846-9454-c26afc42012e">1,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzMtMy0xLTEtMTE4ODMz_77ffa05f-edde-452b-8dfc-424e78442006">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:EquipmentFurnitureAndFixturesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzQtMS0xLTEtMTE4ODMz_82590099-a468-4c4b-99c0-2b55e9fa490e">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:EquipmentFurnitureAndFixturesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzQtMy0xLTEtMTE4ODMz_906bbc35-50e9-498f-938f-7c381783a6bf">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzUtMS0xLTEtMTE4ODMz_aef1456f-94d7-4d75-a4da-27845721e26e">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzUtMy0xLTEtMTE4ODMz_97681994-8b38-4c69-bddd-fe877fef5a4e">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzYtMS0xLTEtMTE4ODMz_54cf79ab-498f-4d38-b545-1c1ea1c32a71">5,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzYtMy0xLTEtMTE4ODMz_9a57c371-32e4-4b3b-8ac7-cdb6a50ace89">5,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzctMS0xLTEtMTE4ODMz_43d9a7c1-1af3-40ee-95d4-234d753699aa">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzctMy0xLTEtMTE4ODMz_a17011b9-082c-4cf8-847d-ad73b3b9519a">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzgtMS0xLTEtMTE4ODMz_3b9eaf7c-c896-413b-96fd-eadbd7de4b40">2,446</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzgtMy0xLTEtMTE4ODMz_260696dd-614b-4e05-82e7-a3aeed0e5a7e">2,252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgxMw_ffdbd552-1f1a-4970-af06-9ca80515222c">333</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgyMw_7b059b53-d6ed-4402-bccd-a3026c305213">352</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgzNg_a9f773ba-34b4-4923-8600-46f8d81fc06b">333</ix:nonFraction> million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk3OA_238fcda6-837f-4dac-a232-f41650168914" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzItMS0xLTEtMTE4ODMz_c8035c0f-434b-4092-b37b-559ab92708f7">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzItMy0xLTEtMTE4ODMz_61a102d2-ad33-4615-a9c5-fc34b221d57f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_a5b4e309-f4c4-47d0-b17f-801e74a45e9d">386</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_d8d77a00-e55e-42b6-9fa3-f29cbcadcebb">435</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzQtMS0xLTEtMTE4ODMz_4e5ef0c7-587c-453a-9170-6aca8f2c2e34">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzQtMy0xLTEtMTE4ODMz_0929315d-7aa6-4fc3-9677-765715074d17">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzUtMS0xLTEtMTE4ODMz_69c3612b-5edb-43d3-8680-f42341d8dc8a">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzUtMy0xLTEtMTE4ODMz_d1f81eb0-6bc4-40e0-b2bc-4b3ab187871f">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzYtMS0xLTEtMTE4ODMz_ced6faec-8518-4970-8771-1dcc5f7c2dcb">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:LicensingArrangementsAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzYtMy0xLTEtMTE4ODMz_5d0869b1-1c0b-45e5-a3dd-fb696d03a316">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:IndemnificationAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMS0xLTEtMTQ2MTcw_97dc82e5-c575-4095-8c3f-fb81e5731fd1">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:IndemnificationAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMy0xLTEtMTQ2MTc4_ee660ca8-def8-47b7-af22-152d6ddd970e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:OtherOtherLongTermAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMS0xLTEtMTE4ODMz_e2ee65c4-3021-4623-b0ec-7a4668699482">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:OtherOtherLongTermAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMy0xLTEtMTE4ODMz_d69cf299-b718-4096-8032-33fc2813e482">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzgtMS0xLTEtMTE4ODMz_df396bf0-eec0-4ae5-9929-752e9ba6a106">1,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzgtMy0xLTEtMTE4ODMz_261fd0c9-a041-4787-855f-58902fe3058f">1,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzEwMjA_748a5a1b-532b-4ca2-a7ed-8cb7fbabd0b1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzItMS0xLTEtMTE4ODMz_fd9901d7-9b77-4b01-8c80-e24e382cff40">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzItMy0xLTEtMTE4ODMz_a9839940-0895-4a3d-b8f7-3c9c2674c3be">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzMtMS0xLTEtMTE4ODMz_0b7653bc-6a4e-4a19-bd82-452cce331e22">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzMtMy0xLTEtMTE4ODMz_11300bd6-0125-42f9-89e9-ffd0bfc80d0a">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:AccruedRebatesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzQtMS0xLTEtMTE4ODMz_895ddc8b-8a50-4be3-aed4-878fa57c4c89">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:AccruedRebatesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzQtMy0xLTEtMTE4ODMz_2411b974-06d8-43a9-9044-18795c6ac337">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzUtMS0xLTEtMTE4ODMz_14936c84-0701-4615-b7eb-d76fa4cd83ac">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzUtMy0xLTEtMTE4ODMz_07235bec-b7d4-47a0-a108-346c602408f8">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzYtMS0xLTEtMTE4ODMz_22cd457a-85cd-4813-bf33-66ad8be4533d">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzYtMy0xLTEtMTE4ODMz_23d2262b-d63f-42c3-979e-c3db5c2e1d3d">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzctMS0xLTEtMTE4ODMz_3504da5b-1320-4a43-ac4a-df87bdc8a5c1">2,160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzctMy0xLTEtMTE4ODMz_84d35998-69cb-4222-a2e1-093aa0d86b1f">2,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7a58da6ac0894424ab88cd91c5490549"><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk1OQ_10c5e48a-2db5-4513-86af-25774b084f8b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzItMS0xLTEtMTE4ODMz_441c5a6f-bd7b-418c-8212-f790fec0e14a">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzItMy0xLTEtMTE4ODMz_9c9f6acd-35c4-4aa0-a46c-60ee633d026c">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzMtMS0xLTEtMTE4ODMz_ebb5b06b-87b3-4a72-9e34-999a0fa587eb">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzMtMy0xLTEtMTE4ODMz_fcaccc18-f344-4373-bf9d-b262cee7444c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzQtMS0xLTEtMTE4ODMz_e3a590dd-1c55-4df9-9de0-a0fbb07b020e">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzQtMy0xLTEtMTE4ODMz_0c4e812f-f357-4093-b771-51b356a40e26">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzYtMS0xLTEtMTE4ODMz_c91649af-7fd4-452f-8b7a-ecc78d124665">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzYtMy0xLTEtMTE4ODMz_a0e4aa45-38c4-4cc2-861f-962e4a4d788f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzctMS0xLTEtMTE4ODMz_6ceab477-ed50-4007-9aec-ecf691e1fc1e">761</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzctMy0xLTEtMTE4ODMz_7541d695-b6ac-4b8a-ae9b-d84894729bec">783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2OA_061ffd24-91bc-4c79-b6e1-b1e4ea56ec5a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzItMS0xLTEtMTE4ODMz_a4588d8e-5263-4ea9-b344-96e2956797e5">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzItMy0xLTEtMTE4ODMz_fcd38c20-15c2-49c0-be01-ca3b6c652623">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="us-gaap:LitigationReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzMtMS0xLTEtMTE4ODMz_82f71247-a85b-43dd-990a-f5a6a30fb9c1">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="us-gaap:LitigationReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzMtMy0xLTEtMTE4ODMz_4966fc24-8958-4e28-bc20-a9c2fc6f0331">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzQtMS0xLTEtMTE4ODMz_16983bc8-024e-4cf4-9fc1-0a7368d342fa">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzQtMy0xLTEtMTE4ODMz_b94b4a94-d8fc-43fe-92f7-849b70c104d2">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzUtMS0xLTEtMTE4ODMz_97afc7a6-0389-4f1c-817e-95f840a322b8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="bsx:LicensingArrangementsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzUtMy0xLTEtMTE4ODMz_775aaf71-8212-4e4f-b162-63319ee313bd">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_6a99f40a-b5ea-48f7-a50a-0aad3c2f2303">347</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_687ef02b-cf2a-43f6-b235-9735bd34d7b9">389</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzctMS0xLTEtMTE4ODMz_b6d8408b-3bd8-4351-adf1-6e27241aa2c0">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzctMy0xLTEtMTE4ODMz_97613871-333d-4893-a981-ec2752e11add">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzgtMS0xLTEtMTE4ODMz_810c9f2c-55fe-4640-9cad-fd96d1067012">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzgtMy0xLTEtMTE4ODMz_d1571efe-a4ba-4782-8558-7a2b7d03dd34">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzktMS0xLTEtMTE4ODMz_68eda759-23fc-461e-ae51-2ffb350a247f">2,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzktMy0xLTEtMTE4ODMz_930e0064-0abd-401b-ae8f-7cec76440f8b">2,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i0700a8f6ea1f4171b75e8081068a452b_127"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NzM_4b2d7d3f-9e84-4357-a42a-ac9b32f016c8" continuedAt="i7231750bb2f24a28bcc8fee5da0ad402" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE H &#8211; INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc5MzI_07f80c32-8eec-44d1-bf18-e325e2dce4d4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItMS0xLTEtMTE4ODMz_215af669-6bf7-4311-8cd1-0dd8b9bd9d9b">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItMy0xLTEtMTE4ODMz_8d4c7b78-7709-4022-ae95-00074833f8eb">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItNS0xLTEtMTE4ODMz_013a443a-b8ad-4c00-8ed7-f0ed9a850b81">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtMS0xLTEtMTE4ODMz_2bcd31c2-be8b-49cc-a9e7-09da45524a27">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtMy0xLTEtMTE4ODMz_c806d886-8758-4643-90ed-f25900df941d">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtNS0xLTEtMTE4ODMz_7246857d-57b7-4833-b79d-faa99ca623cd">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtMS0xLTEtMTE4ODMz_d7efa813-d636-4df5-8a75-d57d96b3c507">1,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtMy0xLTEtMTE4ODMz_56598a2f-298b-4089-bc11-fa56c666a5e4">1,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtNS0xLTEtMTE4ODMz_0177d2c1-6bb7-43f8-ab1d-0ab79fc59e68">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7231750bb2f24a28bcc8fee5da0ad402" continuedAt="ib32e90a6eaad463081425a0143c4a9b0"><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NzQ_c16d6fc6-0dce-4805-9495-0c004d5a6dd1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtMS0xLTEtMTE4ODMz_78e7da50-0a62-4c4b-a1be-fde6675f88f6">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtMy0xLTEtMTE4ODMz_91cac78d-4e73-471f-a0c8-a5f3058a6c7a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtNS0xLTEtMTE4ODMz_b6738c17-2231-487b-9a2c-435eedb167f3">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtMS0xLTEtMTE4ODMz_0c770ca6-ad90-4867-aaf2-491eac03407d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtMy0xLTEtMTE4ODMz_85c17eec-603b-4395-87f0-1c3a74b1e572">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtNS0xLTEtMTE4ODMz_73ac92ff-1a2a-4e82-afda-27dc1e30114a">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtMS0xLTEtMTE4ODMz_2ab16d1f-a351-4886-b75a-822ac43cfcab">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtMy0xLTEtMTE4ODMz_c1ed0560-591d-4eb8-bd42-f8b8cfec2aef">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtNS0xLTEtMTE4ODMz_47ad92f7-ff91-4417-90d2-41fa24bc51d8">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtMS0xLTEtMTE4ODMz_cd87c7ae-9452-49ff-b497-63fd5270481b">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtMy0xLTEtMTE4ODMz_1b746f5b-e55d-4a49-83ac-cb6ab5d73d2b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtNS0xLTEtMTE4ODMz_e8b624fa-e403-4cf6-b0bf-305e8aa9dca3">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktMS0xLTEtMTE4ODMz_04771791-cc32-4ffe-bebb-a7ad883d0f10">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktMy0xLTEtMTE4ODMz_1ddd72eb-dfad-42f7-b643-2073a10d6481">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktNS0xLTEtMTE4ODMz_be6344d2-5217-4858-859e-48ec55fee0ef">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTEtMS0xLTExODgzMw_c622f76d-1013-437a-8ec2-83691a614089">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTMtMS0xLTExODgzMw_49bbac57-1fc8-4ef4-8676-81d6dacc5e85">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTUtMS0xLTExODgzMw_7d2466d8-35b9-4d8c-b0d8-d866d34bbd43">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTEtMS0xLTExODgzMw_c7dda380-eb71-4ab2-b1a8-0b9cfa7625d1">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTMtMS0xLTExODgzMw_dc159eb0-18a1-4725-92bf-55f57125d975">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTUtMS0xLTExODgzMw_ddb73b61-0d8b-49d4-bef8-5eafe414cda4">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTEtMS0xLTExODgzMw_de9bf542-e3cb-4c92-ba8b-661312d274da">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTMtMS0xLTExODgzMw_b906404b-2910-4574-8c75-1f22b66388ff">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTUtMS0xLTExODgzMw_63c9bc93-2055-4e0c-a7ce-ed1ab9f80d23">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTEtMS0xLTExODgzMw_7be8ed30-aba6-41ca-b7a7-1c80d0234de4">443</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTMtMS0xLTExODgzMw_0d511bf3-e33c-4b60-9e7c-334dfe005393">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTUtMS0xLTExODgzMw_0ed48d6f-c547-42b4-a25c-74402326f312">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NjA_e215e1df-0f6c-4ad2-bbd3-cb3474787960" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtMS0xLTEtMTE4ODMz_0dea4582-bd8e-4e58-b2b3-adca008705b8">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtMy0xLTEtMTE4ODMz_71851afc-314e-4e5d-bb02-9e3f7a0d9be6">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtNS0xLTEtMTE4ODMz_58235e10-fc35-4a48-bab3-dbdea623b58e">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtMS0xLTEtMTE4ODMz_c3607961-b4b4-4bb5-8781-82d5b7c0f5cb">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtMy0xLTEtMTE4ODMz_77269e1d-54c6-41e8-8035-f06f4e0b9497">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtNS0xLTEtMTE4ODMz_1b331f9c-8b92-4e63-af5c-6d5dedbc2151">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtMS0xLTEtMTE4ODMz_62ac2f38-d91a-41f9-8b7f-69ed73ca25e7">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtMy0xLTEtMTE4ODMz_5a0a0c6b-7479-49b0-a92e-96a438ac8954">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtNS0xLTEtMTE4ODMz_eb7d72b0-ac83-483a-a7db-b32311b9a5d1">155.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtMS0xLTEtMTE4ODMz_b3a8130d-b259-4563-8c6c-f1dddb8df7dc">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtMy0xLTEtMTE4ODMz_21709c2d-e2f5-4d4e-9770-0f6d94b293f8">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtNS0xLTEtMTE4ODMz_07a818f1-d84d-43db-b4c4-05bf28c96623">40.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctMS0xLTEtMTE4ODMz_b38cc859-76ff-49c9-aeb5-ccc60397de0c">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctMy0xLTEtMTE4ODMz_7ed55679-1aa6-466f-b6f7-0cb4bc71f954">8.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctNS0xLTEtMTE4ODMz_4db9b94f-52b7-4633-8ea8-76585bad26a7">16.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtMS0xLTEtMTE4ODMz_300d6d06-1194-4268-8435-b7d085584729">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtMy0xLTEtMTE4ODMz_36b245a4-d6f5-4731-bc4b-53489cf8092e">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtNS0xLTEtMTE4ODMz_00b9b1c9-b07b-42b2-9999-ef2ad1fedbdb">43.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktMS0xLTEtMTE4ODMz_24caf452-6b18-42e0-9a5b-03084c056efd">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktMy0xLTEtMTE4ODMz_3c544a91-2c30-43fc-a6c1-89ca41223317">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktNS0xLTEtMTE4ODMz_310cff4d-14e6-46f5-b043-fc5f35509849">42.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTEtMS0xLTExODgzMw_03c507f2-aef3-472f-a736-f7d8ba84cff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTMtMS0xLTExODgzMw_2ac29703-529a-4034-a059-56797ba0e46c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTUtMS0xLTExODgzMw_a03efb2e-f490-4be3-841c-dcf5ba8b08cb">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTEtMS0xLTExODgzMw_b17c498f-fa04-4907-95df-e0bf84e44e05">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTMtMS0xLTExODgzMw_e17b3efd-7b41-44bf-80e1-c18240fdda28">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTUtMS0xLTExODgzMw_69a9d642-8540-4b48-8cd5-490be924f9c2">7.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTEtMS0xLTExODgzMw_fb47a69d-1e60-44a3-b82f-314252da6f52">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTMtMS0xLTExODgzMw_28ab0e67-54a9-456f-b830-bdac3ed7b915">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTUtMS0xLTExODgzMw_0016c6cc-6ba2-4059-b211-897482194bbd">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTEtMS0xLTExODgzMw_919ba8c4-6dcb-4ccf-b425-165cc9500f8f">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTMtMS0xLTExODgzMw_32faeb99-38fe-4465-b3f0-a5f3efb56b07">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTUtMS0xLTExODgzMw_e4929989-a5c3-46e7-97be-eb37299ce149">96.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intra-entity asset transfers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTEtMS0xLTExODgzMw_c98a56b4-d601-4689-a28f-41ed38c5cd82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTMtMS0xLTExODgzMw_6b276b5d-932f-4fd0-bd3e-a5dc2d379a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTUtMS0xLTExODgzMw_54c965a9-ac4b-4330-8b24-326f355de070">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" sign="-" name="bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTEtMS0xLTExODgzMw_36096024-b6fb-4484-a04c-854cdbe1c485">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" sign="-" name="bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTMtMS0xLTExODgzMw_2e00cc2c-b5e3-4e8a-999c-4fc8702e7299">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" sign="-" name="bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTUtMS0xLTExODgzMw_2a7501c1-a54d-4711-ba0a-67d487ee5e55">37.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTEtMS0xLTExODgzMw_aa7bff79-1146-49e7-87c6-e81209b55c1e">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTMtMS0xLTExODgzMw_1e6ad666-f6d6-42d0-8d5c-8fcf2ba8aab6">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTUtMS0xLTExODgzMw_94439d77-021f-422f-9d37-2874427a5264">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTEtMS0xLTExODgzMw_8769b4f8-9c44-4739-83f9-1c93d18f2e88">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTMtMS0xLTExODgzMw_97647833-f0aa-4b89-9ce0-bcad4b9c0c4b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTUtMS0xLTExODgzMw_2fd35722-5063-4473-b0c2-522826e6bc0c">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTEtMS0xLTExODgzMw_5889a5d3-4d62-4e0d-8871-be65f4bef6b4">38.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTMtMS0xLTExODgzMw_962dd581-b4fa-4307-9a1f-ec5ac9c2cb02">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTUtMS0xLTExODgzMw_6ebdaf61-b491-4c6a-af5f-ef3a76fa8076">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib32e90a6eaad463081425a0143c4a9b0" continuedAt="ie452b5743c8f42d78b961c0a8491fbe4"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc5MjA_1d71f569-c9ef-409f-8cdc-06aed17a2cb6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:70.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzMtMS0xLTEtMTE4ODMz_4abfdc23-48b1-4562-84b3-9573ccd30951">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzMtMy0xLTEtMTE4ODMz_94cc7ef8-ee77-4708-80b5-d22f578d7047">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzQtMS0xLTEtMTE4ODMz_616158a1-3771-4619-93a2-f109b44b332f">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzQtMy0xLTEtMTE4ODMz_351e6ecd-85ed-4909-b112-b23bc98a931c">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzUtMS0xLTEtMTE4ODMz_536d4b48-147c-40b6-9661-a4792aedd302">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzUtMy0xLTEtMTE4ODMz_319615ad-0089-49e6-87df-8b1db1d32b45">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzYtMS0xLTEtMTE4ODMz_a189ce9f-a40d-4fe1-9ebd-0653edbb04d5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzYtMy0xLTEtMTE4ODMz_30f52617-ebc5-4cc5-be9e-131ba55f5c7e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzctMS0xLTEtMTE4ODMz_e10dd7c8-7c6e-4129-b527-8ef5e89a4953">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzctMy0xLTEtMTE4ODMz_fe581940-5563-4536-bb74-baee638b8729">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzgtMS0xLTEtMTE4ODMz_c8292301-8901-41b4-b4af-9075a1a46646">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzgtMy0xLTEtMTE4ODMz_6432a172-cd91-4a11-9361-834060086eae">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzktMS0xLTEtMTE4ODMz_a789c2ca-f21c-4c54-9a01-72f80b71edfe">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzktMy0xLTEtMTE4ODMz_8b27e289-216f-48e9-910f-976dba95ff60">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:FederalBenefitOfUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEwLTEtMS0xLTExODgzMw_12c46dc5-a24e-4057-bae2-6b99529b7ace">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:FederalBenefitOfUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEwLTMtMS0xLTExODgzMw_3c82f105-d4ab-45ab-9295-003ea6eb979e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzExLTEtMS0xLTExODgzMw_663aebd1-d704-4b6a-bbbd-4360ed871155">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzExLTMtMS0xLTExODgzMw_d42e2bdd-6709-465a-ac42-e02d6e905889">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEyLTEtMS0xLTExODgzMw_f0187864-c948-4ede-9558-b9c82e70ef89">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEyLTMtMS0xLTExODgzMw_976758b3-f759-4933-96dc-aab46460ad84">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEzLTEtMS0xLTExODgzMw_24e51e7a-84bb-45a2-bc49-778e022cbf9d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEzLTMtMS0xLTExODgzMw_97151204-ea2d-49e8-93a2-c26a94d30248">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE0LTEtMS0xLTExODgzMw_8848bf52-2731-45ce-b2cf-7bd13ad6659e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE0LTMtMS0xLTExODgzMw_3eb32142-257d-4ad1-98fe-20e0c5c669a8">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE1LTEtMS0xLTExODgzMw_253b3ed9-68fb-4c7b-875c-337fab901fa5">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE1LTMtMS0xLTExODgzMw_85f18148-2f06-4325-a7ea-9a812c819fab">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE2LTEtMS0xLTExODgzMw_1935fa88-7676-436f-9916-f0ecabd63c9c">1,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE2LTMtMS0xLTExODgzMw_6b606b9f-3db9-45c3-8182-f8da8ada61c6">1,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE3LTEtMS0xLTExODgzMw_a60416cb-223e-4251-9e66-75906a06e2ae">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE3LTMtMS0xLTExODgzMw_51b09533-e986-43c1-bb77-9f0386fcb873">3,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIwLTEtMS0xLTExODgzMw_3961ccdc-0061-45b1-8689-5941e9d9a22b">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIwLTMtMS0xLTExODgzMw_efc1dea5-e80e-4322-8f29-91fb07bfc3aa">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTEtMS0xLTE3NjIyMg_b4c28bc2-9d0b-45e5-b8aa-6699c7538215">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTMtMS0xLTE3NjIyMg_7d2868e6-74a8-4a7b-9391-615e910e3b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTEtMS0xLTExODgzMw_ca088838-bffb-49e0-82e6-ebef1debf93b">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTMtMS0xLTExODgzMw_2825ae3f-0039-44a4-9cb5-1066e63d71e5">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI0LTEtMS0xLTExODgzMw_e9330750-493a-451b-bae3-82ccec578179">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI0LTMtMS0xLTExODgzMw_6f951b52-bab5-4cbe-a40a-f02f74752ab3">3,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI1LTEtMS0xLTExODgzMw_7cf0201a-34f1-473b-ab3b-e05bdd171691">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI1LTMtMS0xLTExODgzMw_d85df5d7-b4a1-40fc-8168-f5c87c574a71">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI2LTEtMS0xLTExODgzMw_742fae42-91aa-459c-bb34-e06f307809ff">4,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI2LTMtMS0xLTExODgzMw_74ac750c-ac3b-4450-8b66-cca2c5216519">4,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7c693c1ad044d5b5d785d5431ee0a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzItMi0xLTEtMTE4ODMz_b87ae755-026b-45b2-8b23-d9e8ecfadb54">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1500544395e942a291c9853a03d49cd6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzItNC0xLTEtMTE4ODMz_4244b1ef-8447-4741-9e27-16c226553f4a">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5c980151684785bcfcbb6bbe9b77cc_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzQtMi0xLTEtMTE4ODMz_6c3186aa-4488-4564-93a9-6d0f261a6ba1">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2eb60a7197b4e5da1ffad49a2eee8b1_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzQtNC0xLTEtMTE4ODMz_7681420b-f6d5-4419-999a-c2a85850bc6d">4,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzUtMi0xLTEtMTE4ODMz_56081fd3-9d9a-441e-900a-257e24d663df">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzUtNC0xLTEtMTE4ODMz_ae68b467-c815-43c6-8199-b6e7dbbadfc6">4,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbe628c58a04e7ab7e6559ead7b48e3_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzctMi0xLTEtMTE4ODMz_616be3b7-934b-4d65-a61d-a9d79b095a9c">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277df0ecaf304cf08357801c32ae2706_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzctNC0xLTEtMTE4ODMz_548c74ab-1db7-4449-a59c-35ca529d6e92">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzktMi0xLTEtMTE4ODMz_6f43649e-fce0-44da-8188-1fb4c88e3319">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzktNC0xLTEtMTE4ODMz_5bda5863-d8d1-4188-9b60-bbbf79fe3dec">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzExLTItMS0xLTExODgzMw_ffec5eab-a8c8-4146-a093-a97c8b8694e5">4,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzExLTQtMS0xLTExODgzMw_e26247d1-c0bd-4f00-aded-184f046d4fb7">4,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzg2OQ_54d2b640-1dee-4e4c-975c-caa11e3ca52a">464</ix:nonFraction> million. As of December&#160;31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzk5NQ_000cb8ed-d3cb-43a9-838f-2ab68c1d94fb">560</ix:nonFraction> million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzExMDk_8815ad59-5703-4d2a-b783-dc193fbb5175">47</ix:nonFraction> million as of December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzExMzc_9885d172-c2fa-4fc1-9279-6c3ecccf88c3">60</ix:nonFraction> million as of December&#160;31, 2021. These tax attributes expire periodically beginning in 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxNzk_1935fa88-7676-436f-9916-f0ecabd63c9c">1.004</ix:nonFraction> billion as of December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTU_6b606b9f-3db9-45c3-8182-f8da8ada61c6">1.014</ix:nonFraction> billion as of December&#160;31, 2021. The decrease in the valuation allowance as of December&#160;31, 2022, compared to December&#160;31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie452b5743c8f42d78b961c0a8491fbe4" continuedAt="ibb35f83c5ad3449bb5ea004ba69f61ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI1NTI_7d70d945-e163-4ecf-b687-f0bb4398e368">56</ix:nonFraction> million in 2022, a charge of $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI1NzU_5e9a1a90-cd74-4c9d-b520-f3a22e8d7106">81</ix:nonFraction> million in 2021 and a benefit of $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI2MDA_2e274574-6ded-4419-8669-4c4698134971">78</ix:nonFraction> million in 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:FreeTradeZoneRegimeTaxIncentive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI4OTE_c1ea43b1-d746-4862-a572-c1d854a6eb60">162</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:FreeTradeZoneRegimeTaxIncentive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI5MDI_45082b36-d414-4853-8187-11242bb9681c">149</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:FreeTradeZoneRegimeTaxIncentive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI5MTY_9e56f84d-f420-4781-b7af-8c7d8f5e5124">64</ix:nonFraction> million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxMjE_715fda15-9ae4-483a-b135-9a908ef06639">0.11</ix:nonFraction> for 2022, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="2" name="bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxMzI_0fd77311-82cb-4d01-aa52-f34b796f7b90">0.10</ix:nonFraction> for 2021 and $<ix:nonFraction unitRef="usdPerShare" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="2" name="bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxNDY_006d6ca5-bb28-4224-8a33-477fcb4ef969">0.04</ix:nonFraction> for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:TaxIncentivesInPuertoRico" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMyNTI_7df2e0d1-c521-4d97-8661-e74f9c51315c">21</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:TaxIncentivesInPuertoRico" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMyNjM_b6d6935e-9062-4e8d-8940-3495d5b7fef1">27</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:TaxIncentivesInPuertoRico" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU0OTc1NTgyMTg1MA_60d32ca7-909f-4955-8f21-ee823086e431">30</ix:nonFraction> million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="bsx:TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMzNzc_8d45cd52-4573-43f7-81c7-794455510644">0.02</ix:nonFraction> in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:TaxIncentivesInMalaysia" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzE2NDkyNjc0NTQwMTA_b18dd4d7-396d-43ce-b5fa-e8e485a09481">17</ix:nonFraction> million in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:TaxIncentivesInMalaysia" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzAzODk_3b87cf86-5ab9-49b1-81ac-c97a4b0948ae"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:TaxIncentivesInMalaysia" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzAzODk_a6877b04-5703-4a69-a0c6-7375c9b9fc50">0</ix:nonFraction></ix:nonFraction> in 2021 and 2020. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="bsx:TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzA0MjE_d64d97bd-7ad4-4995-81c6-6925b626cbdc">0.01</ix:nonFraction> in 2022 and de minimis in 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM0Mzg_0e63c4dd-97a1-4168-997e-968f488a14f2">492</ix:nonFraction> million of gross unrecognized tax benefits, of which a net $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM0OTI_6a173bcc-0f8e-4f76-9667-2094b9e33edf">410</ix:nonFraction> million, if recognized, would affect our effective tax rate. As of December&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM1NjU_b24d2e25-479a-4aef-b6b3-bcebc029b4cd">255</ix:nonFraction> million of gross unrecognized tax benefits, of which a net $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM2MTk_05afb518-1e02-41c5-9137-b615b8a70ec6">177</ix:nonFraction> million, if recognized, would affect our effective tax rate. As of December&#160;31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM2OTI_a022fdbd-8e0b-4521-9996-3ff2d2677136">261</ix:nonFraction> million of gross unrecognized tax benefits, of which a net $<ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM3NDY_3ca71723-0a76-4d1b-830f-7609751c0561">183</ix:nonFraction> million, if recognized, would affect our effective tax rate. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4OTA_f3ffdf96-b223-493f-92af-9363abde3645" continuedAt="ie5fcfcd9d44e4e4898a58cdd7abb84d4" escape="true">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="ie5fcfcd9d44e4e4898a58cdd7abb84d4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItMS0xLTEtMTE4ODMz_8d2580ef-83e4-4a6a-95bb-11382beafcba">255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItMy0xLTEtMTE4ODMz_ac7d30a0-c8f2-4ab3-9f3a-975dfd4fe98d">261</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItNS0xLTEtMTE4ODMz_75add5e7-64ca-4d18-ac60-7c1df70bac9b">455</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtMS0xLTEtMTE4ODMz_1a3d699f-9a3a-48d0-b5d1-bb4ce386ad25">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtMy0xLTEtMTE4ODMz_4a41cf0d-1ee5-4b77-8bc5-dfb7cdbf7849">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtNS0xLTEtMTE4ODMz_81435f67-51d3-4455-a661-327790d0f41c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtMS0xLTEtMTE4ODMz_a26f34b8-f78b-408a-ad6c-36e49be7cab2">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtMy0xLTEtMTE4ODMz_85cdcda3-8814-4162-8921-9bf32f9a7a60">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtNS0xLTEtMTE4ODMz_9f0159f1-3932-425c-bddc-d86d29617ef4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtMS0xLTEtMTE4ODMz_cccde21c-7116-41d9-bc11-2bc6ed3424f7">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtMy0xLTEtMTE4ODMz_2327e63a-33b5-4dbf-b3bd-50fef07fb12f">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtNS0xLTEtMTE4ODMz_3e2d6547-eff7-475b-97d1-2926eeebc2bf">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtMS0xLTEtMTE4ODMz_0dbc3e86-0ff9-4d3e-806e-ad2a44b2b2f0">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtMy0xLTEtMTE4ODMz_62a1209c-fc94-4c78-80db-76e9c9775bbb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtNS0xLTEtMTE4ODMz_a296bbd1-0bbc-4849-b241-cbcad759b09f">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctMS0xLTEtMTE4ODMz_ea6348f7-37f9-4f79-b229-8fcfbe78f20e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctMy0xLTEtMTE4ODMz_453239d4-5ce7-4dbd-a6da-ffd0639705f9">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctNS0xLTEtMTE4ODMz_d1a17391-8853-477b-aaec-182b693952ea">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtMS0xLTEtMTE4ODMz_0e63c4dd-97a1-4168-997e-968f488a14f2">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtMy0xLTEtMTE4ODMz_b24d2e25-479a-4aef-b6b3-bcebc029b4cd">255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtNS0xLTEtMTE4ODMz_a022fdbd-8e0b-4521-9996-3ff2d2677136">261</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i1a2e7463fa724bcf9a0461181ceba4f2_D20210701-20210930" decimals="-6" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ1ODM_ad93f46d-4a38-4982-8098-176ad5fd9916">91</ix:nonFraction>&#160;million to release the reserves related to these years. We received a refund of $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ2NTg_acd6dfa3-47d9-49ba-8cd0-6b165fd9da48">62</ix:nonFraction>&#160;million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income taxes as a component of income tax expense. We had $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ5MDI_0e8689b8-c1e6-4b8e-9afa-aaf6af2c4a58">77</ix:nonFraction> million accrued for gross interest and penalties as of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ5NTk_7cb92c4d-e72e-413f-9be2-5b5c41d537b9">43</ix:nonFraction> million as of December&#160;31, 2021, and $41 million as of December&#160;31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December&#160;31, 2022, compared to December&#160;31, 2021, is related to reaching settlements with taxing authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12&#160;months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU0NzM_c28592a8-d50f-4412-b22f-70cee0c15fa9">75</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU4MTM_f3237835-91de-4b0b-a523-88135228bc2e">937</ix:nonFraction> million as of December&#160;31, 2022, as compared to $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU4NTU_940dbc4f-9e63-4e6a-ad2a-87766575fb1b">938</ix:nonFraction> million as of December&#160;31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:Onetimetransactiontaxpost1986EPnetpayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYwMDI_f284dc7c-0af1-475a-897a-3dfb9348604f">586</ix:nonFraction> million, which will be remitted over an eight-year period. We have begun </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb35f83c5ad3449bb5ea004ba69f61ee" continuedAt="if213faa1a0794a5a87f6e1c6064405fc">remitting the required installment payments, with a balance remaining of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:TransitionTaxPaymentRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYxNDM_75657871-91a9-41cd-a14f-6bd0661967e3">386</ix:nonFraction> million as of December&#160;31, 2022. In addition, we have provided for U.S. state income taxes of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYyMTc_b501f0b9-0dc4-4ad4-9dc0-40cff1460846">14</ix:nonFraction> million on all U.S. dollar-denominated E&amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if213faa1a0794a5a87f6e1c6064405fc">We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_130"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI4ODEz_7188ae13-3909-4936-890f-50173556570f" continuedAt="i92f952c7442048a48d627e18343a4b01" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I &#8211; COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI4ODE1_a33a4ba9-ad69-475a-a532-90018fb3b78b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzM5MTY_5be21b9f-038d-4a29-aa42-d0e7fc41f8a2">443</ix:nonFraction> million as of December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzM5MzI_75be31b2-8393-4930-b72a-812514bed154">548</ix:nonFraction> million as of December&#160;31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzU0OTc1NTg0MzA5NA_18564728-962a-4076-8e52-d57f3434dc4b">149</ix:nonFraction> million as of December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzU0OTc1NTg0MzExMg_c196f8a8-60d3-485c-af7d-26b8188af1ea">188</ix:nonFraction> million as of December&#160;31, 2021. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i92f952c7442048a48d627e18343a4b01" continuedAt="i19bf807310094e718e414bba8619557e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded litigation-related net charges of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI3NDg3NzkxNDczOTc_d068eb83-3be8-4c56-ac48-9c35055ceca8">173</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzQ0Njg_829e2a18-cd26-4fed-bb43-605f73a998ee">430</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI3NDg3NzkxNDc0NzM_05edd9e6-d2ca-4592-94cf-3e4067f055fa">278</ix:nonFraction> million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook&#8217;s Instinct&#8482; Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to &#8220;Drug Releasing Biodegradable Fiber Implant&#8221; and &#8220;Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,&#8221; and affects the manufacture, use and sale of our Synergy&#8482; Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT&#8217;s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT&#8217;s patent was valid and willfully infringed by the Company, and awarded UT $<ix:nonFraction unitRef="usd" contextRef="id15f114eb8804a7c98bcd09d92bb0633_D20230131-20230131" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzE2NDkyNjc2MDUzODc_efdd0bfa-f44b-4c4f-a3b2-f733f2150b42">42</ix:nonFraction> million in damages. The Company intends to appeal the jury's verdict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs&#8217; counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i19bf807310094e718e414bba8619557e" continuedAt="i3a0c67b368f0495881964bac3b0f49b0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a &#8220;technical note,&#8221; announced that it was launching a formal administrative proceeding against Boston Scientific&#8217;s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and <ix:nonFraction unitRef="unit" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="INF" name="bsx:BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzE2NDkyNjc2MDQyNDg_ec767b12-d0b4-472b-89bf-5de8a91f74e4">29</ix:nonFraction> individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB&#8217;s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor&#8217;s office issued a non-binding recommendation that is contrary to the Attorney General&#8217;s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE&#8217;s decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge&#8482; Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company&#8217;s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission&#8217;s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company&#8217;s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company&#8217;s Board of Directors conduct an investigation into actions by the Company&#8217;s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3a0c67b368f0495881964bac3b0f49b0" continuedAt="i2bf2e85ad7714c09a2fe7288541be081"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Concluded Since December 31, 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen&#8217;s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG&#8217;s motion to dismiss the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action. On January 10, 2022, the court granted the parties&#8217; stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza&#8482; Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $<ix:nonFraction unitRef="usd" contextRef="i3290f9f23eb24119a72f6930eead5d1f_D20220805-20220805" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzIxOTkwMjM0MjUwNTM_7355d78d-3b0b-4628-9c21-c14143975ade">85</ix:nonFraction> million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro&#8217;s Senza&#8482; I and Senza&#8482; II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company&#8217;s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above. </span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bf2e85ad7714c09a2fe7288541be081">The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUxMjA_0cadb0ff-b3c2-4a3d-8c04-ee2d38ff8fa9" continuedAt="ifefa2bff25d547aaaa03ed32d4d520b1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J &#8211; STOCKHOLDERS' EQUITY </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzU1_caa7c9e2-2af6-4609-91e2-269e2e416c98">50</ix:nonFraction> million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of <ix:nonFraction unitRef="shares" contextRef="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ3MQ_3630d34c-9f74-4dd6-bf23-4c795701ee3d">10,062,500</ix:nonFraction> shares of <ix:nonFraction unitRef="number" contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ4NA_344c1515-16fa-4b90-bc00-0b27605e7155">5.50</ix:nonFraction>% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527" decimals="2" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzU5Nw_11c42865-7f2f-4ecb-a337-fe08268f44b8">100</ix:nonFraction> per share. The net proceeds from the MCPS offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzY3MA_c96b75f3-d507-4957-aa82-3fa30699ffe0">975</ix:nonFraction> million after deducting underwriting discounts and commissions and offering expenses. As of December&#160;31, 2022, our MCPS had an aggregate liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231" decimals="-6" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzgxMw_2fdde4e5-9374-4c0c-82d1-b796d349bff2">1.006</ix:nonFraction>&#160;billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of <ix:nonFraction unitRef="number" contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzEwMzg_344c1515-16fa-4b90-bc00-0b27605e7155">5.50</ix:nonFraction>% of the liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231" decimals="2" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzEwNzQ_8796ae78-b063-462b-afa7-6457e8c3da01">100</ix:nonFraction> per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231" decimals="2" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzIxODI_8796ae78-b063-462b-afa7-6457e8c3da01">100</ix:nonFraction> per share plus accumulated and unpaid dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between <ix:nonNumeric contextRef="if23c296459144875ad187e30e952915b_D20220101-20221231" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzIzOTk_0192e9fb-a87f-45f4-b436-14fcaa6706db">2.3834</ix:nonNumeric> and <ix:nonNumeric contextRef="ifada2c5db8c74b0f917945eda6797be6_D20220101-20221231" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzI0MDY_3126e34f-d8de-4d23-b067-cd9af3acd005">2.9197</ix:nonNumeric> shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzI3NDg3NzkwNzQ2MjA_e30a8a74-7730-4c8d-8025-e560cb955db1">14</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231" decimals="4" name="us-gaap:PreferredStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzMzNDU_68ccecee-6dd8-414a-bdce-876e557aa134">1.3750</ix:nonFraction> per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6805ad1bd72431da0294f8b9f787280_D20230130-20230130" decimals="4" name="us-gaap:PreferredStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM0OTE_1008b7dc-8f97-4e08-abda-950030b7d445">1.3750</ix:nonFraction> per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December&#160;31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM3Njg_7eeba664-8b9f-43ce-84f9-2e94ba990058">2.000</ix:nonFraction> billion shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM3OTU_b5f4a32d-898c-4e1b-9749-cfb57371aab8">0.01</ix:nonFraction> par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 27, 2020, we completed an offering of <ix:nonFraction unitRef="shares" contextRef="i91bed8161679460e856d9920088ac04a_D20200527-20200527" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ1MzE_990bcb99-24fc-43dd-9e8f-29aea16b9ea1">29,382,500</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6bf3f5d8a9e54dd79aaa2d19b5e4aff0_I20200527" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ1ODc_ce359981-f592-4851-9cda-1d89417272d0">34.25</ix:nonFraction> per share. The net proceeds from the common stock offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i91bed8161679460e856d9920088ac04a_D20200527-20200527" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ2Njg_34e43545-50df-4faa-ac10-d92c6d658cd1">975</ix:nonFraction> million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifefa2bff25d547aaaa03ed32d4d520b1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased approximately <ix:nonFraction unitRef="shares" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-3" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNTI_cd929929-681f-4baa-8a3e-d3520fb2a7f7">15.7</ix:nonFraction> million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNTg_0d0bbcde-aed9-4825-a4cc-b8d4776ec5b5">535</ix:nonFraction> million in cash, which represented the full amount remaining under the existing authorization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i182a1036891e4f75bb208c20f52223a2_I20201214" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNjc_4acc290c-6cfa-45bf-9182-3255e2ada51a">1.000</ix:nonFraction> billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were approximately <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUxMDE_9b2caf1f-b333-4d2f-8d85-4ab4ef086a7d">263</ix:nonFraction> million shares in treasury as of December&#160;31, 2022 and 2021.</span></div></ix:continuation><div id="i0700a8f6ea1f4171b75e8081068a452b_139"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTcy_007986a1-055d-4bb9-a265-71bd33c36f8a" continuedAt="i08cd0d2c4e1f4472aa78462e1f3640e9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K &#8211; STOCK INCENTIVE AND PURCHASE PLANS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Director Stock Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to <ix:nonFraction unitRef="shares" contextRef="i08365277a86440dab883742676202e25_I20201001" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzI1Mw_4ea9cd3d-7ab6-400c-9137-a75004a13675">171</ix:nonFraction> million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzY5OQ_ebbaa57e-6e55-40b5-a233-69c91abf666e">175</ix:nonFraction> million as of December&#160;31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than <ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:VotingPowerOfAllClassesOfStock" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEzMTk_d774ae17-9483-4558-b8d8-e553eef9c5d5">ten</ix:nonFraction> percent of the voting power of all classes of stock, the option granted will be at an exercise price of <ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzE0MjY_2e87c8c0-5445-4a69-bf3d-1f156999f880">110</ix:nonFraction> percent&#160;of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of <ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="bsx:Nonvestedstockawardsexerciseprice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzE3MjE_293f4c51-3863-49d5-9d81-81dba2770a89">zero</ix:nonFraction> and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjE1_342645bb-f8f9-4228-9749-02eb98f526da" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65c415d7afe493a89650f841bc4bf30_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItMS0xLTEtMTE4ODMz_449140b0-742e-49f6-bf42-e8e9b6f382a4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf9fcdaae944b3390aef4cad3b3d62a_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItMy0xLTEtMTE4ODMz_37fd2443-87bd-4997-b786-05b4b3002add">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia933afd979654f88afc557688fdca523_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItNS0xLTEtMTE4ODMz_b912fbd9-cdbd-4ed6-a9ca-42d2a5af491b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaae3391a8f04f3aa64456d9284c46e5_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtMS0xLTEtMTE4ODMz_7410cf85-654e-4b06-960f-50e9157f8c57">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14bcf59fe7c34a8a94840e5aefc3a400_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtMy0xLTEtMTE4ODMz_78ef1021-d100-4991-b299-8004efffe10f">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3db7e9dbfd04e5087fede77d602a86d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtNS0xLTEtMTE4ODMz_1f97197b-1f35-4b8b-b923-b970c237c57d">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0af4e13a75a42c69eb0c61842136ccd_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtMS0xLTEtMTE4ODMz_1a598a29-4cfd-4016-952d-6c6fc1e1fc8a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ac253948f34ac7ab4ff32466a9dc4b_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtMy0xLTEtMTE4ODMz_4451ab09-dcb7-43e1-8083-33c0c2d314ff">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7657382e881145e693f2f7a6e978a9cf_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtNS0xLTEtMTE4ODMz_9a79997c-cfee-4f1c-827d-9034885296a9">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtMS0xLTEtMTE4ODMz_61c927f9-8d90-4837-84ff-0d3194a039ea">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtMy0xLTEtMTE4ODMz_b694a9cd-3b44-46bd-a440-fd8eb9389e54">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtNS0xLTEtMTE4ODMz_c5e1d1b1-4ec1-44e3-bc7e-28f366137912">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtMS0xLTEtMTE4ODMz_208ca6aa-d7f7-420e-89e2-b9b4c7a43a28">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtMy0xLTEtMTE4ODMz_370cb5c3-fbd4-4482-adc4-33c57726b937">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtNS0xLTEtMTE4ODMz_8dcdfa77-0b9f-4531-99a0-8cb6cc57284e">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:ShareBasedCompensationNetOfTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctMS0xLTEtMTE4ODMz_ee2d978e-657f-4ef8-a5f1-1f835cccac3c">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:ShareBasedCompensationNetOfTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctMy0xLTEtMTE4ODMz_a53e7296-20a2-4aa4-9085-bf1c8518801e">165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:ShareBasedCompensationNetOfTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctNS0xLTEtMTE4ODMz_f5e30037-bca1-4849-9277-081c39c1b293">142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:CompensationExpensePerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtMS0xLTEtMTE4ODMz_973c5577-88c1-4258-89da-d5ed6b88cd15">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="bsx:CompensationExpensePerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtMy0xLTEtMTE4ODMz_3e542cd2-183d-43ad-9d2a-7df2c873d068">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="bsx:CompensationExpensePerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtNS0xLTEtMTE4ODMz_e7b31b99-d8b0-474b-91c6-6c640c8ebb2d">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:CompensationExpensePerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktMS0xLTEtMTE4ODMz_39c91b74-2ca5-4afe-9493-ef571449e273">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="bsx:CompensationExpensePerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktMy0xLTEtMTE4ODMz_5ab4e4f9-0649-45b0-a57c-47e28fcfc253">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="bsx:CompensationExpensePerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktNS0xLTEtMTE4ODMz_b8dd8d41-7514-4ba5-a507-3119abbe39ed">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i08cd0d2c4e1f4472aa78462e1f3640e9" continuedAt="ie0135c4df33c4f2a9b4d35fe14e8dfd2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTYw_97e2093f-e974-44d6-b983-cb68a97347a6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItMS0xLTEtMTE4ODMz_d3a67b58-677e-4b1c-85c5-b068b04c9d58">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItNS0xLTEtMTE4ODMz_3793f554-5d85-43e3-a203-97fba916169d">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItOS0xLTEtMTE4ODMz_2859e606-fd30-4eee-8aa7-37b4966e766d">3,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtMS0xLTEtMTE4ODMz_fede2232-59a6-4629-825e-6ac902f31af5">44.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtNS0xLTEtMTE4ODMz_42957fa2-a49f-4bda-97d9-3709371807c5">37.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtOS0xLTEtMTE4ODMz_02d73c42-303e-4b87-8998-8a64b9bbd66e">41.79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtMS0xLTEtMTE4ODMz_2bd0f69c-8ef4-4cfe-ad23-3182b8b70022">13.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtNS0xLTEtMTE4ODMz_c17fc52b-a511-4409-bb04-c5eb3afee71b">10.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtOS0xLTEtMTE4ODMz_1131626e-be1a-44b3-84c9-20fe22496a05">10.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtMS0xLTEtMTE4ODMz_30217dd5-1831-46bb-90e7-fc1d7c173b0a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtNS0xLTEtMTE4ODMz_45c47b52-7ec5-470c-9e94-cae5cade74a7">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtOS0xLTEtMTE4ODMz_d064afc8-2d0c-463c-b188-afefb9880415">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctMS0xLTEtMTE4ODMz_5ca21225-fbe7-4088-8710-05d71ca16f96">6.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctNS0xLTEtMTE4ODMz_161a9c9a-5a63-4e31-a6cb-70ceb6724dfe">5.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctOS0xLTEtMTE4ODMz_ed55a066-24bf-4e56-b8de-64fbd5277d56">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMS0xLTEtMTE4ODMz_40a3eb46-1dfb-461d-b66e-e2fe1abf120e">1.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMy0xLTEtMTE4ODMz_923f0cf2-3bef-4359-9ee1-9cc263b48b13">3.87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaabf66c1b2184034b2b380702d5950c0_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtNS0xLTEtMTE4ODMz_4d68f6cd-ea14-4570-9a66-25331215c02e">0.66</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtNy0xLTEtMTE4ODMz_f123d363-3d68-46e6-87aa-cc59a8f7b140">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtOS0xLTEtMTE4ODMz_1045258f-c93f-4dd5-9206-dfb6086067f0">0.27</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i950414449291498aae88bf9cc6ecb151_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMTEtMS0xLTExODgzMw_0738a387-5182-45b8-bd6c-2a943e125724">1.72</ix:nonFraction>%</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-Free Interest Rate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Dividend Yield</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie0135c4df33c4f2a9b4d35fe14e8dfd2" continuedAt="idb72b37e9ada49d98d7cf18a7c0da6af"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjE5_8194e125-0ee1-4b8d-a363-e9ef3851022e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzktMS0xLTEtMTE4ODMz_9c1719ab-7e28-4444-86f9-87ac2e8e9cf4">23,065</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzktMy0xLTEtMTE4ODMz_0ee7b773-9bd5-4983-93d2-96565ea709fe">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEwLTEtMS0xLTExODgzMw_5062b052-e685-4277-86f5-ec8f0bfddbbb">3,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEwLTMtMS0xLTExODgzMw_5ac45df3-de72-4c26-ba5b-d116d198b135">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzExLTEtMS0xLTExODgzMw_75247acb-5188-4b0f-bd38-cc54d6661409">3,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzExLTMtMS0xLTExODgzMw_0ec1c52a-6b7b-4af0-b52b-92353be81bc7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEyLTEtMS0xLTExODgzMw_588e8fe1-aafc-41cc-a534-90f6b9283496">666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEyLTMtMS0xLTExODgzMw_1ff15e93-d766-4f90-b564-2824b9021d33">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEzLTEtMS0xLTExODgzMw_ab72eb6b-843a-4bb1-9edf-aa8bd826bc77">23,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEzLTMtMS0xLTExODgzMw_ad63f376-0491-4939-9166-4705001a1835">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE0LTEtMS0xLTExODgzMw_11b00630-11f8-4572-9f1f-1286df5c810b">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE0LTMtMS0xLTExODgzMw_32f6aaf8-180e-4b33-b87a-b18d85e112e4">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE1LTEtMS0xLTExODgzMw_9e46d58d-aeee-4de4-bde0-b8cad096c569">4,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE1LTMtMS0xLTExODgzMw_82945f34-990c-45ce-8b45-eb4f3ee9b464">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE2LTEtMS0xLTExODgzMw_b8e977e5-75a2-41f8-92c1-7ea75eeccbe8">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE2LTMtMS0xLTExODgzMw_881a6991-014a-42e3-a350-4b66562d9726">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE3LTEtMS0xLTExODgzMw_7a1159f2-768b-49e9-98e3-1dbb89943ad6">21,448</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE3LTMtMS0xLTExODgzMw_fd1c426d-0dd9-4398-a0e5-a96081b0e756">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTEtMS0xLTE0ODc2MQ_3bb8f925-af19-41c9-b693-33d0431a5337">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTMtMS0xLTE0ODc2MQ_bdd419dd-cb92-48dd-8aba-cfb40b1388d7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTEtMS0xLTE0ODc2MQ_69b6efe6-4d89-499c-a293-0076320322b6">2,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTMtMS0xLTE0ODc2MQ_56f72e14-2e77-46c9-bd08-3c66cbdf90d0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTEtMS0xLTE0ODc2MQ_20fc8739-6e8a-4a5e-9501-a120f576a8a3">502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTMtMS0xLTE0ODc2MQ_38c773bf-5baf-4b16-8014-c0334caa0ca7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTEtMS0xLTE0ODc2MQ_e31cf0ab-f51f-4816-90de-f3dc1bbb5273">21,489</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTMtMS0xLTE0ODc2MQ_bae886b9-6bd4-4c67-a670-81a4aacc22ed">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTUtMS0xLTE0ODc4MA_a963e123-c9ab-4aab-b887-a8cdfadb7fc5">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTctMS0xLTE0ODc4MA_60c7a920-7faa-41d3-9788-f2e636e43fa8">297</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTEtMS0xLTExODgzMw_eb78a49f-9eb1-497e-93af-4592960053f3">13,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTMtMS0xLTExODgzMw_db60b4da-824f-43a4-b872-af2e4ef3faa9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTUtMS0xLTExODgzMw_23d91aa8-b008-4a94-a01c-80c7436d9854">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTctMS0xLTExODgzMw_e1b8041b-9894-4be2-a1db-9b1c1afa84cd">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-3" name="bsx:OptionsExpectedToVest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTEtMS0xLTExODgzMw_28dc8862-cf19-487d-ba79-be8ab6bfaf42">7,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="bsx:OptionsExpectedToVestWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTMtMS0xLTExODgzMw_a02991f4-ad81-4146-8a0a-aadf6808db34">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:OptionsExpectedToVestWeightedAverageRemainingContractualLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTUtMS0xLTExODgzMw_f300fc5a-1a65-4083-ab6e-c6259c2a96a8">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTctMS0xLTExODgzMw_ec007ea6-0595-4ea6-8bd9-91b4a7500b70">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTEtMS0xLTExODgzMw_0fbae48e-7542-4434-9da3-32789a86fa74">21,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTMtMS0xLTExODgzMw_c08f0f35-9b07-46aa-8c06-6d42273db2d3">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTUtMS0xLTExODgzMw_c8536845-f526-41cc-bfe0-a2759c6a0590">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTctMS0xLTExODgzMw_6c46144b-80e6-4357-9b74-a68ee639f3b7">296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzNjM_6f73dba5-3ab7-477c-975d-507920bff5b5">72</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzNzM_d2833bcb-129b-4c53-b695-5044a2498708">137</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzODY_a3398454-381f-4013-9ed9-9d1f0c7669eb">84</ix:nonFraction> million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTY4_12249810-9ad8-4f92-9f29-d5d142a60f26" continuedAt="i87c65aecaf894dbabc518e375bbb4e69" escape="true">Information related to non-vested stock awards is as follows:</ix:nonNumeric></span></div><ix:continuation id="i87c65aecaf894dbabc518e375bbb4e69"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzktMS0xLTEtMTE4ODMz_32353e3e-81d6-41af-8e68-c4583119c4f2">11,079</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzktMy0xLTEtMTE4ODMz_7cc313c6-7e6c-4cc2-90df-68cdf98e1715">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEwLTEtMS0xLTExODgzMw_936cd430-8aad-4cbd-bf0a-8a25899e97ba">3,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEwLTMtMS0xLTExODgzMw_bfcaa3b6-7a08-47fe-bbed-249a5a35605d">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzExLTEtMS0xLTExODgzMw_0e238225-4589-49bc-bbab-6cdaac0b8abc">4,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzExLTMtMS0xLTExODgzMw_092ddde2-6d1f-47bf-b258-850e0a9222bf">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEyLTEtMS0xLTExODgzMw_821274f1-ed7d-4d5c-ba0c-c5ea915e3f87">554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEyLTMtMS0xLTExODgzMw_87ef0430-4515-4d5c-a646-013e7069f453">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEzLTEtMS0xLTExODgzMw_194a2e0e-7635-4a4f-ab26-284420e4d9cd">9,987</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEzLTMtMS0xLTExODgzMw_ef44baf1-6d52-41da-8f7a-0190ae8c0a14">34</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE0LTEtMS0xLTExODgzMw_ec603d03-af27-4473-b68a-09ad27090671">4,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE0LTMtMS0xLTExODgzMw_d5660e33-739b-4b83-9311-ef216c8f7799">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE1LTEtMS0xLTExODgzMw_689779c6-5500-49c0-8ea9-36c81ae3382c">3,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE1LTMtMS0xLTExODgzMw_bbfc38d4-600d-4b03-bc7b-321f9fe939af">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE2LTEtMS0xLTExODgzMw_76c476d0-3aba-4657-af0b-b2478905c0b0">658</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE2LTMtMS0xLTExODgzMw_bf2527df-11d0-4ce4-ae17-e67a9cebee9f">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE3LTEtMS0xLTExODgzMw_2f738b6e-d4bd-4686-b5dc-d644b9e67b06">9,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE3LTMtMS0xLTExODgzMw_ef3d2ca4-81e4-4734-972e-091bd6163bcf">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE4LTEtMS0xLTE0ODY5NQ_edf58273-f2c3-44dd-b13f-1f383e647cfb">3,854</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE4LTMtMS0xLTE0ODY5NQ_bf8507d8-1e75-4cd7-a147-19832a2ea2bb">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE5LTEtMS0xLTE0ODY5NQ_3beda8e6-3a5b-452f-b446-de6a2e7b0da0">3,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE5LTMtMS0xLTE0ODY5NQ_82b831ed-4ea4-4d24-8f6f-c9283fb23bfb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIwLTEtMS0xLTE0ODY5NQ_63b09f6a-a30f-45b6-a522-f683a26d2580">680</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIwLTMtMS0xLTE0ODY5NQ_578f7dcb-6e27-43e6-a559-040b1bf50b6b">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIxLTEtMS0xLTE0ODY5NQ_78cf0d47-818e-445b-a64e-e7321c954885">9,438</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIxLTMtMS0xLTE0ODY5NQ_4f3de63a-826a-4ff8-be59-ab103e4487bb">41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of shares that vested was approximately $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM3ODI_4c071142-90c7-4212-89fe-ea7b7738c4f1">150</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM3OTI_d4391f63-74a4-4f43-905a-1cb150b22d90">148</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM4MDU_f1141c28-f34c-4ec3-af0b-a6d7887493c6">172</ix:nonFraction> million in 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idb72b37e9ada49d98d7cf18a7c0da6af" continuedAt="i712c0c0bda6a49cbb5a1851ba2236355"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from <ix:nonFraction unitRef="number" contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231" decimals="2" name="bsx:RangeofthetargetnumberofmarketbasedDSUsawarded" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQzMzU_f87975c1-3b75-437f-8055-a5b2ad4ceecf">0 percent</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231" decimals="2" name="bsx:RangeofthetargetnumberofmarketbasedDSUsawarded" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQzNDE_444a15fb-230d-43bb-a5cd-934a74e649f5">200</ix:nonFraction> percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjAw_a6e8c612-0f2a-4983-a1ba-14744d326bdc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU and DSU awards to be approximately $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:Fairvalueofmarketbasedawards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ3Nzc_b8f0f80a-8c51-429c-bee3-d5be6e2f09d7">12</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:Fairvalueofmarketbasedawards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ3ODg_c6eb1d0a-2145-43f2-acef-6461a5fa69f3">11</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:Fairvalueofmarketbasedawards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ4MDI_1c953086-2bfc-4c89-9d9b-27fb35a7b4b0">8</ix:nonFraction> million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbed6b4234d64fd6a55a3d61b6c5cc7f_I20210217" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItMS0xLTEtMTE4ODMz_b8edca78-498d-4c4a-9e4d-a1ef01ca5957">44.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c2fdbe96ac342cfb2c6e55914689554_I20200218" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItMy0xLTEtMTE4ODMz_5c1b45f7-d210-4062-9321-54de29973e66">37.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e2523c5f920482192b97a05b9cfd285_I20190221" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItNS0xLTEtMTE4ODMz_188a9628-64c8-4c1d-bcfb-aa2f77efb90c">42.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:Measurementperiodmarketbasedaward" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtMS0xLTEtMTE4ODMz_fa8aaa57-4c90-460c-9438-9e2fa59cf5fd">2.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" name="bsx:Measurementperiodmarketbasedaward" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtMy0xLTEtMTE4ODMz_e6421840-6eb2-4021-9e9b-df3a4a0df310">2.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" name="bsx:Measurementperiodmarketbasedaward" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtNS0xLTEtMTE4ODMz_ea131f34-c6d9-4344-8ac8-98eb7c012fa3">2.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtMS0xLTEtMTE4ODMz_ce93baab-7076-4ec2-9177-875795b6d748">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtMy0xLTEtMTE4ODMz_92c27e05-b2f3-4310-9ddf-f43e2f47496b">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtNS0xLTEtMTE4ODMz_50be8647-5ca2-4312-aaeb-534c4b45310e">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Cash Flow Performance-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from <ix:nonFraction unitRef="number" contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231" decimals="2" name="bsx:RangeofthetargetnumberofperformancebasedDSUsawarded" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzU3NjY_940b5174-02ec-4dba-b043-b99411196ee2">0 percent</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231" decimals="2" name="bsx:RangeofthetargetnumberofperformancebasedDSUsawarded" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzU3NzI_85992d0d-2ead-4cdf-bb1d-d9cedd03b680">150</ix:nonFraction> percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjQ3_9eafb4fc-38f7-48d0-bfb8-7a972573b6e7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:FairValueOfFreeCashFlowFcfPerformanceAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtMS0xLTEtMTE4ODMz_0ee92b01-fd58-45dc-a0b3-a07e0bef8be6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:FairValueOfFreeCashFlowFcfPerformanceAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtMy0xLTEtMTE4ODMz_ffa528c0-8a08-4824-b9cd-c68650add193">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:FairValueOfFreeCashFlowFcfPerformanceAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtNS0xLTEtMTE4ODMz_3edaab6a-a0ec-4436-8d19-57c8cf6cf90e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItMS0xLTEtMTE4ODMz_f9086d29-7542-4b56-a58f-cef76cda10e1">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItMy0xLTEtMTE4ODMz_78313f93-6de8-4449-a097-af4fcbc18c8e">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="2" name="bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItNS0xLTEtMTE4ODMz_685f9b72-4858-4ddd-b587-6c0836e4d52f">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtMS0xLTEtMTE4ODMz_2b769138-0c9e-4bca-a041-8f3dde42b538">46.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtMy0xLTEtMTE4ODMz_38aa5c43-36af-4927-ab6f-e76229bda5d9">42.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtNS0xLTEtMTE4ODMz_208662e3-4fbc-4438-8173-fe86f404e2c8">35.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expense Attribution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i712c0c0bda6a49cbb5a1851ba2236355"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term &#8220;forfeitures&#8221; is distinct from &#8220;cancellations&#8221; or &#8220;expirations&#8221; and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately <ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:Annualweightedaverageforfeiturerate" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzc5ODI_8d1d297a-41c1-4d9a-ba25-e555e1f07cac">five</ix:nonFraction> percent to all unvested stock-based awards as of December&#160;31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Compensation Cost</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjMw_994d2314-2d10-447e-a010-398c0a561dab" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:UnrecognizedCompensationCostStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzEtMS0xLTEtMTE4ODMz_a7721e60-2f68-4df4-9882-eebd17e16ee9">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:UnrecognizedCompensationCostNonVestedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzItMS0xLTEtMTE4ODMz_6193132c-2688-4861-a4d7-43877fe6de3c">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="bsx:UnrecognizedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzMtMS0xLTEtMTE4ODMz_7884e5f1-a5a8-457f-99ee-957bcfb2a689">219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:WeightedAverageRemainingVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzMtMy0xLTEtMTE4ODMz_2eebcbd3-2c5a-4998-9cef-8348eab940b5">1.7</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an additional <ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzI3NDg3NzkwODEzMDY_7b31d95d-8f26-4e10-a444-a8a74add2a86">10</ix:nonFraction> million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzg2ODQ_14d34cc5-3f1f-4761-ace0-3313dd4bf394">60</ix:nonFraction> million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than <ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzg5NDU_b8a61c82-6953-45f3-932c-8516766ce7dd">ten</ix:nonFraction> percent of the employee&#8217;s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="bsx:GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzkyMDQ_c5a309da-940c-448f-91d5-fb222cdc6fd8">85</ix:nonFraction> percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December&#160;31, 2022, there were approximately <ix:nonFraction unitRef="shares" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzkzNTU_ce0a183f-ce5b-4be5-b1d2-00d2696eb075">11</ix:nonFraction> million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjQ5_89218556-054d-446a-b53e-275882580ef3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItMS0xLTEtMTE4ODMz_ada91ac9-cf3a-4236-8f2a-1ed769afe0ec">2,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItNS0xLTEtMTE4ODMz_00200916-5750-459f-86b5-9a7dba4d2174">2,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItOS0xLTEtMTE4ODMz_ec64d6ba-964e-4ab2-9f79-d2639ae4a179">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="2" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtMS0xLTEtMTE4ODMz_f68e6bab-0e9c-423b-aa8e-f3cc9a873334">31.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231" decimals="2" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtMy0xLTEtMTE4ODMz_92fbbc9b-df17-4da1-ad92-4ca5de6cbae6">32.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="2" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtNS0xLTEtMTE4ODMz_6fa37027-1e13-40f7-be87-ca326af03dda">29.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231" decimals="2" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtNy0xLTEtMTQ4NjQy_505c275d-a722-48a9-ba26-8f6710805760">36.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231" decimals="2" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtOS0xLTEtMTE4ODMz_5533db9e-430d-49ff-ade5-aea5b2d14f1d">29.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtMS0xLTEtMTE4ODMz_c38c0fd5-f11f-4432-8881-a9a5621badc5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtNS0xLTEtMTE4ODMz_e184328d-c04d-42c5-92f5-4e0e77d2c121">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtOS0xLTEtMTE4ODMz_9426156f-fe1e-4248-a199-faf79d16bdef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.</span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_142"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MDE_81f6728a-3bf5-4da8-8962-8550f7fe68af" continuedAt="iea3574de41274c5aaf192de179352b30" escape="true"><div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L &#8211; WEIGHTED AVERAGE SHARES OUTSTANDING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MjA_700f0e85-e1a8-4d77-9361-a7b97e67d116" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItMS0xLTEtMTE4ODMz_140b9a1c-5164-4a9a-9124-ca940863cf34">1,430.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItMy0xLTEtMTE4ODMz_6c11343d-18a3-4a09-b032-3158fc8cf67e">1,422.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItNS0xLTEtMTE4ODMz_cd18741d-b3b9-4b93-8c0a-f9b8983d9f7c">1,416.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtMS0xLTEtMTE4ODMz_91b253ae-5f27-4e5b-b3b3-55fb071b5b0a">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtMy0xLTEtMTE4ODMz_7fc45a0c-a6db-48f1-9279-34954eaec06e">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtNS0xLTEtMTE4ODMz_fe79eac8-e168-4c9a-863c-8d95cad696da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtMS0xLTEtMTE4ODMz_03d6c782-7c11-4f4f-9051-60534235ca57">1,439.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtMy0xLTEtMTE4ODMz_66eaaa70-e222-4d60-aa39-22c4df50dd0b">1,433.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtNS0xLTEtMTE4ODMz_53de819d-77e2-4b53-9309-f551423ed6fb">1,416.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MDU_456d7044-cd79-46e3-bc4d-827e4cf40ddb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1d4b247dfcf42b18bdd3d7fc7fef232_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzItNS0xLTEtMTE4ODMz_4b24cbcf-bfef-4056-ad05-76cd79d4462f">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8687933af19a45e89f5ecbc7a113fc9c_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtMS0xLTEtMTE4ODMz_5becdc52-7562-4a2e-8d14-1c842e37911b">6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i040d7807c33b46a4b79cf78c184c0dd7_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtMy0xLTEtMTE4ODMz_89db8667-4885-4f92-9dc0-fbe2985af561">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c56a446b7c417f8ba1d1a6f60d5e8b_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtNS0xLTEtMTE4ODMz_aa45db9b-9d24-4294-a48d-fc53e056172e">6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3043cc21b44462892099dc71ca5ae2f_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtMS0xLTEtMTE4ODMz_f28c8151-4fda-4a06-aff0-18fd0612f044">24</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80e0030da7dd43208fdf78c181acd6b5_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtMy0xLTEtMTE4ODMz_18b6b62c-3a87-40d6-a887-246dbe822326">24</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5740688cc4a24abfa9eca604a6e8a9a6_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtNS0xLTEtMTE4ODMz_8c35b1e4-b767-47cf-97e3-ca23bd4aebe1">14</ix:nonFraction></span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> position in this period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)&#160;per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="iea3574de41274c5aaf192de179352b30" continuedAt="i459e268242834626ace181dad71090a6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented in our consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) available to common stockholders</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i459e268242834626ace181dad71090a6">.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_145"></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3MTY_04e1a303-e41b-4447-a569-a3324d07a657" continuedAt="i81c0c21eda8b4acf87e123a3ac4a7234" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M &#8211; SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into <ix:nonFraction unitRef="reportablesegments" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzU0OTc1NTgxODc1Nw_6381cb99-8180-4628-a756-1d678a719320">two</ix:nonFraction> reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note N &#8211; Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with U.S. GAAP.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i81c0c21eda8b4acf87e123a3ac4a7234" continuedAt="i7b89ded70e324937a4d509236b5c7f67"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2OTM_0f5b5013-ae2d-432a-b873-3ffa10056957" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItMS0xLTEtMTE4ODMz_61ec642a-93e4-4f62-b300-aebb994820db">5,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItMy0xLTEtMTE4ODMz_717549cf-263a-4191-ab62-696e8042d3b0">4,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItNS0xLTEtMTE4ODMz_29320c76-e8e0-485a-bd34-ec3a713cae31">3,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtMS0xLTEtMTE4ODMz_8be41809-3568-4df5-803b-af4093d9303a">8,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtMy0xLTEtMTE4ODMz_d81edf57-512d-4b69-8d17-fe89e819f286">7,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtNS0xLTEtMTE4ODMz_ed1142c4-12dc-417e-9266-f9ed58c10add">5,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtMS0xLTEtMTE4ODMz_999638c2-3440-4df3-8537-d139c0752623">13,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtMy0xLTEtMTE4ODMz_ef9e6057-37ca-4b35-89a4-aee834adaa98">11,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8209cc36f681456ca83869b5c6449383_D20200101-20201231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtNS0xLTEtMTE4ODMz_f37957f9-50ec-4310-a47e-68c3d7e95e1a">9,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231" decimals="-6" sign="-" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtMS0xLTEtMTE4ODMz_f9cc1619-911e-42b9-990f-b91c9aaaad2a">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtMy0xLTEtMTE4ODMz_138310cd-b0f5-4725-a9fc-10e7aca4ee8b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231" decimals="-6" name="bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtNS0xLTEtMTE4ODMz_bc1391d9-0c8e-4de1-ae5d-ddbcaae17415">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMS0xLTEtMTE4ODMz_a6246606-be39-48a1-96e5-ea882b3ec330">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMy0xLTEtMTE4ODMz_d0b22eae-7367-4fb5-836c-51304f30f2e6">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctNS0xLTEtMTE4ODMz_2a14053b-d3f1-4747-a578-1dbe8065e177">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMS0xLTEtMTQ3MTk4_6c6eaf9d-d938-4b1c-82b5-1716976a54ee">12,682</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMy0xLTEtMTQ3MTk4_bbcf54e3-6418-47d4-8afb-96fa7aab2fb2">11,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctNS0xLTEtMTQ3MTk4_48cec28d-6b31-4c09-8717-12c74a4fd63c">9,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3Mjk_f3172034-c54d-4779-a3c6-00fa377154ad" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItMS0xLTEtMTE4ODMz_7d43b30c-eac9-4558-9487-744f4436f302">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItMy0xLTEtMTE4ODMz_b07a0a15-4259-4efe-a282-de916688c42a">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItNS0xLTEtMTE4ODMz_3b675eb7-f7cf-451d-81f2-da39b9306a1d">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtMS0xLTEtMTE4ODMz_d47e35df-0ddf-418a-a813-d42a8ccdc328">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtMy0xLTEtMTE4ODMz_b39b7cd5-dbd4-474d-8ce6-f1f7eafae7f7">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231" decimals="-6" name="bsx:OperatingIncomeLossAllocatedToReportableSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtNS0xLTEtMTE4ODMz_c9ad4673-2b25-4821-9215-486b7f1c0796">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73aacf8162a94e5ca1cbfc7c3bbb8429_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtMS0xLTEtMTE4ODMz_cc4ecb5c-1554-451a-a091-210772168835">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4d1adfd5d54741badb3c93eae8f22f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtMy0xLTEtMTE4ODMz_a8ff26fa-1f6d-4bb3-a63e-3db32fa16666">3,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8022cbc49a3d4c4fac891808fe3df6d5_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtNS0xLTEtMTE4ODMz_85d588d6-c2f9-4476-8456-63a8ca4c22a2">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a81988fde44ba5b6bd50b742952a88_D20220101-20221231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtMS0xLTEtMTE4ODMz_7b610d08-b1cc-4fa5-9525-0ec2e4c5d378">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad42e640c3464b0da50b8fb06d89531e_D20210101-20211231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtMy0xLTEtMTE4ODMz_b295e475-fb48-41c7-9557-30486870abdf">406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828e9990d56940ce9f697d568f80f1ca_D20200101-20201231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtNS0xLTEtMTE4ODMz_03d48934-e71d-4984-a3f7-8f5a1b5de496">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33ec3556bf5a454fa2bd44957535d39c_D20220101-20221231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktMS0xLTEtMTE4ODMz_2234f90b-bf34-410f-9c10-6f413a572bf3">789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2bdc993f6049e2bd23b2de3c4d090c_D20210101-20211231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktMy0xLTEtMTE4ODMz_ecbbb7c7-b649-420c-a178-a12417acd44c">1,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282876cb44e2481c810f077edcb1f925_D20200101-20201231" decimals="-6" sign="-" name="bsx:OperatingIncomeUnallocatedToSegment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktNS0xLTEtMTE4ODMz_744cc839-2f32-41be-90c7-2624829a699c">1,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTEtMS0xLTExODgzMw_224bc14f-303a-401c-981e-ccfcb2dcd644">803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTMtMS0xLTExODgzMw_d88b7c93-589b-4a74-9a27-17bece4ac832">741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTUtMS0xLTExODgzMw_67f91d85-e995-4f99-beb9-2dc46bdae310">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23150e692e7444a6b1096dff0b883677_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTEtMS0xLTE4MTg0OQ_b4c76521-7229-42e5-9c68-998b571126bc">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTMtMS0xLTE4MTg0OQ_354c3603-6dc6-4051-880a-fd12d15673c8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTUtMS0xLTE4MTg0OQ_c3301d1f-9590-42a2-ac9a-21a071a6fe5c">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTEtMS0xLTExODgzMw_62ecfe47-bddb-4bd5-8f2d-a0be4053838f">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTMtMS0xLTExODgzMw_e1cc1420-26e1-4433-98ab-5516d76d8798">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTUtMS0xLTExODgzMw_3ea109c4-c808-452b-9808-a2a4b7ce8e2a">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTEtMS0xLTExODgzMw_3127aeed-d460-40a0-be94-f04e2c3c3f3b">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTMtMS0xLTExODgzMw_68f2f993-0666-40a2-a0a8-ba963a3aa8d4">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTUtMS0xLTExODgzMw_f88d24d2-2e88-4a61-87a3-5e6ae70fb2ce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTEtMS0xLTExODgzMw_ff68197d-3a49-422a-bfa7-7e4d83cb5a5e">1,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTMtMS0xLTExODgzMw_b6eddfe7-6fdc-4f99-bec9-e6dff4a7ff9c">1,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTUtMS0xLTExODgzMw_6ea5d309-eacf-48a2-bf57-8ac3e38e2574">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2OTU_ed915535-0a41-4e3e-98df-cfccbe623c19" escape="true"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItMS0xLTEtMTE4ODMz_0f0a5a63-add2-42d0-924c-b61fec0cbe5f">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItMy0xLTEtMTE4ODMz_9fbca0c6-17e4-42bb-8ab9-0a8e414538c0">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItNS0xLTEtMTE4ODMz_b43a1b16-0d6d-4c6c-8376-4d013b0c8923">30.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtMS0xLTEtMTE4ODMz_40d7bb48-64f8-4aec-9194-4e82e87f050e">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtMy0xLTEtMTE4ODMz_77e3e82b-0ce2-4067-8100-559f63772c73">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231" decimals="3" name="bsx:Segmentoperatingincomeaspercentageofnetsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtNS0xLTEtMTE4ODMz_a60ca69c-970c-4247-bd4e-dbc696bf8960">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItMS0xLTEtMTQ3MTIy_1440f9b8-5092-4b91-a5aa-cf4a272f7261">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItMy0xLTEtMTQ3MTIy_2679c7c3-1f76-47ff-8905-50f8bc850169">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItNS0xLTEtMTQ3MTIy_2d5af265-ac1c-4539-a64e-aeae8df25764">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtMS0xLTEtMTQ3MTIy_763322f6-a7cd-47dc-bcf7-1b6195b3abfa">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtMy0xLTEtMTQ3MTIy_92a8fc01-8010-4869-a2fe-74c0d1aaf39b">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtNS0xLTEtMTQ3MTIy_7f7430d9-e70c-4a2c-bebc-30b5196d6d42">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtMS0xLTEtMTQ3MTIy_d9504934-84af-4732-be5b-4226fd2b770e">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtMy0xLTEtMTQ3MTIy_d6c27052-98f2-47f2-951e-859027d19beb">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8209cc36f681456ca83869b5c6449383_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtNS0xLTEtMTQ3MTIy_3522e5fb-936e-4b28-8378-a2edb51df85c">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23150e692e7444a6b1096dff0b883677_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtMS0xLTEtMTQ3MTIy_12de062f-f9d1-4b5c-b598-6a6ea485e4ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtMy0xLTEtMTQ3MTIy_d6ca6144-fcb8-4a62-88d9-208ef765a30e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtNS0xLTEtMTQ3MTIy_df23c8a8-5040-4c97-a80a-98a85ff8730d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtMS0xLTEtMTQ3MTIy_5bf52203-6ff4-47d1-9831-14007577c55c">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtMy0xLTEtMTQ3MTIy_c6eb781e-bbac-44d3-9d8f-c1b819a72f75">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtNS0xLTEtMTQ3MTIy_cac8739f-6efb-482d-8d64-0728bf3d0a58">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b89ded70e324937a4d509236b5c7f67"><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3MTQ_20c8600e-30bf-4e28-b7d7-31f64f25a407" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0460e71d5b418b813458aae9b11a82_I20221231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzItMS0xLTEtMTE4ODMz_3eb6c976-cb81-47d9-8544-84b4bcbf776b">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc263f43956447489bf00cd95b47d45b_I20211231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzItMy0xLTEtMTE4ODMz_80adcc46-9d5f-4227-8035-518aa90e1ed5">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie847a194b2334592ac9587e3029dbcd2_I20221231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzQtMS0xLTEtMTE4ODMz_c8189c14-c533-45d7-86a9-78a0f996b61a">5,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a5e00fb04b14bd7be7b428099bd5934_I20211231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzQtMy0xLTEtMTE4ODMz_55f8ef08-f24d-461e-b765-fa552f763798">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9912e3f7721e4f4eb02c8a146eb576ad_I20221231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzUtMS0xLTEtMTE4ODMz_ec1fcb76-9cfc-4f11-9f96-16a0a8bebca2">7,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff6c0b60ebb41109c5e430b7cf98bfb_I20211231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzUtMy0xLTEtMTE4ODMz_976069cc-6146-4e7f-8ec0-b7228c10f980">6,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzctMS0xLTEtMTE4ODMz_b0099e53-f80a-4b78-9688-f9b7a387d42e">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzctMy0xLTEtMTE4ODMz_328a52a8-58de-4fd8-9608-ed45779091ad">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzgtMS0xLTEtMTE4ODMz_326c4346-966e-4b48-9386-514288f8c2ce">5,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzgtMy0xLTEtMTE4ODMz_9dab6693-8a67-46b4-820e-5cdf88e67f87">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d25936d40ea49aab12bb59004cd2db9_I20221231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzktMS0xLTEtMTE4ODMz_dd96a2df-ddf9-4dc8-a0a1-e3ef802ae1b6">5,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6cf9fdde614399a2fe497025d3fd04_I20211231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzktMy0xLTEtMTE4ODMz_ca1792b6-0bed-460f-92b9-63312f854532">7,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b22282599f043b7ac5083784fc608f5_I20221231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzEwLTEtMS0xLTExODgzMw_762778c9-39d4-4d70-948d-4c599bdce5b4">32,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b5c422cffd4ce5a6f4a90251a20608_I20211231" decimals="-6" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzEwLTMtMS0xLTExODgzMw_ed52e714-c423-4e9e-8e6f-38be8a0bff00">32,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2NTk_59842a5f-81ed-4bf6-92ec-ebdf9ec2be41" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56a78345d3145e2b9794e539a59c1d5_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzItMS0xLTEtMTE4ODMz_df7842a9-0f0d-4ece-8840-a772ea4ad7ca">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4367e2317d04cf0b38cf472829367fa_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzItMy0xLTEtMTE4ODMz_7342c65b-0d4d-46bb-b623-7a188187018c">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia714a3ddfec449b5b11c7aa4287614fc_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzMtMS0xLTEtMTE4ODMz_05354220-19fc-4ce4-af88-533bdebad07d">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if045c803eadb4661aca54512d1bb0be2_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzMtMy0xLTEtMTE4ODMz_10a4e37d-1e99-43c7-97c9-e96cba362b77">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2970551fa2429a88d913607880908f_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMS0xLTEtMTgxOTM1_4f8fc0be-1b06-47a8-892b-50baa6ddca83">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95029382727473aaf7e493ea3baafeb_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMy0xLTEtMTgxOTQ4_3ffc7963-b32f-46c7-9bb4-3d9d9351e180">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7006856c9d44d2ab1e38d46423fd26_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMS0xLTEtMTE4ODMz_479d882b-ef34-4bf5-a4df-12b941fb8063">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc270f01c02480db0f2bcec5a56070c_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMy0xLTEtMTE4ODMz_4573d15b-07f3-47fc-a649-145ff9306026">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzUtMS0xLTEtMTE4ODMz_b2b9f543-be83-4d67-b010-deee2078e1ad">2,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzUtMy0xLTEtMTE4ODMz_2d431a99-eb12-49aa-8e17-125dad6a87e9">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzYtMS0xLTEtMTE4ODMz_3e4ebf4b-d2a7-4e08-9303-2f9d52c0f187">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzYtMy0xLTEtMTE4ODMz_5f419c63-aeeb-4a78-a171-8235aa23ff3f">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzctMS0xLTEtMTE4ODMz_67eb2d01-e3fe-4192-81dd-694ad522d15e">5,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzctMy0xLTEtMTE4ODMz_252a410a-142b-4231-96eb-9ddac10eeaea">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzgtMS0xLTEtMTE4ODMz_3e5ee9a6-8c1e-40bb-883d-7a3cba1ecf7f">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzgtMy0xLTEtMTE4ODMz_9ef6a660-6488-4786-a201-2c0c8838c344">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzktMS0xLTEtMTE4ODMz_4e414c3a-f7ee-4696-9fe6-8dd4b24b9b42">21,653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzktMy0xLTEtMTE4ODMz_c2e42294-4a6d-448d-b9f8-facf5dceac9e">20,795</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMxODg_b450cc5c-5ab8-4e98-af4c-470babc88b76" continuedAt="ic5617deb29634fa48033025bb5341ea3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N &#8211; REVENUE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMxODU_e10ae81c-7e81-492b-980a-d36ac6536552" continuedAt="i3ba38d7270724c0193edecff526e0c0a" escape="true">The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:</ix:nonNumeric></span></div><ix:continuation id="i3ba38d7270724c0193edecff526e0c0a"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dca525960544c139044f842992c4cd1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMS0xLTEtMTE4ODMz_d232f826-c3dd-4c2a-a961-388b5d6e45bd">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac06cd2de024399894d3c6dfb28070e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMy0xLTEtMTE4ODMz_e63349aa-2463-4901-a89b-172752632536">880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e2ba9581ee4e218b8a89a221a0d400_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtNS0xLTEtMTE4ODMz_af5eb67c-5bbb-4714-a227-de264d44b5ae">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98056bb0e784957b5899a9e833f0fbf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtNy0xLTEtMTE4ODMz_553f0854-95f3-4609-b68e-998898634918">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2e323954f7444eafe535939a1c7edc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtOS0xLTEtMTE4ODMz_404130ef-d828-4a43-83c7-d281d48fc7c3">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3945a09c204b04a2dbb81ac13ccf41_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTEtMS0xLTExODgzMw_8363ffba-a244-4359-9b61-9f44472d4402">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d43ae659ff4513bb97a8edea477a2e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTMtMS0xLTExODgzMw_da67878a-71e9-4b55-bd17-ad6bcef4ab78">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6ae61663a74c268cb97faeae2f6a45_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTUtMS0xLTExODgzMw_4beaa613-b612-416c-a509-c29f31bef10c">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfbdd903babe43e3990ab29bcbe6985e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTctMS0xLTExODgzMw_815773f5-55e9-490e-b82b-7b68431f6019">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5cf1f78e6445dcaf73a56694e9027e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMS0xLTEtMTE4ODMz_30771a68-fa1f-4f4e-84db-75567522e026">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b44455a502404199213289b929b707_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMy0xLTEtMTE4ODMz_087c93b7-37fc-4c0b-9316-32674697ca51">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb65397f906401f908a347b4d777c0f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtNS0xLTEtMTE4ODMz_e2a39339-2830-4109-a602-da93014f6dcf">1,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ede5593b494783a615d880fc8b78d1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtNy0xLTEtMTE4ODMz_b5e27739-2a19-4a95-bc89-cf558039aeec">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea5ae6a8a2245f1b71a59f4740ac05b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtOS0xLTEtMTE4ODMz_f114daeb-fe91-4816-8141-4c1da601147d">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e19ddabb7c473ea576b951929e933d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTEtMS0xLTExODgzMw_ee2fe5d9-8adb-4e16-a964-9275a40947c6">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7fe9c758704bc380ecdd891fe49855_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTMtMS0xLTExODgzMw_b0fb0c8a-265d-4e9a-b86e-94846e073256">918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfe994c194b4ac8ae41f11a8e0cce7a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTUtMS0xLTExODgzMw_0d11e6f4-8e69-4856-8b43-00eebb855d6f">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d8cad94f45467790555d4a57825c01_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTctMS0xLTExODgzMw_64f0fe6f-e34f-4612-8767-9e637721300e">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief043d96b49f4090a6042a4c1e0f9605_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMS0xLTEtMTQxMTUy_22cb4b8d-2cf0-49e8-9126-1b752c8d4cba">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a88f9ce6ad4b2eb993d105654ed940_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMy0xLTEtMTQxMTUy_cfd9c5da-2b03-41b0-a581-62a872436159">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59ce8cc839f4063a3e88b18ffbe49ba_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNS0xLTEtMTQxMTUy_44efddeb-f147-4bc5-9858-a74c109cdb50">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4d8cfc9f3949e0ab3d00ac9a41c0a1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNy0xLTEtMTQxMTUy_0c33a4c1-a28c-4f6a-a2bf-70bbeafa9a4e">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2111a536bd5a4796852fa7ccbf67dc68_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtOS0xLTEtMTQxMTUy_7ab58227-b4f6-4625-905e-78c655cd9f14">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd845dce72c499e927c52977b641d86_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTEtMS0xLTE0MTE1Mg_5778c6c1-df7b-4bb2-b7ee-e92c4c81b280">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266d7b2f5a4648a7aedcb54343a73155_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTMtMS0xLTE0MTE1Mg_037ace18-83dc-46ca-916f-48cd0fb524be">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95007a0364764d788c9f338d90b37fa4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTUtMS0xLTE0MTE1Mg_7775540b-06e4-4546-8dfa-bb7f942a3c67">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6658a131071b4edaa7cac05c6b6aca94_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTctMS0xLTE0MTE1Mg_62cd04ee-69c5-4e2d-955d-fbcaf5a435ab">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5309925cea74e63b88ce62afbe1270d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMS0xLTEtMTQ0MzAw_065962ae-bdc2-4668-81dc-e4699bf68316">3,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97bc9d7d5aef436ca66c436814c83b71_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMy0xLTEtMTQ0MzM2_c9a9ad0f-c423-4180-881f-257d4e8ceb5e">1,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNS0xLTEtMTQ0Mzc1_54def943-d89e-4a26-aea6-16851ce40078">4,911</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea2540506a544eeb708632b6b53f89b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNy0xLTEtMTQ0NDIz_fe321627-dd37-4322-8f1e-d5324013569b">3,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bc255eecd04f718e0dce31409bbb26_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtOS0xLTEtMTQ0NDU1_0c08ab01-cc0d-4758-a337-36cc7de326cc">1,578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTEtMS0xLTE0NDM5OQ_a40384e8-9bf0-437d-9c57-7f6f1cba26d4">4,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4d0840a435a423cb7726c98d53dbb8a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTMtMS0xLTE0NDA2Nw_782e7422-65f2-440d-aec3-a45560fc165d">2,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf111df6fc94178a8bb5ccf9404c15b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTUtMS0xLTE0NDA1OQ_3943bf99-fb5c-4ddb-a0fa-791ca80a792e">1,299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTctMS0xLTE0NDA3NQ_5e411da9-c83d-4a4a-a2ff-a729328aec4f">3,827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b14d4227e848e0add48cdc505946e5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMS0xLTEtMTQxMTgw_00ecc787-f2ee-473e-ae3e-997a813c6e19">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02edf62965645468d841ff2e20bd583_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMy0xLTEtMTQxMTgw_63488e13-7c7f-4b75-96b6-3c77f2f843fc">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ee3c0309a9465098537a7f86a5ed19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctNS0xLTEtMTQxMTgw_3ba4afb9-ab62-4c5b-a9bd-c614aa5139d0">2,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaac1cd808c424895d59867a9db30ba_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctNy0xLTEtMTQxMTgw_9ebe0c94-d35c-4dee-bd08-e6f697e31313">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3cec840750475fa319163520fd421c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctOS0xLTEtMTQxMTgw_5e7c7d2f-0bcc-49f9-875f-5e9c50fd4e23">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if97a3d07e8ae412080d39dd505633b22_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTEtMS0xLTE0MTE4MA_851a231b-6003-4692-9695-0f16b5f5b3d0">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e2fdd1216d48ad9a132b46e9f04cc1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTMtMS0xLTE0MTE4MA_96ae71b8-803a-4686-99e9-5fd417c713a2">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c84859c22a480cb0e62d9cee342cf9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTUtMS0xLTE0MTE4MA_42fe00b0-04ac-4bca-bd0f-13cffa34bb1f">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b43961f16149e79908d1ce39fcce65_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTctMS0xLTE0MTE4MA_c17c586f-a3ff-4deb-a855-0d8c130bc8b0">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6511ff7f1ebd4c868948a72045ca4c95_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMS0xLTEtMTQ0MzA4_f367390a-432c-4730-95b4-081a847f5d7a">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2cccfcfa0da4d0ba64bd068cb216aaa_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMy0xLTEtMTQ0MzQ0_a2c3cab7-dd9c-423b-a343-eaa3ed69307e">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ef965318ec475d8fe145a03272291f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtNS0xLTEtMTQ0Mzc5_3cb52264-a92e-4f8d-b167-408fa2893ded">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f013c49cfa4e968944e9f014b68096_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtNy0xLTEtMTQ0NDMx_e27f11ba-ff40-4016-9f09-d4aab4e85646">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84b586d1c33476cab5cd06fe83b53aa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtOS0xLTEtMTQ0NDYz_2ae6e46c-9404-4613-b73e-de9ee8b47723">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f895c42144907a76b542b549cfab7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTEtMS0xLTE0NDQwMw_e18b9e5c-10bf-4a66-a1cb-bc43f5210a83">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c142c5abcd44f2097601e910946d27f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTMtMS0xLTE0NDA4Mw_5c1215f8-7046-4485-95be-098e2435fb1f">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4badae83fb2143539a2f1dbc8f190c16_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTUtMS0xLTE0NDA5MQ_7760b451-7882-4d53-a265-f6e864f5c93f">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087cbed8b29e42feabd968d6ded400ef_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTctMS0xLTE0NDE3NA_250441db-e774-41db-9732-a2b338c3b5e2">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i788426412f1a40f8ad96ce8056faccd4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMS0xLTEtMTE4ODMz_4f49df4f-e12f-4c3f-a48d-82014aa59431">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bff9d1f551440a688b46d38ff22c6f3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMy0xLTEtMTE4ODMz_b687fd36-9c3c-472d-8409-e16cc72a110b">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3332eee0684d473898c31f79884ac25f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNS0xLTEtMTE4ODMz_f7c37d61-a455-46f1-88ab-272f3ecd068c">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b385711e244459b5bc15b4489ddc67_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNy0xLTEtMTE4ODMz_7dddc5c5-51a0-48f7-8ba3-96cc23e20b85">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c36f07461a4edb956649b1e7840283_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtOS0xLTEtMTE4ODMz_d638a752-e57e-4495-b51f-c41318aa65df">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367ed0de181442618fa9e97ba29c26ec_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTEtMS0xLTExODgzMw_91955050-1c92-437e-a987-206c7a3150d2">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9d01f0516547888439cdac0d45255e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTMtMS0xLTExODgzMw_9882d258-74b1-4aeb-bffb-174132d9effd">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ee1376ff224dada10dcbfa895cde79_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTUtMS0xLTExODgzMw_30ebaba4-e76d-4540-ab44-10f685c68063">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5934a9c4b546c8aa8a37ac4ff145ed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTctMS0xLTExODgzMw_54ecca97-c8f3-47bf-b3cf-316ee5d661bd">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9327fc2252e47e68dedb4bf033c1d99_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMS0xLTEtMTE4ODMz_250f231c-d1fa-461f-a584-4c945af22b77">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980a462ea63b44bfb0e472d26c91addf_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMy0xLTEtMTE4ODMz_c52552d2-05e1-49fb-96c8-c58f0e35e22c">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f3dfdce6e044c1af8a7d768e300200_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNS0xLTEtMTE4ODMz_9fef4904-a945-44d7-b827-8dc819af4385">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5d84cf74294152822468efbefec311_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNy0xLTEtMTE4ODMz_25baa9e8-497f-40e7-a835-c716585e6313">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e041f4904a84a60b8108cc9c8334104_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtOS0xLTEtMTE4ODMz_f797c350-3dee-47f3-9370-9163bf1f36be">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e41d3f89a4c0a99eec3c08767ddc2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTEtMS0xLTExODgzMw_04b6531b-3f31-407e-b86e-cd0a6546bc1d">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67b272c44934fe18e99394c9d6804bb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTMtMS0xLTExODgzMw_d1c8924e-a8ff-46d9-bacd-dc64be96a779">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270ce9e6a3b241c8adb7451d55aeab6e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTUtMS0xLTExODgzMw_1740f473-1697-4749-b515-112ee46eb982">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581ceebdfc92445686149ad51b8ce5c5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTctMS0xLTExODgzMw_3f81514c-8f23-4a19-aabf-2fcd372a0646">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299c0a24457a49c48fa0b7f8274dfbcc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEtMS0xLTE0NDMxNg_978007fb-8de3-4c88-8a10-c0c2d58b0edd">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a11a2bfead64c0d8b223433c88c9be4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTMtMS0xLTE0NDM1OQ_cec00bcf-262c-4a4f-a102-659d7f5278cb">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d0aad282314e139497edd5e2dedbd2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTUtMS0xLTE0NDM4Nw_fba5d427-c1eb-4a25-8d22-ddc60c7ca89d">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f4ab88945f40329c0a824cc3ac5fc8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTctMS0xLTE0NDQzOQ_168e2d8f-4f97-4574-97e5-edee753d6c76">2,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c06369961704a7285b3ca38acb83219_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTktMS0xLTE0NDQ3MQ_9c78cb6d-6860-494f-8bfb-9747858b8771">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe90759eb8f424d8234de45b7a2a52f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTExLTEtMS0xNDQ0MTE_d15349a9-1620-45bb-96d4-d840f05e4f01">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907ac35c98df416294ddae9f68675c91_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEzLTEtMS0xNDQxODI_b546fcc3-e8e9-4644-823f-48faf9e5ae71">2,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa4826270924bc38ed4e2b1152cc626_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE1LTEtMS0xNDQxOTA_a65512be-5b3d-4bc9-ae08-e60c85a52142">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a81b7be7914312a976ebf95b9963e5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE3LTEtMS0xNDQxOTg_5861dcd1-38f8-48ee-bfde-b879d47af0cb">4,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c43cfb6b094f59988dda6095180014_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMS0xLTEtMTE4ODMz_5a0ac541-b6d1-4abe-985a-0d3cb075a628">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49ee4af7f4d4a8687f9f49af6e015b4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMy0xLTEtMTE4ODMz_1a70c72e-c702-4619-b99c-233ca59e5b2c">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff090cbc1c5471fb8af72a026fedd32_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktNS0xLTEtMTE4ODMz_141d9b72-48ff-4088-813d-794655418115">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c4af7a1ce94cab93068e8d456e80ee_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktNy0xLTEtMTE4ODMz_148c2ee2-00d5-47d6-a616-c93121f2cd44">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ce6d1a01654d339cdd042cff9f100c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktOS0xLTEtMTE4ODMz_9de7c77c-b289-403b-b417-44226ecefaaf">824</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bcf6149b1404f96a68187ed3c062a35_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTEtMS0xLTExODgzMw_fd190084-cb06-4731-ad80-c0e621c63a99">1,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9c77c73b8241e1a75da0171dba04aa_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTMtMS0xLTExODgzMw_61f748f6-f884-4ede-b1f7-0df3fcafcb61">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6797d90a509d4ec8834a36e34146765f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTUtMS0xLTExODgzMw_2f70285b-a991-4971-8bcd-359585f0fe94">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242b0d85ba4e4a2fbe4aed3cf9b322a3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTctMS0xLTExODgzMw_ae0c67ca-3b67-4c54-b77d-a6129a08ed5b">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05dda8644a90446b877b0a66f32d173a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTEtMS0xLTE0NDMyNA_3e2ceeae-1e34-461a-925d-2dc6048a38b5">4,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f123aba421447aa9cfc9708023f08c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTMtMS0xLTE0NDM2Nw_531e9fe3-8072-42af-a74f-51063d5c197e">3,512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTUtMS0xLTE0NDM5NQ_2ae78525-dec3-4c1c-81af-526e9735bb3d">7,831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd26528424d45f2883dba765d3955d2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTctMS0xLTE0NDQ0Nw_100366cd-26df-4630-b0c5-671d06ad87af">3,846</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd88a51eb14a4889becd9bf95a373936_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTktMS0xLTE0NDQ3OQ_211f6d8b-54f4-4ccd-bc84-d38ca2274e76">3,396</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTExLTEtMS0xNDQ0MTk_6ea3d39c-0ae1-4cec-a343-f16e01a918aa">7,242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1f6bf8d3c34daab2415fdc9e3dd952_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTEzLTEtMS0xNDQyNzY_ac87b836-c821-4de0-a789-ca4b5c4d533e">2,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210171398abc49e5804c051f9b9fc4cd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTE1LTEtMS0xNDQyODQ_bad7565c-7d91-476c-ba48-63a0894cdf52">2,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTE3LTEtMS0xNDQyOTI_5c5178a4-3b88-4923-b9ec-237186feece6">5,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d2ba2b1796414eb8143d8705a0465a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTEtMS0xLTExODgzMw_d0bba16e-b951-42ae-be39-d1db01dfc0b3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ab10efbdcf47528ab3d60926612e2f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTMtMS0xLTExODgzMw_df2c2002-5893-43e5-9fb8-d8eddeddd097">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTUtMS0xLTExODgzMw_8bcc94cc-9faa-46d7-ac90-49b5d80ddf5a">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5baeedb7124b2f84ddb781633016f5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTctMS0xLTExODgzMw_5ca13ed1-b7f1-4566-bad9-f83f7a365829">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be1b83b1a924f748b1636472e5583be_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTktMS0xLTExODgzMw_c2031c5d-01d4-4860-bfa3-8a19b921b03e">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTExLTEtMS0xMTg4MzM_91a7a7ba-4c9c-46a8-b9b5-3af779834374">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b2f64263444c3080cc6d662586f06c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTEzLTEtMS0xMTg4MzM_ba73e570-03f0-4613-b6ae-217ab03dfbee">193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fe7e8d201c4c45ae3804080539f315_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTE1LTEtMS0xMTg4MzM_101cb585-b693-4a56-ae39-330149c2b5a8">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTE3LTEtMS0xMTg4MzM_4365d31b-cc9c-445b-915d-7c4d6fc03337">219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85ad4347a4c4b54ae5c5fc3193a7800_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEtMS0xLTExODgzMw_ba486110-7b5a-474f-bb90-1babd6a7c464">7,632</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea4c3278ec34a698de1ffba66d08cf6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTMtMS0xLTExODgzMw_8ce7128f-62ba-4f8f-bf85-bafc2a402f87">5,111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTUtMS0xLTExODgzMw_fab9d006-a9ab-4bbf-8975-90b9a9287f66">12,682</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3c6b5d49ff44128141a1fbb83b6e1b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTctMS0xLTExODgzMw_28998b05-2650-4a59-9b2c-c03e8d1d9d62">6,911</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12859b60da9b499db05018d9639782ce_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTktMS0xLTExODgzMw_56a3b13d-0023-4798-ab40-e2ae1e8e74bf">4,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTExLTEtMS0xMTg4MzM_79cdbdb5-d119-4620-9969-6b7336df4a58">11,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d5ab671eea46b3bff921eba5cde3cb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEzLTEtMS0xMTg4MzM_2d821354-4529-44f6-932c-589a52d82474">5,701</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb42a43becfb4015933cfee5cff72004_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE1LTEtMS0xMTg4MzM_85aa3746-f04a-42c3-808c-a6af74bb6b43">4,212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE3LTEtMS0xMTg4MzM_441b8c91-a344-40c1-b6f0-a815eee7f685">9,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M &#8211; Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fd28aa8356476e99b8acb0eca6d645_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItMS0xLTEtMTE4ODMz_272da4fd-036a-4752-b656-6d94906611e7">7,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f7de2437fa49bfac860e607810e395_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItMy0xLTEtMTE4ODMz_8d936e35-0f3c-4284-b28f-c0f1d12c3ae9">6,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa737befb7b447a8ba19436619112479_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItNS0xLTEtMTE4ODMz_1648e2ea-8556-4d89-a053-0e303c5319ee">5,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifead762c7ade4e00b9129c72020dc3b0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtMS0xLTEtMTE4ODMz_86f063f2-d35d-43d4-a159-27aaed13d31b">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b812ed03474859ab0a0548820d732e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtMy0xLTEtMTE4ODMz_45c445ce-3bf4-472c-acbc-622931411d11">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fc248e09be4de88c3b1366bed3d1e2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtNS0xLTEtMTE4ODMz_0569078d-ca4b-410f-9bc2-7e982121eebe">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d8f6746e354f2e87c087199c9722d1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtMS0xLTEtMTE4ODMz_a5b19127-521f-44c2-a48c-aa1c2fbe31f5">2,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75aca95e90e14d6f8ad7d91562c55653_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtMy0xLTEtMTE4ODMz_16c9e0f3-1778-41e2-8193-4449031174bf">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0c54a79abb4963befbf39f66d3391e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtNS0xLTEtMTE4ODMz_9f2309f0-d5de-4494-b0a1-6766d664ee11">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7ba54afdd9452783afd6d19b9919ba_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtMS0xLTEtMTE4ODMz_550ef119-aead-46e6-b33d-4db1f613f7a7">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0809617f4324434aaebbd5728f20d9b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtMy0xLTEtMTE4ODMz_9ea10706-8adc-4e20-94c1-d3554bc998f9">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950de22b68424e98860e7337e3026204_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtNS0xLTEtMTE4ODMz_928bc919-45d2-404f-bc59-547ef2b2608a">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktMS0xLTEtMTE4ODMz_8bcc94cc-9faa-46d7-ac90-49b5d80ddf5a">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktMy0xLTEtMTE4ODMz_91a7a7ba-4c9c-46a8-b9b5-3af779834374">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktNS0xLTEtMTE4ODMz_4365d31b-cc9c-445b-915d-7c4d6fc03337">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTEtMS0xLTExODgzMw_74d9c981-62b6-4ffe-bbe7-9c411ee31855">12,682</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTMtMS0xLTExODgzMw_dbf924b3-ff23-4869-ae3a-c41d8973a711">11,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTUtMS0xLTExODgzMw_441b8c91-a344-40c1-b6f0-a815eee7f685">9,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9523ca0ea2849a3ba7afdb3f792faac_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTEtMS0xLTExODgzMw_2acb1b58-51ea-41c5-b30c-e1535f6bc7bf">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12a969e10ec48b990fe38bdaab38a23_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTMtMS0xLTExODgzMw_e634d522-03a3-47cd-a7b8-78aec7a62ce7">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef567bf8d9645e88d19c89d931dc420_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTUtMS0xLTExODgzMw_f7604dd4-f3d5-4ed6-bb7a-b1b490f71e01">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We define Emerging Markets as the <ix:nonFraction unitRef="countries" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="0" name="bsx:EmergingMarketsTotalNumberOfCountries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMwOA_9d3b583c-0ed0-40e1-a644-a77424f9c7e3">20</ix:nonFraction> countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#252;rkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets. Our deferred revenue balance was $<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzYxMw_0dde9e8d-c7c5-4455-a99d-dce2461c95fb">509</ix:nonFraction> million as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzYyOQ_e96166ee-4821-4be7-823a-5125dbe9353e">484</ix:nonFraction> million as of December&#160;31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE&#8482; Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic5617deb29634fa48033025bb5341ea3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzExOTg_9938cb27-abc1-455e-ac29-7c9ca0072768">156</ix:nonFraction> million in 2022 that was included in the above contract liability balance as of December&#160;31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE&#8482; Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE&#8482; Remote Monitoring Service. These fulfillment costs are amortized over the average service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzEwOTk1MTE2MzQ1MTI_96d821be-b36f-4937-9cd2-0737d59c8076">179</ix:nonFraction>&#160;million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX&#8482; Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on our accounting policies relating to revenue recognition.</span></div></ix:continuation><div id="i0700a8f6ea1f4171b75e8081068a452b_151"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90ZXh0cmVnaW9uOjYyZmM1NWNlNzBiZTQ2MDBhMzY0YWUyMWQ3MmE4Y2Q0XzYxMA_e724b35b-1d2a-4c60-9bc8-f6dfea762d50" continuedAt="ie95e87c48df54e68af040f584decd053" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE O &#8211; CHANGES IN OTHER COMPREHENSIVE INCOME </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90ZXh0cmVnaW9uOjYyZmM1NWNlNzBiZTQ2MDBhMzY0YWUyMWQ3MmE4Y2Q0XzU5OA_a292e68b-459e-424b-b8cd-a8580755ca0d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtMS0xLTEtMTE4ODMz_9705b7d2-e30e-4563-a657-41bc9a75ef23">93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtMy0xLTEtMTE4ODMz_a1a03458-9b39-4ba2-a44a-19b985a5c2ab">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtNy0xLTEtMTE4ODMz_b1ed8bfb-c5ca-465d-b05f-4945492acbf9">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtOS0xLTEtMTE4ODMz_c11ed53f-0bfc-4113-87be-91877e52d9a7">263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItMS0xLTEtMTE4ODMz_3fc80620-9c08-41cf-ae05-a55b855cdfa7">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItMy0xLTEtMTE4ODMz_8bcee189-5d3e-424a-9416-1c2fe4e3eb40">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItNy0xLTEtMTE4ODMz_7852a796-6319-42c5-bf99-9946958b15ff">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItOS0xLTEtMTE4ODMz_07fc8b5b-6ed1-42f5-bc65-69d5c1d35af3">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtMS0xLTEtMTE4ODMz_3f0e7e24-534a-4069-aac5-6162154be177">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtMy0xLTEtMTE4ODMz_291ead42-82b4-4f66-a96d-cc8a710d6e7c">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtNy0xLTEtMTE4ODMz_08dc0511-af74-447a-9f8e-c522b090c886">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtOS0xLTEtMTE4ODMz_da841578-1ff9-42b0-a2c1-a04780fa24eb">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtMS0xLTEtMTE4ODMz_9657a9de-f7b1-4d13-b202-412d3d1eb7bf">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtMy0xLTEtMTE4ODMz_3d67498f-d071-4a3e-b851-5f8483446d8e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtNy0xLTEtMTE4ODMz_2a723380-5b12-47dd-b722-10b822971698">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtOS0xLTEtMTE4ODMz_875b0dbe-d6aa-4bf6-9408-7668e40da323">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtMS0xLTEtMTE4ODMz_7828f077-f237-494d-ab13-0fe15cb22fd1">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtMy0xLTEtMTE4ODMz_bb39542f-58df-48bb-99ff-92dd8bba52e5">269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtNy0xLTEtMTE4ODMz_e84134ba-8825-45dd-ac32-39592326e2aa">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtOS0xLTEtMTE4ODMz_a9581477-4081-47f6-be10-bf28c30d320b">269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtMS0xLTEtMTE4ODMz_a774dfc9-df80-42bd-afaa-30bfbd05312a">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtMy0xLTEtMTE4ODMz_48e007f0-3918-43e8-bc5d-b4c6859e6dca">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtNy0xLTEtMTE4ODMz_1a328ca3-f79f-42c3-89de-05736f8cad60">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtOS0xLTEtMTE4ODMz_e33fad8b-a610-42d4-af6e-97c884c4c8ab">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItMS0xLTEtMTE4ODMz_69e1f539-bb65-48dd-8518-938af86efc7d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItMy0xLTEtMTE4ODMz_c6ca4109-316b-4077-b688-6e64e84d9ca4">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItNy0xLTEtMTE4ODMz_e4be3bac-3d86-4284-be44-db97b63cecc1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItOS0xLTEtMTE4ODMz_88a614ef-274d-4b43-828c-50a5edc394e9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtMS0xLTEtMTE4ODMz_6104e955-657c-467a-8d93-b305005ba5dc">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtMy0xLTEtMTE4ODMz_c57dbda0-5184-4da6-9c18-7409ebb0257e">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtNy0xLTEtMTE4ODMz_e7775119-74bb-4cc6-b69a-034cea09c867">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtOS0xLTEtMTE4ODMz_1430b248-1adc-4658-ad6c-14582f31ad59">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtMS0xLTEtMTE4ODMz_6ed8290c-4833-40a8-9c9f-d8ce86905055">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtMy0xLTEtMTE4ODMz_bc43e799-d385-4345-976a-f6ed3d371c2f">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtNy0xLTEtMTE4ODMz_5fc33b89-2869-410f-9cf5-926e5e1c9da6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtOS0xLTEtMTE4ODMz_07c71172-6d73-4f45-8ab4-f467f023123c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtMS0xLTEtMTE4ODMz_9e6d93fa-6eb0-424a-8792-10c7d829b08c">93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtMy0xLTEtMTE4ODMz_01af0968-c5b8-4462-af5d-e358306dbc89">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtNy0xLTEtMTE4ODMz_1aea7694-0adb-476d-96de-a1e4e8f46bc0">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtOS0xLTEtMTE4ODMz_936cf558-0133-4e90-8cee-dc3553e1267b">263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="ie95e87c48df54e68af040f584decd053" continuedAt="i4cc6db7b54cc4d5ebf205ad60180eee4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4cc6db7b54cc4d5ebf205ad60180eee4"> were reduced by immaterial income tax impacts in 2022 and in 2021.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:NewAccountingPronouncementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzQ4MDc_52d13e47-c5ab-445f-9b91-5a233c9fbaab" continuedAt="i1ddb6c8944d34721b99116092fe59952" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE P &#8211; NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTI_e87cf1af-f983-41e6-a5b3-ab60ebefcf42" continuedAt="i35e145877b5d4bce91605bd21ada81cf" escape="true">ASC Update No. 2021-05</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i35e145877b5d4bce91605bd21ada81cf" continuedAt="i866e56c40d3a4e3f804dfc605394cabc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASC Update No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Lessors&#8212;Certain Leases with Variable Lease Payments</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i866e56c40d3a4e3f804dfc605394cabc">. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzU0OTc1NTgzMDQ0MQ_bf409c21-91b1-43a8-8998-c3c4bf41390d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-06</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the FASB issued ASC Update No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTM_8299b62c-173d-47ea-bce2-dfc58661b995" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTQ_9d0ca528-fc9e-4797-a85c-d5a48c6b670a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTU_05d14281-a8af-4b7b-ba6a-7561a6e5a8be" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="bsx:ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTY_bf76e467-056a-4f68-afbe-90aaff27e916" continuedAt="i9e0669b13bda421c8255ff26edf3d3c4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. </span></ix:nonNumeric></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1ddb6c8944d34721b99116092fe59952"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9e0669b13bda421c8255ff26edf3d3c4">2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.</span></div></ix:continuation><div id="i0700a8f6ea1f4171b75e8081068a452b_160"></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3OTc_340dd8bc-071c-4c65-b853-2441f9cbdfb2" continuedAt="ic44240ee8b9a4620a13f673816b50dc3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE Q &#8211; EMPLOYEE RETIREMENT PLANS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other International Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain retirement plans covering certain international employees. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic44240ee8b9a4620a13f673816b50dc3" continuedAt="i38aad37cec144bc8b9781bd3ea301665"><div style="text-align:justify"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODM_c8b3e4b4-d6df-4a52-979d-eae0e7a344fa" continuedAt="i967e235364b4487f8ab5dc71e9c50987" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December&#160;31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i967e235364b4487f8ab5dc71e9c50987">.</ix:continuation> As of December&#160;31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY4MDc_82dba5fc-4e03-4b97-9651-9365128bc2b9" continuedAt="i832a33b19fa545e69defa7d4f6ad726a" escape="true">The outstanding obligation is as follows:</ix:nonNumeric></span></div><ix:continuation id="i832a33b19fa545e69defa7d4f6ad726a"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItMS0xLTEtMTE4ODMz_7c87a8d8-d67a-49ab-8616-2f3b16880ea9">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItMy0xLTEtMTE4ODMz_b592d9a7-ef1a-4283-a026-e8b92c6154fb">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItNS0xLTEtMTE4ODMz_5d39561a-94d8-4196-b855-e48ff44f98dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItNy0xLTEtMTE4ODMz_91c61d29-ea2b-4d19-8657-1bf93fecdba6">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtMS0xLTEtMTE4ODMz_e0414159-42d4-48f3-94c0-70c65a9b39d0">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtMy0xLTEtMTE4ODMz_ee41ff6c-441e-49a9-ba1e-495b99aed969">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtNS0xLTEtMTE4ODMz_2c1decc5-9711-4db4-a341-f1167d0b8797">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtNy0xLTEtMTE4ODMz_f6e6d558-8acd-4f04-bacf-6fbd48a0cc1d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtMS0xLTEtMTE4ODMz_8364a2d0-2e9b-4381-8ba7-be62906eedff">190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtMy0xLTEtMTE4ODMz_887660e1-41fa-4c54-8078-585f85da46b9">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtNS0xLTEtMTE4ODMz_b1c96cbf-9919-400b-ad01-0756a5956db4">101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtNy0xLTEtMTE4ODMz_cad2a24f-a8bf-4284-89a9-83b8b5db7192">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItMS0xLTEtMTE4ODMz_a3840776-8dd0-4fdc-8b41-fa11a8eca93d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItMy0xLTEtMTE4ODMz_025f2324-3003-432b-bc88-503397c80b3e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItNS0xLTEtMTE4ODMz_e91a730b-a925-466a-b280-f282a75512ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItNy0xLTEtMTE4ODMz_da2e80fd-8b58-495b-a489-71d8479ddf8e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtMS0xLTEtMTE4ODMz_f1e115d4-a24e-4e04-be43-f3e0b96a8b31">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtMy0xLTEtMTE4ODMz_6c9e7483-c76e-4900-a259-8b5aae758ac2">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtNS0xLTEtMTE4ODMz_f6790b06-3680-47c9-b82c-e974255b579e">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtNy0xLTEtMTE4ODMz_34c4a2d1-2222-4cd7-9d3d-948c0d7fd9a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07418139cdce4f5c981ed2c683522433_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtMS0xLTEtMTE4ODMz_af6b66c8-9013-486d-a2af-4a2da17ebc71">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07418139cdce4f5c981ed2c683522433_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtMy0xLTEtMTE4ODMz_7175f06c-a39c-47e0-b86e-b932ca4e58f4">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07418139cdce4f5c981ed2c683522433_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtNS0xLTEtMTE4ODMz_7cb82818-9738-4e1d-bc6c-b78742bead58">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07418139cdce4f5c981ed2c683522433_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtNy0xLTEtMTE4ODMz_8ae79468-27a8-4262-8e53-440a9c5355e0">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtMS0xLTEtMTE4ODMz_42f76969-2fff-4994-abd7-7e14e19d86d2">478</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtMy0xLTEtMTE4ODMz_c8322e82-76aa-41ca-98e5-903002f4d29f">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtNS0xLTEtMTE4ODMz_4612c97c-ec15-4d4f-8aed-d3358d95e62a">336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtNy0xLTEtMTE4ODMz_73e0ec65-71c9-4184-89fe-a018d673db9d">166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODU_98da36dd-4599-474f-acf3-083f2adc5cc6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzItMS0xLTEtMTE4ODMz_0f90d7a4-0523-4c4d-b405-ba59243fe8cd">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzItMy0xLTEtMTE4ODMz_0514183b-4758-4b36-95bd-8d9a29eef9a9">532</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzMtMS0xLTEtMTE4ODMz_cbe307a6-888f-4fb0-be65-bc948b2a6e57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzMtMy0xLTEtMTE4ODMz_9e3fc49e-6a75-463f-8fcb-35cbcadd2c4f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzQtMS0xLTEtMTE4ODMz_01af9806-efdb-486f-a186-8ee007f50f2e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzQtMy0xLTEtMTE4ODMz_62944b07-fa48-4f3d-9e0e-9d59daaf4379">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzUtMS0xLTEtMTE4ODMz_f9e1bef4-d114-4782-af8c-afdccdbae911">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzUtMy0xLTEtMTE4ODMz_493d5db3-8baa-4cdc-8cc1-6ed27c98d68d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzYtMS0xLTEtMTE4ODMz_265d4d25-7bb7-4640-913e-767314b4b6fb">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzYtMy0xLTEtMTE4ODMz_c1d5d3ee-8d70-4b94-9d45-c1dca6793cd6">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMS0xLTEtMTYxODg5_c3d0858b-bd0a-4c1a-aa84-5cd4474da67c">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMy0xLTEtMTYxODk3_89154adc-6afa-4404-9860-d335b0a251cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMS0xLTEtMTE4ODMz_33ade53f-5024-4a62-88fb-be543020dcee">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMy0xLTEtMTE4ODMz_0d82a16b-f167-4647-8488-f11911eeb831">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:Pensionbenefitobligationbenefitspaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzgtMS0xLTEtMTE4ODMz_4f7b05d9-c58a-4bde-8e93-96c517e93524">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:Pensionbenefitobligationbenefitspaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzgtMy0xLTEtMTE4ODMz_01a86f51-85e4-4875-b89a-1860aa060da6">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzktMS0xLTEtMTE4ODMz_c80ed1dd-9a61-4888-a83a-c6d6419dc4e0">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzktMy0xLTEtMTE4ODMz_2c218f0c-066e-4920-bb1d-ba28e6a7a0bf">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzEwLTEtMS0xLTExODgzMw_2d3b2fd7-73f5-4456-a000-b215c0500fc1">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzEwLTMtMS0xLTExODgzMw_49d45ffb-2dd6-4c72-860c-88895c97c1d1">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3Nzg_8910ebb7-1192-4afa-a724-529f8be7b664" continuedAt="i2f6b4c8004644be382236b0582e4d036" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:42.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.155%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i398d31599a9a4c7a862b268487b31675_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzItMS0xLTEtMTE4ODMz_211a129a-9515-4403-8fdb-0257e48a54b5">5.32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i398d31599a9a4c7a862b268487b31675_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzItOS0xLTEtMTE4ODMz_b072a88b-65d0-428a-9482-0249ceda02ac">2.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtMS0xLTEtMTE4ODMz_7b68adab-7de9-465e-a7c8-0b54a7809733">2.62</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231" decimals="4" name="bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtNS0xLTEtMTE4ODMz_2412b637-47e1-4e63-8109-c0310752a2e8">2.27</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtOS0xLTEtMTE4ODMz_5284dd6c-2fe8-4f30-a01a-591619d39e2c">3.00</ix:nonFraction>%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i38aad37cec144bc8b9781bd3ea301665" continuedAt="i087e324ba391481a8cf71f515c1e5701"><ix:continuation id="i2f6b4c8004644be382236b0582e4d036"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2021 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a709d6c9a0b41feab31995bae094f9b_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzEtMS0xLTEtMTE4ODMz_414f629a-9903-41fc-a10f-5c882e098e3b">2.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a709d6c9a0b41feab31995bae094f9b_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzEtNS0xLTEtMTE4ODMz_504b8b3f-f321-4f94-9a0e-90756611e972">1.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzItMS0xLTEtMTE4ODMz_cae6f874-0109-474b-8465-1a053119956e">0.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231" decimals="3" name="bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzItMy0xLTEtMTE4ODMz_8c46bd8b-f32b-40a4-a60a-498a806ff7d5">0.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtMS0xLTEtMTE4ODMz_1e6ae80d-3d20-4836-bd0a-2c2465330564">0.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231" decimals="4" name="bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtMy0xLTEtMTE4ODMz_903a295d-e01a-4b7f-bdd7-395b9d408c26">2.16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtNS0xLTEtMTE4ODMz_fdd8201e-183e-45d6-a3e9-6c8a9e6d67e7">2.60</ix:nonFraction>%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div></ix:continuation><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODc_fdf7047b-554f-4b15-a5d6-2bcd0864e9ea" continuedAt="i1f8519b4722a45619b3e8e6ec23d3143" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzItMS0xLTEtMTE4ODMz_ca46e1cb-cb66-401c-bb4c-fc9e9793a047">336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzItMy0xLTEtMTE4ODMz_6a601fef-e8f3-4ca0-9f0b-c056d3eebc3d">355</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzMtMS0xLTEtMTE4ODMz_7db17906-c704-4295-acf6-05d4fd881d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzMtMy0xLTEtMTE4ODMz_37faac18-01dd-4794-9c74-04c725bd1984">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzQtMS0xLTEtMTE4ODMz_bcad4ad4-479e-4fd0-b796-5da3e8d572da">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzQtMy0xLTEtMTE4ODMz_fb8c57ba-055c-4edb-a3a3-35537ecfeff2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzUtMS0xLTEtMTE4ODMz_07091889-8923-41b2-9231-78001660cbcc">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzUtMy0xLTEtMTE4ODMz_e0fdf22a-54c3-4cf1-a8ba-074be6def165">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzYtMS0xLTEtMTE4ODMz_eb489598-9042-4e6b-a929-897e722a566b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzYtMy0xLTEtMTE4ODMz_1de83568-5ebe-44f0-9bcd-ea4900060bf4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMS0xLTEtMTYxOTA3_43acbb4a-b5b3-400b-8d99-ab48d7678711">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMy0xLTEtMTYxOTE0_7d215eec-9345-43db-bb0c-dfbcbae072da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMS0xLTEtMTE4ODMz_5f6380dc-3362-486f-8453-3d0da95bd34e">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMy0xLTEtMTE4ODMz_10cabc95-aa7f-470f-9fb6-da7cccf40f7a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzgtMS0xLTEtMTE4ODMz_801d9537-cdec-4170-a037-3f322175293c">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzgtMy0xLTEtMTE4ODMz_5689d40d-c045-4521-b7d4-0b543d4ab33b">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzktMS0xLTEtMTE4ODMz_d676de94-6be2-4134-b297-77b90d15d106">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzktMy0xLTEtMTE4ODMz_fd8578a2-f7f1-4b46-98a0-f7236ef5491f">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzEwLTEtMS0xLTExODgzMw_e4c9e798-bb82-49f2-9491-c2a7e207ac51">101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzEwLTMtMS0xLTExODgzMw_f5a25256-82e2-403a-ad52-9b888df9895e">336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. </span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1f8519b4722a45619b3e8e6ec23d3143" continuedAt="i6cbe61fb89e14320baf2505eaab47f5d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-in contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bd241aa7bc46a3bbc132eb60cc014c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtMS0xLTEtMTYwNDc4_e899c09e-77c8-4734-9b5a-8b60259c7e62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec61999347b74ca9980b9262bc2473a0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtMy0xLTEtMTYwNDc4_edce293f-7be7-4410-ade5-aeffb4c7efd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649253125d3e41ff83d40817dfc4b57c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtNS0xLTEtMTYwNDc4_8a98cb44-7721-4557-af1a-86edc668103f">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81025787d2734b4085a77f222cdb83c8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtNy0xLTEtMTYwNDc4_807c5922-2dca-4d53-a187-45d9f52a0563">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464a3ab08a074038b0b11f145f5be6ba_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtMS0xLTEtMTYwNDc4_e57e43f3-0c77-4e97-9010-c1b816a3cd4f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cf5d0c98a64efab2f25564d3cb8718_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtMy0xLTEtMTYwNDc4_ee736141-6d8e-4275-ae4d-b2deb85c1311">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6c0f8faf13418e93bbab3e1cdb4719_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtNS0xLTEtMTYwNDc4_e4fba817-af7e-4742-bb09-bb809cbdaeb3">205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtNy0xLTEtMTYwNDc4_84e91b2b-6f13-45e0-9c02-57c33d481043">205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i087e324ba391481a8cf71f515c1e5701"><div><ix:continuation id="i6cbe61fb89e14320baf2505eaab47f5d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Buy-in Contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzEtMS0xLTEtMTYwNDc4_a1d5c57d-6d32-43e8-9251-92caa469dd60">205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzItMS0xLTEtMTYwNDc4_973477f9-3360-46d1-b68e-d42cbbb2df9f">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzMtMS0xLTEtMTYwNDc4_4c6f8b84-7f10-4aac-a724-9c9d08646667">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzQtMS0xLTEtMTYwNDc4_757926ef-003c-4e79-89c1-5a625dd796f3">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzUtMS0xLTEtMTYwNDc4_b94997f8-3554-4e8c-843e-3ee3ae3045d8">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzYtMS0xLTEtMTYwNDc4_8b6f4ec7-a470-4ca4-bc9a-1c690022e2a3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzctMS0xLTEtMTYwNDc4_77d8645f-183c-4bb7-8642-4fd0726a5ce1">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9720398bfd24fcaa4cd94ccacf55bfa_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzgtMS0xLTEtMTYwNDc4_c6e5cf35-798d-48d4-9c78-2d9807125bb8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December&#160;31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY4MDA_e17bd158-9f88-4a8f-b30b-f0f1d6c69eab" continuedAt="i0a6a5af8f41d4f80a6fa4bc35b0bca26" escape="true">Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i0a6a5af8f41d4f80a6fa4bc35b0bca26"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzEtMS0xLTEtMTE4ODMz_9acc7582-6af6-4b1f-8deb-029c1c1048e9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzItMS0xLTEtMTE4ODMz_127f7f20-a6e0-4c7a-854b-19df9b09a413">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzMtMS0xLTEtMTE4ODMz_6f40c43c-5a1a-4f79-ba5e-b1da0a687f6f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzQtMS0xLTEtMTE4ODMz_9b58d745-6bb0-467b-8ebb-5099a6a7ed2d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzUtMS0xLTEtMTE4ODMz_8a3db0c6-4bba-448e-bfc0-bad10bc6b6c3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzYtMS0xLTEtMTE4ODMz_60a19e61-1098-4c31-9247-135a60898c3e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NzU_1733a6b7-d318-4ee1-8048-a00454484f8f" escape="true">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200&#160;percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="bsx:ExpenseRelatedToMatchingContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NDA_dffb1662-e00b-4183-a306-9066c4333271">123</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="bsx:ExpenseRelatedToMatchingContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NTA_aa63c93e-e9f5-4895-aa4f-f8864135f05f">118</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="bsx:ExpenseRelatedToMatchingContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NjM_cc343897-4236-49a8-815e-189a65a7ccfc">102</ix:nonFraction> million in 2020.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_169"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (CEO) and Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022 pursuant to Rule&#160;13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that as of December&#160;31, 2022, our disclosure controls and procedures were effective.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s annual report on our internal control over financial reporting is contained in Item&#160;7 of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The report of Ernst &amp; Young LLP on our internal control over financial reporting is contained in Item&#160;7 of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended December&#160;31, 2022, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. As the phased implementation occurs, it may result in changes to our processes and procedures which may result in changes to our internal controls over financial reporting. As such changes occur, we will evaluate quarterly whether they materially affect our internal control over financial reporting.</span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_172"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Restructuring Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan is intended to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Restructuring Plan will further build on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expand operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">optimizing certain functional capabilities to better support business growth and achieve cost synergies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in future cash outlays. The following table provides a summary of our estimates of total pre-tax charges associated with the 2023 Restructuring Plan by major type of cost:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Estimated Amount Expected to be Incurred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring-related expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$450</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$550 </span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consists primarily of consulting fees and costs associated with contractual cancellations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_181"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_184"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_187"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_190"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_193"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is Ernst &amp; Young LLP, New York, NY, (PCAOB ID <ix:nonNumeric contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xOTMvZnJhZzpjZWVmYzMxYjUzODU0Y2RiYjVkMjE4OWNiYzdjZDM0Ny90ZXh0cmVnaW9uOmNlZWZjMzFiNTM4NTRjZGJiNWQyMTg5Y2JjN2NkMzQ3XzE0OQ_9bcf2eb4-fbff-4479-8c97-6e8bb5988af3">42</ix:nonNumeric>).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_199"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(1) Financial Statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item&#160;15 is set forth under Item&#160;8.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(2) Financial Statement Schedules.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item&#160;15 (Schedule&#160;II) follows the signature page to this report. All other financial statement schedules are not required under the related instructions or are inapplicable and therefore have been omitted.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(3) Exhibits (* documents filed or furnished with this report, # compensatory plans or arrangements)</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br/>NO.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261308000584/exhibit3-2_15759.txt">Third Restated Certificate of Incorporation (incorporated herein by reference to Exhibit&#160;3.2 to the Company's Annual Report on Form&#160;10-K for the year ended December&#160;31, 2007, filed February 28, 2008, File No.&#160;1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465919029732/a19-9977_1ex3d1.htm">Amended and Restated By-Laws of the Company (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 15, 2019, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000519/ss174270_ex0301.htm">Certificate of Designations of 5.50% Mandatory Convertible Preferred Stock, Series A, filed with the Secretary of State of the State of Delaware on May 26, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's  Current Report on Form 8-K filed on May 28, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen Certificate for shares of the Company's Common Stock (incorporated herein by reference to Exhibit&#160;4.1 to the Company's Registration Statement on Form S-1. File No. 33-46980).</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572522000006/exhibit42-descriptionofthe.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated herein by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000095013504003276/b509658kexv4w1.txt">Indenture dated as of June&#160;25, 2004, between the Company and JPMorgan Chase Bank, as Trustee (incorporated herein by reference to Exhibit&#160;4.1 to the Company's Current Report on Form&#160;8-K filed on June&#160;25, 2004, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261304002201/exh4-1_13106.txt">Indenture dated as of November&#160;18, 2004, between the Company and J.P. Morgan Trust Company, National Association, as Trustee (incorporated herein by reference to Exhibit&#160;4.1 to the Company's Current Report on Form&#160;8-K filed on November&#160;18, 2004, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465906027974/a06-8189_4ex99d4.htm">First Supplemental Indenture dated as of April&#160;21, 2006 between the Company and J.P. Morgan Trust Company, National Association, as Trustee (incorporated herein by reference to Exhibit&#160;99.4 to the Company's Current Report on Form 8-K filed on April&#160;26, 2006, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465906027974/a06-8189_4ex99d6.htm">Second Supplemental Indenture dated as of April&#160;26, 2006 between the Company and The Bank of New York Mellon Trust Company, N.A., as successor to J.P. Morgan Trust Company, National Association, as Trustee (incorporated herein by reference to Exhibit&#160;99.6 to the Company's Current Report on Form&#160;8-K filed on April&#160;26, 2006, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261305002690/exh4-2_13988.htm">Form of Global Security for the 6.25% Notes due 2035 in the aggregate principal amount of $350,000,000, and Notice to Holders thereof (incorporated herein by reference to Exhibit&#160;4.2 and Exhibit 99.7 to the Company's Current Reports on Form&#160;8-K filed on November&#160;17, 2005 and April 26, 2006, respectively, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000095013506003879/b61236bsexv4w1.txt">Indenture dated as of June&#160;1, 2006, between the Company and JPMorgan Chase Bank, N.A., as Trustee (incorporated herein by reference to Exhibit&#160;4.1 to the Company's Current Report on Form&#160;8-K filed on June&#160;9, 2006, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000095012309070623/b78468exv4w4.htm">7.375% Senior Note due January&#160;15, 2040 in the aggregate principal amount of $300,000,000 (incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form&#160;8-K filed on December&#160;14, 2009, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746913006559/a2215392zex-4_1.htm">Indenture dated as of May 29, 2013, between the Company and U.S. Bank Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Com</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746913006559/a2215392zex-4_1.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746913006559/a2215392zex-4_1.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746913006559/a2215392zex-4_1.htm">ny's Registration Statement on Form S-3, File No 333-188918.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000015/exhibit42-xxxnotesdue2028.htm">Form of 4.000% Senior Note Due March 1, 2028 in the aggregate amount of $500,000,000 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on February 26, 2018, File No. 1-11083). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exhibit42-3450notesdue2024.htm">Form of 3.450% Senior Note due March 1, 2024 in the aggregate amount of $850,000,000 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exhibit43-3750notesdue2026.htm">Form of 3.750% Senior Note due March 1, 2026 in the aggregate amount of $850,000,000 (incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exhibit44-4000notesdue2029.htm">Form of 4.000% Senior Note due March 1, 2029 in the aggregate amount of $850,000,000 (incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exhibit45-4550notesdue2039.htm">Form of 4.550% Senior Note due March 1, 2039 in the aggregate amount of $750,000,000 (incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exhibit46-4700notesdue2049.htm">Form of 4.700% Senior Note Due March 1, 2049 in the aggregate amount of $100,000,000 (incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787119000804/ss156905_ex0402.htm">Form of 0.625% Senior Note Due December 1, 2027 in the aggregate amount of &#8364;900,000,000 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on November 12, 2019, File No. 1-11083). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000487/ss173781_ex0402.htm">Form of 1.900% Senior Note Due June 1, 2025 in the aggregate amount of $500,000,000 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 18, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000487/ss173781_ex0403.htm">Form of 2.650% Senior Note due June 1, 2030 in the aggregate amount of $1,200,000,000 (incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on May 18, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465922031615/tm228612d1_ex4-1.htm">Indenture dated as of March 8, 2022, among the Company, American Medical Systems Europe B.V., and U.S. Bank Trust Company, National Association, as Trustee (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 8, 2022, File No. 1-11083).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885725/000110465922031615/tm228612d1_ex4-2.htm">Form of 0.750% Senior Note due March 8, 2025 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on March 8, 2022, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885725/000110465922031615/tm228612d1_ex4-3.htm">Form of 1.375% Senior Note due March 8, 2028 (incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on March 8, 2022, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885725/000110465922031615/tm228612d1_ex4-4.htm">Form of 1.625% Senior Note due March 8, 2031 (incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on March 8, 2022, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885725/000110465922031615/tm228612d1_ex4-5.htm">Form of 1.875% Senior Note due March 8, 2034 (incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on March 8, 2022, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261307000570/exh10-2_14949.htm">Form of Omnibus Amendment dated as of December&#160;21, 2006, among the Company, Boston Scientific Funding Corporation, Variable Funding Capital Company LLC, Victory Receivables Corporation and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch (Amendment No.&#160;1 to Receivables Sale Agreement and Amendment No.&#160;9 to Credit and Security Agreement) (incorporated herein by reference to Exhibit&#160;10.2 to the Company's Annual Report on 10-K for the year ended December&#160;31, 2006 filed on March 1, 2007, File No.&#160;1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261307002697/exhibit10-2_15574.txt">Form of Amended and Restated Receivables Sale Agreement dated as of November&#160;7, 2007 between the Company and each of its Direct or Indirect Wholly-Owned Subsidiaries that Hereafter Becomes a Seller Hereunder, as the Sellers, and Boston Scientific Funding LLC, as the Buyer (incorporated herein by reference to Exhibit&#160;10.2 to the Company's Current Report on Form&#160;8-K filed on November&#160;13, 2007, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000095013503002096/b45658bsexv10w6.txt">License Agreement among Angiotech Pharmaceuticals, Inc., Cook Incorporated and the Company dated July 9, 1997, and related Agreement dated December&#160;13, 1999 (incorporated herein by reference to Exhibit&#160;10.6 to the Company's Annual Report on Form&#160;10-K for the year ended December&#160;31, 2002, filed on March 31, 2003, File No.&#160;1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261304002236/exh10-1_13122.txt">Amendment between Angiotech Pharmaceuticals, Inc. and the Company dated November&#160;23, 2004 modifying July&#160;9, 1997 License Agreement among Angiotech Pharmaceuticals, Inc., Cook Incorporated and the Company (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K filed on November&#160;24, 2004, File No.&#160;1-11083).</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Agreement, dated as of January&#160;8, 2006, as amended, between the Company and Abbott Laboratories (incorporated herein by reference to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746906002665/a2167817zex-10_47.htm">Exhibit&#160;10.47</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746906002665/a2167817zex-10_48.htm">Exhibit&#160;10.48</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746906002665/a2167817zex-10_49.htm">Exhibit&#160;10.49</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000104746906002665/a2167817zex-10_50.htm">Exhibit&#160;10.50</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the Company's Annual Report on Form&#160;10-K for year ended December&#160;31, 2005, filed on March 1, 2006, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465906023741/a06-8189_2ex10d1.htm">Exhibit&#160;10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the Company's Current Report on Form&#160;8-K filed on April&#160;7, 2006, File No.&#160;1-11083).</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572515000012/exhibit101-jjagreement.htm">Settlement Agreement among Johnson &amp; Johnson, Guidant LLC and the Company, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 30, 2015, filed on May 6, 2015, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261304002318/exh10-6_13134.txt">Form of Restricted Stock Award Agreement (Non-Employee Directors) under the Company's 2000 Long Term Incentive Plan (incorporated herein by reference to Exhibit&#160;10.6 to the Company's Current Report on Form&#160;8-K filed on December&#160;10, 2004, File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000029/exhibit101-q2201210xq.htm">Form of Restricted Stock Award Agreement (Non-Employee Directors) under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2012, as filed August 7, 2012. File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Boston Scientific Corporation Excess Benefit Plan, as amended (incorporated herein by reference to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/885725/000107261305001649/exhibit10-1_13649.htm">Exhibits&#160;10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261308002226/exhibit10-4_16230.htm">10.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the Company's Current Reports on Form&#160;8-K filed on July 5, 2005 and December 22, 2008, respectively, File No.&#160;1-11083).#</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261305001649/exhibit10-2_13649.htm">Form of Trust under the Boston Scientific Corporation Excess Benefit Plan (incorporated herein by reference to Exhibit&#160;10.2 to the Company's Current Report on Form&#160;8-K filed on July 5, 2005, File No.&#160;1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261310000567/exh10-1_16834.htm">Boston Scientific Corporation Deferred Bonus Plan (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K filed on May 17, 2010, File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000095012311015112/b83548exv10w39.htm">Boston Scientific Corporation 401(k) Retirement Savings Plan, Amended and Restated, effective January&#160;1, 2011 (incorporated herein by reference to Exhibit 10.39 to the Company's Annual Report on Form&#160;10-K for year ended December&#160;31, 2010, as filed February 17, 2011, File No.&#160;1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000006/exhibit1044-401k.htm">Form of First Amendment to Boston Scientific Corporation 401(k) Retirement Savings Plan, as amended and restated (incorporated herein by reference to Exhibit 10.44 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011, filed on February 17, 2012, File No. 1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000029/exhibit102-q2201210xq.htm">Form of Second Amendment to Boston Scientific Corporation 401(k) Retirement Savings Plan, as amended and restated, (incorporated herein by reference to Exhibit&#160;10.2 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2012, filed on August 7, 2012, File No.&#160;1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000043/exhibit101-q3201210xq.htm">Form of Third Amendment to Boston Scientific Corporation 401(k) Retirement Savings Plan, as amended and restated (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2012, filed on November 6, 2012, File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000006/exhibit1049-ltip.htm">Boston Scientific Corporation 2011 Long-Term Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.49 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011, filed on February 17, 2012, File No. 1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572511000042/exhibit104rsa.htm">Form of Restricted Stock Award Agreement (Non-Employee Directors) under the Company's 2003 and 2011 Long-Term Incentive Plans (incorporated herein by reference to Exhibit&#160;10.4 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2011, filed on August 5, 2011, File No. 1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572511000046/exhibit101_michaelmahoneyo.htm">Form of Offer Letter dated September 6, 2011 between the Company and Michael F. Mahoney, as supplemented September 13, 2011 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form&#160;8-K filed on September 19, 2011, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572512000006/exhibit10100-mahoneyofferl.htm">Form of Amendment, dated February 14, 2012, to Offer Letter dated September 6, 2011 between the Company and Michael F. Mahoney, as supplemented September 13, 2011 (incorporated herein by reference to Exhibit 10.100 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011,  filed on February 17, 2012, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572515000012/exhibit102-offerletterfitz.htm">Form of Offer Letter by and between the Company and Joseph M. Fitzgerald dated February 27, 2014 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 30, 2015, filed on May 6, 2015, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261302001397/exhibit4-1_11477.txt">Boston Scientific Deferred Compensation Option Program (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-8, filed on August 27, 2002, File No. 333-98755).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572513000007/exhibit10118domesticreloca.htm">Boston Scientific Corporation Domestic Relocation Policy Tier 5 Executive Officer Homeowner, effective January 2007 (incorporated herein by reference to Exhibit&#160;10.118 to the Company's Annual Report on Form&#160;10-K for the year ended December 31, 2012, filed on February 22, 2013, File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465913017992/a13-6792_1ex10d1.htm">Form of Letter to Key Management Personnel re: Change in Control Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on March 6, 2013, File No. 1-11083).</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465913077459/a13-22722_1ex10d2.htm">Form of Offer Letter by and between the Company and Daniel J. Brennan, dated October 22, 2013 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K as filed October 24, 2013 File No. 1-11083). #</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572513000037/exhibit104-formofnonxquali.htm">Form of Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, filed on August 7, 2013, File No. 1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572513000037/exhibit106-usseveranceplan.htm">Boston Scientific Corporation U.S. Severance Plan for Exempt Employees, as amended and restated, effective August 1, 2013 (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, filed on August 7, 2013, File No. 1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000107261308001968/exhibit10-1_16156.htm">Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan of the Company, as amended and restated, effective January&#160;1, 2009 (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K filed on October&#160;31, 2008, File No.&#160;1-11083).#</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572513000045/exhibit106-bscnonxemployee.htm">Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as amended and restated, effective January 1, 2014 (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, filed on November 5, 2013, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572514000022/exhibit101-globalemployees.htm">Boston Scientific Corporation 2006 Global Employee Stock Ownership Plan, as amended and restated, effective July 1, 2014 (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, filed on August 6, 2014, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465916135014/a16-15337_1ex10d1.htm">Boston Scientific Corporation Executive Retirement Plan, as amended and restated effective August 1, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 28, 2016, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572514000030/exhibit101-formofnonxquali.htm">Form of Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan (Non-Employee Directors) (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on November 5, 2014, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572514000030/exhibit102-formofrestricte.htm">Form of Restricted Stock Award Agreement under the Company's 2011 Long-Term Incentive Plan (Non-Employee Directors) (incorporated herein by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on November 5, 2014, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572514000030/exhibit103-formofdeferreds.htm">Form of Deferred Stock Unit Award Agreement under the Company's  2011 Long-Term Incentive Plan (Non-Employee Directors) (incorporated herein by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on November 5, 2014, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572514000030/exhibit106-firstamendmentt.htm">First Amendment to Boston Scientific Corporation Deferred Bonus Plan, effective January 1, 2015 (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on November 5, 2014, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572516000035/exhibit102-formofnqsoagree.htm">Form of 2016 Global Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed on May 4, 2016, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572517000019/exhibit101-formofnqsoagree.htm">Form of 2017 Global Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed on May 3, 2017, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787117000108/ss29948_ex1001.htm">Second Amended and Restated Credit and Security Agreement, dated as of February 7, 2017, by and among Boston Scientific Funding LLC, Boston Scientific Corporation, Wells Fargo Bank, National Association and Sumitomo Mitsui Banking Corporation, New York Branch, as Lenders, Wells Fargo Bank, National Association and SMBC Nikko Securities America, Inc., as Co-Agents, and Wells Fargo Bank, National Association, as Administrative Agent (incorporated herein by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K filed on February 10, 2017, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787117000108/ss29948_ex1002.htm">Second Amended and Restated Receivables Sale Agreement, dated as of February 7, 2017, by and among Boston Scientific Corporation, each of its direct or indirect wholly-owned subsidiaries that become a seller thereunder and Boston Scientific Funding LLC (incorporated herein by reference to Exhibit&#160;10.2 to the Company's Current Report on Form&#160;8-K filed on February 10, 2017, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit101-formofnqsoagree.htm">Form of 2018 Global Non-Qualified Stock Option Agreement under the Company's the 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed on May 1, 2018, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit102-formofdsuagreem.htm">Form of 2018 Global Deferred Stock Unit Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed on May 1, 2018,  File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit105-acquisitionxrel.htm">Form of 2018 Acquisition-Related Non-Qualified Stock Option Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed on May 1, 2018, File No. 1-11083). # </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit106-acquisitionxrel.htm">Form of 2018 Acquisition-Related Deferred Stock Unit Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed on May 1, 2018, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit107-2018_rsaxawardx.htm">Form of 2018 Restricted Stock Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed on May 1, 2018, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit108-2018_dsuxawardx.htm">Form of 2018 Deferred Stock Unit Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan incorporated herein by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed on May 1, 2018, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572518000021/exhibit109-2018_nqsoxaward.htm">Form of 2018 Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan# (incorporated herein by reference to Exhibit 10.9 to the Company's Current Report on Form 10-Q quarter ended March 31, 2018, filed on May 1, 2018, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit101-formofnqsoagree.htm">Form of 2019 Global Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 29, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit102-formofdsuagreem.htm">Form of 2019 Global Deferred Stock Unit Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 29, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit105-2019acquisition.htm">Form of 2019 Global Acquisition-Related Non-Qualified Stock Option Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 9, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit106-2019acquisition.htm">Form of 2019 Global Acquisition-Related Deferred Stock Unit Award Agreement under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 29, 2019, File No. 1-11083).#</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit107-2019_rsaxawardx.htm">Form of 2019 Restricted Stock Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 29, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000024/exhibit108-2019_dsuxawardx.htm">Form of 2019 Deferred Stock Unit Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on April 29, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000016/exbibit11-underwritingagre.htm">Underwriting Agreement, dated February 21, 2019, as supplemented by the Terms Agreement, dated February 21, 2019, among the Company and Barclays Capital Inc., Merrill Lynch, Pierce, Fenner &amp; Smith Inc. and Wells Fargo Securities, LLC, as representatives of the underwriters (incorporated herein by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K filed on February 25, 2019, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000048/ex-102.htm">Boston Scientific Corporation 2020 Total Shareholder Return Performance Share Program, Performance Period January 1, 2020 - December 31, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 20, 2019 File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572519000048/ex-103.htm">Boston Scientific Corporation 2020 Free Cash Flow Performance Share Program, Performance Period January 1 - December 31, 2020 (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on November 20, 2019, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.55*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1055-2020grantxnqagreeme.htm">Form of 2020 Global Non-Qualified Stock Option Agreement under the Company's 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1056-2020grantxrsuagreem.htm">Form of 2020 Global Restricted Stock Unit Award Agreement under the Company's 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1057-2020grantxrsabodawa.htm">Form of 2020 Restricted Stock Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.58*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1058-2020grantxdsubodawa.htm">Form of 2020 Deferred Stock Unit Award Agreement for Non-Employee Directors under the Company's 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572520000024/exhibit101amendedandre.htm">Amended and Restated 2011 Long-Term Incentive Plan of the Company (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 12, 2020, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000487/ss173781_ex0101.htm">Underwriting Agreement, dated as of May 14, 2020, as supplemented by the Terms Agreement, dated May 14, 2020, among Boston Scientific Corporation and Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters. (incorporated herein by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K filed on May 18, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000519/ss174270_ex0101.htm">Underwriting Agreement relating to the Common Stock, dated as of May 21, 2020, among Boston Scientific Corporation and J.P. Morgan Securities LLC and BofA Securities Inc., as representatives of the underwriters. (incorporated herein by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K filed on May 28, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000094787120000519/ss174270_ex0102.htm">Underwriting Agreement relating to the Mandatory Convertible Preferred Stock, dated as of May 21, 2020, among Boston Scientific Corporation and J.P. Morgan Securities LLC and BofA Securities Inc., as representatives of the underwriters. (incorporated herein by reference to Exhibit 1.2 to the Company's Current Report on Form 8-K filed on May 28, 2020, File No. 1-11083).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572520000049/exhibit1022021totalsha.htm">Boston Scientific Corporation 2021 Total Shareholder Return Performance Share Program, Performance Period January 1, 2021 - December 31, 2023 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 24, 2020, File No. 1-11083).#</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572520000049/exhibit1032021freecash.htm">Boston Scientific Corporation 2021 Free Cash Flow Performance Share Program, Performance Period January 1 - December 31, 2021 (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on November 24, 2020, File No. 1-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.65*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1065-2021grantxnqagreeme.htm">Form of 2021 Global Non-Qualified Stock Option Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1066-2021grantxrsuagreem.htm">Form of 2021 Global Restricted Stock Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1067-2021grantxtsragreem.htm">Form of 2021 Performance Share Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan (Total Shareholder Return). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1068-2021grantxfcfagreem.htm">Form of 2021 Performance Share Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan (Free Cash Flow). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.69*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1069-2021grantxrsabodawa.htm">Form of 2021 Restricted Stock Award Agreement for Non-Employee Directors under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1070-2021grantxrsubodawa.htm">Form of 2021 Restricted Stock Unit Award Agreement for Non-Employee Directors under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885725/000110465921065917/tm2116033d1_ex10-1.htm">Credit Agreement, dated as of May 10, 2021, by and among Boston Scientific Corporation, the several lenders parties thereto, Barclays Bank PLC, Citibank, N.A., Deutsche Bank Securities Inc., Goldman Sachs Bank USA, and JPMorgan Chase Bank, N.A as documentation agents, and Wells Fargo Bank, National Association, as administrative agent (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 13, 2021, File No. 1-11083)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.72*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1072-amendmentto2021revo.htm">Amendment, dated as of December 21, 2022, to Credit Agreement, dated as of May 10, 2021, by and among Boston Scientific Corporation, the several lenders parties thereto, Barclays Bank PLC, Citibank, N.A., Deutsche Bank Securities Inc., Goldman Sachs Bank USA, and JPMorgan Chase Bank, N.A as documentation agents, and Wells Fargo Bank, National Association, as administrative agent.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572521000056/exhibit101bostonscientific.htm">Boston Scientific Corporation 2022 Annual Bonus Plan, Performance Period January 1 - December 31, 2022 effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 23, 2021, File No. 001-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.74</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572521000056/exhibit102bostonscientific.htm">Boston Scientific Corporation 2022 Total Shareholder Return Performance Share Program, Performance Period January 1, 2022 - December 31, 2024 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 23, 2021, File No. 001-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000088572521000056/exhibit103bostonscientific.htm">Boston Scientific Corporation 2022 Free Cash Flow Performance Share Program, Performance Period January 1 - December 31, 2022 (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on November 23, 2021, File No. 001-11083).#</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.76*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1076-2022grantxnqagreeme.htm">Form of 2022 Global Non-Qualified Stock Option Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1077-2022grantxrsuagreem.htm">Form of 2022 Global Restricted Stock Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1078-2022grantxtsragreem.htm">Form of 2022 Performance Share Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan (Total Shareholder Return). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1079-2022grantxfcfagreem.htm">Form of 2022 Performance Share Unit Award Agreement under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan (Free Cash Flow). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1080-2022grantxrsabodawa.htm">Form of 2022 Restricted Stock Award Agreement for Non-Employee Directors under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.81*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1081-2022grantxrsubodawa.htm">Form of 2022 Restricted Stock Unit Award Agreement for Non-Employee Directors under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885725/000110465922057017/tm2214421d1_ex10-1.htm">Form of EC Non-CEO Change in Control Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 6, 2022, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1083-offerletterartbutch.htm">Form of Offer Letter by and between the Company and Arthur Butcher, dated April 1, 2022. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1084-offerletterjeffmirv.htm">Form of Offer Letter by and between the Company and Jeffrey Mirviss, dated December 11, 2012. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1085-arnonxemployeedirec.htm">Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as amended and restated, effective January 1, 2023. #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/885725/000110465922057017/tm2214421d1_ex10-2.htm">Employee Stock Purchase Plan, Amended and Restated Effective as of July 1, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 6, 2022, File No.1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.87</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/exhibit101bostonscientific.htm">Boston Scientific Corporation 2023 Annual Bonus Plan, Performance Period January 1, 2023 to December 31, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2022, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/exhibit102bostonscientific.htm">Boston Scientific Corporation 2023 Relative Total Shareholder Return Performance Share Program, Performance Period January 1, 2023 &#8211; December 31, 2025 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2022, File No. 1-11083). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/exhibit103bostonscientific.htm">Boston Scientific Corporation 2023 Organic Net Sales Growth Performance Share Program, Performance Period January 1 &#8211; December 31, 2023, (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2022, File No. 1-11083)). #</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-listofsubsidiari.htm">List of Boston Scientific's subsidiaries as of January 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-listofsubsidiari.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-listofsubsidiari.htm">.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23-2022eyconsent.htm">Consent of Independent Registered Public Accounting Firm, Ernst &amp; Young LLP.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-ceo302202210xk.htm">Certification of Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-cfo302202210xk.htm">Certification of Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-ceo906202210xk.htm">Certification of Chief Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-cfo906202210xk.htm">Certification of Chief Financial Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.310%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)</span></div></td></tr></table></div><div><span><br/></span></div><div id="i0700a8f6ea1f4171b75e8081068a452b_202"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston Scientific Corporation</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel J. Brennan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Brennan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(duly authorized officer and principal financial officer)</span></td></tr></table></div><div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel J. Brennan</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Brennan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael F. Mahoney</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Mahoney</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chairman of the Board, <br/>President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan R. Monson</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan R. Monson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Global Controller and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nelda J. Connors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nelda J. Connors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Charles J. Dockendorff</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles J. Dockendorff</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yoshiaki Fujimori</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yoshiaki Fujimori</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donna A. James</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donna A. James</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Edward J. Ludwig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward J. Ludwig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David J. Roux</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Roux</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John E. Sununu</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John E. Sununu</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David S. Wichmann</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David S. Wichmann</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:32.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ellen M. Zane</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ellen M. Zane</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i0700a8f6ea1f4171b75e8081068a452b_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><ix:nonNumeric contextRef="i63c80cf97e92455e89254f71abde961e_D20180101-20181231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90ZXh0cmVnaW9uOmNhMjNhNGRmYTc4ZDQ1ZDM5NTBhMDRiMjliMTg2ZTM3XzEwNDE_1c97e92c-8317-4f95-9f55-a4ff9fe6a62c" escape="true"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:36.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>&#160;Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit loss exposure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Write-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItMS0xLTEtMTE4ODMz_ae3a4d64-19c2-4606-be4f-cc0206f9c98d">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItNS0xLTEtMTE4ODMz_9b90e637-5fa1-477a-a730-527342de23c3">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItNy0xLTEtMTE4ODMz_2e79dc4b-8274-4b06-b62f-dae94f01e08a">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItMTEtMS0xLTExODgzMw_e4d365ac-18cb-449f-8b97-a8156e738a5e">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtMS0xLTEtMTE4ODMz_f59a490f-7ca3-4d16-94d3-cbb2a2c3ba3d">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtNS0xLTEtMTE4ODMz_92ed88f7-52e6-4660-be7e-7494a2ae3727">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtNy0xLTEtMTE4ODMz_5bbf8d56-1baa-4952-a1ea-0e0a3aa4eebc">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtMTEtMS0xLTExODgzMw_08d2faae-fb07-4eeb-b839-6e49640270a3">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for uncollectible accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtMS0xLTEtMTE4ODMz_caaa1ace-1612-41d5-818a-3067bfa642dd">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtNS0xLTEtMTE4ODMz_30f7b31c-4efa-489e-9b54-a0a8a4f9757e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtNy0xLTEtMTE4ODMz_88c97f75-be92-4224-b2a7-fd59ba7ed932">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtMTEtMS0xLTExODgzMw_3d00dd7d-2758-431b-ae30-99a7690e9710">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents actual write-offs of uncollectible accounts.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.55
<SEQUENCE>2
<FILENAME>ex1055-2020grantxnqagreeme.htm
<DESCRIPTION>EX-10.55
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3724b256d3d640428126c0dc577bb7ab_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.55</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation 2011 Long-Term Incentive Plan<br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Non-Qualified Stock Option Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">%%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Optionee&#8221;)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">EMPLOYEE COPY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">PLEASE RETAIN FOR YOUR RECORDS</font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i3724b256d3d640428126c0dc577bb7ab_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Non-Qualified Stock Option Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Non-Qualified Stock Option Agreement (the &#8220;Agreement&#8221;), dated %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%  (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the Non-Qualified Stock Option Award granted to you by the Company.  This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth on herein (the &#8220;Option Shares&#8221;) at the price set forth herein (the &#8220;Grant Price&#8221;).  The Grant Price is equal to the Fair Market Value of the Company&#8217;s Stock on the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term and Vesting of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-% until  %%EXPIRE_DATE_PERIOD1,&#8217;Month DD, YYYY&#8217;%-% (the &#8220;Expiration Date&#8221;) and shall vest in accordance with the vesting schedule.  If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares.  Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following&#58;  (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith.  Notwithstanding the foregoing, if you reside in a country where the local laws and&#47;or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and&#47;or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless &#8220;sell all&#8221; exercise and&#47;or a cashless &#8220;sell to cover&#8221; exercise) as it shall determine in its sole discretion.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised.  The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the Company&#8217;s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company&#8217;s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares.  However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c.&#160;&#160;&#160;&#160;In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d.&#160;&#160;&#160;&#160;Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares.  Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited&#59; provided, however, that the Committee, in its sole discretion, may extend the exercise period and&#47;or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option).  Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;e.&#160;&#160;&#160;&#160;Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;f.&#160;&#160;&#160;&#160;The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;g.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;h.&#160;&#160;&#160;&#160;Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum.  No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer&#59; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum&#59; and (iii) such transfer complies with applicable laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;i.&#160;&#160;&#160;&#160;If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;j.&#160;&#160;&#160;&#160;If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence.  If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines.  If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control.  If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 6, shall have the meaning set forth below&#58;</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members.  During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate.  The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility.  In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Stock Option is intended to be exempt from the requirements of Section&#160;409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">the Stock Option is not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any&#59; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Stock Option, the shares of Stock subject to the Stock Option, and the </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan.  Investment in shares of Stock involves a degree of risk.  Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Choice of Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURE PAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Shares of Stock&#58;   %%TOTAL_SHARES_GRANTED%-%</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Price&#58;     %%OPTION_PRICE,&#8217;$999,999,999.99&#8217;%-% </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:107.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.461%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Percent of <br>Stock Option</font></td><td colspan="6" style="padding:2px 1pt 2px 31.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date Vested</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD1%-%</font></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD2%-%</font></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD3%-%</font></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD4%-%</font></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BOSTON SCIENTIFIC CORPORATION&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1.jpg" src="image_1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael F. Mahoney</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OPTIONEE</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, YOU AGREE THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES YOUR ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) YOU AGREE TO BE BOUND BY THE PROVISIONS OF </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE PLAN, THE AGREEMENT AND THE ADDENDUM&#59; (iii) YOU HAVE REVIEWED THE PLAN, THE AGREEMENT AND THE ADDENDUM IN THEIR ENTIRETY, HAVE HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTAND ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM&#59; (iv)&#160;YOU HAVE BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN AND THE TAX SUPPLEMENT TO THE U.S. PROSPECTUS FOR YOUR COUNTRY, IF APPLICABLE&#59; AND (v) YOU HEREBY AGREE TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND THE ADDENDUM.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section 19 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For the avoidance of doubt, references to the EU &#47; EEA in this Addendum include the United Kingdom.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;thirty (30) days from the date of termination of employment&#59; and (ii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific<br>Green Square<br>Lambroekstraat 5D<br>1831 Diegem<br>Belgium</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn.&#58;  Nathalie Derue</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"><br>The undersigned acknowledges that he&#47;she has been encouraged to discuss this matter with a financial and&#47;or tax advisor and that this decision is made in full knowledge. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date of Acceptance&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Undertaking for Qualifying Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, &#167;6 of the Belgian law of 26 March 1999, you </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death).  If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Previously Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;the period set forth in Section 4 of the Agreement&#59; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (&#8220;SAFE&#8221;))&#59; and (iii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Stock Option Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is being provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option is not granted under the French specific regime provided by Articles L225-177-1 and seq. of the French commercial code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates.  The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Scheme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;  You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.   </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:126%">You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  </font></div></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar la Opci&#243;n, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Ap&#233;ndice, mismos que ha revisado.  Usted reconoce, adem&#225;s, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Ap&#233;ndice.  Tambi&#233;n reconoce que ha le&#237;do y aprueba de forma expresa los t&#233;rminos y condiciones establecidos en la secci&#243;n doce 12 del contrato que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan su participaci&#243;n en el mismo son ofrecidos por la Compa&#241;&#237;a de forma totalmente discrecional&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;La Compa&#241;&#237;a y sus afiliados no son responsables por cualquier disminuci&#243;n en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opci&#243;n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ley Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar el Otorgamiento de la Opci&#243;n, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es &#250;nicamente responsable de la administraci&#243;n del Plan.  Usted adem&#225;s reconoce que su participaci&#243;n en el Plan, la concesi&#243;n de Opci&#243;n y cualquier adquisici&#243;n de acciones de conformidad con el Plan no constituyen una relaci&#243;n de trabajo entre Usted y Boston Scientific Corporation, ya que Usted est&#225; participando en el Plan sobre una base totalmente comercial y su &#250;nico patr&#243;n es una sociedad mercantil Mexicana (&#8220;Boston Scientific-M&#233;xico&#8221;).  Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participaci&#243;n en el Plan no establecen ning&#250;n derecho entre Usted y su Patr&#243;n, Boston Scientific-M&#233;xico, y no forman parte de las condiciones de trabajo y&#47;o prestaciones otorgadas por Boston Scientific-M&#233;xico, y cualquier modificaci&#243;n al Plan o su terminaci&#243;n no constituir&#225; un cambio o perjuicio de los t&#233;rminos y condiciones de su trabajo. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Usted adem&#225;s entiende que su participaci&#243;n en el Plan es resultado de una decisi&#243;n unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y&#47;o discontinuar su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, Usted declara que no se reserva acci&#243;n o derecho alguno para presentar una reclamaci&#243;n o demanda en contra de Boston Scientific Corporation por cualquier compensaci&#243;n o da&#241;o o perjuicio en relaci&#243;n con cualquier disposici&#243;n del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representaci&#243;n, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamaci&#243;n o demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock.  Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58; This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cashless Exercise Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker&#8217;s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Stock Option under the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The Boston Scientific Corporation 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section&#160;11 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment.  In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply.  In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6721321-v7&#92;GESDMS</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.56
<SEQUENCE>3
<FILENAME>ex1056-2020grantxrsuagreem.htm
<DESCRIPTION>EX-10.56
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic5e1dcfb06134e809ed1e713d9fdb7e0_1"></div><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.56</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation 2011 Long-Term Incentive Plan<br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Deferred Stock Unit Award Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">%%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Participant&#8221;)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">EMPLOYEE COPY</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">PLEASE RETAIN FOR YOUR RECORDS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="ic5e1dcfb06134e809ed1e713d9fdb7e0_4"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Deferred Stock Unit Award Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Deferred Stock Unit Award Agreement (the &#8220;Agreement&#8221;), dated %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%  (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the Award of Deferred Stock Units by the Committee under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you that number of Deferred Stock Units as set forth in this Agreement (the &#8220;Units&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement.  This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units shall vest and shares of Stock will be issued to you according to the vesting schedule set forth in this Agreement.  Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below, in approximately equal annual installments on each of the four (4) consecutive anniversaries of the Grant Date, beginning on the first anniversary of the Grant Date.  Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date.  No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest.  Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and&#47;or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and&#47;or regulatory body in your country of residence (or country of employment, if different).  Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion.  Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution.  Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date.  In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety.  Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you.  Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment&#59; Certain Vesting Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause.  Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above.  For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable).  Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control&#59; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement.  In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Control.  Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii)&#59; provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares have been listed or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company&#8217;s legal department.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Code Section 409A.  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i) your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your  personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that  you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when you are no longer actively providing services </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units.  Investment in shares of Stock involves a degree of risk.  Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">system established and maintained by the Company or a third party-designated by the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURE PAGE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Deferred Stock Units&#58;  %%TOTAL_SHARES_GRANTED%-%</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule</font></div><div style="padding-left:72.91pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.055%"><tr><td style="width:1.0%"></td><td style="width:30.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD1%-%</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD2%-%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD3%-%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%%VEST_DATE_PERIOD4%-%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_02b.jpg" src="image_02b.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1b.jpg" src="image_1b.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael F. Mahoney</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, YOU AGREE THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES YOUR ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) YOU AGREE TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM&#59; (iii) YOU HAVE REVIEWED THE PLAN, THE AGREEMENT AND THE ADDENDUM IN THEIR ENTIRETY, HAVE HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTAND ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM&#59; (iv)&#160;YOU HAVE BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN AND THE TAX SUPPLEMENT TO THE U.S. PROSPECTUS FOR YOUR COUNTRY, IF APPLICABLE&#59; AND (v) YOU HEREBY AGREE TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND THE ADDENDUM.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO DEFERRED STOCK UNITS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section 23 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> AND SWITZERLAND&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For the avoidance of doubt, references to the EU &#47; EEA in this Addendum include the United Kingdom.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Act&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Units, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares of Stock Must Be Held with Designated Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company&#8217;s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf.  You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Sale of Shares Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (&#8220;SAFE&#8221;)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf).  If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree to sign any additional agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker&#8217;s fees and similar expenses may be incurred in any such sale.  In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker&#8217;s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia.  Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Units upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).  To the extent any court, tribunal or legal&#47;regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISRAEL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Immediate Sale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold.  You acknowledge and agree that the Company is authorized to issue sales instructions to the Company&#8217;s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company or the Company&#8217;s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company&#8217;s designated broker with respect to such matters.  When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale.  The remaining proceeds will be paid to you as soon as practicable.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that neither the Company nor the Company&#8217;s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale.  Due to fluctuations in the Stock price and&#47;or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest.  You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and&#47;or any applicable exchange rate.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.    You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the  Units may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.</font></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the &#8220;Nature of Grant&#8221; section of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusi&#243;n de este Ap&#233;ndice, que le ha examinado. Usted reconoce, adem&#225;s, que usted acepta todas las disposiciones del Plan y del Contrato.  Usted tambi&#233;n reconoce que ha le&#237;do y, concretamente, y aprobar de forma expresa los t&#233;rminos y condiciones establecidos en la &#8220;Naturaleza del Otorgamiento&#8221; que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminuci&#243;n en el valor de las acciones adquiridas en la adquisici&#243;n de los Unidades.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ausencia de Relaci&#243;n Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es el &#250;nico responsable de la administraci&#243;n del Plan.  Adem&#225;s, usted acepta que su participaci&#243;n en el Plan, la concesi&#243;n de los Unidades y cualquier adquisici&#243;n de acciones en el marco del Plan no constituyen una relaci&#243;n laboral entre usted y Boston Scientific Corporation porque usted est&#225; participando en el Plan en su totalidad sobre una base comercial y su &#250;nico empleador es una sociedad mercantil Mexicana (&#8220;Boston Scientific-Mexico&#8221;).  Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participaci&#243;n en el Plan no establece ning&#250;n derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y &#47; o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n de su contrato no constituir&#225; un cambio o deterioro de los t&#233;rminos y condiciones de su empleo.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adem&#225;s, usted entiende que su participaci&#243;n en el Plan es causada por una decisi&#243;n discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y&#47;o suspender su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para con usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensaci&#243;n o da&#241;o en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representaci&#243;n, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and&#47;or filing with the Philippines Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and&#47;or to pay any proceeds related to the Units to you through local payroll.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The Boston Scientific Corporation 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment.  In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 13 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6721372-v6&#92;GESDMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.57
<SEQUENCE>4
<FILENAME>ex1057-2020grantxrsabodawa.htm
<DESCRIPTION>EX-10.57
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac9f1c831fbf4f3fbae4c967132cff31_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.57</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">RESTRICTED STOCK AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s 2011 Long Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the &#8220;Restricted Stock&#8221;) of the Company&#8217;s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section&#160;6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock are being issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Delivery of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and any applicable laws, rules and regulations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that  the Participant may request a list </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">with the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the shares of Restricted Stock and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language.  If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; 2011 LONG TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Shares&#58; %%TOTAL_SHARES_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_02.jpg" src="image_02.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><img alt="image_12.jpg" src="image_12.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6721493-v3&#92;GESDMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.58
<SEQUENCE>5
<FILENAME>ex1058-2020grantxdsubodawa.htm
<DESCRIPTION>EX-10.58
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id5fa1e9f2c844b9b95d4f4301d0ba947_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.58</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">DEFERRED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s 2011 Long Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of Deferred Stock Units set forth on the Signature Page of this Agreement (the &#8220;Units&#8221;). Each Unit represents the Company&#8217;s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section&#160;11 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant&#8217;s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section&#160;4.a(4)(C) of the Plan), any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant&#8217;s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant&#8217;s Separation From Service is by reason of the Participant&#8217;s death, then any Units that becomes payable under the Plan due to the Participant&#8217;s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant&#8217;s Separation From Service occurs.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall not be obligated to issue any shares of Stock until (a) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">filing with any governmental and&#47;or regulatory body in the Participant&#8217;s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant&#8217;s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and&#47;or cash as provided for hereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Alternatively, the Participant hereby authorizes the Company (on the Participant&#8217;s behalf and at the Participant&#8217;s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant&#8217;s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant&#8217;s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant&#8217;s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant&#8217;s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the Units and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; 2011 LONG TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Units&#58; %%TOTAL_UNITS_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_03.jpg" src="image_03.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><img alt="image_13.jpg" src="image_13.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6721483-v3&#92;GESDMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2019</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.65
<SEQUENCE>6
<FILENAME>ex1065-2021grantxnqagreeme.htm
<DESCRIPTION>EX-10.65
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i13a6a5fc52144db3b5f3681de40a6cc6_1"></div><div style="min-height:77.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.65</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Non-Qualified Stock Option Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Non-Qualified Stock Option Agreement (the &#8220;Agreement&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan.  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the &#8220;Option Shares&#8221;) at the price set forth herein (the &#8220;Grant Price&#8221;).  The Grant Price is equal to the Fair Market Value of the Company&#8217;s Stock on the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term and Vesting of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the &#8220;Expiration Date&#8221; and shall vest in accordance with the vesting schedule.  If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares.  Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following&#58;  (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith.  Notwithstanding the foregoing, if you reside in a country where the local laws and&#47;or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and&#47;or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless &#8220;sell all&#8221; exercise and&#47;or a cashless &#8220;sell to cover&#8221; exercise) as it shall determine in its sole discretion.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised.  The notice and payment in full of the Option Shares being exercised, </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the Company&#8217;s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company&#8217;s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares.  However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c.&#160;&#160;&#160;&#160;In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d.&#160;&#160;&#160;&#160;Upon termination of your employment for reasons other than for Cause (as defined in Section 4.e. below), death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares.  Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited&#59; provided, however, that the Committee, in its sole discretion, may extend the exercise period and&#47;or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option).  Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;e.&#160;&#160;&#160;&#160;Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited. For purposes of this Agreement, &#8220;Cause&#8221; means a felony conviction or your failure to contest prosecution for a felony, or your misconduct or dishonesty that is harmful to the business or reputation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;f.&#160;&#160;&#160;&#160;The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;g.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;h.&#160;&#160;&#160;&#160;Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum.  No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer&#59; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum&#59; and (iii) such transfer complies with applicable laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;i.&#160;&#160;&#160;&#160;If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;j.&#160;&#160;&#160;&#160;If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence.  If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines.  If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control.  If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 6, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160;Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members.  During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate.  The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility.  In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Stock Option is intended to be exempt from the requirements of Section&#160;409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option.  You understand that you may, at </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">the Stock Option is not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any&#59; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan.  Investment in shares of Stock involves a degree of risk.  Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Choice of Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BOSTON SCIENTIFIC CORPORATION&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><img alt="image_0d.jpg" src="image_0d.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1d.jpg" src="image_1d.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael F. Mahoney</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE <br>AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section 19 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU&#47;EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;thirty (30) days from the date of termination of employment&#59; and (ii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific<br>Green Square<br>Lambroekstraat 5D<br>1831 Diegem<br>Belgium</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn.&#58;  Nathalie Derue</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"><br>The undersigned acknowledges that he&#47;she has been encouraged to discuss this matter with a financial and&#47;or tax advisor and that this decision is made in full knowledge. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date of Acceptance&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Undertaking for Qualifying Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Belgium tax purposes pursuant to the article 43, &#167;6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death).  If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Previously Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section 12(k) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of&#58; (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated&#59; (b) the date that you receive a notice of termination of employment or service&#59; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N&#176; 336 of the Commission for the Financial Market (Comisi&#243;n para el Mercado Financiero, &#8220;CMF&#8221;). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and&#47;or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Esta oferta de opci&#243;n sobre acciones (&#8220;Opci&#243;n&#8221;) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesi&#243;n. Esta oferta de Opci&#243;n se acoge a las disposiciones de la Norma de Car&#225;cter General N&#186; 336 (&#8220;NCG 336&#8221;) de la Comisi&#243;n para el Mercado Financiero de Chile (&#8220;CMF&#8221;). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no est&#225;n sujetos a la fiscalizaci&#243;n de &#233;sta. Por tratarse los Opci&#243;nes de valores no registrados en Chile, no existe obligaci&#243;n por parte de la Compa&#241;&#237;a de entregar en Chile informaci&#243;n p&#250;blica respecto de los Opci&#243;nes or sus Acciones. Estos valores no podr&#225;n ser objeto de oferta p&#250;blica en Chile mientras no sean inscritos en el Registro de Valores correspondiente.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;the period set forth in Section 4 of the Agreement&#59; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (&#8220;SAFE&#8221;))&#59; and (iii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Stock Option Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is being provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option is not granted under the French specific regime provided by Articles L225-177 and seq. of the French commercial code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates.  The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Scheme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISRAEL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The grant of Stock Options under the Plan does not constitute a public offering under the Securities Law, 1968.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;  You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.   </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:126%">You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  </font></div></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar la Opci&#243;n, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Ap&#233;ndice, mismos que ha revisado.  Usted reconoce, adem&#225;s, que acepta todas las disposiciones del Plan, y del contrato, incluyendo </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">este Ap&#233;ndice.  Tambi&#233;n reconoce que ha le&#237;do y aprueba de forma expresa los t&#233;rminos y condiciones establecidos en la secci&#243;n doce 12 del contrato que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan su participaci&#243;n en el mismo son ofrecidos por la Compa&#241;&#237;a de forma totalmente discrecional&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;La Compa&#241;&#237;a y sus afiliados no son responsables por cualquier disminuci&#243;n en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opci&#243;n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ley Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar el Otorgamiento de la Opci&#243;n, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es &#250;nicamente responsable de la administraci&#243;n del Plan.  Usted adem&#225;s reconoce que su participaci&#243;n en el Plan, la concesi&#243;n de Opci&#243;n y cualquier adquisici&#243;n de acciones de conformidad con el Plan no constituyen una relaci&#243;n de trabajo entre Usted y Boston Scientific Corporation, ya que Usted est&#225; participando en el Plan sobre una base totalmente comercial y su &#250;nico patr&#243;n es una sociedad mercantil Mexicana (&#8220;Boston Scientific-M&#233;xico&#8221;).  Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participaci&#243;n en el Plan no establecen ning&#250;n derecho </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">entre Usted y su Patr&#243;n, Boston Scientific-M&#233;xico, y no forman parte de las condiciones de trabajo y&#47;o prestaciones otorgadas por Boston Scientific-M&#233;xico, y cualquier modificaci&#243;n al Plan o su terminaci&#243;n no constituir&#225; un cambio o perjuicio de los t&#233;rminos y condiciones de su trabajo. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Usted adem&#225;s entiende que su participaci&#243;n en el Plan es resultado de una decisi&#243;n unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y&#47;o discontinuar su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, Usted declara que no se reserva acci&#243;n o derecho alguno para presentar una reclamaci&#243;n o demanda en contra de Boston Scientific Corporation por cualquier compensaci&#243;n o da&#241;o o perjuicio en relaci&#243;n con cualquier disposici&#243;n del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representaci&#243;n, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamaci&#243;n o demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii)&#160;your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock.  Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58; This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt"> Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERU</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The grant of the Stock Option is considered a private offering in Peru&#59; therefore, it is not subject to registration. For more information concerning the grant, you </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company.&#160;For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form&#160;10-K and quarterly report on Form 10-Q available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Acknowledgement of Nature of Plan and the Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option is being granted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ex gratia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROMANIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language.&#160;You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Consimtamant cu Privire la Limba</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Accept&#226;nd acordarea op&#539;iune de stoc, recunoa&#537;te&#539;i c&#259; sunte&#539;i competen&#539;i &#238;n citirea &#537;i &#238;n&#539;elegerea limbii engleze &#537;i &#238;n&#539;elege&#539;i pe deplin termenii documentelor legate de subven&#539;ie (Acordul de acordare &#537;i planul), care au fost furnizate &#238;n limba englez&#259;. Accepta&#539;i termenii acestor documente &#238;n consecin&#539;&#259;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cashless Exercise Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker&#8217;s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of the Stock Option to a cashless sell-all exercise and&#47;or to pay any proceeds related to the Stock Option to you through local payroll.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SAUDI ARABIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Stock Option under the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section&#160;11 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment.  In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provision shall supplement Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 9 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply.  In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801730-v7&#92;NA_DMS</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.66
<SEQUENCE>7
<FILENAME>ex1066-2021grantxrsuagreem.htm
<DESCRIPTION>EX-10.66
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ief53a13b2a974ed0bf3f310fbc8855da_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.66</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">EMPLOYEE COPY</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">PLEASE RETAIN FOR YOUR RECORDS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Restricted Stock Unit Award Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the award of Restricted Stock Units (the &#8220;Award&#8221;) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the &#8220;Units&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement.  This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary.  Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date.  No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest.  Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and&#47;or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and&#47;or regulatory body in your country of residence (or country of employment, if different).  Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion.  Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution.  Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date.  In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety.  Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you.  Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment&#59; Certain Vesting Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause.  For purposes of this Agreement, &#8220;Cause&#8221; means a felony conviction or your failure to contest prosecution for a felony, or your misconduct or dishonesty that is harmful to the business or reputation of the Company. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above.  For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable).  Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control&#59; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement.  In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which have not yet been issued will be issued immediately prior to the Change in Control.  Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii)&#59; provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares have been listed or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company&#8217;s legal department.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Code Section 409A.  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i) your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your  personal data as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that  you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units.  Investment in shares of Stock involves a degree of risk.  Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-align:right"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael F. Mahoney</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO RESTRICTED STOCK UNITS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE <br>AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section 23 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU&#47;EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Act&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Units, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 16(k) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of&#58;  (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated&#59; (b) the date that you receive a notice of termination of employment or service&#59; and (c)&#160;the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N&#176; 336 of the Commission for the Financial Market (Comisi&#243;n para el Mercado Financiero, &#8220;CMF&#8221;). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and&#47;or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Esta oferta de Unidades de Acciones Restringidas (&#8220;Units&#8221;) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesi&#243;n. Esta oferta de Units se acoge a las disposiciones de la Norma de Car&#225;cter General N&#186; 336 (&#8220;NCG 336&#8221;) de la Comisi&#243;n para el Mercado Financiero de Chile (&#8220;CMF&#8221;). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no est&#225;n sujetos a la fiscalizaci&#243;n de &#233;sta. Por tratarse los Units de valores no registrados en Chile, no existe obligaci&#243;n por parte de la Compa&#241;&#237;a de entregar en Chile informaci&#243;n p&#250;blica respecto de los Units or sus Acciones. Estos valores no podr&#225;n ser objeto de oferta p&#250;blica en Chile mientras no sean inscritos en el Registro de Valores correspondiente.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares of Stock Must Be Held with Designated Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company&#8217;s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf.  You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Sale of Shares Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (&#8220;SAFE&#8221;)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf).  If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree to sign any additional agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker&#8217;s fees and similar expenses may be incurred in any such sale.  In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker&#8217;s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia.  Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Units upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).  To the extent any court, tribunal or legal&#47;regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISRAEL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Immediate Sale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold.  You acknowledge and agree that the Company is authorized to issue sales instructions to the Company&#8217;s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company or the Company&#8217;s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company&#8217;s designated broker with respect to such matters.  When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale.  The remaining proceeds will be paid to you as soon as practicable.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that neither the Company nor the Company&#8217;s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale.  Due to fluctuations in the Stock price and&#47;or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest.  You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and&#47;or any applicable exchange rate.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.    You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59;.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the  Units may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; </font></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the &#8220;Nature of Grant&#8221; section of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusi&#243;n de este Ap&#233;ndice, que le ha examinado. Usted reconoce, adem&#225;s, que usted acepta todas las disposiciones del Plan y del Contrato.  Usted tambi&#233;n reconoce que ha le&#237;do y, concretamente, y aprobar de forma expresa los t&#233;rminos y condiciones establecidos en la &#8220;Naturaleza del Otorgamiento&#8221; que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminuci&#243;n en el valor de las acciones adquiridas en la adquisici&#243;n de los Unidades.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ausencia de Relaci&#243;n Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es el &#250;nico responsable de la administraci&#243;n del Plan.  Adem&#225;s, usted acepta que su participaci&#243;n en el Plan, la concesi&#243;n de los Unidades y cualquier adquisici&#243;n de acciones en el marco del Plan no constituyen una relaci&#243;n laboral entre usted y Boston Scientific Corporation porque usted est&#225; participando en el Plan en su totalidad sobre una base comercial y su &#250;nico empleador es una sociedad mercantil Mexicana (&#8220;Boston Scientific-Mexico&#8221;).  Derivado de lo anterior, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participaci&#243;n en el Plan no establece ning&#250;n derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y &#47; o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n de su contrato no constituir&#225; un cambio o deterioro de los t&#233;rminos y condiciones de su empleo.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adem&#225;s, usted entiende que su participaci&#243;n en el Plan es causada por una decisi&#243;n discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y&#47;o suspender su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para con usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensaci&#243;n o da&#241;o en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representaci&#243;n, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERU</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The grant of Units is considered a private offering in Peru&#59; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company.&#160;For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form&#160;10-K and quarterly report on Form 10-Q available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Acknowledgement of Nature of Plan and the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the Units, you understand, acknowledge and agree that the Units are being granted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ex gratia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and&#47;or filing with the Philippines Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROMANIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language.&#160;You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Consimtamant cu Privire la Limba</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Accept&#226;nd acordarea unit&#259;&#539;ilor de Unit-uri, recunoa&#537;te&#539;i c&#259; sunte&#539;i competen&#539;i &#238;n citirea &#537;i &#238;n&#539;elegerea limbii engleze &#537;i &#238;n&#539;elege&#539;i pe deplin termenii documentelor legate de subven&#539;ie (Acordul de acordare &#537;i planul), care au fost furnizate &#238;n limba englez&#259;. Accepta&#539;i termenii acestor documente &#238;n consecin&#539;&#259;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and&#47;or to pay any proceeds related to the Units to you through local payroll.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SAUDI ARABIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment.  In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provision shall supplement Section 13 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 13 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801729-v7&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 1.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.67
<SEQUENCE>8
<FILENAME>ex1067-2021grantxtsragreem.htm
<DESCRIPTION>EX-10.67
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iad1875e3819744f4bc2b616f67063e56_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.67</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="padding-left:41.73pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.729%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific Corporation</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#58;  %%FIRST_NAME%-% %%LAST_NAME%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;  %%EMPLOYEE_IDENTIFIER%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58; Performance Share Unit Award Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan Name&#58;  TSR PERFORMANCE SHARE PROGRAM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> -</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Date&#58;  %%OPTION_DATE,'Month DD, YYYY'%-%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Granted&#58;  %%TOTAL_SHARES_GRANTED%-%</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INTENT TO GRANT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Total Shareholder Return Performance Share Program (the &#8220;Program&#8221;) for the period beginning January 1, 2021 and ending on December 31, 2023 (the &#8220;Performance Period&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby indicates its award to you that number of Performance Share Units (the &#8220;Units&#8221;) set forth herein this Agreement (the &#8220;Award&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you shares of the Company&#8217;s common stock, par value USD 0.01 per share (&#8220;Stock&#8221;), subject to certain eligibility, performance and other conditions set forth herein.  The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligibility Conditions upon Award of the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Performance-Based Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the satisfaction of the performance conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement during the Performance Period, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company intends to award shares of Stock hereunder to you at the end of the Performance Period.  Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.  Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine.  During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program.  In the event that you terminate your employment due to Retirement prior to January 1, 2022, the Award shall be forfeited in its entirety.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment -- Eligibility Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount  as calculated in accordance with the terms of the Program.  In the event that a Change in Control occurs prior to January 1, 2022, the Award shall be forfeited in its entirety.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December&#160;31,&#160;2021 and a Change in Control occurs after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;3&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with&#59; (ii)&#160;the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (iii)&#160;all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Section&#160;409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i)&#160;your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limits on Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;5&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan and the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award to be made pursuant to this Agreement is made subject to the Plan and the Program.  The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference.  In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail.  However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries&#59; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the &#8220;Appendix&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Appendix shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">evidenced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and&#47;or to be performed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;6&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;remainder of  page intentionally left blank&#93;</font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;7&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><div id="iad1875e3819744f4bc2b616f67063e56_4"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:95.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.215%"><tr><td style="width:1.0%"></td><td style="width:48.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TSR Performance</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percentile Rank</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Share Units<br>as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80th Percentile or above</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">200%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Below 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Percentile</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><div id="iad1875e3819744f4bc2b616f67063e56_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX B</font></div><div style="padding-right:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States.  Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States.  Section II of this Appendix B includes special terms and conditions in the specific countries listed therein. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2021.  Such laws are often complex and change frequently&#59; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner.  In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).  </font></div><div><font><br></font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section I. &#160;&#160;&#160;&#160;All Countries Outside the United States</font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant, you acknowledge that&#58;</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units  and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="padding-left:18pt;padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire,  sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i)&#160;disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section II.&#160;&#160;&#160;&#160; Country-Specific Terms and Conditions</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES OUTSIDE THE EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you do not reside and&#47;or are not employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your  personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES WITHIN THE EU &#47; EEA, UNITED KINGDOM AND SWITZERLAND </font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you reside and&#47;or are employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;). The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801727-v4&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.68
<SEQUENCE>9
<FILENAME>ex1068-2021grantxfcfagreem.htm
<DESCRIPTION>EX-10.68
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i827739d7dd994bb683ee4bfe73942bcd_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.68</font></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.986%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Boston Scientific Corporation</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Participant&#58;  %%FIRST_NAME%-% %%LAST_NAME%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Employee ID&#58;  %%EMPLOYEE_IDENTIFIER%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Award Type&#58; Performance Share Unit Award Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Plan Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">FCF PERFORMANCE SHARE PROGRAM</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Award Date&#58;  %%OPTION_DATE,'Month DD, YYYY'%-%</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Total Granted&#58;  %%TOTAL_SHARES_GRANTED%-%</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INTENT TO GRANT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Free Cash Flow Performance Share Program (the &#8220;Program&#8221;) for the performance period beginning January&#160;1,&#160;2021 and ending on December 31, 2021 (the &#8220;Performance Period&#8221;) and the three-year service period beginning on January 1, 2021 and ending on December&#160;31,&#160;2023 (the &#8220;Service Period&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby indicates its award to you that number of Performance Share Units (the &#8220;Units&#8221;) set forth herein this Agreement (the &#8220;Award&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you shares of the Company&#8217;s common stock, par value USD 0.01 per share (&#8220;Stock&#8221;), subject to certain eligibility, performance and other conditions set forth herein.  The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligibility Conditions upon Award of the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Performance-Based Conditions and Service Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the eligibility conditions described in Section 7 of this Agreement, except as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise provided in Sections 5, 6 and 8 of this Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the satisfaction of the performance conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Service Period (December 31, 2023).  Shares of Stock shall be issued within thirty (30) days following the end of the Service Period based on actual performance during the Performance Period as determined at the first Committee meeting following the end of the Performance Period.  Except as set forth in Sections 5, 6 and 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Service Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine.  During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law) on or before the end of the Performance Period, shares of Stock shall be issued during the period January&#160;1, 2022 to March 15, 2022, based on actual performance as determined at the first Committee meeting following the Performance Period.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability after the end of the Performance Period, shares of Stock shall be issued within seventy (70) days following your termination of employment based on actual performance during the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2021, but prior to the end of the Service Period, shares of Stock shall be issued to you within seventy (70) days following your Retirement on a prorated basis based on actual performance.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of the Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Service Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program.  In the event that you terminate your employment due to Retirement prior to January 1, 2022, the Award shall be forfeited in its entirety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment -- Eligibility Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued.  Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Service Period as set forth in Section 3 above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2021, but prior to the end of the Service Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performance as determined by the Committee immediately prior to the consummation of the Change in Control.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Service Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with terms of the Program.  In the event that a Change in Control occurs prior to January 1, 2022, the Award shall be forfeited in its entirety.  In the event that your employment with the Company or an Affiliate terminates prior to a Change in Control as a result of death, Disability, or Retirement occurring after December 31, 2021, and a Change in Control occurs after December 31, 2021, then shares of Stock for any Units that have vested under Section 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change of Control on outstanding Awards which is in effect as of the Change of Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii)&#59; provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;3&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with&#59; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items.  By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i)&#160;your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limits on Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;5&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan and the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award to be made pursuant to this Agreement is made subject to the Plan and the Program.  The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference.  In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail.  However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries&#59; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the &#8220;Appendix&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Appendix shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">evidenced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and&#47;or to be performed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;6&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;remainder of  page intentionally left blank&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;7&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><div id="i827739d7dd994bb683ee4bfe73942bcd_4"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Share Units will pay out in shares of Stock in a range of 0% to 150% of the number of Performance Share Units as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:122.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.958%"><tr><td style="width:1.0%"></td><td style="width:56.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent to Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Units Vesting</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">125% or above</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">110%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">120%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Less than 50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr></table></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><div id="i827739d7dd994bb683ee4bfe73942bcd_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States.  Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States.  Section II of this Appendix B includes special terms and conditions in the specific countries listed therein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2021.  Such laws are often complex and change frequently&#59; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner.  In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).  </font></div><div style="margin-bottom:12pt;padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section I. &#160;&#160;&#160;&#160;All Countries Outside the United States</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant, you acknowledge that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire,  sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i)&#160;disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii)&#160;&#8221;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section II.&#160;&#160;&#160;&#160; Country-Specific Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES OUTSIDE THE EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you do not reside and&#47;or are not employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES WITHIN THE EU &#47; EEA, UNITED KINGDOM AND SWITZERLAND</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you reside and&#47;or are employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801718-v4&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.69
<SEQUENCE>10
<FILENAME>ex1069-2021grantxrsabodawa.htm
<DESCRIPTION>EX-10.69
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1acf4787b1874dd4ac04e46dcd1c0de2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.69</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">RESTRICTED STOCK AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the &#8220;Restricted Stock&#8221;) of the Company&#8217;s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section&#160;6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause, any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company. For purposes of this Agreement, &#8220;cause&#8221; means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant&#8217;s misconduct or dishonesty that is harmful to the business or reputation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock are being issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Delivery of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and any applicable laws, rules and regulations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that  the Participant may request a list </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">with the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the shares of Restricted Stock and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language.  If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Shares&#58; %%TOTAL_SHARES_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_11.jpg" src="image_11.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801724-v4&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.70
<SEQUENCE>11
<FILENAME>ex1070-2021grantxrsubodawa.htm
<DESCRIPTION>EX-10.70
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i68df5539aa7e491bbbe83e76f99c754b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.70</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of Restricted Stock Units set forth on the Signature Page of this Agreement (the &#8220;Units&#8221;). Each Unit represents the Company&#8217;s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section&#160;11 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant&#8217;s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 1.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause, any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited. For purposes of this Agreement, &#8220;cause&#8221; means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant&#8217;s misconduct or dishonesty that is harmful to the business or reputation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant&#8217;s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant&#8217;s Separation From Service is by reason of the Participant&#8217;s death, then any Units that becomes payable under the Plan due to the Participant&#8217;s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant&#8217;s Separation From Service occurs.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall not be obligated to issue any shares of Stock until (a) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory filing with any governmental and&#47;or regulatory body in the Participant&#8217;s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant&#8217;s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and&#47;or cash as provided for hereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Alternatively, the Participant hereby authorizes the Company (on the Participant&#8217;s behalf and at the Participant&#8217;s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">any amount necessary to pay the Tax-Related Items from the Participant&#8217;s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant&#8217;s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant&#8217;s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant&#8217;s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the Units and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Units&#58; %%TOTAL_UNITS_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><img alt="image_010.jpg" src="image_010.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_18.jpg" src="image_18.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170801717-v5&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 01.2021</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.72
<SEQUENCE>12
<FILENAME>ex1072-amendmentto2021revo.htm
<DESCRIPTION>EX-10.72
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie0a54ed437b14f019bfadcd82d5be146_1"></div><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Exhibit 10.72</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AMENDMENT</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMENDMENT, dated as of December 21, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to the Credit Agreement, dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (ii) the several banks and other financial institutions from time to time parties thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (iii) WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent for the Lenders thereunder (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">W I T N E S S E T H&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to the Credit Agreement&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrower intends to consummate the Target Acquisition (as defined below) pursuant to the terms and conditions set forth in the Takeover Offer Document (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in connection with the Target Acquisition, the Borrower has requested that the Lenders consent to the amendments to the Credit Agreement and the other agreements as set forth herein to, among others, modify the conditions to the agreement of the Lenders to make Loans requested by the Borrower set forth in Section 7.2 of the Credit Agreement during the Certain Funds Period (as defined below)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Lenders and the Administrative Agent are willing to agree to such amendments to the Credit Agreement and such other agreements, subject to the terms and conditions set forth herein&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the Borrower, the Lenders and the Administrative Agent hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. As used in this Amendment, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition Co</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; Boston Scientific Group plc, a public limited company incorporated under the laws of the Republic of Ireland, which is wholly-owned by the Borrower. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bridge Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; that certain credit agreement, dated as of December 9, 2022, among (i) the Borrower, (ii) the several banks and other financial institutions or entities from time to time parties thereto as lenders, and (iii) Citibank, N.A., as administrative agent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58;  any day on which The Stock Exchange of Hong Kong Limited is open for the transaction of business that is not a Saturday, Sunday or other day that is a legal holiday under the laws of the State of New York or is a day on which banking institutions in such state are authorized or required by law to close. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Certain Funds Commitment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#58;  the period from and including the Amendment Effective Date and ending on the occurrence of any Mandatory Cancellation Event.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; During the Certain Funds Period, Revolving Credit Commitments under the Credit Agreement in an amount of $530,000,000 which are subject only to the satisfaction of the Certain Funds Conditions during the Certain Funds Period. Each Revolving Lender shall be deemed to have a Certain Funds Commitment during the Certain Funds Period in an amount equal to its Revolving Credit Commitment Percentage of the aggregate Certain Funds Commitments.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; (a) the Borrowing Date will be a date within the Certain Funds Commitment Period, (b) the Administrative Agent shall have received the notice of Borrowing in accordance with subsection 2.2 of the Credit Agreement, (c) on the date of the notice of Borrowing delivered pursuant to subsection 2.2 of the Credit Agreement and on the proposed Borrowing Date, (i) no Certain Funds Default shall be continuing or would result from the proposed Borrowing and (ii) all Certain Funds Representations shall be true or, if a Certain Funds Representation does not already include a materiality concept, true in all material respects, (d) the Administrative Agent shall have received a certificate, dated the Borrowing Date and signed by the President, a Vice President or a Financial Officer of the Borrower, confirming the applicable requirements of clause (c) of this definition have been satisfied, (e) the Administrative Agent shall have received all fees due and payable on or prior to the Borrowing Date under the Loan Documents on or prior to the Borrowing Date, (f) it not being illegal for any Lender to lend and there being no injunction or restraining order prohibiting any Lender from lending its portion of the Loans or restricting the application of the proceeds thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that such Lender has used commercially reasonable efforts to make the Loans through an Affiliate of such Lender not subject to such legal restriction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the occurrence of such event in relation to one Lender shall not relieve any other Lender of its obligation to make Loans hereunder and (g) the Takeover Offer shall have become wholly unconditional in accordance with the terms of the Takeover Offer Document, in each case, without giving effect to (and there shall not have been) any modifications, amendments, consents, requests or waivers by the Borrower or the Acquisition Co except to the extent permitted pursuant to Section 6(b) of this Amendment.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; means an Event of Default arising from any of the following, with respect to the Borrower or the Acquisition Co only, other than to the extent that such Event of Default relates to circumstances affecting any member of the Target Group&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement as it relates to the payment of principal, interest or other fees under this Agreement in respect of the Certain Funds Commitments&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement as it relates to a Certain Funds Representation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement as it relates to a failure to perform the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 8.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Amendment (other than paragraphs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> thereof), in each case only insofar as such covenants apply to the Borrower or the Acquisition Co and (in respect of any procurement obligation) each of the Borrower and the Acquisition Co shall use its best efforts in complying with its procurement obligations but any failure to perform the covenants by any other person that is not the Borrower or the Acquisition Co shall not constitute a breach of its obligations or a Certain Funds Default&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 10(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement in respect of the Borrower or the Acquisition Co, but excluding, in relation to involuntary proceedings, any Event of Default caused by a frivolous or vexatious action, proceeding or petition in respect of which no order or decree in respect of such involuntary proceeding shall have been entered. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Draw</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; a Borrowing of Revolving Credit Loans in Dollars by the Borrower under the Certain Funds Commitments under the Credit Agreement to finance those purposes set out in the definition of Certain Funds Purposes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; the period commencing on the later of (i) the Amendment Effective Date and (ii) date of the Rule 3.5 Announcement, and ending at the Certain Funds Termination Time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;payment (directly or indirectly) of all or part of the cash price payable by the Acquisition Co to the holders of the Target Shares subject to the Takeover Offer in consideration of the acquisition of such Target Shares pursuant to the Takeover Offer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;financing (directly or indirectly) the fees, costs and expenses in respect of the Transactions and any stamp duty and any other taxes payable in connection with the Target Acquisition.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; each of the representations set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsections 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Amendment, other than to the extent that such representations relates to facts and circumstances affecting any member of the Target Group and in each case only insofar as such representations apply to the Borrower or the Acquisition Co. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Funds Termination Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; 11&#58;59 p.m. (Hong Kong Time) on the first date on which a Mandatory Cancellation Event occurs or exists. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Executive Director of the Corporate Finance Division of the Securities and Futures Commission of Hong Kong or any delegate of the Executive Director. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mandatory Cancellation Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the occurrence of any of the following conditions or events&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:5.8pt">the Takeover Offer lapses, terminates or is withdrawn with the consent of the Executive (or all consideration payable by the Acquisition Co to the holders of the Target Shares for acceptances validly tendered under the Takeover Offer prior to such lapse, withdrawal or termination (and all fees, costs and expenses (including stamp duty) which are necessary to complete the purchase by Acquisition Co of such Target Shares from such holders) have been paid) or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:5.18pt">it becomes illegal for all the Lenders to lend or there is any injunction or restraining order prohibiting all the Lenders from lending the Loans or restricting the application of proceeds thereof, and the Lenders were unable to make the Loans through their respective Affiliates which are not subject to such legal restriction&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:5.8pt">the date falling one hundred twenty (120) days after the date on which the Takeover Offer Document is issued (or such other date as the Lenders may agree in writing with the Borrower).</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Materially Adverse Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#58; a modification, amendment or waiver to or of the terms or conditions of the Takeover Offer compared to the terms and conditions that are included in the draft of the Rule&#160;3.5 Announcement delivered pursuant to Section 3(c) of this Amendment that is, in the opinion of the Lenders (acting reasonably having consulted in good faith with the Borrower), materially adverse to the interests of the Lenders (taken as a whole), it being acknowledged (i) a waiver of a pre-condition which then becomes a condition to be satisfied in connection with the Target Acquisition&#59; and (ii) such modification, amendment or waiver as required by the Takeovers Code or the Executive, would not be materially adverse to the interests of the Lenders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Acceptance Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; valid acceptances of the Takeover Offer being received in respect of a minimum of 156,725,925 Shares (representing approximately 50.01% of the Company&#8217;s issued share capital as at the date of the Rule 3.5 Announcement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; the Takeover Offer Document and the Rule 3.5 Announcement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Original Rule 3.5 Announcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; as defined in Section 6(b)(i) of this Amendment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Rule 3.5 Announcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means an announcement pursuant to Rule 3.5 of the Takeovers Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Takeover Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#58; means any voluntary conditional partial cash offer by or on behalf of the Acquisition Co to acquire a maximum of </font><font style="color:#242021;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">203,702,962 shares in the Target in the issued share capital of the Target (representing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">65% of the issued Target Shares), substantially on the terms and the conditions set out in the Rule&#160;3.5 Announcement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Takeover Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; means the composite offer and response document to be jointly issued by or on behalf of the Acquisition Co and the Target to shareholders of the Target (other than the Acquisition Co and parties acting in concert with it) in accordance with the Takeovers Code containing, among other things, details of the Takeover Offer, as maybe be revised or supplemented as appropriate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Takeovers Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Code on Takeovers and Mergers published by the Securities and Futures Commission of Hong Kong, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; Acotec Scientific Holdings Limited, a company incorporated in the Cayman Islands with limited liability, whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code&#58; 6669).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; the acquisition by the Acquisition Co of the Target Shares which are subject to the Takeover Offer pursuant to the Takeover Offer Document. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; the Target and its subsidiaries. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; up to 65 % of the issued and to be issued ordinary share capital of the Target at the date of the Takeover Offer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transaction Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58; all fees, costs and expenses incurred or payable by the Borrower or any of its Subsidiaries in connection with the Transactions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58;  the (i) execution and delivery of this Amendment and the Bridge Credit Agreement, (ii) the borrowing of Loans pursuant to the Certain Funds Draw and the use of the proceeds thereof, (iii) the consummation of the Target Acquisition and (iv) the payment of Transaction Costs.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Certain Funds Conditionality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the conditions to each Loan set forth in Section 7.2 of the Credit Agreement, the only conditions to the Certain Funds Draw with respect to the Certain Funds Commitments during the Certain Funds Period shall be the satisfaction of the Certain Funds Conditions.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment shall become effective on the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on which (a) the Borrower, the Administrative Agent and the Majority Lenders shall have executed and delivered to the Administrative Agent this Amendment, (b) all fees and expenses payable to the Administrative Agent, the other Agents and any Lender on or prior to the Amendment Effective Date shall have been paid, (c) the Administrative Agent shall have received a copy, certified by the Borrower, of the issued Rule 3.5 Announcement in form and substance reasonably satisfactory to the Administrative Agent&#59; it being acknowledged that the draft provided to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Administrative Agent as of December 12, 2022 is satisfactory to the Administrative Agent and (d) the Borrower shall have delivered a notice of termination of all outstanding commitments under the Bridge Credit Agreement to the Administrative Agent and Citibank, N.A. The Administrative Agent shall promptly notify the Borrower and the Lenders upon satisfaction of the conditions set out in paragraph (a), (b) and (c) and such notice shall also confirm the status to (i) the conditions remaining for the occurrence of the Amendment Effective Date and (ii) the Certain Funds Conditions, and such notice shall be conclusive and binding.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Representation and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To induce the Administrative Agent to enter into this Amendment, the Borrower hereby represents and warrants to the Administrative Agent and all of the Lenders as of the Amendment Effective Date that&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Corporate Power&#59; Authorization&#59; Enforceable Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Borrower has the corporate power and authority, and the legal right, to make and deliver this Amendment and to perform the Loan Documents, as amended by this Amendment, to which it is a party and has taken all necessary corporate action to authorize the execution, delivery and performance of this Amendment and the performance of the Loan Documents, as so amended, to which it is a party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">No consent or authorization of, filing with (other than the Borrower&#8217;s public filing of the Amendment on Form 8-K, if applicable), or notice to or other act by or in respect of, any Governmental Authority or any other Person is required with respect to the Borrower or any of its Subsidiaries in connection with the execution and delivery of this Amendment or with the performance, validity or enforceability of the Loan Documents, as amended by this Amendment, to which the Borrower is party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">This Amendment has been duly executed and delivered on behalf of the Borrower.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">This Amendment and each Loan Document, as amended by this Amendment, to which the Borrower is a party constitutes a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to the effects of bankruptcy, examination, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Offer Documents and Related Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On the first Borrowing Date in respect of a Certain Funds Draw, the Borrower has delivered to the Administrative Agent complete and correct copies of the Offer Documents when issued, including all schedules and exhibits thereto.  The release of the Rule 3.5 Announcement and the posting of the Offer Documents have been or will be, prior to their release or posting (as the case may be), duly authorized by the Acquisition Co and to the best knowledge of the Borrower, the Target. Each of the material obligations of the Acquisition Co under the Offer Documents is or will be, when entered into and delivered, the legal, valid and binding obligation of the Acquisition Co, enforceable against such Persons in accordance with its terms in each case, except as may be limited by (i) bankruptcy, insolvency, examination or other similar laws affecting the rights and remedies of creditors generally and (ii) general principles of equity. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The representations and warranties (except for those made in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsections 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement) made by the Borrower in or pursuant to the Loan Documents are true and correct in all material respects on and as of the Amendment Effective Date, after giving effect to the effectiveness of this Amendment, as if made on and as of the Amendment Effective Date (it being understood that the only conditions to the making of the Certain Funds Draw under the Certain Funds Commitments are the Certain Funds Conditions).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Actions by Lenders During Certain Funds Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the Certain Funds Period and notwithstanding any provision to the contrary in the Loan Documents, none of the Lenders nor the Administrative Agent shall, unless (x) a Certain Funds Default has occurred and is continuing or would result from a proposed Borrowing, (y) a Certain Funds Representation remains untrue or, if a Certain Funds Representation does not already include a materiality concept, untrue in any material respect or (z) it is illegal for such Lender to lend and&#47;or there is an injunction or restraining order prohibiting such Lender from lending its portion of the Loans or restricting the application of the proceeds thereof (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that such Lender used commercially reasonable efforts to make its portion of the Loans through an Affiliate of such Lender not subject to such legal restriction&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the occurrence of an illegality event in relation to one Lender shall not relieve any other Lender of its obligations to make Loans hereunder), be entitled to&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">cancel any of its Certain Funds Commitments&#59; </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">rescind, terminate or cancel the Loan Documents or the Certain Funds Commitments  or exercise any right or remedy or make or enforce any claim under the Loan Documents it may have to the extent to do so would prevent or limit the making of a Loan for Certain Funds Purposes&#59; </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">refuse to participate in the making of the Certain Funds Draw for Certain Funds Purposes unless the Certain Funds Conditions, as applicable, have not been satisfied&#59;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">exercise any right of set-off or counterclaim in respect of a Loan for Certain Funds Purposes to the extent to do so would prevent or limit the making of the Certain Funds Draw for Certain Funds Purposes&#59; or</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">cancel, accelerate or cause repayment or prepayment of any amounts owing under any Loan Document to the extent to do so would prevent or limit the making of the Certain Funds Draw for Certain Funds Purposes&#59; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, immediately upon the expiry of the Certain Funds Period all such rights, remedies and entitlements shall be available to the Lenders and the Administrative Agent notwithstanding that they may not have been used or been available for use during the Certain Funds Period.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">During the Certain Funds Period, the Revolving Lenders shall not make any Revolving Credit Loans to the Borrower to the extent that, after giving effect thereto, the aggregate Available Revolving Credit Commitments of the Revolving Lenders would be less than the Certain Funds Commitments, other than the Certain Funds Draw (it being understood that a Revolving Lender shall not be deemed to be a Defaulting Lender solely as a result of complying with the provisions of this clause (b)).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding anything to the contrary in  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 13.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Credit Agreement, during the Certain Funds Period no Lender shall assign any Commitment or Loan or any other interest of such Lender hereunder or under the other Loan Documents without the prior written consent of the Administrative Agent and (in respect of its Certain Fund Commitment) unless a Certain Funds Default has occurred and is continuing, the Borrower, and if such Lender assigns, transfers, participates or sub-participates prior to the expiry of the Certain Funds Period (in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsection 13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) in respect of any of its Certain Funds Commitment without the consent of the Borrower, such Lender shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">remain liable to fund the amount of such Certain Funds Commitment during the Certain Funds Period notwithstanding such assignment, transfer, participation or sub-participation of such Certain Funds Commitment and provided further that if the assignee, transferee, participant, sub-participant defaults on its obligation to provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">its pro rata share of a Loan to be made during the Certain Funds Period (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Funding Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) then the Lender which has made the assignment, transfer, participation or sub-participation agrees to provide the amount that the Non-Funding Transferee was obliged to provide up to the amount that such Lender had assigned to such Non-Funding Transferee&#59; and</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">unless the Borrower provides its written consent, retain the unrestricted right to exercise all voting and similar rights in respect of its Certain Funds Commitments including for the avoidance of doubt any rights to approve any amendment or waiver until the expiry of the Certain Funds Period, free of any obligation to act on the instructions of any other person.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Actions by the Borrower During Certain Funds Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the Certain Funds Commitment Period and notwithstanding any provision to the contrary in the Loan Documents, the Borrower shall not rescind, terminate or cancel the Loan Documents or the Commitments (or request any Revolving Credit Loans to the extent that, after giving effect thereto, the aggregate Available Revolving Credit Commitments of the Revolving Lenders would be less than the Certain Funds Commitments, other than the Certain Funds Draw), and shall ensure that at least $530,000,000 of Revolving Credit Commitments remains available under the Credit Agreement for the Certain Funds Purposes.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Borrower will, or cause the Acquisition Co to&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#91;reserved&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Comply in all material respects with the Takeover Code (subject to any waivers or dispensations granted by the Executive) in relation to any Takeover Offer. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">Except as consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned), ensure that the Takeover Offer Document corresponds in all material respects to the terms and conditions of the Takeover Offer as contained in the Rule 3.5 Announcement, subject to any variations which are not Materially Adverse Amendments and changes as required pursuant to the Takeovers Code or required by the Executive. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Ensure that the Takeover Offer Document contains all the material terms and conditions of the Takeover Offer and ensure that the conditions to the Takeover Offer include an Acceptance Condition set at a level at not less than the Minimum Acceptance Condition. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned), not amend, treat as satisfied or waive (i) any term or condition of the Takeover Offer Document (other than the Acceptance Condition), as applicable, other than any such amendment, treatment or waiver which is not a Materially Adverse Amendment, or (ii) the Acceptance Condition if the effect of such amendment, treatment or waiver would be that the Acceptance Condition would be capable of being satisfied at a level less than the Minimum Acceptance Condition.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Not take any action, and procure that no Person acting in concert with it takes any action, which would require the Borrower or the Acquisition Co (as the case may be) to make a mandatory offer for the Target Shares in accordance with Rule 26 of the Takeovers Code or which would require a change to be made to the terms of the Takeover Offer pursuant to the Takeovers Code which change, if made voluntarily, would be a Materially Adverse Amendment. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">Provide the Administrative Agent with copies of the Takeover Offer Document and such information as it may reasonably request regarding the current level of acceptances subject to any confidentiality, legal, regulatory or other restrictions relating to the supply of such information. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">Promptly deliver to the Administrative Agent or the receiving agent any written agreement between the Borrower or the Acquisition Co (as the case may be) and the Target to the extent material to the interests of the Lenders in relation to the consummation of the Target Acquisition (in each case, upon such documents or agreements being entered into by the Borrower or the Acquisition Co (as the case may be), and all other material announcements and documents published by the Borrower or the Acquisition Co (as the case may be) or delivered by the Borrower or the Acquisition Co (as the case may be) to the Executive pursuant to the Takeover Offer (other than the cash confirmation) and all legally binding agreements entered into by the Borrower or the Acquisition Co (as the case may be) in connection with a Takeover Offer, in each case to the extent the Borrower, acting reasonably, anticipates they will be material to the interests of the Lenders in connection with the Transactions, except to the extent it is prohibited by legal (including contractual) or regulatory obligations or restrictions from doing so.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Not declare the Takeover Offer unconditional as to acceptances until the Minimum Acceptance Condition has been satisfied. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Not make any public announcement or public statement (other than in the relevant Offer Documents or the Borrower&#8217;s public filing of the Amendment on Form 8-K, if applicable) concerning the Credit Agreement or the Lenders in connection with the financing of the Target Acquisition without the prior consent of the Administrative Agent (such consent not to be unreasonably withheld, delayed or conditioned) unless required to do so by the Takeovers Code, the Executive, other competent regulatory body, stock exchange, or by a court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Other Certain Funds Matters</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything in the Credit Agreement to the contrary, for a period commencing on the Amendment Effective Date and ending on the date falling 120 days after the date on which the Target Acquisition is consummated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Clean-Up Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), notwithstanding any other provision of any Loan Document, any breach of covenants, misrepresentations or other default which arises with respect to the Target Group will not be deemed a breach of a covenant, misrepresentation or a default or an Event of Default, as the case may be, if&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:54pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">it is capable or remedy and reasonable steps are being taken to remedy it&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:54pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.35pt">the circumstances giving rise to it have not knowingly been procured by or approved by the Borrower&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:54pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.35pt">it is not reasonably likely to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the relevant circumstances are continuing on or after the Clean-Up Date, there shall be a breach of covenant, misrepresentation or default or Event of Default, as the case may be, notwithstanding the above. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">Payment of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable and documented out-of-pocket costs and expenses incurred in connection with this Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including, without limitation, the reasonable and documented fees and disbursements of counsel to the Administrative Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt;text-decoration:underline">No Other Amendments&#59; Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly amended, modified and supplemented hereby, the provisions of the Credit Agreement and the other Loan Documents are and shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.1pt;text-decoration:underline">Governing Law&#59; Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This Amendment and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.  The provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsections 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement are incorporated herein, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts (including by facsimile transmission or in electronic (i.e., &#8220;pdf&#8221; or &#8220;tif&#8221;) format), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Amendment shall be deemed to include Electronic Signatures (as defined below), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be. &#8220;Electronic Signatures&#8221; means any electronic symbol or process attached to, or associated with, any contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.1pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Upon and after the Amendment Effective Date, each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221; or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to &#8220;the Credit Agreement&#8221;, &#8220;thereunder&#8221;, &#8220;thereof&#8221; or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified hereby.&#160; This Amendment shall constitute a Loan Document.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under any of the Loan Documents, nor, except as expressly provided herein, constitute a waiver or amendment of any provision of any of the Loan Documents. It is the intent of the parties hereto, and the parties hereto agree, that this Amendment shall not constitute a novation of the Credit Agreement, any other Loan Document or any of the rights, obligations or liabilities thereunder. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie0a54ed437b14f019bfadcd82d5be146_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first above written.</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert J. Castagna</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________<br>Name&#58; Robert J. Castagna&#160;&#160;&#160;&#160;<br>Title&#58; Vice President and Treasurer&#160;&#160;&#160;&#160; </font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature Page to Amendment to Credit Agreement</font></div></div></div><div id="ie0a54ed437b14f019bfadcd82d5be146_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent and as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Darin Mullis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________<br>Name&#58; Darin Mullis<br>Title&#58; Managing Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BANK OF AMERICA, N.A., as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Darren Merten</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Darren Merten<br>Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BARCLAYS BANK PLC </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Warren Veech III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Warren Veech III<br>Title&#58; Vice President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CITIBANK, N.A., </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Richard Rivera</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________<br>Name&#58; Richard Rivera<br>Title&#58; Vice President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JPMORGAN CHASE BANK, N.A., as a Lender and as an Issuing Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Kyle O&#8217;Donnell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; James Kyle O&#8217;Donnell<br>Title&#58; Vice President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOCIETE GENERALE, </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Richard Bernal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Richard Bernal<br>Title&#58; Managing Director</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature Page to Amendment to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BNP PARIBAS,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Andy Strait</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Andy Strait<br>Title&#58; Managing Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Bosco</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; John Bosco<br>Title&#58; Managing Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DNB Capital LLC., </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Devan Patel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Devan Patel<br>Title&#58; Senior Vice President</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Bret Douglas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Bret Douglas<br>Title&#58; Senior Vice President</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goldman Sachs Bank USA,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Dan Martis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Dan Martis<br>Title&#58; Authroized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD.,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jack Lonker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Jack Lonker<br>Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ROYAL BANK OF CANADA, </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Error! No property name supplied.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12&#47;8&#47;2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature Page to Amendment to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott MacVicar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Scott MacVicar<br>Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NOVA SCOTIA,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Arjun Talwalkar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Arjun Talwalkar<br>Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Toronto-Dominion Bank, New York Branch,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mike Tkach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Mike Tkach<br>Title&#58; Authorized Signatory</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. BANK NATIONAL ASSOCIATION,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Maria Massimino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Maria Massimino<br>Title&#58; Senior Vice President</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allied Irish Bank Plc,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Susan O&#8217;Herlihy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Susan O&#8217;Herlihy pp to Mick Murray<br>Title&#58; Business Unit Head</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DEUTSCHE BANK AG NEW YORK BRANCH,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ming K. Chu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Ming K. Chu<br>Title&#58; Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Annie Chung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Annie Chung<br>Title&#58; Director</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Error! No property name supplied.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12&#47;8&#47;2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature Page to Amendment to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">INTESA SANPAOLO S.p.A., New York Branch,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jordan Schweon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Jordan Schweon<br>Title&#58; Managing Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jennifer Feldman Facciola</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________<br>Name&#58; Jennifer Feldman Facciola<br>Title&#58; Business Director</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">STANDARD CHARTERED BANK,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:223.2pt;text-indent:-7.2pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Kristopher Tracy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________<br>Name&#58; Kristopher Tracy<br>Title&#58; Director, Financing Solutions</font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div style="padding-left:237.6pt;text-indent:-21.6pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Error! No property name supplied.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12&#47;8&#47;2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature Page to Amendment to Credit Agreement</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.76
<SEQUENCE>13
<FILENAME>ex1076-2022grantxnqagreeme.htm
<DESCRIPTION>EX-10.76
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icf0ef898fc5a4cc5a0416831b7daca29_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.76</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Non-Qualified Stock Option Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Non-Qualified Stock Option Agreement (the &#8220;Agreement&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan.  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the &#8220;Option Shares&#8221;) at the price set forth herein (the &#8220;Grant Price&#8221;).  The Grant Price is equal to the Fair Market Value of the Company&#8217;s Stock on the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term and Vesting of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the &#8220;Expiration Date&#8221; and shall vest in accordance with the vesting schedule.  If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares.  Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following&#58;  (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith.  Notwithstanding the foregoing, if you reside in a country where the local laws and&#47;or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and&#47;or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless &#8220;sell all&#8221; exercise and&#47;or a cashless &#8220;sell to cover&#8221; exercise) as it shall determine in its sole discretion.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised.  The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the Company&#8217;s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company&#8217;s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares.  However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c.&#160;&#160;&#160;&#160;In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d.&#160;&#160;&#160;&#160;Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares.  Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited&#59; provided, however, that the Committee, in its sole discretion, may extend the exercise period and&#47;or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option).  Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;e.&#160;&#160;&#160;&#160;Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;f.&#160;&#160;&#160;&#160;The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;g.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;h.&#160;&#160;&#160;&#160;Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum.  No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer&#59; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum&#59; and (iii) such transfer complies with applicable laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;i.&#160;&#160;&#160;&#160;If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;j.&#160;&#160;&#160;&#160;If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence.  If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines.  If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control.  If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 6, shall have the meaning set forth below&#58;</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160;Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members.  During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate.  If the obligation for Tax-Related Items is satisfied by withholding shares of Stock to be issued upon exercise of the Stock Option, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Stock Option, notwithstanding that a number of shares of Stock are withheld solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision.  By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility.  In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Stock Option is intended to be exempt from the requirements of Section&#160;409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">the Stock Option is not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of your employment agreement, if any&#59; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan.  Investment in shares of Stock involves a degree of risk.  Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Choice of Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BOSTON SCIENTIFIC CORPORATION&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><img alt="image_0b.jpg" src="image_0b.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1c.jpg" src="image_1c.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael F. Mahoney</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE <br>AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section 19 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU&#47;EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any reason, your vested Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;thirty (30) days from the date of termination of employment&#59; and (ii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific<br>Green Square<br>Lambroekstraat 5D<br>1831 Diegem<br>Belgium</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn.&#58;  Nathalie Derue</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"><br>The undersigned acknowledges that he&#47;she has been encouraged to discuss this matter with a financial and&#47;or tax advisor and that this decision is made in full knowledge. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date of Acceptance&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Undertaking for Qualifying Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, &#167;6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon your death).  If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Signature&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Printed Name&#58;&#160;&#160;&#160;&#160;_______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Previously Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 11 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All or a portion of the shares of Stock subject to the Stock Option may be &#8220;non-qualified securities&#8221; within the meaning of the Income Tax Act (Canada).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section 12(k) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of&#58; (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated&#59; (b) the date that you receive a notice of </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination of employment or service&#59; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N&#176; 336 of the Commission for the Financial Market (Comisi&#243;n para el Mercado Financiero, &#8220;CMF&#8221;). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and&#47;or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Esta oferta de opci&#243;n sobre acciones (&#8220;Opci&#243;n&#8221;) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesi&#243;n. Esta oferta de Opci&#243;n se acoge a las disposiciones de la Norma de Car&#225;cter General N&#186; 336 (&#8220;NCG 336&#8221;) de la Comisi&#243;n para el Mercado Financiero de Chile (&#8220;CMF&#8221;). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no est&#225;n sujetos a la fiscalizaci&#243;n de &#233;sta. Por tratarse los Opci&#243;nes de valores no registrados en Chile, no existe obligaci&#243;n por parte de la Compa&#241;&#237;a de entregar en Chile informaci&#243;n p&#250;blica respecto de los Opci&#243;nes or sus Acciones. Estos valores no podr&#225;n ser objeto de oferta p&#250;blica en Chile mientras no sean inscritos en el Registro de Valores correspondiente.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercisability Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of&#58; (i)&#160;the period set forth in Section 4 of the Agreement&#59; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (&#8220;SAFE&#8221;))&#59; and (iii) the Expiration Date specified in Section&#160;2 of the Agreement.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Stock Option Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is being provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option is not granted under the French specific regime provided by Articles L225-177 and seq. of the French commercial code.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates.  The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Scheme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISRAEL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The grant of Stock Options under the Plan does not constitute a public offering under the Securities Law, 1968.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 12 of the Agreement&#58;  You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KAZAKHSTAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of Shares to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This provision replaces Section&#160;11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.   </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:126%">You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.  </font></div></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896&#59; elly.kho&#64;bsci.com.</font></div></td></tr></table></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You expressly recognize and acknowledge that the Company&#8217;s grant of the Stock Option and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan, the Agreement and any other document relating to the Stock Option may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar la Opci&#243;n, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Ap&#233;ndice, mismos que ha revisado.  Usted reconoce, adem&#225;s, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Ap&#233;ndice.  Tambi&#233;n reconoce que ha le&#237;do y aprueba de forma expresa los t&#233;rminos y condiciones establecidos en la secci&#243;n doce 12 del contrato que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan su participaci&#243;n en el mismo son ofrecidos por la Compa&#241;&#237;a de forma totalmente discrecional&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;La Compa&#241;&#237;a y sus afiliados no son responsables por cualquier disminuci&#243;n en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opci&#243;n.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ley Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar el Otorgamiento de la Opci&#243;n, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es &#250;nicamente responsable de la administraci&#243;n del Plan.  Usted adem&#225;s reconoce que su participaci&#243;n en el Plan, la concesi&#243;n de Opci&#243;n y cualquier adquisici&#243;n de acciones de conformidad con el Plan no constituyen una relaci&#243;n de trabajo entre Usted y Boston Scientific Corporation, ya que Usted est&#225; participando en el Plan sobre una base totalmente comercial y su &#250;nico patr&#243;n es una sociedad mercantil Mexicana (&#8220;Boston Scientific-M&#233;xico&#8221;).  Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participaci&#243;n en el Plan no establecen ning&#250;n derecho entre Usted y su Patr&#243;n, Boston Scientific-M&#233;xico, y no forman parte de las condiciones de trabajo y&#47;o prestaciones otorgadas por Boston Scientific-M&#233;xico, y cualquier modificaci&#243;n al Plan o su terminaci&#243;n no constituir&#225; un cambio o perjuicio de los t&#233;rminos y condiciones de su trabajo. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Usted adem&#225;s entiende que su participaci&#243;n en el Plan es resultado de una decisi&#243;n unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y&#47;o discontinuar su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, Usted declara que no se reserva acci&#243;n o derecho alguno para presentar una reclamaci&#243;n o demanda en contra de Boston Scientific Corporation por cualquier compensaci&#243;n o da&#241;o o perjuicio en relaci&#243;n con cualquier disposici&#243;n del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representaci&#243;n, </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamaci&#243;n o demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii)&#160;your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock.  Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58; This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt"> Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERU</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The grant of the Stock Option is considered a private offering in Peru&#59; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company.&#160;For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form&#160;10-K and quarterly report on Form 10-Q available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Acknowledgement of Nature of Plan and the Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option is being granted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ex gratia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Cashless Sell-All Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As permitted under Section&#160;3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROMANIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language.&#160;You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Consimtamant cu Privire la Limba</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Accept&#226;nd acordarea op&#539;iune de stoc, recunoa&#537;te&#539;i c&#259; sunte&#539;i competen&#539;i &#238;n citirea &#537;i &#238;n&#539;elegerea limbii engleze &#537;i &#238;n&#539;elege&#539;i pe deplin termenii documentelor legate de subven&#539;ie (Acordul de acordare &#537;i planul), care au fost furnizate &#238;n limba englez&#259;. Accepta&#539;i termenii acestor documente &#238;n consecin&#539;&#259;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that the Stock Option, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia.  The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Stock Option nor the shares of Stock may be used for offering or public circulation in Russia.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cashless Exercise Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker&#8217;s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of the Stock Option to a cashless sell-all exercise and&#47;or to pay any proceeds related to the Stock Option to you through local payroll.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SAUDI ARABIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Stock Option under the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document can be accessed at https&#58;&#47;&#47;us.etrade.com&#47;home -&#62; My Stock Plan -&#62;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section&#160;11 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment.  In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provision shall supplement Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 9 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly </font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply.  In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238364-v3&#92;NA_DMS</font></div><div style="height:103.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12. 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.77
<SEQUENCE>14
<FILENAME>ex1077-2022grantxrsuagreem.htm
<DESCRIPTION>EX-10.77
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i44b4ace945df4e54ba18d67f956b149b_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.77</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Restricted Stock Unit Award Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Global Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) is between you and Boston Scientific Corporation, a Delaware corporation, (the &#8220;Company&#8221;) in connection with the award of Restricted Stock Units (the &#8220;Award&#8221;) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan.  The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the &#8220;Units&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement.  This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary.  Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date.  No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest.  Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and&#47;or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and&#47;or regulatory body in your country of residence (or country of employment, if different).  Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion.  Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution.  Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date.  In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety.  Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the &#8220;Age Discrimination Rules&#8221;).  To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you.  Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment&#59; Certain Vesting Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause.  Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above.  For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable).  Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control&#59; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement.  In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.  Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii)&#59; provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the issuance and delivery of the shares have been approved by the Company&#8217;s legal department.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision.  By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Code Section 409A.  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i) your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your  personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that  you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By participating in the Plan, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units.  Investment in shares of Stock involves a degree of risk.  Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">system established and maintained by the Company or a third party-designated by the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.  </font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the &#8220;Addendum&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan.  The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference.  This Agreement contains terms and provisions established by the Committee specifically for the grant described herein.  Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern.  Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company.  You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and&#47;or to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-align:right"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:330px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael F. Mahoney</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO THE AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELATING TO RESTRICTED STOCK UNITS GRANTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURSUANT TO THE <br>AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions.  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.  Pursuant to Section&#160;23 of the Agreement, if you transfer your residence and&#47;or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU&#47;EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Type of Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRALIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Act&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AUSTRIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BELGIUM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BRAZIL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Policy and Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment&#59; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment&#59; and (iii) the income from the Units, if any, is not part of your remuneration from employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CANADA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 15 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors.  You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the New York Stock Exchange).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 16(k) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of&#58;  (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated&#59; (b) the date that you receive a notice of termination of employment or service&#59; and (c)&#160;the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision will apply if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N&#176; 336 of the Commission for the Financial Market (Comisi&#243;n para el Mercado Financiero, &#8220;CMF&#8221;). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and&#47;or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Esta oferta de Unidades de Acciones Restringidas (&#8220;Units&#8221;) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesi&#243;n. Esta oferta de Units se acoge a las disposiciones de la Norma de Car&#225;cter General N&#186; 336 (&#8220;NCG 336&#8221;) de la Comisi&#243;n para el Mercado Financiero de Chile (&#8220;CMF&#8221;). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no est&#225;n sujetos a la fiscalizaci&#243;n de &#233;sta. Por tratarse los Units de valores no registrados en Chile, no existe obligaci&#243;n por parte de la Compa&#241;&#237;a de entregar en Chile informaci&#243;n p&#250;blica respecto de los Units or sus Acciones. Estos valores no podr&#225;n ser objeto de oferta p&#250;blica en Chile mientras no sean inscritos en el Registro de Valores correspondiente.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHINA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions govern your participation in the Plan if you are a national of the People&#8217;s Republic of China (&#8220;China&#8221;) resident in mainland China, as determined by the Company in its sole discretion&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares of Stock Must Be Held with Designated Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company&#8217;s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf.  You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Sale of Shares Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (&#8220;SAFE&#8221;)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf).  If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree to sign any additional agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker&#8217;s fees and similar expenses may be incurred in any such sale.  In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker&#8217;s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan.  You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account.  The proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account.  If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLOMBIA</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your &#8220;salary&#8221; for any legal purpose.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and, therefore, the shares of Stock may not be offered to the public in Colombia.  Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COSTA RICA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CZECH REPUBLIC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Units upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;Stock Option Act&#8221;), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINLAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IMPORTANT NOTICE&#47;WARNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (&#8220;ORSO&#8221;).  To the extent any court, tribunal or legal&#47;regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDONESIA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IRELAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISRAEL</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Immediate Sale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold.  You acknowledge and agree that the Company is authorized to issue sales instructions to the Company&#8217;s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company or the Company&#8217;s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company&#8217;s designated broker with respect to such matters.  When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale.  The remaining proceeds will be paid to you as soon as practicable.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that neither the Company nor the Company&#8217;s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale.  Due to fluctuations in the Stock price and&#47;or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest.  You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and&#47;or any applicable exchange rate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITALY</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 16 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement&#58;  Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAPANHyperlink 'https&#58;&#47;&#47;urldefense.proofpoint.com&#47;v2&#47;url&#63;u&#61;https-3A__us.etrade.com_home&#38;d&#61;DQMGaQ&#38;c&#61;ptMoEJ5oTofwe4L9tBtGCQ&#38;r&#61;dqXjWr1ZkgMeQUKG5xPbfMpFSFecYMcz6uxhhZHJRU6iuwzyUxW2uCfy7XvygFjB&#38;m&#61;iuAM0nNqCfilUazM_Aa47l6Xaj7hBqlwmt7IsxS7MCI&#38;s&#61;2E9ozXpVgHY9i5FUdeuo9WU0u0w8YIJ3qQW4Eo_Oh6k&#38;e&#61;' in document 'ex1056-2020grantxrsuagreem.htm' is not allowed. Return to your document and replace with a document hyperlink or URL beginning with https&#58;&#47;&#47;www.sec.gov&#47;Archives&#47;edgar&#47;data&#47; or https&#58;&#47;&#47;www.sec.gov&#47;ix&#63;doc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KAZAKHSTAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of shares of Stock to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MALAYSIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board.  (You may contact your Employer to request a form letter for this purpose.)  You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision replaces Section 15 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.    You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.  You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the  Units may be deposited.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consent herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.</font></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan. </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan,  dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#8220;Data&#8221;). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda  di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga  dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan.  Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan.  Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas&#59; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda&#58; Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588&#59; +(65) 6418 8896.</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEXICO</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You expressly recognize and acknowledge that the Company&#8217;s grant of the Units and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed.  You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum.  You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the &#8220;Nature of Grant&#8221; section of the Agreement, which clearly provide as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in it are offered by the Company on a wholly discretionary basis&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento del Contrato</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusi&#243;n de este Ap&#233;ndice, que le ha examinado. Usted reconoce, adem&#225;s, que usted acepta todas las disposiciones del Plan y del Contrato.  Usted tambi&#233;n reconoce que ha le&#237;do y, concretamente, y </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">aprobar de forma expresa los t&#233;rminos y condiciones establecidos en la &#8220;Naturaleza del Otorgamiento&#8221; que claramente dispone lo siguiente&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan no constituye un derecho adquirido&#59;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria&#59; y</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminuci&#243;n en el valor de las acciones adquiridas en la adquisici&#243;n de los Unidades.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Acknowledgement and Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, United States of America, is solely responsible for the administration of the Plan.  You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (&#8220;Boston Scientific-Mexico&#8221;).  Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time, without any liability to you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reconocimiento de Ausencia de Relaci&#243;n Laboral y Declaraci&#243;n de la Pol&#237;tica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">300 Boston Scientific Way, Marlborough, Massachusetts 01752</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Estados Unidos de Am&#233;rica, es el &#250;nico responsable de la administraci&#243;n del Plan.  Adem&#225;s, usted acepta que su participaci&#243;n en el Plan, la concesi&#243;n de los Unidades y cualquier adquisici&#243;n de acciones en el marco del Plan no constituyen una relaci&#243;n laboral entre usted y Boston Scientific Corporation porque usted est&#225; participando en el Plan en su totalidad sobre una base comercial y su &#250;nico empleador es una sociedad mercantil Mexicana (&#8220;Boston Scientific-Mexico&#8221;).  Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participaci&#243;n en el Plan no establece ning&#250;n derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y &#47; o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificaci&#243;n del </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan o la terminaci&#243;n de su contrato no constituir&#225; un cambio o deterioro de los t&#233;rminos y condiciones de su empleo.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adem&#225;s, usted entiende que su participaci&#243;n en el Plan es causada por una decisi&#243;n discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y&#47;o suspender su participaci&#243;n en el Plan en cualquier momento, sin responsabilidad alguna para con usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensaci&#243;n o da&#241;o en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representaci&#243;n, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NETHERLANDS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.  You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The shares of Stock are quoted on the New York Stock Exchange.  This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers.  You may get less than you invested.  The price will depend on the demand for the shares of Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to&#58;  Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORWAY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERU</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The grant of Units is considered a private offering in Peru&#59; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company.&#160;For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form&#160;10-K and quarterly report on Form 10-Q available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Acknowledgement of Nature of Plan and the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the Units, you understand, acknowledge and agree that the Units are being granted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ex gratia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PHILIPPINES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and&#47;or filing with the Philippines Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PORTUGAL</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conhecimento da Lingua</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PUERTO RICO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROMANIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language.&#160;You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Consimtamant cu Privire la Limba</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Accept&#226;nd acordarea unit&#259;&#539;ilor de Unit-uri, recunoa&#537;te&#539;i c&#259; sunte&#539;i competen&#539;i &#238;n citirea &#537;i &#238;n&#539;elegerea limbii engleze &#537;i &#238;n&#539;elege&#539;i pe deplin termenii documentelor legate de subven&#539;ie (Acordul de acordare &#537;i planul), care au fost furnizate &#238;n limba englez&#259;. Accepta&#539;i termenii acestor documente &#238;n consecin&#539;&#259;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RUSSIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States.  Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.  In no event will shares of Stock be delivered to you in Russia&#59; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States.  You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that the Units, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia.  The shares of Stock acquired pursuant to the Plan have not and will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be registered in Russia and, therefore, neither the Units nor the shares of Stock may be used for offering or public circulation in Russia.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations.  Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Labor Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and&#47;or to pay any proceeds related to the Units to you through local payroll.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SAUDI ARABIA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SINGAPORE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the Units is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In compliance with South African securities law, the documents listed below are available for review on the Company&#8217;s external and internal sites at the web addresses listed below&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation&#8217;s most recent Annual Report (Form 10-K)&#58;  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.sec.gov&#47;cgi-bin&#47;browse-edgar&#63;CIK&#61;bsx&#38;owner&#61;exclude&#38;action&#61;getcompany&#38;Find&#61;Search.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&#38;A Summary Sheet&#58;  This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Boston Scientific Corporation Equity Award and Acceptance Summary&#58; This document can be accessed at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;us.etrade.com&#47;home</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> -&#62; My Stock Plan -&#62; Holdings -&#62; click on a grant date and select &#8220;View Grant Documents&#8221;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn&#58; Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOUTH KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Collection, Processing and Transfer of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electronically accepting this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Plan&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This provision supplements the terms of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment.  In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article&#160;40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provision shall supplement Section 13 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees.  The Award is not a public offer of securities by a Taiwanese company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED ARAB EMIRATES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of&#160;the&#160;Agreement or the Plan, you should consult an authorized financial advisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED KINGDOM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Income Tax and Social Insurance Contribution Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision shall supplement Section 13 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award.  Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238353-v3&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">&#8211;Rev 12.2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.78
<SEQUENCE>15
<FILENAME>ex1078-2022grantxtsragreem.htm
<DESCRIPTION>EX-10.78
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id3b95725c0d04c0aa521f250c77c1bbe_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.78</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="padding-left:41.73pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.729%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific Corporation</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#58;  %%FIRST_NAME%-% %%LAST_NAME%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;  %%EMPLOYEE_IDENTIFIER%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58; Performance Share Unit Award Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan Name&#58;  TSR PERFORMANCE SHARE PROGRAM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> -</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Date&#58;  %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Granted&#58;  %%TOTAL_SHARES_GRANTED%-%</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INTENT TO GRANT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-% (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Total Shareholder Return Performance Share Program (the &#8220;Program&#8221;) for the period beginning January 1, 2022 and ending on December 31, 2024 (the &#8220;Performance Period&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby indicates its award to you that number of Performance Share Units (the &#8220;Units&#8221;) set forth herein this Agreement (the &#8220;Award&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you shares of the Company&#8217;s common stock, par value USD 0.01 per share (&#8220;Stock&#8221;), subject to certain eligibility, performance and other conditions set forth herein.  The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligibility Conditions upon Award of the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Performance-Based Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the satisfaction of the performance conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement during the Performance Period, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company intends to award shares of Stock hereunder to you at the end of the Performance Period.  Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.  Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine.  During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program.  In the event that you terminate your employment due to Retirement prior to January 1, 2023, the Award shall be forfeited in its entirety.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment -- Eligibility Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount  as calculated in accordance with the terms of the Program.  In the event that a Change in Control occurs prior to January 1, 2023, the Award shall be forfeited in its entirety.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December&#160;31,&#160;2022 and a Change in Control occurs after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;3&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with&#59; (ii)&#160;the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (iii)&#160;all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision.   By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Section&#160;409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i)&#160;your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limits on Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;5&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan and the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award to be made pursuant to this Agreement is made subject to the Plan and the Program.  The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference.  In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail.  However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries&#59; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the &#8220;Appendix&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Appendix shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">evidenced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and&#47;or to be performed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;6&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;remainder of  page intentionally left blank&#93;</font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;7&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><div id="id3b95725c0d04c0aa521f250c77c1bbe_4"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:95.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.215%"><tr><td style="width:1.0%"></td><td style="width:48.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TSR Performance</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percentile Rank</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Share Units<br>as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80th Percentile or above</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">200%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Below 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Percentile</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><div id="id3b95725c0d04c0aa521f250c77c1bbe_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX B</font></div><div style="padding-right:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States.  Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States.  Section II of this Appendix B includes special terms and conditions in the specific countries listed therein. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2021.  Such laws are often complex and change frequently&#59; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner.  In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).  </font></div><div><font><br></font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section I. &#160;&#160;&#160;&#160;All Countries Outside the United States</font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant, you acknowledge that&#58;</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units  and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="padding-left:18pt;padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire,  sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i)&#160;disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section II.&#160;&#160;&#160;&#160; Country-Specific Terms and Conditions</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES OUTSIDE THE EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you do not reside and&#47;or are not employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your  personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES WITHIN THE EU &#47; EEA, UNITED KINGDOM AND SWITZERLAND </font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you reside and&#47;or are employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;). The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238355-v3&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TSR Program</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.79
<SEQUENCE>16
<FILENAME>ex1079-2022grantxfcfagreem.htm
<DESCRIPTION>EX-10.79
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i88409c25937647afa0721251447f152d_1"></div><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.79</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36.78pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.986%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston Scientific Corporation</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#58;  %%FIRST_NAME%-% %%LAST_NAME%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;  %%EMPLOYEE_IDENTIFIER%-%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58; Performance Share Unit Award Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FCF PERFORMANCE SHARE PROGRAM</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Date&#58;  %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Granted&#58;  %%TOTAL_SHARES_GRANTED%-%</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INTENT TO GRANT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY&#8217;%-% (the &#8220;Grant Date&#8221;), is between you and Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;).  Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Free Cash Flow Performance Share Program (the &#8220;Program&#8221;) for the performance period beginning January&#160;1,&#160;2022 and ending on December 31, 2022 (the &#8220;Performance Period&#8221;) and the three-year service period beginning on January 1, 2022 and ending on December&#160;31,&#160;2024 (the &#8220;Service Period&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby indicates its award to you that number of Performance Share Units (the &#8220;Units&#8221;) set forth herein this Agreement (the &#8220;Award&#8221;).  Each Unit represents the Company&#8217;s commitment to issue to you shares of the Company&#8217;s common stock, par value USD 0.01 per share (&#8220;Stock&#8221;), subject to certain eligibility, performance and other conditions set forth herein.  The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligibility Conditions upon Award of the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Performance-Based Conditions and Service Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Sections 5, 6 and 8 of this Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfaction of the performance conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Service Period (December 31, 2024).  Shares of Stock shall be issued within thirty (30) days following the end of the Service Period based on actual performance during the Performance Period as determined at the first Committee meeting following the end of the Performance Period.  Except as set forth in Sections 5, 6 and 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Service Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine.  During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law) on or before the end of the Performance Period, shares of Stock shall be issued during the period January&#160;1, 2023 to March 15, 2023, based on actual performance as determined at the first Committee meeting following the Performance Period.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability after the end of the Performance Period, shares of Stock shall be issued within seventy (70) days following your termination of employment based on actual performance during the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2022, but prior to the end of the Service Period, shares of Stock shall be issued to you within seventy (70) days following your Retirement on a prorated basis based on actual performance.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of the Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Service Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program.  In the event that you terminate your employment due to Retirement prior to January 1, 2023, the Award shall be forfeited in its entirety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Termination of Employment -- Eligibility Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued.  Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Service Period as set forth in Section 3 above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2022, but prior to the end of the Service Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance as determined by the Committee immediately prior to the consummation of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Change in Control.  The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Service Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with terms of the Program.  In the event that a Change in Control occurs prior to January 1, 2023, the Award shall be forfeited in its entirety.  In the event that your employment with the Company or an Affiliate terminates prior to a Change in Control as a result of death, Disability, or Retirement occurring after December 31, 2022, and a Change in Control occurs after December 31, 2022, then shares of Stock for any Units that have vested under Section 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change of Control on outstanding Awards which is in effect as of the Change of Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii)&#59; provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Current Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Company&#8217;s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms, when used in this Section 9, shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#8220;Current Executive Officer&#8221; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#8220;Executive Officer&#8221; means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#8220;Former Executive Officer&#8221; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 under the Securities Exchange&#160; Act of 1934, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Recovery&#8221; means the forfeiture or cancellation of unvested Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;3&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company subsequently determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Stock are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not be obligated to issue any shares of Stock until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with&#59; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Satisfaction of Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or the Affiliate that employs you (the &#8220;Employer&#8221;) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (&#8220;Tax-Related Items&#8221;), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and&#47;or the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and&#47;or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and&#47;or cash as provided for hereunder.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld.  You agree to sign any agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld).  Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility.  In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law.  You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a &#8220;specified employee&#8221; (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of&#58; (i)&#160;your death, or (ii) six (6) months and one (1) day following your termination of employment.  Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence.  If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms &#8220;Retirement&#8221;, &#8220;terminate,&#8221; &#8220;termination,&#8221; &#8220;termination of employment,&#8221; and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a &#8220;separation from service&#8221; as such term is defined under Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limits on Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you.  Transfers of shares of Stock by you are subject to the Company&#8217;s Stock Trading Policy and applicable securities laws.  Shares of Stock issued to you in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;5&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to the Plan and the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award to be made pursuant to this Agreement is made subject to the Plan and the Program.  The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference.  In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail.  However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries&#59; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other.  Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the &#8220;Appendix&#8221;).  Further, if you transfer your residence and&#47;or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  Any applicable Appendix shall constitute part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">evidenced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and&#47;or to be performed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;6&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;remainder of  page intentionally left blank&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;7&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><div id="i88409c25937647afa0721251447f152d_4"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Share Units will pay out in shares of Stock in a range of 0% to 150% of the number of Performance Share Units as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:122.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.958%"><tr><td style="width:1.0%"></td><td style="width:56.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent to Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Units Vesting</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">125% or above</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">110%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">120%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Less than 50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr></table></div><div style="padding-right:-21pt;text-align:center"><font><br></font></div><div style="padding-right:-18pt"><font><br></font></div><div style="padding-right:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 1.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div></div></div><div id="i88409c25937647afa0721251447f152d_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States.  Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States.  Section II of this Appendix B includes special terms and conditions in the specific countries listed therein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2021.  Such laws are often complex and change frequently&#59; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner.  In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).  </font></div><div style="margin-bottom:12pt;padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section I. &#160;&#160;&#160;&#160;All Countries Outside the United States</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant, you acknowledge that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">you are voluntarily participating in the Plan&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the Units are not intended to replace any pension rights or compensation&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence)&#59; and</font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the following provisions apply only if you are providing services outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose&#59; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that, depending on your or your broker&#8217;s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws that may affect your ability to accept, acquire,  sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in your country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information.  Furthermore, you could be prohibited from (i)&#160;disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii)&#160;&#8221;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Keep in mind that third parties include fellow employees.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section II.&#160;&#160;&#160;&#160; Country-Specific Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES OUTSIDE THE EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;), UNITED KINGDOM AND SWITZERLAND</font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you do not reside and&#47;or are not employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.  </font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COUNTRIES WITHIN THE EU &#47; EEA, UNITED KINGDOM AND SWITZERLAND</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  If you reside and&#47;or are employed in the EU &#47; EEA, the United Kingdom or Switzerland, the following provision applies&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan.  The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer&#8217;s administration of the Plan and your participation in the Plan, and your denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan.  As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (&#8220;Personal Data&#8221;).  The Personal Data may be provided by you to or collected, where lawful, from third parties.  The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations.  Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time.  These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States.  By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and&#47;or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.  You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company&#8217;s Human Resources Department.  When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements.  You may request a copy of such safeguards from your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">To the extent provided by law, you may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data.  You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager.  Your provision of Personal Data is a contractual requirement.  You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards.  For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company&#8217;s Human Resources Department.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that you can longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vous reconnaissez et consentez que c&#8217;est votre souhait expr&#232;s qui cet accord, de meme que tous documents, toutes notifications et tous proc&#233;d&#233;s l&#233;gaux est entr&#233; dans, donn&#233; ou institut&#233; conform&#233;ment ci-annex&#233; ou relatant directement ou indirectement ci-annex&#233;, est formul&#233; dans l&#8217;anglais.</font></div><div style="padding-right:-18pt;text-align:justify"><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="padding-right:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238356-v3&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Rev. 12.2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FCF Program</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.80
<SEQUENCE>17
<FILENAME>ex1080-2022grantxrsabodawa.htm
<DESCRIPTION>EX-10.80
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4ddb6ebbd38c4fe2847e47a51af03ea7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.80</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">RESTRICTED STOCK AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the &#8220;Restricted Stock&#8221;) of the Company&#8217;s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section&#160;6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause, any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company. For purposes of this Agreement, &#8220;cause&#8221; means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant&#8217;s misconduct or dishonesty that is harmful to the business or reputation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Restricted Stock are being issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Delivery of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and any applicable laws, rules and regulations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that  the Participant may request a list </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">with the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the shares of Restricted Stock and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language.  If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Shares&#58; %%TOTAL_SHARES_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><img alt="image_011.jpg" src="image_011.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_19.jpg" src="image_19.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238369-v3&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.81
<SEQUENCE>18
<FILENAME>ex1081-2022grantxrsubodawa.htm
<DESCRIPTION>EX-10.81
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9f6f5aca2b694ee5a52b68066946961e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.81</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR NON-EMPLOYEE DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This Agreement, dated as of the %%OPTION_DATE,&#8217;Month DD, YYYY%-% (the &#8220;Grant Date&#8221;), is between Boston Scientific Corporation, a Delaware corporation (the &#8220;Company&#8221;), and the person whose name appears on the Signature Page of this Agreement (the &#8220;Participant&#8221;), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant and Acceptance of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company hereby awards to the Participant that number of Restricted Stock Units set forth on the Signature Page of this Agreement (the &#8220;Units&#8221;). Each Unit represents the Company&#8217;s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section&#160;11 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the &#8220;Director Deferred Compensation Plan&#8221;)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant&#8217;s current term as a non-employee director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Participant&#8217;s Rights in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant&#8217;s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant&#8217;s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause, any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited. For purposes of this Agreement, &#8220;cause&#8221; means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant&#8217;s misconduct or dishonesty that is harmful to the business or reputation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration for Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The shares of Stock subject to the Units are intended to be issued for no cash consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant&#8217;s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant&#8217;s Separation From Service is by reason of the Participant&#8217;s death, then any Units that becomes payable under the Plan due to the Participant&#8217;s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant&#8217;s Separation From Service occurs.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Company shall not be obligated to issue any shares of Stock until (a) all United States (&#8220;U.S.&#8221;) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with&#59; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges&#59; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company&#8217;s legal department. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory filing with any governmental and&#47;or regulatory body in the Participant&#8217;s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant&#8217;s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Responsibility for Taxes&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and&#47;or non-U.S. taxes), social insurance or other taxes of any kind (&#8220;Tax-Related Items&#8221;) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, the Participant is deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. The Participant will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and&#47;or cash as provided for hereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Alternatively, the Participant hereby authorizes the Company (on the Participant&#8217;s behalf and at the Participant&#8217;s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">agreements, forms and&#47;or consents that reasonably may be requested by the Company (or the Company&#8217;s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant&#8217;s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant&#8217;s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Transferability&#59; Restrictions on Shares&#59; Legend on Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company&#8217;s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant&#8217;s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant&#8217;s book entry account or restricted legend(s) affixed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Repatriation and Legal&#47;Tax Compliance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and&#47;or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant&#8217;s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant&#8217;s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant&#8217;s personal legal and tax obligations under local laws, rules and regulations in the Participant&#8217;s country of residence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">.  The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant&#8217;s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant&#8217;s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor (&#8220;Data&#8221;) for the purpose of implementing, managing and administering the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (&#8220;E*TRADE&#8221;) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time.  The Participant understands the recipients of the Data may be located in the Participant&#8217;s country, in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that the Participant may request a list with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">the names and addresses of any potential recipients of the Data by contacting the Company&#8217;s Vice President, Total Rewards.  </font></div><div style="text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:139%">The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company&#8217;s Vice President, Total Rewards.  Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant&#8217;s service with the Company will not be adversely affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards.  Therefore, the Participant understands that refusing or withdrawing the Participant&#8217;s consent may affect the Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of the Participant&#8217;s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company&#8217;s Vice President, Total Rewards.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  By participating in the Plan, the Participant acknowledges, understands and agrees that&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;the grant of the Units and the Participant&#8217;s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates&#59; further, the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;the Participant is voluntarily participating in the Plan&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;the following provisions apply only if the Participant is resident outside the United States&#58; (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose&#59; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant&#8217;s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant&#8217;s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant&#8217;s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant&#8217;s own personal tax, legal and financial advisors before taking any action related to the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.  The Participant acknowledges that, depending on the Participant&#8217;s or his or her broker&#8217;s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and&#47;or market abuse laws that may affect the Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have &#8220;inside information&#8221; regarding the Company, as defined in the laws or regulations in the Participant&#8217;s country.  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any restrictions and is advised to speak to the Participant&#8217;s personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant&#8217;s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he&#47;she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-right:-12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant&#8217;s country of residence as are forth in an applicable addendum to the Agreement, if any (the &#8220;Addendum&#8221;). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant&#8217;s transfer of residence). Any applicable Addendum shall constitute part of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant&#8217;s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Legal Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Award Subject to the Plan&#59; Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant&#8217;s heirs and legal representatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">26. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Participant understands that the waiver by the Company with respect to the Participant&#8217;s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PLAN&#58; AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Number of Units&#58; %%TOTAL_UNITS_GRANTED%-%</font></div><div style="text-indent:180pt"><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-indent:36pt"><img alt="image_08.jpg" src="image_08.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_16.jpg" src="image_16.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Name&#58;  Michael F. Mahoney</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">%%FIRST_NAME%-% %%LAST_NAME%-%</font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">PARTICIPANT*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">*Signed via electronic signature&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i)&#160;SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT&#8217;S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT&#59; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM&#59; (iv)&#160;THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN&#59; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405238328-v3&#92;NA_DMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-Rev. 12.2021</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.83
<SEQUENCE>19
<FILENAME>ex1083-offerletterartbutch.htm
<DESCRIPTION>EX-10.83
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8a3ab6160c624292af4d6d0e36714a4c_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.83</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:right"><font><br></font></div><div style="padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Arthur Butcher</font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADDRESS LINE</font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADDRESS LINE</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dear Art&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congratulations on your promotion to Executive Vice President and Group President, Medsurg and APAC effective May 2, 2022.  You will continue to be a member of Boston Scientific&#8217;s Executive Committee, an &#8220;executive officer&#8221; under the U.S. federal securities laws and an &#8220;officer&#8221; for purposes of Section 16 of the Exchange Act. You will continue to report to Michael Mahoney, Chairman, President and CEO.  This letter and the Agreement Concerning Employment summarize our understanding of the terms of your employment.&#160; We look forward to you formally accepting this offer.   </font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPENSATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Boston Scientific&#8217;s compensation programs provide our employees with significant compensation opportunities on a pay for performance basis.&#160; The objective of these programs is to recognize and reward both individual and company performance during the performance year (defined as January 1st through December 31st of each year).</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Salary&#58;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Your base salary for this position will be $25,000.00 currently payable bi-weekly, equivalent to $650,000 on an annualized basis.&#160;Your performance and base salary will generally be reviewed on an annual basis during the normal executive review process and approved by the Executive Compensation and Human Resources Committee.&#160; Your next performance and base salary review will be conducted during the normal executive review process, expected to commence in the first quarter of 2023.  </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Bonus Plan&#58;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;You will continue to be eligible to participate in the Boston Scientific Corporation Annual Bonus Plan, subject to its terms. The Annual Bonus Plan provides employees with the opportunity for a variable financial incentive in recognition of performance each year.&#160; Your 2022 annual target incentive will be increased from 70% to 75% of your base salary.&#160; Your actual award will be based on your achievement of individual goals and the company's achievement of corporate performance goals.&#160; Under the plan, generally you must be an employee on the date of payment to be eligible to earn and receive any bonus payment.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Bonus Plan&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will continue to be eligible to participate in the Boston Scientific Corporation Deferred Bonus Plan starting in 2022, subject to its terms.  This plan allows you to save additional tax-deferred money for your future by deferring a portion of your annual bonus awarded under the Annual Bonus Plan. Specifically, under the plan, on an annual basis, you can elect to defer up to 75% of the Annual Bonus Plan bonus awarded to you subject to the provisions of the Plan. The open enrollment will be in June 2022 for the 2022 plan year (paid in Q1 2023) and every subsequent year following for which you are eligible</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Promotional Equity Grant&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As part of this offer, we are offering you an equity incentive award having a total value of $700,000 on the date of grant, which we expect to be May 2, 2022, subject to the approval of the Executive Compensation and Human Resources Committee.&#160; Your award will be made pursuant to the Amended and Restated 2011 Boston Scientific Long-Term Incentive Plan (2011 LTIP) and the relevant award agreement. The equity incentive award could be in the form of Restricted Stock Units (RSUs) or non-qualified stock options or a mix of both RSUs and non-qualified stock options, depending on your preference.&#160;Both RSUs and non-qualified options will vest 25% per year, beginning on first anniversary of date of grant, and options expire on the 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> anniversary of the grant date.  The election form will be sent under separate cover shortly after you have formally accepted this offer. </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter, y</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">our performance and entitlement to long term incentive compensation grants will be reviewed in the normal course, on an annual basis. The mix of stock vehicles and target value for your level will be evaluated annually by the Executive Compensation and Human Resources Committee of the Boston Scientific Board of Directors. The current program provides for an equal mix of Total Shareholder Return Performance Shares (TSR PSP), Free Cash Flow Performance Shares (FCF PSP), Restricted Stock Units (RSU&#8217;s) and Non-Qualified Stock Options.</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BENEFITS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>You will remain eligible to continue participation in all benefit&#160;programs for which you were previously eligible and enrolled. Boston Scientific reserves the right to change and&#47;or terminate any aspect of our benefit offerings, including employer contributions toward benefits.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMPLOYMENT AT WILL</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will remain an &#8220;at will&#8221; employee of Boston Scientific.&#160; This means that you remain free to resign at any time.&#160; Likewise, Boston Scientific will continue to have the right to terminate your employment at any time, with or without reason or notice.&#160; Acceptance of this transfer acknowledges your continued understanding and acceptance of the &#8220;at will&#8221; nature of your employment.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCEPTANCE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>This offer is contingent upon the following&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; An acceptance no later than&#160;April 4, 2022&#59;<br> <br>&#8226; A signed Agreement Concerning Employment </font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please indicate your acceptance by acknowledging below.</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Art, we would like to congratulate you on this well-deserved promotion and wish you continued success. We look forward to your acceptance of this offer.&#160;</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael F. Mahoney</font></div><div style="margin-bottom:5pt;padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Mahoney                                                                                                    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                              Chairman, President and Chief Executive Officer </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Agreed to and Accepted by&#58;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">&#47;s&#47; Arthur Butcher&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;Date&#58;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">4&#47;2&#47;2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">                                                       Arthur Butcher</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enclosures&#58;</font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement Concerning Employment</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:25.15pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.84
<SEQUENCE>20
<FILENAME>ex1084-offerletterjeffmirv.htm
<DESCRIPTION>EX-10.84
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0c9eeb71af584e8b8f0d12d8a834d704_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.84</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#114677;font-family:'Times New Roman',sans-serif;font-size:24.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One Boston Scientific Place</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Natick, MA 01760-1537</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650.8000</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 11, 2012</font></div><div><font><br></font></div><div style="text-indent:0.05pt"><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mr</font><font style="color:#525252;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Mirviss </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ADDRESS LINE</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ADDRESS LINE</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Dear Jeff&#58;</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Based on your role within Boston Scientific, we are </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">very</font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">pleased to offer you the position of Senior Vice President and President, Peripheral Interventions reporting to Michael Mahoney, President and Chief Executive Officer, effective January 1, 2013. As part of this offer, you will become a member of Boston Scientific's Executive Committee</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Upon acceptance of this offer, you will be provided the following relative to compensation and benefits</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#58;</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">BASE SALARY</font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Your base salary will be $13,076.93 currently payable bi-weekly, equivalent to $340,000 on an annualized basis</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">This base pay increase is inclusive of any 2013 CMS merit award</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Your performance and compensation will continue to be reviewed on an annual basis starting with the 2014 CMS cycle.</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL BONUS PLAN</font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The Boston Scientific performance year currently runs from January 1st through December 31st of each year</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The Boston Scientific Corporation Annual Bonus Plan provides employees with the opportunity for a variable financial incentive in recognition of performance in a given year</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Per the current plan, your 2013 annual target incentive will be increased from 45% to 50% of base salary. Your actual award will be based on your achievement of individual goals and the company's achievement of corporate performance goals. Under the current plan, you must be an active employee on the date of payment to receive any award pay-out under the plan.</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL EQUITY PROGRAM</font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">You will continue to be eligible for consideration for an annual equity incentive as per Boston Scientific's Long Term Incentive Program during the normal executive review process. An award will depend on both company and individual performance</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The current program provides for a mix of performance shares, options</font><font style="color:#3d3d3d;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">and deferred stock units.&#160;&#160;&#160;&#160;</font><font style="color:#a8a8a8;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#183;</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CHANGE IN CONTROL AGREEMENT</font></div><div style="text-indent:0.15pt"><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Boston Scientific also provides Change in Control agreements to its key executives. In general, the Change in Control agreement entitles you as a member of our Executive Committee to a lump sum payment of three times your base salary and assumed on-plan incentive bonus if either your employment is terminated (other than for cause) or if your duties are diminished following a change in control of Boston Scientific. A copy of the Executive Committee level agreement will be distributed to you in the coming weeks.</font></div><div><font><br></font></div><div><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">EXECUTIVE RETIREMENT PLAN</font></div><div style="text-indent:-0.1pt"><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">As an Executive Committee Member, if you </font><font style="color:#2a2a2a;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#34;Retire&#34; </font><font style="color:#131313;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">from Boston Scientific (as that term is defined in our Executive Retirement Plan), you may be eligible to receive certain Executive Committee level benefits provided under that plan. A copy of Boston Scientific's Executive Retirement Plan is attached for your information.</font></div><div style="text-indent:-0.1pt"><font><br></font></div><div style="text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">DEFERRED BONUS PROGRAM&#58;</font></div><div style="text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You will continue to be eligible to participate in the Boston Scientific Corporation Deferred Bonus Plan. This plan allows you to save additional tax-deferred money for your future by deferring a portion of your annual bonus awarded under the Annual Bonus Plan. Specifically, under the plan, on an annual basis, you can elect to defer up to 75% of the Annual Bonus Plan bonus awarded to you starting with 2013 or any subsequent year.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">BENEFITS</font></div><div style="text-indent:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You will continue to be eligible for Boston Scientific's current U.S. benefit programs. Please understand that the company reserves the right to unilaterally amend or terminate any of these programs, or to require or change employee premium contributions toward benefits.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">EMPLOYMENT AT WILL</font></div><div style="text-indent:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Upon acceptance of this offer you will remain an &#34;at will&#34; employee of Boston Scientific. This means that you will be free to resign at any time. Likewise, Boston Scientific will have the right to terminate your employment at any time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.84</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">with or without reason or notice. Acceptance of this offer acknowledges your understanding and acceptance of the &#34;at will&#34; nature of your employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ACCEPTANCE</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This offer letter is contingent upon the following&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">An acceptance date of no later than December 14, 2012&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Your immediate signing of the 2012 Agreement Concerning Employment.</font></div><div><font><br></font></div><div style="text-indent:-0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeff, we believe this opportunity to be a mutually-rewarding one and look forward to your contributions and success with Boston Scientific.</font></div><div style="text-indent:-0.15pt"><font><br></font></div><div style="text-indent:-0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="text-indent:-0.15pt"><font><br></font></div><div style="text-indent:-0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Mahoney</font></div><div style="text-indent:-0.15pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael Mahoney</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreed to and Accepted by&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jeffrey B. Mirviss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">______________________________   Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">14 Dec 2022</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                                    Jeffrey B. Mirviss</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Enclosures</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement Concerning Employment</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Boston Scientific Corporation Executive Retirement Plan</font></div><div style="margin-top:4.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.85
<SEQUENCE>21
<FILENAME>ex1085-arnonxemployeedirec.htm
<DESCRIPTION>EX-10.85
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0bab9da894c849baaf5729b1f6e6bef2_1"></div><div style="min-height:87.84pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.85</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">NON-EMPLOYEE DIRECTOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">DEFERRED COMPENSATION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">As Amended and Restated Effective January 1, 2023</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table></div></div></div><div id="i0bab9da894c849baaf5729b1f6e6bef2_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">NON-EMPLOYEE DIRECTOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">DEFERRED COMPENSATION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">As Amended and Restated Effective January 1, 2023</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Table of Contents</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Page</font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 1 Nature and Purpose of Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;Nature</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;Purpose</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 2 Participation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Commencement of Participation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;Duration of Participation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 3 Elections and Account</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;Deferral Election</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;Deemed Elections</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;Deferred Account</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;Account Records</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 4 Payment of Deferred Amounts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;Payment of Deferred DSU Accounts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;Designation of Beneficiary</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Delay For Specified Employees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;Change in Control Event</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 5 Nature of Claims for Benefit Payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;Obligation of the Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;Participants&#8217; Rights Unsecured</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 6 Administration</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;Plan Administrator</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;Powers of the Committee as Administrator</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;Finality of Committee Determinations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;Claims Procedures</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;Indemnification</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;Right to Suspend Benefits and Correct Errors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;Incapacity</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.8&#160;&#160;&#160;&#160;Legal Holidays</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 7 Amendment or Termination of the Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 8 Miscellaneous</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;No Assignment or Alienation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;Limitation of Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;Receipt and Release</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;No Effect on Future Service as a Director</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;Severability</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;Successor Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;Headings and Subheadings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;Governing Law</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 9 Definitions and Rules of Construction</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;Definitions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;Rules of Construction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i0bab9da894c849baaf5729b1f6e6bef2_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;iii</font></div></div></div><div id="i0bab9da894c849baaf5729b1f6e6bef2_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Nature and Purpose of Plan</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Nature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This document is an amendment and complete restatement, effective January 1, 2023, of the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan.  Amounts deferred under the Plan prior to January 1, 2023 will be governed by the terms of the Plan as in effect immediately prior to the effective date of this restatement.  The Plan is intended to be a nonqualified deferred compensation plan within the meaning of Code section 409A, to be construed and administered in accordance with the Section 409A Standards.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The purpose of the Plan is to provide deferred compensation for the Company&#8217;s non-employee directors by providing Eligible Directors with an opportunity to defer a portion of their Compensation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Participation</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Commencement of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An Eligible Director will become a Participant by filing an election form in accordance with the provisions of Section 3.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Duration of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant will remain a Participant until he or she has received all payments to which he or she is entitled under the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Elections and Account</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Deferr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">al Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Prior to the beginning of each Plan Year, each Eligible Director may elect in writing, in the manner and on the form prescribed by the Committee, to defer payment of all or a portion of the Eligible Director&#8217;s Compensation by making one or both of the following elections&#58;    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;An election to defer payment of all or a portion, in increments of 25%, of the Director&#8217;s Cash Compensation and have that deferred amount converted to RSUs and credited to a Deferred Account pursuant to Section 3.4.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;An election to defer payment of all or a portion, in increments of 25%, of the Director&#8217;s Equity Compensation and have that portion credited, as RSUs, to a Deferred Account pursuant to Section 3.3. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Participant&#8217;s deferral election for a Plan Year will become irrevocable on the day preceding the first day of the Plan Year. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;If an individual becomes an Eligible Director after the beginning of a Plan Year and has not been eligible to participate in this Plan (or any other plan required to be aggregated with this Plan under the Section 409A Standards) at any time during the 24-month period ending on the date he or she becomes an Eligible Director, then, within thirty (30) days after the date the individual becomes an Eligible Director, he or she may make one or both of the elections described in Section 3.1(a) above with respect to Compensation for the Plan Year for services </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed after the date the election is made, subject to any prorating that may be required under the Section 409A Standards. A deferral election made under this paragraph (b) will become irrevocable on the date the election is made.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.2 Deemed Elections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Participant fails to make a timely deferral election in accordance with Section 3.1 for a Plan Year, the Participant will be deemed to have made the following elections&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Participant will be deemed to have elected not to defer any portion of his Cash Compensation for the Plan Year. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Participant will be deemed to have elected not to defer any portion of his Equity Compensation for the Plan Year.  </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.3 Deferred Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Deferred Account will be established for any Participant who makes an election described in Section 3.1(a)(i) or (a)(ii) for any Plan Year.  For each Plan Year for which a Participant makes an election described in Section 3.1(a)(i), the Participant&#8217;s Deferred Account will be credited with RSUs equal to the quotient (rounded down to the next whole number) of (A) divided by (B), where (A) is the dollar value of the Cash Compensation that the Participant elected to defer, and (B) is the closing price per share of Company Stock on the date the Cash Compensation would have been paid to the Participant in the absence of the Participant making an election described in Section. 3.1(a)(i).  For each Plan Year for which a Participant makes an election described in Section 3.1(a)(i) with respect to a portion of his or her Equity Compensation (the &#8220;Deferred Portion&#8221;), the Participant&#8217;s Deferred Account will be credited with a number of RSUs equal to the number of Restricted Stock Units that would have been granted to the Participant under the LTIP if the Participant had elected to receive the Deferred Portion in the form of Restricted Stock Awards rather than as RSUs deferred under the Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.4 Account Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participants will be able to access records of their Deferred Account balances online or telephonically through the appropriate record keeper.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Payment of Deferred Amounts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Payment of Deferred Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon the Participant&#8217;s Separation From Service for any reason, the total number of vested RSUs credited to the Participant&#8217;s Deferred Account will be settled in shares of Company Stock (with one share of Company Stock payable for each whole RSU) and distributed to the Participant within 60 days after the Participant&#8217;s Separation From Service.  Any RSUs that are not vested as of the date of the Participant&#8217;s Separation From Service will be forfeited.  The extent to which RSUs are vested will be determined by the terms of the LTIP and any applicable award agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Participant may designate a Beneficiary or Beneficiaries under the Plan to receive payment of the Participant&#8217;s Deferred Account upon the Participant&#8217;s death by submitting a completed Beneficiary designation to the Committee&#8217;s designated record keeper, in the form and manner prescribed by the Committee or its designee, before the Participant&#8217;s death.  If the Participant fails to designate a Beneficiary, or if no designated Beneficiary survives the Participant, the Participant&#8217;s Beneficiary will be the Participant&#8217;s estate.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Delay For Specified Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Because the Plan is only for Eligible Directors (those who are not employees of the Company), it is not expected that any Participants will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified Employees.  However, in the event that a Participant is a Specified Employee at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant&#8217;s Separation From Service is by reason of the Participant&#8217;s death, then any amount that becomes payable under the Plan due to the Participant&#8217;s Separation From Service will be paid on the first day that is six months after the date on which the Participant&#8217;s Separation From Service occurs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any other Plan provision, if a Change in Control Event occurs, then any unvested RSUs credited to the Participant&#8217;s Deferred Account will become vested, and all RSUs credited to the Participant&#8217;s Deferred Account will be settled in shares of Company Stock (with one share of Company Stock payable for each whole RSU) and distributed to the Participant following the date on which the Change in Control Event occurs.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Nature of Claims for Benefit Payments</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Obligation of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will establish on its books a liability with respect to its obligations for benefits payable under the Plan to Participants and their Beneficiaries.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Participants&#8217; Rights Unsecured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan is unfunded.  The right of any Participant to receive payment of deferred amounts under the provisions of the Plan will be an unsecured claim against the general assets of the Company.  The maintenance of individual Participant Accounts is for bookkeeping purposes only.  The Company is not obligated to acquire, segregate, or set aside, in trust or otherwise, any assets of any kind for the discharge of its obligations under the Plan, nor will any Participant have any property rights in any particular assets held by the Company, whether or not held for the purpose of funding the Company&#8217;s obligations under the Plan.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Administration</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee will be the administrator of the Plan and will have full discretionary power and authority to administer the Plan in all of its details.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Powers of the Committee as Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee&#8217;s powers as administrator of the Plan will include, but will not be limited to, the following discretionary authority, in addition to all powers and authority provided elsewhere in the Plan&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">to make and enforce such rules, regulations, and procedures, consistent with the terms of the Plan, as the Committee deems necessary or proper for the efficient administration of the Plan&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to interpret the terms and provisions of the Plan and to decide any and all questions arising under the Plan, including, without limitation, the right to remedy possible ambiguities, inconsistencies, or omissions by a general rule or particular decision&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">to determine the amounts to be distributed to any Participant or Beneficiary in accordance with the terms of the Plan and determine the person or persons to whom such amounts will be distributed&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to allocate or delegate its powers to other persons&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">to appoint persons to carry out administrative and recordkeeping functions with respect to the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Finality of Committee Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Determinations by the Committee and any interpretation, rule, or decision adopted by the Committee under the Plan, or in carrying out or administering the Plan, will be final and binding for all purposes and upon all interested persons in the absence of clear and convincing evidence that the determination or interpretation was made arbitrarily or capriciously.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Claims Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any person making a claim for benefits under the Plan must submit the claim in writing to the Committee or its designee.  If the Committee or its designee denies the claim in whole or in part, it will issue to the claimant a written notice explaining the reasons for the denial (with specific reference to the Plan provisions on which the denial is based) and identifying any additional information or documentation that might enable the claimant to perfect the claim.  The claimant may, within 60 days of receiving a written notice of denial, submit a written request for reconsideration to the Committee or its designee, together with a written explanation of the basis for the request.  The Committee or its designee will consider any such request and will provide the claimant with a written decision, which will include a written explanation of the reasons for the decision (with reference to the specific Plan provisions on which the decision is based).  All interpretations, determinations, and decisions of the Committee with respect to any claim will be final and conclusive in the absence of clear and convincing evidence that the interpretation, determination, or decision was made arbitrarily or capriciously.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold harmless any member of the Committee, any employee or former employee to whom the Committee delegates or allocates any of the Committee&#8217;s responsibilities under the Plan, and any employee or former employee who has been asked to assist the Committee in any way (together, the &#8220;indemnified persons&#8221;) against any liability (including, without limitation, payment of attorney&#8217;s fees) that the indemnified person may incur as a result of the discharge of his or her duties and responsibilities in good faith under the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Right to Suspend Benefits and Correct Errors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent consistent with the Section 409A Standards, the Committee or its designee may delay any payment until satisfied as to the correctness of the payment or the person to receive the payment or to allow filing in any court of competent jurisdiction for a legal determination of the benefits to be paid and the person to receive them.  The Committee specifically reserves the right to correct errors of every sort, and each Participant hereby agrees, on his own behalf and on behalf of any Beneficiary, to any method of error correction specified by the Committee or its designee.  The Committee is authorized to recover any payment made in error.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Committee or its designee determines that any person entitled to benefits under the Plan is a minor, an incompetent person, or other person incapable of providing a valid receipt, then any payment due to that person may be paid for the benefit of that person to the person&#8217;s spouse, parent, or other party providing or reasonably appearing to provide for the care of that person, unless a duly qualified guardian or other legal representative has been appointed, in which case payment will be made to that guardian or legal representative.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Legal Holidays</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any day on (or on or before) which action under the Plan must be taken falls on a Saturday, Sunday, or legal holiday, that action may be taken on (or on or before) the next succeeding day that is not a Saturday, Sunday, or legal holiday&#59; provided that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Section 6.8 does not permit any action that must be taken in one calendar year to be taken in any subsequent calendar year.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Amendment or Termination of the Plan</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company hopes and expects to continue the Plan in effect, but it reserves the right to amend the Plan, by action of the Board of Directors or its designee, in any respect at any time (retroactively if the Company so provides) and to terminate the Plan.  Any amendment or termination will be set forth in a written instrument and signed by a duly authorized representative of the Company.  In the event of an amendment or termination of the Plan, a Participant&#8217;s benefits will not be less than the amount credited to the Participant&#8217;s Deferred Account immediately prior to the amendment or termination.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Miscellaneous</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Assignment or Alienation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No payee may assign any payment due him under the Plan.  No benefits at any time payable under the Plan will be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, attachment, garnishment, levy, execution, or other legal or equitable process or encumbrance of any kind.  Any attempt to alienate, sell, transfer, assign, or otherwise encumber any Plan benefit, whether payable presently or in the future, will be void.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Limitation of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the establishment nor amendment of the Plan, nor the payment of any benefits, will be construed as giving any individual any legal or equitable right against the Company or the Committee.  In no event will the Plan be deemed to constitute a contract between any individual and the Company or the Committee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Receipt and Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any payment of a benefit under the Plan to any Participant or Beneficiary will be in full satisfaction of all claims with respect to the benefit under the Plan against the Company and the Committee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Effect on Future Service as a Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in the Plan, nor any action taken under the Plan, shall be construed as giving any Participant a right to continue as a Director or require the nomination of a Participant for a future term as a Director.   </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#160;&#160;&#160;&#160;If any provision of the Plan is held by a court of competent jurisdiction to be invalid or unenforceable, the remaining provisions will remain fully enforceable.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Successor Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of the dissolution, sale, merger, consolidation, or reorganization of the Company, provision may be made by which a successor to all or a major portion of the Company will have all of the powers, duties, and responsibilities of the Company under the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Headings and Subheadings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Headings and subheadings are inserted for convenience only and are not to be considered in the construction of the provisions of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent not preempted by federal law, the Plan will be governed by, and construed and administered in accordance with, the laws of the Commonwealth of Massachusetts.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>Definitions and Rules of Construction</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As used in the Plan, the following words and phrases, when capitalized, have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;Account&#8221; means, with respect to a Participant, a bookkeeping account established for the Participant pursuant to Article 3 as a Deferred Account.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Affiliate&#8221; means (1) any corporation that is a member of a controlled group of corporations (as defined in Code section 414(b)) of which the Company is also a member, (2) any trade or business, whether or not incorporated, that is under common control (as defined in Code section 414(c)) with the Company, (3) any trade or business that is a member of an affiliated service group (as defined in Code section 414(m)) of which the Company is also a member, or (4) to the extent required by regulations issued under Code section 414(o), any other organization.  The term &#8220;Affiliate,&#8221; however, does not include any corporation or unincorporated trade or business prior to the date on which that corporation, trade, or business satisfies the affiliation or control tests of (1), (2), (3), or (4) above.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;Beneficiary&#8221; means the person or persons designated pursuant to Section 4.5 to receive benefits under the Plan in the event of a Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Board of Directors&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt"> &#8220;Cash Compensation&#8221; means, with respect to an Eligible Director for a Plan Year, the Compensation payable to the Eligible Director for the Plan Year in the form of cash as an annual retainer or committee chair fees. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;Change in Control Event&#8221; means a change in the ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, as determined in accordance with the Section 409A Standards, including &#167;1.409A-3(i)(5).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended from time to time.  Reference to a particular section of the Code includes reference to any regulations issued by the Department of Treasury under that section and any notices and other releases issued by the Internal Revenue Service interpreting or implementing that section.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Committee&#8221; means the Executive Human Resources and Compensation Committee of the Board of Directors.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;Company&#8221; means Boston Scientific Corporation.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;Company Stock&#8221; means common stock of the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Compensation&#8221; means, with respect to an Eligible Director for a Plan Year, the annual fees payable by the Company to the Eligible Director for the Plan Year, including retainer fees and committee chair fees and equity-based awards to be granted under the LTIP, for serving as a member of the Board of Directors. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;Deferred Account&#8221; means, with respect to a Participant, the Account established for the Participant pursuant to Section 3.3.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;Director&#8221; means a member of the Board of Directors. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Eligible Director&#8221; means a Director who is not an employee of the Company or any of its Affiliates.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Equity Compensation&#8221; means, with respect to an Eligible Director for a Plan Year, Compensation for the Plan Year that is payable to the Eligible Director in the form of equity-based awards under the LTIP.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;LTIP&#8221; means the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time, and any successor to that plan.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Participant&#8221; means an Eligible Director who becomes a participant in the Plan pursuant to Section 2.1 and has not ceased to be a Participant pursuant to Section 2.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;Plan&#8221; means the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as set forth in this document, as amended from time to time.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">&#8220;Plan Year&#8221; means a calendar year beginning on or after January 1, 2023. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;Restricted Stock Units or RSUs&#8221; means equity compensation awarded to a grantee in the form of notional units of Company Stock, in accordance with section 13 (Defined Terms) of the LTIP, and that are settled and paid to the grantee in the form of shares of Company Stock at the rate of one share of Company Stock for each RSU. Note that when the RSUs are deferred, they vest according to the RSU agreement applicable to the award and are settled and distributed to a Participant in shares of Company Stock in accordance with Section 4.1 following the Participant&#8217;s Separation From Service.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Restricted Stock Award&#8221; means an Award of Stock subject to forfeiture to the Company if specified conditions are not satisfied.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Section 409A Standards&#8221; means the applicable requirements and standards for nonqualified deferred compensation plans established by Code section 409A.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#8220;Separation From Service&#8221; means, with respect to a Participant, the expiration of the contract under which services are performed by the Participant for the Company and its Affiliates if the expiration constitutes a good-faith and complete termination of the Participant&#8217;s contractual relationship with the Company and all of its Affiliates within the meaning of the Section 409A Standards, including &#167;1.409A-1(h).Whether a Separation From Service has occurred will be determined in accordance with the Section 409A Standards, including &#167;1.409A-1(h).  The Committee may, but need not, elect in writing, subject to the applicable limitations under the Section 409A Standards, any of the special elective rules prescribed in &#167;1.409A-1(h) for purposes of determining whether a Separation From Service has occurred.  Any such written election will be deemed to be part of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Specified Employee&#8221; has the meaning given in Code section 409A(a)(2)(B)(i).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Rules of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following rules of construction will govern in interpreting the Plan&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Words used in the masculine gender will be construed to include the feminine gender, where appropriate, and vice versa.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Words used in the singular will be construed to include the plural, where appropriate, and vice versa.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If any provision of the Plan is held to be illegal or invalid for any reason, that provision will be deemed to be null and void, but the invalidation of that provision will not otherwise impair or affect the Plan.&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)&#160;&#160;&#160;&#160;The Plan is intended to comply with Code section 409A, and it will be construed and administered accordingly.  The provisions of the Plan and all deferral elections under Plan will be effected, construed, interpreted, and applied in a manner consistent with Section 409A Standards.  To the extent that any terms of the Plan or a deferral election would subject any Participant to gross income inclusion, interest, or additional tax pursuant to Code section 409A, those terms are to that extent superseded by the applicable Section.</font><img alt="image_06.jpg" src="image_06.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>22
<FILENAME>exhibit21-listofsubsidiari.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icabafdf0a1c4471db179de1e1b2b3a9e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">EXHIBIT 21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Structure of ownership and control&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acurate Industria e Comercio Ltda. (Brazil) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Medical Systems Europe B.V. (The Netherlands)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylis Medical UK Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAYLIS Medical (Deutschland) GmbH (Germany)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylis Medical Company Inc. (Canada)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylis Medical France S.A.R.L. (France)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylis Medical USA Inc. (Delaware) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biocompatibles UK Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biocompatibles, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific (Malaysia) Sdn. Bhd. (Malaysia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific (South Africa) Proprietary Limited (South Africa)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific (Thailand) Ltd. (Thailand)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific (UK) Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific AG (Switzerland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Argentina S.A. (Argentina)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Asia Pacific Pte. Ltd. (Singapore)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Benelux NV (Belgium)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Ceska republika s.r.o. (Czech Republic)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Chile SpA (Chile)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Clonmel Limited, in liquidation (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Colombia Limitada (Colombia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Comercial de Costa Rica BSCR, S.R.L. (Costa Rica)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Cork Limited, in liquidation (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific de Costa Rica S.R.L. (Costa Rica)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific de Mexico, S.A. de C.V. (Mexico)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific del Caribe, Inc. (Puerto Rico)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific do Brasil Ltda. (Brazil)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Far East B.V. (The Netherlands)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Gesellschaft m.b.H. (Austria)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Group plc (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Gulf for Trading (Saudi Arabia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Hellas S.A. (Greece)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Hong Kong Limited (Hong Kong)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Iberica, S.A. (Spain)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific India Private Limited (India)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific International B.V. (The Netherlands)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific International Finance Limited (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific International S.A. (France)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific International Sdn. Bhd.  (Malaysia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Ireland Limited, in liquidation (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Israel Ltd. (Israel)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Japan K.K. (Japan)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Korea Co., Ltd. (Korea)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Korea Holding Co., Ltd. (Korea)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Limited (Ireland)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific LLC (Russian Federation)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Ltd.&#47;Boston Scientifique Ltee. (Canada)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Medical Device (Malaysia) Sdn. Bhd. (Malaysia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Medical Device Limited (Ireland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Medical Technology (Shanghai) Co., Ltd. (China)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Medizintechnik GmbH (Germany)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Middle East FZ-LLC (UAE)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Middle East SAL (Offshore) (Lebanon)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Nederland B.V. (The Netherlands)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Neuromodulation Corporation (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific New Zealand Limited (New Zealand)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Nordic AB (Sweden)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Peru S.A.C. (Peru)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Philippines, Inc. (Philippines)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Polska Sp. z o.o. (Poland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Portugal - Dispositivos Medicos, Lda (Portugal)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Pty Ltd (Australia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Romania S.R.L. (Romania)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific S.A.S. (France)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific S.p.A. (Italy)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Scimed, Inc. (Minnesota)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Technology &#38; Engineering Services Private Limited (India) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific TIP Gerecleri Limited Sirketi (Turkey)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Vietnam Company Limited (Vietnam)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bravo Bidco Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BSC International Medical Trading (Shanghai) Co., Ltd. (China)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BSC Medical Device Technology (Shanghai) Co., Ltd. (China)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG IM Holdings Ltd. (Israel)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG International (Holdings) Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG International Canada Inc. (Canada)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG International Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BTG Management Services Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac Pacemakers, Inc. (Minnesota)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CeloNova BioSciences Germany GmbH, in liquidation (Germany)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DeVoro Medical Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eCardio Sequoia Blocker Corp. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Electron Acquisition Corporation (Delaware) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoChoice Holdings, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoChoice, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoChoice Israel Ltd., in liquidation (Israel) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EP Technologies, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Farapulse, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galil Medical Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galil Medical Ltd. (Israel)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Golden Woods Services, LLC (Texas)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guidant Delaware Holding Corporation (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guidant Europe NV (Belgium)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guidant Puerto Rico B.V. (The Netherlands)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hong Kong Medtech Trading Limited, in liquidation (Hong Kong)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laguna Holdco Ltd. (Israel)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis (Australia) Pty. Ltd. (Australia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis (HK) Limited (Hong Kong)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis (Italy) S.r.l. (Italy)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis (Singapore) Pte. Ltd. (Singapore)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis (UK) Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis Holdings Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis Inc. (Massachusetts)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis India Private Limited (India)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis Ltd. (Israel)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumenis Medical Laser Equipment Trading (Beijing) Co., Ltd. (China)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notebook Merger Sub, Ltd. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NXT Merger Corp. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obsidio, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preventice Services, LLC  (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preventice Solutions, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preventice Technologies, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provensis Limited (England)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PT Boston Scientific Indonesia (Indonesia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMI Acquisition Corp. (California)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert S. Smith, M.D., Inc. (Georgia)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SNS Merger Corp. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special K Merger Corp. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stream Enterprises LLC (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symetis SA (Switzerland)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target Therapeutics, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Textile Merger Sub, Inc. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zuma Investment Pty Ltd (Australia) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 Biomedical Merger Corp. (Delaware)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9357-1867 Quebec Inc. (Canada)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>23
<FILENAME>exhibit23-2022eyconsent.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i33b84d8dae1c4e98a81616a1c4aa9ce6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT 23</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Registration Statement (Form S-3 Nos. 333-262937, 333-238526, 333-76346, 333-61994, and 333-64991) of Boston Scientific Corporation,</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Registration Statement (Form S-4 Nos. 333-131608 and 333-22581) of Boston Scientific Corporation,</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Registration Statement (Form S-8 Nos. 333-25033, 333-25037, 333-36636, 333-61056, 333-61060, 333-76380, 333-98755, 333-111047, 333-131608, 333-133569, 333-134932, 333-151280, 333-174620, 333-174622, 333-188905, 333-196672, 333-241022, and 333-264754) of Boston Scientific Corporation&#59;</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of our reports dated February&#160;23, 2023, with respect to the consolidated financial statements and schedule of Boston Scientific Corporation and the effectiveness of internal control over financial reporting of Boston Scientific Corporation included in this Annual Report (Form 10-K) of Boston Scientific Corporation for the year ended December&#160;31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Boston, Massachusetts&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">February&#160;23, 2023</font></div><div><font><br></font></div><div style="margin-bottom:13pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>24
<FILENAME>exhibit311-ceo302202210xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if463d6f8cc104ecc8e10b67ba088d54e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT 31.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael F. Mahoney, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form&#160;10-K of Boston Scientific Corporation&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael F. Mahoney</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Mahoney</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>25
<FILENAME>exhibit312-cfo302202210xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idf9fae712e3f476cabc4f044d5f80cf7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT 31.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel J. Brennan, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form&#160;10-K of Boston Scientific Corporation&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel J. Brennan</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Brennan</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>26
<FILENAME>exhibit321-ceo906202210xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4d55ce17250f464d937578d287c6cb1c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT 32.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form&#160;10-K of Boston Scientific Corporation (the &#8220;Company&#8221;) for the period ending December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Report fully complies with the requirements of Section&#160;13 (a)&#160;or 15 (d)&#160;of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael F. Mahoney</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Mahoney</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>27
<FILENAME>exhibit322-cfo906202210xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9a9d0de2e8b44721b4a74f49165d120f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT 32.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form&#160;10-K of Boston Scientific Corporation (the &#8220;Company&#8221;) for the period ending December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Report fully complies with the requirements of Section&#160;13 (a)&#160;or 15 (d)&#160;of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel J. Brennan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Brennan</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_010.jpg
<TEXT>
begin 644 image_010.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_011.jpg
<TEXT>
begin 644 image_011.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_02.jpg
<TEXT>
begin 644 image_02.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_03.jpg
<TEXT>
begin 644 image_03.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_06.jpg
<TEXT>
begin 644 image_06.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "7" (    TDP1]   '&TE$051X7NW:
M,0T , S L/(GW?YCL,@^@R&S            A,P;            ^)DM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
M            4FQA            *;8P          " %%L8          !
MBBT,           @Q18&          "08@L#          !(L84!
M  "DV,(           !2;&$            IMC           ( 46Q@
M     $"*+0P          "#%%@8          )!B"P,          $BQA0$
M         *38P@           %)L80           "FV,           @!1;
M&           0(HM#           (,46!@          D&(+ P
M2+&% 0          I-C"            4FQA            *;8P
M  " %%L8          ! BBT,           @Q18&          "08@L#
M      !(L84!          "DV,(           !2;&$            IMC
M         ( 46Q@          $"*+0P          "#%%@8          )!B
M"P,          $BQA0$          *38P@           %)L80
M "FV,           @!1;&           0(HM#           (,46!@
M    D&(+ P          2+&% 0          I-C"            4FQA
M        *;8P          " %%L8          ! BBT,           @Q18&
M          "08@L#          !(L84!          "DV,(           !2
M;&$            IMC           ( 46Q@          $"*+0P
M "#%%@8          )!B"P,          $BQA0$          *38P@
M     %)L80           "FV,           @!1;&           0(HM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
M            4FQA            *;8P          " %%L8          !
MBBT,           @Q18&          "08@L#          !(L84!
M  "DV,(           !2;&$            IMC           ( 46Q@
M     $"*+0P          "#%%@8          )!B"P,          $BQA0$
M         *38P@           %)L80           "FV,           @!1;
M&           0(HM#           (,46!@          D&(+ P
M2+&% 0          I-C"            4FQA            *;8P
M  " %%L8          ! BBT,           @Q18&          "08@L#
M      !(L84!          "DV,(           !2;&$            IMC
M         ( 46Q@          $"*+0P          "#%%@8          )!B
M"P,          $BQA0$          *38P@           %)L80
M "FV,           @!1;&           0(HM#           (,46!@
M    D&(+ P          2+&% 0          I-C"            4FQA
M        *;8P          " %%L8          ! BBT,           @Q18&
M          "08@L#          !(L84!          "DV,(           !2
M;&$            IMC           ( 46Q@          $"*+0P
M "#%%@8          )!B"P,          $BQA0$          *38P@
M     %)L80           "FV,           @!1;&           0(HM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
?            4@YO?]*V9GJ<=     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_08.jpg
<TEXT>
begin 644 image_08.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_12.jpg
<TEXT>
begin 644 image_12.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_13.jpg
<TEXT>
begin 644 image_13.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>image_16.jpg
<TEXT>
begin 644 image_16.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>image_18.jpg
<TEXT>
begin 644 image_18.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>image_19.jpg
<TEXT>
begin 644 image_19.jpg
MB5!.1PT*&@H    -24A$4@  !AL   %H" (   #!PMV:   )F4E$051X7NW8
MH0T , S L/[_=,L')H7;,"=D%@    "*>0,     ?#E*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
M    T#A*     #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-
MHP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!    T#A*
M #2.$@    "-HP0   ! XR@!    T#A*     #2.$@    "-HP0   ! XR@!
G    T#A*     #2.$@    #- 8W9IP#$Q#[S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>41
<FILENAME>bsx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bsx="http://www.bostonscientific.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bostonscientific.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.bostonscientific.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.bostonscientific.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetParanthetical" roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheet Paranthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.bostonscientific.com/role/SignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandStrategicInvestments" roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments">
        <link:definition>0000011 - Disclosure - Acquisitions and Strategic Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000012 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesandFairValueMeasurements" roleURI="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements">
        <link:definition>0000013 - Disclosure - Hedging Activities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractualObligationsandCommitments" roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitments">
        <link:definition>0000014 - Disclosure - Contractual Obligations and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.bostonscientific.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation">
        <link:definition>0000016 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.bostonscientific.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.bostonscientific.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.bostonscientific.com/role/StockholdersEquity">
        <link:definition>0000019 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockInventiveandPurchasePlans" roleURI="http://www.bostonscientific.com/role/StockInventiveandPurchasePlans">
        <link:definition>0000020 - Disclosure - Stock Inventive and Purchase Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WeightedAverageSharesOutstanding" roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding">
        <link:definition>0000021 - Disclosure - Weighted Average Shares Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.bostonscientific.com/role/SegmentReporting">
        <link:definition>0000022 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.bostonscientific.com/role/Revenue">
        <link:definition>0000023 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinOtherComprehensiveIncome" roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome">
        <link:definition>0000024 - Disclosure - Changes in Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncements" roleURI="http://www.bostonscientific.com/role/NewAccountingPronouncements">
        <link:definition>0000025 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansNotes" roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes">
        <link:definition>0000026 - Disclosure - Employee Retirement Plans (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleII" roleURI="http://www.bostonscientific.com/role/ScheduleII">
        <link:definition>0000027 - Disclosure - Schedule II</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies">
        <link:definition>0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresandDisclosuresPolicies" roleURI="http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies">
        <link:definition>0000029 - Disclosure - Fair Value Measures and Disclosures (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesPolicies" roleURI="http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies">
        <link:definition>0000030 - Disclosure - Commitment and Contingencies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncementsPolicies" roleURI="http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies">
        <link:definition>0000031 - Disclosure - New Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansEmployeeRetirementPlansPolicies" roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies">
        <link:definition>0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSignificantAccountingPoliciesTables" roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesTables">
        <link:definition>0000033 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandStrategicInvestmentsTables" roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables">
        <link:definition>0000034 - Disclosure - Acquisitions and Strategic Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables">
        <link:definition>0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesandFairValueMeasurementsTables" roleURI="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables">
        <link:definition>0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractualObligationsandCommitmentsTables" roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables">
        <link:definition>0000037 - Disclosure - Contractual Obligations and Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.bostonscientific.com/role/LeasesTables">
        <link:definition>0000038 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>0000039 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.bostonscientific.com/role/IncomeTaxesTables">
        <link:definition>0000040 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentiveandPurchasePlansTables" roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables">
        <link:definition>0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WeightedAverageSharesOutstandingTables" roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables">
        <link:definition>0000042 - Disclosure - Weighted Average Shares Outstanding (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.bostonscientific.com/role/SegmentReportingTables">
        <link:definition>0000043 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.bostonscientific.com/role/RevenueTables">
        <link:definition>0000044 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinOtherComprehensiveIncomeTables" roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables">
        <link:definition>0000045 - Disclosure - Changes in Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansTables" roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansTables">
        <link:definition>0000046 - Disclosure - Employee Retirement Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails">
        <link:definition>0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandStrategicInvestmentsDetails" roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails">
        <link:definition>0000048 - Disclosure - Acquisitions and Strategic Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationDetails" roleURI="http://www.bostonscientific.com/role/ContingentConsiderationDetails">
        <link:definition>0000049 - Disclosure - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicInvestmentsDetails" roleURI="http://www.bostonscientific.com/role/StrategicInvestmentsDetails">
        <link:definition>0000050 - Disclosure - Strategic Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails">
        <link:definition>0000051 - Disclosure - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.bostonscientific.com/role/FairValueMeasurementsDetails">
        <link:definition>0000052 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractualObligationsandCommitmentsDetails" roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails">
        <link:definition>0000053 - Disclosure - Contractual Obligations and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.bostonscientific.com/role/LeasesDetails">
        <link:definition>0000054 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationDetails" roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails">
        <link:definition>0000055 - Disclosure - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsRateTable" roleURI="http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable">
        <link:definition>0000056 - Disclosure - Income Taxes (Details - Rate Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxesDetails" roleURI="http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails">
        <link:definition>0000057 - Disclosure - Income Taxes Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000058 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.bostonscientific.com/role/StockholdersEquityDetails">
        <link:definition>0000059 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentiveandPurchasePlansDetails" roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails">
        <link:definition>0000060 - Disclosure - Stock Incentive and Purchase Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WeightedAverageSharesOutstandingDetails" roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails">
        <link:definition>0000061 - Disclosure - Weighted Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.bostonscientific.com/role/SegmentReportingDetails">
        <link:definition>0000062 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.bostonscientific.com/role/RevenueDetails">
        <link:definition>0000063 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinOtherComprehensiveIncomeDetails" roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails">
        <link:definition>0000064 - Disclosure - Changes in Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansDetails" roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails">
        <link:definition>0000065 - Disclosure - Employee Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIDetails" roleURI="http://www.bostonscientific.com/role/ScheduleIIDetails">
        <link:definition>0000066 - Disclosure - Schedule II (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bsx_CovenantDomain" abstract="true" name="CovenantDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Measurementperiodmarketbasedaward" abstract="false" name="Measurementperiodmarketbasedaward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bsx_BSXReportableSegmentsMember" abstract="true" name="BSXReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" abstract="false" name="TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_MaximumLeverageRatio" abstract="false" name="MaximumLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bsx_A2021AcquisitionsMember" abstract="true" name="A2021AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_PaymentsForRoyaltyRights" abstract="false" name="PaymentsForRoyaltyRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" abstract="true" name="FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_PaymentOfContingentConsideration" abstract="false" name="PaymentOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ConsolidatedBalanceSheetParentheticalAbstract" abstract="true" name="ConsolidatedBalanceSheetParentheticalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_EuroDenominatedFactoringArrangementsMember" abstract="true" name="EuroDenominatedFactoringArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DeferredTaxAssetsDomain" abstract="true" name="DeferredTaxAssetsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_CardiacRhythmManagementMember" abstract="true" name="CardiacRhythmManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_December2027NotesMember" abstract="true" name="December2027NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_RequirementAsOfMarch312021Member" abstract="true" name="RequirementAsOfMarch312021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" abstract="false" name="ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" abstract="false" name="RangeofthetargetnumberofperformancebasedDSUsawarded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" abstract="false" name="DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_OtherIntangibleAssetsTextualsAbstract" abstract="true" name="OtherIntangibleAssetsTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_SpecialChargesMember" abstract="true" name="SpecialChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" abstract="false" name="ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_LicensingArrangementsAsset" abstract="false" name="LicensingArrangementsAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_November2019AggregateOfferingMember" abstract="true" name="November2019AggregateOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_March2034NotesMember" abstract="true" name="March2034NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_GlobalNeuromodulationNmReportingUnitMember" abstract="true" name="GlobalNeuromodulationNmReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_November2035NotesMember" abstract="true" name="November2035NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_UKPlanMember" abstract="true" name="UKPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_InternationalRetirementPlansMember" abstract="true" name="InternationalRetirementPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ForwardCurrencyContractsTimetoMaturity" abstract="false" name="ForwardCurrencyContractsTimetoMaturity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bsx_OperatingIncomeUnallocatedToSegment" abstract="false" name="OperatingIncomeUnallocatedToSegment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" abstract="false" name="DefinedBenefitPlanPlanAssetsActuarialGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" abstract="false" name="AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" abstract="false" name="SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_October2023NotesMember" abstract="true" name="October2023NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Pensionbenefitobligationbenefitspaid" abstract="false" name="Pensionbenefitobligationbenefitspaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" abstract="false" name="RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_FarapulseMember" abstract="true" name="FarapulseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SeniorNotedue2027Member" abstract="true" name="SeniorNotedue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SpecialtyPharmaceuticalsMember" abstract="true" name="SpecialtyPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_NetCurrencyExchangeGainLoss" abstract="false" name="NetCurrencyExchangeGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ActualCovenantMember" abstract="true" name="ActualCovenantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_NonCashImpactOfTransferredRoyaltyRights" abstract="false" name="NonCashImpactOfTransferredRoyaltyRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" abstract="false" name="Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_TransitionTaxPaymentRemaining" abstract="false" name="TransitionTaxPaymentRemaining" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_LicensingArrangementsLiability" abstract="false" name="LicensingArrangementsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" abstract="false" name="TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ConsolidatedBSXDomain" abstract="true" name="ConsolidatedBSXDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SupplementalBalanceSheetInformationTextualsAbstract" abstract="true" name="SupplementalBalanceSheetInformationTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" abstract="false" name="SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" abstract="false" name="GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_FederalBenefitOfUncertainTaxPositions" abstract="false" name="FederalBenefitOfUncertainTaxPositions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_DevoroMedicalIncMember" abstract="true" name="DevoroMedicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_CardiovascularMember" abstract="true" name="CardiovascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_CovenantAxis" abstract="true" name="CovenantAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" abstract="false" name="LesseeOperatingAndFinanceLeasesOptionToExtend" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bsx_TaxRateAxis" abstract="true" name="TaxRateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_PercentOfFinishedGoodsAtConsignment" abstract="false" name="PercentOfFinishedGoodsAtConsignment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_TotalAllocatedToReportableSegmentsMember" abstract="true" name="TotalAllocatedToReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ExpenseRelatedToMatchingContributions" abstract="false" name="ExpenseRelatedToMatchingContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_AcotecScientificHoldingsLimitedMember" abstract="true" name="AcotecScientificHoldingsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_TheOfferingAggregatePrincipalAmountMember" abstract="true" name="TheOfferingAggregatePrincipalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ScheduleofIncomeTaxRateReconciliationLineItems" abstract="true" name="ScheduleofIncomeTaxRateReconciliationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_PreventiceSolutionsIncMember" abstract="true" name="PreventiceSolutionsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Fairvalueofmarketbasedawards" abstract="false" name="Fairvalueofmarketbasedawards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" abstract="true" name="RequirementSixthQuarterFollowingQualifiedAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_LicensingArrangements" abstract="false" name="LicensingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" abstract="false" name="ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ForeignCurrencyDenominatedInDebtMember" abstract="true" name="ForeignCurrencyDenominatedInDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_GlobalUrologyandPelvicHealthReportingUnitMember" abstract="true" name="GlobalUrologyandPelvicHealthReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_StatementAxis" abstract="true" name="StatementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_InterventionalCardiologyTherapiesMember" abstract="true" name="InterventionalCardiologyTherapiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" abstract="false" name="BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bsx_May2022NotesMember" abstract="true" name="May2022NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_MITechCoLtdMember" abstract="true" name="MITechCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OtherInternationalPlansMember" abstract="true" name="OtherInternationalPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" abstract="false" name="EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" abstract="false" name="LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_RevenueBasedPaymentsMember" abstract="true" name="RevenueBasedPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" abstract="false" name="DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_June2025NotesMember" abstract="true" name="June2025NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_WatchmanMember" abstract="true" name="WatchmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Paymenttonetsharesettleemployeeequityawards" abstract="false" name="Paymenttonetsharesettleemployeeequityawards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_LatinAmericaandCanadaMember" abstract="true" name="LatinAmericaandCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DivestitureAgreementTransferOfFacilities" abstract="false" name="DivestitureAgreementTransferOfFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" abstract="false" name="BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bsx_UnrecognizedCompensationCost" abstract="false" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" abstract="false" name="MaturitiesOfLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_TaxIncentivesInPuertoRico" abstract="false" name="TaxIncentivesInPuertoRico" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ShareBasedCompensationNetOfTaxBenefit" abstract="false" name="ShareBasedCompensationNetOfTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ExclusionFromEbitdaForRestructuringCharges" abstract="false" name="ExclusionFromEbitdaForRestructuringCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_GlobalPeripheralInterventionsPiReportingUnitMember" abstract="true" name="GlobalPeripheralInterventionsPiReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_A2011LtipPlanMember" abstract="true" name="A2011LtipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_RDRegulatoryandCommercializationbasedMilestoneMember" abstract="true" name="RDRegulatoryandCommercializationbasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_March2028SeniorNotesMember" abstract="true" name="March2028SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_AllOther2021AcquisitionsMember" abstract="true" name="AllOther2021AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_UnrecognizedCompensationCostStockOptions" abstract="false" name="UnrecognizedCompensationCostStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" abstract="true" name="RequirementFourQuartersFollowingMaterialAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_LicensingArrangementLiabilitiesMember" abstract="true" name="LicensingArrangementLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DivestitureAgreementTransferOfGlobalEmployees" abstract="false" name="DivestitureAgreementTransferOfGlobalEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bsx_March2029NotesMember" abstract="true" name="March2029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ExecutiveRetirementPlanMember" abstract="true" name="ExecutiveRetirementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_GoodwillTextualsAbstract" abstract="true" name="GoodwillTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" abstract="true" name="RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" abstract="false" name="RangeofthetargetnumberofmarketbasedDSUsawarded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_March2031NotesMember" abstract="true" name="March2031NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" abstract="false" name="ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" abstract="false" name="RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_March2028NotesMember" abstract="true" name="March2028NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_BaylisMedicalMember" abstract="true" name="BaylisMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_USExcludingOtherNetSalesMember" abstract="true" name="USExcludingOtherNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DeemedConsolidatedEBITDA" abstract="false" name="DeemedConsolidatedEBITDA" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_IncomeTaxesAbstract" abstract="true" name="IncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_SignificantAccountingPoliciesAbstract" abstract="true" name="SignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_GlobalCardiologyReportingUnitMember" abstract="true" name="GlobalCardiologyReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_EquipmentFurnitureAndFixturesGross" abstract="false" name="EquipmentFurnitureAndFixturesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" abstract="false" name="FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" abstract="false" name="ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_A550MCPSSeriesAMember" abstract="true" name="A550MCPSSeriesAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Onetimetransactiontaxpost1986EPnetpayment" abstract="false" name="Onetimetransactiontaxpost1986EPnetpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" abstract="false" name="DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_IndemnificationAsset" abstract="false" name="IndemnificationAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" abstract="false" name="TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" abstract="true" name="RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" abstract="true" name="FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_ContingentConsiderationLiabilityProbabilityOfPayment" abstract="false" name="ContingentConsiderationLiabilityProbabilityOfPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" abstract="false" name="NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_May2025NotesMember" abstract="true" name="May2025NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_MedsurgMember" abstract="true" name="MedsurgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_LumenisLTDMember" abstract="true" name="LumenisLTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OptionsExpectedToVest" abstract="false" name="OptionsExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bsx_OperatingIncomeLossAllocatedToReportableSegments" abstract="false" name="OperatingIncomeLossAllocatedToReportableSegments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_March2049NotesMember" abstract="true" name="March2049NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" abstract="false" name="DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_RenminbiDenominatedFactoringArrangementsMember" abstract="true" name="RenminbiDenominatedFactoringArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" abstract="false" name="DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_CompensationExpensePerShareBasic" abstract="false" name="CompensationExpensePerShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_OtherOtherLongTermAssets" abstract="false" name="OtherOtherLongTermAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_StockIncentiveAndPurchasePlansAbstract" abstract="true" name="StockIncentiveAndPurchasePlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" abstract="false" name="FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_OtherNet" abstract="false" name="OtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_Nonvestedstockawardsexerciseprice" abstract="false" name="Nonvestedstockawardsexerciseprice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" abstract="false" name="DeferredTaxAssetsPrepaidonIntercompanyProfit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_CorporateExpensesincludinghedgingactivitiesMember" abstract="true" name="CorporateExpensesincludinghedgingactivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_Annualweightedaverageforfeiturerate" abstract="false" name="Annualweightedaverageforfeiturerate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_WeightedAverageRemainingVestingPeriod" abstract="false" name="WeightedAverageRemainingVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bsx_OptionsExpectedToVestWeightedAverageExercisePrice" abstract="false" name="OptionsExpectedToVestWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_March2039NotesMember" abstract="true" name="March2039NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" abstract="false" name="FairValueOfFreeCashFlowFcfPerformanceAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_January2040NotesMember" abstract="true" name="January2040NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_The2018FacilityDomain" abstract="true" name="The2018FacilityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" abstract="false" name="MarketBasedAwardsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_CompensationExpensePerShareDiluted" abstract="false" name="CompensationExpensePerShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" abstract="true" name="FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_FreeTradeZoneRegimeTaxIncentive" abstract="false" name="FreeTradeZoneRegimeTaxIncentive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_June2030NotesMember" abstract="true" name="June2030NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" abstract="true" name="RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_March2025NotesMember" abstract="true" name="March2025NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" abstract="false" name="ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" abstract="false" name="OptionsExpectedToVestWeightedAverageRemainingContractualLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bsx_InventoryStepUpAmortization" abstract="false" name="InventoryStepUpAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ElectrophysiologyEPMember" abstract="true" name="ElectrophysiologyEPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_UnrecognizedCompensationCostNonVestedStockAwards" abstract="false" name="UnrecognizedCompensationCostNonVestedStockAwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_AccruedRebatesCurrent" abstract="false" name="AccruedRebatesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_Segmentoperatingincomeaspercentageofnetsales" abstract="false" name="Segmentoperatingincomeaspercentageofnetsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" abstract="true" name="ConsolidatedCashFlowSupplementalDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" abstract="true" name="TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" abstract="true" name="FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_EmergingMarketsTotalNumberOfCountries" abstract="false" name="EmergingMarketsTotalNumberOfCountries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bsx_NewAccountingPronouncementsPolicyTextBlock" abstract="false" name="NewAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_March2024NotesMember" abstract="true" name="March2024NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_TaxRateDomain" abstract="true" name="TaxRateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_DeferredTaxLiabilitiesDomain" abstract="true" name="DeferredTaxLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OtherCurrentAssetsAbstract" abstract="true" name="OtherCurrentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvision" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" abstract="false" name="TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" abstract="false" name="ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" abstract="false" name="SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bsx_LitigationAndDebtExclusionFromEbitda" abstract="false" name="LitigationAndDebtExclusionFromEbitda" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_VotingPowerOfAllClassesOfStock" abstract="false" name="VotingPowerOfAllClassesOfStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bsx_TaxIncentivesInMalaysia" abstract="false" name="TaxIncentivesInMalaysia" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" abstract="false" name="ImpactOfForeignCurrencyFluctuationsOnNetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_YenDenominatedFactoringArrangementsMember" abstract="true" name="YenDenominatedFactoringArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ApolloEndosurgeryIncMember" abstract="true" name="ApolloEndosurgeryIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_StatementDomain" abstract="true" name="StatementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_FarapulseIncMember" abstract="true" name="FarapulseIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" abstract="false" name="CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_GlobalEndoscopyEndoReportingUnitMember" abstract="true" name="GlobalEndoscopyEndoReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_March2026NotesMember" abstract="true" name="March2026NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_ScheduleofIncomeTaxRateReconciliationTable" abstract="true" name="ScheduleofIncomeTaxRateReconciliationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" abstract="true" name="RequirementfifthquarterfollowingqualifiedacquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_LicensingArrangementAssetsMember" abstract="true" name="LicensingArrangementAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" abstract="false" name="OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" abstract="false" name="DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>42
<FILENAME>bsx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19a55217-862e-4f96-807d-85fff05cf756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19a55217-862e-4f96-807d-85fff05cf756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_046c9994-4d3e-443a-ba18-51b957c7f200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_RestructuringCharges_046c9994-4d3e-443a-ba18-51b957c7f200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_632c8701-009a-41b4-a2dc-ebf9acb422b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_632c8701-009a-41b4-a2dc-ebf9acb422b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cc2e3827-ddd7-4bf7-a467-95e38f9d1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cc2e3827-ddd7-4bf7-a467-95e38f9d1dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_60465435-e899-4cc9-8cd5-8adee0b9c12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_60465435-e899-4cc9-8cd5-8adee0b9c12a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4a98e87a-fa3f-4bee-9158-43da94fc3f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4a98e87a-fa3f-4bee-9158-43da94fc3f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_8370e32e-f323-4a72-8322-6b9f4bd186eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_RoyaltyExpense_8370e32e-f323-4a72-8322-6b9f4bd186eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f9975373-6a11-414a-9f7e-5d032fcfc733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f9975373-6a11-414a-9f7e-5d032fcfc733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_f1bece8d-c33e-4ff5-9370-fde95f688111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_LitigationSettlementExpense_f1bece8d-c33e-4ff5-9370-fde95f688111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_af0ddadc-9757-41fd-9102-2796212bf312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4dcc23b1-d075-40ac-8ff3-63ecc9f38796" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_af0ddadc-9757-41fd-9102-2796212bf312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7a4c622a-f8fd-43a3-ba47-9570ffb28a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7df733a8-9a9f-4d8e-a8c3-83756042f757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7a4c622a-f8fd-43a3-ba47-9570ffb28a08" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7df733a8-9a9f-4d8e-a8c3-83756042f757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b535b88-e9db-428e-be9c-72974316b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7a4c622a-f8fd-43a3-ba47-9570ffb28a08" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b535b88-e9db-428e-be9c-72974316b32e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1bd61275-61d7-49af-ac0a-6dd68a242e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockStock_57a3da04-533b-4426-93cb-dc2f2cf3aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1bd61275-61d7-49af-ac0a-6dd68a242e56" xlink:to="loc_us-gaap_DividendsPreferredStockStock_57a3da04-533b-4426-93cb-dc2f2cf3aaab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a239d671-8194-48d7-991a-10ed62136ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1bd61275-61d7-49af-ac0a-6dd68a242e56" xlink:to="loc_us-gaap_ProfitLoss_a239d671-8194-48d7-991a-10ed62136ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7a085b5a-8737-4d3a-86a3-339a38712aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4d759c56-ad47-41f3-9657-0e0a783541f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7a085b5a-8737-4d3a-86a3-339a38712aaa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4d759c56-ad47-41f3-9657-0e0a783541f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_507d688d-3f64-42c4-b81d-5596e3e037fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7a085b5a-8737-4d3a-86a3-339a38712aaa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_507d688d-3f64-42c4-b81d-5596e3e037fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd57b4ea-f3ea-47dd-828b-9917d6ecd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c0b86124-3c56-4518-b09a-9241d908c695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fd57b4ea-f3ea-47dd-828b-9917d6ecd5c2" xlink:to="loc_us-gaap_GrossProfit_c0b86124-3c56-4518-b09a-9241d908c695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ae44cd95-d2ed-4bdd-a6c7-e4e4c531350c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fd57b4ea-f3ea-47dd-828b-9917d6ecd5c2" xlink:to="loc_us-gaap_OperatingExpenses_ae44cd95-d2ed-4bdd-a6c7-e4e4c531350c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7726367f-ee38-48f9-b506-58be927604c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_53a7e3f0-6a5c-4b2a-add6-7abcfea86285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7726367f-ee38-48f9-b506-58be927604c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_53a7e3f0-6a5c-4b2a-add6-7abcfea86285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_618cdccc-eea2-4b3c-91e8-ae147473f122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7726367f-ee38-48f9-b506-58be927604c9" xlink:to="loc_us-gaap_InterestExpense_618cdccc-eea2-4b3c-91e8-ae147473f122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_64d8c1e9-4bf3-4a4c-8cb1-85b17a4c4774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7726367f-ee38-48f9-b506-58be927604c9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_64d8c1e9-4bf3-4a4c-8cb1-85b17a4c4774" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d189cd3a-e2ac-457b-85f7-72180a1ef4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ee7cc45f-5479-4e42-93eb-4f8f23c4017f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d189cd3a-e2ac-457b-85f7-72180a1ef4f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ee7cc45f-5479-4e42-93eb-4f8f23c4017f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_489afecd-b60b-4964-ad5d-221ba0d9c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d189cd3a-e2ac-457b-85f7-72180a1ef4f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_489afecd-b60b-4964-ad5d-221ba0d9c3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cfb55a7a-8871-4d84-99ce-7c947155a1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d189cd3a-e2ac-457b-85f7-72180a1ef4f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cfb55a7a-8871-4d84-99ce-7c947155a1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ffff48a1-050e-419b-831e-9816c6f914cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea446410-287a-4f65-91c6-0ff72f8dd9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ffff48a1-050e-419b-831e-9816c6f914cc" xlink:to="loc_us-gaap_ProfitLoss_ea446410-287a-4f65-91c6-0ff72f8dd9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_01dede7d-6055-4008-884c-34fd87b94541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ffff48a1-050e-419b-831e-9816c6f914cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_01dede7d-6055-4008-884c-34fd87b94541" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ce20d672-bf1b-45d8-98ae-e4f1039bb063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ce20d672-bf1b-45d8-98ae-e4f1039bb063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_061064e9-3c02-49e0-a58b-f6bc0d083775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_061064e9-3c02-49e0-a58b-f6bc0d083775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85107dc9-978d-4d5d-b355-5802ab451f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85107dc9-978d-4d5d-b355-5802ab451f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_80748cca-9960-4a92-94e4-5334bde14c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:to="loc_us-gaap_LiabilitiesCurrent_80748cca-9960-4a92-94e4-5334bde14c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6d6153b4-8c82-46e2-ac2b-ff4579cb62ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7439826c-63a2-4168-990c-f752893c8bbf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6d6153b4-8c82-46e2-ac2b-ff4579cb62ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c2310ff2-2760-40c3-b076-95ade75ef7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a768c091-949c-4493-ae46-4afcecab042f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c2310ff2-2760-40c3-b076-95ade75ef7cb" xlink:to="loc_us-gaap_DebtCurrent_a768c091-949c-4493-ae46-4afcecab042f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_62cecbf1-7fd6-4a2c-953c-a2d94ffd9718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c2310ff2-2760-40c3-b076-95ade75ef7cb" xlink:to="loc_us-gaap_AccountsPayableCurrent_62cecbf1-7fd6-4a2c-953c-a2d94ffd9718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_359224a3-2880-462d-b1b6-7d276d010818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c2310ff2-2760-40c3-b076-95ade75ef7cb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_359224a3-2880-462d-b1b6-7d276d010818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_38873017-da2d-4418-b4b0-ee23606b2fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c2310ff2-2760-40c3-b076-95ade75ef7cb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_38873017-da2d-4418-b4b0-ee23606b2fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_db346ad7-46c7-4585-9769-ce0c4d6520d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_db346ad7-46c7-4585-9769-ce0c4d6520d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b4f555db-9d27-4f86-8d7f-2cdc2213141f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_Goodwill_b4f555db-9d27-4f86-8d7f-2cdc2213141f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fa05eb70-8ca0-4ee3-8f97-38fae93cf693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fa05eb70-8ca0-4ee3-8f97-38fae93cf693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_05185f3f-a10f-4dd4-bc9a-919d17cb2f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_05185f3f-a10f-4dd4-bc9a-919d17cb2f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_064bdc1f-206c-4f57-ba45-6008ec5192e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_AssetsCurrent_064bdc1f-206c-4f57-ba45-6008ec5192e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8cac2d1-9ce6-4a56-90c1-39896a45a490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32f5b0ad-a9f4-4738-b920-4c5f8a62d50a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8cac2d1-9ce6-4a56-90c1-39896a45a490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_083d4da2-cafe-4505-bba1-57e256ff6c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_083d4da2-cafe-4505-bba1-57e256ff6c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0705f9cf-ecfc-446d-a6cc-816134145c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_CommonStockValue_0705f9cf-ecfc-446d-a6cc-816134145c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_dd414c44-b11b-4ae5-b68b-54e563df6818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_PreferredStockValue_dd414c44-b11b-4ae5-b68b-54e563df6818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50db397c-5bf0-45c4-8bd2-a01feb058a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50db397c-5bf0-45c4-8bd2-a01feb058a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_19d2b934-e5a4-4da6-b085-267358b48e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_19d2b934-e5a4-4da6-b085-267358b48e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_18205a90-3688-4a11-b9fb-84d8bf8501eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de5b2b6a-82f5-4f4b-8c6c-b4e452686c0e" xlink:to="loc_us-gaap_TreasuryStockValue_18205a90-3688-4a11-b9fb-84d8bf8501eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48f3d599-6fa0-49c7-9e49-7b2790f66886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48f3d599-6fa0-49c7-9e49-7b2790f66886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_22e5b701-e348-43de-b15e-1fe902e5344c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_22e5b701-e348-43de-b15e-1fe902e5344c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b416bb71-d593-4597-a58f-d3fe9b31d04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:to="loc_us-gaap_InventoryNet_b416bb71-d593-4597-a58f-d3fe9b31d04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_8c046828-7342-4492-b8ba-5315df11d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:to="loc_us-gaap_PrepaidTaxes_8c046828-7342-4492-b8ba-5315df11d7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88361945-cfe6-4f8b-9da3-76f25cbfa704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02aeaf36-5378-4099-bad3-9a0af12b2a7a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88361945-cfe6-4f8b-9da3-76f25cbfa704" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22553e55-1280-4424-ae5e-c705018b9904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_ProfitLoss_22553e55-1280-4424-ae5e-c705018b9904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3997d8dc-9577-4557-ac60-220755d5a234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3997d8dc-9577-4557-ac60-220755d5a234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d36f00ec-0b63-403d-9c67-d3346c89d2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d36f00ec-0b63-403d-9c67-d3346c89d2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f31e434d-8ce0-48d5-9cc8-f59da88c333c" xlink:href="bsx-20221231.xsd#bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f31e434d-8ce0-48d5-9cc8-f59da88c333c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_868525fb-abb9-4ad1-abe5-1b06777190f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_ShareBasedCompensation_868525fb-abb9-4ad1-abe5-1b06777190f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_27cda4dc-4e12-4bec-acfe-d5c9d314ce03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_27cda4dc-4e12-4bec-acfe-d5c9d314ce03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_e47b3461-b5c2-4a13-9f52-cbbfb0497a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_GainLossOnInvestments_e47b3461-b5c2-4a13-9f52-cbbfb0497a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f873ce41-b091-447c-97f9-16c5262a6d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f873ce41-b091-447c-97f9-16c5262a6d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InventoryStepUpAmortization_77b3ff77-3d7f-4560-a982-18268e0ddadb" xlink:href="bsx-20221231.xsd#bsx_InventoryStepUpAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_bsx_InventoryStepUpAmortization_77b3ff77-3d7f-4560-a982-18268e0ddadb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss_2b02ca12-c03d-4b5d-a3db-17a965655fd5" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_bsx_NetCurrencyExchangeGainLoss_2b02ca12-c03d-4b5d-a3db-17a965655fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherNet_d9bd67f3-0548-4690-bf8e-e0828d6d8c0f" xlink:href="bsx-20221231.xsd#bsx_OtherNet"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_bsx_OtherNet_d9bd67f3-0548-4690-bf8e-e0828d6d8c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01029eef-221c-45cd-9ebf-2608b8fd7568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01029eef-221c-45cd-9ebf-2608b8fd7568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b69f78f2-2689-440d-8008-bd0319184794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b69f78f2-2689-440d-8008-bd0319184794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_79baf4da-b858-4bbb-bf8d-75be94bea67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_79baf4da-b858-4bbb-bf8d-75be94bea67a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a1ef79fe-fca6-470a-9d54-6a70a4804d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecf74347-7a44-4125-8764-18e6b9f38792" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a1ef79fe-fca6-470a-9d54-6a70a4804d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e391452f-ba1b-41e4-8d2e-d6f200226927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e391452f-ba1b-41e4-8d2e-d6f200226927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_38b44c42-fdef-418f-ba47-3c0d3ba502d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_38b44c42-fdef-418f-ba47-3c0d3ba502d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea514b6a-94b4-4b40-b874-21eb69840b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea514b6a-94b4-4b40-b874-21eb69840b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c96ef529-c2ff-4903-b021-c95e66ee5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c96ef529-c2ff-4903-b021-c95e66ee5af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0bfb2019-a1ee-4604-9544-edb6df9807a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0bfb2019-a1ee-4604-9544-edb6df9807a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_2536383c-0a65-4e20-9f5c-952e45af964d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_2536383c-0a65-4e20-9f5c-952e45af964d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_8cb37d92-d645-420e-8a5e-cd48931c7193" xlink:href="bsx-20221231.xsd#bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7aec70c2-a0e2-4737-94f4-ed98f6e564ce" xlink:to="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_8cb37d92-d645-420e-8a5e-cd48931c7193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60d785e3-a7ec-4b6f-9458-6ebf319fa16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fcabcf33-06a3-49f6-b633-fb55ea109834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60d785e3-a7ec-4b6f-9458-6ebf319fa16a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fcabcf33-06a3-49f6-b633-fb55ea109834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e022b0de-6786-4ea6-8f70-6c8ee36c3f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60d785e3-a7ec-4b6f-9458-6ebf319fa16a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e022b0de-6786-4ea6-8f70-6c8ee36c3f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eec60aad-5745-4eb3-9596-fdd191131ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60d785e3-a7ec-4b6f-9458-6ebf319fa16a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eec60aad-5745-4eb3-9596-fdd191131ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b76f6e18-dbfd-4af3-aefc-bdcaa277ef12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60d785e3-a7ec-4b6f-9458-6ebf319fa16a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b76f6e18-dbfd-4af3-aefc-bdcaa277ef12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_af2469b4-ad7a-4fda-8a4c-7ea15573ad4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_af2469b4-ad7a-4fda-8a4c-7ea15573ad4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentsForRoyaltyRights_bf039e47-6b5e-40c1-891d-e1a7e00eea5d" xlink:href="bsx-20221231.xsd#bsx_PaymentsForRoyaltyRights"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_bsx_PaymentsForRoyaltyRights_bf039e47-6b5e-40c1-891d-e1a7e00eea5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_701694e2-5f00-44ad-aedb-56c8a754f4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_701694e2-5f00-44ad-aedb-56c8a754f4a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_a2296c1a-2449-4a5a-9b10-c931b5cf0f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_a2296c1a-2449-4a5a-9b10-c931b5cf0f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_416d01f8-9620-4e87-bb8c-5b45bb53ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_416d01f8-9620-4e87-bb8c-5b45bb53ffb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_322970d9-7886-4626-8730-53472c97b168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_322970d9-7886-4626-8730-53472c97b168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_7a238473-8a92-43fa-b390-54d4eee3306d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_7a238473-8a92-43fa-b390-54d4eee3306d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_568128b9-d949-413d-8fda-32eaa5e6bb58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_568128b9-d949-413d-8fda-32eaa5e6bb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_cc340b77-0427-4839-8f5d-da620ac22bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_cc340b77-0427-4839-8f5d-da620ac22bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_25233e0b-2e67-4f3a-91b2-22e3995b1ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_PaymentsOfDividends_25233e0b-2e67-4f3a-91b2-22e3995b1ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_750e6b4c-eb5b-41f9-92f6-54c1f2a1e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_750e6b4c-eb5b-41f9-92f6-54c1f2a1e7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_712044a9-361d-429c-9745-d7d9e90656b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_712044a9-361d-429c-9745-d7d9e90656b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74555113-8fb2-4d49-8a3e-283c34c86569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74555113-8fb2-4d49-8a3e-283c34c86569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Paymenttonetsharesettleemployeeequityawards_5b203b34-aa47-4fa1-9edf-59161851e1a0" xlink:href="bsx-20221231.xsd#bsx_Paymenttonetsharesettleemployeeequityawards"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_bsx_Paymenttonetsharesettleemployeeequityawards_5b203b34-aa47-4fa1-9edf-59161851e1a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_75f0889c-3fc8-40ef-9cc8-543b104f9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f964ea1f-0c08-43bc-aca2-1511495f3071" xlink:to="loc_us-gaap_ProceedsFromStockPlans_75f0889c-3fc8-40ef-9cc8-543b104f9bac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_5872493e-d923-45b4-88a3-5be96d1d2041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_5872493e-d923-45b4-88a3-5be96d1d2041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_23be9c07-08ad-45c9-8f8e-065ba63f4d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_23be9c07-08ad-45c9-8f8e-065ba63f4d09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_07cf2eda-1f5d-45de-9fd1-60e9e4be8857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_07cf2eda-1f5d-45de-9fd1-60e9e4be8857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4c93f924-84d6-4723-bc93-065c67b58e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4c93f924-84d6-4723-bc93-065c67b58e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_2cffe0ad-a94f-4455-ac19-2853c5f48770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_2cffe0ad-a94f-4455-ac19-2853c5f48770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_70b6fe8c-d383-46f2-8e3b-5d6afb5c3b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_c9cf0c7c-06d8-40c9-b9cb-c7caee7cb2ca" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_70b6fe8c-d383-46f2-8e3b-5d6afb5c3b12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_98a837d5-d68d-44d0-9f5f-d4229d9f9f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_8ccb6377-2b0f-452b-be49-c6ed71d99e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_98a837d5-d68d-44d0-9f5f-d4229d9f9f9c" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_8ccb6377-2b0f-452b-be49-c6ed71d99e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7a81c03b-879e-4a4f-a6a7-4621031e9399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_98a837d5-d68d-44d0-9f5f-d4229d9f9f9c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7a81c03b-879e-4a4f-a6a7-4621031e9399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3bbc48af-c703-4c93-932c-f1b558d0b5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3bbc48af-c703-4c93-932c-f1b558d0b5d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fd59965c-b117-44bb-be72-28f534c5ef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fd59965c-b117-44bb-be72-28f534c5ef4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_1ee7c1a3-7d16-4ec5-91b0-b0d47c300f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:to="loc_us-gaap_LitigationReserveCurrent_1ee7c1a3-7d16-4ec5-91b0-b0d47c300f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0874bd39-2328-4199-94da-8c96d11bf8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0874bd39-2328-4199-94da-8c96d11bf8bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AccruedRebatesCurrent_c9243277-63d0-40b0-9eb7-9ce18a9586ed" xlink:href="bsx-20221231.xsd#bsx_AccruedRebatesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_91870313-a7e6-4d61-8ec7-342aeed69a6c" xlink:to="loc_bsx_AccruedRebatesCurrent_c9243277-63d0-40b0-9eb7-9ce18a9586ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2836073b-f569-4fba-bf91-c898efa3c13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2836073b-f569-4fba-bf91-c898efa3c13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b4d8653d-84b2-48e5-840d-15a9c00985fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_us-gaap_DerivativeAssets_b4d8653d-84b2-48e5-840d-15a9c00985fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_2c858302-8126-4059-9033-3a3e00a31df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_2c858302-8126-4059-9033-3a3e00a31df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IndemnificationAsset_5355cc7d-332f-4032-b913-a9d194fd26f2" xlink:href="bsx-20221231.xsd#bsx_IndemnificationAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_bsx_IndemnificationAsset_5355cc7d-332f-4032-b913-a9d194fd26f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherOtherLongTermAssets_8b35568d-4f96-4833-aff5-52c0d95548eb" xlink:href="bsx-20221231.xsd#bsx_OtherOtherLongTermAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_bsx_OtherOtherLongTermAssets_8b35568d-4f96-4833-aff5-52c0d95548eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsAsset_2b470669-dd9e-46fd-960f-49d4a66846bf" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_bsx_LicensingArrangementsAsset_2b470669-dd9e-46fd-960f-49d4a66846bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ba38b625-3f2f-4325-932f-3ea0173e8442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_562e82a7-33aa-4f71-b906-fb637410a6b0" xlink:to="loc_us-gaap_Investments_ba38b625-3f2f-4325-932f-3ea0173e8442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3bc4214a-65d8-424f-b04e-745a5543c3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_d23d22cd-b9b1-48dd-a6ed-4c338c2de4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_3bc4214a-65d8-424f-b04e-745a5543c3c3" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_d23d22cd-b9b1-48dd-a6ed-4c338c2de4e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c1f35f71-268a-43ff-9755-bc0aa99946cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_3bc4214a-65d8-424f-b04e-745a5543c3c3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c1f35f71-268a-43ff-9755-bc0aa99946cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangements_7555eedf-aa7f-4e3f-91cd-80128547a53d" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_3bc4214a-65d8-424f-b04e-745a5543c3c3" xlink:to="loc_bsx_LicensingArrangements_7555eedf-aa7f-4e3f-91cd-80128547a53d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_38b7e74d-9179-4558-9037-ec889ae6bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_3bc4214a-65d8-424f-b04e-745a5543c3c3" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_38b7e74d-9179-4558-9037-ec889ae6bfcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_800d23ed-e253-4b8c-a25b-cc4c39ed1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b85140a3-c631-4593-87f4-68638946b0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_800d23ed-e253-4b8c-a25b-cc4c39ed1aff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b85140a3-c631-4593-87f4-68638946b0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05042333-6fd2-430a-adcf-646c816d8029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_800d23ed-e253-4b8c-a25b-cc4c39ed1aff" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05042333-6fd2-430a-adcf-646c816d8029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fb9740bb-5ab5-446a-9f0a-78abe3de22b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_13422745-8b92-487c-a26e-283cabafab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fb9740bb-5ab5-446a-9f0a-78abe3de22b7" xlink:to="loc_us-gaap_Land_13422745-8b92-487c-a26e-283cabafab2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_c9d1753c-e656-4fd9-8cd8-ce7241c9231c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fb9740bb-5ab5-446a-9f0a-78abe3de22b7" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_c9d1753c-e656-4fd9-8cd8-ce7241c9231c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EquipmentFurnitureAndFixturesGross_e430cff1-bf5a-4226-ac72-f9b3eafb7d12" xlink:href="bsx-20221231.xsd#bsx_EquipmentFurnitureAndFixturesGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fb9740bb-5ab5-446a-9f0a-78abe3de22b7" xlink:to="loc_bsx_EquipmentFurnitureAndFixturesGross_e430cff1-bf5a-4226-ac72-f9b3eafb7d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_eb0b0c8e-1836-4806-b476-ff901f587538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fb9740bb-5ab5-446a-9f0a-78abe3de22b7" xlink:to="loc_us-gaap_ConstructionInProgressGross_eb0b0c8e-1836-4806-b476-ff901f587538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_a82d3cec-8d30-469c-b0cc-5b8d4aa28363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_a82d3cec-8d30-469c-b0cc-5b8d4aa28363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_6093aa4c-6a38-445c-b782-af577a82e4db" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_bsx_LicensingArrangementsLiability_6093aa4c-6a38-445c-b782-af577a82e4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea2c568e-dc8d-4dc2-9b52-7782c0266e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea2c568e-dc8d-4dc2-9b52-7782c0266e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_69964152-46ff-4c09-847f-a61afc5619a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_us-gaap_DeferredRevenue_69964152-46ff-4c09-847f-a61afc5619a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e0a61c62-67d5-4925-8b70-45a9252648b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e0a61c62-67d5-4925-8b70-45a9252648b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_da6ca255-5cbf-4ebe-b1d2-db5e25d5339a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f53e7a47-abb3-47fe-8001-278914b17d80" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_da6ca255-5cbf-4ebe-b1d2-db5e25d5339a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#WeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_988b7f54-47a6-419f-9698-1a4cded5a387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ccdccb09-7df8-4670-8bd1-35624d662d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_988b7f54-47a6-419f-9698-1a4cded5a387" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ccdccb09-7df8-4670-8bd1-35624d662d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee24588e-55d8-43ff-9b51-e31cbc43a184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_988b7f54-47a6-419f-9698-1a4cded5a387" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee24588e-55d8-43ff-9b51-e31cbc43a184" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SegmentReportingDetails"/>
  <link:calculationLink xlink:role="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85f50b92-f1c6-45cc-b726-e44015625118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b6cdbcdf-1acc-40e8-919a-acf8bdf11c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85f50b92-f1c6-45cc-b726-e44015625118" xlink:to="loc_us-gaap_OperatingIncomeLoss_b6cdbcdf-1acc-40e8-919a-acf8bdf11c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f7e524ed-b208-4643-8af6-d2023809dce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85f50b92-f1c6-45cc-b726-e44015625118" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f7e524ed-b208-4643-8af6-d2023809dce0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>43
<FILENAME>bsx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/Cover" xlink:type="simple" xlink:href="bsx-20221231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/Cover" xlink:type="extended" id="i872023e764dd4addb503a3a0a9b74640_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2fa19cfa-eaba-41fe-bff2-16fb7310c6b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentType_2fa19cfa-eaba-41fe-bff2-16fb7310c6b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_97544216-22c4-4017-ba89-63aff119161c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentAnnualReport_97544216-22c4-4017-ba89-63aff119161c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cea6789b-2407-409e-bf28-91019af3acb1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentPeriodEndDate_cea6789b-2407-409e-bf28-91019af3acb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c4ffaafe-4e5f-442c-b717-6f3799bf270e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentTransitionReport_c4ffaafe-4e5f-442c-b717-6f3799bf270e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_21496ba2-7d6e-485e-8d9c-d467d1602b1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityFileNumber_21496ba2-7d6e-485e-8d9c-d467d1602b1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c755150f-dc7a-41dc-a940-96b550ee31cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityRegistrantName_c755150f-dc7a-41dc-a940-96b550ee31cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fbc3e724-26dd-47cf-932b-248871907a11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fbc3e724-26dd-47cf-932b-248871907a11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3d70c926-9dd2-4de6-b129-df16c2e5615b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityTaxIdentificationNumber_3d70c926-9dd2-4de6-b129-df16c2e5615b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4f491ac-466b-4740-ad20-cc2943c372ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressAddressLine1_b4f491ac-466b-4740-ad20-cc2943c372ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_24e74b86-2ee0-42d9-a846-e929e1c31903" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressCityOrTown_24e74b86-2ee0-42d9-a846-e929e1c31903" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cbe12430-249a-4f8d-b8c8-cfd426e642c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressStateOrProvince_cbe12430-249a-4f8d-b8c8-cfd426e642c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_acf766eb-67ab-41da-b928-0ab216375007" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressPostalZipCode_acf766eb-67ab-41da-b928-0ab216375007" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d10d79cc-a9a1-41d2-b957-5eff0a403760" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_CityAreaCode_d10d79cc-a9a1-41d2-b957-5eff0a403760" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1743af96-3f37-4b61-9efe-c40c2dd691c5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_LocalPhoneNumber_1743af96-3f37-4b61-9efe-c40c2dd691c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e52d07bf-4873-4245-a93a-5c66c18d11c5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_Security12bTitle_e52d07bf-4873-4245-a93a-5c66c18d11c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_478d06c2-e86b-469e-9741-011495f39aa1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_TradingSymbol_478d06c2-e86b-469e-9741-011495f39aa1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e325d22-3f41-4a28-b2c0-e5e60ea557a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_SecurityExchangeName_5e325d22-3f41-4a28-b2c0-e5e60ea557a2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_157c1135-d8d1-4be6-8fd5-61187ac153ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_157c1135-d8d1-4be6-8fd5-61187ac153ea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_35a9f9f4-e3d0-4033-b9a5-dbc1a5724228" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityVoluntaryFilers_35a9f9f4-e3d0-4033-b9a5-dbc1a5724228" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2ccf4807-069f-4d92-b400-7ec1a3887a18" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCurrentReportingStatus_2ccf4807-069f-4d92-b400-7ec1a3887a18" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7056c08c-e40e-429d-95b5-927a86863da7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityInteractiveDataCurrent_7056c08c-e40e-429d-95b5-927a86863da7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d7cd4d03-4b79-4aed-b434-f63d760b20dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityFilerCategory_d7cd4d03-4b79-4aed-b434-f63d760b20dd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_478b2267-c3f8-4bcf-baa4-571837b73e66" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntitySmallBusiness_478b2267-c3f8-4bcf-baa4-571837b73e66" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d3675ee6-6500-4c4a-a53b-86750cb8b502" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityEmergingGrowthCompany_d3675ee6-6500-4c4a-a53b-86750cb8b502" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_952ea0c8-8d1d-475c-a274-4498c6dac3cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_952ea0c8-8d1d-475c-a274-4498c6dac3cd" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fc1f9519-a81b-47f3-ab37-efb925aec135" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityShellCompany_fc1f9519-a81b-47f3-ab37-efb925aec135" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_78391a37-55f0-473e-9ede-9f182e0fb1f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityPublicFloat_78391a37-55f0-473e-9ede-9f182e0fb1f1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingParValuePerShare_c5fb9580-234f-4aee-9da4-92e5a961f709" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityListingParValuePerShare_c5fb9580-234f-4aee-9da4-92e5a961f709" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3b32de9d-7608-4014-88db-51072726ea3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3b32de9d-7608-4014-88db-51072726ea3a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49b7d812-0930-41c1-8c19-cc28c28e2e52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCentralIndexKey_49b7d812-0930-41c1-8c19-cc28c28e2e52" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fa4c00c0-a89a-4a12-991a-816757df46be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_CurrentFiscalYearEndDate_fa4c00c0-a89a-4a12-991a-816757df46be" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c674b0eb-2a91-49e4-be9f-9167588a24e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentFiscalYearFocus_c674b0eb-2a91-49e4-be9f-9167588a24e7" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e230632-8669-4c0a-a4f4-6c01db479909" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e230632-8669-4c0a-a4f4-6c01db479909" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_da3580c3-90a4-4e86-9745-fb7e43c41e14" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_AmendmentFlag_da3580c3-90a4-4e86-9745-fb7e43c41e14" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_700ce533-04cc-4e5e-9983-0d4514d027f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:to="loc_us-gaap_ClassOfStockDomain_700ce533-04cc-4e5e-9983-0d4514d027f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:to="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a7e3517-8540-4793-875f-5fac680ad9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_us-gaap_CommonStockMember_1a7e3517-8540-4793-875f-5fac680ad9e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_f67cfcc7-b10a-42cf-b897-0a8fdc422651" xlink:href="bsx-20221231.xsd#bsx_SeniorNotedue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_bsx_SeniorNotedue2027Member_f67cfcc7-b10a-42cf-b897-0a8fdc422651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_d04c8bdd-be77-4b3f-aa3d-5f5e8271c2bf" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_bsx_A550MCPSSeriesAMember_d04c8bdd-be77-4b3f-aa3d-5f5e8271c2bf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i4089073ff3394202ab8a73d1b1277650_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e89352-d5c6-4e3f-98d2-800c1cb06a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e89352-d5c6-4e3f-98d2-800c1cb06a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_496909d0-9073-4c76-8e99-0b43b6c779b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_496909d0-9073-4c76-8e99-0b43b6c779b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e5918db7-b50c-4756-9d68-bad3c0aa8775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_GrossProfit_e5918db7-b50c-4756-9d68-bad3c0aa8775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e2301f58-b053-42b4-8740-f070f45ec60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e2301f58-b053-42b4-8740-f070f45ec60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_01a195aa-a518-4a0a-8794-ade2ef3f3c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_01a195aa-a518-4a0a-8794-ade2ef3f3c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_13f0bc80-5ac9-4dbb-87bd-67df1e2a56b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_RoyaltyExpense_13f0bc80-5ac9-4dbb-87bd-67df1e2a56b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5f49cdf-884d-45ab-8f15-344c5b7e95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5f49cdf-884d-45ab-8f15-344c5b7e95e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f5487210-8f27-496d-9a23-358cd027d41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f5487210-8f27-496d-9a23-358cd027d41d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e4c4870f-dac9-4022-ac3e-a38bfbee0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e4c4870f-dac9-4022-ac3e-a38bfbee0aca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5e5c592e-4eb5-4e36-8a1a-b952b2fe7f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5e5c592e-4eb5-4e36-8a1a-b952b2fe7f97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e36aa9d4-e588-4e9b-b118-babfe636e119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_RestructuringCharges_e36aa9d4-e588-4e9b-b118-babfe636e119" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_bdeb274b-1a76-4d08-81ea-6debff11955f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_LitigationSettlementExpense_bdeb274b-1a76-4d08-81ea-6debff11955f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_2e75434d-15b1-44a6-a69f-1cbf289f271f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_2e75434d-15b1-44a6-a69f-1cbf289f271f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1fde068a-a801-4e3a-868d-64b8cf177b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_OperatingExpenses_1fde068a-a801-4e3a-868d-64b8cf177b21" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1e8fcfd-7aa1-4146-b893-8e8012f478db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1e8fcfd-7aa1-4146-b893-8e8012f478db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b38dcc10-768a-421d-90fc-f496d5f89929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:to="loc_us-gaap_InterestExpense_b38dcc10-768a-421d-90fc-f496d5f89929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6737ec-1966-4938-9d63-3a9cb9431a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6737ec-1966-4938-9d63-3a9cb9431a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ce7b6d9-08c1-4af3-afe6-b2015bcd09e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ce7b6d9-08c1-4af3-afe6-b2015bcd09e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eb36d9eb-498c-4983-9fc3-28dd8cbdbe00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eb36d9eb-498c-4983-9fc3-28dd8cbdbe00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aded3cdd-f292-4a1c-bb8e-23f8acb57476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_ProfitLoss_aded3cdd-f292-4a1c-bb8e-23f8acb57476" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockStock_01adc504-0d62-4094-bb18-701ca09a200a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_DividendsPreferredStockStock_01adc504-0d62-4094-bb18-701ca09a200a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d4f3a0e-b6aa-47a5-9673-a80a4b0bdf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d4f3a0e-b6aa-47a5-9673-a80a4b0bdf32" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f7b10251-2dfb-4a07-8774-e50186b8679c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_f7b10251-2dfb-4a07-8774-e50186b8679c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_260db8d4-a942-42a0-a051-6ffa3723f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_260db8d4-a942-42a0-a051-6ffa3723f15c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49c7580a-a2fe-49f0-a203-eb92ca1e70e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49c7580a-a2fe-49f0-a203-eb92ca1e70e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de5e7803-b27b-45df-8050-0756438161d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de5e7803-b27b-45df-8050-0756438161d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:to="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_81f44d8b-6047-4ebd-8ba1-b43cbec97af5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_81f44d8b-6047-4ebd-8ba1-b43cbec97af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b9906b04-3cb1-4687-82b6-ea7c1de7881a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b9906b04-3cb1-4687-82b6-ea7c1de7881a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="i0188c57139d84068afa248a0cc34c442_ConsolidatedStatementsofComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_72428de9-c303-4709-b65a-35244792bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_ProfitLoss_72428de9-c303-4709-b65a-35244792bf07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6fa3a936-20a6-4b53-8437-c06bb5b2a522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6fa3a936-20a6-4b53-8437-c06bb5b2a522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_021884d4-4328-4c5e-97d5-38a252aea0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_021884d4-4328-4c5e-97d5-38a252aea0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_682ac166-67fe-474a-a343-a2ece42bf1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_682ac166-67fe-474a-a343-a2ece42bf1e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e75c1179-a446-43d8-95cb-b111f9ee0143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e75c1179-a446-43d8-95cb-b111f9ee0143" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95669264-3916-4906-9c2c-818e0abf9489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95669264-3916-4906-9c2c-818e0abf9489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:to="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4a7aa7ba-f8cf-4531-8025-36d8397a9f92_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4a7aa7ba-f8cf-4531-8025-36d8397a9f92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2ee905d4-4379-4c0f-86d0-c9cb46260db9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2ee905d4-4379-4c0f-86d0-c9cb46260db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2102edb3-4bea-45d1-b6dd-cb640d709201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:to="loc_us-gaap_EquityComponentDomain_2102edb3-4bea-45d1-b6dd-cb640d709201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:to="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_97328c9c-ec23-4b4b-ac0f-16c17c472d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:to="loc_us-gaap_PreferredStockMember_97328c9c-ec23-4b4b-ac0f-16c17c472d20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i473c4cc45b3e4a52b0bd2f47826ce172_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:to="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3117c15d-943b-4737-b71e-e4348b107cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3117c15d-943b-4737-b71e-e4348b107cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8edb4136-650a-42ee-a73f-aad21efa69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8edb4136-650a-42ee-a73f-aad21efa69c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33077ad6-703b-424a-a7f0-78e4b256df26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_InventoryNet_33077ad6-703b-424a-a7f0-78e4b256df26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_93c57b83-9140-4c56-80f4-25ff1853e134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_PrepaidTaxes_93c57b83-9140-4c56-80f4-25ff1853e134" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_013d5c25-b111-4ce6-9ab1-7d832c0cff43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_013d5c25-b111-4ce6-9ab1-7d832c0cff43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c960efe7-bdd0-4942-9da1-e59b8944de83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_AssetsCurrent_c960efe7-bdd0-4942-9da1-e59b8944de83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_01139db7-f048-45fe-a673-0e6ff1002bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_01139db7-f048-45fe-a673-0e6ff1002bb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be87f23d-e4ad-4c10-8915-fbacff523e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_Goodwill_be87f23d-e4ad-4c10-8915-fbacff523e76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a4124b-d330-4588-af55-407e3ff6be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a4124b-d330-4588-af55-407e3ff6be25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d79465-d5b4-42b1-b210-30058897d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d79465-d5b4-42b1-b210-30058897d1f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5780edcd-dbc2-4cdb-a59d-4734ed516c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5780edcd-dbc2-4cdb-a59d-4734ed516c47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b134b1b1-c8a0-4f9d-9c0a-5926c180449b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_Assets_b134b1b1-c8a0-4f9d-9c0a-5926c180449b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_47c0b3ec-05ae-4f20-8b0e-e1e58345fc80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_DebtCurrent_47c0b3ec-05ae-4f20-8b0e-e1e58345fc80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4ae59ea2-32a4-4d2c-a1f3-2d80ea3177d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_AccountsPayableCurrent_4ae59ea2-32a4-4d2c-a1f3-2d80ea3177d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c75e0568-f5c0-4bde-8fcd-0944b883f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c75e0568-f5c0-4bde-8fcd-0944b883f6e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2a898d0e-e732-496f-9c8d-1f0f9807d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2a898d0e-e732-496f-9c8d-1f0f9807d48a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b80e21ba-0136-4ed9-b937-2f7dbc205608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_LiabilitiesCurrent_b80e21ba-0136-4ed9-b937-2f7dbc205608" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6df97e46-bf8e-4bfe-9d4b-0965ebae7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6df97e46-bf8e-4bfe-9d4b-0965ebae7ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_558948b8-b1b8-4090-a026-94c3a218bfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_558948b8-b1b8-4090-a026-94c3a218bfd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_17a28bd4-612d-4f17-a1f5-9b30b0f413ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_17a28bd4-612d-4f17-a1f5-9b30b0f413ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c99a13cf-0c5f-4800-a582-7264a36f1233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c99a13cf-0c5f-4800-a582-7264a36f1233" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_79ed34bd-dc2c-4180-9079-a44070d39b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_79ed34bd-dc2c-4180-9079-a44070d39b68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eace836c-997f-4392-95cb-d8449a76ff51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_PreferredStockValue_eace836c-997f-4392-95cb-d8449a76ff51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_47f4436f-3f9e-427c-9457-0d21b4913f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_CommonStockValue_47f4436f-3f9e-427c-9457-0d21b4913f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_b9b9a293-798b-4b2a-80bc-4b9026ee78fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_TreasuryStockShares_b9b9a293-798b-4b2a-80bc-4b9026ee78fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_cbe1d9a8-33bb-4982-9c5a-6e101f696e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_TreasuryStockValue_cbe1d9a8-33bb-4982-9c5a-6e101f696e88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2dc9e27-46ca-4ca7-97ba-b5d354f97305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2dc9e27-46ca-4ca7-97ba-b5d354f97305" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4e9571d-1f41-4605-9dda-3ab966cc60aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4e9571d-1f41-4605-9dda-3ab966cc60aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96b105e0-1494-4a7f-a2f7-2b52ff26664f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96b105e0-1494-4a7f-a2f7-2b52ff26664f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6af8f362-a2d3-4d52-b28a-ec06748db195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6af8f362-a2d3-4d52-b28a-ec06748db195" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a95a95a0-e464-4e51-9466-b5355e883c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a95a95a0-e464-4e51-9466-b5355e883c35" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:to="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:to="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3c3d4276-4e36-47c6-ad20-b32394a8d1de_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3c3d4276-4e36-47c6-ad20-b32394a8d1de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fad74d9c-1220-4cfa-b28a-b941f0ff80ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fad74d9c-1220-4cfa-b28a-b941f0ff80ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i6a83528c979046feae1e685510ea6d95_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1fa51e5f-50ea-48c1-9330-4d724efa1063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_SharesIssued_1fa51e5f-50ea-48c1-9330-4d724efa1063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1de0ae06-a7fd-4499-a216-fde285fd3d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1de0ae06-a7fd-4499-a216-fde285fd3d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e730455-74e0-48ce-a393-9e0a7e7d34f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e730455-74e0-48ce-a393-9e0a7e7d34f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_91bf73d3-fb5f-4cb6-8816-a16e4872a78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_91bf73d3-fb5f-4cb6-8816-a16e4872a78b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_1dd3ca6f-4083-4ebb-aafa-3b73f600e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_1dd3ca6f-4083-4ebb-aafa-3b73f600e8b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2f03f723-3a12-43bf-b0f1-3fe5fa436430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2f03f723-3a12-43bf-b0f1-3fe5fa436430" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_46e616fd-debb-4a7e-a92e-640d2c737a68" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_46e616fd-debb-4a7e-a92e-640d2c737a68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_1a1c4c41-b8cf-4b51-bd32-733c75915520" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_1a1c4c41-b8cf-4b51-bd32-733c75915520" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_0fcdda8d-b72f-4b63-8262-29a5c5f7d04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_0fcdda8d-b72f-4b63-8262-29a5c5f7d04f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9af84b71-d50e-4d2a-874a-fa441511dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_ProfitLoss_9af84b71-d50e-4d2a-874a-fa441511dd46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_a5a96896-cac9-48ce-97ca-132ecccfca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_a5a96896-cac9-48ce-97ca-132ecccfca8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_aa386104-f83a-4a7e-a450-639aef924de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_DividendsPreferredStockCash_aa386104-f83a-4a7e-a450-639aef924de8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cc10303e-760d-49ea-a8d3-e74a6950172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f61a1bb6-d49f-4c77-98e7-59661f6640be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f61a1bb6-d49f-4c77-98e7-59661f6640be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_adbe3617-e748-4b02-9c62-f80bbdfd2131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_adbe3617-e748-4b02-9c62-f80bbdfd2131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15a23d82-94f2-47e2-ad06-f008fb6ccd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15a23d82-94f2-47e2-ad06-f008fb6ccd90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a099a683-96c6-4dfd-bfa3-711eb052a8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_98ff9ec5-140a-455b-9b11-7e1d02800644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:to="loc_us-gaap_CommonStockSharesIssued_98ff9ec5-140a-455b-9b11-7e1d02800644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:to="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a123c495-4dc4-4f10-a4a8-f9b08cf31758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:to="loc_us-gaap_EquityComponentDomain_a123c495-4dc4-4f10-a4a8-f9b08cf31758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:to="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f5d20bab-3b6d-4d20-ae56-987029358e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_PreferredStockMember_f5d20bab-3b6d-4d20-ae56-987029358e29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4fa55762-44c1-4763-94cd-8f6a018b30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_CommonStockMember_4fa55762-44c1-4763-94cd-8f6a018b30ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ca7e4470-e911-4b86-9267-2548d3b37d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_TreasuryStockMember_ca7e4470-e911-4b86-9267-2548d3b37d81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d7763075-85c9-4fd6-b133-25b724c6cb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d7763075-85c9-4fd6-b133-25b724c6cb4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c60e485-2f4f-4882-bcdf-d6492058e69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_RetainedEarningsMember_3c60e485-2f4f-4882-bcdf-d6492058e69f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb2fe21d-508b-4120-8d1c-9e652ffeaa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb2fe21d-508b-4120-8d1c-9e652ffeaa5f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="ie42b83cd361d49acb1c8a67b8f08ceed_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c98ed823-ea93-44b5-a7ab-7f72d6bc0079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ProfitLoss_c98ed823-ea93-44b5-a7ab-7f72d6bc0079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0756af16-c12d-47be-94d7-0dfa092e75bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0756af16-c12d-47be-94d7-0dfa092e75bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c7b08ebe-9312-4c44-ad9f-9ae77abf3142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c7b08ebe-9312-4c44-ad9f-9ae77abf3142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f1e29765-ebf2-4d98-a3ae-9f09601aadc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f1e29765-ebf2-4d98-a3ae-9f09601aadc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f5208dc1-a75f-4d9c-b4d2-89320bbd21cb" xlink:href="bsx-20221231.xsd#bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f5208dc1-a75f-4d9c-b4d2-89320bbd21cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4fec8429-4901-42f8-afe8-83cc6811d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ShareBasedCompensation_4fec8429-4901-42f8-afe8-83cc6811d8c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0ee177bc-b623-4471-b564-09f95223a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0ee177bc-b623-4471-b564-09f95223a356" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b1c7bea0-203d-4d05-a49b-bc2c985b1f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_GainLossOnInvestments_b1c7bea0-203d-4d05-a49b-bc2c985b1f95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f466cc0e-8a13-4caf-861a-f814d2fa6d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f466cc0e-8a13-4caf-861a-f814d2fa6d5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InventoryStepUpAmortization_9ea4d4a9-5382-48ec-ac09-6e901c8a0bf3" xlink:href="bsx-20221231.xsd#bsx_InventoryStepUpAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_InventoryStepUpAmortization_9ea4d4a9-5382-48ec-ac09-6e901c8a0bf3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss_5a5e52b8-3d12-4d4d-9b1e-7dbde83dc6d0" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_NetCurrencyExchangeGainLoss_5a5e52b8-3d12-4d4d-9b1e-7dbde83dc6d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherNet_fe89538a-8747-4e1b-99bb-c1e5dfeab4e1" xlink:href="bsx-20221231.xsd#bsx_OtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_OtherNet_fe89538a-8747-4e1b-99bb-c1e5dfeab4e1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f92318f5-1f56-432c-9b7b-d72f47877523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f92318f5-1f56-432c-9b7b-d72f47877523" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad2d937b-ec2c-483c-9465-59675333e6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad2d937b-ec2c-483c-9465-59675333e6f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_285f1aba-4cd8-4efb-8058-ef922d306862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_285f1aba-4cd8-4efb-8058-ef922d306862" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1e585a4b-1556-40ae-ae1f-6a6f8d779943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1e585a4b-1556-40ae-ae1f-6a6f8d779943" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5b9a6c-47f9-4e5e-9d99-9bbe5c965430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5b9a6c-47f9-4e5e-9d99-9bbe5c965430" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4e7d607-3a02-4ee4-a9b7-4617b9330e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4e7d607-3a02-4ee4-a9b7-4617b9330e61" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31898e1a-5d43-401e-a9c6-382ce0800c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31898e1a-5d43-401e-a9c6-382ce0800c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_165b1ebc-600b-4aae-8d34-73218aa8da57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_165b1ebc-600b-4aae-8d34-73218aa8da57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e56dd7db-0112-4cd5-bc86-94e763fddab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e56dd7db-0112-4cd5-bc86-94e763fddab1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c183cd45-b617-490e-b5df-a727ce042061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c183cd45-b617-490e-b5df-a727ce042061" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_569be753-806a-49d0-8867-9c1f03ebe5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_569be753-806a-49d0-8867-9c1f03ebe5b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_58f87556-a194-4135-9f54-f0bb150c2280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_58f87556-a194-4135-9f54-f0bb150c2280" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_21904d0c-c96e-45cf-98ae-60c336fe0adb" xlink:href="bsx-20221231.xsd#bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_21904d0c-c96e-45cf-98ae-60c336fe0adb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b719f27-d28c-427e-add4-f9696400f110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b719f27-d28c-427e-add4-f9696400f110" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bf81123-105c-4350-9ad8-b4c7f32fa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bf81123-105c-4350-9ad8-b4c7f32fa31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentsForRoyaltyRights_3e21e2cf-0747-4cf6-93ef-e05314b81da6" xlink:href="bsx-20221231.xsd#bsx_PaymentsForRoyaltyRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_bsx_PaymentsForRoyaltyRights_3e21e2cf-0747-4cf6-93ef-e05314b81da6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_f2adef11-1991-4a0e-981a-6533f90c6b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_f2adef11-1991-4a0e-981a-6533f90c6b40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_88bc8846-b967-4991-8261-2055ff13b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_88bc8846-b967-4991-8261-2055ff13b0aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_5b65889a-5b04-4fd9-b366-e4378a12d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_5b65889a-5b04-4fd9-b366-e4378a12d0e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_926e021d-65ba-48d6-8b7e-1845ea034647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_926e021d-65ba-48d6-8b7e-1845ea034647" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a9341e92-9209-4e50-92d2-42628b7d3cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a9341e92-9209-4e50-92d2-42628b7d3cb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_324f21ec-6288-40e8-a771-6001cf82a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_324f21ec-6288-40e8-a771-6001cf82a3c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b24d48e7-9a41-4a27-bf06-6637677ee520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b24d48e7-9a41-4a27-bf06-6637677ee520" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_33165262-4a58-46aa-84a8-4973c8db3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentsOfDividends_33165262-4a58-46aa-84a8-4973c8db3dec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_036329ba-713c-4aee-a9c3-ad5db4cc0b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_036329ba-713c-4aee-a9c3-ad5db4cc0b1e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4e00c5b-4f65-489f-b228-16777a3cbfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4e00c5b-4f65-489f-b228-16777a3cbfc2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7af0d0aa-598c-46e3-b1ed-5ad5b06a2a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7af0d0aa-598c-46e3-b1ed-5ad5b06a2a5e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Paymenttonetsharesettleemployeeequityawards_3491b8cf-04a4-4dda-9221-9e2b2301ad6a" xlink:href="bsx-20221231.xsd#bsx_Paymenttonetsharesettleemployeeequityawards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_bsx_Paymenttonetsharesettleemployeeequityawards_3491b8cf-04a4-4dda-9221-9e2b2301ad6a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a317bb39-e06f-4659-a13a-4e40faeb0ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a317bb39-e06f-4659-a13a-4e40faeb0ac5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e343c936-8beb-4788-a8cd-0f9801ae2827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e343c936-8beb-4788-a8cd-0f9801ae2827" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9bc5dbf-aa20-4d31-80a5-acd0bbb89632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9bc5dbf-aa20-4d31-80a5-acd0bbb89632" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4860e7b2-fa1c-4bf5-b98a-4c4c79c77797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4860e7b2-fa1c-4bf5-b98a-4c4c79c77797" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_205df94f-6e70-462f-bc17-0fc85dc44887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_205df94f-6e70-462f-bc17-0fc85dc44887" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f4df1b-4af2-4452-a8a6-18f44ac865ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_53e82a9d-879f-4045-baee-c7230f99f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_IncomeTaxesPaid_53e82a9d-879f-4045-baee-c7230f99f1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_91e9cbf4-813f-4b68-9801-3f51d90dd769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_InterestPaidNet_91e9cbf4-813f-4b68-9801-3f51d90dd769" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_88f640fd-2e85-4be1-a4a3-810cb96d1ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_88f640fd-2e85-4be1-a4a3-810cb96d1ce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NonCashImpactOfTransferredRoyaltyRights_63985ee4-5c15-475b-b90b-968e83301643" xlink:href="bsx-20221231.xsd#bsx_NonCashImpactOfTransferredRoyaltyRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_bsx_NonCashImpactOfTransferredRoyaltyRights_63985ee4-5c15-475b-b90b-968e83301643" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:to="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7e8397b0-29fb-4e78-8597-b986778d4fdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7e8397b0-29fb-4e78-8597-b986778d4fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5ca73b61-a491-4fcf-8a3f-6bef2477f5dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5ca73b61-a491-4fcf-8a3f-6bef2477f5dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" xlink:type="extended" id="i67eac9ece17642738598889f26a04e76_ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38f5cdf7-65f1-48aa-8feb-bc1bc3030484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38f5cdf7-65f1-48aa-8feb-bc1bc3030484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_028b6af4-78ad-48d0-a1b5-f9e56ec1a8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_028b6af4-78ad-48d0-a1b5-f9e56ec1a8ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_c40355ca-eda5-4b1f-84c2-094dd3bb314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_c40355ca-eda5-4b1f-84c2-094dd3bb314a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bfcc1de-3736-40f6-a35b-080825ab15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bfcc1de-3736-40f6-a35b-080825ab15b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:href="bsx-20221231.xsd#bsx_StatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:to="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementDomain_445d57f4-f013-47f5-b9b7-087812bb1a14_default" xlink:href="bsx-20221231.xsd#bsx_StatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:to="loc_bsx_StatementDomain_445d57f4-f013-47f5-b9b7-087812bb1a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementDomain_e6acf33c-745e-448f-884c-1a7fcc38e512" xlink:href="bsx-20221231.xsd#bsx_StatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:to="loc_bsx_StatementDomain_e6acf33c-745e-448f-884c-1a7fcc38e512" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansEmployeeRetirementPlansPolicies"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" xlink:type="extended" id="i6326f0addcd84a3aac36a4f0aa9b04dc_EmployeeRetirementPlansEmployeeRetirementPlansPolicies">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_0ef9c861-8d04-48bb-b96a-3ad2c11a075b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_0ef9c861-8d04-48bb-b96a-3ad2c11a075b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2ce90c05-e355-4536-83dc-0b7bf23b2f9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2ce90c05-e355-4536-83dc-0b7bf23b2f9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExecutiveRetirementPlanMember_12d6c909-a5cf-45f3-b16f-cdc9a3ee1d94" xlink:href="bsx-20221231.xsd#bsx_ExecutiveRetirementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:to="loc_bsx_ExecutiveRetirementPlanMember_12d6c909-a5cf-45f3-b16f-cdc9a3ee1d94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InternationalRetirementPlansMember_1d35b374-b3ba-4255-ae35-f1c994340206" xlink:href="bsx-20221231.xsd#bsx_InternationalRetirementPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:to="loc_bsx_InternationalRetirementPlansMember_1d35b374-b3ba-4255-ae35-f1c994340206" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#AcquisitionsandStrategicInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" xlink:type="extended" id="i84b6530efa2f4abe80aaaa9de9edfab2_AcquisitionsandStrategicInvestmentsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0b4aa011-7541-4b3e-af35-d862487b3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0b4aa011-7541-4b3e-af35-d862487b3d5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb179aa-69e0-411a-87fc-fd7e62f292eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb179aa-69e0-411a-87fc-fd7e62f292eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_efcf456f-181f-43f3-a11f-7fca53d75377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_efcf456f-181f-43f3-a11f-7fca53d75377" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d7f7ec9f-7588-4563-b45f-b1195f8eb14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d7f7ec9f-7588-4563-b45f-b1195f8eb14f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c0246380-831c-4718-a770-51792e19693f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c0246380-831c-4718-a770-51792e19693f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_0c30a710-0180-4c33-b834-0fafad89bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_0c30a710-0180-4c33-b834-0fafad89bab1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85fe7779-708f-47ab-b42f-93ae03ec17fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85fe7779-708f-47ab-b42f-93ae03ec17fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BaylisMedicalMember_02f81f2f-98e2-46b4-b1c9-a4afc36caace" xlink:href="bsx-20221231.xsd#bsx_BaylisMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_BaylisMedicalMember_02f81f2f-98e2-46b4-b1c9-a4afc36caace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PreventiceSolutionsIncMember_312134f4-cb21-4972-90f0-cd79ec074874" xlink:href="bsx-20221231.xsd#bsx_PreventiceSolutionsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_PreventiceSolutionsIncMember_312134f4-cb21-4972-90f0-cd79ec074874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LumenisLTDMember_dc7620d4-8910-4fd9-a9d8-b6c6111cc741" xlink:href="bsx-20221231.xsd#bsx_LumenisLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_LumenisLTDMember_dc7620d4-8910-4fd9-a9d8-b6c6111cc741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AllOther2021AcquisitionsMember_3aa69bcf-e976-430e-a19e-4907eb00ce66" xlink:href="bsx-20221231.xsd#bsx_AllOther2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_AllOther2021AcquisitionsMember_3aa69bcf-e976-430e-a19e-4907eb00ce66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_150eef28-5cd6-410f-9a04-e4c44b74eccf" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_A2021AcquisitionsMember_150eef28-5cd6-410f-9a04-e4c44b74eccf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ddc8f471-af59-4b00-aefe-6854dff92676_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ddc8f471-af59-4b00-aefe-6854dff92676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78baa7cb-a381-4f07-808d-8a6d0af1e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78baa7cb-a381-4f07-808d-8a6d0af1e03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:to="loc_srt_OwnershipDomain_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7f899c44-3de9-47e9-9c5b-2f6eb7b48407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:to="loc_srt_OwnershipDomain_7f899c44-3de9-47e9-9c5b-2f6eb7b48407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_db61b8be-20ab-4abf-bd89-806ff8fa92de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:to="loc_us-gaap_ClassOfStockDomain_db61b8be-20ab-4abf-bd89-806ff8fa92de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68a735f4-9a7f-44f4-a8c2-e4aab1daaa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:to="loc_us-gaap_ClassOfStockDomain_68a735f4-9a7f-44f4-a8c2-e4aab1daaa46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#HedgingActivitiesandFairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" xlink:type="extended" id="i4bfb2ea6707d4847b16c83a1eb48150e_HedgingActivitiesandFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ea25ec37-5ab9-402d-b13a-50718fcc0a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ea25ec37-5ab9-402d-b13a-50718fcc0a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ee7bf9ae-b01d-42cd-a694-d67d39f45c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ee7bf9ae-b01d-42cd-a694-d67d39f45c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_ca11fd27-8e06-44a6-b812-13d0056401b3" xlink:href="bsx-20221231.xsd#bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_ca11fd27-8e06-44a6-b812-13d0056401b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3350731d-affa-4ced-a247-f30f2656bfed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3350731d-affa-4ced-a247-f30f2656bfed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1cdaaa0a-e87c-4daa-9927-05cca10f5d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1cdaaa0a-e87c-4daa-9927-05cca10f5d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b85ddfd-f990-4e4a-b701-5545216dec92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b85ddfd-f990-4e4a-b701-5545216dec92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5b84fd0-1f35-41d1-8f61-db2906187e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5b84fd0-1f35-41d1-8f61-db2906187e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9695f34f-4ffc-4a2e-95ea-c7b8bb02e2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9695f34f-4ffc-4a2e-95ea-c7b8bb02e2ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5076dc07-208b-4365-a978-e3cc6f5b7cb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5076dc07-208b-4365-a978-e3cc6f5b7cb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_70fb0252-3814-40a1-af98-e21f680e4d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_70fb0252-3814-40a1-af98-e21f680e4d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87ac129a-d195-448f-8f98-a14c711911eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87ac129a-d195-448f-8f98-a14c711911eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3792f14e-0ec8-40b4-9d80-3512eac23d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3792f14e-0ec8-40b4-9d80-3512eac23d3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitmentsTables"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" xlink:type="extended" id="ie4127a2fa7ea4adf84d3bbead5b2ff93_ContractualObligationsandCommitmentsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_0e43f44f-1bcd-436f-83f5-2140b4522c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_0e43f44f-1bcd-436f-83f5-2140b4522c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_487a9187-5c1d-436e-9852-bce9292af759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_487a9187-5c1d-436e-9852-bce9292af759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b79a9662-e495-47c5-b66f-e51365eee0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:to="loc_us-gaap_CommercialPaperMember_b79a9662-e495-47c5-b66f-e51365eee0a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:to="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bacb0c5d-573e-4fad-8086-c37a2476c4e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bacb0c5d-573e-4fad-8086-c37a2476c4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5b023131-b7e1-464b-98c7-0a8db3b05b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5b023131-b7e1-464b-98c7-0a8db3b05b16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockIncentiveandPurchasePlansTables"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" xlink:type="extended" id="i77a98abe8cf643bf975beff00143431d_StockIncentiveandPurchasePlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_c2c39201-e9a1-45f1-bcac-b362f42bff89" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_c2c39201-e9a1-45f1-bcac-b362f42bff89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_72710261-06e1-4304-899a-95570b0d9976_default" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_72710261-06e1-4304-899a-95570b0d9976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_1a4b8855-5baf-4091-ae50-c1c3fec04fc7" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_1a4b8855-5baf-4091-ae50-c1c3fec04fc7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" xlink:type="extended" id="if3a7b9881b764c0da41ff3632a83b659_SignificantAccountingPoliciesSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae492473-e4dd-48c2-868d-c14696101d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae492473-e4dd-48c2-868d-c14696101d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_6d9e45ff-9576-4106-8c77-7b95373857ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_6d9e45ff-9576-4106-8c77-7b95373857ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_12f69618-cbeb-4c1a-bc03-ed1ddf010962" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_bsx_PaymentOfContingentConsideration_12f69618-cbeb-4c1a-bc03-ed1ddf010962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_98f95466-2d8a-4cd7-a28a-579a14a69989_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:to="loc_us-gaap_TypeOfAdoptionMember_98f95466-2d8a-4cd7-a28a-579a14a69989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8254b17-7be6-4238-ab6d-3533db848911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8254b17-7be6-4238-ab6d-3533db848911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20bf424b-5e2b-40b1-8500-bade42740d29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20bf424b-5e2b-40b1-8500-bade42740d29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fa0ad33f-20d7-4b58-b212-537e3b97ee37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fa0ad33f-20d7-4b58-b212-537e3b97ee37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eb61281-2673-423c-8dcd-cf7c7b189242_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:to="loc_srt_RangeMember_4eb61281-2673-423c-8dcd-cf7c7b189242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:to="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8b10abd1-44b0-4638-a7f1-36eb15660015" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:to="loc_srt_MinimumMember_8b10abd1-44b0-4638-a7f1-36eb15660015" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79a2811e-e704-441f-9e0d-fdd1e908d582" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:to="loc_srt_MaximumMember_79a2811e-e704-441f-9e0d-fdd1e908d582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376b8de3-608a-42ef-a9cb-9e2b9c51280b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376b8de3-608a-42ef-a9cb-9e2b9c51280b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_72a47484-87ef-4027-9ed4-9c37d9cf8dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:to="loc_us-gaap_PatentsMember_72a47484-87ef-4027-9ed4-9c37d9cf8dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0af12fdd-af71-4653-95e3-8a638f27c743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0af12fdd-af71-4653-95e3-8a638f27c743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29e73f73-4fcd-463c-8af7-1eb87c837445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29e73f73-4fcd-463c-8af7-1eb87c837445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73b259a7-3d9a-4b46-9785-0a3b41b92e96_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:to="loc_srt_ProductsAndServicesDomain_73b259a7-3d9a-4b46-9785-0a3b41b92e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2914dfd3-db97-4fa7-b7c9-900567bde69b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:to="loc_srt_ProductsAndServicesDomain_2914dfd3-db97-4fa7-b7c9-900567bde69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6c55f64-932d-455b-9279-eb051e3f1815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6c55f64-932d-455b-9279-eb051e3f1815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseMember_eaa26aa6-bde3-4642-83e7-4035b4089e9e" xlink:href="bsx-20221231.xsd#bsx_FarapulseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:to="loc_bsx_FarapulseMember_eaa26aa6-bde3-4642-83e7-4035b4089e9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#AcquisitionsandStrategicInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" xlink:type="extended" id="id7e4587027ae4a86afe33e9fd1eef29f_AcquisitionsandStrategicInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_379d7a9e-eb33-4248-8ef6-c17c54029cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_379d7a9e-eb33-4248-8ef6-c17c54029cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_62d99a7a-ca5d-48dd-b4b3-b930c46feff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_62d99a7a-ca5d-48dd-b4b3-b930c46feff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_581516ed-6d8e-41a7-b0c6-3af09df1bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_581516ed-6d8e-41a7-b0c6-3af09df1bfc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_20f78d18-ac19-4308-a90f-71e7c6bd4755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_20f78d18-ac19-4308-a90f-71e7c6bd4755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d0899a5a-4b5b-467a-9e25-8b306c3190d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d0899a5a-4b5b-467a-9e25-8b306c3190d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92cfda20-8322-43df-a848-a629dfd8bca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_Goodwill_92cfda20-8322-43df-a848-a629dfd8bca4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_894f4262-2134-4a88-afab-39eb4dfbd6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_894f4262-2134-4a88-afab-39eb4dfbd6a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5b74cd6c-da00-4562-afd8-91b946cc6f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5b74cd6c-da00-4562-afd8-91b946cc6f14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_acc28336-54d3-4466-a3f8-871a951d5007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_acc28336-54d3-4466-a3f8-871a951d5007" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d563c03b-401b-4f4d-b3c0-6e0b1fb4f418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d563c03b-401b-4f4d-b3c0-6e0b1fb4f418" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4609e520-fd75-462b-ac46-19ec52aa6820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4609e520-fd75-462b-ac46-19ec52aa6820" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_2e9ff88b-bcef-438a-8bc8-552965fbebba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_2e9ff88b-bcef-438a-8bc8-552965fbebba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_406e2e5c-38e9-43cf-a9d9-d969558dfacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_406e2e5c-38e9-43cf-a9d9-d969558dfacc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ca0e6e81-3e69-4ea6-a8de-4cc79d0a9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ca0e6e81-3e69-4ea6-a8de-4cc79d0a9ec3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_8dfd8a55-afd8-4f25-8800-67c63fcc2f4d" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DiscountRateFairValueInput_8dfd8a55-afd8-4f25-8800-67c63fcc2f4d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_db186915-949f-4982-8684-4d07f44c8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_db186915-949f-4982-8684-4d07f44c8f37" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_050cb774-ab85-435f-89cd-d64ec1fde1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_050cb774-ab85-435f-89cd-d64ec1fde1a7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bd33f87d-be58-45b1-84fb-6ca9d6abac28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bd33f87d-be58-45b1-84fb-6ca9d6abac28" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_122c1bd1-3e83-4bf0-8d1d-eda3cd3208f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_da16c466-5aef-459b-92b7-bade3e05f21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_da16c466-5aef-459b-92b7-bade3e05f21d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_567f0b3f-74c6-4338-844b-28ea4c5ad396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_567f0b3f-74c6-4338-844b-28ea4c5ad396" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfFacilities_ecd63699-8fa6-4314-afb5-4fcb871670f5" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DivestitureAgreementTransferOfFacilities_ecd63699-8fa6-4314-afb5-4fcb871670f5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees_3c3ac2ad-92d5-4b9b-a77c-9277760b3c6f" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfGlobalEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees_3c3ac2ad-92d5-4b9b-a77c-9277760b3c6f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1f8d9ba0-bd34-4119-8122-4d05805334eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1f8d9ba0-bd34-4119-8122-4d05805334eb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3622961c-1813-4f95-87bb-246feef36046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3622961c-1813-4f95-87bb-246feef36046" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_355012d5-70fd-48bb-ad83-a494dba7af5d" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_355012d5-70fd-48bb-ad83-a494dba7af5d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_99578679-1e8c-4dc0-bf98-7706bca58141" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_99578679-1e8c-4dc0-bf98-7706bca58141" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f6c7d9d5-9d19-4b92-a7fc-ccf231e59857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f6c7d9d5-9d19-4b92-a7fc-ccf231e59857" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_fc0aaabe-7bbe-47d9-87e2-0f5b2f61b2c1" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_fc0aaabe-7bbe-47d9-87e2-0f5b2f61b2c1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_c9cef704-4942-47ee-a36b-2dc6f3878b03" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_PaymentOfContingentConsideration_c9cef704-4942-47ee-a36b-2dc6f3878b03" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d487f90-ab8e-4fcc-b534-14eb61629504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d487f90-ab8e-4fcc-b534-14eb61629504" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_6aa4a5bb-f799-485b-a4c0-b145b557ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_6aa4a5bb-f799-485b-a4c0-b145b557ebff" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_65892b11-21c4-4bb8-a0e7-073d1697ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_65892b11-21c4-4bb8-a0e7-073d1697ddaf" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_c8d3c644-347f-4482-8c3e-c072cb32182d" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PreventiceSolutionsIncMember_f9fab30c-6842-4230-9234-ef1cfe4c56e9" xlink:href="bsx-20221231.xsd#bsx_PreventiceSolutionsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_PreventiceSolutionsIncMember_f9fab30c-6842-4230-9234-ef1cfe4c56e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseIncMember_2b85cf87-0624-4d7a-8e85-590d06de0371" xlink:href="bsx-20221231.xsd#bsx_FarapulseIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_FarapulseIncMember_2b85cf87-0624-4d7a-8e85-590d06de0371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LumenisLTDMember_36378f91-9af3-4c50-9445-a1912f281f6d" xlink:href="bsx-20221231.xsd#bsx_LumenisLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_LumenisLTDMember_36378f91-9af3-4c50-9445-a1912f281f6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DevoroMedicalIncMember_cbd528e6-8133-4193-a5fa-74cd3dce1e09" xlink:href="bsx-20221231.xsd#bsx_DevoroMedicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_DevoroMedicalIncMember_cbd528e6-8133-4193-a5fa-74cd3dce1e09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AllOther2021AcquisitionsMember_a6c5788b-c596-4ab9-9af0-e0e0f3802a44" xlink:href="bsx-20221231.xsd#bsx_AllOther2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_AllOther2021AcquisitionsMember_a6c5788b-c596-4ab9-9af0-e0e0f3802a44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_3b6801e4-c5d7-426b-b395-7bd3715be15d" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_A2021AcquisitionsMember_3b6801e4-c5d7-426b-b395-7bd3715be15d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BaylisMedicalMember_844e3dac-539f-4ef0-bfc1-68a4feb0db62" xlink:href="bsx-20221231.xsd#bsx_BaylisMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_BaylisMedicalMember_844e3dac-539f-4ef0-bfc1-68a4feb0db62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MITechCoLtdMember_80e1437d-b96e-4b20-ba5d-f4d51f3fa10d" xlink:href="bsx-20221231.xsd#bsx_MITechCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_MITechCoLtdMember_80e1437d-b96e-4b20-ba5d-f4d51f3fa10d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AcotecScientificHoldingsLimitedMember_f5bd88d9-476b-469e-b28b-fb11d07bd4b1" xlink:href="bsx-20221231.xsd#bsx_AcotecScientificHoldingsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_AcotecScientificHoldingsLimitedMember_f5bd88d9-476b-469e-b28b-fb11d07bd4b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ApolloEndosurgeryIncMember_33ef9744-f66d-4085-89a9-df14211a31c4" xlink:href="bsx-20221231.xsd#bsx_ApolloEndosurgeryIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_ApolloEndosurgeryIncMember_33ef9744-f66d-4085-89a9-df14211a31c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseMember_b0d6a315-0fb1-45aa-b16f-f872557f73ed" xlink:href="bsx-20221231.xsd#bsx_FarapulseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_FarapulseMember_b0d6a315-0fb1-45aa-b16f-f872557f73ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d01f5ca6-e6af-47a7-83d2-29f3700cfcba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d01f5ca6-e6af-47a7-83d2-29f3700cfcba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6b45c0b0-b71c-4a51-bd3b-496c1d2718f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6b45c0b0-b71c-4a51-bd3b-496c1d2718f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_82480db4-1ce2-418f-9a02-663f0b37e2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_82480db4-1ce2-418f-9a02-663f0b37e2dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e8809d88-1503-46fe-8078-f55c08a87d30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e8809d88-1503-46fe-8078-f55c08a87d30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e243ae0d-b3ed-4211-b331-38a41f782dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e243ae0d-b3ed-4211-b331-38a41f782dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_570d50bf-1f06-4041-bd0c-9f8eb7f10291_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:to="loc_srt_RangeMember_570d50bf-1f06-4041-bd0c-9f8eb7f10291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:to="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_8a1a21b4-11fd-4814-a559-445150b36918" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_WeightedAverageMember_8a1a21b4-11fd-4814-a559-445150b36918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ebacc8ac-ea5f-44d6-aeab-05472ac3169c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_MinimumMember_ebacc8ac-ea5f-44d6-aeab-05472ac3169c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ec4a02a-06e5-4f76-ae67-d605c5cdae26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_MaximumMember_5ec4a02a-06e5-4f76-ae67-d605c5cdae26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_876a84c9-c53d-459d-aba7-ce5655de8889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:to="loc_us-gaap_SegmentDomain_876a84c9-c53d-459d-aba7-ce5655de8889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:to="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_1fc7db78-6555-4633-bfbb-76440816a759" xlink:href="bsx-20221231.xsd#bsx_GlobalPeripheralInterventionsPiReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:to="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_1fc7db78-6555-4633-bfbb-76440816a759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_254df9b4-e128-4009-9e7b-af40d313804a" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_254df9b4-e128-4009-9e7b-af40d313804a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d80611e9-efdb-4df1-805c-5e1995983e1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d80611e9-efdb-4df1-805c-5e1995983e1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda8a1f6-4e23-406a-abad-2097e88ee84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:to="loc_us-gaap_SubsequentEventMember_dda8a1f6-4e23-406a-abad-2097e88ee84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_84db0298-f298-4e1c-b11c-4e7e5dd57804_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_84db0298-f298-4e1c-b11c-4e7e5dd57804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_baa9167b-2ff5-4914-bbd1-866cce5a0f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_baa9167b-2ff5-4914-bbd1-866cce5a0f9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bd0bcb02-e4f5-48f4-8b66-077598fcf46d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bd0bcb02-e4f5-48f4-8b66-077598fcf46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_928b8621-d6b6-44f0-97c4-06b73f2865ae" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_928b8621-d6b6-44f0-97c4-06b73f2865ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContingentConsiderationDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ContingentConsiderationDetails" xlink:type="extended" id="i9f28e8bb00814347ac0afee04b577013_ContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f92e1d07-aa9b-43cd-8e60-1b805078a236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f92e1d07-aa9b-43cd-8e60-1b805078a236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_9431404d-c925-4323-9f88-b35bd6054c39" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_bsx_PaymentOfContingentConsideration_9431404d-c925-4323-9f88-b35bd6054c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4a5bda7-97a3-46eb-87a6-0f4d1f57daec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4a5bda7-97a3-46eb-87a6-0f4d1f57daec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_39104f1d-fb10-4b0f-a58f-7b415b79e673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_39104f1d-fb10-4b0f-a58f-7b415b79e673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_91b4e77b-daa5-4c2a-950d-d80d09b36386" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_91b4e77b-daa5-4c2a-950d-d80d09b36386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_075284fe-e38f-4726-a8d2-f6331f40d1bc" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_bsx_DiscountRateFairValueInput_075284fe-e38f-4726-a8d2-f6331f40d1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2dd44be6-8286-4ba2-83bd-6fd6778b6a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2dd44be6-8286-4ba2-83bd-6fd6778b6a8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_480e72c9-6803-4798-a3bc-86e1601ef684" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_480e72c9-6803-4798-a3bc-86e1601ef684" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da40495b-43b2-4cb1-b578-fb3ec3f1c83f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:to="loc_srt_RangeMember_da40495b-43b2-4cb1-b578-fb3ec3f1c83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:to="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_518259b8-dce6-4e08-8766-24b276ea8396" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_MinimumMember_518259b8-dce6-4e08-8766-24b276ea8396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_614f69ab-565c-4d19-8708-675a5db211e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_MaximumMember_614f69ab-565c-4d19-8708-675a5db211e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4923e597-033e-4468-926f-669136789b32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_WeightedAverageMember_4923e597-033e-4468-926f-669136789b32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7c94bdb9-34da-4255-b64b-ec3b01365e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7c94bdb9-34da-4255-b64b-ec3b01365e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf936c6f-afba-45aa-a237-03c3ac67f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf936c6f-afba-45aa-a237-03c3ac67f3e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_6be12a71-bb94-45da-bbc3-87bea81f64ce" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:to="loc_bsx_A2021AcquisitionsMember_6be12a71-bb94-45da-bbc3-87bea81f64ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseIncMember_9fd970f3-a6a2-4dc8-97c6-91ff496f368a" xlink:href="bsx-20221231.xsd#bsx_FarapulseIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:to="loc_bsx_FarapulseIncMember_9fd970f3-a6a2-4dc8-97c6-91ff496f368a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_df69ef6d-507b-4d49-9740-4f554a49ed86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_df69ef6d-507b-4d49-9740-4f554a49ed86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_5f57c957-4fe0-46c4-b1d5-8449c9832228" xlink:href="bsx-20221231.xsd#bsx_RDRegulatoryandCommercializationbasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:to="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_5f57c957-4fe0-46c4-b1d5-8449c9832228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenueBasedPaymentsMember_2393b54b-39b1-45d8-bb80-c38a26db6230" xlink:href="bsx-20221231.xsd#bsx_RevenueBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:to="loc_bsx_RevenueBasedPaymentsMember_2393b54b-39b1-45d8-bb80-c38a26db6230" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StrategicInvestmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StrategicInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/StrategicInvestmentsDetails" xlink:type="extended" id="i80dcd57877bb4aa09d6df47e6a1efc77_StrategicInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_be7a0047-77eb-4a22-bac6-4967a2b09872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_be7a0047-77eb-4a22-bac6-4967a2b09872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_358ef465-1066-4379-8200-97d3279e3cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquityMethodInvestments_358ef465-1066-4379-8200-97d3279e3cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_233ac754-be9a-4d34-b6e2-2abe01ddefbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_233ac754-be9a-4d34-b6e2-2abe01ddefbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f3fbcbee-5c99-4765-b190-450adc01dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f3fbcbee-5c99-4765-b190-450adc01dd10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3828142c-61c9-4241-bf54-3f0e28af725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3828142c-61c9-4241-bf54-3f0e28af725f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_22c83f01-9f6d-4a8f-b6f3-c49af72d72d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_Investments_22c83f01-9f6d-4a8f-b6f3-c49af72d72d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_c9452824-b9a7-42a6-bbea-5a276d1e468f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_466fd70f-7a91-4970-8f37-5ba12f35e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_466fd70f-7a91-4970-8f37-5ba12f35e34c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_04c25c28-77c7-42a5-b073-a0603e5ebfca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_04c25c28-77c7-42a5-b073-a0603e5ebfca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_06f8104d-25c4-44d3-a47e-d032cffd2ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:to="loc_us-gaap_SubsequentEventMember_06f8104d-25c4-44d3-a47e-d032cffd2ec9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#GoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" xlink:type="extended" id="i7ef77563dad14164b6f8217535964ed3_GoodwillandOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50469f2-18a2-4a1f-8e38-e2fe8104fb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50469f2-18a2-4a1f-8e38-e2fe8104fb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52feaea6-bdca-4b0e-b220-376c32fab641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52feaea6-bdca-4b0e-b220-376c32fab641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_0d23bacd-758c-4dc7-a4db-de76ab766029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_GoodwillGross_0d23bacd-758c-4dc7-a4db-de76ab766029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cfbd56d4-b54f-4603-b299-c76d4d7075ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cfbd56d4-b54f-4603-b299-c76d4d7075ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9f3ef63c-1f88-4043-9810-dece6bb95186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9f3ef63c-1f88-4043-9810-dece6bb95186" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb780c42-b264-4190-b06b-8aa2e8a8ad95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb780c42-b264-4190-b06b-8aa2e8a8ad95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:href="bsx-20221231.xsd#bsx_GoodwillTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_edba825b-b347-46dc-aad9-977c80e5fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_Goodwill_edba825b-b347-46dc-aad9-977c80e5fd19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_bc6430fa-99df-4b8e-a4b8-162d5e56965f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_bc6430fa-99df-4b8e-a4b8-162d5e56965f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3c8f3d3e-e653-4521-8933-64d9282e67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3c8f3d3e-e653-4521-8933-64d9282e67d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2749a524-cd8f-4af6-a299-273c558c26d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2749a524-cd8f-4af6-a299-273c558c26d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:href="bsx-20221231.xsd#bsx_OtherIntangibleAssetsTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d7b330fe-793f-416a-b421-0ba827c10d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d7b330fe-793f-416a-b421-0ba827c10d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82dcd8c8-5906-4c8b-a4d9-5bcb2383334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82dcd8c8-5906-4c8b-a4d9-5bcb2383334c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c497239d-3971-4312-ab2b-7d9957f05d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c497239d-3971-4312-ab2b-7d9957f05d2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_62e8a992-7978-4cc4-be8c-776fe8fadf59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_62e8a992-7978-4cc4-be8c-776fe8fadf59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3228e6f4-eb6e-4f85-8073-53a3f23baac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3228e6f4-eb6e-4f85-8073-53a3f23baac6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_150f3dd5-3f7a-45f7-84df-330617fee4f8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:to="loc_srt_RangeMember_150f3dd5-3f7a-45f7-84df-330617fee4f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:to="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_375ceb37-4b26-4cb2-897f-d02697af306f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:to="loc_srt_MinimumMember_375ceb37-4b26-4cb2-897f-d02697af306f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_492cbf0f-0424-4951-839f-2a3ec365c872" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:to="loc_srt_MaximumMember_492cbf0f-0424-4951-839f-2a3ec365c872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57c7ce72-0098-4255-9909-f76876389039_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57c7ce72-0098-4255-9909-f76876389039_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b18a0f2a-5534-4335-8594-68b02b075074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b18a0f2a-5534-4335-8594-68b02b075074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_55ee4102-c402-4624-8fdd-81a78091de56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_PatentsMember_55ee4102-c402-4624-8fdd-81a78091de56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5f3d1a26-5b1d-466f-9978-0c7c1553ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5f3d1a26-5b1d-466f-9978-0c7c1553ddc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d54daf1-d279-4251-8a81-a14d1f1889f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d54daf1-d279-4251-8a81-a14d1f1889f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1a228452-7f6a-4ef0-a544-cfd40ea00508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1a228452-7f6a-4ef0-a544-cfd40ea00508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_43b4d594-24dd-434e-9102-9f159124542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_43b4d594-24dd-434e-9102-9f159124542c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:to="loc_us-gaap_SegmentDomain_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:to="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_15390995-da45-4c80-961d-41cfac282d04" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_MedsurgMember_15390995-da45-4c80-961d-41cfac282d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_0a488773-4332-4195-926a-575c171a8b92" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_CardiovascularMember_0a488773-4332-4195-926a-575c171a8b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_a0237d50-66e3-4c8b-8646-5ae64b490736" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_a0237d50-66e3-4c8b-8646-5ae64b490736" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i2c2a796a90d2425485d18547cb1f8470_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_99b66b87-414a-4a68-8602-9602c629e9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_LongTermDebt_99b66b87-414a-4a68-8602-9602c629e9a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07df48cd-50cc-4a67-98e3-d5505ce8b854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07df48cd-50cc-4a67-98e3-d5505ce8b854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7d23df2e-5b1f-4810-9f54-bda3550b7fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7d23df2e-5b1f-4810-9f54-bda3550b7fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_286b024b-a61f-445c-a23c-883114507928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_286b024b-a61f-445c-a23c-883114507928" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0cf18167-5692-4c51-9e6a-49b36f6f6468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0cf18167-5692-4c51-9e6a-49b36f6f6468" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForwardCurrencyContractsTimetoMaturity_9ffea805-c782-45d1-ba8f-af1996ef0a09" xlink:href="bsx-20221231.xsd#bsx_ForwardCurrencyContractsTimetoMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_ForwardCurrencyContractsTimetoMaturity_9ffea805-c782-45d1-ba8f-af1996ef0a09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_029f8438-37b3-4ca6-8915-92c583d7c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_029f8438-37b3-4ca6-8915-92c583d7c4e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_0068b5d5-f903-4bca-bd57-51334e8dd742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_0068b5d5-f903-4bca-bd57-51334e8dd742" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_979dfd5f-0b8d-4ead-ad64-ddc2ca118651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_979dfd5f-0b8d-4ead-ad64-ddc2ca118651" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_129af048-1553-4fcb-a36c-7645b7334bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_129af048-1553-4fcb-a36c-7645b7334bba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_215bee60-ffe8-433d-aa70-aba2f5172d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_215bee60-ffe8-433d-aa70-aba2f5172d3a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_79c78de0-170f-49d1-a880-a2f3270c4c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_79c78de0-170f-49d1-a880-a2f3270c4c69" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cde92e33-75b5-44e6-b75f-ea8feecaa4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cde92e33-75b5-44e6-b75f-ea8feecaa4ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_34d16478-3c55-43a1-b983-382e433432fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_34d16478-3c55-43a1-b983-382e433432fc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_f984ef3f-551f-463a-8370-b0bf715187c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_f984ef3f-551f-463a-8370-b0bf715187c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_9c7975c3-6587-4f3c-81ea-45448018c8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_9c7975c3-6587-4f3c-81ea-45448018c8f7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b4f36be0-90fd-40df-8d9e-f37c3a1b4a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_InterestExpense_b4f36be0-90fd-40df-8d9e-f37c3a1b4a7a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f83dd074-d0c3-41b3-a3ee-4e6e68f558e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f83dd074-d0c3-41b3-a3ee-4e6e68f558e3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_5e6f03f8-90b4-4cd3-85de-879c6c6f518f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_5e6f03f8-90b4-4cd3-85de-879c6c6f518f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_ad8da73e-7939-42f2-82ed-70eed32ebcbf" xlink:href="bsx-20221231.xsd#bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_ad8da73e-7939-42f2-82ed-70eed32ebcbf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_d068fac3-53dd-4c10-ada9-1c16fba0d4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_d068fac3-53dd-4c10-ada9-1c16fba0d4d4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e066f0c7-c786-4b16-a9f6-a28bd21929de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e066f0c7-c786-4b16-a9f6-a28bd21929de" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_2b0af565-3122-43fb-9b5a-7f73343e88d5" xlink:href="bsx-20221231.xsd#bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_2b0af565-3122-43fb-9b5a-7f73343e88d5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_6cbec087-a9c1-4f2c-ba1e-76dd0bfd5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_6cbec087-a9c1-4f2c-ba1e-76dd0bfd5b18" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a752b9d-ecea-46d9-a5f4-7a55784fe944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a752b9d-ecea-46d9-a5f4-7a55784fe944" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_1064f941-719b-4671-bab6-d2e0d241c3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_1064f941-719b-4671-bab6-d2e0d241c3eb" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_a3c9fb4f-90bb-4685-8167-f2440606f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_a3c9fb4f-90bb-4685-8167-f2440606f94f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2642b8df-1674-48e6-8208-97be2da08be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2642b8df-1674-48e6-8208-97be2da08be3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_34be2ed1-29ee-4463-b1a7-d92f1e3c95d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_34be2ed1-29ee-4463-b1a7-d92f1e3c95d9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_f9f6417a-9bae-45d2-b8b6-57481169c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_f9f6417a-9bae-45d2-b8b6-57481169c10f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e8854dd4-13e0-4bd6-b043-3916c49ad918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e8854dd4-13e0-4bd6-b043-3916c49ad918" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a2c3f82-db64-4e13-892b-6c90a769b841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss_2b5a6d87-6495-4037-8983-0c9c0737fc0f" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_NetCurrencyExchangeGainLoss_2b5a6d87-6495-4037-8983-0c9c0737fc0f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2ecf1ecd-d80a-49f7-bde2-29154c1d521b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2ecf1ecd-d80a-49f7-bde2-29154c1d521b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c0e7171d-7b5f-4d26-abad-743bc6c231ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:to="loc_us-gaap_CashFlowHedgingMember_c0e7171d-7b5f-4d26-abad-743bc6c231ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0adb7a1e-f6b7-4b07-a3ee-9c95bbc521d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0adb7a1e-f6b7-4b07-a3ee-9c95bbc521d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cbfeb893-30af-4289-af77-d0b784a2025d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:to="loc_us-gaap_HedgingDesignationDomain_cbfeb893-30af-4289-af77-d0b784a2025d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:to="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ae242c62-bc7d-4fde-ad81-9238055f637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ae242c62-bc7d-4fde-ad81-9238055f637b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5b2e6408-b97c-4b09-bd64-a31fd67dd56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:to="loc_us-gaap_NondesignatedMember_5b2e6408-b97c-4b09-bd64-a31fd67dd56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c9101073-6539-4e99-9402-8beba7ed2ebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c9101073-6539-4e99-9402-8beba7ed2ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0eabf21d-1466-47fb-8a1c-1bf0877a08a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0eabf21d-1466-47fb-8a1c-1bf0877a08a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_880584e3-580d-4b75-8af7-5e1abfe39e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_880584e3-580d-4b75-8af7-5e1abfe39e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_74d22e2a-c06d-41bf-b873-92ff34e6f974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_InterestRateContractMember_74d22e2a-c06d-41bf-b873-92ff34e6f974" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForeignCurrencyDenominatedInDebtMember_dde15418-8c68-45fa-953b-d55acf21d8fd" xlink:href="bsx-20221231.xsd#bsx_ForeignCurrencyDenominatedInDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_bsx_ForeignCurrencyDenominatedInDebtMember_dde15418-8c68-45fa-953b-d55acf21d8fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60ea8e77-4df4-445f-8e27-07d322ad3b53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60ea8e77-4df4-445f-8e27-07d322ad3b53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MITechCoLtdMember_9874b564-f4a6-462b-a998-2a8c3f01e90b" xlink:href="bsx-20221231.xsd#bsx_MITechCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:to="loc_bsx_MITechCoLtdMember_9874b564-f4a6-462b-a998-2a8c3f01e90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2f2cdc9b-1a79-41cb-8e03-2391570e659d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2f2cdc9b-1a79-41cb-8e03-2391570e659d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2019AggregateOfferingMember_865698de-d96a-4c0c-96ba-6996ce846a60" xlink:href="bsx-20221231.xsd#bsx_November2019AggregateOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:to="loc_bsx_November2019AggregateOfferingMember_865698de-d96a-4c0c-96ba-6996ce846a60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_December2027NotesMember_b8a0f82c-85d8-44a3-b203-1260c28a6e8a" xlink:href="bsx-20221231.xsd#bsx_December2027NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:to="loc_bsx_December2027NotesMember_b8a0f82c-85d8-44a3-b203-1260c28a6e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_01db2b59-c0e5-420a-9644-1ce6e1c55f36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_01db2b59-c0e5-420a-9644-1ce6e1c55f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementAssetsMember_9307113a-1125-4da5-b82d-ac477a7ff292" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_bsx_LicensingArrangementAssetsMember_9307113a-1125-4da5-b82d-ac477a7ff292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d5ffb4d8-5440-4db9-b813-931a673cc0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d5ffb4d8-5440-4db9-b813-931a673cc0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_715aa988-38d5-4927-b225-31a6e760040c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_715aa988-38d5-4927-b225-31a6e760040c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_511a7ec4-8586-4988-a6f2-ec33988d09d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_511a7ec4-8586-4988-a6f2-ec33988d09d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c6a6f2d2-b7d0-4a7a-b1bc-bd61124d7958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c6a6f2d2-b7d0-4a7a-b1bc-bd61124d7958" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8cdbf86a-56e6-48c7-8301-2f3d01cfe731_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8cdbf86a-56e6-48c7-8301-2f3d01cfe731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_31d782ee-65e3-4fef-8f00-5dc8b415ac03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_CostOfSalesMember_31d782ee-65e3-4fef-8f00-5dc8b415ac03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_275ab737-e6c3-4406-92b3-233924ec77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_InterestExpenseMember_275ab737-e6c3-4406-92b3-233924ec77b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_027a10f2-d474-4446-9e66-7054e7b6c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_027a10f2-d474-4446-9e66-7054e7b6c74e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_78307279-f30a-4c74-93a6-a119a4e87eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_78307279-f30a-4c74-93a6-a119a4e87eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_882c0237-4bb9-42fd-9b4d-1f5bcf92f896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_882c0237-4bb9-42fd-9b4d-1f5bcf92f896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e30f2ef0-4e37-41ff-ba96-9105a676c441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DerivativeAssets_e30f2ef0-4e37-41ff-ba96-9105a676c441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsAsset_05c528ed-6eca-498a-aed3-8b62dc8351a3" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_LicensingArrangementsAsset_05c528ed-6eca-498a-aed3-8b62dc8351a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_613518f2-d943-4e98-ac71-9f4d78590816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_613518f2-d943-4e98-ac71-9f4d78590816" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7fc3a2c7-9a9d-4a3a-a68a-7bb9e76f4f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DerivativeLiabilities_7fc3a2c7-9a9d-4a3a-a68a-7bb9e76f4f7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e9a9b4e6-d759-4198-bec0-e64512266563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e9a9b4e6-d759-4198-bec0-e64512266563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_e3b9411d-cf82-4d7e-96c2-662d1aafa541" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_LicensingArrangementsLiability_e3b9411d-cf82-4d7e-96c2-662d1aafa541" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40c8d8c4-c859-4f51-ae0b-0ca0a1e820ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40c8d8c4-c859-4f51-ae0b-0ca0a1e820ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_74af562b-1f58-44c4-8861-39f24e2db619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_Cash_74af562b-1f58-44c4-8861-39f24e2db619" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_1678e567-2d65-4b73-9a18-0996df25ca2b" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_DiscountRateFairValueInput_1678e567-2d65-4b73-9a18-0996df25ca2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_c5043174-c48d-4a49-8ea1-6e92d5bde0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_c5043174-c48d-4a49-8ea1-6e92d5bde0f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_c8f97a92-2180-4c61-afe9-1b20467f8bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_PaymentsForRoyalties_c8f97a92-2180-4c61-afe9-1b20467f8bfb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_2a7c394f-5bdc-45a8-983c-7a78c4dd8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_2a7c394f-5bdc-45a8-983c-7a78c4dd8d11" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2032ff43-51db-459d-aa3c-e18ec8335a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2032ff43-51db-459d-aa3c-e18ec8335a40" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_272c6287-1382-4e2b-b519-c8fa659ac5e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:to="loc_srt_RangeMember_272c6287-1382-4e2b-b519-c8fa659ac5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:to="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a8d085db-976d-423f-91dd-0c90df2f94ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_WeightedAverageMember_a8d085db-976d-423f-91dd-0c90df2f94ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06f7324c-cf5b-49b6-bdb9-5914354a3b28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_MinimumMember_06f7324c-cf5b-49b6-bdb9-5914354a3b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9220ea03-19be-4ac5-93b3-dd00ee936b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_MaximumMember_9220ea03-19be-4ac5-93b3-dd00ee936b0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94a8f7ec-08c6-45ac-a266-818e79cacfb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94a8f7ec-08c6-45ac-a266-818e79cacfb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48dc1da5-3a4e-4f19-ad34-1c44d8cfb7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48dc1da5-3a4e-4f19-ad34-1c44d8cfb7e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_128d9288-9619-4ba4-983c-e3fd88ccaeac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_128d9288-9619-4ba4-983c-e3fd88ccaeac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d4d3da09-e58d-4bf5-9799-d6eaa0b6927c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d4d3da09-e58d-4bf5-9799-d6eaa0b6927c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8fc66b1d-7796-4ded-ae8d-f1487b0c40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8fc66b1d-7796-4ded-ae8d-f1487b0c40fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_352e0311-04f3-4523-87dc-76a47d25ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_352e0311-04f3-4523-87dc-76a47d25ffb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08b8e2af-b8f6-4c75-9e78-ef12f2273d74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08b8e2af-b8f6-4c75-9e78-ef12f2273d74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementAssetsMember_d784a701-5899-4143-8bc6-f13d51846d6e" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:to="loc_bsx_LicensingArrangementAssetsMember_d784a701-5899-4143-8bc6-f13d51846d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementLiabilitiesMember_aab1e07c-0fd1-4663-8955-37e478a56c01" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:to="loc_bsx_LicensingArrangementLiabilitiesMember_aab1e07c-0fd1-4663-8955-37e478a56c01" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="extended" id="id91c1b88a6c34f2683048bc15e047dd5_ContractualObligationsandCommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_3549a3dc-eed2-406f-8101-39729a1cf112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_3549a3dc-eed2-406f-8101-39729a1cf112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f69bde84-cd86-4bb0-b1af-84f3d81c3e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtCurrent_f69bde84-cd86-4bb0-b1af-84f3d81c3e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a19e09c5-7c26-449e-8e06-e0898548b324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a19e09c5-7c26-449e-8e06-e0898548b324" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_55f1a468-cc1e-4ba6-9f24-1538c069e548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_55f1a468-cc1e-4ba6-9f24-1538c069e548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_025cbc19-5045-417e-b66e-9e305c84f360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_025cbc19-5045-417e-b66e-9e305c84f360" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1097243d-77e3-42f0-a847-182b61171f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1097243d-77e3-42f0-a847-182b61171f60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MaximumLeverageRatio_c22bc277-165b-48b4-9b70-4cf32eef4297" xlink:href="bsx-20221231.xsd#bsx_MaximumLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_MaximumLeverageRatio_c22bc277-165b-48b4-9b70-4cf32eef4297" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeemedConsolidatedEBITDA_c696889e-7b39-40e7-a60d-beb067c641ae" xlink:href="bsx-20221231.xsd#bsx_DeemedConsolidatedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_DeemedConsolidatedEBITDA_c696889e-7b39-40e7-a60d-beb067c641ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExclusionFromEbitdaForRestructuringCharges_79339a3e-6a64-4780-9d23-915b06d26ab2" xlink:href="bsx-20221231.xsd#bsx_ExclusionFromEbitdaForRestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_ExclusionFromEbitdaForRestructuringCharges_79339a3e-6a64-4780-9d23-915b06d26ab2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_73738e27-b0e7-4725-9789-66e866b0ca5a" xlink:href="bsx-20221231.xsd#bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_73738e27-b0e7-4725-9789-66e866b0ca5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LitigationAndDebtExclusionFromEbitda_6c990e1f-7b3e-4618-b28d-5278ae59cf72" xlink:href="bsx-20221231.xsd#bsx_LitigationAndDebtExclusionFromEbitda"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_LitigationAndDebtExclusionFromEbitda_6c990e1f-7b3e-4618-b28d-5278ae59cf72" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_85957bc9-46cd-4821-8a0f-2b18b820bd26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_85957bc9-46cd-4821-8a0f-2b18b820bd26" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_8e7d0ed0-6c88-4ccd-b762-751f129f356b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_8e7d0ed0-6c88-4ccd-b762-751f129f356b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_161fe4ba-cd41-4603-9f71-31c3c9f5caff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_161fe4ba-cd41-4603-9f71-31c3c9f5caff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_53806f91-ad91-4a59-9510-93376b8d00bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebt_53806f91-ad91-4a59-9510-93376b8d00bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_16825e33-cf68-485e-ac06-39e5535e283f" xlink:href="bsx-20221231.xsd#bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_16825e33-cf68-485e-ac06-39e5535e283f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d63d91a1-c29f-470b-a85f-53e8b3d454b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d63d91a1-c29f-470b-a85f-53e8b3d454b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_2174e24f-66c8-4f57-9ae1-be13817d375d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_2174e24f-66c8-4f57-9ae1-be13817d375d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_95c472a5-f69d-4740-8775-a3e224ac216a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_95c472a5-f69d-4740-8775-a3e224ac216a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_1d9ca80a-0824-422a-8802-719082276240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_1d9ca80a-0824-422a-8802-719082276240" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_ce7ad826-ac23-46f2-a310-60025042958c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_ce7ad826-ac23-46f2-a310-60025042958c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_f2358eba-733c-4181-8753-7f82837a5549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_f2358eba-733c-4181-8753-7f82837a5549" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6b5416d6-8ce2-4864-8009-c5033710e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligation_6b5416d6-8ce2-4864-8009-c5033710e7ca" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d9f975e1-c6f3-474c-b684-4d4fd4f7ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d9f975e1-c6f3-474c-b684-4d4fd4f7ad94" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_41960fd4-1bc8-4843-bed2-d557fb9ddb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ShortTermBorrowings_41960fd4-1bc8-4843-bed2-d557fb9ddb67" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_12ce5aba-5bbb-4c2f-b77d-d15350176775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_12ce5aba-5bbb-4c2f-b77d-d15350176775" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_882aeafd-656e-4036-b995-ddf15ff79bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_882aeafd-656e-4036-b995-ddf15ff79bba" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_de4385c0-f72f-4c54-9af9-0019ca32b008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_de4385c0-f72f-4c54-9af9-0019ca32b008" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_774b6f30-3063-4c41-90b6-5b19ad4a6ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_774b6f30-3063-4c41-90b6-5b19ad4a6ab7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_bbbee0af-72a4-411f-a291-036147813c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_bbbee0af-72a4-411f-a291-036147813c35" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_d816a274-44c0-4377-ba27-306659f3b187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_d816a274-44c0-4377-ba27-306659f3b187" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_5bdd4c48-28be-4aaf-b27e-96658b2fa912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_5bdd4c48-28be-4aaf-b27e-96658b2fa912" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14808d5a-b47c-4e85-b673-bbeafb62c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14808d5a-b47c-4e85-b673-bbeafb62c6f2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:to="loc_us-gaap_ClassOfStockDomain_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:to="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_62feefaa-b7af-4f68-b629-aa70ff4a6632" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:to="loc_bsx_A550MCPSSeriesAMember_62feefaa-b7af-4f68-b629-aa70ff4a6632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caa71c66-6572-4f9b-9ffd-daa07a4036a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caa71c66-6572-4f9b-9ffd-daa07a4036a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EuroDenominatedFactoringArrangementsMember_861044ba-2a9c-4514-935f-4bcb085920ca" xlink:href="bsx-20221231.xsd#bsx_EuroDenominatedFactoringArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_EuroDenominatedFactoringArrangementsMember_861044ba-2a9c-4514-935f-4bcb085920ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_YenDenominatedFactoringArrangementsMember_8a62f53e-6ccb-4daa-9e56-46f8ef43e25b" xlink:href="bsx-20221231.xsd#bsx_YenDenominatedFactoringArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_YenDenominatedFactoringArrangementsMember_8a62f53e-6ccb-4daa-9e56-46f8ef43e25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RenminbiDenominatedFactoringArrangementsMember_1e0d891e-0502-4a7d-aa73-27196e207364" xlink:href="bsx-20221231.xsd#bsx_RenminbiDenominatedFactoringArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_RenminbiDenominatedFactoringArrangementsMember_1e0d891e-0502-4a7d-aa73-27196e207364" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_34a7be25-e737-4b92-a7be-576fb725a854_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_34a7be25-e737-4b92-a7be-576fb725a854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2019AggregateOfferingMember_7b2c3b69-b2f3-408a-a3a6-34e53f9c7783" xlink:href="bsx-20221231.xsd#bsx_November2019AggregateOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_November2019AggregateOfferingMember_7b2c3b69-b2f3-408a-a3a6-34e53f9c7783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2022NotesMember_bae1f3ec-b7c1-455b-ae90-dd75569d27c5" xlink:href="bsx-20221231.xsd#bsx_May2022NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_May2022NotesMember_bae1f3ec-b7c1-455b-ae90-dd75569d27c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_October2023NotesMember_e611ad67-1305-41bb-9c21-5eb2d8c883b2" xlink:href="bsx-20221231.xsd#bsx_October2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_October2023NotesMember_e611ad67-1305-41bb-9c21-5eb2d8c883b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_007bbec3-a9ef-4c45-b1ec-8983fd9d5869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_007bbec3-a9ef-4c45-b1ec-8983fd9d5869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2024NotesMember_c7861ebb-f7ee-4012-b38c-df7a9f6d69e3" xlink:href="bsx-20221231.xsd#bsx_March2024NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2024NotesMember_c7861ebb-f7ee-4012-b38c-df7a9f6d69e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2025NotesMember_f19d113d-d7e5-4aad-a28b-3d666b67bb33" xlink:href="bsx-20221231.xsd#bsx_May2025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_May2025NotesMember_f19d113d-d7e5-4aad-a28b-3d666b67bb33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2025NotesMember_ecc007c1-3e75-4032-b275-059d6ea4f25b" xlink:href="bsx-20221231.xsd#bsx_June2025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_June2025NotesMember_ecc007c1-3e75-4032-b275-059d6ea4f25b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2026NotesMember_f8d0d18a-5d32-458c-91a9-5a5145e22df0" xlink:href="bsx-20221231.xsd#bsx_March2026NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2026NotesMember_f8d0d18a-5d32-458c-91a9-5a5145e22df0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_December2027NotesMember_93a8d8a8-4eb1-4677-bb23-c9725ce61685" xlink:href="bsx-20221231.xsd#bsx_December2027NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_December2027NotesMember_93a8d8a8-4eb1-4677-bb23-c9725ce61685" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028NotesMember_28348c37-a14e-4ff9-bc9c-74e6c1e17661" xlink:href="bsx-20221231.xsd#bsx_March2028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2028NotesMember_28348c37-a14e-4ff9-bc9c-74e6c1e17661" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2029NotesMember_567b8c72-0fa2-45d7-baf9-233bf3a58c59" xlink:href="bsx-20221231.xsd#bsx_March2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2029NotesMember_567b8c72-0fa2-45d7-baf9-233bf3a58c59" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2030NotesMember_90b75f1f-f22c-40b3-a031-da5656a4b45b" xlink:href="bsx-20221231.xsd#bsx_June2030NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_June2030NotesMember_90b75f1f-f22c-40b3-a031-da5656a4b45b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2035NotesMember_9506c4a8-2229-4344-b4c1-ab1537f4aa2c" xlink:href="bsx-20221231.xsd#bsx_November2035NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_November2035NotesMember_9506c4a8-2229-4344-b4c1-ab1537f4aa2c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2039NotesMember_b11785a5-3d5f-436b-93c9-1640516247d9" xlink:href="bsx-20221231.xsd#bsx_March2039NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2039NotesMember_b11785a5-3d5f-436b-93c9-1640516247d9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_January2040NotesMember_0abc18e0-30a1-4997-ab28-936874e5c6cb" xlink:href="bsx-20221231.xsd#bsx_January2040NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_January2040NotesMember_0abc18e0-30a1-4997-ab28-936874e5c6cb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2049NotesMember_b839ec3d-5cbe-4e70-88ed-3634ea2206e9" xlink:href="bsx-20221231.xsd#bsx_March2049NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2049NotesMember_b839ec3d-5cbe-4e70-88ed-3634ea2206e9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d082a4f8-6df2-49ce-8e89-1b01f683ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_InterestRateSwapMember_d082a4f8-6df2-49ce-8e89-1b01f683ffb9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_773dc61b-96fb-41f5-b4de-ec30a932e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_773dc61b-96fb-41f5-b4de-ec30a932e9b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c8175e43-3f82-4ad2-96e2-f737bdcdb6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_SeniorNotesMember_c8175e43-3f82-4ad2-96e2-f737bdcdb6e9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028SeniorNotesMember_ea113c46-92a7-4498-a2b9-f01af6fe5ffc" xlink:href="bsx-20221231.xsd#bsx_March2028SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2028SeniorNotesMember_ea113c46-92a7-4498-a2b9-f01af6fe5ffc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2031NotesMember_40590d61-72ba-4af9-a3c0-fd9470787317" xlink:href="bsx-20221231.xsd#bsx_March2031NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2031NotesMember_40590d61-72ba-4af9-a3c0-fd9470787317" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2034NotesMember_4b3091a6-b5c8-4fb7-960e-ca892bf4b5f3" xlink:href="bsx-20221231.xsd#bsx_March2034NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2034NotesMember_4b3091a6-b5c8-4fb7-960e-ca892bf4b5f3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingAggregatePrincipalAmountMember_d23c2f7a-5312-4ac4-a626-989db497da74" xlink:href="bsx-20221231.xsd#bsx_TheOfferingAggregatePrincipalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_TheOfferingAggregatePrincipalAmountMember_d23c2f7a-5312-4ac4-a626-989db497da74" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2025NotesMember_57a0d857-8c6f-4e54-8caa-998876683eb2" xlink:href="bsx-20221231.xsd#bsx_March2025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2025NotesMember_57a0d857-8c6f-4e54-8caa-998876683eb2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_edba4870-49f2-4594-b253-3b20a2dbab8e" xlink:href="bsx-20221231.xsd#bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_edba4870-49f2-4594-b253-3b20a2dbab8e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_823770fa-9282-49e8-b926-05f171dc193f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_823770fa-9282-49e8-b926-05f171dc193f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_The2018FacilityDomain_f7d90577-7580-4785-8194-bdb49038bb64" xlink:href="bsx-20221231.xsd#bsx_The2018FacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:to="loc_bsx_The2018FacilityDomain_f7d90577-7580-4785-8194-bdb49038bb64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_04de772b-f365-40e0-a90b-f2db6ddc259c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:to="loc_us-gaap_CreditFacilityDomain_04de772b-f365-40e0-a90b-f2db6ddc259c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:to="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_261b39a3-249f-4490-aac7-23e47f16a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_261b39a3-249f-4490-aac7-23e47f16a19a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:href="bsx-20221231.xsd#bsx_CovenantAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantDomain_de5e5738-2e99-4500-adb2-29e3b2cd2a0e_default" xlink:href="bsx-20221231.xsd#bsx_CovenantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:to="loc_bsx_CovenantDomain_de5e5738-2e99-4500-adb2-29e3b2cd2a0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:href="bsx-20221231.xsd#bsx_CovenantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:to="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ActualCovenantMember_ec2a8260-abb8-40cf-a3da-0e5ff9b95724" xlink:href="bsx-20221231.xsd#bsx_ActualCovenantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_ActualCovenantMember_ec2a8260-abb8-40cf-a3da-0e5ff9b95724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfMarch312021Member_f0d38a71-660f-4388-9104-dbff96bacbb0" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfMarch312021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementAsOfMarch312021Member_f0d38a71-660f-4388-9104-dbff96bacbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_bbd71caa-69bd-4a47-8a7f-a4f8762bc4bb" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_bbd71caa-69bd-4a47-8a7f-a4f8762bc4bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_14197004-087d-48b0-a2ea-0f314708c6f1" xlink:href="bsx-20221231.xsd#bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_14197004-087d-48b0-a2ea-0f314708c6f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_bb700a1f-9e04-435e-851c-64ff7dc58f76" xlink:href="bsx-20221231.xsd#bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_bb700a1f-9e04-435e-851c-64ff7dc58f76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_b2dcc4d9-5c69-4b69-bc7f-b019288b69ab" xlink:href="bsx-20221231.xsd#bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_b2dcc4d9-5c69-4b69-bc7f-b019288b69ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_f155b843-1aff-48eb-b370-048e9110ab10" xlink:href="bsx-20221231.xsd#bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_f155b843-1aff-48eb-b370-048e9110ab10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_6d197a74-bdb0-4d5c-9f7a-7aae46d8d84d" xlink:href="bsx-20221231.xsd#bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_6d197a74-bdb0-4d5c-9f7a-7aae46d8d84d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7527d35e-486d-48d7-9c4a-ea3058d50cda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7527d35e-486d-48d7-9c4a-ea3058d50cda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_33e848a6-de33-438f-81e0-890d06159d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:to="loc_us-gaap_CommercialPaperMember_33e848a6-de33-438f-81e0-890d06159d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2022NotesMember_ae6f848c-1f17-40fb-8d49-84178e7c70d3" xlink:href="bsx-20221231.xsd#bsx_May2022NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:to="loc_bsx_May2022NotesMember_ae6f848c-1f17-40fb-8d49-84178e7c70d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/LeasesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/LeasesDetails" xlink:type="extended" id="i2db93578580f4948936d227a2b5cdec6_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_105cc6d6-9b4d-441c-8038-d2bd2bbdbb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_105cc6d6-9b4d-441c-8038-d2bd2bbdbb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_5835c824-69ba-41d2-931f-30561024c566" xlink:href="bsx-20221231.xsd#bsx_LesseeOperatingAndFinanceLeasesOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_5835c824-69ba-41d2-931f-30561024c566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae20c3fc-753c-49f4-9f33-c7667354d0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae20c3fc-753c-49f4-9f33-c7667354d0e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14a3358f-3b8c-40d1-b5c6-740b0aa4778e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14a3358f-3b8c-40d1-b5c6-740b0aa4778e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0eab078f-c83c-4282-8ffe-5144b2c12512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0eab078f-c83c-4282-8ffe-5144b2c12512" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_311940a7-93e8-485d-af9c-597e6d46d019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_311940a7-93e8-485d-af9c-597e6d46d019" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3b917e0f-caa6-45ad-9c08-6e581a96111a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseCost_3b917e0f-caa6-45ad-9c08-6e581a96111a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a742e48b-e014-4379-9027-632e78c56087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeasePayments_a742e48b-e014-4379-9027-632e78c56087" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02df90b4-e520-419b-9ac6-40980f4a4f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02df90b4-e520-419b-9ac6-40980f4a4f36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_023ebfb3-c5ec-4b6a-8611-550fc5661d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_023ebfb3-c5ec-4b6a-8611-550fc5661d2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_dd25820e-3fc6-4baf-bed1-bc42754e4e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_dd25820e-3fc6-4baf-bed1-bc42754e4e0d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_8df4cf0e-175d-4baa-8a2e-44344841e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_8df4cf0e-175d-4baa-8a2e-44344841e40e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_bcfec66f-7635-423a-bbd1-9765e755b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_bcfec66f-7635-423a-bbd1-9765e755b4c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_ea9e15dc-009f-40cf-8f9f-df1bec3ecc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_ea9e15dc-009f-40cf-8f9f-df1bec3ecc0b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_c6d796ab-c4e1-40a5-b061-21315aca7542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_c6d796ab-c4e1-40a5-b061-21315aca7542" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6b33e86-66f8-4e8c-aa4a-cb390ff65876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6b33e86-66f8-4e8c-aa4a-cb390ff65876" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b70a49d-94af-4ab0-990e-38145681982e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b70a49d-94af-4ab0-990e-38145681982e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83c13bd8-5e0b-4610-bdcc-89d0dce80da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiability_83c13bd8-5e0b-4610-bdcc-89d0dce80da5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2dacf6cc-d700-4a2e-89c9-ffc040c63e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2dacf6cc-d700-4a2e-89c9-ffc040c63e7e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e4904a6a-3534-4c4a-b5c2-321a7e3d6eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e4904a6a-3534-4c4a-b5c2-321a7e3d6eae" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:to="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f81b1d6-bcb4-40f7-b93b-83689d1717e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:to="loc_srt_RangeMember_3f81b1d6-bcb4-40f7-b93b-83689d1717e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:to="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16222919-90ad-4e14-baeb-93aeee42200f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:to="loc_srt_MinimumMember_16222919-90ad-4e14-baeb-93aeee42200f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0466f3d9-afd3-4216-a48e-4da85f7dcc51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:to="loc_srt_MaximumMember_0466f3d9-afd3-4216-a48e-4da85f7dcc51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_29fff278-d2e1-4374-8369-d3482218d07f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_29fff278-d2e1-4374-8369-d3482218d07f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9dd65f85-6d2a-4962-a45c-50c39da2ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9dd65f85-6d2a-4962-a45c-50c39da2ccf1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SupplementalBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="extended" id="i179328c44c824087a8b228ec3e67b7a0_SupplementalBalanceSheetInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_4d903462-9048-4be0-8563-6d7da1df84a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_4d903462-9048-4be0-8563-6d7da1df84a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_4c6534c8-31a1-4b17-b035-e3416c7ad950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_4c6534c8-31a1-4b17-b035-e3416c7ad950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_755bb0a3-5a2e-4efc-b1db-5f2b321c666a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_755bb0a3-5a2e-4efc-b1db-5f2b321c666a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_ed5ccf28-0dfb-4ff5-a8f2-425fdfd7f11e" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_bsx_LicensingArrangementsLiability_ed5ccf28-0dfb-4ff5-a8f2-425fdfd7f11e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc39230c-0c3e-4e57-8f78-62826dd488b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc39230c-0c3e-4e57-8f78-62826dd488b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e0d88dd4-0cbe-439d-94cb-71bdb2079d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e0d88dd4-0cbe-439d-94cb-71bdb2079d1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_c05193e1-31e6-45ad-a6c6-57b83308c875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_DeferredRevenue_c05193e1-31e6-45ad-a6c6-57b83308c875" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c18ff219-e343-43f8-89e7-25774911d6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c18ff219-e343-43f8-89e7-25774911d6a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_952a89ee-3cb6-4dd7-bfe9-d01e2c194fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_952a89ee-3cb6-4dd7-bfe9-d01e2c194fd9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IndemnificationAsset_2aba512c-d62c-4687-92a8-d9e12d117867" xlink:href="bsx-20221231.xsd#bsx_IndemnificationAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_bsx_IndemnificationAsset_2aba512c-d62c-4687-92a8-d9e12d117867" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_64728b50-be8a-4c32-bccd-18faa71a6126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_64728b50-be8a-4c32-bccd-18faa71a6126" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba9a54ed-549b-4a00-87bb-6fc3b8767517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba9a54ed-549b-4a00-87bb-6fc3b8767517" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_367c8c21-86c1-4edf-8c83-df2ec89eb27c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_367c8c21-86c1-4edf-8c83-df2ec89eb27c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0a007096-f008-45a6-aca8-c9d5680d24db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0a007096-f008-45a6-aca8-c9d5680d24db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_c4fdcf2b-93f5-4bf5-80e0-52d6d4c35a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_c4fdcf2b-93f5-4bf5-80e0-52d6d4c35a2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxesDetailsRateTable"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" xlink:type="extended" id="if46142730d964cb7a0b2df9c46961ba5_IncomeTaxesDetailsRateTable">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1291ced8-9e26-40e2-99c4-ffeff6fad2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1291ced8-9e26-40e2-99c4-ffeff6fad2d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_159b6046-1cd3-4b4d-834c-21836c4c7e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_159b6046-1cd3-4b4d-834c-21836c4c7e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_bd9b0423-1979-4403-a62a-0778c4b533ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_bd9b0423-1979-4403-a62a-0778c4b533ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5bdca00f-4a73-4870-8fb0-536bf20acbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5bdca00f-4a73-4870-8fb0-536bf20acbbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6ae62f-844d-4ca6-8796-a433d41a1653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6ae62f-844d-4ca6-8796-a433d41a1653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e251fdce-ab43-47d0-a794-33f37d6131f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e251fdce-ab43-47d0-a794-33f37d6131f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3fc4f0f7-03a9-4fb3-b14d-c5726e6a70a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3fc4f0f7-03a9-4fb3-b14d-c5726e6a70a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c483543f-7ecb-422a-abe1-dee084199925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c483543f-7ecb-422a-abe1-dee084199925" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_deb3263e-6930-48b2-84ba-c572ce7fd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_deb3263e-6930-48b2-84ba-c572ce7fd1dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b29e704c-9ec0-48b5-b19d-a9a138e111e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b29e704c-9ec0-48b5-b19d-a9a138e111e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_be79fc25-60ed-496b-94d9-e50a3b9437be" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_be79fc25-60ed-496b-94d9-e50a3b9437be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_d4a8c68d-f047-453f-af7f-b4697aef25b4" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_d4a8c68d-f047-453f-af7f-b4697aef25b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_5fc7b75f-1bc5-439d-a6c4-505f55c45b2c" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_5fc7b75f-1bc5-439d-a6c4-505f55c45b2c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5f73dc34-6927-4040-a4de-c9aa4b6655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5f73dc34-6927-4040-a4de-c9aa4b6655fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9c935b98-79a1-41fe-a4c4-1c59233654f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9c935b98-79a1-41fe-a4c4-1c59233654f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a69c5a7-17b6-4994-a7c1-7560d4137f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a69c5a7-17b6-4994-a7c1-7560d4137f9f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:href="bsx-20221231.xsd#bsx_TaxRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:to="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateDomain_15541335-c696-49af-a582-ed3930cade35_default" xlink:href="bsx-20221231.xsd#bsx_TaxRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:to="loc_bsx_TaxRateDomain_15541335-c696-49af-a582-ed3930cade35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateDomain_40c58887-443d-445a-a5dc-820635f8a05d" xlink:href="bsx-20221231.xsd#bsx_TaxRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:to="loc_bsx_TaxRateDomain_40c58887-443d-445a-a5dc-820635f8a05d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxesIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" xlink:type="extended" id="i4f1a2e9227534a13b77d6c2d5a7a876d_IncomeTaxesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_80a989e6-096e-48bd-8d04-a7f73df6ed90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_80a989e6-096e-48bd-8d04-a7f73df6ed90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aaa252a1-78a2-45b7-a861-49ba3103785c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aaa252a1-78a2-45b7-a861-49ba3103785c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfd8f1e9-5ea3-4efc-95db-149c04920997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfd8f1e9-5ea3-4efc-95db-149c04920997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1a30cd4-5011-4882-9c52-77da1748452b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1a30cd4-5011-4882-9c52-77da1748452b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c8bfb0d2-a2d1-4998-8d53-348e9917da26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c8bfb0d2-a2d1-4998-8d53-348e9917da26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3eccfd30-d203-49e9-b9b2-2ed5afd653de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3eccfd30-d203-49e9-b9b2-2ed5afd653de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be0261fe-0532-40e5-9fb5-8eb9c0bf4fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be0261fe-0532-40e5-9fb5-8eb9c0bf4fd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dbdd672-e1b3-467f-8e51-ce688618ccef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dbdd672-e1b3-467f-8e51-ce688618ccef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6441efb8-eb38-42b0-9423-630489a62c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6441efb8-eb38-42b0-9423-630489a62c19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2e4d7bf9-c119-47db-aadc-339e283f1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2e4d7bf9-c119-47db-aadc-339e283f1235" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e677dd06-3a9c-44f2-9aac-8d74c7156001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e677dd06-3a9c-44f2-9aac-8d74c7156001" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff7469ed-7da1-4e68-b51c-9ff56f794c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff7469ed-7da1-4e68-b51c-9ff56f794c77" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f537d7bd-6e4e-4e38-8623-53fbc87c43bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f537d7bd-6e4e-4e38-8623-53fbc87c43bd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02efbbcf-feba-413e-8669-d3ece3c7c413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02efbbcf-feba-413e-8669-d3ece3c7c413" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ae3f3fe-626e-48e8-9b08-8b3edd895208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ae3f3fe-626e-48e8-9b08-8b3edd895208" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_cb213439-2763-41bc-947f-6188ae3eafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_cb213439-2763-41bc-947f-6188ae3eafc3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_e586b62a-9595-4807-9c4f-ba7475859d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_e586b62a-9595-4807-9c4f-ba7475859d52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_5941fba6-dc43-4c14-87f8-0f3037b0f6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_5941fba6-dc43-4c14-87f8-0f3037b0f6c4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_77ce8351-35ea-416d-a10a-854ec7a9d16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_77ce8351-35ea-416d-a10a-854ec7a9d16d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FederalBenefitOfUncertainTaxPositions_1e79f36b-6c7c-4c3f-91ed-e3d0205efe4e" xlink:href="bsx-20221231.xsd#bsx_FederalBenefitOfUncertainTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FederalBenefitOfUncertainTaxPositions_1e79f36b-6c7c-4c3f-91ed-e3d0205efe4e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ddecf556-3efd-40d3-a641-93c9cfe8982b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ddecf556-3efd-40d3-a641-93c9cfe8982b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6b88405c-4de5-4fe2-8454-07187f4a6e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6b88405c-4de5-4fe2-8454-07187f4a6e8e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8921416c-3369-4c78-8bb7-66cd87591d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8921416c-3369-4c78-8bb7-66cd87591d2c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d7f9ccfc-a532-4524-9a37-2d0b008e40a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d7f9ccfc-a532-4524-9a37-2d0b008e40a9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d8142aa5-5243-419e-ac82-6647827fd7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d8142aa5-5243-419e-ac82-6647827fd7b3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6ec4a953-8c9a-4065-87fe-18ac487eb3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6ec4a953-8c9a-4065-87fe-18ac487eb3d0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c55e0229-f29e-4cf4-8fd5-1e30fed84765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c55e0229-f29e-4cf4-8fd5-1e30fed84765" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f6da2ca7-011e-4bab-9a03-5db49c4b0327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f6da2ca7-011e-4bab-9a03-5db49c4b0327" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4a7aa7af-7d5a-4e68-91dc-7f996788be69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4a7aa7af-7d5a-4e68-91dc-7f996788be69" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d07f1-d2b9-41fc-8c2d-e506337bec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d07f1-d2b9-41fc-8c2d-e506337bec8d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6d2e1da7-cd4c-4ce4-a4e8-efad42270731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6d2e1da7-cd4c-4ce4-a4e8-efad42270731" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_057ddc76-6e32-4a13-be9d-f731bacf187e" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_057ddc76-6e32-4a13-be9d-f731bacf187e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_782500a1-5c95-464b-83b0-a09cbd8f543a" xlink:href="bsx-20221231.xsd#bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_782500a1-5c95-464b-83b0-a09cbd8f543a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c53dd568-d479-4ec2-8c4e-bde0445ffad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c53dd568-d479-4ec2-8c4e-bde0445ffad6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cebb2930-0958-4ec1-95a8-6255239fe68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_cebb2930-0958-4ec1-95a8-6255239fe68b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_057d6c40-7d9f-4ccb-9db1-4f186c41e7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_057d6c40-7d9f-4ccb-9db1-4f186c41e7c9" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_bc61fc37-2c4a-4a40-b995-12df01eaa296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_bc61fc37-2c4a-4a40-b995-12df01eaa296" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_7f99edc7-17c5-4562-88c8-db3cfc217946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_7f99edc7-17c5-4562-88c8-db3cfc217946" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentive_d53dfe70-aae0-4e57-a888-595358ee0756" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FreeTradeZoneRegimeTaxIncentive_d53dfe70-aae0-4e57-a888-595358ee0756" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRico_143eabc4-a587-42ea-9799-9b2d89ce5cf4" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRico"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInPuertoRico_143eabc4-a587-42ea-9799-9b2d89ce5cf4" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a252373f-08ff-4a5f-9bac-aa17eec57e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a252373f-08ff-4a5f-9bac-aa17eec57e79" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9fe5de1c-c08e-4e71-9bb9-f690eef17f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9fe5de1c-c08e-4e71-9bb9-f690eef17f8e" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce6f66d6-34a8-4f16-ac4a-03b34887df91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce6f66d6-34a8-4f16-ac4a-03b34887df91" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15c86e2f-284b-435e-b460-95c00f0de9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15c86e2f-284b-435e-b460-95c00f0de9f8" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_015bc059-23d5-421c-8868-dc0f99c77afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_015bc059-23d5-421c-8868-dc0f99c77afa" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_773cc822-2231-4b77-b562-dd8d8542fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_773cc822-2231-4b77-b562-dd8d8542fea0" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6e7b9784-b7b6-424d-a0b7-215d3904adec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6e7b9784-b7b6-424d-a0b7-215d3904adec" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_50577954-78a2-44a8-a110-a78a16ae5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_50577954-78a2-44a8-a110-a78a16ae5c9b" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_ec2dc734-42e5-4a44-aed7-70110f6f7f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_ec2dc734-42e5-4a44-aed7-70110f6f7f63" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_db7a660a-8e37-4b26-b709-ac4080273c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_db7a660a-8e37-4b26-b709-ac4080273c0e" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_58f3a7da-4665-4f93-bef8-b3b0f19bb1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_58f3a7da-4665-4f93-bef8-b3b0f19bb1a8" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment_16e24904-b187-4bb0-8296-027f2a505a93" xlink:href="bsx-20221231.xsd#bsx_Onetimetransactiontaxpost1986EPnetpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment_16e24904-b187-4bb0-8296-027f2a505a93" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_b0d7366f-f25b-4e0b-86bd-17b9c3a2d1a0" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_b0d7366f-f25b-4e0b-86bd-17b9c3a2d1a0" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_a40d12a5-2e12-4e8c-9a1c-27f7163962bb" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_a40d12a5-2e12-4e8c-9a1c-27f7163962bb" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TransitionTaxPaymentRemaining_4bc1e773-cad1-45c0-8e5b-43297f1f4416" xlink:href="bsx-20221231.xsd#bsx_TransitionTaxPaymentRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TransitionTaxPaymentRemaining_4bc1e773-cad1-45c0-8e5b-43297f1f4416" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysia_00fb17cc-c228-4c73-adc3-dd53d207176b" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysia"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInMalaysia_00fb17cc-c228-4c73-adc3-dd53d207176b" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_adcb079c-712e-404b-88d5-ef5f43122aed" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_adcb079c-712e-404b-88d5-ef5f43122aed" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_38e616ac-3c62-412a-b195-932fd1c0ed1b" xlink:href="bsx-20221231.xsd#bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_38e616ac-3c62-412a-b195-932fd1c0ed1b" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_687f1ece-ddc9-4e31-a8af-55cd156b7176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_687f1ece-ddc9-4e31-a8af-55cd156b7176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsDomain_5a538f56-0841-4588-bc64-108551eff566" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_bsx_DeferredTaxAssetsDomain_5a538f56-0841-4588-bc64-108551eff566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxLiabilitiesDomain_d447c32b-158e-4a26-84da-988db400d230" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_bsx_DeferredTaxLiabilitiesDomain_d447c32b-158e-4a26-84da-988db400d230" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i31d28330e7d24cf183f630b7ad8959f8_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1843be9b-7a8d-44a4-97b4-57b5a66b616b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1843be9b-7a8d-44a4-97b4-57b5a66b616b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ce05ef91-ff1b-4b61-b218-71a4b12f5d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ce05ef91-ff1b-4b61-b218-71a4b12f5d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_874beb1f-68b3-41c9-a355-3a4c27d6f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LitigationSettlementExpense_874beb1f-68b3-41c9-a355-3a4c27d6f7fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e05a7411-eeff-4851-b591-61c9299399d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e05a7411-eeff-4851-b591-61c9299399d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_c8e65c91-7e4f-4254-804b-97936702779e" xlink:href="bsx-20221231.xsd#bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_c8e65c91-7e4f-4254-804b-97936702779e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_970fd188-a425-4126-9c81-34a268f78131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_970fd188-a425-4126-9c81-34a268f78131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c8c4617-92e2-4797-a9cc-b0a492ecfcec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c8c4617-92e2-4797-a9cc-b0a492ecfcec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_07a01a9d-17d8-4e6f-9418-4af7647d49fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:to="loc_us-gaap_LitigationStatusDomain_07a01a9d-17d8-4e6f-9418-4af7647d49fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dcb1b486-950b-4dd7-93ee-43735f44ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:to="loc_us-gaap_LitigationStatusDomain_dcb1b486-950b-4dd7-93ee-43735f44ea03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5b47ce98-f632-4b99-b923-def4ae431dd1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:to="loc_srt_LitigationCaseTypeDomain_5b47ce98-f632-4b99-b923-def4ae431dd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9a8349f5-fb54-400f-86c0-04ddd3a2c8e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:to="loc_srt_LitigationCaseTypeDomain_9a8349f5-fb54-400f-86c0-04ddd3a2c8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3ebab494-ea8d-48ef-afed-7ce926e55615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3ebab494-ea8d-48ef-afed-7ce926e55615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_81d8bfc1-cd22-4c5a-85c7-87d7b36727b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:to="loc_us-gaap_SubsequentEventMember_81d8bfc1-cd22-4c5a-85c7-87d7b36727b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/StockholdersEquityDetails" xlink:type="extended" id="ic439a9677f604c55a7cbc28da30e72cc_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b1004324-bffe-4294-bd86-f10eb9033142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b1004324-bffe-4294-bd86-f10eb9033142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_31413bd0-a070-4a52-be64-97511bb35127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_31413bd0-a070-4a52-be64-97511bb35127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_349cb848-61e5-4549-9689-cf29b6ccb9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_349cb848-61e5-4549-9689-cf29b6ccb9cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_dc581dbc-0fe4-48b3-a0dd-59b91e64db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_dc581dbc-0fe4-48b3-a0dd-59b91e64db0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_9e0ae328-c830-4204-879e-67668c842568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_9e0ae328-c830-4204-879e-67668c842568" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_b43ed2b6-1a5f-4aa5-a934-b61430dc7d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_b43ed2b6-1a5f-4aa5-a934-b61430dc7d60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_be94941b-13ab-4e5a-a493-7ac242a3f792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_be94941b-13ab-4e5a-a493-7ac242a3f792" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_869e71ec-bc03-4bee-8411-effda8600724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_869e71ec-bc03-4bee-8411-effda8600724" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_054ffcb9-2dbb-433b-8123-e1c5218b220d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PaymentsOfDividends_054ffcb9-2dbb-433b-8123-e1c5218b220d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_64d558c7-e7fb-421f-8ade-3b1d51df5be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_64d558c7-e7fb-421f-8ade-3b1d51df5be0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b1e7a6ac-7261-425f-8de8-be51fc7c1a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b1e7a6ac-7261-425f-8de8-be51fc7c1a7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df7d5279-9f4d-483e-9cb2-5963472b3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df7d5279-9f4d-483e-9cb2-5963472b3a66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_47ada9ec-d912-49c7-9e35-68a486ec03bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_47ada9ec-d912-49c7-9e35-68a486ec03bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230dd34a-7d27-4511-8786-412d5873aa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230dd34a-7d27-4511-8786-412d5873aa5f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5866345c-aead-438e-bbd0-d9ea6720b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5866345c-aead-438e-bbd0-d9ea6720b8f9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_72319bf6-af33-422e-a15a-58d2681ab741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_72319bf6-af33-422e-a15a-58d2681ab741" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea975e66-30e5-46f6-b76b-e278fc4bd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea975e66-30e5-46f6-b76b-e278fc4bd7f7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_df9b1fe2-6007-4ea9-b2d2-571b139ce3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_DividendsCash_df9b1fe2-6007-4ea9-b2d2-571b139ce3cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2cca8d3f-4d9f-42a0-84a3-350ff0047c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_TreasuryStockShares_2cca8d3f-4d9f-42a0-84a3-350ff0047c76" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b6457e7-0a75-41ef-88f2-2818a6ce20bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:to="loc_us-gaap_ClassOfStockDomain_3b6457e7-0a75-41ef-88f2-2818a6ce20bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:to="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_c37c3119-746f-4be4-8abf-315d08a43d28" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:to="loc_bsx_A550MCPSSeriesAMember_c37c3119-746f-4be4-8abf-315d08a43d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_422fa706-0bb5-497e-a3ba-bfbcabd89407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:to="loc_us-gaap_CommonStockMember_422fa706-0bb5-497e-a3ba-bfbcabd89407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc954da6-0397-49bb-9747-dfa3bbdfc843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc954da6-0397-49bb-9747-dfa3bbdfc843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9d4e10f4-2e1f-4a54-9d09-4b9c52abf656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:to="loc_us-gaap_SubsequentEventMember_9d4e10f4-2e1f-4a54-9d09-4b9c52abf656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d2c515d-9297-415f-8dec-3af1c08d4954_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:to="loc_srt_RangeMember_5d2c515d-9297-415f-8dec-3af1c08d4954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:to="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd4852e-687c-4f5d-94ca-17fad242526b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:to="loc_srt_MinimumMember_dbd4852e-687c-4f5d-94ca-17fad242526b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46c7b70d-7562-4202-9762-a70b641ee16e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:to="loc_srt_MaximumMember_46c7b70d-7562-4202-9762-a70b641ee16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dad70ea8-da08-4128-a9a8-3dd1205cd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_596e5fd3-b126-4f90-be19-147392d86b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_02480b2c-f188-4404-824e-97ebd7a309c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_16ad4a3c-0d34-4c69-ad0e-8c2f5b56699f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_16ad4a3c-0d34-4c69-ad0e-8c2f5b56699f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0e53937-82bd-4ee3-9574-4cc0f528d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c10a0113-e36d-417a-beea-74817583aa40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6fb88390-bcf5-44ac-b94b-aba6219f0b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6fb88390-bcf5-44ac-b94b-aba6219f0b87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ae67666-0b60-4348-ab7b-dab03c8c1a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_cecf2cd9-c0b4-4c5a-9f45-770dcf9cb4bf" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockIncentiveandPurchasePlansDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" xlink:type="extended" id="ic6ce9a843819431ab7cef8fcb4f1ecfc_StockIncentiveandPurchasePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Fairvalueofmarketbasedawards_242485d5-c44e-45fe-8fac-b7a96d9e395a" xlink:href="bsx-20221231.xsd#bsx_Fairvalueofmarketbasedawards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Fairvalueofmarketbasedawards_242485d5-c44e-45fe-8fac-b7a96d9e395a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3da32d78-f4a8-42ed-9d11-f2ee5ba5230c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharePrice_3da32d78-f4a8-42ed-9d11-f2ee5ba5230c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostStockOptions_5b3dc974-4062-41f2-b27a-ca14faf3aae5" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCostStockOptions_5b3dc974-4062-41f2-b27a-ca14faf3aae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_e5dd8896-3e25-4449-9281-c20ebd57b1cf" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofperformancebasedDSUsawarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_e5dd8896-3e25-4449-9281-c20ebd57b1cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ed6080af-54bc-46e1-91cc-865e6aed35c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ed6080af-54bc-46e1-91cc-865e6aed35c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_37d9b60e-5f9c-435d-85cf-d5ee4642c71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_37d9b60e-5f9c-435d-85cf-d5ee4642c71c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ae7f916-c421-4799-a152-3df5713c8734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ae7f916-c421-4799-a152-3df5713c8734" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ad2569-0212-4fd4-a9a8-1a591ed4539e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ad2569-0212-4fd4-a9a8-1a591ed4539e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14d3df14-5e0e-4217-8842-6e9a6e2b25aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14d3df14-5e0e-4217-8842-6e9a6e2b25aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Measurementperiodmarketbasedaward_b4a59b55-b718-4c72-b0d9-5377bf39d27b" xlink:href="bsx-20221231.xsd#bsx_Measurementperiodmarketbasedaward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Measurementperiodmarketbasedaward_b4a59b55-b718-4c72-b0d9-5377bf39d27b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ded9562f-18af-4ae7-8224-c9e9814d3850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ded9562f-18af-4ae7-8224-c9e9814d3850" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb6add-b2fe-428e-a6df-25eac5515670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb6add-b2fe-428e-a6df-25eac5515670" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afdab049-e701-4a4a-966b-7eab6f7305cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afdab049-e701-4a4a-966b-7eab6f7305cb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80d0cc6a-a27e-4f7c-8871-2b92218d7d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80d0cc6a-a27e-4f7c-8871-2b92218d7d3c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0b3fb5d5-8edb-4217-812f-ced0c286acca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0b3fb5d5-8edb-4217-812f-ced0c286acca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e7f5c3d8-2e07-4319-b2c6-8ac872a68bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e7f5c3d8-2e07-4319-b2c6-8ac872a68bb7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65f4c8c3-9d6c-4976-8cb4-bc10c59d0691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65f4c8c3-9d6c-4976-8cb4-bc10c59d0691" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a636ad86-9273-4bee-a8e2-ac7d00848211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a636ad86-9273-4bee-a8e2-ac7d00848211" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e00d8a8a-4020-4582-a9bc-c34708320cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e00d8a8a-4020-4582-a9bc-c34708320cfc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dd3383e-fdc6-469c-84b6-fb152b7fc916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dd3383e-fdc6-469c-84b6-fb152b7fc916" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f004b87d-a32c-4adf-a466-60cd8e847cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f004b87d-a32c-4adf-a466-60cd8e847cbf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_131d36b5-82e7-421e-9ba3-4d2a4061c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_131d36b5-82e7-421e-9ba3-4d2a4061c1bf" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_425c7143-ffed-4672-baf2-7f540c84ddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_425c7143-ffed-4672-baf2-7f540c84ddf2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f3f5aa1-7063-4934-a794-95f5c381e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f3f5aa1-7063-4934-a794-95f5c381e76b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8beef9a-a425-4d87-8bd0-0de693df2665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8beef9a-a425-4d87-8bd0-0de693df2665" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7581c661-4dd6-42a3-b386-a689b56e4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensation_7581c661-4dd6-42a3-b386-a689b56e4f8f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2334ed3e-837b-4a70-bcfb-550562ef68d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2334ed3e-837b-4a70-bcfb-550562ef68d1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ba885da5-fd05-4247-bed1-df42bcd24502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ba885da5-fd05-4247-bed1-df42bcd24502" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1acc79f1-bdaf-4201-949e-27b2607a9c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1acc79f1-bdaf-4201-949e-27b2607a9c5c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ShareBasedCompensationNetOfTaxBenefit_fa778553-2723-494b-94c5-66ebc1c84e53" xlink:href="bsx-20221231.xsd#bsx_ShareBasedCompensationNetOfTaxBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_ShareBasedCompensationNetOfTaxBenefit_fa778553-2723-494b-94c5-66ebc1c84e53" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareBasic_24b3cddc-407e-4f1b-9dec-fbbc6aacbdad" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_CompensationExpensePerShareBasic_24b3cddc-407e-4f1b-9dec-fbbc6aacbdad" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareDiluted_86a8005e-b8d2-40a5-a463-07b62abfb2f6" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_CompensationExpensePerShareDiluted_86a8005e-b8d2-40a5-a463-07b62abfb2f6" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55b9fac6-0351-402e-aa7d-1dc7e54e80ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55b9fac6-0351-402e-aa7d-1dc7e54e80ad" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cfbbfc23-6d42-4745-99db-b048c4987df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cfbbfc23-6d42-4745-99db-b048c4987df9" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3602f458-7e6d-43e6-b849-57374b9e13b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3602f458-7e6d-43e6-b849-57374b9e13b6" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0cd368bd-1d2b-4db1-8dc4-c787dc52b640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0cd368bd-1d2b-4db1-8dc4-c787dc52b640" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_263bfb3a-364b-4df7-b0d7-5d8dc034114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_263bfb3a-364b-4df7-b0d7-5d8dc034114b" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b5c0764-690d-440e-beb8-8f71e7707be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b5c0764-690d-440e-beb8-8f71e7707be6" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_574b337f-1e15-49a6-b030-bf2e4093df79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_574b337f-1e15-49a6-b030-bf2e4093df79" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b57a3417-87d9-46a2-ba76-7143b33bdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b57a3417-87d9-46a2-ba76-7143b33bdc9c" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0a30bc1a-93da-4516-90c5-29b6b83069b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0a30bc1a-93da-4516-90c5-29b6b83069b3" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVest_d86e89e8-4c8e-4a6e-8f00-da8f5512b097" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVest_d86e89e8-4c8e-4a6e-8f00-da8f5512b097" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_5ef45910-64a5-4178-b702-7ccdf12a07e8" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_5ef45910-64a5-4178-b702-7ccdf12a07e8" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_b396e825-f2ba-4233-bfd5-100ed94856bb" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_b396e825-f2ba-4233-bfd5-100ed94856bb" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_543d5119-db85-4eda-be57-2273318b1e0c" xlink:href="bsx-20221231.xsd#bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_543d5119-db85-4eda-be57-2273318b1e0c" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f5136f87-ba9b-4bdf-a63e-1ce2794f3ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f5136f87-ba9b-4bdf-a63e-1ce2794f3ff0" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_366a1647-f518-40ce-9d8d-5d66690c567f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_366a1647-f518-40ce-9d8d-5d66690c567f" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_456daee6-48c4-408a-98c9-a852b8706153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_456daee6-48c4-408a-98c9-a852b8706153" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3eda669e-72b7-4085-ba41-8dd5aa6272a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3eda669e-72b7-4085-ba41-8dd5aa6272a3" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bd129c63-31e9-4a70-a66f-b5e24877d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bd129c63-31e9-4a70-a66f-b5e24877d55d" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_88fb664e-7de7-4de8-ade4-27dce7d4f53a" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofmarketbasedDSUsawarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_88fb664e-7de7-4de8-ade4-27dce7d4f53a" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7c34523c-e276-4218-8c9f-cf5a4659232e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7c34523c-e276-4218-8c9f-cf5a4659232e" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_8a3b4698-bf29-4e9a-bb68-a0cc1f1899e7" xlink:href="bsx-20221231.xsd#bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_8a3b4698-bf29-4e9a-bb68-a0cc1f1899e7" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_a7c2f714-d78e-4773-9965-63f227546985" xlink:href="bsx-20221231.xsd#bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_a7c2f714-d78e-4773-9965-63f227546985" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32ce061e-ae57-4b1d-a224-cb1ecc884261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32ce061e-ae57-4b1d-a224-cb1ecc884261" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards_146ba92b-e7d4-45f5-b74b-6874e28967dd" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostNonVestedStockAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards_146ba92b-e7d4-45f5-b74b-6874e28967dd" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCost_71f39183-65bf-4b10-8b01-e140eb58b203" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCost_71f39183-65bf-4b10-8b01-e140eb58b203" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WeightedAverageRemainingVestingPeriod_3d9b38da-6021-4c3f-a22d-ec2327f5bb22" xlink:href="bsx-20221231.xsd#bsx_WeightedAverageRemainingVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_WeightedAverageRemainingVestingPeriod_3d9b38da-6021-4c3f-a22d-ec2327f5bb22" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Annualweightedaverageforfeiturerate_3fcd8b51-6969-417e-8db0-71f7f77f5876" xlink:href="bsx-20221231.xsd#bsx_Annualweightedaverageforfeiturerate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Annualweightedaverageforfeiturerate_3fcd8b51-6969-417e-8db0-71f7f77f5876" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_VotingPowerOfAllClassesOfStock_4d80af0a-edb3-40c7-9989-37c5a77b63a7" xlink:href="bsx-20221231.xsd#bsx_VotingPowerOfAllClassesOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_VotingPowerOfAllClassesOfStock_4d80af0a-edb3-40c7-9989-37c5a77b63a7" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_72d12017-22e9-455d-93ae-15dc498f4b19" xlink:href="bsx-20221231.xsd#bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_72d12017-22e9-455d-93ae-15dc498f4b19" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Nonvestedstockawardsexerciseprice_aad88a86-df9f-4b2c-bf1c-f5090e3ae2e3" xlink:href="bsx-20221231.xsd#bsx_Nonvestedstockawardsexerciseprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Nonvestedstockawardsexerciseprice_aad88a86-df9f-4b2c-bf1c-f5090e3ae2e3" xlink:type="arc" order="61"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_e8a2bdbc-02dc-4e67-8e8e-680c5e267c7f" xlink:href="bsx-20221231.xsd#bsx_FairValueOfFreeCashFlowFcfPerformanceAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_e8a2bdbc-02dc-4e67-8e8e-680c5e267c7f" xlink:type="arc" order="62"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_0ec0596b-3e61-45a3-b549-0bf1f23ff34a" xlink:href="bsx-20221231.xsd#bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_0ec0596b-3e61-45a3-b549-0bf1f23ff34a" xlink:type="arc" order="63"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_341e4d9e-e71b-496c-ba1e-98c712bde542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_341e4d9e-e71b-496c-ba1e-98c712bde542" xlink:type="arc" order="64"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdaa1771-94a4-453b-b30b-cc4c59cd1e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdaa1771-94a4-453b-b30b-cc4c59cd1e6e" xlink:type="arc" order="65"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc7635a5-d393-4c41-82a5-3ab4c534f779_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc7635a5-d393-4c41-82a5-3ab4c534f779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_512eed98-73b1-4845-9ad8-31fd4b5f9594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_CostOfSalesMember_512eed98-73b1-4845-9ad8-31fd4b5f9594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_684fbf7e-8756-445d-9ca7-d6979edbba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_684fbf7e-8756-445d-9ca7-d6979edbba00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fad1fd53-5706-4dea-b881-9d4dd79cac84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fad1fd53-5706-4dea-b881-9d4dd79cac84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_68aa477f-2521-43ff-8920-233744748ddc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:to="loc_us-gaap_PlanNameDomain_68aa477f-2521-43ff-8920-233744748ddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:to="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2011LtipPlanMember_23a3f06f-b268-428c-8b5a-eb670a47cbe3" xlink:href="bsx-20221231.xsd#bsx_A2011LtipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:to="loc_bsx_A2011LtipPlanMember_23a3f06f-b268-428c-8b5a-eb670a47cbe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca0ee10e-7604-434d-bc3a-bd825abcc630_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:to="loc_srt_RangeMember_ca0ee10e-7604-434d-bc3a-bd825abcc630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:to="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0997491b-164c-4a20-bd1d-8bcd1f613a89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:to="loc_srt_MinimumMember_0997491b-164c-4a20-bd1d-8bcd1f613a89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e6ac4bb-3508-483e-9fc2-1f23e9b74a7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:to="loc_srt_MaximumMember_8e6ac4bb-3508-483e-9fc2-1f23e9b74a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6c09fc5-a168-4e9e-a04f-66de0babefac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#WeightedAverageSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="extended" id="i974b173156ef44529d314aaf229f54b1_WeightedAverageSharesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3de03027-7c94-4b5d-91c6-9fb81eb964d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3de03027-7c94-4b5d-91c6-9fb81eb964d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd44ee05-61d9-4758-a4a7-fbbfd9d5c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd44ee05-61d9-4758-a4a7-fbbfd9d5c842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb4b5d53-3f7a-41c3-95e2-46560e32be04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb4b5d53-3f7a-41c3-95e2-46560e32be04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84bba990-19d7-4419-a13e-ba2a6c94c28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84bba990-19d7-4419-a13e-ba2a6c94c28a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1dd17007-f9d2-47be-b736-bc6c45628925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1dd17007-f9d2-47be-b736-bc6c45628925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_15c95dd8-5d8c-4fb7-b361-de13a686a0b9" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_bsx_A550MCPSSeriesAMember_15c95dd8-5d8c-4fb7-b361-de13a686a0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_69ab5efb-2df2-431e-9245-ece5616f9bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_us-gaap_StockCompensationPlanMember_69ab5efb-2df2-431e-9245-ece5616f9bfb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="extended" id="i695dd281518848b2a82919183435cf27_SegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_0b2bcc2c-402b-4825-a1ca-153160d4d768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NumberOfReportableSegments_0b2bcc2c-402b-4825-a1ca-153160d4d768" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1103e2e4-e041-40fc-90db-8fdd2324e152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1103e2e4-e041-40fc-90db-8fdd2324e152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeUnallocatedToSegment_069186dd-4620-43da-be4a-842f07f9fc79" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeUnallocatedToSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_OperatingIncomeUnallocatedToSegment_069186dd-4620-43da-be4a-842f07f9fc79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0295d394-2dfc-46df-85d1-5e534141a498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_Depreciation_0295d394-2dfc-46df-85d1-5e534141a498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments_9706603a-0d80-40b1-893f-ef44356cac3a" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeLossAllocatedToReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments_9706603a-0d80-40b1-893f-ef44356cac3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85ced95c-62eb-40d5-975c-a0fd410ff8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OperatingIncomeLoss_85ced95c-62eb-40d5-975c-a0fd410ff8cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7e01f38c-c9cb-4118-a575-38497b3b82b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7e01f38c-c9cb-4118-a575-38497b3b82b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46be0954-e1cc-407b-b553-0ba70a01e36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46be0954-e1cc-407b-b553-0ba70a01e36a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7963ae1c-38b8-44b0-a42e-06b6d96ad2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7963ae1c-38b8-44b0-a42e-06b6d96ad2ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Segmentoperatingincomeaspercentageofnetsales_decad104-fc67-4e02-8e89-f83f6d4c1fd5" xlink:href="bsx-20221231.xsd#bsx_Segmentoperatingincomeaspercentageofnetsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_Segmentoperatingincomeaspercentageofnetsales_decad104-fc67-4e02-8e89-f83f6d4c1fd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_ffcd9a6b-6151-4fd3-af4c-7e4d2bddcb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OtherAssets_ffcd9a6b-6151-4fd3-af4c-7e4d2bddcb52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6eb0f95b-eb28-42c2-8aae-4e5e8f96edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_Goodwill_6eb0f95b-eb28-42c2-8aae-4e5e8f96edd1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2467746a-cd4e-49a8-8a9b-3f82378ff750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2467746a-cd4e-49a8-8a9b-3f82378ff750" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_493cb87b-3bb4-445a-ac79-6073a354b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_493cb87b-3bb4-445a-ac79-6073a354b85d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_f5a50425-76e5-4ccd-8d43-947b7a8f4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NoncurrentAssets_f5a50425-76e5-4ccd-8d43-947b7a8f4e22" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4d44e0e8-e437-4b38-8f2a-bd3ae78832fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4d44e0e8-e437-4b38-8f2a-bd3ae78832fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_455ffffb-6f85-4a10-aee3-1d6f1e2c7432" xlink:href="bsx-20221231.xsd#bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_455ffffb-6f85-4a10-aee3-1d6f1e2c7432" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_dd0f5d80-9be4-453c-81ac-018fdebb291e" xlink:href="bsx-20221231.xsd#bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_dd0f5d80-9be4-453c-81ac-018fdebb291e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_218563d9-ca4c-4f57-9b29-075982e964c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:to="loc_us-gaap_SegmentDomain_218563d9-ca4c-4f57-9b29-075982e964c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:to="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_b28e8363-0daa-4f55-8404-9aa1817164b9" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_MedsurgMember_b28e8363-0daa-4f55-8404-9aa1817164b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_715d80b4-f7d0-4f5f-aae1-9eb6e9ee6d25" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_CardiovascularMember_715d80b4-f7d0-4f5f-aae1-9eb6e9ee6d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BSXReportableSegmentsMember_991659b3-09fb-4956-b2e6-ebbcd875204d" xlink:href="bsx-20221231.xsd#bsx_BSXReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_BSXReportableSegmentsMember_991659b3-09fb-4956-b2e6-ebbcd875204d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TotalAllocatedToReportableSegmentsMember_baab17e7-c1cc-4449-a0f8-bb2c8dce574e" xlink:href="bsx-20221231.xsd#bsx_TotalAllocatedToReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_TotalAllocatedToReportableSegmentsMember_baab17e7-c1cc-4449-a0f8-bb2c8dce574e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_63dac6b9-3f81-4601-a1f4-45a2b00a16f6" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_63dac6b9-3f81-4601-a1f4-45a2b00a16f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember_84b88abf-0a79-4a72-816a-11b786f5246a" xlink:href="bsx-20221231.xsd#bsx_CorporateExpensesincludinghedgingactivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember_84b88abf-0a79-4a72-816a-11b786f5246a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialChargesMember_be99c8f4-fde4-4c39-8886-5b5d42ee3af8" xlink:href="bsx-20221231.xsd#bsx_SpecialChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_SpecialChargesMember_be99c8f4-fde4-4c39-8886-5b5d42ee3af8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_6ed1acdc-cbf1-40a9-a5f7-f330d93f329a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_us-gaap_CorporateMember_6ed1acdc-cbf1-40a9-a5f7-f330d93f329a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedBSXDomain_a0cc1816-71e5-4957-9a19-e597f4042bd8" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedBSXDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_ConsolidatedBSXDomain_a0cc1816-71e5-4957-9a19-e597f4042bd8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_59435d74-8005-4b06-ada5-fffa272e5514" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_OtherMember_59435d74-8005-4b06-ada5-fffa272e5514" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_744ed675-d5a7-42e9-800b-837b833eb802_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:to="loc_srt_SegmentGeographicalDomain_744ed675-d5a7-42e9-800b-837b833eb802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:to="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6bd84f39-a81c-4aa3-9f60-96c9b2b08ecc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_US_6bd84f39-a81c-4aa3-9f60-96c9b2b08ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_39cf74fc-9355-4faa-b02f-019b9c7a10e1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_IE_39cf74fc-9355-4faa-b02f-019b9c7a10e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherCountriesMember_272916ce-2533-448d-851c-63cc3d4181f0" xlink:href="bsx-20221231.xsd#bsx_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_bsx_OtherCountriesMember_272916ce-2533-448d-851c-63cc3d4181f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR_6e72a210-3cf6-43fc-9e66-441361a74493" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_CR_6e72a210-3cf6-43fc-9e66-441361a74493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a4cf6606-c273-4afa-b252-6686a2d52791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a4cf6606-c273-4afa-b252-6686a2d52791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1f6effad-4f99-411c-a133-cb1cfd1692f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1f6effad-4f99-411c-a133-cb1cfd1692f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dc5216e4-66ea-4a0a-9343-0f48aef1e776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dc5216e4-66ea-4a0a-9343-0f48aef1e776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_942ad77d-f558-48a0-b903-5ac58066d5e6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:to="loc_srt_ProductsAndServicesDomain_942ad77d-f558-48a0-b903-5ac58066d5e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:to="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_37802df9-886c-4245-9352-231445e83d15" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:to="loc_bsx_OtherMember_37802df9-886c-4245-9352-231445e83d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3bdb85f4-9257-4bf4-a746-471e814f9c0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3bdb85f4-9257-4bf4-a746-471e814f9c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_696126a9-f44c-4317-b066-de2bd1edde99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_696126a9-f44c-4317-b066-de2bd1edde99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/RevenueDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/RevenueDetails" xlink:type="extended" id="i02b0f4abbf93480794f17bdd4b6c8455_RevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsTotalNumberOfCountries_215c5bfc-2576-4458-9660-495f04f5157e" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsTotalNumberOfCountries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_bsx_EmergingMarketsTotalNumberOfCountries_215c5bfc-2576-4458-9660-495f04f5157e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc7de6d2-f5a6-4fb3-9efb-110f60e7fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc7de6d2-f5a6-4fb3-9efb-110f60e7fc7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7686ddd0-e43c-4b50-b7a0-70f679dab62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7686ddd0-e43c-4b50-b7a0-70f679dab62c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_89e20d46-ab39-4ac3-b144-56c116b74c1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:to="loc_us-gaap_SegmentDomain_89e20d46-ab39-4ac3-b144-56c116b74c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:to="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BSXReportableSegmentsMember_d98e83e1-b14d-42b9-b731-8e5a8b6ce997" xlink:href="bsx-20221231.xsd#bsx_BSXReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_BSXReportableSegmentsMember_d98e83e1-b14d-42b9-b731-8e5a8b6ce997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_5baa52fd-5c7d-4d74-947f-635a6a327bf4" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_MedsurgMember_5baa52fd-5c7d-4d74-947f-635a6a327bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_fc741a28-8aa4-4e77-86e3-42eb9dbf4655" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_CardiovascularMember_fc741a28-8aa4-4e77-86e3-42eb9dbf4655" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28fd0470-ae09-4fed-afdc-6e31a1d5687b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:to="loc_srt_ProductsAndServicesDomain_28fd0470-ae09-4fed-afdc-6e31a1d5687b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:to="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEndoscopyEndoReportingUnitMember_8f29c465-e957-4a00-b024-d72b225bbef7" xlink:href="bsx-20221231.xsd#bsx_GlobalEndoscopyEndoReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalEndoscopyEndoReportingUnitMember_8f29c465-e957-4a00-b024-d72b225bbef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_fa8416f1-087e-4f40-919f-cb2933b81394" xlink:href="bsx-20221231.xsd#bsx_GlobalUrologyandPelvicHealthReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_fa8416f1-087e-4f40-919f-cb2933b81394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalNeuromodulationNmReportingUnitMember_31ebe3ee-22c6-4a11-948f-a82892f68b34" xlink:href="bsx-20221231.xsd#bsx_GlobalNeuromodulationNmReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalNeuromodulationNmReportingUnitMember_31ebe3ee-22c6-4a11-948f-a82892f68b34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_795d7e12-fb39-4e80-a3fd-aa5d71504b4b" xlink:href="bsx-20221231.xsd#bsx_GlobalPeripheralInterventionsPiReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_795d7e12-fb39-4e80-a3fd-aa5d71504b4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_70ed4b08-983a-4e54-a965-f4f038d6990b" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_70ed4b08-983a-4e54-a965-f4f038d6990b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InterventionalCardiologyTherapiesMember_38a87554-b0a7-4ba4-a1dd-36f332b7df4c" xlink:href="bsx-20221231.xsd#bsx_InterventionalCardiologyTherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_InterventionalCardiologyTherapiesMember_38a87554-b0a7-4ba4-a1dd-36f332b7df4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiacRhythmManagementMember_fb636467-a74e-4e97-8036-9f98212a301f" xlink:href="bsx-20221231.xsd#bsx_CardiacRhythmManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_CardiacRhythmManagementMember_fb636467-a74e-4e97-8036-9f98212a301f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ElectrophysiologyEPMember_d77b27d9-987a-45d8-a4bf-7c840a85361a" xlink:href="bsx-20221231.xsd#bsx_ElectrophysiologyEPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_ElectrophysiologyEPMember_d77b27d9-987a-45d8-a4bf-7c840a85361a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WatchmanMember_44230cd8-13e6-4466-a4d9-0a0169a95046" xlink:href="bsx-20221231.xsd#bsx_WatchmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_WatchmanMember_44230cd8-13e6-4466-a4d9-0a0169a95046" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalCardiologyReportingUnitMember_c14bc9c0-d86d-43ee-adb4-8320c479ca2f" xlink:href="bsx-20221231.xsd#bsx_GlobalCardiologyReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalCardiologyReportingUnitMember_c14bc9c0-d86d-43ee-adb4-8320c479ca2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_e2e0e719-ff54-48ec-a696-d87e14c96f7d" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_OtherMember_e2e0e719-ff54-48ec-a696-d87e14c96f7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc3b44f8-f450-4e62-89a0-70992cb40c1e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:to="loc_srt_SegmentGeographicalDomain_fc3b44f8-f450-4e62-89a0-70992cb40c1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:to="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d075727c-eb34-41c0-bd2b-5ffc466b7945" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_country_US_d075727c-eb34-41c0-bd2b-5ffc466b7945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3d0f56bb-c234-452f-80d5-7ed4e0e6bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_us-gaap_NonUsMember_3d0f56bb-c234-452f-80d5-7ed4e0e6bb09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_af100558-d3ea-42b8-a480-b3f94229d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_us-gaap_EMEAMember_af100558-d3ea-42b8-a480-b3f94229d9c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_65956ed1-60e1-462f-8c66-c76a668e3057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_srt_AsiaPacificMember_65956ed1-60e1-462f-8c66-c76a668e3057" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LatinAmericaandCanadaMember_d8de7b89-af1e-4abd-8960-00d6b3e0ade5" xlink:href="bsx-20221231.xsd#bsx_LatinAmericaandCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_LatinAmericaandCanadaMember_d8de7b89-af1e-4abd-8960-00d6b3e0ade5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsMember_62f87830-7db5-4073-a56f-d1a2bf2ed8d4" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_EmergingMarketsMember_62f87830-7db5-4073-a56f-d1a2bf2ed8d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_USExcludingOtherNetSalesMember_f232ecea-f8f1-4dc1-bda3-5b74d94897a7" xlink:href="bsx-20221231.xsd#bsx_USExcludingOtherNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_USExcludingOtherNetSalesMember_f232ecea-f8f1-4dc1-bda3-5b74d94897a7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" xlink:type="extended" id="ia7dfe946dbde430eafba0d1519b661dd_EmployeeRetirementPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_1ad9d6ff-c293-45c6-be59-4736dc2f60a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_1ad9d6ff-c293-45c6-be59-4736dc2f60a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5aed4da8-681a-415c-ac23-9a3093689cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5aed4da8-681a-415c-ac23-9a3093689cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e8e5fba8-bbde-496f-a81f-a97b38722320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e8e5fba8-bbde-496f-a81f-a97b38722320" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_222770e7-2d65-4728-ab16-f44bde22f4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_222770e7-2d65-4728-ab16-f44bde22f4c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_30d5f383-8e6c-4586-ba32-c09ae0cab8c1" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_30d5f383-8e6c-4586-ba32-c09ae0cab8c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_24fa01f9-5a98-40d2-8318-267b20c56c86" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_24fa01f9-5a98-40d2-8318-267b20c56c86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_a09938b1-02a1-48d7-bdb1-b3763e7341b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_a09938b1-02a1-48d7-bdb1-b3763e7341b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_00da9f0c-1711-4d74-8567-f90e4ec1c9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_00da9f0c-1711-4d74-8567-f90e4ec1c9d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d16e31ac-c113-45e8-ab4c-ca848ba5f320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d16e31ac-c113-45e8-ab4c-ca848ba5f320" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Pensionbenefitobligationbenefitspaid_0c6611c4-ce4d-4d9f-b0c2-ad5e056b4b4d" xlink:href="bsx-20221231.xsd#bsx_Pensionbenefitobligationbenefitspaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_Pensionbenefitobligationbenefitspaid_0c6611c4-ce4d-4d9f-b0c2-ad5e056b4b4d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0476c54f-edaa-456c-a5a7-bfcd73297c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0476c54f-edaa-456c-a5a7-bfcd73297c4d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_62f470f6-b5d7-45e4-b440-1e960aa7f073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_62f470f6-b5d7-45e4-b440-1e960aa7f073" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_69458d42-7a0e-462e-b1db-058a7cdbe652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_69458d42-7a0e-462e-b1db-058a7cdbe652" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_354d4ce3-cee9-4098-bf74-2b51542675d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_354d4ce3-cee9-4098-bf74-2b51542675d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_c5188f55-2716-4f81-801c-2ae02f66cdb9" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_c5188f55-2716-4f81-801c-2ae02f66cdb9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4b5daa69-a21b-49a1-a3c2-bd3b872f4968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4b5daa69-a21b-49a1-a3c2-bd3b872f4968" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_91295eb2-4d8e-4588-a5c9-dd1b2310cc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_91295eb2-4d8e-4588-a5c9-dd1b2310cc33" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e8658b90-560d-4374-8cc3-81241d1b3983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e8658b90-560d-4374-8cc3-81241d1b3983" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_1a731ce3-6d07-4bf9-95fe-34d857f4249f" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_1a731ce3-6d07-4bf9-95fe-34d857f4249f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f25c920f-8631-4461-96f8-dd6eaa3611b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f25c920f-8631-4461-96f8-dd6eaa3611b5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c3baa149-6fab-42fe-81c3-9d2fcebfa4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c3baa149-6fab-42fe-81c3-9d2fcebfa4b3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_0c74cf01-e136-4af1-9124-b6d59ee7a7dc" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_0c74cf01-e136-4af1-9124-b6d59ee7a7dc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExpenseRelatedToMatchingContributions_a2286654-9149-4045-bf37-18e140a1a157" xlink:href="bsx-20221231.xsd#bsx_ExpenseRelatedToMatchingContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_ExpenseRelatedToMatchingContributions_a2286654-9149-4045-bf37-18e140a1a157" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_fd7eed49-a011-4bee-99ca-eff4fda1315e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_fd7eed49-a011-4bee-99ca-eff4fda1315e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2b7fac85-16d7-40ef-978e-17bf752b117b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2b7fac85-16d7-40ef-978e-17bf752b117b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ac212511-0a8e-4e15-bbd5-fd8a50ed6723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ac212511-0a8e-4e15-bbd5-fd8a50ed6723" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_0e1edd35-406c-4e15-9689-153dda502af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_0e1edd35-406c-4e15-9689-153dda502af1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a09321-a65d-4ebc-93a8-481b6ff4f84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a09321-a65d-4ebc-93a8-481b6ff4f84b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_c78e6c03-e702-4fe4-86d7-1a7d1a44d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_c78e6c03-e702-4fe4-86d7-1a7d1a44d20b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a70b06ce-6e48-40b5-9a64-86463855fb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a70b06ce-6e48-40b5-9a64-86463855fb1b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e866eb9c-fe2d-44b9-bbe3-871f82574add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e866eb9c-fe2d-44b9-bbe3-871f82574add" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_1ca836ed-3a32-4ba5-b9b6-c20236a2f833_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:to="loc_us-gaap_RetirementPlanNameDomain_1ca836ed-3a32-4ba5-b9b6-c20236a2f833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:to="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExecutiveRetirementPlanMember_8c6f83f8-0631-4e9e-9053-1a4f594c06bb" xlink:href="bsx-20221231.xsd#bsx_ExecutiveRetirementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_ExecutiveRetirementPlanMember_8c6f83f8-0631-4e9e-9053-1a4f594c06bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InternationalRetirementPlansMember_425a9dff-83e5-48a6-8e08-db9a5e09917a" xlink:href="bsx-20221231.xsd#bsx_InternationalRetirementPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_InternationalRetirementPlansMember_425a9dff-83e5-48a6-8e08-db9a5e09917a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UKPlanMember_9a15ae85-20cb-4ceb-bdb8-e18ea963f115" xlink:href="bsx-20221231.xsd#bsx_UKPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_UKPlanMember_9a15ae85-20cb-4ceb-bdb8-e18ea963f115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2808558d-ed42-432d-8dce-2077f464e739_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2808558d-ed42-432d-8dce-2077f464e739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_187532e1-430e-46a6-a8a8-6a5ca9c846fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_187532e1-430e-46a6-a8a8-6a5ca9c846fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_3e43aa90-03f4-4576-ba6a-b284da87bbff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_3e43aa90-03f4-4576-ba6a-b284da87bbff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_73e82411-3ee0-4071-91b2-a6afc3bd5eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:to="loc_us-gaap_OtherContractMember_73e82411-3ee0-4071-91b2-a6afc3bd5eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d11b9a6-e105-4820-9062-28a380438dd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d11b9a6-e105-4820-9062-28a380438dd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e384312-b89c-4cfd-bea2-f44c62625c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e384312-b89c-4cfd-bea2-f44c62625c3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aae5ca3a-f2e3-4a09-bed3-d15f7d966c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aae5ca3a-f2e3-4a09-bed3-d15f7d966c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_404e6fb9-5af4-4da7-8015-c74ddca20a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_404e6fb9-5af4-4da7-8015-c74ddca20a1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_801382f6-f4a9-4b92-afba-796adacff831_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_801382f6-f4a9-4b92-afba-796adacff831_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8437bad2-adba-4331-9d2f-47dc51fa39d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_us-gaap_DomesticPlanMember_8437bad2-adba-4331-9d2f-47dc51fa39d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UKPlanMember_9eaaf713-8b99-401c-b60f-ef87cea7ce30" xlink:href="bsx-20221231.xsd#bsx_UKPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_bsx_UKPlanMember_9eaaf713-8b99-401c-b60f-ef87cea7ce30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherInternationalPlansMember_701b5639-1152-4cc7-90a2-42e39ab58f13" xlink:href="bsx-20221231.xsd#bsx_OtherInternationalPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_bsx_OtherInternationalPlansMember_701b5639-1152-4cc7-90a2-42e39ab58f13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:to="loc_srt_RangeMember_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:to="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87b8345e-27b7-41c1-b8be-6ab5b5d49a31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:to="loc_srt_MaximumMember_87b8345e-27b7-41c1-b8be-6ab5b5d49a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08b65118-846e-483a-b0eb-5eb510cdd42d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:to="loc_srt_MinimumMember_08b65118-846e-483a-b0eb-5eb510cdd42d" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>44
<FILENAME>bsx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_caab2325-6104-4777-9906-62b759817ce6_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_c517e8d6-ac50-4be3-b88e-afb757b5f24c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ad3ccf56-d269-4744-b33d-2043b8517b5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_45848f0b-3ff4-468f-a573-933f7a7ce199_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock_273c48d5-ed1c-484b-9bf1-f5f593859a05_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_43df4222-5c11-4a62-b59f-6415686e35a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5d7cdc65-9e3e-4385-8ec8-bbb19eaa1988_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_941b913f-82ca-472b-b38c-b0811200b30e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_1a3ebe0a-e0fb-4c7e-bf56-1e2874b09537_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DevoroMedicalIncMember_5ea9c4a1-9493-420e-8dc2-569a10a13311_terseLabel_en-US" xlink:label="lab_bsx_DevoroMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devoro Medical, Inc.</link:label>
    <link:label id="lab_bsx_DevoroMedicalIncMember_label_en-US" xlink:label="lab_bsx_DevoroMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devoro Medical, Inc. [Member]</link:label>
    <link:label id="lab_bsx_DevoroMedicalIncMember_documentation_en-US" xlink:label="lab_bsx_DevoroMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devoro Medical, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DevoroMedicalIncMember" xlink:href="bsx-20221231.xsd#bsx_DevoroMedicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DevoroMedicalIncMember" xlink:to="lab_bsx_DevoroMedicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_WatchmanMember_71125767-7076-4d90-970a-e2ddcb0ff18a_terseLabel_en-US" xlink:label="lab_bsx_WatchmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Watchman</link:label>
    <link:label id="lab_bsx_WatchmanMember_label_en-US" xlink:label="lab_bsx_WatchmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Watchman [Member]</link:label>
    <link:label id="lab_bsx_WatchmanMember_documentation_en-US" xlink:label="lab_bsx_WatchmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Watchman</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WatchmanMember" xlink:href="bsx-20221231.xsd#bsx_WatchmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_WatchmanMember" xlink:to="lab_bsx_WatchmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_02106d1a-3158-45a6-a081-0276e88e9a0c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_9c4533fe-78ec-4ee4-b961-a399d11db2bd_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_38beab3f-ddc9-492b-a240-bb3558086620_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4159ee3d-c841-4c18-a048-ba4c28b2b729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_24db57f8-2025-4344-ab15-7cedb7407b96_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration previously established in purchase accounting</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb160986-caba-4f20-85b8-4ab918b0ec99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_dc6d64ac-219f-4066-9136-b17f0a2dae97_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_5a044087-b610-4091-8a8a-f7ba3fffb6b0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac1e2d3f-91b0-446c-98fa-a92752eea7c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_a3df8403-702d-492f-aa7c-d35fef9cca91_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5978c2e2-0cda-4389-8210-1b1a0f7b8e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c87ff8ed-3f1a-4249-9fe3-81c3c0ebcf67_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease)&#160;in cash, cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed0be874-12ec-4ed2-b3ec-c3d906fbee3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e7186dcc-54e9-488d-acd6-b67e6f822558_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherCurrentAssetsAbstract_61a31a5d-469c-4a8b-be9c-18750fcc3958_terseLabel_en-US" xlink:label="lab_bsx_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Abstract]</link:label>
    <link:label id="lab_bsx_OtherCurrentAssetsAbstract_label_en-US" xlink:label="lab_bsx_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Abstract]</link:label>
    <link:label id="lab_bsx_OtherCurrentAssetsAbstract_documentation_en-US" xlink:label="lab_bsx_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherCurrentAssetsAbstract" xlink:href="bsx-20221231.xsd#bsx_OtherCurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherCurrentAssetsAbstract" xlink:to="lab_bsx_OtherCurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9377af98-d136-42ce-b18e-80458fb693d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_45ce9bee-bbe6-48fe-93ed-c1a6730a25ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_b5e8be5b-57fa-454d-9213-05a15658d708_terseLabel_en-US" xlink:label="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, four quarters following material acquisition</link:label>
    <link:label id="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_label_en-US" xlink:label="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, four quarters following material acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_documentation_en-US" xlink:label="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, four quarters following qualified acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:href="bsx-20221231.xsd#bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:to="lab_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_90f5257c-7512-4d27-8426-7fd993aec704_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_72454848-d389-469e-828f-6acc51bba953_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d156c21c-0a39-449a-bf7c-405e286de4a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_00076c5a-4f12-437e-88eb-eee47b527ffd_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_PaymentOfContingentConsideration_02bac4de-a2c7-4398-812e-2d4d3b37d24b_terseLabel_en-US" xlink:label="lab_bsx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_bsx_PaymentOfContingentConsideration_label_en-US" xlink:label="lab_bsx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_bsx_PaymentOfContingentConsideration_documentation_en-US" xlink:label="lab_bsx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_PaymentOfContingentConsideration" xlink:to="lab_bsx_PaymentOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1f467d83-01ae-4679-b0ef-b2d3bcf2e961_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_5e5aaa51-dca8-4522-b330-6c0a4af00144_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term borrowings, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_ff1060a7-e288-4e96-b607-83e768c0dbbe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_408aec03-ac1e-4de5-840f-1a81bdc7a84d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e8979e6b-3db8-45cc-b0b4-cdfb49592d7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ActualCovenantMember_3b594933-d9f4-4bf3-98ad-302e5ead21e1_terseLabel_en-US" xlink:label="lab_bsx_ActualCovenantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual, Covenant [Member]</link:label>
    <link:label id="lab_bsx_ActualCovenantMember_label_en-US" xlink:label="lab_bsx_ActualCovenantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual, Covenant [Member]</link:label>
    <link:label id="lab_bsx_ActualCovenantMember_documentation_en-US" xlink:label="lab_bsx_ActualCovenantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Covenant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ActualCovenantMember" xlink:href="bsx-20221231.xsd#bsx_ActualCovenantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ActualCovenantMember" xlink:to="lab_bsx_ActualCovenantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dd8a95e0-8626-4d9a-bcba-44851996724c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9916f099-2042-47a4-a97a-21dd99d5a018_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_49e09f08-605a-4eb2-a94e-77ec408207d4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_ea260032-acef-4dde-9a56-2368b2acd101_terseLabel_en-US" xlink:label="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:label id="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_label_en-US" xlink:label="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:label id="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_documentation_en-US" xlink:label="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:href="bsx-20221231.xsd#bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:to="lab_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9b97c24f-9b79-4b4c-ba2f-46f8ecc7e0be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_54172474-e1b4-46e2-967b-825897982616_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_093247ee-7e6f-4ee3-9703-2f394471a16e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_eaca9001-77e9-4472-8c3e-6c555ac186c8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_bcf4c7a2-5d8c-4ef3-95ce-fd695ea68b74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_993b494f-f9f1-4203-a7f7-01c667a19df7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementAsOfMarch312021Member_dce06bf5-c712-4ff6-b147-b1a4c4f04a72_terseLabel_en-US" xlink:label="lab_bsx_RequirementAsOfMarch312021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of March 31, 2021</link:label>
    <link:label id="lab_bsx_RequirementAsOfMarch312021Member_label_en-US" xlink:label="lab_bsx_RequirementAsOfMarch312021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of March 31, 2021 [Member]</link:label>
    <link:label id="lab_bsx_RequirementAsOfMarch312021Member_documentation_en-US" xlink:label="lab_bsx_RequirementAsOfMarch312021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of March 31, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfMarch312021Member" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfMarch312021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementAsOfMarch312021Member" xlink:to="lab_bsx_RequirementAsOfMarch312021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_16d127ee-3bcb-42c6-8922-64b096066c7d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxRateAxis_55fafcf6-6e52-4c45-8a6c-1467716ef2b7_terseLabel_en-US" xlink:label="lab_bsx_TaxRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Axis]</link:label>
    <link:label id="lab_bsx_TaxRateAxis_label_en-US" xlink:label="lab_bsx_TaxRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Axis]</link:label>
    <link:label id="lab_bsx_TaxRateAxis_documentation_en-US" xlink:label="lab_bsx_TaxRateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateAxis" xlink:href="bsx-20221231.xsd#bsx_TaxRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxRateAxis" xlink:to="lab_bsx_TaxRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9a6928d0-4852-4861-b5a4-1c737c13165c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b3451d2b-2b72-4dbe-96b9-dc2fab2dbb88_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_dcf1b791-039e-4b7e-8837-cbb7be8a6408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6a764ba5-fcf1-4e68-84ae-8bbb8a13148e_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_3e099112-17f1-4ddd-ae7e-a8613854bf1d_terseLabel_en-US" xlink:label="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:href="bsx-20221231.xsd#bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:to="lab_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_47928a39-3039-462e-b199-d436633fd3df_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_fae1362d-d540-47cc-9e6b-bded7eef8542_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_79c8aea3-4bd9-45a6-96ca-f2a051a789f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a4b52ecb-b96d-4ddb-944b-476719baf3e3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_cbcdcafc-7394-4f02-8c16-c7e6c510f31a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_a0fb9781-b001-4d69-9b77-855ee895da8e_terseLabel_en-US" xlink:label="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D, Regulatory and Commercialization-based Milestone [Member]</link:label>
    <link:label id="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_label_en-US" xlink:label="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D, Regulatory and Commercialization-based Milestone [Member]</link:label>
    <link:label id="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_documentation_en-US" xlink:label="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D, Regulatory and Commercialization-based Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:href="bsx-20221231.xsd#bsx_RDRegulatoryandCommercializationbasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:to="lab_bsx_RDRegulatoryandCommercializationbasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_a0a665b4-ee13-4c21-9d43-d137169c422a_terseLabel_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_label_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_documentation_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:to="lab_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CR_36542167-33aa-47ea-83f8-ee92ea562f8e_terseLabel_en-US" xlink:label="lab_country_CR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COSTA RICA</link:label>
    <link:label id="lab_country_CR_label_en-US" xlink:label="lab_country_CR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COSTA RICA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CR" xlink:to="lab_country_CR" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EuroDenominatedFactoringArrangementsMember_a1bb74bd-f20c-4e76-a8a3-99fc571441f9_terseLabel_en-US" xlink:label="lab_bsx_EuroDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_EuroDenominatedFactoringArrangementsMember_label_en-US" xlink:label="lab_bsx_EuroDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_EuroDenominatedFactoringArrangementsMember_documentation_en-US" xlink:label="lab_bsx_EuroDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Factoring Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EuroDenominatedFactoringArrangementsMember" xlink:href="bsx-20221231.xsd#bsx_EuroDenominatedFactoringArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EuroDenominatedFactoringArrangementsMember" xlink:to="lab_bsx_EuroDenominatedFactoringArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_852447d2-4404-42cf-8e1e-8923a0e2122a_terseLabel_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_label_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_documentation_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:to="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bd22cf7-f2fc-4867-8896-8f12d67c48a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock_6dde34c8-aa1c-4c17-b24a-1359fd9a6d76_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2020-10 Codification Improvements</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2020-10 Codification Improvements [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2020-10 Codification Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_5161f4a0-4128-440a-8e35-78ee0c90bd21_terseLabel_en-US" xlink:label="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Urology and Pelvic Health Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_label_en-US" xlink:label="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Urology and Pelvic Health Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_documentation_en-US" xlink:label="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Urology and Pelvic Health Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:href="bsx-20221231.xsd#bsx_GlobalUrologyandPelvicHealthReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:to="lab_bsx_GlobalUrologyandPelvicHealthReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b4730265-e7ea-44b9-a837-e2879b0c001d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TransitionTaxPaymentRemaining_ed98c5f4-2084-4338-b969-583eb0f6231a_terseLabel_en-US" xlink:label="lab_bsx_TransitionTaxPaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">transition tax payment remaining</link:label>
    <link:label id="lab_bsx_TransitionTaxPaymentRemaining_label_en-US" xlink:label="lab_bsx_TransitionTaxPaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Tax Payment Remaining</link:label>
    <link:label id="lab_bsx_TransitionTaxPaymentRemaining_documentation_en-US" xlink:label="lab_bsx_TransitionTaxPaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Tax Payment Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TransitionTaxPaymentRemaining" xlink:href="bsx-20221231.xsd#bsx_TransitionTaxPaymentRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TransitionTaxPaymentRemaining" xlink:to="lab_bsx_TransitionTaxPaymentRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherIntangibleAssetsTextualsAbstract_ba3ff483-8cf8-402a-afac-b5ce838a4a79_terseLabel_en-US" xlink:label="lab_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets (Textuals) [Abstract]</link:label>
    <link:label id="lab_bsx_OtherIntangibleAssetsTextualsAbstract_label_en-US" xlink:label="lab_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets (Textuals) [Abstract]</link:label>
    <link:label id="lab_bsx_OtherIntangibleAssetsTextualsAbstract_documentation_en-US" xlink:label="lab_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets (Textuals) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:href="bsx-20221231.xsd#bsx_OtherIntangibleAssetsTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:to="lab_bsx_OtherIntangibleAssetsTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e869589-6602-4e6e-8c94-7f015a40ca00_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e95bd724-1aee-4dbf-9c77-7804c13d83f2_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4b200303-5b15-45f4-b61a-8fa0e9d19b47_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_fe206e04-870d-44cc-8676-abba8b18160c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveNoncurrent" xlink:to="lab_us-gaap_LitigationReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_f554b8fe-85a8-4be6-bc00-ed9b40ea4f69_terseLabel_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_label_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_documentation_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:to="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_c79fd7b4-7c27-472f-a751-2a89510aced5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_07cb5abe-0767-4730-90ac-fc760eabdbe5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ae9bdf8d-11b6-4622-8b01-9cc4f7ffa0c6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share &#8212; basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CovenantAxis_a18e283a-3375-4cdd-84be-9035a04847ef_terseLabel_en-US" xlink:label="lab_bsx_CovenantAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant [Axis]</link:label>
    <link:label id="lab_bsx_CovenantAxis_label_en-US" xlink:label="lab_bsx_CovenantAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant [Axis]</link:label>
    <link:label id="lab_bsx_CovenantAxis_documentation_en-US" xlink:label="lab_bsx_CovenantAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantAxis" xlink:href="bsx-20221231.xsd#bsx_CovenantAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CovenantAxis" xlink:to="lab_bsx_CovenantAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0002561d-4a24-4f80-b132-4ee27537381f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2be5a0a0-76d7-4778-9767-bf1d5f7b459f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of preferred stock in connection with public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eaf9c0ec-367c-4e66-aa4f-62451c8497ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2028NotesMember_523b81a9-7e39-4a1e-a743-5f5122bdb93b_terseLabel_en-US" xlink:label="lab_bsx_March2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2028NotesMember_label_en-US" xlink:label="lab_bsx_March2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2028NotesMember_documentation_en-US" xlink:label="lab_bsx_March2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2028NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2028NotesMember" xlink:to="lab_bsx_March2028NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_7754e7f6-c4df-44e9-bbb2-6d63ee71347d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_faba986c-b80e-41a0-af16-ac75ccb34e05_terseLabel_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_label_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_documentation_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:to="lab_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_407bfafb-a622-4b55-9cc3-f703c1f4705a_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_ea2e0eb2-89e8-4dd2-bea5-0274a2cb8a05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e1217d1b-d214-48fd-9d20-f0cb296b3d97_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_fcc6318c-7ae5-4132-84b8-df81d0f10097_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_263e40d0-3061-4372-988d-89ee86f60078_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_cdda76f1-835d-4f1d-83e4-1fd8f6805505_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_26fc773d-fa91-4038-9251-ccb446655bd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_355e4d59-fd84-4f67-9b59-38f33b411655_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_7eacecb0-ec1b-439c-9f98-dcbb1ba34aad_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_709b64c6-47c5-4643-b7dd-291b42c5a353_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Paymenttonetsharesettleemployeeequityawards_3de190b0-f614-44ff-8e4f-21eae4caed3e_negatedTerseLabel_en-US" xlink:label="lab_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used to net share settle employee equity awards</link:label>
    <link:label id="lab_bsx_Paymenttonetsharesettleemployeeequityawards_label_en-US" xlink:label="lab_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to net share settle employee equity awards</link:label>
    <link:label id="lab_bsx_Paymenttonetsharesettleemployeeequityawards_documentation_en-US" xlink:label="lab_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to net share settle employee equity awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:href="bsx-20221231.xsd#bsx_Paymenttonetsharesettleemployeeequityawards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:to="lab_bsx_Paymenttonetsharesettleemployeeequityawards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f95760d8-0cf6-4503-8caa-2fba4595562b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d9c44b56-ecbf-46ec-af88-454caf64ac9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_320cf588-aed2-4709-8604-2e79f68e29c9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2031eb9c-84a7-4c6a-9fda-cbf6b5f843a2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b5041b8a-b8cc-4404-a7eb-70c7896231f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_23237fff-427e-495b-82ca-9d5549a7671f_terseLabel_en-US" xlink:label="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration liability, probability of payment</link:label>
    <link:label id="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_label_en-US" xlink:label="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration liability, probability of payment</link:label>
    <link:label id="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_documentation_en-US" xlink:label="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration liability, probability of payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:to="lab_bsx_ContingentConsiderationLiabilityProbabilityOfPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c3b20382-053e-4f9e-955e-8a87174d6b59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_993f345f-4d1c-4c37-92e8-b341f6790e07_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6a928df5-7d8e-4757-a2cf-730278994fda_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in Other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_9bab3bbb-1d4c-4e04-8e10-51c37a2b4870_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents included in Other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_AcotecScientificHoldingsLimitedMember_fcd995c0-44db-4ae7-9df6-8540c9bc7113_terseLabel_en-US" xlink:label="lab_bsx_AcotecScientificHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acotec Scientific Holdings Limited</link:label>
    <link:label id="lab_bsx_AcotecScientificHoldingsLimitedMember_label_en-US" xlink:label="lab_bsx_AcotecScientificHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acotec Scientific Holdings Limited [Member]</link:label>
    <link:label id="lab_bsx_AcotecScientificHoldingsLimitedMember_documentation_en-US" xlink:label="lab_bsx_AcotecScientificHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acotec Scientific Holdings Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AcotecScientificHoldingsLimitedMember" xlink:href="bsx-20221231.xsd#bsx_AcotecScientificHoldingsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_AcotecScientificHoldingsLimitedMember" xlink:to="lab_bsx_AcotecScientificHoldingsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_aff6a725-975a-469c-b522-e424cd0a2a99_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_52ca0e1f-0eae-4a1e-b19c-9b72602d8602_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_3d443804-1fe2-4508-bac1-87031351ecf3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance (Par value)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_IndemnificationAsset_3987c042-9df2-421d-80a2-dbcaeef5cb3f_terseLabel_en-US" xlink:label="lab_bsx_IndemnificationAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification asset</link:label>
    <link:label id="lab_bsx_IndemnificationAsset_label_en-US" xlink:label="lab_bsx_IndemnificationAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification asset</link:label>
    <link:label id="lab_bsx_IndemnificationAsset_documentation_en-US" xlink:label="lab_bsx_IndemnificationAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IndemnificationAsset" xlink:href="bsx-20221231.xsd#bsx_IndemnificationAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_IndemnificationAsset" xlink:to="lab_bsx_IndemnificationAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_77339381-65d9-49e4-8d72-af3b86199aa1_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_ec84a0cf-9914-49b9-bd1b-e12e54b68b2a_verboseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_b2da26bd-3694-4899-b56e-dca5270792c8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CovenantDomain_cb11209f-e5b9-4ba4-b04d-6a7ee971a885_terseLabel_en-US" xlink:label="lab_bsx_CovenantDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant [Domain]</link:label>
    <link:label id="lab_bsx_CovenantDomain_label_en-US" xlink:label="lab_bsx_CovenantDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant [Domain]</link:label>
    <link:label id="lab_bsx_CovenantDomain_documentation_en-US" xlink:label="lab_bsx_CovenantDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantDomain" xlink:href="bsx-20221231.xsd#bsx_CovenantDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CovenantDomain" xlink:to="lab_bsx_CovenantDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_68b591a4-f5db-4c76-8f2d-ac4fafe6c5c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_4a88d6c2-aa39-4b61-9fab-817e6dbfd372_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_afe74d75-cf1f-4210-b655-da4412d97811_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54402269-64d8-4f4e-a421-edf749b16a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8bb820a1-9206-4d5c-a595-c533a6953cf8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_fd4ed801-7182-459f-9b11-e9915f321a3f_terseLabel_en-US" xlink:label="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</link:label>
    <link:label id="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_label_en-US" xlink:label="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</link:label>
    <link:label id="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_documentation_en-US" xlink:label="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:to="lab_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_NonCashImpactOfTransferredRoyaltyRights_d42a7958-65aa-4429-941c-5079f1b33aaf_terseLabel_en-US" xlink:label="lab_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of transferred royalty rights</link:label>
    <link:label id="lab_bsx_NonCashImpactOfTransferredRoyaltyRights_label_en-US" xlink:label="lab_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of transferred royalty rights</link:label>
    <link:label id="lab_bsx_NonCashImpactOfTransferredRoyaltyRights_documentation_en-US" xlink:label="lab_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of transferred royalty rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:href="bsx-20221231.xsd#bsx_NonCashImpactOfTransferredRoyaltyRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:to="lab_bsx_NonCashImpactOfTransferredRoyaltyRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_273d90d0-51e4-46c4-a475-3a72d50ef549_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Gain on Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_04430db3-084b-4ac7-86f5-13b2cbd0c849_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_07aef868-f6f9-4bbb-a3b0-bfee248fcf6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_d7ea2729-67f3-4848-bfa0-5680cc631e8a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Annualweightedaverageforfeiturerate_31919f78-5709-4d08-b328-66be427a6378_terseLabel_en-US" xlink:label="lab_bsx_Annualweightedaverageforfeiturerate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">annualweightedaverageforfeiturerate</link:label>
    <link:label id="lab_bsx_Annualweightedaverageforfeiturerate_label_en-US" xlink:label="lab_bsx_Annualweightedaverageforfeiturerate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">annualweightedaverageforfeiturerate</link:label>
    <link:label id="lab_bsx_Annualweightedaverageforfeiturerate_documentation_en-US" xlink:label="lab_bsx_Annualweightedaverageforfeiturerate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Annualweightedaverageforfeiturerate" xlink:href="bsx-20221231.xsd#bsx_Annualweightedaverageforfeiturerate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Annualweightedaverageforfeiturerate" xlink:to="lab_bsx_Annualweightedaverageforfeiturerate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a115a84f-dc87-4c6c-9e57-a24e80c86031_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a990946f-85d6-4ea2-af2a-37aa57eb7cd6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ad6a43e2-b5df-4277-9585-a9bc8197bb72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits, Research</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_64a5f4a4-8488-41db-9f73-2fdf5d255fa5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2bd91116-b244-4fd9-a27e-06d22425a163_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDisclosuresAbstract_ed0411f1-4521-4391-9ddf-98fb3b36cab7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="lab_us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_56e50898-3d7d-4b0d-888b-ffb0377b330d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_905f164a-63c6-4beb-b6b4-31cffbfcad90_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bcfcf026-95dd-4a3b-b3bd-797973d379b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration net expense (benefit)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7e9c41dd-04e6-470e-ac3a-6a01615e3667_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration net expense (benefit)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Measurementperiodmarketbasedaward_7e7c3a0e-83e3-4a2c-8ef1-fb78578832fd_terseLabel_en-US" xlink:label="lab_bsx_Measurementperiodmarketbasedaward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period - market based awards</link:label>
    <link:label id="lab_bsx_Measurementperiodmarketbasedaward_label_en-US" xlink:label="lab_bsx_Measurementperiodmarketbasedaward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period - market based award</link:label>
    <link:label id="lab_bsx_Measurementperiodmarketbasedaward_documentation_en-US" xlink:label="lab_bsx_Measurementperiodmarketbasedaward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period - market based awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Measurementperiodmarketbasedaward" xlink:href="bsx-20221231.xsd#bsx_Measurementperiodmarketbasedaward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Measurementperiodmarketbasedaward" xlink:to="lab_bsx_Measurementperiodmarketbasedaward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_fcde9536-28eb-49f4-9db5-d9d4f4c256fd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EmergingMarketsTotalNumberOfCountries_21fd5e87-a908-4a7f-bc16-c8ad793e019a_terseLabel_en-US" xlink:label="lab_bsx_EmergingMarketsTotalNumberOfCountries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets total number of countries</link:label>
    <link:label id="lab_bsx_EmergingMarketsTotalNumberOfCountries_label_en-US" xlink:label="lab_bsx_EmergingMarketsTotalNumberOfCountries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets total number of countries</link:label>
    <link:label id="lab_bsx_EmergingMarketsTotalNumberOfCountries_documentation_en-US" xlink:label="lab_bsx_EmergingMarketsTotalNumberOfCountries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets total number of countries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsTotalNumberOfCountries" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsTotalNumberOfCountries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EmergingMarketsTotalNumberOfCountries" xlink:to="lab_bsx_EmergingMarketsTotalNumberOfCountries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_4aaf3f7a-9e27-45ca-b47d-a36590c369e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_20d0717c-d6c1-4e8a-a9ab-58997cd49ed0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_adadc02c-e960-4d90-a435-743bc1dd42cd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_457b70ad-d542-46c3-b2ad-1552ae4be0a2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Pensionbenefitobligationbenefitspaid_0c28fb78-4e85-4b83-a7cc-d51ea11f8289_negatedTerseLabel_en-US" xlink:label="lab_bsx_Pensionbenefitobligationbenefitspaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">pension benefit obligation, benefits paid</link:label>
    <link:label id="lab_bsx_Pensionbenefitobligationbenefitspaid_label_en-US" xlink:label="lab_bsx_Pensionbenefitobligationbenefitspaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">pension benefit obligation, benefits paid</link:label>
    <link:label id="lab_bsx_Pensionbenefitobligationbenefitspaid_documentation_en-US" xlink:label="lab_bsx_Pensionbenefitobligationbenefitspaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">pension benefit obligation, benefits paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Pensionbenefitobligationbenefitspaid" xlink:href="bsx-20221231.xsd#bsx_Pensionbenefitobligationbenefitspaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Pensionbenefitobligationbenefitspaid" xlink:to="lab_bsx_Pensionbenefitobligationbenefitspaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ddab898c-c42b-4a30-a434-d0b7d738e19b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_229c0e3c-0f1b-4a44-a8ca-42fb13ba0f1d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0656f99a-ac07-4478-bac9-6dbaee27ffef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_82ebaac1-ce1a-4d9b-9d9e-3905e965a81f_terseLabel_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average exercise price</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_label_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average exercise price</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:to="lab_bsx_OptionsExpectedToVestWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_fba4e6c1-d575-4d2d-99d4-9c0ebc03b855_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:to="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_f8de3bd6-2639-4772-a8c4-9598b7af18c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_1422660b-96ff-4599-9335-9e8d8473875e_terseLabel_en-US" xlink:label="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil CADE - # of individuals for alleged anti-competitive behavior</link:label>
    <link:label id="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_label_en-US" xlink:label="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil CADE - # of individuals for alleged anti-competitive behavior</link:label>
    <link:label id="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_documentation_en-US" xlink:label="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil CADE - # of individuals for alleged anti-competitive behavior</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:href="bsx-20221231.xsd#bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:to="lab_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_fbb195f7-c97f-4d1c-aa8a-dfb1d707e63b_terseLabel_en-US" xlink:label="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_documentation_en-US" xlink:label="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:href="bsx-20221231.xsd#bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:to="lab_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a6c8f60e-eb45-4aab-9bb8-463d3cb9a5cd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c43fcee4-130a-4085-9e75-1822d54c771b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d26cfb92-b1dd-4795-8a76-1882c29c2dfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ConsolidatedBalanceSheetParentheticalAbstract_label_en-US" xlink:label="lab_bsx_ConsolidatedBalanceSheetParentheticalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheet (Parenthetical) [Abstract]</link:label>
    <link:label id="lab_bsx_ConsolidatedBalanceSheetParentheticalAbstract_documentation_en-US" xlink:label="lab_bsx_ConsolidatedBalanceSheetParentheticalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheet (Parenthetical)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedBalanceSheetParentheticalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract" xlink:to="lab_bsx_ConsolidatedBalanceSheetParentheticalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fa5f9a7c-6b09-44f5-8121-c3e03aef4488_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_09a1c7a9-febf-4748-8b55-6ec51c57b174_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_873da909-7308-468a-bd47-2015cfda309b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_e31b40c1-f42b-4cea-971b-08af04b5854b_verboseLabel_en-US" xlink:label="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges remaining to be excluded from calculation of consolidated EBITDA</link:label>
    <link:label id="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_label_en-US" xlink:label="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges remaining to be excluded from calculation of consolidated EBITDA</link:label>
    <link:label id="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_documentation_en-US" xlink:label="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:href="bsx-20221231.xsd#bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:to="lab_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_487e88fa-8750-4672-9b92-c5be64736f93_terseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_label_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_420e9079-f103-41d0-a36c-6bda8873c068_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c4376ca2-7f48-4bdd-98fa-6811823c4437_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2f9f9919-9232-4dcb-ab20-a050ba12c549_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_330c38ab-8a3e-4928-a533-828db7c72e90_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3d64006d-beb9-4547-b618-04efd59c635d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b4af4f30-d3f0-4c4f-a428-46bc8a82778a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_89e9cc1b-2437-4e8f-913d-7acfd8273b27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_fd8dd333-a8d8-4f23-8f07-115b40d86aba_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS AND STRATEGIC INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_17108b6f-bf5f-4cf9-96fe-c8006d0a805d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a1718e72-e1e1-4874-bbdf-d405294c0a26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_A2021AcquisitionsMember_8290ebd8-287b-4a87-956a-b2da7cd8eb89_terseLabel_en-US" xlink:label="lab_bsx_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:label id="lab_bsx_A2021AcquisitionsMember_label_en-US" xlink:label="lab_bsx_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions [Member]</link:label>
    <link:label id="lab_bsx_A2021AcquisitionsMember_documentation_en-US" xlink:label="lab_bsx_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_A2021AcquisitionsMember" xlink:to="lab_bsx_A2021AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_79fb151a-9471-4659-b99f-25eb2593db2d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_7a85ff0c-e91b-46cb-9343-0c772801fc4e_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_edf36642-e731-4d90-a391-eb0648fc831b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_4ff28837-e7b8-4de1-9d49-667f92fd722b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_68cb932e-7826-4b6b-8627-9a4ce8de8fbc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_016f07ac-3bac-448f-88f1-c1847ece7858_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_99ee7b45-1861-474a-8f42-909b6389daee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_768f1785-7a25-4193-aef1-a85faef1ea53_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30ce62f8-d7cd-4b4c-a8af-c04a43fb15d6_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f31bd5f1-6331-46cb-8a1c-6f9dbcd66d57_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_82fcdbdc-1585-4dc4-a7b7-275ad539302d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6780b246-2d0c-4aac-a464-98a5b88cb7af_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fc5b3ee-8ded-40c6-8ebd-8f13c6c6bfa4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3a55bf0d-1e01-457c-b0e2-8fb790136d6f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_05c00329-4c8b-400c-a485-daf1c1001cc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ExpenseRelatedToMatchingContributions_170f4744-1d56-43f3-888d-0764a1f32e19_terseLabel_en-US" xlink:label="lab_bsx_ExpenseRelatedToMatchingContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense related to matching contributions</link:label>
    <link:label id="lab_bsx_ExpenseRelatedToMatchingContributions_label_en-US" xlink:label="lab_bsx_ExpenseRelatedToMatchingContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense related to matching contributions</link:label>
    <link:label id="lab_bsx_ExpenseRelatedToMatchingContributions_documentation_en-US" xlink:label="lab_bsx_ExpenseRelatedToMatchingContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense related to matching contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExpenseRelatedToMatchingContributions" xlink:href="bsx-20221231.xsd#bsx_ExpenseRelatedToMatchingContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ExpenseRelatedToMatchingContributions" xlink:to="lab_bsx_ExpenseRelatedToMatchingContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_4df3d84e-243d-4c57-ac7b-a3771bbc877a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Segmentoperatingincomeaspercentageofnetsales_3e1ac147-82f2-4339-9d37-8b382095bd31_terseLabel_en-US" xlink:label="lab_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales</link:label>
    <link:label id="lab_bsx_Segmentoperatingincomeaspercentageofnetsales_label_en-US" xlink:label="lab_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales</link:label>
    <link:label id="lab_bsx_Segmentoperatingincomeaspercentageofnetsales_documentation_en-US" xlink:label="lab_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:href="bsx-20221231.xsd#bsx_Segmentoperatingincomeaspercentageofnetsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:to="lab_bsx_Segmentoperatingincomeaspercentageofnetsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c93079b7-f200-4735-bba4-36a8400fde63_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_c498e806-9d5f-43e4-a2c9-1877679723f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d31ea6a8-d64c-4972-a80a-134c3e6cea56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_52364d7d-e5c2-4b23-89df-bdf1d4d74ed4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DiscountRateFairValueInput_5d8fc130-4a82-4827-b19d-92b0582a3e8d_terseLabel_en-US" xlink:label="lab_bsx_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_bsx_DiscountRateFairValueInput_label_en-US" xlink:label="lab_bsx_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_bsx_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_bsx_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DiscountRateFairValueInput" xlink:to="lab_bsx_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_a9b8b950-6e5b-49be-97eb-344b11fe53fa_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_1da109eb-338a-41fd-87e7-605d6db3f674_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7ef35e69-3ba7-48b2-b817-8ec456cdf791_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c81611d1-7e40-496c-976e-39deda2aad25_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1e0efbaa-e867-466e-91a3-a06f592e2c79_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_44845bd7-a794-4a1a-a36e-b3d89583a014_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c3a7d15-1499-404d-b9a1-d3a229c2697e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b5c34939-9641-4f2d-b9b4-501efaf2d5ab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8a24e243-d8f8-4846-88c2-94f107b08ee5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_ba52b554-7fb5-4e8a-9e69-ec37e75e14fe_terseLabel_en-US" xlink:label="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - early redemption of combined aggregate principal SN</link:label>
    <link:label id="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_label_en-US" xlink:label="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - early redemption of combined aggregate principal SN [Member]</link:label>
    <link:label id="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_documentation_en-US" xlink:label="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - early redemption of combined aggregate principal SN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:href="bsx-20221231.xsd#bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:to="lab_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_f5aa5f30-1aab-4484-ad0f-ef0bf047badb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c4f7b6e9-79cf-44bf-b4c1-0c746a6a073e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_a1c3d64d-6dce-4f95-84f0-5a4384ba2235_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_935a8b6a-3187-485d-ae96-b3469fb2773c_terseLabel_en-US" xlink:label="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, eighth quarter and thereafter following qualified acquisition</link:label>
    <link:label id="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_label_en-US" xlink:label="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, eighth quarter and thereafter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_documentation_en-US" xlink:label="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, eighth quarter and thereafter following qualified acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:href="bsx-20221231.xsd#bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:to="lab_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_75d7a45c-319a-4227-888a-bfa8df3a0bb0_terseLabel_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_label_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_documentation_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:to="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_b41fe148-ce30-4d24-b3be-af9e7324e04f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_dd0e69b8-0b04-4583-83ee-0635c95a5691_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock_0bfe5094-a7b5-420e-baaa-1a28717ad69a_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_be806e91-c9fd-45fa-bda6-ddf665b98835_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DeferredTaxAssetsDomain_25fc0913-6114-43cd-ba95-acc1447943f6_terseLabel_en-US" xlink:label="lab_bsx_DeferredTaxAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets [Domain]</link:label>
    <link:label id="lab_bsx_DeferredTaxAssetsDomain_label_en-US" xlink:label="lab_bsx_DeferredTaxAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets [Domain]</link:label>
    <link:label id="lab_bsx_DeferredTaxAssetsDomain_documentation_en-US" xlink:label="lab_bsx_DeferredTaxAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsDomain" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DeferredTaxAssetsDomain" xlink:to="lab_bsx_DeferredTaxAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b97a4bb3-b7d8-4b96-9c70-26acd09aa215_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalty rights</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_efa00df2-8f73-42fd-b63c-cd97434e3e38_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_43481f09-4a95-432c-9d7d-3a13da97ab3d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ba4ce6a9-5159-484e-a71c-600b0cc94f8b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_8f484a34-6f17-4678-9470-bd62d091e41f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fb31318c-54fe-49d1-b6d5-58b320b71159_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_1734f20a-8b62-401c-af1f-8cd4edb9e5f2_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High end of range [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_96edfb0b-0f1a-4b4e-b294-9f4276671433_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_10734e52-15ae-4c7f-ac49-68bddaff8549_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2916580a-13d8-4c9c-ade7-9298ef28fe55_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_9eddd529-3133-463c-9e9d-1073f1d8144d_terseLabel_en-US" xlink:label="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign currency fluctuations on net sales</link:label>
    <link:label id="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_label_en-US" xlink:label="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign currency fluctuations on net sales</link:label>
    <link:label id="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_documentation_en-US" xlink:label="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign currency fluctuations on net sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:href="bsx-20221231.xsd#bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:to="lab_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_469b5ad8-120f-4ef2-930b-234f7435c3f6_terseLabel_en-US" xlink:label="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)</link:label>
    <link:label id="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_label_en-US" xlink:label="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)</link:label>
    <link:label id="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_documentation_en-US" xlink:label="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:href="bsx-20221231.xsd#bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:to="lab_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1eff61e4-1a3a-43fa-97af-84ec73da7cb7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d70c10fe-2f6c-447b-be3a-7da767cabdb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_8bb6184e-d203-4c0b-b10a-e876db8ae997_terseLabel_en-US" xlink:label="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of employees total compensation eligible for GESOP purchase</link:label>
    <link:label id="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_label_en-US" xlink:label="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of employees total compensation eligible for GESOP purchase</link:label>
    <link:label id="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_documentation_en-US" xlink:label="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of employees total compensation eligible for GESOP purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:href="bsx-20221231.xsd#bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:to="lab_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_2fe41b6a-f981-46d5-925c-5585ca6a5a1c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net</link:label>
    <link:label id="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:to="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e387c1ed-1fc9-458f-ac0b-7178234e10e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted cash equivalents included in Other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b4a03c7d-ab40-4282-ab68-7f8e32ec62e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_199bc710-197b-4ea9-9dfb-5eef2d230e32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f2dea13f-6555-44b5-8190-4b67b65904f5_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b3e52e8-8761-4ca4-9025-6707671d315d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_0e8a674b-91a1-4382-8960-84f76ca0329e_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_7e29e691-0067-4844-8c72-83afb38c219b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on long-term borrowings and debt extinguishment costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DeferredTaxLiabilitiesDomain_84ac5d92-f8a3-4f5b-8a9d-7b8bc77bd965_terseLabel_en-US" xlink:label="lab_bsx_DeferredTaxLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities [Domain]</link:label>
    <link:label id="lab_bsx_DeferredTaxLiabilitiesDomain_label_en-US" xlink:label="lab_bsx_DeferredTaxLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities [Domain]</link:label>
    <link:label id="lab_bsx_DeferredTaxLiabilitiesDomain_documentation_en-US" xlink:label="lab_bsx_DeferredTaxLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxLiabilitiesDomain" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DeferredTaxLiabilitiesDomain" xlink:to="lab_bsx_DeferredTaxLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a4b85d2d-937e-4e08-837e-5137616db71f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_d27dee60-e46f-4442-90dd-94a534831ea3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6ead182e-ca0e-4e6b-852b-e75a11b7b6e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_6727529e-4b76-45db-896f-88f718e55a6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of businesses and assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_9aac7226-9dc4-458e-8bc6-24ac3f301941_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c2103abd-7b04-42f1-b577-9c5249dee265_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_79fa2a52-a419-4d4f-920f-85088d022f87_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_PercentOfFinishedGoodsAtConsignment_fccc338f-a2bf-4a7a-9be1-2e2fc9c67c83_terseLabel_en-US" xlink:label="lab_bsx_PercentOfFinishedGoodsAtConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of finished goods at consignment</link:label>
    <link:label id="lab_bsx_PercentOfFinishedGoodsAtConsignment_label_en-US" xlink:label="lab_bsx_PercentOfFinishedGoodsAtConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of finished goods at consignment</link:label>
    <link:label id="lab_bsx_PercentOfFinishedGoodsAtConsignment_documentation_en-US" xlink:label="lab_bsx_PercentOfFinishedGoodsAtConsignment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of finished goods at consignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PercentOfFinishedGoodsAtConsignment" xlink:href="bsx-20221231.xsd#bsx_PercentOfFinishedGoodsAtConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_PercentOfFinishedGoodsAtConsignment" xlink:to="lab_bsx_PercentOfFinishedGoodsAtConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7c268af5-04b5-4343-9a16-676470efc487_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_17232942-a975-4607-abb9-f7fa6105e184_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_d334c523-d447-43de-93e4-3be009e9fc52_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2f625fdd-91b5-4439-a5d8-dab34a18e774_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_4a31e940-ee62-47c8-9218-b0e0a92aa20c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_cba86066-f99e-4e46-9bac-863d06c3f1f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_251d8be8-0cde-4508-84a3-eef1926fb8ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationAbstract_3a0bf507-21c9-4eee-81e8-c3a612d3f340_terseLabel_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationAbstract" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_bsx_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LicensingArrangements_f2b3f918-45d9-4efb-b9ce-25d714c86db2_terseLabel_en-US" xlink:label="lab_bsx_LicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements</link:label>
    <link:label id="lab_bsx_LicensingArrangements_label_en-US" xlink:label="lab_bsx_LicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements</link:label>
    <link:label id="lab_bsx_LicensingArrangements_documentation_en-US" xlink:label="lab_bsx_LicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangements" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LicensingArrangements" xlink:to="lab_bsx_LicensingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_63373e3c-e06c-4504-951e-16c2aa4c74b5_terseLabel_en-US" xlink:label="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, seventh quarter following qualified acquisition</link:label>
    <link:label id="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_label_en-US" xlink:label="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, seventh quarter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_documentation_en-US" xlink:label="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, seventh quarter following qualified acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:href="bsx-20221231.xsd#bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:to="lab_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9c402d0a-08e1-4f21-99fc-d9641a30ba2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_db1618d1-a214-4097-9db1-2586d1845cc4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2cf4bc07-978d-4ea8-a3c2-5c3160512868_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_34108fb2-9020-4f9d-aa71-d50f3a04dee5_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average interest rate of de-recognized receivables</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable with Imputed Interest, Effective Yield (Interest Rate)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:to="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3a46c391-a49c-49d9-8f3c-70d21495f9b5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_75080c4c-bbae-480f-a350-ca1b75bfaea7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_28981fda-2c42-45b5-ac70-6b9adbf694e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d59b892f-80c6-4dcd-82f3-c207e41f9b0e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ApolloEndosurgeryIncMember_966f3b1f-4105-45ca-ac89-1ade3cb19da8_terseLabel_en-US" xlink:label="lab_bsx_ApolloEndosurgeryIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Endosurgery, Inc.</link:label>
    <link:label id="lab_bsx_ApolloEndosurgeryIncMember_label_en-US" xlink:label="lab_bsx_ApolloEndosurgeryIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Endosurgery, Inc. [Member]</link:label>
    <link:label id="lab_bsx_ApolloEndosurgeryIncMember_documentation_en-US" xlink:label="lab_bsx_ApolloEndosurgeryIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Endosurgery, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ApolloEndosurgeryIncMember" xlink:href="bsx-20221231.xsd#bsx_ApolloEndosurgeryIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ApolloEndosurgeryIncMember" xlink:to="lab_bsx_ApolloEndosurgeryIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_92496abc-cd00-4a3b-b79a-2142f4cdff42_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_StatementAxis_1daca0fe-dd6f-4255-9f8e-021719d44fa0_terseLabel_en-US" xlink:label="lab_bsx_StatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">statement [Axis]</link:label>
    <link:label id="lab_bsx_StatementAxis_label_en-US" xlink:label="lab_bsx_StatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">statement [Axis]</link:label>
    <link:label id="lab_bsx_StatementAxis_documentation_en-US" xlink:label="lab_bsx_StatementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">statement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementAxis" xlink:href="bsx-20221231.xsd#bsx_StatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_StatementAxis" xlink:to="lab_bsx_StatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_ffbfdfeb-2842-459b-aa9a-508399c6a4da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Indemnification Assets, Amount as of Acquisition Date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Indemnification Assets, Amount as of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" xlink:to="lab_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsPerShareCashPaid_756d316d-2050-4a0b-be58-f3a49fed51ab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d284367f-b29d-48c9-b028-cbab0d129f35_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5adc54a5-c933-4956-b691-6f6166b7a655_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_cecb6054-6131-4654-8f95-b7a4ed56361b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_e8b2300a-957e-42fb-b525-866f921a390a_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC [Member]</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_86dc24b1-0f56-4f32-a76b-4ca0f1d2f981_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards_62cb2ce6-fad9-419e-a044-454b3628a666_terseLabel_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Non-vested stock awards</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards_label_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Non-vested stock awards</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards_documentation_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Non-vested stock awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostNonVestedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:to="lab_bsx_UnrecognizedCompensationCostNonVestedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f4b09486-bc90-4963-b5b2-a46e2ed4a102_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_08d4500f-8712-4430-9711-00079908b47c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9c9a65ef-dadc-456e-a80a-e7e6aee4c54b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f20ff1da-06e5-4dfe-bcae-7c12b3e646f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_96bde614-b586-4e73-a669-d28d771e212f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2aeb5f0c-e880-410f-9b89-fd39c0af7b2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_86e68577-74b7-4e7c-87b7-7162b15a9ad7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_75ed6daf-c154-4a1b-9e9e-dfed774508d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_f8b6bc49-1b7a-4538-84c1-dd992d2bd42f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_WeightedAverageRemainingVestingPeriod_93b0a7ee-abfa-4ce6-85c9-3cfc1acbc394_terseLabel_en-US" xlink:label="lab_bsx_WeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted average remaining vesting period</link:label>
    <link:label id="lab_bsx_WeightedAverageRemainingVestingPeriod_label_en-US" xlink:label="lab_bsx_WeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted average remaining vesting period</link:label>
    <link:label id="lab_bsx_WeightedAverageRemainingVestingPeriod_documentation_en-US" xlink:label="lab_bsx_WeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted average remaining vesting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WeightedAverageRemainingVestingPeriod" xlink:href="bsx-20221231.xsd#bsx_WeightedAverageRemainingVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_WeightedAverageRemainingVestingPeriod" xlink:to="lab_bsx_WeightedAverageRemainingVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_c64d3149-5def-48e5-ac0c-f9f602baf026_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b15516c7-e78b-49dd-af58-23eefa90357f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_f5665977-ede5-41a7-873c-abcf8fc063e1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_b9bce64f-8147-487c-b497-8f84f24f0a28_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0dca512b-79f8-4d20-adc5-62a1fadac04f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_29d40533-e2ca-4899-9a53-ed66a1f24de0_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f42d5d3-9dd5-4450-8ab7-55a7096aea45_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_838564bd-28a1-4de8-b979-0e48a05f5925_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_5a1c58b6-9493-42a9-a41c-e59f3a9fd30d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ForwardCurrencyContractsTimetoMaturity_0ce5c358-cef1-44ad-a183-4af42a18764d_terseLabel_en-US" xlink:label="lab_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Contracts, Time to Maturity</link:label>
    <link:label id="lab_bsx_ForwardCurrencyContractsTimetoMaturity_label_en-US" xlink:label="lab_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Contracts, Time to Maturity</link:label>
    <link:label id="lab_bsx_ForwardCurrencyContractsTimetoMaturity_documentation_en-US" xlink:label="lab_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Contracts, Time to Maturity in Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:href="bsx-20221231.xsd#bsx_ForwardCurrencyContractsTimetoMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:to="lab_bsx_ForwardCurrencyContractsTimetoMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_USExcludingOtherNetSalesMember_3ba73497-6257-48d5-98a2-73fd8a81fd5b_terseLabel_en-US" xlink:label="lab_bsx_USExcludingOtherNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">country_US excluding Other Net Sales</link:label>
    <link:label id="lab_bsx_USExcludingOtherNetSalesMember_label_en-US" xlink:label="lab_bsx_USExcludingOtherNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US excluding Other Net Sales [Member]</link:label>
    <link:label id="lab_bsx_USExcludingOtherNetSalesMember_documentation_en-US" xlink:label="lab_bsx_USExcludingOtherNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US excluding Other Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_USExcludingOtherNetSalesMember" xlink:href="bsx-20221231.xsd#bsx_USExcludingOtherNetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_USExcludingOtherNetSalesMember" xlink:to="lab_bsx_USExcludingOtherNetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2049NotesMember_f0778d1f-8b18-4ba6-9b8b-a872b042257a_terseLabel_en-US" xlink:label="lab_bsx_March2049NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2049 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2049NotesMember_label_en-US" xlink:label="lab_bsx_March2049NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2049 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2049NotesMember_documentation_en-US" xlink:label="lab_bsx_March2049NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2049 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2049NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2049NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2049NotesMember" xlink:to="lab_bsx_March2049NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2039NotesMember_5008b893-e3b0-41da-80fd-d4ae681aa469_terseLabel_en-US" xlink:label="lab_bsx_March2039NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2039 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2039NotesMember_label_en-US" xlink:label="lab_bsx_March2039NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2039 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2039NotesMember_documentation_en-US" xlink:label="lab_bsx_March2039NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2039 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2039NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2039NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2039NotesMember" xlink:to="lab_bsx_March2039NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b0bd021-3bdd-4a1e-affc-62d2a6b8fe62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_731d10ab-14b6-4538-9dc5-b9b517bb2914_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0e944c83-38bd-4d63-a71b-d500cec932f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2caaada0-2f41-41f2-9abc-9733b4c7adb9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OperatingIncomeUnallocatedToSegment_e96908fb-635c-4bc0-9349-1b61cbdaf0ca_terseLabel_en-US" xlink:label="lab_bsx_OperatingIncomeUnallocatedToSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Unallocated to Segment</link:label>
    <link:label id="lab_bsx_OperatingIncomeUnallocatedToSegment_label_en-US" xlink:label="lab_bsx_OperatingIncomeUnallocatedToSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Unallocated to Segment</link:label>
    <link:label id="lab_bsx_OperatingIncomeUnallocatedToSegment_documentation_en-US" xlink:label="lab_bsx_OperatingIncomeUnallocatedToSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Unallocated to Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeUnallocatedToSegment" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeUnallocatedToSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OperatingIncomeUnallocatedToSegment" xlink:to="lab_bsx_OperatingIncomeUnallocatedToSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EmergingMarketsMember_c81b5651-13be-4fb7-9420-846ed0ed8552_terseLabel_en-US" xlink:label="lab_bsx_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_bsx_EmergingMarketsMember_label_en-US" xlink:label="lab_bsx_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_bsx_EmergingMarketsMember_documentation_en-US" xlink:label="lab_bsx_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsMember" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EmergingMarketsMember" xlink:to="lab_bsx_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_18387ef0-29c4-4a1e-b6d8-c43e131cff24_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_caa2b1a0-664a-4f31-9ad3-c85deaccdab8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_814aa362-389c-4981-9f6c-eddcdde48795_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_153df5c7-4002-4650-81f1-e6d6a44c4200_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_a3ac98da-1fc3-4a26-9877-56daf46efe5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable_9807c6e1-9c74-4e64-8dd1-f03871820cae_terseLabel_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable_label_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable_documentation_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:to="lab_bsx_ScheduleofIncomeTaxRateReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c26bcc69-5638-49fb-a538-eaa1bf5f3e2e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_803e9043-cf08-434f-b737-a00c1fd60c97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Projected Benefit Obligations [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Projected Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTextBlock_94d62fdd-371a-486f-9028-4d8a2038fe0b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ad4ad0b8-0adc-4c51-a389-aed60db39dbc_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average (Member)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_f8fda060-18dd-47a4-8011-c349b4b2c9f4_terseLabel_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of performance-based DSUs awarded</link:label>
    <link:label id="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_label_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of performance-based DSUs awarded</link:label>
    <link:label id="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_documentation_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of performance-based DSUs awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofperformancebasedDSUsawarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:to="lab_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_616901bb-d709-4107-8574-fa8fb5444cd5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_02e79bee-acf3-4513-aff4-2679ac72e067_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_020e5c8a-b751-4b8b-93f1-53957214f197_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0930198e-00e3-4b0b-9451-27bf9c65d443_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8c543ffd-934b-4d4a-a9ea-b30eb6038995_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a78ca485-e439-4ca9-b166-a664ce26913d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_a6dcf0e3-c88f-4bc3-acb8-67a40bbeca67_terseLabel_en-US" xlink:label="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, sixth quarter and thereafter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_label_en-US" xlink:label="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, sixth quarter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_documentation_en-US" xlink:label="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, sixth quarter following qualified acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:href="bsx-20221231.xsd#bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:to="lab_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_02782f02-3708-4bbb-a607-94e43b31683d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_c2024dad-04b7-46a6-b38a-92d90cbff87b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment for adoption of ASC 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Change in Method, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal" xlink:to="lab_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_aa799eeb-5562-4114-9870-4c0819df92d0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2a36835c-d1fe-4b08-9a55-a1868f97d970_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherCountriesMember_9a8bf9ce-ee12-4058-bff8-44b8b47139f6_terseLabel_en-US" xlink:label="lab_bsx_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries [Member]</link:label>
    <link:label id="lab_bsx_OtherCountriesMember_label_en-US" xlink:label="lab_bsx_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries [Member]</link:label>
    <link:label id="lab_bsx_OtherCountriesMember_documentation_en-US" xlink:label="lab_bsx_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherCountriesMember" xlink:href="bsx-20221231.xsd#bsx_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherCountriesMember" xlink:to="lab_bsx_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_1cf407ff-27c8-4288-99dc-187c94c71886_terseLabel_en-US" xlink:label="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from contracts with customers, disaggregated - performance measurement</link:label>
    <link:label id="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_label_en-US" xlink:label="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from contracts with customers, disaggregated - performance measurement</link:label>
    <link:label id="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_documentation_en-US" xlink:label="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from contracts with customers, disaggregated - performance measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:href="bsx-20221231.xsd#bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:to="lab_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_39e4d4c6-7951-4e15-a293-5747fcd6c143_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CompensationExpensePerShareDiluted_3ee32448-1442-44a4-aadd-4e5686441452_terseLabel_en-US" xlink:label="lab_bsx_CompensationExpensePerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - diluted</link:label>
    <link:label id="lab_bsx_CompensationExpensePerShareDiluted_label_en-US" xlink:label="lab_bsx_CompensationExpensePerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - diluted</link:label>
    <link:label id="lab_bsx_CompensationExpensePerShareDiluted_documentation_en-US" xlink:label="lab_bsx_CompensationExpensePerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareDiluted" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CompensationExpensePerShareDiluted" xlink:to="lab_bsx_CompensationExpensePerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_b096bad8-2ce9-42c1-b3d8-d27e0d96de7b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Translation and Purchase Accounting Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Translation and Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_291bc12f-f6a4-478e-add0-778ef5925573_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1a721fd3-8cb6-4020-bcb8-4fcc7e9ce0e1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9d8003b5-1645-4acb-abcb-2b96f7767b4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e1241743-c200-4a61-ab18-307b9fca61a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a78988c7-f1f1-4cc3-9b8b-b781c84faf16_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CompensationExpensePerShareBasic_bc37867b-4732-4d19-8ae9-ed34a0251973_terseLabel_en-US" xlink:label="lab_bsx_CompensationExpensePerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - basic</link:label>
    <link:label id="lab_bsx_CompensationExpensePerShareBasic_label_en-US" xlink:label="lab_bsx_CompensationExpensePerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - basic</link:label>
    <link:label id="lab_bsx_CompensationExpensePerShareBasic_documentation_en-US" xlink:label="lab_bsx_CompensationExpensePerShareBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">compensation expense, per share - basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareBasic" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CompensationExpensePerShareBasic" xlink:to="lab_bsx_CompensationExpensePerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_AuditInformationAbstract_label_en-US" xlink:label="lab_bsx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bsx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bsx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AuditInformationAbstract" xlink:href="bsx-20221231.xsd#bsx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_AuditInformationAbstract" xlink:to="lab_bsx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_fe6ba23f-accc-4c32-b71d-3b231de93b72_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28defa01-8fc8-4a24-8bf4-956796a742f0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL BALANCE SHEET INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a064d776-7579-4dee-912c-e21972da7728_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed189fe8-e29d-42c8-872c-94d175bbf881_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_83903a39-e0a6-4381-b71e-d3380457010f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_56bb6d22-652d-4f68-af42-e246fe5f79b3_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_UnrecognizedCompensationCostStockOptions_d07610e3-8138-43c2-be93-33e786fb4562_terseLabel_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Stock Options</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCostStockOptions_label_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Stock Options</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCostStockOptions_documentation_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCostStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost - Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostStockOptions" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_UnrecognizedCompensationCostStockOptions" xlink:to="lab_bsx_UnrecognizedCompensationCostStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55ec99d9-e893-4bde-9103-dc5cf608cfa3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_366f7e2e-b179-4873-b6db-b4bca666f965_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_December2027NotesMember_7e936ea7-79eb-4de3-a889-7ea88eeb79f7_terseLabel_en-US" xlink:label="lab_bsx_December2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2027 Notes [Member]</link:label>
    <link:label id="lab_bsx_December2027NotesMember_label_en-US" xlink:label="lab_bsx_December2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2027 Notes [Member]</link:label>
    <link:label id="lab_bsx_December2027NotesMember_documentation_en-US" xlink:label="lab_bsx_December2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2027 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_December2027NotesMember" xlink:href="bsx-20221231.xsd#bsx_December2027NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_December2027NotesMember" xlink:to="lab_bsx_December2027NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfFacilities_c343a8fb-e3bf-41a8-a0f4-bcdc2cf7b521_terseLabel_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of facilities</link:label>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfFacilities_label_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of facilities</link:label>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfFacilities_documentation_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfFacilities" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DivestitureAgreementTransferOfFacilities" xlink:to="lab_bsx_DivestitureAgreementTransferOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a33cebf8-cf1d-4ba5-ad74-75435f4f646b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FederalBenefitOfUncertainTaxPositions_22e8e70b-2c43-47b8-a543-e0aea08f2cb5_terseLabel_en-US" xlink:label="lab_bsx_FederalBenefitOfUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal benefit of uncertain tax positions</link:label>
    <link:label id="lab_bsx_FederalBenefitOfUncertainTaxPositions_label_en-US" xlink:label="lab_bsx_FederalBenefitOfUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal benefit of uncertain tax positions</link:label>
    <link:label id="lab_bsx_FederalBenefitOfUncertainTaxPositions_documentation_en-US" xlink:label="lab_bsx_FederalBenefitOfUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal benefit of uncertain tax positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FederalBenefitOfUncertainTaxPositions" xlink:href="bsx-20221231.xsd#bsx_FederalBenefitOfUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FederalBenefitOfUncertainTaxPositions" xlink:to="lab_bsx_FederalBenefitOfUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_699d2c3f-d70a-4990-806a-731f39ef6316_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9b9a52d4-6899-4c5f-95de-352edfa9c53b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_9afd04d2-b473-4845-9e47-0e92357f7072_verboseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_3bf0f5aa-6b00-4fe2-907f-a821b53a07ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b6a70434-7f1a-4757-9586-264f3a93eabc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_6ef4ce28-c644-437d-95de-201c8ab639d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_YenDenominatedFactoringArrangementsMember_2cb3d2f9-e553-4669-aded-c336872bea42_terseLabel_en-US" xlink:label="lab_bsx_YenDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yen Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_YenDenominatedFactoringArrangementsMember_label_en-US" xlink:label="lab_bsx_YenDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yen Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_YenDenominatedFactoringArrangementsMember_documentation_en-US" xlink:label="lab_bsx_YenDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yen denominated factoring arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_YenDenominatedFactoringArrangementsMember" xlink:href="bsx-20221231.xsd#bsx_YenDenominatedFactoringArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_YenDenominatedFactoringArrangementsMember" xlink:to="lab_bsx_YenDenominatedFactoringArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_6940c5cb-a055-475a-a015-56a6e7d8c5b8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateMember_dcf6c8ec-f3e2-47a8-971d-819aa894212c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Segment</link:label>
    <link:label id="lab_us-gaap_CorporateMember_label_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_9717bd9f-6a11-4811-a471-b6973cb5caad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cf628b3-112b-4e81-9377-460c9e0fdece_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by (used for) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_d6e60169-e7c8-4096-9f7a-f3aa21c3686f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_845986d2-51eb-491f-8786-800b98473914_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_NewAccountingPronouncementsPolicyTextBlock_96da48f6-1d0b-46a6-aa9e-35c41d7ff831_terseLabel_en-US" xlink:label="lab_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_bsx_NewAccountingPronouncementsPolicyTextBlock_label_en-US" xlink:label="lab_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Text Block]</link:label>
    <link:label id="lab_bsx_NewAccountingPronouncementsPolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_NewAccountingPronouncementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:to="lab_bsx_NewAccountingPronouncementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_June2025NotesMember_6dd135a3-7b18-4410-a2d6-532a04d6b2af_terseLabel_en-US" xlink:label="lab_bsx_June2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2025 Notes [Member]</link:label>
    <link:label id="lab_bsx_June2025NotesMember_label_en-US" xlink:label="lab_bsx_June2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2025 Notes [Member]</link:label>
    <link:label id="lab_bsx_June2025NotesMember_documentation_en-US" xlink:label="lab_bsx_June2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2025 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2025NotesMember" xlink:href="bsx-20221231.xsd#bsx_June2025NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_June2025NotesMember" xlink:to="lab_bsx_June2025NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ad24e917-2824-463f-bbff-8b5562e1c816_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2e951a55-a9c8-417c-a9a1-470773c59768_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring net charges (credits)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_d5a294c0-36d4-4e7d-bca6-8b68e5319134_terseLabel_en-US" xlink:label="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]</link:label>
    <link:label id="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_label_en-US" xlink:label="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Additional Revenue Payment, period</link:label>
    <link:label id="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_documentation_en-US" xlink:label="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:to="lab_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_19332b1b-ab72-4943-bd13-63d60b881c51_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_d3fe553e-b034-4f73-afe2-8b338df1d8be_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings on credit facilities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_5da0e717-4a2f-4b8d-8de2-56b3eca04daf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal reserves</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_34b06f38-e913-4dbe-bc71-66a7e5a38498_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_121d6f2a-2208-4ea0-8730-ca7bc0fd39f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_edf14738-d8fe-4d75-883f-c70f65519906_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7af9ea99-f728-4e6e-88e2-cf40d6d4f499_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3aa29cdf-87a1-40d6-8907-45b61f771e0f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2031NotesMember_ecede0f5-c19a-4970-99f0-f2787f903086_terseLabel_en-US" xlink:label="lab_bsx_March2031NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2031 Notes</link:label>
    <link:label id="lab_bsx_March2031NotesMember_label_en-US" xlink:label="lab_bsx_March2031NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2031 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2031NotesMember_documentation_en-US" xlink:label="lab_bsx_March2031NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2031 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2031NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2031NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2031NotesMember" xlink:to="lab_bsx_March2031NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_5ab0cd69-f704-4733-b39d-bc6f02ff1484_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a675c0f3-0acd-43fa-be89-795c88c6b9cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_70e5d3d5-46d2-4de0-bc68-b25670821c52_terseLabel_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_label_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_documentation_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:to="lab_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_InternationalRetirementPlansMember_163e16fb-4b80-43e3-84a1-60d0ea7dbe6c_terseLabel_en-US" xlink:label="lab_bsx_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans [Member]</link:label>
    <link:label id="lab_bsx_InternationalRetirementPlansMember_label_en-US" xlink:label="lab_bsx_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans [Member]</link:label>
    <link:label id="lab_bsx_InternationalRetirementPlansMember_documentation_en-US" xlink:label="lab_bsx_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InternationalRetirementPlansMember" xlink:href="bsx-20221231.xsd#bsx_InternationalRetirementPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_InternationalRetirementPlansMember" xlink:to="lab_bsx_InternationalRetirementPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4770b012-fe10-4e13-84ef-7475c51eec28_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6139995-4e3b-4cfa-9faa-9780c76443f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_40b5b96e-aca7-4b66-ad58-44453dc7f769_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LicensingArrangementsLiability_050e0e9c-b08b-49a7-9244-93da1a2d3865_terseLabel_en-US" xlink:label="lab_bsx_LicensingArrangementsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, liability</link:label>
    <link:label id="lab_bsx_LicensingArrangementsLiability_label_en-US" xlink:label="lab_bsx_LicensingArrangementsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, liability</link:label>
    <link:label id="lab_bsx_LicensingArrangementsLiability_documentation_en-US" xlink:label="lab_bsx_LicensingArrangementsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LicensingArrangementsLiability" xlink:to="lab_bsx_LicensingArrangementsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_8dcd377a-e19c-4497-9d1f-c9fb65bfa28f_terseLabel_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_label_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_documentation_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:to="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8cfb9f5c-a4da-4c07-acac-dc6631be4b5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_088f2e3b-1039-4694-8961-317c470a9d98_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_6016c866-699a-41e7-8fdb-d2faf821bf73_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0d2ea39e-98f3-415d-91fb-e73931ef5f72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3090ab0b-3fd4-47ae-ba60-58720d895a01_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_db18ede4-da74-4f9b-8fd1-fcd21905039f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_821b532f-ce52-479c-9049-7ac17cf475cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ElectrophysiologyEPMember_aba09acb-d16f-4de5-94a7-42e7e0dc9559_terseLabel_en-US" xlink:label="lab_bsx_ElectrophysiologyEPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology (EP)</link:label>
    <link:label id="lab_bsx_ElectrophysiologyEPMember_label_en-US" xlink:label="lab_bsx_ElectrophysiologyEPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology (EP) [Member]</link:label>
    <link:label id="lab_bsx_ElectrophysiologyEPMember_documentation_en-US" xlink:label="lab_bsx_ElectrophysiologyEPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology (EP)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ElectrophysiologyEPMember" xlink:href="bsx-20221231.xsd#bsx_ElectrophysiologyEPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ElectrophysiologyEPMember" xlink:to="lab_bsx_ElectrophysiologyEPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2104d8e4-6a3a-4a5b-bd82-98e2f02653c0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_8879b230-9a49-4fda-b19a-4623e5a2da8f_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividends</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_53bd6e67-b302-4278-81af-90b97de436a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1ae4dcfc-566f-49e7-9481-3ed505012bd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_4bd21e75-ea5e-49aa-95cf-36c1d9009428_terseLabel_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:label id="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_label_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:label id="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_documentation_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:to="lab_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3e706986-b4eb-4498-9bc7-7c5775f5e605_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_6f6d1615-7bcc-4f0f-98f2-3a55dd721240_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss (beginning balance)</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_015c3b40-3b3a-476a-8b71-b91669e2a739_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss (ending balance)</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9a20b5bc-7d93-45cd-905e-4f2bb878f09a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_ca7b9114-17c9-4b93-9707-10fc29687ed0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract (Member)</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock_a378a4af-28c8-4e38-9563-467c0b7ccbcd_terseLabel_en-US" xlink:label="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]</link:label>
    <link:label id="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock_label_en-US" xlink:label="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]</link:label>
    <link:label id="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock_documentation_en-US" xlink:label="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of term loan and revolving credit facility agreement compliance with debt covenants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:to="lab_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_72360a4b-1325-4fe5-85c0-7db0a7e5b575_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for legal matters that are probable and estimable</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06c319d9-daed-4e0c-9cbd-9f0acb94da22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_030462f6-ead3-4196-87d4-53be7024e2d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FarapulseIncMember_71eb40cf-94b8-4f2b-9295-ccd8ce5b26a6_terseLabel_en-US" xlink:label="lab_bsx_FarapulseIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse, Inc.</link:label>
    <link:label id="lab_bsx_FarapulseIncMember_label_en-US" xlink:label="lab_bsx_FarapulseIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse, Inc. [Member]</link:label>
    <link:label id="lab_bsx_FarapulseIncMember_documentation_en-US" xlink:label="lab_bsx_FarapulseIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseIncMember" xlink:href="bsx-20221231.xsd#bsx_FarapulseIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FarapulseIncMember" xlink:to="lab_bsx_FarapulseIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_648368dd-54a5-4200-982a-0921d14e4301_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock_22e44a8a-62a3-4e8b-a28a-bf897994a8b4_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_d1671305-4de5-47d4-b22b-4e38e407229f_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_04c06e96-9371-464d-a93d-0b30e8e0778a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3bb2f254-db4d-477b-ac1a-c67d1ada118a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalEndoscopyEndoReportingUnitMember_e8b3f6f2-a042-4a86-9afa-9900582f8311_terseLabel_en-US" xlink:label="lab_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Endoscopy (Endo) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalEndoscopyEndoReportingUnitMember_label_en-US" xlink:label="lab_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Endoscopy (Endo) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalEndoscopyEndoReportingUnitMember_documentation_en-US" xlink:label="lab_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Endoscopy (Endo) Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:href="bsx-20221231.xsd#bsx_GlobalEndoscopyEndoReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:to="lab_bsx_GlobalEndoscopyEndoReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_91e704a7-c1ce-4f7a-9b2d-132b4fa06f9b_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_202b7a39-dce9-4783-a34d-ba52f0bb9b96_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_fa4f06fd-ccf6-4542-a7c2-548e38a4fa7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DeemedConsolidatedEBITDA_6ac96bf5-f9bf-42c2-acb5-6e0339ef95c0_terseLabel_en-US" xlink:label="lab_bsx_DeemedConsolidatedEBITDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Consolidated EBITDA [Member]</link:label>
    <link:label id="lab_bsx_DeemedConsolidatedEBITDA_label_en-US" xlink:label="lab_bsx_DeemedConsolidatedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Consolidated EBITDA</link:label>
    <link:label id="lab_bsx_DeemedConsolidatedEBITDA_documentation_en-US" xlink:label="lab_bsx_DeemedConsolidatedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Consolidated EBITDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeemedConsolidatedEBITDA" xlink:href="bsx-20221231.xsd#bsx_DeemedConsolidatedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DeemedConsolidatedEBITDA" xlink:to="lab_bsx_DeemedConsolidatedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_0f7bcf8e-89c9-41c2-a914-ab94ffdf8827_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_2bb847e0-50f5-4dae-9f41-c41425006ebf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_85749123-ee03-4c27-adc8-3365ce0d8818_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_8f73a594-ccdc-4c2b-8864-5652c55e2ca0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_a4d422d9-a257-4a39-9d78-8cb8b83f812b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (Shares Issued)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b74b886b-9263-4ba6-896a-a7ece42c9b2f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States [Member]</link:label>
    <link:label id="lab_country_US_0356ea42-a864-47fc-b910-019706cf236a_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_b0723fea-4dc9-4519-9503-c2b7c7311317_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_eb6db5f0-1be4-43b7-992f-0164e0c0c904_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_VotingPowerOfAllClassesOfStock_7845c0f6-6ec8-4e8c-8e74-ba72754b6e02_verboseLabel_en-US" xlink:label="lab_bsx_VotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting power of all classes of stock</link:label>
    <link:label id="lab_bsx_VotingPowerOfAllClassesOfStock_label_en-US" xlink:label="lab_bsx_VotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting power of all classes of stock</link:label>
    <link:label id="lab_bsx_VotingPowerOfAllClassesOfStock_documentation_en-US" xlink:label="lab_bsx_VotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting power of all classes of stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_VotingPowerOfAllClassesOfStock" xlink:href="bsx-20221231.xsd#bsx_VotingPowerOfAllClassesOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_VotingPowerOfAllClassesOfStock" xlink:to="lab_bsx_VotingPowerOfAllClassesOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_52b47d5e-dbb2-4241-a4bb-0810d206751d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e12c309a-6cdf-41cc-9a91-5b6a98742bfd_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fd1e547c-8dc1-4953-b2c0-deede34e6c1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_36c38565-7b32-49fe-af19-f4a70b9f0416_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_714d5aaa-9a99-44c1-b700-6648a8aed29d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_57dfbc9d-4adb-46f6-bad0-a51d7b6e4f58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_33b0ec72-4a2e-44bc-bd46-8089b0a1c229_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments Due, Current</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae0cb07f-912c-4100-ba92-f63fd530bfdf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assuming dilution</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dfaff112-e787-4585-9667-b9af94ed0922_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5a39bfb4-23eb-47ce-9c5b-b71fc24a0ba7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6c48be77-96d9-41e1-a3f8-bfb9ea4995ca_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ca3079c9-b426-4589-b5d7-29715516cd9d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_c07a7662-c008-4b1a-8a18-d7d7848f5b14_terseLabel_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution</link:label>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_label_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution</link:label>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_documentation_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:to="lab_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8952db1d-6313-4839-9bb2-d10569e2e80f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SignificantAccountingPoliciesTable_092ecf4c-5c84-4a81-9772-cc4eeba51c31_terseLabel_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesTable" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SignificantAccountingPoliciesTable" xlink:to="lab_bsx_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TotalAllocatedToReportableSegmentsMember_0948fb57-ff2b-41d9-a404-c957f1268f55_terseLabel_en-US" xlink:label="lab_bsx_TotalAllocatedToReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allocated to reportable segments [Member]</link:label>
    <link:label id="lab_bsx_TotalAllocatedToReportableSegmentsMember_label_en-US" xlink:label="lab_bsx_TotalAllocatedToReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allocated to reportable segments [Member]</link:label>
    <link:label id="lab_bsx_TotalAllocatedToReportableSegmentsMember_documentation_en-US" xlink:label="lab_bsx_TotalAllocatedToReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allocated to reportable segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TotalAllocatedToReportableSegmentsMember" xlink:href="bsx-20221231.xsd#bsx_TotalAllocatedToReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TotalAllocatedToReportableSegmentsMember" xlink:to="lab_bsx_TotalAllocatedToReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_cd07de02-d913-4191-a9b8-cfd931b1f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7d7c7788-02fb-461f-8102-9f3033eb0982_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_61b86764-487e-4c7e-82f8-2906b8947b66_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_722c7629-0cb1-48d2-a55f-f9cd5da8449f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_2283bf5b-4dae-47ff-94b8-ca7219966f27_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_07d89d4d-4b28-4c76-acd4-226418263924_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_606cf1c0-b1d4-4bc6-a14d-01f6c6e4ff76_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRico_c75adaa7-8ca6-4c26-bf0f-513c4484fa0c_terseLabel_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRico" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico</link:label>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRico_label_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRico" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico</link:label>
    <link:label id="lab_bsx_TaxIncentivesInPuertoRico_documentation_en-US" xlink:label="lab_bsx_TaxIncentivesInPuertoRico" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Incentives in Puerto Rico</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRico" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRico"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxIncentivesInPuertoRico" xlink:to="lab_bsx_TaxIncentivesInPuertoRico" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_dbfcb8ad-5c78-4e16-b2dc-282bc601e244_terseLabel_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of market-based DSUs awarded</link:label>
    <link:label id="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_label_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of market-based DSUs awarded</link:label>
    <link:label id="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_documentation_en-US" xlink:label="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of the target number of market-based DSUs awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofmarketbasedDSUsawarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:to="lab_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5877ec0b-4ddd-4ed2-846f-85356d6acefe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0a0efc3d-24fc-4953-85ac-359f3b87e3a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3b9da90f-0835-44a9-8198-24b0fd1a9e1b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_658e9c42-1223-4494-a922-80948d339536_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fec3b142-05cd-4e2b-a62b-58c3852d5501_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4b5f32c6-3b22-4eee-a46c-cd01583ae8b1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_cba048da-045a-4df0-a7b7-ee1f20ed43af_terseLabel_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_label_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_documentation_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:to="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock_856b7952-aa88-4d63-853d-a4f931c004a3_terseLabel_en-US" xlink:label="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities</link:label>
    <link:label id="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:to="lab_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_167a0a10-c3eb-470e-890a-b8f0ab0d6b85_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_336bb428-e38a-452b-b84a-7b6315d26bbd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b2405715-9159-4dd7-a38c-794fe092cbfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_67624f8d-cc66-4b70-90af-954fc6c02e01_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f92a5398-7a14-4264-b5fe-cf3ca93b1c39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b555fa27-802a-4f22-828a-0f0a9368fb76_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_StockIncentiveAndPurchasePlansAbstract_6d7a6c71-f5d2-404a-9d1a-5b063468dcc5_terseLabel_en-US" xlink:label="lab_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive and Ownership Plans [Abstract]</link:label>
    <link:label id="lab_bsx_StockIncentiveAndPurchasePlansAbstract_label_en-US" xlink:label="lab_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive and Purchase Plans [Abstract]</link:label>
    <link:label id="lab_bsx_StockIncentiveAndPurchasePlansAbstract_documentation_en-US" xlink:label="lab_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive and Purchase Plans [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:href="bsx-20221231.xsd#bsx_StockIncentiveAndPurchasePlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:to="lab_bsx_StockIncentiveAndPurchasePlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_33f9ea5e-769c-46f6-a330-9f4c9e686d64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ForeignCurrencyDenominatedInDebtMember_7ad142ed-7c52-4256-8d14-2ef7a8d6db54_terseLabel_en-US" xlink:label="lab_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency denominated in debt [Member]</link:label>
    <link:label id="lab_bsx_ForeignCurrencyDenominatedInDebtMember_label_en-US" xlink:label="lab_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency denominated in debt [Member]</link:label>
    <link:label id="lab_bsx_ForeignCurrencyDenominatedInDebtMember_documentation_en-US" xlink:label="lab_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency denominated in debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:href="bsx-20221231.xsd#bsx_ForeignCurrencyDenominatedInDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:to="lab_bsx_ForeignCurrencyDenominatedInDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_751fa3d0-13ae-442c-a7be-1ee20674498a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_4729b902-d6c5-41ce-b65c-d64d10b477d8_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_7cd26c3c-8b2e-42c7-90d4-717a43ed5408_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_41b12baf-fc9a-45d4-bfe8-9febe4dd939f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxIncentivesInMalaysia_f2d6c9b9-a78f-4fef-a80a-f9a53a8308f2_terseLabel_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysia" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentives in Malaysia</link:label>
    <link:label id="lab_bsx_TaxIncentivesInMalaysia_label_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysia" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentives in Malaysia</link:label>
    <link:label id="lab_bsx_TaxIncentivesInMalaysia_documentation_en-US" xlink:label="lab_bsx_TaxIncentivesInMalaysia" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentives in Malaysia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysia" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysia"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxIncentivesInMalaysia" xlink:to="lab_bsx_TaxIncentivesInMalaysia" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a1b63a59-3483-4a8c-a1d6-fe1623ccca9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments (Table Text Block)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_adf0ffba-c47a-41ed-8d4c-d89bb892f080_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fd597a22-481c-4d6e-b0ed-64591db4cd4d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_PreventiceSolutionsIncMember_1c107682-6dd5-421c-a32d-7f3792421828_terseLabel_en-US" xlink:label="lab_bsx_PreventiceSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preventice Solutions, Inc. [Member]</link:label>
    <link:label id="lab_bsx_PreventiceSolutionsIncMember_label_en-US" xlink:label="lab_bsx_PreventiceSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preventice Solutions, Inc. [Member]</link:label>
    <link:label id="lab_bsx_PreventiceSolutionsIncMember_documentation_en-US" xlink:label="lab_bsx_PreventiceSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preventice Solutions, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PreventiceSolutionsIncMember" xlink:href="bsx-20221231.xsd#bsx_PreventiceSolutionsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_PreventiceSolutionsIncMember" xlink:to="lab_bsx_PreventiceSolutionsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_35873266-9f5d-43f5-b06c-a6c251fd7118_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_5499ed05-144f-4af8-a205-2778bcba4c54_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_9ba143f4-a576-4339-9da6-c699bc8842e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_247803d6-360b-448f-af23-1ecd28dd3fd1_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_03764843-c1df-4864-8917-033357802d4e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_06aa9ae9-7a33-44e9-8412-bed7268fb91b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_November2019AggregateOfferingMember_05ae00aa-1661-4ad9-854f-6e47f4e1291d_terseLabel_en-US" xlink:label="lab_bsx_November2019AggregateOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Aggregate Offering [Member]</link:label>
    <link:label id="lab_bsx_November2019AggregateOfferingMember_label_en-US" xlink:label="lab_bsx_November2019AggregateOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Aggregate Offering [Member]</link:label>
    <link:label id="lab_bsx_November2019AggregateOfferingMember_documentation_en-US" xlink:label="lab_bsx_November2019AggregateOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Aggregate Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2019AggregateOfferingMember" xlink:href="bsx-20221231.xsd#bsx_November2019AggregateOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_November2019AggregateOfferingMember" xlink:to="lab_bsx_November2019AggregateOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ea56e64c-426f-468b-a0a9-96bd07e201df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ff865d1c-4bd4-4247-a19a-407f989a14f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_12fbc598-2a59-4b45-9540-cd93929b2876_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2025NotesMember_a561042d-dd73-49c8-af30-fa336eba265a_terseLabel_en-US" xlink:label="lab_bsx_March2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025 Notes</link:label>
    <link:label id="lab_bsx_March2025NotesMember_label_en-US" xlink:label="lab_bsx_March2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2025NotesMember_documentation_en-US" xlink:label="lab_bsx_March2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2025NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2025NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2025NotesMember" xlink:to="lab_bsx_March2025NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9b0b5e6a-011b-4d80-908b-76c18144f607_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8fe6bfb-3f3f-4f3d-95af-5c7beba0e682_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_491feda2-e2cf-426a-bc24-d4e396065453_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2f46f408-2f22-4a2c-b285-8737b483aa94_verboseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0ca32ecc-a81c-4fba-9046-70f1da507c99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_2162a55d-0f25-46d7-a3e2-3cd40d57d5c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_9a517223-5b4e-4fae-bc30-f068497242c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2034NotesMember_01a9d8b8-0958-41d0-af0e-38427f3fb95c_terseLabel_en-US" xlink:label="lab_bsx_March2034NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2034 Notes</link:label>
    <link:label id="lab_bsx_March2034NotesMember_label_en-US" xlink:label="lab_bsx_March2034NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2034 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2034NotesMember_documentation_en-US" xlink:label="lab_bsx_March2034NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2034 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2034NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2034NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2034NotesMember" xlink:to="lab_bsx_March2034NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_81ea01a8-83df-4082-a47c-176e833d73c5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_24228efd-5ae4-4181-8b25-099e89706926_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aeb21c02-069d-42e7-a08a-b1ee61971e56_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_2aa51cd4-cc6c-47b9-ae55-42852d336650_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1979f47b-9c7d-4f20-87db-884e01c67e30_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f663d71c-c9c3-4599-97de-2638c2966733_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7488dae6-4952-44ad-a6ba-061831cbe2b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_3235a8a8-5da5-42c6-9507-2b32c77380e1_terseLabel_en-US" xlink:label="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal payments remaining to be excluded from calculation of consolidated EBITDA</link:label>
    <link:label id="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_label_en-US" xlink:label="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal payments remaining to be excluded from calculation of consolidated EBITDA</link:label>
    <link:label id="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_documentation_en-US" xlink:label="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal payments remaining to be excluded from calculation of consolidated EBITDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:href="bsx-20221231.xsd#bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:to="lab_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_d4e7e4cf-c656-422f-b87e-9a15282a079b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_c4fb1657-6738-42ba-8c72-49894815950a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_80780db1-5f08-406f-aae3-bc4e142e9eb4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_59ab9a75-e4e2-45a0-b9b6-3a9a7ab57de7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_365c9d9c-38a4-47f8-929e-976cff25d9d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related liabilities</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_c913f90f-d8c4-4ce0-a29d-df0a24a7eb12_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_91a856eb-385b-4b13-8379-0740091f735f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6b37fed8-2d89-482a-94db-5b5280211750_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_467320a7-fb3d-4c94-846c-4af13221cf38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_efafec41-6b07-4e56-9473-9422658d993f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TheOfferingAggregatePrincipalAmountMember_0d1aa562-5581-43de-9715-63aedd216d51_terseLabel_en-US" xlink:label="lab_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - aggregate principal amount</link:label>
    <link:label id="lab_bsx_TheOfferingAggregatePrincipalAmountMember_label_en-US" xlink:label="lab_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - aggregate principal amount [Member]</link:label>
    <link:label id="lab_bsx_TheOfferingAggregatePrincipalAmountMember_documentation_en-US" xlink:label="lab_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the Offering - aggregate principal amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:href="bsx-20221231.xsd#bsx_TheOfferingAggregatePrincipalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:to="lab_bsx_TheOfferingAggregatePrincipalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments_dbf66d16-3776-40ef-b92b-60cc35d815ee_terseLabel_en-US" xlink:label="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) Allocated to Reportable Segments</link:label>
    <link:label id="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments_label_en-US" xlink:label="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) Allocated to Reportable Segments</link:label>
    <link:label id="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments_documentation_en-US" xlink:label="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) Allocated to Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeLossAllocatedToReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:to="lab_bsx_OperatingIncomeLossAllocatedToReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_238ae071-d3b8-4937-9dc1-c510e5be6c36_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fe6021c4-c534-43da-9a03-a3b7fe088685_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_436f3c2f-4563-4cc1-b9a4-27e9ad637ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_564bdedb-e286-47f6-922e-e45c7834d50d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7d201bba-274f-42ec-8874-d948e481f5d3_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_786b0cf7-f35b-4ba5-8be0-f85d0cf56cc6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1913cfc2-2e15-4863-a21b-ddfc4bfc3ee6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_81579756-2771-49f8-98c1-3de9c1a63c3d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets (total)</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_a1a88b77-13a4-4030-a923-db2fa670420f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e83119a3-2336-46be-b36a-72a8553eaa3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_293b5225-1635-44f6-9c39-d3a431f6b2f8_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LicensingArrangementLiabilitiesMember_a644cd6f-66f5-4fb2-879f-c47f6c41a3e5_terseLabel_en-US" xlink:label="lab_bsx_LicensingArrangementLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement liabilities (Member)</link:label>
    <link:label id="lab_bsx_LicensingArrangementLiabilitiesMember_label_en-US" xlink:label="lab_bsx_LicensingArrangementLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement liabilities [Member]</link:label>
    <link:label id="lab_bsx_LicensingArrangementLiabilitiesMember_documentation_en-US" xlink:label="lab_bsx_LicensingArrangementLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementLiabilitiesMember" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LicensingArrangementLiabilitiesMember" xlink:to="lab_bsx_LicensingArrangementLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_48386613-8d7f-4e8c-b3ae-fb5fcb0ad6bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (payments for) settlements of hedge contracts</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_eb647c76-49e6-4279-8583-b2966902c7bb_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_777e335f-970f-4662-8c1f-1de2dbf26b0e_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_The2018FacilityDomain_56ce06d5-8bcb-4f80-a592-382a754cbf1d_terseLabel_en-US" xlink:label="lab_bsx_The2018FacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the 2018 Facility [Domain]</link:label>
    <link:label id="lab_bsx_The2018FacilityDomain_label_en-US" xlink:label="lab_bsx_The2018FacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the 2018 Facility [Domain]</link:label>
    <link:label id="lab_bsx_The2018FacilityDomain_documentation_en-US" xlink:label="lab_bsx_The2018FacilityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the 2018 Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_The2018FacilityDomain" xlink:href="bsx-20221231.xsd#bsx_The2018FacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_The2018FacilityDomain" xlink:to="lab_bsx_The2018FacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_77556f7c-c772-403c-a50a-1db1ae9354f8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cf997094-b0b1-44b1-bb76-5224a73c2374_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees_ce9da233-ccaf-4164-9477-c6b60c8a3ddc_terseLabel_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of global employees</link:label>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees_label_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of global employees</link:label>
    <link:label id="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees_documentation_en-US" xlink:label="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture, agreement, transfer of global employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfGlobalEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:to="lab_bsx_DivestitureAgreementTransferOfGlobalEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_7c47c2cc-b61e-41d9-a02c-4e8ab0b584a9_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_48a43762-121c-484f-abe0-88fdeb4b458d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation-related net charges (credits)</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_2354ec52-e0ae-4ae0-ac1e-e25aaf3b4883_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_548c956a-9d9c-4b38-9633-f8c4ac664090_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_52eba1f4-d355-467f-b07d-1e525c595c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_d33006cd-047a-4ca1-81c1-d1706dbf4a24_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_e3a341e4-cbef-4b0e-a0ca-e2559c416c56_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_MedsurgMember_e53dd0a6-69a0-45fa-bfda-50df9e4a1724_terseLabel_en-US" xlink:label="lab_bsx_MedsurgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedSurg [Member]</link:label>
    <link:label id="lab_bsx_MedsurgMember_label_en-US" xlink:label="lab_bsx_MedsurgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedSurg [Member]</link:label>
    <link:label id="lab_bsx_MedsurgMember_documentation_en-US" xlink:label="lab_bsx_MedsurgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedSurg [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_MedsurgMember" xlink:to="lab_bsx_MedsurgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_b0f7c107-81bc-4449-b0a9-9e8894568fbe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SeniorNotedue2027Member_c4d013b3-91fa-42ea-b605-897787e0f31e_terseLabel_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_label_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_documentation_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member" xlink:href="bsx-20221231.xsd#bsx_SeniorNotedue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SeniorNotedue2027Member" xlink:to="lab_bsx_SeniorNotedue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_cae91cf3-7634-47f2-a13d-ebf4acac8bde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38d8acde-0901-4a71-a925-62cccfac5076_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c7429d55-514f-4742-9d77-3ada0383bb3a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_110b0e03-9f45-4fa4-a83f-4b5acf5f4e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ab5c1a4-07bf-4189-a033-59efa45d30e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_UnrecognizedCompensationCost_3dbf3112-367a-4e25-940a-a790a1df1f2a_terseLabel_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCost_label_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost</link:label>
    <link:label id="lab_bsx_UnrecognizedCompensationCost_documentation_en-US" xlink:label="lab_bsx_UnrecognizedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCost" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_UnrecognizedCompensationCost" xlink:to="lab_bsx_UnrecognizedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_56b41f43-09fa-4588-8fce-5b68cf3b585f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8e93bfff-9360-4d78-99e6-f814bc0403c5_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2b17c2d2-0408-4042-8b3c-e0f8be81f482_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49be3d9e-f7ea-4129-8b0f-42d4cf294c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_edfd3ffb-bb62-4705-b80e-abfd1c949d8c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20ceec25-92d6-4890-bde0-05a7862cd2f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_64b9b2c3-2ae2-4448-b9aa-6702c8310fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c1ebf152-d6a6-4993-b5ce-72a9164c5e1e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92e161e7-b20e-4e7d-b67e-5335fef23dae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CardiovascularMember_164045a1-0827-42cd-a756-3af4bcd03313_terseLabel_en-US" xlink:label="lab_bsx_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:label id="lab_bsx_CardiovascularMember_label_en-US" xlink:label="lab_bsx_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:label id="lab_bsx_CardiovascularMember_documentation_en-US" xlink:label="lab_bsx_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CardiovascularMember" xlink:to="lab_bsx_CardiovascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7ebf6e71-74fc-436b-81c1-36f472f62fa4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ef15a282-6dd0-42ae-be23-15b370534db8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f134a0dd-aed9-4588-81cb-32898053a376_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Retirement Plan Discount Rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FarapulseMember_896459fa-b5e9-4b31-8579-947e2440f339_terseLabel_en-US" xlink:label="lab_bsx_FarapulseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse</link:label>
    <link:label id="lab_bsx_FarapulseMember_label_en-US" xlink:label="lab_bsx_FarapulseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse [Member]</link:label>
    <link:label id="lab_bsx_FarapulseMember_documentation_en-US" xlink:label="lab_bsx_FarapulseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Farapulse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseMember" xlink:href="bsx-20221231.xsd#bsx_FarapulseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FarapulseMember" xlink:to="lab_bsx_FarapulseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fe2a05b5-08bf-460d-9387-a337e42d9fa9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_06f84a55-cb9a-4eb0-895d-1cc71ae5ff93_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_fb355ae3-55e6-4302-b657-cd8456f2c372_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4097d42-5a32-4df9-9e84-6bad1abb9f87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_9e8b47d4-d633-47d4-8eae-605af5a0b359_terseLabel_en-US" xlink:label="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Peripheral Interventions (PI) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_label_en-US" xlink:label="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Peripheral Interventions (PI) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_documentation_en-US" xlink:label="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Peripheral Interventions (PI) Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:href="bsx-20221231.xsd#bsx_GlobalPeripheralInterventionsPiReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:to="lab_bsx_GlobalPeripheralInterventionsPiReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock_3544f10d-2ab0-40ed-8d2e-3b22c5f66c0f_terseLabel_en-US" xlink:label="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales [Table Text Block]</link:label>
    <link:label id="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock_label_en-US" xlink:label="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales [Table Text Block]</link:label>
    <link:label id="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock_documentation_en-US" xlink:label="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income as percentage of net sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:to="lab_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_4f356b69-8dcc-44c4-86f1-ec805871643f_terseLabel_en-US" xlink:label="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:label id="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_label_en-US" xlink:label="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:label id="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_documentation_en-US" xlink:label="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:href="bsx-20221231.xsd#bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:to="lab_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6cdca55f-4962-4185-be9f-41dfd1d841ee_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ccfc648f-3833-4753-808f-853d9f2966a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b8938d1a-c856-47d0-b063-cb2e3972534f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a56e5f0b-a01d-4c08-8bff-ea001fac5fc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_e9e6d6a5-5837-4217-a827-9361ea8f2bc4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_d0adb167-bba4-44e2-869a-6a03f3d775ab_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_abb6597e-e14a-466b-89f8-6805c15e15cd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c321ccf5-4b7e-4c80-ab4c-c78827e6d9b3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_a3f80a7b-aa31-4554-bb23-47e25978ec32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4b21aa3b-4f2e-475a-a479-93c6468bde75_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_106a9d13-4140-4083-8641-38feba78af99_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ecde29cd-34b7-4bb9-865d-f371b5ba00e9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in defined benefit pensions and other items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f7695da5-ec6b-4c81-9a26-0e19209426ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in defined benefit pensions and other items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7926ffe0-0522-4c04-8a8a-1ae85550470b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember_22037d38-ab4a-4731-bfa1-dd38e37d9755_terseLabel_en-US" xlink:label="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Expenses including hedging activities [Member]</link:label>
    <link:label id="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember_label_en-US" xlink:label="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Expenses including hedging activities [Member]</link:label>
    <link:label id="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember_documentation_en-US" xlink:label="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Expenses including hedging activities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:href="bsx-20221231.xsd#bsx_CorporateExpensesincludinghedgingactivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:to="lab_bsx_CorporateExpensesincludinghedgingactivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GoodwillTextualsAbstract_28796c6a-ae53-479e-a0cc-5a30927411b5_terseLabel_en-US" xlink:label="lab_bsx_GoodwillTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Roll Forward)</link:label>
    <link:label id="lab_bsx_GoodwillTextualsAbstract_label_en-US" xlink:label="lab_bsx_GoodwillTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Textuals) [Abstract]</link:label>
    <link:label id="lab_bsx_GoodwillTextualsAbstract_documentation_en-US" xlink:label="lab_bsx_GoodwillTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Textuals) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GoodwillTextualsAbstract" xlink:href="bsx-20221231.xsd#bsx_GoodwillTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GoodwillTextualsAbstract" xlink:to="lab_bsx_GoodwillTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_InterventionalCardiologyTherapiesMember_92d826e3-c01a-48c6-9414-51e195e3696d_terseLabel_en-US" xlink:label="lab_bsx_InterventionalCardiologyTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Cardiology Therapies</link:label>
    <link:label id="lab_bsx_InterventionalCardiologyTherapiesMember_label_en-US" xlink:label="lab_bsx_InterventionalCardiologyTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Cardiology Therapies [Member]</link:label>
    <link:label id="lab_bsx_InterventionalCardiologyTherapiesMember_documentation_en-US" xlink:label="lab_bsx_InterventionalCardiologyTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Cardiology Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InterventionalCardiologyTherapiesMember" xlink:href="bsx-20221231.xsd#bsx_InterventionalCardiologyTherapiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_InterventionalCardiologyTherapiesMember" xlink:to="lab_bsx_InterventionalCardiologyTherapiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_466e6309-5af5-4f5a-b516-b0ce218e63b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_8ba2fb2f-0954-46dd-a941-56801f1fba87_terseLabel_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance (Value in excess of par)</link:label>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_label_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues (Common stock)</link:label>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_documentation_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues (Common stock)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:to="lab_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_82d576b0-5ae7-453d-a5fd-6d3b360436f8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e26df3aa-7967-4477-86f0-e3dccffcfa75_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1974c2d0-d989-40ad-8e4d-a3e91e46e232_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_135d1822-6a9c-4b5f-ad56-f4a6c3ff548e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ExclusionFromEbitdaForRestructuringCharges_4fbdc495-5d2f-464b-ac28-c799fa898959_verboseLabel_en-US" xlink:label="lab_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusion from EBITDA for Restructuring Charges</link:label>
    <link:label id="lab_bsx_ExclusionFromEbitdaForRestructuringCharges_label_en-US" xlink:label="lab_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusion from EBITDA for Restructuring Charges</link:label>
    <link:label id="lab_bsx_ExclusionFromEbitdaForRestructuringCharges_documentation_en-US" xlink:label="lab_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusion from EBITDA for Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:href="bsx-20221231.xsd#bsx_ExclusionFromEbitdaForRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:to="lab_bsx_ExclusionFromEbitdaForRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_6a36cd5c-d245-4d7f-85f8-9ccfe82a2844_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_b7141e04-21ac-4fa2-b8ce-c1c3eadf638e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ShareBasedCompensationNetOfTaxBenefit_b4adbd33-bed0-4f66-a94f-6654cca323ac_terseLabel_en-US" xlink:label="lab_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, net of tax benefit</link:label>
    <link:label id="lab_bsx_ShareBasedCompensationNetOfTaxBenefit_label_en-US" xlink:label="lab_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, net of tax benefit</link:label>
    <link:label id="lab_bsx_ShareBasedCompensationNetOfTaxBenefit_documentation_en-US" xlink:label="lab_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, net of tax benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:href="bsx-20221231.xsd#bsx_ShareBasedCompensationNetOfTaxBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:to="lab_bsx_ShareBasedCompensationNetOfTaxBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ed8410f9-9718-48a3-ab02-ee42c9ba62c8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">effective income tax reconciliation, compensation-related</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_c4323a0d-f872-4722-8763-8c653ce4eaa3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a3541965-48da-4c79-8781-123b2092e6ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_802a7341-a0e0-4a96-b3b2-daa330dfdfd4_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (credits) charges to expenses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_InventoryStepUpAmortization_643cc564-81a4-4cea-88c7-9df52e338039_terseLabel_en-US" xlink:label="lab_bsx_InventoryStepUpAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory step-up amortization</link:label>
    <link:label id="lab_bsx_InventoryStepUpAmortization_label_en-US" xlink:label="lab_bsx_InventoryStepUpAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InventoryStepUpAmortization</link:label>
    <link:label id="lab_bsx_InventoryStepUpAmortization_documentation_en-US" xlink:label="lab_bsx_InventoryStepUpAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Step Up Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InventoryStepUpAmortization" xlink:href="bsx-20221231.xsd#bsx_InventoryStepUpAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_InventoryStepUpAmortization" xlink:to="lab_bsx_InventoryStepUpAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_1ceb97c2-6971-4686-bec1-d413d00a22f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock_d268696b-c655-4d5b-ab5c-d5c3b6c27a92_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion_34e8c676-b2e4-4ec7-869d-02c1b3e4c67c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e155c793-6633-4807-ab8a-45dafd6f2596_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_90d33bed-1c2c-4f1c-a6ca-8ab535cb7d2b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_001582f5-a2ac-4bc0-a395-75b63ba43858_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_eff1c7d1-5963-4377-b00b-9b043758058c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d0812b8c-9670-4c2b-bfe6-62eca187514a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_cbe7e9dd-58cb-400c-a0b9-3ad6fe3a9825_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9c5b5848-5633-4735-8a71-4cf86555b5a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_2f844335-6325-4032-9157-45d62b1acf52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalCardiologyReportingUnitMember_979b366a-19c0-44c2-a778-ebdab142b15d_terseLabel_en-US" xlink:label="lab_bsx_GlobalCardiologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Cardiology Reporting Unit</link:label>
    <link:label id="lab_bsx_GlobalCardiologyReportingUnitMember_label_en-US" xlink:label="lab_bsx_GlobalCardiologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Cardiology Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalCardiologyReportingUnitMember_documentation_en-US" xlink:label="lab_bsx_GlobalCardiologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Cardiology Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalCardiologyReportingUnitMember" xlink:href="bsx-20221231.xsd#bsx_GlobalCardiologyReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalCardiologyReportingUnitMember" xlink:to="lab_bsx_GlobalCardiologyReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_f0ad1e94-c447-4263-95db-63b2bd7555ed_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_5d69d251-e0b6-4264-809f-f69e886415d6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_6ec37f0f-920f-465b-85dd-6944025c77cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_c6e5bd7e-efcb-4e7e-bdc7-c975e65d7a74_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ffa49165-59ae-4abd-8066-ffb9cc4ef2d3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ed53d035-a38b-47b1-9d7f-c493405c9624_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d85ab3f5-53e0-4603-94c4-768965105d89_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a4a55941-dcbc-4655-9735-d7ac85ee6905_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_63dd324f-a6a7-4f17-9180-a08f8badfa3a_terseLabel_en-US" xlink:label="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liabilities and Prepaid on Intercompany Profit</link:label>
    <link:label id="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_label_en-US" xlink:label="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets and Prepaid on Intercompany Profit</link:label>
    <link:label id="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_documentation_en-US" xlink:label="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets and Prepaid on Intercompany Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:href="bsx-20221231.xsd#bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:to="lab_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3ba952d4-a187-4267-b27b-9e92e8d65163_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_0d72d41c-39ba-4e82-8383-626377a0395d_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_cfaa0dc4-ec8c-448c-9fd5-5a5c3b154231_terseLabel_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:to="lab_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SpecialtyPharmaceuticalsMember_ed11cf3b-c6ca-493c-9ce6-801efb842461_terseLabel_en-US" xlink:label="lab_bsx_SpecialtyPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmaceuticals [Member]</link:label>
    <link:label id="lab_bsx_SpecialtyPharmaceuticalsMember_label_en-US" xlink:label="lab_bsx_SpecialtyPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmaceuticals [Member]</link:label>
    <link:label id="lab_bsx_SpecialtyPharmaceuticalsMember_documentation_en-US" xlink:label="lab_bsx_SpecialtyPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SpecialtyPharmaceuticalsMember" xlink:to="lab_bsx_SpecialtyPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9d748102-9513-47cc-abc3-d1eaffb24231_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15707451-0169-497e-8427-5cad733c3a89_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_185f365e-65b4-4dc3-80d0-e6d9c014bbfc_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments, Due in Five Years</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3af71005-4fb4-4c54-a827-422ef349ddbb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_bdf6387d-044c-4a8e-b9ed-48fc88e86d10_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7c39dc4b-df10-42cd-9e94-4bb17dca1975_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2777be6c-9bec-4ec2-8669-52571e7cb3da_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0baa4907-3702-4648-86b4-a8d6f8d548fb_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f965b9ee-1c7c-4c60-8fb4-3ce9d6a02938_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ConsolidatedBSXDomain_4dfd0a1b-3194-46c2-b577-f26e9de7cda6_terseLabel_en-US" xlink:label="lab_bsx_ConsolidatedBSXDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated BSX [Domain]</link:label>
    <link:label id="lab_bsx_ConsolidatedBSXDomain_label_en-US" xlink:label="lab_bsx_ConsolidatedBSXDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated BSX [Domain]</link:label>
    <link:label id="lab_bsx_ConsolidatedBSXDomain_documentation_en-US" xlink:label="lab_bsx_ConsolidatedBSXDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated BSX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedBSXDomain" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedBSXDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ConsolidatedBSXDomain" xlink:to="lab_bsx_ConsolidatedBSXDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_8af25ed7-fd87-4b5d-a983-a570f529fd75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_4aa76cf2-6071-4b42-9bf8-720dac7848f2_terseLabel_en-US" xlink:label="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Leases, Option to Extend</link:label>
    <link:label id="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_label_en-US" xlink:label="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Leases, Option to Extend</link:label>
    <link:label id="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_documentation_en-US" xlink:label="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Leases, Option to Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:href="bsx-20221231.xsd#bsx_LesseeOperatingAndFinanceLeasesOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:to="lab_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_324dd062-3ba0-4227-9739-682b6543a67f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SignificantAccountingPoliciesLineItems_15cd8b54-3290-44d0-a4ed-9202afc2c83f_terseLabel_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesLineItems" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems" xlink:to="lab_bsx_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_June2030NotesMember_d7d5d06b-814c-4a01-ab5b-a238031a4814_terseLabel_en-US" xlink:label="lab_bsx_June2030NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2030 Notes [Member]</link:label>
    <link:label id="lab_bsx_June2030NotesMember_label_en-US" xlink:label="lab_bsx_June2030NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2030 Notes [Member]</link:label>
    <link:label id="lab_bsx_June2030NotesMember_documentation_en-US" xlink:label="lab_bsx_June2030NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2030 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2030NotesMember" xlink:href="bsx-20221231.xsd#bsx_June2030NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_June2030NotesMember" xlink:to="lab_bsx_June2030NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c3e50b17-dbcf-4c1f-9f56-691521561533_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_490c4908-298b-468d-89d9-468a3841fb0d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c914dae8-ab2a-48bc-bfdc-56418700b778_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_65d373f3-fbd3-463f-9fbc-220323362f54_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a73648e5-1ba8-49d0-9e0a-e90e524f0e50_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_73f9c533-f2d6-497c-bc7a-2b24d21c3feb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1b22be73-64aa-4b16-a5cd-bb379f0c9d0b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_da962688-6e44-4fa2-96fc-f06ef2af2c94_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_4c4aff90-275a-4578-85ff-434cb2e401c2_terseLabel_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_label_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_documentation_en-US" xlink:label="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest, weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:to="lab_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_f99acdd8-0c06-45f4-9bf7-d77cacf8877c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8f282790-2c1a-46cc-bb9e-7ff58f393e43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_c5a15fba-040a-4113-a0b0-92ac69c77d05_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings, Schedule of Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_141ace28-66f5-4918-ac80-901f7d1af9af_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c1244fa-f483-4e3c-961d-7d67958f5223_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance (Shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9f8dbd09-a432-4bda-9476-759716a3f327_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_cea051d7-c8c9-4506-971e-15679a01a837_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_be01b6eb-c078-4c9c-bf4d-f2fb66e472ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f7977826-ad79-4cf5-9f7c-74393a0aca46_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_26919cc5-85ff-4b0a-a39c-f8ed12c18ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9e1e2f67-5fd9-4e51-9c9c-05792d7c7cb5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) from foreign currency transaction exposures</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherInternationalPlansMember_5f4ffb94-a552-4f87-b329-65b39e526383_terseLabel_en-US" xlink:label="lab_bsx_OtherInternationalPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International Plans</link:label>
    <link:label id="lab_bsx_OtherInternationalPlansMember_label_en-US" xlink:label="lab_bsx_OtherInternationalPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International Plans [Member]</link:label>
    <link:label id="lab_bsx_OtherInternationalPlansMember_documentation_en-US" xlink:label="lab_bsx_OtherInternationalPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherInternationalPlansMember" xlink:href="bsx-20221231.xsd#bsx_OtherInternationalPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherInternationalPlansMember" xlink:to="lab_bsx_OtherInternationalPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_24691ece-a4a4-4437-8821-e9c66b13f1dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0ac7f131-4192-47a4-8c5b-4e4fd27c093c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_08617a6a-8334-48ee-b3e6-080bec4744fd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2c8e1a5c-0ef2-434a-815a-ae9a7ee790e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_12571d4e-f891-43df-8eb2-4e61c9d5ffb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7db53d8c-ad5a-454e-8576-414aad48e380_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0a4bad4e-5d0c-4be3-920d-30e6c97d7419_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_acabced1-f46c-4d23-9d48-42fa7198f678_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_October2023NotesMember_9471c628-761f-4fe5-a727-0e006c241e3a_terseLabel_en-US" xlink:label="lab_bsx_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2023 Notes [Member]</link:label>
    <link:label id="lab_bsx_October2023NotesMember_label_en-US" xlink:label="lab_bsx_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2023 Notes [Member]</link:label>
    <link:label id="lab_bsx_October2023NotesMember_documentation_en-US" xlink:label="lab_bsx_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2023 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_October2023NotesMember" xlink:href="bsx-20221231.xsd#bsx_October2023NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_October2023NotesMember" xlink:to="lab_bsx_October2023NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_PaymentsForRoyaltyRights_2004b909-06b9-4db9-90d5-9aaaf3d4c596_negatedTerseLabel_en-US" xlink:label="lab_bsx_PaymentsForRoyaltyRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for royalty rights</link:label>
    <link:label id="lab_bsx_PaymentsForRoyaltyRights_label_en-US" xlink:label="lab_bsx_PaymentsForRoyaltyRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for royalty rights</link:label>
    <link:label id="lab_bsx_PaymentsForRoyaltyRights_documentation_en-US" xlink:label="lab_bsx_PaymentsForRoyaltyRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for royalty rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentsForRoyaltyRights" xlink:href="bsx-20221231.xsd#bsx_PaymentsForRoyaltyRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_PaymentsForRoyaltyRights" xlink:to="lab_bsx_PaymentsForRoyaltyRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_7da233c1-9caf-4d4b-a16f-1ecac69fef8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_2d5c080b-4e5c-4274-8205-aac4a09cb8f8_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_83ced1a9-f0ce-464a-b6b4-26fa01e9e8d5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_GlobalNeuromodulationNmReportingUnitMember_462f407b-6304-4e55-b6a8-98876a41d2bc_terseLabel_en-US" xlink:label="lab_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Neuromodulation (NM) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalNeuromodulationNmReportingUnitMember_label_en-US" xlink:label="lab_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Neuromodulation (NM) Reporting Unit [Member]</link:label>
    <link:label id="lab_bsx_GlobalNeuromodulationNmReportingUnitMember_documentation_en-US" xlink:label="lab_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Neuromodulation (NM) Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:href="bsx-20221231.xsd#bsx_GlobalNeuromodulationNmReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:to="lab_bsx_GlobalNeuromodulationNmReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_05f17ff8-9cfb-4674-864f-85172addc661_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_d0c537aa-1cfc-4505-9604-4955cdeca748_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_bf9212c9-c4ee-457f-aebb-d939fc349839_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentive_0cbff37a-4b98-4ca8-9a5d-bcc10f461227_terseLabel_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive</link:label>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentive_label_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive</link:label>
    <link:label id="lab_bsx_FreeTradeZoneRegimeTaxIncentive_documentation_en-US" xlink:label="lab_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Trade Zone Regime Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:to="lab_bsx_FreeTradeZoneRegimeTaxIncentive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_fceb9a7e-f93b-479b-87bc-ea1f5c41863b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b52c66fa-7eb9-4338-a0dd-2f78ebc383e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_dbb1aa3b-4de3-4aba-9dd3-78d388aab5b0_terseLabel_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to provision</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_label_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to provision</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_documentation_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:to="lab_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_41ba04f8-ebfe-457e-a0e8-be17e0d6fc0e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9bf34be2-9f18-4894-9d19-475dd870df2f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_24bd49e7-2e1b-4582-982d-dc2613fc3e6c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_a5b19570-f851-4b08-834b-b15301047569_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_AllOther2021AcquisitionsMember_ac9b39f9-fd06-43a5-925f-67e743c587b7_terseLabel_en-US" xlink:label="lab_bsx_AllOther2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other 2021 Acquisitions</link:label>
    <link:label id="lab_bsx_AllOther2021AcquisitionsMember_label_en-US" xlink:label="lab_bsx_AllOther2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other 2021 Acquisitions [Member]</link:label>
    <link:label id="lab_bsx_AllOther2021AcquisitionsMember_documentation_en-US" xlink:label="lab_bsx_AllOther2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other 2021 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AllOther2021AcquisitionsMember" xlink:href="bsx-20221231.xsd#bsx_AllOther2021AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_AllOther2021AcquisitionsMember" xlink:to="lab_bsx_AllOther2021AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SignificantAccountingPoliciesAbstract_513ade67-d6a9-44ec-bf7c-256e52af6841_terseLabel_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_bsx_SignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_bsx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesAbstract" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract" xlink:to="lab_bsx_SignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_f7f15a24-bef6-4fcf-bf76-bd2ddfd55418_terseLabel_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_label_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, PBO</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_documentation_en-US" xlink:label="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Acquired and Established Plan Changes, PBO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:to="lab_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b2bc761d-d863-4254-8cac-add86e7e7b0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_b1a4a2d0-4253-4596-824e-2903dda0dced_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Retirement Plan Rate of Compensation Increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_c6cc2077-b309-4aa9-b2e4-7b40b7c5bc22_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RenminbiDenominatedFactoringArrangementsMember_52a342f5-b593-47f9-ac06-a4bff31329fa_terseLabel_en-US" xlink:label="lab_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renminbi Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_RenminbiDenominatedFactoringArrangementsMember_label_en-US" xlink:label="lab_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renminbi Denominated Factoring Arrangements [Member]</link:label>
    <link:label id="lab_bsx_RenminbiDenominatedFactoringArrangementsMember_documentation_en-US" xlink:label="lab_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renminbi Denominated Factoring Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:href="bsx-20221231.xsd#bsx_RenminbiDenominatedFactoringArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:to="lab_bsx_RenminbiDenominatedFactoringArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d244f661-b4e3-4012-aa36-66b2cabfd24f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_5e8f0891-345e-4c3f-b9f2-c957de6f3ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_0b0ccdaf-ed53-4b8e-a8e6-cd288271ca3f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Obligation</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_8fb28d28-f4b5-4dc6-bcc1-fb53bce43a89_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_6527f6cd-6341-4016-8b8e-90fa916dc52b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid on preferred stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_76301cc6-0c3b-4824-a7ab-6c7ac87b076b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a7a056b8-b0d7-4f0c-a2e5-2dba07a1f52c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_88ae8512-aa73-4918-bd86-e5fe4eef0f62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f32e9c24-5b78-439c-bb3e-d11e0bd3e1d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9cb49fae-d7ba-4e63-9c94-ee96a3a18f16_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_747e1e72-b80f-4514-b523-75c419584e7f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income allocated to reportable segments</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_96ac5706-9721-4727-8ba1-59efe00d8126_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_16fe78fb-32bb-4f95-a48d-0a16fc086e36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_83cb32d6-302f-4392-a626-dd1983b0e5d5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_9674295c-796e-44ef-822f-7aa6c016f134_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ffe89b91-c121-4707-a32c-5df03abd5ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42a158d3-2091-4321-89cc-92d65b229505_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_61994884-7d72-46e9-9a1f-d36cea136001_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_08db83cc-d631-47a7-8dd4-d158129a89d5_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_e764a047-8c51-4d56-9043-a2d381829321_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock_af8437ec-170a-4818-b2ef-8ebe174dc9d7_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Nonvestedstockawardsexerciseprice_0383157f-79c3-4af5-8553-6b2ae87a3acf_terseLabel_en-US" xlink:label="lab_bsx_Nonvestedstockawardsexerciseprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified options exercise price</link:label>
    <link:label id="lab_bsx_Nonvestedstockawardsexerciseprice_label_en-US" xlink:label="lab_bsx_Nonvestedstockawardsexerciseprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock awards exercise price</link:label>
    <link:label id="lab_bsx_Nonvestedstockawardsexerciseprice_documentation_en-US" xlink:label="lab_bsx_Nonvestedstockawardsexerciseprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock awards exercise price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Nonvestedstockawardsexerciseprice" xlink:href="bsx-20221231.xsd#bsx_Nonvestedstockawardsexerciseprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Nonvestedstockawardsexerciseprice" xlink:to="lab_bsx_Nonvestedstockawardsexerciseprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_832aa259-4912-4e0f-8eaa-ed84eed40962_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_747423fe-6517-4629-b8d8-ae9cdc9e3930_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Fairvalueofmarketbasedawards_69f9d0e0-6f07-46a8-aa65-60331e96a21e_terseLabel_en-US" xlink:label="lab_bsx_Fairvalueofmarketbasedawards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of market based awards</link:label>
    <link:label id="lab_bsx_Fairvalueofmarketbasedawards_label_en-US" xlink:label="lab_bsx_Fairvalueofmarketbasedawards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of market based awards</link:label>
    <link:label id="lab_bsx_Fairvalueofmarketbasedawards_documentation_en-US" xlink:label="lab_bsx_Fairvalueofmarketbasedawards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of market based awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Fairvalueofmarketbasedawards" xlink:href="bsx-20221231.xsd#bsx_Fairvalueofmarketbasedawards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Fairvalueofmarketbasedawards" xlink:to="lab_bsx_Fairvalueofmarketbasedawards" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_BaylisMedicalMember_cb96483d-43da-4113-be87-6bdfeabd066a_terseLabel_en-US" xlink:label="lab_bsx_BaylisMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baylis Medical</link:label>
    <link:label id="lab_bsx_BaylisMedicalMember_label_en-US" xlink:label="lab_bsx_BaylisMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baylis Medical [Member]</link:label>
    <link:label id="lab_bsx_BaylisMedicalMember_documentation_en-US" xlink:label="lab_bsx_BaylisMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baylis Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BaylisMedicalMember" xlink:href="bsx-20221231.xsd#bsx_BaylisMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_BaylisMedicalMember" xlink:to="lab_bsx_BaylisMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_4ed79edd-cbaa-499b-b6c9-643f33ecbdcb_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations, Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d62b2490-c162-4a74-b5f2-fcc2753b8de3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_1745ce16-dc8c-4d51-b097-ab58b10bc12d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_52843879-c6b6-4b4f-a11c-16e523aa3b3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_aae95747-7a31-41f3-bb41-d634fc1ea065_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d4f133b1-dda3-4763-b87e-8ac71958728e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_A2011LtipPlanMember_c9cf9b28-83f0-4646-ba13-ed30f5c54b8f_terseLabel_en-US" xlink:label="lab_bsx_A2011LtipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 LTIP Plan [Member]</link:label>
    <link:label id="lab_bsx_A2011LtipPlanMember_label_en-US" xlink:label="lab_bsx_A2011LtipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 LTIP Plan [Member]</link:label>
    <link:label id="lab_bsx_A2011LtipPlanMember_documentation_en-US" xlink:label="lab_bsx_A2011LtipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 LTIP Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2011LtipPlanMember" xlink:href="bsx-20221231.xsd#bsx_A2011LtipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_A2011LtipPlanMember" xlink:to="lab_bsx_A2011LtipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_7326cf27-19b2-4140-810b-17b456dd7ee5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55e8248a-bc54-4154-a943-29a91ff85074_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment and internal use software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3a9b2afa-4bf1-4158-9818-07ae5d2bb92e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_348ce8e2-fbd7-499c-8049-6e4e21959b10_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_06d9390a-de01-4251-a0bd-7a46d4b46d46_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_11c5ce93-2da8-451d-b1a0-45f5797b65a3_negatedLabel_en-US" xlink:label="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (payments for) investments and acquisitions of certain technologies</link:label>
    <link:label id="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_label_en-US" xlink:label="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (payments for) investments and acquisitions of certain technologies</link:label>
    <link:label id="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_documentation_en-US" xlink:label="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (payments for) investments and acquisitions of certain technologies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:href="bsx-20221231.xsd#bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:to="lab_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_2d56f87f-6c87-4209-b20d-0f64cd332a1b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_672eecfa-67fd-4d02-8bec-edefc0dc29ee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ExecutiveRetirementPlanMember_fe9cd220-a733-4580-b569-c59fa3d253f4_terseLabel_en-US" xlink:label="lab_bsx_ExecutiveRetirementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive retirement plan [Member]</link:label>
    <link:label id="lab_bsx_ExecutiveRetirementPlanMember_label_en-US" xlink:label="lab_bsx_ExecutiveRetirementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive retirement plan [Member]</link:label>
    <link:label id="lab_bsx_ExecutiveRetirementPlanMember_documentation_en-US" xlink:label="lab_bsx_ExecutiveRetirementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive retirement plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExecutiveRetirementPlanMember" xlink:href="bsx-20221231.xsd#bsx_ExecutiveRetirementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ExecutiveRetirementPlanMember" xlink:to="lab_bsx_ExecutiveRetirementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_76eb4b23-d28b-4db6-b184-deca8a0d0eb7_terseLabel_en-US" xlink:label="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of the fair market value of our common stock on the date of grant</link:label>
    <link:label id="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_label_en-US" xlink:label="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of the fair market value of our common stock on the date of grant</link:label>
    <link:label id="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_documentation_en-US" xlink:label="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of the fair market value of our common stock on the date of grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:href="bsx-20221231.xsd#bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:to="lab_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b75f95ed-fbde-44f8-8f18-106b26ae9126_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense, Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09bed85d-3404-4d40-8b6a-16255805dc54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1c20df26-7d7d-4878-b106-4efcb7d5af56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_a1ccb700-a44e-45a5-992d-6aefc049145b_terseLabel_en-US" xlink:label="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, fifth quarter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_label_en-US" xlink:label="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, fifth quarter following qualified acquisition [Member]</link:label>
    <link:label id="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_documentation_en-US" xlink:label="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, fifth quarter following qualified acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:href="bsx-20221231.xsd#bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:to="lab_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_d5915211-40eb-4469-82b5-b2a5df7cefb6_terseLabel_en-US" xlink:label="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred and prepaid income taxes</link:label>
    <link:label id="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow impact of deferred income tax expense (benefit)</link:label>
    <link:label id="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow impact of deferred income tax expense (benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:href="bsx-20221231.xsd#bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:to="lab_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock_ce35315c-bdc6-4ad7-a095-5cbbcdcb28c0_terseLabel_en-US" xlink:label="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based awards, valuation assumptions [Table Text Block]</link:label>
    <link:label id="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based awards, valuation assumptions [Table Text Block]</link:label>
    <link:label id="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based awards, valuation assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:to="lab_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b7bb769c-c25a-4912-b49d-d93735e4213b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9f0a3f60-4241-423a-851d-424d952aee1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_d8156699-54e6-4383-9563-71beb538ae57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_aa472d25-445e-4153-97e0-cfa6c45e18d5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5ce56086-a2c3-4770-a573-f8140e571540_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_BSXReportableSegmentsMember_9cf903ab-edb7-45fd-bf2a-0ef1dfde5d7f_terseLabel_en-US" xlink:label="lab_bsx_BSXReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSX Reportable Segments</link:label>
    <link:label id="lab_bsx_BSXReportableSegmentsMember_label_en-US" xlink:label="lab_bsx_BSXReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSX Reportable Segments [Member]</link:label>
    <link:label id="lab_bsx_BSXReportableSegmentsMember_documentation_en-US" xlink:label="lab_bsx_BSXReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSX Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BSXReportableSegmentsMember" xlink:href="bsx-20221231.xsd#bsx_BSXReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_BSXReportableSegmentsMember" xlink:to="lab_bsx_BSXReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4950ba62-fcfe-44b5-8cd1-30dacf8d4222_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e42e1774-218c-499d-9951-ae75f534f3d6_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_November2035NotesMember_6d6c9064-546f-421c-a25a-25b0e785f103_terseLabel_en-US" xlink:label="lab_bsx_November2035NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2035 Notes [Member]</link:label>
    <link:label id="lab_bsx_November2035NotesMember_label_en-US" xlink:label="lab_bsx_November2035NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2035 Notes [Member]</link:label>
    <link:label id="lab_bsx_November2035NotesMember_documentation_en-US" xlink:label="lab_bsx_November2035NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2035 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2035NotesMember" xlink:href="bsx-20221231.xsd#bsx_November2035NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_November2035NotesMember" xlink:to="lab_bsx_November2035NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_9df148cb-214e-45c0-b7be-9aa0415303cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d7db17fb-45c7-49bf-b88c-936db2175873_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1a9eddb0-091f-40b3-a71d-59acc7044c22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock_17f9bfd6-72bd-4b3b-9048-32c44241c982_terseLabel_en-US" xlink:label="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock_label_en-US" xlink:label="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block]</link:label>
    <link:label id="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock_documentation_en-US" xlink:label="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:to="lab_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_42d07031-167a-4e63-bdda-57219e413a7b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_05c2aaaf-a93b-470c-8bf9-81c258898f4d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_70bb7275-4994-48e2-a985-0fcd1a6f948c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_c14720f8-068b-47da-aa4e-c4e3f486a37f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3cce2e27-4a96-425f-9755-575090470fe6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_780fec4e-ed92-4610-985e-df601922cba8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_dbec2f20-72a1-4c82-bd1d-5ec3269834d5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_UKPlanMember_4d203d82-9f69-4cf9-af4d-cdc73f817be8_terseLabel_en-US" xlink:label="lab_bsx_UKPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Plan</link:label>
    <link:label id="lab_bsx_UKPlanMember_label_en-US" xlink:label="lab_bsx_UKPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Plan [Member]</link:label>
    <link:label id="lab_bsx_UKPlanMember_documentation_en-US" xlink:label="lab_bsx_UKPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UKPlanMember" xlink:href="bsx-20221231.xsd#bsx_UKPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_UKPlanMember" xlink:to="lab_bsx_UKPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ac14b9e8-161b-4c07-840f-0c5edc618b75_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_6f2d3433-1418-4c09-a6fb-d5a46247402d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_NetCurrencyExchangeGainLoss_4e593651-100e-4a36-97dc-789398bd8c7c_negatedTerseLabel_en-US" xlink:label="lab_bsx_NetCurrencyExchangeGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment costs</link:label>
    <link:label id="lab_bsx_NetCurrencyExchangeGainLoss_1c7ea8bb-554e-4d80-8fa3-804cd85e3767_terseLabel_en-US" xlink:label="lab_bsx_NetCurrencyExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net currency exchange gain (loss)</link:label>
    <link:label id="lab_bsx_NetCurrencyExchangeGainLoss_label_en-US" xlink:label="lab_bsx_NetCurrencyExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net currency exchange gain (loss)</link:label>
    <link:label id="lab_bsx_NetCurrencyExchangeGainLoss_documentation_en-US" xlink:label="lab_bsx_NetCurrencyExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net currency exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_NetCurrencyExchangeGainLoss" xlink:to="lab_bsx_NetCurrencyExchangeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2b129ae3-39a0-4245-bf63-0be8ae802a58_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_427e2d56-56ec-4442-8194-d3b87102d333_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3b793943-5046-4f95-891d-4297efc287e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_046cc133-6ee5-48c1-9102-bb7b10e19939_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherOtherLongTermAssets_11d2ba65-26e2-4e1a-b738-28f951a56bf2_terseLabel_en-US" xlink:label="lab_bsx_OtherOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Other Long-term Assets</link:label>
    <link:label id="lab_bsx_OtherOtherLongTermAssets_label_en-US" xlink:label="lab_bsx_OtherOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Other Long-term Assets</link:label>
    <link:label id="lab_bsx_OtherOtherLongTermAssets_documentation_en-US" xlink:label="lab_bsx_OtherOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Other Long-term Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherOtherLongTermAssets" xlink:href="bsx-20221231.xsd#bsx_OtherOtherLongTermAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherOtherLongTermAssets" xlink:to="lab_bsx_OtherOtherLongTermAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b610da9c-3c93-4907-9305-f434f9f402fa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_0ea112fd-7335-4ab6-8175-8ed94260dbd8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6d3f9006-dea8-4501-a4a9-8cc2b792023d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_049b9887-18c5-421c-92ab-4969d3362893_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) on investments and notes receivable</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dafbc4dc-d2c1-4c64-9f7c-9d4dd30492ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d978a0d5-324f-486d-83c7-f63cf4e4376d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_7c69be6d-508b-4536-a400-161230fcd865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract_e643e2ef-9149-497f-8cb3-3229e7faaeab_verboseLabel_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information (Textuals)</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract_label_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information (Textuals) [Abstract]</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract_documentation_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information (Textuals)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:to="lab_bsx_SupplementalBalanceSheetInformationTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3ee5b48b-ef24-42a6-bea6-febb34fbeea1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_ec44106c-eddd-4e0f-b091-afce9d731c13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3fb76fbd-d78c-476a-9d7a-a79c971e3bb2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_5cc5323f-f170-4f1c-bf99-99326a4ae439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2e7b06c-3bfa-4f49-a134-754474208831_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_765f5c60-a3bf-4c5d-b57a-429e9fa1c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bc4823e-1d43-424e-83ac-4950e1be9f5d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d130e7e-49ae-4ff6-99ad-601a71ac78f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_859f822d-bc2b-4264-89ba-b8fc0bcc1df7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a3505d2d-6692-4b1f-a11a-c75f018f6740_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_53bf7501-371b-43e7-926f-579a3e916991_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_33aac488-d42d-47e2-908d-f1a76bb5bcf4_verboseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_29c5940e-d74e-4a60-99de-9b96c13cf686_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_CardiacRhythmManagementMember_4c32d559-d07e-4e43-aae8-0a86b29aa135_terseLabel_en-US" xlink:label="lab_bsx_CardiacRhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiac Rhythm Management</link:label>
    <link:label id="lab_bsx_CardiacRhythmManagementMember_label_en-US" xlink:label="lab_bsx_CardiacRhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiac Rhythm Management [Member]</link:label>
    <link:label id="lab_bsx_CardiacRhythmManagementMember_documentation_en-US" xlink:label="lab_bsx_CardiacRhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiac Rhythm Management</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiacRhythmManagementMember" xlink:href="bsx-20221231.xsd#bsx_CardiacRhythmManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_CardiacRhythmManagementMember" xlink:to="lab_bsx_CardiacRhythmManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_98bcf8a5-ee6b-4f3c-b527-7fbd50762459_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fb81801e-81ac-40b8-9ffa-dc95f6bfebd3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_f25cbbdd-2110-412d-8c9c-7a1829c2dde8_terseLabel_en-US" xlink:label="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Free Cash Flow (FCF) performance awards</link:label>
    <link:label id="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_label_en-US" xlink:label="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Free Cash Flow (FCF) performance awards</link:label>
    <link:label id="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_documentation_en-US" xlink:label="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Free Cash Flow (FCF) performance awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:href="bsx-20221231.xsd#bsx_FairValueOfFreeCashFlowFcfPerformanceAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:to="lab_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_99ff4565-5c9f-4a4e-b1a8-9f478326b065_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4617e3be-f3eb-438a-9f74-73b9dab2fa5c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract_501b5e6c-61d9-44b4-878a-7cdcf807d472_terseLabel_en-US" xlink:label="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Cash Flow Supplemental Disclosure [Abstract]</link:label>
    <link:label id="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract_label_en-US" xlink:label="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Cash Flow Supplemental Disclosure [Abstract]</link:label>
    <link:label id="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract_documentation_en-US" xlink:label="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Cash Flow Supplemental Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:to="lab_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4b74df51-0116-4634-808d-d4dbbd72bfe3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9aff68a-a490-4ac5-ad64-7f4389c7b882_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_99e7f232-c899-4f3d-9508-05be0f8b0634_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LumenisLTDMember_d872f6c4-5fb7-49a6-9575-1eae74f1f5c1_terseLabel_en-US" xlink:label="lab_bsx_LumenisLTDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumenis LTD</link:label>
    <link:label id="lab_bsx_LumenisLTDMember_label_en-US" xlink:label="lab_bsx_LumenisLTDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumenis LTD [Member]</link:label>
    <link:label id="lab_bsx_LumenisLTDMember_documentation_en-US" xlink:label="lab_bsx_LumenisLTDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumenis LTD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LumenisLTDMember" xlink:href="bsx-20221231.xsd#bsx_LumenisLTDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LumenisLTDMember" xlink:to="lab_bsx_LumenisLTDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_eabc8ae1-cd30-49a8-a91e-d18108c16efa_terseLabel_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_label_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_documentation_en-US" xlink:label="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:to="lab_bsx_ScheduleofIncomeTaxRateReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_54004210-8e99-490a-9fad-aa4367a26e2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2b3f4c65-4c8d-4c8c-87dc-a53f56bcde15_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c6f92d97-eb22-4af0-b4b0-034839cd50ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement alternative investments (1)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_608f3ae4-5cf5-4ced-96c1-22708d395a89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_29d92940-59c4-4b0b-90ec-34d59f286f7b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_418d500b-183d-4167-8a98-e82052d13b6b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_f969512c-5d4b-4961-b585-274586cb4c70_terseLabel_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_label_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_documentation_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:to="lab_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2028SeniorNotesMember_13383bf8-1346-4796-9a32-a505b33863dc_terseLabel_en-US" xlink:label="lab_bsx_March2028SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Senior Notes</link:label>
    <link:label id="lab_bsx_March2028SeniorNotesMember_label_en-US" xlink:label="lab_bsx_March2028SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Senior Notes [Member]</link:label>
    <link:label id="lab_bsx_March2028SeniorNotesMember_documentation_en-US" xlink:label="lab_bsx_March2028SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2028 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028SeniorNotesMember" xlink:href="bsx-20221231.xsd#bsx_March2028SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2028SeniorNotesMember" xlink:to="lab_bsx_March2028SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockStock_573d8385-e13e-4185-b396-a41a08f5cf9d_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividends</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock, Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockStock" xlink:to="lab_us-gaap_DividendsPreferredStockStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_06acc208-886e-49f1-9038-1f29130bafee_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7d2fe4a1-94f0-4c96-add7-7034438ffa2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ff93757b-f3e5-4a56-97be-2af2562fdd96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_5eee3310-6433-4794-9d11-4b236c6555db_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_8d388a84-cc23-4204-8bc8-6bb16677d748_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (Shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b48be721-e11a-4604-a79b-b9c0d6b14134_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3daeef92-7b9d-4cbd-97b2-59d9188a22e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_6524be46-355d-4aeb-a06f-b8ad9ecd9400_terseLabel_en-US" xlink:label="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of December 31, 2021 and through remaining term of facility</link:label>
    <link:label id="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_label_en-US" xlink:label="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of December 31, 2021 and through remaining term of facility [Member]</link:label>
    <link:label id="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_documentation_en-US" xlink:label="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement, as of December 31, 2021 and through remaining term of facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:to="lab_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_1296fa3e-57d9-4dcc-9d90-bdf2f944eaf2_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_3da10ade-6e7f-42d6-b348-35aa69ece3fa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_ace49b6b-69db-44ec-be0c-71ac9c23a680_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61469517-b70c-43e7-ad16-75dacd1bd645_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d84592c0-8138-4f6a-ba8d-46070e9aeb4c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_b86f4b4c-50d2-435b-8382-2ae4be282dc8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6e38e32d-f716-4f82-94b9-ffe9a0ebf4d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_9b60fbd4-7693-4c9f-92c7-70d9a9cfaa18_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03acd6fe-16fb-4bf2-9e7e-bebb6ae160d9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_08cce8d3-6a58-4a8d-aaba-3e6a03951ec2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_IncomeTaxesAbstract_4af3ae9a-b278-4990-94ae-2fc0cde4efba_terseLabel_en-US" xlink:label="lab_bsx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_bsx_IncomeTaxesAbstract_label_en-US" xlink:label="lab_bsx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_bsx_IncomeTaxesAbstract_documentation_en-US" xlink:label="lab_bsx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IncomeTaxesAbstract" xlink:href="bsx-20221231.xsd#bsx_IncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_IncomeTaxesAbstract" xlink:to="lab_bsx_IncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_27ff934f-b31b-4449-b3fe-91b2b4ff4eab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_f4171272-cc15-4f72-9004-e6dec51194f3_terseLabel_en-US" xlink:label="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target payout of Free Cash Flows (FCF) performance awards</link:label>
    <link:label id="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_label_en-US" xlink:label="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target payout of Free Cash Flows (FCF) performance awards</link:label>
    <link:label id="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_documentation_en-US" xlink:label="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target payout of Free Cash Flows (FCF) performance awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:href="bsx-20221231.xsd#bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:to="lab_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_edee7019-a826-4ea8-bf01-e81de44502c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d103f89a-6e37-4699-a60a-2df00794af8b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_248f5d76-eb73-4675-9225-684939562ef8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9134b470-418b-4ba8-98f5-cebcd770f8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_37a706a0-55c1-4b8f-b2a2-75c0594febc7_terseLabel_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issuance (Value in excess of par)</link:label>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_label_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues (Preferred stock)</link:label>
    <link:label id="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_documentation_en-US" xlink:label="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues (Preferred stock)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:to="lab_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_be6ffa27-6d58-48b3-8da3-d6b71c8736f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_9bb09496-b078-4887-bc19-e36125791678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_May2022NotesMember_d729263a-3aba-4df6-9205-1264d3f0c390_verboseLabel_en-US" xlink:label="lab_bsx_May2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Notes [Member]</link:label>
    <link:label id="lab_bsx_May2022NotesMember_ecf23b44-57a1-43f1-b2fa-2b9163d72c43_terseLabel_en-US" xlink:label="lab_bsx_May2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Notes [Member]</link:label>
    <link:label id="lab_bsx_May2022NotesMember_label_en-US" xlink:label="lab_bsx_May2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Notes [Member]</link:label>
    <link:label id="lab_bsx_May2022NotesMember_documentation_en-US" xlink:label="lab_bsx_May2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2022NotesMember" xlink:href="bsx-20221231.xsd#bsx_May2022NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_May2022NotesMember" xlink:to="lab_bsx_May2022NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_42d1fb69-dffa-4294-9c6d-c1a8517c61c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock in connection with public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b5d6e259-80f6-4b89-a518-56a7d5bd1361_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_376b554a-4e3f-42e7-bbe1-f106931c1c9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_930ad9be-4872-4936-80ea-408487858c28_terseLabel_en-US" xlink:label="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]</link:label>
    <link:label id="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_label_en-US" xlink:label="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]</link:label>
    <link:label id="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_documentation_en-US" xlink:label="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:to="lab_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bf7ee692-da9c-44f0-9503-07f40c584a6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7ddfda00-c901-4392-8a0e-ca0013d32ae3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ccfe9b18-d49a-4180-9001-43c9dbab31ee_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment_7b1f3b30-1c55-4127-a4da-6657d4f0394e_terseLabel_en-US" xlink:label="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time transaction tax post-1986 E&amp;P - net payment</link:label>
    <link:label id="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment_label_en-US" xlink:label="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time transaction tax post-1986 E&amp;P - net payment</link:label>
    <link:label id="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment_documentation_en-US" xlink:label="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time transaction tax post-1986 E&amp;P - net payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:href="bsx-20221231.xsd#bsx_Onetimetransactiontaxpost1986EPnetpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:to="lab_bsx_Onetimetransactiontaxpost1986EPnetpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_bf9c90f3-5c93-415f-8396-a9decaa669a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_fa3a8286-53ae-40b5-9dea-ba0446a3342e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_72be2674-cea7-4f44-9989-501531a4a3cb_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_1948085e-88e0-486c-97f6-5e9c2c2b16d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2cb61412-0058-4b42-a427-8c7a1525f872_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_d01fa587-cd6b-4a2f-b6e9-eec9d0fed366_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3634ec1a-37c0-43ff-a88d-ad3df33372b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by (used for) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_2f25f873-974f-42a2-84cb-f97cbe1c9b50_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ee0b362-f95d-44fb-a67d-118fbaae6562_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a470c5e3-a14e-41a3-b76b-d4b0a3164fcd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_3706796a-ef35-4d38-a619-b7b9a39c762d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_5baf234f-fe7d-4222-98c9-b45c0c641ee0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_002f67a3-fea2-4776-bf99-8f4a2b564652_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16f4c25b-3ef2-49b4-8275-303ed07c9b8f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eaf63ff5-0471-43b6-8d0a-3e7aa0814a31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_994fcbb7-d69d-42d3-bfab-350d439c2015_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share &#8212; assuming dilution</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_16fed954-1f56-4ade-811a-78fd718b26b2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_1fd42724-792d-44ce-b980-1435b6b95a4c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_0dab7413-3d32-4a2b-b5ca-ecdc53c11971_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on borrowings from credit facilities</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b7176190-3b3e-4bb6-9640-c32b45fc8520_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_182f83bd-9f40-48e5-8081-1a55d764883c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_a3daa236-fae9-4eef-b6b0-b1ffbbcc84de_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_3a223c8d-18b5-4a15-8c7b-05edb48cdd37_terseLabel_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_label_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions</link:label>
    <link:label id="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_documentation_en-US" xlink:label="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:to="lab_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_TaxRateDomain_e52a50f2-d448-48b6-9eb4-ab4358155899_terseLabel_en-US" xlink:label="lab_bsx_TaxRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Domain]</link:label>
    <link:label id="lab_bsx_TaxRateDomain_label_en-US" xlink:label="lab_bsx_TaxRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Domain]</link:label>
    <link:label id="lab_bsx_TaxRateDomain_documentation_en-US" xlink:label="lab_bsx_TaxRateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateDomain" xlink:href="bsx-20221231.xsd#bsx_TaxRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_TaxRateDomain" xlink:to="lab_bsx_TaxRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2026NotesMember_8852bf94-c79f-494c-9d0b-380d4ada53d0_terseLabel_en-US" xlink:label="lab_bsx_March2026NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2026NotesMember_label_en-US" xlink:label="lab_bsx_March2026NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2026NotesMember_documentation_en-US" xlink:label="lab_bsx_March2026NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2026NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2026NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2026NotesMember" xlink:to="lab_bsx_March2026NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_73c2375b-ceef-4755-b322-c88244437e72_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SpecialChargesMember_dc622a0e-ff11-4db8-aeb0-57d8ff531fd3_terseLabel_en-US" xlink:label="lab_bsx_SpecialChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs</link:label>
    <link:label id="lab_bsx_SpecialChargesMember_label_en-US" xlink:label="lab_bsx_SpecialChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Charges [Member]</link:label>
    <link:label id="lab_bsx_SpecialChargesMember_documentation_en-US" xlink:label="lab_bsx_SpecialChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialChargesMember" xlink:href="bsx-20221231.xsd#bsx_SpecialChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SpecialChargesMember" xlink:to="lab_bsx_SpecialChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_15934066-0856-466d-af31-ed59840b057b_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_df9ed345-8f16-437f-8512-4ab73d1503ba_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9445a100-d967-443d-8781-d26299f12246_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7f5de5a9-5e9f-4dba-9e87-f7d4d8399152_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_221194d4-ccf3-46ad-b16c-cd7fab50fa58_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_3809aa93-99f5-45de-ba34-cef76b8e42c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_cc9d24d3-1c0d-4dc7-802a-eb1783e42096_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2b66e733-82fb-4ff2-b75c-cd3bae31d7e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_775df075-3e28-46d0-a1f5-f8c7ee7041ac_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_781af01f-f573-42d7-9c4d-a9e31010d215_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2024NotesMember_5c7ed176-0a75-4bec-8ba6-93fe67ab25e4_terseLabel_en-US" xlink:label="lab_bsx_March2024NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2024 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2024NotesMember_label_en-US" xlink:label="lab_bsx_March2024NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2024 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2024NotesMember_documentation_en-US" xlink:label="lab_bsx_March2024NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2024NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2024NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2024NotesMember" xlink:to="lab_bsx_March2024NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_e12895e3-6b3c-4211-9d69-ef4bac3d90d7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_efc3f2b6-4156-42bc-871e-dffe5c1ec005_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_61c7e3ea-4a90-4b00-9a3c-0bdb4763bc6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d159796-1f6e-4259-ae08-a836f295d0b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4fdd3662-810a-414d-976c-8beefcb88f4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_7f472ff9-e96c-4bed-898c-bc0baba8e93a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets (segment reporting)</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_6a999133-c2a2-4f82-ab4c-f0e9b3f01a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32f62fae-b05b-4443-a0a7-397ce7429f4a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8dd8501a-ea3e-4391-a15e-0b56610640a1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3b66d9a6-44a2-4bfc-b1ae-09ca815e6534_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LitigationAndDebtExclusionFromEbitda_c114bb4e-3af0-43b2-b455-cadc035952b2_terseLabel_en-US" xlink:label="lab_bsx_LitigationAndDebtExclusionFromEbitda" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and Debt Exclusion from EBITDA</link:label>
    <link:label id="lab_bsx_LitigationAndDebtExclusionFromEbitda_label_en-US" xlink:label="lab_bsx_LitigationAndDebtExclusionFromEbitda" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and Debt Exclusion from EBITDA</link:label>
    <link:label id="lab_bsx_LitigationAndDebtExclusionFromEbitda_documentation_en-US" xlink:label="lab_bsx_LitigationAndDebtExclusionFromEbitda" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusion of litigation payments and any debt Issued to fund tax deficiency payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LitigationAndDebtExclusionFromEbitda" xlink:href="bsx-20221231.xsd#bsx_LitigationAndDebtExclusionFromEbitda"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LitigationAndDebtExclusionFromEbitda" xlink:to="lab_bsx_LitigationAndDebtExclusionFromEbitda" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_46ce1133-65d8-491f-b721-cfc10ca07186_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of certain businesses and assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_58e87a46-e7f3-4423-adcb-28f10684cf1f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfe8fd45-fb7d-428f-bd6b-b620011010d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_025c7118-263c-49f1-adb7-47381c910a14_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_MITechCoLtdMember_db138968-456a-4abd-b54d-29de5ec0d2ed_terseLabel_en-US" xlink:label="lab_bsx_MITechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M.I. Tech Co., Ltd</link:label>
    <link:label id="lab_bsx_MITechCoLtdMember_label_en-US" xlink:label="lab_bsx_MITechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M.I. Tech Co., Ltd [Member]</link:label>
    <link:label id="lab_bsx_MITechCoLtdMember_documentation_en-US" xlink:label="lab_bsx_MITechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M.I. Tech Co., Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MITechCoLtdMember" xlink:href="bsx-20221231.xsd#bsx_MITechCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_MITechCoLtdMember" xlink:to="lab_bsx_MITechCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_90628b89-0581-49ec-ad08-f175586cb406_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_1b5f3d7f-b18d-4b38-97a4-6cf0b1f697b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6d7d7240-f579-4f47-ae66-1863f944129e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_daff6948-0cb8-494c-b17e-4bb9175b2333_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_79d0248f-f875-4375-826f-5131e07941df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_2bb43e50-1fe1-40ec-aa77-3a5efb70211c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2dc511a9-e6ec-4cdd-b6fb-5b56429c632a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LatinAmericaandCanadaMember_023ae799-aae7-47a8-a2f8-9dbe4b02357f_terseLabel_en-US" xlink:label="lab_bsx_LatinAmericaandCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America and Canada [Member]</link:label>
    <link:label id="lab_bsx_LatinAmericaandCanadaMember_label_en-US" xlink:label="lab_bsx_LatinAmericaandCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America and Canada [Member]</link:label>
    <link:label id="lab_bsx_LatinAmericaandCanadaMember_documentation_en-US" xlink:label="lab_bsx_LatinAmericaandCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America and Canada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LatinAmericaandCanadaMember" xlink:href="bsx-20221231.xsd#bsx_LatinAmericaandCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LatinAmericaandCanadaMember" xlink:to="lab_bsx_LatinAmericaandCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e8c7ab92-630a-4afd-a737-1b74b0aec6d0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_29776f7b-081b-4888-8a4d-65483ed39140_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_941f33fb-3d21-4e99-be2f-5ed36a0a6e2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in commercial paper</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_c33592bd-903b-4cbc-8190-d5945ac9bc95_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_StatementDomain_1a13587d-1db5-4025-ba50-3020fd009902_terseLabel_en-US" xlink:label="lab_bsx_StatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">statement [Domain]</link:label>
    <link:label id="lab_bsx_StatementDomain_label_en-US" xlink:label="lab_bsx_StatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">statement [Domain]</link:label>
    <link:label id="lab_bsx_StatementDomain_documentation_en-US" xlink:label="lab_bsx_StatementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for statement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementDomain" xlink:href="bsx-20221231.xsd#bsx_StatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_StatementDomain" xlink:to="lab_bsx_StatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_c5f197df-5a67-48d3-a68b-8924c17019e0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f73d68f2-4c44-44e5-b569-9c512d46cc2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3f870a9d-998f-49bf-9837-d3f71378565b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a891706c-2ec7-44cb-ab1e-f212747a833d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_369a03de-0912-47f9-a8f8-40397599ff84_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_17744a12-89b1-4251-a03c-741864550e13_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_a36fff66-f6eb-468c-b831-244e1415e619_terseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0ab194fd-793f-4a26-ab7d-1cbb7a7bd163_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0039e98f-18c5-48ef-a0ef-10973e4a47b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d9e58db1-96a9-4e01-a499-fe8a4d2053a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_7ca46bbe-fdea-41a4-b68f-ee42255112de_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LicensingArrangementAssetsMember_49aad137-7794-457e-a63a-55ec550a4d12_terseLabel_en-US" xlink:label="lab_bsx_LicensingArrangementAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement assets (Member)</link:label>
    <link:label id="lab_bsx_LicensingArrangementAssetsMember_label_en-US" xlink:label="lab_bsx_LicensingArrangementAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement assets [Member]</link:label>
    <link:label id="lab_bsx_LicensingArrangementAssetsMember_documentation_en-US" xlink:label="lab_bsx_LicensingArrangementAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangement assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementAssetsMember" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LicensingArrangementAssetsMember" xlink:to="lab_bsx_LicensingArrangementAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_727c845e-6237-4007-90c1-03d902fb7213_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_3dd7cec7-c701-4b46-9222-bea723981079_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_05c51eaa-0c46-4dd6-98fd-d3edbacd810f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2ca7af1e-3d17-405c-8fdd-0330641f2b8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_MaximumLeverageRatio_43c6cdc6-badd-4aa6-84f0-d4d2d991b9e7_terseLabel_en-US" xlink:label="lab_bsx_MaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Leverage Ratio</link:label>
    <link:label id="lab_bsx_MaximumLeverageRatio_label_en-US" xlink:label="lab_bsx_MaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Leverage Ratio</link:label>
    <link:label id="lab_bsx_MaximumLeverageRatio_documentation_en-US" xlink:label="lab_bsx_MaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum leverage ratio permitted by revolving credit facility agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MaximumLeverageRatio" xlink:href="bsx-20221231.xsd#bsx_MaximumLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_MaximumLeverageRatio" xlink:to="lab_bsx_MaximumLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1d304935-24b9-475a-9963-fb3c44b7a0bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_8742e34a-26f9-4fa3-a053-7eaa68e5699f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_d7960590-42ee-480b-beb2-4792d292ee75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_RevenueBasedPaymentsMember_217e3f0d-8dc9-466e-ab14-95d0d71b6f12_terseLabel_en-US" xlink:label="lab_bsx_RevenueBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">revenue-based payments [Member]</link:label>
    <link:label id="lab_bsx_RevenueBasedPaymentsMember_label_en-US" xlink:label="lab_bsx_RevenueBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">revenue-based payments [Member]</link:label>
    <link:label id="lab_bsx_RevenueBasedPaymentsMember_documentation_en-US" xlink:label="lab_bsx_RevenueBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">revenue-based payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenueBasedPaymentsMember" xlink:href="bsx-20221231.xsd#bsx_RevenueBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_RevenueBasedPaymentsMember" xlink:to="lab_bsx_RevenueBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_d89ac940-0339-43b4-85ec-b1a2ad057e2c_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_bdd48430-16e0-4103-b61e-610718702a1b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7610a084-7871-467e-9a40-580ad34e9be8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_91592479-1289-4b07-868f-8a6a37634f91_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_7ff02156-1296-4a72-ad55-02d991a1dbd5_terseLabel_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b25f0ae7-1c16-453b-af38-242f6a82e51c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_55e73708-ae22-4ae2-b3af-37ad71d10cbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a4c00b0b-2e1b-41ab-94ec-ab547682e708_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9bedd40-9311-4afe-8303-bfb613c98889_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c78ebd5-2318-4b6a-81f7-212904da7423_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d05e4d9b-83ba-4e2f-b24d-63bdf82f3f6c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_735ce1a6-9d7a-4d73-87f3-c375b24cb14e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_d22c2e0d-0e81-4bf9-816f-c624e9a631f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6a7f08e3-0af9-4f92-9a22-309708a84b15_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a6a23152-a003-4f7d-9978-5450bd8d472d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_888f28ca-02da-4bea-b072-fb0b45ef0057_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_87a0839b-ae94-4177-bfcd-00a44444841b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_120e5bfb-dc1e-4777-960b-c204480de115_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21f0c5e4-91c3-4c68-98d0-f49d2af34f03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_490df96c-26eb-4d0a-8d23-586eb0aff4b9_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_EquipmentFurnitureAndFixturesGross_f7bc7880-85d2-49b2-933f-fe64410735c7_terseLabel_en-US" xlink:label="lab_bsx_EquipmentFurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, furniture and fixtures</link:label>
    <link:label id="lab_bsx_EquipmentFurnitureAndFixturesGross_label_en-US" xlink:label="lab_bsx_EquipmentFurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, furniture and fixtures Gross</link:label>
    <link:label id="lab_bsx_EquipmentFurnitureAndFixturesGross_documentation_en-US" xlink:label="lab_bsx_EquipmentFurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, furniture and fixtures Gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EquipmentFurnitureAndFixturesGross" xlink:href="bsx-20221231.xsd#bsx_EquipmentFurnitureAndFixturesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_EquipmentFurnitureAndFixturesGross" xlink:to="lab_bsx_EquipmentFurnitureAndFixturesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_03e68b81-fa1a-40ad-935d-b061b6717a88_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1055b293-e974-4c4b-b738-47ba18e6a7f1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d4135bc5-1cba-440c-95eb-32d7a006092d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_9877ed22-77c1-417e-87ef-df8281afe7db_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization of allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_4201d67c-4aa4-4c41-a80a-567059adf086_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization of allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_540cbc94-fd30-4105-b759-0d56033d00cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDER'S EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_0dea2b0e-c31c-49b9-82e0-86e4155adb9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_249e6550-80c0-4340-a1ec-9de2a09db317_terseLabel_en-US" xlink:label="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Related to Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:href="bsx-20221231.xsd#bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d4cbbcc0-d90e-48af-8762-8332b747170b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense, Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_60b17956-4b4e-4fc6-bcaf-6be257d69a4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_16eb4df4-1ed7-4144-98d9-96e730170c14_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f78aae0c-24de-4458-8196-32e58d586e5c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_AccruedRebatesCurrent_c73af41c-5929-40d9-a1b8-230faf96e368_terseLabel_en-US" xlink:label="lab_bsx_AccruedRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates, Current</link:label>
    <link:label id="lab_bsx_AccruedRebatesCurrent_label_en-US" xlink:label="lab_bsx_AccruedRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates, Current</link:label>
    <link:label id="lab_bsx_AccruedRebatesCurrent_documentation_en-US" xlink:label="lab_bsx_AccruedRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AccruedRebatesCurrent" xlink:href="bsx-20221231.xsd#bsx_AccruedRebatesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_AccruedRebatesCurrent" xlink:to="lab_bsx_AccruedRebatesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8400e785-bf9f-4ceb-8fd5-100a40849d04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by (used for) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_1eb7ec9c-9d66-48e7-b98f-a1ac727d5b5e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a442ed37-209c-4dbb-88b8-4ec24e66b700_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a24ddbf7-953d-459a-b9de-c828b6580c1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating assets and liabilities, excluding purchase accounting:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherNet_8327482f-e199-490d-93d9-9285b29ad17c_terseLabel_en-US" xlink:label="lab_bsx_OtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bsx_OtherNet_label_en-US" xlink:label="lab_bsx_OtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bsx_OtherNet_documentation_en-US" xlink:label="lab_bsx_OtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherNet" xlink:href="bsx-20221231.xsd#bsx_OtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherNet" xlink:to="lab_bsx_OtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_March2029NotesMember_8bc31f1b-958f-4c3c-9f1e-3490ae023c8e_terseLabel_en-US" xlink:label="lab_bsx_March2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2029 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2029NotesMember_label_en-US" xlink:label="lab_bsx_March2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2029 Notes [Member]</link:label>
    <link:label id="lab_bsx_March2029NotesMember_documentation_en-US" xlink:label="lab_bsx_March2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2029 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2029NotesMember" xlink:href="bsx-20221231.xsd#bsx_March2029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_March2029NotesMember" xlink:to="lab_bsx_March2029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingParValuePerShare_3b978a96-ce0d-47e0-b9c9-d0572e2a98da_terseLabel_en-US" xlink:label="lab_dei_EntityListingParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
    <link:label id="lab_dei_EntityListingParValuePerShare_label_en-US" xlink:label="lab_dei_EntityListingParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingParValuePerShare" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingParValuePerShare" xlink:to="lab_dei_EntityListingParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_531e5f9c-18a3-4bfc-b012-e49fced70a54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_f21fcec3-72c6-4956-ac69-cc6c8d463d0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_ea311177-7917-4a90-aa7b-4229ee535206_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_87a87fff-791f-40df-bd6a-250dc8ddd9bb_terseLabel_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_label_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, plan assets, actuarial gain loss</link:label>
    <link:label id="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_documentation_en-US" xlink:label="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, plan assets, actuarial gain loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:to="lab_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c90f4670-c895-4053-b5e8-f16ed5e03591_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_256f9619-05b2-4a1d-b5b9-c3ef3f7ba519_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_d6c880a1-ef26-4bd8-b971-cdbbca980ccc_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b51d71f4-b6b1-4c15-8e9c-b460bde5cadf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_eb40adc4-2e54-496f-a82b-1abab0e93258_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_28ef0dd4-430c-4373-95e1-b679cec7bd72_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_A550MCPSSeriesAMember_4c18ccf3-008d-4788-8700-24ee85c3b6fe_terseLabel_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A [Member]</link:label>
    <link:label id="lab_bsx_A550MCPSSeriesAMember_label_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A [Member]</link:label>
    <link:label id="lab_bsx_A550MCPSSeriesAMember_documentation_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_A550MCPSSeriesAMember" xlink:to="lab_bsx_A550MCPSSeriesAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_35210e13-d6bb-41b9-a1be-bdceecb8e602_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3344206d-ee46-46cc-80e7-8fa07ad2036b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_5d0c5cd5-b37d-41cf-9368-c8e391b3e8c8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_a2813a5b-ea99-4a21-a365-148408eaba52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_84883ee3-0b0e-4b46-8dc7-a19529c51402_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_ff7a8f02-abcc-4f18-b6e8-78dbf6b451df_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OptionsExpectedToVest_035c6eed-3176-4560-aff0-0c475e2b3f4d_terseLabel_en-US" xlink:label="lab_bsx_OptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVest_label_en-US" xlink:label="lab_bsx_OptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest</link:label>
    <link:label id="lab_bsx_OptionsExpectedToVest_documentation_en-US" xlink:label="lab_bsx_OptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVest" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OptionsExpectedToVest" xlink:to="lab_bsx_OptionsExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_OtherMember_b69b7491-b70a-496a-adc0-90cb1cb959e1_terseLabel_en-US" xlink:label="lab_bsx_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bsx_OtherMember_label_en-US" xlink:label="lab_bsx_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_bsx_OtherMember_documentation_en-US" xlink:label="lab_bsx_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_OtherMember" xlink:to="lab_bsx_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_5df7152e-d5b2-4317-a4bb-978d589f9f7f_terseLabel_en-US" xlink:label="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid on Intercompany Profit</link:label>
    <link:label id="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_label_en-US" xlink:label="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid on Intercompany Profit</link:label>
    <link:label id="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_documentation_en-US" xlink:label="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid on Intercompany Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:to="lab_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_6559cba1-5bdc-4b2e-bd40-0d921242259d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f290e001-d41d-4783-acc8-fac9d093fee4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_eca30017-f35d-4707-be27-5905135992d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_d863f5ad-3627-4392-97d6-c6af3b033484_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_80436bdf-3fb4-4be9-bb22-29088ba87bed_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_9115ad7c-1701-419e-a0af-6f0ccc253f44_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_January2040NotesMember_1075e17d-2a11-4c3d-8689-9a63523406c5_terseLabel_en-US" xlink:label="lab_bsx_January2040NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2040 Notes [Member]</link:label>
    <link:label id="lab_bsx_January2040NotesMember_label_en-US" xlink:label="lab_bsx_January2040NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2040 Notes [Member]</link:label>
    <link:label id="lab_bsx_January2040NotesMember_documentation_en-US" xlink:label="lab_bsx_January2040NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2040 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_January2040NotesMember" xlink:href="bsx-20221231.xsd#bsx_January2040NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_January2040NotesMember" xlink:to="lab_bsx_January2040NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_159285a6-3fc9-4870-98ed-24089ed52d75_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_da65f2f4-7789-42a1-bfdf-f8e8aa7e5983_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ee141573-6b8e-4fe2-abd2-1f8015e0c136_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0a76ae38-31d6-4082-92ab-ba5e192b7efd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_2472f5bf-9c37-4d63-a642-5f3ed9cbb7b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_0ab94ef8-9daa-4c77-800f-864d7bd383c7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b5299636-53ba-4581-be13-9eb72fed2c49_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_55a159e7-3cb8-40d1-9061-ace8280d4a6f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_May2025NotesMember_9b427a6b-253a-4403-b2a0-8d9b6883f5b8_terseLabel_en-US" xlink:label="lab_bsx_May2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2025 Notes [Member]</link:label>
    <link:label id="lab_bsx_May2025NotesMember_label_en-US" xlink:label="lab_bsx_May2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2025 Notes [Member]</link:label>
    <link:label id="lab_bsx_May2025NotesMember_documentation_en-US" xlink:label="lab_bsx_May2025NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2025 Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2025NotesMember" xlink:href="bsx-20221231.xsd#bsx_May2025NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_May2025NotesMember" xlink:to="lab_bsx_May2025NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_181d7fb8-e3e1-4ee6-a8a1-5f2bba6eea76_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_LicensingArrangementsAsset_8e586b52-a2f2-43e4-8a98-782f6116400c_terseLabel_en-US" xlink:label="lab_bsx_LicensingArrangementsAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, asset</link:label>
    <link:label id="lab_bsx_LicensingArrangementsAsset_label_en-US" xlink:label="lab_bsx_LicensingArrangementsAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, asset</link:label>
    <link:label id="lab_bsx_LicensingArrangementsAsset_documentation_en-US" xlink:label="lab_bsx_LicensingArrangementsAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing arrangements, asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsAsset" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_LicensingArrangementsAsset" xlink:to="lab_bsx_LicensingArrangementsAsset" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>45
<FILENAME>bsx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8958ee0a-f5f8-4d49-b83c-57ef1423359a,g:e1e42f3c-1eea-46c7-aa64-a7e5247c20c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bostonscientific.com/role/Cover" xlink:type="simple" xlink:href="bsx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3f6efb5e-9b5c-4487-a378-8a2fccce9f35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f6efb5e-9b5c-4487-a378-8a2fccce9f35" xlink:to="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_700ce533-04cc-4e5e-9983-0d4514d027f5" xlink:to="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a7e3517-8540-4793-875f-5fac680ad9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_us-gaap_CommonStockMember_1a7e3517-8540-4793-875f-5fac680ad9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_f67cfcc7-b10a-42cf-b897-0a8fdc422651" xlink:href="bsx-20221231.xsd#bsx_SeniorNotedue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_bsx_SeniorNotedue2027Member_f67cfcc7-b10a-42cf-b897-0a8fdc422651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_d04c8bdd-be77-4b3f-aa3d-5f5e8271c2bf" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae782fd6-92d3-480f-9bff-ca56b6045fdb" xlink:to="loc_bsx_A550MCPSSeriesAMember_d04c8bdd-be77-4b3f-aa3d-5f5e8271c2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3fd84dd4-b6df-4aa8-8651-33bdfa920c1a" xlink:to="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2fa19cfa-eaba-41fe-bff2-16fb7310c6b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentType_2fa19cfa-eaba-41fe-bff2-16fb7310c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_97544216-22c4-4017-ba89-63aff119161c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentAnnualReport_97544216-22c4-4017-ba89-63aff119161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cea6789b-2407-409e-bf28-91019af3acb1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentPeriodEndDate_cea6789b-2407-409e-bf28-91019af3acb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c4ffaafe-4e5f-442c-b717-6f3799bf270e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentTransitionReport_c4ffaafe-4e5f-442c-b717-6f3799bf270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_21496ba2-7d6e-485e-8d9c-d467d1602b1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityFileNumber_21496ba2-7d6e-485e-8d9c-d467d1602b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c755150f-dc7a-41dc-a940-96b550ee31cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityRegistrantName_c755150f-dc7a-41dc-a940-96b550ee31cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fbc3e724-26dd-47cf-932b-248871907a11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fbc3e724-26dd-47cf-932b-248871907a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3d70c926-9dd2-4de6-b129-df16c2e5615b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityTaxIdentificationNumber_3d70c926-9dd2-4de6-b129-df16c2e5615b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4f491ac-466b-4740-ad20-cc2943c372ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressAddressLine1_b4f491ac-466b-4740-ad20-cc2943c372ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_24e74b86-2ee0-42d9-a846-e929e1c31903" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressCityOrTown_24e74b86-2ee0-42d9-a846-e929e1c31903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cbe12430-249a-4f8d-b8c8-cfd426e642c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressStateOrProvince_cbe12430-249a-4f8d-b8c8-cfd426e642c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_acf766eb-67ab-41da-b928-0ab216375007" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityAddressPostalZipCode_acf766eb-67ab-41da-b928-0ab216375007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d10d79cc-a9a1-41d2-b957-5eff0a403760" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_CityAreaCode_d10d79cc-a9a1-41d2-b957-5eff0a403760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1743af96-3f37-4b61-9efe-c40c2dd691c5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_LocalPhoneNumber_1743af96-3f37-4b61-9efe-c40c2dd691c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e52d07bf-4873-4245-a93a-5c66c18d11c5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_Security12bTitle_e52d07bf-4873-4245-a93a-5c66c18d11c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_478d06c2-e86b-469e-9741-011495f39aa1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_TradingSymbol_478d06c2-e86b-469e-9741-011495f39aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e325d22-3f41-4a28-b2c0-e5e60ea557a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_SecurityExchangeName_5e325d22-3f41-4a28-b2c0-e5e60ea557a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_157c1135-d8d1-4be6-8fd5-61187ac153ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_157c1135-d8d1-4be6-8fd5-61187ac153ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_35a9f9f4-e3d0-4033-b9a5-dbc1a5724228" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityVoluntaryFilers_35a9f9f4-e3d0-4033-b9a5-dbc1a5724228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2ccf4807-069f-4d92-b400-7ec1a3887a18" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCurrentReportingStatus_2ccf4807-069f-4d92-b400-7ec1a3887a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7056c08c-e40e-429d-95b5-927a86863da7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityInteractiveDataCurrent_7056c08c-e40e-429d-95b5-927a86863da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d7cd4d03-4b79-4aed-b434-f63d760b20dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityFilerCategory_d7cd4d03-4b79-4aed-b434-f63d760b20dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_478b2267-c3f8-4bcf-baa4-571837b73e66" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntitySmallBusiness_478b2267-c3f8-4bcf-baa4-571837b73e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d3675ee6-6500-4c4a-a53b-86750cb8b502" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityEmergingGrowthCompany_d3675ee6-6500-4c4a-a53b-86750cb8b502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_952ea0c8-8d1d-475c-a274-4498c6dac3cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_952ea0c8-8d1d-475c-a274-4498c6dac3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fc1f9519-a81b-47f3-ab37-efb925aec135" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityShellCompany_fc1f9519-a81b-47f3-ab37-efb925aec135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_78391a37-55f0-473e-9ede-9f182e0fb1f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityPublicFloat_78391a37-55f0-473e-9ede-9f182e0fb1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingParValuePerShare_c5fb9580-234f-4aee-9da4-92e5a961f709" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingParValuePerShare"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityListingParValuePerShare_c5fb9580-234f-4aee-9da4-92e5a961f709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3b32de9d-7608-4014-88db-51072726ea3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3b32de9d-7608-4014-88db-51072726ea3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49b7d812-0930-41c1-8c19-cc28c28e2e52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_EntityCentralIndexKey_49b7d812-0930-41c1-8c19-cc28c28e2e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fa4c00c0-a89a-4a12-991a-816757df46be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_CurrentFiscalYearEndDate_fa4c00c0-a89a-4a12-991a-816757df46be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c674b0eb-2a91-49e4-be9f-9167588a24e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentFiscalYearFocus_c674b0eb-2a91-49e4-be9f-9167588a24e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e230632-8669-4c0a-a4f4-6c01db479909" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e230632-8669-4c0a-a4f4-6c01db479909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_da3580c3-90a4-4e86-9745-fb7e43c41e14" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c21a32ca-bc55-4387-8ca9-733d76a7042b" xlink:to="loc_dei_AmendmentFlag_da3580c3-90a4-4e86-9745-fb7e43c41e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AuditInformation" xlink:type="simple" xlink:href="bsx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AuditInformationAbstract_902fb47f-df33-4824-8ca8-893b90e116d3" xlink:href="bsx-20221231.xsd#bsx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_41041ed3-fb24-4961-ba36-4c6fb1f6ee01" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_AuditInformationAbstract_902fb47f-df33-4824-8ca8-893b90e116d3" xlink:to="loc_dei_AuditorName_41041ed3-fb24-4961-ba36-4c6fb1f6ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c3d6c646-e14d-411f-8ef1-9ce1a5c2cc5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_AuditInformationAbstract_902fb47f-df33-4824-8ca8-893b90e116d3" xlink:to="loc_dei_AuditorFirmId_c3d6c646-e14d-411f-8ef1-9ce1a5c2cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_8686ea80-77f6-43e5-8cd3-f7ecca803e2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_AuditInformationAbstract_902fb47f-df33-4824-8ca8-893b90e116d3" xlink:to="loc_dei_AuditorLocation_8686ea80-77f6-43e5-8cd3-f7ecca803e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_34ce8a67-2955-4b09-8888-7a9a33bc9d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34ce8a67-2955-4b09-8888-7a9a33bc9d0e" xlink:to="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:to="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b9906b04-3cb1-4687-82b6-ea7c1de7881a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_81f44d8b-6047-4ebd-8ba1-b43cbec97af5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b9906b04-3cb1-4687-82b6-ea7c1de7881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c42e6c68-c667-47d4-b92f-5700967ddcaa" xlink:to="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e89352-d5c6-4e3f-98d2-800c1cb06a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e89352-d5c6-4e3f-98d2-800c1cb06a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_496909d0-9073-4c76-8e99-0b43b6c779b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_496909d0-9073-4c76-8e99-0b43b6c779b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e5918db7-b50c-4756-9d68-bad3c0aa8775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_GrossProfit_e5918db7-b50c-4756-9d68-bad3c0aa8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e2301f58-b053-42b4-8740-f070f45ec60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e2301f58-b053-42b4-8740-f070f45ec60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_01a195aa-a518-4a0a-8794-ade2ef3f3c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_01a195aa-a518-4a0a-8794-ade2ef3f3c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_13f0bc80-5ac9-4dbb-87bd-67df1e2a56b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_RoyaltyExpense_13f0bc80-5ac9-4dbb-87bd-67df1e2a56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5f49cdf-884d-45ab-8f15-344c5b7e95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5f49cdf-884d-45ab-8f15-344c5b7e95e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f5487210-8f27-496d-9a23-358cd027d41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f5487210-8f27-496d-9a23-358cd027d41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e4c4870f-dac9-4022-ac3e-a38bfbee0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e4c4870f-dac9-4022-ac3e-a38bfbee0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5e5c592e-4eb5-4e36-8a1a-b952b2fe7f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5e5c592e-4eb5-4e36-8a1a-b952b2fe7f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e36aa9d4-e588-4e9b-b118-babfe636e119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_RestructuringCharges_e36aa9d4-e588-4e9b-b118-babfe636e119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_bdeb274b-1a76-4d08-81ea-6debff11955f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_LitigationSettlementExpense_bdeb274b-1a76-4d08-81ea-6debff11955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_2e75434d-15b1-44a6-a69f-1cbf289f271f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_2e75434d-15b1-44a6-a69f-1cbf289f271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1fde068a-a801-4e3a-868d-64b8cf177b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5986aa44-d500-404c-b1ef-549e415c774a" xlink:to="loc_us-gaap_OperatingExpenses_1fde068a-a801-4e3a-868d-64b8cf177b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1e8fcfd-7aa1-4146-b893-8e8012f478db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1e8fcfd-7aa1-4146-b893-8e8012f478db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b38dcc10-768a-421d-90fc-f496d5f89929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:to="loc_us-gaap_InterestExpense_b38dcc10-768a-421d-90fc-f496d5f89929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6737ec-1966-4938-9d63-3a9cb9431a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c76fea78-aba2-41c9-a8f7-6dd33b262a6a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6737ec-1966-4938-9d63-3a9cb9431a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ce7b6d9-08c1-4af3-afe6-b2015bcd09e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ce7b6d9-08c1-4af3-afe6-b2015bcd09e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eb36d9eb-498c-4983-9fc3-28dd8cbdbe00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eb36d9eb-498c-4983-9fc3-28dd8cbdbe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aded3cdd-f292-4a1c-bb8e-23f8acb57476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_ProfitLoss_aded3cdd-f292-4a1c-bb8e-23f8acb57476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockStock_01adc504-0d62-4094-bb18-701ca09a200a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_DividendsPreferredStockStock_01adc504-0d62-4094-bb18-701ca09a200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d4f3a0e-b6aa-47a5-9673-a80a4b0bdf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d4f3a0e-b6aa-47a5-9673-a80a4b0bdf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f7b10251-2dfb-4a07-8774-e50186b8679c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_f7b10251-2dfb-4a07-8774-e50186b8679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_260db8d4-a942-42a0-a051-6ffa3723f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_260db8d4-a942-42a0-a051-6ffa3723f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79c99235-8df4-4e53-b0a3-f77b98cb11c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49c7580a-a2fe-49f0-a203-eb92ca1e70e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49c7580a-a2fe-49f0-a203-eb92ca1e70e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de5e7803-b27b-45df-8050-0756438161d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68e1cb6a-0950-483f-bd96-3e1efc77be55" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de5e7803-b27b-45df-8050-0756438161d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ad4b2c3-fa0c-410a-b295-bd1aaac0b254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ad4b2c3-fa0c-410a-b295-bd1aaac0b254" xlink:to="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:to="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2ee905d4-4379-4c0f-86d0-c9cb46260db9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4a7aa7ba-f8cf-4531-8025-36d8397a9f92" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2ee905d4-4379-4c0f-86d0-c9cb46260db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2102edb3-4bea-45d1-b6dd-cb640d709201" xlink:to="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_97328c9c-ec23-4b4b-ac0f-16c17c472d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a0f9e457-d0fb-419f-8c93-b48d4e1d5062" xlink:to="loc_us-gaap_PreferredStockMember_97328c9c-ec23-4b4b-ac0f-16c17c472d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49b83c68-e0da-4e43-b0ac-ede587759451" xlink:to="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_72428de9-c303-4709-b65a-35244792bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_ProfitLoss_72428de9-c303-4709-b65a-35244792bf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6fa3a936-20a6-4b53-8437-c06bb5b2a522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6fa3a936-20a6-4b53-8437-c06bb5b2a522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_021884d4-4328-4c5e-97d5-38a252aea0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_021884d4-4328-4c5e-97d5-38a252aea0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_682ac166-67fe-474a-a343-a2ece42bf1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_682ac166-67fe-474a-a343-a2ece42bf1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e75c1179-a446-43d8-95cb-b111f9ee0143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_309b9786-376f-4986-a253-731abc493283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e75c1179-a446-43d8-95cb-b111f9ee0143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95669264-3916-4906-9c2c-818e0abf9489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a405aa95-1176-4ed8-a212-e452032f9c0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95669264-3916-4906-9c2c-818e0abf9489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_43df4a63-5a4f-412c-8e61-1b1a20fc81b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_43df4a63-5a4f-412c-8e61-1b1a20fc81b7" xlink:to="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:to="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fad74d9c-1220-4cfa-b28a-b941f0ff80ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3c3d4276-4e36-47c6-ad20-b32394a8d1de" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fad74d9c-1220-4cfa-b28a-b941f0ff80ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d341295f-919e-450a-bdab-eaf9fac5f172" xlink:to="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:to="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3117c15d-943b-4737-b71e-e4348b107cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3117c15d-943b-4737-b71e-e4348b107cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8edb4136-650a-42ee-a73f-aad21efa69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8edb4136-650a-42ee-a73f-aad21efa69c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33077ad6-703b-424a-a7f0-78e4b256df26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_InventoryNet_33077ad6-703b-424a-a7f0-78e4b256df26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_93c57b83-9140-4c56-80f4-25ff1853e134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_PrepaidTaxes_93c57b83-9140-4c56-80f4-25ff1853e134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_013d5c25-b111-4ce6-9ab1-7d832c0cff43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_013d5c25-b111-4ce6-9ab1-7d832c0cff43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c960efe7-bdd0-4942-9da1-e59b8944de83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_204f080a-8a86-4fe0-8bfa-a5328ea1191f" xlink:to="loc_us-gaap_AssetsCurrent_c960efe7-bdd0-4942-9da1-e59b8944de83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_01139db7-f048-45fe-a673-0e6ff1002bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_01139db7-f048-45fe-a673-0e6ff1002bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be87f23d-e4ad-4c10-8915-fbacff523e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_Goodwill_be87f23d-e4ad-4c10-8915-fbacff523e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a4124b-d330-4588-af55-407e3ff6be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a4124b-d330-4588-af55-407e3ff6be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d79465-d5b4-42b1-b210-30058897d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d79465-d5b4-42b1-b210-30058897d1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5780edcd-dbc2-4cdb-a59d-4734ed516c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5780edcd-dbc2-4cdb-a59d-4734ed516c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b134b1b1-c8a0-4f9d-9c0a-5926c180449b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4922406f-45a6-4080-83eb-9c8bd3d5f6d6" xlink:to="loc_us-gaap_Assets_b134b1b1-c8a0-4f9d-9c0a-5926c180449b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ba62f92-5e4a-48c1-9e26-2e8565259cad" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_47c0b3ec-05ae-4f20-8b0e-e1e58345fc80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_DebtCurrent_47c0b3ec-05ae-4f20-8b0e-e1e58345fc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4ae59ea2-32a4-4d2c-a1f3-2d80ea3177d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_AccountsPayableCurrent_4ae59ea2-32a4-4d2c-a1f3-2d80ea3177d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c75e0568-f5c0-4bde-8fcd-0944b883f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c75e0568-f5c0-4bde-8fcd-0944b883f6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2a898d0e-e732-496f-9c8d-1f0f9807d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2a898d0e-e732-496f-9c8d-1f0f9807d48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b80e21ba-0136-4ed9-b937-2f7dbc205608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d09aeca-b46b-4100-9c02-e4b585a96922" xlink:to="loc_us-gaap_LiabilitiesCurrent_b80e21ba-0136-4ed9-b937-2f7dbc205608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6df97e46-bf8e-4bfe-9d4b-0965ebae7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6df97e46-bf8e-4bfe-9d4b-0965ebae7ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_558948b8-b1b8-4090-a026-94c3a218bfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_558948b8-b1b8-4090-a026-94c3a218bfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_17a28bd4-612d-4f17-a1f5-9b30b0f413ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_17a28bd4-612d-4f17-a1f5-9b30b0f413ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c99a13cf-0c5f-4800-a582-7264a36f1233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c99a13cf-0c5f-4800-a582-7264a36f1233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_79ed34bd-dc2c-4180-9079-a44070d39b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_79ed34bd-dc2c-4180-9079-a44070d39b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eace836c-997f-4392-95cb-d8449a76ff51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_PreferredStockValue_eace836c-997f-4392-95cb-d8449a76ff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_47f4436f-3f9e-427c-9457-0d21b4913f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_CommonStockValue_47f4436f-3f9e-427c-9457-0d21b4913f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_b9b9a293-798b-4b2a-80bc-4b9026ee78fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_TreasuryStockShares_b9b9a293-798b-4b2a-80bc-4b9026ee78fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_cbe1d9a8-33bb-4982-9c5a-6e101f696e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_TreasuryStockValue_cbe1d9a8-33bb-4982-9c5a-6e101f696e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2dc9e27-46ca-4ca7-97ba-b5d354f97305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2dc9e27-46ca-4ca7-97ba-b5d354f97305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4e9571d-1f41-4605-9dda-3ab966cc60aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4e9571d-1f41-4605-9dda-3ab966cc60aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96b105e0-1494-4a7f-a2f7-2b52ff26664f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96b105e0-1494-4a7f-a2f7-2b52ff26664f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6af8f362-a2d3-4d52-b28a-ec06748db195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc7880f7-c5f5-429b-b782-d4ba9279ab1d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6af8f362-a2d3-4d52-b28a-ec06748db195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a95a95a0-e464-4e51-9466-b5355e883c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c17c203b-d72b-4286-83df-a6da04ce2d9e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a95a95a0-e464-4e51-9466-b5355e883c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedBalanceSheetParanthetical"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedBalanceSheetParentheticalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6bf3c056-ee83-45e8-8111-a87270e27bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6bf3c056-ee83-45e8-8111-a87270e27bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ef1b4cd5-c733-4a21-8a93-ce77314cc349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ef1b4cd5-c733-4a21-8a93-ce77314cc349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b0dee3a1-764a-4baa-bbc9-81f356b2b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b0dee3a1-764a-4baa-bbc9-81f356b2b0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb584825-f045-4ed3-8c61-bbe4338816f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb584825-f045-4ed3-8c61-bbe4338816f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_36c8fd2b-b930-49f3-a39d-408a82fd82f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_36c8fd2b-b930-49f3-a39d-408a82fd82f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_548e91cd-2fab-4ad5-8e21-3ad31ad41ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_CommonStockSharesIssued_548e91cd-2fab-4ad5-8e21-3ad31ad41ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_3fb9607e-3032-4c84-87df-8d069cdd2336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedBalanceSheetParentheticalAbstract_65b73be8-ed9f-452b-b7cb-e214fef42e73" xlink:to="loc_us-gaap_TreasuryStockShares_3fb9607e-3032-4c84-87df-8d069cdd2336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9deac482-1cbf-4d9a-95bb-4ca8fe315bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9deac482-1cbf-4d9a-95bb-4ca8fe315bf3" xlink:to="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a123c495-4dc4-4f10-a4a8-f9b08cf31758" xlink:to="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f5d20bab-3b6d-4d20-ae56-987029358e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_PreferredStockMember_f5d20bab-3b6d-4d20-ae56-987029358e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4fa55762-44c1-4763-94cd-8f6a018b30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_CommonStockMember_4fa55762-44c1-4763-94cd-8f6a018b30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ca7e4470-e911-4b86-9267-2548d3b37d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_TreasuryStockMember_ca7e4470-e911-4b86-9267-2548d3b37d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d7763075-85c9-4fd6-b133-25b724c6cb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d7763075-85c9-4fd6-b133-25b724c6cb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c60e485-2f4f-4882-bcdf-d6492058e69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_RetainedEarningsMember_3c60e485-2f4f-4882-bcdf-d6492058e69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb2fe21d-508b-4120-8d1c-9e652ffeaa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1981cbb-e812-4999-9f54-3a0189da6589" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb2fe21d-508b-4120-8d1c-9e652ffeaa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10812ca5-d48a-44e1-9f13-f0723a7da25d" xlink:to="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1fa51e5f-50ea-48c1-9330-4d724efa1063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_SharesIssued_1fa51e5f-50ea-48c1-9330-4d724efa1063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1de0ae06-a7fd-4499-a216-fde285fd3d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1de0ae06-a7fd-4499-a216-fde285fd3d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e730455-74e0-48ce-a393-9e0a7e7d34f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e730455-74e0-48ce-a393-9e0a7e7d34f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_91bf73d3-fb5f-4cb6-8816-a16e4872a78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_91bf73d3-fb5f-4cb6-8816-a16e4872a78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_1dd3ca6f-4083-4ebb-aafa-3b73f600e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_1dd3ca6f-4083-4ebb-aafa-3b73f600e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2f03f723-3a12-43bf-b0f1-3fe5fa436430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2f03f723-3a12-43bf-b0f1-3fe5fa436430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_46e616fd-debb-4a7e-a92e-640d2c737a68" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock_46e616fd-debb-4a7e-a92e-640d2c737a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_1a1c4c41-b8cf-4b51-bd32-733c75915520" xlink:href="bsx-20221231.xsd#bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock_1a1c4c41-b8cf-4b51-bd32-733c75915520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_0fcdda8d-b72f-4b63-8262-29a5c5f7d04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_0fcdda8d-b72f-4b63-8262-29a5c5f7d04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9af84b71-d50e-4d2a-874a-fa441511dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_ProfitLoss_9af84b71-d50e-4d2a-874a-fa441511dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_a5a96896-cac9-48ce-97ca-132ecccfca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_a5a96896-cac9-48ce-97ca-132ecccfca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_aa386104-f83a-4a7e-a450-639aef924de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_DividendsPreferredStockCash_aa386104-f83a-4a7e-a450-639aef924de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cc10303e-760d-49ea-a8d3-e74a6950172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_SharesIssued_cc10303e-760d-49ea-a8d3-e74a6950172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f61a1bb6-d49f-4c77-98e7-59661f6640be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f61a1bb6-d49f-4c77-98e7-59661f6640be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_adbe3617-e748-4b02-9c62-f80bbdfd2131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_adbe3617-e748-4b02-9c62-f80bbdfd2131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15a23d82-94f2-47e2-ad06-f008fb6ccd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_63b729f9-69f6-43ca-a85f-568060ee5e8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15a23d82-94f2-47e2-ad06-f008fb6ccd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a099a683-96c6-4dfd-bfa3-711eb052a8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe8ef34-9e67-4032-ba3c-aa0f8d091109" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a099a683-96c6-4dfd-bfa3-711eb052a8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_98ff9ec5-140a-455b-9b11-7e1d02800644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b812ce84-3901-4326-9cc1-063f1b3f0515" xlink:to="loc_us-gaap_CommonStockSharesIssued_98ff9ec5-140a-455b-9b11-7e1d02800644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d1ca12fe-8997-413d-80ee-a9cedf7eb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d1ca12fe-8997-413d-80ee-a9cedf7eb4c1" xlink:to="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:to="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5ca73b61-a491-4fcf-8a3f-6bef2477f5dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7e8397b0-29fb-4e78-8597-b986778d4fdf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5ca73b61-a491-4fcf-8a3f-6bef2477f5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fc9b16d-45d7-42c3-bbb8-431a85ee579f" xlink:to="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c98ed823-ea93-44b5-a7ab-7f72d6bc0079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ProfitLoss_c98ed823-ea93-44b5-a7ab-7f72d6bc0079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0756af16-c12d-47be-94d7-0dfa092e75bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0756af16-c12d-47be-94d7-0dfa092e75bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c7b08ebe-9312-4c44-ad9f-9ae77abf3142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c7b08ebe-9312-4c44-ad9f-9ae77abf3142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f1e29765-ebf2-4d98-a3ae-9f09601aadc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f1e29765-ebf2-4d98-a3ae-9f09601aadc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f5208dc1-a75f-4d9c-b4d2-89320bbd21cb" xlink:href="bsx-20221231.xsd#bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit_f5208dc1-a75f-4d9c-b4d2-89320bbd21cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4fec8429-4901-42f8-afe8-83cc6811d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ShareBasedCompensation_4fec8429-4901-42f8-afe8-83cc6811d8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0ee177bc-b623-4471-b564-09f95223a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0ee177bc-b623-4471-b564-09f95223a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b1c7bea0-203d-4d05-a49b-bc2c985b1f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_GainLossOnInvestments_b1c7bea0-203d-4d05-a49b-bc2c985b1f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f466cc0e-8a13-4caf-861a-f814d2fa6d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f466cc0e-8a13-4caf-861a-f814d2fa6d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InventoryStepUpAmortization_9ea4d4a9-5382-48ec-ac09-6e901c8a0bf3" xlink:href="bsx-20221231.xsd#bsx_InventoryStepUpAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_InventoryStepUpAmortization_9ea4d4a9-5382-48ec-ac09-6e901c8a0bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss_5a5e52b8-3d12-4d4d-9b1e-7dbde83dc6d0" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_NetCurrencyExchangeGainLoss_5a5e52b8-3d12-4d4d-9b1e-7dbde83dc6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherNet_fe89538a-8747-4e1b-99bb-c1e5dfeab4e1" xlink:href="bsx-20221231.xsd#bsx_OtherNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_bsx_OtherNet_fe89538a-8747-4e1b-99bb-c1e5dfeab4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f92318f5-1f56-432c-9b7b-d72f47877523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f92318f5-1f56-432c-9b7b-d72f47877523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad2d937b-ec2c-483c-9465-59675333e6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad2d937b-ec2c-483c-9465-59675333e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_285f1aba-4cd8-4efb-8058-ef922d306862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_285f1aba-4cd8-4efb-8058-ef922d306862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1e585a4b-1556-40ae-ae1f-6a6f8d779943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1e585a4b-1556-40ae-ae1f-6a6f8d779943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5b9a6c-47f9-4e5e-9d99-9bbe5c965430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5b9a6c-47f9-4e5e-9d99-9bbe5c965430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4e7d607-3a02-4ee4-a9b7-4617b9330e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4e7d607-3a02-4ee4-a9b7-4617b9330e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31898e1a-5d43-401e-a9c6-382ce0800c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31898e1a-5d43-401e-a9c6-382ce0800c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_165b1ebc-600b-4aae-8d34-73218aa8da57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_165b1ebc-600b-4aae-8d34-73218aa8da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e56dd7db-0112-4cd5-bc86-94e763fddab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e56dd7db-0112-4cd5-bc86-94e763fddab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c183cd45-b617-490e-b5df-a727ce042061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c183cd45-b617-490e-b5df-a727ce042061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_569be753-806a-49d0-8867-9c1f03ebe5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_569be753-806a-49d0-8867-9c1f03ebe5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_58f87556-a194-4135-9f54-f0bb150c2280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_58f87556-a194-4135-9f54-f0bb150c2280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_21904d0c-c96e-45cf-98ae-60c336fe0adb" xlink:href="bsx-20221231.xsd#bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies_21904d0c-c96e-45cf-98ae-60c336fe0adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b719f27-d28c-427e-add4-f9696400f110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_993ca35a-c5cc-41f7-9a57-55e3280d29ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b719f27-d28c-427e-add4-f9696400f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bf81123-105c-4350-9ad8-b4c7f32fa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bf81123-105c-4350-9ad8-b4c7f32fa31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentsForRoyaltyRights_3e21e2cf-0747-4cf6-93ef-e05314b81da6" xlink:href="bsx-20221231.xsd#bsx_PaymentsForRoyaltyRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_bsx_PaymentsForRoyaltyRights_3e21e2cf-0747-4cf6-93ef-e05314b81da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_f2adef11-1991-4a0e-981a-6533f90c6b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_f2adef11-1991-4a0e-981a-6533f90c6b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_88bc8846-b967-4991-8261-2055ff13b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_88bc8846-b967-4991-8261-2055ff13b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_5b65889a-5b04-4fd9-b366-e4378a12d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_5b65889a-5b04-4fd9-b366-e4378a12d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_926e021d-65ba-48d6-8b7e-1845ea034647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_926e021d-65ba-48d6-8b7e-1845ea034647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a9341e92-9209-4e50-92d2-42628b7d3cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a9341e92-9209-4e50-92d2-42628b7d3cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_324f21ec-6288-40e8-a771-6001cf82a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_324f21ec-6288-40e8-a771-6001cf82a3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b24d48e7-9a41-4a27-bf06-6637677ee520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b24d48e7-9a41-4a27-bf06-6637677ee520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_33165262-4a58-46aa-84a8-4973c8db3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentsOfDividends_33165262-4a58-46aa-84a8-4973c8db3dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_036329ba-713c-4aee-a9c3-ad5db4cc0b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_036329ba-713c-4aee-a9c3-ad5db4cc0b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4e00c5b-4f65-489f-b228-16777a3cbfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4e00c5b-4f65-489f-b228-16777a3cbfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7af0d0aa-598c-46e3-b1ed-5ad5b06a2a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7af0d0aa-598c-46e3-b1ed-5ad5b06a2a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Paymenttonetsharesettleemployeeequityawards_3491b8cf-04a4-4dda-9221-9e2b2301ad6a" xlink:href="bsx-20221231.xsd#bsx_Paymenttonetsharesettleemployeeequityawards"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_bsx_Paymenttonetsharesettleemployeeequityawards_3491b8cf-04a4-4dda-9221-9e2b2301ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a317bb39-e06f-4659-a13a-4e40faeb0ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a317bb39-e06f-4659-a13a-4e40faeb0ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e343c936-8beb-4788-a8cd-0f9801ae2827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bbcc14b4-4e63-4e20-bb4c-3ccd1b6f9c08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e343c936-8beb-4788-a8cd-0f9801ae2827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9bc5dbf-aa20-4d31-80a5-acd0bbb89632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9bc5dbf-aa20-4d31-80a5-acd0bbb89632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4860e7b2-fa1c-4bf5-b98a-4c4c79c77797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4860e7b2-fa1c-4bf5-b98a-4c4c79c77797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_205df94f-6e70-462f-bc17-0fc85dc44887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_205df94f-6e70-462f-bc17-0fc85dc44887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f4df1b-4af2-4452-a8a6-18f44ac865ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f4df1b-4af2-4452-a8a6-18f44ac865ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_080f88bd-262d-4a74-a447-69d9e014f38d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_53e82a9d-879f-4045-baee-c7230f99f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_IncomeTaxesPaid_53e82a9d-879f-4045-baee-c7230f99f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_91e9cbf4-813f-4b68-9801-3f51d90dd769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_InterestPaidNet_91e9cbf4-813f-4b68-9801-3f51d90dd769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_88f640fd-2e85-4be1-a4a3-810cb96d1ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_88f640fd-2e85-4be1-a4a3-810cb96d1ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NonCashImpactOfTransferredRoyaltyRights_63985ee4-5c15-475b-b90b-968e83301643" xlink:href="bsx-20221231.xsd#bsx_NonCashImpactOfTransferredRoyaltyRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ab61487a-21b2-44eb-a338-e01798bfc145" xlink:to="loc_bsx_NonCashImpactOfTransferredRoyaltyRights_63985ee4-5c15-475b-b90b-968e83301643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" xlink:type="simple" xlink:href="bsx-20221231.xsd#ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract_768dec63-0696-4be7-9d41-7ca286af4073" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract_768dec63-0696-4be7-9d41-7ca286af4073" xlink:to="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:href="bsx-20221231.xsd#bsx_StatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:to="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StatementDomain_e6acf33c-745e-448f-884c-1a7fcc38e512" xlink:href="bsx-20221231.xsd#bsx_StatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StatementAxis_445d57f4-f013-47f5-b9b7-087812bb1a14" xlink:to="loc_bsx_StatementDomain_e6acf33c-745e-448f-884c-1a7fcc38e512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b65883b4-0ff0-41fb-8753-f7840dfb8bc0" xlink:to="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38f5cdf7-65f1-48aa-8feb-bc1bc3030484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38f5cdf7-65f1-48aa-8feb-bc1bc3030484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_028b6af4-78ad-48d0-a1b5-f9e56ec1a8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_028b6af4-78ad-48d0-a1b5-f9e56ec1a8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_c40355ca-eda5-4b1f-84c2-094dd3bb314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_c40355ca-eda5-4b1f-84c2-094dd3bb314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bfcc1de-3736-40f6-a35b-080825ab15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eda84e57-0ecf-4cf3-be5e-93128e3498c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bfcc1de-3736-40f6-a35b-080825ab15b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_176d5fe4-d9eb-41de-a309-fae6a8620273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9d86ff06-c6e0-4909-bcb4-2a126a0d33cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_176d5fe4-d9eb-41de-a309-fae6a8620273" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9d86ff06-c6e0-4909-bcb4-2a126a0d33cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments" xlink:type="simple" xlink:href="bsx-20221231.xsd#AcquisitionsandStrategicInvestments"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d9fc96fe-fba5-4e03-bbf4-ca5708b6f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_723104e6-3e1a-46e6-a98b-6bec894e4df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d9fc96fe-fba5-4e03-bbf4-ca5708b6f64b" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_723104e6-3e1a-46e6-a98b-6bec894e4df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="bsx-20221231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe16415c-7558-4f84-ae77-c1028a9d1d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d0f936c8-ab42-4462-9537-b42998f88a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe16415c-7558-4f84-ae77-c1028a9d1d99" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d0f936c8-ab42-4462-9537-b42998f88a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" xlink:type="simple" xlink:href="bsx-20221231.xsd#HedgingActivitiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_697ab0df-d106-4824-aa09-6d38f6a1aee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bafd2e3-3b9f-4ac2-8a4b-57d60e0d0cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_697ab0df-d106-4824-aa09-6d38f6a1aee9" xlink:to="loc_us-gaap_FairValueDisclosuresAbstract_0bafd2e3-3b9f-4ac2-8a4b-57d60e0d0cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c16ae560-7083-4a03-a14e-8e97ba9d4a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bafd2e3-3b9f-4ac2-8a4b-57d60e0d0cf9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c16ae560-7083-4a03-a14e-8e97ba9d4a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitments" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitments"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fe4be1e6-c94b-4f57-ab3c-54865394cc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_37305d72-696e-4b36-bbde-b59e17190f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fe4be1e6-c94b-4f57-ab3c-54865394cc7c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_37305d72-696e-4b36-bbde-b59e17190f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/Leases" xlink:type="simple" xlink:href="bsx-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_00883471-b410-4f20-84cc-018465868af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_86011f4e-b6b5-44a5-8500-60fdbae07471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00883471-b410-4f20-84cc-018465868af8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_86011f4e-b6b5-44a5-8500-60fdbae07471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="bsx-20221231.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationAbstract_dc24fb8e-89dd-406f-bb0f-21d74dba8669" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_c8f74cda-0c60-4030-9d15-908586391182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_dc24fb8e-89dd-406f-bb0f-21d74dba8669" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_c8f74cda-0c60-4030-9d15-908586391182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25bcb712-27c4-456b-8f1d-9993e9120c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_bf2f51a9-8fb7-44a8-b725-f79539a7cbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25bcb712-27c4-456b-8f1d-9993e9120c59" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_bf2f51a9-8fb7-44a8-b725-f79539a7cbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bsx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6311fe8-ef78-4197-ba21-c8234d74f470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_01f0fc92-d458-4dda-8392-73a0f6030ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6311fe8-ef78-4197-ba21-c8234d74f470" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_01f0fc92-d458-4dda-8392-73a0f6030ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockholdersEquity" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e0389216-8492-4751-8604-0cb0fe3eb0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d2256297-e8aa-4295-8870-99cf12729055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e0389216-8492-4751-8604-0cb0fe3eb0f9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d2256297-e8aa-4295-8870-99cf12729055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockInventiveandPurchasePlans" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockInventiveandPurchasePlans"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StockInventiveandPurchasePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIncentiveAndPurchasePlansAbstract_4ab8fedd-b1fb-4f46-94c1-8041514313cc" xlink:href="bsx-20221231.xsd#bsx_StockIncentiveAndPurchasePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f44a73e-5b4e-4cb0-923a-fb26fc1f1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_4ab8fedd-b1fb-4f46-94c1-8041514313cc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f44a73e-5b4e-4cb0-923a-fb26fc1f1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" xlink:type="simple" xlink:href="bsx-20221231.xsd#WeightedAverageSharesOutstanding"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a9bc3d0f-50b8-4125-ad5e-c1cf3d239b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_202d03e2-7afd-4f4c-a5ec-76c4a804c9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9bc3d0f-50b8-4125-ad5e-c1cf3d239b34" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_202d03e2-7afd-4f4c-a5ec-76c4a804c9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SegmentReporting" xlink:type="simple" xlink:href="bsx-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6b35970c-d990-4732-ae9e-1d07e0e50f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_8d838d9c-d238-43f3-af67-f3988809e85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b35970c-d990-4732-ae9e-1d07e0e50f12" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_8d838d9c-d238-43f3-af67-f3988809e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/Revenue" xlink:type="simple" xlink:href="bsx-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0afb156-4d0a-4f96-a474-9f23b03566cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_51073559-99ee-4b6c-9e5e-7db4e272ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0afb156-4d0a-4f96-a474-9f23b03566cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_51073559-99ee-4b6c-9e5e-7db4e272ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" xlink:type="simple" xlink:href="bsx-20221231.xsd#ChangesinOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_fb4a547c-363c-4fd7-8c41-2349018ce7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0791683f-7b29-443b-b35b-ad5056795f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_fb4a547c-363c-4fd7-8c41-2349018ce7dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0791683f-7b29-443b-b35b-ad5056795f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/NewAccountingPronouncements" xlink:type="simple" xlink:href="bsx-20221231.xsd#NewAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/NewAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_28fb53fe-b974-42d4-8ede-192bf0848055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NewAccountingPronouncementsPolicyTextBlock_4e4a3f8c-b502-49f6-92d3-62cd196c4021" xlink:href="bsx-20221231.xsd#bsx_NewAccountingPronouncementsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_28fb53fe-b974-42d4-8ede-192bf0848055" xlink:to="loc_bsx_NewAccountingPronouncementsPolicyTextBlock_4e4a3f8c-b502-49f6-92d3-62cd196c4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansNotes"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cae4fb66-aa7c-436c-8182-fc5e59bc7b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_24edf784-79ca-42ff-bb54-910991e207d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cae4fb66-aa7c-436c-8182-fc5e59bc7b9d" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_24edf784-79ca-42ff-bb54-910991e207d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ScheduleII" xlink:type="simple" xlink:href="bsx-20221231.xsd#ScheduleII"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ScheduleII" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_b71f87e8-9bbc-48c9-a541-7b4370077335" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_8e3ca4e3-1edf-4146-8a0c-fceda078e31d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_b71f87e8-9bbc-48c9-a541-7b4370077335" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_8e3ca4e3-1edf-4146-8a0c-fceda078e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e6b45100-55fe-4626-b9e4-bb60204fce64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e6b45100-55fe-4626-b9e4-bb60204fce64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_2729d9d8-affd-429f-ac4c-bdf24f9b72c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_2729d9d8-affd-429f-ac4c-bdf24f9b72c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_43b52cb2-0cc1-443a-a75b-108e4e6a1208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_UseOfEstimates_43b52cb2-0cc1-443a-a75b-108e4e6a1208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_aa8cc787-684f-49e1-b965-dda436c53ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_aa8cc787-684f-49e1-b965-dda436c53ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_427e83bf-0e20-4f6e-a769-52bee87de7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_427e83bf-0e20-4f6e-a769-52bee87de7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_17bc6fcf-0180-439e-a6e4-4351078a8fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_17bc6fcf-0180-439e-a6e4-4351078a8fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_dceb6565-7194-41e1-bc37-9cff08dd591a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_dceb6565-7194-41e1-bc37-9cff08dd591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1c975c96-ff6f-4cef-9bf7-76d496a03884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1c975c96-ff6f-4cef-9bf7-76d496a03884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fccb1440-8945-4b00-9a03-02b5fd5983af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fccb1440-8945-4b00-9a03-02b5fd5983af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8fc5d344-48ab-4aa5-a17b-38fa4c1367d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8fc5d344-48ab-4aa5-a17b-38fa4c1367d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_e889b88c-1cae-4a67-9a25-28a7e9d349cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_e889b88c-1cae-4a67-9a25-28a7e9d349cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_8151952b-0444-45a1-890f-28f01e612494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_8151952b-0444-45a1-890f-28f01e612494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_858c420a-c3fe-4c90-b447-cf44677d45ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_858c420a-c3fe-4c90-b447-cf44677d45ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1cb825bc-3dad-40a9-adcc-72f18bbb43af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1cb825bc-3dad-40a9-adcc-72f18bbb43af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d69b6486-9634-48ed-889b-839c490a8a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d69b6486-9634-48ed-889b-839c490a8a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_a3a95d2d-21c2-47fe-b102-e06c864193ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_a3a95d2d-21c2-47fe-b102-e06c864193ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_21298b91-6d33-4016-ae19-42cc096db216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_21298b91-6d33-4016-ae19-42cc096db216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b9e8405c-5444-48d8-b7d1-814530ffb87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b9e8405c-5444-48d8-b7d1-814530ffb87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_e1ff7a36-ea00-4d2a-9390-724332a5102f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_e1ff7a36-ea00-4d2a-9390-724332a5102f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bc9be69c-8155-4a1c-b807-05a04decffd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_c0b926cb-00d4-4add-aee3-760ed5cbfb2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bc9be69c-8155-4a1c-b807-05a04decffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#FairValueMeasuresandDisclosuresPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4240b6c1-1e0a-4796-8a8c-df37d915fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6fb0f1e1-18c1-4411-9609-b003141a1bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4240b6c1-1e0a-4796-8a8c-df37d915fcb7" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6fb0f1e1-18c1-4411-9609-b003141a1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6ec9eea2-4d45-493c-999c-da679233b031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4240b6c1-1e0a-4796-8a8c-df37d915fcb7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6ec9eea2-4d45-493c-999c-da679233b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#CommitmentandContingenciesPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d1c30fd-b069-4827-990d-14ab2139203a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_4c3f1d44-5332-45d9-bac4-462160f3caea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d1c30fd-b069-4827-990d-14ab2139203a" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_4c3f1d44-5332-45d9-bac4-462160f3caea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#NewAccountingPronouncementsPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock_54e50442-a273-4b57-8d17-580b458c41f7" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock_54e50442-a273-4b57-8d17-580b458c41f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock_9dc79d88-b0d0-4015-a66b-2167235218d6" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock_9dc79d88-b0d0-4015-a66b-2167235218d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock_6d9712b6-1615-4697-9443-49cae86d431d" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock_6d9712b6-1615-4697-9443-49cae86d431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock_96e08124-9325-402f-8e50-1bed2bb7e936" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock_96e08124-9325-402f-8e50-1bed2bb7e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock_80587d50-77cc-48ae-89ac-b4d4968f7165" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock_80587d50-77cc-48ae-89ac-b4d4968f7165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock_0f9f79c4-a07b-4a47-a521-e823c559d146" xlink:href="bsx-20221231.xsd#bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6caecb5a-8289-4162-aabf-b1b2c57cdc81" xlink:to="loc_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock_0f9f79c4-a07b-4a47-a521-e823c559d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansEmployeeRetirementPlansPolicies"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e4b18d73-350d-460d-a25c-4ecf1dbf34f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e4b18d73-350d-460d-a25c-4ecf1dbf34f2" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2ce90c05-e355-4536-83dc-0b7bf23b2f9e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExecutiveRetirementPlanMember_12d6c909-a5cf-45f3-b16f-cdc9a3ee1d94" xlink:href="bsx-20221231.xsd#bsx_ExecutiveRetirementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:to="loc_bsx_ExecutiveRetirementPlanMember_12d6c909-a5cf-45f3-b16f-cdc9a3ee1d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InternationalRetirementPlansMember_1d35b374-b3ba-4255-ae35-f1c994340206" xlink:href="bsx-20221231.xsd#bsx_InternationalRetirementPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_7d99f1da-1d4b-4c74-93e3-5faf35b9054c" xlink:to="loc_bsx_InternationalRetirementPlansMember_1d35b374-b3ba-4255-ae35-f1c994340206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4951428e-85d6-4329-b6d5-7d5bb7d60316" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_0ef9c861-8d04-48bb-b96a-3ad2c11a075b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3b1d6401-cb38-4271-ab67-3d0811327491" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_0ef9c861-8d04-48bb-b96a-3ad2c11a075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#SignificantAccountingPoliciesSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#AcquisitionsandStrategicInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b818baff-235a-471a-9887-14aae4159372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b818baff-235a-471a-9887-14aae4159372" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85fe7779-708f-47ab-b42f-93ae03ec17fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BaylisMedicalMember_02f81f2f-98e2-46b4-b1c9-a4afc36caace" xlink:href="bsx-20221231.xsd#bsx_BaylisMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_BaylisMedicalMember_02f81f2f-98e2-46b4-b1c9-a4afc36caace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PreventiceSolutionsIncMember_312134f4-cb21-4972-90f0-cd79ec074874" xlink:href="bsx-20221231.xsd#bsx_PreventiceSolutionsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_PreventiceSolutionsIncMember_312134f4-cb21-4972-90f0-cd79ec074874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LumenisLTDMember_dc7620d4-8910-4fd9-a9d8-b6c6111cc741" xlink:href="bsx-20221231.xsd#bsx_LumenisLTDMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_LumenisLTDMember_dc7620d4-8910-4fd9-a9d8-b6c6111cc741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AllOther2021AcquisitionsMember_3aa69bcf-e976-430e-a19e-4907eb00ce66" xlink:href="bsx-20221231.xsd#bsx_AllOther2021AcquisitionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_AllOther2021AcquisitionsMember_3aa69bcf-e976-430e-a19e-4907eb00ce66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_150eef28-5cd6-410f-9a04-e4c44b74eccf" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe8ad982-ee5d-4a68-b7f5-4c874cd99df7" xlink:to="loc_bsx_A2021AcquisitionsMember_150eef28-5cd6-410f-9a04-e4c44b74eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78baa7cb-a381-4f07-808d-8a6d0af1e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddc8f471-af59-4b00-aefe-6854dff92676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78baa7cb-a381-4f07-808d-8a6d0af1e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7f899c44-3de9-47e9-9c5b-2f6eb7b48407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1b195fec-13f7-4699-a42b-4f6c1fa6b3a9" xlink:to="loc_srt_OwnershipDomain_7f899c44-3de9-47e9-9c5b-2f6eb7b48407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68a735f4-9a7f-44f4-a8c2-e4aab1daaa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db61b8be-20ab-4abf-bd89-806ff8fa92de" xlink:to="loc_us-gaap_ClassOfStockDomain_68a735f4-9a7f-44f4-a8c2-e4aab1daaa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0fd8f8-84ef-4635-9531-94aedac127ce" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0b4aa011-7541-4b3e-af35-d862487b3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0b4aa011-7541-4b3e-af35-d862487b3d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb179aa-69e0-411a-87fc-fd7e62f292eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb179aa-69e0-411a-87fc-fd7e62f292eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_efcf456f-181f-43f3-a11f-7fca53d75377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_efcf456f-181f-43f3-a11f-7fca53d75377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d7f7ec9f-7588-4563-b45f-b1195f8eb14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d7f7ec9f-7588-4563-b45f-b1195f8eb14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c0246380-831c-4718-a770-51792e19693f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c0246380-831c-4718-a770-51792e19693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_0c30a710-0180-4c33-b834-0fafad89bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1755c01b-b950-4e10-ba3e-ecad540b577a" xlink:to="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_0c30a710-0180-4c33-b834-0fafad89bab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_034559c8-f92f-469e-ade6-8c52297294a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9aca3be5-fa5e-4e1c-b03f-093f00a2ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_034559c8-f92f-469e-ade6-8c52297294a4" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9aca3be5-fa5e-4e1c-b03f-093f00a2ee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_7473c501-3ca3-44ef-862b-33f0400d3a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_034559c8-f92f-469e-ade6-8c52297294a4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_7473c501-3ca3-44ef-862b-33f0400d3a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d023f7f8-3fe4-40da-b972-5ace606ea6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_034559c8-f92f-469e-ade6-8c52297294a4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d023f7f8-3fe4-40da-b972-5ace606ea6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#HedgingActivitiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1814907-d41f-4999-94c1-128a5a778eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1814907-d41f-4999-94c1-128a5a778eda" xlink:to="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5b84fd0-1f35-41d1-8f61-db2906187e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b85ddfd-f990-4e4a-b701-5545216dec92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5b84fd0-1f35-41d1-8f61-db2906187e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_37491473-5349-4695-8a1a-3fc8c03e9502" xlink:to="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ea25ec37-5ab9-402d-b13a-50718fcc0a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ea25ec37-5ab9-402d-b13a-50718fcc0a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ee7bf9ae-b01d-42cd-a694-d67d39f45c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ee7bf9ae-b01d-42cd-a694-d67d39f45c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_ca11fd27-8e06-44a6-b812-13d0056401b3" xlink:href="bsx-20221231.xsd#bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock_ca11fd27-8e06-44a6-b812-13d0056401b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3350731d-affa-4ced-a247-f30f2656bfed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3350731d-affa-4ced-a247-f30f2656bfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1cdaaa0a-e87c-4daa-9927-05cca10f5d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a56bf4c1-d26b-4da2-87fc-79a44b184c13" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1cdaaa0a-e87c-4daa-9927-05cca10f5d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_97373b42-5f72-409f-aeab-8aeed32e03d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1814907-d41f-4999-94c1-128a5a778eda" xlink:to="loc_us-gaap_FairValueDisclosuresAbstract_97373b42-5f72-409f-aeab-8aeed32e03d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97373b42-5f72-409f-aeab-8aeed32e03d4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_70fb0252-3814-40a1-af98-e21f680e4d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5076dc07-208b-4365-a978-e3cc6f5b7cb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_70fb0252-3814-40a1-af98-e21f680e4d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3792f14e-0ec8-40b4-9d80-3512eac23d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87ac129a-d195-448f-8f98-a14c711911eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3792f14e-0ec8-40b4-9d80-3512eac23d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f8a9a8-ae8f-4e11-98bf-1c77f4695280" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9695f34f-4ffc-4a2e-95ea-c7b8bb02e2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e578822a-82d9-4d4c-80fc-2413118341a6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9695f34f-4ffc-4a2e-95ea-c7b8bb02e2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_487a9187-5c1d-436e-9852-bce9292af759" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b79a9662-e495-47c5-b66f-e51365eee0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_293669ee-26e2-44ef-b3b3-5d478735befa" xlink:to="loc_us-gaap_CommercialPaperMember_b79a9662-e495-47c5-b66f-e51365eee0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:to="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5b023131-b7e1-464b-98c7-0a8db3b05b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bacb0c5d-573e-4fad-8086-c37a2476c4e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5b023131-b7e1-464b-98c7-0a8db3b05b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_69ea4aa1-97bc-4918-b837-07f41c1b210c" xlink:to="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_0e43f44f-1bcd-436f-83f5-2140b4522c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_137a922f-e569-4f1f-ba5c-36775824aac5" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_0e43f44f-1bcd-436f-83f5-2140b4522c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_97159f5c-0f05-47d4-b672-aee8ddf7308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_97159f5c-0f05-47d4-b672-aee8ddf7308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock_9861104f-5fb2-44dc-a6b7-14ce3f831ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock_9861104f-5fb2-44dc-a6b7-14ce3f831ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTextBlock_7b2ebc08-dac9-4366-8f3c-d67b0cbeed74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTextBlock_7b2ebc08-dac9-4366-8f3c-d67b0cbeed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock_2f3a9691-a352-4959-b564-3d3923ccee09" xlink:href="bsx-20221231.xsd#bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock_2f3a9691-a352-4959-b564-3d3923ccee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_65c0a3f7-9151-455a-8950-711357862898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8efbf8-8ed3-4c36-a48f-b12f801bc5a6" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_65c0a3f7-9151-455a-8950-711357862898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/LeasesTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_73155fab-678c-4cca-82b1-4aa15d2f3d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_94459b0a-5295-4422-9c76-f55d8b212eda" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_73155fab-678c-4cca-82b1-4aa15d2f3d64" xlink:to="loc_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_94459b0a-5295-4422-9c76-f55d8b212eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_63ada817-b155-4c88-8a12-d5c6efa19514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_73155fab-678c-4cca-82b1-4aa15d2f3d64" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_63ada817-b155-4c88-8a12-d5c6efa19514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_80648557-e3f1-44da-b2b4-e62eb5247088" xlink:href="bsx-20221231.xsd#bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_73155fab-678c-4cca-82b1-4aa15d2f3d64" xlink:to="loc_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_80648557-e3f1-44da-b2b4-e62eb5247088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock_d5217878-7c6e-448b-857c-c010bab498a3" xlink:href="bsx-20221231.xsd#bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_73155fab-678c-4cca-82b1-4aa15d2f3d64" xlink:to="loc_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock_d5217878-7c6e-448b-857c-c010bab498a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_fd8ad997-3b5a-4137-ba93-7ef07fcdc313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_fd8ad997-3b5a-4137-ba93-7ef07fcdc313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5f9d6239-537a-4c35-95e2-b2402aa5f5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5f9d6239-537a-4c35-95e2-b2402aa5f5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_65e9a15d-3ab0-492b-9f87-322ba512d93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_65e9a15d-3ab0-492b-9f87-322ba512d93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1bbfb3e5-1450-4e9b-bfe6-648ce38fcdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1bbfb3e5-1450-4e9b-bfe6-648ce38fcdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_5741b53a-ed38-4fac-a87a-4c942f36e246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_5741b53a-ed38-4fac-a87a-4c942f36e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_933b1682-e395-47df-ae6b-8774a6eb6a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_933b1682-e395-47df-ae6b-8774a6eb6a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3c037217-4b0c-4c12-9831-ae1adb777f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3c037217-4b0c-4c12-9831-ae1adb777f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_6a78ab0e-04e4-4dfb-9ff0-356f0be217fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_949e2160-0134-4ff0-8762-45e22237b6c1" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_6a78ab0e-04e4-4dfb-9ff0-356f0be217fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b44caf0d-4af5-4077-8b8d-a885ac54ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b44caf0d-4af5-4077-8b8d-a885ac54ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_49363cfb-d282-4912-a7e1-30bc012f58db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_49363cfb-d282-4912-a7e1-30bc012f58db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f278828c-74a0-43ad-93ad-b0dd49363219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f278828c-74a0-43ad-93ad-b0dd49363219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_1f09c991-c06e-4fa5-9336-1642c1c7850c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_1f09c991-c06e-4fa5-9336-1642c1c7850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_04b4a0b1-0a47-4d22-b082-83f5304ef33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d4b96660-705f-4cbd-b2f3-0063a817b581" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_04b4a0b1-0a47-4d22-b082-83f5304ef33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockIncentiveandPurchasePlansTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:href="bsx-20221231.xsd#bsx_StockIncentiveAndPurchasePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_1a4b8855-5baf-4091-ae50-c1c3fec04fc7" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis_72710261-06e1-4304-899a-95570b0d9976" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain_1a4b8855-5baf-4091-ae50-c1c3fec04fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable_72c610dc-c917-41c5-9ffa-305c370e37c4" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_c2c39201-e9a1-45f1-bcac-b362f42bff89" xlink:href="bsx-20221231.xsd#bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems_9a0969ba-7b62-4d86-bebd-cbc3b07945c5" xlink:to="loc_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock_c2c39201-e9a1-45f1-bcac-b362f42bff89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2e47549e-00e5-4c3f-9d30-731f146f9178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2e47549e-00e5-4c3f-9d30-731f146f9178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_23a113e2-46a8-4906-90a4-008983540078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_23a113e2-46a8-4906-90a4-008983540078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3760dd90-6137-4e8f-923a-767ce104c6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3760dd90-6137-4e8f-923a-767ce104c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9d60966f-2774-4f5d-96c1-af60fc01d942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9d60966f-2774-4f5d-96c1-af60fc01d942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_9cbc7984-97e7-4c80-acd1-e4c9ea7db3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_9cbc7984-97e7-4c80-acd1-e4c9ea7db3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock_62a74dd6-520d-4056-ac9e-d976149bb167" xlink:href="bsx-20221231.xsd#bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock_62a74dd6-520d-4056-ac9e-d976149bb167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_05efb31a-39ca-4f5c-91b5-9653dcf4c51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_8580becd-5d9f-4df0-9776-5d7138a49722" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_05efb31a-39ca-4f5c-91b5-9653dcf4c51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#WeightedAverageSharesOutstandingTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bdf1027f-9041-470c-8db3-2cf415290d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_04c4fefa-3773-45c6-abbd-d43ac4a977b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bdf1027f-9041-470c-8db3-2cf415290d2e" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_04c4fefa-3773-45c6-abbd-d43ac4a977b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_41b220d5-2d6f-4512-a609-efdd9d58cf02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bdf1027f-9041-470c-8db3-2cf415290d2e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_41b220d5-2d6f-4512-a609-efdd9d58cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_ae280ea5-2d97-41b6-9195-ccf2255bc3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_ae280ea5-2d97-41b6-9195-ccf2255bc3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_2cf8cae9-63e4-4de3-b918-eda34f7d4087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_2cf8cae9-63e4-4de3-b918-eda34f7d4087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock_eefa1df9-5e3d-4c50-8adc-05331ae167e7" xlink:href="bsx-20221231.xsd#bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:to="loc_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock_eefa1df9-5e3d-4c50-8adc-05331ae167e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_1d8036d3-0cac-4304-964e-b73f68bf44c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_1d8036d3-0cac-4304-964e-b73f68bf44c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_9a5208e4-607d-4fd9-8937-008d028dd973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51508b85-b75e-4f62-90ec-229eaac5a500" xlink:to="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_9a5208e4-607d-4fd9-8937-008d028dd973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/RevenueTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a2524792-96da-4893-984d-0df80c3b9339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_0376fa82-247b-4898-8790-42f130a80889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a2524792-96da-4893-984d-0df80c3b9339" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_0376fa82-247b-4898-8790-42f130a80889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d60e047a-4a0b-46ac-b0ed-592014eba920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_0376fa82-247b-4898-8790-42f130a80889" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d60e047a-4a0b-46ac-b0ed-592014eba920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#ChangesinOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_4491e65e-9ddb-49b0-8760-c6602a467585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_50d6b54f-e9fa-4cf0-bfa1-3f38dd01abc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_4491e65e-9ddb-49b0-8760-c6602a467585" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_50d6b54f-e9fa-4cf0-bfa1-3f38dd01abc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansTables"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_69f4c4d6-c208-4e3f-b243-b2bcfc908019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_69f4c4d6-c208-4e3f-b243-b2bcfc908019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_530d4e6a-98be-4630-972e-f2a371094579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_530d4e6a-98be-4630-972e-f2a371094579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_0a387723-7b56-4657-b963-b35b55946809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_0a387723-7b56-4657-b963-b35b55946809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_942f5d39-b006-4b94-b0c0-7421f4d255df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_942f5d39-b006-4b94-b0c0-7421f4d255df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_d994071c-6ddd-4cdd-9f51-6510b93f6e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_d994071c-6ddd-4cdd-9f51-6510b93f6e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_b0f4b6eb-a0c1-4e9d-b024-5a5678f2a440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45fbd3eb-c103-4ffb-aee7-806e3f0c27a9" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_b0f4b6eb-a0c1-4e9d-b024-5a5678f2a440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesAbstract_175850bf-c485-47f4-a9f1-946857482cae" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesAbstract_175850bf-c485-47f4-a9f1-946857482cae" xlink:to="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8254b17-7be6-4238-ab6d-3533db848911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_98f95466-2d8a-4cd7-a28a-579a14a69989" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8254b17-7be6-4238-ab6d-3533db848911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fa0ad33f-20d7-4b58-b212-537e3b97ee37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_20bf424b-5e2b-40b1-8500-bade42740d29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fa0ad33f-20d7-4b58-b212-537e3b97ee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4eb61281-2673-423c-8dcd-cf7c7b189242" xlink:to="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8b10abd1-44b0-4638-a7f1-36eb15660015" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:to="loc_srt_MinimumMember_8b10abd1-44b0-4638-a7f1-36eb15660015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79a2811e-e704-441f-9e0d-fdd1e908d582" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_88d9ed51-d4b6-4471-a3cd-455bc9b015df" xlink:to="loc_srt_MaximumMember_79a2811e-e704-441f-9e0d-fdd1e908d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_376b8de3-608a-42ef-a9cb-9e2b9c51280b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_72a47484-87ef-4027-9ed4-9c37d9cf8dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_733a088b-f9ab-44a8-b8df-11debe8346ba" xlink:to="loc_us-gaap_PatentsMember_72a47484-87ef-4027-9ed4-9c37d9cf8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29e73f73-4fcd-463c-8af7-1eb87c837445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0af12fdd-af71-4653-95e3-8a638f27c743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29e73f73-4fcd-463c-8af7-1eb87c837445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2914dfd3-db97-4fa7-b7c9-900567bde69b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73b259a7-3d9a-4b46-9785-0a3b41b92e96" xlink:to="loc_srt_ProductsAndServicesDomain_2914dfd3-db97-4fa7-b7c9-900567bde69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6c55f64-932d-455b-9279-eb051e3f1815" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseMember_eaa26aa6-bde3-4642-83e7-4035b4089e9e" xlink:href="bsx-20221231.xsd#bsx_FarapulseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ef7ea2-0840-4012-87e7-018d36a23622" xlink:to="loc_bsx_FarapulseMember_eaa26aa6-bde3-4642-83e7-4035b4089e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:href="bsx-20221231.xsd#bsx_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesTable_7c98cd9b-efb7-4104-be55-eb704a316b97" xlink:to="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae492473-e4dd-48c2-868d-c14696101d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae492473-e4dd-48c2-868d-c14696101d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_6d9e45ff-9576-4106-8c77-7b95373857ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_6d9e45ff-9576-4106-8c77-7b95373857ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_12f69618-cbeb-4c1a-bc03-ed1ddf010962" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SignificantAccountingPoliciesLineItems_a61013a0-418f-4666-8a55-d2369f7fc8c3" xlink:to="loc_bsx_PaymentOfContingentConsideration_12f69618-cbeb-4c1a-bc03-ed1ddf010962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#AcquisitionsandStrategicInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a8a6f4a8-6e35-4f7f-8426-d4457f09bf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8a6f4a8-6e35-4f7f-8426-d4457f09bf8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a1e355b-49a0-47d9-87a2-96ed6ce4ecef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PreventiceSolutionsIncMember_f9fab30c-6842-4230-9234-ef1cfe4c56e9" xlink:href="bsx-20221231.xsd#bsx_PreventiceSolutionsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_PreventiceSolutionsIncMember_f9fab30c-6842-4230-9234-ef1cfe4c56e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseIncMember_2b85cf87-0624-4d7a-8e85-590d06de0371" xlink:href="bsx-20221231.xsd#bsx_FarapulseIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_FarapulseIncMember_2b85cf87-0624-4d7a-8e85-590d06de0371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LumenisLTDMember_36378f91-9af3-4c50-9445-a1912f281f6d" xlink:href="bsx-20221231.xsd#bsx_LumenisLTDMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_LumenisLTDMember_36378f91-9af3-4c50-9445-a1912f281f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DevoroMedicalIncMember_cbd528e6-8133-4193-a5fa-74cd3dce1e09" xlink:href="bsx-20221231.xsd#bsx_DevoroMedicalIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_DevoroMedicalIncMember_cbd528e6-8133-4193-a5fa-74cd3dce1e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AllOther2021AcquisitionsMember_a6c5788b-c596-4ab9-9af0-e0e0f3802a44" xlink:href="bsx-20221231.xsd#bsx_AllOther2021AcquisitionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_AllOther2021AcquisitionsMember_a6c5788b-c596-4ab9-9af0-e0e0f3802a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_3b6801e4-c5d7-426b-b395-7bd3715be15d" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_A2021AcquisitionsMember_3b6801e4-c5d7-426b-b395-7bd3715be15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BaylisMedicalMember_844e3dac-539f-4ef0-bfc1-68a4feb0db62" xlink:href="bsx-20221231.xsd#bsx_BaylisMedicalMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_BaylisMedicalMember_844e3dac-539f-4ef0-bfc1-68a4feb0db62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MITechCoLtdMember_80e1437d-b96e-4b20-ba5d-f4d51f3fa10d" xlink:href="bsx-20221231.xsd#bsx_MITechCoLtdMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_MITechCoLtdMember_80e1437d-b96e-4b20-ba5d-f4d51f3fa10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AcotecScientificHoldingsLimitedMember_f5bd88d9-476b-469e-b28b-fb11d07bd4b1" xlink:href="bsx-20221231.xsd#bsx_AcotecScientificHoldingsLimitedMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_AcotecScientificHoldingsLimitedMember_f5bd88d9-476b-469e-b28b-fb11d07bd4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ApolloEndosurgeryIncMember_33ef9744-f66d-4085-89a9-df14211a31c4" xlink:href="bsx-20221231.xsd#bsx_ApolloEndosurgeryIncMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_ApolloEndosurgeryIncMember_33ef9744-f66d-4085-89a9-df14211a31c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseMember_b0d6a315-0fb1-45aa-b16f-f872557f73ed" xlink:href="bsx-20221231.xsd#bsx_FarapulseMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_676aa212-2b77-4d8c-8168-6624e79c6e9c" xlink:to="loc_bsx_FarapulseMember_b0d6a315-0fb1-45aa-b16f-f872557f73ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_02c8ca66-fb2d-4461-b0c5-2ce76ec81b28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d01f5ca6-e6af-47a7-83d2-29f3700cfcba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d01f5ca6-e6af-47a7-83d2-29f3700cfcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6b45c0b0-b71c-4a51-bd3b-496c1d2718f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6b45c0b0-b71c-4a51-bd3b-496c1d2718f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_82480db4-1ce2-418f-9a02-663f0b37e2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4e4ccea-7c3d-44ed-bdbe-b5f24730bc27" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_82480db4-1ce2-418f-9a02-663f0b37e2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e8809d88-1503-46fe-8078-f55c08a87d30" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e243ae0d-b3ed-4211-b331-38a41f782dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_009acd91-61f1-4a3a-9b3d-458a7378047e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e243ae0d-b3ed-4211-b331-38a41f782dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_570d50bf-1f06-4041-bd0c-9f8eb7f10291" xlink:to="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_8a1a21b4-11fd-4814-a559-445150b36918" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_WeightedAverageMember_8a1a21b4-11fd-4814-a559-445150b36918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ebacc8ac-ea5f-44d6-aeab-05472ac3169c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_MinimumMember_ebacc8ac-ea5f-44d6-aeab-05472ac3169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ec4a02a-06e5-4f76-ae67-d605c5cdae26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4853a778-7d30-43a1-8d1c-245cfd55b2fd" xlink:to="loc_srt_MaximumMember_5ec4a02a-06e5-4f76-ae67-d605c5cdae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_876a84c9-c53d-459d-aba7-ce5655de8889" xlink:to="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_1fc7db78-6555-4633-bfbb-76440816a759" xlink:href="bsx-20221231.xsd#bsx_GlobalPeripheralInterventionsPiReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:to="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_1fc7db78-6555-4633-bfbb-76440816a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_254df9b4-e128-4009-9e7b-af40d313804a" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac6ca4c-f01b-4aae-a858-2fa2b4a1ce0e" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_254df9b4-e128-4009-9e7b-af40d313804a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d80611e9-efdb-4df1-805c-5e1995983e1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda8a1f6-4e23-406a-abad-2097e88ee84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02ad5baa-8d7f-4328-a726-ad2087dd3574" xlink:to="loc_us-gaap_SubsequentEventMember_dda8a1f6-4e23-406a-abad-2097e88ee84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_84db0298-f298-4e1c-b11c-4e7e5dd57804" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_baa9167b-2ff5-4914-bbd1-866cce5a0f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b76ee8fc-5699-400c-a0ea-8558c7b4b0b1" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_baa9167b-2ff5-4914-bbd1-866cce5a0f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd0bcb02-e4f5-48f4-8b66-077598fcf46d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_928b8621-d6b6-44f0-97c4-06b73f2865ae" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2dba5da0-f7b2-429b-9c21-aaa5569a76c4" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_928b8621-d6b6-44f0-97c4-06b73f2865ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3716faa2-9ec9-4c89-97b2-cf0e5ec7a08e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_379d7a9e-eb33-4248-8ef6-c17c54029cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_379d7a9e-eb33-4248-8ef6-c17c54029cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_62d99a7a-ca5d-48dd-b4b3-b930c46feff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_62d99a7a-ca5d-48dd-b4b3-b930c46feff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_581516ed-6d8e-41a7-b0c6-3af09df1bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_581516ed-6d8e-41a7-b0c6-3af09df1bfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_20f78d18-ac19-4308-a90f-71e7c6bd4755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_20f78d18-ac19-4308-a90f-71e7c6bd4755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d0899a5a-4b5b-467a-9e25-8b306c3190d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d0899a5a-4b5b-467a-9e25-8b306c3190d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92cfda20-8322-43df-a848-a629dfd8bca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_Goodwill_92cfda20-8322-43df-a848-a629dfd8bca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_894f4262-2134-4a88-afab-39eb4dfbd6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_894f4262-2134-4a88-afab-39eb4dfbd6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5b74cd6c-da00-4562-afd8-91b946cc6f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5b74cd6c-da00-4562-afd8-91b946cc6f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_acc28336-54d3-4466-a3f8-871a951d5007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_acc28336-54d3-4466-a3f8-871a951d5007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d563c03b-401b-4f4d-b3c0-6e0b1fb4f418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d563c03b-401b-4f4d-b3c0-6e0b1fb4f418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4609e520-fd75-462b-ac46-19ec52aa6820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4609e520-fd75-462b-ac46-19ec52aa6820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_2e9ff88b-bcef-438a-8bc8-552965fbebba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_2e9ff88b-bcef-438a-8bc8-552965fbebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_406e2e5c-38e9-43cf-a9d9-d969558dfacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_406e2e5c-38e9-43cf-a9d9-d969558dfacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ca0e6e81-3e69-4ea6-a8de-4cc79d0a9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ca0e6e81-3e69-4ea6-a8de-4cc79d0a9ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_8dfd8a55-afd8-4f25-8800-67c63fcc2f4d" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DiscountRateFairValueInput_8dfd8a55-afd8-4f25-8800-67c63fcc2f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_db186915-949f-4982-8684-4d07f44c8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_db186915-949f-4982-8684-4d07f44c8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_050cb774-ab85-435f-89cd-d64ec1fde1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_050cb774-ab85-435f-89cd-d64ec1fde1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bd33f87d-be58-45b1-84fb-6ca9d6abac28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bd33f87d-be58-45b1-84fb-6ca9d6abac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_122c1bd1-3e83-4bf0-8d1d-eda3cd3208f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_122c1bd1-3e83-4bf0-8d1d-eda3cd3208f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_da16c466-5aef-459b-92b7-bade3e05f21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_da16c466-5aef-459b-92b7-bade3e05f21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_567f0b3f-74c6-4338-844b-28ea4c5ad396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_567f0b3f-74c6-4338-844b-28ea4c5ad396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfFacilities_ecd63699-8fa6-4314-afb5-4fcb871670f5" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfFacilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DivestitureAgreementTransferOfFacilities_ecd63699-8fa6-4314-afb5-4fcb871670f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees_3c3ac2ad-92d5-4b9b-a77c-9277760b3c6f" xlink:href="bsx-20221231.xsd#bsx_DivestitureAgreementTransferOfGlobalEmployees"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_DivestitureAgreementTransferOfGlobalEmployees_3c3ac2ad-92d5-4b9b-a77c-9277760b3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1f8d9ba0-bd34-4119-8122-4d05805334eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1f8d9ba0-bd34-4119-8122-4d05805334eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3622961c-1813-4f95-87bb-246feef36046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3622961c-1813-4f95-87bb-246feef36046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_355012d5-70fd-48bb-ad83-a494dba7af5d" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_355012d5-70fd-48bb-ad83-a494dba7af5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_99578679-1e8c-4dc0-bf98-7706bca58141" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod_99578679-1e8c-4dc0-bf98-7706bca58141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f6c7d9d5-9d19-4b92-a7fc-ccf231e59857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f6c7d9d5-9d19-4b92-a7fc-ccf231e59857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_fc0aaabe-7bbe-47d9-87e2-0f5b2f61b2c1" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_fc0aaabe-7bbe-47d9-87e2-0f5b2f61b2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_c9cef704-4942-47ee-a36b-2dc6f3878b03" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_bsx_PaymentOfContingentConsideration_c9cef704-4942-47ee-a36b-2dc6f3878b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d487f90-ab8e-4fcc-b534-14eb61629504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d487f90-ab8e-4fcc-b534-14eb61629504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_6aa4a5bb-f799-485b-a4c0-b145b557ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate_6aa4a5bb-f799-485b-a4c0-b145b557ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_65892b11-21c4-4bb8-a0e7-073d1697ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_031ded0d-a367-4264-808e-c7cb434030e7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_65892b11-21c4-4bb8-a0e7-073d1697ddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_c8d3c644-347f-4482-8c3e-c072cb32182d" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContingentConsiderationDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_023e369b-4985-484f-82eb-670c8fb365e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_023e369b-4985-484f-82eb-670c8fb365e0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da40495b-43b2-4cb1-b578-fb3ec3f1c83f" xlink:to="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_518259b8-dce6-4e08-8766-24b276ea8396" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_MinimumMember_518259b8-dce6-4e08-8766-24b276ea8396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_614f69ab-565c-4d19-8708-675a5db211e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_MaximumMember_614f69ab-565c-4d19-8708-675a5db211e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4923e597-033e-4468-926f-669136789b32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6e98efc-8533-416d-b967-38478c23114e" xlink:to="loc_srt_WeightedAverageMember_4923e597-033e-4468-926f-669136789b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7c94bdb9-34da-4255-b64b-ec3b01365e40" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf936c6f-afba-45aa-a237-03c3ac67f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f681c417-5073-4d52-ac53-a9bd0f7df4c1" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf936c6f-afba-45aa-a237-03c3ac67f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d4d6b4-9e23-40f2-9bfd-7abf93d9430d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2021AcquisitionsMember_6be12a71-bb94-45da-bbc3-87bea81f64ce" xlink:href="bsx-20221231.xsd#bsx_A2021AcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:to="loc_bsx_A2021AcquisitionsMember_6be12a71-bb94-45da-bbc3-87bea81f64ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FarapulseIncMember_9fd970f3-a6a2-4dc8-97c6-91ff496f368a" xlink:href="bsx-20221231.xsd#bsx_FarapulseIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d700d412-962d-465a-b968-4b4fc8b4a1ab" xlink:to="loc_bsx_FarapulseIncMember_9fd970f3-a6a2-4dc8-97c6-91ff496f368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_df69ef6d-507b-4d49-9740-4f554a49ed86" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_5f57c957-4fe0-46c4-b1d5-8449c9832228" xlink:href="bsx-20221231.xsd#bsx_RDRegulatoryandCommercializationbasedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:to="loc_bsx_RDRegulatoryandCommercializationbasedMilestoneMember_5f57c957-4fe0-46c4-b1d5-8449c9832228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenueBasedPaymentsMember_2393b54b-39b1-45d8-bb80-c38a26db6230" xlink:href="bsx-20221231.xsd#bsx_RevenueBasedPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_50ce6107-ab4f-48b0-98a1-49e94d82cc31" xlink:to="loc_bsx_RevenueBasedPaymentsMember_2393b54b-39b1-45d8-bb80-c38a26db6230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_03da4be3-4ea6-4efb-b9c4-17f9e4db2335" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f92e1d07-aa9b-43cd-8e60-1b805078a236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f92e1d07-aa9b-43cd-8e60-1b805078a236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PaymentOfContingentConsideration_9431404d-c925-4323-9f88-b35bd6054c39" xlink:href="bsx-20221231.xsd#bsx_PaymentOfContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_bsx_PaymentOfContingentConsideration_9431404d-c925-4323-9f88-b35bd6054c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4a5bda7-97a3-46eb-87a6-0f4d1f57daec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract_ddd907cc-eb95-407c-98fd-475e886a7897" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4a5bda7-97a3-46eb-87a6-0f4d1f57daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_39104f1d-fb10-4b0f-a58f-7b415b79e673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_39104f1d-fb10-4b0f-a58f-7b415b79e673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract_80e94249-0a6a-4344-8389-272c86fa27fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_91b4e77b-daa5-4c2a-950d-d80d09b36386" xlink:href="bsx-20221231.xsd#bsx_ContingentConsiderationLiabilityProbabilityOfPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_bsx_ContingentConsiderationLiabilityProbabilityOfPayment_91b4e77b-daa5-4c2a-950d-d80d09b36386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_075284fe-e38f-4726-a8d2-f6331f40d1bc" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_bsx_DiscountRateFairValueInput_075284fe-e38f-4726-a8d2-f6331f40d1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2dd44be6-8286-4ba2-83bd-6fd6778b6a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b2408a91-dec8-4a11-8d0c-da094b722bca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2dd44be6-8286-4ba2-83bd-6fd6778b6a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_480e72c9-6803-4798-a3bc-86e1601ef684" xlink:href="bsx-20221231.xsd#bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08b908ab-a79d-411c-ac3a-8c9f670bd9fd" xlink:to="loc_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest_480e72c9-6803-4798-a3bc-86e1601ef684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StrategicInvestmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StrategicInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StrategicInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_5373c93a-2537-4326-8016-c44acb2385f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_5373c93a-2537-4326-8016-c44acb2385f8" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04c25c28-77c7-42a5-b073-a0603e5ebfca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_06f8104d-25c4-44d3-a47e-d032cffd2ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_261d308e-ad68-4f96-88dd-544209f4e474" xlink:to="loc_us-gaap_SubsequentEventMember_06f8104d-25c4-44d3-a47e-d032cffd2ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_e7d993a5-8feb-4bf5-83ea-f5695958b970" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_be7a0047-77eb-4a22-bac6-4967a2b09872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_be7a0047-77eb-4a22-bac6-4967a2b09872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_358ef465-1066-4379-8200-97d3279e3cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquityMethodInvestments_358ef465-1066-4379-8200-97d3279e3cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_233ac754-be9a-4d34-b6e2-2abe01ddefbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_233ac754-be9a-4d34-b6e2-2abe01ddefbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f3fbcbee-5c99-4765-b190-450adc01dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f3fbcbee-5c99-4765-b190-450adc01dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3828142c-61c9-4241-bf54-3f0e28af725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3828142c-61c9-4241-bf54-3f0e28af725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_22c83f01-9f6d-4a8f-b6f3-c49af72d72d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_Investments_22c83f01-9f6d-4a8f-b6f3-c49af72d72d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_c9452824-b9a7-42a6-bbea-5a276d1e468f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_466fd70f-7a91-4970-8f37-5ba12f35e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_04252ba0-c258-4405-8f4a-04e74265a7a0" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_466fd70f-7a91-4970-8f37-5ba12f35e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#GoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f63dda0-ba3b-43a1-9736-fd814c11eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f63dda0-ba3b-43a1-9736-fd814c11eb62" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_150f3dd5-3f7a-45f7-84df-330617fee4f8" xlink:to="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_375ceb37-4b26-4cb2-897f-d02697af306f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:to="loc_srt_MinimumMember_375ceb37-4b26-4cb2-897f-d02697af306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_492cbf0f-0424-4951-839f-2a3ec365c872" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0aaaac9c-3222-4f6a-9753-02cfe0ec6e08" xlink:to="loc_srt_MaximumMember_492cbf0f-0424-4951-839f-2a3ec365c872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57c7ce72-0098-4255-9909-f76876389039" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b18a0f2a-5534-4335-8594-68b02b075074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b18a0f2a-5534-4335-8594-68b02b075074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_55ee4102-c402-4624-8fdd-81a78091de56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_PatentsMember_55ee4102-c402-4624-8fdd-81a78091de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5f3d1a26-5b1d-466f-9978-0c7c1553ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8da98e0f-17a2-4181-8eef-a473c2c4b4e4" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5f3d1a26-5b1d-466f-9978-0c7c1553ddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9d54daf1-d279-4251-8a81-a14d1f1889f4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1a228452-7f6a-4ef0-a544-cfd40ea00508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1a228452-7f6a-4ef0-a544-cfd40ea00508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_43b4d594-24dd-434e-9102-9f159124542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_93104452-f06a-4644-a67e-9954253b35c8" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_43b4d594-24dd-434e-9102-9f159124542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9c664a3e-e437-4bc5-9b16-3c46ddf7c6c1" xlink:to="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_15390995-da45-4c80-961d-41cfac282d04" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_MedsurgMember_15390995-da45-4c80-961d-41cfac282d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_0a488773-4332-4195-926a-575c171a8b92" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_CardiovascularMember_0a488773-4332-4195-926a-575c171a8b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_a0237d50-66e3-4c8b-8646-5ae64b490736" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_34582454-e0d4-4524-9240-7a5728c2b22b" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_a0237d50-66e3-4c8b-8646-5ae64b490736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_052275e9-18b0-44c8-99e6-c240e5bd1406" xlink:to="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50469f2-18a2-4a1f-8e38-e2fe8104fb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50469f2-18a2-4a1f-8e38-e2fe8104fb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52feaea6-bdca-4b0e-b220-376c32fab641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52feaea6-bdca-4b0e-b220-376c32fab641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_0d23bacd-758c-4dc7-a4db-de76ab766029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_GoodwillGross_0d23bacd-758c-4dc7-a4db-de76ab766029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cfbd56d4-b54f-4603-b299-c76d4d7075ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cfbd56d4-b54f-4603-b299-c76d4d7075ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9f3ef63c-1f88-4043-9810-dece6bb95186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9f3ef63c-1f88-4043-9810-dece6bb95186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb780c42-b264-4190-b06b-8aa2e8a8ad95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb780c42-b264-4190-b06b-8aa2e8a8ad95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:href="bsx-20221231.xsd#bsx_GoodwillTextualsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_edba825b-b347-46dc-aad9-977c80e5fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_Goodwill_edba825b-b347-46dc-aad9-977c80e5fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_bc6430fa-99df-4b8e-a4b8-162d5e56965f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_bc6430fa-99df-4b8e-a4b8-162d5e56965f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3c8f3d3e-e653-4521-8933-64d9282e67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3c8f3d3e-e653-4521-8933-64d9282e67d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2749a524-cd8f-4af6-a299-273c558c26d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_GoodwillTextualsAbstract_fb521771-2c19-41b1-a2b3-230f04aa0692" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2749a524-cd8f-4af6-a299-273c558c26d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:href="bsx-20221231.xsd#bsx_OtherIntangibleAssetsTextualsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d2695264-f225-40d1-a2d7-c19c2fe37b42" xlink:to="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d7b330fe-793f-416a-b421-0ba827c10d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d7b330fe-793f-416a-b421-0ba827c10d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82dcd8c8-5906-4c8b-a4d9-5bcb2383334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82dcd8c8-5906-4c8b-a4d9-5bcb2383334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c497239d-3971-4312-ab2b-7d9957f05d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c497239d-3971-4312-ab2b-7d9957f05d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_62e8a992-7978-4cc4-be8c-776fe8fadf59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_62e8a992-7978-4cc4-be8c-776fe8fadf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3228e6f4-eb6e-4f85-8073-53a3f23baac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherIntangibleAssetsTextualsAbstract_811ab447-b6d4-43e7-961f-bcaa0d1e0ce5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3228e6f4-eb6e-4f85-8073-53a3f23baac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_14183f3d-8625-4f7b-b218-2688a762d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_14183f3d-8625-4f7b-b218-2688a762d3f0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ecf1ecd-d80a-49f7-bde2-29154c1d521b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c0e7171d-7b5f-4d26-abad-743bc6c231ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:to="loc_us-gaap_CashFlowHedgingMember_c0e7171d-7b5f-4d26-abad-743bc6c231ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0adb7a1e-f6b7-4b07-a3ee-9c95bbc521d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a65fdb7c-673b-426c-97fb-f95d39b1f4ee" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0adb7a1e-f6b7-4b07-a3ee-9c95bbc521d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbfeb893-30af-4289-af77-d0b784a2025d" xlink:to="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ae242c62-bc7d-4fde-ad81-9238055f637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ae242c62-bc7d-4fde-ad81-9238055f637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5b2e6408-b97c-4b09-bd64-a31fd67dd56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_caa776c3-4808-4bcc-86bb-2e43eafed9a0" xlink:to="loc_us-gaap_NondesignatedMember_5b2e6408-b97c-4b09-bd64-a31fd67dd56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c9101073-6539-4e99-9402-8beba7ed2ebc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0eabf21d-1466-47fb-8a1c-1bf0877a08a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0eabf21d-1466-47fb-8a1c-1bf0877a08a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_880584e3-580d-4b75-8af7-5e1abfe39e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_880584e3-580d-4b75-8af7-5e1abfe39e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_74d22e2a-c06d-41bf-b873-92ff34e6f974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_us-gaap_InterestRateContractMember_74d22e2a-c06d-41bf-b873-92ff34e6f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForeignCurrencyDenominatedInDebtMember_dde15418-8c68-45fa-953b-d55acf21d8fd" xlink:href="bsx-20221231.xsd#bsx_ForeignCurrencyDenominatedInDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06f74b4a-b1ce-4589-a6e5-bf175d05928e" xlink:to="loc_bsx_ForeignCurrencyDenominatedInDebtMember_dde15418-8c68-45fa-953b-d55acf21d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ea8e77-4df4-445f-8e27-07d322ad3b53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MITechCoLtdMember_9874b564-f4a6-462b-a998-2a8c3f01e90b" xlink:href="bsx-20221231.xsd#bsx_MITechCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08f9d3de-8e00-4051-8c48-67fc96e2ec03" xlink:to="loc_bsx_MITechCoLtdMember_9874b564-f4a6-462b-a998-2a8c3f01e90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2f2cdc9b-1a79-41cb-8e03-2391570e659d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2019AggregateOfferingMember_865698de-d96a-4c0c-96ba-6996ce846a60" xlink:href="bsx-20221231.xsd#bsx_November2019AggregateOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:to="loc_bsx_November2019AggregateOfferingMember_865698de-d96a-4c0c-96ba-6996ce846a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_December2027NotesMember_b8a0f82c-85d8-44a3-b203-1260c28a6e8a" xlink:href="bsx-20221231.xsd#bsx_December2027NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbf2b9d5-975c-485f-a3af-fc726e1bcc3b" xlink:to="loc_bsx_December2027NotesMember_b8a0f82c-85d8-44a3-b203-1260c28a6e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01db2b59-c0e5-420a-9644-1ce6e1c55f36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementAssetsMember_9307113a-1125-4da5-b82d-ac477a7ff292" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_bsx_LicensingArrangementAssetsMember_9307113a-1125-4da5-b82d-ac477a7ff292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d5ffb4d8-5440-4db9-b813-931a673cc0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d5ffb4d8-5440-4db9-b813-931a673cc0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_715aa988-38d5-4927-b225-31a6e760040c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_715aa988-38d5-4927-b225-31a6e760040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_511a7ec4-8586-4988-a6f2-ec33988d09d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_511a7ec4-8586-4988-a6f2-ec33988d09d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c6a6f2d2-b7d0-4a7a-b1bc-bd61124d7958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_746fd681-ce79-45b7-b6b8-3a73c3338dee" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c6a6f2d2-b7d0-4a7a-b1bc-bd61124d7958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8cdbf86a-56e6-48c7-8301-2f3d01cfe731" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_31d782ee-65e3-4fef-8f00-5dc8b415ac03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_CostOfSalesMember_31d782ee-65e3-4fef-8f00-5dc8b415ac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_275ab737-e6c3-4406-92b3-233924ec77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_InterestExpenseMember_275ab737-e6c3-4406-92b3-233924ec77b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_027a10f2-d474-4446-9e66-7054e7b6c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e168885-244b-4c2e-8920-9ad858f45fb6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_027a10f2-d474-4446-9e66-7054e7b6c74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7242da8d-78aa-4032-8c75-80915524ee13" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_99b66b87-414a-4a68-8602-9602c629e9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_LongTermDebt_99b66b87-414a-4a68-8602-9602c629e9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07df48cd-50cc-4a67-98e3-d5505ce8b854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07df48cd-50cc-4a67-98e3-d5505ce8b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7d23df2e-5b1f-4810-9f54-bda3550b7fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7d23df2e-5b1f-4810-9f54-bda3550b7fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_286b024b-a61f-445c-a23c-883114507928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_286b024b-a61f-445c-a23c-883114507928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0cf18167-5692-4c51-9e6a-49b36f6f6468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0cf18167-5692-4c51-9e6a-49b36f6f6468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ForwardCurrencyContractsTimetoMaturity_9ffea805-c782-45d1-ba8f-af1996ef0a09" xlink:href="bsx-20221231.xsd#bsx_ForwardCurrencyContractsTimetoMaturity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_ForwardCurrencyContractsTimetoMaturity_9ffea805-c782-45d1-ba8f-af1996ef0a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_029f8438-37b3-4ca6-8915-92c583d7c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_029f8438-37b3-4ca6-8915-92c583d7c4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_0068b5d5-f903-4bca-bd57-51334e8dd742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_0068b5d5-f903-4bca-bd57-51334e8dd742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_979dfd5f-0b8d-4ead-ad64-ddc2ca118651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_979dfd5f-0b8d-4ead-ad64-ddc2ca118651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_129af048-1553-4fcb-a36c-7645b7334bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_129af048-1553-4fcb-a36c-7645b7334bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_215bee60-ffe8-433d-aa70-aba2f5172d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_215bee60-ffe8-433d-aa70-aba2f5172d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_79c78de0-170f-49d1-a880-a2f3270c4c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_79c78de0-170f-49d1-a880-a2f3270c4c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cde92e33-75b5-44e6-b75f-ea8feecaa4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cde92e33-75b5-44e6-b75f-ea8feecaa4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_34d16478-3c55-43a1-b983-382e433432fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_34d16478-3c55-43a1-b983-382e433432fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_f984ef3f-551f-463a-8370-b0bf715187c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax_f984ef3f-551f-463a-8370-b0bf715187c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_9c7975c3-6587-4f3c-81ea-45448018c8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_9c7975c3-6587-4f3c-81ea-45448018c8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b4f36be0-90fd-40df-8d9e-f37c3a1b4a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_InterestExpense_b4f36be0-90fd-40df-8d9e-f37c3a1b4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f83dd074-d0c3-41b3-a3ee-4e6e68f558e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f83dd074-d0c3-41b3-a3ee-4e6e68f558e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_5e6f03f8-90b4-4cd3-85de-879c6c6f518f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_5e6f03f8-90b4-4cd3-85de-879c6c6f518f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_ad8da73e-7939-42f2-82ed-70eed32ebcbf" xlink:href="bsx-20221231.xsd#bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax_ad8da73e-7939-42f2-82ed-70eed32ebcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_d068fac3-53dd-4c10-ada9-1c16fba0d4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_d068fac3-53dd-4c10-ada9-1c16fba0d4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e066f0c7-c786-4b16-a9f6-a28bd21929de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e066f0c7-c786-4b16-a9f6-a28bd21929de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_2b0af565-3122-43fb-9b5a-7f73343e88d5" xlink:href="bsx-20221231.xsd#bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_2b0af565-3122-43fb-9b5a-7f73343e88d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_6cbec087-a9c1-4f2c-ba1e-76dd0bfd5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_6cbec087-a9c1-4f2c-ba1e-76dd0bfd5b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a752b9d-ecea-46d9-a5f4-7a55784fe944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a752b9d-ecea-46d9-a5f4-7a55784fe944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_1064f941-719b-4671-bab6-d2e0d241c3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_1064f941-719b-4671-bab6-d2e0d241c3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_a3c9fb4f-90bb-4685-8167-f2440606f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_a3c9fb4f-90bb-4685-8167-f2440606f94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2642b8df-1674-48e6-8208-97be2da08be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2642b8df-1674-48e6-8208-97be2da08be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_34be2ed1-29ee-4463-b1a7-d92f1e3c95d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_34be2ed1-29ee-4463-b1a7-d92f1e3c95d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_f9f6417a-9bae-45d2-b8b6-57481169c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_f9f6417a-9bae-45d2-b8b6-57481169c10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e8854dd4-13e0-4bd6-b043-3916c49ad918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e8854dd4-13e0-4bd6-b043-3916c49ad918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a2c3f82-db64-4e13-892b-6c90a769b841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a2c3f82-db64-4e13-892b-6c90a769b841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetCurrencyExchangeGainLoss_2b5a6d87-6495-4037-8983-0c9c0737fc0f" xlink:href="bsx-20221231.xsd#bsx_NetCurrencyExchangeGainLoss"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_17edaeb8-0d7e-46d4-8c25-2bd21653fa8a" xlink:to="loc_bsx_NetCurrencyExchangeGainLoss_2b5a6d87-6495-4037-8983-0c9c0737fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_14183f3d-8625-4f7b-b218-2688a762d3f0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_272c6287-1382-4e2b-b519-c8fa659ac5e5" xlink:to="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a8d085db-976d-423f-91dd-0c90df2f94ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_WeightedAverageMember_a8d085db-976d-423f-91dd-0c90df2f94ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06f7324c-cf5b-49b6-bdb9-5914354a3b28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_MinimumMember_06f7324c-cf5b-49b6-bdb9-5914354a3b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9220ea03-19be-4ac5-93b3-dd00ee936b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b13ae8ce-2283-43e0-aabb-707b839bb3b4" xlink:to="loc_srt_MaximumMember_9220ea03-19be-4ac5-93b3-dd00ee936b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_94a8f7ec-08c6-45ac-a266-818e79cacfb6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48dc1da5-3a4e-4f19-ad34-1c44d8cfb7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb5afd90-d8c4-40d3-8e19-86f1e55961f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48dc1da5-3a4e-4f19-ad34-1c44d8cfb7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128d9288-9619-4ba4-983c-e3fd88ccaeac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d4d3da09-e58d-4bf5-9799-d6eaa0b6927c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d4d3da09-e58d-4bf5-9799-d6eaa0b6927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8fc66b1d-7796-4ded-ae8d-f1487b0c40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8fc66b1d-7796-4ded-ae8d-f1487b0c40fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_352e0311-04f3-4523-87dc-76a47d25ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0fe3072-bdfe-4230-8b23-6351f4e9c78a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_352e0311-04f3-4523-87dc-76a47d25ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08b8e2af-b8f6-4c75-9e78-ef12f2273d74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementAssetsMember_d784a701-5899-4143-8bc6-f13d51846d6e" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:to="loc_bsx_LicensingArrangementAssetsMember_d784a701-5899-4143-8bc6-f13d51846d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementLiabilitiesMember_aab1e07c-0fd1-4663-8955-37e478a56c01" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c7b390d-2ffa-4c68-9feb-1e9503a2fdce" xlink:to="loc_bsx_LicensingArrangementLiabilitiesMember_aab1e07c-0fd1-4663-8955-37e478a56c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2c73ef6f-34dd-4b61-823e-8860ce642282" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_78307279-f30a-4c74-93a6-a119a4e87eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_78307279-f30a-4c74-93a6-a119a4e87eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_882c0237-4bb9-42fd-9b4d-1f5bcf92f896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_882c0237-4bb9-42fd-9b4d-1f5bcf92f896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e30f2ef0-4e37-41ff-ba96-9105a676c441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DerivativeAssets_e30f2ef0-4e37-41ff-ba96-9105a676c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsAsset_05c528ed-6eca-498a-aed3-8b62dc8351a3" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_LicensingArrangementsAsset_05c528ed-6eca-498a-aed3-8b62dc8351a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_613518f2-d943-4e98-ac71-9f4d78590816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_613518f2-d943-4e98-ac71-9f4d78590816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7fc3a2c7-9a9d-4a3a-a68a-7bb9e76f4f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DerivativeLiabilities_7fc3a2c7-9a9d-4a3a-a68a-7bb9e76f4f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e9a9b4e6-d759-4198-bec0-e64512266563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e9a9b4e6-d759-4198-bec0-e64512266563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_e3b9411d-cf82-4d7e-96c2-662d1aafa541" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_LicensingArrangementsLiability_e3b9411d-cf82-4d7e-96c2-662d1aafa541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40c8d8c4-c859-4f51-ae0b-0ca0a1e820ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40c8d8c4-c859-4f51-ae0b-0ca0a1e820ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_74af562b-1f58-44c4-8861-39f24e2db619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_Cash_74af562b-1f58-44c4-8861-39f24e2db619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DiscountRateFairValueInput_1678e567-2d65-4b73-9a18-0996df25ca2b" xlink:href="bsx-20221231.xsd#bsx_DiscountRateFairValueInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_bsx_DiscountRateFairValueInput_1678e567-2d65-4b73-9a18-0996df25ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_c5043174-c48d-4a49-8ea1-6e92d5bde0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_c5043174-c48d-4a49-8ea1-6e92d5bde0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_c8f97a92-2180-4c61-afe9-1b20467f8bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_PaymentsForRoyalties_c8f97a92-2180-4c61-afe9-1b20467f8bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_2a7c394f-5bdc-45a8-983c-7a78c4dd8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_2a7c394f-5bdc-45a8-983c-7a78c4dd8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2032ff43-51db-459d-aa3c-e18ec8335a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f29676d3-fda5-42b8-b4b1-f8d6c551f86b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2032ff43-51db-459d-aa3c-e18ec8335a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ContractualObligationsandCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_01e09ac8-cba8-4c82-a661-bdb435a49514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_01e09ac8-cba8-4c82-a661-bdb435a49514" xlink:to="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23a44cc3-6ed4-46ac-9b85-5f0d92c42b68" xlink:to="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_62feefaa-b7af-4f68-b629-aa70ff4a6632" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113402c4-0dac-4e8a-a63a-053256605090" xlink:to="loc_bsx_A550MCPSSeriesAMember_62feefaa-b7af-4f68-b629-aa70ff4a6632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_caa71c66-6572-4f9b-9ffd-daa07a4036a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EuroDenominatedFactoringArrangementsMember_861044ba-2a9c-4514-935f-4bcb085920ca" xlink:href="bsx-20221231.xsd#bsx_EuroDenominatedFactoringArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_EuroDenominatedFactoringArrangementsMember_861044ba-2a9c-4514-935f-4bcb085920ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_YenDenominatedFactoringArrangementsMember_8a62f53e-6ccb-4daa-9e56-46f8ef43e25b" xlink:href="bsx-20221231.xsd#bsx_YenDenominatedFactoringArrangementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_YenDenominatedFactoringArrangementsMember_8a62f53e-6ccb-4daa-9e56-46f8ef43e25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RenminbiDenominatedFactoringArrangementsMember_1e0d891e-0502-4a7d-aa73-27196e207364" xlink:href="bsx-20221231.xsd#bsx_RenminbiDenominatedFactoringArrangementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a59cd5c-a9a4-4567-b88a-11180e16bba8" xlink:to="loc_bsx_RenminbiDenominatedFactoringArrangementsMember_1e0d891e-0502-4a7d-aa73-27196e207364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34a7be25-e737-4b92-a7be-576fb725a854" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2019AggregateOfferingMember_7b2c3b69-b2f3-408a-a3a6-34e53f9c7783" xlink:href="bsx-20221231.xsd#bsx_November2019AggregateOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_November2019AggregateOfferingMember_7b2c3b69-b2f3-408a-a3a6-34e53f9c7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2022NotesMember_bae1f3ec-b7c1-455b-ae90-dd75569d27c5" xlink:href="bsx-20221231.xsd#bsx_May2022NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_May2022NotesMember_bae1f3ec-b7c1-455b-ae90-dd75569d27c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_October2023NotesMember_e611ad67-1305-41bb-9c21-5eb2d8c883b2" xlink:href="bsx-20221231.xsd#bsx_October2023NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_October2023NotesMember_e611ad67-1305-41bb-9c21-5eb2d8c883b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_007bbec3-a9ef-4c45-b1ec-8983fd9d5869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_007bbec3-a9ef-4c45-b1ec-8983fd9d5869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2024NotesMember_c7861ebb-f7ee-4012-b38c-df7a9f6d69e3" xlink:href="bsx-20221231.xsd#bsx_March2024NotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2024NotesMember_c7861ebb-f7ee-4012-b38c-df7a9f6d69e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2025NotesMember_f19d113d-d7e5-4aad-a28b-3d666b67bb33" xlink:href="bsx-20221231.xsd#bsx_May2025NotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_May2025NotesMember_f19d113d-d7e5-4aad-a28b-3d666b67bb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2025NotesMember_ecc007c1-3e75-4032-b275-059d6ea4f25b" xlink:href="bsx-20221231.xsd#bsx_June2025NotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_June2025NotesMember_ecc007c1-3e75-4032-b275-059d6ea4f25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2026NotesMember_f8d0d18a-5d32-458c-91a9-5a5145e22df0" xlink:href="bsx-20221231.xsd#bsx_March2026NotesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2026NotesMember_f8d0d18a-5d32-458c-91a9-5a5145e22df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_December2027NotesMember_93a8d8a8-4eb1-4677-bb23-c9725ce61685" xlink:href="bsx-20221231.xsd#bsx_December2027NotesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_December2027NotesMember_93a8d8a8-4eb1-4677-bb23-c9725ce61685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028NotesMember_28348c37-a14e-4ff9-bc9c-74e6c1e17661" xlink:href="bsx-20221231.xsd#bsx_March2028NotesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2028NotesMember_28348c37-a14e-4ff9-bc9c-74e6c1e17661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2029NotesMember_567b8c72-0fa2-45d7-baf9-233bf3a58c59" xlink:href="bsx-20221231.xsd#bsx_March2029NotesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2029NotesMember_567b8c72-0fa2-45d7-baf9-233bf3a58c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_June2030NotesMember_90b75f1f-f22c-40b3-a031-da5656a4b45b" xlink:href="bsx-20221231.xsd#bsx_June2030NotesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_June2030NotesMember_90b75f1f-f22c-40b3-a031-da5656a4b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_November2035NotesMember_9506c4a8-2229-4344-b4c1-ab1537f4aa2c" xlink:href="bsx-20221231.xsd#bsx_November2035NotesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_November2035NotesMember_9506c4a8-2229-4344-b4c1-ab1537f4aa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2039NotesMember_b11785a5-3d5f-436b-93c9-1640516247d9" xlink:href="bsx-20221231.xsd#bsx_March2039NotesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2039NotesMember_b11785a5-3d5f-436b-93c9-1640516247d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_January2040NotesMember_0abc18e0-30a1-4997-ab28-936874e5c6cb" xlink:href="bsx-20221231.xsd#bsx_January2040NotesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_January2040NotesMember_0abc18e0-30a1-4997-ab28-936874e5c6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2049NotesMember_b839ec3d-5cbe-4e70-88ed-3634ea2206e9" xlink:href="bsx-20221231.xsd#bsx_March2049NotesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2049NotesMember_b839ec3d-5cbe-4e70-88ed-3634ea2206e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d082a4f8-6df2-49ce-8e89-1b01f683ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_InterestRateSwapMember_d082a4f8-6df2-49ce-8e89-1b01f683ffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_773dc61b-96fb-41f5-b4de-ec30a932e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_773dc61b-96fb-41f5-b4de-ec30a932e9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c8175e43-3f82-4ad2-96e2-f737bdcdb6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_us-gaap_SeniorNotesMember_c8175e43-3f82-4ad2-96e2-f737bdcdb6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2028SeniorNotesMember_ea113c46-92a7-4498-a2b9-f01af6fe5ffc" xlink:href="bsx-20221231.xsd#bsx_March2028SeniorNotesMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2028SeniorNotesMember_ea113c46-92a7-4498-a2b9-f01af6fe5ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2031NotesMember_40590d61-72ba-4af9-a3c0-fd9470787317" xlink:href="bsx-20221231.xsd#bsx_March2031NotesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2031NotesMember_40590d61-72ba-4af9-a3c0-fd9470787317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2034NotesMember_4b3091a6-b5c8-4fb7-960e-ca892bf4b5f3" xlink:href="bsx-20221231.xsd#bsx_March2034NotesMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2034NotesMember_4b3091a6-b5c8-4fb7-960e-ca892bf4b5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingAggregatePrincipalAmountMember_d23c2f7a-5312-4ac4-a626-989db497da74" xlink:href="bsx-20221231.xsd#bsx_TheOfferingAggregatePrincipalAmountMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_TheOfferingAggregatePrincipalAmountMember_d23c2f7a-5312-4ac4-a626-989db497da74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_March2025NotesMember_57a0d857-8c6f-4e54-8caa-998876683eb2" xlink:href="bsx-20221231.xsd#bsx_March2025NotesMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_March2025NotesMember_57a0d857-8c6f-4e54-8caa-998876683eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_edba4870-49f2-4594-b253-3b20a2dbab8e" xlink:href="bsx-20221231.xsd#bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25e600a6-7024-4e0c-9add-e14cbfe46140" xlink:to="loc_bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember_edba4870-49f2-4594-b253-3b20a2dbab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_823770fa-9282-49e8-b926-05f171dc193f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_The2018FacilityDomain_f7d90577-7580-4785-8194-bdb49038bb64" xlink:href="bsx-20221231.xsd#bsx_The2018FacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9ce15c14-99af-4409-b020-74ff371f2baf" xlink:to="loc_bsx_The2018FacilityDomain_f7d90577-7580-4785-8194-bdb49038bb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_04de772b-f365-40e0-a90b-f2db6ddc259c" xlink:to="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_261b39a3-249f-4490-aac7-23e47f16a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_79487307-e034-4fcb-90d4-2e7c3a0662bf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_261b39a3-249f-4490-aac7-23e47f16a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:href="bsx-20221231.xsd#bsx_CovenantAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:href="bsx-20221231.xsd#bsx_CovenantDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantAxis_de5e5738-2e99-4500-adb2-29e3b2cd2a0e" xlink:to="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ActualCovenantMember_ec2a8260-abb8-40cf-a3da-0e5ff9b95724" xlink:href="bsx-20221231.xsd#bsx_ActualCovenantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_ActualCovenantMember_ec2a8260-abb8-40cf-a3da-0e5ff9b95724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfMarch312021Member_f0d38a71-660f-4388-9104-dbff96bacbb0" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfMarch312021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementAsOfMarch312021Member_f0d38a71-660f-4388-9104-dbff96bacbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_bbd71caa-69bd-4a47-8a7f-a4f8762bc4bb" xlink:href="bsx-20221231.xsd#bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember_bbd71caa-69bd-4a47-8a7f-a4f8762bc4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_14197004-087d-48b0-a2ea-0f314708c6f1" xlink:href="bsx-20221231.xsd#bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember_14197004-087d-48b0-a2ea-0f314708c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_bb700a1f-9e04-435e-851c-64ff7dc58f76" xlink:href="bsx-20221231.xsd#bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember_bb700a1f-9e04-435e-851c-64ff7dc58f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_b2dcc4d9-5c69-4b69-bc7f-b019288b69ab" xlink:href="bsx-20221231.xsd#bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember_b2dcc4d9-5c69-4b69-bc7f-b019288b69ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_f155b843-1aff-48eb-b370-048e9110ab10" xlink:href="bsx-20221231.xsd#bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember_f155b843-1aff-48eb-b370-048e9110ab10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_6d197a74-bdb0-4d5c-9f7a-7aae46d8d84d" xlink:href="bsx-20221231.xsd#bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_CovenantDomain_385c7f98-77c5-4b7c-82aa-810e7292dedf" xlink:to="loc_bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember_6d197a74-bdb0-4d5c-9f7a-7aae46d8d84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7527d35e-486d-48d7-9c4a-ea3058d50cda" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_33e848a6-de33-438f-81e0-890d06159d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:to="loc_us-gaap_CommercialPaperMember_33e848a6-de33-438f-81e0-890d06159d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_May2022NotesMember_ae6f848c-1f17-40fb-8d49-84178e7c70d3" xlink:href="bsx-20221231.xsd#bsx_May2022NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_22e5cd4c-7606-436a-b490-89fcd0423e77" xlink:to="loc_bsx_May2022NotesMember_ae6f848c-1f17-40fb-8d49-84178e7c70d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2819572a-a170-454a-abe9-492d0f6e085b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_3549a3dc-eed2-406f-8101-39729a1cf112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_3549a3dc-eed2-406f-8101-39729a1cf112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f69bde84-cd86-4bb0-b1af-84f3d81c3e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtCurrent_f69bde84-cd86-4bb0-b1af-84f3d81c3e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a19e09c5-7c26-449e-8e06-e0898548b324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a19e09c5-7c26-449e-8e06-e0898548b324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_55f1a468-cc1e-4ba6-9f24-1538c069e548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_55f1a468-cc1e-4ba6-9f24-1538c069e548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_025cbc19-5045-417e-b66e-9e305c84f360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_025cbc19-5045-417e-b66e-9e305c84f360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1097243d-77e3-42f0-a847-182b61171f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1097243d-77e3-42f0-a847-182b61171f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MaximumLeverageRatio_c22bc277-165b-48b4-9b70-4cf32eef4297" xlink:href="bsx-20221231.xsd#bsx_MaximumLeverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_MaximumLeverageRatio_c22bc277-165b-48b4-9b70-4cf32eef4297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeemedConsolidatedEBITDA_c696889e-7b39-40e7-a60d-beb067c641ae" xlink:href="bsx-20221231.xsd#bsx_DeemedConsolidatedEBITDA"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_DeemedConsolidatedEBITDA_c696889e-7b39-40e7-a60d-beb067c641ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExclusionFromEbitdaForRestructuringCharges_79339a3e-6a64-4780-9d23-915b06d26ab2" xlink:href="bsx-20221231.xsd#bsx_ExclusionFromEbitdaForRestructuringCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_ExclusionFromEbitdaForRestructuringCharges_79339a3e-6a64-4780-9d23-915b06d26ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_73738e27-b0e7-4725-9789-66e866b0ca5a" xlink:href="bsx-20221231.xsd#bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_73738e27-b0e7-4725-9789-66e866b0ca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LitigationAndDebtExclusionFromEbitda_6c990e1f-7b3e-4618-b28d-5278ae59cf72" xlink:href="bsx-20221231.xsd#bsx_LitigationAndDebtExclusionFromEbitda"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_LitigationAndDebtExclusionFromEbitda_6c990e1f-7b3e-4618-b28d-5278ae59cf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_85957bc9-46cd-4821-8a0f-2b18b820bd26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_85957bc9-46cd-4821-8a0f-2b18b820bd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_8e7d0ed0-6c88-4ccd-b762-751f129f356b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_8e7d0ed0-6c88-4ccd-b762-751f129f356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_161fe4ba-cd41-4603-9f71-31c3c9f5caff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_161fe4ba-cd41-4603-9f71-31c3c9f5caff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_53806f91-ad91-4a59-9510-93376b8d00bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebt_53806f91-ad91-4a59-9510-93376b8d00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_16825e33-cf68-485e-ac06-39e5535e283f" xlink:href="bsx-20221231.xsd#bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda_16825e33-cf68-485e-ac06-39e5535e283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d63d91a1-c29f-470b-a85f-53e8b3d454b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d63d91a1-c29f-470b-a85f-53e8b3d454b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_2174e24f-66c8-4f57-9ae1-be13817d375d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_2174e24f-66c8-4f57-9ae1-be13817d375d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_95c472a5-f69d-4740-8775-a3e224ac216a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_95c472a5-f69d-4740-8775-a3e224ac216a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_1d9ca80a-0824-422a-8802-719082276240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_1d9ca80a-0824-422a-8802-719082276240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_ce7ad826-ac23-46f2-a310-60025042958c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_ce7ad826-ac23-46f2-a310-60025042958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_f2358eba-733c-4181-8753-7f82837a5549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_f2358eba-733c-4181-8753-7f82837a5549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6b5416d6-8ce2-4864-8009-c5033710e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_PurchaseObligation_6b5416d6-8ce2-4864-8009-c5033710e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d9f975e1-c6f3-474c-b684-4d4fd4f7ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d9f975e1-c6f3-474c-b684-4d4fd4f7ad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_41960fd4-1bc8-4843-bed2-d557fb9ddb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ShortTermBorrowings_41960fd4-1bc8-4843-bed2-d557fb9ddb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_12ce5aba-5bbb-4c2f-b77d-d15350176775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_12ce5aba-5bbb-4c2f-b77d-d15350176775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_882aeafd-656e-4036-b995-ddf15ff79bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_882aeafd-656e-4036-b995-ddf15ff79bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_de4385c0-f72f-4c54-9af9-0019ca32b008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_de4385c0-f72f-4c54-9af9-0019ca32b008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_774b6f30-3063-4c41-90b6-5b19ad4a6ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_774b6f30-3063-4c41-90b6-5b19ad4a6ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_bbbee0af-72a4-411f-a291-036147813c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_bbbee0af-72a4-411f-a291-036147813c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_d816a274-44c0-4377-ba27-306659f3b187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_d816a274-44c0-4377-ba27-306659f3b187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_5bdd4c48-28be-4aaf-b27e-96658b2fa912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_5bdd4c48-28be-4aaf-b27e-96658b2fa912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14808d5a-b47c-4e85-b673-bbeafb62c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c36321bc-b2d2-4bff-aced-a48b4e0d0556" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14808d5a-b47c-4e85-b673-bbeafb62c6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/LeasesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7687e620-7aaa-4001-9a64-57184e7661a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7687e620-7aaa-4001-9a64-57184e7661a0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:to="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f81b1d6-bcb4-40f7-b93b-83689d1717e2" xlink:to="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16222919-90ad-4e14-baeb-93aeee42200f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:to="loc_srt_MinimumMember_16222919-90ad-4e14-baeb-93aeee42200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0466f3d9-afd3-4216-a48e-4da85f7dcc51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9653407-d6d2-4f63-ad50-e47032de7fd3" xlink:to="loc_srt_MaximumMember_0466f3d9-afd3-4216-a48e-4da85f7dcc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_29fff278-d2e1-4374-8369-d3482218d07f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9dd65f85-6d2a-4962-a45c-50c39da2ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce1414b4-d0fa-4b84-a925-d43ef94bfae9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9dd65f85-6d2a-4962-a45c-50c39da2ccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_beed18d5-a9e6-4e89-bcec-37f3f51e55e9" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_105cc6d6-9b4d-441c-8038-d2bd2bbdbb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_105cc6d6-9b4d-441c-8038-d2bd2bbdbb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_5835c824-69ba-41d2-931f-30561024c566" xlink:href="bsx-20221231.xsd#bsx_LesseeOperatingAndFinanceLeasesOptionToExtend"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend_5835c824-69ba-41d2-931f-30561024c566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae20c3fc-753c-49f4-9f33-c7667354d0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae20c3fc-753c-49f4-9f33-c7667354d0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14a3358f-3b8c-40d1-b5c6-740b0aa4778e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14a3358f-3b8c-40d1-b5c6-740b0aa4778e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0eab078f-c83c-4282-8ffe-5144b2c12512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0eab078f-c83c-4282-8ffe-5144b2c12512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_311940a7-93e8-485d-af9c-597e6d46d019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_311940a7-93e8-485d-af9c-597e6d46d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3b917e0f-caa6-45ad-9c08-6e581a96111a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseCost_3b917e0f-caa6-45ad-9c08-6e581a96111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a742e48b-e014-4379-9027-632e78c56087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeasePayments_a742e48b-e014-4379-9027-632e78c56087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02df90b4-e520-419b-9ac6-40980f4a4f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02df90b4-e520-419b-9ac6-40980f4a4f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_023ebfb3-c5ec-4b6a-8611-550fc5661d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_023ebfb3-c5ec-4b6a-8611-550fc5661d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_dd25820e-3fc6-4baf-bed1-bc42754e4e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_dd25820e-3fc6-4baf-bed1-bc42754e4e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_8df4cf0e-175d-4baa-8a2e-44344841e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_8df4cf0e-175d-4baa-8a2e-44344841e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_bcfec66f-7635-423a-bbd1-9765e755b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_bcfec66f-7635-423a-bbd1-9765e755b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_ea9e15dc-009f-40cf-8f9f-df1bec3ecc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_ea9e15dc-009f-40cf-8f9f-df1bec3ecc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_c6d796ab-c4e1-40a5-b061-21315aca7542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_c6d796ab-c4e1-40a5-b061-21315aca7542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6b33e86-66f8-4e8c-aa4a-cb390ff65876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6b33e86-66f8-4e8c-aa4a-cb390ff65876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b70a49d-94af-4ab0-990e-38145681982e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b70a49d-94af-4ab0-990e-38145681982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83c13bd8-5e0b-4610-bdcc-89d0dce80da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiability_83c13bd8-5e0b-4610-bdcc-89d0dce80da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2dacf6cc-d700-4a2e-89c9-ffc040c63e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2dacf6cc-d700-4a2e-89c9-ffc040c63e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e4904a6a-3534-4c4a-b5c2-321a7e3d6eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5495797e-5256-45d7-82b1-4e862c7525e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e4904a6a-3534-4c4a-b5c2-321a7e3d6eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:href="bsx-20221231.xsd#bsx_OtherCurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2c7e99af-36a4-441f-9211-e41a3cd8b545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2c7e99af-36a4-441f-9211-e41a3cd8b545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4df67678-b40c-4dc9-84c8-22a3a9e38583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4df67678-b40c-4dc9-84c8-22a3a9e38583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangements_60cb408a-0f7b-4f65-9ae0-bf6cdf379e7d" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:to="loc_bsx_LicensingArrangements_60cb408a-0f7b-4f65-9ae0-bf6cdf379e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_307ad1b0-6848-487c-81ef-20fb4c44f744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_307ad1b0-6848-487c-81ef-20fb4c44f744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_105fa4d5-c4b8-40e8-bd30-d349a660674e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_OtherCurrentAssetsAbstract_5c29eb56-3926-4a95-8c67-711e7d078903" xlink:to="loc_us-gaap_OtherAssetsCurrent_105fa4d5-c4b8-40e8-bd30-d349a660674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_636553a2-dbb1-40e4-9f2a-41b26d4168e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_636553a2-dbb1-40e4-9f2a-41b26d4168e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_3c7b19f1-5b90-41ec-96d0-02b8f545ca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_636553a2-dbb1-40e4-9f2a-41b26d4168e8" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_3c7b19f1-5b90-41ec-96d0-02b8f545ca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2db28040-1f50-4652-b70b-26a019bac171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_636553a2-dbb1-40e4-9f2a-41b26d4168e8" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2db28040-1f50-4652-b70b-26a019bac171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_30387c45-311f-4a0a-aac5-a70efa2f6b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract_636553a2-dbb1-40e4-9f2a-41b26d4168e8" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_30387c45-311f-4a0a-aac5-a70efa2f6b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_09ec8b6e-ff22-4db5-8135-4a6d91f47e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_09ec8b6e-ff22-4db5-8135-4a6d91f47e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_16ee1c6d-406b-4e83-b13c-9bcc5a26685d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_16ee1c6d-406b-4e83-b13c-9bcc5a26685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_94407dea-6aa6-4542-8094-88e9872d63ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_94407dea-6aa6-4542-8094-88e9872d63ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_64bea1c2-2b84-4746-a899-b845a3c14ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_64bea1c2-2b84-4746-a899-b845a3c14ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_22e4712d-218c-4511-b965-efe4ab6b4c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_505ffedb-7212-425d-94de-ab6f363cbdb9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_22e4712d-218c-4511-b965-efe4ab6b4c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be8b46bb-88c9-4580-9943-01f9464c1628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be8b46bb-88c9-4580-9943-01f9464c1628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fcf44d41-75d1-46e0-9b84-805cef09abe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fcf44d41-75d1-46e0-9b84-805cef09abe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_714e635b-1940-4bb6-9953-4225bbb32a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_714e635b-1940-4bb6-9953-4225bbb32a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a3af0af-06d8-4101-b951-9eb5308e3aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1c75ac50-69a7-4365-8c67-80c5c673f55c" xlink:to="loc_us-gaap_InventoryNet_7a3af0af-06d8-4101-b951-9eb5308e3aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_12b98a15-7f95-456f-974d-c25427d90bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_Land_12b98a15-7f95-456f-974d-c25427d90bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_b336dca2-de4c-440c-b5e0-91073decaa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_b336dca2-de4c-440c-b5e0-91073decaa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EquipmentFurnitureAndFixturesGross_6f24290d-8494-418a-b215-c80f278217a9" xlink:href="bsx-20221231.xsd#bsx_EquipmentFurnitureAndFixturesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_bsx_EquipmentFurnitureAndFixturesGross_6f24290d-8494-418a-b215-c80f278217a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_cb908006-b934-490b-89a6-a430ce6e3fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_ConstructionInProgressGross_cb908006-b934-490b-89a6-a430ce6e3fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_87e5a41b-72d7-4d61-9ab2-acf2b0e52d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_87e5a41b-72d7-4d61-9ab2-acf2b0e52d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5f03eef2-e4f8-4286-8b45-976b30490078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5f03eef2-e4f8-4286-8b45-976b30490078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_42cf2488-be53-4019-bc20-950140b10bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8ba5b09-7941-413f-afe3-ac8912f5d2f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_42cf2488-be53-4019-bc20-950140b10bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract_67856a6f-2fb5-4d46-9de1-4e415b96e922" xlink:href="bsx-20221231.xsd#bsx_SupplementalBalanceSheetInformationTextualsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract_67856a6f-2fb5-4d46-9de1-4e415b96e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_PercentOfFinishedGoodsAtConsignment_e988a98c-5eee-4f7b-bb74-4d5a1b52086b" xlink:href="bsx-20221231.xsd#bsx_PercentOfFinishedGoodsAtConsignment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract_67856a6f-2fb5-4d46-9de1-4e415b96e922" xlink:to="loc_bsx_PercentOfFinishedGoodsAtConsignment_e988a98c-5eee-4f7b-bb74-4d5a1b52086b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ace70dc0-2bd3-4b40-9c4b-1c017254a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationTextualsAbstract_67856a6f-2fb5-4d46-9de1-4e415b96e922" xlink:to="loc_us-gaap_Depreciation_ace70dc0-2bd3-4b40-9c4b-1c017254a3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_eb4dd063-6d9c-4c26-81e0-ff85d2679b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_eb4dd063-6d9c-4c26-81e0-ff85d2679b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7fae0003-18b6-40c9-a507-3e28ccf6765a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7fae0003-18b6-40c9-a507-3e28ccf6765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_dfd2fa73-93e3-4874-ae52-618bcb61d380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_us-gaap_DerivativeAssets_dfd2fa73-93e3-4874-ae52-618bcb61d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_19077abd-8076-4386-8e23-856fd25d6a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_us-gaap_Investments_19077abd-8076-4386-8e23-856fd25d6a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsAsset_04008f05-d634-43f1-8290-8099a4b8f19e" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_bsx_LicensingArrangementsAsset_04008f05-d634-43f1-8290-8099a4b8f19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherOtherLongTermAssets_2bcfd4dd-1028-4732-a2a4-595726b8c045" xlink:href="bsx-20221231.xsd#bsx_OtherOtherLongTermAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_bsx_OtherOtherLongTermAssets_2bcfd4dd-1028-4732-a2a4-595726b8c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_12b4ef6f-338d-4dad-aae7-3c83139c6baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_89130428-5a39-4203-92d9-555b26083ebc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_12b4ef6f-338d-4dad-aae7-3c83139c6baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_31d3d77d-d7ca-4de1-816e-6b03d02d910b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_us-gaap_LitigationReserveCurrent_31d3d77d-d7ca-4de1-816e-6b03d02d910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_063dded2-c8ac-4476-b1c0-1668b82100e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_063dded2-c8ac-4476-b1c0-1668b82100e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AccruedRebatesCurrent_b113211f-7dc3-40fe-8dc2-7148c72c98cc" xlink:href="bsx-20221231.xsd#bsx_AccruedRebatesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_bsx_AccruedRebatesCurrent_b113211f-7dc3-40fe-8dc2-7148c72c98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2442d6cb-9726-4c17-956a-1fac0c0c6eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2442d6cb-9726-4c17-956a-1fac0c0c6eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63348d70-8368-439a-91de-9b34d671044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63348d70-8368-439a-91de-9b34d671044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5a632d1f-d4aa-449a-a58d-9b3f4cb3a130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_62f2c2c5-e986-43bc-87e4-bf030568de00" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5a632d1f-d4aa-449a-a58d-9b3f4cb3a130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_e2c4f181-996b-4d31-b4ca-feb8ddba053a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:to="loc_us-gaap_DeferredRevenueCurrent_e2c4f181-996b-4d31-b4ca-feb8ddba053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_423c78f7-e4fb-4f3c-977d-d6d291f3ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_423c78f7-e4fb-4f3c-977d-d6d291f3ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e54bdb67-be44-4291-ab9e-8bcddc92177b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:to="loc_us-gaap_TaxesPayableCurrent_e54bdb67-be44-4291-ab9e-8bcddc92177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_d9e61fbb-4c9a-416d-8c25-9c51c4cff292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_d9e61fbb-4c9a-416d-8c25-9c51c4cff292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_de8628dd-41d2-454a-a894-e5f30fe209e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_c2d66c7d-e2a3-4613-a5c6-617f17071163" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_de8628dd-41d2-454a-a894-e5f30fe209e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3459d47e-ea58-4efe-9e74-1b6b2c74220a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3459d47e-ea58-4efe-9e74-1b6b2c74220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_a6384659-9832-42d6-97a5-a213983e1c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_a6384659-9832-42d6-97a5-a213983e1c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8515651a-9dd6-405a-a510-8e0bff855432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8515651a-9dd6-405a-a510-8e0bff855432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_e6601b55-b5b1-4b7a-88de-1ddc187fce75" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_bsx_LicensingArrangementsLiability_e6601b55-b5b1-4b7a-88de-1ddc187fce75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e27e7242-72df-4406-a519-fcea706b7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e27e7242-72df-4406-a519-fcea706b7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_eef71bf0-46e8-4f7d-8cf6-22455481af78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_eef71bf0-46e8-4f7d-8cf6-22455481af78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_65aaf79a-d646-4e88-9db1-4602ac666fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_DeferredRevenue_65aaf79a-d646-4e88-9db1-4602ac666fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_15eaeace-ad28-4a08-bab1-c0d8b641bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_15eaeace-ad28-4a08-bab1-c0d8b641bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0270cb31-a774-40c6-8216-f229a6a4839e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_c25389e4-d605-4c5f-a92c-74ecc3b1085c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0270cb31-a774-40c6-8216-f229a6a4839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_SupplementalBalanceSheetInformationAbstract_0a4a53b6-9e6b-45b8-8c10-e101903e8a28" xlink:to="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_367c8c21-86c1-4edf-8c83-df2ec89eb27c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0a007096-f008-45a6-aca8-c9d5680d24db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0a007096-f008-45a6-aca8-c9d5680d24db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_c4fdcf2b-93f5-4bf5-80e0-52d6d4c35a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82080b4d-3c02-4d90-97de-4a126e78e932" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_c4fdcf2b-93f5-4bf5-80e0-52d6d4c35a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e89c4b9e-c987-41dc-b555-e05cb36479ec" xlink:to="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_4d903462-9048-4be0-8563-6d7da1df84a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_4d903462-9048-4be0-8563-6d7da1df84a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_4c6534c8-31a1-4b17-b035-e3416c7ad950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_4c6534c8-31a1-4b17-b035-e3416c7ad950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_755bb0a3-5a2e-4efc-b1db-5f2b321c666a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_755bb0a3-5a2e-4efc-b1db-5f2b321c666a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LicensingArrangementsLiability_ed5ccf28-0dfb-4ff5-a8f2-425fdfd7f11e" xlink:href="bsx-20221231.xsd#bsx_LicensingArrangementsLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_bsx_LicensingArrangementsLiability_ed5ccf28-0dfb-4ff5-a8f2-425fdfd7f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc39230c-0c3e-4e57-8f78-62826dd488b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc39230c-0c3e-4e57-8f78-62826dd488b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e0d88dd4-0cbe-439d-94cb-71bdb2079d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e0d88dd4-0cbe-439d-94cb-71bdb2079d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_c05193e1-31e6-45ad-a6c6-57b83308c875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_DeferredRevenue_c05193e1-31e6-45ad-a6c6-57b83308c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c18ff219-e343-43f8-89e7-25774911d6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c18ff219-e343-43f8-89e7-25774911d6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_952a89ee-3cb6-4dd7-bfe9-d01e2c194fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_952a89ee-3cb6-4dd7-bfe9-d01e2c194fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IndemnificationAsset_2aba512c-d62c-4687-92a8-d9e12d117867" xlink:href="bsx-20221231.xsd#bsx_IndemnificationAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_bsx_IndemnificationAsset_2aba512c-d62c-4687-92a8-d9e12d117867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_64728b50-be8a-4c32-bccd-18faa71a6126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_64728b50-be8a-4c32-bccd-18faa71a6126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba9a54ed-549b-4a00-87bb-6fc3b8767517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a4cda83-8c4e-4198-87bb-33e6b84c9ca8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba9a54ed-549b-4a00-87bb-6fc3b8767517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxesDetailsRateTable"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IncomeTaxesAbstract_461c2df1-226b-47d6-bbad-b4405f6e2f24" xlink:href="bsx-20221231.xsd#bsx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_IncomeTaxesAbstract_461c2df1-226b-47d6-bbad-b4405f6e2f24" xlink:to="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:href="bsx-20221231.xsd#bsx_TaxRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:to="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxRateDomain_40c58887-443d-445a-a5dc-820635f8a05d" xlink:href="bsx-20221231.xsd#bsx_TaxRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_TaxRateAxis_15541335-c696-49af-a582-ed3930cade35" xlink:to="loc_bsx_TaxRateDomain_40c58887-443d-445a-a5dc-820635f8a05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:href="bsx-20221231.xsd#bsx_ScheduleofIncomeTaxRateReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationTable_d2092df0-a7f8-4b61-99cb-7aa2e54fea6b" xlink:to="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1291ced8-9e26-40e2-99c4-ffeff6fad2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1291ced8-9e26-40e2-99c4-ffeff6fad2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_159b6046-1cd3-4b4d-834c-21836c4c7e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_159b6046-1cd3-4b4d-834c-21836c4c7e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_bd9b0423-1979-4403-a62a-0778c4b533ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_bd9b0423-1979-4403-a62a-0778c4b533ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5bdca00f-4a73-4870-8fb0-536bf20acbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5bdca00f-4a73-4870-8fb0-536bf20acbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6ae62f-844d-4ca6-8796-a433d41a1653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6ae62f-844d-4ca6-8796-a433d41a1653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e251fdce-ab43-47d0-a794-33f37d6131f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e251fdce-ab43-47d0-a794-33f37d6131f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3fc4f0f7-03a9-4fb3-b14d-c5726e6a70a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3fc4f0f7-03a9-4fb3-b14d-c5726e6a70a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c483543f-7ecb-422a-abe1-dee084199925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c483543f-7ecb-422a-abe1-dee084199925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_deb3263e-6930-48b2-84ba-c572ce7fd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_deb3263e-6930-48b2-84ba-c572ce7fd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b29e704c-9ec0-48b5-b19d-a9a138e111e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b29e704c-9ec0-48b5-b19d-a9a138e111e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_be79fc25-60ed-496b-94d9-e50a3b9437be" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions_be79fc25-60ed-496b-94d9-e50a3b9437be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_d4a8c68d-f047-453f-af7f-b4697aef25b4" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers_d4a8c68d-f047-453f-af7f-b4697aef25b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_5fc7b75f-1bc5-439d-a6c4-505f55c45b2c" xlink:href="bsx-20221231.xsd#bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision_5fc7b75f-1bc5-439d-a6c4-505f55c45b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5f73dc34-6927-4040-a4de-c9aa4b6655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5f73dc34-6927-4040-a4de-c9aa4b6655fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9c935b98-79a1-41fe-a4c4-1c59233654f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9c935b98-79a1-41fe-a4c4-1c59233654f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a69c5a7-17b6-4994-a7c1-7560d4137f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_ScheduleofIncomeTaxRateReconciliationLineItems_a949d207-6d07-422a-8a67-217b14db3f1b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a69c5a7-17b6-4994-a7c1-7560d4137f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#IncomeTaxesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_IncomeTaxesAbstract_6844aa98-6aba-4528-80be-6ff276b6c95d" xlink:href="bsx-20221231.xsd#bsx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_IncomeTaxesAbstract_6844aa98-6aba-4528-80be-6ff276b6c95d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ac3d3ab-c547-4ad0-b171-c83e0ca29de9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_687f1ece-ddc9-4e31-a8af-55cd156b7176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_687f1ece-ddc9-4e31-a8af-55cd156b7176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsDomain_5a538f56-0841-4588-bc64-108551eff566" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_bsx_DeferredTaxAssetsDomain_5a538f56-0841-4588-bc64-108551eff566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxLiabilitiesDomain_d447c32b-158e-4a26-84da-988db400d230" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxLiabilitiesDomain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_10b0d84a-44bc-4e11-aeb5-99e8501a95e5" xlink:to="loc_bsx_DeferredTaxLiabilitiesDomain_d447c32b-158e-4a26-84da-988db400d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_680ad599-9fd2-41b7-a79f-c2283ececf46" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_80a989e6-096e-48bd-8d04-a7f73df6ed90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_80a989e6-096e-48bd-8d04-a7f73df6ed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aaa252a1-78a2-45b7-a861-49ba3103785c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aaa252a1-78a2-45b7-a861-49ba3103785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfd8f1e9-5ea3-4efc-95db-149c04920997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfd8f1e9-5ea3-4efc-95db-149c04920997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1a30cd4-5011-4882-9c52-77da1748452b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1a30cd4-5011-4882-9c52-77da1748452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c8bfb0d2-a2d1-4998-8d53-348e9917da26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c8bfb0d2-a2d1-4998-8d53-348e9917da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3eccfd30-d203-49e9-b9b2-2ed5afd653de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3eccfd30-d203-49e9-b9b2-2ed5afd653de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be0261fe-0532-40e5-9fb5-8eb9c0bf4fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be0261fe-0532-40e5-9fb5-8eb9c0bf4fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dbdd672-e1b3-467f-8e51-ce688618ccef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dbdd672-e1b3-467f-8e51-ce688618ccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6441efb8-eb38-42b0-9423-630489a62c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6441efb8-eb38-42b0-9423-630489a62c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2e4d7bf9-c119-47db-aadc-339e283f1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2e4d7bf9-c119-47db-aadc-339e283f1235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e677dd06-3a9c-44f2-9aac-8d74c7156001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e677dd06-3a9c-44f2-9aac-8d74c7156001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff7469ed-7da1-4e68-b51c-9ff56f794c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff7469ed-7da1-4e68-b51c-9ff56f794c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f537d7bd-6e4e-4e38-8623-53fbc87c43bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f537d7bd-6e4e-4e38-8623-53fbc87c43bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02efbbcf-feba-413e-8669-d3ece3c7c413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02efbbcf-feba-413e-8669-d3ece3c7c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ae3f3fe-626e-48e8-9b08-8b3edd895208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ae3f3fe-626e-48e8-9b08-8b3edd895208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_cb213439-2763-41bc-947f-6188ae3eafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_cb213439-2763-41bc-947f-6188ae3eafc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_e586b62a-9595-4807-9c4f-ba7475859d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_e586b62a-9595-4807-9c4f-ba7475859d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_5941fba6-dc43-4c14-87f8-0f3037b0f6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_5941fba6-dc43-4c14-87f8-0f3037b0f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_77ce8351-35ea-416d-a10a-854ec7a9d16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_77ce8351-35ea-416d-a10a-854ec7a9d16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FederalBenefitOfUncertainTaxPositions_1e79f36b-6c7c-4c3f-91ed-e3d0205efe4e" xlink:href="bsx-20221231.xsd#bsx_FederalBenefitOfUncertainTaxPositions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FederalBenefitOfUncertainTaxPositions_1e79f36b-6c7c-4c3f-91ed-e3d0205efe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ddecf556-3efd-40d3-a641-93c9cfe8982b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ddecf556-3efd-40d3-a641-93c9cfe8982b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6b88405c-4de5-4fe2-8454-07187f4a6e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6b88405c-4de5-4fe2-8454-07187f4a6e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8921416c-3369-4c78-8bb7-66cd87591d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8921416c-3369-4c78-8bb7-66cd87591d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d7f9ccfc-a532-4524-9a37-2d0b008e40a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d7f9ccfc-a532-4524-9a37-2d0b008e40a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d8142aa5-5243-419e-ac82-6647827fd7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d8142aa5-5243-419e-ac82-6647827fd7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6ec4a953-8c9a-4065-87fe-18ac487eb3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6ec4a953-8c9a-4065-87fe-18ac487eb3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c55e0229-f29e-4cf4-8fd5-1e30fed84765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c55e0229-f29e-4cf4-8fd5-1e30fed84765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f6da2ca7-011e-4bab-9a03-5db49c4b0327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f6da2ca7-011e-4bab-9a03-5db49c4b0327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4a7aa7af-7d5a-4e68-91dc-7f996788be69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4a7aa7af-7d5a-4e68-91dc-7f996788be69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d07f1-d2b9-41fc-8c2d-e506337bec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d07f1-d2b9-41fc-8c2d-e506337bec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6d2e1da7-cd4c-4ce4-a4e8-efad42270731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6d2e1da7-cd4c-4ce4-a4e8-efad42270731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_057ddc76-6e32-4a13-be9d-f731bacf187e" xlink:href="bsx-20221231.xsd#bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit_057ddc76-6e32-4a13-be9d-f731bacf187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_782500a1-5c95-464b-83b0-a09cbd8f543a" xlink:href="bsx-20221231.xsd#bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit_782500a1-5c95-464b-83b0-a09cbd8f543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c53dd568-d479-4ec2-8c4e-bde0445ffad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c53dd568-d479-4ec2-8c4e-bde0445ffad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cebb2930-0958-4ec1-95a8-6255239fe68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_cebb2930-0958-4ec1-95a8-6255239fe68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_057d6c40-7d9f-4ccb-9db1-4f186c41e7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_057d6c40-7d9f-4ccb-9db1-4f186c41e7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_bc61fc37-2c4a-4a40-b995-12df01eaa296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_bc61fc37-2c4a-4a40-b995-12df01eaa296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_7f99edc7-17c5-4562-88c8-db3cfc217946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_7f99edc7-17c5-4562-88c8-db3cfc217946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentive_d53dfe70-aae0-4e57-a888-595358ee0756" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentive"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FreeTradeZoneRegimeTaxIncentive_d53dfe70-aae0-4e57-a888-595358ee0756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRico_143eabc4-a587-42ea-9799-9b2d89ce5cf4" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRico"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInPuertoRico_143eabc4-a587-42ea-9799-9b2d89ce5cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a252373f-08ff-4a5f-9bac-aa17eec57e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a252373f-08ff-4a5f-9bac-aa17eec57e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9fe5de1c-c08e-4e71-9bb9-f690eef17f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9fe5de1c-c08e-4e71-9bb9-f690eef17f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce6f66d6-34a8-4f16-ac4a-03b34887df91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce6f66d6-34a8-4f16-ac4a-03b34887df91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15c86e2f-284b-435e-b460-95c00f0de9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15c86e2f-284b-435e-b460-95c00f0de9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_015bc059-23d5-421c-8868-dc0f99c77afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_015bc059-23d5-421c-8868-dc0f99c77afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_773cc822-2231-4b77-b562-dd8d8542fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_773cc822-2231-4b77-b562-dd8d8542fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6e7b9784-b7b6-424d-a0b7-215d3904adec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6e7b9784-b7b6-424d-a0b7-215d3904adec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_50577954-78a2-44a8-a110-a78a16ae5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_50577954-78a2-44a8-a110-a78a16ae5c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_ec2dc734-42e5-4a44-aed7-70110f6f7f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_ec2dc734-42e5-4a44-aed7-70110f6f7f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_db7a660a-8e37-4b26-b709-ac4080273c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_db7a660a-8e37-4b26-b709-ac4080273c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_58f3a7da-4665-4f93-bef8-b3b0f19bb1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_58f3a7da-4665-4f93-bef8-b3b0f19bb1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment_16e24904-b187-4bb0-8296-027f2a505a93" xlink:href="bsx-20221231.xsd#bsx_Onetimetransactiontaxpost1986EPnetpayment"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_Onetimetransactiontaxpost1986EPnetpayment_16e24904-b187-4bb0-8296-027f2a505a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_b0d7366f-f25b-4e0b-86bd-17b9c3a2d1a0" xlink:href="bsx-20221231.xsd#bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution_b0d7366f-f25b-4e0b-86bd-17b9c3a2d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_a40d12a5-2e12-4e8c-9a1c-27f7163962bb" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution_a40d12a5-2e12-4e8c-9a1c-27f7163962bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TransitionTaxPaymentRemaining_4bc1e773-cad1-45c0-8e5b-43297f1f4416" xlink:href="bsx-20221231.xsd#bsx_TransitionTaxPaymentRemaining"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TransitionTaxPaymentRemaining_4bc1e773-cad1-45c0-8e5b-43297f1f4416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysia_00fb17cc-c228-4c73-adc3-dd53d207176b" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysia"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInMalaysia_00fb17cc-c228-4c73-adc3-dd53d207176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_adcb079c-712e-404b-88d5-ef5f43122aed" xlink:href="bsx-20221231.xsd#bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution_adcb079c-712e-404b-88d5-ef5f43122aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_38e616ac-3c62-412a-b195-932fd1c0ed1b" xlink:href="bsx-20221231.xsd#bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_472f2062-6cbc-4296-8c21-e369c28d8c5d" xlink:to="loc_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_38e616ac-3c62-412a-b195-932fd1c0ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d8e44a04-23f5-4b55-9046-d182a2838959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d8e44a04-23f5-4b55-9046-d182a2838959" xlink:to="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c8c4617-92e2-4797-a9cc-b0a492ecfcec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_970fd188-a425-4126-9c81-34a268f78131" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c8c4617-92e2-4797-a9cc-b0a492ecfcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dcb1b486-950b-4dd7-93ee-43735f44ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_07a01a9d-17d8-4e6f-9418-4af7647d49fe" xlink:to="loc_us-gaap_LitigationStatusDomain_dcb1b486-950b-4dd7-93ee-43735f44ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9a8349f5-fb54-400f-86c0-04ddd3a2c8e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5b47ce98-f632-4b99-b923-def4ae431dd1" xlink:to="loc_srt_LitigationCaseTypeDomain_9a8349f5-fb54-400f-86c0-04ddd3a2c8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3ebab494-ea8d-48ef-afed-7ce926e55615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_81d8bfc1-cd22-4c5a-85c7-87d7b36727b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_036fa52e-6a75-47b2-be83-b44a3ba7a0b8" xlink:to="loc_us-gaap_SubsequentEventMember_81d8bfc1-cd22-4c5a-85c7-87d7b36727b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df73b782-83ac-43b3-b3fa-5516fb8cef88" xlink:to="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1843be9b-7a8d-44a4-97b4-57b5a66b616b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1843be9b-7a8d-44a4-97b4-57b5a66b616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ce05ef91-ff1b-4b61-b218-71a4b12f5d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ce05ef91-ff1b-4b61-b218-71a4b12f5d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_874beb1f-68b3-41c9-a355-3a4c27d6f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LitigationSettlementExpense_874beb1f-68b3-41c9-a355-3a4c27d6f7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e05a7411-eeff-4851-b591-61c9299399d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e05a7411-eeff-4851-b591-61c9299399d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_c8e65c91-7e4f-4254-804b-97936702779e" xlink:href="bsx-20221231.xsd#bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9851589-0be6-4ed7-8b76-659d5877f3b9" xlink:to="loc_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior_c8e65c91-7e4f-4254-804b-97936702779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_28df157d-769e-4f13-a4d9-5ff7a741555b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDisclosuresAbstract_4bda7b61-a3dc-4f08-9a80-e9a5d92e8cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_28df157d-769e-4f13-a4d9-5ff7a741555b" xlink:to="loc_us-gaap_ClassOfStockDisclosuresAbstract_4bda7b61-a3dc-4f08-9a80-e9a5d92e8cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDisclosuresAbstract_4bda7b61-a3dc-4f08-9a80-e9a5d92e8cf9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3b6457e7-0a75-41ef-88f2-2818a6ce20bc" xlink:to="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_c37c3119-746f-4be4-8abf-315d08a43d28" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:to="loc_bsx_A550MCPSSeriesAMember_c37c3119-746f-4be4-8abf-315d08a43d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_422fa706-0bb5-497e-a3ba-bfbcabd89407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8502346c-7353-41e2-a041-6e86ae0c6400" xlink:to="loc_us-gaap_CommonStockMember_422fa706-0bb5-497e-a3ba-bfbcabd89407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc954da6-0397-49bb-9747-dfa3bbdfc843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9d4e10f4-2e1f-4a54-9d09-4b9c52abf656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ad90c9b-9357-43ab-b238-347230e7a8f8" xlink:to="loc_us-gaap_SubsequentEventMember_9d4e10f4-2e1f-4a54-9d09-4b9c52abf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d2c515d-9297-415f-8dec-3af1c08d4954" xlink:to="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd4852e-687c-4f5d-94ca-17fad242526b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:to="loc_srt_MinimumMember_dbd4852e-687c-4f5d-94ca-17fad242526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46c7b70d-7562-4202-9762-a70b641ee16e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c92b154-e83a-4174-91b6-c1b708ded802" xlink:to="loc_srt_MaximumMember_46c7b70d-7562-4202-9762-a70b641ee16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_416cebb6-83fa-4b6a-808d-087cb3244715" xlink:to="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b1004324-bffe-4294-bd86-f10eb9033142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b1004324-bffe-4294-bd86-f10eb9033142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_31413bd0-a070-4a52-be64-97511bb35127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_31413bd0-a070-4a52-be64-97511bb35127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_349cb848-61e5-4549-9689-cf29b6ccb9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_349cb848-61e5-4549-9689-cf29b6ccb9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_dc581dbc-0fe4-48b3-a0dd-59b91e64db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_dc581dbc-0fe4-48b3-a0dd-59b91e64db0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_9e0ae328-c830-4204-879e-67668c842568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_9e0ae328-c830-4204-879e-67668c842568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_b43ed2b6-1a5f-4aa5-a934-b61430dc7d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_b43ed2b6-1a5f-4aa5-a934-b61430dc7d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_be94941b-13ab-4e5a-a493-7ac242a3f792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_be94941b-13ab-4e5a-a493-7ac242a3f792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_869e71ec-bc03-4bee-8411-effda8600724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_869e71ec-bc03-4bee-8411-effda8600724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_054ffcb9-2dbb-433b-8123-e1c5218b220d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PaymentsOfDividends_054ffcb9-2dbb-433b-8123-e1c5218b220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_64d558c7-e7fb-421f-8ade-3b1d51df5be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_64d558c7-e7fb-421f-8ade-3b1d51df5be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b1e7a6ac-7261-425f-8de8-be51fc7c1a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b1e7a6ac-7261-425f-8de8-be51fc7c1a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df7d5279-9f4d-483e-9cb2-5963472b3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df7d5279-9f4d-483e-9cb2-5963472b3a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_47ada9ec-d912-49c7-9e35-68a486ec03bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_47ada9ec-d912-49c7-9e35-68a486ec03bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230dd34a-7d27-4511-8786-412d5873aa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230dd34a-7d27-4511-8786-412d5873aa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5866345c-aead-438e-bbd0-d9ea6720b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5866345c-aead-438e-bbd0-d9ea6720b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_72319bf6-af33-422e-a15a-58d2681ab741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_72319bf6-af33-422e-a15a-58d2681ab741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea975e66-30e5-46f6-b76b-e278fc4bd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea975e66-30e5-46f6-b76b-e278fc4bd7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_df9b1fe2-6007-4ea9-b2d2-571b139ce3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_DividendsCash_df9b1fe2-6007-4ea9-b2d2-571b139ce3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2cca8d3f-4d9f-42a0-84a3-350ff0047c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bb3813-60d3-4519-86fa-b71e7052b0b1" xlink:to="loc_us-gaap_TreasuryStockShares_2cca8d3f-4d9f-42a0-84a3-350ff0047c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_02480b2c-f188-4404-824e-97ebd7a309c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_28df157d-769e-4f13-a4d9-5ff7a741555b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_02480b2c-f188-4404-824e-97ebd7a309c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_16ad4a3c-0d34-4c69-ad0e-8c2f5b56699f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0e53937-82bd-4ee3-9574-4cc0f528d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c10a0113-e36d-417a-beea-74817583aa40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6fb88390-bcf5-44ac-b94b-aba6219f0b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ae67666-0b60-4348-ab7b-dab03c8c1a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_cecf2cd9-c0b4-4c5a-9f45-770dcf9cb4bf" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dad70ea8-da08-4128-a9a8-3dd1205cd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareCashPaid_596e5fd3-b126-4f90-be19-147392d86b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#StockIncentiveandPurchasePlansDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bsx_StockIncentiveAndPurchasePlansAbstract_c91400a0-efcc-4bf6-9455-b8af34b28623" xlink:href="bsx-20221231.xsd#bsx_StockIncentiveAndPurchasePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bsx_StockIncentiveAndPurchasePlansAbstract_c91400a0-efcc-4bf6-9455-b8af34b28623" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc7635a5-d393-4c41-82a5-3ab4c534f779" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_512eed98-73b1-4845-9ad8-31fd4b5f9594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_CostOfSalesMember_512eed98-73b1-4845-9ad8-31fd4b5f9594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_684fbf7e-8756-445d-9ca7-d6979edbba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_684fbf7e-8756-445d-9ca7-d6979edbba00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fad1fd53-5706-4dea-b881-9d4dd79cac84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29d08de1-8b17-4d48-845d-36db137474b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fad1fd53-5706-4dea-b881-9d4dd79cac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_68aa477f-2521-43ff-8920-233744748ddc" xlink:to="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A2011LtipPlanMember_23a3f06f-b268-428c-8b5a-eb670a47cbe3" xlink:href="bsx-20221231.xsd#bsx_A2011LtipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2eec865a-32c1-4296-8cfc-c19f8db12dbb" xlink:to="loc_bsx_A2011LtipPlanMember_23a3f06f-b268-428c-8b5a-eb670a47cbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ca0ee10e-7604-434d-bc3a-bd825abcc630" xlink:to="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0997491b-164c-4a20-bd1d-8bcd1f613a89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:to="loc_srt_MinimumMember_0997491b-164c-4a20-bd1d-8bcd1f613a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e6ac4bb-3508-483e-9fc2-1f23e9b74a7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:to="loc_srt_MaximumMember_8e6ac4bb-3508-483e-9fc2-1f23e9b74a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6c09fc5-a168-4e9e-a04f-66de0babefac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6073f36-4cd8-450b-bac4-88232d92bb1b" xlink:to="loc_srt_MaximumMember_f6c09fc5-a168-4e9e-a04f-66de0babefac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eff4162-4f59-4782-ad86-0eaaa1b3f66b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Fairvalueofmarketbasedawards_242485d5-c44e-45fe-8fac-b7a96d9e395a" xlink:href="bsx-20221231.xsd#bsx_Fairvalueofmarketbasedawards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Fairvalueofmarketbasedawards_242485d5-c44e-45fe-8fac-b7a96d9e395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3da32d78-f4a8-42ed-9d11-f2ee5ba5230c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharePrice_3da32d78-f4a8-42ed-9d11-f2ee5ba5230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostStockOptions_5b3dc974-4062-41f2-b27a-ca14faf3aae5" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCostStockOptions_5b3dc974-4062-41f2-b27a-ca14faf3aae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_e5dd8896-3e25-4449-9281-c20ebd57b1cf" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofperformancebasedDSUsawarded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded_e5dd8896-3e25-4449-9281-c20ebd57b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ed6080af-54bc-46e1-91cc-865e6aed35c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ed6080af-54bc-46e1-91cc-865e6aed35c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_37d9b60e-5f9c-435d-85cf-d5ee4642c71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_37d9b60e-5f9c-435d-85cf-d5ee4642c71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ae7f916-c421-4799-a152-3df5713c8734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ae7f916-c421-4799-a152-3df5713c8734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ad2569-0212-4fd4-a9a8-1a591ed4539e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ad2569-0212-4fd4-a9a8-1a591ed4539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14d3df14-5e0e-4217-8842-6e9a6e2b25aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14d3df14-5e0e-4217-8842-6e9a6e2b25aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Measurementperiodmarketbasedaward_b4a59b55-b718-4c72-b0d9-5377bf39d27b" xlink:href="bsx-20221231.xsd#bsx_Measurementperiodmarketbasedaward"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Measurementperiodmarketbasedaward_b4a59b55-b718-4c72-b0d9-5377bf39d27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ded9562f-18af-4ae7-8224-c9e9814d3850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ded9562f-18af-4ae7-8224-c9e9814d3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb6add-b2fe-428e-a6df-25eac5515670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb6add-b2fe-428e-a6df-25eac5515670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afdab049-e701-4a4a-966b-7eab6f7305cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afdab049-e701-4a4a-966b-7eab6f7305cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80d0cc6a-a27e-4f7c-8871-2b92218d7d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80d0cc6a-a27e-4f7c-8871-2b92218d7d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0b3fb5d5-8edb-4217-812f-ced0c286acca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0b3fb5d5-8edb-4217-812f-ced0c286acca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e7f5c3d8-2e07-4319-b2c6-8ac872a68bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e7f5c3d8-2e07-4319-b2c6-8ac872a68bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65f4c8c3-9d6c-4976-8cb4-bc10c59d0691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65f4c8c3-9d6c-4976-8cb4-bc10c59d0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a636ad86-9273-4bee-a8e2-ac7d00848211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a636ad86-9273-4bee-a8e2-ac7d00848211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e00d8a8a-4020-4582-a9bc-c34708320cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e00d8a8a-4020-4582-a9bc-c34708320cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dd3383e-fdc6-469c-84b6-fb152b7fc916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dd3383e-fdc6-469c-84b6-fb152b7fc916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f004b87d-a32c-4adf-a466-60cd8e847cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f004b87d-a32c-4adf-a466-60cd8e847cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_131d36b5-82e7-421e-9ba3-4d2a4061c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_131d36b5-82e7-421e-9ba3-4d2a4061c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_425c7143-ffed-4672-baf2-7f540c84ddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_425c7143-ffed-4672-baf2-7f540c84ddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f3f5aa1-7063-4934-a794-95f5c381e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f3f5aa1-7063-4934-a794-95f5c381e76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8beef9a-a425-4d87-8bd0-0de693df2665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8beef9a-a425-4d87-8bd0-0de693df2665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7581c661-4dd6-42a3-b386-a689b56e4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensation_7581c661-4dd6-42a3-b386-a689b56e4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2334ed3e-837b-4a70-bcfb-550562ef68d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2334ed3e-837b-4a70-bcfb-550562ef68d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ba885da5-fd05-4247-bed1-df42bcd24502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ba885da5-fd05-4247-bed1-df42bcd24502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1acc79f1-bdaf-4201-949e-27b2607a9c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1acc79f1-bdaf-4201-949e-27b2607a9c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ShareBasedCompensationNetOfTaxBenefit_fa778553-2723-494b-94c5-66ebc1c84e53" xlink:href="bsx-20221231.xsd#bsx_ShareBasedCompensationNetOfTaxBenefit"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_ShareBasedCompensationNetOfTaxBenefit_fa778553-2723-494b-94c5-66ebc1c84e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareBasic_24b3cddc-407e-4f1b-9dec-fbbc6aacbdad" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareBasic"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_CompensationExpensePerShareBasic_24b3cddc-407e-4f1b-9dec-fbbc6aacbdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CompensationExpensePerShareDiluted_86a8005e-b8d2-40a5-a463-07b62abfb2f6" xlink:href="bsx-20221231.xsd#bsx_CompensationExpensePerShareDiluted"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_CompensationExpensePerShareDiluted_86a8005e-b8d2-40a5-a463-07b62abfb2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55b9fac6-0351-402e-aa7d-1dc7e54e80ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55b9fac6-0351-402e-aa7d-1dc7e54e80ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cfbbfc23-6d42-4745-99db-b048c4987df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cfbbfc23-6d42-4745-99db-b048c4987df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3602f458-7e6d-43e6-b849-57374b9e13b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3602f458-7e6d-43e6-b849-57374b9e13b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0cd368bd-1d2b-4db1-8dc4-c787dc52b640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0cd368bd-1d2b-4db1-8dc4-c787dc52b640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_263bfb3a-364b-4df7-b0d7-5d8dc034114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_263bfb3a-364b-4df7-b0d7-5d8dc034114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b5c0764-690d-440e-beb8-8f71e7707be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b5c0764-690d-440e-beb8-8f71e7707be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_574b337f-1e15-49a6-b030-bf2e4093df79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_574b337f-1e15-49a6-b030-bf2e4093df79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b57a3417-87d9-46a2-ba76-7143b33bdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b57a3417-87d9-46a2-ba76-7143b33bdc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0a30bc1a-93da-4516-90c5-29b6b83069b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0a30bc1a-93da-4516-90c5-29b6b83069b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVest_d86e89e8-4c8e-4a6e-8f00-da8f5512b097" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVest"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVest_d86e89e8-4c8e-4a6e-8f00-da8f5512b097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_5ef45910-64a5-4178-b702-7ccdf12a07e8" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageExercisePrice"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVestWeightedAverageExercisePrice_5ef45910-64a5-4178-b702-7ccdf12a07e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_b396e825-f2ba-4233-bfd5-100ed94856bb" xlink:href="bsx-20221231.xsd#bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife_b396e825-f2ba-4233-bfd5-100ed94856bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_543d5119-db85-4eda-be57-2273318b1e0c" xlink:href="bsx-20221231.xsd#bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue_543d5119-db85-4eda-be57-2273318b1e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f5136f87-ba9b-4bdf-a63e-1ce2794f3ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f5136f87-ba9b-4bdf-a63e-1ce2794f3ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_366a1647-f518-40ce-9d8d-5d66690c567f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_366a1647-f518-40ce-9d8d-5d66690c567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_456daee6-48c4-408a-98c9-a852b8706153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_456daee6-48c4-408a-98c9-a852b8706153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3eda669e-72b7-4085-ba41-8dd5aa6272a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3eda669e-72b7-4085-ba41-8dd5aa6272a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bd129c63-31e9-4a70-a66f-b5e24877d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bd129c63-31e9-4a70-a66f-b5e24877d55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_88fb664e-7de7-4de8-ade4-27dce7d4f53a" xlink:href="bsx-20221231.xsd#bsx_RangeofthetargetnumberofmarketbasedDSUsawarded"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded_88fb664e-7de7-4de8-ade4-27dce7d4f53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7c34523c-e276-4218-8c9f-cf5a4659232e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7c34523c-e276-4218-8c9f-cf5a4659232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_8a3b4698-bf29-4e9a-bb68-a0cc1f1899e7" xlink:href="bsx-20221231.xsd#bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase_8a3b4698-bf29-4e9a-bb68-a0cc1f1899e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_a7c2f714-d78e-4773-9965-63f227546985" xlink:href="bsx-20221231.xsd#bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless_a7c2f714-d78e-4773-9965-63f227546985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32ce061e-ae57-4b1d-a224-cb1ecc884261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32ce061e-ae57-4b1d-a224-cb1ecc884261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards_146ba92b-e7d4-45f5-b74b-6874e28967dd" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCostNonVestedStockAwards"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCostNonVestedStockAwards_146ba92b-e7d4-45f5-b74b-6874e28967dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UnrecognizedCompensationCost_71f39183-65bf-4b10-8b01-e140eb58b203" xlink:href="bsx-20221231.xsd#bsx_UnrecognizedCompensationCost"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_UnrecognizedCompensationCost_71f39183-65bf-4b10-8b01-e140eb58b203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WeightedAverageRemainingVestingPeriod_3d9b38da-6021-4c3f-a22d-ec2327f5bb22" xlink:href="bsx-20221231.xsd#bsx_WeightedAverageRemainingVestingPeriod"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_WeightedAverageRemainingVestingPeriod_3d9b38da-6021-4c3f-a22d-ec2327f5bb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Annualweightedaverageforfeiturerate_3fcd8b51-6969-417e-8db0-71f7f77f5876" xlink:href="bsx-20221231.xsd#bsx_Annualweightedaverageforfeiturerate"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Annualweightedaverageforfeiturerate_3fcd8b51-6969-417e-8db0-71f7f77f5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_VotingPowerOfAllClassesOfStock_4d80af0a-edb3-40c7-9989-37c5a77b63a7" xlink:href="bsx-20221231.xsd#bsx_VotingPowerOfAllClassesOfStock"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_VotingPowerOfAllClassesOfStock_4d80af0a-edb3-40c7-9989-37c5a77b63a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_72d12017-22e9-455d-93ae-15dc498f4b19" xlink:href="bsx-20221231.xsd#bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant_72d12017-22e9-455d-93ae-15dc498f4b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Nonvestedstockawardsexerciseprice_aad88a86-df9f-4b2c-bf1c-f5090e3ae2e3" xlink:href="bsx-20221231.xsd#bsx_Nonvestedstockawardsexerciseprice"/>
    <link:presentationArc order="62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_Nonvestedstockawardsexerciseprice_aad88a86-df9f-4b2c-bf1c-f5090e3ae2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_e8a2bdbc-02dc-4e67-8e8e-680c5e267c7f" xlink:href="bsx-20221231.xsd#bsx_FairValueOfFreeCashFlowFcfPerformanceAwards"/>
    <link:presentationArc order="63" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards_e8a2bdbc-02dc-4e67-8e8e-680c5e267c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_0ec0596b-3e61-45a3-b549-0bf1f23ff34a" xlink:href="bsx-20221231.xsd#bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards"/>
    <link:presentationArc order="64" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards_0ec0596b-3e61-45a3-b549-0bf1f23ff34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_341e4d9e-e71b-496c-ba1e-98c712bde542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:presentationArc order="65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_341e4d9e-e71b-496c-ba1e-98c712bde542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdaa1771-94a4-453b-b30b-cc4c59cd1e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="66" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06962883-4b3f-497c-8612-f5c1c2d67bd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdaa1771-94a4-453b-b30b-cc4c59cd1e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#WeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5ca679f0-49b3-4030-84f9-aa5be32deb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ca679f0-49b3-4030-84f9-aa5be32deb33" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3082d503-3487-4ebf-82d7-e4a4ca8e1ca8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1dd17007-f9d2-47be-b736-bc6c45628925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1dd17007-f9d2-47be-b736-bc6c45628925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_15c95dd8-5d8c-4fb7-b361-de13a686a0b9" xlink:href="bsx-20221231.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_bsx_A550MCPSSeriesAMember_15c95dd8-5d8c-4fb7-b361-de13a686a0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_69ab5efb-2df2-431e-9245-ece5616f9bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd0802c1-bcb4-49df-a17a-9a0428220934" xlink:to="loc_us-gaap_StockCompensationPlanMember_69ab5efb-2df2-431e-9245-ece5616f9bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d9abe02-d25a-4db6-930a-973131372242" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3de03027-7c94-4b5d-91c6-9fb81eb964d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3de03027-7c94-4b5d-91c6-9fb81eb964d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd44ee05-61d9-4758-a4a7-fbbfd9d5c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd44ee05-61d9-4758-a4a7-fbbfd9d5c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb4b5d53-3f7a-41c3-95e2-46560e32be04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb4b5d53-3f7a-41c3-95e2-46560e32be04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84bba990-19d7-4419-a13e-ba2a6c94c28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_28eafbde-b688-41ad-808c-a74e5d131f44" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84bba990-19d7-4419-a13e-ba2a6c94c28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7f67ab30-7822-4462-9a30-479b9ef63b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7f67ab30-7822-4462-9a30-479b9ef63b50" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_218563d9-ca4c-4f57-9b29-075982e964c6" xlink:to="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_b28e8363-0daa-4f55-8404-9aa1817164b9" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_MedsurgMember_b28e8363-0daa-4f55-8404-9aa1817164b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_715d80b4-f7d0-4f5f-aae1-9eb6e9ee6d25" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_CardiovascularMember_715d80b4-f7d0-4f5f-aae1-9eb6e9ee6d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BSXReportableSegmentsMember_991659b3-09fb-4956-b2e6-ebbcd875204d" xlink:href="bsx-20221231.xsd#bsx_BSXReportableSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_BSXReportableSegmentsMember_991659b3-09fb-4956-b2e6-ebbcd875204d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_TotalAllocatedToReportableSegmentsMember_baab17e7-c1cc-4449-a0f8-bb2c8dce574e" xlink:href="bsx-20221231.xsd#bsx_TotalAllocatedToReportableSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_TotalAllocatedToReportableSegmentsMember_baab17e7-c1cc-4449-a0f8-bb2c8dce574e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_63dac6b9-3f81-4601-a1f4-45a2b00a16f6" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_63dac6b9-3f81-4601-a1f4-45a2b00a16f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember_84b88abf-0a79-4a72-816a-11b786f5246a" xlink:href="bsx-20221231.xsd#bsx_CorporateExpensesincludinghedgingactivitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_CorporateExpensesincludinghedgingactivitiesMember_84b88abf-0a79-4a72-816a-11b786f5246a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialChargesMember_be99c8f4-fde4-4c39-8886-5b5d42ee3af8" xlink:href="bsx-20221231.xsd#bsx_SpecialChargesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_SpecialChargesMember_be99c8f4-fde4-4c39-8886-5b5d42ee3af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_6ed1acdc-cbf1-40a9-a5f7-f330d93f329a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_us-gaap_CorporateMember_6ed1acdc-cbf1-40a9-a5f7-f330d93f329a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ConsolidatedBSXDomain_a0cc1816-71e5-4957-9a19-e597f4042bd8" xlink:href="bsx-20221231.xsd#bsx_ConsolidatedBSXDomain"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_ConsolidatedBSXDomain_a0cc1816-71e5-4957-9a19-e597f4042bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_59435d74-8005-4b06-ada5-fffa272e5514" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b22480b2-3a64-45d7-88bd-10eba073c632" xlink:to="loc_bsx_OtherMember_59435d74-8005-4b06-ada5-fffa272e5514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_744ed675-d5a7-42e9-800b-837b833eb802" xlink:to="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6bd84f39-a81c-4aa3-9f60-96c9b2b08ecc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_US_6bd84f39-a81c-4aa3-9f60-96c9b2b08ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_39cf74fc-9355-4faa-b02f-019b9c7a10e1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_IE_39cf74fc-9355-4faa-b02f-019b9c7a10e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherCountriesMember_272916ce-2533-448d-851c-63cc3d4181f0" xlink:href="bsx-20221231.xsd#bsx_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_bsx_OtherCountriesMember_272916ce-2533-448d-851c-63cc3d4181f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR_6e72a210-3cf6-43fc-9e66-441361a74493" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CR"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_866bcc80-74ab-4bed-8050-7ed71ce9c700" xlink:to="loc_country_CR_6e72a210-3cf6-43fc-9e66-441361a74493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a4cf6606-c273-4afa-b252-6686a2d52791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_342fce65-ddab-4a1f-9eb8-c7e8db3ad03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a4cf6606-c273-4afa-b252-6686a2d52791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dc5216e4-66ea-4a0a-9343-0f48aef1e776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1f6effad-4f99-411c-a133-cb1cfd1692f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dc5216e4-66ea-4a0a-9343-0f48aef1e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_942ad77d-f558-48a0-b903-5ac58066d5e6" xlink:to="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_37802df9-886c-4245-9352-231445e83d15" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2b6d722-6c42-4725-b014-ae999be463d3" xlink:to="loc_bsx_OtherMember_37802df9-886c-4245-9352-231445e83d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bdb85f4-9257-4bf4-a746-471e814f9c0f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_696126a9-f44c-4317-b066-de2bd1edde99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09f0f17a-f84a-4bcd-a5da-b55b4b1fbe66" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_696126a9-f44c-4317-b066-de2bd1edde99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76c03474-cd60-4549-a82a-850492864acc" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_0b2bcc2c-402b-4825-a1ca-153160d4d768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NumberOfReportableSegments_0b2bcc2c-402b-4825-a1ca-153160d4d768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1103e2e4-e041-40fc-90db-8fdd2324e152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1103e2e4-e041-40fc-90db-8fdd2324e152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeUnallocatedToSegment_069186dd-4620-43da-be4a-842f07f9fc79" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeUnallocatedToSegment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_OperatingIncomeUnallocatedToSegment_069186dd-4620-43da-be4a-842f07f9fc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0295d394-2dfc-46df-85d1-5e534141a498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_Depreciation_0295d394-2dfc-46df-85d1-5e534141a498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments_9706603a-0d80-40b1-893f-ef44356cac3a" xlink:href="bsx-20221231.xsd#bsx_OperatingIncomeLossAllocatedToReportableSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_OperatingIncomeLossAllocatedToReportableSegments_9706603a-0d80-40b1-893f-ef44356cac3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85ced95c-62eb-40d5-975c-a0fd410ff8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OperatingIncomeLoss_85ced95c-62eb-40d5-975c-a0fd410ff8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7e01f38c-c9cb-4118-a575-38497b3b82b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7e01f38c-c9cb-4118-a575-38497b3b82b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46be0954-e1cc-407b-b553-0ba70a01e36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46be0954-e1cc-407b-b553-0ba70a01e36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7963ae1c-38b8-44b0-a42e-06b6d96ad2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7963ae1c-38b8-44b0-a42e-06b6d96ad2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Segmentoperatingincomeaspercentageofnetsales_decad104-fc67-4e02-8e89-f83f6d4c1fd5" xlink:href="bsx-20221231.xsd#bsx_Segmentoperatingincomeaspercentageofnetsales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_Segmentoperatingincomeaspercentageofnetsales_decad104-fc67-4e02-8e89-f83f6d4c1fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_ffcd9a6b-6151-4fd3-af4c-7e4d2bddcb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OtherAssets_ffcd9a6b-6151-4fd3-af4c-7e4d2bddcb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6eb0f95b-eb28-42c2-8aae-4e5e8f96edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_Goodwill_6eb0f95b-eb28-42c2-8aae-4e5e8f96edd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2467746a-cd4e-49a8-8a9b-3f82378ff750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2467746a-cd4e-49a8-8a9b-3f82378ff750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_493cb87b-3bb4-445a-ac79-6073a354b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_493cb87b-3bb4-445a-ac79-6073a354b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_f5a50425-76e5-4ccd-8d43-947b7a8f4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_NoncurrentAssets_f5a50425-76e5-4ccd-8d43-947b7a8f4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4d44e0e8-e437-4b38-8f2a-bd3ae78832fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4d44e0e8-e437-4b38-8f2a-bd3ae78832fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_455ffffb-6f85-4a10-aee3-1d6f1e2c7432" xlink:href="bsx-20221231.xsd#bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement_455ffffb-6f85-4a10-aee3-1d6f1e2c7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_dd0f5d80-9be4-453c-81ac-018fdebb291e" xlink:href="bsx-20221231.xsd#bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73b9ae92-e48c-4581-9fc8-8e5ec7356eae" xlink:to="loc_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales_dd0f5d80-9be4-453c-81ac-018fdebb291e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/RevenueDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b7fc3fb-1553-4cac-b35f-437d3ad18bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b7fc3fb-1553-4cac-b35f-437d3ad18bfb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_89e20d46-ab39-4ac3-b144-56c116b74c1b" xlink:to="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_BSXReportableSegmentsMember_d98e83e1-b14d-42b9-b731-8e5a8b6ce997" xlink:href="bsx-20221231.xsd#bsx_BSXReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_BSXReportableSegmentsMember_d98e83e1-b14d-42b9-b731-8e5a8b6ce997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_MedsurgMember_5baa52fd-5c7d-4d74-947f-635a6a327bf4" xlink:href="bsx-20221231.xsd#bsx_MedsurgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_MedsurgMember_5baa52fd-5c7d-4d74-947f-635a6a327bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiovascularMember_fc741a28-8aa4-4e77-86e3-42eb9dbf4655" xlink:href="bsx-20221231.xsd#bsx_CardiovascularMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9b84817a-0b8f-4e58-ad17-67bf74a0c9d5" xlink:to="loc_bsx_CardiovascularMember_fc741a28-8aa4-4e77-86e3-42eb9dbf4655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28fd0470-ae09-4fed-afdc-6e31a1d5687b" xlink:to="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalEndoscopyEndoReportingUnitMember_8f29c465-e957-4a00-b024-d72b225bbef7" xlink:href="bsx-20221231.xsd#bsx_GlobalEndoscopyEndoReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalEndoscopyEndoReportingUnitMember_8f29c465-e957-4a00-b024-d72b225bbef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_fa8416f1-087e-4f40-919f-cb2933b81394" xlink:href="bsx-20221231.xsd#bsx_GlobalUrologyandPelvicHealthReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalUrologyandPelvicHealthReportingUnitMember_fa8416f1-087e-4f40-919f-cb2933b81394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalNeuromodulationNmReportingUnitMember_31ebe3ee-22c6-4a11-948f-a82892f68b34" xlink:href="bsx-20221231.xsd#bsx_GlobalNeuromodulationNmReportingUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalNeuromodulationNmReportingUnitMember_31ebe3ee-22c6-4a11-948f-a82892f68b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_795d7e12-fb39-4e80-a3fd-aa5d71504b4b" xlink:href="bsx-20221231.xsd#bsx_GlobalPeripheralInterventionsPiReportingUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalPeripheralInterventionsPiReportingUnitMember_795d7e12-fb39-4e80-a3fd-aa5d71504b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SpecialtyPharmaceuticalsMember_70ed4b08-983a-4e54-a965-f4f038d6990b" xlink:href="bsx-20221231.xsd#bsx_SpecialtyPharmaceuticalsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_SpecialtyPharmaceuticalsMember_70ed4b08-983a-4e54-a965-f4f038d6990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InterventionalCardiologyTherapiesMember_38a87554-b0a7-4ba4-a1dd-36f332b7df4c" xlink:href="bsx-20221231.xsd#bsx_InterventionalCardiologyTherapiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_InterventionalCardiologyTherapiesMember_38a87554-b0a7-4ba4-a1dd-36f332b7df4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_CardiacRhythmManagementMember_fb636467-a74e-4e97-8036-9f98212a301f" xlink:href="bsx-20221231.xsd#bsx_CardiacRhythmManagementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_CardiacRhythmManagementMember_fb636467-a74e-4e97-8036-9f98212a301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ElectrophysiologyEPMember_d77b27d9-987a-45d8-a4bf-7c840a85361a" xlink:href="bsx-20221231.xsd#bsx_ElectrophysiologyEPMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_ElectrophysiologyEPMember_d77b27d9-987a-45d8-a4bf-7c840a85361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_WatchmanMember_44230cd8-13e6-4466-a4d9-0a0169a95046" xlink:href="bsx-20221231.xsd#bsx_WatchmanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_WatchmanMember_44230cd8-13e6-4466-a4d9-0a0169a95046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_GlobalCardiologyReportingUnitMember_c14bc9c0-d86d-43ee-adb4-8320c479ca2f" xlink:href="bsx-20221231.xsd#bsx_GlobalCardiologyReportingUnitMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_GlobalCardiologyReportingUnitMember_c14bc9c0-d86d-43ee-adb4-8320c479ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherMember_e2e0e719-ff54-48ec-a696-d87e14c96f7d" xlink:href="bsx-20221231.xsd#bsx_OtherMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_240928fd-8b09-4ae3-b58f-5e4023277caf" xlink:to="loc_bsx_OtherMember_e2e0e719-ff54-48ec-a696-d87e14c96f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fc3b44f8-f450-4e62-89a0-70992cb40c1e" xlink:to="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d075727c-eb34-41c0-bd2b-5ffc466b7945" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_country_US_d075727c-eb34-41c0-bd2b-5ffc466b7945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3d0f56bb-c234-452f-80d5-7ed4e0e6bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_us-gaap_NonUsMember_3d0f56bb-c234-452f-80d5-7ed4e0e6bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_af100558-d3ea-42b8-a480-b3f94229d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_us-gaap_EMEAMember_af100558-d3ea-42b8-a480-b3f94229d9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_65956ed1-60e1-462f-8c66-c76a668e3057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_srt_AsiaPacificMember_65956ed1-60e1-462f-8c66-c76a668e3057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_LatinAmericaandCanadaMember_d8de7b89-af1e-4abd-8960-00d6b3e0ade5" xlink:href="bsx-20221231.xsd#bsx_LatinAmericaandCanadaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_LatinAmericaandCanadaMember_d8de7b89-af1e-4abd-8960-00d6b3e0ade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsMember_62f87830-7db5-4073-a56f-d1a2bf2ed8d4" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_EmergingMarketsMember_62f87830-7db5-4073-a56f-d1a2bf2ed8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_USExcludingOtherNetSalesMember_f232ecea-f8f1-4dc1-bda3-5b74d94897a7" xlink:href="bsx-20221231.xsd#bsx_USExcludingOtherNetSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_da561123-b736-4a96-ae04-52f8b85db196" xlink:to="loc_bsx_USExcludingOtherNetSalesMember_f232ecea-f8f1-4dc1-bda3-5b74d94897a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_452fa1a2-f20f-4592-b1ae-af23cbf954e5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_EmergingMarketsTotalNumberOfCountries_215c5bfc-2576-4458-9660-495f04f5157e" xlink:href="bsx-20221231.xsd#bsx_EmergingMarketsTotalNumberOfCountries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_bsx_EmergingMarketsTotalNumberOfCountries_215c5bfc-2576-4458-9660-495f04f5157e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc7de6d2-f5a6-4fb3-9efb-110f60e7fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc7de6d2-f5a6-4fb3-9efb-110f60e7fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7686ddd0-e43c-4b50-b7a0-70f679dab62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50222cb0-bf14-42b8-af80-b1c2f5a05eca" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7686ddd0-e43c-4b50-b7a0-70f679dab62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_3fc15aff-46c9-4ae1-8572-cb74ed6ce37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b7fc3fb-1553-4cac-b35f-437d3ad18bfb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_3fc15aff-46c9-4ae1-8572-cb74ed6ce37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e877b378-1dbd-452a-b434-d2357d61f532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_3fc15aff-46c9-4ae1-8572-cb74ed6ce37d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e877b378-1dbd-452a-b434-d2357d61f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_818b6d9c-6e11-408a-b13a-0b7570e79e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b7fc3fb-1553-4cac-b35f-437d3ad18bfb" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_818b6d9c-6e11-408a-b13a-0b7570e79e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ee17afc3-35aa-4f88-b287-2b741af5a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_818b6d9c-6e11-408a-b13a-0b7570e79e9d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ee17afc3-35aa-4f88-b287-2b741af5a2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4f47b971-5df2-49bc-8e3a-8e887cecf724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_818b6d9c-6e11-408a-b13a-0b7570e79e9d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4f47b971-5df2-49bc-8e3a-8e887cecf724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ChangesinOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f65af35f-07be-43ed-bd7e-54ab61d27bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f65af35f-07be-43ed-bd7e-54ab61d27bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_983d806b-91f6-48e5-b32c-ae6a592e6b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_983d806b-91f6-48e5-b32c-ae6a592e6b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_28a280fc-ffa8-4495-9410-c710e8e5e11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_28a280fc-ffa8-4495-9410-c710e8e5e11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcdcc1cb-b421-47b9-99a8-b475c7aa5026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcdcc1cb-b421-47b9-99a8-b475c7aa5026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b4539016-2302-448c-8e23-86c3becfb008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b4539016-2302-448c-8e23-86c3becfb008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_5fd01173-2530-4251-ac54-fc90033f95ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_5fd01173-2530-4251-ac54-fc90033f95ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_b54426d2-58a2-4db0-870f-f6538637e99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_b54426d2-58a2-4db0-870f-f6538637e99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5554be0-2244-4feb-8acf-29f99212bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5554be0-2244-4feb-8acf-29f99212bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_bc010a45-f302-40e2-b52f-4bf1e833cea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax_bc010a45-f302-40e2-b52f-4bf1e833cea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a23e8904-8d45-4414-96a9-0238929f30c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a23e8904-8d45-4414-96a9-0238929f30c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_76ec6e4a-e7dd-4476-a12b-590e90e0efde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_76ec6e4a-e7dd-4476-a12b-590e90e0efde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_49604a0e-e3aa-4e9d-b0bd-04aa2d751bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_49604a0e-e3aa-4e9d-b0bd-04aa2d751bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f883c05-4ebf-493b-a9f4-d6bdb9c9b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f883c05-4ebf-493b-a9f4-d6bdb9c9b74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ee7ff29d-5349-4960-8e7e-8182b2b452d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ee7ff29d-5349-4960-8e7e-8182b2b452d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5e84cb2d-f98a-4812-9fce-a57d9910c089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5e84cb2d-f98a-4812-9fce-a57d9910c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_53cd297f-1f57-424f-9cfd-2390a1895260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_69a08f67-7094-4e9b-af9e-3ae63c3ee316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_53cd297f-1f57-424f-9cfd-2390a1895260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#EmployeeRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e98618a4-18fc-4a8b-badc-3abeb59e89af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e98618a4-18fc-4a8b-badc-3abeb59e89af" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1ca836ed-3a32-4ba5-b9b6-c20236a2f833" xlink:to="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExecutiveRetirementPlanMember_8c6f83f8-0631-4e9e-9053-1a4f594c06bb" xlink:href="bsx-20221231.xsd#bsx_ExecutiveRetirementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_ExecutiveRetirementPlanMember_8c6f83f8-0631-4e9e-9053-1a4f594c06bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_InternationalRetirementPlansMember_425a9dff-83e5-48a6-8e08-db9a5e09917a" xlink:href="bsx-20221231.xsd#bsx_InternationalRetirementPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_InternationalRetirementPlansMember_425a9dff-83e5-48a6-8e08-db9a5e09917a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UKPlanMember_9a15ae85-20cb-4ceb-bdb8-e18ea963f115" xlink:href="bsx-20221231.xsd#bsx_UKPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_272ece1b-ba25-40d3-a79b-edc220759c49" xlink:to="loc_bsx_UKPlanMember_9a15ae85-20cb-4ceb-bdb8-e18ea963f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_187532e1-430e-46a6-a8a8-6a5ca9c846fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2808558d-ed42-432d-8dce-2077f464e739" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_187532e1-430e-46a6-a8a8-6a5ca9c846fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3e43aa90-03f4-4576-ba6a-b284da87bbff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_73e82411-3ee0-4071-91b2-a6afc3bd5eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0231b2a6-0ea9-4c2b-b2fa-c6afefe4587c" xlink:to="loc_us-gaap_OtherContractMember_73e82411-3ee0-4071-91b2-a6afc3bd5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d11b9a6-e105-4820-9062-28a380438dd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e384312-b89c-4cfd-bea2-f44c62625c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e384312-b89c-4cfd-bea2-f44c62625c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aae5ca3a-f2e3-4a09-bed3-d15f7d966c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aae5ca3a-f2e3-4a09-bed3-d15f7d966c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_404e6fb9-5af4-4da7-8015-c74ddca20a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f414c2f-2447-454d-9205-1d6cca1a6154" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_404e6fb9-5af4-4da7-8015-c74ddca20a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_801382f6-f4a9-4b92-afba-796adacff831" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8437bad2-adba-4331-9d2f-47dc51fa39d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_us-gaap_DomesticPlanMember_8437bad2-adba-4331-9d2f-47dc51fa39d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_UKPlanMember_9eaaf713-8b99-401c-b60f-ef87cea7ce30" xlink:href="bsx-20221231.xsd#bsx_UKPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_bsx_UKPlanMember_9eaaf713-8b99-401c-b60f-ef87cea7ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_OtherInternationalPlansMember_701b5639-1152-4cc7-90a2-42e39ab58f13" xlink:href="bsx-20221231.xsd#bsx_OtherInternationalPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1c8003c1-0b45-4a06-9fe7-a264d3eda17b" xlink:to="loc_bsx_OtherInternationalPlansMember_701b5639-1152-4cc7-90a2-42e39ab58f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a15fa8c7-55ea-48d6-90ab-9a2ca6f93a7e" xlink:to="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87b8345e-27b7-41c1-b8be-6ab5b5d49a31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:to="loc_srt_MaximumMember_87b8345e-27b7-41c1-b8be-6ab5b5d49a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08b65118-846e-483a-b0eb-5eb510cdd42d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_520c9bbd-b258-4b3a-bea2-a058a3b27db6" xlink:to="loc_srt_MinimumMember_08b65118-846e-483a-b0eb-5eb510cdd42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable_7ba955ba-6a97-456f-9dcc-346dd6f2de7b" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_1ad9d6ff-c293-45c6-be59-4736dc2f60a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_1ad9d6ff-c293-45c6-be59-4736dc2f60a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5aed4da8-681a-415c-ac23-9a3093689cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5aed4da8-681a-415c-ac23-9a3093689cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e8e5fba8-bbde-496f-a81f-a97b38722320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e8e5fba8-bbde-496f-a81f-a97b38722320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_222770e7-2d65-4728-ab16-f44bde22f4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_222770e7-2d65-4728-ab16-f44bde22f4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_30d5f383-8e6c-4586-ba32-c09ae0cab8c1" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets_30d5f383-8e6c-4586-ba32-c09ae0cab8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_24fa01f9-5a98-40d2-8318-267b20c56c86" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO_24fa01f9-5a98-40d2-8318-267b20c56c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_a09938b1-02a1-48d7-bdb1-b3763e7341b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_a09938b1-02a1-48d7-bdb1-b3763e7341b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_00da9f0c-1711-4d74-8567-f90e4ec1c9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_00da9f0c-1711-4d74-8567-f90e4ec1c9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d16e31ac-c113-45e8-ab4c-ca848ba5f320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d16e31ac-c113-45e8-ab4c-ca848ba5f320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_Pensionbenefitobligationbenefitspaid_0c6611c4-ce4d-4d9f-b0c2-ad5e056b4b4d" xlink:href="bsx-20221231.xsd#bsx_Pensionbenefitobligationbenefitspaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_Pensionbenefitobligationbenefitspaid_0c6611c4-ce4d-4d9f-b0c2-ad5e056b4b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0476c54f-edaa-456c-a5a7-bfcd73297c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0476c54f-edaa-456c-a5a7-bfcd73297c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_62f470f6-b5d7-45e4-b440-1e960aa7f073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_62f470f6-b5d7-45e4-b440-1e960aa7f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_69458d42-7a0e-462e-b1db-058a7cdbe652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_69458d42-7a0e-462e-b1db-058a7cdbe652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_354d4ce3-cee9-4098-bf74-2b51542675d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_354d4ce3-cee9-4098-bf74-2b51542675d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_c5188f55-2716-4f81-801c-2ae02f66cdb9" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO_c5188f55-2716-4f81-801c-2ae02f66cdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4b5daa69-a21b-49a1-a3c2-bd3b872f4968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4b5daa69-a21b-49a1-a3c2-bd3b872f4968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_91295eb2-4d8e-4588-a5c9-dd1b2310cc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_91295eb2-4d8e-4588-a5c9-dd1b2310cc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e8658b90-560d-4374-8cc3-81241d1b3983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e8658b90-560d-4374-8cc3-81241d1b3983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_1a731ce3-6d07-4bf9-95fe-34d857f4249f" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss_1a731ce3-6d07-4bf9-95fe-34d857f4249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f25c920f-8631-4461-96f8-dd6eaa3611b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f25c920f-8631-4461-96f8-dd6eaa3611b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c3baa149-6fab-42fe-81c3-9d2fcebfa4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c3baa149-6fab-42fe-81c3-9d2fcebfa4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_0c74cf01-e136-4af1-9124-b6d59ee7a7dc" xlink:href="bsx-20221231.xsd#bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn_0c74cf01-e136-4af1-9124-b6d59ee7a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_ExpenseRelatedToMatchingContributions_a2286654-9149-4045-bf37-18e140a1a157" xlink:href="bsx-20221231.xsd#bsx_ExpenseRelatedToMatchingContributions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_bsx_ExpenseRelatedToMatchingContributions_a2286654-9149-4045-bf37-18e140a1a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_fd7eed49-a011-4bee-99ca-eff4fda1315e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_fd7eed49-a011-4bee-99ca-eff4fda1315e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2b7fac85-16d7-40ef-978e-17bf752b117b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2b7fac85-16d7-40ef-978e-17bf752b117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ac212511-0a8e-4e15-bbd5-fd8a50ed6723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ac212511-0a8e-4e15-bbd5-fd8a50ed6723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_0e1edd35-406c-4e15-9689-153dda502af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_0e1edd35-406c-4e15-9689-153dda502af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a09321-a65d-4ebc-93a8-481b6ff4f84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a09321-a65d-4ebc-93a8-481b6ff4f84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_c78e6c03-e702-4fe4-86d7-1a7d1a44d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_c78e6c03-e702-4fe4-86d7-1a7d1a44d20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a70b06ce-6e48-40b5-9a64-86463855fb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a70b06ce-6e48-40b5-9a64-86463855fb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e866eb9c-fe2d-44b9-bbe3-871f82574add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_e5adee7f-bc81-4e5b-b011-bc31067b0e16" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e866eb9c-fe2d-44b9-bbe3-871f82574add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/ScheduleIIDetails" xlink:type="simple" xlink:href="bsx-20221231.xsd#ScheduleIIDetails"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/ScheduleIIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3f7bdce3-fcb9-43f7-9025-b863ed7bccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3f7bdce3-fcb9-43f7-9025-b863ed7bccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_d94aad90-f969-45aa-9410-c697e0aa4c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal_d94aad90-f969-45aa-9410-c697e0aa4c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b7ac3d19-1030-405f-a34c-0ca8979ed338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b7ac3d19-1030-405f-a34c-0ca8979ed338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2cae11cb-ab74-4b78-a223-91d7e0f462e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2cae11cb-ab74-4b78-a223-91d7e0f462e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_15ddd7e5-a4d9-4a52-911a-83bf10c09a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_15ddd7e5-a4d9-4a52-911a-83bf10c09a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_51138407-919f-410b-b808-17eee0892059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67e4245f-d3a0-46de-9a15-1778e71faed4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_51138407-919f-410b-b808-17eee0892059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
M6]^Z=>O8L6-145$C1HS@+#=HT,#1T;%7KUY3IT[=NG7KP8,'D5U$6=^=#.1L
M_#OB2\P8" ]]L.>>/7O6J%'#Q<6%DULR\66K*5.F8,]Q">HV<Z 4',V:-6.V
M25',U>S9LYDW=3_AY?)+T-_<W%SBJ6_?OG@<RLS(R,A]^_8570;\/73H4+S)
MY<N7?]ZL"'3 *0\8,(!UB/_U\O+"/A\Y<D3=K]3P1NO6K6O5JE6C1HUFS9JE
M;BXG<!08S&^__18#B[H5K=8Q5J&AH:;H*383C^SKZTN>Z]2IT]BQ8YD9]G;V
M[-F+%R_B9 M>Y,&#!Z3#,V?.H" A(2%8;.KH7AHX]5@Y!&7-FC5H*+EVX\:-
MNW?O)L.94KY@#.WL[)*2DC")ZC9CD$H'#ASXZ:>?4BJA\NIFTV"H(T>.9"=$
M!8FYH$0*;@ TO7'CQBU;MB138K&I#$A4I IU/^&E4[[UEP7&JB-V1X\>_<TW
MWZQ8L0(SHNI#08=24('NV+%#U:3 4I\W;U[GSIT17_H0G6W:M,$ZJ?N9 Y86
MJ_TWO_D-XR%/E,!M60.7+EUBPJGNL;I%7Z<,IWXOUO=TT=/Y\^<'!P>3C3@+
M2Y<N90]H&;::TT'61%@YLW/FS*$/?W J%R]>S"9+EBSA#V6KR9,GAX6%H<L(
MM-%["E4@^AA#3G<)5&_OWKU]^O2AWEJX<"%SHFXVQL.'#RD@&#PEUQMOO%&Y
M<F5LQ-V[=]7]2@?&HGGSYH3WKEV[%*?">J$L4/<3+$&YU%^6"A7NLF7+_/W]
ML3_X(&ROSL\*LK*RIDV;AIEEH:(.ZN;GS_%QK&U6>T!  .8+0:>6M+>WYV]U
M5S.!Z4-*T)T2+'AK@!IBW+AQU-K:MY<=.W9LPX8-Q3TN^B,Z3#C2@)!-G#@1
MY47<W=S<NG?O3E'"V4'F.-'\3742$1&!2;QQXT8)[&I1LK.S8V)B"!X4L+CW
M /#6.'U$K5*E2LQ&<0_YN>:9:HL6+2+84/\WWWRS8L6*%!.FU VF0UV"SC9M
MVK1]^_9*4N1-63(<=0D&+)0%Y4Q_T5 4$]> _U(^X^-O=:>?(,A8S\0?EE,[
MX%A"QX\?]_+R8@U$1T<K+U+ UJM7S\"U>[. )=?W660)R,O+0_@X%E-J[5*"
MZI$\!@\>K'U_549&!G6NN3ZT>58$[7-7>I2[CRET2J">]">)?OWUUS5JU!@[
M=JS.Q&\ G')24A)1U[IU:]P]"0 ))M-LV[:MN",Q0('F)I.Z=>L2_[&QL2P<
MQHP7H6A0=Q4L1_G0WT>/'K%@#A\^C%?MT*$#RV;8L&'X+U1,G^BP;D^>/$GE
M-7[\>.TKVFR("W!U=>W=N_?MV[>5G=#?R<D)DU6L&I9 9V_:;_%R((N0,] "
M:G8S:KI.\%.3)DUB?C"YJFEGMDE:\^?/-Z^#*R/R\_,Y$(0)]31\G5 ;#C S
M,Q/U;-2HT=2I4TV_4XTX0033T]/QN1A2"HAUZ];%Q<5A[?'1.W;LT!?))2,W
M-[=QX\;5JE5;L& !^9[%0E51LKL[A+*C'.AO5E86D8K5=7!PZ-*EB_*-*>+8
M\%(GVQ/6'3MVU+XJPDI@)\[.SD%!044_+PX(".!=BOO(+K*"GY\?CD;=4/9P
M(,HM'QPIKLKPA)0>9'?HT*$'#AS0_NH@OGCY\N4E^ S4(JQ>O?JKK[[BK)'4
MU6W&V+ES)^F?O,Y.T#AULQX*--_W9?907E]?W_W[]Z>EI:'=/CX^-C8V[+-8
M*=\H'!<U2OWZ]:E(SI\_OVG3)B*$#&V=W\=[E;%>_25D,:3X%+P&-1IUXOKU
MZQ,3$TVY;KMKURZV(N&GI*2HFGB%H/?P\-BZ=6OAM_MY+W;.2C#]VQ8%FN\[
M??/--_CQ>O7JS9LW3]VCC$$$9\^>W:!! UM;VY?P%;+(R$B6M,XWXHQ,GCR9
M&2CK!& 6\.EDK+Y]^VI?JC6 $HT$8<N6+;MV[4J :2<A?2AU@[N[^\2)$ZFZ
MSIPYH[S.E-:N77O(D"'F%=\3)TX@]'7KUL7=$^&QL;'*5Y#.GCVK[BI8&BO5
MW[5KUXX?/QY#BDDAZ"ELB_4$AL# 0"<GI\)O]!>"$:!\9B6P#(J^CE_@]>[=
MNU^\>+'HZ_JX??MV1$0$^O[YYY__^M>__NRSSXIUT=\LH'>5*E6J5:M665_+
M+M#<TDO5O&;-&G6;IA7[YN7EI?V-,BN$<L'1T1$=/';LF+I-/WEY>03,P($#
MR= (=W)RLKJ'?A!9=)#Y(5D6C6%VB"R2OXLU$J-P.A#T:M6J^?O[DRQW[-@Q
M9<H48K6\E":O&M:EOT>.'%FY<B4.A01.=!))V[=O5W<R2&9F)M'FX. 0'Q]?
M]/6,C S$%^6E"E,UW;]_G[71L6-'4S24^&9SRCHW-S=75U?>Z(,//NC3IX]Y
M/[PS"F+WR2>?4&!RL"8:]A*#AQHT:-"$"1.80W6;YD-SI%G[<IRU<??N71(5
MIXR\?N[<.76S?JARID^?7KUZ];???IN -#'-$%3*O8S$QH@1([9LV5*TE2EU
M<7&AJ5@C,0IO&A<75Z=.G3%CQAP]>I1XGC%CAOQLG353$OW-TZ!^M13@.BGH
ME#L3.W?NC'4-#0TM0=#<N7-GVK1I]O;V&.>B%T:4I[VT:]<N*"A(>[>$+)M0
MH&DW%85ZD\H18]ZK5Z].G3J%A(0</'APV+!AC1HU(F%H;UM&Q3A"SZ)MW[X]
M17186)BZV=P@6TP=]DWG57Z.<>[<N:SV\^?/J]NLB?3T],6+%^-\\9O:9TH?
M.3DY6-TN7;J\\<8;K[WV&KDV+2U-W4D+YH1*G[?#0!!RS)[J/CGE.^X]>O0P
MU[TB"O?NW<.[M&G39M2H42DI*1B7X.!@_+ZZGV!-%$-_"2-"!RVC8D("3(]C
M?3QZ]"@K*PL5H_:O7;MVBQ8ML+T$?6YN;@FNTC*>;[_]MEFS9@1WH?@J3X1@
M_VCZG#ESM*]6HZI4E/WZ]3-P'9P5E9V='1X>SE)D1:&\J!(ZR#BK5JV*)])Y
M(RK%)JI4^EDJRI,G3S U' N%\.K5J\W[N:$V!9IGSZ,C.A,,[TY5R[1<OGQ9
MN]5ZX.R0=VUM;?W\_+0#0"<<VJU;M^;/GX]*LB'E/-6&44] "!'/WWWW'>'4
MN'%CDM;>O7M5<<4>5JQ886=G1S0:WENQ8%<(+KMMVK0I\8E+0/<QX"581\++
MI!CZR^E$VI8M6W;JU"G\;RG]'9$1&1G9M6O7MFW;^OO[4]0CZZ9<6],';H+D
MCX,N^CT+WH(EY.GI2<+0^<TB%I4^ ZM0H'F:(GMHWKPYA23.0MD_KP<&!K(X
M<>[J;320#/KW[V_&>\*4-=:A0X<J5:I0%)M^_:?$\([CQHU#1W1.'=,R=>I4
MT^\!L!31T=&NKJ[4"B9>_>>H8V-CG9V=>_?N/7OV;"PSY0Y)6N<D%*)<$F K
M2A.$_N3)DSIOI&'GOKZ^!)+9G[.S?/GRO_WM;^^\\PX6@07%4GH)$2*4$E/U
MEY6&'2"?HY*$6HF=5X'F1P<F3YZ,)\4YX@*V;=M6>$6XQ+ '5@C&L+!,9H2L
M'&4)Z;O$<>/&#0\/#U12WX-(2#/*3C!0FS9M*OIIW<Z=.]W<W#"A^BS&FC5K
M4/9APX:9\MM%3 L+4E\.4$#ING?O7KER99V?HI0%J:FI2(_.QW4R@/'CQ^.S
MU U6QKY]^QP=':FK##R,N) "S6- $&OEV3UD5B3[\.'#39HTX42K>VLHT%Q^
MI.3OTZ</MG?BQ(F;-V^^<.&"NI\&0D5YR(Z^@"R$M,VT8PZT[Y[4"<,(#@[^
MXQ__^-O?_I:M3 DYP1HPKK]$ !4-/H@X4[>9#/%QY<H54C3QAZ(1INP3O\"+
MZJ[%AVCS]O9NUJQ9X>,(6#.\"TN"=S3P X@L%314^S8)!;QS0$" \EAQ[=^A
M&3UZ].#!@PVL:@K FC5K8LF-WN>4EI;&5/!>N%IUFP:2RN+%BTE75+6D$P.3
MIB^1E( "S><Y5 _:$T@%0-9D)-K38E7$Q<41&$PLOD'=I@6>%PG#G!*<2%CA
M)',>/__\<Y6B,3F7+EU:NG0IZV*@!K(1_S7\>W>XC:^__IJXTI>S%0CC,6/&
MV-G9D?R,+CI&0H"M6K6J18L65:M6]?'QL?Z*1"C$N/ZN7+FR8\>.1D5$'V3R
MY.1D8F[&C!E4LKA4E"LI*<E<#@[;2/1_]MEG+)L"S=,=457\"&_$FZI[%R$S
M,Q,!94BJ#U*4*]>LI6[=NN%>==[=A2W"%)-"]'T(<_SX\6K5JE$,,GN&CY2>
M++:__.4O.!?M[U)G9V>C"].G3T?'WW__?8Y4YXT6^_?O9P4R9K(.@S?P6;;I
MW+MW#\7'!JKVEI&1@3Q-FC1)Y^T0U@.Y 1N+F35\YR(9=,^>/>1I*B%/3T_M
M^[BQSPT;-BQ\7@?A@29R6HDWY9[%08,&;=FRQ?!9!O3:UM:6X#?0DSX)"0GL
M5OF)6"R%@0N;1 +K")N\<.%"Q/=?__J7N[O[)1/N,RO0/$SNYLV;S QK4U_6
M%UX"QO67%8A.Z5SV!J"T3TE)24Q,1!>H_MJV;=NE2Q<$PG#F+RYH!,80F^GG
MYT>D7KQX<<*$"4@5$6SXXC(A2'79O'ESUEOA>F!LF'UVB"ENU:H5UD;GY1IE
M6Q:VOINNL(<,X#__^4^#!@T,?_Z+M>S9L^<?_O '>J*MER]?+FQBPY,G3\Z=
M.]?%Q:5KUZZ<@J9-F_K[^Q<J/L?.:-$"2N.1(T>V;MV:)(2.XX!T#KNXG#Y]
MNG___JI[794;"3"545%1.H_=2D!?2$7.SLYHJ[KM)_")QXX=6[%BQ?#APY6O
MI6E_'8YC9#_UZ]<GWS 5^.@-&S:0LSD73'A86)B)DT WYHU58.#'+EDRY/OJ
MU:L[.3E1==6I4X?\H1T_CQ\_)LY_^.$'<@"!RC#('.0 .C-4U0>#Y$X.BOY4
MA(R?V8B/CR=;K%NW#K//)LHS*/0-"7/#%!'ME#L,3]TLE!KC^LOR1HR^__Y[
M=8,6RBT!Y%5DEVBFU**&(C,C9%30-.F\3Z#$$%O8%L:&^A <)'.BEG@B86A'
MK8H"S95]ZCM%JI3G2Z"G*)V-C<V($2-8:?HN7[ MIJ-ERY8Z#X<%0-G.J!@&
M?A8_HB^X>5/4OW+ERMB< P<.,'OT1%X)>HZ%::?V1T$6+5IT]^[=O+P\7"=N
M"U'F8/EWP8(%+%14WL'!@:R#ZT<.,&MKUZXM?.H\,I2C@0EA_K'\F%;.!?MG
M 9,@#7Q^0@+#_Q9^Y*V<7.6K!%ARG<=N)11H?E^#V,.B:A<H!9K'K9%(F$^F
ME_.(;'&P^DXW$<+9Q%W6J%&#8&83*CFBA5DUW4SPIB@X1D3?A1/E3KY*E2J]
M^>:;R#1ZVKAQ8S91QL_82.JL+,X[ZDFJKEV[-B-GE9'".1S.+RZ8FFS)DB5I
M:6E$"/]26A'2%$_X>A+&%U]\P28<"W^WU$#PU*I5*R @0#M$.=WLEB-MI$'Y
MT@I.V?!%2*&X&-=?EBLZA7LUX"@Y?T0D21*;AGXI"9Q08(7CT5CVZ@U*C6(H
M4%LB%?%B;%A.ED=X>+C.YTQJ$Q@8B/?$%#"\R,A(#I!A$]!$K>'*ND!S"Q&U
MI+I!@W(;!LZ1W:*#^FZ4+M!\J8R=U*U;=_[\^8IB8FDI/UDM[=JU0_N0X+-G
MSQ;F$CP+92EKADW^^]__LDI9$G%Q<0PX*RL+041,F83.G3NC^ZFIJ5@MG!V#
M0<<I>VFRM[=GBI@T"FI\%G4#POW"L(K &L89%5IR3!#_Q?7OW[_?+)]OE!W,
M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
M%04!);0,7*Y$9PE=3NN''W[XWGOO??#!!_R-PR4D.+^S9LW"Y"KJ23W$68N)
MB6%4A2M+23E(]C__^<\O-)#4E1^[Z].G3U!0$#O'%7'NB$\VI+CA6)B$#ATZ
M:%\S*- \K8)9(M+(-R@[(<IB(9:Z=>MF].*A8#K&]?>YYBM K#U.//4.WG#F
MS)DL>U[<NG4K7H^BB7/C[NZN?$MJV;)EV,.#!P^6Z74 ?!DY&>M'5%%;\=9$
M4E)2DCX7HXV?GQ\%._F?R"9;8(*(Z4NF?7Q&K%.3JALT3<P,(F7TLG6!YK:V
M3S_]]!__^ <C9_:86U8+?S P\@$RH?(:)$+T@CZ8=)P1DZ]](8[5A6=AARR_
M>O7JO?ONNQ4J5/CHHX^08':+)2=SL"&K$2O]_OOO-VG2Q, E([2&A8=J4*L2
M )S<8GWUUB(4:!XZ2NV%22_Z.FF,%(((*C&,F)+_#"NO"FV3:#J$*.94Y],S
M"B'A4761=*M5J\99>_WUU_D#225KHJ&4.U%14;1R^G3>?8]IB(^/5W[:>?SX
M\9QHHHC.NW?OYCQJ/^F?U]D_M:GJ]>>:(YTV;1IIX'>_^QT1PL+'*+S]]MN,
MZJVWWF(P13\RII;""1%=C$U[5()A3-+?YYJ%S5*<,F4*%:B/CP]"@",@T%F9
MN##$:\R8,533)-B74)FBDL0',D>0H6(44"0 "G!U/_T0*,HOQ[ 30I :OUA/
M)SE__KR^"VL$(DY39Y.*,V?.,'),*)8'H]&K5R\L.4Y'W_T8SS4&F7#'O!A(
M,]>N76.M(C1X7LY76%@8)XZEBZ 7WIS'\/@;&?KDDT\XH=K9@C=B&)Q?*F+&
MQBR1G$Q\.(9E08;P^,@6\U"@ :-':8\D$:MD(.IQHS<5F!V2 4E1WWUI12&T
MR!#D2Q\-WM[>A#HIL.BU 0/DY.2@X_JJKJ(0_P0JTZ(]*B8-%_755U]5J5*%
MR20R"2>6/#K+0FO:M"G%&<F8Z%5^G83_4E%1MYT\>5*U*\$PINKO<\U9N7W[
M-B:"<\,*YU],!*I'/6+T\U8S@NF;/'ERITZ=\( 8;1(^ 5K<QT0\UT0JK@0M
M,T4KM=&W%44?,:JO507'PN )W]#04 ,?[Q0717=(A,H?ZN:?4'YV#"-/44DF
M0Z/7KU^_:M6JY<N74^(@WU0&S+/RM# TVL"NK ?4AR(=:S]\^' .A!#%%I!I
M<&TH;XE/=RE)24FAX#!\6RX)@\1 )#!L#&9F9B995CF)ZJYF@K7,>^D432PV
MF1O9Q1"0N1\\>*#$$A.(8\ %XYV5KZ70)R0D!!5FVF?/GJW>D6"08NBO-?#L
MV3,$"U-6O7IUE(Z4B_M6=[(<!.C_-)3=FC$OJ!6FNVW;M@X.#HZ.COS1NG5K
M_L7CH!?(<7IZ.D88'XW]>9E9ML0P\PR5\=>K5\_&QJ9]^_9D:+R>9<\(]01U
M!IE ^_H57C4U-143@YD@MK$UJ@Y6!=/HXN)"/83L;MNVK?!*":_WU%"FGSK^
M\BAG^HL+(\W^_O>_KUBQXD<??41U9DJI]3+!/^("++O:BP4FZ_KUZW@<K.+"
MA0MC8F*P:5E962A%X<5Z^F"6R\L=2(\>/<+3*<_?H&)3O)NZT\NE0%/1X\'Y
ME[E%I"B_LC0D)"10R/?NW9N:D@QGEGL'RQ2B)3L[FY!0W5O"4;1HT2(N+L[B
MLUV.*$_Z>^G2)2+XC3?>^-6O?E6E2A6,FQ5^_XHEI/V%L7(!*PJITG>#%*+V
M$C[9_P6#YG[WW7?]^_>G;ALU:A36H4>/'L.&#2/G7;AP@;J^6!<#K0VT."0D
MA()CTZ9-HK^F4Y[T=^G2I1]__'&%"A6J5Z\>'AZN?=^,(%@SB-2N7;O6K%D3
M'Q^_=^_>@P</'CAPP/#7\\H19)&Z=>O.F#%#W2#HI]SH+]ZA:M6J%2M6='!P
MB(Z.UKZ?1A#*!:APR9ZP:OTX.3E1H8K_-9WRH;\%FJ^K<6K]_?UQ$'*"!<$*
MF3=OGJ.CHRE/.Q(4RH?^*ERY<L7ZKTX(PBO+N7/GVK9MZ^[N+I<*3*0\Z:\@
M"-;,K5NW7%U=.W;LJ//9\X(VHK^"()B'IT^?;MRXL7OW[OOV[5.W";H0_14$
MP6P\>/!@\.#!LV;-4C<(NA#]%03!;!04%$R8, $+K&X0="'Z*PB"V7CV[%E8
M6)B=G5WAPYX$ XC^"H)@-O"_Z]>OM[&Q*?K+,H(^1'\%03 G^?GY;FYN?GY^
MHK]&$?T5!,',+%JTR-?7M[@_&OD*(OHK"(*924A(\/;VEB>T&$7T5Q $,W/P
MX,$^??IH_ZZ*B3QZ] CMOGSY\KESYU)34R]HX(]SNN!=KEZ]6DZ?IR'Z*PB"
MF4E+2W-Q<5FT:)'V[T^KN'OW[I4K5_;LV1,='1T1$8%QWKESY]:M6]>L6;-R
MY<K(R,@-&S:LU1 5%<7?&U^$5]:O7\\?L;&QFS=OWK1I$W_0<\>.'>BU@9_I
MLA)$?P5!,#/9V=E]^_9U=75]\.!!T=?S\_,QMIC6(T>.'#IT*#$Q,28F9OGR
MY<J/D;=KUZYITZ9MV[9E0P\/C^'#AT^;-FWFS)GC- 0'!\^:-6NV%J&AH;2R
MB9V='=NV:=.F8\>. P<.9$/D&&5/24DY=NP8<IR1D6%M/]TM^BL(@OF)CX]'
M4J]>O?KDR9.\O#P4^<2)$P@B,LKK-C8VS9HUL[>WY^_ITZ=OV[;MY,F3Z#(2
MF9651><[=^[DYN;>OW\?!;^G0?E;&W9.*YNPK?(D^\.'#R/K?GY^:'&#!@V:
M-&G2JE6KWKU[3YHT"7=,3^4G2*Q!BT5_!4$P/Q<O7G1W=P\/#]^R90O"U[ES
M9P<'!VSIPH4+=^[<B40F)R=C@9'+&S=NF/VYA@\?/KQV[1HN>^_>O;P11IMA
MA(6%>7M[MV_?OE&C1FYN;OP7O;;L37*BOX(@F)F<G)PY<^;4J%'#UM8V("!@
M]>K5JU:M6K)D"3XW-375(D^GQ".?/W\^(2%AV;)EY("(B(@%"Q8@P<H/YJY8
ML0*]?OE:+/HK"()YP/-NW[X=49L[=ZZ-C4W5JE5=7%Q07C17W=729&=G[]JU
M:_GRY1,F3%BT:!&#W*"!M+%CQXZ7]EM\HK^"()2*O+R\??OVK5V[-B0D9-*D
M2;Z^OH,U].[=&YNI[FV5[-FS9^K4J9Z>GD.&# D/#X^)B4&%=^[<6=8/,A;]
M%02A)/SXXX]4]"C7RI4KO;R\FC1IXNSL3%&O5/%/GCP9.G1H>?PY3I27D3LZ
M.@8$!&S9LN74J5/7KU\OHUO91'\%02@>*&]N;BXFT<W-K6;-FNW:M0L-#<4J
M4M07ZI1R"S#E_(N;E@,>/WY\Y\Z=C(R,0X<.+5RX<-2H43-GSDQ.3N;0\O/S
MS?NE:M%?01"*P=6K5[_YYILV;=KT[]\_.#@X.CKZ\.'#"):J&R_VZ-%CUZY=
MJM?+$1AY5/CTZ=,G3IQ(3$P,#P^/C8T]=^Z<NE\I$/T5!,$DT",T:.3(D?WZ
M]9LT:=+V[=LQN>I./[%[]VYW=_<S9\ZH&\HG5ZY<.7+DB'+'L1EODQ#]%03!
M"#=OWL3GSIT[-R@H",\;$1%Q_?IU=:<7H6#'_Y;X$1#6"<J;G9VM?K44B/X*
M@J 7Y=Z&)4N6C!DS9NS8L:BP*>[OZ=.G2Y<N[=:MVX4+%]1M0A%$?P5!T U>
M+RHJJG___AX>'N'AX:9;OYR<G*Y=N[JZNIJ^R:N)Z*\@"&HPN0\>/!@_?GS/
MGCT# P.1T6)]1?C2I4M.3DYL:PW/6+!F1'\%05"S=^]>7U_?/GWZ'#QX,#T]
M7=ULC,3$Q)8M6ZY>O=KH\R=?<41_!4%X@:=/GXX9,\;/SV_W[MWJ-M,8-VY<
MFS9M,C,SU0W"BXC^"H+P,[C=S9LWSY@QX]"A0^HVTTA-375V=@X,##3E2MTK
MCNBO( @_$QH:.GKTZ'OW[JD;3 /-G3-G3KMV[1(3$]5M@A:BOX(@_!^YN;EN
M;FXA(2$EMJZW;MUR=W</"@I2-PBZ$/T5!.'_@^8F)25UZ=)E]>K5)=/?Z]>O
M>WEY>7IZ7KUZ5=TFZ$+T5Q"$_R,S,W/ @ &1D9'%U5_Z'SAP8,2($35JU-BS
M9X^Z6="#Z*\@"#^S:M6JD)"0_?OWFR[!J/:L6;/L[>WKU*DS=>I4\SXA[)>-
MZ*\@"#^3GIX>%Q>'C"+$L;&QR@]HJOKDY^??N'%CW[Y]])D]>W9P<'"G3IW<
MW-Q6K%B1D9&AZBP80/17$ 0UJ.KHT:-#0T.___[[Y.3DI*2DK5NW1D='Q\3$
M;-Z\F3_"P\/GS)DS=NQ8;V]O'Q^?>?/FG3Y]VG3++"B(_@J"H 8E??KTZ:%#
MA\+"PCP]/5NW;FUO;__%%U_8VMJV:M7*R<G)P\-CQHP9B8F)&&'YDEN)$?T5
M!$$W".O]^_<S,S/3TM(N7[Y\2<.U:]?2T].SLK)HDH]Z2XGHKR (@F40_14$
M0; ,HK^"( B60?17$ 3!,HC^"H(@6 ;17T$0!,L@^BL(@F 91'\%01 L@^BO
M( B"91#]%01!L RBOX(@")9!]%<0!,$RB/X*@B!8!M%?01 $RR#Z*PB"8!E$
M?P5!$"R#Z*\@"()E$/T5!$&P#**_@B (ED'T5Q $P3*(_@J"(%@&T5]!$ 3+
M(/HK"()@&41_!4$0+(/HKR (@F40_14$0; ,HK^"( B60?17$ 3!,HC^"H(@
86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>image_02b.jpg
<TEXT>
begin 644 image_02b.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>image_0c.jpg
<TEXT>
begin 644 image_0c.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@  !K8   &*" (   #&Z.9R   +04E$051X7NW8
M,0$   B ,/N7UM\*;"<1F 4     PN8'     *#$(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @[0!>9R:^^\[&
-80    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>image_1b.jpg
<TEXT>
begin 644 image_1b.jpg
MB5!.1PT*&@H    -24A$4@  !K8   &*" (   #&Z.9R   +04E$051X7NW8
M,0$   B ,/N7UM\*;"<1F 4     PN8'     *#$(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @[0!>9R:^^\[&
-80    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>image_1c.jpg
<TEXT>
begin 644 image_1c.jpg
MB5!.1PT*&@H    -24A$4@  !K8   &*" (   #&Z.9R   +04E$051X7NW8
M,0$   B ,/N7UM\*;"<1F 4     PN8'     *#$(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @[0!>9R:^^\[&
-80    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>image_0d.jpg
<TEXT>
begin 644 image_0d.jpg
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MY&3R1'F/_O7KUV,J8V-C$6+E%0Z0"A<-4F9>'X@@*N#DY$2.3$A(*-D\/-7
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M+4F"4Z#M9Y]K'@Q"E'[YY9><\3ESYA"?AN^+8&]XP#5KUD1$1!P]>I0S8F*
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86(;_!Q_6I[A(.M G     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>image_1d.jpg
<TEXT>
begin 644 image_1d.jpg
MB5!.1PT*&@H    -24A$4@  !K8   &*" (   #&Z.9R   +04E$051X7NW8
M,0$   B ,/N7UM\*;"<1F 4     PN8'     *#$(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+
M$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$
M  #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!
M(,TB!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2
M+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB
M!    ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M    2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!
M ( TBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(
M2+,( 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( T
MBQ      TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,(
M 0   "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
M    TBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0
M "#-(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ
MTBQ"     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-
M(@0   " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M     $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0
M  " -(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"
M $BS" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   "
M-(L0     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS
M" $    @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M     -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $
M   @S2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0
M -(L0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @
MS2($    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L
M0@    !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M    @#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@
M  !(LP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @S2($
M@#2+$     #2+$(     2+,( 0   "#-(@0   " -(L0     -(L0@    !(
MLP@!    (,TB!    ( TBQ      TBQ"     $BS" $    @[0!>9R:^^\[&
-80    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>bsx-20221231_g1.jpg
<TEXT>
begin 644 bsx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_X2Z*17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C Q.C$Q(# X.C0Q.C4R   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,3HQ,2 P.#HS-CHT,  R,#(S.C Q.C$Q(# X.C,V.C0P      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  '-T         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ \@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M'EMB=MMYOS,.,$X!(Y/H>E9^F^.[[4[U;2/2;:*4Q2/B6Z<?,I<8QY61G9W
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M],MK>UM5*Q(2%!8GL: +E% !10 44 %% !10 44 %% !10 44 %% !10 44
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M=($_N0C<?^^B/Y 5)%8V\3[PF^3^_(=S?F: +-% !10 44 %% !10 44 %%
M!10 44 %% %=["SD,A>T@8R'<Y:,'<>.3Z]!^0J&;2]/D>W+V-JWEL0F85.W
MOQQQR ?PH MF&)AAHT/.>5%5SI6G]K&W!]5B /;N/H/RH 8=)MCG#W:Y[+=R
M@#Z -Q3C8L"2E[=)DDXWAL=?[P/K^@H 7[',>NHW1&.F(Q_):JRZ''+>0W#W
M5VQB[&=QGIZ$#G SQ0!>ALK6W_U-M%'[J@!/X_@*GH ** "B@ HH ** "B@
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M_?!_PH 7S5]'_P"^#_A1YJ^C_P#?!_PH /-7T?\ [X/^%'FKZ/\ ]\'_  H
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M %74()[FU\NVG,$@D1MP[@,"1]" 1^-8=OH^OI<V\DVJ*\:!1(HD?DAN>W/
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M&SC\<?@: -.B@ HH ** "B@!" P((!!X(-+0 44 %% !10 44 %% !10 44
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MI_SUH C_ .$:T["@"8!<@8F;ID''7U _*FIX9L(I \1G3.=RB4X;.?\ 'M0
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M* &#Q7IK)O7[05/0^0W)]/\ /I6CI^HP:G TUONV*Y3YQ@\>W^- %NB@ HH
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M%!04%!04%!3_P  1" CM"7 # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*3<* <T +1110 44E)N'
M_P!>@!U%)NHH 6BD+8]_I1N'2@!:*0'/2@M@XH 6BDS1NYQS^5 "T4F[-% "
MT4F:* %HHI"P% "T4W<*=0 44A;;1F@!:*2C- "T44A.* %HI-PHH 6BDS2;
M@* '44W=[4H.>E "T44E "T4FX#KQ]:3=]: '44E&Z@!:*3</6B@!:*0MBDW
M"@!U%(#FEH ***3- "T4A8#K1N% "T4E+0 44A8+UHSF@!:*2C=B@!:*2EH
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MBD!SR*"<4 +12;O8T9S0 M%%% !112;NU "T4F:* %HI,T4 +12%L>_THS0
MM%)10 M%(6 __510 M%)10 M%)N I-W?!_*@!U%-W"EH 6BD+ 4GF#)'>@!U
M%-W4N: %HI*,T +124;NU "T4FX4*VX9'2@!:*0MCW^E)N&<=30 ZBDW"C=0
M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXVL?AOX"\1^+-2R=/T/3KC49U4@%DBC9RHSW.W ]S7YY?\$3OB=_:7P_\?\
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MMZ9K]&_#^KKKF@Z;J(C,(O;:.X$9.2H= V,XYQFOYE/BO_R5+QC_ -AF\_\
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MO(B2#V+1OCV&: /ZB%Z54U>\&FZ;=WA3S!;PO,4SC.T$X_2O!/V"?CH/C_\
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MX1? ?XF:)XZ\,W/B1];TAI6MUO[^.6$F2)XFW*(E)^61N_6@#IOVSOVQ;/\
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MT%:>"O%DE_'I$VG75TS:=,L4N^-05P65AW]* /MUO^"X6A_]$DO_ /P>1_\
MQBOT0^$?C]/BI\+?"7C.*R?3XO$&EVVIK:-()# )HUD"%@!NQNQD"OD0_P#!
M&_X#$?\ '[XP'_<4A_\ C%?3U]=>'/V6?V?FE>2X;POX&T$)'YSAIY(;>$*B
M9X!=MJJ.@)8=* *7[0?[4'P[_9C\.QZMXZUL64EP&%EIELGG7MZR]1%$.H&1
MEF(49&6&17P+XT_X+?*NH3Q^$OA8TEBN?*NM:U79(_/5HHXR%^@D-?GQ\5_B
MAXS_ &I?C'=:_JOG:MXDU^\CMK+3[?+",,VR"UA7^Z"P4#J223DL37Z:_ /_
M ((U^#-/\+V=]\5]7U#6O$<Z!YM,TBX%O9VI.#Y>\*7E8=V!5>3@<!B <=X-
M_P""WSF\AC\5?"P"S/\ K;G1M5S(O/58I(P#QV+CZU]\_L^?M4?#C]IK0YM0
M\#:XMY<VX5KS2[I/)O+3/3S(R>1VWJ64]F-?(_QN_P""-OP\U[P[>3_#/5]2
M\,^)8U9[>VU*Y-U8S-R0CDKYJ9. '#-CNK5^6WA'Q;XY_96^-"ZC8M-H'C+P
MQJ#V]S;2'@LC%98)0#AXVP5(S@@Y!Z&@#^B[XN_$"+X5_"WQ;XSELVU&+P_I
M5SJC6:/Y;3"&-I-@8@[2=N,X./2OSQ'_  7#T0_\TDO_ /P>Q_\ QBON#P=X
M@\-_M@?LS6U_F6+P_P"-]#DMKR.VD'FVYD1HKB(.0?GC?S$SCJN:^<_^'-_P
M&/)O/&'_ (-(?_C% 'E?_#\/0_\ HD>H?^#Q/_C%(?\ @N)H8_YI)?\ _@\C
M_P#C%?$7[>WP#\,_LU_M"7G@OPG)?RZ1#IUK=*VI3+++OD4ELLJJ,<#M7U1^
MP5_P3L^%7[2W[/EGXU\6W'B&+6)=0N;5ETZ^CBBV1L ORM$QSSZT >_?LX_\
M%6-)_:*^-7AKX>VWPYO-#GUIYD6_DU5)UB\N"2;)01 G(C(ZCK7WFIP,5\G?
M!?\ X)E_"+X#_$S1/'7AFY\2/K>D-*UNM_?QRPDR1/$VY1$I/RR-WZU]674\
M-E:RSW$B0P1*SO)(0%10"22?0#^5 'R7^V7_ ,%$/#_[(OC30_#$WABX\5ZK
MJ%B;^>.WOEMOLL1<I'G*,26*R>F-HZYK(_9%_P""EWAW]JKXH2>!QX2N/".I
M-8R7EI+<:@MRMTT97?$ $4AMA9_HC?C^1W[3'Q4U#]IC]I/Q5XGLDFO?[9U3
M[)I%LHRYMU(AM4"]F*!,C^\Q/>L?X=>+?$'[,?Q^TK6I+:2UU_P?K6V\LB<$
MM%(4G@)]&42(?8F@#^EM>E>7_M+?'6Q_9L^#NM_$+4M+N-8L]+>W1[.U=4D?
MS9TA&&;C@R _A7>^%_$>G^,/#>E:[I-PMWI>IVL5[:7"])(I$#HWXJ17R]_P
M53_Y,=\??]=M-_\ 3A;T <O^S7_P5"\+_M)_&/1/A[IO@C5M'O-46X=+R[N8
MGC3RH))B"J\\B/'XU]MKQ7X'?\$K?^3X_ '_ %QU+_T@N*_?(4 +1110 5Y'
M^U-\?H/V9/@UJOQ N=&DU^'3YK>$V,5P(&?S95C!WE6QC=GIVKUROC__ (*P
M?\F3^+O^OW3O_2N.@#P!?^"X6B=!\(]0/_<<C_\ C%'_  _#T/\ Z))?_P#@
M]C_^,5\-_L(_ CPW^T?^T1I?@CQ6]_'HUU974[MITRQ2AHXBRX9E8=1Z5^G'
M_#G#X# _\?GC#CM_:D7_ ,8H X;PQ_P6U\!7UXL?B#X<^(-*MF;!FL+J"\*C
MU*MY7\Z^[?A#\:/!OQV\&6_BGP/K<.NZ-,YB,T:LC12  M'(C ,C@,I*D9P0
M>A!/Y*_M]_\ !-?1/V:/AS'X_P# NNZGJ.B17<=KJ&G:P8Y)8/,)6.5)$1 5
MW;5*LN?G!SV&1_P1\^*6I^%?VG)?!Z7#G1_%6FSI-;$G;]HMT:>.4#U")*OT
MD.><4 ?JO^U9^T-;_LP_!V_\?7.BR^((;6Y@MC8PW @9O-<(#O*MC&<]*^(5
M_P""X6B'I\(]0)_[#D?_ ,8KW3_@K5_R9?X@_P"PII__ */%?E/^PC\"/#?[
M1_[1&E^"/%;WT>C75E=3NVG3+%+NCB++AF5AU'I0!]R?\/Q-#'_-(]0_\'D?
M_P 8H_X?B:'_ -$CU#_P>1__ !BO5?\ AS?\!3_R^>,/_!I%_P#&*3_AS?\
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M<:S+J-W-&^R6(QD(8PJNB'Y7QM)VBOT,7O\ 6@!U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK<*IZRW$GEH&]U6W)'M*?6OC[XK:->?LP?M=:];Z?&UO-X0\5&\T]<E<PQW
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M/8>@K/\ @U^SC\-?V>[34(/A[X3L_#BZA)YMU)$\DTTN/N@RRNS[!V0':,\
M9- 'XC:#^W=^TO\ !OQ8#J7C3Q ]Y"P>?2?%<33I(N?NM',-R@XQE"K=<$5^
MO_[%?[86A_M=?#635H+==(\4:4R0:UHX;<(9&!*RQD]8GVMMSR"K*<XR?%_^
M"O\ \+=%\3?LR/XREL[<>(/#>HVOV>^VJ)3!-+Y3PYQEE+2*^WL4SZY^,?\
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M\$\?^3+?A5_V#&_]'RU^//\ P4EM6L_VW/BBC+L+75K)C_?LH&!_\>K]@?\
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M%>/^3R=3_P"P-8?^@&OW27[M?A;_ ,%>/^3R=3_[ UA_Z : /O\ _P""0_\
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M@:P_] -??_\ P2'_ .3-]._[#-__ .AK7P!_P5X_Y/)U/_L#6'_H!K[_ /\
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M6>T7./-BB9O)DQG)213G& R\U_0UX%U[P_XH\&Z)JGA2XM+KPY=VD<NG2V(
MA,!4;-@ X &!C QC! QB@#Y5_P""M7_)E_B#_L)Z?_Z/%?CU^S#^T%J'[,7Q
M:L?'NEZ3;:U=VMO/;K9W<C)&PE0J22O/&:_83_@K3_R9;X@_["FGG_R.*_+7
M_@GS\&?"OQ\_:4TGP?XSL9=1T&XL;N>6WAN)("6CB+(=R$'J/6@#Z8_X?=^.
M!_S37P^?^WZ>C_A]UXX;G_A6OA__ ,#9_P#"OKX_\$H?V;2>?"&H?^#N[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IK+FG44 ?FW_P5T_9'U#X@:#I_P 7
M/"6G->ZGH-J;77+2W0M++9*2R3JHY/E$ON[[&!Z(:^)_V&_V[-:_9!UO4+"Y
MT^3Q%X%U:02WNEQR!)8)@-OVB GC=M !4X#!5R5V@U^_3*3].]?%'Q^_X)/_
M  D^,>K7>MZ!+>?#O7+EB\O]D(DEC(YR2[6S8VGVC=%]B: .2\2_\%H/@]8^
M'Y;C1?#7BW5=8,>Z&QNK:"VB\S'"R2^<VT9[JK_2ORK^.7QI\5?M.?%_4O%^
MN*USJ^J2K!::?:AG6"(';%;0KR2!G'0EF8DY+&OT&M_^"&[_ &S%Q\9@]FNT
M_N_#1$C?WAS=D+]>>O2OJW]F7_@G-\*?V9]4AUZQMKGQ5XNB_P!5K6ME7:V)
MX)@B4!(SC^+#..0& )% &K^P#^S?<?LT_LYZ/H6JPK#XHU21M7UE>"8[B0*%
MAR/^><:1H>2-P8CK7S%_P5T_9%U/QQ8V7QA\)6+7U]H]G]CUZQMX]TKVJEFC
MN0!RWE[G#]]NT\!#7Z7*,"D9=_!Y'O0!_/9^QC^VUXG_ &0?$U\]E:+K_A+5
M&4ZEH4TOE;F7A9HGP?+D R,X(8<$9"E?T=C_ ."S'P0?2EN)-%\91W@CW&S_
M +/MR=V/NAO/V]>_IZ5U'Q[_ ."4WP>^,VK7.MZ0+WX?ZU<%GE;0PALY9#_&
MUNPP#GM&R Y.<GFOGAO^"&LWV@*/C0GD;<^9_P (N=X;/ V_;,$8[Y_"@#Y7
M_;:_;S\2?M=:I9Z=%8GPWX&TV8S6>CK-YDDTN"HGG<8!?!.U0,(&898DL?J_
M_@D/^R-J>DZA-\;?%-@]G%);26?ANWN8R))%< 2W@!Y"E=T:'^(/(>FTM[G\
M"?\ @DM\'_A/J-MJ_B-[WXBZO;D/&NKA8[!&!^\+9/O?25G7IQQFOMF.%(8T
MCC541 %55&  .P':@#XX_P""M7_)E_B ?]1/3_\ T>*^(?\ @BOQ^U-XI_[$
MRZ_]+K&OU0_:>_9[T_\ :=^$M]X#U/5KG1;.ZN(+@W=I&KR*8G#@ -QSBO'?
MV1_^"=/AW]D?XD:EXOTCQ?JFO7-[I,NDM;7MO%&BH\T,I<%><Y@ _P"!&@#X
M,_X+)_#7_A%_VE-)\5PP[;7Q1HL;R2$??N;<F%Q^$7V?\Z\6_P"">/PW'Q._
M;#^'5C)'YMGIM\=9N3V5;56F3/L9$C7_ ($*_8[]L+]B_P /?MAZ+X;LM:UF
M\T"XT.XFFM[RRA21BLJJ'0ANQ*1G_@ KDOV1?^"=GA?]D?QYJGBS2_$VH^(M
M0O=.;356^@CC6%&DCD9EV]R8E'TS0!\[?\%PN?"GPD/_ $^ZE_Z+MZM_\$0.
M/ /Q3S_T$[+_ -%25]3_ +8O[%^B_MB:?X8M-8\17WAY="EN)8VL84D,OFJ@
M(;=TQY8_.I?V._V-='_8\T3Q'INC^(K[Q"FMW$-Q(]]"D9C,:LH "GG.XT ?
ME_\ \%@AG]L!_P#L7['^<M?=/_!'K_DS]/\ L8+[^45:_P"U5_P35\-?M4?%
M0^-]5\9:KH=U]AAL?LEG;1R1[8RQ#9;G)W?I7LW[*O[-NF_LK?"L>!]*UBZU
MRU%]-??:KR-8WW2!05PO&!M_6@#V*FM[].].ILBEE8*=K8P#Z4 ?AS_P5L^.
M!^)W[2Q\+65SYNC>";;^SU"G*&\DQ)<N/<'RHS[PU[1^P5_P36^'WQJ_9\T_
MQS\1K75)-1UF[GDL$LKUK=4M$(C4D ')9TE;/]UEKT;7_P#@C%X7\4:]J.LZ
MG\4O$-WJ>HW,EY=3O909EED8N['GNS$U]^^!?!NG?#OP5H/A;2(_*TO1;&'3
M[5#U$<2!%SZG"C)[F@#Y'_X=#_L]?] [Q!_X.'_^)KX@_P""EW["_AC]EW3_
M  =XE\ PW\?AO499=/U!+VX,YBN@-\1#$='02#'_ $R]Z_;2O+_VDO@%HG[3
M'PDU;P'KL\ME:WK12Q7UNH:6VEC<,KH#QG 93ZAB* /SG_X(M_'3[#KWBWX3
M:C<XBOD_MO24=O\ EL@5+A!ZED$3 =A$YKX _:$_Y+Y\2SC'_%3:F>G_ $]2
M5^NGP6_X).^'_@;\5/#7CO0_B3KKZEHEVMPD,EG"$F4@K)$Q'\+HSJ<<X:L7
MQS_P1N\&^.O&OB#Q)<?$/7+:?6-1N-1DACLX2L;2R-(5!/) +8_"@#[6^">6
M^#/@'T_L#3__ $FCKYG_ ."F'['W_#1GPI'B7P[9B;X@>%XGFM$B7]Y?VOWI
M;7C[S<;XQ@_-N4?ZPFOK?P;X<C\'^$=$T&&9KB+2[&"Q29P TBQ1J@8@="=M
M:S*3B@#^;']F?X_:W^S1\9-$\<:.&F%K)Y%_8[MJWMHY FA;W(&X$\*ZHW\(
M%?T7> ?'6B_$KP3HOBOP]>K?Z'J]JEY:W"\;D< X(_A8<@J>000>17Q=\9O^
M"1/P]^+'Q.UWQA9^)]4\*KK%P;N;2[&VB>!)FYD9-W0,V6V] 6.,# 'T#^R;
M^S'_ ,,I^!+WPA9^,=1\4Z(]T;NSAU*!$-D6'[U4*G[K'#;>@8L?XC0!_/I\
M6!_Q=+QC_P!AF\_]'O7[E?MB? 6\_:'_ &)4T'2(3=>(=-T^RUG2H%Y,L\,(
MS&H[L\3S(H[LZUXYXF_X(P^#/$WB35M9E^(VO0S:A=S7;1K9PD*TCEB <Y[U
M^@VAZ0NAZ+IVFQR&2.SMX[<.W!8(H4'CZ4 ?S>_LY_'KQ%^R]\8-+\:Z)#YM
MU8EK:^TVX)1;JW8XE@<X)7. 0<':RJ<'&#^KOAW_ (+)?!#4-#BN=4TSQ3H^
MI"-?-L!8Q3C>>&"2++AE'JVW(/3/%>@?M*?\$T?A/^T9K-SXB:*Z\'^*[AM]
MQJFB[%2Z?NTT+ HS'J67:Q/4FOENZ_X(<W/V]1;?&.$V1SEI?#A$B#G P+K#
M<8YR/I0!\W_M^?MV_P##7FL:+IFB:-/HG@S0Y))K6.^8&YNYW 7S90I*H HV
MJH)QN8ECD ?6G_!%WX(:MX=\+^,/B=JEL]K::]Y6F:2)(RIFBB9FFF![H7*H
M".\3UU_P@_X(T_#+P5JEMJ/C7Q)JGCZ6!]XLA"NGV4OH)$5GD(]A* >X/2OO
MC1]%L?#^E6FF:;9V^GZ=9Q+;VUK:Q".*&-0%5%4 !0   !Z4 ?&'_!4;]DG4
MOVAOA78^)_"EF;WQEX2\Z6.RB3=+?V;@&6% .6D4JKHO.?G4<N*_)W]E_P#:
M=\7?LE_$S_A)?#T:7$,B?9-4T6\)2*]A#9V/W1U(RK@94YX(+ _T>;3G/3VK
MY8_:._X)N_"']HS5I]>N[*Z\)^*9V+SZMX?9(C<L?XIHF5D<^K *Y[M0!Y9X
M>_X+.?!B^T:"?5_#_B[2=2*_OK2.T@N$5O\ 9D\Y=P]R%/7BOC']N'_@I1JW
M[4&D-X-\*Z3/X6\!&59;F.Z=6O-292&3S=N51%8 ^6I;) )8X 'NUU_P0V8W
M2_9_C*HMF9L^;X9RZ+VZ7?S'H/X?Z5ZQ\&O^"./PL\!ZC!J/C36]3^(5U"=P
MLY$%C8.>N7B1FD;D=#+M.2"#0!\L?\$HOV1M3^(GQ2L?BSK]@UOX/\,3&73F
MN(SC4;\ A#'GJL)^<L/XU0#/S;?TX_;5_P"31_BZ/^I9OAU_Z9&O7=&T6Q\.
MZ3::7I5E;Z;IMG$L%M9VD:Q10QJ,*BJ!A5 XP/2N>^+GPYMOBY\+_%'@J\O)
M;"UU[3IM.ENH%#/$LBE2R@\$C- 'X4?\$RQ_QG%\,#_TVOC_ .2%S7[]ZIIM
MIK6FW6G7]M'>6-W"UO<6TZADEC<%61@>H()!'<&OB?\ 9Z_X)6>%?V>OC%X=
M^(6G^.=8U>^T5IGCL[JTA2.4R020G)7D8$A/X5]P[3T[4 ?SO_MN?LQ7G[+/
MQRU+P_'%(_A:_+7^A7DF2)+5F/[MF/5XS\C=SA6P PKI?^"77'[=7PS[_P#(
M3_\ 39=U^QG[6/[)7A;]KCP)9^'_ !%<W&EWFGW0NM/U:S1&GMB>)$&X<HZ\
M%?54/517B7[.7_!+/PO^SG\9O#OQ$T_QSK&L7VC?:/+L[JUB2.3S;>6 Y(Y&
M!*6^HH ^WA2TB\4M #6!_#WK\*O^"EW[(>J? 7XQ:IXQTJQ:7P%XJNY+VWN(
M(SY=C=.=TML^.%^8LR= 5.!]QJ_=>LCQ9X1T;QUX>OM"\0Z9:ZSHU]'Y5S8W
ML0EBE7K@J1C@X(]" >U 'XT?L3_\%1-0_9Z\*VG@3Q[I%YXI\'V9*V%Y8.OV
M_3XR<F(*Y"RH#G:&92N< E0JK]5>+?\ @LY\']+T6>;P_P"&_%.MZJ ?(M+B
MWAM86;!^_+YCE5SW5&//2J?Q6_X(O_#?Q5J$][X(\6:MX&,S[OL4\ U*UB&?
MNQAGCD Q_>D:O/M,_P""'(6\W:A\8S):K)S';>'-KR)_O&Z(4_@W2@#\_OCQ
M\<_&G[5GQ8E\3>(%:\U6]9+/3M)L49H[:+)$5O G)/+'U+,Q)Y-?M)_P3E_9
M5N?V8O@;LUZ&./QIXDE34=611\ULH3$-J3W,:EB?]N1P,@ G=_9M_8"^$W[,
MEU'JN@Z7/K7BE%('B#7)%GN8\C!$0"JD7!(RJAB"06.:^D!Q0!^2_P#P7#'_
M !5/PE_Z\]2_]#MZZG_@AW_R*_Q;_P"OS3?_ $"XKZB_;&_84T+]L34O"]YK
M/B?4?#[:#%<11I8P1R"42M&26W=,>6/SK2_8[_8OT;]CO3?%%GHWB._\0KKT
MMO+*]]"D9B\I9  H7KGS#^5 'T72T@XI: "BBB@#\]/^"N5U\5O OA7PGXY^
M'WB[Q-X>T*W>33]<30M2FM4C+,IMYF\M@1EBZ%O4QCN*\"_X)X_\%(M.^%-G
MK7A'XRZ]K%[IU[=_;['Q)>//J+VSE%5X91EY-AV*5V@X8OD?-D?KIXG\,Z7X
MS\/ZCH>MV,&J:/J,#VMW97*;XYHV!#*P]"#7YZ?$K_@BGX&\1:Q<WG@SQYJO
MA&UF8NFGWMDNI10Y/W48R1OMQP-S,?4F@#QG_@IA_P % /!GQV\#:?\ #GX:
MW=QJ^CM=I?:IK,EK);Q2^7N$<$:R!7(W'<S%0/E4#.3CH_\ @B_\ ]277/$_
MQ?U&-H-,^R/H.E+)&0+AV>.2>92?X4\M8\C()=QU0UW_ ,*_^"*O@SPYK4-]
MXZ\=ZAXPM8V63^S-/L1IT3D<E))/,D=E/3Y#&?<5^A_AOPSI?@_0-/T30["W
MTK2;"%;>UL[2,)%%&HPJJH["@#37IC^=+2*,4M !7Y6?\%S.?^%)_P#<;_\
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M1@_[6ZO4?^'0_P"SV.FG>(.O_07?_P")_P XK[2AA2WB2*-%CC0;551@ #H
M*?0!^"/_  4>_9&TG]E/XIZ'#X5CO!X-UW3_ #K0WDIE:.XC;;/%OXSP8G_[
M:X[5]B_\$F?CF?%_[._C;X::A<[M0\*QSW5BC-RUC<*[$#UV3>82>WFH*^M?
MVN/V2_#W[77@73/#VN:C<Z+-IM\+VUU*RC5Y8_D9'CPW&U@PS[JOI7C?[./_
M  3&T7]FOXC'Q9H?Q#UJ^::PN-.N[&XM(DCN(94QM)4Y&UPCCW04 ?BC\/\
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M(U/4A00,^U 'JO\ P2C^''_" _L>:%?RQ>5>>)KVZUJ4,.=I?R8_P,<",/\
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MS,"NWKG=W]* /J$\U^!/_!3;X,_\*A_:R\32VT'DZ1XH5?$%GA?EW3$B=?\
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M?V?/^"S.D6WABTTOXO>'M3DUJUB$9UW08XI4O"!C?)"S)Y;'OL+ D\*HX'Z
M?&S]GOP'^T-X6&@^//#]OK=K&2]O,28[BU<C&^*53N0].AP<#((XKX.\9_\
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M;_9'_P""=/AW]DCXD:EXPTCQ?JFOW-]I,NDM;7MO'&JH\T,I<%><Y@ _X$:
M/KH4M(HQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%)NYQ2;ATH =124M !1110 4
M444 %%%% !1110 4444 %%%% !1129YQWH 6BF[A2[J %HI*6@ HHHH ****
M "BD+8HH 6BBB@ HHHH **** "BD9MM)N'3D&@!U%4K?6K"ZNGMH+VWFN$SN
MACE5G7!P<@'-6]PSB@!U%(K;J6@ HI-P%&Z@!:*0'<,TM !1110 444A8+UH
M 6BDS1N% "T5%<7,5I"\LTBQ1(-S.[!0!ZDGI26UY!>6Z3V\J3PORLD3!E/T
M(H FHI <TM !1110 444A8+C- "T56O-1M=-C$EW<Q6L9;:'F<(">3C)[\'\
MJGWB@!U%(#FEH **** "BBB@ HHHH **** "BBB@ HHHH ***0MB@!:*;N]C
M1N!Q[T .HI =U+0 4444 %%%% !1110 44A;%&[C- "T4WS!QWS2T +1110
M4444 %%%)N&['?K0 M%5;S4[33HEEN[F&UC8[0\[A%)],FI8;F*YB26*198W
M&5="""#W!% $M%)NI-PH =15>UO[>_C,EM/'<1ABA>%PXR.HR#U%3;A0 ZBD
MS2;N^.* '44TL!2@YH 6BBD+!>O% "T4F:"V* %HIN\9QWI=U "T4W>.O:@.
M#[4 .HIN\<]:56W<CI0 M%%(6QC@T +129S2T %%%% !12%@*0,#0 ZBDI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_C[Q9\9/!7[-?PHU6;1=<\2B.76-4M)#')'%(6VQ;U.Y$6.-Y9-O)3:!P6!
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MM=\7ZSKWB32M0\)ZS83VEOH]Y%%;SLN90)E>)RPS&HP"."?P /<O$6J7B_\
M!:SPK9+=SBS;37+6_FMY9_XDURW*YQU -?I*+B-9%B+CS&!94S@D#&3C\1^8
M]:_(+]KN/QU<_P#!533K+X;Z@ND^,[^SM;"QU!T#K:">Q>*:;!!QLB>5L@$C
M&1SBO9O'7_!'G1+[PC>:Q8_$_P 8:M\3XK=IXM6U2>-[>XNE!8?($,J M@9\
MUBN<_-TH _1S<*3>./>OAO\ X).?M!>*/C5\$]>TGQ?J5QK6J^%M02VBU&[<
MO/+;2)NC65B2SLK+(-QYQM';->2_$OQ9X^_X*%?M:>(_A)X/\7ZAX+^%'@PR
M1:Q>6#E'O9(W\N1B%*F0M+N2-68H%0R8S\I /T\29),A6#%3M."#@^AIX.:_
M-_XF?\$M8_@UX/OO&?P*^(?C#1_'>C0M?)%?7T12_,8+&/=%''M=AD#=N4]"
M "37T;^P'^T_/^U+\!+37M6"KXJTJY;2]9\M J2SJJLLR@< .CJV!P&W < 4
M ?2E?,7_  4-_:8U3]E_]G^;7/#WECQ/J]ZFD:;-+&)$MG='=YRIX)5(VV@Y
M&]DR&&17TX#GI7SO^W9^R])^U=\#9_#&GW<-AXAT^Z34])GNB1"9T1T,<A&2
M%=9&&<'!VG!Q0!\A_"__ ()4WWQV\):5X]^,_P 4?$6H>)]=M8[\VULRRO:I
M*H=4>6;>6;##(55"G@9 R>3^//[)GQ'_ ."<VBP_%;X-_$G5K[PU8W4,>JZ3
MJ  "+(X56F0$1S1,Y1"-JLI=2/[RV?"'[=W[0G[%^@Z=X*^,'PEGUO1M&BCL
M+759#):LT* *@%VJR0S[5  (&XX^8YR:^B/AI_P5"_9^^.T,7AKQ;%-X6>_9
M8Y+/Q;:12:=*V0R@R@O&%! ^:4( 0.G% 'TS^SS\7K3X]?!7PCX^M(1:QZW9
M+/+; Y$,RL8YD![A9$< ]Q@U\*?MG>)/$/[1W[<7A#]FFY\2WOA'X?S0)/J1
ML9/+?4'-N]RP8]'&V-8T5@5#DMAC@5^D.C:?8:3IL%KI=M;6=@H+0PV<:QQ
M,=QVJO R23[Y)K\GO^"JOB_P!XA^-'A*X^'&LZC>_'3P_.MI<1>'X6F6)(RT
ML8:13D7$3Y(5 Q +!]NT"@#/_:N^!Z?\$RO&WP\^(WP<\4:S%'J5S):ZAI&J
M70D6[6+8Y1RBKOB<,5((RIVL""1M_7NUF^T6\<H5H]ZAMD@PRY&<'W%?D]^Q
M/H<G_!0CXP2?$;XS^.(O$>J>"6B-AX'2W$,6SADN&484Q&0?,%!+,JAR%VJW
MZQQ3QRJQ217"L5)4YP0<$'WS0!^37_!1?PO<_$O_ (*(?##P(=;O]&T_Q!I6
MF6$LUG*0T0EO;I6<+G!/U]!7J-Q_P1OTIH6^S_&?Q7%.1Q)) C#MG(#C^=>:
M_M]^,M'^'G_!3CX.^)_$-W_9VAZ3I^DWE[=&)Y/*B2^NBS;4!8X Z*":^N?^
M'HO[,8_YJ9_Y0-3_ /D:@#XJ^-7P_P#C=_P2]U+PQXO\+?$^_P#&G@"]OUM)
M]-U'S$@,VUG,,L#.Z@2(DF)(R&&T], G]7/ASXVL/B3X!\.>+=+W?V=KFGV^
MI6XD^\$EC5U!]P&P?I7Y4_M[_MA:)^VQ_P (?\&/@QI^I>)I;K6X[I]0:U:!
M;B54>...-'PX0"5W=W5 H0'IN(_4?X,^ 1\*_A'X,\&B5+AM!T>TTUYXP=LK
MQ0JCR#/]Y@6_&@#L2VVOSJ_X*V>+]?O=6^"OPV\+ZQ>:5JWB35Y69K&=XWR6
MBMX0=C D%IWX[[:_11CCGVK\E/V\O'GBFZ_X*2?#V'PCX7D\8:[X7L[--*T5
MPPBN+XF2Y#D@C"KYD+,<@ 1<E0,T >AG_@D;XV_Z.>\0 >^D3_\ RPKZE_8_
M_9<UC]EWPWXATS6/B+??$275+N.YCNKZU>!K953:4 :>7(/7J/I7S#XY\8?\
M% OAII-UXWO;7PIKVE6\7VFY\/:5;0W!MXQRWRJ%E? Z[)'..1T-?3G[%O[8
M&B_M>?#>?6+:R71?$>ES+;:OHXE\P0NRY25&P,QOAMN><JPYQD@'S'^T=\3_
M (@_M<_M:2?LY?#3Q1<>#_">A1--XGUO3V9)9"H7SP2I#%$9TB$>5#2,VX[0
M,<[\:OV ?&/[)/@B^^*WP3^*GBB36?#D1U#5+'4)E(NH$&Z9P% 5PH!9HI%8
M%5;G( -W_@EJI\2_M2_M+>*+K,U\=0*&=_O8GO;EV'XF%?R%?HUXYTA-?\$^
M(-+F3S(K[3KBV=&Z,KQLI'ZT >;?LD?'Z#]ICX"^'/'*0QVFHW*-;:G:Q?=A
MNXSLD5<_PGAUR2=KKWKXAUC7?'O_  4L_:6\9>"?#WC2^\%_!7P8Y@NIM)=E
M>_;>Z*S ,/,:5DD*A_D6./.W=G==_P""1/BJ[TO]EGXPK#*RC2=0FU"!E_A=
MK)>1GI_J5K=_X(G:/''\$_B!K&W-S>>(EMI)#]YA';1N ?H9F/XT <%\=OV9
M?B!_P3ETVS^+GP>^(>N:UX8T^ZBCUS0M<E\Q&CD<(K2*@5)(V=MA.U70R*5/
M4C]*/A!\3-+^,GPP\,^-M&R-.URQCO8XV.6B++\T;8_B1MRGW4UY[^V_I":W
M^R+\6[>5 ZIX=N[G:WK$GF@_@4!_"O+/^"3>L3ZG^Q;X:@F<NMAJ.H6T>>RF
MX:3'YR&@#[%K\P/^"H>K7MC^UK^SW#;W=Q;PRRP;XXI2JM_I\?4 \U^G]?EK
M_P %3O\ D[O]G?\ Z[0?^E\= 'ZD_6HYKJ*W4-+(L:LP4%CC+$X ^I/&*_.;
M_@LUXFO_  GX9^$6I:?.\4UOK-S-M61E#E$B8!L$9&1^M/T;_@F5??M)>&;7
MQ[\=/B9XHO?'>MVZWJV6GM"EII(E 9;=4=7R%& 5C**#P,XW$ _1EF"]:7</
M?\J_,/\ 8+\2^.?V=/VR?&?[-/B/Q'<>)O#UM;23::TTC%;=ECCN(GC#9\L/
M!)\T8. ^",X)/9?\%#OCUX]\2?&'P/\ LW?"O59M$USQ0(I=7U2UD:.6.*5V
M58MZG<B*D<DLFWDIM'0L" ?H*MQ%+*\:R*TB %D5AN4'."1V!P?KBOSE_P""
M?^J7M[^WA^U-;W%W//!#K&H"*.25F5!_:DPPH)XXP.*TT_X)$Z/X)\/PZUX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FORW_X*+?$+3OA-_P %(/A5XTU>&ZN=+T'2M+U"YALE5YVCCO;IF"*S*I;
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M(WJ-P5L>J>U?4G[)>AVGA_\ 9>^$UC8JBP+X6TV3<@X9Y+9)'?\ X$SLWXT
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M]BWX[7'[1G[./A3QI?QK%K,T;VFI+& %-U"YCD=0.@?:' [;\>] 'M]?D?\
M\%%O!FG?$;_@I)\(O"NLK(^D:W9:-I]VD+E':&74+E'"MV.&//O7ZX5^0?\
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M$MY?X=^''_#"?_!3CP1X.\$:I>/X0\:6L+3:;<R%L03O/"(W(QO,<L)D1L9
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M=M/.YYX5%<EB,'('3O7PS_P3W./V^/VK<?\ 09U$_P#E5FKUK7O^"4/P*N/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUCQ?XJUWQ=IGA_2XO.NKIM2B;:"0JA56#+,S,JA1DDD8ZU](_L-^&/A;X8^
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M)Q^%=3X6_8C_ &MO#>A6_@2V_:,L=.^'\40MTFM8Y7U""(9 2,M$'4 8  G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#Y.^-'[(/B7XE_ML_#+XT6&LZ5:Z
M%X5L+>TN=/N#+]JE:.:ZD)3"%<8N% RPY!KZP4;1BEHH **** "ODC]IS]CG
MQ-\</VH/@[\3=)UK2;#2?!5W9W%Y:7GF^?.(;U;@B/:A7E1@9(Y_.OK>B@!!
MQ2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%-9@M "EL=LT5X7^TE^V-\,_V9=+E3Q3X@MU\236DD^GZ#"KS7%RP4[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$GQ6\-:POACQ1;6,M]J=K+$9;34?)BSNX(,,FQ,%@&5L#*@EF/Y_?!?XY_M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M."_7 P, L#_0_>:)8:E(DEY96UVZ#"M/"KE?H2.*KCPEH8_Y@VG_ /@*G^%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5R_Q2_P"29^+O^P1=_P#HEZZBN7^*7_),_%W_
M &"+O_T2] !\+?\ DF7A'_L#V?\ Z)2NHKE_A;_R3+PC_P!@>S_]$I744 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5R_Q2_Y)GXN_P"P1=_^B7KJ*Y?XI?\ ),_%W_8(N_\ T2]
M!\+?^29>$?\ L#V?_HE*ZBN7^%O_ "3+PC_V![/_ -$I744 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5R_Q2_P"29^+O^P1=_P#HEZZBN7^*7_),_%W_ &"+O_T2] !\+?\ DF7A
M'_L#V?\ Z)2NHKE_A;_R3+PC_P!@>S_]$I744 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_Q2_Y
M)GXN_P"P1=_^B7KJ*Y?XI?\ ),_%W_8(N_\ T2] !\+?^29>$?\ L#V?_HE*
MZBN7^%O_ "3+PC_V![/_ -$I744 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_Q2_P"29^+O^P1=
M_P#HEZZBN7^*7_),_%W_ &"+O_T2] !\+?\ DF7A'_L#V?\ Z)2NHKE_A;_R
M3+PC_P!@>S_]$I744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5R_Q2_Y)GXN_P"P1=_^B7KJ*Y?X
MI?\ ),_%W_8(N_\ T2] !\+?^29>$?\ L#V?_HE*ZBN7^%O_ "3+PC_V![/_
M -$I744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5R_Q2_P"29^+O^P1=_P#HEZZBN7^*7_),_%W_
M &"+O_T2] !\+?\ DF7A'_L#V?\ Z)2NHKE_A;_R3+PC_P!@>S_]$I744 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5R_Q2_Y)GXN_P"P1=_^B7KJ*Y?XI?\ ),_%W_8(N_\ T2]
M!\+?^29>$?\ L#V?_HE*ZBN7^%O_ "3+PC_V![/_ -$I744 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N7^*7_),_%W_8(N__ $2]=17+_%+_ ))GXN_[!%W_ .B7H /A
M;_R3+PC_ -@>S_\ 1*5U%<O\+?\ DF7A'_L#V?\ Z)2NHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5[XT;XB3^(K8V4EG;V,-@;,.'*DF?]ZX<+MX QS@Y&,4 ?<-+2+D#GDUX_\
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MZBN7^%O_ "3+PC_V![/_ -$I744 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYL=3GA_B)\8-2N_^",WA!WN9/M>HW$/AF63=\WDV]Y,$7/IY-JBX]#BO5/\
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M^29>$?\ L$6?_HE*ZBN7^%O_ "3+PC_V"+/_ -$I744 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4F1TH+!:\H^.G[4GPQ_9STM;O
MQWXIM=+N9(_-M]+B)FOKE>0"D"98KD$;R @/5A0!ZON&<=ZY+XE_%KP;\'=
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M7Q%XCAPW]O>(-MU<!NNZ-<".+!Z%%#<\DU])%<]Z %7/>D92>E*HVC\:6@!
M,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M";_[&OC']E;PWXFO/&>OPW.J>(F@D.B6$S36UGY8;YV<@!ICOVDJ, (/F;/
M!]F'YJ^#_CU_P2JTG]H#]HK5?B'K'Q"U2ST/5?*DN](AM5>Y#H@CV13LVU$P
MH(S&Q'(]Q]XJ"!SS2T >3? _]E?X7_LZZ>(/ WA.RTR[*[9=5E7S[Z8=P\[Y
M?'^R"%'8"O5MF.GI3Z* $48I:** "BBB@ HHHH **** "BBB@ HHHH ****
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MC..E '7T4FX4A<#'6@!U%-WC&>U*&_"@!:*** "BBB@ HHHH **** "BBB@
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M1&Q/]T8 1 #S@D"OLO[O!^M #J*3=2;AU[4 .HI,YI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Y?XI?\DS\7?]@B[_ /1+UU%<O\4O
M^29^+O\ L$7?_HEZ #X6_P#),O"/_8'L_P#T2E=17+_"W_DF7A'_ + ]G_Z)
M2NHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT/P)I'[)6HZA]C5Y;O4CXSLXGO;EVS),R^2V,G@ L<*%&2!FO4O^&KOVD?\
MHT'4?_"XM/\ XQ0!YQ=?#'PU_P $\?VM/ _B#PIIW]C?"+XA0#POJ<4EQ+<+
MINH[M]O*99F9@KD#JV %F/917T?\6OV&_@A\<O&$WBKQIX#M]5\03QI'-?17
MUU:-*$4*I<02H'8* NY@3A0.@%?-?[2'C;X]?M)_!SQ!X"UC]DC4+&/4(PUM
M?CQG9RO9W*'=%,J^2N[:P&0&&Y2RY :OKG]EZY\>7'P%\'#XFZ:VE^.(+,6V
MI0R3I,\C1L429V1F7?(BI(P!X9S0!XO#_P $I_V;X;J*;_A#+R01N&\N36KP
MJV#G:?WO3M7O/Q@^!?A3XW_"K4?AYXCM)%\.7D447EV+B&2#RV5HFC."%*%%
MP"",#!!!(/H5% 'YV:Q_P1.^%DRM_97CGQA9-@;3>/:W !SR3MACR,=J]I_8
MP_8'T;]CO5/$FJ6?BV_\47^M0Q6S&>V6VBBC1BV @9LL6/4G@#&.2:^JJ* /
MS&_;2_X)Z_''XL?'S7?B/X)\7Z?>V=XD*V=G<:E-9W=BB1JIB3"^7LW!F!##
M.XDC/)\?\-?"G_@H)\*?$.FPZ?=>+;I#<(L(NO$$&J6(RW\:R32*B<'.X# S
MZYK]F".::RYH \)_:Z_:!UK]F3]GF_\ '5MH$?B/6[9K>W:&/<MI%)(P5II"
M/G$0/'J2R#(SD?$W@C_@MZO[N+Q?\+6Z_/=:'JN?RAD3_P!J5^ILENDT3Q2(
MLL4@*NCC(93P00>M>0^-_P!CSX*?$3<=<^%_ABXF<G?<V^GI:SOGKF6$*Y_$
M_E0!3_9;_:^\!_M;:#J^H>#/[0M;C2)(H]0TW5(%BGM_,#&-CL9D96\N3!#'
M[AR!7K\?B#2Y-6DTM-1M6U.- [V0G7SE4C()3.0".^*\^^!G[,_PY_9OTS5;
M#X>^'4T&'5)EGO&^T2W$DI7(13)*[-M4,VU<X&XGJ23\ ?M3?\$H?B/XX^+G
MBGXA> _&VGZE-K&H2ZF++69I;:[MW=BWEQS*K*P4\+G9A0H[9H _4_<*%8-T
MK\A_@+X?_;J^#7Q<\*>'KZV\3:CX>DOX8[R/6+M-4TP6N\>9FXW2>2NS)&QE
M;/0$\'[[_:Z_; \,_L?^$]&U;7M*U#6[C6+I[:SL; !2=B[I'9W^50 5XZG<
M,# ) ![[2U\B?"O_ (*G? #XE>3!=>)+GP7J$F +7Q+:F!<]_P!^A>(#_><=
M>G7'U3H/B32O%6CVVK:)J5IK&EW2>9!>V$Z3PS+TRCH2K#W!H TJ*3=_A0#F
M@!:*** "BBB@ HHHH **** "BBB@ HHHH *0TM% 'YS?\%(?V8_CSXT^)&C?
M$[X5ZYJFH6NCV*11Z+I-]);7EA*K$O+;J& ?>"N=IWG:!A@!CQWX _\ !7+Q
MQ\,]0'A;XW^'KG7XK1_(FU.W@%KJUL0<$30':DA'3_EFW<EB:_7EES].AKQW
MX_?LC_"_]I;3S%XV\-PW.I*FR#6K,^1?V_7&V91E@,G".&7/.V@#?^#'[0'P
M^^/WAY=7\">)[+7H%4--;Q-LN;;/:6%L/&?]X8/8FO0]P_K7XS_&C_@F'\9/
MV;-?/C3X+Z[?>*+2Q;S8)-(D:VUJU7T,:D"8=!^[)+<YC KK/V=_^"P'B3P;
M>1>&?CAH$VJI;R>1+KVGP""_@(.#]HMCA'(.<E-A&/NL>H!^MN:6N%^$GQN\
M#?'+PVNN>!O$MCXBL.!(;63][ Q_AEC;#Q-CG:Z@XYQ7<T +1110 4444 %%
M%% !1110 4444 %%%% !1110 5R_CGXI>#/AC#:2^,?%VA>$XKQF2VDUS4H;
M-9F4 L$,K+N(R,XZ9'K745\/?MK>$=$\>?ME_LKZ!XCTNUUO1;V374N;"^B$
ML,P%O"P#*>#A@#]10!]%C]K+X('_ )K'X '_ '-%C_\ ':7_ (:Q^"'_ $63
MX?\ _A46/_QVLC_ABOX"]_A'X0_'28?\*#^Q7\!!U^$7A ?]PF+_  H U_\
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M@_X-^!_VM/B_\*?"?C:#]IFRTN+7]-AU%;.3P3I\C0B1 VTMY8SC/7 KL?\
MA0/[7/\ T=1I_P#X0FG_ /Q% 'U]N&<4;A7R#_PS_P#M<'K^U/IY_P"Y%T\9
M_P#'*;^Q[\1OBO<?M!?&KX7_ !-\<0^/6\'QZ7)::E'I-OI_-Q"TC@)"B\$,
MH^;=]S(QDT ?8(.:6D7I2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_LU_"'1? .B7=SJ%KI_F227EW@//-(Y>1]HX4%F.%'08&2<D^E[>W:E48H
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MY_\ Q0_X(T?";Q49I_!NNZWX%NGSLA+C4;1.O\$A$I_&;_&OHO\ 9C_9S?\
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MN&\MXI[>5)X)5#QR1,&5U(R""."".] $U%)FEH **** "BBB@ HHHH ****
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M#9P>?RH 6BF[J4'- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5NC_ /!,W]I/]HKQW=:Q\8O$@T-1,T<FJ:OJ"ZG<2)N_Y=X8G*JG'",T8 Z
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M*D,.O!S3MP[<T +12;JR/$/C+0/"-OY^NZWIVBPXW>9J%W' N.><N1QP?R-
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MU)".VT$",C!5@=_;'/TC10!\?_\ "@/VN.W[4^GC_N1=/_\ B:/^% _M<_\
M1U&G_P#A":?_ /$5]@44 ?%'C']E/]J+Q]X3UCPUKW[3FGW^BZO:2V-[:_\
M"$V47FPR*4=-R ,N5)&5(([&OJ'X)_#@_!_X0^#O!+7_ /:C:!I5OIS7HB\H
M3F.,*7"9.T$C.,G'J:[:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KE_BE_P DS\7?]@B[_P#1+UU%<O\ %+_DF?B[_L$7?_HEZ #X
M6_\ ),O"/_8'L_\ T2E=17+_  M_Y)EX1_[ ]G_Z)2NHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3.* %HI-P[<
MUR_Q ^*?@_X4Z0=4\8^)M+\,Z?R%GU2[2 .?[J!CEF]E!- '4%L49KX$^,'_
M  6-^$O@SSK;P3I6K?$"_0?).J&PL<_]=)5,GY18]Z^4=:_X*"?M5_M2ZI-I
M'PQT6ZT>T9MC6_@_3'GF13T\VZ<,8^OWU,8Z=* /V*\9?$#PQ\.M);5/%7B'
M3/#FG+G_ $K5+N.VC.!D@,Y )QV'-?(_Q2_X*W_ GP#)-;Z)=ZMX[OERH&BV
M92#=SP99B@(]T#_C7QUX/_X)1_'[XT:M_;7Q1\56WAV:?'G7&LW[ZOJ)SST1
MBK=^#,#[5]<?"G_@D%\$? ZQ7'B8ZOX^O@ 6_M&Z-K:AAW6* JV/9W<4 ?+7
MCS_@LI\4O&MW_9GPZ\#Z7X>DN#Y<+3"35+TD]"@ 1,].#&WXURH^'?[=O[47
M[W5)/&%IIEP?WBZI>+H5IM/<VX,6Y?I&U?L'\/\ X/>!_A39_9O!OA'1?#,)
M&&_LNPC@:3_?91EC[DDUU^T^M 'Y&?#S_@B;XMU0I<>.OB+I6C[CNDM]$M9;
MZ0YYP9)#$%/OA_QKZ4\"_P#!'WX"^%]CZTOB'QA,.674M2\B(GV6W6-@/8L?
MK7W HQ2T >1^"/V2?@U\.=A\/?#+PQ8RQC"W4FG1SW '_760,_\ X]S7JUO;
M1VL*0PQI%$@"I'&H55'H .@J:B@!NTX[&C:?6G44 (*\L_:JT6_\1_LS_%72
MM*LY]1U*\\+ZE#;VELA>6:1K:0*B*.68G@ <DG KU2FLNZ@#\_\ ]GG]N.U^
M$OP-\"^"]7^"/QFN=4T'1[?3[F:Q\)AH'DC0*Q0M,K%<CC*@^U>A?\/)M#_Z
M(7\</_"0C_\ DBOK\#'O2T ?'_\ P\FT/_HA?QP_\)"/_P"2*YW]B?6=5^(W
M[5G[0OQ(D\&>*?"/A_Q%#HRV*>*=+:RG=HH&B<8)*D@IGY6. RYQFON*FLNX
MYH 5?ZT'-"C:,4M #=ISD8_*D>-9(V1U#HPP589!I]% 'D7Q _9'^#/Q067_
M (23X:>&[Z>7[]Y'8);W)_[;1!9.Y_B[U\O_ !&_X(S_  @\3>;-X4UOQ#X,
MN6SLB$R7UJG_  "0>8?^_O\ C7W[10!^,_C+_@DO\>/@_J7]N?##Q;9^(;FW
MR89=)O9-'U(>Z[F"#\)LUB6?[<7[7?[*=Y%IGQ"TZ^U&RC;RUB\::2SK*,\E
M+M-C2'T;S'%?MD<U6O\ 3;75;.:TO;>&\M)EV2V]Q&'CD4]0RG@B@#\\O@__
M ,%H/A[XEDAM/B%X7U/P7<L0K7U@W]HV8]6;:%E7Z*C_ %K[<^%_QT^'WQGT
M\WG@CQAI'B6-5#R1V-TK31 XQYD1P\9Y'# &O#_B]_P3+^ GQ<\^X_X13_A#
M]4DY^W>%9!9D'_KCAH3S_P!,\^]?%'Q0_P"".GQ+\ 7QUOX5>-;7Q$]L3+;P
M3LVF:A&><".0,T9;_:+Q]>E '[ [J,U^*'A_]NS]JG]D'68= ^)NEWVMV*-L
M6T\96KF615^\8;U?FE_WBTH'I7V=\#_^"N'P;^)@M[+Q7]M^'&L2$*1J@\^Q
M+'LMS&.![R(@'K0!]Q45GZ'X@TOQ1I-MJFC:C::MIERF^"]L9UFAE4]U=258
M>X-7MPH =12 YZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-?J?H>@V7AO1=/TC3+:.RTS3[>.TM;:/[L,4:A$1?8* /PK0%+0 F.,44M%
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MQ1CCTKIP<TM #0M&VG44 -V^]+2T4 %%%% !36&:=10 W;2KG'-+10!\M_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%(6 HW4 %)N%>??%WX_?#SX%:6+_QYXMTWPY$R%XH;J7=<
M3@'K% N9)/\ @*FOS]^.7_!::PM?M.G?"7P?)J$N2JZWXD)CBSTREM&VY@>H
M+.A]5H _3^ZO(+&VDN+B5(((U+R22,%5% R22>@]Z^1_CI_P5&^"'P=\^RT[
M6'^(&N1Y LO#>V: -VWW)/E8SUV%V']VOSWM?A7^U_\ M_W4=WKLNK)X6N&#
MQW&N2'3-(C7.5>.W51YF.FY(W;U-?7'P+_X(V_#SP?Y%_P#$C6[SQUJ"X+:?
M:EK+3U/7!VGS9,'OO0'NM 'S3XT_X*:?M%_M':U+X=^%7A]_#J3G"6?AFRDU
M'43&3C+SE3@#^^B1X]:L_#__ ()4_'7XYZPOB'XL^*5\,M<<S3ZQ=MJNJN#R
M 4#E1G/1I05S]WM7Z\>!_AWX8^&FAQZ-X3\/:9X;TI.?L>EVJ01DXQDA0-S'
MNQR3WKH=I]: /CWX._\ !*OX$?"TP76HZ+<^/-4C^;[1XDF$D.>^+= L9'LX
M?ZU]9Z'X?TSPUI<&FZ1IUII6GP+MBM+&!88HQZ*B@ ?A6@.*6@!NT]J4<4M%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#C)W0M\Q _O+N7WKU[<* '44E+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 44A.*3</I0 ZDS7%?$3XV^ /A):F
MX\9^,=%\-+C*QZE?1Q22>R(3N<^R@FOD;XJ?\%AO@QX.$\'A2TUKQY>J,(UK
M;_8K0D=C)-AQ]1&U 'W=FC</6OQF\8_\%:OCQ\7-3;1OAEX2L?#LLW^HATRR
MDU;4<?5E*'MTA%6/AE^S1^VS\<O'.B>)O$_BCQ+X/@M[N.Y74_$.K-"UL X9
MC'8JV00!G88T4]"<9P ?LC7SI_P4,\&ZEX\_8X^)FDZ193:CJ!LH+M+>W&79
M;>ZAG<@=\)$QQU.,#D\_12=*&7//>@#\-= ^)G[:'[8FEV]KX3N?$LOAN("T
MCET-4TBQ 4;61KK*>80.JM(QYZ5ZA\+O^"+?C;Q%<1ZA\2?'FGZ&LK>9+::1
M&]_=/GDAI'V(K'U'F#ZU]2>)/V?_ (J?LH_$#6_&W[/=G8^*/!6NW!O-;^&-
M_/\ 9E28XW36$A.V,D#E3TP %<!52\O_  40U&S1K/5?V</C#:^(1@'3[;P_
MY\);OMEW*6'7!"'/M0!8\&_\$[OV;_V=?#=[XEUSP^OB*+2+:2\N]6\73?:X
MXXHU+.QAPL. !G_5D\4G_!,+PS<6_P "_$WC2735T>'QWXLU'Q#8V0B$0@M'
M98XD"  !<Q.1@ ;2N.,5S.K?#WXX?MU7]I9?$K1'^#/P4CG2XN/#"W/FZQKF
MQ@R).PP(H\@'!"D$?=8[67[;T/1K'P[HMCI6EVD-AIEC!';6MK;H%CAB10J(
MH'0!0 ![4 70,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444UFVT +NI-PK!\<^.M!^&_A/4_$_B?4X=&T'3(3/=WMR3L
MC0>P!))) "@$DD  DBORU_:/_P""P.O^)[R3PU\#M&DTY)I/LZ>(=2@$UY.S
M':/L]L<JF3T+[R<_=4T ?J]JVJ6VBZ7=ZC>2>19VD+W$\I!.V-%+,<#G@ U^
M0'Q\_P""J7Q,^.6NMX+^!V@WWA^VO)#!!<V<+76M7W7_ %:*"(<C/"!FX!WC
MI7W)_P $\[?XWO\ !6[N/CA/=S:A=WQETJ+6%']H):LH)$_&0"Y)57^8#(.!
MM ]K^'OP*^'WPGOM2O?!W@S1?#=YJ,C275QIUHD4DI)S@L!G;GG:/E&>!0!\
M9_\ !-']C;XJ_!'Q5XB^(GQ)U>:PN?$%EY#>'7O#<S32-*)/M-V02HD7!"\L
MP\U\[3D'] Q"JL7"J'("E@!G S@9]LG\S4BC'%+0 U5VKBG444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(6Q2U\Y?MN?M >,/@#X+
M\%S>!--T74?$GB;Q/:>'K<:^)6M8S,DA#,(W5OO(O.>,G@]* /HRBOD#^V/V
MZ.V@_!#_ +[U/_X[1_;'[=/_ $ ?@?\ ]]ZG_P#': /K_.**^/+C7OVYK>&2
M9]"^".V-2Q"R:GG Y_Y[5ZA^Q5\>-9_:2_9W\/>//$-A8Z=K%]+=0W$.FJZP
M9BG>-2JNS,,JJ\%CSWH ]THI,T;@.: %I,UYMXU_:6^$_P .=Z^)/B/X8TB9
M<DV]QJL/GG!P<1!MYQ["OG[QO_P5H_9X\*;A8ZYJ_BR1<YCT72I!S[-<>4I^
MH)% 'V5FDW#MS]*_+GQG_P %O=/C\R/PI\*[JXSG9<ZUJJPX]"8HXWS_ -]B
MO(-1_P""K_[2'Q/O)+/P5X<TC3Y<@)'H>B37]R,],^8T@)SZ(/I0!^TVZJ.L
M:]IGAZS:[U74+73+5>L]Y.L2#ZLQ K\7?[+_ ."@7QUSYA^(%C%-G<LDL?AU
M".^5S!Q[8YJ]HW_!(KX__$"\6_\ &7BC0=,E<#?)J6ISWUT,]OD1E/?/[R@#
M]+_&7[<WP#\![QJOQ6\..Z [H]-NO[0=<=05MPY!]NM>$^,_^"Q7P)\/;UT>
M#Q/XJ<?=:QTY8(C]3.Z,!_P$UY=X-_X(AZ#!Y;^*OBAJ-^"?GAT;3([7;[!Y
M'ES]2H^E>Z>#_P#@DW^SQX7\MKW0-5\4S)C$NM:M-R1W*P&)3^(Q[4 ?-'C#
M_@M]>R>9'X4^%<$&,[+G6=7,N?3,4<:X_P"^S7F,G_!2W]K+XN2>7X*T.&W=
MV 1?"OAB2];TP!+Y^?RK]6?!O[+/P@^'S1OX?^&?A739XSE;E=)A><'&/]:R
ME_U_K7IT5NEO"L42K'&HVJB@!5 Z  4 ?BK_ ,(7_P % OC1CSY/'UE#(1N6
M?44T),'CYDWPY'MC\*M:3_P2*^/_ (^O$O/%WB?P_I[L0))-3U.XO;G!SG&V
M-E)X_OBOVCVCTHV_RQ0!^7'A'_@A_91^7)XF^*]Q/G&^WTC1UBQZXEDE;/;^
M 5[3X1_X(^_ 3PZT;ZD/$OB=U(9O[1U3RE)[\6Z1$#\<CUK[?I: /!O"7["/
MP \$^6=-^%'AR9H\;6U2V.H,,# .;@N<^_\ 6O8?#_@_0_"=K]FT/1M/T:VP
M!Y.GVJ0)@# &$4#%;%% #=M&W\Z=10 E+110 4444 %(1FEHH ;M/K7/?$/P
M)IOQ-\">(?"6L>:-*URPGTZZ-N^R01RH48J<<'#$CW[&NCHH _&+XJ?\$O?C
MA^SGKQ\6?![Q%<^*8K3,D4^B3-8:Q O4CRPV)!T&(V);^X.E?6/_  39_::^
M,GQHG\4^%_BKX>NB_AZ%/+\175@UE*9BP4VTZ%0K28^;("D!3N!W U]U,,T;
M<\$\=* ,.W\=>&[CQ1<>&8=?TN;Q);QB:?1X[R,W<2-R':$-O4$<@D<UN[OS
MK\KOVPO^"7OQ"U#XJ>(_BI\)?$/]J7^J:A+K+Z3/=&TO[:X=R[_9I\A64,25
MR8RH(4;L9.;^Q[^W!\?_  G\=O#7P6^*V@ZEXC?4+M;)O[6LGBU>Q1B1Y[/@
M>=$N&9G<,=JDA\#! /UC!W#(Z4M4KK5['39[6"[O8+>>[?R[>.:54:5\?=4$
M_,?85;W\XP?RH =12 YZ4M !1110 4444 %%%% !24M% #2O.:^<OVBOV OA
M#^T@MS>:SH*Z%XFEY'B'0]MO=,WK*,%)L\9WJ3C@$5]'T4 ?C+XF_P"":W[1
M_P"S3X^MM;^#6O2>((S*$AU+1;U=/NHUSTN(9'"E#T(#2*1U Z5^P/@Q=;3P
MAHB^)7MI/$:V, U-[($0-=>6OG&//.S?NQGMBM=ESWI0,4 &:3</Z5Y_^T!-
MXZMO@WXME^&<<$OCM;!SI27 4J9>.@;Y2^W=MW?+NV[N,U^5?PS_ ."IWQO^
M ?B>7PW\9O#DOB=(9/\ 2(-2M1IFJ6X)/W2J!6'4@,GS8&' YH _97K2U\Y?
M ?\ ;^^"WQ_-O9Z-XJBT77YBJC0]?VVET6/14))CE/M&[&OHII%4$L0H R23
MP* '9I P.*^0O%G[=>K^.O&&I>#_ -GCX=77Q<U33G,-_P"(6N5M-#LY!V^T
M-Q*1SP&3<!E"]4I/B=^VMX9#:EJGPE^'OBG3XQYCZ7H&K2VUYL!.Y0\TK(6P
M >%/7@$\4 ?98.<TM>#_ +./[7WA/]H2ZU/018:CX,^(&C_\A7P=X@B\F^MN
M!EU!QYD>2/F !&5W*NY<^[@YH 6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N7^*7_),_%W_8(N__ $2]=17+_%+_ ))GXN_[!%W_ .B7
MH /A;_R3+PC_ -@>S_\ 1*5U%<O\+?\ DF7A'_L#V?\ Z)2NHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM58P1U$:J#W!KWD#%+0 BC%+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 44E&X4 +24R:XCMXWDE=4C0%F=C@* ,DD]J\$^)_[>?P
M'^$OG1ZU\1M)NKV/(-CHSG4)MP_@(@#!#_OE: /?LU\;?\%*"3I?P$ _Z*GH
MWK_=FKR'XA?\%LO!&E^9#X+^'^MZ_(,@3ZQ<Q6$?^\ GG,1]=OX5\<?M ?\
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M!.=EN(@1GL<^^:H?\$I_A9X,NOV4/#'B>;PEH<_B2XO+Y9=8ETZ%KMPEU(J
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M2#QEI^D7&@W%O>R:;?:?/)YHAN$1'(23 \Q2LJ$' /)! Q7MVZ@!U%)N%+0
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M-]X!_9[^&WAS4T>+4]+\.V%K=QN<E)EMT#K^#9'X4 >DT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5R_Q2_Y)GXN_[!%W_P"B7KJ*Y?XI
M?\DS\7?]@B[_ /1+T 'PM_Y)EX1_[ ]G_P"B4KJ*Y?X6_P#),O"/_8'L_P#T
M2E=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 44A8 XJMJ&J6>D6,][?74-G9VZ
M&26XN)%CCC4=69F( ''4T 6<BH+[4+;3+.>[O+B.TM($,DL\[A$C4#)9F/
M'>OA+]I#_@KC\-?A>;K2?A[#_P +'\0QY07,$ABTN%_4S8S-CKB,%3_?4U\7
M6^B_M6_\%+=66XN7N(O!C2C9+-NT[0+<@]54 F=E/<"5QGD@4 ?;_P"T5_P5
MG^%7PH:YTSP2C?$GQ$F4WV$OE:;$W^U<D'S,$@XC5@>?F4U\-:AXZ_:N_P""
MC^I36&F07H\(/)LDM=-!T[0X!GD2RL?WQ'7:[2-_=':OMW]G?_@D?\+OA<+7
M5?'4K?$GQ!'A_)NX_)TR)NO$ ),O<'S693_<6ON33=+M-'L+>QL;6"RL[=!'
M#;V\8CCC4<!550  !V% 'Y[_ +.__!'3P/X+^S:K\4M6;QUJRX8Z39;[;38V
M]&.1)-VYR@[%#7W[X9\)Z-X+T6VT?P_I-EHFDVJ[(+'3[=8(8U]%10 /RK5
MQ2T (HVTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/(Y,RBNI^'?_  1Z^+?Q'U$ZU\4/&5CX9DN6\R=6E;5M1<]]Y#"/)]?,;Z4
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M1M//_;JG^'^<5I6MK%9P+#!$D,2\*D:A5'T H EHHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_BE_R3/Q=_V"+O\
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MW_$PA":; W7"6V2).IYE+ ]0JFOMRVM([.VBMX(T@AB01I'$H544< *.@ '
M':@#XE_9O_X)0?"SX0+:ZMXQ'_"R?$T>&W:E"$TZ!O\ 8MLD/CD9E+@\$*IK
M[:M[2*TMXX((T@@C4(D<2A510,  #@  =*F'%+0 @XI:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T4F
M[C//Y4A8"@ *G=G/:O ?VDOV'_A7^T]:RS>)M$&G^(]FV+Q'I.V&^7 P [8(
ME4?W9 <#ICK7M^N>(=+\,Z?+?ZQJ-II5A%_K+J]G2&)/JS$ 4NA>(-+\5:3!
MJ>C:C::MIL^?*O+&=)H9,$J=KJ2#@@C@]0: /Q6^)O[%7[1'["?B2?QM\-M:
MU#6M$MOG;6_#2L)4B4DXO+,[MR8!8Y$D8')(KZ$_9B_X+$Z/KPM-"^,^F+H-
M]Q&OB;2HF>TD/3,T(R\9]63<N3]U *_3)^O3)Q7XE_M_? GXF?$K]K3Q#8^$
MO@G=6MBOEBUO_#NC2^5J<94,;J>91Y1<LQ!;Y<8VME@20#]EM+^('AC6/"L'
MB:Q\0Z7=^'9T\V/5H;R-K5E]?-SM_7M7B'Q(_P""AW[/WPS:6.^^(NG:K>("
M/LN@J^HLQ';?"&0'_>85^*GQ<_9!^-?P+\,VVK^-? ^J:3H4IW_:HI8KJ"%C
MP/-,+N(F/&-^T]O6NP_8[^'O[.?Q&UA--^,?C+Q!X4U5Y,6HC,-OI<XSPKW)
M5V0]<[@B_P"WDXH ^T_B/_P6T\-6?FP^!/AUJ>KMRJW>O7D=HHQW\J(2EA[;
ME_I7CF@_\%%?VNOCSXOL$^'?AZW,8N5']GZ%X?\ M%LXS]R>:;>40@C<V^/
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M44 %%%% !12,VVJ>L:U8>'=)O-4U.[AT_3;*%[BYN[APD<,:@EG9CP  "<T
M7,TR2154NQPBC))Z =:_-+]IS_@L5H>@?:M$^#6ECQ!J W1GQ)JT;1V<1Z9A
MA.'E/^T^P#'1@:]K_P"";OQ ^//Q*\ ^(]=^,Z2O8W5U%+H%S?V*6=U*C!S-
M^[1$_<_ZK8Q7G+8)7;0!\M_M-_\ !6_Q'XNU>Y\&_ G2Y;5)9FM(_$<UOY][
M>,6V@VD&"$#'&UF#.01\J$5Z3_P3=_92^-_@GXE:C\5_BAK>I:6FK6+Q2:+J
M5X\]]J+N05EN@S$)LY*ACOR2"%&=WVC\/_V9?A9\+/%6I>)?"G@31=$UV_=I
M);ZVMQYB[B21'G/E*<G*Q[0?2O3@O?B@!-G4CD^].5=O%%+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%(2!UHW4 +29 KGO&WQ$\,?#71WU;Q7X@
MTSPYIB9S=ZI=QV\><9V@N1ECV Y-?%/QJ_X+#_"7P+]HM/ ^GZE\0]23*B:)
M38V.?>61=Y_X#&0>S=Z /O;S%YYX'6N!^*7[0'PY^"=F;CQQXRTCPW\F](+R
MX'VB1?5(5S(__ 5-?D7K/[;/[67[8>J3Z/\ #G3]1TK3W;RVMO!=H\?E>AEO
M6):(X(YWQ@\<5VOPI_X(X?$3QU>?VU\5_&=MX<>X;S9K6S8ZEJ$A/422DB-6
M/]X-)]* /8OC%_P6@\"^'VGL_AQX3U+Q?=+E5U'5'^P6GLZIAI7'LRQGWKYD
MG_:4_;*_;2NI;3P7;ZS9:+.^PIX2M?[-LH\\;7O68,..H>;'7BOT7^#O_!-K
MX#?!Q8)X/"$?BO58L'^TO%+"^<L.0PB($*D'H5C!Z<U]-6]G%:6\<,$:011K
ML2.-0JJ!P  !@8':@#\D_A+_ ,$7_%WB29=4^*?CFUT7SF\R:PT93>W;Y/(>
M:3:B-WR!)_A]L_"?_@G)\!?A$8)[3P1;^(]3B(/]H>)G-_(2.C;''E*1U!6,
M'/X5],JNT8'%+0!7L[*&PM8K:WAC@MXE"QPQ(%1 .@4#H/:IU&*6B@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 44F:3<* %+8IKRI&C.[!44$EF.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IK FG44 <3\3_@OX(^-.@G1_'/AC3?$UA@[%OH0S
MPD]3%(/GB;_:1@?>N=^ ?[,?P\_9ET;5-,\ Z*VEPZG<"YNY9IWN)I64$(I=
MR3M4,P4=!DGJQ)]8IK+NZ\T ?CK\4OVQ/VP?V4_B_K5YXZMUO=!NK^3[/;7V
MF!]&GCW$(+6>,*RC9C"^9N'!=2U?77[(_P#P4\\$_M+>)M/\&ZIHUYX.\:WB
M-Y%O(XN+.[=%+,L4PPP8JK-M=!TP&8U]C:II-EKFG3V&I6=OJ%C<(8YK:ZB6
M2*53U#(P((]C7CO@G]BOX+_#CXH#X@^&? >GZ+XF1'2&:U:000%P59XH-WE1
ML5)7**."1W- 'MF\>OZT!P>E?GQ_P4@T_P#:BT7QYX>\7_"#5->D\&:=8?O]
M/\,L6EAN@[;Y+BV&3<(RE,95U78V57JWC7P/_P""RWB3P[=0Z-\8O"*ZLD+B
M*;6-%06UY&1PQEMG(C=L]0ICQZ4 ?K;2UF>'/$&G^*/#VF:WI<_VG2]2M8[V
MUN-I420R('1\$ C*L#R.]:.X=.] "E@*3<*1OFZ>G:OF_P"#_P"W#X*^,G[1
M7C;X2Z5!)#?>'M_V74WF5H=3:)@ER(ACC8Y&.3O4,W % 'TDK;AD4M-7I3J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^*7_),_%W
M_8(N_P#T2]=17+_%+_DF?B[_ +!%W_Z)>@ ^%O\ R3+PC_V![/\ ]$I745R_
MPM_Y)EX1_P"P/9_^B4KJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSX=^?:>$8]0^(NJQY .GJ;6R##/!N)!D_5$<'/!KXY\0_M]?M3_M::M/X?\
MAGI-YHMI(?+:U\&V;M.BGH9;QLM'_O*8A0!^NOQ0^.GP_P#@KIGV_P <>+])
M\-0,I:-;ZY59IL=?+B&7D/LJDU\)?&S_ (+1^#]"\^Q^&'A.\\4W0RJZKK1-
MG9@]F6(9DD'LWEFO'_A?_P $?_BI\3-2.O?%KQC;^&VNF\VYB$S:KJ<I[B1]
MWEJ3_>\R3W%?=/P5_P""</P,^"?D7-IX43Q1K,6#_:OB9A>R[AW6,J(D([%4
M!]Z /S<D^(7[97[>4C1:,FMQ>%[DD;-(C&D:0$Z%6G)7S@,\JSR'VKW+X*?\
M$4XH_(OOBKXW\T\,VC^%TP,]<-<RKDCL0L8]FK]2TA6- BJJJ!@*!P .G%/]
M: /)_@W^RK\*O@';H/!'@K3-(O%7:=2>,W%ZWUN)"TF.^T''/2O5MGYT^B@!
M%'7ZTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGZ5^8?[:W[??QW\$_'S6_A5\,O"_]FM9+"+:\CTI]1U"^WQA_-B1@T>P[MH
MC8Y4Y.?E7]/2":39COVH _$M/V4_VTOVK9%E\:7>N66E3G<?^$PU8V=K&3W^
MQKED_P" PBO<?AC_ ,$2-/A6*?X@_$>YNF./,L/#=HL(![XN)MVX?]LE_7C]
M1-OYTHXH ^;_ (8_\$[_ ( ?"ORI;#X>Z?K-['@_;/$);47)'1MLI,:G_=5:
M^A['3;72[.&TL[>*TM(1MC@@0(B#.<*H&!5JB@!%&T8I:** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK*3WQ^-.HH X+XN?
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M9AY<8/\ WRBC\*^(/V6Y&\%_\%9[O3K,"*W3Q=XATYHE/RF/;>(!] 0I_P"
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M#'Q$TL:GX6\0Z7XDTXX_TK2;R.YCY[%D) /L: .@HIH8,,BEW"@!:*2@L!0
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M*7B"-)+ ^(+6]@FM+9RH\Q8HX&8(Q5AG>[D!N" >0#R[_@H3XX_:LU+XO0>
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M?8#<Y]V)-=?2T -VGG)R/I2BEHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "FLN6]J=10!\#?MO?\ !,_PG\8;
MGQ+\2_#FJW'A3Q4+.;4+^S@MOM-OJ4L<9;(3<ICD;:067().2I8DGQK]@O\
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M1QQ1*%1% P% '   Z"I12T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZF@#]<O /_!17]GKX@QQ"U^)&G:/<O\ >M]?5].*'T+S*J'ZAB/>O(/VBO\
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M-\0/"_@N/?XA\1Z3H28SNU.^BMQCU^=A7XZ?\,@_MS?%K]WXCU;Q);VC<?\
M$^\8#R0.G^J2=R.G/R<Y[UO>&?\ @BG\3=683>)?'OAG2FD^9_L2W%[)D\G.
MY(P3GKS^)H _0#QG_P %#OV=_ V];WXH:3?R+D!-%674=Q]FMT=?Q)Q7@GC7
M_@M%\)-'61/#GA;Q1XDG4':TT4-G WI\Q=G_ /'.,UB^#?\ @B7X!T_:?%7Q
M$\0ZXRG=MTNU@L%/L0_GG'T->[^"_P#@F'^SIX+\J3_A!!KMU&>+C6K^>XW?
M6/>(S_WQ0!\.>-O^"TWQ,\03&V\&> ]!\/\ G':GVV2;4K@>FT@Q*3]4(]JY
M9O'7[>7[3#+#91>.+2QN/]6UA9KH%J5/83[80PP>[FOV+\&?"GP7\.81%X3\
M):'X9CQ@C2=.AMLCWV*,_C758YS0!^-O@G_@CI\8?'U\-3^('C/1_#C7!W3,
MTTNJWV>^X#:A/_;4U].?#?\ X(V_!OPOY4WBK5?$'C6Z7_61R7 L;5_HD0\P
M?]_:^]A2T >6_#?]EWX3?",1-X2^'OA_1[B/&V\2R62ZXZ?OWW2'\6KU#;^5
M.HH 04M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(L="TFW&V*QTVW2"&,?[*( !6NN>]+0 @I:** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?XI?\ ),_%W_8(N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M18M(\*Z%IOAW2X_NV>EVL=O%Z9*J!D^YY-;]+0 BKM&!2T44 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^SU\.--\$^#[66WT>RW/NN)?,FGE8Y>61L %F/)P !T   %=XHP*6@ HHHH
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M%MXCO(B")]>O9;D'!S\T098F[=4[>YKZIM[6.UACAA188HU")&@ 55 P  .
M!Z"IJ* &A<=Z4+BEHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HINX#K1NH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'##&H2..-0JJH'  '  ]JGHH 11BEHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- !7'_$7XP>#?A+%HTG
MC#Q!:: FLWT>FV!NB?W]P_W4& <#U8X4=R*ZYB#GM7YO_$GX62?\%)/CY\3(
MEOY;7X?_  YTZX\.^'KI'(AN->?F6?(^\B,JA@.JK$1]XT ?I$#FEKY5_9 _
M:PT?Q-^S];2?$WQ#IWA3QAX2N)/#OB,:]?16K+=6^%\QVD8#+KM)/3?O Z5Z
M)\.?VQO@S\6O'Q\%>$/'NGZYXE\IYDM+>.8+*JC+>7*R".0@ MA&)P"<8&:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKL57:,4Z@! N**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KE_BE_R3/Q=_V"+O_P!$O745R_Q2_P"29^+O^P1=
M_P#HEZ #X6_\DR\(_P#8'L__ $2E=17+_"W_ ))EX1_[ ]G_ .B4KJ* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"V*-WX4
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M_P"A0U#_ ,'=W_\ '*^OZ* /C_\ X=0?LX9X\(W^/^PW=_\ QRO8/@#^R?\
M#;]F,:W_ ,*]T6;26UGR?MK3WT]R9/*#^6!YC-MQYC],9W>PKV"B@!%7:,"E
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  = !VJ2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M= .B:OI]OK6E/&L<EKJ<2W,<H7!!=7!#G(!R>XS0!^,.I?MB?M>_MB7TVF^
M;'5=+TR1S&T/@JR>WBBSP/-O6)9"!U)E0$GI7Z2_L(_"SXJ?"WX%C1OC!KCZ
MUK\U]+<06]Q=_;9;&W94Q \Y)WG>)&QE@ X .!@?0^GZ9:Z39PVEE;0V=I H
M2*WMXQ''&HZ!5 P![#BK*C% 'SMX0_X)\? #P1XFNM?T_P"&NE7&HS3M.JZD
MTEY;P,6W8B@E9HT /3"C& !C Q]!6UE#9VL=O;Q1P01J$2*-0JJHZ  # 'L!
M5BB@!%XI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/%'B^6V:T.J:@%BCA1B-XAA7A=VT9+,[8& 0"<_5.T^M*HQ2T ,"X^M.I:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:QH6QD9,\D9 SCL3[&O&/%__  6^MH_,C\+?"F67LEUJ^L!,>F8HXC[_ ,=
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M#@&OV0A4I&H)W$#KC% %?5M6LM!TN\U+4;F*RT^SA>YN;J=@L<,2*6=V8\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0Q1I'%& J(@"JJCH !T %2@8I:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPN/C5\9_B]\)?"7@CP_J?C_6OB#K=W>>+]>TV.Z7P_HZ3A6>,,I^=I"P'H>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\'?#:74-8B@OVU&[DELI(3YYC\J&%$8;G?\ >2@X&,[<$YKZ<^*'[(>NQ?\
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MZT]P^@]: '44W=[&@N!_*@!U%-W"@," 1SGI0 ZBDW>G- .: %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "DW?G17B/[6W[4V@_LF?#&/Q9K%C+K-U=7D=C8:3!,(I+F1LLWS$':JH
MK,3@_P (_B% 'MP;=2US7PX\?:1\4/ .@>+M!G^TZ/K5E%>VS\;MKJ#M8#HR
MG*D=B".U=)F@!:*3=1N'^10 M%)N%1SW45K!)--(L,,:EWDD(554#)))Z 4
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M(R3U)R<^N^ ?AQX:^%?ABU\.^$M%L] T6VSY5E91!$!)RS'NS$]6))-=+10
M@I&7-.HH _,_XA?\$F_&.M_%CQ]XK\/_ !(T&"R\57=].]KK&@)=M!'=3&5D
M7S-X5U.T"9-KC&05R:32/V$OVD/@1\,];LO#/[0EO'X=MK"=I-&GLWGM_)$;
M%TB282+'D9'R@=?QK],:Y?XI?\DS\7?]@B[_ /1+T ?G1KW_  3U_:!_: \
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M.>WG149D;:S*?EDC8%6/#COD  ]7HKX2\2?\%DO@;X>\0:CID>C>-=72SG>
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?XI?\DS\7?\
M8(N__1+UU%<O\4O^29^+O^P1=_\ HEZ #X6_\DR\(_\ 8'L__1*5U%<O\+?^
M29>$?^P/9_\ HE*ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *0BEHH ;MI OK3Z* &JI4<G-(T>['3'4
MT^B@!GE].]9&H^#="UA9EO\ 1=-OA,VZ07%I'('.006R.3D \^E;5% %33]+
MM=(LX[2PMH;*UB&V."WC"(@SG 4# YKS[Q!^S'\(/%E_>7^L_"WP9JFH7C&2
MXO+K0+62>5CR6:0Q[B2>^<UZ910!Y7X1_98^$'@'Q!9Z[X<^&GA?1M9LR6M[
MZTTR))H2002C[<J<$C(YP:V_BO\ !'P-\<M!AT;QWX9L?$NG0R^?#%=J0T4F
M"-R.I#*<$CY2*[FB@#YI/_!-[]F\]?A=I_\ X&W?_P >KV?X8?"7PC\&?"47
MAGP5H5KX>T2.1YA:6H)#._WG9F)9F. ,L2< #H!77T4 ?,FO_P#!-7]F[Q-K
M5]JVH?#2!KZ]F:>8VVK7]O&78Y)6..=449[* *T_A[_P3Z^ 'PK\8:;XH\,_
M#RWLM=TV3SK2ZN-2O;L0R#HZQS3.FX'D-C((!&#S7T110!YS\:OV>?A[^T1H
M=GI'Q#\-0>([&SF-Q;"2::"2%R,$I+$Z. 1U ;!P,@X%>1V7_!,G]FG3Y&DB
M^&,+,RX_?:OJ$H_ -<'!]QS7U%10!R7PS^%/A/X-^%8/#?@O0;3P]HD+M*MI
M:*0"['YG9CEF8X'S,2> .PKA=2_8S^!NL:[?:S??"OPM=ZE?2-+<32Z=&1([
M'+,5QM#$DDD#))KV>B@#S'P7^S)\)_ASKT.M>%_ASX8T+5X581:A9:7"EQ%D
M8.U]N1D<<=LCO7>ZSH&G>(K,VFJ6%KJ5H2&-O>0K+&2.A*L",UHT4 4-/T.P
MT=2NGV-K8A@ 1;0K&"!T' Z#^M7/+Z#WS3Z* &;.G3 ]J-N,9ZT^FLNX]<4
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M0 ?"W_DF7A'_ + ]G_Z)2NHKE_A;_P DR\(_]@>S_P#1*5U% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<O\4O\ DF?B[_L$7?\ Z)>NHKE_BE_R3/Q=_P!@B[_]$O0 ?"W_ ))E
MX1_[ ]G_ .B4KJ*Y?X6_\DR\(_\ 8'L__1*5U% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\4O
M^29^+O\ L$7?_HEZZBN7^*7_ "3/Q=_V"+O_ -$O0 ?"W_DF7A'_ + ]G_Z)
M2NHKE_A;_P DR\(_]@>S_P#1*5U% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\4O\ DF?B[_L$
M7?\ Z)>NHKE_BE_R3/Q=_P!@B[_]$O0 ?"W_ ))EX1_[ ]G_ .B4KJ*Y?X6_
M\DR\(_\ 8'L__1*5U% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<O\4O^29^+O\ L$7?_HEZZBN7
M^*7_ "3/Q=_V"+O_ -$O0 ?"W_DF7A'_ + ]G_Z)2NHKE_A;_P DR\(_]@>S
M_P#1*5U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<O\4O\ DF?B[_L$7?\ Z)>NHKE_BE_R3/Q=
M_P!@B[_]$O0 ?"W_ ))EX1_[ ]G_ .B4KJ*Y?X6_\DR\(_\ 8'L__1*5U% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<O\4O^29^+O\ L$7?_HEZZBN7^*7_ "3/Q=_V"+O_ -$O
M0 ?"W_DF7A'_ + ]G_Z)2NHKE_A;_P DR\(_]@>S_P#1*5U% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<O\4O\ DF?B[_L$7?\ Z)>NHKE_BE_R3/Q=_P!@B[_]$O0 ?"W_ ))E
MX1_[ ]G_ .B4KJ*Y?X6_\DR\(_\ 8'L__1*5U% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\4O
M^29^+O\ L$7?_HEZZBN7^*7_ "3/Q=_V"+O_ -$O0 ?"W_DF7A'_ + ]G_Z)
M2NHKE_A;_P DR\(_]@>S_P#1*5U% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS_Q*+O\ ]$O0 ?"W_DF7A'_L#V?_ *)2NHKE_A;_ ,DR\(_]@BS_ /1*5U%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/>/_"_AWQKX
M/U70_%MG::AX<U"$V]Y:WQ A="1P2<8.<$$$$$ CD"OQH_:J_P"">>F?#WX\
M?#;P?\*_$<EZGCY;J73EUJ8>7:M$JNH%Q&I+HP;"G;D8&2<YK]"/^"D'[+>I
M_M/? N.U\-0I<>,/#]V-1TVW9E0W2E2DMN'8@+N4AADX+1("0#FORAT3X_\
MQ8^%GC;X0Z?XA\)W-QKOPU>\@T+3-6LYX;B03@ 0R+PSK&P^4+@X^7/ ( /K
M[_@FK^TM\3?#GQZU?]GWXGWU[JAMUNH;5=4G^T7%A=VV6DA$Q+%XBBN0-Q V
M+MX)KW#XE?\ !*SP)\6OCOJOQ&\3^+-=O[;5;TWM[HBB.-9. $B68?,J *HX
M^; QN!YKS#_@G/\ LR_$O5?CKXF_:%^+&F3Z#J>J?:I+'3[N V\\T]P_[V4P
MM\T4:KN55;!.X'H 6\R_:H^'/QU_9'_:RE^,?A"+6/%_A"749M3M&+3WEM;+
M<;O/L[B(,3&@WLJMPN"A!##  &_\%0/V'?AI^S_\,_#7CKX=:7-X<WZJFCWF
MG?:YKB*8/#+(DP,SLRLIA*D X(8'&02>F^,'Q&U[XU?\$>=%\0ZS<2WVK6-_
M;65_=.,F98+UK>-V;N2IAW-W;/K7C_QP^/WQL_X*7:CX9\#>&OAM+I>D6-Y]
MID@M/-EA%SAXO/N;EU5(T13(H! P6?EB0!^D]C^QUI.G_L32? -+Q)$DT=[9
MM193L-^SFX^T$==HN"' /(4 >E 'C'_!&&9&_95UZ-7!=/%MV&4'D9M;0U\=
MZ+"=<_X*_2BT7=L\?W!(7G_4LY<\>GEL:J? _P".'QS_ ."<6I>+_!.H?#>2
M_AU*Z5XXM1@G$ NE4JLT$T?RRHZ[<@'Y@B\K@@^X_P#!,W]EGQ[KWQRU3X__
M !)TBYT<RO>76GIJ$)@GO+ZY+B:<1-AEC"R2X+ !C(NW.,T ?JJO>EIJ]*=0
M!S_C27Q'#IL3>%[;3[G4/. D74G=8Q'ALD;>=V=OX9KS'Q]>?%)_ OB1=0TS
MPRFGMIMR+AK>XG,@C\IMQ4'C.,XSWKVVN7^**_\ %L_%W;_B47?_ *)>@!?A
M;_R3/PE_V"+/_P!$I745R_PM_P"28^$?^P19_P#HE*ZB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!K+N//2O)OB5^SCHGQ-^,GPY^(]
M_J5_:ZKX':X>RM;8H(+@S !O-RI;C;QM(_&O6Z* &;><^U*R[J=10 P)USSG
MK1LXQ3Z* &;,]:3RSQSSGFI** $4;:6BB@ KE_BE_P DS\7?]@B[_P#1+UU%
M<O\ %+_DF?B[_L$7?_HEZ #X6_\ ),O"/_8'L_\ T2E=17+_  M_Y)EX1_[
M]G_Z)2NHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KE_BE_R3/Q=_P!@B[_]$O745R_Q2_Y)GXN_
M[!%W_P"B7H /A;_R3+PC_P!@>S_]$I745R_PM_Y)EX1_[ ]G_P"B4KJ* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Y?XI?\ ),_%W_8(N_\ T2]=17+_ !2_Y)GXN_[!%W_Z)>@
M^%O_ "3+PC_V![/_ -$I745R_P +?^29>$?^P/9_^B4KJ* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Y?XI?\DS\7?\ 8(N__1+UU%<O\4O^29^+O^P1=_\ HEZ #X6_\DR\(_\
M8'L__1*5U%<O\+?^29>$?^P/9_\ HE*ZB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^*7_ "3/
MQ=_V"+O_ -$O745R_P 4O^29^+O^P1=_^B7H /A;_P DR\(_]@>S_P#1*5U%
M<O\ "W_DF7A'_L#V?_HE*ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^*7_),_%W_ &"+O_T2
M]=17+_%+_DF?B[_L$7?_ *)>@ ^%O_),O"/_ &![/_T2E=17+_"W_DF7A'_L
M#V?_ *)2NHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KE_BE_P DS\7?]@B[_P#1+UU%<O\ %+_D
MF?B[_L$7?_HEZ #X6_\ ),O"/_8'L_\ T2E=17+_  M_Y)EX1_[ ]G_Z)2NH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KE_BE_R3/Q=_P!@B[_]$O745R_Q2_Y)GXN_[!%W_P"B
M7H /A;_R3+PC_P!@>S_]$I745R_PM_Y)EX1_[ ]G_P"B4KJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^*7_ "3/Q=_V"+O_
M -$O745R_P 4O^29^+O^P1=_^B7H /A;_P DR\(_]@>S_P#1*5U%<O\ "W_D
MF7A'_L#V?_HE*ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***3<!0 M%)N%(6 Z\4 .HI-U% "T444 %<O\ %+_DF?B[_L$7
M?_HEZZBN7^*7_),_%W_8(N__ $2] !\+?^29>$?^P/9_^B4KJ*Y?X6_\DR\(
M_P#8'L__ $2E=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^P/9_P#HE*Z?- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC-
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MA;Z>;J.?_ <4 >GTM(*,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC-
M"T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS
M0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:
M,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "U4;5K)=373C=P_V@T7
MGBU\Q?-,><;]N<[<\9JUFO,+CG]I2T[G_A%G_P#2K_\ 50!Z?2T@X%&: %HI
M,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:
M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
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M4 >5VGP!AL;6&VMO'?C>WMX46..&+6 J(H& J@1X    'M4O_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
MP=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_Z
MJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A
M7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_Z
MJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A
M1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
MP=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_Z
MJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A
M7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_Z
MJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A
M1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
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M?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH
M\P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#
MK_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_
M (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X
M47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["
MC_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O
M_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U
M4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1
M?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]
M/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW
M_P"#K_["C_A1?_50?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50
M?'?_ (.O_L*]/HH \P_X47_U4'QW_P"#K_["C_A1?_50?'?_ (.O_L*]/HH
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M5Z?10!YA_P *+_ZJ#X[_ /!U_P#84?\ "B_^J@^._P#P=?\ V%>GT4 >8?\
M"B_^J@^._P#P=?\ V%'_  HO_JH/CO\ \'7_ -A7I]% 'F'_  HO_JH/CO\
M\'7_ -A1_P *+_ZJ#X[_ /!U_P#85Z?10!YA_P *+_ZJ#X[_ /!U_P#84?\
M"B_^J@^._P#P=?\ V%>GT4 >8?\ "B_^J@^._P#P=?\ V%'_  HO_JH/CO\
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M\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\
MU4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH
M \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^
M#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'Q
MW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_
MX47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_[
M"C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.
MO_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_
M -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A
M1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*
M]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!
M\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\
MU4'QW_X.O_L*]/HH \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH
M \P_X47_ -5!\=_^#K_["C_A1?\ U4'QW_X.O_L*]/HH \P_X47_ -5!\=_^
M#K_["JK?L[V;:F-1/C;QI_: B\@7?]K#S1'G.S=Y>=N><>M>LT4 >8?\*+_Z
MJ#XZ_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A
M1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
MP=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_Z
MJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A
M7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_Z
MJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A
M1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
MP=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_Z
MJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A
M7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_Z
MJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A
M1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\
MP=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_ZJ#X[_P#!U_\ 85Z?10!Y
MA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A7I]% 'F'_"B_^J@^._\
MP=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >8?\*+_ZJ#X[_P#!U_\ 84?\*+_Z
MJ#X[_P#!U_\ 85Z?10!YA_PHO_JH/CO_ ,'7_P!A1_PHO_JH/CO_ ,'7_P!A
M7I]% 'F'_"B_^J@^._\ P=?_ &%'_"B_^J@^._\ P=?_ &%>GT4 >7GX%_\
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M) 8=P>15_P 1^)--\)>'M3UW5KI;/2=,M9;V[N6!810Q(7D<@ D@*I/ )XH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNK]Q]+U"#5M-M;ZUD\VVNHEGBD'\2,H93^1%?D!_P6TQ_P +G^'O3_D7Y/\
MTI>OU1^!OF_\*5\ >?\ Z_\ X1_3_,Q_>^S1YH [BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML@M&9[>+7--AO5A9@ 602JP4D 9(]* /)/V!0/\ AC?X3_\ 8%0?^/M7Q_\
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M'X?Z7\./"UVUEKOBV&634+R)B);;3U.PJA[&5BR[NRHXZD$?GU^Q=^U%\/\
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MV=K+<>63C?L0MC..,X_6@#1!S1N]J_);_A^)KO\ T233_P#P>2?_ !BG1_\
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MNS0 M%(#FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@D*<XH _3:EJKI>I6NLZ;:ZA8W,5Y97<2SP7$#AXY8V 9'5@<$%2"".H-6J
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M#Q)NQR3AP<= : /U$HK$\$^,]$^(GA/2O$OAS4(=5T/5(%N;2\@SMDC8<'!
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M@D>_<"$;.:^,_P#A^)K@Z?"73_\ P>2?_&* /UH+!>OUI:_)=?\ @N%KC?\
M-)-/_P#!Y)_\8K] _P!D/X_7'[37P+T;X@7.BQ:!-J$]S";&&X,ZIY4SQ@[R
MJYSMST[T >S44F:3?[&@!U%-W>@)I=U "TF:3=]:3[WTH 7<*6O@;]L;_@II
MJG[+/QJN? EKX!M/$4,-C!=B^FU-[=B9%)V[1&W0CUYS7WE9W N+2&;&/,0/
MC(.,C.,]Z +%%-W4;A0 ZBF[A1N% #J*3=1NH 6BF[A1N'UH =13=P]:7=0
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M9W_;:^+7[#5OJ/@9O"]C_9S7S7EUHOB+3Y;>ZBF941F5@4<$K&H^<,!C@#-
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M&^,;?$O2[+5X==34VU6TM8[[R;.RE+%ML442I^[Y(V,6&TX((XKXD_X+=?\
M)5/AI_V!KC_T>* /TR^$GQ(TG5OV=_"7CRZM++PAH4_ANVUB6TB8+;:=;FW6
M4H"% V(O'W1P.E?!'Q0_X+/E/%%UI7PM^'8UW3H7Q#JFK3R*URHZLMM&N47K
M@E\XQE5/%7?VMO&=[X3_ ."2WPDM+*XEM_[>T[0-+G,+%2T7V,SLI(_A/V<
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MWCE<1AP=I8W !(ZA /J ?3'PE_;IL=:_9&F^.7Q(T1?!^G1W$UO!:V4YN6U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU=7^; _O D$$$@_"WQ8_X(EW"O-<_#7XA1R)R8].\46Y5AZ#[1"#G_OT.GY
M'7_&C_@E'X7^/?Q&N_'?PR\>Z'X5\+ZJD<PL=)T\75JDP #R0M',J!6X;:O
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M%?8]<?\ !_X5Z#\$?AGX?\#^&H6AT71;;[/#YA!>1B2TDCD  L[L[G  RQP
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M%]W)&3W46EFN?S5A^%??% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UF"]:=7F?[2
M7B+QQX3^!_C#5OAMI7]M>-[6RWZ;8^493(^]0Q5!]]E0NRI_$5 P<XH ]+S1
MFOQ8?]I;_@H4SL5T;Q\@))"K\.8L#\[&D_X:6_X*&?\ 0(^('_AN(?\ Y!H
M_:C-&:_%?_AI;_@H9_T"/B!_X;B'_P"0:/\ AI;_ (*&?] CX@?^&XA_^0:
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M.=8?/GV,.ZL8\$=P2.E 'U%KW_!:[Q-9^(DN+/X36<7AJ0LT$=]J$JW5PF0
M_F*FQ>,Y 5AR!DXR?T"_97_:8\.?M5?"NW\9>'X)M/=)VL]0TRX96EL[E0K,
MA8<,I#*RM@9!&0#D#S;_ (*9^%=+U?\ 8E\>&ZLH9&TJ.TN[)O+ -O*MS$@9
M./E^1G0X_A=AWKYF_P""'=U+)H'Q?MB[&WCNM+D1,\!F6Z#'\0B_E0!^H><U
M\B_\%1OC3??!S]E754TBY>TU?Q/=1Z#!/$VUXHY%=YV![9BC=,CD>8#7UT*_
M.C_@MEI=S/\  WP'?QAC:V_B(PRX' :2VD*D_P#?MOSH \;_ ."2/[(_A/XJ
M6?B#XH>-=)M?$5MI>H#2])TZ^C\R 3K&LDTTD9^63"RQ!000#O.,[2/T5^.7
M[)OPX^.GP]U#PSJWAC2[5WMVCL-1M+*.*XL) #L>)U ( ."5SAAD$8-?./\
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M_P#,I:M_Z1RU^7'_  1,_P"2^^.O^Q9/_I5!0![=^W5^VUX9^!/Q\O/"NJ?
M[PIX]NX]/M;@ZQJXB\]@ZDA/F@<X7MSW[5]3_M@?M,7'[+/P-B\>V?AZ'Q!(
MUY;68L);HVZ@2JQW;PC=-O3'>ORJ_P""NW_)Y&I?]@6P_P#0#7W5_P %;O\
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M5K_#OX,^!/A%92VO@KPAHOA>*8 3'2[*.%YL=/,<#<^/]HF@#YT\=>#OB?\
ML@_L0^'=%^#5KI^O>)/"EJAU*.>S:X:X1M\EW+;QAURPFD,@4AB5W#!/7Y4^
M"O\ P5"\!^//!=YH?[3'A&'Q9J23R26VH1:%:W5L\)&1&T38V.I! 8 YXR01
MD_K1M/'.?6O*?''[*/P>^)&JS:GXD^&OAG5-3G.Z:^DT^-9Y6]7D4!F/N2:
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MF,>K.$ #D_[0/>O3O#/A'1/!.C0:1X=T>PT+2H,^58Z;:QVT"9Y^5$  _ 4
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MMGQCX \,_$32!I7BOP]I/B?2UE$XL=8L8KN$2#(#[)%(W ,V#C/)I?!?P_\
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M12;KCA'G3KV#=\&O9_A[\&? WPEM9(/!7A#1/"ZR+MD;2[&.!Y0.F]U&Y_\
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M)/&WPJ\&?$V&TB\9>$="\6QV;.ULNN:;#>B MC<4$JMMSM7.,9P/04 ?.O\
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M1;O1]=TNRUK2;M/+GL=0MTG@E7.<.C@JP^HH _&?]L[_ (*76W[4GP4T_P
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M36TA:]U0(P;;=3,9'3(X.P,L>1UV9KW2D VTM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4A%+10 U5('7-+2T4 )12T4 -9<]\5A>./!FE_$'P9KGA;6H?M&CZS93
M:?=PJ<$Q2H4;!['!.#V.*WZ:RY]/RH ^)?A!^T%<_L>_9/@Y\>I)]*TW2O\
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M=NO]WMVKU_X=_ _X?_"-)5\%^"]"\,-*NV672[".&64#H'=1N;\2:[7:>>:
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MS?-C/S'U-:7A?X:>$O _AZXT'P[X7T70=#N&=IM,TS3X;:VD+@*Y:)%"DL
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M'3$@=B.O[T'N"?W VG.:Y_QQ\.?#'Q,T-M&\7>'M+\3:47$OV/5;1+B,..C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB/PSI
M'C#1KO2-=TNRUK2;M/+N+#4;=+B"9<YP\;@JPR <$=JTZ* .3\#_  E\$?#'
M[;_PAO@WP_X2^W;/M?\ 86EP67VC9NV>9Y2+NV[WQGIN..IKJU7;FEHH ***
M* "L+QEX%\-_$31_[)\5>']*\3:5YBR_8=8LH[N#>N=K;)%*Y&3@XXS6[10!
MSW@GX>^%OAKI,NF>$?#6C^%M-FF-S)9Z+816<+RE54R%(U4%BJ*-V,X4#M70
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW-E>0!S0!ZQ2TT'UZTNX<^U "T4W<*-W)'I0 I;%%?.G[:'[77_#(OA?PQK
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M?&OX7ZQ\%M2U?Y=-U'5+@SV-PV0 #(8H]H+'&X;E!(W%<T ?:8.>E&:0,/\
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MS@+O,YDBC=V;A51#-'N).?F^4,>*]64Y% #J**3- "TC,%I-PZTTD-R/3Z4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#_VXOVAOVD?"]C=_ WX2Z1J"VEK"FMZ]KLQALOM[1JTMO:H\T9(0L!N+/VR
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M96'P1\(P^'Y(?M":#<7,AU9H2-P;'VA?GQ_#L#<XV9( \X_X*FR>(M4_:?\
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MWP1\#O@WJ/Q<^#T5Q\,_&7A-X;H7&C7LT<=U"TJ1M&P9R PW!@1][!4@[A@
M_0#PSIL^C^'=*T^ZN3>7-I:102W+=975 I?\2":_+WXZ?L(^*K?X'_$KXS?'
MGQS/XW^(MKI#S6&GV<K"QTUBR]#A=V,G$:*D8.?OY!'WS^R3\5-2^.'[-_@+
MQMK"!-7U33@;QE38))XW:&20+@8#M&6 ' #<<5SO[?2[?V-?BN!P/[&;&/\
M?2@#+_X)O\_L2_"W_KRN._\ T]STW_@HS\3#\+_V0_'=S!)LU'6;==!M%7[S
M-=-Y;@>XB,K<?W:=_P $W_\ DR7X6?\ 7E<?^E<]>:?MJ-_PN#]J_P#9T^#,
M9\VR349/&&LP-RI@M@3$&'HWE7*?\#% 'N/PU^%GB'X1_L@Z5X&\(-;Z?XUT
MWPH]O933[?*35FMV;>V05V_:7+'((Y/!K\Y/VQ/V&9_@K^S9KWQ/^(GC*\^(
M7Q7U'5+.&;49)9/LUJCN=Z1[CNDZ8W,% '"HN.?V'P6!Z8KXL_X*\#;^QKJ(
M_P"HU8?^AM0!]*?L]J?^%!_#3_L6=,_])8Z] X7J?>N!_9Z_Y(%\-/\ L6=,
M_P#26.KWQB^(EI\(_A9XL\:7H5[?0M,N+\QL<>:R(2D>?5FPH]V% 'PC^V1X
MPUG]L;]I[P_^R_X.OY;/POI<BZEXSU&V;H$VLT?H1$K( #D&:500/+S7Z#>#
M/!^C_#_PKI7AOP_80Z7HNEVZ6MI9P#"Q1J, >Y[DGDDDGDU\-?\ !(_X7WDW
MPY\7?&?Q'_IOBGQ[JT[B_F +O;QRMYCCT+W)F) X/EH>U??R]* /+?VHOBOJ
M/P-^ GC+QYI-G:ZAJ.B6BW$-M>[O*=C*BX;:0<88]#VKYZ^(W[<GBSP;^PCX
M.^.5KH&CS^(=:GABFTZ43?9$#R3*2N'#<>6.K'K7IW_!0[_DR_XJ?]@Q/_1\
M5?$'QURO_!''X6'M]LM/_1US0![>O[7'[3OQUL7\1_ CX.Z-<>!8V,=MJOBF
M<1S:JR'#O#&UQ#MCW*RC.>GW@P*CTC]B/]MB]_:6U+Q;X0\8>&!X*^(?A9P;
M[359MDT>\H[*C_,C1N K*Q/WD(8Y(7V[]GC1[?0?@#\-=.M$6.WMO#>G1HJ@
M#I;1\G'<GD^IKXM_9R41?\%>OCY$@"(?#;N57@%O,TLY^N23^)H _15>E>)?
MM>?M.Z3^R?\ "2;QCJ%@^LWL]PFGZ9I4<GEFZN7#, SX.U J.Q.#T ')%>VB
MOG_]MC]E>#]K;X/_ /"*)JB:)K5C>)J6EW\L>^-9E5D*2 ?-L978$KR#M.#C
M! /#-0^./[<.B^%Y_&%[\'O \FCQ0?:Y-"@N)3J<4(!8Y'VDYDV\E0I/0;,Y
M%>F?#S]J_P 6?M(_LNK\0?@[X1T^_P#&\=\-/N?#FM7H$,$JLIE'FAH]P\MU
M=2<9W#BOGJ'XI?MT_LQV:1>*O!.G_&#PU8H$.I:>/M-R\:]P\!68\=7DA8D<
MDYR:^I?V+?VG/ _[37PWN]1\(Z''X3OM-F6+5/#J(BBTD<,49615#H^&P^T$
ME6R 10!\.?\ !(GQ%\7;#2;S3/"_A;1=2^&UQXBSKVLWET$N[1_L\8(BC\P;
MAM$9^ZWWC7T[\?/VY/%.G_&EO@U\"O!$/Q%^(-K&)=2NKR4BPT[@$K(59.5W
M)N9G15+!>6) \W_X(HX;X"^.>,_\5,?_ $D@JM_P29ACUKXA_M%^)-2BC_X2
MBY\01K<LX!DB5Y;J1U#=<,^<^OE@]J -OQ!^VW^T'^S-JND7?[0?PHT>+P1J
M$_V=M?\ !LK2?97(R RF:0%A@_(Q3<!\I)4Y^U=?^*7A;PW\,[GX@7VKPKX1
M@TT:L=20[XWMB@='3NV]2-H')W #DUY9^WMI6G:O^QW\58M2CBF@CT62XB\Y
M P$T9#Q,,]PZK@CI7PWXL\0:Q>?\$4/#<@+;9+Q;*=E/+6T>KRJF>O&Z.)<>
MU 'L/@W]L#]J#]I:&^\1_!7X3^&[#P#%/)#::AXPN'\^^*,02A6:,=L$*&56
MRN\X->K?LE?MG:K\9O'7B7X7?$CPF/ ?Q8\.H9;O38Y"UO=1 @-)%DDKC?&<
M;G#*RLK,"<>H_LEZ7IVB_LN_"6VTN...S/A;395,:A0[O;([N0/XF=F8^[$U
MTO\ PAOP^A^*)\0-I'AX?$.:V5?[1:&'^TS %*C#$>9MV@KQP0/;@ ^(OV,S
MY?\ P4D_:>9CA0)<D\#_ (^DS7I4W[;'BOXR_M#-\-_@'H&C^)M#T<X\1^,]
M8,K:?:_-@^3Y;KYF,,!S^\;.W"*7/P]XD\!_%WXK_ML?M&>"/A+<QZ;-K4]T
MFM7LDP@ LU<.(O-ZKYK[$^49(;!PF^OKS_@DW\2O#5S\']4^&*Z%;^%?'WA*
M]E&MV&PI/>[I"/M+AOF+@CRG!)VE$'RAE4 'W=%N$8#,&;N0,#/TKQ?]K+]J
M3PU^R=\,SXJUZ)]2O+B86FF:/;RK'->SD$D G.U% RSX.T$<$E0?:5Z5^<G[
M?D">)/V]?V7M!UF))?#_ -LBE6.8!HY97O4#QE3U!\J '_>[T ;\/[0'[<5]
MX;_X3&#X(>$UT!H3=)H4DLHU9H<;@=GVD-Y@ ^YY8<YQLSP/H/\ 9$_:T\/_
M +67@.\U;3[&;0?$&D3K:ZSH5TX>2TF(RK*<#=&V'"L54Y1Q@8KWCJ1STK\W
MOV45@\._\%6/V@-%TB**+2;C2Y[N>.%=BK-YUD[M@<??FE[=6/3)H TO'7_!
M23XA:7\:OB1\*?"GP]L?%?C/3]872_#%G:I,QG5?-:>>YPXRJ(B<*4^^26 4
MU]+_ +(?Q#^,WQ$\':U<_&CP58^"M=LM0^QVT%BDB"YC$:L9=K22#&6P&5R"
M5;@8Y^5?V.]#M[S_ (*A?M&ZE*-]Q9174461G'F74&X_7"8_$U^DFW\: .>^
M(7B";PCX!\2:];11S7&EZ9=7T<4N=CM%$S@''."5QQVKY(^'/[<GBSQI^PCX
MP^.%UH.C0>(=&GFAATZ$3?9'"/"H+9??R)3_ !#H*^H_C;_R1?Q]_P!B_J'_
M *325^9GP)_Y0W_%$_\ 3Y=_^CK6@#USP?\ MQ?M#?M(^%[&[^!OPETC4%M+
M6%-;U[79C#9?;VC5I;>U1YHR0A8#<6?MD $%N[_90_;B\7?$CXV:Q\&/C!X(
MM? OQ&T^W:>%;%V^SW.P*SQA&9\'8?,5U=U=0Q!&!N[G_@F]H]MI'[%/PQCM
MD"">TN+F0]V>2ZF=B3WY/Y #H*\!^(RB'_@M!\*]@VF7PS,9"O&__0=2Y/KT
M'Y"@#WS]LK]LV#]F.'P[X?T'0)/&GQ)\3RB'1_#\);D%P@D<*"Q!<A511ESD
M C!(\/\ %W[2_P"U3\)_!=]K_P :/A)X?;X?WEK);W]QX2F+WFE>:AC1Y%-S
M*&0-M)[?-@N.!67XF5/$'_!9[PW%K"K)#I?A_.F),NY<BQGD! /]UY)F![,,
M]J^^/B1HMAXB^'?B?2=32-],OM+NK:Y$R[D,;Q,K;@>HP3UH ^,_^",O_)J>
MN=<_\);=C_R5M*U?'7[<GQ!^(OQBU[X:_LY?#^R\:ZAX>=X=9\1:Y<&/3;>0
M,5PNR1-P#!AG>"Q5MJD+N/$?\$I=0N])_84^(%[IZ;[^VUK5)K=!U,JV%LRC
M\P*\-_X)PWW[1^B_!S7[OX->&/A_K6B7>N2?;K[Q-+.+P7*00CRSLG0; C*P
MXSF1^>P /IS0OVWOBM\%?B9X>\(_M*_#O3?#&F^()EM=-\7>&Y2UAYI?;^]W
M2. O*EOF5E'S;"IX]!_;=_:6^(W[*MAX=\8Z'X6TGQ1\/9+F.VUR242B\LV9
M^&5E?8%=?E5BN%<*#G<!7SW^TM\'?VQ_VJ/A['X-\7^"_AC::?%>Q7\5QI5W
M-'<QRHKJ"K23NN"KL#\O0]J^W(?"MC=?LVVN@?%>.S:RC\,Q0>)OM$VZW39;
M*+ES+QPI5FW\8QD8Q0!QWQL_;,\$_"?]FN#XN6EY'K%CK%JC^'[0/M;4+B12
M8XCW7;R9.Z!&'4 'H/V5?'7Q&^*/P?TOQ;\2=$TOPUJNK_Z3::7IJ2AH[1@#
M&TWF,Q#ODMM'12N<'('XZ?LLCP7XB_::\!^&O'6M:UJ/P7L-<OU\(_VS%LM+
MBX,JF-9E)VJ)&\EI%&1N958!78C]ZU(48H <*6D!W<BEH ^6OCY^UAXB^$_[
M6'PB^%>G:1IEWH_C/9]KO;H2?:(,S-&?+VN%Z*.H->>_'S_@H=KGP/\ VGM:
M^&">"X_%,(TJW?1+/35D-_?ZC/Y?EP$Y*A/G<DA"<+@9) KDOVSO^4E'[,7_
M &R_]*I*HZEI%MJG_!::PDN(Q(UEH/VJ(,,C>-.= <>P<D>A H L?$;]L#]L
M'X#Z0?&WQ#^"WA5? R21BYCTZ[+3V@9AM$DB7,NTG(7>8RF[;T)P?N#X7_%S
M0/BM\)-#^(6FW M=!U33QJ!:Z95^S*%/F+*<[08V5E8YP"AYQS7%_ML1+)^R
M/\70ZJZCPU>G:PSR(B0?P(!KY4^#-]?V?_!%^]FL';[3_P ([KL>0>1$VH7:
M2?AY9;\* -C3?VXOC?\ M*^+-=M?V;OAOHU]X.T:X-K+XJ\72/'%<L.1L421
M["1SL^=@K*6";@*[;X _MK>,[[XYGX*?';P39^!?B!<0-<Z7>:7(S6&H*%9M
MJ;F?;E4D(<2,"493M88.W_P2YTK3]._8C\ 36*(LE\]_<W4RKAI9OML\9+'N
M0L:)D]D6O>/$_@WX?:EXYT'7/$.D>';OQ=:J8](OM3@A>]B"MN_T=G&X$,V<
MKR"WN<@'Q#H_S?\ !:#7<=?^$94_^2,->X?L[_M7>(?C%^T]\9/AEJ>D:;9:
M3X)N'BL[RU\SSYPMP8QYFYBO0=@*\0T7_E-#KQ_ZEE?_ $AAIO[#L@C_ ."B
M'[4L;AE=KJ9PI!Z"\//ZC\Z /IW]M?\ : UG]F/X!ZGX\T'3['5-0M;NVMUM
MM1#^41+(%).QE/ )[UTVE_'#3=(_9OT?XL>,)8=)T^3PW:Z]J @!*Q&2W24Q
MQ@G+$L^U5SDD@5X-_P %;95'[&&NH6 9]4T\+GN?.!Q^0/Y5Y=^VUJ5[9_\
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M3[1!F9HSY>UPO11U!KSWX^?\%#M<^!_[3VM?#!/!<?BF$:5;OHEGIJR&_O\
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M+K2;J*Z290R&,PL&R#P1BOC7_@C'J5W>_LL:[;3C-O9^*KJ*W8] IMK5RO\
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M^'?B?2=32-],OM+NK:Y$R[D,;Q,K;@>HP3UH ^,O^",ZY_93UO\ [&V[Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 T@]J^&_VWOV7_B/=?&+P=\?O@E'#>>//
M#D:VUYHLLBI]MA7> 4W,JME))(W3<"R$;?F'/W-3&4L1C&/2@#\F?!_[1W[0
M^J?'/X[OX+^!>H67Q$\56VA6M]#<SL8O#[0VLL4<SET13YH<R1[V 78?]8 :
M^U/V#?V4YOV4_@[+I&K7L6I>+=8NVU'6+F!BT2R;0J1(Q +*JCJ1RS/VQ7LO
MAWX5^'O"OQ \7^---M'B\0>+%LUU:X:9V686D;1080G:F%=L[0,]ZZ]5VT (
M?E_^M7Q1_P $X_@7XZ^"_B#XVS^-/#TVA1:]KT=UIK32Q/\ :8@]R2PV,<<.
MO7'6OM@C--VGUQ0!Y/\ M3? /3_VE_@CXA\!WMPME->HLMC?,F[[-=1MOBDQ
MW&1M8#DJS 8-?(?P_P#CK^UE^SUX#M?AQK?P!NOB'JNCQ#3M)\3Z;>%K6:%
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M_P $[?V.?BCX!^-DGBSXNZ5-:0^#M%;0_"YN)XIE822RLS1;&)"(KS ;L?\
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M=K[789HVG&,T >6?M4>%-6\>_LX_$GPYH-DVHZUJF@W=I9VB,JM-*\9"H"Q
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MQU^W-\!?'&A>'IM1\*>'?+_M34DFB5+7$[L<AF#'Y2#P#UH_X47XZ_X>C?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQO(&4X(.".A%4[3]J;X,7]PD%M\7? EQ._W(HO$MDS-] )<FOSKL_@?X)_:
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M%?JB* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FLN:=1
M0 SR]W7^=. Q2T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RK_ ,%1O^3%OB8?
M^P9_Z=+2OJJOE7_@J-_R8M\2_7_B6?\ ITM* /EK]F/PO^VU>? +P1/\/?&'
M@NQ\%2:>K:5;ZA#$9XX=S8#DVS'.<_Q&OI+X!^&OVQ-/^*FD3_%KQ7X1U3P(
MJS_;K72HHUN'8PN(MI6W0\2%"?FZ UWG[ ?_ "9O\)\<?\29/_0WKW_;SGO0
M!^=G_!7O('P(!_Z&:3 Q_P!<:YG_ (*+R/\ #/\ ;"^%7Q2\?>#[GQW\'=/T
MXVLNGK )+>*YW3[@RL?++YD@E DP)/+VYPI(Z;_@K[_S0<?]3-)TZ_\ +&O5
M_C]^VA)\!?VFO#_@'XA^'K&Q^%'B*P+IXHF224&3:59)%QL"K(%###$+*C'
M- 'E'C3Q9^QW^W9X/M_#%IK^C_#_ ,4M/&UE>W&F1Z7?0MN ,2NZK'*)!E?+
M#MR0<9 K2_X*A>,-9^"_[(/A#X>Z+K%]>WFN7-MH-SJ,S*+B\M(8#Y@<J!\T
MC+$&P ""PQ@XK@_V^/#?['UY\$_$&O\ AF\\%1>/Y(E;1_\ A"+Z$RSS>8,^
M9!;/Y90@-N=UXP<'=BL_X]_!'XD?$+_@EQ\*]3U6&[O_ !GX1*ZU=0SAFNSI
MQ,ZQ\8R62"2V8@\[8VSR,4 ?;/P;_8U^%GPE^%>G>#_^$*T'62+1(M4OM0TZ
M.>749BH$LDC2*Q(9LD+G:H(   KG/V4?V/9?V5/&/Q"ET3Q>U[X)\1WGVJP\
M+/:OC3&#':PF,IW'8VP_("P2,ECMJ;X0_M]_!GXD?"W3?%.I>/\ P]X:U#[(
MLFI:1JFH1V]S:SA1YD:QN0\@W9"L@.[C')Q7GG[,7[47Q/\ VFO%'QG\1:%8
M6O\ PJ_289[7PC)<61CGO+T+F/+D\KM&YE*Y'G(,\$4 <QX+^#_[/O[(?CSQ
MGXC^,_Q,\+^.?B#X@O6U SZ_8QFZLT<ER$MM\S!F8D[\ D *!@'/RG^WM\<?
M@'XU\5^ O$'P,6WM?&>D:L)KS6-%TB33H64,KQLQ*1F2177(8 G&[YL8KL?^
M";NC_ +QAI_C;6_C==^']5^*DNM2O/#X^GCYA*JQD"7!V2.TIEWD@L"%! R-
MV+_P4^^/GPW\9Z7X/\&?"6'3+_0_#FH-?:IJ7A^U1=-CN'CVP0I(BA'8I',W
MRG!"C!."  >^?\%;/^1H_9S_ .QFF_\ 0[2OT5K\YO\ @K%<1W?B']FZ:%Q)
M%)XCE='7H5+VF"/SK]&10!R7Q:^'6G_%SX:>)_!FJA?L&N:=-82,R[O+WJ0L
M@]U;##W45\;?\$E_'VH6OP[\;_!SQ&3#XB^'NM36_P!FD/*02R/N49ZA9TGR
M>V]/45][$9K\K_VQ_$6I?L.?MG:I\4]#@D72?B-X4O[4K$,*NI)"%4D9' F2
MSD8]<228H [#X2ZQ!\?O^"@GQ;^,U[_I?@_X3Z9+I>DR-RAF1)4+*<<@[;V3
M(Z>9&?2O!_V-/CQ\ ;SQIX[^+7[16O6=]\2-:U5FL;+4]&N]0AM+?8K>9&$A
MDC&2WEJ"<HL(P #S]O\ _!/O]GR+X?\ [&>FZ3JL)34_&UK-JVJ%P=Y%W&%B
M4YY!$ BR.S%O>OF']A#QQX _9G\1>.O@3\=[#0M!\0Z?K,EWINM>(+6(6MS&
MR(A032+A$(C$L98@,)6&<@ @'%_MO?'#]F_6H_"WQ%^ VOV6D_%KP_J\-RAT
MG0KO3UNH1N8M('@CC9E8(<GEE+*<@\?:/[37P?TK]L?X%_#3Q#XC^(D/P^\"
M11VOB75898E-M>1RPHRJTSS((MJO(JL=W,F<' K@/VEOVNOA7X!U3PUX2^#G
M@WP1\6OB!K&HI;?V;I=I!<6\49R,&6$%?-+E0%!^4;RV,#/F_P#P5&N+J/QO
M^SOX;\<M)HGPGDFC_MU-'#K:I(LD*3A5 Z1PEO+X)"L^T>H!ZUXN_:'_ &&/
M!_A&3PO./!.IZ3'$8ET[2?#[7N_"E<B2.$C?@']X7![[LG->>?\ !&368IK?
MXX:5I4UR/"]KK%G<Z9:7)^:)9!<KDC)PY2&$-S_ *]ME^(7['G[-?@D>)=";
MX<Q>1!YMFN@BTO-3NV4918RI:5VR0-S'"D_,1FO!O^".?B"[UCQQ^T-)JMLV
MG:O>:CI]]-8S*5EB=Y+XR*5(!&UF .0,$T >>?\ !-;]FOPA\<OBA\7-;\>:
M1'XDTCP]J9@TW2[]B]G]HN))3+,T?1F"01+SP0W(R%(_5;X=_#GPW\*?"=IX
M9\):/;Z#H5JTCPV-J"$C:1VD?&23RS,>O?'2O@[_ ()!_P#->.?^9F3O_P!=
MZ_11: ,WQ+K4/AOP_J>KW/\ Q[Z?:RW<G./E1"Q_0&OQX_8S^/'P"NO&GCSX
MM?M%Z]97OQ)UK56:RLM2T6[OX+2WV*3)&J0R1KRWEJ"=R+" , \_L/XDT6#Q
M)H&I:1<C-MJ%K+:2<9^5U*G]":_+G]@_QQX!_9F\1>.O@3\=[#0M!\0Z?K$E
MWIVM>(+6/[+<QM&B%!/(N$0B,2HS$!A*W(. 0#C/VWOCA^S?K4?A;XB_ ;7[
M+2?BUX?U>&Y0Z3H5WIZW4(W,6D#P1QLRL$.3RREE.0>/0_\ @JQXHG^)'P9_
M9T\0Z6_V6ZU^<7]JT#$>6T]O;NA5AR,%QC'/3TKT_P#:6_:Z^%?@'5/#7A+X
M.>#?!'Q:^(&L:BEM_9NEVD%Q;Q1G(P9805\TN5 4'Y1O+8P,\I_P5:MYK/P_
M^SK;W-M:V=Q#KHCDM[%=L$3!( RQ# P@(P!Z 4 ?5GA']A_X)^$_AM:^##\.
M_#^JV26P@N+Z_P!/BDO+E]N&F:<KY@D)R0RL-O\ #C Q\O?\$C8YO"OB?]HK
MX?V]U--H7AGQ' ME'*<D,TEY [G_ &F2UAS_ +M?HQNK\[/^"7 Q\??VML_]
M#/;_ /I5JE '+_L8> ]$_;$_:P^-?Q<^(=A#XGMM#U)=.T+3-3C$]K"ADE$9
MV-\I,<4*  @@M*SXW8(UO^"L_P"RWX*L/@FOQ,\-Z!8>'=?TF^@M[Z32[98(
M[VVF?9B5$PI99#&0YYQD<\8Q/V7O'FD?L(_M;?%SX7_$FY7PWX;\57BZGH&O
M7IV6K('E,6Z3[JAXY=I8\*\)4D9K3_X*G?M<^ _%GP-G^''@CQ#8^,=5U"ZM
M[K4YM#G%U:V-I%*K!I)H\IN:80J%SD9YQE<@'K/QR7_C4ZF./^* T?\ ]%6M
M?-?QU^7_ ((X_"PYQ_IMI_Z.NJ^D_C@W_&IU!G/_ !0&C=?^N5K7S;\=N/\
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MGQ/XBTR:S$&CP22QV=H\9^T7$S[0$"Q%^.N<9  8@ ]4_P""7/\ R8K\,_\
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M2=/BM98MUU#$R%HU!92DC JV1G!Z@&N6^)>/^'T'PGS_ -"Q/G_P!U.O=?\
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MY].EFGM9+<B=8XY&7;(H)&V5.>G/M7I% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>$?!,.N?#O62I\0:Z]A<2MI^964XE218TPH!^=6ZT ?08YI:8''(YS2E@,T
M+F@<U\^_&+XL?%[PK^T7\-O"W@_P3#KGP[UC:/$.NO87$KZ?F5E.)4D$:?*
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MVJ< D9..17!_LL?'Z']ICX.V'C^WT=]"M;^[NH8;*6<2NL<4S1JSL !N(7)
MX&<9.,T >O44W>,X[T;O;% #J*0-NZ49H 6BF[QMSVHW#./SH =13=P]#Z]*
M!(#0 ZBDW>U)N]C^5 #J*;N%&Z@!U%-W"@-F@!U%-W#FC>,X[T .HI-W&<&C
M<* %I*-PK*\5:I)H?AG5]1A$;36=I-<(LN2I9$+#/(XR* -7K2U\S?\ !/S]
MICQ1^U9\$=0\8>+;'2=/U.VUN?3$BT:&6.$Q)#!(&(DDD.[,K9.[' XKZ9H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW3TU#6O%&K6ZW#\B(LL*.KJ0/M$2XV$EMWS*HR>4_;.&W_@I+^S&>,_NNO\
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M\;_\%3/@#XH^/'[.]L/"%I-JNL>'=375CI5N"TEW"(I(Y!&O\4BB0,%ZD!P
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M.)V,:3.,@$LX8*&8*!&[,0%PWD'_  5JX\3_ +.>/^AFF.1Q_':5#XC<1?\
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M#T- 'M/[7?[3-I^S'\"K_P >0V::]=R/%::7:JY\F>>4$HSLO_+,*K.2.H7
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MWUNRT*>&\UZ:+R7O)1<V6]BFYMN&.W&3C:*[+]AO/_#PK]J@G_G]F_\ 2QJ
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M[:>H? #X _#C4-/TZ/Q/\3_'-E:II.GR1GRGF>&)I9G5,94/+&HC4J6:0 8
M)'/?\%@EV_L>L/\ J8+'^4M>'_'IEL/VI_V(+W5#_P 29M'TB.'<V%6X$D?/
M/ ^9X/R'3B@#U6U\,_MY>$_#_P#PF]WXW\)>*KZ*/[7<> &L( 9(P=WD)-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$%MI*COG_5CIT[5I_"7_@G'XQ\8?$S2_B;^T=\1I_'7B339TN;+2-.F?[+
MR/O0&0JF$#?-Y42(N1]X@D'[^VDTM 'R3^W=^RWXR_:.UKX177A272XXO"VM
M27]^-2N7B+1LT!'EX1MQ_=-P<=15[]M#]C6Z_:%O/#?C?P3KR>#_ (J^%6\S
M2M69#Y=PJN'2*9@"RA7W%6PP&]P5(;CZHQ[T@6@#X \5Z5^WI\2_#5QX$OK3
MP!X5L[R)K6[\7:?<LDTD1&'(P\A0L-PRL*GGC:1FOI3]DG]EW0_V3?A/!X1T
MJZ;5+Z>9KW5-5D38UW<E0I8+D[$"JJJN3@#))))/M>#FEQ^= 'YC_"/]A?\
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M$77OV@#\=_V@M=T[5O&-G&8-%T+2"6M-/7#*I)(  4.Y55W<OO+%J^W2/PI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4AI:* &LN?Y4M+10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564534688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BOSTON SCIENTIFIC CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-2695240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Boston Scientific Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marlborough<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01752-1234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">683-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,780,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member', window );">Senior Note due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Senior Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX PR A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572964816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564579760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 12,682<span></span>
</td>
<td class="nump">$ 11,888<span></span>
</td>
<td class="nump">$ 9,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="nump">3,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">8,727<span></span>
</td>
<td class="nump">8,177<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration net expense (benefit)</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring net charges (credits)</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation-related net charges (credits)</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">6,978<span></span>
</td>
<td class="nump">6,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(470)<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) available to common stockholders</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 985<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share &#8212; basic</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share &#8212; assuming dilution</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">1,430,500<span></span>
</td>
<td class="nump">1,422,300<span></span>
</td>
<td class="nump">1,416,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Assuming dilution</a></td>
<td class="nump">1,439,700<span></span>
</td>
<td class="nump">1,433,800<span></span>
</td>
<td class="nump">1,416,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564304368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="num">$ (82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change in derivative financial instruments</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in defined benefit pensions and other items</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income (loss)</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="num">$ (145)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800563500112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 1,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,760<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,446<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">6,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">3,942<span></span>
</td>
<td class="nump">4,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">32,469<span></span>
</td>
<td class="nump">32,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,803<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">8,915<span></span>
</td>
<td class="nump">8,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">263,289,848<span></span>
</td>
<td class="nump">263,289,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021</a></td>
<td class="num">$ (2,251)<span></span>
</td>
<td class="num">$ (2,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">20,289<span></span>
</td>
<td class="nump">19,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">17,573<span></span>
</td>
<td class="nump">16,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 32,469<span></span>
</td>
<td class="nump">$ 32,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572956816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Paranthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ConsolidatedBalanceSheetParentheticalAbstract', window );"><strong>Consolidated Balance Sheet (Parenthetical) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">1,696,633,993<span></span>
</td>
<td class="nump">1,688,810,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">263,289,848<span></span>
</td>
<td class="nump">263,289,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ConsolidatedBalanceSheetParentheticalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheet (Parenthetical)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ConsolidatedBalanceSheetParentheticalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564103376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,642,488,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">$ (1,717)<span></span>
</td>
<td class="nump">$ 17,561<span></span>
</td>
<td class="num">$ (2,253)<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuance (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">29,382,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Stock-based compensation (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,040,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Stock Issuance (Par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock', window );">Preferred stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Common stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (Shares Issued) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">1,679,911,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change in derivative financial instruments</a></td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in defined benefit pensions and other items</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2020</a></td>
<td class="nump">$ 15,326<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(2,251)<span></span>
</td>
<td class="nump">19,732<span></span>
</td>
<td class="num">(2,378)<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">1,679,911,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuance (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Stock-based compensation (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,898,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Stock Issuance (Par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock', window );">Preferred stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Common stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (Shares Issued) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">1,688,810,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change in derivative financial instruments</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in defined benefit pensions and other items</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2021</a></td>
<td class="nump">$ 16,622<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(2,251)<span></span>
</td>
<td class="nump">19,986<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">1,688,810,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuance (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Stock-based compensation (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,823,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Stock Issuance (Par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock', window );">Preferred stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Common stock issuance (Value in excess of par)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (Shares Issued) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change in derivative financial instruments</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in defined benefit pensions and other items</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2022</a></td>
<td class="nump">$ 17,573<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">$ (2,251)<span></span>
</td>
<td class="nump">$ 20,289<span></span>
</td>
<td class="num">$ (750)<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">1,696,633,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues (Common stock)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues (Preferred stock)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559300160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 698,000,000<span></span>
</td>
<td class="nump">$ 1,041,000,000<span></span>
</td>
<td class="num">$ (82,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss (gain) on disposal of businesses and assets</a></td>
<td class="nump">22,000,000<span></span>
</td>
<td class="num">(78,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,136,000,000<span></span>
</td>
<td class="nump">1,093,000,000<span></span>
</td>
<td class="nump">1,123,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit', window );">Deferred and prepaid income taxes</a></td>
<td class="num">(63,000,000)<span></span>
</td>
<td class="num">(124,000,000)<span></span>
</td>
<td class="num">(82,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">220,000,000<span></span>
</td>
<td class="nump">194,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Goodwill and other intangible asset impairment charges</a></td>
<td class="nump">132,000,000<span></span>
</td>
<td class="nump">370,000,000<span></span>
</td>
<td class="nump">533,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net loss (gain) on investments and notes receivable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="num">(333,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration net expense (benefit)</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="num">(136,000,000)<span></span>
</td>
<td class="num">(100,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_InventoryStepUpAmortization', window );">Inventory step-up amortization</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NetCurrencyExchangeGainLoss', window );">Debt extinguishment costs</a></td>
<td class="nump">194,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherNet', window );">Other, net</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">78,000,000<span></span>
</td>
<td class="nump">244,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (decrease) in operating assets and liabilities, excluding purchase accounting:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(220,000,000)<span></span>
</td>
<td class="num">(279,000,000)<span></span>
</td>
<td class="nump">335,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(321,000,000)<span></span>
</td>
<td class="num">(346,000,000)<span></span>
</td>
<td class="num">(65,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(209,000,000)<span></span>
</td>
<td class="num">(134,000,000)<span></span>
</td>
<td class="num">(265,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(255,000,000)<span></span>
</td>
<td class="nump">408,000,000<span></span>
</td>
<td class="num">(28,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash provided by (used for) operating activities</a></td>
<td class="nump">1,526,000,000<span></span>
</td>
<td class="nump">1,870,000,000<span></span>
</td>
<td class="nump">1,508,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment and internal use software</a></td>
<td class="num">(588,000,000)<span></span>
</td>
<td class="num">(554,000,000)<span></span>
</td>
<td class="num">(376,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(1,542,000,000)<span></span>
</td>
<td class="num">(2,258,000,000)<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from disposal of certain businesses and assets</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">826,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Proceeds from royalty rights</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">82,000,000<span></span>
</td>
<td class="nump">87,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Proceeds from (payments for) settlements of hedge contracts</a></td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies', window );">Proceeds from (payments for) investments and acquisitions of certain technologies</a></td>
<td class="num">(24,000,000)<span></span>
</td>
<td class="nump">279,000,000<span></span>
</td>
<td class="num">(146,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by (used for) investing activities</a></td>
<td class="num">(2,011,000,000)<span></span>
</td>
<td class="num">(1,597,000,000)<span></span>
</td>
<td class="num">(411,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration previously established in purchase accounting</a></td>
<td class="num">(335,000,000)<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="num">(49,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentsForRoyaltyRights', window );">Payments for royalty rights</a></td>
<td class="num">(75,000,000)<span></span>
</td>
<td class="num">(85,000,000)<span></span>
</td>
<td class="num">(97,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on short-term borrowings</a></td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,950,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings, net of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,245,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Net increase (decrease) in commercial paper</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(714,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payments on borrowings from credit facilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,919,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from borrowings on credit facilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payments on long-term borrowings and debt extinguishment costs</a></td>
<td class="num">(3,184,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,260,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from long-term borrowings, net of debt issuance costs</a></td>
<td class="nump">3,270,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,683,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Cash dividends paid on preferred stock</a></td>
<td class="num">(55,000,000)<span></span>
</td>
<td class="num">(55,000,000)<span></span>
</td>
<td class="num">(28,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of preferred stock in connection with public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">975,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in connection with public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">975,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(535,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Paymenttonetsharesettleemployeeequityawards', window );">Cash used to net share settle employee equity awards</a></td>
<td class="num">(53,000,000)<span></span>
</td>
<td class="num">(50,000,000)<span></span>
</td>
<td class="num">(59,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans</a></td>
<td class="nump">136,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">111,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by (used for) financing activities</a></td>
<td class="num">(548,000,000)<span></span>
</td>
<td class="num">(95,000,000)<span></span>
</td>
<td class="nump">293,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash</a></td>
<td class="num">(9,000,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease)&#160;in cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="num">(1,042,000,000)<span></span>
</td>
<td class="nump">173,000,000<span></span>
</td>
<td class="nump">1,388,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period</a></td>
<td class="nump">2,168,000,000<span></span>
</td>
<td class="nump">1,995,000,000<span></span>
</td>
<td class="nump">607,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period</a></td>
<td class="nump">1,126,000,000<span></span>
</td>
<td class="nump">2,168,000,000<span></span>
</td>
<td class="nump">1,995,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">662,000,000<span></span>
</td>
<td class="nump">302,000,000<span></span>
</td>
<td class="nump">207,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">338,000,000<span></span>
</td>
<td class="nump">359,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NonCashImpactOfTransferredRoyaltyRights', window );">Non-cash impact of transferred royalty rights</a></td>
<td class="num">$ (70,000,000)<span></span>
</td>
<td class="num">$ (82,000,000)<span></span>
</td>
<td class="num">$ (87,000,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flow impact of deferred income tax expense (benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_InventoryStepUpAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Step Up Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_InventoryStepUpAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_NetCurrencyExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net currency exchange gain (loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_NetCurrencyExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_NonCashImpactOfTransferredRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash impact of transferred royalty rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_NonCashImpactOfTransferredRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_PaymentsForRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for royalty rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_PaymentsForRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Paymenttonetsharesettleemployeeequityawards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to net share settle employee equity awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Paymenttonetsharesettleemployeeequityawards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (payments for) investments and acquisitions of certain technologies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572967680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 928,000,000<span></span>
</td>
<td class="nump">$ 1,925,000,000<span></span>
</td>
<td class="nump">$ 1,734,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and restricted cash equivalents included in Other current assets</a></td>
<td class="nump">149,000,000<span></span>
</td>
<td class="nump">188,000,000<span></span>
</td>
<td class="nump">208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in Other long-term assets</a></td>
<td class="nump">48,000,000<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">52,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">$ 1,126,000,000<span></span>
</td>
<td class="nump">$ 2,168,000,000<span></span>
</td>
<td class="nump">$ 1,995,000,000<span></span>
</td>
<td class="nump">$ 607,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800570725248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A &#8211; SIGNIFICANT ACCOUNTING POLICIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity&#8217;s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation&#160;S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets are related to deferred compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is adequate as of December&#160;31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#8482; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149&#160;million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40&#160;years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#8217;s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects&#8217; stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20&#160;years; amortizable technology-related and customer relationships, five to 25&#160;years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50&#160;percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee&#8217;s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H &#8211; Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We record such costs into expense over the employee&#8217;s future service period, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573715152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Strategic Investments<br></strong></div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS AND STRATEGIC INVESTMENTS</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B &#8211; ACQUISITIONS AND STRATEGIC INVESTMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2&#160;billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG&#8482; and VersaCross&#8482; Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price was comprised of the amount presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:84.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy&#174; Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification&#160;(ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of prior interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation for these acquisitions was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheet of $183&#160;million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding adjustments to the indemnification asset are being recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note G &#8211; Supplemental Balance Sheet Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding our indemnification asset.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Preventice:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lumenis:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">All Other:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Divestiture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $73&#160;million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December&#160;31, 2022, the maximum amount of future contingent consideration (undiscounted)&#160;that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&amp;D program. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$136 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to our R&amp;D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December&#160;31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Publicly-held equity securities are measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span> associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December&#160;31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $232 million, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573538320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C &#8211; GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management&#8217;s decision </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to discontinue commercialization of the VICI VENOUS STENT&#8482; System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&amp;D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&amp;D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management&#8217;s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our goodwill balance by reportable segment.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of our goodwill and intangible asset impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December&#160;31, 2022 is as follows (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573624176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D &#8211; HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Foreign currency translation adjustment (CTA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we reclassify amortization of the excluded component from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December&#160;31, 2022 and 2021, we designated as a net investment hedge our &#8364;900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reclassify these gains and losses to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December&#160;31, 2022, we had entered into $228 million in aggregate notional amount of these contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a $8 million loss as of December&#160;31, 2022 and a $24 million loss as of December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as fair value hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which generally offset. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Foreign currency-denominated debt is the &#8364;900 million debt principal designated as a net investment hedge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining time to maturity as of December&#160;31, 2022 is within 48&#160;months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O &#8211; Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Foreign currency-denominated debt is the &#8364;900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Inputs to the valuation methodology are unobservable inputs based on management&#8217;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:31.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December&#160;31, 2022 and $1.632 billion as of December&#160;31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December&#160;31, 2022 and $293 million as of December&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the changes in the fair value of our contingent consideration liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga&#8482; Drug. We own the contractual right to receive 50 percent of the future Zytiga&#8482; Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from royalty rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and payments we remit to inventors reduce the fair value of the financial liability and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash impact of transferred royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December&#160;31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December&#160;31, 2022 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations was $8.203 billion as of December&#160;31, 2022 and $10.196 billion as of December&#160;31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573658992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Obligations and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E &#8211; CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $8.935 billion as of December&#160;31, 2022 and $9.065 billion as of December&#160;31, 2021, with current maturities of $20 million as of December&#160;31, 2022 and $261 million as of December&#160;31, 2021. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.125%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.850%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Gain on Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November&#160;2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250&#160;million of 3.375% May 2022 Senior Notes classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Current Debt Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 times</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December&#160;31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December&#160;31, 2022, we had $866 million of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us.&#160;In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December&#160;31, 2022 and 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $8.986 billion as of December&#160;31, 2022 and $9.121 billion as of December&#160;31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of &#8364;3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of &#8364;1.000 billion of 0.750% Senior Notes due 2025, &#8364;750 million of 1.375% Senior Notes due 2028, &#8364;750 million of 1.625% Senior Notes due 2031 and &#8364;500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a &#8220;finance subsidiary&#8221; as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275&#160;billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $135 million as of December&#160;31, 2022 and $134 million as of December&#160;31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December&#160;31, 2022 and December&#160;31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December&#160;31, 2022 (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573713488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F &#8211; LEASES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease right-of-use assets are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding liabilities are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E &#8211; Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">61</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">71</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90&#160;million in 2021 and $92&#160;million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December&#160;31, 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573598304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">SUPPLEMENTAL BALANCE SHEET INFORMATION</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G &#8211; SUPPLEMENTAL BALANCE SHEET INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in our accompanying consolidated balance sheets are as follows:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset&#8217;s contractual life. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 27 percent of our finished goods inventory as of December&#160;31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da">386</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602">435</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">347</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">389</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573715152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE H &#8211; INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intra-entity asset transfers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:70.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December&#160;31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December&#160;31, 2022, and $60 million as of December&#160;31, 2021. These tax attributes expire periodically beginning in 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December&#160;31, 2022, and $1.014 billion as of December&#160;31, 2021. The decrease in the valuation allowance as of December&#160;31, 2022, compared to December&#160;31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.01 in 2022 and de minimis in 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December&#160;31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December&#160;31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91&#160;million to release the reserves related to these years. We received a refund of $62&#160;million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December&#160;31, 2022, $43 million as of December&#160;31, 2021, and $41 million as of December&#160;31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December&#160;31, 2022, compared to December&#160;31, 2021, is related to reaching settlements with taxing authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12&#160;months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December&#160;31, 2022, as compared to $938 million as of December&#160;31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun </span></div>remitting the required installment payments, with a balance remaining of $386 million as of December&#160;31, 2022. In addition, we have provided for U.S. state income taxes of $14 million on all U.S. dollar-denominated E&amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573976880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I &#8211; COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $443 million as of December&#160;31, 2022, and $548 million as of December&#160;31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $149 million as of December&#160;31, 2022, and $188 million as of December&#160;31, 2021. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook&#8217;s Instinct&#8482; Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to &#8220;Drug Releasing Biodegradable Fiber Implant&#8221; and &#8220;Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,&#8221; and affects the manufacture, use and sale of our Synergy&#8482; Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT&#8217;s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT&#8217;s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs&#8217; counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a &#8220;technical note,&#8221; announced that it was launching a formal administrative proceeding against Boston Scientific&#8217;s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB&#8217;s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor&#8217;s office issued a non-binding recommendation that is contrary to the Attorney General&#8217;s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE&#8217;s decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge&#8482; Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company&#8217;s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission&#8217;s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company&#8217;s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company&#8217;s Board of Directors conduct an investigation into actions by the Company&#8217;s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Concluded Since December 31, 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen&#8217;s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG&#8217;s motion to dismiss the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action. On January 10, 2022, the court granted the parties&#8217; stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza&#8482; Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro&#8217;s Senza&#8482; I and Senza&#8482; II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company&#8217;s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above. </span></div>The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573613088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDER'S EQUITY</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J &#8211; STOCKHOLDERS' EQUITY </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December&#160;31, 2022, our MCPS had an aggregate liquidation preference of $1.006&#160;billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December&#160;31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were approximately 263 million shares in treasury as of December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564505008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Inventive and Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_StockIncentiveAndPurchasePlansAbstract', window );"><strong>Stock Incentive and Purchase Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K &#8211; STOCK INCENTIVE AND PURCHASE PLANS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Director Stock Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December&#160;31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent&#160;of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-Free Interest Rate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Dividend Yield</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,674&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Cash Flow Performance-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expense Attribution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term &#8220;forfeitures&#8221; is distinct from &#8220;cancellations&#8221; or &#8220;expirations&#8221; and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December&#160;31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Compensation Cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee&#8217;s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December&#160;31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_StockIncentiveAndPurchasePlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Incentive and Purchase Plans [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_StockIncentiveAndPurchasePlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573648400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Weighted Average Shares Outstanding<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"><div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L &#8211; WEIGHTED AVERAGE SHARES OUTSTANDING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,416.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> position in this period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)&#160;per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented in our consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) available to common stockholders</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573594720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M &#8211; SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note N &#8211; Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with U.S. GAAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573976880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N &#8211; REVENUE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M &#8211; Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#252;rkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December&#160;31, 2022 and $484 million as of December&#160;31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE&#8482; Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December&#160;31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE&#8482; Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE&#8482; Remote Monitoring Service. These fulfillment costs are amortized over the average service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we recorded $179&#160;million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX&#8482; Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A &#8211; Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on our accounting policies relating to revenue recognition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573594720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Income (Loss) Note [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE O &#8211; CHANGES IN OTHER COMPREHENSIVE INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span> were reduced by immaterial income tax impacts in 2022 and in 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573658992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NewAccountingPronouncementsPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE P &#8211; NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2021-05</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASC Update No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Lessors&#8212;Certain Leases with Variable Lease Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-06</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the FASB issued ASC Update No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_NewAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_NewAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573567856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE Q &#8211; EMPLOYEE RETIREMENT PLANS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other International Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain retirement plans covering certain international employees. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December&#160;31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:42.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.155%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2021 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-in contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Buy-in Contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December&#160;31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200&#160;percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573776048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</a></td>
<td class="text"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:36.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>&#160;Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit loss exposure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Write-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for uncollectible accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents actual write-offs of uncollectible accounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564743504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity&#8217;s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation&#160;S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span>within our consolidated balance sheets are related to deferred compensation plans.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span> is adequate as of December&#160;31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#8482; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#8482; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Standard Product Warranty, Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a </span></div>liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149&#160;million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.</span></div>We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40&#160;years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#8217;s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In Process Research and Development, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects&#8217; stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div>For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20&#160;years; amortizable technology-related and customer relationships, five to 25&#160;years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C &#8211; Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div>For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span>, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50&#160;percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B &#8211; Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee&#8217;s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment&#8217;s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H &#8211; Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span><span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We record such costs into expense over the employee&#8217;s future service period, if any. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span> in our consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573610432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures and Disclosures (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D &#8211; Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span>, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573563024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span><span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800565536336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock', window );">ASC Update No. 2020-10 Codification Improvements</a></td>
<td class="text">ASC Update No. 2021-05<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASC Update No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Lessors&#8212;Certain Leases with Variable Lease Payments</span>. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock', window );">ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock', window );">ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock', window );">ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock', window );">ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. </span>2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock', window );">ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-06</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the FASB issued ASC Update No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2020-10 Codification Improvements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573787920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans Employee Retirement Plans (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December&#160;31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572921056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Strategic Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Preventice:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lumenis:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">All Other:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$136 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock', window );">Investment [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Publicly-held equity securities are measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:84.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember', window );">2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text">in accordance with Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification&#160;(ASC) Topic 805, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of prior interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation for these acquisitions was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573596048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our goodwill balance by reportable segment.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December&#160;31, 2022 is as follows (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564742128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss) [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O &#8211; Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock', window );">Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives Not Designated as Hedging Instruments (Table Text Block)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block)</a></td>
<td class="text">The following are the balances of our derivative and nonderivative assets and liabilities:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Foreign currency-denominated debt is the &#8364;900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:31.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December&#160;31, 2022 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564269152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Obligations and Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.125%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.850%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Gain on Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November&#160;2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250&#160;million of 3.375% May 2022 Senior Notes classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Current Debt Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock', window );">Transfer of Financial Assets Accounted for as Sales [Table Text Block]</a></td>
<td class="text">Amounts de-recognized for accounts and notes receivable, which are excluded from <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentTextBlock', window );">Long-term Purchase Commitment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock', window );">Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 times</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Contractual Obligation, Fiscal Year Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Debt [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of term loan and revolving credit facility agreement compliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559351856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text">The following table presents supplemental balance sheet information related to our operating leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">61</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">71</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December&#160;31, 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturities of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information Related to Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information Related to Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559327184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Trade accounts receivable, net [Table Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset&#8217;s contractual life.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment, net [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da">386</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602">435</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Other long-term liabilities [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">347</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">389</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572967088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:70.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies [Table Text Block]</a></td>
<td class="text">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Tax rate</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intra-entity asset transfers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564563248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Purchase Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems', window );"><strong>Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock', window );">Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</a></td>
<td class="text">Information related to non-vested stock awards is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock', window );">Market-based awards, valuation assumptions [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,674&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market-based awards, valuation assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800566482816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Weighted Average Shares Outstanding (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted Average Number of Shares [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,416.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> position in this period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564291936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock', window );">Segment operating income as percentage of net sales [Table Text Block]</a></td>
<td class="text"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment operating income as percentage of net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800573721408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M &#8211; Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#252;rkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800571511952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559324688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension and Other Postretirement Plans, Policy [Policy Text Block]</a></td>
<td class="text">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200&#160;percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]</a></td>
<td class="text">The outstanding obligation is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock', window );">Schedule of Changes in Projected Benefit Obligations [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:42.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.155%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2021 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-in contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Buy-in Contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text">Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564755472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">$ 4,520<span></span>
</td>
<td class="nump">$ 4,359<span></span>
</td>
<td class="nump">$ 3,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Production Related Impairments or Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember', window );">Farapulse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800547602240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Strategic Investments (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from disposal of certain businesses and assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 826,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000,000<span></span>
</td>
<td class="nump">486,000,000<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,920,000,000<span></span>
</td>
<td class="nump">11,988,000,000<span></span>
</td>
<td class="nump">9,951,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542,000,000<span></span>
</td>
<td class="nump">2,258,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,000,000)<span></span>
</td>
<td class="num">(486,000,000)<span></span>
</td>
<td class="num">(196,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000,000<span></span>
</td>
<td class="nump">370,000,000<span></span>
</td>
<td class="nump">460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration net expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="num">(136,000,000)<span></span>
</td>
<td class="num">(100,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Specialty Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DivestitureAgreementTransferOfFacilities', window );">Divestiture, agreement, transfer of facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DivestitureAgreementTransferOfGlobalEmployees', window );">Divestiture, agreement, transfer of global employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember', window );">Preventice Solutions, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest', window );">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember', window );">Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember', window );">Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember', window );">Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember', window );">Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember', window );">Farapulse, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest', window );">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod', window );">Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,032,000,000.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate', window );">Business Combination, Indemnification Assets, Amount as of Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | In Process Research and Development [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 388,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | Technology-Based Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember', window );">Lumenis LTD | Other Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_DevoroMedicalIncMember', window );">Devoro Medical, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest', window );">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(218,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions | In Process Research and Development [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember', window );">All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember', window );">2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,053,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(325,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,258,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(440,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical | Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical | Technology-Based Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical | Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Asset, Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember', window );">Baylis Medical | Other Intangible Assets [Member] | Weighted Average (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember', window );">M.I. Tech Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="nump">$ 615,000,000<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="nump">&#8361; 291,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember', window );">M.I. Tech Co., Ltd | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_AcotecScientificHoldingsLimitedMember', window );">Acotec Scientific Holdings Limited | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_ApolloEndosurgeryIncMember', window );">Apollo Endosurgery, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember', window );">Farapulse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DivestitureAgreementTransferOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestiture, agreement, transfer of facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DivestitureAgreementTransferOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DivestitureAgreementTransferOfGlobalEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestiture, agreement, transfer of global employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DivestitureAgreementTransferOfGlobalEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bsx_SpecialtyPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bsx_SpecialtyPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_PreventiceSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_LumenisLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_DevoroMedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_DevoroMedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_AllOther2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_BaylisMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_AcotecScientificHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_AcotecScientificHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_ApolloEndosurgeryIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_ApolloEndosurgeryIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_FarapulseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559202896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract', window );"><strong>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration net expense (benefit)</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember', window );">2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract', window );"><strong>Business Combination, Contingent Consideration Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember', window );">Farapulse, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract', window );"><strong>Business Combination, Contingent Consideration Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest', window );">Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Valuation Technique, Discounted Cash Flow [Member] | R&amp;D, Regulatory and Commercialization-based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment', window );">contingent consideration liability, probability of payment</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&amp;D, Regulatory and Commercialization-based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment', window );">contingent consideration liability, probability of payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&amp;D, Regulatory and Commercialization-based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment', window );">contingent consideration liability, probability of payment</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | R&amp;D, Regulatory and Commercialization-based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment', window );">contingent consideration liability, probability of payment</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment', window );">contingent consideration liability, probability of payment</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ContingentConsiderationLiabilityProbabilityOfPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>contingent consideration liability, probability of payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ContingentConsiderationLiabilityProbabilityOfPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_A2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_FarapulseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bsx_RDRegulatoryandCommercializationbasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bsx_RDRegulatoryandCommercializationbasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bsx_RevenueBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bsx_RevenueBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559773312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Measurement alternative investments (1)</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Notes receivable</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800558127568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 14,843<span></span>
</td>
<td class="nump">$ 14,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(9,173)<span></span>
</td>
<td class="num">(8,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, Gross</a></td>
<td class="nump">22,820<span></span>
</td>
<td class="nump">21,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="num">(9,900)<span></span>
</td>
<td class="num">(9,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_GoodwillTextualsAbstract', window );"><strong>Goodwill (Roll Forward)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
<td class="nump">9,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Goodwill, Translation and Purchase Accounting Adjustments</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherIntangibleAssetsTextualsAbstract', window );"><strong>Other Intangible Assets (Textuals) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future Amortization Expense, Year One</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future Amortization Expense, Year Two</a></td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future Amortization Expense, Year Three</a></td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future Amortization Expense, Year Four</a></td>
<td class="nump">665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Future Amortization Expense, Year Five</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_GoodwillTextualsAbstract', window );"><strong>Goodwill (Roll Forward)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Goodwill, Translation and Purchase Accounting Adjustments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_GoodwillTextualsAbstract', window );"><strong>Goodwill (Roll Forward)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,684<span></span>
</td>
<td class="nump">7,741<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Goodwill, Translation and Purchase Accounting Adjustments</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">12,397<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(7,378)<span></span>
</td>
<td class="num">(6,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="num">$ (1,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_GoodwillTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill (Textuals) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_GoodwillTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OtherIntangibleAssetsTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Intangible Assets (Textuals) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OtherIntangibleAssetsTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800557071392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>units</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet', window );">Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">8,321<span></span>
</td>
<td class="nump">9,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="nump">$ 3,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Operating Income (Expense), Net</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax', window );">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative Asset, Fair Value, Gross Asset</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liability, Fair Value, Gross Liability</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NetCurrencyExchangeGainLoss', window );">Net currency exchange gain (loss)</a></td>
<td class="num">(194)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">8,203<span></span>
</td>
<td class="nump">10,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember', window );">November 2019 Aggregate Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember', window );">December 2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bsx_LicensingArrangementAssetsMember', window );">Licensing arrangement assets (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember', window );">M.I. Tech Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, at Carrying Value</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, at Carrying Value</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, at Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, at Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement assets (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from Royalties Received</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption', window );">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement liabilities (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption', window );">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ForwardCurrencyContractsTimetoMaturity', window );">Forward Currency Contracts, Time to Maturity | units</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign Currency Transaction Gain (Loss), before Tax</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net gain (loss) from foreign currency transaction exposures</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NetCurrencyExchangeGainLoss', window );">Net currency exchange gain (loss)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">4,235<span></span>
</td>
<td class="nump">3,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average (Member) | Licensing arrangement assets (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average (Member) | Licensing arrangement liabilities (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Licensing arrangement liabilities (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Licensing arrangement liabilities (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet', window );">Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax', window );">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax', window );">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax', window );">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax', window );">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ForwardCurrencyContractsTimetoMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward Currency Contracts, Time to Maturity in Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ForwardCurrencyContractsTimetoMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LicensingArrangementsAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangements, asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LicensingArrangementsAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LicensingArrangementsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangements, liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LicensingArrangementsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_NetCurrencyExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net currency exchange gain (loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_NetCurrencyExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bsx_LicensingArrangementAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bsx_LicensingArrangementAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bsx_MITechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bsx_LicensingArrangementLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bsx_LicensingArrangementLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bsx_ForeignCurrencyDenominatedInDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bsx_ForeignCurrencyDenominatedInDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800545952560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Obligations and Commitments (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 27, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,935<span></span>
</td>
<td class="nump">$ 8,935<span></span>
</td>
<td class="nump">$ 9,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Capital Lease Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,915<span></span>
</td>
<td class="nump">8,915<span></span>
</td>
<td class="nump">8,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DeemedConsolidatedEBITDA', window );">Deemed Consolidated EBITDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ExclusionFromEbitdaForRestructuringCharges', window );">Exclusion from EBITDA for Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda', window );">Restructuring charges remaining to be excluded from calculation of consolidated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LitigationAndDebtExclusionFromEbitda', window );">Litigation and Debt Exclusion from EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda', window );">Legal payments remaining to be excluded from calculation of consolidated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase Obligations, Future Minimum Payments Due, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase Obligations, Future Minimum Payments, Due in Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase Obligations, Future Minimum Payments, Due in Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Purchase Obligations, Future Minimum Payments, Due in Four Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">Purchase Obligations, Future Minimum Payments, Due in Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Purchase Obligations, Future Minimum Payments, Due Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase Obligations, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths', window );">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive', window );">Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from long-term borrowings, net of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bsx_May2022NotesMember', window );">May 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.375%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_ActualCovenantMember', window );">Actual, Covenant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementAsOfMarch312021Member', window );">Requirement, as of March 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember', window );">Requirement, as of December 31, 2021 and through remaining term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember', window );">Requirement, four quarters following material acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember', window );">Requirement, fifth quarter following qualified acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember', window );">Requirement, sixth quarter and thereafter following qualified acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember', window );">Requirement, seventh quarter following qualified acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CovenantAxis=bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember', window );">Requirement, eighth quarter and thereafter following qualified acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_MaximumLeverageRatio', window );">Maximum Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bsx_The2018FacilityDomain', window );">the 2018 Facility [Domain] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember', window );">November 2019 Aggregate Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_May2022NotesMember', window );">May 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.125%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_October2023NotesMember', window );">October 2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.45%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2024NotesMember', window );">March 2024 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.75%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_May2025NotesMember', window );">May 2025 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.85%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_June2025NotesMember', window );">June 2025 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2026NotesMember', window );">March 2026 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.75%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember', window );">December 2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.625%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2028NotesMember', window );">March 2028 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2029NotesMember', window );">March 2029 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_June2030NotesMember', window );">June 2030 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.65%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_November2035NotesMember', window );">November 2035 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.75%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2039NotesMember', window );">March 2039 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.55%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_January2040NotesMember', window );">January 2040 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.375%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2049NotesMember', window );">March 2049 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_InterestRateSwapMember', window );">Unamortized Gain on Fair Value Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="nump">9,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2028SeniorNotesMember', window );">March 2028 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.375%)<span></span>
</td>
<td class="num">(1.375%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2031NotesMember', window );">March 2031 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.625%)<span></span>
</td>
<td class="num">(1.625%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2034NotesMember', window );">March 2034 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.875%)<span></span>
</td>
<td class="num">(1.875%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingAggregatePrincipalAmountMember', window );">the Offering - aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_March2025NotesMember', window );">March 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.75%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember', window );">the Offering - early redemption of combined aggregate principal SN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,275<span></span>
</td>
<td class="nump">3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bsx_EuroDenominatedFactoringArrangementsMember', window );">Euro Denominated Factoring Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate', window );">Average interest rate of de-recognized receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bsx_YenDenominatedFactoringArrangementsMember', window );">Yen Denominated Factoring Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate', window );">Average interest rate of de-recognized receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bsx_RenminbiDenominatedFactoringArrangementsMember', window );">Renminbi Denominated Factoring Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate', window );">Average interest rate of de-recognized receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DeemedConsolidatedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed Consolidated EBITDA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DeemedConsolidatedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ExclusionFromEbitdaForRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exclusion from EBITDA for Restructuring Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ExclusionFromEbitdaForRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal payments remaining to be excluded from calculation of consolidated EBITDA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LitigationAndDebtExclusionFromEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exclusion of litigation payments and any debt Issued to fund tax deficiency payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LitigationAndDebtExclusionFromEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_MaximumLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum leverage ratio permitted by revolving credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_MaximumLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=bsx_May2022NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=bsx_May2022NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_ActualCovenantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_ActualCovenantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementAsOfMarch312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementAsOfMarch312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CovenantAxis=bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CovenantAxis=bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bsx_The2018FacilityDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bsx_The2018FacilityDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_November2019AggregateOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_May2022NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_May2022NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_October2023NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_October2023NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_May2025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_May2025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_June2025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_June2025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2026NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2026NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_December2027NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_June2030NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_June2030NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_November2035NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_November2035NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2039NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2039NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_January2040NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_January2040NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2049NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2049NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2028SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2028SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2031NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2031NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2034NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2034NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingAggregatePrincipalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingAggregatePrincipalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_March2025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_March2025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bsx_EuroDenominatedFactoringArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bsx_EuroDenominatedFactoringArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bsx_YenDenominatedFactoringArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bsx_YenDenominatedFactoringArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bsx_RenminbiDenominatedFactoringArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bsx_RenminbiDenominatedFactoringArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559398896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</a></td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, to be Paid</a></td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">54 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend', window );">Lessee, Operating and Finance Leases, Option to Extend</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LesseeOperatingAndFinanceLeasesOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Leases, Option to Extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LesseeOperatingAndFinanceLeasesOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800564202816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and restricted cash equivalents included in Other current assets</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative Asset, Current</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangements', window );">Licensing arrangements</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other Assets, Miscellaneous, Current</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets, Current</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract', window );"><strong>Trade accounts receivable, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">2,079<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss (beginning balance)</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Net (credits) charges to expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Utilization of allowances</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss (ending balance)</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Inventory, Work in Process, Net of Reserves</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, Raw Materials, Net of Reserves</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements</a></td>
<td class="nump">1,695<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_EquipmentFurnitureAndFixturesGross', window );">Equipment, furniture and fixtures</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Capital in progress</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">5,728<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 2,446<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SupplementalBalanceSheetInformationTextualsAbstract', window );"><strong>Supplemental Balance Sheet Information (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_PercentOfFinishedGoodsAtConsignment', window );">Percent of finished goods at consignment</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents included in Other long-term assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsAsset', window );">Licensing arrangements, asset</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OtherOtherLongTermAssets', window );">Other, Other Long-term Assets</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets (total)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal reserves</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related liabilities</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_AccruedRebatesCurrent', window );">Accrued Rebates, Current</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities, current</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued Royalties, Current</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes Payable, Current</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other Sundry Liabilities, Current</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">$ 2,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_IndemnificationAsset', window );">Indemnification asset</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Estimated Litigation Liability, Noncurrent</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Business Combination, Contingent Consideration, Liability, Noncurrent</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other Accrued Liabilities, Noncurrent</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Estimated Litigation Liability, Noncurrent</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Business Combination, Contingent Consideration, Liability, Noncurrent</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_LicensingArrangementsLiability', window );">Licensing arrangements, liability</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other Accrued Liabilities, Noncurrent</a></td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_EquipmentFurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment, furniture and fixtures Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_EquipmentFurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_IndemnificationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_IndemnificationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LicensingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LicensingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LicensingArrangementsAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangements, asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LicensingArrangementsAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_LicensingArrangementsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangements, liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_LicensingArrangementsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OtherOtherLongTermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other, Other Long-term Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OtherOtherLongTermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_PercentOfFinishedGoodsAtConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of finished goods at consignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_PercentOfFinishedGoodsAtConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SupplementalBalanceSheetInformationTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information (Textuals)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SupplementalBalanceSheetInformationTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800568673584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details - Rate Table)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ScheduleofIncomeTaxRateReconciliationLineItems', window );"><strong>Schedule of Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">16.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">155.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(14.30%)<span></span>
</td>
<td class="num">(40.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Effective Income Tax Rate Reconciliation, Tax Credits, Research</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(43.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="num">(42.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">effective income tax reconciliation, compensation-related</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">64.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions', window );">Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(96.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers', window );">Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision', window );">Effective Income Tax Rate Reconciliation, Return to provision</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="num">(37.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">51.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Reported tax rate</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return to provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ScheduleofIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ScheduleofIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800560040496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income Taxes (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,119)<span></span>
</td>
<td class="num">$ (648)<span></span>
</td>
<td class="num">$ (660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income (Loss) from Continuing Operations before Income Taxes, Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current Federal Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State and Local Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current Foreign Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred Federal Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred State and Local Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred Foreign Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Deferred Tax Assets, Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FederalBenefitOfUncertainTaxPositions', window );">Federal benefit of uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Deferred Tax Assets, Goodwill and Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,668<span></span>
</td>
<td class="nump">3,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, in Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Deferred Tax Assets, Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Deferred Tax Assets, Tax Deferred Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">4,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="nump">3,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Deferred Tax Liabilities, Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">3,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit', window );">Deferred Tax Assets, Prepaid on Intercompany Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit', window );">Net Deferred Tax Liabilities and Prepaid on Intercompany Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">4,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FreeTradeZoneRegimeTaxIncentive', window );">Free Trade Zone Regime Tax Incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TaxIncentivesInPuertoRico', window );">Tax Incentives in Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Tax Adjustments, Settlements, and Unusual Provisions</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income Tax Examination, Penalties and Interest Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in Unrecognized Tax Benefits is Reasonably Possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Onetimetransactiontaxpost1986EPnetpayment', window );">One-time transaction tax post-1986 E&amp;P - net payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution', window );">Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution', window );">Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TransitionTaxPaymentRemaining', window );">transition tax payment remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TaxIncentivesInMalaysia', window );">Tax incentives in Malaysia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution', window );">Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense', window );">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxAssetsDomain', window );">Deferred tax assets [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,942<span></span>
</td>
<td class="nump">4,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxLiabilitiesDomain', window );">Deferred tax liabilities [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid on Intercompany Profit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FederalBenefitOfUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal benefit of uncertain tax positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FederalBenefitOfUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FreeTradeZoneRegimeTaxIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free Trade Zone Regime Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FreeTradeZoneRegimeTaxIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets and Prepaid on Intercompany Profit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Onetimetransactiontaxpost1986EPnetpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One-time transaction tax post-1986 E&amp;P - net payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Onetimetransactiontaxpost1986EPnetpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TaxIncentivesInMalaysia">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax incentives in Malaysia</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TaxIncentivesInMalaysia</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TaxIncentivesInPuertoRico">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Incentives in Puerto Rico</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TaxIncentivesInPuertoRico</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TransitionTaxPaymentRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transition Tax Payment Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TransitionTaxPaymentRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxAssetsDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxAssetsDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxLiabilitiesDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bsx_DeferredTaxLiabilitiesDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800565615472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrual for legal matters that are probable and estimable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and restricted cash equivalents included in Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior', window );">Brazil CADE - # of individuals for alleged anti-competitive behavior | Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Brazil CADE - # of individuals for alleged anti-competitive behavior</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800558641008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of preferred stock in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends, Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,289,848<span></span>
</td>
<td class="nump">263,289,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock, Liquidation Preference Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of preferred stock in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Preferred Stock, Dividends, Per Share, Cash Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2.3834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2.9197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Preferred Stock, Dividends, Per Share, Cash Paid</a></td>
<td class="nump">$ 1.3750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,382,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800563786688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Purchase Plans (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 17, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Fairvalueofmarketbasedawards', window );">Fair value of market based awards</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 46.27<span></span>
</td>
<td class="nump">$ 42.48<span></span>
</td>
<td class="nump">$ 35.95<span></span>
</td>
<td class="nump">$ 44.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_UnrecognizedCompensationCostStockOptions', window );">Unrecognized Compensation Cost - Stock Options</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="nump">2,850,000<span></span>
</td>
<td class="nump">2,578,000<span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</a></td>
<td class="nump">$ 31.68<span></span>
</td>
<td class="nump">$ 29.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">9,438,000<span></span>
</td>
<td class="nump">9,745,000<span></span>
</td>
<td class="nump">9,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">3,854,000<span></span>
</td>
<td class="nump">4,240,000<span></span>
</td>
<td class="nump">3,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Measurementperiodmarketbasedaward', window );">Measurement period - market based awards</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(3,482,000)<span></span>
</td>
<td class="num">(3,823,000)<span></span>
</td>
<td class="num">(4,147,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(680,000)<span></span>
</td>
<td class="num">(658,000)<span></span>
</td>
<td class="num">(554,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">21,489,000<span></span>
</td>
<td class="nump">21,448,000<span></span>
</td>
<td class="nump">23,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,065,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">3,287,000<span></span>
</td>
<td class="nump">3,822,000<span></span>
</td>
<td class="nump">3,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 44.02<span></span>
</td>
<td class="nump">$ 37.69<span></span>
</td>
<td class="nump">$ 41.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="num">(2,745,000)<span></span>
</td>
<td class="num">(4,796,000)<span></span>
</td>
<td class="num">(3,096,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="num">(502,000)<span></span>
</td>
<td class="num">(699,000)<span></span>
</td>
<td class="num">(666,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ShareBasedCompensationNetOfTaxBenefit', window );">Share-based compensation, net of tax benefit</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CompensationExpensePerShareBasic', window );">compensation expense, per share - basic</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_CompensationExpensePerShareDiluted', window );">compensation expense, per share - diluted</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 13.64<span></span>
</td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="nump">$ 10.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">13,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OptionsExpectedToVest', window );">Options expected to vest</a></td>
<td class="nump">7,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OptionsExpectedToVestWeightedAverageExercisePrice', window );">Options expected to vest, weighted average exercise price</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife', window );">Options expected to vest, weighted average remaining contractual life</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</a></td>
<td class="nump">21,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase', window );">Amount of employees total compensation eligible for GESOP purchase</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless', window );">Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_UnrecognizedCompensationCostNonVestedStockAwards', window );">Unrecognized Compensation Cost - Non-vested stock awards</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_UnrecognizedCompensationCost', window );">Unrecognized Compensation Cost</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_WeightedAverageRemainingVestingPeriod', window );">weighted average remaining vesting period</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Annualweightedaverageforfeiturerate', window );">annualweightedaverageforfeiturerate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_VotingPowerOfAllClassesOfStock', window );">Voting power of all classes of stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant', window );">Exercise price of the fair market value of our common stock on the date of grant</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Nonvestedstockawardsexerciseprice', window );">Qualified options exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards', window );">Fair value of the Free Cash Flow (FCF) performance awards</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards', window );">Target payout of Free Cash Flows (FCF) performance awards</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">131.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Employee Stock Ownership Plan (ESOP), Compensation Expense</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded', window );">Range of the target number of performance-based DSUs awarded</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded', window );">Range of the target number of market-based DSUs awarded</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">High end of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded', window );">Range of the target number of performance-based DSUs awarded</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</a></td>
<td class="nump">$ 32.31<span></span>
</td>
<td class="nump">$ 36.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">3.87%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded', window );">Range of the target number of market-based DSUs awarded</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bsx_A2011LtipPlanMember', window );">2011 LTIP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of employees total compensation eligible for GESOP purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Annualweightedaverageforfeiturerate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Annualweightedaverageforfeiturerate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CompensationExpensePerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>compensation expense, per share - basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CompensationExpensePerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_CompensationExpensePerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>compensation expense, per share - diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_CompensationExpensePerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the fair market value of our common stock on the date of grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_FairValueOfFreeCashFlowFcfPerformanceAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the Free Cash Flow (FCF) performance awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_FairValueOfFreeCashFlowFcfPerformanceAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Fairvalueofmarketbasedawards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of market based awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Fairvalueofmarketbasedawards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Measurementperiodmarketbasedaward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Measurement period - market based awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Measurementperiodmarketbasedaward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Nonvestedstockawardsexerciseprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-vested stock awards exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Nonvestedstockawardsexerciseprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OptionsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OptionsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OptionsExpectedToVestWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options expected to vest, weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OptionsExpectedToVestWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options expected to vest, weighted average remaining contractual life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_RangeofthetargetnumberofmarketbasedDSUsawarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of the target number of market-based DSUs awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_RangeofthetargetnumberofmarketbasedDSUsawarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_RangeofthetargetnumberofperformancebasedDSUsawarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of the target number of performance-based DSUs awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_RangeofthetargetnumberofperformancebasedDSUsawarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ShareBasedCompensationNetOfTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation, net of tax benefit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ShareBasedCompensationNetOfTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Target payout of Free Cash Flows (FCF) performance awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Compensation Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_UnrecognizedCompensationCostNonVestedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Compensation Cost - Non-vested stock awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_UnrecognizedCompensationCostNonVestedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_UnrecognizedCompensationCostStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Compensation Cost - Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_UnrecognizedCompensationCostStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_VotingPowerOfAllClassesOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voting power of all classes of stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_VotingPowerOfAllClassesOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_WeightedAverageRemainingVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted average remaining vesting period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_WeightedAverageRemainingVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bsx_A2011LtipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bsx_A2011LtipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800565616208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Weighted Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">1,430,500<span></span>
</td>
<td class="nump">1,422,300<span></span>
</td>
<td class="nump">1,416,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">1,439,700<span></span>
</td>
<td class="nump">1,433,800<span></span>
</td>
<td class="nump">1,416,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bsx_A550MCPSSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bsx_A550MCPSSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800548651184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reportablesegments</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | reportablesegments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 12,682<span></span>
</td>
<td class="nump">$ 11,888<span></span>
</td>
<td class="nump">$ 9,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income allocated to reportable segments</a></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="num">(803)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
<td class="num">(789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
<td class="nump">9,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">6,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">21,653<span></span>
</td>
<td class="nump">20,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">2,446<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales', window );">Impact of foreign currency fluctuations on net sales</a></td>
<td class="num">(476)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement', window );">Revenues from contracts with customers, disaggregated - performance measurement</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">7,632<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bsx_OtherCountriesMember', window );">Other countries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CR', window );">COSTA RICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,911<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OperatingIncomeLossAllocatedToReportableSegments', window );">Operating Income (Loss) Allocated to Reportable Segments</a></td>
<td class="nump">$ 1,625<span></span>
</td>
<td class="nump">$ 1,524<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Segmentoperatingincomeaspercentageofnetsales', window );">Segment operating income as percentage of net sales</a></td>
<td class="nump">32.10%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets (segment reporting)</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">$ 2,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">$ 3,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement', window );">Revenues from contracts with customers, disaggregated - performance measurement</a></td>
<td class="nump">5,057<span></span>
</td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,312<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">7,831<span></span>
</td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OperatingIncomeLossAllocatedToReportableSegments', window );">Operating Income (Loss) Allocated to Reportable Segments</a></td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 1,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Segmentoperatingincomeaspercentageofnetsales', window );">Segment operating income as percentage of net sales</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">26.20%<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets (segment reporting)</a></td>
<td class="nump">$ 5,205<span></span>
</td>
<td class="nump">$ 4,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,684<span></span>
</td>
<td class="nump">7,741<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement', window );">Revenues from contracts with customers, disaggregated - performance measurement</a></td>
<td class="nump">8,161<span></span>
</td>
<td class="nump">7,212<span></span>
</td>
<td class="nump">5,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,319<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember', window );">BSX Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement', window );">Revenues from contracts with customers, disaggregated - performance measurement</a></td>
<td class="nump">13,218<span></span>
</td>
<td class="nump">11,828<span></span>
</td>
<td class="nump">9,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_TotalAllocatedToReportableSegmentsMember', window );">Total allocated to reportable segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income allocated to reportable segments</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">3,412<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets (segment reporting)</a></td>
<td class="nump">7,706<span></span>
</td>
<td class="nump">6,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CorporateExpensesincludinghedgingactivitiesMember', window );">Corporate Expenses including hedging activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OperatingIncomeUnallocatedToSegment', window );">Operating Income Unallocated to Segment</a></td>
<td class="num">(436)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialChargesMember', window );">Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_OperatingIncomeUnallocatedToSegment', window );">Operating Income Unallocated to Segment</a></td>
<td class="num">(789)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets (segment reporting)</a></td>
<td class="nump">5,941<span></span>
</td>
<td class="nump">7,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_ConsolidatedBSXDomain', window );">Consolidated BSX [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets (segment reporting)</a></td>
<td class="nump">32,469<span></span>
</td>
<td class="nump">32,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income allocated to reportable segments</a></td>
<td class="num">$ (60)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of foreign currency fluctuations on net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OperatingIncomeLossAllocatedToReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income (Loss) Allocated to Reportable Segments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OperatingIncomeLossAllocatedToReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_OperatingIncomeUnallocatedToSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income Unallocated to Segment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_OperatingIncomeUnallocatedToSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from contracts with customers, disaggregated - performance measurement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Segmentoperatingincomeaspercentageofnetsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment operating income as percentage of net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Segmentoperatingincomeaspercentageofnetsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bsx_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bsx_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_TotalAllocatedToReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_TotalAllocatedToReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CorporateExpensesincludinghedgingactivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_CorporateExpensesincludinghedgingactivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_ConsolidatedBSXDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_ConsolidatedBSXDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800559533456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>countries</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_EmergingMarketsTotalNumberOfCountries', window );">Emerging Markets total number of countries | countries</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 12,682<span></span>
</td>
<td class="nump">$ 11,888<span></span>
</td>
<td class="nump">$ 9,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Change in Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">7,632<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,111<span></span>
</td>
<td class="nump">4,978<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">APAC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,116<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember', window );">Latin America and Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bsx_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bsx_USExcludingOtherNetSalesMember', window );">country_US excluding Other Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">7,632<span></span>
</td>
<td class="nump">6,901<span></span>
</td>
<td class="nump">5,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember', window );">Global Endoscopy (Endo) Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">1,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember', window );">Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember', window );">Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember', window );">Global Urology and Pelvic Health Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember', window );">Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember', window );">Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember', window );">Global Neuromodulation (NM) Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember', window );">Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember', window );">Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember', window );">Global Peripheral Interventions (PI) Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember', window );">Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">996<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember', window );">Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">824<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember', window );">Interventional Cardiology Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember', window );">Interventional Cardiology Therapies | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember', window );">Interventional Cardiology Therapies | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember', window );">Cardiac Rhythm Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember', window );">Cardiac Rhythm Management | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember', window );">Cardiac Rhythm Management | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember', window );">Electrophysiology (EP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember', window );">Electrophysiology (EP) | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember', window );">Electrophysiology (EP) | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_WatchmanMember', window );">Watchman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_WatchmanMember', window );">Watchman | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_WatchmanMember', window );">Watchman | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember', window );">Global Cardiology Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,932<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember', window );">Global Cardiology Reporting Unit | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,271<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember', window );">Global Cardiology Reporting Unit | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_OtherMember', window );">Other | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bsx_OtherMember', window );">Other | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,911<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,312<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember', window );">MedSurg [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">7,831<span></span>
</td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,319<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember', window );">Cardiovascular [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 3,512<span></span>
</td>
<td class="nump">$ 3,396<span></span>
</td>
<td class="nump">$ 2,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_EmergingMarketsTotalNumberOfCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Markets total number of countries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_EmergingMarketsTotalNumberOfCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bsx_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bsx_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bsx_USExcludingOtherNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bsx_USExcludingOtherNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_WatchmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_WatchmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800572944576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax', window );">Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change in derivative financial instruments</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800556964176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined Benefit Plan, Accumulated Benefit Obligation</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets', window );">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO', window );">Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Defined Benefit Plan, Service Cost</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Defined Benefit Plan, Interest Cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_Pensionbenefitobligationbenefitspaid', window );">pension benefit obligation, benefits paid</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Defined Benefit Plan, Plan Assets, Payment for Settlement</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO', window );">Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined Benefit Plan, Plan Assets, Contributions by Employer</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss', window );">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Defined Benefit Plan, Benefit Obligation, Benefits Paid</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_ExpenseRelatedToMatchingContributions', window );">Expense related to matching contributions</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">Defined Benefit Plan, Expected Future Benefit Payment, Year One</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember', window );">Domestic Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Executive Retirement Plan Discount Rate</a></td>
<td class="nump">5.32%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Executive Retirement Plan Rate of Compensation Increase</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=bsx_UKPlanMember', window );">U.K. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn', window );">Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Executive Retirement Plan Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=bsx_OtherInternationalPlansMember', window );">Other International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn', window );">Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</a></td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Executive Retirement Plan Discount Rate</a></td>
<td class="nump">2.62%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Executive Retirement Plan Rate of Compensation Increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Defined Benefit Plan, Plan Assets, Payment for Settlement</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Defined Benefit Plan, Plan Assets, Benefits Paid</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined Benefit Plan, Plan Assets, Contributions by Employer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Other Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Other Contract | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Other Contract | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Other Contract | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_ExecutiveRetirementPlanMember', window );">Executive retirement plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined Benefit Plan, Accumulated Benefit Obligation</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_InternationalRetirementPlansMember', window );">International retirement plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined Benefit Plan, Accumulated Benefit Obligation</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember', window );">U.K. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined Benefit Plan, Accumulated Benefit Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember', window );">U.K. Plan | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember', window );">U.K. Plan | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember', window );">U.K. Plan | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Acquired and Established Plan Changes, PBO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan, plan assets, actuarial gain loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_ExpenseRelatedToMatchingContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to matching contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_ExpenseRelatedToMatchingContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bsx_Pensionbenefitobligationbenefitspaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>pension benefit obligation, benefits paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bsx_Pensionbenefitobligationbenefitspaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=bsx_UKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=bsx_UKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=bsx_OtherInternationalPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=bsx_OtherInternationalPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=bsx_ExecutiveRetirementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=bsx_ExecutiveRetirementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=bsx_InternationalRetirementPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=bsx_InternationalRetirementPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=bsx_UKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800574252416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss (beginning balance)</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal', window );">Cumulative effect adjustment for adoption of ASC 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Net (credits) charges to expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Utilization of allowances</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss (ending balance)</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>bsx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bsx="http://www.bostonscientific.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bsx-20221231.xsd" xlink:type="simple"/>
    <context id="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b1c201a7f894798953b951e25210181_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46385d71ef6d4d5d84809dc420bb3280_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i22375819fd604f498598a0c0ad1d2ecc_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i768fc9449917456fa6ad3dc07b48a7de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1341e21d90443af90de6592dad0f9ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb83d68d15234b64aca503ff713f9dc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b0b26deeb85428db3cd49a32a784be2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e82af43990a43a5806aec1a1b7cffc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a0e880d55a44638a412708352acd0fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c98902d1100477fb76e88964a02c7fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79dc2df78f7b482183a5fdbd827980dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87a7639e46664d8fa457ee6d81350081_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4da3f796ab7b4c4789b43fb01dbff97e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a848010fed34536975f3f72d972321b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i987efda00d924bb3ac9171caadacb1a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icca748a50e2c4b028776ec23b7576190_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie55cc43cb62e422cba78b408deb3fbe9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i910cb43c8c984811951e0a50cf31e4b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e78cc828ad64fd2a08ac51a9ab110e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if11723763d0f4a7f9db1745ccb1925ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f33f8343cf341e081c829b309c949a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2e12b27d5b94e89971f0a98991944b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0412e24c28c14e22992835fa7fabd269_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3d8c8b108e34010b4bed817e2a890d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabd9e2d2be054f858e0733f3f3365bbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc5a34dafaee43739ad795081962c7a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8645703dda44b3d867bbb14b332875b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76729449762445b59ec9bcba12070a3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6af7edc70c84446284ff6b173c1e6e62_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc1ce07457004d06a149601f4c4f99ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0357c11625794ac7a3d84a5f74c260a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20d6ae39de2543159b001084dffe037d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cf5487b407e432ead1e4e694ed618be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i39f7478fc1994fa5ae2a4818204ac7c3_I20220615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="i91739b0d9fae4d91a17da45404a70bd4_I20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:ApolloEndosurgeryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="i52eb55d7ac10453695894b8ed3be958c_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:ApolloEndosurgeryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="i2d7591fa55b4499f8bcaade3bba40cff_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="i4de90588254145949ff313db5ff70926_I20230220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AcotecScientificHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-20</instant>
        </period>
    </context>
    <context id="if26a25d3f1534945a3bc82415ed7fc25_D20230101-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="ieea77466150d48c9a38a34a0031f8c09_D20230101-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AcotecScientificHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib76d0b974c2249e39200438329a79acb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c12e4b8e88946ea9f918f099eca4382_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a57f87953d04bcb90ea07b09c5d17be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if226113987c44049a2899b6e0639d557_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fae4e1ae03a42d985a17ed55da3dd73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bdd48bb3d8f42bda231800746b62182_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if611a01731ac40b8a3f718fdab5f1fef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:BaylisMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="i683be7f8eded4529b408b52a5cef0564_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="i9244733cac7643bd91fbc8831f903805_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="idc1450ea84df4039beb33b363a40d4ab_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="ib0472293542444a397c435d4b743117f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:FarapulseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9433d2d803b946a2a1c5f7f1eef556b3_D20210901-20210901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-01</endDate>
        </period>
    </context>
    <context id="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:DevoroMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="i16dfec677c164b2db255f582287df56d_I20211108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:DevoroMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc362728b97e470189a743db7df633f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29dcadcc844744ce80267d06b1d1bee8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida522649c73f489991dc9d869ad4cb1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if86cd5fe3fca484b870d2bca0d5beae5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ideb4a49895044b7f93b87f1125e9a416_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02d216afbb77411a8e7a88fc901eb047_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide1123ea65934f2e965ed236c8440439_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f2d335c16564091877bbf5b8ea02230_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:PreventiceSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i083186e7733646c894ee4a0c3759132d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a8c96c67e8f436cbff8a3f7e7cf61ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03e104fe52bd4eaf9ecabbd0966f5c0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e8992dd65c54f5a8d206129a6e43300_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf6bacafeb2c4ee19ca76f16ce8b05d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e2f9147295b4342ae1ef9f9a08e5b1c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i298875e7f6c14315a22aa84704cb2ce9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0d8c251041c479c83a81894f74cb3a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:LumenisLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3bda1329ad5a4a2f81c742cf431791e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae118e7e63dd4c05b064ed16436ebc0b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d1c3e36b9104f7d9dd2b0619383a285_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia1ad30b208f74b9dbc3abb41b51d5b1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id779a81f335b433c9e90f850b830d36d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36b821fcbadb4bd3aacf50d87394be76_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:AllOther2021AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib279fd9ff9e24cabbeea019d2dce793a_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bsx:SpecialtyPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="ibc9e93fb57d049aba15e55858f4ab28e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9c455c38cc5418c8c1d20f41ec12d1c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie352ea4b79494664ac3998f2352658f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc984d89ba45490889622ccc6fb20531_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic745df5cf86544beb987a6cdbf4ae321_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8236d39ea3a54b19b58c9057e3712dd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09fdfdce24574b16ae9fca57363d0048_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RDRegulatoryandCommercializationbasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie344ff9d360c43ec88274800d50d23fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e5dd3a9e74146d9bdbd43b08724c65a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b8770fe069a48c28a36571ec7f42a16_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea319dadfcac4428bed6eb3806fa0d6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60295929e3534f219e8dd476fdc06494_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bsx:RevenueBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b643ca1df374b79a206f73c4e819e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i493e85aa50f24f0caa296c0a869c9130_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i829f5796ec4446fda9daa222c9e48016_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cb6963c5fa24817900cf506ab2e8417_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39aec4b0808e4322ac9eaa857e19619e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a09f7d28b7a4d58918c0fc8fd00608b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5be5738945b41cc9caa3ecef19ee3b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6476257158644418375f2f260ef1d9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia479b11e592d47a89236ff2bfeba753b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iecb9fb9238a440629faa09412375647f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc263f43956447489bf00cd95b47d45b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a5e00fb04b14bd7be7b428099bd5934_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab0460e71d5b418b813458aae9b11a82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie847a194b2334592ac9587e3029dbcd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2019AggregateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f4f307170e14ffa98c3396e76d5b034_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:December2027NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07415990883e4ca3b5f954aa8871d444_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bsx:MITechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b264f96121f49c4947c5cebac003441_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0ba4efd839e41a5a81e781338fa73f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if424464b0a3c4a39857873d850185168_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f6d5b5ab6e344e9bf988dc3bff46611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13b57c132f9d416694b1d85ee5e9c012_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefadff6b78cd431aa59e065d0ae8d019_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7034c0c152ad405b805f9b28b7b18795_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ca004ff852f4e619fad9a26264773a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id838054c9b624ef88ede2a3ac03cca10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i775054b201874b0995c880d7f1742de0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48954fc8363d443494d7a35d45e950af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bsx:ForeignCurrencyDenominatedInDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i438b83212971494182ffbef2037ce1dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5dc8106ccc3e4b4f8afb7eed48c9a6ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i497eeb11153a4392b98631c49308f079_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e775c256acb4b869fa12bfa169522f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6965149134094476b73632a7c3d75d1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43976490229f4082a87ca1ad777107c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c931f3e9e82412985cdead08af7d632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55b5902a38e94fb0bc7726cc131b7909_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b0fbd55b32b490e9fdb76b959b0201f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbf44831547f46288e08f02ae1ef637a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf6b63466c604373ae38da6289aeb97b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e21397bfa8444b681ef8632f7075281_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf9f9f3e82c944209c2e074ec8df6017_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c65a02c0b2346b8906129d0669bf500_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic80d5979815640db88b06b04ebcb6895_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia66ab9c892884deaade76365d66fd129_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7356fcfc65574de19d26d52fc3344322_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f9d72a0fc2a4e5a95b3b411d70ff7cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i023ada48280d48fbaabe57b9e17d60d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30ada0ca796d42c992dc5e35b941a368_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d3c5b387d0440dab8c546b5c1842949_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09b6905a25fa4d699bf3d10ecb906a32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i840959e741f54e53bcfa7cee090f415b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e0f8ffbda174d938d2297ace40124d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14049c0347434075a00f370f84a4db4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07b89ace1eaa46269adec5e0008ec73b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3d5b145adac4671bb050182a0d509da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ffcb904865b4d6580df24d96533c364_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee69410e5a5d4b89bc83f76bb50d6b38_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2e9c8a5b25844acb555957ab3a50fda_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia769df42f17c44b6b313f45d148ee393_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd5679aa760c46509687a1dde91bab70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i306eeeee59414185854b583778c80597_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i65715ea926ee481fb6c5149bad0221f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29915dcac5094d979b75f1f2f98cb3d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2194ed16e8554a818134176f669c6463_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5c030aed5a44a2c9b75bda87f7ac3e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifee8da85a7114dbf9b80f1b1ad1b7309_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4af424844b524fbc975d6d2534326bb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i707b6e8943e4427a9a804100e6c467b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bsx:LicensingArrangementLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3ab0e4e1b614daf98a769c6518ac202_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e5897f9c4874d42b04253217254d1e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf8cb2626e924fb8839e71109d5af54e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:October2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04324fd6d5b24d29b46e19849e7f37a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:October2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie06c81ca089f4d1995643384dc902e2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b2144f30d3644df97a834f3542eaa50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53531cf73b884a88961411dfb1a4df93_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2025NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02be01898d4d4188b550ce6554ad5461_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:May2025NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2025NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id76f019bce26489da0bbcda06c714fcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2025NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b88044a72ca47a791ceb58f044afebf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if96adf1f1d5d4c17ba33895d23e7b110_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:December2027NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0895858ef274288a9fce1cc6baf793d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i864e95597acb4043a3697acb3ad55e62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08a4d41448224bea93d0c944e7acd848_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe00cfc2a6d34b918d4ceff8a2a7df0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida72d7a38e1b45739fe07b735a844490_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i018346feef584486b99651353c8ff6a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i682827fd95b7499d8506ecce105a57a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2030NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb00400334214dfba90153fcbfa6c190_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:June2030NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0b7e8de32b04e2b9d457be393d35239_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2031NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a66dc38d4684266bdecece733ad71b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2031NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2034NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6171ca5966e144cda0bde8a3dec28ca5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2034NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2035NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0e76a81818f4be58bec07896afe0da9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:November2035NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6bb195cd673465b82fb0f2af7d23b13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2039NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3999962f0a5340baaeffd9b46c41b048_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2039NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:January2040NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb1499dcaa0a4582b01d18fba8f0a457_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:January2040NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58dd8cfee9114b3094575d06ba47b061_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2049NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i928315b0c4a64541aef04d53faebc49b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2049NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99f56a60724c4866875a8a4eae6f3274_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic32b67209ba7458d8464a71b457bf2e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65b71607a73c4b9581145cffe097fb22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1115f7919aed4133876eff1699223515_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7989d8c3104e4c619e77b27f533f298b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icaa67b35af59447dbc5102119a3de9dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc9cb66ce623493d8cf1bce6f5823751_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bsx:May2022NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a25ee3da32a468a9bfc070a0c89a839_I20210510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bsx:The2018FacilityDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="i9d77a9f992e540f08a1ba2d26480abde_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id03e9205a64d476ab1ffbccbf9a5d6f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:ActualCovenantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i423e15598ef9473093d58996221c5647_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementAsOfMarch312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44684946d0c54e399e9c2de5643d2c10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a893ba0e00b4645b7c556abf4dec609_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cb6963457e3481da9017401ed9b31fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09ab63ee90e44984aa45a30f812a5e31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3172cf749dd40e98dad112948210e77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bsx:CovenantAxis">bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ca8697fd7e248dbacff201a7b724e96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0251b7614994e199486b144a5575677_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:TheOfferingAggregatePrincipalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:March2025NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf36b03a92634587a78fe98ecbda2739_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31b0bfab9628416589521c0cc6480c67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i643af335931a4a30a480266df6ef95d9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i98de3ef86645434aa333bc3813270c7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id65dea5f8a5b4ac18eaa23709148f19b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:EuroDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ce90adb5f284d558cee43d226b9984f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba3abf20e7914152b66511a2593d8f69_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife73119c01544765a2e816448d123ab4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33dfc13e3d6d4ae1bf1a49a51cf7ae03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:YenDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf9016a91a7f4898bd6a07d00738ca87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0b9dfecd89c48c796f6821c64cd7270_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iccc10de8eb9b4b38a11dcc2d78d8200a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a3c6f2ec1ae4c93b758ace41955b687_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bsx:RenminbiDenominatedFactoringArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f5f7d93752e444488110da50a259559_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f29c696e3e14cde8b3aa694d11cc79f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i609bef3b8f6b4492835318799ad63507_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic937ceba64df47d49bd0da69ef3f015d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a7c693c1ad044d5b5d785d5431ee0a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1500544395e942a291c9853a03d49cd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a5c980151684785bcfcbb6bbe9b77cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxAssetsDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2eb60a7197b4e5da1ffad49a2eee8b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxAssetsDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cbe628c58a04e7ab7e6559ead7b48e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxLiabilitiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i277df0ecaf304cf08357801c32ae2706_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bsx:DeferredTaxLiabilitiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a2e7463fa724bcf9a0461181ceba4f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id15f114eb8804a7c98bcd09d92bb0633_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i3290f9f23eb24119a72f6930eead5d1f_D20220805-20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2022-08-05</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <context id="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-27</instant>
        </period>
    </context>
    <context id="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i62bc5e62d5db4d23866e0c44a56c5628_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if23c296459144875ad187e30e952915b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifada2c5db8c74b0f917945eda6797be6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6805ad1bd72431da0294f8b9f787280_D20230130-20230130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="i91bed8161679460e856d9920088ac04a_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i6bf3f5d8a9e54dd79aaa2d19b5e4aff0_I20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-27</instant>
        </period>
    </context>
    <context id="i182a1036891e4f75bb208c20f52223a2_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i08365277a86440dab883742676202e25_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bsx:A2011LtipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="if65c415d7afe493a89650f841bc4bf30_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6cf9fcdaae944b3390aef4cad3b3d62a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia933afd979654f88afc557688fdca523_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaaae3391a8f04f3aa64456d9284c46e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14bcf59fe7c34a8a94840e5aefc3a400_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3db7e9dbfd04e5087fede77d602a86d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0af4e13a75a42c69eb0c61842136ccd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i70ac253948f34ac7ab4ff32466a9dc4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7657382e881145e693f2f7a6e978a9cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaabf66c1b2184034b2b380702d5950c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i950414449291498aae88bf9cc6ecb151_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbed6b4234d64fd6a55a3d61b6c5cc7f_I20210217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="i6c2fdbe96ac342cfb2c6e55914689554_I20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="i6e2523c5f920482192b97a05b9cfd285_I20190221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <instant>2019-02-21</instant>
        </period>
    </context>
    <context id="ie1d4b247dfcf42b18bdd3d7fc7fef232_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8687933af19a45e89f5ecbc7a113fc9c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i040d7807c33b46a4b79cf78c184c0dd7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03c56a446b7c417f8ba1d1a6f60d5e8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3043cc21b44462892099dc71ca5ae2f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80e0030da7dd43208fdf78c181acd6b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5740688cc4a24abfa9eca604a6e8a9a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8209cc36f681456ca83869b5c6449383_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:BSXReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73aacf8162a94e5ca1cbfc7c3bbb8429_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d4d1adfd5d54741badb3c93eae8f22f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8022cbc49a3d4c4fac891808fe3df6d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41a81988fde44ba5b6bd50b742952a88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad42e640c3464b0da50b8fb06d89531e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i828e9990d56940ce9f697d568f80f1ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CorporateExpensesincludinghedgingactivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33ec3556bf5a454fa2bd44957535d39c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf2bdc993f6049e2bd23b2de3c4d090c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i282876cb44e2481c810f077edcb1f925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:SpecialChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23150e692e7444a6b1096dff0b883677_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9912e3f7721e4f4eb02c8a146eb576ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ff6c0b60ebb41109c5e430b7cf98bfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:TotalAllocatedToReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d25936d40ea49aab12bb59004cd2db9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e6cf9fdde614399a2fe497025d3fd04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b22282599f043b7ac5083784fc608f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:ConsolidatedBSXDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88b5c422cffd4ce5a6f4a90251a20608_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:ConsolidatedBSXDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic56a78345d3145e2b9794e539a59c1d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4367e2317d04cf0b38cf472829367fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia714a3ddfec449b5b11c7aa4287614fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if045c803eadb4661aca54512d1bb0be2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife2970551fa2429a88d913607880908f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic95029382727473aaf7e493ea3baafeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c7006856c9d44d2ab1e38d46423fd26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bc270f01c02480db0f2bcec5a56070c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dca525960544c139044f842992c4cd1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ac06cd2de024399894d3c6dfb28070e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02e2ba9581ee4e218b8a89a221a0d400_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia98056bb0e784957b5899a9e833f0fbf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf2e323954f7444eafe535939a1c7edc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f3945a09c204b04a2dbb81ac13ccf41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41d43ae659ff4513bb97a8edea477a2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd6ae61663a74c268cb97faeae2f6a45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfbdd903babe43e3990ab29bcbe6985e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalEndoscopyEndoReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d5cf1f78e6445dcaf73a56694e9027e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i35b44455a502404199213289b929b707_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfb65397f906401f908a347b4d777c0f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9ede5593b494783a615d880fc8b78d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ea5ae6a8a2245f1b71a59f4740ac05b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3e19ddabb7c473ea576b951929e933d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida7fe9c758704bc380ecdd891fe49855_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbfe994c194b4ac8ae41f11a8e0cce7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84d8cad94f45467790555d4a57825c01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalUrologyandPelvicHealthReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief043d96b49f4090a6042a4c1e0f9605_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4a88f9ce6ad4b2eb993d105654ed940_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id59ce8cc839f4063a3e88b18ffbe49ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e4d8cfc9f3949e0ab3d00ac9a41c0a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2111a536bd5a4796852fa7ccbf67dc68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcd845dce72c499e927c52977b641d86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i266d7b2f5a4648a7aedcb54343a73155_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95007a0364764d788c9f338d90b37fa4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6658a131071b4edaa7cac05c6b6aca94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalNeuromodulationNmReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5309925cea74e63b88ce62afbe1270d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97bc9d7d5aef436ca66c436814c83b71_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ea2540506a544eeb708632b6b53f89b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65bc255eecd04f718e0dce31409bbb26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4d0840a435a423cb7726c98d53dbb8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6cf111df6fc94178a8bb5ccf9404c15b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:MedsurgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78b14d4227e848e0add48cdc505946e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie02edf62965645468d841ff2e20bd583_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3ee3c0309a9465098537a7f86a5ed19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibaaac1cd808c424895d59867a9db30ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd3cec840750475fa319163520fd421c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if97a3d07e8ae412080d39dd505633b22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4e2fdd1216d48ad9a132b46e9f04cc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2c84859c22a480cb0e62d9cee342cf9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4b43961f16149e79908d1ce39fcce65_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:InterventionalCardiologyTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6511ff7f1ebd4c868948a72045ca4c95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2cccfcfa0da4d0ba64bd068cb216aaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41ef965318ec475d8fe145a03272291f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44f013c49cfa4e968944e9f014b68096_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id84b586d1c33476cab5cd06fe83b53aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib63f895c42144907a76b542b549cfab7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c142c5abcd44f2097601e910946d27f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4badae83fb2143539a2f1dbc8f190c16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i087cbed8b29e42feabd968d6ded400ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:WatchmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i788426412f1a40f8ad96ce8056faccd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bff9d1f551440a688b46d38ff22c6f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3332eee0684d473898c31f79884ac25f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47b385711e244459b5bc15b4489ddc67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83c36f07461a4edb956649b1e7840283_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i367ed0de181442618fa9e97ba29c26ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc9d01f0516547888439cdac0d45255e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46ee1376ff224dada10dcbfa895cde79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd5934a9c4b546c8aa8a37ac4ff145ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:CardiacRhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9327fc2252e47e68dedb4bf033c1d99_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i980a462ea63b44bfb0e472d26c91addf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24f3dfdce6e044c1af8a7d768e300200_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d5d84cf74294152822468efbefec311_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e041f4904a84a60b8108cc9c8334104_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i050e41d3f89a4c0a99eec3c08767ddc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie67b272c44934fe18e99394c9d6804bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i270ce9e6a3b241c8adb7451d55aeab6e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i581ceebdfc92445686149ad51b8ce5c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:ElectrophysiologyEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i299c0a24457a49c48fa0b7f8274dfbcc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a11a2bfead64c0d8b223433c88c9be4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i93d0aad282314e139497edd5e2dedbd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44f4ab88945f40329c0a824cc3ac5fc8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c06369961704a7285b3ca38acb83219_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fe90759eb8f424d8234de45b7a2a52f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i907ac35c98df416294ddae9f68675c91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fa4826270924bc38ed4e2b1152cc626_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77a81b7be7914312a976ebf95b9963e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalCardiologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16c43cfb6b094f59988dda6095180014_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib49ee4af7f4d4a8687f9f49af6e015b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieff090cbc1c5471fb8af72a026fedd32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i45c4af7a1ce94cab93068e8d456e80ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84ce6d1a01654d339cdd042cff9f100c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bcf6149b1404f96a68187ed3c062a35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d9c77c73b8241e1a75da0171dba04aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6797d90a509d4ec8834a36e34146765f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i242b0d85ba4e4a2fbe4aed3cf9b322a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:GlobalPeripheralInterventionsPiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05dda8644a90446b877b0a66f32d173a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i19f123aba421447aa9cfc9708023f08c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2fd26528424d45f2883dba765d3955d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd88a51eb14a4889becd9bf95a373936_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e1f6bf8d3c34daab2415fdc9e3dd952_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i210171398abc49e5804c051f9b9fc4cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bsx:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4d2ba2b1796414eb8143d8705a0465a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib2ab10efbdcf47528ab3d60926612e2f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb5baeedb7124b2f84ddb781633016f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9be1b83b1a924f748b1636472e5583be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50b2f64263444c3080cc6d662586f06c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30fe7e8d201c4c45ae3804080539f315_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bsx:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if85ad4347a4c4b54ae5c5fc3193a7800_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ea4c3278ec34a698de1ffba66d08cf6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c3c6b5d49ff44128141a1fbb83b6e1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12859b60da9b499db05018d9639782ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21d5ab671eea46b3bff921eba5cde3cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb42a43becfb4015933cfee5cff72004_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51fd28aa8356476e99b8acb0eca6d645_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63f7de2437fa49bfac860e607810e395_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifa737befb7b447a8ba19436619112479_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:USExcludingOtherNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifead762c7ade4e00b9129c72020dc3b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5b812ed03474859ab0a0548820d732e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4fc248e09be4de88c3b1366bed3d1e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0d8f6746e354f2e87c087199c9722d1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75aca95e90e14d6f8ad7d91562c55653_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b0c54a79abb4963befbf39f66d3391e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d7ba54afdd9452783afd6d19b9919ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0809617f4324434aaebbd5728f20d9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i950de22b68424e98860e7337e3026204_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:LatinAmericaandCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9523ca0ea2849a3ba7afdb3f792faac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id12a969e10ec48b990fe38bdaab38a23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ef567bf8d9645e88d19c89d931dc420_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bsx:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i139d04cb2ec14e418ffc5d45192844cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:ExecutiveRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2c3fb77fc3542338e354336e20bc3a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:InternationalRetirementPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie472ffec11ea4927bd1542ae98aa108f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:ExecutiveRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07418139cdce4f5c981ed2c683522433_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:InternationalRetirementPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i398d31599a9a4c7a862b268487b31675_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:OtherInternationalPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a709d6c9a0b41feab31995bae094f9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">bsx:OtherInternationalPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05bd241aa7bc46a3bbc132eb60cc014c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec61999347b74ca9980b9262bc2473a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i649253125d3e41ff83d40817dfc4b57c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81025787d2734b4085a77f222cdb83c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i464a3ab08a074038b0b11f145f5be6ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54cf5d0c98a64efab2f25564d3cb8718_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d6c0f8faf13418e93bbab3e1cdb4719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9720398bfd24fcaa4cd94ccacf55bfa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bsx:UKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63c80cf97e92455e89254f71abde961e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="units">
        <measure>bsx:units</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="unit">
        <measure>bsx:Unit</measure>
    </unit>
    <unit id="reportablesegments">
        <measure>bsx:reportablesegments</measure>
    </unit>
    <unit id="countries">
        <measure>bsx:countries</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV8zLTEtMS0xLTExODgzMw_6c056f77-ab9c-469b-8068-274ce78db049">0000885725</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV80LTEtMS0xLTExODgzMw_297a38c8-9026-40a0-a124-65eddfe6525c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV81LTEtMS0xLTExODgzMw_d684aded-701d-4a0e-8f10-04a540dedeac">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV82LTEtMS0xLTExODgzMw_6175f673-3dc4-412d-9317-ecb4151c1eee">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl80L2ZyYWc6OWFlYjkxOTRiZGQ5NDUyNWE4OTkzZDNlYWExNDFjZWUvdGFibGU6MDM2Yzk4MTNlN2YwNDUwNzkwNjMyM2YyZDAxZTdjNDkvdGFibGVyYW5nZTowMzZjOTgxM2U3ZjA0NTA3OTA2MzIzZjJkMDFlN2M0OV83LTEtMS0xLTExODgzMw_79bafe8c-990c-4ea4-9dcf-7166852a64a1">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA4_9787e394-bb7e-42b0-9f15-81145ec49039">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZTEzYzNiNDVjYmEwNDgyOTliYjU0NWRhNDA5OTlhYjgvdGFibGVyYW5nZTplMTNjM2I0NWNiYTA0ODI5OWJiNTQ1ZGE0MDk5OWFiOF8wLTAtMS0xLTExODgzMw_74573491-e445-42f6-8d43-1a2ac0843de4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8xMTQ_16f1ceb8-4351-410f-b3a0-4488d0d2fd7b">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OTY3YjMyYjg0NzkxNDQ0MTk2MDBjNmNlODcyYWNiNTgvdGFibGVyYW5nZTo5NjdiMzJiODQ3OTE0NDQxOTYwMGM2Y2U4NzJhY2I1OF8wLTAtMS0xLTExODgzMw_6999e608-8468-4b16-8e1b-c47e50c51a85">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA5_80418b68-43c9-41da-bbfe-d9152ea0fe58">1-11083</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEw_a12338bb-82e5-455a-b8d9-bc8ae77cf83f">BOSTON SCIENTIFIC CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6MmY3YjFjNWNiYWQ5NDkyZWI2ZjVjNDYyYWVkYjE1YmMvdGFibGVyYW5nZToyZjdiMWM1Y2JhZDk0OTJlYjZmNWM0NjJhZWRiMTViY18wLTAtMS0xLTExODgzMw_0cb326a3-326a-4975-8d01-6d35f4a6b59c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6MmY3YjFjNWNiYWQ5NDkyZWI2ZjVjNDYyYWVkYjE1YmMvdGFibGVyYW5nZToyZjdiMWM1Y2JhZDk0OTJlYjZmNWM0NjJhZWRiMTViY18wLTItMS0xLTExODgzMw_1801be3b-6328-47f2-a790-dbb34e167fbd">04-2695240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEx_3f8dc664-309c-49c0-96f6-7e79cb71be74">300 Boston Scientific Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEy_9cc03364-196a-413b-ab82-88389f15fdec">Marlborough</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjEz_ec7cee86-3b75-4d4c-8c91-6f5a7cae0ac7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE0_fa217d3b-08ca-4dfc-be99-bff182e464e6">01752-1234</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjAz_bbf65ac1-b427-42cf-aead-1e2df60c9f98">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA1_a6cdf955-5849-4220-b239-6de7eb536762">683-4000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTAtMS0xLTExODgzMw_97571bb9-ebb2-4b8a-8152-b4d01a4d8dc0">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTItMS0xLTExODgzMw_98f1b545-8eb4-4ed2-a22a-99b9203e7e38">BSX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i986ed245b1e94a8aba6232568f6f5b5a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8xLTQtMS0xLTExODgzMw_d4bf4cdd-8fbe-45c4-9776-564301aa7493">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTAtMS0xLTExODgzMw_98344972-8737-4552-a243-4ed0c05b243e">0.625% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTItMS0xLTExODgzMw_171b90e3-7d40-4793-893c-b4cd68c4d558">BSX27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2b1c201a7f894798953b951e25210181_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8yLTQtMS0xLTExODgzMw_063b2521-b416-44d4-97d7-68c1857835d5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTAtMS0xLTExODgzMw_837f4c40-8623-4365-b360-e4d454c671ee">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTItMS0xLTExODgzMw_1e91adc7-89c6-49cf-82c4-2dce50017de0">BSX PR A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6OGIyZWNkNzMwYWIxNGY5ZjhkZDk5OWJiNWM2ODU1YjUvdGFibGVyYW5nZTo4YjJlY2Q3MzBhYjE0ZjlmOGRkOTk5YmI1YzY4NTViNV8zLTQtMS0xLTExODgzMw_a54a391c-c16d-46d8-90a3-2ba3c285845c">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE1_60eb76ac-4805-4219-813a-0ba70bce8267">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA2_acbd7b01-ea80-4ce0-ad89-4d8a38c04fc7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE2_65bed8e7-ab3a-40fc-9d8c-b051989561b4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE3_d8ce1be0-5e4e-4c28-8903-ec8c716fa0b5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8wLTAtMS0xLTExODgzMw_30851c90-e030-4047-ab2b-977a655a6bd4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8xLTMtMS0xLTExODgzMw_129aa1b1-2bb2-457c-a98e-f54c78c09997">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGFibGU6ZGIzYzU3ZmY5M2ExNGQ3NTkxZTYwNDliM2U1YjgyOTgvdGFibGVyYW5nZTpkYjNjNTdmZjkzYTE0ZDc1OTFlNjA0OWIzZTViODI5OF8yLTMtMS0xLTExODgzMw_6250a0ed-9a93-4011-a183-254b2f52b208">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjA3_27f2f1e8-411c-4bb3-8323-883df44af767">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zNjE4_93c6d51a-d59e-49d9-b564-9d785c7738e5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i46385d71ef6d4d5d84809dc420bb3280_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8yNjY2_d61662e8-f8d1-4812-b610-d351b9cead78"
      unitRef="usd">53200000000</dei:EntityPublicFloat>
    <dei:EntityListingParValuePerShare
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zMjYw_f9f0e5ff-e263-4087-8c11-37d4c0bba2ef"
      unitRef="usdPerShare">0.01</dei:EntityListingParValuePerShare>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i22375819fd604f498598a0c0ad1d2ecc_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xL2ZyYWc6ZjE3YTFiMThjZjVmNDU1NTk1Y2M1OThhZTgwNjJiNmYvdGV4dHJlZ2lvbjpmMTdhMWIxOGNmNWY0NTU1OTVjYzU5OGFlODA2MmI2Zl8zMzEx_914bd29d-776d-4d3a-bced-045e610fad1a"
      unitRef="shares">1434780104</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83My9mcmFnOjk3ZTk0YjFlZDhkMTQzMDg4NGUzY2I5NWViOWVlODMyL3RleHRyZWdpb246OTdlOTRiMWVkOGQxNDMwODg0ZTNjYjk1ZWI5ZWU4MzJfMzYzNA_f706f846-1439-4e98-9faf-27560938f3f7">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83My9mcmFnOjk3ZTk0YjFlZDhkMTQzMDg4NGUzY2I5NWViOWVlODMyL3RleHRyZWdpb246OTdlOTRiMWVkOGQxNDMwODg0ZTNjYjk1ZWI5ZWU4MzJfMzYzNg_728d86f4-af46-410e-9e87-a10602050ae9">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy0xLTEtMS0xMTg4MzM_af776dc2-c745-478e-8bcf-ae106299673a"
      unitRef="usd">12682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy0zLTEtMS0xMTg4MzM_849cb7de-2f18-4c43-8596-3a8224d66fb4"
      unitRef="usd">11888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMy01LTEtMS0xMTg4MzM_9d662dfe-902e-4901-a1a5-a8aa5afeb3cc"
      unitRef="usd">9913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC0xLTEtMS0xMTg4MzM_b89f5f77-04ed-4fa9-965a-3e48ef2caccc"
      unitRef="usd">3956000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC0zLTEtMS0xMTg4MzM_aa968464-3d53-4b13-959e-9d83d74e95ce"
      unitRef="usd">3711000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNC01LTEtMS0xMTg4MzM_c574ef45-eac7-4dd9-a939-255b19efb84a"
      unitRef="usd">3465000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS0xLTEtMS0xMTg4MzM_3e8a4667-e4e5-46a6-bdca-b98c057f6879"
      unitRef="usd">8727000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS0zLTEtMS0xMTg4MzM_aef286fe-e06d-47c4-94b7-a274314d3354"
      unitRef="usd">8177000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfNS01LTEtMS0xMTg4MzM_bf9d5db5-3fc0-41ef-8d22-bd4e0343e178"
      unitRef="usd">6448000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC0xLTEtMS0xMTg4MzM_e9226087-a425-4ca5-924a-17dd5b1cfaa6"
      unitRef="usd">4520000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC0zLTEtMS0xMTg4MzM_5ee54169-4914-4153-9a9b-a2620c9f7fa7"
      unitRef="usd">4359000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOC01LTEtMS0xMTg4MzM_2a446d10-6d96-4c87-a6a1-5b668017171f"
      unitRef="usd">3787000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS0xLTEtMS0xMTg4MzM_33b05680-58be-4803-9fd0-3d69e5abb67f"
      unitRef="usd">1323000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS0zLTEtMS0xMTg4MzM_4fed18ef-064c-4cd8-b4e6-d0eee86775b5"
      unitRef="usd">1204000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfOS01LTEtMS0xMTg4MzM_b781a29e-872c-44a5-ad06-a3652a9a214c"
      unitRef="usd">1143000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:RoyaltyExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtMS0xLTEtMTE4ODMz_83ef4104-fa46-4663-9493-13138c90531f"
      unitRef="usd">47000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtMy0xLTEtMTE4ODMz_9427448f-0a3b-4dcc-9d6f-1dda61c3f26e"
      unitRef="usd">49000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTAtNS0xLTEtMTE4ODMz_561cfd29-7080-45d7-8898-b996014b1163"
      unitRef="usd">45000000</us-gaap:RoyaltyExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtMS0xLTEtMTE4ODMz_50b21509-3986-49bd-a4b9-7d58c44fe3f0"
      unitRef="usd">803000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtMy0xLTEtMTE4ODMz_d77aeffe-010d-4a63-971a-d5ac1dae7ee6"
      unitRef="usd">741000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTEtNS0xLTEtMTE4ODMz_6c7c0c53-8135-42b8-90eb-d1aeb70f2d64"
      unitRef="usd">789000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItMS0xLTEtMTE4ODMz_ac526290-bfeb-4c2b-97a6-995aecdfffd5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItMy0xLTEtMTE4ODMz_4592bd04-2711-4a4e-8b8a-b1c96dab7423"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTItNS0xLTEtMTE4ODMz_5aa45f01-b56e-4ed4-b7d2-22d88c6f687b"
      unitRef="usd">73000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtMS0xLTEtMTE4ODMz_f219adb4-5b19-4d2e-b864-135a0194f36e"
      unitRef="usd">132000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtMy0xLTEtMTE4ODMz_2dcd1bac-1faf-4729-80b4-c8f50dc2d77a"
      unitRef="usd">370000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTMtNS0xLTEtMTE4ODMz_15820e0a-d473-4b0c-9b19-f636679c02eb"
      unitRef="usd">460000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtMS0xLTEtMTE4ODMz_565f4534-3655-4c53-b078-a4ecd7c74514"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtMy0xLTEtMTE4ODMz_1f129adc-444e-4940-b87e-0d046c2728e7"
      unitRef="usd">-136000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTQtNS0xLTEtMTE4ODMz_b2f8817f-8d1f-4067-b60c-9559d082f0da"
      unitRef="usd">-100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtMS0xLTEtMTE4ODMz_7a5ba2f6-b0cf-475a-bbd0-c098fb333e4c"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtMy0xLTEtMTE4ODMz_3bc6e187-2f21-45a6-9c29-5496bd88ed55"
      unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTUtNS0xLTEtMTE4ODMz_f3809505-bc6e-47fc-9f8d-8a882b8a8c2b"
      unitRef="usd">52000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtMS0xLTEtMTE4ODMz_dfabb3d5-2e05-46a9-b4dc-e7e5de5cce81"
      unitRef="usd">173000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtMy0xLTEtMTE4ODMz_829e2a18-cd26-4fed-bb43-605f73a998ee"
      unitRef="usd">430000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTYtNS0xLTEtMTE4ODMz_05edd9e6-d2ca-4592-94cf-3e4067f055fa"
      unitRef="usd">278000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctMS0xLTEtMTE4ODMz_48a791ac-7281-42d2-bcdd-b53b856513f4"
      unitRef="usd">-22000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctMy0xLTEtMTE4ODMz_cad47bbc-87d0-4e01-a1e8-285d34744065"
      unitRef="usd">78000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTctNS0xLTEtMTE4ODMz_e1a0b63c-11fa-4ba6-acd7-847227e3259e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingExpenses
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtMS0xLTEtMTE4ODMz_79e1c2d2-3fed-4ed1-96a9-d8a99346f39a"
      unitRef="usd">7078000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtMy0xLTEtMTE4ODMz_2b2a9ef4-243b-4f05-adbd-5018ae3c7f25"
      unitRef="usd">6978000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTgtNS0xLTEtMTE4ODMz_d06c2393-6f4d-4475-8cd4-efa97efb9848"
      unitRef="usd">6528000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktMS0xLTEtMTE4ODMz_4be11557-f172-443c-852f-883f43510dc4"
      unitRef="usd">1649000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktMy0xLTEtMTE4ODMz_7d7caf0e-a6d5-4d37-a091-a956b4cbd360"
      unitRef="usd">1199000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMTktNS0xLTEtMTE4ODMz_9dc87eff-cf2d-4907-8010-bba02eff3659"
      unitRef="usd">-80000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItMS0xLTEtMTE4ODMz_16e2c289-46ff-4679-9288-2b4171753ce2"
      unitRef="usd">470000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItMy0xLTEtMTE4ODMz_0e86498c-b97f-490d-89fb-d3850396d7d9"
      unitRef="usd">341000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjItNS0xLTEtMTE4ODMz_5ec15edc-024e-4438-b36c-a4051c865098"
      unitRef="usd">361000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtMS0xLTEtMTE4ODMz_b77dcb85-7f21-4191-9aea-d45d665a4ff4"
      unitRef="usd">-38000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtMy0xLTEtMTE4ODMz_0a5a531d-f546-42a3-b217-1406d22f3477"
      unitRef="usd">218000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjMtNS0xLTEtMTE4ODMz_ab81265d-9b0e-4ff4-86bd-3cc689469f2d"
      unitRef="usd">362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtMS0xLTEtMTE4ODMz_a8993706-e15c-45c0-a43a-a485751d3964"
      unitRef="usd">1141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtMy0xLTEtMTE4ODMz_bb7c55e9-157f-49b7-a845-f6861a17f3d5"
      unitRef="usd">1076000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjQtNS0xLTEtMTE4ODMz_191adbc5-b5ff-4cd5-866a-14afa4958bf2"
      unitRef="usd">-79000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtMS0xLTEtMTE4ODMz_263f4582-bfea-4bb0-b6ba-2d1feeeacfe9"
      unitRef="usd">443000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtMy0xLTEtMTE4ODMz_1a7f2f77-eb38-4944-be16-036e0b7fb95c"
      unitRef="usd">36000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjUtNS0xLTEtMTE4ODMz_180f71a4-6dfa-41ac-ac79-5cc1007bcd1a"
      unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtMS0xLTEtMTE4ODMz_940b54da-d15b-4c5f-b1a4-e7400f39e34f"
      unitRef="usd">698000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtMy0xLTEtMTE4ODMz_35f995b5-5d51-4fec-84dd-0f5811db5876"
      unitRef="usd">1041000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjYtNS0xLTEtMTE4ODMz_34a0e93d-642a-49d4-a423-3d3d7d001c72"
      unitRef="usd">-82000000</us-gaap:ProfitLoss>
    <us-gaap:DividendsPreferredStockStock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctMS0xLTEtMTE4ODMz_204c78c5-cc8f-402f-a6a2-3196bd31514c"
      unitRef="usd">55000000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctMy0xLTEtMTE4ODMz_6b819d76-fe3f-47d2-96d8-58856f10ef2a"
      unitRef="usd">55000000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjctNS0xLTEtMTE4ODMz_bc5eb57a-2fd4-4b99-adb0-1186ca81d6b3"
      unitRef="usd">33000000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtMS0xLTEtMTE4ODMz_a855516f-ffe6-4671-a693-20218fc6487c"
      unitRef="usd">642000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtMy0xLTEtMTE4ODMz_19820d3f-d120-4091-8b90-c36e83bc7cfa"
      unitRef="usd">985000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMjgtNS0xLTEtMTE4ODMz_82b8c1da-600e-447d-8694-e5468dbe374d"
      unitRef="usd">-115000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtMS0xLTEtMTE4ODMz_2d38e201-666e-4899-bdea-a70fed470bb5"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtMy0xLTEtMTE4ODMz_52e371b4-696a-4295-bcb2-d6577db46d8e"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzAtNS0xLTEtMTE4ODMz_841c9654-b65a-4446-8b19-67c2815d921a"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtMS0xLTEtMTE4ODMz_03b11f7f-3ee3-4458-a136-5f2d330b13e6"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtMy0xLTEtMTE4ODMz_aed6f052-5e77-4210-afe4-74a23de96135"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzEtNS0xLTEtMTE4ODMz_b4fd8cc0-52e4-48fa-b4e8-3fa887813a0e"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtMS0xLTEtMTE4ODMz_19a2ce74-86cf-4934-8993-d5792dac5a92"
      unitRef="shares">1430500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtMy0xLTEtMTE4ODMz_6c11343d-18a3-4a09-b032-3158fc8cf67e"
      unitRef="shares">1422300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzQtNS0xLTEtMTE4ODMz_cd18741d-b3b9-4b93-8c0a-f9b8983d9f7c"
      unitRef="shares">1416700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtMS0xLTEtMTE4ODMz_1dfd270d-1828-4ccb-ad1a-935637892c29"
      unitRef="shares">1439700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtMy0xLTEtMTE4ODMz_781a14e1-0780-4ee6-bbab-4af1e148e1e5"
      unitRef="shares">1433800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl83OS9mcmFnOmEzNWUzODk2YWIzYzRiMmJhZTFkZWY2ZGQwMTFhMWM1L3RhYmxlOjE2MmY0ODAzNzBmODQzNTc4MWMyNDY5NmFkZjk1ZTFiL3RhYmxlcmFuZ2U6MTYyZjQ4MDM3MGY4NDM1NzgxYzI0Njk2YWRmOTVlMWJfMzUtNS0xLTEtMTE4ODMz_18ba125e-99ad-4a71-a6e6-0036cac070f0"
      unitRef="shares">1416700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi0xLTEtMS0xMTg4MzM_940b54da-d15b-4c5f-b1a4-e7400f39e34f"
      unitRef="usd">698000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi0zLTEtMS0xMTg4MzM_35f995b5-5d51-4fec-84dd-0f5811db5876"
      unitRef="usd">1041000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfMi01LTEtMS0xMTg4MzM_34a0e93d-642a-49d4-a423-3d3d7d001c72"
      unitRef="usd">-82000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC0xLTEtMS0xMTg4MzM_9657a9de-f7b1-4d13-b202-412d3d1eb7bf"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC0zLTEtMS0xMTg4MzM_6ed8290c-4833-40a8-9c9f-d8ce86905055"
      unitRef="usd">-125000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNC01LTEtMS0xMTg4MzM_227fad27-21d0-4d8f-8702-8c744912f409"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS0xLTEtMS0xMTg4MzM_3d67498f-d071-4a3e-b851-5f8483446d8e"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS0zLTEtMS0xMTg4MzM_bc43e799-d385-4345-976a-f6ed3d371c2f"
      unitRef="usd">170000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNS01LTEtMS0xMTg4MzM_b13ce5e9-50fb-4910-96c4-3e41601dfccf"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy0xLTEtMS0xMTg4MzM_2a723380-5b12-47dd-b722-10b822971698"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy0zLTEtMS0xMTg4MzM_5fc33b89-2869-410f-9cf5-926e5e1c9da6"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfNy01LTEtMS0xMTg4MzM_40f3687b-f48c-409f-8f97-22bd94e2dc58"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC0xLTEtMS0xMTg4MzM_8a8c6338-aa31-4fa2-b1aa-ace393a7ab07"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC0zLTEtMS0xMTg4MzM_2188b743-3afc-4541-a822-dade4649802e"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOC01LTEtMS0xMTg4MzM_d29dae54-e728-4f70-9254-c3c78fd6f54d"
      unitRef="usd">-63000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS0xLTEtMS0xMTg4MzM_3a9a4441-9db2-431e-9772-70521397506f"
      unitRef="usd">704000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS0zLTEtMS0xMTg4MzM_3e2ec739-d5b5-4fc6-b2d2-40bfef346ea4"
      unitRef="usd">1096000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84Mi9mcmFnOjNlMWMwNmJlNWZiMjQyNDZiZTljN2ZhMThhOWJkYzQwL3RhYmxlOjE0MmQyMzI4Mzg2ZDQ0ZmE5ZjhiMDBiNTRjZjhjMzJjL3RhYmxlcmFuZ2U6MTQyZDIzMjgzODZkNDRmYTlmOGIwMGI1NGNmOGMzMmNfOS01LTEtMS0xMTg4MzM_b8a9c9a1-733d-4763-8812-4beed5326184"
      unitRef="usd">-145000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNC0xLTEtMS0xMTg4MzM_2adc141d-d958-4a16-b18b-3e2cc0192223"
      unitRef="usd">928000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNC0zLTEtMS0xMTg4MzM_295bfd6c-2340-4545-b9b7-c056c0cb8f76"
      unitRef="usd">1925000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNS0xLTEtMS0xMTg4MzM_a758869b-9f11-4abd-8234-9f0dd795b1d3"
      unitRef="usd">1970000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNS0zLTEtMS0xMTg4MzM_bd7e6f66-81a5-40f5-89e1-3cf94b1c6018"
      unitRef="usd">1778000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNi0xLTEtMS0xMTg4MzM_c668f3e9-d00d-48c2-ad30-9290313377ba"
      unitRef="usd">1867000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNi0zLTEtMS0xMTg4MzM_af2ebb34-2802-444f-88d1-8dec7a2ecdda"
      unitRef="usd">1610000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNy0xLTEtMS0xMTg4MzM_3a6ce4c9-ef34-4041-84a4-c7f35bc8ca17"
      unitRef="usd">264000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNy0zLTEtMS0xMTg4MzM_c62293f7-b3fd-46f1-b610-684dcdc938f4"
      unitRef="usd">205000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfOS0xLTEtMS0xMTg4MzM_85891873-53da-44df-b940-833eef851fae"
      unitRef="usd">731000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfOS0zLTEtMS0xMTg4MzM_9a019931-ce80-444e-9564-0d2c2bbfe762"
      unitRef="usd">799000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTAtMS0xLTEtMTE4ODMz_45e8c302-c475-43b4-b1b6-ba83fd7c6d47"
      unitRef="usd">5760000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTAtMy0xLTEtMTE4ODMz_06a83e07-f665-4b49-9271-166f75d31191"
      unitRef="usd">6317000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTEtMS0xLTEtMTE4ODMz_161e7581-eb4e-47e5-8b98-7c83d9ea6005"
      unitRef="usd">2446000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTEtMy0xLTEtMTE4ODMz_2d431a99-eb12-49aa-8e17-125dad6a87e9"
      unitRef="usd">2252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTItMS0xLTEtMTE4ODMz_b0099e53-f80a-4b78-9688-f9b7a387d42e"
      unitRef="usd">12920000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTItMy0xLTEtMTE4ODMz_328a52a8-58de-4fd8-9608-ed45779091ad"
      unitRef="usd">11988000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTMtMS0xLTEtMTE4ODMz_326c4346-966e-4b48-9386-514288f8c2ce"
      unitRef="usd">5902000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTMtMy0xLTEtMTE4ODMz_9dab6693-8a67-46b4-820e-5cdf88e67f87"
      unitRef="usd">6121000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTQtMS0xLTEtMTE4ODMz_e1f69a83-0c62-452d-8f13-ba2301bcc6bc"
      unitRef="usd">3942000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTQtMy0xLTEtMTE4ODMz_352504c0-b484-4e0a-be2e-8b3449442fc5"
      unitRef="usd">4142000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTUtMS0xLTEtMTE4ODMz_a3389488-6b98-4857-932b-2ddd1ae38cb1"
      unitRef="usd">1500000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTUtMy0xLTEtMTE4ODMz_aca48e2a-0241-456f-bafa-7e43ff0aa222"
      unitRef="usd">1410000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTYtMS0xLTEtMTE4ODMz_3f165a37-54c7-4e69-b090-f7391ed9635a"
      unitRef="usd">32469000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMTYtMy0xLTEtMTE4ODMz_682c90f7-734b-45ec-b7f9-3b750a80cf8a"
      unitRef="usd">32229000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjAtMS0xLTEtMTE4ODMz_d5e0237a-7342-4fcf-8d13-5c8adf0c74e6"
      unitRef="usd">20000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjAtMy0xLTEtMTE4ODMz_7c722033-a61e-49cc-92f2-c36d3ff8333f"
      unitRef="usd">261000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjEtMS0xLTEtMTE4ODMz_e3cc976f-81c8-4571-8433-13d82f2c541e"
      unitRef="usd">862000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjEtMy0xLTEtMTE4ODMz_e9c6d362-fdbf-4c78-96a5-f72135f57a02"
      unitRef="usd">794000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjItMS0xLTEtMTE4ODMz_5ec4266f-d79c-4386-83da-5702046ff11c"
      unitRef="usd">2160000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjItMy0xLTEtMTE4ODMz_7b07ce03-2c82-44d5-8208-8d01a5168f60"
      unitRef="usd">2436000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjMtMS0xLTEtMTE4ODMz_357e2541-0631-4077-ac2b-90f8dead9b48"
      unitRef="usd">761000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjMtMy0xLTEtMTE4ODMz_9f6ab0a5-ba56-49a8-b671-070b168c861d"
      unitRef="usd">783000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjQtMS0xLTEtMTE4ODMz_24cfac86-5081-4def-a141-0bf9b9e05973"
      unitRef="usd">3803000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjQtMy0xLTEtMTE4ODMz_04df14f6-8fa8-4eb9-ab9a-cfb507a42e3c"
      unitRef="usd">4274000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjUtMS0xLTEtMTE4ODMz_c141edf1-c84d-4279-a039-a764c5c17cf9"
      unitRef="usd">8915000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjUtMy0xLTEtMTE4ODMz_79304af1-2577-40dd-8404-a4bf7608a468"
      unitRef="usd">8804000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjYtMS0xLTEtMTE4ODMz_3442b55b-d42c-4868-b444-e042bef27e1f"
      unitRef="usd">144000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjYtMy0xLTEtMTE4ODMz_ae798504-abb5-43ff-a1e9-b61d849c4bf3"
      unitRef="usd">310000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjctMS0xLTEtMTE4ODMz_cc065951-ff6b-4373-b08b-c81940bbb4f0"
      unitRef="usd">2035000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjctMy0xLTEtMTE4ODMz_4835beab-bc0b-40c4-a56b-d9e20a3da41e"
      unitRef="usd">2220000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjktMS0xLTEtMTE4ODMz_2fa27480-a2fa-47e9-812f-f77544bfbf2e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMjktMy0xLTEtMTE4ODMz_c21c1fcf-6c9a-4588-b705-6c9ba7199b79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfMjE_0abbf763-3330-4aa0-ba37-d077d33db8a4"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfMjE_c2297788-0b71-4584-bb4e-baf139d11ec0"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNDc_237a50f2-fedd-4824-8c43-ddabbc888666"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNDc_9a3dd059-0012-47fc-a997-eb10cdd1cd2b"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNjU_37d4ddf7-a60b-4172-a23b-b93c2edf11e3"
      unitRef="shares">10062500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMC0xLTEtMTE4ODMzL3RleHRyZWdpb246ZGZiNTQwZDgzNDgxNDdkMDkzMjMxY2VmMDVhMTNhZjdfNjU_cb80c136-9dab-493f-b78a-b709e448d517"
      unitRef="shares">10062500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMS0xLTEtMTE4ODMz_988c05ee-177c-4729-9bc2-2be8b499f061"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzItMy0xLTEtMTE4ODMz_b6db1a25-56be-4a2c-8b17-4295e7c0d0f1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTg_4d1c3860-7d70-4b64-afed-575a5aaf7421"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTg_9037d5c7-f83e-4f08-91ed-32c42c10cb9e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNDQ_853bf742-1b75-418a-9458-873ce6f74a15"
      unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNDQ_fb75b9fe-c0b3-4546-b8ed-4db64772eb6a"
      unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfNjI_85cd3bf1-e54f-4008-aea3-e52cefb97420"
      unitRef="shares">1696633993</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246YmZiZDg3MWRkODBkNGU2N2EwOGVhNGY4NzUyZTg2MmVfMTAw_5bfce81a-ad6a-46ee-96c3-bd0206320b57"
      unitRef="shares">1688810052</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMS0xLTEtMTE4ODMz_75365877-c6df-4682-9c9f-9d6675687538"
      unitRef="usd">17000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzMtMy0xLTEtMTE4ODMz_0f5cfe53-4e4a-41fb-99e9-28d891f62a20"
      unitRef="usd">17000000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246NDMwMTY0NzkzYjMwNDUyNjkzZGU4ZjhjYjA0NDNkN2JfMzA_08f5429c-fd7c-45f0-b0e3-5ffed7027ceb"
      unitRef="shares">263289848</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMC0xLTEtMTE4ODMzL3RleHRyZWdpb246NDMwMTY0NzkzYjMwNDUyNjkzZGU4ZjhjYjA0NDNkN2JfMzA_976cfdf8-309b-4199-aa50-65b8008914ed"
      unitRef="shares">263289848</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMS0xLTEtMTE4ODMz_8a50f6e5-6ac5-43d4-9b1d-1d7d8ee1e388"
      unitRef="usd">2251000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzQtMy0xLTEtMTE4ODMz_673801a9-7f57-4d0b-8fd4-9675c9fda0d1"
      unitRef="usd">2251000000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzUtMS0xLTEtMTE4ODMz_8a2ed3d8-b77b-4f4c-ade3-63c905ed2072"
      unitRef="usd">20289000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzUtMy0xLTEtMTE4ODMz_6d457a43-cd4d-451b-8ef6-952f3d9b3f69"
      unitRef="usd">19986000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzYtMS0xLTEtMTE4ODMz_c4af3f7f-23aa-4d6a-b02d-1438e1c9b32e"
      unitRef="usd">-750000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzYtMy0xLTEtMTE4ODMz_7919b762-c95b-41f1-a5cb-46679da7091c"
      unitRef="usd">-1392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzctMS0xLTEtMTY1Njk1_25fadc24-36ad-4f99-98b8-94171cff0ae0"
      unitRef="usd">269000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfMzctMy0xLTEtMTY1NzAz_93f75916-0d63-42e3-847a-82bfbac8e3e6"
      unitRef="usd">263000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDItMS0xLTEtMTE4ODMz_9e2c578e-f114-443f-b238-bb8ae49099e9"
      unitRef="usd">17573000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDItMy0xLTEtMTE4ODMz_13cafe52-80f6-4163-9dd0-70efdd9b0701"
      unitRef="usd">16622000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDMtMS0xLTEtMTE4ODMz_d3a07631-3ac9-4e04-bb88-3427e935c05f"
      unitRef="usd">32469000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84NS9mcmFnOjc1YjkyMDZkNmNjMjQ1NzRiMzA1ZmMxYmQ3ZjZmYzRjL3RhYmxlOmUzNTM2ZDQwZGFmZTQyYjk5NTQyNmQ2YmE2YWQ2YWI1L3RhYmxlcmFuZ2U6ZTM1MzZkNDBkYWZlNDJiOTk1NDI2ZDZiYTZhZDZhYjVfNDMtMy0xLTEtMTE4ODMz_328adf8c-b3bf-4515-aebd-8677ef6f759a"
      unitRef="usd">32229000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy0xLTEtMS0xMTg4MzM_14f59cf1-7ac2-4761-b700-3e4e031b7118"
      unitRef="shares">10062500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy0zLTEtMS0xMTg4MzM_8d04ae46-b644-4338-9dd1-07e5d48df92f"
      unitRef="shares">10062500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="i5b0b26deeb85428db3cd49a32a784be2_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMy01LTEtMS0xMTg4MzM_6f588860-bb66-418b-8af2-e77650ee6add"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC0xLTEtMS0xMTg4MzM_c95cfbfb-38f1-4b1a-8119-7aa2b5195ff3"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC0zLTEtMS0xMTg4MzM_be55f86e-ada4-40de-a136-7c11ae3db116"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNC01LTEtMS0xMTg4MzM_73814b52-764b-43a8-8b56-bd333cad1d38"
      unitRef="shares">10062500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssued
      contextRef="i4e82af43990a43a5806aec1a1b7cffc4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS0xLTEtMS0xMTg4MzM_df47fdbc-c04b-4ede-affb-3e5fd1440284"
      unitRef="shares">10062500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS0zLTEtMS0xMTg4MzM_6ed7b658-d33a-4459-b180-0256f8bdbb6a"
      unitRef="shares">10062500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNS01LTEtMS0xMTg4MzM_3a5f5e01-431c-40d8-a2f6-b67148fbee00"
      unitRef="shares">10062500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy0xLTEtMS0xMTg4MzM_1de024b5-479b-494f-aeed-920cd12eb814"
      unitRef="shares">1688810052</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy0zLTEtMS0xMTg4MzM_3d4238ca-1713-4efd-9027-4313f7ecbf1f"
      unitRef="shares">1679911918</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="i79dc2df78f7b482183a5fdbd827980dc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNy01LTEtMS0xMTg4MzM_8b9f94a8-8876-4cca-afb1-3da5671b9372"
      unitRef="shares">1642488911</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC0xLTEtMS0xMTg4MzM_b13fd8fc-1123-4581-8cb1-3d11608bbb67"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC0zLTEtMS0xMTg4MzM_951e85f3-2af9-483a-a55b-8c0bc6cfe3a6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOC01LTEtMS0xMTg4MzM_6c9cd968-6712-4758-b506-3d551949b47c"
      unitRef="shares">29382500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS0xLTEtMS0xMTg4MzM_1293b227-2b10-4643-b7e9-508d5de04552"
      unitRef="shares">7823941</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS0zLTEtMS0xMTg4MzM_02bc4eb3-b7f9-425b-b107-8fd2e7ff4216"
      unitRef="shares">8898134</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfOS01LTEtMS0xMTg4MzM_0a379cdf-e29e-4c69-b360-9fdb2f5c6411"
      unitRef="shares">8040507</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesIssued
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtMS0xLTEtMTE4ODMz_6a3b6890-49ce-4a33-8238-0c74ea0d4b1f"
      unitRef="shares">1696633993</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtMy0xLTEtMTE4ODMz_a58763d7-660f-42fe-a2fa-4622f5d830f2"
      unitRef="shares">1688810052</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTAtNS0xLTEtMTE4ODMz_3226d5af-fc21-45c5-8a70-db4d1d5fea1d"
      unitRef="shares">1679911918</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtMS0xLTEtMTE4ODMz_8cddecc9-b0b9-4c83-903b-58f8205b9298"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtMy0xLTEtMTE4ODMz_3e74b09e-7a9f-4868-9966-c0d6a2dcb39f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b0b26deeb85428db3cd49a32a784be2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTMtNS0xLTEtMTE4ODMz_a2dfbc8a-b22a-4925-84c1-22b32e7f9349"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i5edf298a40c646d99c91341e7a59d254_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtMS0xLTEtMTE4ODMz_672bf5fe-7929-4537-8287-690ca7135e6c"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i0c55cdf30f594855ae36693a66dfe6c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtMy0xLTEtMTE4ODMz_bd43d3e1-4cc9-486c-b1a8-679739644c40"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i8b8949c45829436bbb48dc3f2e144002_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTQtNS0xLTEtMTE4ODMz_6c860748-3ad9-4e13-86c5-df63db4993ca"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e82af43990a43a5806aec1a1b7cffc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtMS0xLTEtMTE4ODMz_f968c4be-afdd-487a-b656-e418e549202b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1341e21d90443af90de6592dad0f9ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtMy0xLTEtMTE4ODMz_c7f3f3f2-bcaa-4979-9c64-df05407f7a33"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb83d68d15234b64aca503ff713f9dc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTUtNS0xLTEtMTE4ODMz_21ff7631-31e1-4dfc-8edd-4a9f5bdcdbd3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctMS0xLTEtMTE4ODMz_9274c3ad-86fc-4f8b-830a-d17711461104"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctMy0xLTEtMTE4ODMz_bd3d59a5-85a3-41a1-8480-8da673bd8fef"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79dc2df78f7b482183a5fdbd827980dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTctNS0xLTEtMTE4ODMz_01289517-1a91-4816-9236-f4dc20db8947"
      unitRef="usd">16000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtMS0xLTEtMTE4ODMz_79879507-1217-42a8-96ff-c325f293daf2"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtMy0xLTEtMTE4ODMz_aa520ec1-a8e8-4976-8cf3-589d91f7146b"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTgtNS0xLTEtMTE4ODMz_0398ba54-f68c-4826-bf4d-3073cdecca80"
      unitRef="usd">0</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia3d2277ce26b41919359799ff4dd4b3d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktMS0xLTEtMTE4ODMz_094ad2cd-1fc8-418d-8568-1f2155aa61fb"
      unitRef="usd">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i50455fbc75dd4f31b54575fe61e18c02_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktMy0xLTEtMTE4ODMz_9b6e14ce-56de-4597-bf1a-06a915cf8177"
      unitRef="usd">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="if1dee727d0cf414c951bb6dc12700f14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMTktNS0xLTEtMTE4ODMz_ef1cadf9-8c44-445c-ab19-ee1972b935be"
      unitRef="usd">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4da3f796ab7b4c4789b43fb01dbff97e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtMS0xLTEtMTE4ODMz_ebaecd95-9f8d-4473-b1a0-7e45c24b4afc"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a0e880d55a44638a412708352acd0fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtMy0xLTEtMTE4ODMz_57959cd7-b1ef-4271-bbf0-0684724ade5a"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c98902d1100477fb76e88964a02c7fc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjAtNS0xLTEtMTE4ODMz_22d730ea-9a77-499e-b546-f13bfe4e5104"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a848010fed34536975f3f72d972321b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItMS0xLTEtMTE4ODMz_80d85a00-d68d-4d19-9f7e-b9eb12b06311"
      unitRef="usd">-2251000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i987efda00d924bb3ac9171caadacb1a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItMy0xLTEtMTE4ODMz_5b403ea6-4b87-4366-bc2b-243349a43275"
      unitRef="usd">-2251000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icca748a50e2c4b028776ec23b7576190_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjItNS0xLTEtMTE4ODMz_8d124ed0-2c0a-4d79-8493-43c22af8990d"
      unitRef="usd">-1717000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie55cc43cb62e422cba78b408deb3fbe9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtMS0xLTEtMTE4ODMz_f200d165-ce27-44bc-8b59-489d8127a55e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i910cb43c8c984811951e0a50cf31e4b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtMy0xLTEtMTE4ODMz_f581d98b-f410-4e57-8790-cd200cd50ce1"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6e78cc828ad64fd2a08ac51a9ab110e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjMtNS0xLTEtMTE4ODMz_e6e768ee-9630-48c3-9da5-3885a1b1529c"
      unitRef="usd">-535000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if11723763d0f4a7f9db1745ccb1925ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtMS0xLTEtMTE4ODMz_7628cddb-0e0a-4bc2-9ec9-97a7f9d862b0"
      unitRef="usd">-2251000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a848010fed34536975f3f72d972321b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtMy0xLTEtMTE4ODMz_49f2eb6a-d44d-4c25-98a8-9b466d925961"
      unitRef="usd">-2251000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i987efda00d924bb3ac9171caadacb1a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjQtNS0xLTEtMTE4ODMz_c5bd6e29-bb5c-42f3-8bce-a6ce3f393812"
      unitRef="usd">-2251000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f33f8343cf341e081c829b309c949a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtMS0xLTEtMTE4ODMz_1aa4a41f-80f1-4917-9b12-2e6a71e32ab6"
      unitRef="usd">19986000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2e12b27d5b94e89971f0a98991944b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtMy0xLTEtMTE4ODMz_e7567ddf-8b83-4ba8-9716-3a3e2cfe838c"
      unitRef="usd">19732000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0412e24c28c14e22992835fa7fabd269_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjYtNS0xLTEtMTE4ODMz_7f4e6d0e-5fc9-4335-be86-c135c34800e1"
      unitRef="usd">17561000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock
      contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctMS0xLTEtMTE4ODMz_5bea4cd8-dd0a-41ec-94dc-cdf5eb702a0b"
      unitRef="usd">0</bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock>
    <bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock
      contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctMy0xLTEtMTE4ODMz_0f6ea933-6283-4557-828b-8b3ff8f8408c"
      unitRef="usd">0</bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock>
    <bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock
      contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjctNS0xLTEtMTE4ODMz_c13e7bdf-0061-402e-9512-adeedc3acdb4"
      unitRef="usd">975000000</bsx:StockIssuedDuringPeriodValueNewIssuesPreferredStock>
    <bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtMS0xLTEtMTE4ODMz_6ae3f2a8-55fd-43c2-a583-deaa9a4d3f32"
      unitRef="usd">0</bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtMy0xLTEtMTE4ODMz_1b81dbab-ba4b-455c-9ba0-0d3c364cf08b"
      unitRef="usd">0</bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjgtNS0xLTEtMTE4ODMz_3b9b9d2f-5dd9-4228-9d12-4765293d3a98"
      unitRef="usd">975000000</bsx:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="icdfaf3dfc26c4007a0710900d00d819e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktMS0xLTEtMTE4ODMz_f206943b-5d13-4a53-85ff-1de5c0fd4edf"
      unitRef="usd">303000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i7a5e6609456f4a969397baa0c8094f7a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktMy0xLTEtMTE4ODMz_cd59d239-be8a-40fa-b77a-01dde297d67b"
      unitRef="usd">254000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i5b01de5bee6d4e92bcde2ba987e50cd9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMjktNS0xLTEtMTE4ODMz_a35ce84e-ceb2-4cee-a6f4-73967ee7d86d"
      unitRef="usd">221000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3d8c8b108e34010b4bed817e2a890d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtMS0xLTEtMTE4ODMz_dcb13f40-b05c-4be2-bc83-54d6765ae026"
      unitRef="usd">20289000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f33f8343cf341e081c829b309c949a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtMy0xLTEtMTE4ODMz_f50614ef-889c-41fb-a61b-765ae9639831"
      unitRef="usd">19986000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2e12b27d5b94e89971f0a98991944b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzAtNS0xLTEtMTE4ODMz_b7d30679-5954-4da6-9a62-c508140d67af"
      unitRef="usd">19732000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd9e2d2be054f858e0733f3f3365bbb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItMS0xLTEtMTE4ODMz_a585ac08-bdd6-49fe-a0b8-357fe40349af"
      unitRef="usd">-1392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc5a34dafaee43739ad795081962c7a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItMy0xLTEtMTE4ODMz_d2572f84-4f70-440d-a401-c5d50e353778"
      unitRef="usd">-2378000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8645703dda44b3d867bbb14b332875b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzItNS0xLTEtMTE4ODMz_f7b12280-0fb6-4b30-b6fb-fc40b626cf41"
      unitRef="usd">-2253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtMS0xLTEtMTE4ODMz_4251e938-bd54-4fd6-9ee4-4e716194dc00"
      unitRef="usd">698000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtMy0xLTEtMTE4ODMz_f5b6e575-7105-4fd2-afa9-7f38b8e495f0"
      unitRef="usd">1041000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzMtNS0xLTEtMTE4ODMz_1302648e-9244-428d-b071-53a1aa01a176"
      unitRef="usd">-82000000</us-gaap:ProfitLoss>
    <us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal
      contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtMS0xLTEtMTE4ODMz_34b5dd56-5ed3-4d1c-a8fa-21aad67e5849"
      unitRef="usd">0</us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal>
    <us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal
      contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtMy0xLTEtMTE4ODMz_fc8610e6-ad33-40c5-b9b6-a8d2a85efb59"
      unitRef="usd">0</us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal>
    <us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal
      contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzQtNS0xLTEtMTE4ODMz_e713e73f-7e37-4050-8aac-e3b140e52017"
      unitRef="usd">-10000000</us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i0f70797b213b42dd9b0055381d8ddcbc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtMS0xLTEtMTE4ODMz_68def251-3b1e-413c-a1dd-dcf7dbe3f504"
      unitRef="usd">-55000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i76729449762445b59ec9bcba12070a3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtMy0xLTEtMTE4ODMz_115e86ce-e617-444d-858e-acebfec96996"
      unitRef="usd">-55000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="ic5271bdd37f542ebbb4e6641658d1129_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzUtNS0xLTEtMTE4ODMz_dfba549a-8e70-4df8-9de1-b8bf16bbb8ea"
      unitRef="usd">-33000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6af7edc70c84446284ff6b173c1e6e62_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtMS0xLTEtMTE4ODMz_db058d1b-60ef-4ceb-9b32-5357393115c3"
      unitRef="usd">-750000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd9e2d2be054f858e0733f3f3365bbb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtMy0xLTEtMTE4ODMz_d475420d-3fc2-448b-910b-5d7ab2c88521"
      unitRef="usd">-1392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc5a34dafaee43739ad795081962c7a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzYtNS0xLTEtMTE4ODMz_29d38ad1-55fb-45d6-b84f-4eb279eb3d86"
      unitRef="usd">-2378000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc1ce07457004d06a149601f4c4f99ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtMS0xLTEtMTE4ODMz_9ad65c6b-64e5-4977-93c7-f798538ba203"
      unitRef="usd">263000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtMy0xLTEtMTE4ODMz_72874a79-22e6-4ce5-9b6b-d97598ad55ed"
      unitRef="usd">207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0357c11625794ac7a3d84a5f74c260a9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfMzgtNS0xLTEtMTE4ODMz_a20111d7-67c3-422b-9ed7-9c3c664d59c4"
      unitRef="usd">270000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtMS0xLTEtMTE4ODMz_81ca5087-278e-4a81-b180-33cbfa763079"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtMy0xLTEtMTE4ODMz_70679c8a-6213-459e-8776-e551e2de8705"
      unitRef="usd">-125000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDAtNS0xLTEtMTE4ODMz_0b63d534-faa1-4474-85da-f14f8aea7eca"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtMS0xLTEtMTE4ODMz_12c888b0-bb1f-4fdc-b96b-cb42b3f8a040"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtMy0xLTEtMTE4ODMz_2501a331-bf72-40cb-893e-ba7e990c6a3f"
      unitRef="usd">170000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDEtNS0xLTEtMTE4ODMz_56a84837-193c-4854-8736-f28331b28594"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7cf9ed8267a145ecabbb7868733d06ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItMS0xLTEtMTE4ODMz_6391e6fb-c8e0-43ea-b7d4-6c78598173ef"
      unitRef="usd">37000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i18b9297aebfb43ec9b2833473f36b12b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItMy0xLTEtMTE4ODMz_88a3e58a-5a02-43f3-bdb3-f9e1162cc4ea"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="icae6c9ff9e6e4cee98a1d8ff76ee3b32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDItNS0xLTEtMTE4ODMz_bad6a78f-9b5e-4d93-a0d4-832d88a96ec8"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20d6ae39de2543159b001084dffe037d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtMS0xLTEtMTE4ODMz_2261e0ba-bc04-4be2-ac6a-30d12a8615ad"
      unitRef="usd">269000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc1ce07457004d06a149601f4c4f99ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtMy0xLTEtMTE4ODMz_1406798a-ff9c-47f5-bd62-e5ebb0da087e"
      unitRef="usd">263000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2462ca42a3dd46e0bd9f5128f0afb7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDMtNS0xLTEtMTE4ODMz_6f744bdb-7320-41b6-83f7-a2964f582c29"
      unitRef="usd">207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtMS0xLTEtMTE4ODMz_200c801a-c673-4ab0-ac07-8a86122041d6"
      unitRef="usd">17573000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtMy0xLTEtMTE4ODMz_8d6c2d60-7c99-4f1e-83db-8a994d999530"
      unitRef="usd">16622000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl84OC9mcmFnOjNkMDRhNmM4M2Y5YTRjOWQ4ZTQ0ODlkYjc0NjY2NTExL3RhYmxlOmQ3MTc5MGI2NDQ3MTRjYTlhODU2YjFiODNlYmRlODRiL3RhYmxlcmFuZ2U6ZDcxNzkwYjY0NDcxNGNhOWE4NTZiMWI4M2ViZGU4NGJfNDQtNS0xLTEtMTE4ODMz_3c8bbdce-102e-4286-838e-14b12739bce2"
      unitRef="usd">15326000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy0xLTEtMS0xMTg4MzM_0c06fb88-28fa-42c2-8d97-f883df0f92fc"
      unitRef="usd">698000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy0zLTEtMS0xMTg4MzM_543326f0-5fc8-43fe-872e-811af5cd3154"
      unitRef="usd">1041000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMy01LTEtMS0xMTg4MzM_e9185411-baef-4b48-87c5-e2c6121f75b1"
      unitRef="usd">-82000000</us-gaap:ProfitLoss>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS0xLTEtMS0xMTg4MzM_7d7ae3eb-414a-49e2-93e8-c43f6a7fc4ae"
      unitRef="usd">-22000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS0zLTEtMS0xMTg4MzM_674c3e46-7c1e-40c3-ae28-db8f9a1fddb9"
      unitRef="usd">78000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNS01LTEtMS0xMTg4MzM_d3266b80-e0a8-4094-875b-991a1e3a780b"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy0xLTEtMS0xMTg4MzM_d4dbdc33-5988-421a-9530-8c119469c3cb"
      unitRef="usd">1136000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy0zLTEtMS0xMTg4MzM_7533bab9-f977-4585-ae76-58a52755be68"
      unitRef="usd">1093000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNy01LTEtMS0xMTg4MzM_58b75126-b013-48e7-b768-1c7e3e55b58f"
      unitRef="usd">1123000000</us-gaap:DepreciationDepletionAndAmortization>
    <bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC0xLTEtMS0xMTg4MzM_269f3940-6922-4164-a890-6f5da5670ee3"
      unitRef="usd">-63000000</bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit>
    <bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC0zLTEtMS0xMTg4MzM_7a473b72-6f77-4ace-a1b8-895e94d79d72"
      unitRef="usd">-124000000</bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit>
    <bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOC01LTEtMS0xMTg4MzM_9357ef6c-09cb-4031-8e62-90b4a7a60201"
      unitRef="usd">-82000000</bsx:CashFlowImpactOfDeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS0xLTEtMS0xMTg4MzM_83ac8a30-5257-4fe1-bf65-b24995399120"
      unitRef="usd">220000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS0zLTEtMS0xMTg4MzM_932b4cce-c538-4db7-8fc6-d7baa577b9f2"
      unitRef="usd">194000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfOS01LTEtMS0xMTg4MzM_3cf104dc-f1a0-4cc6-a8e2-7d21bcdb84fa"
      unitRef="usd">170000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtMS0xLTEtMTE4ODMz_7686862b-bece-4781-8c6c-61ca59804c5e"
      unitRef="usd">132000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtMy0xLTEtMTE4ODMz_627bac87-c07d-4939-b46f-e565e96f3624"
      unitRef="usd">370000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTEtNS0xLTEtMTE4ODMz_d831291f-996e-4928-be94-e574e5ab0226"
      unitRef="usd">533000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnInvestments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItMS0xLTEtMTE4ODMz_96600354-7780-40f0-879c-6f81c6af743e"
      unitRef="usd">-1000000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItMy0xLTEtMTE4ODMz_e3b4c881-1528-4068-9e71-b75521d729c9"
      unitRef="usd">250000000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTItNS0xLTEtMTE4ODMz_6c1dca5c-5e77-4165-9c15-f8ec2bba6b0c"
      unitRef="usd">333000000</us-gaap:GainLossOnInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtMS0xLTEtMTE4ODMz_039ddf5c-1016-4ecc-908d-976bac32e502"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtMy0xLTEtMTE4ODMz_9d947c19-9c68-4786-9f8e-1e37abf98241"
      unitRef="usd">-136000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTMtNS0xLTEtMTE4ODMz_622ce23f-d6ac-420a-9aa4-bdeca84fd44a"
      unitRef="usd">-100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bsx:InventoryStepUpAmortization
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtMS0xLTEtMTE4ODMz_8aca7dca-18f3-4606-a265-6ec14b0cb475"
      unitRef="usd">32000000</bsx:InventoryStepUpAmortization>
    <bsx:InventoryStepUpAmortization
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtMy0xLTEtMTE4ODMz_ac29665e-6340-43b7-afae-730dd5a8efbd"
      unitRef="usd">34000000</bsx:InventoryStepUpAmortization>
    <bsx:InventoryStepUpAmortization
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTUtNS0xLTEtMTE4ODMz_6d7ab08f-1df6-4879-bef4-d4b19a23fd84"
      unitRef="usd">58000000</bsx:InventoryStepUpAmortization>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtMS0xLTEtMTE4ODMz_d0c25a23-fd7e-42c7-a4fc-97ba4996b4ff"
      unitRef="usd">-194000000</bsx:NetCurrencyExchangeGainLoss>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtMy0xLTEtMTE4ODMz_eb231260-79c8-4a74-a35a-80c77c3659cb"
      unitRef="usd">0</bsx:NetCurrencyExchangeGainLoss>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTYtNS0xLTEtMTE4ODMz_2fcbefdf-b173-4316-b12c-3ab3891edcc8"
      unitRef="usd">0</bsx:NetCurrencyExchangeGainLoss>
    <bsx:OtherNet
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctMS0xLTEtMTE4ODMz_f247a153-170f-4883-960c-b97b36810632"
      unitRef="usd">125000000</bsx:OtherNet>
    <bsx:OtherNet
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctMy0xLTEtMTE4ODMz_49818b3d-72a0-4821-bbf3-59d57394af38"
      unitRef="usd">78000000</bsx:OtherNet>
    <bsx:OtherNet
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTctNS0xLTEtMTE4ODMz_b70bb694-df00-4cfa-ae53-d808c632184c"
      unitRef="usd">244000000</bsx:OtherNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktMS0xLTEtMTE4ODMz_546c08ea-57dd-425a-894d-d120ceb8bf8c"
      unitRef="usd">220000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktMy0xLTEtMTE4ODMz_f6c39462-2eb7-4167-87d7-5034d56d9225"
      unitRef="usd">279000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMTktNS0xLTEtMTE4ODMz_a94aa688-d202-49fd-bdd0-66394fe0a085"
      unitRef="usd">-335000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtMS0xLTEtMTE4ODMz_e5947468-c7ae-47ff-979f-e9a77f4347c7"
      unitRef="usd">321000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtMy0xLTEtMTE4ODMz_4b21f897-dac4-4706-88d4-b9891db15969"
      unitRef="usd">346000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjAtNS0xLTEtMTE4ODMz_f841301d-52cf-44a8-b860-aa113f7f7c97"
      unitRef="usd">65000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtMS0xLTEtMTE4ODMz_b2af8c31-669d-4878-9f3c-a4aa6eaff371"
      unitRef="usd">209000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtMy0xLTEtMTE4ODMz_8346ae0a-2d38-44b7-92f8-028ce5c74d39"
      unitRef="usd">134000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjEtNS0xLTEtMTE4ODMz_758df244-b9e7-4040-83d5-afffcc7fe349"
      unitRef="usd">265000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItMS0xLTEtMTE4ODMz_1eb9bdc0-1024-4b2c-a4d5-27578c168922"
      unitRef="usd">-255000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItMy0xLTEtMTE4ODMz_966db5f3-73bc-459a-ba30-d6f344e5d0a3"
      unitRef="usd">408000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjItNS0xLTEtMTE4ODMz_f077a4cd-d349-4028-bac4-32c9cdd2ef5b"
      unitRef="usd">-28000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtMS0xLTEtMTE4ODMz_447697a8-0a0c-45fc-a9ba-232e181213e2"
      unitRef="usd">1526000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtMy0xLTEtMTE4ODMz_e92ffddf-81ee-4afa-8deb-2306d0e35f3e"
      unitRef="usd">1870000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjQtNS0xLTEtMTE4ODMz_c8b5b3c8-0beb-478b-b218-51cfcbca00b1"
      unitRef="usd">1508000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtMS0xLTEtMTE4ODMz_9b30f857-095e-4afb-92bb-8cba4250f5bd"
      unitRef="usd">588000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtMy0xLTEtMTE4ODMz_ed87b6a6-81b0-47f4-a33f-7696ee3aefca"
      unitRef="usd">554000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjYtNS0xLTEtMTE4ODMz_c461b262-fadd-476d-8c37-bad6262e321f"
      unitRef="usd">376000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctMS0xLTEtMTE4ODMz_4b86b82a-bdd8-4fee-b8fe-ebe839514ae9"
      unitRef="usd">12000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctMy0xLTEtMTE4ODMz_e0adc42f-a012-4b4b-afee-7903cc709658"
      unitRef="usd">14000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjctNS0xLTEtMTE4ODMz_8fe82922-22cf-48e3-83cd-e68c3d162e91"
      unitRef="usd">12000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtMS0xLTEtMTE4ODMz_ba41f49a-3d84-4c8f-9de1-3587cf7b1780"
      unitRef="usd">1542000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtMy0xLTEtMTE4ODMz_df9026e9-766d-4945-8b63-0470871d0f9f"
      unitRef="usd">2258000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjgtNS0xLTEtMTE4ODMz_e0a499a3-d918-447d-9c5b-943d6ec35c13"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMS0xLTEtMTUwNDY0_bead5775-c7e4-4b7a-8a19-82a4a1d9e2f8"
      unitRef="usd">24000000</bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies>
    <bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMy0xLTEtMTUwNDY0_a990d84e-5c2d-4e25-b631-8729f2b42ab2"
      unitRef="usd">-279000000</bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies>
    <bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktNS0xLTEtMTUwNDY0_a905ff6e-e8fe-45f2-a6bd-ca32ea06a92a"
      unitRef="usd">146000000</bsx:ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMS0xLTEtMTE4ODMz_5236bba0-d2b9-4c6e-8cd7-edfede48319b"
      unitRef="usd">5000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktMy0xLTEtMTE4ODMz_e199ff6e-4f0f-4d33-95d5-48b5f437af9d"
      unitRef="usd">826000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMjktNS0xLTEtMTE4ODMz_96ca4bc2-f2a2-47ef-a243-36f9f4c581bd"
      unitRef="usd">15000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtMS0xLTEtMTE4ODMz_36a42e8c-a4dc-4faa-9113-abb24447a800"
      unitRef="usd">-70000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtMy0xLTEtMTE4ODMz_f31aad5c-f76a-4d9d-ae10-5c69e83aac39"
      unitRef="usd">-82000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzAtNS0xLTEtMTE4ODMz_b44a7bbd-469e-4bbf-bfbc-5f2f4057503f"
      unitRef="usd">-87000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtMS0xLTEtMTE4ODMz_75ce2fa6-df00-43ea-8990-951ee349e36d"
      unitRef="usd">-56000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtMy0xLTEtMTE4ODMz_c6c4fa77-ccbe-44aa-a00c-41f8663d1f62"
      unitRef="usd">-15000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzEtNS0xLTEtMTE4ODMz_dfcc74d7-8195-4b74-ab31-d99bba2c3fcb"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtMS0xLTEtMTE4ODMz_09eb00d0-27b0-45ec-a825-dfb825be599a"
      unitRef="usd">-2011000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtMy0xLTEtMTE4ODMz_19ecd4d7-975e-4150-b1b0-782ac89a9004"
      unitRef="usd">-1597000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzUtNS0xLTEtMTE4ODMz_f6fb33a4-189a-4cec-bdc5-1cd96ec7808c"
      unitRef="usd">-411000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctMS0xLTEtMTE4ODMz_0d45de04-a615-4f07-9a64-d4dfe405f690"
      unitRef="usd">335000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctMy0xLTEtMTE4ODMz_77cf0d62-a120-4c20-9604-8cb01005ff97"
      unitRef="usd">15000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzctNS0xLTEtMTE4ODMz_a9fe5ebc-27f7-4c79-917e-96df4207039f"
      unitRef="usd">49000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <bsx:PaymentsForRoyaltyRights
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtMS0xLTEtMTE4ODMz_fd33ce7f-aaf9-47d1-a87e-38f2fefea5e6"
      unitRef="usd">75000000</bsx:PaymentsForRoyaltyRights>
    <bsx:PaymentsForRoyaltyRights
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtMy0xLTEtMTE4ODMz_2eca70ff-6d8d-4e8c-ace1-c1e8cf718db3"
      unitRef="usd">85000000</bsx:PaymentsForRoyaltyRights>
    <bsx:PaymentsForRoyaltyRights
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfMzgtNS0xLTEtMTE4ODMz_7e4b62bb-5d9c-4618-9a5b-ba4398466c48"
      unitRef="usd">97000000</bsx:PaymentsForRoyaltyRights>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtMS0xLTEtMTE4ODMz_fd095333-06d6-420f-89f7-894ab19368c3"
      unitRef="usd">250000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtMy0xLTEtMTE4ODMz_5a89ea25-0203-468a-b531-77a8f8c92018"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDAtNS0xLTEtMTE4ODMz_169a3f8a-d54e-4206-8309-28c9afb139e7"
      unitRef="usd">2950000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtMS0xLTEtMTE4ODMz_85b92412-041e-470f-b3b9-a0fca1d9505a"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtMy0xLTEtMTE4ODMz_7bfbc7a7-e2d2-4765-b1e8-b2b1af150f0c"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDEtNS0xLTEtMTE4ODMz_19e0174c-14ad-4255-bec7-b853d2e54f33"
      unitRef="usd">2245000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItMS0xLTEtMTE4ODMz_303a58f6-0abb-44f2-a239-a4e5446b7003"
      unitRef="usd">-1000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItMy0xLTEtMTE4ODMz_2b149a2f-8084-4277-9a8f-c4f3835e9499"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDItNS0xLTEtMTE4ODMz_4ff33039-9eb4-49b3-acc0-ea27263397a6"
      unitRef="usd">-714000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtMS0xLTEtMTE4ODMz_3115e14d-cdba-454a-8a19-bb57aacf76f0"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtMy0xLTEtMTE4ODMz_393ac494-9bb5-4119-8ae9-867ead8bfe74"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDMtNS0xLTEtMTE4ODMz_3b26e370-fd28-481c-b03e-673a6df2b2d4"
      unitRef="usd">1919000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtMS0xLTEtMTE4ODMz_e87906a6-dbae-42d1-babd-b34757021110"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtMy0xLTEtMTE4ODMz_f7817083-511f-40cb-98da-b3d077424744"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDQtNS0xLTEtMTE4ODMz_d0c641a6-6bd8-4b33-869e-4ae8ab5d6d5e"
      unitRef="usd">1916000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtMS0xLTEtMTE4ODMz_056c8bac-9960-4f32-b149-8c2b7f101307"
      unitRef="usd">3184000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtMy0xLTEtMTE4ODMz_92a368d5-71a1-45aa-8836-53f9373ac90d"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDUtNS0xLTEtMTE4ODMz_add4c802-8085-49b6-b97f-7e476f85e66f"
      unitRef="usd">1260000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtMS0xLTEtMTE4ODMz_f905a2d0-3b74-444f-a02c-6b50de3f2597"
      unitRef="usd">3270000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtMy0xLTEtMTE4ODMz_42465cfd-a41a-4064-98b3-6f913400b89a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDYtNS0xLTEtMTE4ODMz_2e27c745-636e-4020-9919-46606cd46818"
      unitRef="usd">1683000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctMS0xLTEtMTE4ODMz_c89e4ba1-a2ef-4288-8a62-1e6c368b70a3"
      unitRef="usd">55000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctMy0xLTEtMTE4ODMz_5eeb4aaa-5e74-45a9-85e2-e6a9094ce2b9"
      unitRef="usd">55000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDctNS0xLTEtMTE4ODMz_2da8e03d-0efa-4ca3-b1e6-4722fbbc11b9"
      unitRef="usd">28000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtMS0xLTEtMTE4ODMz_fc035360-6b22-444c-b477-c75b03ad54f4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtMy0xLTEtMTE4ODMz_180ea527-dbd9-4716-bfbc-54a1da28c6c1"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDgtNS0xLTEtMTE4ODMz_178144e4-7706-4d64-8eb4-a7c39ea4a015"
      unitRef="usd">975000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktMS0xLTEtMTE4ODMz_68df96b0-e82e-4845-a2c5-d72a8b2e635e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktMy0xLTEtMTE4ODMz_a71c8264-f44d-4112-b36f-d44548e73a69"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNDktNS0xLTEtMTE4ODMz_250037cc-2492-44df-a8d0-cfd85e91b6ee"
      unitRef="usd">975000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtMS0xLTEtMTE4ODMz_169a80d8-091e-4488-9c83-80ecca412616"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtMy0xLTEtMTE4ODMz_cf28340b-110a-4f19-94e1-958baff280e1"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTAtNS0xLTEtMTE4ODMz_889f1c4e-a335-4620-922b-61130f23cdb6"
      unitRef="usd">535000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <bsx:Paymenttonetsharesettleemployeeequityawards
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtMS0xLTEtMTE4ODMz_cafd2acc-0737-4004-a1a5-b662da975f81"
      unitRef="usd">53000000</bsx:Paymenttonetsharesettleemployeeequityawards>
    <bsx:Paymenttonetsharesettleemployeeequityawards
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtMy0xLTEtMTE4ODMz_6de568e2-b0ab-43ed-851d-5caa998b09c8"
      unitRef="usd">50000000</bsx:Paymenttonetsharesettleemployeeequityawards>
    <bsx:Paymenttonetsharesettleemployeeequityawards
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTEtNS0xLTEtMTE4ODMz_e2ce0819-a664-43f7-81fc-d00e21deb937"
      unitRef="usd">59000000</bsx:Paymenttonetsharesettleemployeeequityawards>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItMS0xLTEtMTE4ODMz_3ff8f48c-41b8-4519-bd52-ee9ada6cbd28"
      unitRef="usd">136000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItMy0xLTEtMTE4ODMz_8aabb1ea-6116-4ace-9505-270471d76f4f"
      unitRef="usd">110000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTItNS0xLTEtMTE4ODMz_8b590c58-ec0a-4a3f-b9e8-12aef8032b25"
      unitRef="usd">111000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtMS0xLTEtMTE4ODMz_ac03697a-588f-4110-b3d4-5d768a935ccf"
      unitRef="usd">-548000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtMy0xLTEtMTE4ODMz_afddc395-0434-4c95-a0aa-8c468f47cd51"
      unitRef="usd">-95000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTMtNS0xLTEtMTE4ODMz_3553f10b-5f2d-4597-88b7-a971aff51a18"
      unitRef="usd">293000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtMS0xLTEtMTE4ODMz_5eb9e67d-829e-4f4a-8a3d-1986d7eb58df"
      unitRef="usd">-9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtMy0xLTEtMTE4ODMz_6563e4bc-fd29-4424-bb41-2f0b19be9360"
      unitRef="usd">-6000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTQtNS0xLTEtMTE4ODMz_2463501a-9f3a-4ea8-9857-8f215bf73588"
      unitRef="usd">-2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtMS0xLTEtMTE4ODMz_f6ff048b-9633-4abc-a355-2ea10e406be8"
      unitRef="usd">-1042000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtMy0xLTEtMTE4ODMz_e5648e96-9ba0-49f4-8f07-d76033e57981"
      unitRef="usd">173000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTUtNS0xLTEtMTE4ODMz_9d28d9ca-6ad4-4d6a-96ff-9c6729b03de3"
      unitRef="usd">1388000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtMS0xLTEtMTE4ODMz_0b2b121b-c0d8-4a47-a1b4-fcf4a6403e3d"
      unitRef="usd">2168000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtMy0xLTEtMTE4ODMz_01bc3d6c-bd47-45f5-9344-bf69844804f1"
      unitRef="usd">1995000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTYtNS0xLTEtMTE4ODMz_0e328b4d-a889-4dfc-964f-00310c2fed44"
      unitRef="usd">607000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctMS0xLTEtMTE4ODMz_c361849a-434f-43b0-bfb6-ee9ed2e36d33"
      unitRef="usd">1126000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctMy0xLTEtMTE4ODMz_17054481-dc71-48da-adb2-7f75411cee05"
      unitRef="usd">2168000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOjQzOWRkODc4YWVkNDRkNDc4NDc3MzU3YmQ2NmYxOWI0L3RhYmxlcmFuZ2U6NDM5ZGQ4NzhhZWQ0NGQ0Nzg0NzczNTdiZDY2ZjE5YjRfNTctNS0xLTEtMTE4ODMz_893a85df-054b-4386-b145-ce77f672ee56"
      unitRef="usd">1995000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy0xLTEtMS0xMTg4MzM_3816988a-66d0-40e9-8811-361c94e733e0"
      unitRef="usd">662000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy0zLTEtMS0xMTg4MzM_47cfa8aa-bb95-46a2-8c0b-c4043b225c2c"
      unitRef="usd">302000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMy01LTEtMS0xMTg4MzM_9dc3b01a-0628-442f-b32a-d47bf04fe2d1"
      unitRef="usd">207000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC0xLTEtMS0xMTg4MzM_f215f366-8fd0-44c5-8483-22b0dc44080a"
      unitRef="usd">450000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC0zLTEtMS0xMTg4MzM_4348ef50-9b2a-4928-b993-d53b41c39698"
      unitRef="usd">338000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNC01LTEtMS0xMTg4MzM_7fbe558c-8548-429e-939e-a7cc2182d87d"
      unitRef="usd">359000000</us-gaap:InterestPaidNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS0xLTEtMS0xMTg4MzM_9c38b7a7-ae32-4077-bc7e-d01d60445c55"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS0zLTEtMS0xMTg4MzM_e8db67f8-efa5-4291-b8a3-4b373a88b953"
      unitRef="usd">440000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNS01LTEtMS0xMTg4MzM_a7e68917-35eb-4451-bedf-39e77f01beb3"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <bsx:NonCashImpactOfTransferredRoyaltyRights
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi0xLTEtMS0xMTg4MzM_003208cc-15ec-40f0-937c-eb70393916f0"
      unitRef="usd">-70000000</bsx:NonCashImpactOfTransferredRoyaltyRights>
    <bsx:NonCashImpactOfTransferredRoyaltyRights
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi0zLTEtMS0xMTg4MzM_ed0fa654-7b1a-49df-9ff3-37f91847a154"
      unitRef="usd">-82000000</bsx:NonCashImpactOfTransferredRoyaltyRights>
    <bsx:NonCashImpactOfTransferredRoyaltyRights
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfNi01LTEtMS0xMTg4MzM_fa77f66f-f659-4062-a4a4-156f4f3a97ad"
      unitRef="usd">-87000000</bsx:NonCashImpactOfTransferredRoyaltyRights>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtMS0xLTEtMTE4ODMz_aec166f0-7495-4704-b1bc-cebefb57dade"
      unitRef="usd">928000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtMy0xLTEtMTE4ODMz_d0117375-0428-463a-8816-c3e097d03427"
      unitRef="usd">1925000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTEtNS0xLTEtMTE4ODMz_c228ae1f-f774-4423-bdbc-34c387dee62f"
      unitRef="usd">1734000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItMS0xLTEtMTE4ODMz_003211f4-fcc5-4bd2-8607-a44829b272af"
      unitRef="usd">149000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItMy0xLTEtMTE4ODMz_32b73cc0-6709-4312-a313-90d278ba93ef"
      unitRef="usd">188000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTItNS0xLTEtMTE4ODMz_63c7c4c9-61e8-4f5c-9d83-63e9f47d506e"
      unitRef="usd">208000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtMS0xLTEtMTE4ODMz_1d96370a-b3e6-4201-ba4a-d81641b90948"
      unitRef="usd">48000000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtMy0xLTEtMTE4ODMz_dfeffcce-e858-4b10-9f65-79142a943943"
      unitRef="usd">55000000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTMtNS0xLTEtMTE4ODMz_ffef3c01-899f-44a3-a048-c984ba8c1c1e"
      unitRef="usd">52000000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtMS0xLTEtMTE4ODMz_85a8f270-f0ac-44ce-915c-8e94f6d50cc9"
      unitRef="usd">1126000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtMy0xLTEtMTE4ODMz_0cf9c72e-929d-43de-aad7-7480a5b3a559"
      unitRef="usd">2168000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85MS9mcmFnOmUzYTFmNjNlNDdmODRhNjdiOGQ2NTAxNTI5Yjc0NTJiL3RhYmxlOmY1ZDE3ODI2MmM2MzQxMjVhZjkwMzY0YjgwMTQyNmYzL3RhYmxlcmFuZ2U6ZjVkMTc4MjYyYzYzNDEyNWFmOTAzNjRiODAxNDI2ZjNfMTQtNS0xLTEtMTE4ODMz_97625789-7545-43a7-881d-55d36759263f"
      unitRef="usd">1995000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2MTA_53a36a52-45cf-4241-8ef2-07692b627caa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE A &#x2013; SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity&#x2019;s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation&#160;S-X.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note I &#x2013; Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note J &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Critical Accounting Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated balance sheets are related to deferred compensation plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record credit loss reserves to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when we establish &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is adequate as of December&#160;31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have a contract with a customer that creates enforceable rights and obligations,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Promised products or services are identified,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The transaction price, or the amount we expect to receive, is determinable and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have transferred control of the promised items to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#x2122; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Post-Implant Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warranty Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149&#160;million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40&#160;years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#x2019;s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived Intangibles and IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;amp;D intangible assets acquired in a business combination. Our IPR&amp;amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;amp;D intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the income approach to determine the fair values of our IPR&amp;amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects&#x2019; stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information related to indefinite-lived intangibles, including IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization and Impairment of Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20&#160;years; amortizable technology-related and customer relationships, five to 25&#160;years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of products sold; Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as appropriate within our accompanying consolidated statements of operations, and include in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information related to impairments of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Publicly Traded and Privately-Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50&#160;percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details on our investment balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee&#x2019;s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment&#x2019;s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment&#x2019;s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net gains and losses and impairments associated with our investment portfolio are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note H &#x2013; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal and Product Liability Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation-related charges (credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note I &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for discussion of our individual material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs Associated with Exit Activities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record employee termination costs in accordance with FASB ASC Topic 712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Nonretirement and Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. We record such costs into expense over the employee&#x2019;s future service period, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring net charges (credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs of products sold, Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Translation of Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss), net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency transaction gains and losses are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note D &#x2013; Hedging Activities and Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on our hedging instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense research and development (R&amp;amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Indefinite-lived Intangibles and IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for our policy regarding R&amp;amp;D projects acquired in connection with our business combinations and asset purchases.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2ODQ_05f0fe00-4c56-43e3-a04d-c7b1e566face">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity&#x2019;s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation&#160;S-X.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDM_383181d6-7a1c-424e-a422-d8830a86e9b6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note I &#x2013; Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note J &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NzU_567c1cde-267b-42d7-bdec-75df0060c203">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Critical Accounting Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NTQ_601a1ea0-d75e-4772-862b-8ce4b5273749">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets &lt;/span&gt;within our consolidated balance sheets are related to deferred compensation plans.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDQ_48a631cf-e2b5-4602-9aa7-5bb4cc082652">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record credit loss reserves to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when we establish &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt; is adequate as of December&#160;31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NDY_6b08227e-0993-4f0d-ade7-c00355cd8f24">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have a contract with a customer that creates enforceable rights and obligations,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Promised products or services are identified,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The transaction price, or the amount we expect to receive, is determinable and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have transferred control of the promised items to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#x2122; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Post-Implant Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.&#160;Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1NjI_9df9e290-14d0-469b-b53b-5db8662e5d9a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warranty Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a &lt;/span&gt;&lt;/div&gt;liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NDc_64e8f743-f5ca-4fdc-b5ac-8a5c9c2ac7a9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149&#160;million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMTQ4NDg_1ebd1f65-267b-4278-b980-878b90304e38"
      unitRef="usd">149000000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1ODg_2f99e962-e486-465e-86ed-2884a22c59d4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40&#160;years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2Mjc_4412441c-3032-4b80-9ebc-bd68499ab18f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;amp;D, on detailed valuations that use information and assumptions provided by management, which consider management&#x2019;s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1ODM_4e09066f-c2c5-426c-b273-bb4d972c5c57">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived Intangibles and IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;amp;D intangible assets acquired in a business combination. Our IPR&amp;amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;amp;D intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the income approach to determine the fair values of our IPR&amp;amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects&#x2019; stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information related to indefinite-lived intangibles, including IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2OTA_f278276a-04cc-4158-af14-7aabc7baed05">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization and Impairment of Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20&#160;years; amortizable technology-related and customer relationships, five to 25&#160;years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of products sold; Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as appropriate within our accompanying consolidated statements of operations, and include in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information related to impairments of intangible assets.&lt;/span&gt;&lt;/div&gt;For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1MTk_ca70869c-b223-48b8-af6e-27104464ef5a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other&lt;/span&gt;, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2MjQ_8f675808-67d8-4073-9ae7-983db5be731e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Publicly Traded and Privately-Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50&#160;percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details on our investment balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee&#x2019;s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment&#x2019;s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment&#x2019;s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net gains and losses and impairments associated with our investment portfolio are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;in our consolidated statements of operations.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MTM_8dc96c53-a0cc-41a1-8257-2f112bbd2e9f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note H &#x2013; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2Njk_6b3d303f-73a4-4f74-9cb5-c8516622a78e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal and Product Liability Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation-related charges (credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note I &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for discussion of our individual material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY1MTA_643d3f14-4ddb-434f-8617-02848ed4283e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs Associated with Exit Activities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record employee termination costs in accordance with FASB ASC Topic 712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Nonretirement and Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. We record such costs into expense over the employee&#x2019;s future service period, if any. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring net charges (credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs of products sold, Selling, general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt; in our consolidated statements of operations.</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NDE_11e03ba8-c2a3-48af-b567-b3dd1c852874">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Translation of Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss), net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency transaction gains and losses are included within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY2NTA_b4095140-c9f3-4fe7-922a-80cc12339a01">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note D &#x2013; Hedging Activities and Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on our hedging instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl85Ny9mcmFnOjEwNDg2MjU5ODllNTQzOTI4MDQ2NDVjY2E1N2JjMzcyL3RleHRyZWdpb246MTA0ODYyNTk4OWU1NDM5MjgwNDY0NWNjYTU3YmMzNzJfMzY3MDU_8d6e4539-5da8-4c82-bfdf-c811c14ed1ee">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense research and development (R&amp;amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Indefinite-lived Intangibles and IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for our policy regarding R&amp;amp;D projects acquired in connection with our business combinations and asset purchases.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjE3_95e61cba-b200-4388-a18b-9a2035e92ed6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE B &#x2013; ACQUISITIONS AND STRATEGIC INVESTMENTS &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2&#160;billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG&#x2122; and VersaCross&#x2122; Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price was comprised of the amount presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment for acquisition, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation was comprised of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,463&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated a portion of the purchase price to the specific intangible asset categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Assigned&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Risk-Adjusted Discount &lt;br/&gt;Rates used in Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy&#xae; Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification&#160;(ASC) Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preventice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lumenis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment for acquisition, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of prior interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation for these acquisitions was comprised of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preventice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lumenis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other non-current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our consolidated balance sheet of $183&#160;million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and corresponding adjustments to the indemnification asset are being recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note G &#x2013; Supplemental Balance Sheet Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding our indemnification asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated a portion of the purchase price to the specific intangible asset categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Assigned&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Risk-Adjusted Discount &lt;br/&gt;Rates used in Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Preventice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lumenis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;All Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill impairment charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $73&#160;million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our contingent consideration liability were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount recorded related to current year acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December&#160;31, 2022, the maximum amount of future contingent consideration (undiscounted)&#160;that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&amp;amp;D program. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D, Regulatory and Commercialization-based Milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$13 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue-based Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$136 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projected contingent payment amounts related to our R&amp;amp;D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate carrying amount of our strategic investments was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement alternative investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Publicly-held securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Publicly-held equity securities are measured at fair value with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These investments are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt; associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December&#160;31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $232 million, which represents amortizable intangible assets, IPR&amp;amp;D, goodwill and deferred tax liabilities.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i39f7478fc1994fa5ae2a4818204ac7c3_I20220615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc2MA_27bc329d-1e18-44f3-9a6e-e51fd6689898"
      unitRef="number">0.64</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc3OA_a92dc058-62ac-4b45-858f-4c244a7f8357"
      unitRef="krw">291200000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i4d25814cddce4634abc61c9bebe5bfc5_D20220615-20220615"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0Mjc5NA_f0d257bb-59f2-497f-850e-b916f7795e8c"
      unitRef="usd">230000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i91739b0d9fae4d91a17da45404a70bd4_I20221129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI3NDg3NzkxMTA5ODM_23ef0403-a8a1-4f65-88d6-2d3a9a31c0bc"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i52eb55d7ac10453695894b8ed3be958c_D20221129-20221129"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgyNQ_94fc42e0-a629-4adb-b2ee-99d71d08a4b7"
      unitRef="usd">10.00</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i2d7591fa55b4499f8bcaade3bba40cff_D20221129-20221129"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgxMw_025f2d98-eb52-41d0-9ba1-993420aca426"
      unitRef="usd">615000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i4de90588254145949ff313db5ff70926_I20230220"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg4MjQ_f355a9b2-5fff-4a69-9f91-eeba0179367f"
      unitRef="number">0.65</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="if26a25d3f1534945a3bc82415ed7fc25_D20230101-20230223"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg3ODk_24c0a9bb-4f02-44f6-bc7a-f35695cc61d3"
      unitRef="krw">20.00</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="ieea77466150d48c9a38a34a0031f8c09_D20230101-20230223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NTg4MDg_a8e0167a-3fb0-4ff4-9e7a-78f69946e72b"
      unitRef="usd">520000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg0MjgzMQ_9e4a46ea-761c-41ce-8b9a-523c3cae2cd4"
      unitRef="usd">1463000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIyOA_3fef7d8d-7dff-404a-bf1d-dfc9a50c2a51">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment for acquisition, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzEtMS0xLTEtMTQ5NTA4_3433c1f0-aa07-486d-8218-0e540c668437"
      unitRef="usd">1463000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzEtMS0xLTEtMTQ5NTA4_cb4b3295-6c0c-489f-8eee-88ef7aee95ad"
      unitRef="usd">1463000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzItMS0xLTEtMTUwMTcx_3433c1f0-aa07-486d-8218-0e540c668437"
      unitRef="usd">1463000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo3MDAwMzY3OTViN2U0NmRlOGRhNTYzYzc4OGU1MDgwMS90YWJsZXJhbmdlOjcwMDAzNjc5NWI3ZTQ2ZGU4ZGE1NjNjNzg4ZTUwODAxXzItMS0xLTEtMTUwMTcx_cb4b3295-6c0c-489f-8eee-88ef7aee95ad"
      unitRef="usd">1463000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIyOQ_34006245-c62c-43ad-866b-54c1833b5c0c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation was comprised of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,463&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:Goodwill
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzEtMS0xLTEtMTQ5NTA4_42b41253-328e-4f1c-8bd5-606572642f4d"
      unitRef="usd">988000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzItMS0xLTEtMTQ5NTA4_0d0f86b8-947c-45ef-bd2e-210e79616f04"
      unitRef="usd">657000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzQtMS0xLTEtMTQ5NTA4_df673c4a-d34f-4f2c-8523-9960e0b218a7"
      unitRef="usd">112000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzYtMS0xLTEtMTQ5NTA4_121565a3-2122-4d7f-87c6-9c22cf070dfe"
      unitRef="usd">287000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzctMS0xLTEtMTQ5NTA4_a7f7025d-042b-4f06-9e1c-a51ced4e9fe2"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkMDM5YTM4NzJhY2M0MTE1YmNhMTBkMDdkZmM1ZTliMy90YWJsZXJhbmdlOmQwMzlhMzg3MmFjYzQxMTViY2ExMGQwN2RmYzVlOWIzXzgtMS0xLTEtMTQ5NTA4_815844ff-f2a9-49da-a0c1-d6cd8dceb318"
      unitRef="usd">1463000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="i1e30917f50054e2e8db54b72793e645c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU0OTc1NTg2NDIzMA_419e69dd-116c-4de6-bec6-53a51db567a0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated a portion of the purchase price to the specific intangible asset categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Assigned&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Risk-Adjusted Discount &lt;br/&gt;Rates used in Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i2c12e4b8e88946ea9f918f099eca4382_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtMS0xLTEtMTQ5NTA4_2f9f1cd1-1cd3-44dd-a545-ff7f646eb5b0"
      unitRef="usd">622000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9a57f87953d04bcb90ea07b09c5d17be_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtMy0xLTEtMTQ5NTA4_f9938fe0-d00c-48c2-a3b2-8019dc9a6e76">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="if226113987c44049a2899b6e0639d557_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzItNS0xLTMtMTcxMjY3_ba04a126-f2df-4a42-81c1-33fbbe43d221"
      unitRef="number">0.11</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i5fae4e1ae03a42d985a17ed55da3dd73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzUtMS0xLTEtMTQ5NTA4_ffbdf5d9-c180-4b0b-89d9-bfa92e69d345"
      unitRef="usd">36000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5bdd48bb3d8f42bda231800746b62182_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzUtMy0xLTEtMTQ5NTA4_be959a4b-d6e8-4049-a0d3-92eaf17e1dac">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="if611a01731ac40b8a3f718fdab5f1fef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzMtNS0xLTMtMTcxMjY3_2bd23a3e-c1aa-4054-86a9-d630d630f7b5"
      unitRef="number">0.11</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib76d0b974c2249e39200438329a79acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpmYjQ5ZDljNTIyZmI0ZTA4YTE1Mjg5ZTQ5M2YxZTIxZC90YWJsZXJhbmdlOmZiNDlkOWM1MjJmYjRlMDhhMTUyODllNDkzZjFlMjFkXzQtMS0xLTEtMTUwMjEy_7bd27c27-bde3-4dcb-82cc-62cde87188cf"
      unitRef="usd">657000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE0MDM_a250104c-b05d-449a-9767-db66f4f49764"
      unitRef="usd">925000000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest
      contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE0MzA_f8d2693a-4545-4951-af86-23cee63d9593"
      unitRef="usd">300000000</bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE1Njk_edfa30e2-9c2c-4bf3-907d-6fc53e1eeeb6"
      unitRef="number">0.22</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE3ODc_aaa98c29-575d-440e-bd81-4d69de4f3de3"
      unitRef="usd">196000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibab59c9e3f6e4171af365c2a27a279dd_D20210301-20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE5MTE_69ca143a-8ba1-4281-802f-f7632c4e84a0"
      unitRef="usd">706000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i683be7f8eded4529b408b52a5cef0564_I20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE5NjE_e8aab1ad-e096-4a73-801c-733862248f55"
      unitRef="usd">216000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzIzOTE_52ee6dad-8e13-4283-96a9-3741b43ba2dd"
      unitRef="usd">450000000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest
      contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI0MDE_edbf7aaa-120f-462c-bf47-6441daf5fa6e"
      unitRef="usd">125000000</bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest>
    <bsx:BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod
      contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI1MTk_8fd15fde-baf4-4505-9fc2-7dae1a2eab68">P3Y</bsx:BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI2MTM_af73eb84-d48e-434c-b009-d30016457626"
      unitRef="number">0.27</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI4MzA_eb787d2f-6ecc-452b-90be-3a482b729cc9"
      unitRef="usd">222000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9244733cac7643bd91fbc8831f903805_D20210806-20210806"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI5NTQ_9f405d11-5ae1-4340-a032-8ca6a77c2bce"
      unitRef="usd">268000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="idc1450ea84df4039beb33b363a40d4ab_I20210806"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzMwMDQ_1fe2c4ac-8fc7-45dc-a2c3-55594e752dc1"
      unitRef="usd">92000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <bsx:PaymentOfContingentConsideration
      contextRef="ib0472293542444a397c435d4b743117f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzI3NDg3NzkxMjI3NTY_c30aaa04-0586-45dd-aed4-0009872a5c31"
      unitRef="usd">114000000</bsx:PaymentOfContingentConsideration>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9433d2d803b946a2a1c5f7f1eef556b3_D20210901-20210901"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzM0ODE_57b8a31a-c971-4bd3-b424-4484035d4b0b"
      unitRef="usd">1032000000.000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzM5OTA_ee707419-c3d5-4681-98fc-0b9515c4fe1c"
      unitRef="usd">320000000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest
      contextRef="i16dfec677c164b2db255f582287df56d_I20211108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQwMDM_6383ed79-54f1-45f3-8ff8-2e2b26efbdd2"
      unitRef="usd">80000000</bsx:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="i16dfec677c164b2db255f582287df56d_I20211108"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQxNjU_cccccace-1bfb-4697-9f8f-5cf7b43df1a8"
      unitRef="number">0.16</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQzNDA_bd465acf-5b13-4898-a98b-dfe4fa9e185c"
      unitRef="usd">57000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iab304344ac354d9aaac92a0315964d7a_D20211108-20211108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQ0NjQ_e5fb3ab3-7445-4176-99bd-67058c115e2d"
      unitRef="usd">251000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i16dfec677c164b2db255f582287df56d_I20211108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzQ1MTQ_4a1f1abb-6006-46cb-8ba1-3accff5c656a"
      unitRef="usd">67000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjI0_465478c4-633e-4035-b959-92023dd19b6b">in accordance with Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification&#160;(ASC) Topic 805, &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preventice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lumenis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment for acquisition, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of prior interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtMS0xLTEtMTE4ODMz_f1f5776b-0638-464a-a946-0727991f8cc7"
      unitRef="usd">706000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifc362728b97e470189a743db7df633f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtMy0xLTEtMTE4ODMz_4210867f-b67b-41d1-b454-ed37c87b381a"
      unitRef="usd">1032000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtNS0xLTEtMTE4ODMz_937038f4-e98f-47e0-b2ad-b570fdd96d21"
      unitRef="usd">519000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzEtNi0xLTEtMTE4ODMz_8f081a96-267a-41db-b546-80f0bd34e958"
      unitRef="usd">2258000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItMS0xLTEtMTE4ODMz_4019e961-5768-4cad-a7ce-6afd7868f513"
      unitRef="usd">221000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItMy0xLTEtMTE4ODMz_45667216-580c-4af7-87fe-0870e102d365"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItNS0xLTEtMTE4ODMz_125b86ca-66e6-4aba-b5e7-2129b8f409c5"
      unitRef="usd">218000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzItNi0xLTEtMTE4ODMz_be9da697-a76f-4cc9-ad0a-62740b33fac5"
      unitRef="usd">440000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="ib1b7003f664a4b14859ac8f96a6b7197_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtMS0xLTEtMTE4ODMz_dfafca01-8b7b-4dcc-bb73-1c03693d42af"
      unitRef="usd">269000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="ifc362728b97e470189a743db7df633f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtMy0xLTEtMTE4ODMz_961380c5-15ec-436c-b3ae-802319ff08bf"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i22bde28311424e80946eee2b8c4efa59_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtNS0xLTEtMTE4ODMz_3f482eb7-8de5-49ac-8383-a1400ac73e1e"
      unitRef="usd">287000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzMtNi0xLTEtMTE4ODMz_95edc7a5-6178-4935-abb6-672d9f13d010"
      unitRef="usd">556000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtMS0xLTEtMTE4ODMz_a9ad6068-3fec-417e-9ee0-a96241fc545d"
      unitRef="usd">1197000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtMy0xLTEtMTE4ODMz_7e1ed929-cc89-47c9-93ea-088e3d496aa8"
      unitRef="usd">1032000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtNS0xLTEtMTE4ODMz_133b0bac-1203-4c0b-a496-1f66b0c0728d"
      unitRef="usd">1025000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTo0MDg5Mzk2NWMwODU0ZjE0OGFhZDhkZmM0ZGI2ZWNhNi90YWJsZXJhbmdlOjQwODkzOTY1YzA4NTRmMTQ4YWFkOGRmYzRkYjZlY2E2XzQtNi0xLTEtMTE4ODMz_9f2a616d-8e43-4571-ae44-11b4f1332502"
      unitRef="usd">3254000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i7fede03db2c74766bef3ae36be77b2c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTkx_65668f03-1d03-4b18-9738-c57ec5c558c1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation for these acquisitions was comprised of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preventice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lumenis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:Goodwill
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtMS0xLTEtMTE4ODMz_743a7468-ef54-45a6-b95d-023f39112583"
      unitRef="usd">926000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtMy0xLTEtMTE4ODMz_4aa6fa83-f689-4673-97de-e51800d3f468"
      unitRef="usd">534000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtNS0xLTEtMTE4ODMz_2bc43871-d56b-4733-85c9-27c7bcafeb9a"
      unitRef="usd">594000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzEtNi0xLTEtMTE4ODMz_c464b99e-160d-43d9-bbdc-67174ec8bd20"
      unitRef="usd">2053000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItMS0xLTEtMTE4ODMz_4eab596e-363e-4955-8392-654b834e7592"
      unitRef="usd">237000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItMy0xLTEtMTE4ODMz_70625f16-071e-4770-a1c7-4d5cd1eab882"
      unitRef="usd">423000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItNS0xLTEtMTE4ODMz_7069aed0-31f5-4c90-85ea-79aaab8f8082"
      unitRef="usd">465000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzItNi0xLTEtMTE4ODMz_003d1270-fa1b-4252-bc58-238f19f37a4e"
      unitRef="usd">1125000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtMS0xLTEtMTE4ODMz_75d90a0b-dd95-4487-8724-31412743ded7"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtMy0xLTEtMTE4ODMz_a4b8692e-c790-4128-844a-0ee469354849"
      unitRef="usd">69000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtNS0xLTEtMTE4ODMz_7abc98b2-7e02-4e2a-b796-a15d0f586a6f"
      unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzMtNi0xLTEtMTE4ODMz_7f73604c-cb9d-41cb-b345-f6098cda8d32"
      unitRef="usd">112000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtMS0xLTEtMTE4ODMz_91769143-c441-4871-9e0d-a4087117202a"
      unitRef="usd">65000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtMy0xLTEtMTE4ODMz_ba89cf38-271a-4a0e-8783-f48079d19604"
      unitRef="usd">297000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtNS0xLTEtMTE4ODMz_dbb0ccce-76d1-4e77-a826-82c0eac5c842"
      unitRef="usd">9000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzQtNi0xLTEtMTE4ODMz_4db99b66-945e-4d4d-988c-985dd02d1ca0"
      unitRef="usd">372000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtMS0xLTEtMTE4ODMz_1d73b952-d828-4863-87a9-b76367806c6d"
      unitRef="usd">32000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtMy0xLTEtMTE4ODMz_6374dc1b-5f3f-451f-ab15-2a65d1545926"
      unitRef="usd">282000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtNS0xLTEtMTE4ODMz_d375497c-a080-4cf1-a3c4-a4de0288cb6e"
      unitRef="usd">11000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzYtNi0xLTEtMTE4ODMz_1ff230be-9f73-429c-bfc1-5c6a15edd8a5"
      unitRef="usd">325000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctMS0xLTEtMTE4ODMz_04b55d61-1320-4d0b-88a2-2fa3458cc266"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctMy0xLTEtMTE4ODMz_9f7c2aad-87c8-4528-8d83-e284c1a5959d"
      unitRef="usd">9000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctNS0xLTEtMTE4ODMz_26565b4c-567e-411e-9e81-26a52fa15f3c"
      unitRef="usd">75000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzctNi0xLTEtMTE4ODMz_a47e2b97-c649-406a-baf8-0909a8745fc8"
      unitRef="usd">84000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtMS0xLTEtMTE4ODMz_ed1df75b-4159-4e60-b43f-141f7d199dfd"
      unitRef="usd">1197000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtMy0xLTEtMTE4ODMz_4d1bed1a-a99f-4ca3-a3dc-af507397b892"
      unitRef="usd">1032000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtNS0xLTEtMTE4ODMz_432a49ba-3f1f-4c8a-bd25-6f6259cc709d"
      unitRef="usd">1025000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToyM2RlZGI5ZGI5YWM0N2VkOThhNTlkZGNkMjA5Nzc3YS90YWJsZXJhbmdlOjIzZGVkYjlkYjlhYzQ3ZWQ5OGE1OWRkY2QyMDk3NzdhXzgtNi0xLTEtMTE4ODMz_e764c63b-76a5-4023-8395-3de09d502b3e"
      unitRef="usd">3254000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzQzODc_32e51ffe-b732-450b-9555-929d3711aaf0"
      unitRef="usd">183000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzQzNjg_7ee9ca0b-f918-4a5a-ada7-b8dd3519c301"
      unitRef="usd">177000000</us-gaap:BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjQz_c5f4fbdb-69d6-42d8-a4c9-2e0b6df71dda">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated a portion of the purchase price to the specific intangible asset categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Assigned&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Risk-Adjusted Discount &lt;br/&gt;Rates used in Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Preventice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lumenis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;All Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ida522649c73f489991dc9d869ad4cb1f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtMS0xLTEtMTE4ODMz_42378641-83b3-49d1-98b6-e7a904e3e40a"
      unitRef="usd">215000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if86cd5fe3fca484b870d2bca0d5beae5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtMy0xLTEtMTE4ODMz_6bda4499-eeda-4857-810c-90e228d28531">P9Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="ideb4a49895044b7f93b87f1125e9a416_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzMtNS0xLTEtMTE4ODMz_5d06fad8-5f93-425d-a920-9c7cde4c85d2"
      unitRef="number">0.10</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i02d216afbb77411a8e7a88fc901eb047_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtMS0xLTEtMTE4ODMz_b8936d69-9584-4bab-81c9-ee721f305afe"
      unitRef="usd">22000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ide1123ea65934f2e965ed236c8440439_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtMy0xLTEtMTE4ODMz_e212cec4-29e2-4c80-913f-1aea35d8db3b">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="i4f2d335c16564091877bbf5b8ea02230_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzUtNS0xLTEtMTE4ODMz_097bd0c9-89d6-43d2-b5b8-1290f869a15c"
      unitRef="number">0.10</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i079f8fb406dd4589b7c07d3fc9e121f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzgtMS0xLTEtMTE4ODMz_55f98049-7ce0-4b64-aaed-f7f7b70304f6"
      unitRef="usd">237000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i083186e7733646c894ee4a0c3759132d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTEtMS0xLTExODgzMw_4ba4420d-3349-4c04-b935-0384648cebdf"
      unitRef="usd">388000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1a8c96c67e8f436cbff8a3f7e7cf61ed_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTMtMS0xLTExODgzMw_0f132df9-7616-4bd8-8893-a6c9d949fe30">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="i03e104fe52bd4eaf9ecabbd0966f5c0c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzExLTUtMS0zLTExODgzMw_8b832358-c1fb-45da-b089-fd11660e66c7"
      unitRef="number">0.11</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1e8992dd65c54f5a8d206129a6e43300_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTEtMS0xLTExODgzMw_912505ee-367d-4b92-b41b-7e6d0f25bbeb"
      unitRef="usd">35000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idf6bacafeb2c4ee19ca76f16ce8b05d5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTMtMS0xLTExODgzMw_3ab28ccb-6ff3-4592-99db-6bee9af0a24c">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="i2e2f9147295b4342ae1ef9f9a08e5b1c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzEzLTUtMS0zLTExODgzMw_3d698375-be22-4a0a-acfb-adb313db5b2f"
      unitRef="number">0.11</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i298875e7f6c14315a22aa84704cb2ce9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE1LTEtMS0xLTExODgzMw_6e9148b1-3451-4d38-8b7f-fb45d406dd25"
      unitRef="usd">69000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <bsx:DiscountRateFairValueInput
      contextRef="ic0d8c251041c479c83a81894f74cb3a1_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE1LTUtMS0xLTExODgzMw_0366b2b2-da64-43ee-a67f-5fd433ee3b9c"
      unitRef="number">0.12</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6a4e06a16a5e407d8bb4ef91d86ad63e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE2LTEtMS0xLTExODgzMw_e5ddabda-73e2-4010-b2d8-117fc3eba837"
      unitRef="usd">492000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3bda1329ad5a4a2f81c742cf431791e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTEtMS0xLTExODgzMw_6cb98189-92e6-4220-b978-7301dae11b9f"
      unitRef="usd">465000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iae118e7e63dd4c05b064ed16436ebc0b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTMtMS0xLTExODgzMw_86c571ff-3517-4c70-8046-d97858a45f68">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <bsx:DiscountRateFairValueInput
      contextRef="i0d1c3e36b9104f7d9dd2b0619383a285_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTUtMS0xLTExODgzMw_7c395773-5516-4b88-959c-bb34170838d4"
      unitRef="number">0.16</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="ia1ad30b208f74b9dbc3abb41b51d5b1f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzE5LTctMS0xLTExODgzMw_52e9f694-079a-4967-853c-385c52c86304"
      unitRef="number">0.17</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id779a81f335b433c9e90f850b830d36d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzIzLTEtMS0xLTExODgzMw_c5900649-6776-495b-8f8c-d028f3de4a8a"
      unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <bsx:DiscountRateFairValueInput
      contextRef="i36b821fcbadb4bd3aacf50d87394be76_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzIzLTUtMS0xLTExODgzMw_9b1919c0-aade-4ca8-a1f8-3c90c0ce1393"
      unitRef="number">0.17</bsx:DiscountRateFairValueInput>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i29dcadcc844744ce80267d06b1d1bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpkZmMyNzJlNGQ4ODk0OTE0OWQ0NTc4NzY1NGQ1OWJhNy90YWJsZXJhbmdlOmRmYzI3MmU0ZDg4OTQ5MTQ5ZDQ1Nzg3NjU0ZDU5YmE3XzI0LTEtMS0xLTExODgzMw_cf46c13d-5f70-425b-ac0c-bf10ea6581dc"
      unitRef="usd">508000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU4OTg_3536ecbc-cf39-4771-bef8-3928678dfbdd"
      unitRef="usd">800000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <bsx:DivestitureAgreementTransferOfFacilities
      contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU5NDE_e2c1b182-3db1-4ba4-8116-080b197d229e"
      unitRef="usd">5</bsx:DivestitureAgreementTransferOfFacilities>
    <bsx:DivestitureAgreementTransferOfGlobalEmployees
      contextRef="ib279fd9ff9e24cabbeea019d2dce793a_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzU5NzM_6b01f0ba-d28a-456d-986f-643c2af0b237"
      unitRef="usd">280</bsx:DivestitureAgreementTransferOfGlobalEmployees>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEwOTk1MTE2NzU1MTY_5aa45f01-b56e-4ed4-b7d2-22d88c6f687b"
      unitRef="usd">73000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MjM0_5fcc4732-287f-44c2-ad02-4d490c92253e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our contingent consideration liability were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount recorded related to current year acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration net expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzEtMS0xLTEtMTE4ODMz_3352a38f-c8f7-49bf-8f7e-1e16740f8c39"
      unitRef="usd">196000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzItMS0xLTEtMTQ5ODUz_ab4f531d-f91b-46f9-9fb5-da36dc9264ef"
      unitRef="usd">440000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzItMS0xLTEtMTE4ODMz_dc13b5dc-508a-45c1-ae9b-b4e9d5ccce4e"
      unitRef="usd">-136000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bsx:PaymentOfContingentConsideration
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzMtMS0xLTEtMTE4ODMz_4ccd13c6-5078-4afd-868d-b3f79ddc1841"
      unitRef="usd">15000000</bsx:PaymentOfContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzQtMS0xLTEtMTE4ODMz_d6a83912-fe2d-42e8-9bfc-b55f866d0703"
      unitRef="usd">486000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzYtMS0xLTEtMTE4ODMz_8210325a-d406-41de-b6c1-e1b282a0d628"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bsx:PaymentOfContingentConsideration
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzctMS0xLTEtMTE4ODMz_175cf0dc-8302-4653-8373-6aca43994ce7"
      unitRef="usd">371000000</bsx:PaymentOfContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTowMTI3M2UwOTRkNzY0ZjZiYjJlYjE0N2IzMmY4ZWI1NC90YWJsZXJhbmdlOjAxMjczZTA5NGQ3NjRmNmJiMmViMTQ3YjMyZjhlYjU0XzgtMS0xLTEtMTE4ODMz_db3e484d-54fe-4bf8-9981-21e778bff41c"
      unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i8f91e37c6dbf483e98eae52fb1512fb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNTEw_cfeecbea-808c-42b6-8747-f05cbf05748e"
      unitRef="usd">417000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNjUw_565f4534-3655-4c53-b078-a4ecd7c74514"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzEzNjU3_1f129adc-444e-4940-b87e-0d046c2728e7"
      unitRef="usd">-136000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTg4_d3fb7172-b362-4447-b8aa-d1e4946f2582">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D, Regulatory and Commercialization-based Milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$13 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue-based Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$136 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibc9e93fb57d049aba15e55858f4ab28e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtMS0xLTEtMTE4ODMz_7fe9c011-cde4-44bd-a2f3-719f6fdeb8be"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bsx:DiscountRateFairValueInput
      contextRef="ie9c455c38cc5418c8c1d20f41ec12d1c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNC0xLTEtMTE4ODMz_0c3a00ba-b069-43bb-a095-d7188fca8aed"
      unitRef="number">0.01</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="ie352ea4b79494664ac3998f2352658f9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNi0xLTEtMTE4ODMz_ee5bf024-5001-47b5-90b6-6e8927332ded"
      unitRef="number">0.02</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="ifc984d89ba45490889622ccc6fb20531_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzEtNy0xLTEtMTE4ODMz_0834a89c-cfa8-45ea-89c2-bd8a4e81e7cd"
      unitRef="number">0.02</bsx:DiscountRateFairValueInput>
    <bsx:ContingentConsiderationLiabilityProbabilityOfPayment
      contextRef="ic745df5cf86544beb987a6cdbf4ae321_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNC0xLTEtMTE4ODMz_117b95ac-f817-48c9-ad39-036e68851721"
      unitRef="number">0.10</bsx:ContingentConsiderationLiabilityProbabilityOfPayment>
    <bsx:ContingentConsiderationLiabilityProbabilityOfPayment
      contextRef="i8236d39ea3a54b19b58c9057e3712dd5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNi0xLTEtMTE4ODMz_c57ae405-43c7-4608-a5c1-03fd5efd9237"
      unitRef="number">0.25</bsx:ContingentConsiderationLiabilityProbabilityOfPayment>
    <bsx:ContingentConsiderationLiabilityProbabilityOfPayment
      contextRef="i09fdfdce24574b16ae9fca57363d0048_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzItNy0xLTEtMTE4ODMz_b8d1d428-adf7-4306-8609-4c842d204ec0"
      unitRef="number">0.22</bsx:ContingentConsiderationLiabilityProbabilityOfPayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie344ff9d360c43ec88274800d50d23fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtMS0xLTEtMTE4ODMz_002ad889-a9cf-4b7f-8f9a-f3a09fa34e70"
      unitRef="usd">136000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bsx:DiscountRateFairValueInput
      contextRef="i2e5dd3a9e74146d9bdbd43b08724c65a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNC0xLTEtMTE4ODMz_b06e4482-23a2-4765-891a-24a4bf12d8d4"
      unitRef="number">0.06</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="i3b8770fe069a48c28a36571ec7f42a16_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNi0xLTEtMTE4ODMz_37c89962-0d77-4984-9619-895a28ae5e5e"
      unitRef="number">0.14</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="iea319dadfcac4428bed6eb3806fa0d6a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzQtNy0xLTEtMTE4ODMz_91468d99-36f9-49e3-83be-29a04536c48e"
      unitRef="number">0.07</bsx:DiscountRateFairValueInput>
    <bsx:ContingentConsiderationLiabilityProbabilityOfPayment
      contextRef="ie344ff9d360c43ec88274800d50d23fd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzUtNC0xLTEtMTE4ODMz_e562b07f-6693-4201-97e8-ceab0be3da4a"
      unitRef="number">1</bsx:ContingentConsiderationLiabilityProbabilityOfPayment>
    <bsx:ContingentConsiderationLiabilityProbabilityOfPayment
      contextRef="i60295929e3534f219e8dd476fdc06494_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZTpjZTg5MWY4NjE2OTI0N2I0YmIxNDFkY2E2MWY2MjIxMi90YWJsZXJhbmdlOmNlODkxZjg2MTY5MjQ3YjRiYjE0MWRjYTYxZjYyMjEyXzUtNy0xLTEtMTE4ODMz_38980167-9513-4b14-9a54-0e1857f91501"
      unitRef="number">1</bsx:ContingentConsiderationLiabilityProbabilityOfPayment>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MTg5_3dda468d-077c-40ff-ba58-3f3355cc7a06">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate carrying amount of our strategic investments was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement alternative investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Publicly-held securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Publicly-held equity securities are measured at fair value with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzItMS0xLTEtMTE4ODMz_9773943d-a104-431f-b1a8-d3f7c1f9a763"
      unitRef="usd">188000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzItMy0xLTEtMTE4ODMz_1163101f-353d-48ab-aad5-ebc0b972c2e3"
      unitRef="usd">259000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzMtMS0xLTEtMTE4ODMz_437906f0-3987-4552-b901-c4a819e0bf04"
      unitRef="usd">216000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzMtMy0xLTEtMTE4ODMz_08560ce0-3a30-4ba7-bd82-0a7e933c40aa"
      unitRef="usd">142000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzQtMS0xLTEtMTE4ODMz_a2d214c7-7b94-49a5-b614-be8933aaf945"
      unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzQtMy0xLTEtMTE4ODMz_fa561cd8-35cf-4e1b-a0f8-97e439c09336"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzUtMS0xLTEtMTE4ODMz_77d9180c-442b-458e-989b-e2f522af2156"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzUtMy0xLTEtMTE4ODMz_2f6a1f3d-e32e-4452-8950-801ea1b5a067"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:Investments
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzYtMS0xLTEtMTE4ODMz_de2fd2d8-5b94-4690-89c8-fcba53bde8c4"
      unitRef="usd">407000000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90YWJsZToxZjJlOTUyMDVmY2Y0ZmI0YmFhMDU2N2ZkMWZiMWI5Ni90YWJsZXJhbmdlOjFmMmU5NTIwNWZjZjRmYjRiYWEwNTY3ZmQxZmIxYjk2XzYtMy0xLTEtMTE4ODMz_6dee8e37-a47d-4e5e-b8b1-8e1f6832c353"
      unitRef="usd">412000000</us-gaap:Investments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE1Njc5_50f6edf5-be55-4ee7-91e1-861bdad9b696"
      unitRef="usd">178000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDAvZnJhZzpjYzMzNTE0OTY0MTc0ZDkwODYyZjY4NTRiNDNkYTRiNy90ZXh0cmVnaW9uOmNjMzM1MTQ5NjQxNzRkOTA4NjJmNjg1NGI0M2RhNGI3XzE2MDg4_f78b692a-9347-4fc5-afd6-e753048f1551"
      unitRef="usd">232000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMDU_f312d928-3c2a-460b-a6b6-08442e388b33">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE C &#x2013; GOODWILL AND OTHER INTANGIBLE ASSETS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization/&lt;br/&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization/&lt;br/&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible asset impairment charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management&#x2019;s decision &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to discontinue commercialization of the VICI VENOUS STENT&#x2122; System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&amp;amp;D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&amp;amp;D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management&#x2019;s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our goodwill balance by reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency fluctuations and other changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency fluctuations and other changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note A &#x2013; Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further discussion of our goodwill and intangible asset impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December&#160;31, 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December&#160;31, 2022.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMTE_89608bc4-4b22-4f97-a8fc-732de7fd8236">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization/&lt;br/&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization/&lt;br/&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItMS0xLTEtMTE4ODMz_3d6456e8-7954-4350-a759-895f7947fcbe"
      unitRef="usd">12397000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c4a2ecaee3d4a3991734761c2a2536a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItMy0xLTEtMTE4ODMz_7fac5968-16b4-4038-a378-5ac222df586f"
      unitRef="usd">7378000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0b643ca1df374b79a206f73c4e819e2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItNS0xLTEtMTE4ODMz_7d056e21-4d16-4d55-8b00-85df92418e04"
      unitRef="usd">11957000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0b643ca1df374b79a206f73c4e819e2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzItNy0xLTEtMTE4ODMz_6df01060-d884-4dbe-8838-0f21b2a3203e"
      unitRef="usd">6754000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i493e85aa50f24f0caa296c0a869c9130_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtMS0xLTEtMTE4ODMz_591b57c4-49f0-43ba-969e-2c4a1010c931"
      unitRef="usd">486000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i493e85aa50f24f0caa296c0a869c9130_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtMy0xLTEtMTE4ODMz_d48eed6b-c7c6-4903-98ed-3137a61638ac"
      unitRef="usd">394000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtNS0xLTEtMTE4ODMz_57499d46-662d-4c26-a64d-852239a3b13d"
      unitRef="usd">494000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5c0b19dbd6c8412cb24b4ea0cfc73f99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzMtNy0xLTEtMTE4ODMz_a06e06d6-5c51-467d-aa7a-b106b947a98f"
      unitRef="usd">398000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i829f5796ec4446fda9daa222c9e48016_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtMS0xLTEtMTE4ODMz_08873390-b241-47e7-8c69-76b64cf454dd"
      unitRef="usd">1960000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i829f5796ec4446fda9daa222c9e48016_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtMy0xLTEtMTE4ODMz_383d8c66-4f56-4b88-b0e4-148c50f151a9"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtNS0xLTEtMTE4ODMz_48c6abf9-c69b-4a44-863f-640024cd4bd3"
      unitRef="usd">1900000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9b5c8dacc5294e8eb8c54f21ded06d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzQtNy0xLTEtMTE4ODMz_4b86c9de-bdab-4015-a0c0-cc74e9b9b5de"
      unitRef="usd">1325000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtMS0xLTEtMTE4ODMz_97d58ca9-383b-424f-80a4-ab05d6063a4c"
      unitRef="usd">14843000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtMy0xLTEtMTE4ODMz_f69e16e0-9dc5-4a42-8f7d-7858b9d6582c"
      unitRef="usd">9173000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtNS0xLTEtMTE4ODMz_4c8eed7a-cf12-4fbb-a960-2247b9d34cbc"
      unitRef="usd">14351000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzUtNy0xLTEtMTE4ODMz_a294e560-0cce-4ec0-9045-e49390724a1e"
      unitRef="usd">8476000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:GoodwillGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctMS0xLTEtMTE4ODMz_2c3289b1-caa9-4073-ac14-62f13454752d"
      unitRef="usd">22820000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctMy0xLTEtMTE4ODMz_56474836-2490-4395-a478-f5952492d9ba"
      unitRef="usd">9900000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctNS0xLTEtMTE4ODMz_51178ba7-8cc7-4430-899d-e336821c75bc"
      unitRef="usd">21888000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzctNy0xLTEtMTE4ODMz_21688922-764a-4c6f-9560-a6d98e3bf18c"
      unitRef="usd">9900000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3cb6963c5fa24817900cf506ab2e8417_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzktMS0xLTEtMTE4ODMz_23ef267b-eca0-4bb6-affa-68d366b5029f"
      unitRef="usd">112000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i39aec4b0808e4322ac9eaa857e19619e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzktNS0xLTEtMTE4ODMz_30b90567-e65c-4155-98cb-735007fc83f7"
      unitRef="usd">126000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5a09f7d28b7a4d58918c0fc8fd00608b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzEwLTEtMS0xLTExODgzMw_644d92b5-aaac-439b-981a-4b9369824808"
      unitRef="usd">120000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if5be5738945b41cc9caa3ecef19ee3b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzEwLTUtMS0xLTExODgzMw_e4cf30bf-d068-4ca5-95bf-ea63ca726a26"
      unitRef="usd">120000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzExLTEtMS0xLTExODgzMw_009fb786-d912-4b75-b650-0c9c0abe301e"
      unitRef="usd">232000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZToyYjAxZTMzNmMyMzU0MDU4OWNlOWE1MWRlNjQxZjMyYi90YWJsZXJhbmdlOjJiMDFlMzM2YzIzNTQwNTg5Y2U5YTUxZGU2NDFmMzJiXzExLTUtMS0xLTExODgzMw_8f896f2c-4f46-4b20-98a5-8058ccec6751"
      unitRef="usd">246000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc1OA_f219adb4-5b19-4d2e-b864-135a0194f36e"
      unitRef="usd">132000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc2OA_2dcd1bac-1faf-4729-80b4-c8f50dc2d77a"
      unitRef="usd">370000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzc4MQ_15820e0a-d473-4b0c-9b19-f636679c02eb"
      unitRef="usd">460000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMzQ_f866aeaf-7241-404f-b75e-2d35664622b5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our goodwill balance by reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency fluctuations and other changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency fluctuations and other changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ib6476257158644418375f2f260ef1d9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtMS0xLTEtMTE4ODMz_2b7d455c-fde5-45b5-8320-04c107df6a6e"
      unitRef="usd">3707000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia479b11e592d47a89236ff2bfeba753b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtNS0xLTEtMTE4ODMz_946b005d-5284-4704-a818-562948973bb9"
      unitRef="usd">6243000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEtOS0xLTEtMTE4ODMz_1de3cd92-8342-42bc-a86a-8db57694906a"
      unitRef="usd">9951000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtMS0xLTEtMTE4ODMz_57510838-c8a2-4795-93a4-6f6538d21ae8"
      unitRef="usd">544000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtNS0xLTEtMTE4ODMz_a2483f57-f979-4e98-a293-a13a8acb359d"
      unitRef="usd">1520000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzMtOS0xLTEtMTE4ODMz_b83e5b11-ffa9-4a3b-a27c-5a8b7f3dffe3"
      unitRef="usd">2064000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtMS0xLTEtMTE4ODMz_6d6f7d86-2b21-48b9-8efb-4cf051538326"
      unitRef="usd">-5000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtNS0xLTEtMTE4ODMz_956bd47c-6a30-4fdd-8f63-8388a1d46377"
      unitRef="usd">-21000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzYtOS0xLTEtMTE4ODMz_60f10a75-ef6a-4592-9d51-c3f24165f2ab"
      unitRef="usd">-27000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="ibc263f43956447489bf00cd95b47d45b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtMS0xLTEtMTE4ODMz_52339acb-5d05-4440-a5d7-40dc89f243e7"
      unitRef="usd">4246000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0a5e00fb04b14bd7be7b428099bd5934_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtNS0xLTEtMTE4ODMz_a317fa63-6966-4410-8411-ee74d19e4671"
      unitRef="usd">7741000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzgtOS0xLTEtMTE4ODMz_c1fbc667-415f-4127-94de-1bc35aeaad4f"
      unitRef="usd">11988000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTEtMS0xLTExODgzMw_4bf11454-1b6d-4c16-8bac-38cd338dc44d"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTUtMS0xLTExODgzMw_625dfd31-d409-4e23-8d22-8f00ee5e2f08"
      unitRef="usd">1030000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzExLTktMS0xLTExODgzMw_c0243194-0bc0-405e-97cf-fd93559f4632"
      unitRef="usd">1030000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTEtMS0xLTExODgzMw_01841cd3-af92-4af9-acd1-f2395d3b236f"
      unitRef="usd">-10000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTUtMS0xLTExODgzMw_e582b23a-34ea-4864-a151-6c2f1b2d2f4f"
      unitRef="usd">-88000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzEzLTktMS0xLTExODgzMw_9164a2bf-ac04-4447-8605-5507d659e27b"
      unitRef="usd">-98000000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="iab0460e71d5b418b813458aae9b11a82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTEtMS0xLTExODgzMw_5366e5ae-819a-4571-a290-929c2bd1cd51"
      unitRef="usd">4237000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie847a194b2334592ac9587e3029dbcd2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTUtMS0xLTExODgzMw_3bd95c0a-6578-498d-a157-e0406ee9e933"
      unitRef="usd">8684000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTphYzZiNmMxMjgxMmY0OTA0OWUzY2U3ZWVhZmUyZmIyNi90YWJsZXJhbmdlOmFjNmI2YzEyODEyZjQ5MDQ5ZTNjZTdlZWFmZTJmYjI2XzE1LTktMS0xLTExODgzMw_7d5cc6fe-f1f0-499a-b513-a3274d2b15d2"
      unitRef="usd">12920000000</us-gaap:Goodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90ZXh0cmVnaW9uOmJhYzVhNjE4MGE2ZDRjOTY5NDExNWYxNjUxODVhY2JjXzIyMzI_d2301c76-60ab-41d0-9a77-ba7ad8fb715f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December&#160;31, 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzItMS0xLTEtMTE4ODMz_41bf33a9-b7d3-4200-8e91-862d352a838a"
      unitRef="usd">781000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzMtMS0xLTEtMTE4ODMz_3d3cb992-d925-42a0-807e-6d0572905fa0"
      unitRef="usd">741000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzQtMS0xLTEtMTE4ODMz_d824b824-554f-4ec4-9d8f-79dca8d3e0f6"
      unitRef="usd">683000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzUtMS0xLTEtMTE4ODMz_09b0f356-457c-44cb-9769-820098a74624"
      unitRef="usd">665000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDYvZnJhZzpiYWM1YTYxODBhNmQ0Yzk2OTQxMTVmMTY1MTg1YWNiYy90YWJsZTo3NTg0YTFmNzM5MGM0OTZkYTMwZTg2YTExNjUxN2ViNi90YWJsZXJhbmdlOjc1ODRhMWY3MzkwYzQ5NmRhMzBlODZhMTE2NTE3ZWI2XzYtMS0xLTEtMTE4ODMz_434186f2-70ba-46e9-ba90-a0ba143b4569"
      unitRef="usd">625000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE5MDAz_2fceb257-e0ab-4649-a85a-26ffeaa16dfa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE D &#x2013; HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Currency Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Management Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hedge Designations and Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net change in derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss), net of tax (OCI)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Foreign currency translation adjustment (CTA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and we reclassify amortization of the excluded component from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to current period earnings within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December&#160;31, 2022 and 2021, we designated as a net investment hedge our &#x20ac;900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We reclassify these gains and losses to current period earnings within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December&#160;31, 2022, we had entered into $228 million in aggregate notional amount of these contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Interest Rate Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Management Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hedge Designations and Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was a $8 million loss as of December&#160;31, 2022 and a $24 million loss as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no interest rate derivative instruments designated as fair value hedges outstanding as of December&#160;31, 2022 and December&#160;31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which generally offset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of our hedging instruments outstanding:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;FASB ASC Topic 815 Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Notional Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,321&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated debt is the &#x20ac;900 million debt principal designated as a net investment hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining time to maturity as of December&#160;31, 2022 is within 48&#160;months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note O &#x2013; Changes in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effect of Hedging Relationships on Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Recognized in OCI on Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Reclassified from AOCI into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pre-Tax Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain (Loss) Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location of Amount Reclassified and Total Amount of Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pre-Tax (Gain) Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax (Benefit) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to earnings represent the effect of the hedging relationships on earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to earnings as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;CTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. No amounts were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to current period earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to earnings within the next twelve months are presented below (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Designated Hedging Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;FASB ASC Topic 815 Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) on currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) on currency transaction exposures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net currency exchange gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative and Nonderivative Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Non-Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Derivative and Nonderivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative and Nonderivative Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Non-Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Derivative and Nonderivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;Foreign currency-denominated debt is the &#x20ac;900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Inputs to the valuation methodology are unobservable inputs based on management&#x2019;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Publicly-held securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December&#160;31, 2022 and $1.632 billion as of December&#160;31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December&#160;31, 2022 and $293 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a discussion of the changes in the fair value of our contingent consideration liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga&#x2122; Drug. We own the contractual right to receive 50 percent of the future Zytiga&#x2122; Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceeds from royalty rights,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and payments we remit to inventors reduce the fair value of the financial liability and are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payments for royalty rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transfers and Servicing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-cash impact of transferred royalty rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December&#160;31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December&#160;31, 2022 include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licensing Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$159 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our licensing arrangements' financial asset were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our licensing arrangements' financial liability were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note B &#x2013; Acquisitions and Strategic Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a discussion of our strategic investments and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note C &#x2013; Goodwill and Other Intangible Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a discussion of the fair values of our intangible assets including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our outstanding debt obligations was $8.203 billion as of December&#160;31, 2022 and $10.196 billion as of December&#160;31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note E &#x2013; Contractual Obligations and Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a discussion of our debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzQ3MDU_fb2eac35-de3c-4684-a322-01d1d960b4a0"
      unitRef="eur">900000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzQ3MDk_ed05bea9-4da9-4dfd-9a54-42c9e46c47af"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i07415990883e4ca3b5f954aa8871d444_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEwOTk1MTE2NDg1MjM_19c30975-7dd0-4577-959a-ea32db5d593f"
      unitRef="usd">228000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4Xzc5OTQ_3fd1a45d-af0c-4959-ad5a-2bb211684554"
      unitRef="usd">8000000</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzgwMTc_930ddcae-fc1f-4d3a-bb05-c8d862685c4e"
      unitRef="usd">24000000</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTE1_323cc7ea-c47b-4c51-8308-3bb347f861e2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of our hedging instruments outstanding:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;FASB ASC Topic 815 Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Notional Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,321&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3b264f96121f49c4947c5cebac003441_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzItNC0xLTEtMTE4ODMz_a9395292-f201-40cd-9719-e3f83bd469ac"
      unitRef="usd">2725000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie0ba4efd839e41a5a81e781338fa73f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzItNi0xLTEtMTE4ODMz_9e3c4598-1867-41fd-a4d0-75a6a9b42402"
      unitRef="usd">3996000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if424464b0a3c4a39857873d850185168_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzMtNC0xLTEtMTE4ODMz_156ff6e0-b961-42bf-a9d4-c1d58fcdbe0e"
      unitRef="usd">365000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6f6d5b5ab6e344e9bf988dc3bff46611_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzMtNi0xLTEtMTE4ODMz_0ba60569-cd22-49fa-bbc4-e2a1ea9e8b5f"
      unitRef="usd">493000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i13b57c132f9d416694b1d85ee5e9c012_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzQtNC0xLTEtMTE4ODMz_ed1f50dc-d792-4884-b3d0-1d827e55f906"
      unitRef="usd">997000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iefadff6b78cd431aa59e065d0ae8d019_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzQtNi0xLTEtMTE4ODMz_977958ab-612e-467f-b899-986ecba7137b"
      unitRef="usd">997000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7034c0c152ad405b805f9b28b7b18795_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzUtNC0xLTEtMTE4ODMz_93605465-76c5-4ae9-a5eb-7439f56f2ee1"
      unitRef="usd">4235000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7ca004ff852f4e619fad9a26264773a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzUtNi0xLTEtMTE4ODMz_47d0a5ae-5f77-484d-bed4-bb25fe4008ef"
      unitRef="usd">3892000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzctNC0xLTEtMTE4ODMz_94ce4853-e704-4b6f-ab20-6f19930e5e6c"
      unitRef="usd">8321000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpkOTI1NGFiMzdlM2I0N2UwYWRmYWFlMWNmYmUxOThjZC90YWJsZXJhbmdlOmQ5MjU0YWIzN2UzYjQ3ZTBhZGZhYWUxY2ZiZTE5OGNkXzctNi0xLTEtMTE4ODMz_a3817dbc-8580-4627-89f0-7948007534bd"
      unitRef="usd">9378000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:LongTermDebt
      contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4Xzg5Nzg_fb2eac35-de3c-4684-a322-01d1d960b4a0"
      unitRef="eur">900000000</us-gaap:LongTermDebt>
    <bsx:ForwardCurrencyContractsTimetoMaturity
      contextRef="id838054c9b624ef88ede2a3ac03cca10_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzkwODU_16a28dd1-e45e-4807-8379-25dc52320673"
      unitRef="units">48</bsx:ForwardCurrencyContractsTimetoMaturity>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTU3_26ea5475-a073-4c9c-bd6a-a320a510ee36">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note O &#x2013; Changes in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effect of Hedging Relationships on Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Recognized in OCI on Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount Reclassified from AOCI into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pre-Tax Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain (Loss) Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location of Amount Reclassified and Total Amount of Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pre-Tax (Gain) Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax (Benefit) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to earnings represent the effect of the hedging relationships on earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to earnings as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;CTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. No amounts were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to current period earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMS0xLTEtMTE4ODMz_13e3189b-18f8-435d-977c-9bcb847accde"
      unitRef="usd">-276000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMi0xLTEtMTE4ODMz_84959653-2f39-49bb-a590-c3627dfcd4fe"
      unitRef="usd">62000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMy0xLTEtMTE4ODMz_992f1314-77d7-43d4-9d8b-1259cfecab8d"
      unitRef="usd">-214000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtNi0xLTEtMTE4ODMz_b89f5f77-04ed-4fa9-965a-3e48ef2caccc"
      unitRef="usd">3956000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtOC0xLTEtMTE4ODMz_67606590-4c8f-48c4-ba11-d541d18c189d"
      unitRef="usd">209000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtOS0xLTEtMTE4ODMz_127810de-f566-4c6d-8dde-ed273388073c"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i49fbe0ec5426427e9244daaa0ec5b773_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzUtMTAtMS0xLTExODgzMw_f3137771-bce6-491a-bd77-8bc78363407f"
      unitRef="usd">-162000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMS0xLTEtMTE4ODMz_4d28a80b-ce61-424e-81cf-d29f81ddc98e"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMi0xLTEtMTE4ODMz_31fe2f9f-51f0-4838-8cf3-0483189817b6"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMy0xLTEtMTE4ODMz_8aed8bf3-1a74-491f-bf7e-affd6659824e"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:InterestExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtNi0xLTEtMTE4ODMz_3018eb11-8082-470c-a312-2632d1df2c09"
      unitRef="usd">470000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtOC0xLTEtMTE4ODMz_af1e4581-2b83-4596-b27a-c28f03580ea9"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtOS0xLTEtMTE4ODMz_c19b5f8b-5bed-4285-a5c3-aae7a0bde41e"
      unitRef="usd">2000000</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i925ca6a755a147e286f0928e8aa9ec73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzYtMTAtMS0xLTExODgzMw_f5b0032e-209c-4844-8c4c-1da9a895ebe3"
      unitRef="usd">8000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMS0xLTEtMTE4ODMz_9644ce2e-7930-42a9-a5a6-b492cd02f5bf"
      unitRef="usd">61000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMi0xLTEtMTE4ODMz_0707a4f6-35b0-4980-b6fb-2d15e1ad5a41"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMy0xLTEtMTE4ODMz_7cb59d15-5c48-4581-9d4e-967914eedbca"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtNi0xLTEtMTE4ODMz_d661cbaf-c7e4-4459-9d93-0aa729543863"
      unitRef="usd">38000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtOC0xLTEtMTE4ODMz_fc4dc4fe-82fb-48da-89ef-504dbc2eec07"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtOS0xLTEtMTE4ODMz_195054b4-8e18-4e54-8e07-1df6b997de84"
      unitRef="usd">0</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i2298021edccd4d9bb40cd933acd02a84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzgtMTAtMS0xLTExODgzMw_9c5c37ac-7f15-4372-ad33-1eedd9068476"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTEtMS0xLTExODgzMw_cd82ee27-bf94-490f-b2a4-31609f15009b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTItMS0xLTExODgzMw_4edf956b-830f-432b-99d7-1d8cfd8e7a8e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTMtMS0xLTExODgzMw_c8b96275-5ec5-4a38-b87d-4e35f1548caa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:InterestExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTYtMS0xLTExODgzMw_3018eb11-8082-470c-a312-2632d1df2c09"
      unitRef="usd">470000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTgtMS0xLTExODgzMw_8313cd3f-97dc-41de-9013-d93960cfc5e7"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTktMS0xLTExODgzMw_058b72c7-fd01-43d6-849b-50790060766e"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i775054b201874b0995c880d7f1742de0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEwLTEwLTEtMS0xMTg4MzM_a2c47a86-b3b6-49f2-88b7-3b1ee6c49b70"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTEtMS0xLTExODgzMw_4c879923-b51c-42b7-885e-e0312f992e16"
      unitRef="usd">-268000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTItMS0xLTExODgzMw_1dbf83e9-ffb7-4d55-8ab7-0730df06ff8a"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTMtMS0xLTExODgzMw_751b7b98-71f4-4661-b964-4b72f3a93b0c"
      unitRef="usd">-208000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTYtMS0xLTExODgzMw_aa968464-3d53-4b13-959e-9d83d74e95ce"
      unitRef="usd">3711000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTgtMS0xLTExODgzMw_6006e2a1-fc74-4532-9204-340bbbe5fbb1"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTktMS0xLTExODgzMw_2fd1d03a-b220-459d-9438-656993872f1c"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic71d5edd774a45e0b0736e6edd202e64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzEzLTEwLTEtMS0xMTg4MzM_4881edb9-476a-465c-8866-fb4e837e6512"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTEtMS0xLTExODgzMw_36ea2b1e-fb5d-4605-ae0d-17c56579aae3"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTItMS0xLTExODgzMw_3a7719f3-bce5-4b90-9b79-eacdbe6d3025"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTMtMS0xLTExODgzMw_191408b2-816f-42d5-8404-2d3f7334968d"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:InterestExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTYtMS0xLTExODgzMw_46c2b3aa-1065-4d6d-841e-e12cfa527d6e"
      unitRef="usd">341000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTgtMS0xLTExODgzMw_d511a69a-ff86-4904-9507-93c30b6b35e6"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTktMS0xLTExODgzMw_810ab373-7fd3-476e-94e4-3bea9ebcd2d4"
      unitRef="usd">3000000</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i46ce77f9d2714f01bf561b3a5242a47c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE0LTEwLTEtMS0xMTg4MzM_75f90d7c-ba79-4dac-80ec-23bea0008f56"
      unitRef="usd">10000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTEtMS0xLTExODgzMw_11f4b84b-00e5-4594-9021-94199cd1fe7e"
      unitRef="usd">82000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTItMS0xLTExODgzMw_393cb697-ca11-439e-a0b3-6c76d663004b"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTMtMS0xLTExODgzMw_82f9cb9a-e34a-480e-b7bf-6d1443503e25"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTYtMS0xLTExODgzMw_dc00bbe7-8fb4-4980-9e67-abe106e47e0e"
      unitRef="usd">-218000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTgtMS0xLTExODgzMw_af2efb63-9cac-45d6-8bd8-141071c44028"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTktMS0xLTExODgzMw_417ecf31-811d-4c38-904b-6ee817267acb"
      unitRef="usd">0</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i7dd43ef68122459198fc3ab36ea15b8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE2LTEwLTEtMS0xMTg4MzM_102a81ca-7b20-4015-b8a9-69522f6ae94e"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTEtMS0xLTExODgzMw_ca082669-81b6-4e81-8843-87ccee6b1448"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTItMS0xLTExODgzMw_21fba026-fa93-4f06-b1aa-769b7315873a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTMtMS0xLTExODgzMw_d9e23230-5c8a-4c88-ba7e-8636874228b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:InterestExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTYtMS0xLTExODgzMw_46c2b3aa-1065-4d6d-841e-e12cfa527d6e"
      unitRef="usd">341000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTgtMS0xLTExODgzMw_23560a85-98a9-4e25-a5c7-b9e0e3dc259c"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTktMS0xLTExODgzMw_470a3e7b-38aa-45f1-9c2d-2c23521caa70"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i48954fc8363d443494d7a35d45e950af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzE4LTEwLTEtMS0xMTg4MzM_9d7d0b84-756a-4368-afdf-e574b4a7f4e1"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTEtMS0xLTExODgzMw_8be8588b-057b-49c3-bbb7-fddfc5fe1272"
      unitRef="usd">99000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTItMS0xLTExODgzMw_18fc7bd1-ef14-496e-b68c-d1e1cd850f4b"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTMtMS0xLTExODgzMw_5342c9bc-6f4b-4d31-a5b8-e5f65d4a3a60"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTYtMS0xLTExODgzMw_c574ef45-eac7-4dd9-a939-255b19efb84a"
      unitRef="usd">3465000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTgtMS0xLTExODgzMw_28c1c586-3262-41e3-99c3-54d9b9fd7ff8"
      unitRef="usd">83000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTktMS0xLTExODgzMw_4d0be6bc-a6d7-431e-8ede-7e16eb5e4917"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1a0cb9305f4149e8818ba931bee7acd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIxLTEwLTEtMS0xMTg4MzM_383925bc-de46-4c8c-9109-a5995455ec44"
      unitRef="usd">-64000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTEtMS0xLTExODgzMw_09033882-0b73-4f76-b5be-e4433d098e64"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTItMS0xLTExODgzMw_9e9cf967-6ff5-428a-9d72-dcc9bd90c815"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTMtMS0xLTExODgzMw_a9ed8574-b5b5-49a6-a66b-08b2a288150c"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:InterestExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTYtMS0xLTExODgzMw_458a0696-728f-4a83-a7b6-34c8151087c8"
      unitRef="usd">361000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTgtMS0xLTExODgzMw_c2b694d8-dda4-4e7f-bd7e-097037b40eed"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTktMS0xLTExODgzMw_457bda19-1e55-4941-8c06-ef2a19022030"
      unitRef="usd">5000000</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i98a55b3baf974861bf3399d3f1e74a8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzIyLTEwLTEtMS0xMTg4MzM_4b550557-2321-4c12-ac2f-365fb7e0cb06"
      unitRef="usd">19000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTEtMS0xLTExODgzMw_0ab2d807-37f3-4df9-bf86-664e4259a554"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTItMS0xLTExODgzMw_d6e809ae-cc33-43ca-8e75-b37773983aaf"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTMtMS0xLTExODgzMw_48cc6cd9-03ae-4816-bfa2-907e2019c33a"
      unitRef="usd">-68000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTYtMS0xLTExODgzMw_483eec6f-da3a-4619-a431-ebe1df87d1b6"
      unitRef="usd">-362000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTgtMS0xLTExODgzMw_96701c3e-74c2-40a1-8bb6-eae51101dea4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTktMS0xLTExODgzMw_36874885-e5eb-4bee-b8f9-5b823ca256aa"
      unitRef="usd">0</bsx:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="ib078a44b88d54707a0dd08854eafb3f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI0LTEwLTEtMS0xMTg4MzM_2492901e-cbca-484e-9496-4cc5e9b8682a"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTEtMS0xLTExODgzMw_c3700a1e-6129-4221-9be3-97aa27dd608c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTItMS0xLTExODgzMw_7fbf5a44-c0c7-4f10-a010-5b4cc3cef5fd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTMtMS0xLTExODgzMw_933b4b6e-c274-4b52-a7df-b3c9111f0d69"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:InterestExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTYtMS0xLTExODgzMw_458a0696-728f-4a83-a7b6-34c8151087c8"
      unitRef="usd">361000000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTgtMS0xLTExODgzMw_1f1e2e1e-268c-41a0-9a3c-9892e078f47f"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTktMS0xLTExODgzMw_014354f0-f812-4269-8ecb-ed3c414d9e39"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i438b83212971494182ffbef2037ce1dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxNmVmMDZiY2NkMmU0MmFiOTZhNjdhZDJkZmQ2MWZlZC90YWJsZXJhbmdlOjE2ZWYwNmJjY2QyZTQyYWI5NmE2N2FkMmRmZDYxZmVkXzI2LTEwLTEtMS0xMTg4MzM_fd423629-3ed8-4cd1-83cd-98051956a66e"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <bsx:DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTIw_81ac0a7c-f5fb-4afc-a273-1ecce4baf698">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to earnings within the next twelve months are presented below (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Designated Hedging Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;FASB ASC Topic 815 Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bsx:DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i5dc8106ccc3e4b4f8afb7eed48c9a6ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzEtNi0xLTEtMTE4ODMz_ddd87c4f-d1c8-4c53-a889-ddcd5223cfa6"
      unitRef="usd">223000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <bsx:DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet
      contextRef="i497eeb11153a4392b98631c49308f079_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzItNi0xLTEtMTE4ODMz_69b9d50d-4877-42bb-8b25-69574cc09a13"
      unitRef="usd">10000000</bsx:DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i0e775c256acb4b869fa12bfa169522f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToyNjRiN2E1OTQ3NmM0MjliODMwZWQ5ODUyYTY4ZjZiMC90YWJsZXJhbmdlOjI2NGI3YTU5NDc2YzQyOWI4MzBlZDk4NTJhNjhmNmIwXzMtNi0xLTEtMTE4ODMz_0a26ab98-e40f-484e-ba75-df1f8ed05c5a"
      unitRef="usd">-3000000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTgw_5c50f9dc-f6ab-4eb4-bd3d-0fa80928b5de">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) on currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) on currency transaction exposures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net currency exchange gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItNC0xLTEtMTE4ODMz_41bf979e-f207-498d-83d4-c48d64b6ef35"
      unitRef="usd">-53000000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItNi0xLTEtMTE4ODMz_5325faeb-1493-47b8-a370-7f8779b3c884"
      unitRef="usd">-16000000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzItOC0xLTEtMTE4ODMz_d156dc0c-b0c7-4606-a0bf-961758df81a4"
      unitRef="usd">73000000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtNC0xLTEtMTE4ODMz_7bccf065-7f55-489c-bc86-d5aa4f1da62b"
      unitRef="usd">21000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtNi0xLTEtMTE4ODMz_28bcaf7b-7db0-40cb-b362-b5746786f949"
      unitRef="usd">-12000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzMtOC0xLTEtMTE4ODMz_a9f16ffa-427a-44d9-bac2-83992976a224"
      unitRef="usd">-105000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="i6965149134094476b73632a7c3d75d1f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtNC0xLTEtMTE4ODMz_f0549358-856a-4c38-9e9c-3dea55045818"
      unitRef="usd">-31000000</bsx:NetCurrencyExchangeGainLoss>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="if470fcf4792149f3beeb7cd1a22a0922_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtNi0xLTEtMTE4ODMz_d0de3890-5a4b-4912-81f3-2a1e69dc9b7f"
      unitRef="usd">-27000000</bsx:NetCurrencyExchangeGainLoss>
    <bsx:NetCurrencyExchangeGainLoss
      contextRef="i8aea48c6a1c1417aaf7d4e318d4d5ff5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiMTI0ZWQ4M2I4ZTk0NmM1OWM3MjVjNjM1NTRkMzExMC90YWJsZXJhbmdlOmIxMjRlZDgzYjhlOTQ2YzU5YzcyNWM2MzU1NGQzMTEwXzQtOC0xLTEtMTE4ODMz_cf01213c-0e99-4f65-9147-8da60f06bf7e"
      unitRef="usd">-32000000</bsx:NetCurrencyExchangeGainLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTYx_08827868-a043-432d-99e1-0d80a681b8ea">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTI4_46e84ef2-9d2e-44de-a611-e6e67af85a2c">The following are the balances of our derivative and nonderivative assets and liabilities:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative and Nonderivative Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Non-Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Derivative and Nonderivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative and Nonderivative Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Non-Designated Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Derivative and Nonderivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;Foreign currency-denominated debt is the &#x20ac;900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i43976490229f4082a87ca1ad777107c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzQtNC0xLTEtMTE4ODMz_e8899791-5303-4118-a4dd-107637e68644"
      unitRef="usd">196000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i9c931f3e9e82412985cdead08af7d632_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzQtNi0xLTEtMTE4ODMz_c1d9fb62-332c-4a57-a3f7-e2a8b597c88f"
      unitRef="usd">183000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i55b5902a38e94fb0bc7726cc131b7909_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzUtNC0xLTEtMTE4ODMz_e3e0aa64-6886-47e5-9f68-658449238f6e"
      unitRef="usd">149000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i9b0fbd55b32b490e9fdb76b959b0201f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzUtNi0xLTEtMTE4ODMz_073757d1-9446-48d0-ab1f-d306cc8deea8"
      unitRef="usd">169000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ifbf44831547f46288e08f02ae1ef637a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzYtNC0xLTEtMTE4ODMz_8e4d0625-9d19-4658-b008-176ae8dd13b0"
      unitRef="usd">345000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iaf6b63466c604373ae38da6289aeb97b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzYtNi0xLTEtMTE4ODMz_b840244b-aa1d-4af4-8166-21452cb47cf1"
      unitRef="usd">352000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i3e21397bfa8444b681ef8632f7075281_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzgtNC0xLTEtMTE4ODMz_45503aa0-10e6-4fd9-9dfc-a371ea9237aa"
      unitRef="usd">36000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ibf9f9f3e82c944209c2e074ec8df6017_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzgtNi0xLTEtMTE4ODMz_98171a63-aef4-4a7a-bb22-4f686c65aa38"
      unitRef="usd">42000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzktNC0xLTEtMTE4ODMz_f82656bc-5de3-4805-ae18-0e97feef94b9"
      unitRef="usd">381000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzktNi0xLTEtMTE4ODMz_10b55e0a-ee4e-4d39-933f-08f6db4c614b"
      unitRef="usd">394000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i6c65a02c0b2346b8906129d0669bf500_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzEzLTQtMS0xLTExODgzMw_26d2780e-0b2a-476d-ba06-bd587d62b208"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic80d5979815640db88b06b04ebcb6895_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzEzLTYtMS0xLTExODgzMw_c51b8ffe-885e-44e7-9cf2-bb31bc625418"
      unitRef="usd">32000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia66ab9c892884deaade76365d66fd129_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE0LTQtMS0xLTExODgzMw_12a6a126-2486-4f77-85b4-2f940e490a36"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7356fcfc65574de19d26d52fc3344322_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE0LTYtMS0xLTExODgzMw_1c19fa1e-a085-445f-a403-d9b93b4eca8b"
      unitRef="usd">6000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2f9d72a0fc2a4e5a95b3b411d70ff7cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE1LTQtMS0xLTExODgzMw_9ac82ae2-f668-4a04-b20c-bbc63be8848a"
      unitRef="usd">952000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i023ada48280d48fbaabe57b9e17d60d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE1LTYtMS0xLTExODgzMw_df71495e-3a3f-43a8-847a-d4f3230bafa4"
      unitRef="usd">1011000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ifbf44831547f46288e08f02ae1ef637a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE3LTQtMS0xLTExODgzMw_960ae9b1-65d4-415d-8be7-91990711c463"
      unitRef="usd">953000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iaf6b63466c604373ae38da6289aeb97b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE3LTYtMS0xLTExODgzMw_fee9c6b5-6f73-42bf-b8fc-2081f5d1c558"
      unitRef="usd">1049000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i30ada0ca796d42c992dc5e35b941a368_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE5LTQtMS0xLTExODgzMw_0776c476-e44b-44e1-8573-522d729d05f5"
      unitRef="usd">52000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i4d3c5b387d0440dab8c546b5c1842949_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzE5LTYtMS0xLTExODgzMw_a8cd9b3d-104b-4b67-b33f-3fdca711b09d"
      unitRef="usd">22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzIwLTQtMS0xLTExODgzMw_c79f3db2-f1d8-4777-a5d4-4039130a832f"
      unitRef="usd">1005000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpjNzM4NDg5YWQzMTg0MWU4OWY1Njc2N2NiNDU4ZmE5NC90YWJsZXJhbmdlOmM3Mzg0ODlhZDMxODQxZTg5ZjU2NzY3Y2I0NThmYTk0XzIwLTYtMS0xLTExODgzMw_a077e514-2f17-4f3a-a35b-b11bd8435e81"
      unitRef="usd">1071000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:LongTermDebt
      contextRef="i9a523a86f5de42f0a2b6fdf708f0a0c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEyNTg4_fb2eac35-de3c-4684-a322-01d1d960b4a0"
      unitRef="eur">900000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4OTYy_a7bc3e71-46a9-4873-bd4b-1db88c23982c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Publicly-held securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December&#160;31, 2022 include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licensing Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$159 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Year of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our licensing arrangements' financial asset were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our licensing arrangements' financial liability were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMS0xLTEtMTE4ODMz_7a4db560-3a46-4bd0-9569-bb82994c796e"
      unitRef="usd">673000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMy0xLTEtMTE4ODMz_47c1673a-477f-4a29-8c2f-24e1bba74915"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtNS0xLTEtMTE4ODMz_83eba745-8acb-4ce2-aadc-7d45bd603b00"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtNy0xLTEtMTE4ODMz_c57c3097-d47d-47d4-8502-13e3b45b2582"
      unitRef="usd">673000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtOS0xLTEtMTE4ODMz_80244967-1cc6-431f-9302-f67b225a863b"
      unitRef="usd">1632000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTEtMS0xLTExODgzMw_82a6fbbf-9bf3-47ba-a911-8a47a090c388"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTMtMS0xLTExODgzMw_edb84046-4969-42f6-8cf4-b8a92167cd23"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzQtMTUtMS0xLTExODgzMw_336c3a4a-972b-4489-ae20-da05361ee631"
      unitRef="usd">1632000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMS0xLTEtMTE4ODMz_59ca5d67-cd85-4e76-b400-e6fae07117fd"
      unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMy0xLTEtMTE4ODMz_0cc33e12-b01c-453d-bff6-0912e8362f08"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtNS0xLTEtMTE4ODMz_cc260e7f-fc7a-46dd-b1f7-fcba7957d76e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtNy0xLTEtMTE4ODMz_adc8ac2d-9c48-476a-ba68-eb05d55f7d0f"
      unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtOS0xLTEtMTE4ODMz_c5dbd7db-9cfa-41aa-9b8d-d5860374f238"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTEtMS0xLTExODgzMw_cc7fa679-b83c-4623-b312-3af2094db44f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTMtMS0xLTExODgzMw_7ecaced6-8af6-49b5-807a-13c1a79c41c7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzUtMTUtMS0xLTExODgzMw_66288285-5a06-4294-88ec-f58c44341fc7"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMS0xLTEtMTE4ODMz_f01ada1d-92bd-404b-851b-638a6888f635"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMy0xLTEtMTE4ODMz_64e68af3-905f-4456-aa9e-455e76321855"
      unitRef="usd">381000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtNS0xLTEtMTE4ODMz_8f6a2e78-e044-4682-aaa7-86bef4426667"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtNy0xLTEtMTE4ODMz_508aa863-d020-4e72-92fd-54542e84489b"
      unitRef="usd">381000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtOS0xLTEtMTE4ODMz_5a3f70cf-9539-4171-a7b9-c0765edc3e45"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTEtMS0xLTExODgzMw_d59a2a8b-b780-4477-9ac2-e7c7359a3c49"
      unitRef="usd">394000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTMtMS0xLTExODgzMw_aa6aa0fa-242c-4143-8939-9eee5a0e2e41"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzYtMTUtMS0xLTExODgzMw_4bb64ec3-800e-4bc4-a40c-2aae64fc57fb"
      unitRef="usd">394000000</us-gaap:DerivativeAssets>
    <bsx:LicensingArrangementsAsset
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMS0xLTEtMTE4ODMz_1dd73d43-be11-4a1c-a2ce-ac352b7ce1f4"
      unitRef="usd">0</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMy0xLTEtMTE4ODMz_6587d4d4-5c83-42e9-b51e-fa0caac3a1ff"
      unitRef="usd">0</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctNS0xLTEtMTE4ODMz_c3cf6f88-57a2-4b01-ae11-73a1f16b210b"
      unitRef="usd">127000000</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctNy0xLTEtMTE4ODMz_5ce94766-4601-4686-beec-c8b02980f31d"
      unitRef="usd">127000000</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctOS0xLTEtMTE4ODMz_9f46dbf9-ad92-4ace-847a-4febe19a35ef"
      unitRef="usd">0</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTEtMS0xLTExODgzMw_2298bef1-c414-4eae-9e00-dbf41635e530"
      unitRef="usd">0</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTMtMS0xLTExODgzMw_ef4c47d4-b5b3-41bd-b6d8-8cea7e042bff"
      unitRef="usd">246000000</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzctMTUtMS0xLTExODgzMw_ed325134-285f-4e1e-96d7-c6d2dbd78943"
      unitRef="usd">246000000</bsx:LicensingArrangementsAsset>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMS0xLTEtMTE4ODMz_0021504c-db43-46cc-9caf-195649ca2a21"
      unitRef="usd">674000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMy0xLTEtMTE4ODMz_224c7bab-29ab-483e-a79f-da93cb0c362c"
      unitRef="usd">381000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtNS0xLTEtMTE4ODMz_6f27a1d4-c5ba-4779-8dbd-0bfb1f3db141"
      unitRef="usd">127000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtNy0xLTEtMTE4ODMz_2efb1b94-a908-4ba5-ab15-6826b468619c"
      unitRef="usd">1182000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtOS0xLTEtMTE4ODMz_61ec6824-6636-4c6e-8884-4fdc9ffe9fb4"
      unitRef="usd">1642000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTEtMS0xLTExODgzMw_3ff1d45f-da0e-4552-8c84-3c07d6517255"
      unitRef="usd">394000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTMtMS0xLTExODgzMw_57338d7e-0ede-4461-adef-6e912286a1e4"
      unitRef="usd">246000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzgtMTUtMS0xLTExODgzMw_829c3c28-e1e6-4f44-b19e-8b26f510ace3"
      unitRef="usd">2282000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTEtMS0xLTExODgzMw_992d0332-2a5b-4c18-9a74-c1202bbdd036"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTMtMS0xLTExODgzMw_7287c898-c78a-4ac1-b795-d6d18055aad1"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTUtMS0xLTExODgzMw_3eda3ede-b145-49bd-bf63-62718d003877"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTctMS0xLTExODgzMw_24cb729c-2e81-4168-9aa1-bf2cab0c46ee"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTktMS0xLTExODgzMw_5b5a319d-98b5-4e6c-b1db-d48067cbcd9c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTExLTEtMS0xMTg4MzM_92875a7f-e523-4bb3-926b-69ca150ac74c"
      unitRef="usd">1071000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTEzLTEtMS0xMTg4MzM_87688b45-1227-4a77-a75e-06c374d6b52a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEwLTE1LTEtMS0xMTg4MzM_9ddd1f2e-d1d3-486e-8073-4ab6ee548930"
      unitRef="usd">1071000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTEtMS0xLTExODgzMw_1fd306e5-c4a6-4148-b28e-013ebcc945d7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTMtMS0xLTExODgzMw_97afc279-b0f3-448b-ba1b-ae7e01a1699c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTUtMS0xLTExODgzMw_e1fe0272-748a-4d0b-9cac-8326931b8f83"
      unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTctMS0xLTExODgzMw_1daa30da-1b99-4c76-bf21-88cb5d468073"
      unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTktMS0xLTExODgzMw_19b025c3-a677-426f-a1a8-5fedb180066c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTExLTEtMS0xMTg4MzM_86ba664a-584c-4673-b04a-33ab627d60d1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTEzLTEtMS0xMTg4MzM_a5cd7e47-6738-4f38-9083-be8a06ea8410"
      unitRef="usd">486000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzExLTE1LTEtMS0xMTg4MzM_61abed93-eb27-479e-8571-22294b63ddde"
      unitRef="usd">486000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTEtMS0xLTExODgzMw_4911ae8a-7a5c-411f-bd4e-578ecbe78810"
      unitRef="usd">0</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTMtMS0xLTExODgzMw_102157aa-fca1-4d40-a33c-de73427dc1dd"
      unitRef="usd">0</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTUtMS0xLTExODgzMw_e85e6738-4067-4e03-b3e3-ee54f56ca1df"
      unitRef="usd">159000000</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTctMS0xLTExODgzMw_00165eea-4cb2-4f1d-b839-3547a7cd277f"
      unitRef="usd">159000000</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTktMS0xLTExODgzMw_824a1d2a-86b4-464d-ac5a-9af458d09d5e"
      unitRef="usd">0</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTExLTEtMS0xMTg4MzM_800c9991-15c2-4820-93a2-0151dcd269ff"
      unitRef="usd">0</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTEzLTEtMS0xMTg4MzM_9cc81f8c-565f-4dbd-9969-4df5e8347af9"
      unitRef="usd">281000000</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEyLTE1LTEtMS0xMTg4MzM_6416836f-e306-4437-a8f8-d8974e35912b"
      unitRef="usd">281000000</bsx:LicensingArrangementsLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTEtMS0xLTExODgzMw_5faf5655-55ce-4caa-9ffe-fcd057e19423"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i840959e741f54e53bcfa7cee090f415b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTMtMS0xLTExODgzMw_a80ce959-9de7-4b12-8c44-877eec8f6c5a"
      unitRef="usd">1005000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a6335d803ad40d3a7c34639f0aadbb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTUtMS0xLTExODgzMw_c4cf90fe-3a4a-415b-af7e-a836e159e91c"
      unitRef="usd">308000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4e0f8ffbda174d938d2297ace40124d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTctMS0xLTExODgzMw_d7b32457-9fb5-4081-85a8-cf767819dcf5"
      unitRef="usd">1313000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTktMS0xLTExODgzMw_3e788f38-b08d-48bd-879e-810009e02463"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i07b89ace1eaa46269adec5e0008ec73b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTExLTEtMS0xMTg4MzM_fd28b7c2-4260-4e01-90a2-c65f5f9ce6ee"
      unitRef="usd">1071000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic3d5b145adac4671bb050182a0d509da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTEzLTEtMS0xMTg4MzM_0e0c9c05-a639-4900-a81a-eb095419267d"
      unitRef="usd">767000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6d0e41762c9e419389adb68bc5d9ac5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTo2ZWI3Y2I0OTU0ZTM0MWI0OTI1YzI1ODZkOWE1YzIxYy90YWJsZXJhbmdlOjZlYjdjYjQ5NTRlMzQxYjQ5MjVjMjU4NmQ5YTVjMjFjXzEzLTE1LTEtMS0xMTg4MzM_78dfaa9f-188b-43d9-94e8-92c93cd4ed57"
      unitRef="usd">1838000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i09b6905a25fa4d699bf3d10ecb906a32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0MzM5_7a4db560-3a46-4bd0-9569-bb82994c796e"
      unitRef="usd">673000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i14049c0347434075a00f370f84a4db4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NDA0_80244967-1cc6-431f-9302-f67b225a863b"
      unitRef="usd">1632000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:Cash
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NDI1_454070a0-b0d9-49fd-b60d-61154d934df6"
      unitRef="usd">256000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE0NTAw_ed53bf94-d152-49de-98e1-8a45f62e04b6"
      unitRef="usd">293000000</us-gaap:Cash>
    <bsx:LicensingArrangementsAsset
      contextRef="i1ffcb904865b4d6580df24d96533c364_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtMS0xLTEtMTE4ODMz_e685c714-ec2a-4c4f-bfe1-f3d5ab9e75f3"
      unitRef="usd">127000000</bsx:LicensingArrangementsAsset>
    <bsx:DiscountRateFairValueInput
      contextRef="iee69410e5a5d4b89bc83f76bb50d6b38_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtNC0xLTEtMTE4ODMz_cf503295-3add-46f2-becb-4f9defee1330"
      unitRef="number">0.15</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="ie2e9c8a5b25844acb555957ab3a50fda_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzEtNy0xLTEtMTE4ODMz_549e1a4a-8e3d-4eee-88e2-94fd3fa09046"
      unitRef="number">0.15</bsx:DiscountRateFairValueInput>
    <bsx:LicensingArrangementsLiability
      contextRef="i1ffcb904865b4d6580df24d96533c364_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtMS0xLTEtMTE4ODMz_515a760c-d5f5-417d-bc19-12335c01cb78"
      unitRef="usd">159000000</bsx:LicensingArrangementsLiability>
    <bsx:DiscountRateFairValueInput
      contextRef="ia769df42f17c44b6b313f45d148ee393_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNC0xLTEtMTE4ODMz_25229b33-406e-4013-929e-1626e4783d4d"
      unitRef="number">0.12</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="idd5679aa760c46509687a1dde91bab70_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNi0xLTEtMTE4ODMz_44910da7-ae07-4a82-a288-36b117498234"
      unitRef="number">0.15</bsx:DiscountRateFairValueInput>
    <bsx:DiscountRateFairValueInput
      contextRef="i306eeeee59414185854b583778c80597_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZToxYzMyNjQ1NTI4ODg0NDcwYTJhYTdjMDZlN2JhMTdjZC90YWJsZXJhbmdlOjFjMzI2NDU1Mjg4ODQ0NzBhMmFhN2MwNmU3YmExN2NkXzQtNy0xLTEtMTE4ODMz_eba8edfc-782a-4b64-af2f-6dd4ec4d070d"
      unitRef="number">0.13</bsx:DiscountRateFairValueInput>
    <bsx:LicensingArrangementsAsset
      contextRef="i65715ea926ee481fb6c5149bad0221f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzEtMS0xLTEtMTE4ODMz_3f5effce-5b26-448a-b2ae-f3ca03fe60d5"
      unitRef="usd">365000000</bsx:LicensingArrangementsAsset>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzItMS0xLTEtMTE4ODMz_00f102dc-5176-44a7-bd78-2d7036cd5154"
      unitRef="usd">163000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="ifbc7ae37460940468093664006bbc2f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzMtMS0xLTEtMTE4ODMz_59b10a1c-4342-4dc8-a58d-e4c9eab4f281"
      unitRef="usd">44000000</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <bsx:LicensingArrangementsAsset
      contextRef="i29915dcac5094d979b75f1f2f98cb3d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzQtMS0xLTEtMTE4ODMz_964b5fc6-565e-40e2-b1a4-6f1b2b2f0a73"
      unitRef="usd">246000000</bsx:LicensingArrangementsAsset>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="i2194ed16e8554a818134176f669c6463_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzUtMS0xLTEtMTE4ODMz_442b9e97-e090-4aee-a04f-855936710cf1"
      unitRef="usd">141000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="i2194ed16e8554a818134176f669c6463_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzYtMS0xLTEtMTE4ODMz_88181438-36d6-42a1-a10c-1c498170342a"
      unitRef="usd">22000000</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <bsx:LicensingArrangementsAsset
      contextRef="ic5c030aed5a44a2c9b75bda87f7ac3e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTpiYTA4NjVmMjg5ODA0NGU5ODYyMGNmM2I5OWY0YmMzNC90YWJsZXJhbmdlOmJhMDg2NWYyODk4MDQ0ZTk4NjIwY2YzYjk5ZjRiYzM0XzctMS0xLTEtMTE4ODMz_11d73e08-a64b-4899-b44d-8a69544be0cb"
      unitRef="usd">127000000</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsLiability
      contextRef="ifee8da85a7114dbf9b80f1b1ad1b7309_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzEtMS0xLTEtMTE4ODMz_11fd85b0-92ad-4f93-b605-163261f6be81"
      unitRef="usd">407000000</bsx:LicensingArrangementsLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzItMS0xLTEtMTE4ODMz_c215dac1-98bb-46d9-bbe3-0ac4faee67cc"
      unitRef="usd">166000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="ie797734e41d84f0396db9d79530f6cce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzMtMS0xLTEtMTE4ODMz_54775849-3fee-47c2-972e-a046d80ef999"
      unitRef="usd">41000000</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <bsx:LicensingArrangementsLiability
      contextRef="i4af424844b524fbc975d6d2534326bb5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzQtMS0xLTEtMTE4ODMz_11964e29-1062-40b2-b9f8-d7a8566a8722"
      unitRef="usd">281000000</bsx:LicensingArrangementsLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzUtMS0xLTEtMTE4ODMz_f8deb919-8316-441f-be4f-bdb90a036f41"
      unitRef="usd">145000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="id312c2d566e74fcb901d33acf750b8d5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzYtMS0xLTEtMTE4ODMz_67e2d643-004e-4eba-8d86-f9f5fb90bd44"
      unitRef="usd">23000000</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <bsx:LicensingArrangementsLiability
      contextRef="i707b6e8943e4427a9a804100e6c467b8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90YWJsZTplYTJmMTFiNzk5NDI0ZmEzOWJjNGU5ODdmNmI3MTYxNy90YWJsZXJhbmdlOmVhMmYxMWI3OTk0MjRmYTM5YmM0ZTk4N2Y2YjcxNjE3XzctMS0xLTEtMTE4ODMz_a3a93de0-2c58-4cdf-987b-c512dca6c7b7"
      unitRef="usd">159000000</bsx:LicensingArrangementsLiability>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzE4NDQx_b3f5a3b8-8143-486d-bf0f-ee7a8387d49d"
      unitRef="usd">8203000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMDkvZnJhZzplYmJiZGY0ZTllZTM0ZjBjYmFmZjFjMjNlNzI0ZjljOC90ZXh0cmVnaW9uOmViYmJkZjRlOWVlMzRmMGNiYWZmMWMyM2U3MjRmOWM4XzEwOTk1MTE2NDkzMjM_c80f367b-d8b3-4164-80d8-351f57c94d06"
      unitRef="usd">10196000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTYx_d7bbeb4c-a088-4ec5-9f1a-17da32e5f419">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE E &#x2013; CONTRACTUAL OBLIGATIONS AND COMMITMENTS &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Borrowings and Credit Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total debt outstanding of $8.935 billion as of December&#160;31, 2022 and $9.065 billion as of December&#160;31, 2021, with current maturities of $20 million as of December&#160;31, 2022 and $261 million as of December&#160;31, 2021. The debt maturity schedule for our long-term debt obligations is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Coupon Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.125%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024 Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.450%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2025 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2025 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.850%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.900%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2027 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.625%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2029 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2030 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.650%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2031 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2034 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2035 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2005&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2039 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2040 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.375%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2049 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.700%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized Debt Issuance Discount and Deferred Financing Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 - 2049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized Gain on Fair Value Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance Lease Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Note:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November&#160;2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250&#160;million of 3.375% May 2022 Senior Notes classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current Debt Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revolving Credit Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December&#160;31, 2022 or December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Covenant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Covenant Requirement&lt;br/&gt;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Actual&lt;br/&gt;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum permitted leverage ratio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75 times&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57 times&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December&#160;31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December&#160;31, 2022, we had $866 million of the litigation exclusion remaining.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us.&#160;In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable&lt;/span&gt;&lt;span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Paper &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had senior notes outstanding of $8.986 billion as of December&#160;31, 2022 and $9.121 billion as of December&#160;31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of &#x20ac;3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of &#x20ac;1.000 billion of 0.750% Senior Notes due 2025, &#x20ac;750 million of 1.375% Senior Notes due 2028, &#x20ac;750 million of 1.625% Senior Notes due 2031 and &#x20ac;500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a &#x201c;finance subsidiary&#x201d; as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275&#160;billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transfers and Servicing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Factoring Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;De-recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;De-recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro denominated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yen denominated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renminbi denominated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Contractual Obligations and Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had outstanding letters of credit of $135 million as of December&#160;31, 2022 and $134 million as of December&#160;31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December&#160;31, 2022 and December&#160;31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecorded Purchase Obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzgw_fac2d9e5-a7f2-499f-a65b-750f7fab4577"
      unitRef="usd">8935000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzk2_498f5246-08b1-48a9-8bd5-0510ff3ed1f6"
      unitRef="usd">9065000000.000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNg_d5e0237a-7342-4fcf-8d13-5c8adf0c74e6"
      unitRef="usd">20000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzE1Mg_7c722033-a61e-49cc-92f2-c36d3ff8333f"
      unitRef="usd">261000000</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNjA4_9a0dd8b8-212d-46d0-b2ae-79f897a8f911">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Coupon Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.125%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024 Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.450%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2025 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2025 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.850%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.900%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2027 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.625%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2029 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2030 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.650%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2031 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2034 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2035 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2005&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.750%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2039 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2040 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.375%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2049 Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.700%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized Debt Issuance Discount and Deferred Financing Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 - 2049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized Gain on Fair Value Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance Lease Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Note:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November&#160;2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250&#160;million of 3.375% May 2022 Senior Notes classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current Debt Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="ic3ab0e4e1b614daf98a769c6518ac202_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItNi0xLTEtMTE4ODMz_87b58c20-62af-4231-be58-adaef37bfaa8"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1e5897f9c4874d42b04253217254d1e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItOC0xLTEtMTE4ODMz_558f6ecd-cc5a-4792-b3c0-b6e752a9f96c"
      unitRef="usd">244000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic3ab0e4e1b614daf98a769c6518ac202_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzItMTAtMS0xLTExODgzMw_764b2658-7ab9-4316-8bf5-3b4b69cfd4cd"
      unitRef="number">0.04125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ibf8cb2626e924fb8839e71109d5af54e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtNi0xLTEtMTE4ODMz_6671e119-2a9a-49c9-a505-7bb2b06ff6e7"
      unitRef="usd">504000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04324fd6d5b24d29b46e19849e7f37a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtOC0xLTEtMTE4ODMz_57ae6820-380f-444b-90ed-63767a07b077"
      unitRef="usd">850000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibf8cb2626e924fb8839e71109d5af54e_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzMtMTAtMS0xLTExODgzMw_fd491d8d-286e-40bd-a3be-19d33022c5f7"
      unitRef="number">0.03450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie06c81ca089f4d1995643384dc902e2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtNi0xLTEtMTE4ODMz_cd70994c-f274-4dcb-9fee-47f7dfd51241"
      unitRef="usd">1067000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3b2144f30d3644df97a834f3542eaa50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtOC0xLTEtMTE4ODMz_7256a4d8-bd1a-405c-96e8-f489ca6bdc4b"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie06c81ca089f4d1995643384dc902e2d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzQtMTAtMS0xLTExODgzMw_bebcf8d9-472e-4a6d-b33d-fbd21d494863"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i53531cf73b884a88961411dfb1a4df93_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtNi0xLTEtMTE4ODMz_adea30db-5db8-4433-b207-2694a8186bbd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i02be01898d4d4188b550ce6554ad5461_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtOC0xLTEtMTE4ODMz_fb5ef362-bcba-40dc-a804-ceac01f7b996"
      unitRef="usd">523000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53531cf73b884a88961411dfb1a4df93_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzUtMTAtMS0xLTExODgzMw_f2e76f95-8420-4d41-99ea-6ac91dd45119"
      unitRef="number">0.03850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtNi0xLTEtMTE4ODMz_acca3266-c700-4422-9c2c-80d76f681e34"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id76f019bce26489da0bbcda06c714fcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtOC0xLTEtMTE4ODMz_7ce40dba-c038-4d27-a38f-0877729091d5"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib4d00968eede4e01b21d4e8ba2d7552a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzYtMTAtMS0xLTExODgzMw_07425366-fdeb-4f23-9d65-581416d269ec"
      unitRef="number">0.01900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctNi0xLTEtMTE4ODMz_6472cdb1-946d-48b6-8ac5-af10a887059e"
      unitRef="usd">255000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2b88044a72ca47a791ceb58f044afebf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctOC0xLTEtMTE4ODMz_90eb3169-0d9c-4cef-a155-2d6d5d864300"
      unitRef="usd">850000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic9e254ad79484ba2a5dab10aec03a3ad_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzctMTAtMS0xLTExODgzMw_955d7ad3-3513-42cf-82d3-26ce47171dba"
      unitRef="number">0.03750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtNi0xLTEtMTE4ODMz_17f1206e-06bf-4fd5-9c90-72340c3a69f0"
      unitRef="usd">960000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if96adf1f1d5d4c17ba33895d23e7b110_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtOC0xLTEtMTE4ODMz_54a113e0-8dd2-4e4b-9c63-67158842aead"
      unitRef="usd">1021000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f4f307170e14ffa98c3396e76d5b034_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzgtMTAtMS0xLTExODgzMw_ed05bea9-4da9-4dfd-9a54-42c9e46c47af"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktNi0xLTEtMTQ2Mzk5_8758bb2a-b80e-468b-9ba1-d21899073923"
      unitRef="usd">800000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i864e95597acb4043a3697acb3ad55e62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktOC0xLTEtMTQ2Mzk5_f20ded2e-a525-45a4-af8a-8029c6280ea0"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktMTAtMS0xLTE0NjQwOQ_07708cdb-7973-451d-be29-11e17f29a0ca"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i08a4d41448224bea93d0c944e7acd848_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktNi0xLTEtMTE4ODMz_8f83511e-1c7e-4e31-9d03-da96c381a251"
      unitRef="usd">344000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibe00cfc2a6d34b918d4ceff8a2a7df0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktOC0xLTEtMTE4ODMz_be8fafe3-e660-422c-819c-6798d2c2c052"
      unitRef="usd">434000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08a4d41448224bea93d0c944e7acd848_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzktMTAtMS0xLTExODgzMw_e6e0ee47-45ba-4622-9be8-29bdc4c84d1c"
      unitRef="number">0.04000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ida72d7a38e1b45739fe07b735a844490_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTYtMS0xLTExODgzMw_8959ce2a-a80c-415b-968e-be2003ec7c42"
      unitRef="usd">272000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i018346feef584486b99651353c8ff6a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTgtMS0xLTExODgzMw_c6a804e8-c628-4da3-83d4-4fc0966684ac"
      unitRef="usd">850000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ida72d7a38e1b45739fe07b735a844490_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEwLTEwLTEtMS0xMTg4MzM_024f7c14-116a-4ad3-8782-d2c21fc83efe"
      unitRef="number">0.04000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i682827fd95b7499d8506ecce105a57a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTYtMS0xLTExODgzMw_0e0ab4fd-4222-4d02-bb8d-43797e964ea6"
      unitRef="usd">1200000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibb00400334214dfba90153fcbfa6c190_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTgtMS0xLTExODgzMw_74624b80-9e93-4f64-bdfe-0632c5285a56"
      unitRef="usd">1200000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i682827fd95b7499d8506ecce105a57a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzExLTEwLTEtMS0xMTg4MzM_1064780c-79a7-4720-afbd-7211900a5e22"
      unitRef="number">0.02650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTYtMS0xLTE0NjQyNQ_2ce48de3-682b-4578-9fb8-66704d3ab4ae"
      unitRef="usd">800000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9a66dc38d4684266bdecece733ad71b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTgtMS0xLTE0NjQyNQ_70993b91-f71e-4f10-9052-e5bf12e004ea"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTEwLTEtMS0xNDY0Mzk_eacd52ea-c639-401f-88e4-8dc2eb5ce81d"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTYtMS0xLTE0NjQyNQ_030b36d3-be09-494b-9c0a-a4b0e392989a"
      unitRef="usd">534000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6171ca5966e144cda0bde8a3dec28ca5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTgtMS0xLTE0NjQyNQ_70a4fda4-f08e-4376-ba36-9c2cb6915ed5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTEwLTEtMS0xNDY0Mzk_74bd3482-8e9f-4645-9929-d312dbd286c9"
      unitRef="number">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTYtMS0xLTExODgzMw_2e96fbfa-76cd-4d49-968b-f292f6b2383f"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie0e76a81818f4be58bec07896afe0da9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTgtMS0xLTExODgzMw_775fec8a-1aca-4ca8-ab5d-de8d37938c7f"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2fa33eb5c6bd4a29901a47afce3e1533_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEyLTEwLTEtMS0xMTg4MzM_b19f8b3e-11ae-4ae9-ba2e-6a6efa7be144"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia6bb195cd673465b82fb0f2af7d23b13_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTYtMS0xLTExODgzMw_9bf712f6-8ce9-43f2-8b77-f64972be99fb"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3999962f0a5340baaeffd9b46c41b048_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTgtMS0xLTExODgzMw_385ae416-58bc-484f-89d8-5005ea51eef0"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia6bb195cd673465b82fb0f2af7d23b13_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzEzLTEwLTEtMS0xMTg4MzM_3db332f5-6c3b-4ddf-a0ce-e8773d06513d"
      unitRef="number">0.04550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTYtMS0xLTExODgzMw_1fa39ec6-c14d-4f17-a934-e64fc3474e18"
      unitRef="usd">300000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idb1499dcaa0a4582b01d18fba8f0a457_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTgtMS0xLTExODgzMw_1f4f5ba1-fbeb-460b-97e9-c4af1aa2432f"
      unitRef="usd">300000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id5ec5dfe2680459fae22e0f7c4a3c740_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE0LTEwLTEtMS0xMTg4MzM_19607ac3-1517-4ccb-b814-c22698972b5d"
      unitRef="number">0.07375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i58dd8cfee9114b3094575d06ba47b061_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTYtMS0xLTExODgzMw_b499dab7-101f-4098-a75a-f55ab5891824"
      unitRef="usd">650000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i928315b0c4a64541aef04d53faebc49b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTgtMS0xLTExODgzMw_265920c0-f39e-4cb2-b3a2-33d17580c09c"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i58dd8cfee9114b3094575d06ba47b061_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE1LTEwLTEtMS0xMTg4MzM_a9b2cdda-c69a-455c-8e2a-b04eae6f02bc"
      unitRef="number">0.04700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i99f56a60724c4866875a8a4eae6f3274_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE2LTYtMS0xLTExODgzMw_965440d4-0cbe-4288-a35d-54a74f9bc930"
      unitRef="usd">76000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ic32b67209ba7458d8464a71b457bf2e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE2LTgtMS0xLTExODgzMw_2497569a-41d6-4961-ae04-0e666e073dbd"
      unitRef="usd">76000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i65b71607a73c4b9581145cffe097fb22_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE3LTYtMS0xLTExODgzMw_7f0a1f0b-7694-4170-99d0-e45c62475d8d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1115f7919aed4133876eff1699223515_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE3LTgtMS0xLTExODgzMw_bf256874-d76c-4fc1-87dd-18dd32a9906c"
      unitRef="usd">3000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7989d8c3104e4c619e77b27f533f298b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE4LTYtMS0xLTExODgzMw_a3235516-5fb3-4972-bce3-4ac02c768749"
      unitRef="usd">5000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icaa67b35af59447dbc5102119a3de9dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE4LTgtMS0xLTExODgzMw_fd203136-4972-4d15-a5ad-9fb75e735c8c"
      unitRef="usd">6000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE5LTYtMS0xLTExODgzMw_565ea843-1c02-44f6-826b-c6b7d4fb2a63"
      unitRef="usd">8915000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpjMjEzNzRjZTE1MDM0OTU5ODhhODA1ZWQ2YjczNGM0OC90YWJsZXJhbmdlOmMyMTM3NGNlMTUwMzQ5NTk4OGE4MDVlZDZiNzM0YzQ4XzE5LTgtMS0xLTExODgzMw_530d18fb-a90f-411d-820a-1e38acc6300a"
      unitRef="usd">8804000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ShortTermBorrowings
      contextRef="icc9cb66ce623493d8cf1bce6f5823751_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTY4NTk_bff1b764-b252-4ba5-86e4-91eba1435dff"
      unitRef="usd">250000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc9cb66ce623493d8cf1bce6f5823751_I20220331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzU0OTc1NTg0MjE0MQ_bb1a45c5-3006-4ad5-8434-2b928bc000c1"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzU0OTc1NTg0MjEzMw_6db4409d-2d7a-43f1-8f96-ea5f824ed70e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzItMS0xLTEtMTg4NjIz_f5c47829-e00e-4bd2-8c85-e8aa32ec8f6c"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzItMS0xLTEtMTgxNTcx_6646d177-465d-463b-b478-2a9a331325ea"
      unitRef="usd">504000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzMtMS0xLTEtMTgxNTc1_f3a01bbe-ef7e-46a6-a1db-063580b253fc"
      unitRef="usd">1567000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzQtMS0xLTEtMTgxNTc4_4d38ba2c-98b8-4784-961e-6082b320953b"
      unitRef="usd">255000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzUtMS0xLTEtMTgxNTgx_dce0de4d-c2c2-4424-b309-eb6259286d25"
      unitRef="usd">960000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTo2MTEzZjExYzAxY2E0MTNjOGNkNGNlYmYyZTM5Yzg2Yy90YWJsZXJhbmdlOjYxMTNmMTFjMDFjYTQxM2M4Y2Q0Y2ViZjJlMzljODZjXzYtMS0xLTEtMTgxNTg0_07b4b178-ebc9-48e1-bec6-a9ad0697591a"
      unitRef="usd">5700000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2a25ee3da32a468a9bfc070a0c89a839_I20210510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzMjg_2f890a6f-ad63-4153-80cc-14ab7dc61a94"
      unitRef="usd">2750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bsx:SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTg3_656bfae2-9f40-4e6e-929e-9c2483907d39">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Covenant Requirement&lt;br/&gt;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Actual&lt;br/&gt;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum permitted leverage ratio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75 times&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57 times&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.&lt;/span&gt;&lt;/div&gt;</bsx:SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock>
    <bsx:MaximumLeverageRatio
      contextRef="i9d77a9f992e540f08a1ba2d26480abde_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTowMGE0MzU5OTJhY2U0ODI1OGI0OGJjYmNmMjQ0MDkzNi90YWJsZXJhbmdlOjAwYTQzNTk5MmFjZTQ4MjU4YjQ4YmNiY2YyNDQwOTM2XzEtMS0xLTEtMTE4ODMz_713924c1-389d-4173-adf5-1f46891ab812"
      unitRef="number">3.75</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="id03e9205a64d476ab1ffbccbf9a5d6f8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTowMGE0MzU5OTJhY2U0ODI1OGI0OGJjYmNmMjQ0MDkzNi90YWJsZXJhbmdlOjAwYTQzNTk5MmFjZTQ4MjU4YjQ4YmNiY2YyNDQwOTM2XzEtMy0xLTEtMTE4ODMz_d4a9a76d-f08e-40b2-94b5-bcb8a6c300fd"
      unitRef="number">2.57</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="i423e15598ef9473093d58996221c5647_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzYzNzA_48101e0c-ba64-47f8-a2a3-8232c8e44e99"
      unitRef="number">3.75</bsx:MaximumLeverageRatio>
    <bsx:DeemedConsolidatedEBITDA
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzY3Mzk_83b651f8-71f7-460a-889d-761412aacea2"
      unitRef="usd">1000000000</bsx:DeemedConsolidatedEBITDA>
    <bsx:MaximumLeverageRatio
      contextRef="i44684946d0c54e399e9c2de5643d2c10_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzY5MzE_3d6fc05e-616b-4e38-bf56-6a6359e60fd2"
      unitRef="number">4.75</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="i5a893ba0e00b4645b7c556abf4dec609_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMDU_6d678ae2-fe99-4d99-be02-f25834babadf"
      unitRef="number">4.50</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="i4cb6963457e3481da9017401ed9b31fa_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMDk_2e58221d-8fe2-477c-9daa-235567fb91e3"
      unitRef="number">4.25</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="i09ab63ee90e44984aa45a30f812a5e31_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwMTY_7a937fd7-8ec6-4f72-a375-d516c42f4085"
      unitRef="number">4.00</bsx:MaximumLeverageRatio>
    <bsx:MaximumLeverageRatio
      contextRef="ib3172cf749dd40e98dad112948210e77_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzcwNzQ_7a3beb0b-513e-4cae-bb8a-cc05c1eca469"
      unitRef="number">3.75</bsx:MaximumLeverageRatio>
    <bsx:ExclusionFromEbitdaForRestructuringCharges
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzczNDM_9638d6e2-459e-4c84-8b73-f592f21dbef4"
      unitRef="usd">500000000</bsx:ExclusionFromEbitdaForRestructuringCharges>
    <bsx:RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc0Nzc_3c885070-952a-452d-a165-7d8ed303a581"
      unitRef="usd">265000000</bsx:RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda>
    <bsx:LitigationAndDebtExclusionFromEbitda
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc4MDk_efcb5784-a324-410d-a0c2-46ec2f71589e"
      unitRef="usd">1455000000</bsx:LitigationAndDebtExclusionFromEbitda>
    <bsx:LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2Xzc4NDc_f4aa7814-0626-4a1b-af8b-9de0a19f87b0"
      unitRef="usd">866000000</bsx:LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="i9ca8697fd7e248dbacff201a7b724e96_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTky_9f1a59af-0032-4267-b6d0-19c9ea196d5b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Paper &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i99f56a60724c4866875a8a4eae6f3274_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzkwNDM_f29dc940-9c56-4ffa-a529-90356de84980"
      unitRef="usd">8986000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic32b67209ba7458d8464a71b457bf2e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzkwNTk_29abfb8b-2513-444e-a29e-04e68a5da04f"
      unitRef="usd">9121000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id0251b7614994e199486b144a5575677_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5NjU_4fc86f23-f9f2-442e-bfdb-d039549d256b"
      unitRef="eur">3000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5NzI_b34f43e0-3384-4676-b94f-8e633065d773"
      unitRef="eur">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i910dbef0a6fd4e408a80c1d9c9e2e62b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5ODE_7d283f29-9469-4f06-ab98-a9abe49735af"
      unitRef="rate">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5OTY_665b1967-18d2-464e-880f-777438aeea43"
      unitRef="eur">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0895858ef274288a9fce1cc6baf793d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTM5OTA_e207e560-6614-4397-a904-309e635d671f"
      unitRef="rate">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMDU_b21cc03c-2214-4b9f-8538-fad4c936f0d0"
      unitRef="eur">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie0b7e8de32b04e2b9d457be393d35239_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMjE_add8f2be-bafb-4ec7-88cb-7dbf0dc88d93"
      unitRef="rate">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMjU_a85776c1-0647-4e62-95b1-c13c23a3bf3a"
      unitRef="eur">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ba97b9a77bb4c5aaa0898cc847b3368_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMzU_9f55bddb-9cde-4c17-9293-12d6980600ba"
      unitRef="rate">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwMzk_fdf4183c-b571-4ffa-8887-68d27008ee00"
      unitRef="usd">3270000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaf36b03a92634587a78fe98ecbda2739_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwNTE_82aef472-993e-42bd-bf19-0a8805075e35"
      unitRef="usd">3275000000</us-gaap:LongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzI3NDg3NzkwOTQwNTk_80fd473c-1741-4069-bc66-f02d8a7df8eb"
      unitRef="usd">194000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNTkw_d35b8db3-3104-4d2f-8cc5-c5e3f48f4864">Amounts de-recognized for accounts and notes receivable, which are excluded from &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Factoring Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;De-recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;De-recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro denominated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yen denominated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renminbi denominated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i31b0bfab9628416589521c0cc6480c67_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItMS0xLTEtMTE4ODMz_60b24c00-d74f-43ea-9e8e-884d4e06f0c5"
      unitRef="usd">161000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="i643af335931a4a30a480266df6ef95d9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItMy0xLTEtMTE4ODMz_758bb99d-ab4b-45fb-a889-9dec6ac12e34"
      unitRef="number">0.024</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i98de3ef86645434aa333bc3813270c7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItNS0xLTEtMTE4ODMz_88c783c1-01ca-4d98-a693-7c3950dc7d80"
      unitRef="usd">141000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="id65dea5f8a5b4ac18eaa23709148f19b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzItNy0xLTEtMTE4ODMz_7a4982cc-bf4e-45e2-b776-c90d37a60767"
      unitRef="number">0.021</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i9ce90adb5f284d558cee43d226b9984f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtMS0xLTEtMTE4ODMz_1b717105-9c99-4813-84af-12b16059ba9e"
      unitRef="usd">194000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="iba3abf20e7914152b66511a2593d8f69_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtMy0xLTEtMTE4ODMz_eaa2caae-173e-42f4-bbc7-b06d05c04fe8"
      unitRef="number">0.006</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ife73119c01544765a2e816448d123ab4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtNS0xLTEtMTE4ODMz_9d2e61e3-6d08-48fa-833f-1b2f7e712ab3"
      unitRef="usd">223000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="i33dfc13e3d6d4ae1bf1a49a51cf7ae03_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzMtNy0xLTEtMTE4ODMz_b066d13d-6dee-4cf5-8fc0-40231d394e8e"
      unitRef="number">0.006</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="idf9016a91a7f4898bd6a07d00738ca87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtMS0xLTEtMTE4ODMz_ee3e69c8-35d1-4ef2-b30e-8fc0876100e4"
      unitRef="usd">13000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="ic0b9dfecd89c48c796f6821c64cd7270_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtMy0xLTEtMTE4ODMz_28599d10-dc83-4c67-ae8f-ee4c608a1392"
      unitRef="number">0.031</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="iccc10de8eb9b4b38a11dcc2d78d8200a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtNS0xLTEtMTE4ODMz_a451162d-ad44-4967-9eb2-ccee7c8c7907"
      unitRef="usd">11000000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="i2a3c6f2ec1ae4c93b758ace41955b687_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZToyOGUzYmExMGZkYjE0ZDc3YWQxNTFlNTRmN2ZmYmY2NC90YWJsZXJhbmdlOjI4ZTNiYTEwZmRiMTRkNzdhZDE1MWU1NGY3ZmZiZjY0XzQtNy0xLTEtMTE4ODMz_6327cb8b-b337-478f-8a30-9bf70f9cacd0"
      unitRef="number">0.032</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEyOTcx_ad325840-6fcf-4913-8ac8-b177810dc43b"
      unitRef="usd">135000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEyOTg3_95a1e5cf-6d60-4958-8564-ce4b3a78df13"
      unitRef="usd">134000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LongTermPurchaseCommitmentTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90ZXh0cmVnaW9uOjM4MWMwMzY1OGQ4ODQzNjFiMDQxZDQxNDgxMzRmOTM2XzEzNjEx_3f2bfc4c-4ab7-4df3-8388-9de2fe6b0494">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecorded Purchase Obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermPurchaseCommitmentTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzEtMS0xLTEtMTE4ODMz_cf8a6de5-a00d-453f-8325-b992b049e4cc"
      unitRef="usd">755000000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzItMS0xLTEtMTE4ODMz_3be46f01-6480-4b63-aa87-875ce090d272"
      unitRef="usd">119000000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzMtMS0xLTEtMTE4ODMz_3a16647f-b568-4c89-b0ee-bc44a05ebcb5"
      unitRef="usd">71000000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzQtMS0xLTEtMTE4ODMz_f8d064b3-5f4e-4f4f-9a02-b8be13fbf46f"
      unitRef="usd">35000000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzUtMS0xLTEtMTE4ODMz_f9618bf1-f63b-47c2-9cc1-370e0dfa870b"
      unitRef="usd">19000000</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueAfterFifthYear
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzYtMS0xLTEtMTE4ODMz_c953e7c0-12f3-480f-9d52-c7e852277fe0"
      unitRef="usd">21000000</us-gaap:PurchaseObligationDueAfterFifthYear>
    <us-gaap:PurchaseObligation
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTIvZnJhZzozODFjMDM2NThkODg0MzYxYjA0MWQ0MTQ4MTM0ZjkzNi90YWJsZTpkMWFjMDI5MDE5Y2M0MDlkYTFjNTllN2U0NjJjN2NmYy90YWJsZXJhbmdlOmQxYWMwMjkwMTljYzQwOWRhMWM1OWU3ZTQ2MmM3Y2ZjXzctMS0xLTEtMTE4ODMz_cfccf8c7-6f4f-4a3e-b072-3423a260ed0c"
      unitRef="usd">1021000000</us-gaap:PurchaseObligation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNDY_5a325064-1020-4c2f-a221-cd4040851cde">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE F &#x2013; LEASES &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating lease right-of-use assets are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and corresponding liabilities are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note E &#x2013; Contractual Obligations and Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414"&gt;61&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328"&gt;71&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90&#160;million in 2021 and $92&#160;million in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the maturities of our operating lease liabilities as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5f5f7d93752e444488110da50a259559_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEyMzM_02df202d-843f-4061-930b-bc5fc8f229f9">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1f29c696e3e14cde8b3aa694d11cc79f_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEyNTM_f53bc01e-b4ff-44a2-9955-6d1abfc71a02">P54Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bsx:LesseeOperatingAndFinanceLeasesOptionToExtend
      contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEzMjI_5c2ffef4-0787-4ad9-8297-a96fbfd43cfb">P10Y</bsx:LesseeOperatingAndFinanceLeasesOptionToExtend>
    <bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNTM_d5b7f2d8-4df7-4635-a0ac-adfe941daef4">The following table presents supplemental balance sheet information related to our operating leases:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414"&gt;61&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328"&gt;71&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzMtMS0xLTEtMTE4ODMz_3e5ee9a6-8c1e-40bb-883d-7a3cba1ecf7f"
      unitRef="usd">386000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzMtMy0xLTEtMTE4ODMz_9a84d3be-ef9c-45e0-9e30-3467e0506b53"
      unitRef="usd">435000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_81f8bbbf-aec6-4d61-9673-c05cd50e1871"
      unitRef="usd">61000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_d030d6ba-750f-441c-b420-f09e1215f100"
      unitRef="usd">71000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzYtMS0xLTEtMTE4ODMz_85a404a8-0f16-407b-8ccb-f7493b944626"
      unitRef="usd">347000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzYtMy0xLTEtMTE4ODMz_c7cab5b3-8c93-4925-95e3-1e7e9a7b604c"
      unitRef="usd">389000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNTQ_9b95134c-3cef-4f95-8966-95c9a5f645c5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzItMS0xLTEtMTE4ODMz_9261490d-f168-47ab-a35b-77597b9a53e1">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzItMy0xLTEtMTE4ODMz_9c105fcb-afbe-40fe-b634-303da38765d9">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzMtMS0xLTEtMTE4ODMz_86225b53-d7a8-48e0-a91c-b176348ab20b"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZToyMjY2NjExYzZlMWE0ODBkYWQxZDAwMjRiODI0NGMxMC90YWJsZXJhbmdlOjIyNjY2MTFjNmUxYTQ4MGRhZDFkMDAyNGI4MjQ0YzEwXzMtMy0xLTEtMTE4ODMz_bf71ce01-b19c-441f-ace2-666e26094c58"
      unitRef="number">0.026</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3NzE_3aa331d9-1cf1-4816-bea5-d59c5f6870d0"
      unitRef="usd">91000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3ODE_daf4db18-de78-495f-a3cf-4e9573e1fcbe"
      unitRef="usd">90000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI3OTQ_a32e6f2f-1e79-48b6-8063-cd799464932d"
      unitRef="usd">92000000</us-gaap:OperatingLeaseCost>
    <bsx:SupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNjY_5c9047c1-1f6b-4ce8-90da-0155f96bb66b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bsx:SupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTozNmM2ZWQyZDcxM2Q0Y2RlOTc5MzA1NTFlMWJiZDM2Yi90YWJsZXJhbmdlOjM2YzZlZDJkNzEzZDRjZGU5NzkzMDU1MWUxYmJkMzZiXzMtMS0xLTEtMTE4ODMz_f62578a8-4914-4065-9e9c-7c231fb14fb2"
      unitRef="usd">91000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTozNmM2ZWQyZDcxM2Q0Y2RlOTc5MzA1NTFlMWJiZDM2Yi90YWJsZXJhbmdlOjM2YzZlZDJkNzEzZDRjZGU5NzkzMDU1MWUxYmJkMzZiXzMtMy0xLTEtMTE4ODMz_537c10f2-0038-4d65-9c1f-65ac08e7e3b4"
      unitRef="usd">87000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzI5ODM_92341f6d-ed0e-4c20-a3e6-7a170e4c1fcc"
      unitRef="usd">43000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzEwOTk1MTE2MzMxMzg_e36cfe40-0fdc-460a-aadb-affcc527693a"
      unitRef="usd">68000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <bsx:MaturitiesOfLeaseLiabilitiesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90ZXh0cmVnaW9uOjk4ZmYwOTMzMDhkZjRkZjdhZWNkYTEyNDliOTA2ODZkXzMxNjE_f9a78de2-e9b5-4f89-9903-2c88fce91bbd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the maturities of our operating lease liabilities as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bsx:MaturitiesOfLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzEtMS0xLTEtMTE4ODMz_dd275732-56d1-48b6-8f46-ec4b74ce888c"
      unitRef="usd">80000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzItMS0xLTEtMTE4ODMz_0b31a626-6517-4808-8100-a8f0aa10a26b"
      unitRef="usd">66000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzMtMS0xLTEtMTE4ODMz_547542c4-c307-4caf-b821-df3d0695cbd0"
      unitRef="usd">55000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzQtMS0xLTEtMTE4ODMz_70efbfdf-9c8d-4daa-ae56-6c6a5e64ef61"
      unitRef="usd">43000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzUtMS0xLTEtMTE4ODMz_322838bb-870f-4a10-8485-3679c446770f"
      unitRef="usd">34000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzYtMS0xLTEtMTE4ODMz_2e462d1f-e83d-4a31-bc11-83cf0bc5023c"
      unitRef="usd">214000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzctMS0xLTEtMTE4ODMz_670664f9-347f-41b5-80e4-7bb2e5df204c"
      unitRef="usd">492000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzgtMS0xLTEtMTE4ODMz_854671c3-5d4f-4af0-b984-d57dee57c3a7"
      unitRef="usd">84000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTpiODU1ZDk3MDA4ZjM0MWM3YWYzNTE4YWZiNDY0NTRhOS90YWJsZXJhbmdlOmI4NTVkOTcwMDhmMzQxYzdhZjM1MThhZmI0NjQ1NGE5XzktMS0xLTEtMTE4ODMz_070aee59-0559-467e-a1f0-408dd7e0d5b5"
      unitRef="usd">408000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2MQ_1ad93b6a-30f6-4a12-b2a0-3de39b71522a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE G &#x2013; SUPPLEMENTAL BALANCE SHEET INFORMATION &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of selected captions in our accompanying consolidated balance sheets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trade accounts receivable, net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative effect adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset&#x2019;s contractual life. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 27 percent of our finished goods inventory as of December&#160;31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other current assets&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;799&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other long-term assets&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da"&gt;386&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602"&gt;435&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accrued expenses&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other current liabilities&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other long-term liabilities&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663"&gt;347&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55"&gt;389&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk4MQ_d0b6bebd-f2db-40aa-9c31-58df7f9d43bb">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trade accounts receivable, net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative effect adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset&#x2019;s contractual life.</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzItMS0xLTEtMTE4ODMz_5251dfa9-2e10-4321-9381-bc97c9127449"
      unitRef="usd">2079000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzItMy0xLTEtMTE4ODMz_eaddc108-80e9-451f-aaa6-55895f88b13d"
      unitRef="usd">1886000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzMtMS0xLTEtMTE4ODMz_5b8c2b83-d259-4c6b-ad2d-ae9edc4ce430"
      unitRef="usd">109000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzMtMy0xLTEtMTE4ODMz_681a32bd-227d-4a13-ac0e-a9841a066c45"
      unitRef="usd">108000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzUtMS0xLTEtMTE4ODMz_3ba9866c-5f5b-45cb-a782-543d40d2ef18"
      unitRef="usd">1970000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo1Yjk2MThjODEyYjY0MjM2OWYyZTBjYTVjMTZjNGYwZC90YWJsZXJhbmdlOjViOTYxOGM4MTJiNjQyMzY5ZjJlMGNhNWMxNmM0ZjBkXzUtMy0xLTEtMTE4ODMz_5a2b0d74-3533-4059-9bbb-ca89c91504ab"
      unitRef="usd">1778000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItMS0xLTEtMTE4ODMz_d533ba51-f4a4-4eb8-aa0e-57997edd3cd6"
      unitRef="usd">108000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItMy0xLTEtMTE4ODMz_5054217a-1e55-461e-833c-1b975b82ddc5"
      unitRef="usd">105000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzItNS0xLTEtMTE4ODMz_b87b0e88-6325-4836-8884-3b2be79da683"
      unitRef="usd">74000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzMtNS0xLTEtMTQ2MTk3_041432f2-9ad9-44a9-acdd-d40ea3d51b2b"
      unitRef="usd">10000000</us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtMS0xLTEtMTE4ODMz_9b90e637-5fa1-477a-a730-527342de23c3"
      unitRef="usd">35000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtMy0xLTEtMTE4ODMz_659ff20d-f99f-4776-8aaa-bb3b02b3e76a"
      unitRef="usd">28000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzQtNS0xLTEtMTE4ODMz_1275ac14-60c5-4959-9e58-efc1299e5932"
      unitRef="usd">49000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtMS0xLTEtMTE4ODMz_2e79dc4b-8274-4b06-b62f-dae94f01e08a"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtMy0xLTEtMTE4ODMz_5a53661a-af78-42ea-912b-d520e62a8505"
      unitRef="usd">25000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzUtNS0xLTEtMTE4ODMz_e33457ab-2063-42e3-833e-060815b2c0bb"
      unitRef="usd">27000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtMS0xLTEtMTE4ODMz_8eec1f0b-6fd5-46ad-b6d0-3222dfcbb09a"
      unitRef="usd">109000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtMy0xLTEtMTE4ODMz_99f3c1bc-73ff-4e59-bad8-e5ebf9a7c2ed"
      unitRef="usd">108000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2NGJmOTIzZjMyN2E0MGYwODMyZTQxZTdjMjA2Y2VkNy90YWJsZXJhbmdlOjY0YmY5MjNmMzI3YTQwZjA4MzJlNDFlN2MyMDZjZWQ3XzYtNS0xLTEtMTE4ODMz_458df8f3-67ec-4d58-a8ea-efebb9007dbc"
      unitRef="usd">105000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzEwMTA_e11a4de2-38b1-4481-becf-14d7fb14108d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzItMS0xLTEtMTE4ODMz_43ac89a7-1045-42f0-84f8-0d4eafe17bb0"
      unitRef="usd">1171000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzItMy0xLTEtMTE4ODMz_0f4fdb96-0a36-4321-b44a-c9aee2274091"
      unitRef="usd">1029000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzMtMS0xLTEtMTE4ODMz_b79f41be-c309-4d4e-9a73-03f9f520d6f6"
      unitRef="usd">147000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzMtMy0xLTEtMTE4ODMz_88a6d836-295a-419a-8664-0f0401ee9f70"
      unitRef="usd">128000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzQtMS0xLTEtMTE4ODMz_730f3804-3189-43f3-9192-8ac6e9dcab7f"
      unitRef="usd">548000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzQtMy0xLTEtMTE4ODMz_3fab1de5-0a75-453d-9115-07dbbaaf03bb"
      unitRef="usd">452000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzUtMS0xLTEtMTE4ODMz_178b9a60-a5c5-4c0f-b0b1-f6f82324a604"
      unitRef="usd">1867000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpkMjE2MGYxYTA4Nzk0NDY4ODQ3NTdkYjlhMzEzNDhjYy90YWJsZXJhbmdlOmQyMTYwZjFhMDg3OTQ0Njg4NDc1N2RiOWEzMTM0OGNjXzUtMy0xLTEtMTE4ODMz_f7a0b579-0917-407a-9144-38859f56e988"
      unitRef="usd">1610000000</us-gaap:InventoryNet>
    <bsx:PercentOfFinishedGoodsAtConsignment
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzU0Mw_7581e6d2-f093-40e2-86a2-f7e8719bf5b4"
      unitRef="number">0.27</bsx:PercentOfFinishedGoodsAtConsignment>
    <bsx:PercentOfFinishedGoodsAtConsignment
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzYwNQ_c923fb99-5769-4998-bf03-0b37047d06e3"
      unitRef="number">0.30</bsx:PercentOfFinishedGoodsAtConsignment>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2NQ_b95c3fc8-310f-413f-a164-e6e1ec45e503">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other current assets&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;799&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzItMS0xLTEtMTE4ODMz_45242a57-89f8-4a58-b6fb-96720e507cd2"
      unitRef="usd">149000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzItMy0xLTEtMTE4ODMz_c9337927-57f8-4719-9acf-2ef00a660fa7"
      unitRef="usd">188000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzMtMS0xLTEtMTE4ODMz_c64e9757-ef0e-45a3-b48b-9e3fd6146a8d"
      unitRef="usd">232000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzMtMy0xLTEtMTE4ODMz_ba32aa32-df23-48f8-bb6d-738a17fb9f98"
      unitRef="usd">226000000</us-gaap:DerivativeAssetsCurrent>
    <bsx:LicensingArrangements
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzQtMS0xLTEtMTE4ODMz_6a087f6a-0cc9-488a-8323-2f14c99dcc35"
      unitRef="usd">60000000</bsx:LicensingArrangements>
    <bsx:LicensingArrangements
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzQtMy0xLTEtMTE4ODMz_7b782c82-72ee-400d-8463-670a55e40a05"
      unitRef="usd">132000000</bsx:LicensingArrangements>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzYtMS0xLTEtMTE4ODMz_c707d34b-497c-4d3b-b7ce-dc6a5716e93d"
      unitRef="usd">290000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzYtMy0xLTEtMTE4ODMz_05a5d839-59fd-4291-a713-6388e2482112"
      unitRef="usd">254000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzctMS0xLTEtMTE4ODMz_a1edd477-f791-4da4-a7e3-bb18f4bae2fc"
      unitRef="usd">731000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2Njc2OGM4NmY0YWE0NTg1YjNjMmQzZTJlYWQ0ODY2ZC90YWJsZXJhbmdlOjY2NzY4Yzg2ZjRhYTQ1ODViM2MyZDNlMmVhZDQ4NjZkXzctMy0xLTEtMTE4ODMz_4f367ca1-f504-4dfb-8a08-ea433c0762b7"
      unitRef="usd">799000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk5Mw_4def8c70-8645-4dbb-a879-73cd1464b1d7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzItMS0xLTEtMTE4ODMz_9d447d79-9d78-4853-9ef9-c64c92dc711b"
      unitRef="usd">137000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzItMy0xLTEtMTE4ODMz_706426e9-6637-4feb-a319-aa9603354a31"
      unitRef="usd">109000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzMtMS0xLTEtMTE4ODMz_abf2ea4d-44ae-4846-9454-c26afc42012e"
      unitRef="usd">1695000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzMtMy0xLTEtMTE4ODMz_77ffa05f-edde-452b-8dfc-424e78442006"
      unitRef="usd">1523000000</us-gaap:BuildingsAndImprovementsGross>
    <bsx:EquipmentFurnitureAndFixturesGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzQtMS0xLTEtMTE4ODMz_82590099-a468-4c4b-99c0-2b55e9fa490e"
      unitRef="usd">3297000000</bsx:EquipmentFurnitureAndFixturesGross>
    <bsx:EquipmentFurnitureAndFixturesGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzQtMy0xLTEtMTE4ODMz_906bbc35-50e9-498f-938f-7c381783a6bf"
      unitRef="usd">3287000000</bsx:EquipmentFurnitureAndFixturesGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzUtMS0xLTEtMTE4ODMz_aef1456f-94d7-4d75-a4da-27845721e26e"
      unitRef="usd">598000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzUtMy0xLTEtMTE4ODMz_97681994-8b38-4c69-bddd-fe877fef5a4e"
      unitRef="usd">605000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzYtMS0xLTEtMTE4ODMz_54cf79ab-498f-4d38-b545-1c1ea1c32a71"
      unitRef="usd">5728000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzYtMy0xLTEtMTE4ODMz_9a57c371-32e4-4b3b-8ac7-cdb6a50ace89"
      unitRef="usd">5525000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzctMS0xLTEtMTE4ODMz_43d9a7c1-1af3-40ee-95d4-234d753699aa"
      unitRef="usd">3282000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzctMy0xLTEtMTE4ODMz_a17011b9-082c-4cf8-847d-ad73b3b9519a"
      unitRef="usd">3273000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzgtMS0xLTEtMTE4ODMz_3b9eaf7c-c896-413b-96fd-eadbd7de4b40"
      unitRef="usd">2446000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo2MWNhNTY5YWJkMzg0ZWNlODU5OTcxZDAyYjY4NGYzNS90YWJsZXJhbmdlOjYxY2E1NjlhYmQzODRlY2U4NTk5NzFkMDJiNjg0ZjM1XzgtMy0xLTEtMTE4ODMz_260696dd-614b-4e05-82e7-a3aeed0e5a7e"
      unitRef="usd">2252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgxMw_ffdbd552-1f1a-4970-af06-9ca80515222c"
      unitRef="usd">333000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgyMw_7b059b53-d6ed-4402-bccd-a3026c305213"
      unitRef="usd">352000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzgzNg_a9f773ba-34b4-4923-8600-46f8d81fc06b"
      unitRef="usd">333000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk3OA_238fcda6-837f-4dac-a232-f41650168914">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other long-term assets&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da"&gt;386&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602"&gt;435&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzItMS0xLTEtMTE4ODMz_c8035c0f-434b-4092-b37b-559ab92708f7"
      unitRef="usd">48000000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzItMy0xLTEtMTE4ODMz_61a102d2-ad33-4615-a9c5-fc34b221d57f"
      unitRef="usd">55000000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_a5b4e309-f4c4-47d0-b17f-801e74a45e9d"
      unitRef="usd">386000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_d8d77a00-e55e-42b6-9fa3-f29cbcadcebb"
      unitRef="usd">435000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DerivativeAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzQtMS0xLTEtMTE4ODMz_4e5ef0c7-587c-453a-9170-6aca8f2c2e34"
      unitRef="usd">149000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzQtMy0xLTEtMTE4ODMz_0929315d-7aa6-4fc3-9677-765715074d17"
      unitRef="usd">169000000</us-gaap:DerivativeAssets>
    <us-gaap:Investments
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzUtMS0xLTEtMTE4ODMz_69c3612b-5edb-43d3-8680-f42341d8dc8a"
      unitRef="usd">407000000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzUtMy0xLTEtMTE4ODMz_d1f81eb0-6bc4-40e0-b2bc-4b3ab187871f"
      unitRef="usd">412000000</us-gaap:Investments>
    <bsx:LicensingArrangementsAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzYtMS0xLTEtMTE4ODMz_ced6faec-8518-4970-8771-1dcc5f7c2dcb"
      unitRef="usd">67000000</bsx:LicensingArrangementsAsset>
    <bsx:LicensingArrangementsAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzYtMy0xLTEtMTE4ODMz_5d0869b1-1c0b-45e5-a3dd-fb696d03a316"
      unitRef="usd">114000000</bsx:LicensingArrangementsAsset>
    <bsx:IndemnificationAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMS0xLTEtMTQ2MTcw_97dc82e5-c575-4095-8c3f-fb81e5731fd1"
      unitRef="usd">172000000</bsx:IndemnificationAsset>
    <bsx:IndemnificationAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMy0xLTEtMTQ2MTc4_ee660ca8-def8-47b7-af22-152d6ddd970e"
      unitRef="usd">0</bsx:IndemnificationAsset>
    <bsx:OtherOtherLongTermAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMS0xLTEtMTE4ODMz_e2ee65c4-3021-4623-b0ec-7a4668699482"
      unitRef="usd">271000000</bsx:OtherOtherLongTermAssets>
    <bsx:OtherOtherLongTermAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzctMy0xLTEtMTE4ODMz_d69cf299-b718-4096-8032-33fc2813e482"
      unitRef="usd">225000000</bsx:OtherOtherLongTermAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzgtMS0xLTEtMTE4ODMz_df396bf0-eec0-4ae5-9929-752e9ba6a106"
      unitRef="usd">1500000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzgtMy0xLTEtMTE4ODMz_261fd0c9-a041-4787-855f-58902fe3058f"
      unitRef="usd">1410000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2XzEwMjA_748a5a1b-532b-4ca2-a7ed-8cb7fbabd0b1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accrued expenses&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzItMS0xLTEtMTE4ODMz_fd9901d7-9b77-4b01-8c80-e24e382cff40"
      unitRef="usd">231000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzItMy0xLTEtMTE4ODMz_a9839940-0895-4a3d-b8f7-3c9c2674c3be"
      unitRef="usd">264000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzMtMS0xLTEtMTE4ODMz_0b7653bc-6a4e-4a19-bd82-452cce331e22"
      unitRef="usd">830000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzMtMy0xLTEtMTE4ODMz_11300bd6-0125-42f9-89e9-ffd0bfc80d0a"
      unitRef="usd">848000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bsx:AccruedRebatesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzQtMS0xLTEtMTE4ODMz_895ddc8b-8a50-4be3-aed4-878fa57c4c89"
      unitRef="usd">352000000</bsx:AccruedRebatesCurrent>
    <bsx:AccruedRebatesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzQtMy0xLTEtMTE4ODMz_2411b974-06d8-43a9-9044-18795c6ac337"
      unitRef="usd">350000000</bsx:AccruedRebatesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzUtMS0xLTEtMTE4ODMz_14936c84-0701-4615-b7eb-d76fa4cd83ac"
      unitRef="usd">74000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzUtMy0xLTEtMTE4ODMz_07235bec-b7d4-47a0-a108-346c602408f8"
      unitRef="usd">289000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzYtMS0xLTEtMTE4ODMz_22cd457a-85cd-4813-bf33-66ad8be4533d"
      unitRef="usd">674000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzYtMy0xLTEtMTE4ODMz_23d2262b-d63f-42c3-979e-c3db5c2e1d3d"
      unitRef="usd">686000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzctMS0xLTEtMTE4ODMz_3504da5b-1320-4a43-ac4a-df87bdc8a5c1"
      unitRef="usd">2160000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTo4OGYwYzI4NDNhMmI0OGYyOTMyYWFlZWVlOGI2YjBkZi90YWJsZXJhbmdlOjg4ZjBjMjg0M2EyYjQ4ZjI5MzJhYWVlZWU4YjZiMGRmXzctMy0xLTEtMTE4ODMz_84d35998-69cb-4222-a2e1-093aa0d86b1f"
      unitRef="usd">2436000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk1OQ_10c5e48a-2db5-4513-86af-25774b084f8b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other current liabilities&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzItMS0xLTEtMTE4ODMz_441c5a6f-bd7b-418c-8212-f790fec0e14a"
      unitRef="usd">220000000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzItMy0xLTEtMTE4ODMz_9c9f6acd-35c4-4aa0-a46c-60ee633d026c"
      unitRef="usd">208000000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzMtMS0xLTEtMTE4ODMz_ebb5b06b-87b3-4a72-9e34-999a0fa587eb"
      unitRef="usd">79000000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzMtMy0xLTEtMTE4ODMz_fcaccc18-f344-4373-bf9d-b262cee7444c"
      unitRef="usd">138000000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzQtMS0xLTEtMTE4ODMz_e3a590dd-1c55-4df9-9de0-a0fbb07b020e"
      unitRef="usd">232000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzQtMy0xLTEtMTE4ODMz_0c4e812f-f357-4093-b771-51b356a40e26"
      unitRef="usd">209000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzYtMS0xLTEtMTE4ODMz_c91649af-7fd4-452f-8b7a-ecc78d124665"
      unitRef="usd">230000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzYtMy0xLTEtMTE4ODMz_a0e4aa45-38c4-4cc2-861f-962e4a4d788f"
      unitRef="usd">228000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzctMS0xLTEtMTE4ODMz_6ceab477-ed50-4007-9aec-ecf691e1fc1e"
      unitRef="usd">761000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpmYWViNDlhNmY4NjQ0MTcwOWUxYWJhODIyZWIwOGM0Yi90YWJsZXJhbmdlOmZhZWI0OWE2Zjg2NDQxNzA5ZTFhYmE4MjJlYjA4YzRiXzctMy0xLTEtMTE4ODMz_7541d695-b6ac-4b8a-ae9b-d84894729bec"
      unitRef="usd">783000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90ZXh0cmVnaW9uOjgyODc2YmFlODYyMDQwZTBhNzQ5MTdlYzIxYzY5NzU2Xzk2OA_061ffd24-91bc-4c79-b6e1-b1e4ea56ec5a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other long-term liabilities&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663"&gt;347&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55"&gt;389&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzItMS0xLTEtMTE4ODMz_a4588d8e-5263-4ea9-b344-96e2956797e5"
      unitRef="usd">597000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzItMy0xLTEtMTE4ODMz_fcd38c20-15c2-49c0-be01-ca3b6c652623"
      unitRef="usd">442000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzMtMS0xLTEtMTE4ODMz_82f71247-a85b-43dd-990a-f5a6a30fb9c1"
      unitRef="usd">212000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzMtMy0xLTEtMTE4ODMz_4966fc24-8958-4e28-bc20-a9c2fc6f0331"
      unitRef="usd">284000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzQtMS0xLTEtMTE4ODMz_16983bc8-024e-4cf4-9fc1-0a7368d342fa"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzQtMy0xLTEtMTE4ODMz_b94b4a94-d8fc-43fe-92f7-849b70c104d2"
      unitRef="usd">197000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <bsx:LicensingArrangementsLiability
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzUtMS0xLTEtMTE4ODMz_97afc7a6-0389-4f1c-817e-95f840a322b8"
      unitRef="usd">80000000</bsx:LicensingArrangementsLiability>
    <bsx:LicensingArrangementsLiability
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzUtMy0xLTEtMTE4ODMz_775aaf71-8212-4e4f-b162-63319ee313bd"
      unitRef="usd">143000000</bsx:LicensingArrangementsLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_6a99f40a-b5ea-48f7-a50a-0aad3c2f2303"
      unitRef="usd">347000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_687ef02b-cf2a-43f6-b235-9735bd34d7b9"
      unitRef="usd">389000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenue
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzctMS0xLTEtMTE4ODMz_b6d8408b-3bd8-4351-adf1-6e27241aa2c0"
      unitRef="usd">289000000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzctMy0xLTEtMTE4ODMz_97613871-333d-4893-a981-ec2752e11add"
      unitRef="usd">276000000</us-gaap:DeferredRevenue>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="ieebdba85492e49fbb27526cf8a8b4bb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzgtMS0xLTEtMTE4ODMz_810c9f2c-55fe-4640-9cad-fd96d1067012"
      unitRef="usd">434000000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="ic937ceba64df47d49bd0da69ef3f015d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzgtMy0xLTEtMTE4ODMz_d1571efe-a4ba-4782-8558-7a2b7d03dd34"
      unitRef="usd">489000000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzktMS0xLTEtMTE4ODMz_68eda759-23fc-461e-ae51-2ffb350a247f"
      unitRef="usd">2035000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzktMy0xLTEtMTE4ODMz_930e0064-0abd-401b-ae8f-7cec76440f8b"
      unitRef="usd">2220000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NzM_4b2d7d3f-9e84-4357-a42a-ac9b32f016c8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE H &#x2013; INCOME TAXES &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The related expense (benefit) for income taxes consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intra-entity asset transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory costs and related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit of net operating losses and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and product liability reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal benefit of uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains and losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid on intercompany profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Net Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,062&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid on intercompany profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,062&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December&#160;31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December&#160;31, 2022, and $60 million as of December&#160;31, 2021. These tax attributes expire periodically beginning in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December&#160;31, 2022, and $1.014 billion as of December&#160;31, 2021. The decrease in the valuation allowance as of December&#160;31, 2022, compared to December&#160;31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss) per common share - assuming dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss) per common share - assuming dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss) per common share - assuming dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $0.01 in 2022 and de minimis in 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December&#160;31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December&#160;31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91&#160;million to release the reserves related to these years. We received a refund of $62&#160;million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December&#160;31, 2022, $43 million as of December&#160;31, 2021, and $41 million as of December&#160;31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December&#160;31, 2022, compared to December&#160;31, 2021, is related to reaching settlements with taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that within the next 12&#160;months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;amp;P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December&#160;31, 2022, as compared to $938 million as of December&#160;31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun &lt;/span&gt;&lt;/div&gt;remitting the required installment payments, with a balance remaining of $386 million as of December&#160;31, 2022. In addition, we have provided for U.S. state income taxes of $14 million on all U.S. dollar-denominated E&amp;amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&amp;amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc5MzI_07f80c32-8eec-44d1-bf18-e325e2dce4d4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItMS0xLTEtMTE4ODMz_215af669-6bf7-4311-8cd1-0dd8b9bd9d9b"
      unitRef="usd">-1119000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItMy0xLTEtMTE4ODMz_8d4c7b78-7709-4022-ae95-00074833f8eb"
      unitRef="usd">-648000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzItNS0xLTEtMTE4ODMz_013a443a-b8ad-4c00-8ed7-f0ed9a850b81"
      unitRef="usd">-660000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtMS0xLTEtMTE4ODMz_2bcd31c2-be8b-49cc-a9e7-09da45524a27"
      unitRef="usd">2260000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtMy0xLTEtMTE4ODMz_c806d886-8758-4643-90ed-f25900df941d"
      unitRef="usd">1724000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzMtNS0xLTEtMTE4ODMz_7246857d-57b7-4833-b79d-faa99ca623cd"
      unitRef="usd">581000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtMS0xLTEtMTE4ODMz_d7efa813-d636-4df5-8a75-d57d96b3c507"
      unitRef="usd">1141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtMy0xLTEtMTE4ODMz_56598a2f-298b-4089-bc11-fa56c666a5e4"
      unitRef="usd">1076000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowZjVlMzM0ZmNhNjY0OTY0OWNmN2ZiMzg2ZDA3YmRlZC90YWJsZXJhbmdlOjBmNWUzMzRmY2E2NjQ5NjQ5Y2Y3ZmIzODZkMDdiZGVkXzQtNS0xLTEtMTE4ODMz_0177d2c1-6bb7-43f8-ab1d-0ab79fc59e68"
      unitRef="usd">-79000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NzQ_c16d6fc6-0dce-4805-9495-0c004d5a6dd1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The related expense (benefit) for income taxes consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtMS0xLTEtMTE4ODMz_78e7da50-0a62-4c4b-a1be-fde6675f88f6"
      unitRef="usd">51000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtMy0xLTEtMTE4ODMz_91cac78d-4e73-471f-a0c8-a5f3058a6c7a"
      unitRef="usd">18000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzMtNS0xLTEtMTE4ODMz_b6738c17-2231-487b-9a2c-435eedb167f3"
      unitRef="usd">-29000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtMS0xLTEtMTE4ODMz_0c770ca6-ad90-4867-aaf2-491eac03407d"
      unitRef="usd">19000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtMy0xLTEtMTE4ODMz_85c17eec-603b-4395-87f0-1c3a74b1e572"
      unitRef="usd">33000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzQtNS0xLTEtMTE4ODMz_73ac92ff-1a2a-4e82-afda-27dc1e30114a"
      unitRef="usd">-35000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtMS0xLTEtMTE4ODMz_2ab16d1f-a351-4886-b75a-822ac43cfcab"
      unitRef="usd">381000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtMy0xLTEtMTE4ODMz_c1ed0560-591d-4eb8-bd42-f8b8cfec2aef"
      unitRef="usd">127000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzUtNS0xLTEtMTE4ODMz_47ad92f7-ff91-4417-90d2-41fa24bc51d8"
      unitRef="usd">151000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtMS0xLTEtMTE4ODMz_cd87c7ae-9452-49ff-b497-63fd5270481b"
      unitRef="usd">451000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtMy0xLTEtMTE4ODMz_1b746f5b-e55d-4a49-83ac-cb6ab5d73d2b"
      unitRef="usd">178000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzYtNS0xLTEtMTE4ODMz_e8b624fa-e403-4cf6-b0bf-305e8aa9dca3"
      unitRef="usd">87000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktMS0xLTEtMTE4ODMz_04771791-cc32-4ffe-bebb-a7ad883d0f10"
      unitRef="usd">-92000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktMy0xLTEtMTE4ODMz_1ddd72eb-dfad-42f7-b643-2073a10d6481"
      unitRef="usd">-256000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzktNS0xLTEtMTE4ODMz_be6344d2-5217-4858-859e-48ec55fee0ef"
      unitRef="usd">-26000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTEtMS0xLTExODgzMw_c622f76d-1013-437a-8ec2-83691a614089"
      unitRef="usd">-32000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTMtMS0xLTExODgzMw_49bbac57-1fc8-4ef4-8676-81d6dacc5e85"
      unitRef="usd">-3000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEwLTUtMS0xLTExODgzMw_7d2466d8-35b9-4d8c-b0d8-d866d34bbd43"
      unitRef="usd">-6000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTEtMS0xLTExODgzMw_c7dda380-eb71-4ab2-b1a8-0b9cfa7625d1"
      unitRef="usd">117000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTMtMS0xLTExODgzMw_dc159eb0-18a1-4725-92bf-55f57125d975"
      unitRef="usd">117000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzExLTUtMS0xLTExODgzMw_ddb73b61-0d8b-49d4-bef8-5eafe414cda4"
      unitRef="usd">-53000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTEtMS0xLTExODgzMw_de9bf542-e3cb-4c92-ba8b-661312d274da"
      unitRef="usd">-7000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTMtMS0xLTExODgzMw_b906404b-2910-4574-8c75-1f22b66388ff"
      unitRef="usd">-142000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEyLTUtMS0xLTExODgzMw_63c9bc93-2055-4e0c-a7ce-ed1ab9f80d23"
      unitRef="usd">-85000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTEtMS0xLTExODgzMw_7be8ed30-aba6-41ca-b7a7-1c80d0234de4"
      unitRef="usd">443000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTMtMS0xLTExODgzMw_0d511bf3-e33c-4b60-9e7c-334dfe005393"
      unitRef="usd">36000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTpkNDAwMzQ3OWY2Nzc0YTE5ODQ5MWM4MDBiM2ZiNDE4Mi90YWJsZXJhbmdlOmQ0MDAzNDc5ZjY3NzRhMTk4NDkxYzgwMGIzZmI0MTgyXzEzLTUtMS0xLTExODgzMw_0ed48d6f-c547-42b4-a25c-74402326f312"
      unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4NjA_e215e1df-0f6c-4ad2-bbd3-cb3474787960">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intra-entity asset transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtMS0xLTEtMTE4ODMz_0dea4582-bd8e-4e58-b2b3-adca008705b8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtMy0xLTEtMTE4ODMz_71851afc-314e-4e5d-bb02-9e3f7a0d9be6"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzMtNS0xLTEtMTE4ODMz_58235e10-fc35-4a48-bab3-dbdea623b58e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtMS0xLTEtMTE4ODMz_c3607961-b4b4-4bb5-8781-82d5b7c0f5cb"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtMy0xLTEtMTE4ODMz_77269e1d-54c6-41e8-8035-f06f4e0b9497"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzQtNS0xLTEtMTE4ODMz_1b331f9c-8b92-4e63-af5c-6d5dedbc2151"
      unitRef="number">0.166</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtMS0xLTEtMTE4ODMz_62ac2f38-d91a-41f9-8b7f-69ed73ca25e7"
      unitRef="number">0.153</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtMy0xLTEtMTE4ODMz_5a0a0c6b-7479-49b0-a92e-96a438ac8954"
      unitRef="number">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzUtNS0xLTEtMTE4ODMz_eb7d72b0-ac83-483a-a7db-b32311b9a5d1"
      unitRef="number">1.554</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtMS0xLTEtMTE4ODMz_b3a8130d-b259-4563-8c6c-f1dddb8df7dc"
      unitRef="number">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtMy0xLTEtMTE4ODMz_21709c2d-e2f5-4d4e-9770-0f6d94b293f8"
      unitRef="number">-0.143</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzYtNS0xLTEtMTE4ODMz_07a818f1-d84d-43db-b4c4-05bf28c96623"
      unitRef="number">-0.407</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctMS0xLTEtMTE4ODMz_b38cc859-76ff-49c9-aeb5-ccc60397de0c"
      unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctMy0xLTEtMTE4ODMz_7ed55679-1aa6-466f-b6f7-0cb4bc71f954"
      unitRef="number">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzctNS0xLTEtMTE4ODMz_4db9b94f-52b7-4633-8ea8-76585bad26a7"
      unitRef="number">-0.167</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtMS0xLTEtMTE4ODMz_300d6d06-1194-4268-8435-b7d085584729"
      unitRef="number">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtMy0xLTEtMTE4ODMz_36b245a4-d6f5-4731-bc4b-53489cf8092e"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzgtNS0xLTEtMTE4ODMz_00b9b1c9-b07b-42b2-9999-ef2ad1fedbdb"
      unitRef="number">0.430</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktMS0xLTEtMTE4ODMz_24caf452-6b18-42e0-9a5b-03084c056efd"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktMy0xLTEtMTE4ODMz_3c544a91-2c30-43fc-a6c1-89ca41223317"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzktNS0xLTEtMTE4ODMz_310cff4d-14e6-46f5-b043-fc5f35509849"
      unitRef="number">-0.420</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTEtMS0xLTExODgzMw_03c507f2-aef3-472f-a736-f7d8ba84cff4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTMtMS0xLTExODgzMw_2ac29703-529a-4034-a059-56797ba0e46c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzExLTUtMS0xLTExODgzMw_a03efb2e-f490-4be3-841c-dcf5ba8b08cb"
      unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTEtMS0xLTExODgzMw_b17c498f-fa04-4907-95df-e0bf84e44e05"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTMtMS0xLTExODgzMw_e17b3efd-7b41-44bf-80e1-c18240fdda28"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEyLTUtMS0xLTExODgzMw_69a9d642-8540-4b48-8cd5-490be924f9c2"
      unitRef="number">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTEtMS0xLTExODgzMw_fb47a69d-1e60-44a3-b82f-314252da6f52"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTMtMS0xLTExODgzMw_28ab0e67-54a9-456f-b830-bdac3ed7b915"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzEzLTUtMS0xLTExODgzMw_0016c6cc-6ba2-4059-b211-897482194bbd"
      unitRef="number">0.644</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTEtMS0xLTExODgzMw_919ba8c4-6dcb-4ccf-b425-165cc9500f8f"
      unitRef="number">0.077</bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions>
    <bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTMtMS0xLTExODgzMw_32faeb99-38fe-4465-b3f0-a5f3efb56b07"
      unitRef="number">0.012</bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions>
    <bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE0LTUtMS0xLTExODgzMw_e4929989-a5c3-46e7-97be-eb37299ce149"
      unitRef="number">-0.968</bsx:EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions>
    <bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTEtMS0xLTExODgzMw_c98a56b4-d601-4689-a28f-41ed38c5cd82"
      unitRef="number">0</bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers>
    <bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTMtMS0xLTExODgzMw_6b276b5d-932f-4fd0-bd3e-a5dc2d379a2b"
      unitRef="number">0</bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers>
    <bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE1LTUtMS0xLTExODgzMw_54c965a9-ac4b-4330-8b24-326f355de070"
      unitRef="number">0.102</bsx:EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers>
    <bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTEtMS0xLTExODgzMw_36096024-b6fb-4484-a04c-854cdbe1c485"
      unitRef="number">-0.021</bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTMtMS0xLTExODgzMw_2e00cc2c-b5e3-4e8a-999c-4fc8702e7299"
      unitRef="number">-0.057</bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE2LTUtMS0xLTExODgzMw_2a7501c1-a54d-4711-ba0a-67d487ee5e55"
      unitRef="number">-0.373</bsx:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTEtMS0xLTExODgzMw_aa7bff79-1146-49e7-87c6-e81209b55c1e"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTMtMS0xLTExODgzMw_1e6ad666-f6d6-42d0-8d5c-8fcf2ba8aab6"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE3LTUtMS0xLTExODgzMw_94439d77-021f-422f-9d37-2874427a5264"
      unitRef="number">0.518</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTEtMS0xLTExODgzMw_8769b4f8-9c44-4739-83f9-1c93d18f2e88"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTMtMS0xLTExODgzMw_97647833-f0aa-4b89-9ce0-bcad4b9c0c4b"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE4LTUtMS0xLTExODgzMw_2fd35722-5063-4473-b0c2-522826e6bc0c"
      unitRef="number">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTEtMS0xLTExODgzMw_5889a5d3-4d62-4e0d-8871-be65f4bef6b4"
      unitRef="number">0.389</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTMtMS0xLTExODgzMw_962dd581-b4fa-4307-9a1f-ec5ac9c2cb02"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo1ODQ4Mzk3MDk3YmM0M2E2OGY4Mzk2YjViZjczYzRiOC90YWJsZXJhbmdlOjU4NDgzOTcwOTdiYzQzYTY4ZjgzOTZiNWJmNzNjNGI4XzE5LTUtMS0xLTExODgzMw_6ebdaf61-b491-4c6a-af5f-ef3a76fa8076"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc5MjA_1d71f569-c9ef-409f-8cdc-06aed17a2cb6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory costs and related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit of net operating losses and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and product liability reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal benefit of uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains and losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid on intercompany profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Net Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,062&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid on intercompany profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Tax Assets and Prepaid on Intercompany Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,062&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzMtMS0xLTEtMTE4ODMz_4abfdc23-48b1-4562-84b3-9573ccd30951"
      unitRef="usd">19000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzMtMy0xLTEtMTE4ODMz_94cc7ef8-ee77-4708-80b5-d22f578d7047"
      unitRef="usd">10000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzQtMS0xLTEtMTE4ODMz_616158a1-3771-4619-93a2-f109b44b332f"
      unitRef="usd">511000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzQtMy0xLTEtMTE4ODMz_351e6ecd-85ed-4909-b112-b23bc98a931c"
      unitRef="usd">620000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzUtMS0xLTEtMTE4ODMz_536d4b48-147c-40b6-9661-a4792aedd302"
      unitRef="usd">304000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzUtMy0xLTEtMTE4ODMz_319615ad-0089-49e6-87df-8b1db1d32b45"
      unitRef="usd">324000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzYtMS0xLTEtMTE4ODMz_a189ce9f-a40d-4fe1-9ebd-0653edbb04d5"
      unitRef="usd">6000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzYtMy0xLTEtMTE4ODMz_30f52617-ebc5-4cc5-be9e-131ba55f5c7e"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzctMS0xLTEtMTE4ODMz_e10dd7c8-7c6e-4129-b527-8ef5e89a4953"
      unitRef="usd">103000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzctMy0xLTEtMTE4ODMz_fe581940-5563-4536-bb74-baee638b8729"
      unitRef="usd">127000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzgtMS0xLTEtMTE4ODMz_c8292301-8901-41b4-b4af-9075a1a46646"
      unitRef="usd">38000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzgtMy0xLTEtMTE4ODMz_6432a172-cd91-4a11-9361-834060086eae"
      unitRef="usd">31000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzktMS0xLTEtMTE4ODMz_a789c2ca-f21c-4c54-9a01-72f80b71edfe"
      unitRef="usd">136000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzktMy0xLTEtMTE4ODMz_8b27e289-216f-48e9-910f-976dba95ff60"
      unitRef="usd">130000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bsx:FederalBenefitOfUncertainTaxPositions
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEwLTEtMS0xLTExODgzMw_12c46dc5-a24e-4057-bae2-6b99529b7ace"
      unitRef="usd">9000000</bsx:FederalBenefitOfUncertainTaxPositions>
    <bsx:FederalBenefitOfUncertainTaxPositions
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEwLTMtMS0xLTExODgzMw_3c82f105-d4ab-45ab-9295-003ea6eb979e"
      unitRef="usd">8000000</bsx:FederalBenefitOfUncertainTaxPositions>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzExLTEtMS0xLTExODgzMw_663aebd1-d704-4b6a-bbbd-4360ed871155"
      unitRef="usd">3668000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzExLTMtMS0xLTExODgzMw_d42e2bdd-6709-465a-ac42-e02d6e905889"
      unitRef="usd">3546000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEyLTEtMS0xLTExODgzMw_f0187864-c948-4ede-9558-b9c82e70ef89"
      unitRef="usd">160000000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEyLTMtMS0xLTExODgzMw_976758b3-f759-4933-96dc-aab46460ad84"
      unitRef="usd">67000000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEzLTEtMS0xLTExODgzMw_24e51e7a-84bb-45a2-bc49-778e022cbf9d"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzEzLTMtMS0xLTExODgzMw_97151204-ea2d-49e8-93a2-c26a94d30248"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE0LTEtMS0xLTExODgzMw_8848bf52-2731-45ce-b2cf-7bd13ad6659e"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE0LTMtMS0xLTExODgzMw_3eb32142-257d-4ad1-98fe-20e0c5c669a8"
      unitRef="usd">35000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE1LTEtMS0xLTExODgzMw_253b3ed9-68fb-4c7b-875c-337fab901fa5"
      unitRef="usd">4954000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE1LTMtMS0xLTExODgzMw_85f18148-2f06-4325-a7ea-9a812c819fab"
      unitRef="usd">4926000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE2LTEtMS0xLTExODgzMw_1935fa88-7676-436f-9916-f0ecabd63c9c"
      unitRef="usd">1004000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE2LTMtMS0xLTExODgzMw_6b606b9f-3db9-45c3-8182-f8da8ada61c6"
      unitRef="usd">1014000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE3LTEtMS0xLTExODgzMw_a60416cb-223e-4251-9e66-75906a06e2ae"
      unitRef="usd">3950000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzE3LTMtMS0xLTExODgzMw_51b09533-e986-43c1-bb77-9f0386fcb873"
      unitRef="usd">3912000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIwLTEtMS0xLTExODgzMw_3961ccdc-0061-45b1-8689-5941e9d9a22b"
      unitRef="usd">117000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIwLTMtMS0xLTExODgzMw_efc1dea5-e80e-4322-8f29-91fb07bfc3aa"
      unitRef="usd">79000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTEtMS0xLTE3NjIyMg_b4c28bc2-9d0b-45e5-b8aa-6699c7538215"
      unitRef="usd">34000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTMtMS0xLTE3NjIyMg_7d2868e6-74a8-4a7b-9391-615e910e3b87"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTEtMS0xLTExODgzMw_ca088838-bffb-49e0-82e6-ebef1debf93b"
      unitRef="usd">151000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzIyLTMtMS0xLTExODgzMw_2825ae3f-0039-44a4-9cb5-1066e63d71e5"
      unitRef="usd">79000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI0LTEtMS0xLTExODgzMw_e9330750-493a-451b-bae3-82ccec578179"
      unitRef="usd">3799000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI0LTMtMS0xLTExODgzMw_6f951b52-bab5-4cbe-a40a-f02f74752ab3"
      unitRef="usd">3833000000</us-gaap:DeferredTaxAssetsGross>
    <bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI1LTEtMS0xLTExODgzMw_7cf0201a-34f1-473b-ab3b-e05bdd171691"
      unitRef="usd">264000000</bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit>
    <bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI1LTMtMS0xLTExODgzMw_d85df5d7-b4a1-40fc-8168-f5c87c574a71"
      unitRef="usd">205000000</bsx:DeferredTaxAssetsPrepaidonIntercompanyProfit>
    <bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI2LTEtMS0xLTExODgzMw_742fae42-91aa-459c-bb34-e06f307809ff"
      unitRef="usd">4062000000</bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit>
    <bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZToyMGFjNTQ0MWJkM2Y0NGU0ODg2ZjllMjQ2ZWIxNTMyMS90YWJsZXJhbmdlOjIwYWM1NDQxYmQzZjQ0ZTQ4ODZmOWUyNDZlYjE1MzIxXzI2LTMtMS0xLTExODgzMw_74ac750c-ac3b-4450-8b66-cca2c5216519"
      unitRef="usd">4038000000</bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i9a7c693c1ad044d5b5d785d5431ee0a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzItMi0xLTEtMTE4ODMz_b87ae755-026b-45b2-8b23-d9e8ecfadb54"
      unitRef="usd">264000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1500544395e942a291c9853a03d49cd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzItNC0xLTEtMTE4ODMz_4244b1ef-8447-4741-9e27-16c226553f4a"
      unitRef="usd">205000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8a5c980151684785bcfcbb6bbe9b77cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzQtMi0xLTEtMTE4ODMz_6c3186aa-4488-4564-93a9-6d0f261a6ba1"
      unitRef="usd">3942000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie2eb60a7197b4e5da1ffad49a2eee8b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzQtNC0xLTEtMTE4ODMz_7681420b-f6d5-4419-999a-c2a85850bc6d"
      unitRef="usd">4142000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzUtMi0xLTEtMTE4ODMz_56081fd3-9d9a-441e-900a-257e24d663df"
      unitRef="usd">4206000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzUtNC0xLTEtMTE4ODMz_ae68b467-c815-43c6-8199-b6e7dbbadfc6"
      unitRef="usd">4348000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2cbe628c58a04e7ab7e6559ead7b48e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzctMi0xLTEtMTE4ODMz_616be3b7-934b-4d65-a61d-a9d79b095a9c"
      unitRef="usd">144000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i277df0ecaf304cf08357801c32ae2706_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzctNC0xLTEtMTE4ODMz_548c74ab-1db7-4449-a59c-35ca529d6e92"
      unitRef="usd">310000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzktMi0xLTEtMTE4ODMz_6f43649e-fce0-44da-8188-1fb4c88e3319"
      unitRef="usd">144000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzktNC0xLTEtMTE4ODMz_5bda5863-d8d1-4188-9b60-bbbf79fe3dec"
      unitRef="usd">310000000</us-gaap:DeferredTaxLiabilities>
    <bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzExLTItMS0xLTExODgzMw_ffec5eab-a8c8-4146-a093-a97c8b8694e5"
      unitRef="usd">4062000000</bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit>
    <bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTowYzUxOGEyM2VhOTU0Yzk5YmExYTM3OWQ1MmFiMzQxNS90YWJsZXJhbmdlOjBjNTE4YTIzZWE5NTRjOTliYTFhMzc5ZDUyYWIzNDE1XzExLTQtMS0xLTExODgzMw_e26247d1-c0bd-4f00-aded-184f046d4fb7"
      unitRef="usd">4038000000</bsx:NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzg2OQ_54d2b640-1dee-4e4c-975c-caa11e3ca52a"
      unitRef="usd">464000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzk5NQ_000cb8ed-d3cb-43a9-838f-2ab68c1d94fb"
      unitRef="usd">560000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzExMDk_8815ad59-5703-4d2a-b783-dc193fbb5175"
      unitRef="usd">47000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzExMzc_9885d172-c2fa-4fc1-9279-6c3ecccf88c3"
      unitRef="usd">60000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxNzk_1935fa88-7676-436f-9916-f0ecabd63c9c"
      unitRef="usd">1004000000.000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTU_6b606b9f-3db9-45c3-8182-f8da8ada61c6"
      unitRef="usd">1014000000.000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI1NTI_7d70d945-e163-4ecf-b687-f0bb4398e368"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI1NzU_5e9a1a90-cd74-4c9d-b520-f3a22e8d7106"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI2MDA_2e274574-6ded-4419-8669-4c4698134971"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <bsx:FreeTradeZoneRegimeTaxIncentive
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI4OTE_c1ea43b1-d746-4862-a572-c1d854a6eb60"
      unitRef="usd">162000000</bsx:FreeTradeZoneRegimeTaxIncentive>
    <bsx:FreeTradeZoneRegimeTaxIncentive
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI5MDI_45082b36-d414-4853-8187-11242bb9681c"
      unitRef="usd">149000000</bsx:FreeTradeZoneRegimeTaxIncentive>
    <bsx:FreeTradeZoneRegimeTaxIncentive
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzI5MTY_9e56f84d-f420-4781-b7af-8c7d8f5e5124"
      unitRef="usd">64000000</bsx:FreeTradeZoneRegimeTaxIncentive>
    <bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxMjE_715fda15-9ae4-483a-b135-9a908ef06639"
      unitRef="usdPerShare">0.11</bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution>
    <bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxMzI_0fd77311-82cb-4d01-aa52-f34b796f7b90"
      unitRef="usdPerShare">0.10</bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution>
    <bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMxNDY_006d6ca5-bb28-4224-8a33-477fcb4ef969"
      unitRef="usdPerShare">0.04</bsx:FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution>
    <bsx:TaxIncentivesInPuertoRico
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMyNTI_7df2e0d1-c521-4d97-8661-e74f9c51315c"
      unitRef="usd">21000000</bsx:TaxIncentivesInPuertoRico>
    <bsx:TaxIncentivesInPuertoRico
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMyNjM_b6d6935e-9062-4e8d-8940-3495d5b7fef1"
      unitRef="usd">27000000</bsx:TaxIncentivesInPuertoRico>
    <bsx:TaxIncentivesInPuertoRico
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU0OTc1NTgyMTg1MA_60d32ca7-909f-4955-8f21-ee823086e431"
      unitRef="usd">30000000</bsx:TaxIncentivesInPuertoRico>
    <bsx:TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzMzNzc_8d45cd52-4573-43f7-81c7-794455510644"
      unitRef="usdPerShare">0.02</bsx:TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution>
    <bsx:TaxIncentivesInMalaysia
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzE2NDkyNjc0NTQwMTA_b18dd4d7-396d-43ce-b5fa-e8e485a09481"
      unitRef="usd">17000000</bsx:TaxIncentivesInMalaysia>
    <bsx:TaxIncentivesInMalaysia
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzAzODk_3b87cf86-5ab9-49b1-81ac-c97a4b0948ae"
      unitRef="usd">0</bsx:TaxIncentivesInMalaysia>
    <bsx:TaxIncentivesInMalaysia
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzAzODk_a6877b04-5703-4a69-a0c6-7375c9b9fc50"
      unitRef="usd">0</bsx:TaxIncentivesInMalaysia>
    <bsx:TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzIxOTkwMjMyNzA0MjE_d64d97bd-7ad4-4995-81c6-6925b626cbdc"
      unitRef="usdPerShare">0.01</bsx:TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM0Mzg_0e63c4dd-97a1-4168-997e-968f488a14f2"
      unitRef="usd">492000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM0OTI_6a173bcc-0f8e-4f76-9667-2094b9e33edf"
      unitRef="usd">410000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM1NjU_b24d2e25-479a-4aef-b6b3-bcebc029b4cd"
      unitRef="usd">255000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM2MTk_05afb518-1e02-41c5-9137-b615b8a70ec6"
      unitRef="usd">177000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM2OTI_a022fdbd-8e0b-4521-9996-3ff2d2677136"
      unitRef="usd">261000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzM3NDY_3ca71723-0a76-4d1b-830f-7609751c0561"
      unitRef="usd">183000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2Xzc4OTA_f3ffdf96-b223-493f-92af-9363abde3645">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItMS0xLTEtMTE4ODMz_8d2580ef-83e4-4a6a-95bb-11382beafcba"
      unitRef="usd">255000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItMy0xLTEtMTE4ODMz_ac7d30a0-c8f2-4ab3-9f3a-975dfd4fe98d"
      unitRef="usd">261000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzItNS0xLTEtMTE4ODMz_75add5e7-64ca-4d18-ac60-7c1df70bac9b"
      unitRef="usd">455000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtMS0xLTEtMTE4ODMz_1a3d699f-9a3a-48d0-b5d1-bb4ce386ad25"
      unitRef="usd">88000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtMy0xLTEtMTE4ODMz_4a41cf0d-1ee5-4b77-8bc5-dfb7cdbf7849"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzMtNS0xLTEtMTE4ODMz_81435f67-51d3-4455-a661-327790d0f41c"
      unitRef="usd">28000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtMS0xLTEtMTE4ODMz_a26f34b8-f78b-408a-ad6c-36e49be7cab2"
      unitRef="usd">177000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtMy0xLTEtMTE4ODMz_85cdcda3-8814-4162-8921-9bf32f9a7a60"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzQtNS0xLTEtMTE4ODMz_9f0159f1-3932-425c-bddc-d86d29617ef4"
      unitRef="usd">6000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtMS0xLTEtMTE4ODMz_cccde21c-7116-41d9-bc11-2bc6ed3424f7"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtMy0xLTEtMTE4ODMz_2327e63a-33b5-4dbf-b3bd-50fef07fb12f"
      unitRef="usd">36000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzUtNS0xLTEtMTE4ODMz_3e2d6547-eff7-475b-97d1-2926eeebc2bf"
      unitRef="usd">186000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtMS0xLTEtMTE4ODMz_0dbc3e86-0ff9-4d3e-806e-ad2a44b2b2f0"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtMy0xLTEtMTE4ODMz_62a1209c-fc94-4c78-80db-76e9c9775bbb"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzYtNS0xLTEtMTE4ODMz_a296bbd1-0bbc-4849-b241-cbcad759b09f"
      unitRef="usd">27000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctMS0xLTEtMTE4ODMz_ea6348f7-37f9-4f79-b229-8fcfbe78f20e"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctMy0xLTEtMTE4ODMz_453239d4-5ce7-4dbd-a6da-ffd0639705f9"
      unitRef="usd">17000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzctNS0xLTEtMTE4ODMz_d1a17391-8853-477b-aaec-182b693952ea"
      unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtMS0xLTEtMTE4ODMz_0e63c4dd-97a1-4168-997e-968f488a14f2"
      unitRef="usd">492000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtMy0xLTEtMTE4ODMz_b24d2e25-479a-4aef-b6b3-bcebc029b4cd"
      unitRef="usd">255000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90YWJsZTo2MjllNWJhM2RmZWU0NTEyYWIwMTk3OWRmMjJlMjY3Yy90YWJsZXJhbmdlOjYyOWU1YmEzZGZlZTQ1MTJhYjAxOTc5ZGYyMmUyNjdjXzgtNS0xLTEtMTE4ODMz_a022fdbd-8e0b-4521-9996-3ff2d2677136"
      unitRef="usd">261000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="i1a2e7463fa724bcf9a0461181ceba4f2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ1ODM_ad93f46d-4a38-4982-8098-176ad5fd9916"
      unitRef="usd">91000000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ2NTg_acd6dfa3-47d9-49ba-8cd0-6b165fd9da48"
      unitRef="usd">62000000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ5MDI_0e8689b8-c1e6-4b8e-9afa-aaf6af2c4a58"
      unitRef="usd">77000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzQ5NTk_7cb92c4d-e72e-413f-9be2-5b5c41d537b9"
      unitRef="usd">43000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU0NzM_c28592a8-d50f-4412-b22f-70cee0c15fa9"
      unitRef="usd">75000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU4MTM_f3237835-91de-4b0b-a523-88135228bc2e"
      unitRef="usd">937000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzU4NTU_940dbc4f-9e63-4e6a-ad2a-87766575fb1b"
      unitRef="usd">938000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <bsx:Onetimetransactiontaxpost1986EPnetpayment
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYwMDI_f284dc7c-0af1-475a-897a-3dfb9348604f"
      unitRef="usd">586000000</bsx:Onetimetransactiontaxpost1986EPnetpayment>
    <bsx:TransitionTaxPaymentRemaining
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYxNDM_75657871-91a9-41cd-a14f-6bd0661967e3"
      unitRef="usd">386000000</bsx:TransitionTaxPaymentRemaining>
    <bsx:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjcvZnJhZzo5YTlhYzEyNWQxMTE0NDA4YTllZDI2NTFkZDcwNGEyNi90ZXh0cmVnaW9uOjlhOWFjMTI1ZDExMTQ0MDhhOWVkMjY1MWRkNzA0YTI2XzYyMTc_b501f0b9-0dc4-4ad4-9dc0-40cff1460846"
      unitRef="usd">14000000</bsx:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI4ODEz_7188ae13-3909-4936-890f-50173556570f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE I &#x2013; COMMITMENTS AND CONTINGENCIES &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accrual for legal matters that are probable and estimable was $443 million as of December&#160;31, 2022, and $548 million as of December&#160;31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $149 million as of December&#160;31, 2022, and $188 million as of December&#160;31, 2021. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note A &#x2013; Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook&#x2019;s Instinct&#x2122; Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to &#x201c;Drug Releasing Biodegradable Fiber Implant&#x201d; and &#x201c;Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,&#x201d; and affects the manufacture, use and sale of our Synergy&#x2122; Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT&#x2019;s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT&#x2019;s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs&#x2019; counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental Investigations and Qui Tam Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a &#x201c;technical note,&#x201d; announced that it was launching a formal administrative proceeding against Boston Scientific&#x2019;s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB&#x2019;s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor&#x2019;s office issued a non-binding recommendation that is contrary to the Attorney General&#x2019;s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge&#x2122; Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company&#x2019;s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission&#x2019;s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company&#x2019;s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company&#x2019;s Board of Directors conduct an investigation into actions by the Company&#x2019;s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Matters Concluded Since December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen&#x2019;s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG&#x2019;s motion to dismiss the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action. On January 10, 2022, the court granted the parties&#x2019; stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza&#x2122; Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro&#x2019;s Senza&#x2122; I and Senza&#x2122; II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company&#x2019;s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above. &lt;/span&gt;&lt;/div&gt;The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI4ODE1_a33a4ba9-ad69-475a-a532-90018fb3b78b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.&lt;/span&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzM5MTY_5be21b9f-038d-4a29-aa42-d0e7fc41f8a2"
      unitRef="usd">443000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzM5MzI_75be31b2-8393-4930-b72a-812514bed154"
      unitRef="usd">548000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzU0OTc1NTg0MzA5NA_18564728-962a-4076-8e52-d57f3434dc4b"
      unitRef="usd">149000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzU0OTc1NTg0MzExMg_c196f8a8-60d3-485c-af7d-26b8188af1ea"
      unitRef="usd">188000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI3NDg3NzkxNDczOTc_d068eb83-3be8-4c56-ac48-9c35055ceca8"
      unitRef="usd">173000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzQ0Njg_829e2a18-cd26-4fed-bb43-605f73a998ee"
      unitRef="usd">430000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzI3NDg3NzkxNDc0NzM_05edd9e6-d2ca-4592-94cf-3e4067f055fa"
      unitRef="usd">278000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="id15f114eb8804a7c98bcd09d92bb0633_D20230131-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzE2NDkyNjc2MDUzODc_efdd0bfa-f44b-4c4f-a3b2-f733f2150b42"
      unitRef="usd">42000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bsx:BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzE2NDkyNjc2MDQyNDg_ec767b12-d0b4-472b-89bf-5de8a91f74e4"
      unitRef="unit">29</bsx:BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i3290f9f23eb24119a72f6930eead5d1f_D20220805-20220805"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzAvZnJhZzoyMjA3ZTMyNzcyZmM0NDUxYWE3ZWU1ZmNjY2JmZjEwYi90ZXh0cmVnaW9uOjIyMDdlMzI3NzJmYzQ0NTFhYTdlZTVmY2NjYmZmMTBiXzIxOTkwMjM0MjUwNTM_7355d78d-3b0b-4628-9c21-c14143975ade"
      unitRef="usd">85000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUxMjA_0cadb0ff-b3c2-4a3d-8c04-ee2d38ff8fa9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE J &#x2013; STOCKHOLDERS' EQUITY &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December&#160;31, 2022, our MCPS had an aggregate liquidation preference of $1.006&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated balance sheets as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were approximately 263 million shares in treasury as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzU1_caa7c9e2-2af6-4609-91e2-269e2e416c98"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ3MQ_3630d34c-9f74-4dd6-bf23-4c795701ee3d"
      unitRef="shares">10062500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ4NA_344c1515-16fa-4b90-bc00-0b27605e7155"
      unitRef="number">0.0550</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="i23afc4468fc44cc5a8c3bd55cf2316a4_I20200527"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzU5Nw_11c42865-7f2f-4ecb-a337-fe08268f44b8"
      unitRef="usdPerShare">100</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzY3MA_c96b75f3-d507-4957-aa82-3fa30699ffe0"
      unitRef="usd">975000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzgxMw_2fdde4e5-9374-4c0c-82d1-b796d349bff2"
      unitRef="usd">1006000000.000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="i616a124eb56f4d46a04c22dff6341e4d_D20200527-20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzEwMzg_344c1515-16fa-4b90-bc00-0b27605e7155"
      unitRef="number">0.0550</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzEwNzQ_8796ae78-b063-462b-afa7-6457e8c3da01"
      unitRef="usdPerShare">100</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="i62bc5e62d5db4d23866e0c44a56c5628_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzIxODI_8796ae78-b063-462b-afa7-6457e8c3da01"
      unitRef="usdPerShare">100</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="if23c296459144875ad187e30e952915b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzIzOTk_0192e9fb-a87f-45f4-b436-14fcaa6706db">2.3834</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="ifada2c5db8c74b0f917945eda6797be6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzI0MDY_3126e34f-d8de-4d23-b067-cd9af3acd005">2.9197</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:DividendsCash
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzI3NDg3NzkwNzQ2MjA_e30a8a74-7730-4c8d-8025-e560cb955db1"
      unitRef="usd">14000000</us-gaap:DividendsCash>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="ic53ca80353df4a95be28f72ebdb9ce41_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzMzNDU_68ccecee-6dd8-414a-bdce-876e557aa134"
      unitRef="usdPerShare">1.3750</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="ia6805ad1bd72431da0294f8b9f787280_D20230130-20230130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM0OTE_1008b7dc-8f97-4e08-abda-950030b7d445"
      unitRef="usdPerShare">1.3750</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM3Njg_7eeba664-8b9f-43ce-84f9-2e94ba990058"
      unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzM3OTU_b5f4a32d-898c-4e1b-9749-cfb57371aab8"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i91bed8161679460e856d9920088ac04a_D20200527-20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ1MzE_990bcb99-24fc-43dd-9e8f-29aea16b9ea1"
      unitRef="shares">29382500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i6bf3f5d8a9e54dd79aaa2d19b5e4aff0_I20200527"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ1ODc_ce359981-f592-4851-9cda-1d89417272d0"
      unitRef="usdPerShare">34.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i91bed8161679460e856d9920088ac04a_D20200527-20200527"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzQ2Njg_34e43545-50df-4faa-ac10-d92c6d658cd1"
      unitRef="usd">975000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNTI_cd929929-681f-4baa-8a3e-d3520fb2a7f7"
      unitRef="shares">15700000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNTg_0d0bbcde-aed9-4825-a4cc-b8d4776ec5b5"
      unitRef="usd">535000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i182a1036891e4f75bb208c20f52223a2_I20201214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUwNjc_4acc290c-6cfa-45bf-9182-3255e2ada51a"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockShares
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzMvZnJhZzo0MzFkYmNhYmU0N2Q0Y2JjOWMwMjFmMGIwNGFjMDBlMS90ZXh0cmVnaW9uOjQzMWRiY2FiZTQ3ZDRjYmM5YzAyMWYwYjA0YWMwMGUxXzUxMDE_9b2caf1f-b333-4d2f-8d85-4ab4ef086a7d"
      unitRef="shares">263000000</us-gaap:TreasuryStockShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTcy_007986a1-055d-4bb9-a265-71bd33c36f8a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE K &#x2013; STOCK INCENTIVE AND PURCHASE PLANS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee and Director Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December&#160;31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent&#160;of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following presents the impact of stock-based compensation on our consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net impact per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net impact per common share - assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years, weighted)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to stock options under stock incentive plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total vested and expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Vested Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Vested&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Award Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant-Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,987&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market-based RSU and DSU Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;amp;P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price on date of grant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free Cash Flow Performance-based RSU and DSU Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 AFCF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 AFCF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 AFCF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, net of forfeitures to date &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Achievement of target payout&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year-end stock price used in determining fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expense Attribution&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term &#x201c;forfeitures&#x201d; is distinct from &#x201c;cancellations&#x201d; or &#x201c;expirations&#x201d; and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December&#160;31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect to recognize the following future expense for awards outstanding as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Compensation Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;Amounts presented represent compensation cost, net of estimated forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee&#x2019;s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December&#160;31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued or to be issued&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range of purchase prices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expense recognized&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i08365277a86440dab883742676202e25_I20201001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzI1Mw_4ea9cd3d-7ab6-400c-9137-a75004a13675"
      unitRef="shares">171000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzY5OQ_ebbaa57e-6e55-40b5-a233-69c91abf666e"
      unitRef="shares">175000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bsx:VotingPowerOfAllClassesOfStock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEzMTk_d774ae17-9483-4558-b8d8-e553eef9c5d5"
      unitRef="number">0.10</bsx:VotingPowerOfAllClassesOfStock>
    <bsx:Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzE0MjY_2e87c8c0-5445-4a69-bf3d-1f156999f880"
      unitRef="number">1.10</bsx:Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant>
    <bsx:Nonvestedstockawardsexerciseprice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzE3MjE_293f4c51-3863-49d5-9d81-81dba2770a89"
      unitRef="usdPerShare">0</bsx:Nonvestedstockawardsexerciseprice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjE1_342645bb-f8f9-4228-9749-02eb98f526da">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following presents the impact of stock-based compensation on our consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net impact per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net impact per common share - assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="if65c415d7afe493a89650f841bc4bf30_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItMS0xLTEtMTE4ODMz_449140b0-742e-49f6-bf42-e8e9b6f382a4"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6cf9fcdaae944b3390aef4cad3b3d62a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItMy0xLTEtMTE4ODMz_37fd2443-87bd-4997-b786-05b4b3002add"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia933afd979654f88afc557688fdca523_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzItNS0xLTEtMTE4ODMz_b912fbd9-cdbd-4ed6-a9ca-42d2a5af491b"
      unitRef="usd">9000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaaae3391a8f04f3aa64456d9284c46e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtMS0xLTEtMTE4ODMz_7410cf85-654e-4b06-960f-50e9157f8c57"
      unitRef="usd">167000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i14bcf59fe7c34a8a94840e5aefc3a400_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtMy0xLTEtMTE4ODMz_78ef1021-d100-4991-b299-8004efffe10f"
      unitRef="usd">147000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic3db7e9dbfd04e5087fede77d602a86d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzMtNS0xLTEtMTE4ODMz_1f97197b-1f35-4b8b-b923-b970c237c57d"
      unitRef="usd">130000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib0af4e13a75a42c69eb0c61842136ccd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtMS0xLTEtMTE4ODMz_1a598a29-4cfd-4016-952d-6c6fc1e1fc8a"
      unitRef="usd">41000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i70ac253948f34ac7ab4ff32466a9dc4b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtMy0xLTEtMTE4ODMz_4451ab09-dcb7-43e1-8083-33c0c2d314ff"
      unitRef="usd">36000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7657382e881145e693f2f7a6e978a9cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzQtNS0xLTEtMTE4ODMz_9a79997c-cfee-4f1c-827d-9034885296a9"
      unitRef="usd">30000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtMS0xLTEtMTE4ODMz_61c927f9-8d90-4837-84ff-0d3194a039ea"
      unitRef="usd">220000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtMy0xLTEtMTE4ODMz_b694a9cd-3b44-46bd-a440-fd8eb9389e54"
      unitRef="usd">194000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzUtNS0xLTEtMTE4ODMz_c5e1d1b1-4ec1-44e3-bc7e-28f366137912"
      unitRef="usd">170000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtMS0xLTEtMTE4ODMz_208ca6aa-d7f7-420e-89e2-b9b4c7a43a28"
      unitRef="usd">32000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtMy0xLTEtMTE4ODMz_370cb5c3-fbd4-4482-adc4-33c57726b937"
      unitRef="usd">29000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzYtNS0xLTEtMTE4ODMz_8dcdfa77-0b9f-4531-99a0-8cb6cc57284e"
      unitRef="usd">28000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <bsx:ShareBasedCompensationNetOfTaxBenefit
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctMS0xLTEtMTE4ODMz_ee2d978e-657f-4ef8-a5f1-1f835cccac3c"
      unitRef="usd">188000000</bsx:ShareBasedCompensationNetOfTaxBenefit>
    <bsx:ShareBasedCompensationNetOfTaxBenefit
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctMy0xLTEtMTE4ODMz_a53e7296-20a2-4aa4-9085-bf1c8518801e"
      unitRef="usd">165000000</bsx:ShareBasedCompensationNetOfTaxBenefit>
    <bsx:ShareBasedCompensationNetOfTaxBenefit
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzctNS0xLTEtMTE4ODMz_f5e30037-bca1-4849-9277-081c39c1b293"
      unitRef="usd">142000000</bsx:ShareBasedCompensationNetOfTaxBenefit>
    <bsx:CompensationExpensePerShareBasic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtMS0xLTEtMTE4ODMz_973c5577-88c1-4258-89da-d5ed6b88cd15"
      unitRef="usdPerShare">0.13</bsx:CompensationExpensePerShareBasic>
    <bsx:CompensationExpensePerShareBasic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtMy0xLTEtMTE4ODMz_3e542cd2-183d-43ad-9d2a-7df2c873d068"
      unitRef="usdPerShare">0.12</bsx:CompensationExpensePerShareBasic>
    <bsx:CompensationExpensePerShareBasic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzgtNS0xLTEtMTE4ODMz_e7b31b99-d8b0-474b-91c6-6c640c8ebb2d"
      unitRef="usdPerShare">0.10</bsx:CompensationExpensePerShareBasic>
    <bsx:CompensationExpensePerShareDiluted
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktMS0xLTEtMTE4ODMz_39c91b74-2ca5-4afe-9493-ef571449e273"
      unitRef="usdPerShare">0.13</bsx:CompensationExpensePerShareDiluted>
    <bsx:CompensationExpensePerShareDiluted
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktMy0xLTEtMTE4ODMz_5ab4e4f9-0649-45b0-a57c-47e28fcfc253"
      unitRef="usdPerShare">0.12</bsx:CompensationExpensePerShareDiluted>
    <bsx:CompensationExpensePerShareDiluted
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDk3NWFiZjgzNmQ0NzdmOGUxZjNiNmYzY2M5NmZhZS90YWJsZXJhbmdlOmJkOTc1YWJmODM2ZDQ3N2Y4ZTFmM2I2ZjNjYzk2ZmFlXzktNS0xLTEtMTE4ODMz_b8dd8d41-7514-4ba5-a507-3119abbe39ed"
      unitRef="usdPerShare">0.10</bsx:CompensationExpensePerShareDiluted>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTYw_97e2093f-e974-44d6-b983-cb68a97347a6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years, weighted)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItMS0xLTEtMTE4ODMz_d3a67b58-677e-4b1c-85c5-b068b04c9d58"
      unitRef="shares">3287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItNS0xLTEtMTE4ODMz_3793f554-5d85-43e3-a203-97fba916169d"
      unitRef="shares">3822000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzItOS0xLTEtMTE4ODMz_2859e606-fd30-4eee-8aa7-37b4966e766d"
      unitRef="shares">3819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtMS0xLTEtMTE4ODMz_fede2232-59a6-4629-825e-6ac902f31af5"
      unitRef="usdPerShare">44.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtNS0xLTEtMTE4ODMz_42957fa2-a49f-4bda-97d9-3709371807c5"
      unitRef="usdPerShare">37.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzMtOS0xLTEtMTE4ODMz_02d73c42-303e-4b87-8998-8a64b9bbd66e"
      unitRef="usdPerShare">41.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtMS0xLTEtMTE4ODMz_2bd0f69c-8ef4-4cfe-ad23-3182b8b70022"
      unitRef="usdPerShare">13.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtNS0xLTEtMTE4ODMz_c17fc52b-a511-4409-bb04-c5eb3afee71b"
      unitRef="usdPerShare">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzQtOS0xLTEtMTE4ODMz_1131626e-be1a-44b3-84c9-20fe22496a05"
      unitRef="usdPerShare">10.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtMS0xLTEtMTE4ODMz_30217dd5-1831-46bb-90e7-fc1d7c173b0a"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtNS0xLTEtMTE4ODMz_45c47b52-7ec5-470c-9e94-cae5cade74a7"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzYtOS0xLTEtMTE4ODMz_d064afc8-2d0c-463c-b188-afefb9880415"
      unitRef="number">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctMS0xLTEtMTE4ODMz_5ca21225-fbe7-4088-8710-05d71ca16f96">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctNS0xLTEtMTE4ODMz_161a9c9a-5a63-4e31-a6cb-70ceb6724dfe">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzctOS0xLTEtMTE4ODMz_ed55a066-24bf-4e56-b8de-64fbd5277d56">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMS0xLTEtMTE4ODMz_40a3eb46-1dfb-461d-b66e-e2fe1abf120e"
      unitRef="number">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMy0xLTEtMTE4ODMz_923f0cf2-3bef-4359-9ee1-9cc263b48b13"
      unitRef="number">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaabf66c1b2184034b2b380702d5950c0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtNS0xLTEtMTE4ODMz_4d68f6cd-ea14-4570-9a66-25331215c02e"
      unitRef="number">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtNy0xLTEtMTE4ODMz_f123d363-3d68-46e6-87aa-cc59a8f7b140"
      unitRef="number">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtOS0xLTEtMTE4ODMz_1045258f-c93f-4dd5-9206-dfb6086067f0"
      unitRef="number">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i950414449291498aae88bf9cc6ecb151_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpkZDU3NGM3YjBhZDM0MjRjODkyMjBhNGQ2MmZhNjFjZC90YWJsZXJhbmdlOmRkNTc0YzdiMGFkMzQyNGM4OTIyMGE0ZDYyZmE2MWNkXzgtMTEtMS0xLTExODgzMw_0738a387-5182-45b8-bd6c-2a943e125724"
      unitRef="number">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjE5_8194e125-0ee1-4b8d-a363-e9ef3851022e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to stock options under stock incentive plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total vested and expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzktMS0xLTEtMTE4ODMz_9c1719ab-7e28-4444-86f9-87ac2e8e9cf4"
      unitRef="shares">23065000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzktMy0xLTEtMTE4ODMz_0ee7b773-9bd5-4983-93d2-96565ea709fe"
      unitRef="usdPerShare">19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEwLTEtMS0xLTExODgzMw_5062b052-e685-4277-86f5-ec8f0bfddbbb"
      unitRef="shares">3819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEwLTMtMS0xLTExODgzMw_5ac45df3-de72-4c26-ba5b-d116d198b135"
      unitRef="usdPerShare">42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzExLTEtMS0xLTExODgzMw_75247acb-5188-4b0f-bd38-cc54d6661409"
      unitRef="shares">3096000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzExLTMtMS0xLTExODgzMw_0ec1c52a-6b7b-4af0-b52b-92353be81bc7"
      unitRef="usdPerShare">13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEyLTEtMS0xLTExODgzMw_588e8fe1-aafc-41cc-a534-90f6b9283496"
      unitRef="shares">666000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEyLTMtMS0xLTExODgzMw_1ff15e93-d766-4f90-b564-2824b9021d33"
      unitRef="usdPerShare">27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEzLTEtMS0xLTExODgzMw_ab72eb6b-843a-4bb1-9edf-aa8bd826bc77"
      unitRef="shares">23122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzEzLTMtMS0xLTExODgzMw_ad63f376-0491-4939-9166-4705001a1835"
      unitRef="usdPerShare">24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE0LTEtMS0xLTExODgzMw_11b00630-11f8-4572-9f1f-1286df5c810b"
      unitRef="shares">3822000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE0LTMtMS0xLTExODgzMw_32f6aaf8-180e-4b33-b87a-b18d85e112e4"
      unitRef="usdPerShare">38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE1LTEtMS0xLTExODgzMw_9e46d58d-aeee-4de4-bde0-b8cad096c569"
      unitRef="shares">4796000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE1LTMtMS0xLTExODgzMw_82945f34-990c-45ce-8b45-eb4f3ee9b464"
      unitRef="usdPerShare">13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE2LTEtMS0xLTExODgzMw_b8e977e5-75a2-41f8-92c1-7ea75eeccbe8"
      unitRef="shares">699000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE2LTMtMS0xLTExODgzMw_881a6991-014a-42e3-a350-4b66562d9726"
      unitRef="usdPerShare">26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE3LTEtMS0xLTExODgzMw_7a1159f2-768b-49e9-98e3-1dbb89943ad6"
      unitRef="shares">21448000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE3LTMtMS0xLTExODgzMw_fd1c426d-0dd9-4398-a0e5-a96081b0e756"
      unitRef="usdPerShare">29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTEtMS0xLTE0ODc2MQ_3bb8f925-af19-41c9-b693-33d0431a5337"
      unitRef="shares">3287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTMtMS0xLTE0ODc2MQ_bdd419dd-cb92-48dd-8aba-cfb40b1388d7"
      unitRef="usdPerShare">44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTEtMS0xLTE0ODc2MQ_69b6efe6-4d89-499c-a293-0076320322b6"
      unitRef="shares">2745000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTMtMS0xLTE0ODc2MQ_56f72e14-2e77-46c9-bd08-3c66cbdf90d0"
      unitRef="usdPerShare">17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTEtMS0xLTE0ODc2MQ_20fc8739-6e8a-4a5e-9501-a120f576a8a3"
      unitRef="shares">502000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTMtMS0xLTE0ODc2MQ_38c773bf-5baf-4b16-8014-c0334caa0ca7"
      unitRef="usdPerShare">34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTEtMS0xLTE0ODc2MQ_e31cf0ab-f51f-4816-90de-f3dc1bbb5273"
      unitRef="shares">21489000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTMtMS0xLTE0ODc2MQ_bae886b9-6bd4-4c67-a670-81a4aacc22ed"
      unitRef="usdPerShare">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTUtMS0xLTE0ODc4MA_a963e123-c9ab-4aab-b887-a8cdfadb7fc5">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIxLTctMS0xLTE0ODc4MA_60c7a920-7faa-41d3-9788-f2e636e43fa8"
      unitRef="usd">297000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTEtMS0xLTExODgzMw_eb78a49f-9eb1-497e-93af-4592960053f3"
      unitRef="shares">13674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTMtMS0xLTExODgzMw_db60b4da-824f-43a4-b872-af2e4ef3faa9"
      unitRef="usdPerShare">27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTUtMS0xLTExODgzMw_23d91aa8-b008-4a94-a01c-80c7436d9854">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE4LTctMS0xLTExODgzMw_e1b8041b-9894-4be2-a1db-9b1c1afa84cd"
      unitRef="usd">258000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <bsx:OptionsExpectedToVest
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTEtMS0xLTExODgzMw_28dc8862-cf19-487d-ba79-be8ab6bfaf42"
      unitRef="shares">7535000</bsx:OptionsExpectedToVest>
    <bsx:OptionsExpectedToVestWeightedAverageExercisePrice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTMtMS0xLTExODgzMw_a02991f4-ad81-4146-8a0a-aadf6808db34"
      unitRef="usdPerShare">41</bsx:OptionsExpectedToVestWeightedAverageExercisePrice>
    <bsx:OptionsExpectedToVestWeightedAverageRemainingContractualLife
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTUtMS0xLTExODgzMw_f300fc5a-1a65-4083-ab6e-c6259c2a96a8">P8Y2M12D</bsx:OptionsExpectedToVestWeightedAverageRemainingContractualLife>
    <bsx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzE5LTctMS0xLTExODgzMw_ec007ea6-0595-4ea6-8bd9-91b4a7500b70"
      unitRef="usd">38000000</bsx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTEtMS0xLTExODgzMw_0fbae48e-7542-4434-9da3-32789a86fa74"
      unitRef="shares">21209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTMtMS0xLTExODgzMw_c08f0f35-9b07-46aa-8c06-6d42273db2d3"
      unitRef="usdPerShare">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTUtMS0xLTExODgzMw_c8536845-f526-41cc-bfe0-a2759c6a0590">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTo5YjVjMzM4ODljODg0YTQ4YjIyNjUxNWQ2NTcxNTE5ZS90YWJsZXJhbmdlOjliNWMzMzg4OWM4ODRhNDhiMjI2NTE1ZDY1NzE1MTllXzIwLTctMS0xLTExODgzMw_6c46144b-80e6-4357-9b74-a68ee639f3b7"
      unitRef="usd">296000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzNjM_6f73dba5-3ab7-477c-975d-507920bff5b5"
      unitRef="usd">72000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzNzM_d2833bcb-129b-4c53-b695-5044a2498708"
      unitRef="usd">137000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzMzODY_a3398454-381f-4013-9ed9-9d1f0c7669eb"
      unitRef="usd">84000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMTY4_12249810-9ad8-4f92-9f29-d5d142a60f26">Information related to non-vested stock awards is as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Vested&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Award Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant-Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,987&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzktMS0xLTEtMTE4ODMz_32353e3e-81d6-41af-8e68-c4583119c4f2"
      unitRef="shares">11079000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzktMy0xLTEtMTE4ODMz_7cc313c6-7e6c-4cc2-90df-68cdf98e1715"
      unitRef="usdPerShare">29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEwLTEtMS0xLTExODgzMw_936cd430-8aad-4cbd-bf0a-8a25899e97ba"
      unitRef="shares">3609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEwLTMtMS0xLTExODgzMw_bfcaa3b6-7a08-47fe-bbed-249a5a35605d"
      unitRef="usdPerShare">41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzExLTEtMS0xLTExODgzMw_0e238225-4589-49bc-bbab-6cdaac0b8abc"
      unitRef="shares">4147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzExLTMtMS0xLTExODgzMw_092ddde2-6d1f-47bf-b258-850e0a9222bf"
      unitRef="usdPerShare">25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEyLTEtMS0xLTExODgzMw_821274f1-ed7d-4d5c-ba0c-c5ea915e3f87"
      unitRef="shares">554000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEyLTMtMS0xLTExODgzMw_87ef0430-4515-4d5c-a646-013e7069f453"
      unitRef="usdPerShare">34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEzLTEtMS0xLTExODgzMw_194a2e0e-7635-4a4f-ab26-284420e4d9cd"
      unitRef="shares">9987000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzEzLTMtMS0xLTExODgzMw_ef44baf1-6d52-41da-8f7a-0190ae8c0a14"
      unitRef="usdPerShare">34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE0LTEtMS0xLTExODgzMw_ec603d03-af27-4473-b68a-09ad27090671"
      unitRef="shares">4240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE0LTMtMS0xLTExODgzMw_d5660e33-739b-4b83-9311-ef216c8f7799"
      unitRef="usdPerShare">39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE1LTEtMS0xLTExODgzMw_689779c6-5500-49c0-8ea9-36c81ae3382c"
      unitRef="shares">3823000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE1LTMtMS0xLTExODgzMw_bbfc38d4-600d-4b03-bc7b-321f9fe939af"
      unitRef="usdPerShare">31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE2LTEtMS0xLTExODgzMw_76c476d0-3aba-4657-af0b-b2478905c0b0"
      unitRef="shares">658000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE2LTMtMS0xLTExODgzMw_bf2527df-11d0-4ce4-ae17-e67a9cebee9f"
      unitRef="usdPerShare">36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE3LTEtMS0xLTExODgzMw_2f738b6e-d4bd-4686-b5dc-d644b9e67b06"
      unitRef="shares">9745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE3LTMtMS0xLTExODgzMw_ef3d2ca4-81e4-4734-972e-091bd6163bcf"
      unitRef="usdPerShare">37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE4LTEtMS0xLTE0ODY5NQ_edf58273-f2c3-44dd-b13f-1f383e647cfb"
      unitRef="shares">3854000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE4LTMtMS0xLTE0ODY5NQ_bf8507d8-1e75-4cd7-a147-19832a2ea2bb"
      unitRef="usdPerShare">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE5LTEtMS0xLTE0ODY5NQ_3beda8e6-3a5b-452f-b446-de6a2e7b0da0"
      unitRef="shares">3482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzE5LTMtMS0xLTE0ODY5NQ_82b831ed-4ea4-4d24-8f6f-c9283fb23bfb"
      unitRef="usdPerShare">36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIwLTEtMS0xLTE0ODY5NQ_63b09f6a-a30f-45b6-a522-f683a26d2580"
      unitRef="shares">680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIwLTMtMS0xLTE0ODY5NQ_578f7dcb-6e27-43e6-a559-040b1bf50b6b"
      unitRef="usdPerShare">44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIxLTEtMS0xLTE0ODY5NQ_78cf0d47-818e-445b-a64e-e7321c954885"
      unitRef="shares">9438000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZDdlNDg3NTFiYmQ0OWVmOTdlOTVkMDU5NjkyMDE5ZC90YWJsZXJhbmdlOmJkN2U0ODc1MWJiZDQ5ZWY5N2U5NWQwNTk2OTIwMTlkXzIxLTMtMS0xLTE0ODY5NQ_4f3de63a-826a-4ff8-be59-ab103e4487bb"
      unitRef="usdPerShare">41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM3ODI_4c071142-90c7-4212-89fe-ea7b7738c4f1"
      unitRef="usd">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM3OTI_d4391f63-74a4-4f43-905a-1cb150b22d90"
      unitRef="usd">148000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzM4MDU_f1141c28-f34c-4ec3-af0b-a6d7887493c6"
      unitRef="usd">172000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <bsx:RangeofthetargetnumberofmarketbasedDSUsawarded
      contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQzMzU_f87975c1-3b75-437f-8055-a5b2ad4ceecf"
      unitRef="number">0</bsx:RangeofthetargetnumberofmarketbasedDSUsawarded>
    <bsx:RangeofthetargetnumberofmarketbasedDSUsawarded
      contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQzNDE_444a15fb-230d-43bb-a5cd-934a74e649f5"
      unitRef="number">2</bsx:RangeofthetargetnumberofmarketbasedDSUsawarded>
    <bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjAw_a6e8c612-0f2a-4983-a1ba-14744d326bdc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price on date of grant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock>
    <bsx:Fairvalueofmarketbasedawards
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ3Nzc_b8f0f80a-8c51-429c-bee3-d5be6e2f09d7"
      unitRef="usd">12000000</bsx:Fairvalueofmarketbasedawards>
    <bsx:Fairvalueofmarketbasedawards
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ3ODg_c6eb1d0a-2145-43f2-acef-6461a5fa69f3"
      unitRef="usd">11000000</bsx:Fairvalueofmarketbasedawards>
    <bsx:Fairvalueofmarketbasedawards
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzQ4MDI_1c953086-2bfc-4c89-9d9b-27fb35a7b4b0"
      unitRef="usd">8000000</bsx:Fairvalueofmarketbasedawards>
    <us-gaap:SharePrice
      contextRef="icbed6b4234d64fd6a55a3d61b6c5cc7f_I20210217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItMS0xLTEtMTE4ODMz_b8edca78-498d-4c4a-9e4d-a1ef01ca5957"
      unitRef="usdPerShare">44.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i6c2fdbe96ac342cfb2c6e55914689554_I20200218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItMy0xLTEtMTE4ODMz_5c1b45f7-d210-4062-9321-54de29973e66"
      unitRef="usdPerShare">37.50</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i6e2523c5f920482192b97a05b9cfd285_I20190221"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzItNS0xLTEtMTE4ODMz_188a9628-64c8-4c1d-bcfb-aa2f77efb90c"
      unitRef="usdPerShare">42.16</us-gaap:SharePrice>
    <bsx:Measurementperiodmarketbasedaward
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtMS0xLTEtMTE4ODMz_fa8aaa57-4c90-460c-9438-9e2fa59cf5fd">P2Y10M24D</bsx:Measurementperiodmarketbasedaward>
    <bsx:Measurementperiodmarketbasedaward
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtMy0xLTEtMTE4ODMz_e6421840-6eb2-4021-9e9b-df3a4a0df310">P2Y10M24D</bsx:Measurementperiodmarketbasedaward>
    <bsx:Measurementperiodmarketbasedaward
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzMtNS0xLTEtMTE4ODMz_ea131f34-c6d9-4344-8ac8-98eb7c012fa3">P2Y10M24D</bsx:Measurementperiodmarketbasedaward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtMS0xLTEtMTE4ODMz_ce93baab-7076-4ec2-9177-875795b6d748"
      unitRef="number">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtMy0xLTEtMTE4ODMz_92c27e05-b2f3-4310-9ddf-f43e2f47496b"
      unitRef="number">0.0020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZToxYmVmYTNkNzRmMDE0Mzk1OGVkY2Y5MjAxZmJkZDUzMy90YWJsZXJhbmdlOjFiZWZhM2Q3NGYwMTQzOTU4ZWRjZjkyMDFmYmRkNTMzXzQtNS0xLTEtMTE4ODMz_50be8647-5ca2-4312-aaeb-534c4b45310e"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <bsx:RangeofthetargetnumberofperformancebasedDSUsawarded
      contextRef="ife61dc3d6a02417dac73b015a578bb44_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzU3NjY_940b5174-02ec-4dba-b043-b99411196ee2"
      unitRef="number">0</bsx:RangeofthetargetnumberofperformancebasedDSUsawarded>
    <bsx:RangeofthetargetnumberofperformancebasedDSUsawarded
      contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzU3NzI_85992d0d-2ead-4cdf-bb1d-d9cedd03b680"
      unitRef="number">1.50</bsx:RangeofthetargetnumberofperformancebasedDSUsawarded>
    <bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjQ3_9eafb4fc-38f7-48d0-bfb8-7a972573b6e7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 AFCF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 AFCF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 AFCF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, net of forfeitures to date &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Achievement of target payout&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year-end stock price used in determining fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock>
    <bsx:FairValueOfFreeCashFlowFcfPerformanceAwards
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtMS0xLTEtMTE4ODMz_0ee92b01-fd58-45dc-a0b3-a07e0bef8be6"
      unitRef="usd">7000000</bsx:FairValueOfFreeCashFlowFcfPerformanceAwards>
    <bsx:FairValueOfFreeCashFlowFcfPerformanceAwards
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtMy0xLTEtMTE4ODMz_ffa528c0-8a08-4824-b9cd-c68650add193"
      unitRef="usd">12000000</bsx:FairValueOfFreeCashFlowFcfPerformanceAwards>
    <bsx:FairValueOfFreeCashFlowFcfPerformanceAwards
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzEtNS0xLTEtMTE4ODMz_3edaab6a-a0ec-4436-8d19-57c8cf6cf90e"
      unitRef="usd">6000000</bsx:FairValueOfFreeCashFlowFcfPerformanceAwards>
    <bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItMS0xLTEtMTE4ODMz_f9086d29-7542-4b56-a58f-cef76cda10e1"
      unitRef="number">0.88</bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards>
    <bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItMy0xLTEtMTE4ODMz_78313f93-6de8-4449-a097-af4fcbc18c8e"
      unitRef="number">1.31</bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards>
    <bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzItNS0xLTEtMTE4ODMz_685f9b72-4858-4ddd-b587-6c0836e4d52f"
      unitRef="number">0.89</bsx:TargetPayoutOfFreeCashFlowsFcfPerformanceAwards>
    <us-gaap:SharePrice
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtMS0xLTEtMTE4ODMz_2b769138-0c9e-4bca-a041-8f3dde42b538"
      unitRef="usdPerShare">46.27</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtMy0xLTEtMTE4ODMz_38aa5c43-36af-4927-ab6f-e76229bda5d9"
      unitRef="usdPerShare">42.48</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpmZGQzZWM1OWViNzA0MzkwOTk5MDBmZTQzYTFmYzYyMS90YWJsZXJhbmdlOmZkZDNlYzU5ZWI3MDQzOTA5OTkwMGZlNDNhMWZjNjIxXzMtNS0xLTEtMTE4ODMz_208662e3-4fbc-4438-8173-fe86f404e2c8"
      unitRef="usdPerShare">35.95</us-gaap:SharePrice>
    <bsx:Annualweightedaverageforfeiturerate
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzc5ODI_8d1d297a-41c1-4d9a-ba25-e555e1f07cac"
      unitRef="number">0.05</bsx:Annualweightedaverageforfeiturerate>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjMw_994d2314-2d10-447e-a010-398c0a561dab">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect to recognize the following future expense for awards outstanding as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Compensation Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;Amounts presented represent compensation cost, net of estimated forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <bsx:UnrecognizedCompensationCostStockOptions
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzEtMS0xLTEtMTE4ODMz_a7721e60-2f68-4df4-9882-eebd17e16ee9"
      unitRef="usd">38000000</bsx:UnrecognizedCompensationCostStockOptions>
    <bsx:UnrecognizedCompensationCostNonVestedStockAwards
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzItMS0xLTEtMTE4ODMz_6193132c-2688-4861-a4d7-43877fe6de3c"
      unitRef="usd">181000000</bsx:UnrecognizedCompensationCostNonVestedStockAwards>
    <bsx:UnrecognizedCompensationCost
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzMtMS0xLTEtMTE4ODMz_7884e5f1-a5a8-457f-99ee-957bcfb2a689"
      unitRef="usd">219000000</bsx:UnrecognizedCompensationCost>
    <bsx:WeightedAverageRemainingVestingPeriod
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTplZDA3YTJlMDU5MzA0MTk1YTkwMThjNjIyMzIxNjEyZC90YWJsZXJhbmdlOmVkMDdhMmUwNTkzMDQxOTVhOTAxOGM2MjIzMjE2MTJkXzMtMy0xLTEtMTE4ODMz_2eebcbd3-2c5a-4998-9cef-8348eab940b5">P1Y8M12D</bsx:WeightedAverageRemainingVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzI3NDg3NzkwODEzMDY_7b31d95d-8f26-4e10-a444-a8a74add2a86"
      unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzg2ODQ_14d34cc5-3f1f-4761-ace0-3313dd4bf394"
      unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bsx:AmountOfEmployeesTotalCompensationEligibleForGesopPurchase
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzg5NDU_b8a61c82-6953-45f3-932c-8516766ce7dd"
      unitRef="number">0.10</bsx:AmountOfEmployeesTotalCompensationEligibleForGesopPurchase>
    <bsx:GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzkyMDQ_c5a309da-940c-448f-91d5-fb222cdc6fd8"
      unitRef="number">0.85</bsx:GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzkzNTU_ce0a183f-ce5b-4be5-b1d2-00d2696eb075"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90ZXh0cmVnaW9uOjA3MmU2YzMzY2UxMjQ0N2Q4ODNiZTcxMWYxZTkwOTEzXzEwMjQ5_89218556-054d-446a-b53e-275882580ef3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued or to be issued&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range of purchase prices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expense recognized&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItMS0xLTEtMTE4ODMz_ada91ac9-cf3a-4236-8f2a-1ed769afe0ec"
      unitRef="shares">2850000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItNS0xLTEtMTE4ODMz_00200916-5750-459f-86b5-9a7dba4d2174"
      unitRef="shares">2578000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzItOS0xLTEtMTE4ODMz_ec64d6ba-964e-4ab2-9f79-d2639ae4a179"
      unitRef="shares">1387000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtMS0xLTEtMTE4ODMz_f68e6bab-0e9c-423b-aa8e-f3cc9a873334"
      unitRef="usdPerShare">31.68</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="i609bef3b8f6b4492835318799ad63507_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtMy0xLTEtMTE4ODMz_92fbbc9b-df17-4da1-ad92-4ca5de6cbae6"
      unitRef="usdPerShare">32.31</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtNS0xLTEtMTE4ODMz_6fa37027-1e13-40f7-be87-ca326af03dda"
      unitRef="usdPerShare">29.98</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="ic508baeb96a74d3a92eb58264383d883_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtNy0xLTEtMTQ4NjQy_505c275d-a722-48a9-ba26-8f6710805760"
      unitRef="usdPerShare">36.11</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="id7bee05287db4da4b68d2bb42fb4c667_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzMtOS0xLTEtMTE4ODMz_5533db9e-430d-49ff-ade5-aea5b2d14f1d"
      unitRef="usdPerShare">29.84</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtMS0xLTEtMTE4ODMz_c38c0fd5-f11f-4432-8881-a9a5621badc5"
      unitRef="usd">28000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtNS0xLTEtMTE4ODMz_e184328d-c04d-42c5-92f5-4e0e77d2c121"
      unitRef="usd">24000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMzkvZnJhZzowNzJlNmMzM2NlMTI0NDdkODgzYmU3MTFmMWU5MDkxMy90YWJsZTpiZTJhMTZmMmYyOTM0ZGY1OTU5YWY4NmY2OWE3NGU4OS90YWJsZXJhbmdlOmJlMmExNmYyZjI5MzRkZjU5NTlhZjg2ZjY5YTc0ZTg5XzQtOS0xLTEtMTE4ODMz_9426156f-fe1e-4248-a199-faf79d16bdef"
      unitRef="usd">10000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MDE_81f6728a-3bf5-4da8-8962-8550f7fe68af">&lt;div style="margin-top:20pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE L &#x2013; WEIGHTED AVERAGE SHARES OUTSTANDING&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net effect of common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding - assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,439.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,433.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,416.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MCPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; position in this period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents common stock issuable upon the conversion of MCPS. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note J &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We base &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss)&#160;per common share - assuming dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was reduced by cumulative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred stock dividends&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as presented in our consolidated statements of operations, for purposes of calculating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income (loss) available to common stockholders&lt;/span&gt;.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MjA_700f0e85-e1a8-4d77-9361-a7b97e67d116">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net effect of common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding - assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,439.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,433.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,416.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItMS0xLTEtMTE4ODMz_140b9a1c-5164-4a9a-9124-ca940863cf34"
      unitRef="shares">1430500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItMy0xLTEtMTE4ODMz_6c11343d-18a3-4a09-b032-3158fc8cf67e"
      unitRef="shares">1422300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzItNS0xLTEtMTE4ODMz_cd18741d-b3b9-4b93-8c0a-f9b8983d9f7c"
      unitRef="shares">1416700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtMS0xLTEtMTE4ODMz_91b253ae-5f27-4e5b-b3b3-55fb071b5b0a"
      unitRef="shares">9200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtMy0xLTEtMTE4ODMz_7fc45a0c-a6db-48f1-9279-34954eaec06e"
      unitRef="shares">11500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzMtNS0xLTEtMTE4ODMz_fe79eac8-e168-4c9a-863c-8d95cad696da"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtMS0xLTEtMTE4ODMz_03d6c782-7c11-4f4f-9051-60534235ca57"
      unitRef="shares">1439700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtMy0xLTEtMTE4ODMz_66eaaa70-e222-4d60-aa39-22c4df50dd0b"
      unitRef="shares">1433800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTowMjA4YTEwMGMyY2Q0ZWEzOTEyZjY1OGMzZTI3NjE3YS90YWJsZXJhbmdlOjAyMDhhMTAwYzJjZDRlYTM5MTJmNjU4YzNlMjc2MTdhXzQtNS0xLTEtMTE4ODMz_53de819d-77e2-4b53-9309-f551423ed6fb"
      unitRef="shares">1416700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90ZXh0cmVnaW9uOmI1ZjRkY2NiODllZDRmZTQ5ZjJlZWNmMDI2MjgyMWFhXzE3MDU_456d7044-cd79-46e3-bc4d-827e4cf40ddb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MCPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; position in this period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents common stock issuable upon the conversion of MCPS. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note J &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie1d4b247dfcf42b18bdd3d7fc7fef232_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzItNS0xLTEtMTE4ODMz_4b24cbcf-bfef-4056-ad05-76cd79d4462f"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8687933af19a45e89f5ecbc7a113fc9c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtMS0xLTEtMTE4ODMz_5becdc52-7562-4a2e-8d14-1c842e37911b"
      unitRef="shares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i040d7807c33b46a4b79cf78c184c0dd7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtMy0xLTEtMTE4ODMz_89db8667-4885-4f92-9dc0-fbe2985af561"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03c56a446b7c417f8ba1d1a6f60d5e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzMtNS0xLTEtMTE4ODMz_aa45db9b-9d24-4294-a48d-fc53e056172e"
      unitRef="shares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id3043cc21b44462892099dc71ca5ae2f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtMS0xLTEtMTE4ODMz_f28c8151-4fda-4a06-aff0-18fd0612f044"
      unitRef="shares">24000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80e0030da7dd43208fdf78c181acd6b5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtMy0xLTEtMTE4ODMz_18b6b62c-3a87-40d6-a887-246dbe822326"
      unitRef="shares">24000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5740688cc4a24abfa9eca604a6e8a9a6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDIvZnJhZzpiNWY0ZGNjYjg5ZWQ0ZmU0OWYyZWVjZjAyNjI4MjFhYS90YWJsZTphOWI3ZjVkM2E4MDM0ZDcyYmExNjc3NjBiODc1MDI0OS90YWJsZXJhbmdlOmE5YjdmNWQzYTgwMzRkNzJiYTE2Nzc2MGI4NzUwMjQ5XzQtNS0xLTEtMTE4ODMz_8c35b1e4-b767-47cf-97e3-ca23bd4aebe1"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3MTY_04e1a303-e41b-4447-a569-a3324d07a657">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE M &#x2013; SEGMENT REPORTING &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our consolidated statements of operations and are included in the reconciliation below. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note N &#x2013; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for net sales by reportable segment presented in accordance with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales of reportable segments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating income of reportable segments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income of reportable segments as a percentage of net sales of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation expense of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,795&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzU0OTc1NTgxODc1Nw_6381cb99-8180-4628-a756-1d678a719320"
      unitRef="reportablesegments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2OTM_0f5b5013-ae2d-432a-b873-3ffa10056957">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales of reportable segments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItMS0xLTEtMTE4ODMz_61ec642a-93e4-4f62-b300-aebb994820db"
      unitRef="usd">5057000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItMy0xLTEtMTE4ODMz_717549cf-263a-4191-ab62-696e8042d3b0"
      unitRef="usd">4616000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzItNS0xLTEtMTE4ODMz_29320c76-e8e0-485a-bd34-ec3a713cae31"
      unitRef="usd">3844000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtMS0xLTEtMTE4ODMz_8be41809-3568-4df5-803b-af4093d9303a"
      unitRef="usd">8161000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtMy0xLTEtMTE4ODMz_d81edf57-512d-4b69-8d17-fe89e819f286"
      unitRef="usd">7212000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzQtNS0xLTEtMTE4ODMz_ed1142c4-12dc-417e-9266-f9ed58c10add"
      unitRef="usd">5913000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtMS0xLTEtMTE4ODMz_999638c2-3440-4df3-8537-d139c0752623"
      unitRef="usd">13218000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtMy0xLTEtMTE4ODMz_ef9e6057-37ca-4b35-89a4-aee834adaa98"
      unitRef="usd">11828000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i8209cc36f681456ca83869b5c6449383_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzUtNS0xLTEtMTE4ODMz_f37957f9-50ec-4310-a47e-68c3d7e95e1a"
      unitRef="usd">9756000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtMS0xLTEtMTE4ODMz_f9cc1619-911e-42b9-990f-b91c9aaaad2a"
      unitRef="usd">-60000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtMy0xLTEtMTE4ODMz_138310cd-b0f5-4725-a9fc-10e7aca4ee8b"
      unitRef="usd">13000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
      contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzYtNS0xLTEtMTE4ODMz_bc1391d9-0c8e-4de1-ae5d-ddbcaae17415"
      unitRef="usd">219000000</bsx:RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement>
    <bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMS0xLTEtMTE4ODMz_a6246606-be39-48a1-96e5-ea882b3ec330"
      unitRef="usd">-476000000</bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales>
    <bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMy0xLTEtMTE4ODMz_d0b22eae-7367-4fb5-836c-51304f30f2e6"
      unitRef="usd">47000000</bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales>
    <bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctNS0xLTEtMTE4ODMz_2a14053b-d3f1-4747-a578-1dbe8065e177"
      unitRef="usd">-65000000</bsx:ImpactOfForeignCurrencyFluctuationsOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMS0xLTEtMTQ3MTk4_6c6eaf9d-d938-4b1c-82b5-1716976a54ee"
      unitRef="usd">12682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctMy0xLTEtMTQ3MTk4_bbcf54e3-6418-47d4-8afb-96fa7aab2fb2"
      unitRef="usd">11888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo4MjQxNTVmYmJkYTM0ZTRkYTM4ZjBiMmFiODRjY2M4Mi90YWJsZXJhbmdlOjgyNDE1NWZiYmRhMzRlNGRhMzhmMGIyYWI4NGNjYzgyXzctNS0xLTEtMTQ3MTk4_48cec28d-6b31-4c09-8717-12c74a4fd63c"
      unitRef="usd">9913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3Mjk_f3172034-c54d-4779-a3c6-00fa377154ad">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating income of reportable segments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItMS0xLTEtMTE4ODMz_7d43b30c-eac9-4558-9487-744f4436f302"
      unitRef="usd">1625000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItMy0xLTEtMTE4ODMz_b07a0a15-4259-4efe-a282-de916688c42a"
      unitRef="usd">1524000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzItNS0xLTEtMTE4ODMz_3b675eb7-f7cf-451d-81f2-da39b9306a1d"
      unitRef="usd">1156000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtMS0xLTEtMTE4ODMz_d47e35df-0ddf-418a-a813-d42a8ccdc328"
      unitRef="usd">2113000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtMy0xLTEtMTE4ODMz_b39b7cd5-dbd4-474d-8ce6-f1f7eafae7f7"
      unitRef="usd">1888000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <bsx:OperatingIncomeLossAllocatedToReportableSegments
      contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzQtNS0xLTEtMTE4ODMz_c9ad4673-2b25-4821-9215-486b7f1c0796"
      unitRef="usd">1043000000</bsx:OperatingIncomeLossAllocatedToReportableSegments>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73aacf8162a94e5ca1cbfc7c3bbb8429_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtMS0xLTEtMTE4ODMz_cc4ecb5c-1554-451a-a091-210772168835"
      unitRef="usd">3737000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d4d1adfd5d54741badb3c93eae8f22f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtMy0xLTEtMTE4ODMz_a8ff26fa-1f6d-4bb3-a63e-3db32fa16666"
      unitRef="usd">3412000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8022cbc49a3d4c4fac891808fe3df6d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzUtNS0xLTEtMTE4ODMz_85d588d6-c2f9-4476-8456-63a8ca4c22a2"
      unitRef="usd">2198000000</us-gaap:OperatingIncomeLoss>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="i41a81988fde44ba5b6bd50b742952a88_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtMS0xLTEtMTE4ODMz_7b610d08-b1cc-4fa5-9525-0ec2e4c5d378"
      unitRef="usd">-436000000</bsx:OperatingIncomeUnallocatedToSegment>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="iad42e640c3464b0da50b8fb06d89531e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtMy0xLTEtMTE4ODMz_b295e475-fb48-41c7-9557-30486870abdf"
      unitRef="usd">-406000000</bsx:OperatingIncomeUnallocatedToSegment>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="i828e9990d56940ce9f697d568f80f1ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzgtNS0xLTEtMTE4ODMz_03d48934-e71d-4984-a3f7-8f5a1b5de496"
      unitRef="usd">-424000000</bsx:OperatingIncomeUnallocatedToSegment>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="i33ec3556bf5a454fa2bd44957535d39c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktMS0xLTEtMTE4ODMz_2234f90b-bf34-410f-9c10-6f413a572bf3"
      unitRef="usd">-789000000</bsx:OperatingIncomeUnallocatedToSegment>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="iaf2bdc993f6049e2bd23b2de3c4d090c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktMy0xLTEtMTE4ODMz_ecbbb7c7-b649-420c-a178-a12417acd44c"
      unitRef="usd">-1070000000</bsx:OperatingIncomeUnallocatedToSegment>
    <bsx:OperatingIncomeUnallocatedToSegment
      contextRef="i282876cb44e2481c810f077edcb1f925_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzktNS0xLTEtMTE4ODMz_744cc839-2f32-41be-90c7-2624829a699c"
      unitRef="usd">-1208000000</bsx:OperatingIncomeUnallocatedToSegment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTEtMS0xLTExODgzMw_224bc14f-303a-401c-981e-ccfcb2dcd644"
      unitRef="usd">803000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTMtMS0xLTExODgzMw_d88b7c93-589b-4a74-9a27-17bece4ac832"
      unitRef="usd">741000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTUtMS0xLTExODgzMw_67f91d85-e995-4f99-beb9-2dc46bdae310"
      unitRef="usd">789000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="i23150e692e7444a6b1096dff0b883677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTEtMS0xLTE4MTg0OQ_b4c76521-7229-42e5-9c68-998b571126bc"
      unitRef="usd">-60000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTMtMS0xLTE4MTg0OQ_354c3603-6dc6-4051-880a-fd12d15673c8"
      unitRef="usd">4000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEwLTUtMS0xLTE4MTg0OQ_c3301d1f-9590-42a2-ac9a-21a071a6fe5c"
      unitRef="usd">143000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTEtMS0xLTExODgzMw_62ecfe47-bddb-4bd5-8f2d-a0be4053838f"
      unitRef="usd">1649000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTMtMS0xLTExODgzMw_e1cc1420-26e1-4433-98ab-5516d76d8798"
      unitRef="usd">1199000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzExLTUtMS0xLTExODgzMw_3ea109c4-c808-452b-9808-a2a4b7ce8e2a"
      unitRef="usd">-80000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTEtMS0xLTExODgzMw_3127aeed-d460-40a0-be94-f04e2c3c3f3b"
      unitRef="usd">-508000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTMtMS0xLTExODgzMw_68f2f993-0666-40a2-a0a8-ba963a3aa8d4"
      unitRef="usd">-123000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEyLTUtMS0xLTExODgzMw_f88d24d2-2e88-4a61-87a3-5e6ae70fb2ce"
      unitRef="usd">1000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTEtMS0xLTExODgzMw_ff68197d-3a49-422a-bfa7-7e4d83cb5a5e"
      unitRef="usd">1141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTMtMS0xLTExODgzMw_b6eddfe7-6fdc-4f99-bec9-e6dff4a7ff9c"
      unitRef="usd">1076000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo3Mjg2NGRiYmRhY2I0ZjdiOWE2NzIyODNmY2VkMzk0NS90YWJsZXJhbmdlOjcyODY0ZGJiZGFjYjRmN2I5YTY3MjI4M2ZjZWQzOTQ1XzEzLTUtMS0xLTExODgzMw_6ea5d309-eacf-48a2-bf57-8ac3e38e2574"
      unitRef="usd">-79000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <bsx:SegmentoperatingincomeaspercentageofnetsalesTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2OTU_ed915535-0a41-4e3e-98df-cfccbe623c19">&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income of reportable segments as a percentage of net sales of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation expense of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bsx:SegmentoperatingincomeaspercentageofnetsalesTableTextBlock>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItMS0xLTEtMTE4ODMz_0f0a5a63-add2-42d0-924c-b61fec0cbe5f"
      unitRef="number">0.321</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItMy0xLTEtMTE4ODMz_9fbca0c6-17e4-42bb-8ab9-0a8e414538c0"
      unitRef="number">0.330</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzItNS0xLTEtMTE4ODMz_b43a1b16-0d6d-4c6c-8376-4d013b0c8923"
      unitRef="number">0.301</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtMS0xLTEtMTE4ODMz_40d7bb48-64f8-4aec-9194-4e82e87f050e"
      unitRef="number">0.259</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtMy0xLTEtMTE4ODMz_77e3e82b-0ce2-4067-8100-559f63772c73"
      unitRef="number">0.262</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <bsx:Segmentoperatingincomeaspercentageofnetsales
      contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTphYTNmOGNkNjZmYzI0ZWQ3YTBkYTllNTZmNmUwZjQ5Yi90YWJsZXJhbmdlOmFhM2Y4Y2Q2NmZjMjRlZDdhMGRhOWU1NmY2ZTBmNDliXzQtNS0xLTEtMTE4ODMz_a60ca69c-970c-4247-bd4e-dbc696bf8960"
      unitRef="number">0.176</bsx:Segmentoperatingincomeaspercentageofnetsales>
    <us-gaap:Depreciation
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItMS0xLTEtMTQ3MTIy_1440f9b8-5092-4b91-a5aa-cf4a272f7261"
      unitRef="usd">88000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItMy0xLTEtMTQ3MTIy_2679c7c3-1f76-47ff-8905-50f8bc850169"
      unitRef="usd">91000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzItNS0xLTEtMTQ3MTIy_2d5af265-ac1c-4539-a64e-aeae8df25764"
      unitRef="usd">90000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtMS0xLTEtMTQ3MTIy_763322f6-a7cd-47dc-bcf7-1b6195b3abfa"
      unitRef="usd">245000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtMy0xLTEtMTQ3MTIy_92a8fc01-8010-4869-a2fe-74c0d1aaf39b"
      unitRef="usd">261000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzMtNS0xLTEtMTQ3MTIy_7f7430d9-e70c-4a2c-bebc-30b5196d6d42"
      unitRef="usd">240000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i961acb741b0e41738c2c75afda571ed9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtMS0xLTEtMTQ3MTIy_d9504934-84af-4732-be5b-4226fd2b770e"
      unitRef="usd">333000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i28f99981fe094e4eaefc6a44abdfe153_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtMy0xLTEtMTQ3MTIy_d6c27052-98f2-47f2-951e-859027d19beb"
      unitRef="usd">352000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8209cc36f681456ca83869b5c6449383_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzQtNS0xLTEtMTQ3MTIy_3522e5fb-936e-4b28-8378-a2edb51df85c"
      unitRef="usd">330000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i23150e692e7444a6b1096dff0b883677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtMS0xLTEtMTQ3MTIy_12de062f-f9d1-4b5c-b598-6a6ea485e4ec"
      unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i012c54e4642f41bcbbeaa3efd1dbe09d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtMy0xLTEtMTQ3MTIy_d6ca6144-fcb8-4a62-88d9-208ef765a30e"
      unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7b4f89a7a7be416b900dc3b89930f061_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzUtNS0xLTEtMTQ3MTIy_df23c8a8-5040-4c97-a80a-98a85ff8730d"
      unitRef="usd">3000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtMS0xLTEtMTQ3MTIy_5bf52203-6ff4-47d1-9831-14007577c55c"
      unitRef="usd">333000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtMy0xLTEtMTQ3MTIy_c6eb781e-bbac-44d3-9d8f-c1b819a72f75"
      unitRef="usd">352000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplODdjMGQ0NWUwZGQ0NDcxYTNiMjZmOGZhMWYzMWU4Yy90YWJsZXJhbmdlOmU4N2MwZDQ1ZTBkZDQ0NzFhM2IyNmY4ZmExZjMxZThjXzYtNS0xLTEtMTQ3MTIy_cac8739f-6efb-482d-8d64-0728bf3d0a58"
      unitRef="usd">333000000</us-gaap:Depreciation>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI3MTQ_20c8600e-30bf-4e28-b7d7-31f64f25a407">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets of reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:OtherAssets
      contextRef="iab0460e71d5b418b813458aae9b11a82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzItMS0xLTEtMTE4ODMz_3eb6c976-cb81-47d9-8544-84b4bcbf776b"
      unitRef="usd">2501000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="ibc263f43956447489bf00cd95b47d45b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzItMy0xLTEtMTE4ODMz_80adcc46-9d5f-4227-8035-518aa90e1ed5"
      unitRef="usd">2178000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="ie847a194b2334592ac9587e3029dbcd2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzQtMS0xLTEtMTE4ODMz_c8189c14-c533-45d7-86a9-78a0f996b61a"
      unitRef="usd">5205000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i0a5e00fb04b14bd7be7b428099bd5934_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzQtMy0xLTEtMTE4ODMz_55f8ef08-f24d-461e-b765-fa552f763798"
      unitRef="usd">4417000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i9912e3f7721e4f4eb02c8a146eb576ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzUtMS0xLTEtMTE4ODMz_ec1fcb76-9cfc-4f11-9f96-16a0a8bebca2"
      unitRef="usd">7706000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i2ff6c0b60ebb41109c5e430b7cf98bfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzUtMy0xLTEtMTE4ODMz_976069cc-6146-4e7f-8ec0-b7228c10f980"
      unitRef="usd">6595000000</us-gaap:OtherAssets>
    <us-gaap:Goodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzctMS0xLTEtMTE4ODMz_b0099e53-f80a-4b78-9688-f9b7a387d42e"
      unitRef="usd">12920000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzctMy0xLTEtMTE4ODMz_328a52a8-58de-4fd8-9608-ed45779091ad"
      unitRef="usd">11988000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzgtMS0xLTEtMTE4ODMz_326c4346-966e-4b48-9386-514288f8c2ce"
      unitRef="usd">5902000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzgtMy0xLTEtMTE4ODMz_9dab6693-8a67-46b4-820e-5cdf88e67f87"
      unitRef="usd">6121000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets
      contextRef="i6d25936d40ea49aab12bb59004cd2db9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzktMS0xLTEtMTE4ODMz_dd96a2df-ddf9-4dc8-a0a1-e3ef802ae1b6"
      unitRef="usd">5941000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i7e6cf9fdde614399a2fe497025d3fd04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzktMy0xLTEtMTE4ODMz_ca1792b6-0bed-460f-92b9-63312f854532"
      unitRef="usd">7525000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i5b22282599f043b7ac5083784fc608f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzEwLTEtMS0xLTExODgzMw_762778c9-39d4-4d70-948d-4c599bdce5b4"
      unitRef="usd">32469000000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i88b5c422cffd4ce5a6f4a90251a20608_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTplZDQxNWZkZDc5YWQ0OTI5YjUwNjg4NWIzYzM4YjFiYi90YWJsZXJhbmdlOmVkNDE1ZmRkNzlhZDQ5MjliNTA2ODg1YjNjMzhiMWJiXzEwLTMtMS0xLTExODgzMw_ed52e714-c423-4e9e-8e6f-38be8a0bff00"
      unitRef="usd">32229000000</us-gaap:OtherAssets>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90ZXh0cmVnaW9uOjMzODFjMzUzMTE1NTRiMWE4ZGZlZTUwNWMzZDAwNDdkXzI2NTk_59842a5f-81ed-4bf6-92ec-ebdf9ec2be41">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,795&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="ic56a78345d3145e2b9794e539a59c1d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzItMS0xLTEtMTE4ODMz_df7842a9-0f0d-4ece-8840-a772ea4ad7ca"
      unitRef="usd">1241000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia4367e2317d04cf0b38cf472829367fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzItMy0xLTEtMTE4ODMz_7342c65b-0d4d-46bb-b623-7a188187018c"
      unitRef="usd">1190000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia714a3ddfec449b5b11c7aa4287614fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzMtMS0xLTEtMTE4ODMz_05354220-19fc-4ce4-af88-533bdebad07d"
      unitRef="usd">478000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if045c803eadb4661aca54512d1bb0be2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzMtMy0xLTEtMTE4ODMz_10a4e37d-1e99-43c7-97c9-e96cba362b77"
      unitRef="usd">436000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ife2970551fa2429a88d913607880908f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMS0xLTEtMTgxOTM1_4f8fc0be-1b06-47a8-892b-50baa6ddca83"
      unitRef="usd">246000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic95029382727473aaf7e493ea3baafeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMy0xLTEtMTgxOTQ4_3ffc7963-b32f-46c7-9bb4-3d9d9351e180"
      unitRef="usd">185000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9c7006856c9d44d2ab1e38d46423fd26_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMS0xLTEtMTE4ODMz_479d882b-ef34-4bf5-a4df-12b941fb8063"
      unitRef="usd">481000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0bc270f01c02480db0f2bcec5a56070c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzQtMy0xLTEtMTE4ODMz_4573d15b-07f3-47fc-a649-145ff9306026"
      unitRef="usd">440000000</us-gaap:NoncurrentAssets>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzUtMS0xLTEtMTE4ODMz_b2b9f543-be83-4d67-b010-deee2078e1ad"
      unitRef="usd">2446000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzUtMy0xLTEtMTE4ODMz_2d431a99-eb12-49aa-8e17-125dad6a87e9"
      unitRef="usd">2252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzYtMS0xLTEtMTE4ODMz_3e4ebf4b-d2a7-4e08-9303-2f9d52c0f187"
      unitRef="usd">12920000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzYtMy0xLTEtMTE4ODMz_5f419c63-aeeb-4a78-a171-8235aa23ff3f"
      unitRef="usd">11988000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzctMS0xLTEtMTE4ODMz_67eb2d01-e3fe-4192-81dd-694ad522d15e"
      unitRef="usd">5902000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzctMy0xLTEtMTE4ODMz_252a410a-142b-4231-96eb-9ddac10eeaea"
      unitRef="usd">6121000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzgtMS0xLTEtMTE4ODMz_3e5ee9a6-8c1e-40bb-883d-7a3cba1ecf7f"
      unitRef="usd">386000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzgtMy0xLTEtMTE4ODMz_9ef6a660-6488-4786-a201-2c0c8838c344"
      unitRef="usd">435000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:NoncurrentAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzktMS0xLTEtMTE4ODMz_4e414c3a-f7ee-4696-9fe6-8dd4b24b9b42"
      unitRef="usd">21653000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDUvZnJhZzozMzgxYzM1MzExNTU0YjFhOGRmZWU1MDVjM2QwMDQ3ZC90YWJsZTo1ZjYxNDExZDUyNGI0NTkyOGY1ZmRkZjYzMWM5Mjg2NS90YWJsZXJhbmdlOjVmNjE0MTFkNTI0YjQ1OTI4ZjVmZGRmNjMxYzkyODY1XzktMy0xLTEtMTE4ODMz_c2e42294-4a6d-448d-b9f8-facf5dceac9e"
      unitRef="usd">20795000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMxODg_b450cc5c-5ab8-4e98-af4c-470babc88b76">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE N &#x2013; REVENUE&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Urology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interventional Cardiology Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Watchman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cardiac Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Peripheral Interventions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,396&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#160;&#160;&#160;&#160;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note M &#x2013; Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for information on our reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Geographic Regions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America and Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#xfc;rkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December&#160;31, 2022 and $484 million as of December&#160;31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE&#x2122; Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December&#160;31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE&#x2122; Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE&#x2122; Remote Monitoring Service. These fulfillment costs are amortized over the average service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2020, we recorded $179&#160;million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX&#x2122; Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note A &#x2013; Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on our accounting policies relating to revenue recognition.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMxODU_e10ae81c-7e81-492b-980a-d36ac6536552">The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Int'l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Urology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MedSurg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interventional Cardiology Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Watchman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cardiac Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Peripheral Interventions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,396&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#160;&#160;&#160;&#160;In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note M &#x2013; Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for information on our reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Geographic Regions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America and Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, T&#xfc;rkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dca525960544c139044f842992c4cd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMS0xLTEtMTE4ODMz_d232f826-c3dd-4c2a-a961-388b5d6e45bd"
      unitRef="usd">1341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ac06cd2de024399894d3c6dfb28070e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMy0xLTEtMTE4ODMz_e63349aa-2463-4901-a89b-172752632536"
      unitRef="usd">880000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02e2ba9581ee4e218b8a89a221a0d400_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtNS0xLTEtMTE4ODMz_af5eb67c-5bbb-4714-a227-de264d44b5ae"
      unitRef="usd">2221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia98056bb0e784957b5899a9e833f0fbf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtNy0xLTEtMTE4ODMz_553f0854-95f3-4609-b68e-998898634918"
      unitRef="usd">1222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf2e323954f7444eafe535939a1c7edc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtOS0xLTEtMTE4ODMz_404130ef-d828-4a43-83c7-d281d48fc7c3"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f3945a09c204b04a2dbb81ac13ccf41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTEtMS0xLTExODgzMw_8363ffba-a244-4359-9b61-9f44472d4402"
      unitRef="usd">2141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41d43ae659ff4513bb97a8edea477a2e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTMtMS0xLTExODgzMw_da67878a-71e9-4b55-bd17-ad6bcef4ab78"
      unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd6ae61663a74c268cb97faeae2f6a45_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTUtMS0xLTExODgzMw_4beaa613-b612-416c-a509-c29f31bef10c"
      unitRef="usd">780000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfbdd903babe43e3990ab29bcbe6985e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzMtMTctMS0xLTExODgzMw_815773f5-55e9-490e-b82b-7b68431f6019"
      unitRef="usd">1780000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d5cf1f78e6445dcaf73a56694e9027e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMS0xLTEtMTE4ODMz_30771a68-fa1f-4f4e-84db-75567522e026"
      unitRef="usd">1257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35b44455a502404199213289b929b707_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMy0xLTEtMTE4ODMz_087c93b7-37fc-4c0b-9316-32674697ca51"
      unitRef="usd">516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfb65397f906401f908a347b4d777c0f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtNS0xLTEtMTE4ODMz_e2a39339-2830-4109-a602-da93014f6dcf"
      unitRef="usd">1773000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9ede5593b494783a615d880fc8b78d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtNy0xLTEtMTE4ODMz_b5e27739-2a19-4a95-bc89-cf558039aeec"
      unitRef="usd">1120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ea5ae6a8a2245f1b71a59f4740ac05b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtOS0xLTEtMTE4ODMz_f114daeb-fe91-4816-8141-4c1da601147d"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3e19ddabb7c473ea576b951929e933d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTEtMS0xLTExODgzMw_ee2fe5d9-8adb-4e16-a964-9275a40947c6"
      unitRef="usd">1583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida7fe9c758704bc380ecdd891fe49855_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTMtMS0xLTExODgzMw_b0fb0c8a-265d-4e9a-b86e-94846e073256"
      unitRef="usd">918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbfe994c194b4ac8ae41f11a8e0cce7a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTUtMS0xLTExODgzMw_0d11e6f4-8e69-4856-8b43-00eebb855d6f"
      unitRef="usd">368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84d8cad94f45467790555d4a57825c01_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzQtMTctMS0xLTExODgzMw_64f0fe6f-e34f-4612-8767-9e637721300e"
      unitRef="usd">1286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief043d96b49f4090a6042a4c1e0f9605_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMS0xLTEtMTQxMTUy_22cb4b8d-2cf0-49e8-9126-1b752c8d4cba"
      unitRef="usd">715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4a88f9ce6ad4b2eb993d105654ed940_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMy0xLTEtMTQxMTUy_cfd9c5da-2b03-41b0-a581-62a872436159"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id59ce8cc839f4063a3e88b18ffbe49ba_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNS0xLTEtMTQxMTUy_44efddeb-f147-4bc5-9858-a74c109cdb50"
      unitRef="usd">917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e4d8cfc9f3949e0ab3d00ac9a41c0a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNy0xLTEtMTQxMTUy_0c33a4c1-a28c-4f6a-a2bf-70bbeafa9a4e"
      unitRef="usd">713000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2111a536bd5a4796852fa7ccbf67dc68_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtOS0xLTEtMTQxMTUy_7ab58227-b4f6-4625-905e-78c655cd9f14"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd845dce72c499e927c52977b641d86_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTEtMS0xLTE0MTE1Mg_5778c6c1-df7b-4bb2-b7ee-e92c4c81b280"
      unitRef="usd">909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i266d7b2f5a4648a7aedcb54343a73155_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTMtMS0xLTE0MTE1Mg_037ace18-83dc-46ca-916f-48cd0fb524be"
      unitRef="usd">610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95007a0364764d788c9f338d90b37fa4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTUtMS0xLTE0MTE1Mg_7775540b-06e4-4546-8dfa-bb7f942a3c67"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6658a131071b4edaa7cac05c6b6aca94_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTctMS0xLTE0MTE1Mg_62cd04ee-69c5-4e2d-955d-fbcaf5a435ab"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5309925cea74e63b88ce62afbe1270d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMS0xLTEtMTQ0MzAw_065962ae-bdc2-4668-81dc-e4699bf68316"
      unitRef="usd">3312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97bc9d7d5aef436ca66c436814c83b71_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMy0xLTEtMTQ0MzM2_c9a9ad0f-c423-4180-881f-257d4e8ceb5e"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a35093b025c442e91e33f19fb5407bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNS0xLTEtMTQ0Mzc1_54def943-d89e-4a26-aea6-16851ce40078"
      unitRef="usd">4911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ea2540506a544eeb708632b6b53f89b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNy0xLTEtMTQ0NDIz_fe321627-dd37-4322-8f1e-d5324013569b"
      unitRef="usd">3055000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65bc255eecd04f718e0dce31409bbb26_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtOS0xLTEtMTQ0NDU1_0c08ab01-cc0d-4758-a337-36cc7de326cc"
      unitRef="usd">1578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb16e9319e664cac9a96f3740dd8c930_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTEtMS0xLTE0NDM5OQ_a40384e8-9bf0-437d-9c57-7f6f1cba26d4"
      unitRef="usd">4633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4d0840a435a423cb7726c98d53dbb8a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTMtMS0xLTE0NDA2Nw_782e7422-65f2-440d-aec3-a45560fc165d"
      unitRef="usd">2528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cf111df6fc94178a8bb5ccf9404c15b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTUtMS0xLTE0NDA1OQ_3943bf99-fb5c-4ddb-a0fa-791ca80a792e"
      unitRef="usd">1299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8f9352783e947fabf0e74936ba854ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTctMS0xLTE0NDA3NQ_5e411da9-c83d-4a4a-a2ff-a729328aec4f"
      unitRef="usd">3827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b14d4227e848e0add48cdc505946e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMS0xLTEtMTQxMTgw_00ecc787-f2ee-473e-ae3e-997a813c6e19"
      unitRef="usd">744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie02edf62965645468d841ff2e20bd583_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMy0xLTEtMTQxMTgw_63488e13-7c7f-4b75-96b6-3c77f2f843fc"
      unitRef="usd">1485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ee3c0309a9465098537a7f86a5ed19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctNS0xLTEtMTQxMTgw_3ba4afb9-ab62-4c5b-a9bd-c614aa5139d0"
      unitRef="usd">2228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaaac1cd808c424895d59867a9db30ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctNy0xLTEtMTQxMTgw_9ebe0c94-d35c-4dee-bd08-e6f697e31313"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd3cec840750475fa319163520fd421c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctOS0xLTEtMTQxMTgw_5e7c7d2f-0bcc-49f9-875f-5e9c50fd4e23"
      unitRef="usd">1431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if97a3d07e8ae412080d39dd505633b22_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTEtMS0xLTE0MTE4MA_851a231b-6003-4692-9695-0f16b5f5b3d0"
      unitRef="usd">2209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4e2fdd1216d48ad9a132b46e9f04cc1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTMtMS0xLTE0MTE4MA_96ae71b8-803a-4686-99e9-5fd417c713a2"
      unitRef="usd">728000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2c84859c22a480cb0e62d9cee342cf9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTUtMS0xLTE0MTE4MA_42fe00b0-04ac-4bca-bd0f-13cffa34bb1f"
      unitRef="usd">1247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4b43961f16149e79908d1ce39fcce65_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzctMTctMS0xLTE0MTE4MA_c17c586f-a3ff-4deb-a855-0d8c130bc8b0"
      unitRef="usd">1975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6511ff7f1ebd4c868948a72045ca4c95_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMS0xLTEtMTQ0MzA4_f367390a-432c-4730-95b4-081a847f5d7a"
      unitRef="usd">915000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2cccfcfa0da4d0ba64bd068cb216aaa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMy0xLTEtMTQ0MzQ0_a2c3cab7-dd9c-423b-a343-eaa3ed69307e"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41ef965318ec475d8fe145a03272291f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtNS0xLTEtMTQ0Mzc5_3cb52264-a92e-4f8d-b167-408fa2893ded"
      unitRef="usd">1019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f013c49cfa4e968944e9f014b68096_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtNy0xLTEtMTQ0NDMx_e27f11ba-ff40-4016-9f09-d4aab4e85646"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id84b586d1c33476cab5cd06fe83b53aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtOS0xLTEtMTQ0NDYz_2ae6e46c-9404-4613-b73e-de9ee8b47723"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib63f895c42144907a76b542b549cfab7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTEtMS0xLTE0NDQwMw_e18b9e5c-10bf-4a66-a1cb-bc43f5210a83"
      unitRef="usd">829000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c142c5abcd44f2097601e910946d27f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTMtMS0xLTE0NDA4Mw_5c1215f8-7046-4485-95be-098e2435fb1f"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4badae83fb2143539a2f1dbc8f190c16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTUtMS0xLTE0NDA5MQ_7760b451-7882-4d53-a265-f6e864f5c93f"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i087cbed8b29e42feabd968d6ded400ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzgtMTctMS0xLTE0NDE3NA_250441db-e774-41db-9732-a2b338c3b5e2"
      unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i788426412f1a40f8ad96ce8056faccd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMS0xLTEtMTE4ODMz_4f49df4f-e12f-4c3f-a48d-82014aa59431"
      unitRef="usd">1337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bff9d1f551440a688b46d38ff22c6f3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMy0xLTEtMTE4ODMz_b687fd36-9c3c-472d-8409-e16cc72a110b"
      unitRef="usd">763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3332eee0684d473898c31f79884ac25f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNS0xLTEtMTE4ODMz_f7c37d61-a455-46f1-88ab-272f3ecd068c"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47b385711e244459b5bc15b4489ddc67_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtNy0xLTEtMTE4ODMz_7dddc5c5-51a0-48f7-8ba3-96cc23e20b85"
      unitRef="usd">1214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83c36f07461a4edb956649b1e7840283_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtOS0xLTEtMTE4ODMz_d638a752-e57e-4495-b51f-c41318aa65df"
      unitRef="usd">805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i367ed0de181442618fa9e97ba29c26ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTEtMS0xLTExODgzMw_91955050-1c92-437e-a987-206c7a3150d2"
      unitRef="usd">2019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc9d01f0516547888439cdac0d45255e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTMtMS0xLTExODgzMw_9882d258-74b1-4aeb-bffb-174132d9effd"
      unitRef="usd">992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46ee1376ff224dada10dcbfa895cde79_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTUtMS0xLTExODgzMw_30ebaba4-e76d-4540-ab44-10f685c68063"
      unitRef="usd">712000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd5934a9c4b546c8aa8a37ac4ff145ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzUtMTctMS0xLTExODgzMw_54ecca97-c8f3-47bf-b3cf-316ee5d661bd"
      unitRef="usd">1704000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9327fc2252e47e68dedb4bf033c1d99_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMS0xLTEtMTE4ODMz_250f231c-d1fa-461f-a584-4c945af22b77"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i980a462ea63b44bfb0e472d26c91addf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMy0xLTEtMTE4ODMz_c52552d2-05e1-49fb-96c8-c58f0e35e22c"
      unitRef="usd">310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24f3dfdce6e044c1af8a7d768e300200_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNS0xLTEtMTE4ODMz_9fef4904-a945-44d7-b827-8dc819af4385"
      unitRef="usd">585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d5d84cf74294152822468efbefec311_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtNy0xLTEtMTE4ODMz_25baa9e8-497f-40e7-a835-c716585e6313"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e041f4904a84a60b8108cc9c8334104_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtOS0xLTEtMTE4ODMz_f797c350-3dee-47f3-9370-9163bf1f36be"
      unitRef="usd">237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i050e41d3f89a4c0a99eec3c08767ddc2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTEtMS0xLTExODgzMw_04b6531b-3f31-407e-b86e-cd0a6546bc1d"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie67b272c44934fe18e99394c9d6804bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTMtMS0xLTExODgzMw_d1c8924e-a8ff-46d9-bacd-dc64be96a779"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i270ce9e6a3b241c8adb7451d55aeab6e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTUtMS0xLTExODgzMw_1740f473-1697-4749-b515-112ee46eb982"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i581ceebdfc92445686149ad51b8ce5c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzYtMTctMS0xLTExODgzMw_3f81514c-8f23-4a19-aabf-2fcd372a0646"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i299c0a24457a49c48fa0b7f8274dfbcc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEtMS0xLTE0NDMxNg_978007fb-8de3-4c88-8a10-c0c2d58b0edd"
      unitRef="usd">3271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a11a2bfead64c0d8b223433c88c9be4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTMtMS0xLTE0NDM1OQ_cec00bcf-262c-4a4f-a102-659d7f5278cb"
      unitRef="usd">2662000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93d0aad282314e139497edd5e2dedbd2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTUtMS0xLTE0NDM4Nw_fba5d427-c1eb-4a25-8d22-ddc60c7ca89d"
      unitRef="usd">5932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f4ab88945f40329c0a824cc3ac5fc8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTctMS0xLTE0NDQzOQ_168e2d8f-4f97-4574-97e5-edee753d6c76"
      unitRef="usd">2850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c06369961704a7285b3ca38acb83219_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTktMS0xLTE0NDQ3MQ_9c78cb6d-6860-494f-8bfb-9747858b8771"
      unitRef="usd">2572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fe90759eb8f424d8234de45b7a2a52f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTExLTEtMS0xNDQ0MTE_d15349a9-1620-45bb-96d4-d840f05e4f01"
      unitRef="usd">5422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i907ac35c98df416294ddae9f68675c91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEzLTEtMS0xNDQxODI_b546fcc3-e8e9-4644-823f-48faf9e5ae71"
      unitRef="usd">2091000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fa4826270924bc38ed4e2b1152cc626_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE1LTEtMS0xNDQxOTA_a65512be-5b3d-4bc9-ae08-e60c85a52142"
      unitRef="usd">2199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a81b7be7914312a976ebf95b9963e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE3LTEtMS0xNDQxOTg_5861dcd1-38f8-48ee-bfde-b879d47af0cb"
      unitRef="usd">4290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16c43cfb6b094f59988dda6095180014_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMS0xLTEtMTE4ODMz_5a0ac541-b6d1-4abe-985a-0d3cb075a628"
      unitRef="usd">1048000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib49ee4af7f4d4a8687f9f49af6e015b4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMy0xLTEtMTE4ODMz_1a70c72e-c702-4619-b99c-233ca59e5b2c"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieff090cbc1c5471fb8af72a026fedd32_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktNS0xLTEtMTE4ODMz_141d9b72-48ff-4088-813d-794655418115"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c4af7a1ce94cab93068e8d456e80ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktNy0xLTEtMTE4ODMz_148c2ee2-00d5-47d6-a616-c93121f2cd44"
      unitRef="usd">996000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84ce6d1a01654d339cdd042cff9f100c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktOS0xLTEtMTE4ODMz_9de7c77c-b289-403b-b417-44226ecefaaf"
      unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bcf6149b1404f96a68187ed3c062a35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTEtMS0xLTExODgzMw_fd190084-cb06-4731-ad80-c0e621c63a99"
      unitRef="usd">1820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d9c77c73b8241e1a75da0171dba04aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTMtMS0xLTExODgzMw_61f748f6-f884-4ede-b1f7-0df3fcafcb61"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6797d90a509d4ec8834a36e34146765f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTUtMS0xLTExODgzMw_2f70285b-a991-4971-8bcd-359585f0fe94"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i242b0d85ba4e4a2fbe4aed3cf9b322a3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzktMTctMS0xLTExODgzMw_ae0c67ca-3b67-4c54-b77d-a6129a08ed5b"
      unitRef="usd">1577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05dda8644a90446b877b0a66f32d173a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTEtMS0xLTE0NDMyNA_3e2ceeae-1e34-461a-925d-2dc6048a38b5"
      unitRef="usd">4319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19f123aba421447aa9cfc9708023f08c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTMtMS0xLTE0NDM2Nw_531e9fe3-8072-42af-a74f-51063d5c197e"
      unitRef="usd">3512000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaebb18f5a9d54b678ab70d269fb7f7c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTUtMS0xLTE0NDM5NQ_2ae78525-dec3-4c1c-81af-526e9735bb3d"
      unitRef="usd">7831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fd26528424d45f2883dba765d3955d2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTctMS0xLTE0NDQ0Nw_100366cd-26df-4630-b0c5-671d06ad87af"
      unitRef="usd">3846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd88a51eb14a4889becd9bf95a373936_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTktMS0xLTE0NDQ3OQ_211f6d8b-54f4-4ccd-bc84-d38ca2274e76"
      unitRef="usd">3396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecb9fb9238a440629faa09412375647f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTExLTEtMS0xNDQ0MTk_6ea3d39c-0ae1-4cec-a343-f16e01a918aa"
      unitRef="usd">7242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e1f6bf8d3c34daab2415fdc9e3dd952_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTEzLTEtMS0xNDQyNzY_ac87b836-c821-4de0-a789-ca4b5c4d533e"
      unitRef="usd">2979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i210171398abc49e5804c051f9b9fc4cd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTE1LTEtMS0xNDQyODQ_bad7565c-7d91-476c-ba48-63a0894cdf52"
      unitRef="usd">2888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i274cfeec0ff2441cb77cbbf065496cf8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEzLTE3LTEtMS0xNDQyOTI_5c5178a4-3b88-4923-b9ec-237186feece6"
      unitRef="usd">5866000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4d2ba2b1796414eb8143d8705a0465a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTEtMS0xLTExODgzMw_d0bba16e-b951-42ae-be39-d1db01dfc0b3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ab10efbdcf47528ab3d60926612e2f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTMtMS0xLTExODgzMw_df2c2002-5893-43e5-9fb8-d8eddeddd097"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTUtMS0xLTExODgzMw_8bcc94cc-9faa-46d7-ac90-49b5d80ddf5a"
      unitRef="usd">-60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb5baeedb7124b2f84ddb781633016f5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTctMS0xLTExODgzMw_5ca13ed1-b7f1-4566-bad9-f83f7a365829"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9be1b83b1a924f748b1636472e5583be_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTktMS0xLTExODgzMw_c2031c5d-01d4-4860-bfa3-8a19b921b03e"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTExLTEtMS0xMTg4MzM_91a7a7ba-4c9c-46a8-b9b5-3af779834374"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50b2f64263444c3080cc6d662586f06c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTEzLTEtMS0xMTg4MzM_ba73e570-03f0-4613-b6ae-217ab03dfbee"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30fe7e8d201c4c45ae3804080539f315_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTE1LTEtMS0xMTg4MzM_101cb585-b693-4a56-ae39-330149c2b5a8"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzEwLTE3LTEtMS0xMTg4MzM_4365d31b-cc9c-445b-915d-7c4d6fc03337"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if85ad4347a4c4b54ae5c5fc3193a7800_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEtMS0xLTExODgzMw_ba486110-7b5a-474f-bb90-1babd6a7c464"
      unitRef="usd">7632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ea4c3278ec34a698de1ffba66d08cf6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTMtMS0xLTExODgzMw_8ce7128f-62ba-4f8f-bf85-bafc2a402f87"
      unitRef="usd">5111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTUtMS0xLTExODgzMw_fab9d006-a9ab-4bbf-8975-90b9a9287f66"
      unitRef="usd">12682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c3c6b5d49ff44128141a1fbb83b6e1b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTctMS0xLTExODgzMw_28998b05-2650-4a59-9b2c-c03e8d1d9d62"
      unitRef="usd">6911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12859b60da9b499db05018d9639782ce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTktMS0xLTExODgzMw_56a3b13d-0023-4798-ab40-e2ae1e8e74bf"
      unitRef="usd">4978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTExLTEtMS0xMTg4MzM_79cdbdb5-d119-4620-9969-6b7336df4a58"
      unitRef="usd">11888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d5ab671eea46b3bff921eba5cde3cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTEzLTEtMS0xMTg4MzM_2d821354-4529-44f6-932c-589a52d82474"
      unitRef="usd">5701000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb42a43becfb4015933cfee5cff72004_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE1LTEtMS0xMTg4MzM_85aa3746-f04a-42c3-808c-a6af74bb6b43"
      unitRef="usd">4212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTpjNTY4YWQwM2M0YjA0ZDg1YjIzNzJjNWQxNzNhZTg2OC90YWJsZXJhbmdlOmM1NjhhZDAzYzRiMDRkODViMjM3MmM1ZDE3M2FlODY4XzExLTE3LTEtMS0xMTg4MzM_441b8c91-a344-40c1-b6f0-a815eee7f685"
      unitRef="usd">9913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51fd28aa8356476e99b8acb0eca6d645_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItMS0xLTEtMTE4ODMz_272da4fd-036a-4752-b656-6d94906611e7"
      unitRef="usd">7632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63f7de2437fa49bfac860e607810e395_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItMy0xLTEtMTE4ODMz_8d936e35-0f3c-4284-b28f-c0f1d12c3ae9"
      unitRef="usd">6901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa737befb7b447a8ba19436619112479_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzItNS0xLTEtMTE4ODMz_1648e2ea-8556-4d89-a053-0e303c5319ee"
      unitRef="usd">5508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifead762c7ade4e00b9129c72020dc3b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtMS0xLTEtMTE4ODMz_86f063f2-d35d-43d4-a159-27aaed13d31b"
      unitRef="usd">2526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5b812ed03474859ab0a0548820d732e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtMy0xLTEtMTE4ODMz_45c445ce-3bf4-472c-acbc-622931411d11"
      unitRef="usd">2518000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4fc248e09be4de88c3b1366bed3d1e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzMtNS0xLTEtMTE4ODMz_0569078d-ca4b-410f-9bc2-7e982121eebe"
      unitRef="usd">2097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0d8f6746e354f2e87c087199c9722d1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtMS0xLTEtMTE4ODMz_a5b19127-521f-44c2-a48c-aa1c2fbe31f5"
      unitRef="usd">2116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75aca95e90e14d6f8ad7d91562c55653_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtMy0xLTEtMTE4ODMz_16c9e0f3-1778-41e2-8193-4449031174bf"
      unitRef="usd">2070000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b0c54a79abb4963befbf39f66d3391e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzQtNS0xLTEtMTE4ODMz_9f2309f0-d5de-4494-b0a1-6766d664ee11"
      unitRef="usd">1781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d7ba54afdd9452783afd6d19b9919ba_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtMS0xLTEtMTE4ODMz_550ef119-aead-46e6-b33d-4db1f613f7a7"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0809617f4324434aaebbd5728f20d9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtMy0xLTEtMTE4ODMz_9ea10706-8adc-4e20-94c1-d3554bc998f9"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i950de22b68424e98860e7337e3026204_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzUtNS0xLTEtMTE4ODMz_928bc919-45d2-404f-bc59-547ef2b2608a"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03d22f9c33104b9ab0866975be8b8ad2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktMS0xLTEtMTE4ODMz_8bcc94cc-9faa-46d7-ac90-49b5d80ddf5a"
      unitRef="usd">-60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ce71bb91b04ba29696f4a106a3b64c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktMy0xLTEtMTE4ODMz_91a7a7ba-4c9c-46a8-b9b5-3af779834374"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc313555a9045148da0ff038ffebe93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzktNS0xLTEtMTE4ODMz_4365d31b-cc9c-445b-915d-7c4d6fc03337"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTEtMS0xLTExODgzMw_74d9c981-62b6-4ffe-bbe7-9c411ee31855"
      unitRef="usd">12682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTMtMS0xLTExODgzMw_dbf924b3-ff23-4869-ae3a-c41d8973a711"
      unitRef="usd">11888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEwLTUtMS0xLTExODgzMw_441b8c91-a344-40c1-b6f0-a815eee7f685"
      unitRef="usd">9913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9523ca0ea2849a3ba7afdb3f792faac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTEtMS0xLTExODgzMw_2acb1b58-51ea-41c5-b30c-e1535f6bc7bf"
      unitRef="usd">1715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id12a969e10ec48b990fe38bdaab38a23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTMtMS0xLTExODgzMw_e634d522-03a3-47cd-a7b8-78aec7a62ce7"
      unitRef="usd">1429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ef567bf8d9645e88d19c89d931dc420_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90YWJsZTo3Yzc4YTA0ZWVjZmE0MTg5YTg3NDQ1ZDg4ZmVjNWMyNy90YWJsZXJhbmdlOjdjNzhhMDRlZWNmYTQxODlhODc0NDVkODhmZWM1YzI3XzEyLTUtMS0xLTExODgzMw_f7604dd4-f3d5-4ed6-bb7a-b1b490f71e01"
      unitRef="usd">1138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bsx:EmergingMarketsTotalNumberOfCountries
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzMwOA_9d3b583c-0ed0-40e1-a644-a77424f9c7e3"
      unitRef="countries">20</bsx:EmergingMarketsTotalNumberOfCountries>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzYxMw_0dde9e8d-c7c5-4455-a99d-dce2461c95fb"
      unitRef="usd">509000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzYyOQ_e96166ee-4821-4be7-823a-5125dbe9353e"
      unitRef="usd">484000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzExOTg_9938cb27-abc1-455e-ac29-7c9ca0072768"
      unitRef="usd">156000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNDgvZnJhZzplY2YzNWY5YzU4YjU0YWYxODhhNWJhM2FkNTNjNDMxOC90ZXh0cmVnaW9uOmVjZjM1ZjljNThiNTRhZjE4OGE1YmEzYWQ1M2M0MzE4XzEwOTk1MTE2MzQ1MTI_96d821be-b36f-4937-9cd2-0737d59c8076"
      unitRef="usd">179000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90ZXh0cmVnaW9uOjYyZmM1NWNlNzBiZTQ2MDBhMzY0YWUyMWQ3MmE4Y2Q0XzYxMA_e724b35b-1d2a-4c60-9bc8-f6dfea762d50">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE O &#x2013; CHANGES IN OTHER COMPREHENSIVE INCOME &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the reclassifications out of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Defined Benefit Pensions and Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) loss amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Defined Benefit Pensions and Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) loss amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note D &#x2013; Hedging Activities and Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further detail on our net investment hedges recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and our cash flow hedges recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net change in derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss), net of tax&lt;/span&gt; were reduced by immaterial income tax impacts in 2022 and in 2021.</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90ZXh0cmVnaW9uOjYyZmM1NWNlNzBiZTQ2MDBhMzY0YWUyMWQ3MmE4Y2Q0XzU5OA_a292e68b-459e-424b-b8cd-a8580755ca0d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the reclassifications out of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Defined Benefit Pensions and Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) loss amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Change in Defined Benefit Pensions and Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) loss amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtMS0xLTEtMTE4ODMz_9705b7d2-e30e-4563-a657-41bc9a75ef23"
      unitRef="usd">93000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtMy0xLTEtMTE4ODMz_a1a03458-9b39-4ba2-a44a-19b985a5c2ab"
      unitRef="usd">206000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtNy0xLTEtMTE4ODMz_b1ed8bfb-c5ca-465d-b05f-4945492acbf9"
      unitRef="usd">36000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzEtOS0xLTEtMTE4ODMz_c11ed53f-0bfc-4113-87be-91877e52d9a7"
      unitRef="usd">263000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItMS0xLTEtMTE4ODMz_3fc80620-9c08-41cf-ae05-a55b855cdfa7"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItMy0xLTEtMTE4ODMz_8bcee189-5d3e-424a-9416-1c2fe4e3eb40"
      unitRef="usd">214000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItNy0xLTEtMTE4ODMz_7852a796-6319-42c5-bf99-9946958b15ff"
      unitRef="usd">36000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzItOS0xLTEtMTE4ODMz_07fc8b5b-6ed1-42f5-bc65-69d5c1d35af3"
      unitRef="usd">163000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtMS0xLTEtMTE4ODMz_3f0e7e24-534a-4069-aac5-6162154be177"
      unitRef="usd">-8000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtMy0xLTEtMTE4ODMz_291ead42-82b4-4f66-a96d-cc8a710d6e7c"
      unitRef="usd">150000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtNy0xLTEtMTE4ODMz_08dc0511-af74-447a-9f8e-c522b090c886"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzMtOS0xLTEtMTE4ODMz_da841578-1ff9-42b0-a2c1-a04780fa24eb"
      unitRef="usd">-157000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtMS0xLTEtMTE4ODMz_9657a9de-f7b1-4d13-b202-412d3d1eb7bf"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtMy0xLTEtMTE4ODMz_3d67498f-d071-4a3e-b851-5f8483446d8e"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtNy0xLTEtMTE4ODMz_2a723380-5b12-47dd-b722-10b822971698"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzQtOS0xLTEtMTE4ODMz_875b0dbe-d6aa-4bf6-9408-7668e40da323"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtMS0xLTEtMTE4ODMz_7828f077-f237-494d-ab13-0fe15cb22fd1"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtMy0xLTEtMTE4ODMz_bb39542f-58df-48bb-99ff-92dd8bba52e5"
      unitRef="usd">269000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtNy0xLTEtMTE4ODMz_e84134ba-8825-45dd-ac32-39592326e2aa"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToxNGUyZWMwNWZhMzk0MWM0OWM1YzVkNzEyYTAxOTg5My90YWJsZXJhbmdlOjE0ZTJlYzA1ZmEzOTQxYzQ5YzVjNWQ3MTJhMDE5ODkzXzUtOS0xLTEtMTE4ODMz_a9581477-4081-47f6-be10-bf28c30d320b"
      unitRef="usd">269000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtMS0xLTEtMTE4ODMz_a774dfc9-df80-42bd-afaa-30bfbd05312a"
      unitRef="usd">218000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtMy0xLTEtMTE4ODMz_48e007f0-3918-43e8-bc5d-b4c6859e6dca"
      unitRef="usd">36000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtNy0xLTEtMTE4ODMz_1a328ca3-f79f-42c3-89de-05736f8cad60"
      unitRef="usd">47000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzEtOS0xLTEtMTE4ODMz_e33fad8b-a610-42d4-af6e-97c884c4c8ab"
      unitRef="usd">207000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItMS0xLTEtMTE4ODMz_69e1f539-bb65-48dd-8518-938af86efc7d"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItMy0xLTEtMTE4ODMz_c6ca4109-316b-4077-b688-6e64e84d9ca4"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItNy0xLTEtMTE4ODMz_e4be3bac-3d86-4284-be44-db97b63cecc1"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzItOS0xLTEtMTE4ODMz_88a614ef-274d-4b43-828c-50a5edc394e9"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtMS0xLTEtMTE4ODMz_6104e955-657c-467a-8d93-b305005ba5dc"
      unitRef="usd">-137000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtMy0xLTEtMTE4ODMz_c57dbda0-5184-4da6-9c18-7409ebb0257e"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtNy0xLTEtMTE4ODMz_e7775119-74bb-4cc6-b69a-034cea09c867"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzMtOS0xLTEtMTE4ODMz_1430b248-1adc-4658-ad6c-14582f31ad59"
      unitRef="usd">-173000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtMS0xLTEtMTE4ODMz_6ed8290c-4833-40a8-9c9f-d8ce86905055"
      unitRef="usd">-125000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtMy0xLTEtMTE4ODMz_bc43e799-d385-4345-976a-f6ed3d371c2f"
      unitRef="usd">170000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtNy0xLTEtMTE4ODMz_5fc33b89-2869-410f-9cf5-926e5e1c9da6"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzQtOS0xLTEtMTE4ODMz_07c71172-6d73-4f45-8ab4-f467f023123c"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtMS0xLTEtMTE4ODMz_9e6d93fa-6eb0-424a-8792-10c7d829b08c"
      unitRef="usd">93000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtMy0xLTEtMTE4ODMz_01af0968-c5b8-4462-af5d-e358306dbc89"
      unitRef="usd">206000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtNy0xLTEtMTE4ODMz_1aea7694-0adb-476d-96de-a1e4e8f46bc0"
      unitRef="usd">36000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTEvZnJhZzo2MmZjNTVjZTcwYmU0NjAwYTM2NGFlMjFkNzJhOGNkNC90YWJsZToyN2JkNzhjNGFjMmM0MzUyODMwZDQzZmU4YWM5NmIxNy90YWJsZXJhbmdlOjI3YmQ3OGM0YWMyYzQzNTI4MzBkNDNmZThhYzk2YjE3XzUtOS0xLTEtMTE4ODMz_936cf558-0133-4e90-8cee-dc3553e1267b"
      unitRef="usd">263000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <bsx:NewAccountingPronouncementsPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzQ4MDc_52d13e47-c5ab-445f-9b91-5a233c9fbaab">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE P &#x2013; NEW ACCOUNTING PRONOUNCEMENTS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Update No. 2021-05&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the FASB issued ASC Update No. 2021-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Lessors&#x2014;Certain Leases with Variable Lease Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Update No. 2022-06&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the FASB issued ASC Update No. 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Standards to be Implemented&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASC Update No. 2022-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASC Update No. 2022-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASC Update No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the FASB issued ASC Update No. 2022-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</bsx:NewAccountingPronouncementsPolicyTextBlock>
    <bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTI_e87cf1af-f983-41e6-a5b3-ab60ebefcf42">ASC Update No. 2021-05&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the FASB issued ASC Update No. 2021-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Lessors&#x2014;Certain Leases with Variable Lease Payments&lt;/span&gt;. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.</bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock>
    <bsx:ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzU0OTc1NTgzMDQ0MQ_bf409c21-91b1-43a8-8998-c3c4bf41390d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Update No. 2022-06&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the FASB issued ASC Update No. 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.&lt;/span&gt;&lt;/div&gt;</bsx:ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock>
    <bsx:ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTM_8299b62c-173d-47ea-bce2-dfc58661b995">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASC Update No. 2022-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;</bsx:ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock>
    <bsx:ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTQ_9d0ca528-fc9e-4797-a85c-d5a48c6b670a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASC Update No. 2022-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;</bsx:ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock>
    <bsx:ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTU_05d14281-a8af-4b7b-ba6a-7561a6e5a8be">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASC Update No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.&lt;/span&gt;</bsx:ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock>
    <bsx:ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNTQvZnJhZzo5ZjlmZmZiZjk4NTI0OGI1YTM4ODNmMTFkOGRkZDlhMy90ZXh0cmVnaW9uOjlmOWZmZmJmOTg1MjQ4YjVhMzg4M2YxMWQ4ZGRkOWEzXzE2NDkyNjc0NTY2OTY_bf76e467-056a-4f68-afbe-90aaff27e916">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the FASB issued ASC Update No. 2022-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. &lt;/span&gt;2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</bsx:ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3OTc_340dd8bc-071c-4c65-b853-2441f9cbdfb2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE Q &#x2013; EMPLOYEE RETIREMENT PLANS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.K. Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we maintain retirement plans covering certain international employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a December&#160;31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December&#160;31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligation (ABO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected&lt;br/&gt;Benefit&lt;br/&gt;Obligation (PBO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unfunded/Underfunded&lt;br/&gt;PBO Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligation (ABO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected&lt;br/&gt;Benefit&lt;br/&gt;Obligation (PBO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unfunded/Underfunded PBO Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes in the PBO for our retirement plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments and assumption changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The critical assumptions associated with our employee retirement plans for 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Expected Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Rate of Compensation Increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The critical assumptions associated with our employee retirement plans for 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Expected Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Rate of Compensation Increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buy-in contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of the U.K. Plan Level 3 assets were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Buy-in Contracts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December&#160;31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Post Retirement Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 - 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200&#160;percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODM_c8b3e4b4-d6df-4a52-979d-eae0e7a344fa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a December&#160;31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;.</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY4MDc_82dba5fc-4e03-4b97-9651-9365128bc2b9">The outstanding obligation is as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligation (ABO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected&lt;br/&gt;Benefit&lt;br/&gt;Obligation (PBO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unfunded/Underfunded&lt;br/&gt;PBO Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligation (ABO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected&lt;br/&gt;Benefit&lt;br/&gt;Obligation (PBO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unfunded/Underfunded PBO Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItMS0xLTEtMTE4ODMz_7c87a8d8-d67a-49ab-8616-2f3b16880ea9"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItMy0xLTEtMTE4ODMz_b592d9a7-ef1a-4283-a026-e8b92c6154fb"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItNS0xLTEtMTE4ODMz_5d39561a-94d8-4196-b855-e48ff44f98dd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i139d04cb2ec14e418ffc5d45192844cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzItNy0xLTEtMTE4ODMz_91c61d29-ea2b-4d19-8657-1bf93fecdba6"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtMS0xLTEtMTE4ODMz_e0414159-42d4-48f3-94c0-70c65a9b39d0"
      unitRef="usd">140000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtMy0xLTEtMTE4ODMz_ee41ff6c-441e-49a9-ba1e-495b99aed969"
      unitRef="usd">152000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtNS0xLTEtMTE4ODMz_2c1decc5-9711-4db4-a341-f1167d0b8797"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ib2c3fb77fc3542338e354336e20bc3a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzUtNy0xLTEtMTE4ODMz_f6e6d558-8acd-4f04-bacf-6fbd48a0cc1d"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtMS0xLTEtMTE4ODMz_8364a2d0-2e9b-4381-8ba7-be62906eedff"
      unitRef="usd">190000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtMy0xLTEtMTE4ODMz_887660e1-41fa-4c54-8078-585f85da46b9"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtNS0xLTEtMTE4ODMz_b1c96cbf-9919-400b-ad01-0756a5956db4"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo1ZmU5NDAwMmFjOGY0ZDI4YjlhZDcxOWE3ODc5Mjg4NC90YWJsZXJhbmdlOjVmZTk0MDAyYWM4ZjRkMjhiOWFkNzE5YTc4NzkyODg0XzYtNy0xLTEtMTE4ODMz_cad2a24f-a8bf-4284-89a9-83b8b5db7192"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItMS0xLTEtMTE4ODMz_a3840776-8dd0-4fdc-8b41-fa11a8eca93d"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItMy0xLTEtMTE4ODMz_025f2324-3003-432b-bc88-503397c80b3e"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItNS0xLTEtMTE4ODMz_e91a730b-a925-466a-b280-f282a75512ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ie472ffec11ea4927bd1542ae98aa108f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzItNy0xLTEtMTE4ODMz_da2e80fd-8b58-495b-a489-71d8479ddf8e"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtMS0xLTEtMTE4ODMz_f1e115d4-a24e-4e04-be43-f3e0b96a8b31"
      unitRef="usd">209000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtMy0xLTEtMTE4ODMz_6c9e7483-c76e-4900-a259-8b5aae758ac2"
      unitRef="usd">209000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtNS0xLTEtMTE4ODMz_f6790b06-3680-47c9-b82c-e974255b579e"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzMtNy0xLTEtMTE4ODMz_34c4a2d1-2222-4cd7-9d3d-948c0d7fd9a8"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i07418139cdce4f5c981ed2c683522433_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtMS0xLTEtMTE4ODMz_af6b66c8-9013-486d-a2af-4a2da17ebc71"
      unitRef="usd">214000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i07418139cdce4f5c981ed2c683522433_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtMy0xLTEtMTE4ODMz_7175f06c-a39c-47e0-b86e-b932ca4e58f4"
      unitRef="usd">234000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i07418139cdce4f5c981ed2c683522433_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtNS0xLTEtMTE4ODMz_7cb82818-9738-4e1d-bc6c-b78742bead58"
      unitRef="usd">130000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i07418139cdce4f5c981ed2c683522433_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzQtNy0xLTEtMTE4ODMz_8ae79468-27a8-4262-8e53-440a9c5355e0"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtMS0xLTEtMTE4ODMz_42f76969-2fff-4994-abd7-7e14e19d86d2"
      unitRef="usd">478000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtMy0xLTEtMTE4ODMz_c8322e82-76aa-41ca-98e5-903002f4d29f"
      unitRef="usd">502000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtNS0xLTEtMTE4ODMz_4612c97c-ec15-4d4f-8aed-d3358d95e62a"
      unitRef="usd">336000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2OTQ2ZWRlZjVhNTA0MWQzOThlNTk0MTNmMzQ5MDY2YS90YWJsZXJhbmdlOjY5NDZlZGVmNWE1MDQxZDM5OGU1OTQxM2YzNDkwNjZhXzUtNy0xLTEtMTE4ODMz_73e0ec65-71c9-4184-89fe-a018d673db9d"
      unitRef="usd">166000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODU_98da36dd-4599-474f-acf3-083f2adc5cc6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes in the PBO for our retirement plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments and assumption changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzItMS0xLTEtMTE4ODMz_0f90d7a4-0523-4c4d-b405-ba59243fe8cd"
      unitRef="usd">502000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzItMy0xLTEtMTE4ODMz_0514183b-4758-4b36-95bd-8d9a29eef9a9"
      unitRef="usd">532000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzMtMS0xLTEtMTE4ODMz_cbe307a6-888f-4fb0-be65-bc948b2a6e57"
      unitRef="usd">0</bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO>
    <bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzMtMy0xLTEtMTE4ODMz_9e3fc49e-6a75-463f-8fcb-35cbcadd2c4f"
      unitRef="usd">4000000</bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzQtMS0xLTEtMTE4ODMz_01af9806-efdb-486f-a186-8ee007f50f2e"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzQtMy0xLTEtMTE4ODMz_62944b07-fa48-4f3d-9e0e-9d59daaf4379"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzUtMS0xLTEtMTE4ODMz_f9e1bef4-d114-4782-af8c-afdccdbae911"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzUtMy0xLTEtMTE4ODMz_493d5db3-8baa-4cdc-8cc1-6ed27c98d68d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzYtMS0xLTEtMTE4ODMz_265d4d25-7bb7-4640-913e-767314b4b6fb"
      unitRef="usd">-54000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzYtMy0xLTEtMTE4ODMz_c1d5d3ee-8d70-4b94-9d45-c1dca6793cd6"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMS0xLTEtMTYxODg5_c3d0858b-bd0a-4c1a-aa84-5cd4474da67c"
      unitRef="usd">191000000</bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO>
    <bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMy0xLTEtMTYxODk3_89154adc-6afa-4404-9860-d335b0a251cd"
      unitRef="usd">0</bsx:DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMS0xLTEtMTE4ODMz_33ade53f-5024-4a62-88fb-be543020dcee"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzctMy0xLTEtMTE4ODMz_0d82a16b-f167-4647-8488-f11911eeb831"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <bsx:Pensionbenefitobligationbenefitspaid
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzgtMS0xLTEtMTE4ODMz_4f7b05d9-c58a-4bde-8e93-96c517e93524"
      unitRef="usd">6000000</bsx:Pensionbenefitobligationbenefitspaid>
    <bsx:Pensionbenefitobligationbenefitspaid
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzgtMy0xLTEtMTE4ODMz_01a86f51-85e4-4875-b89a-1860aa060da6"
      unitRef="usd">22000000</bsx:Pensionbenefitobligationbenefitspaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzktMS0xLTEtMTE4ODMz_c80ed1dd-9a61-4888-a83a-c6d6419dc4e0"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzktMy0xLTEtMTE4ODMz_2c218f0c-066e-4920-bb1d-ba28e6a7a0bf"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzEwLTEtMS0xLTExODgzMw_2d3b2fd7-73f5-4456-a000-b215c0500fc1"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTplZmRhMzdiMDRiYjI0ZDY5ODE2MzE4ODQ0NzgyNzYyYi90YWJsZXJhbmdlOmVmZGEzN2IwNGJiMjRkNjk4MTYzMTg4NDQ3ODI3NjJiXzEwLTMtMS0xLTExODgzMw_49d45ffb-2dd6-4c72-860c-88895c97c1d1"
      unitRef="usd">502000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3Nzg_8910ebb7-1192-4afa-a724-529f8be7b664">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The critical assumptions associated with our employee retirement plans for 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Expected Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Rate of Compensation Increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The critical assumptions associated with our employee retirement plans for 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Expected Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Rate of Compensation Increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other International Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i398d31599a9a4c7a862b268487b31675_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzItMS0xLTEtMTE4ODMz_211a129a-9515-4403-8fdb-0257e48a54b5"
      unitRef="number">0.0532</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i398d31599a9a4c7a862b268487b31675_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzItOS0xLTEtMTE4ODMz_b072a88b-65d0-428a-9482-0249ceda02ac"
      unitRef="number">0.0200</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtMS0xLTEtMTE4ODMz_7b68adab-7de9-465e-a7c8-0b54a7809733"
      unitRef="number">0.0262</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn
      contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtNS0xLTEtMTE4ODMz_2412b637-47e1-4e63-8109-c0310752a2e8"
      unitRef="number">0.0227</bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ifc9b3b9fa25c4e5cb37a77efdeffa647_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo0ZmY3NjZiMjlmZGU0OTIzODU1NDI3N2I0MjNjODhmMC90YWJsZXJhbmdlOjRmZjc2NmIyOWZkZTQ5MjM4NTU0Mjc3YjQyM2M4OGYwXzQtOS0xLTEtMTE4ODMz_5284dd6c-2fe8-4f30-a01a-591619d39e2c"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i0a709d6c9a0b41feab31995bae094f9b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzEtMS0xLTEtMTE4ODMz_414f629a-9903-41fc-a10f-5c882e098e3b"
      unitRef="number">0.0240</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i0a709d6c9a0b41feab31995bae094f9b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzEtNS0xLTEtMTE4ODMz_504b8b3f-f321-4f94-9a0e-90756611e972"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzItMS0xLTEtMTE4ODMz_cae6f874-0109-474b-8465-1a053119956e"
      unitRef="number">0.0070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn
      contextRef="i612cb9d1f2e9439e8b5538c65cd7ec37_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzItMy0xLTEtMTE4ODMz_8c46bd8b-f32b-40a4-a60a-498a806ff7d5"
      unitRef="number">0.0070</bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtMS0xLTEtMTE4ODMz_1e6ae80d-3d20-4836-bd0a-2c2465330564"
      unitRef="number">0.0082</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn
      contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtMy0xLTEtMTE4ODMz_903a295d-e01a-4b7f-bdd7-395b9d408c26"
      unitRef="number">0.0216</bsx:DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ib0defaaf4f864ebf8ba1161c5141c0da_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpkMGVmNGFiYzQ4YTQ0YzQwYjQzZmEzMTNhNTYzMTU3NC90YWJsZXJhbmdlOmQwZWY0YWJjNDhhNDRjNDBiNDNmYTMxM2E1NjMxNTc0XzMtNS0xLTEtMTE4ODMz_fdd8201e-183e-45d6-a3e9-6c8a9e6d67e7"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3ODc_fdf7047b-554f-4b15-a5d6-2bcd0864e9ea">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buy-in contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of the U.K. Plan Level 3 assets were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Buy-in Contracts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments/settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency fluctuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzItMS0xLTEtMTE4ODMz_ca46e1cb-cb66-401c-bb4c-fc9e9793a047"
      unitRef="usd">336000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzItMy0xLTEtMTE4ODMz_6a601fef-e8f3-4ca0-9f0b-c056d3eebc3d"
      unitRef="usd">355000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzMtMS0xLTEtMTE4ODMz_7db17906-c704-4295-acf6-05d4fd881d6d"
      unitRef="usd">0</bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets>
    <bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzMtMy0xLTEtMTE4ODMz_37faac18-01dd-4794-9c74-04c725bd1984"
      unitRef="usd">1000000</bsx:DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzQtMS0xLTEtMTE4ODMz_bcad4ad4-479e-4fd0-b796-5da3e8d572da"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzQtMy0xLTEtMTE4ODMz_fb8c57ba-055c-4edb-a3a3-35537ecfeff2"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzUtMS0xLTEtMTE4ODMz_07091889-8923-41b2-9231-78001660cbcc"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzUtMy0xLTEtMTE4ODMz_e0fdf22a-54c3-4cf1-a8ba-074be6def165"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzYtMS0xLTEtMTE4ODMz_eb489598-9042-4e6b-a929-897e722a566b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzYtMy0xLTEtMTE4ODMz_1de83568-5ebe-44f0-9bcd-ea4900060bf4"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMS0xLTEtMTYxOTA3_43acbb4a-b5b3-400b-8d99-ab48d7678711"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMy0xLTEtMTYxOTE0_7d215eec-9345-43db-bb0c-dfbcbae072da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMS0xLTEtMTE4ODMz_5f6380dc-3362-486f-8453-3d0da95bd34e"
      unitRef="usd">-25000000</bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss>
    <bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzctMy0xLTEtMTE4ODMz_10cabc95-aa7f-470f-9fb6-da7cccf40f7a"
      unitRef="usd">-4000000</bsx:DefinedBenefitPlanPlanAssetsActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzgtMS0xLTEtMTE4ODMz_801d9537-cdec-4170-a037-3f322175293c"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzgtMy0xLTEtMTE4ODMz_5689d40d-c045-4521-b7d4-0b543d4ab33b"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzktMS0xLTEtMTE4ODMz_d676de94-6be2-4134-b297-77b90d15d106"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzktMy0xLTEtMTE4ODMz_fd8578a2-f7f1-4b46-98a0-f7236ef5491f"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzEwLTEtMS0xLTExODgzMw_e4c9e798-bb82-49f2-9491-c2a7e207ac51"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTphMzAwZDc2NTRjNDE0OWI5OGEzNDRiZTc0ZWU1NjdkZi90YWJsZXJhbmdlOmEzMDBkNzY1NGM0MTQ5Yjk4YTM0NGJlNzRlZTU2N2RmXzEwLTMtMS0xLTExODgzMw_f5a25256-82e2-403a-ad52-9b888df9895e"
      unitRef="usd">336000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i05bd241aa7bc46a3bbc132eb60cc014c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtMS0xLTEtMTYwNDc4_e899c09e-77c8-4734-9b5a-8b60259c7e62"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec61999347b74ca9980b9262bc2473a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtMy0xLTEtMTYwNDc4_edce293f-7be7-4410-ade5-aeffb4c7efd8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i649253125d3e41ff83d40817dfc4b57c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtNS0xLTEtMTYwNDc4_8a98cb44-7721-4557-af1a-86edc668103f"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i81025787d2734b4085a77f222cdb83c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzMtNy0xLTEtMTYwNDc4_807c5922-2dca-4d53-a187-45d9f52a0563"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i464a3ab08a074038b0b11f145f5be6ba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtMS0xLTEtMTYwNDc4_e57e43f3-0c77-4e97-9010-c1b816a3cd4f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54cf5d0c98a64efab2f25564d3cb8718_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtMy0xLTEtMTYwNDc4_ee736141-6d8e-4275-ae4d-b2deb85c1311"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d6c0f8faf13418e93bbab3e1cdb4719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtNS0xLTEtMTYwNDc4_e4fba817-af7e-4742-bb09-bb809cbdaeb3"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTpjN2E1YjAyZmMyYzk0YmU4OThlNjgwODcwZTNiYWI2NC90YWJsZXJhbmdlOmM3YTViMDJmYzJjOTRiZTg5OGU2ODA4NzBlM2JhYjY0XzUtNy0xLTEtMTYwNDc4_84e91b2b-6f13-45e0-9c02-57c33d481043"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifeb08f1519b743dbb5fc9131d58b1a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzEtMS0xLTEtMTYwNDc4_a1d5c57d-6d32-43e8-9251-92caa469dd60"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzItMS0xLTEtMTYwNDc4_973477f9-3360-46d1-b68e-d42cbbb2df9f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzMtMS0xLTEtMTYwNDc4_4c6f8b84-7f10-4aac-a724-9c9d08646667"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzQtMS0xLTEtMTYwNDc4_757926ef-003c-4e79-89c1-5a625dd796f3"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzUtMS0xLTEtMTYwNDc4_b94997f8-3554-4e8c-843e-3ee3ae3045d8"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzYtMS0xLTEtMTYwNDc4_8b6f4ec7-a470-4ca4-bc9a-1c690022e2a3"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iea0a26b009444019b8f5a47c9b7f440d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzctMS0xLTEtMTYwNDc4_77d8645f-183c-4bb7-8642-4fd0726a5ce1"
      unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if9720398bfd24fcaa4cd94ccacf55bfa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTozNzU4NGIzMTVhN2Y0ZjM5ODMyY2UyMGMxMTRmODc3YS90YWJsZXJhbmdlOjM3NTg0YjMxNWE3ZjRmMzk4MzJjZTIwYzExNGY4NzdhXzgtMS0xLTEtMTYwNDc4_c6e5cf35-798d-48d4-9c78-2d9807125bb8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY4MDA_e17bd158-9f88-4a8f-b30b-f0f1d6c69eab">Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Post Retirement Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 - 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzEtMS0xLTEtMTE4ODMz_9acc7582-6af6-4b1f-8deb-029c1c1048e9"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzItMS0xLTEtMTE4ODMz_127f7f20-a6e0-4c7a-854b-19df9b09a413"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzMtMS0xLTEtMTE4ODMz_6f40c43c-5a1a-4f79-ba5e-b1da0a687f6f"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzQtMS0xLTEtMTE4ODMz_9b58d745-6bb0-467b-8ebb-5099a6a7ed2d"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzUtMS0xLTEtMTE4ODMz_8a3db0c6-4bba-448e-bfc0-bad10bc6b6c3"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90YWJsZTo2NWYyY2QzMjM5ODI0NDM1YTcxMTEwODlkOWI4ZGYyMC90YWJsZXJhbmdlOjY1ZjJjZDMyMzk4MjQ0MzVhNzExMTA4OWQ5YjhkZjIwXzYtMS0xLTEtMTE4ODMz_60a19e61-1098-4c31-9247-135a60898c3e"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NzU_1733a6b7-d318-4ee1-8048-a00454484f8f">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200&#160;percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <bsx:ExpenseRelatedToMatchingContributions
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NDA_dffb1662-e00b-4183-a306-9066c4333271"
      unitRef="usd">123000000</bsx:ExpenseRelatedToMatchingContributions>
    <bsx:ExpenseRelatedToMatchingContributions
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NTA_aa63c93e-e9f5-4895-aa4f-f8864135f05f"
      unitRef="usd">118000000</bsx:ExpenseRelatedToMatchingContributions>
    <bsx:ExpenseRelatedToMatchingContributions
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xNjAvZnJhZzo3OWNkZTQ3YTk0NDU0MDEyOTcyYmU3ZGQzMTM4MWQyMC90ZXh0cmVnaW9uOjc5Y2RlNDdhOTQ0NTQwMTI5NzJiZTdkZDMxMzgxZDIwXzY3NjM_cc343897-4236-49a8-815e-189a65a7ccfc"
      unitRef="usd">102000000</bsx:ExpenseRelatedToMatchingContributions>
    <dei:AuditorFirmId
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xOTMvZnJhZzpjZWVmYzMxYjUzODU0Y2RiYjVkMjE4OWNiYzdjZDM0Ny90ZXh0cmVnaW9uOmNlZWZjMzFiNTM4NTRjZGJiNWQyMTg5Y2JjN2NkMzQ3XzE0OQ_9bcf2eb4-fbff-4479-8c97-6e8bb5988af3">42</dei:AuditorFirmId>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i63c80cf97e92455e89254f71abde961e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90ZXh0cmVnaW9uOmNhMjNhNGRmYTc4ZDQ1ZDM5NTBhMDRiMjliMTg2ZTM3XzEwNDE_1c97e92c-8317-4f95-9f55-a4ff9fe6a62c">&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;&#160;Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative effect adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit loss exposure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for uncollectible accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; when we establish &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Represents actual write-offs of uncollectible accounts.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItMS0xLTEtMTE4ODMz_ae3a4d64-19c2-4606-be4f-cc0206f9c98d"
      unitRef="usd">108000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItNS0xLTEtMTE4ODMz_9b90e637-5fa1-477a-a730-527342de23c3"
      unitRef="usd">35000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i1b040767773e4f94a046df2b061c0e48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItNy0xLTEtMTE4ODMz_2e79dc4b-8274-4b06-b62f-dae94f01e08a"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i768fc9449917456fa6ad3dc07b48a7de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzItMTEtMS0xLTExODgzMw_e4d365ac-18cb-449f-8b97-a8156e738a5e"
      unitRef="usd">109000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtMS0xLTEtMTE4ODMz_f59a490f-7ca3-4d16-94d3-cbb2a2c3ba3d"
      unitRef="usd">105000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtNS0xLTEtMTE4ODMz_92ed88f7-52e6-4660-be7e-7494a2ae3727"
      unitRef="usd">28000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i00f6953c47124fe29ad1455657d9b435_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtNy0xLTEtMTE4ODMz_5bbf8d56-1baa-4952-a1ea-0e0a3aa4eebc"
      unitRef="usd">25000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8722c1d4d5cd4a7f9e485658e623e39d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzQtMTEtMS0xLTExODgzMw_08d2faae-fb07-4eeb-b839-6e49640270a3"
      unitRef="usd">108000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3cf5487b407e432ead1e4e694ed618be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtMS0xLTEtMTE4ODMz_caaa1ace-1612-41d5-818a-3067bfa642dd"
      unitRef="usd">74000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtNS0xLTEtMTE4ODMz_30f7b31c-4efa-489e-9b54-a0a8a4f9757e"
      unitRef="usd">49000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtNy0xLTEtMTE4ODMz_88c97f75-be92-4224-b2a7-fd59ba7ed932"
      unitRef="usd">27000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i87a7639e46664d8fa457ee6d81350081_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8yMDgvZnJhZzpjYTIzYTRkZmE3OGQ0NWQzOTUwYTA0YjI5YjE4NmUzNy90YWJsZTo4YjBhODNlNzEwNDI0ZTUzYjNlYzM3MTI3YTE0MmI1ZC90YWJsZXJhbmdlOjhiMGE4M2U3MTA0MjRlNTNiM2VjMzcxMjdhMTQyYjVkXzYtMTEtMS0xLTExODgzMw_3d00dd7d-2758-431b-ae30-99a7690e9710"
      unitRef="usd">105000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>123
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (."5U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "#@E=6>&=H&.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITU%,'1S43PI""XHWL)D=C?8M"$9:??M;>-N%]$'\)B9/]]\
M ]-B4#A$>HY#H,B.TM7DNSXI#!MQ8 X*(.&!O$GEG.CGYFZ(WO#\C'L(!C_,
MGD!6U0UX8F,-&UB 15B)0K<6%48R/,03WN**#Y^QRS"+0!UYZCE!7=8@]#(Q
M'*>NA0M@@3%%G[X+9%=BKOZ)S1T0I^24W)H:Q[$<FYR;=ZCA[>GQ):];N#ZQ
MZ9'F7\DI/@;:B//DU^;N?OL@M*QD4U2RD,U6UJJ^5=?R?7']X7<1]H-U._>/
MC<^"NH5?=Z&_ %!+ P04    " "#@E=6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (."5U:#8;$#DP@  *,]   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9OK<Z.Z&<;_%8V[IW/.3!QS<^+=)IEQ<-*Z9Y-XXNQNMV?Z00'%9A:0*T0N
M_WW%Q<C:"@'MFR\)8+\/\+,NS\/E[(6R']F6$(Y>DSC-SD=;SG>?)I,LV)($
M9\=T1U+QR1-E">9BE6TFV8X1')9%23QQ+.MDDN H'5V<E=M6[.*,YCR.4K)B
M*,N3!+.W2Q+3E_.1/=ION(\V6UYLF%R<[?"&K G_LELQL39I5,(H(6D6T10Q
M\G0^FMN?%M['HJ#\QM>(O&0'RZ@XE4=*?Q0KR_!\9!5'1&(2\$("BW_/Q"=Q
M7"B)X_AW+3IJ]ED4'B[OU:_+DQ<G\X@SXM/X6Q3R[?EH-D(A><)YS._IR]](
M?4+30B^@<5;^12_5=Z=BCT&><9K4Q6(]B=+J/WZM01P4S*R6 J<N<'XJL+V6
M K<N</L6>'6!5Y*I3J7DL, <7YPQ^H)8\6VA5BR4,,MJ<?I16OSN:\[$IY&H
MXQ<^?28,C=&7]0+]^N$W] %-4+;%C&0H2M&7-.+9D=@HEF^B.!:_5'8VX6*_
M1?4DJ/=Q6>W#:=F'[: ;FO)MAJ[2D(2JP$0<<'/4SOZH+QVCXH($Q\BUCY!C
M.8[F@'QS^=]QVI2[FO)%1WE>E%MEN6TX&[?Y#=Q2SVW1NTIYQ-_0,JVZ<=$=
M_O@LOH.6G"39OW3 *T%/+UB,%9^R'0[(^4@,!AEASV1T\><_V2?67W2P(,46
M0&(*2*\!Z9G4+Q8TR,68Q-'#VX[HL)G+;6O\NXZ/L6HH'R QA<^TX3/MQV>>
MICF.T3W94<9UH,PZG.4ZO+ZQ:B@H(#$%U$D#ZJ0?J!5A$0V+<0N)X57;ICJ4
M]B-5ZU!EK!\*#4A,@7;:0#OMV?L8%KZ@',?:6YA9ZPG'F;:)&<N&T@(24VC-
M&EHSXQG6@_YU%!-TFR>/A.DHF37LL6U;,]T,YAL+AW("$E,X?6PX?>S#Z9YL
MHHR+AL71+4ZT'=&L<WFW?KB[16M_>77[L+Q>^LB_NU_=W<\?EG>W.H)&N:$$
M@<04@K8E/9[5A^$R#2@3_;&T&$=HS<6(ABA#/LU3SM[$_U +MD-]<:7#9RX:
MR@]*305X8)+M/@ ?\"M:AF*(BYZBH#)J[5VW0]+RQL[)QZGC65IZQN+!](#4
M5'J.I.?TH3</0Z$NXD2]@$J/>Y?JVYQ9TK4L=$E%.DK1.HCJ7P1]PV]:F$:M
MP3"!U%28,BO81@?]7S#]8DUTX@?ZDFI!FN5N,(L?*:/Y9JM%!YH-H-14=#(=
MV&9__S.Z9@!<,?H<I8&^(9HU;^9:;*"1 4I-Q29#@VUV^S]C6XE^)\+#/Z-=
M^XQA5K3LTZDSMAW7T\(#C1%0:BH\&21LL_\ON^><$=S.RBPPM69:2*"Q 4I-
MA22#@VUV^Y]I(!K4:DM3DQ?N$#F9N6//LO33*6AL@%)3:<G@8/=*#M]('(]_
MI&+81VN",\$N1,LLRUO@F36_$]UU/=]<-9C;>^0(6P8)NU>2^$IC87<QJ[(7
MTU_/-"O=4BTLT,0 I:9>7Y61P>D5&?R<L2+25SD^2C?EI)EKH74HMC0Q<]50
M:E!J*C69$YQ>.6&9<L*J.QK%92.\QZBE9E9LHP::#Z#45&HR'SB]\D'9'9$O
M/-F&,IV1O^S0^8S9AJ!Y$! A)&3"2E++#S020*FI_&0D<'I%@G6"XQA=YIGX
M.-/W4+-.ZT4W<]U@6N^1 AR9 IQ>*> J(6Q3#&A_%0I\*^Q9LL.IOMF9!=NQ
M@:8 *#45FTP!CMFS+_WK>S3/PXB+P#3GG(@04%X!N8[Q1DOM?[N'8"X;#.T]
MW+\CW;]C-N_[GKD57LW8PLPR[2T,- 5 J:FP9 IPS :^AK7*'^,H$,V*8OV$
M">GE?5"U1:TV+=6*1RZ>+Z:N4V229QT::?F=7I;_<Y05'DQ$<,S05QSGI+A!
M)9H79MIH6:N>'!R.=6S9S='4"$!-/I2:2DJ:?*>7R1=]+2FN#7(:_#BJ &7H
M+N=BT$I#@5!+"]*_^[7:Z0%[VW.]TYEE6Y[Z"RR@]JP^?2"]OMO/ZPN'RD0.
M7Z8A>46_$^U(U2$E\K<UFTU/G:GV00-0KP^EIE*37M\U._-]-+J.LN+JQ7<B
M^J3I/G&'W'AL.V/7UF(#-?M0:BHV:?9=LTEO[A(?<KL6&[6.M4.L[9ZZN6PP
ML?>P]^[!TT%F6_XSL?J9A'9F9KGK[UIBL \!O8?%=Z7%=\V.?"YPA16R%G/:
M(=!JN,QU@S&]AZ5WI:5WS1;\<))$?]R0XL*K_FDS2$_N@ZHMH-14AM+ANY4I
MAGQV#]*T^Z!J"R@UE::, *XY CQ$/":(/B';^?7Q-[0F0<X$7BU%LY)J #\4
MMA?MQ$SS7+AF+4?0( "EIG*4><$UYX4'AL/R8NU;\DAC+3ZSP.7Z'UI(H%$!
M2DV%)*.":XX*^]:%KEZ#+4XWI/7)H@ZAV^]K[2,PYK+!M-XC)'@R)'AF9[\F
M:409NJ6<H% $3V&]3HV3AEEOZ# 'JK: 4E-9RNC@V="3A@>9 7Q0M064FDI3
M)@K/' (&3!H=2M;QB3/]!1TT]:QIZUJ,H#$#2DW%*&.&9\X%W7-&AX"8,UHP
M@68+*#45T\$K!N9HT'_6Z!!JFS7,98-IO4?$\&3$\,P18WH\M7Y!-_YJ?22Z
M%8M$AYJ;9PW0J &JMH!24UG*J.&!1PT/-&J JBV@U%2:,FIX8%&C0ZENXS@-
M,:?E8]3I,V$\>A3Z*T:>"&,D;"Y%UYW@2*:1?3HAK'KS3HL>-)U J:GH93KQ
M_M]TTB$@9AJTND?:1R_-I8-)O4=$\61$\: B2H=0ZV0#&E&@U"I:DX.W6HN;
M]>7;P1D*BK<5JA=<FZW-&\CS\KW;B?QZ]?KR#2[N]6<H)D^BU#H^%2,YJ]X(
MKE8XW97OR#Y2SFE2+FX)#@DKOB ^?Z+"#-8KQ0Z:][(O_@-02P,$%     @
M@X)75L+)^MD[ @  O04  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6R-
ME&UOFS 0Q[^*Q:2^J@(A#]M20$J:5HN43%&K;9JFO7#@ E:QS>RCM-]^MDE8
M)B4H;[#/OOOY?S9W42/5BRX D+SQ4NC8*Q"KF>_KM !.]4!6(,S.7BI.T9@J
M]W6E@&8NB)=^& 13GU,FO"1R:UN51++&D@G8*J)KSJEZ7T IF]@;>L>%)Y87
M:!?\)*IH#L^ WZJM,I;?43+&06@F!5&PC[WY<+:86G_G\)U!HT_FQ&:RD_+%
M&JLL]@(K"$I(T1*H&5[A'LK2@HR,/P>FUQUI T_G1_JCR]WDLJ,:[F7Y@V58
MQ-XGCV2PIW6)3[+Y H=\)I:7RE*[+VE:W_"S1]):H^2'8*. ,]&.].UP#Z<!
MX86 \! 0.MWM04[EDB)-(B4;HJRWH=F)2]5%&W%,V$=Y1F5VF8G#9%YG#,E*
MM,]K[BGRT6#MII\>$(L6$5Y #$.RD0(+31Y$!MG_ -_HZ42%1U&+L)>XA'1
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MHFS>KG@*%4 +X/N%$.KY0O] >T([^1]02P,$%     @ @X)75GJ, ZAG P
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M U;\[LTP<#YUY> _!6MEQ&LRXAV+'L]Q]X 0F(Z%XLG=F5Y]P@7V3(YN**N
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M(1#: -^O.%>/'7W@-O>K^!]02P,$%     @ @X)75C>R; QS#   :X@  !@
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M)M;HVZ:JP-&!,^S)L^P.#&%3E(40U E=MFT),Y+-74T[HA?;O6R(UDGT$Q;
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MQB5R&[-=4>PO\-!;BF6?#)%&P[.-LF*G**AH;=2U<X5%/Q<^P*(4_0G!+[Y
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M&[L4FDT*RXN%G&6"C8T1UIQT+':B^9VDEGKNI48O2 TC]D45=FG859&*]*F
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M5&2H^MNW%H:E>(>#M9#YK-)&-#AEF2@ U:]"&/[+(+RZGMQ-WL3O5FA9(GV
MO^ EU8O"H]( Z<Q'4&VL)EAI=T(UYP6Z/X+%59?A!\ I$NFZ/F":HA*CE9 $
M.<(C%QJ 9$TJAPH4)M\F%Q-2]^;/*9O>75W?050\BCZPZ:.Q(M\RD[-[E2&E
MH@$E] %(T'@O4<9Z+^8(1P#JZP]:4#]J*^TT@F]^"$M!R'B:.K1(AB;QY$1
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M8K,,0+/>L.$Z+XVXX\H2#GP?>R;%T00&9;.)BG,3C[W'].LM)EGT\F<X^[G
MV6G6,[7^N5#KET98R_\G:A9JA&Q0=,?;JA2-U>44?I]-G7-\,QRWE)3(FDUH
MJ#.XPK'C2WPSQ >;C!"@'+X9#V'(X%R,G+I3,+X<\)>..)L=8T=:EAF=BRDN
M,SY'F*R\PFC&\N>\J/V];?.Y.G!U<"Y[8\.I. . AJ,N6CW%KR!:36=$JP'1
M:C#KH-7E$*WTV62,0X<.OAYW4@IH>S8$5(Y']0V-B(SPY8@)]B.DF@&UA\!
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MBYG7 00&B;=F!\<WWASUD!>[M_IK4WV0(Y.K.*&"HEM%*^[8;4#KW@Z9FX
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MJ=]D\9;^S<4BSK)X0R_7$H*<! ? ]\L8$*#>X +F_YZ\^E]02P,$%     @
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M.8@"&H]R+)K2EE0.$.-U1?RH8+/,OUKPC]N8 DN65%A/M:0?=AZ6/#$M 6#
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M$3Y[25(<U&M!!12*54&!F";?=[NI=[IVGT6-A#;(DC <$ S-WTY-&ZPHG32
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M-GQ,W;& Y!3!!UN:*B8"M,W&^-:;LU #RQ\%4JYL%<4<B3S$TR1/SMUMR@4
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MG5K;RBO!AO19[:-:ZR2'0KI)E L@":'^K'2)L@Z#VE\@/JRQ!<?HH'%J4*Z
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MT0:L9Q;MKKZA ]IOE5?_!5!+ P04    " "#@E=6GV%\5\0&  #9#P  &0
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M'$4)4B3\D+[C:)Y"FS\">&8ZM4<G'A8#_+ML>FP?-"A!L$-K-<!#4CXMKHZ
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MX\AG?7Z"0^068!9-3C#&9#CEH2'C)>#K:T!#K_1"DKJAS"R%)(9PDR$\+ZM
M0*NR;'"@="G@KG/X;*')11&QVTYUQK.?%+WJ.$,I\HS)/X<^;\ ".=@B,VZ]
MRK(NKQB*;C,Z>#RU\A^LRYZUA5<5\ U!:459$A:J!GKRQ1A.?561HH=RL<@1
M0HP(O4B$B/9X6N2 2IF#3 VL"H]CX4?B/<1?.W"#!(Q(V*I5<]<PZWLA1UF2
MS!2,[%VN"_5LF>TH!D-'>T"NQ?41*/W0J\-P2\[R $1G8DJ(!%H8Y<YFX6 \
MQC*#4306YW*K"QGK?V.!J^]ELGWQ!L'&$^.)N,Q)=<7=0&QC @3)I1 5MLQS
M0%(SOFHPAR,1#6:CB([!6+Q7!@:\Z73Z@>=%QWSV<0XQRZ,CJK@]%+QOD/4<
M?HA:WW*ZAJ@.>]:F( ^EZ!M)E;58Z13K:.@(PV"YA%%,>6@R<SR'4<TVI3O<
M_PBL=$ 0;$UFR)6#*=+E9:X0CI:TG$X+E9./R/2.S$V6",81H#PZ2(H8;I&X
M:).XM"20% ?>.+!G@.%3M]\-]F_N>2##[T$^I2VKXI)R'8&F779 I0MIX;/3
MQ0:/R??A$Y8&C:":)8OUDF$YES$;E2M_L^_=S\5[1XQ8.6]/>^VF7=MI'7'B
MO I K1CQB &JQWMIOL=VZ5G+(.PO7('TM5H;H[4B'& 9!; &"I?_U:C1(/#&
M.(;1]# '3:AX<\BT?H1XA"AWR$?J =\0@!V&(7,,Q$Z)C5SNET-$WW"%0ZQ_
M'7W%0N;Y'6J0G<R7EAT:Z*+Q@(%(-U1=K^PV&I7%#BFE%\&*#EG# VSY_P>V
M1HB6-5L7"'/+)4??FI56R?7-53*IEJ:DVVTGHMAK>#PPT!]2 6[L6K(H<CTO
MJ:Q 8:01+<"RSI8H#.+X#HEGK5.J-BEV8&X(<ZR )-O++%DZ6[UCN,M&B,K$
M2*K6-D2K&PR$_[.6YBK6"C>+#2I\8!"%>4*M7ZR_**R'VZE(L\(^EZ"85PL<
M*DNX=J0I<VHJ;-9@T$A*Q&5<\+K4;N04 V5GF@+]'LIV% 'S)RD98_W'QEH]
M@V<86!I51=^NY0\NQA[+ F=='@#M;7.=R%Q#=\NR;HQ01_"2(-JQ'.?0JHI@
M[[$><["$:E!Z#\)[2VXEH%3CX7ZW,L#-%07>^1V/I^[/Q<9YJ>.Z)^ZT#BAR
M*K=\-IBU&F[U8]1#6-<A6N5^&2'0%5H_K-,-X8HITZU<;6CC[Z:F:(-)MOBR
MR6)@W?R5BR*$;?)(Z:I"QLYH7#N==10"2GL ^NW] ;ZM/]NE70]-^/X@;RA^
MQ?QY7>^!,6HXJ+@L-GE6KC?B7:Z4^)S+I1+_@%"H8-<ZH47A*C;GGZ.<EN(*
M+NT""FN6RE./O)THPOE5LF6UK_(LV5.I*QIT;C",]AO%'8QJ6X6MBP 6)Z,N
M>E\5'2OR9"9!Y@.$]P1S3FLY;[%AY TWO>RI2%I?J;OG1[-.'?>:9-*H]?-&
MW5N7]@R>J!&.E0C1UB]=W+2D)P,NI5CD3G7<FQ"Z*%$!-^6$KO=VQ[86GPD>
MF@T5=,\H]I4)*7.IXY+I<I+PAFAR2!"G$OSVJM].&=X00<[=LO!"^Y/5,&19
M[R$-C%Z6"!<982BK@2?%#[FT/G21+DM#WA]S"?*VEK;/0XXKW&VW,=>M,#)Z
M)A?'JQT=@@5^2VI?;)&'H&'1X!+0 3@$]WV+1 \FW6 (O2XPP*16&&L;XXP3
M.6LB*64M\Q4JY5Q/]ZL: *+[HP;6W\ZB7D#,* G]N;!FW<_*60MF)3FKN8GO
M7+Y]T*X?4)K?&;T7&&">58F<RJ5(;4G\)3(M5]+UQL2,@1/0'H)(%!<,R'4W
M>J&JEACF<P4,I>@]-YEU*1;)0.TZ]+H"M\](:('*(W'F:AQW ST])6C<!T3@
M'&(/'TUT^&;V\_?60YC&,)UHT['N8Q5X+YHUD0\CUSFE,TISBVR=<J(KFFT1
MSKF593F[]R*_AC^JAY5H)F*-K$0:EJ[XA#/:.I147+GIX\5X+QB-_A"'_F3R
M9W#HM3@<^W^,PVGX!SGLV/PFOVZ*;=Y_29=\F61EZG9^#K#XU-WM!]\EO*X7
MK]IUM-&P);74]%(APG4570R_D^2^LMF JO:N7#U8%7?LM].IF(I@^F0"*&HS
M5R,( D3DBS$*&][#I:$4(_:WOZ"?]J1^X-$;"GIMX4_IO84JBEC9S2&;G^4M
M:[<L-EEN.^J^3R\YZ']B7W2@PB2Z,9RUL(;B&.8*GOZ4B/-[CM$QJ7M?=^2I
M;0U2HD6@,.7\-\(&A-SK6UM!"Z;<*01,:=IWP4A"F7"+[.C*X+1I.']#3#:(
MP<P:9_6-O+%%MMWZH?;LT(()"FK:LZX2>^#Y8UO[EG,LA2C+O2"1P%#%:;YA
M@?:0'B,7=;'T-?5*FH>)C;CWKGT:3J'@7TOJ 7E#NZG9"(<75]<8LD:[0O:A
M.^I6(@++=E])+.Z+3VM;*)&D=JI[)_53IH'K<X1_#=ZX.T'18^E1&Q$K3D0%
M(?I&JYUM&2M>VJOO;.;*XAMJ6=^TFRG<+%NQP77KS-']?I:"4BL<<+*;-2&.
M$ZMM!QUINSF][Z]&5;7+KRV54J&V*E-NSGJMHON>=E?\N8-3+[%3;132O@#'
M+SCHSJY5FJH#I+FR>S.!W2!=VHT_A;Z#&DUV^J\YM1&Q&<J;H@IU SMU2\K]
M]XO<P+7[P!;HW"LB!UJDC$EK\X7>&"A;_MG4<6#E@SU]+PH?VZ%QNPR1_\A
ME P?G?6KEZ![ G<R1JC32>W)=<G<50.ES=X%^4GZ7R_V!W8V6L1S*G\)8.;Q
M.([H4-CITJ!\G".V($T8?BO"/NRVNBU6;POA ]?V>Q+X%9>JSB>;@*M1W"FW
MH@M2@^XMQWO,W&M@7.-3]<6DTI:K'$[P]'!+BNA-1LT.Y#OK$#;%JJZWV?Z$
M@\4.EL'*OY>:% Y_5G;BY_.?SH@J OBBC#F@(YJI9P5M(/"[3&UK<^*E2MC<
MIF6%Y.V^XID_FX[KP$TA72^US"'Z7YL7U>XU&8O2?\NOGBZ/G3&H6T"8S$I#
M6UC5_AX'&,Y7;:_=V]:SFULYS83&:6^*/[9R:K>A[D83TTT)=4\FWL;9@K-;
M3>X !GJS\"G[K&8/OI@T?7S/E0H )+N%WDJN*V@SS 5-H+5Y)2#YC1=UHMK8
MYWO;M ,+H2K:UE;=RCM^60=^[HDTFHZ;>K75D/%^*><PV/5&<=?%^SNVU[+[
MP$WB1G5:IJ+K:Z.3UI=@B<K7_+T;J0A:MQ^%U7?K3^K.[)=DS7#[/=X'F:_I
M?5^L5ICJ#2>C(Y';;]SLCR+;\G=E\ZPHLH0O-TH"T#0 SU=95E0_:('Z0\/3
M_P!02P,$%     @ @X)75NK:E$+:'0  )U<  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&ULU5S[;]M&MOY7!MYB-P$4QW:<Q&W: +;CI.Z-XVSDM-B]
MN#^,R)'$AN*H?%C1_O7W.X\9#B793=-=X%Z@2"V*G#ESGM]Y4-^O?/VIF3O7
MFL^+LFI^V)NW[?*[QX^;;.X6MMGW2U?AFZFO%[;%QWKVN%G6SN;\T*)\?'1P
M\.SQPA;5WLOO^=K[^N7WOFO+HG+O:]-TBX6MUV>N]*L?]@[WPH4/Q6S>TH7'
M+[]?VID;N_;C\GV-3X_C*GFQ<%53^,K4;OK#WNGA=V?'=#_?\'/A5DWRMZ&3
M3+S_1!\N\Q_V#H@@5[JLI14L_G?KSEU9TD(@XS==<R]N20^F?X?57_/9<9:)
M;=RY+W\I\G;^P][)GLG=U'9E^\&O?G1ZGJ>T7N;+AO\U*[GWZ=&>R;JF]0M]
M&!0LBDK^;S\K'Y('3@[N>.!('SABNF4CIO*5;>W+[VN_,C7=C=7H#SXJ/PWB
MBHJ$,FYK?%O@N?;EN5\LBA9<;AMCJ]R<^ZHMJIFKLL(UWS]NL07=^#C3Y<YD
MN:,[ECL\,E=88=Z8BRIW^7"!QZ M$G@4"#P[NG?%5R[;-T\.1^;HX.CHGO6>
MQ ,_X?6>?,V!S:NBR4K?=+4S_WTZ:=H:6O,_N]@@FQSOWH0LZ;MF:3/WPQY,
MI7'UK=M[^=>_'#X[>''/$8[C$8[O6_WE^?75U>7-U<6[F[$Y???*G%^_N[E\
M]^;BW?GEQ7@7L?<NMYO8=]<W%^;2_/4O)T>'AR_,O5N:F[DS"Y<7F2UA$;=%
MAH^V_@274E1F-2^RN5DYL[1U6V3%TK;.%(TI;3USY=JT+IM7OO2SM<EK6&BU
M;TXA&EA\ \L:88D6-@LC[K#ZLH8[JMNUJ<G:FI$NVF$Q+$5+![E"=+DSC<MJ
MQ_>5=HU%FV)6%5,06K6F]J4C K%FWF4M40X?M235X!7R8CIU-3X5EAS(OKF^
M=;5I<=:ULS76Q)_0D[EMS,2YRI1%6\SX5JQ:T%,N-W8&Q]BTIL--:^/ID8;.
ME)5=#K4SOJM-YA=+UQ:MIZ^RTA8+^J:=VU:^[FJBPOC:D!,&#8%B3P3BW@8+
M3ND/%UG@5Q5VQR,EI%$U^!O;8_?%OKG<R="4>EIOSD<'4XFZTGUFEG05- 1R
M;NVD=+22L7E>T$.C< I0SC*!,4UK]ULGBTP+\'H!>198"Q&@ (FM-R587MM(
MMEGZNIWZLO"085;[IHE'):4EE@=EH?6)HIGSL]HNY^$S%IW8TE90P;IH/O$U
M]WDI)CUQ[8HD13)4(OD0C5\XD\&W8X>&22I3H1A;Q_M)8>CQQN(1$)<Y1W(<
M$:OQ%30,$L%M?@H%+ED%^KN:D4B$.9WP8^IL"_KX*=+1:H:+4(2&KXA%@5*8
M6>-,OJ[LHL@&[&7#P=9M6SK6W\I#.RIB/-.5%[=%3N+60TXZJ'C9>/XZI1FQ
MGM62V+;T+2M_B67"640)PB=>#>9:MG/?S>9FX2O7(K3S;47U:U=QS*6G"S<E
MO6K72_(26+&A)V#>M2//H=(##\#R3N(UF ZW3,+ [72@W+6NAFTXHJ$M2A9$
MYLF6&". ?KK2U@7+KZO;E/>\ 0P?6@!"8=P%&0CV62Z=+7&*+/,UW5FNV;1A
M>RV40/BRR4*FCAP$^9Z6M*X%5(&;$?,@,?_6P<D44V$&W>ZGX"<.03PF&75+
M7VUMQ!Y"]X ^R<=$R??-JXXL':S*:!%U12LRJ@Q:TDP[9I>;>?5 (9YA\:#;
MI:]FCYK6BJQ+-\,U !QP5[@TMRRTS$%XN9G:6U^3P9NZ*]7;Q*6$0'WXA9G[
M%7T1?&/&P;5S;.P3/FG<=K=?[]T0)))CJ2;A#S&D<L3<A9<3M6P2@7;(O%3J
M+5UTK E6EW'PEB2:BKVJG138:TV$ 2-"K-C>]M% &*'W$FV671O"V@S^? 2'
M5L')T/+P+>H!)6*)&.4)7_$ZC]GJ?^L*^,KUAMOL'9Q21"X(+K]H@U'@['#Z
MO!<'AT9.R#$'+@)T#^,,/=,@AB FA@<6"'Y@_ZZ[U9]-._) T<[!%<B1 @D9
MWJ<*X82N+6P%;RT1LA4W2H@!'TG]]\TO) L(EAAI*0Q"\]@7+^'4LS4=%E;$
M2@<"63N]1H! 4G)X)9[. _TF$VJZ">F/.B7(;?J(]\!"JZ*=DP26)&.0NL77
M=#DQDGN?WZV>(<XR"V1!]LM0)[ A$RM+,$8[+^K\$<6.=<*->&C@ &129.ND
M9M'A]A$+A'05'5AP4QX.06Y;U3IW64'N#X2\O^/,]ZE4$O=9X]F>Q26DSG.@
M)J3J,UOGI9,(A6^*.ICIZ/^E&9;%)Q><+R*_K9)8OP%M$0N0E]7K4:*5OZK6
MN,\M):SL/F= I<Q7(*^*_[(E)-%2Z*=3E9X6G9$N5&)2(0O1?3_NC_<3H8"M
M55OK]Q%5RQ%A>Z]KOV S#-$HD,=P14D$3W!^T]H%Y\/*F(0(4%14MQ2&9\HX
M"5NXZ,M;"3Q\,$\,$)0? (.0.4$PKAQ#-]HB02Y_=&?1(Q%GX EK+FR(&8;3
M9 C+I>AT3;AYJ+:CU&.0LA#X0?RU930%F^.I@C(]A2H)'/DR%?ZS.LBX@_T"
M^Z#7I^,S<SH^-S<>6,D</ST8;22IHGA95G>D2(EO\(ULV0/!D<GM GJ%8P,&
MD*,AQ'>?;QS!X>2D;6J(".%B(Y2;A UR-Z6D8L0%$;;/.5CH:S83."_"D^P-
M:U9&R(T- ]X=[I5\8Z"&D77M)PPO&*M#_@O)+JY)G58%;;-RO"JVU(@OE%@R
M!4Z/<K!2T)\LT#K!TG%MVH\ */)*2WD2[55Y8Q=D5,QX53#Y&G<RQ""W4*Y3
MAK-#@,8LND5X6G$G/PFRR:O1O:1QOMZ 5YS5W7UJL\*9OCD^?H(]RI*=,C/\
M%<#88@*QA$K(B)_[YNGQR>_<>3A2-$X9)P55E6O@T_UJ(XFP2!LDXXFZ2-*!
MW7%6 EH$'\G-9"ZPM*JYM3.V502Y&2L-X-T\.GU /TX%%=334\+%E*^_OTX@
M@,1>4L42Z1 I-TB9UYRPT,K Z:4D TG^1/>9!W\?OWXX4E?+23'SD)C)F0K4
M7;.@><Q>TFM(SXI;6S*,PB/7XL4UFR<L)FS_YO#XVR\4]^')[XI[WWR N-CN
MW@%/@).AAC-.< DE.QW[%/.>H%FAGB$$1';&4O)E*/X+YP/P4SA;CQ@>!=$B
M[3/9G HZ>J+GO0+CY'*";XZ?'&Q</91C'3T_V?CB8+1;VY"X>(&//6II&I])
MJL/^\PMUC-:OR',2$MP,N*<4X*$6=D1L7A$PL4UT.L/]@D&ER$FMG?D6,%[.
M6P0-WEQE0#$3JLJ+0UL1%@L(7*YFF@KAH,&*&T5DQ)M$C1EF)*RB=)SC#D'6
M(+ H6&4]S@O_Q.6!0G+K6_6F6AU,!1(3C-P1SK%@DBV+8+D*=EJ$ALJMFY#/
M!YNBTAG 0J;)C!">,]="YLCGIU#1>ZX-Q-KS*=8'A-/LG*G8!M(KSNGA>I,,
M9D)5"0 ." #RG5")I\A)SJ'VR"?HLGF:.0PWUSP7@D&02FQ'HUM(NSAR2/&$
M]]@ T\(,03L!:T I%6V0>@*09NT&!E:(,1)?,RW]*@*,#6#-%;QU;QT]8*%$
MA-(+!B(]:_X&*UXBQA&241!)::"Z+K870H.B,N#MCGQ!K $LIZ-Z!(\0^<7>
MJ  B3G="?2'EP2BIL^ N*:FQ+&<STN_V#R87Z4&K@/2W\5C/P'WSL>*D)G7U
MV^&'6!S "9.<L3GH40+$@/8PZM@T=6)84D^*9]AD(A6KB.T3,CC;0+$F8$J,
MVTCWI&CZME?):_R7M9[BP=$)Q8/#IU++.N><1NJP.==?8\)][OTG\P;Q<(F5
M)"F7O@@N7VGF\_;MN7F0><Z'X0T($='W#Z/CK/BY<<NNZ%4A<1#W4 V.@S5N
MBI<Y;)5V17KUX/"[PZ>/LMM'!P??GAP\A-L!&Z0\E&3:!/35^L-)0J&[]WM$
M$<>ZYR\:Z#/X5&4M+AR?'+V@=I1O,D;4/[J%S\IB*5XPK-<X]ZDA@7'1<%J0
M9=F>\9"!7R-MT'(>D@C$QHIH"W5."I/L5N'K&<:Q2T<HKL53#E@PY,P8J3/4
MJ1JPZ!(J HO<%TF(X*AT7T/N-;'Y ])1MS(/+M]_>&BX%DSA2:))"&:J(D3S
M#35$*&$SUU2V!.L_CM_?7#^,BC#ER#EWU:-8)U(F!Q<E+L?E?3)&IX"37TO#
M0@\OQ5D*)50;+@T(;+1.FZMVX=.TJ!<:% &2.!]*Y1P*'5/C+'G'.6D&]"$0
MQ2[KM9O (.LU;?9DM(O%1=-TK/'<<S:_=OF,-2J4,O.B6> >-K?AS@GRI0R6
M350+MD@2<2.?>>7-)K<(*E+S/.](9"3C*RL4#C6.HA]'V:T%!J8)BMZPLHGJ
M)>;V7Z @]PLE3I*I?N.A:>J]='7 -$T.XA;X\Q3(J%1ZX5#>(48PPB10!H_R
M?,2G./,P.Q+/!S<3'<%.Y(15CC?N,\XW7C>M6XC^L2C>4'_OLLKV-_W)QYN'
M5*:J*:I8 ^\P<%)]H?(7:/FFJ?!>:GT4ZZ@$&1]-W1][%YB.MILV?0Q)D\UF
MV$4#KOEX,Q+4PT+WC*F/#EZ\JKL9&%#"2] 79X7/W0QVQ@[C=4%<NR1ZJI8?
M  @G3GSYPZ0\<)7$5V$JO(1=N@XY?S-*E[0<]QK)3FW538$7&%MTC628#?*0
MD$N-UT!ALW5PC6/FA4@* ? F0=[B%'>Y05:-*UO#- ^/6"].=MI?<'%WBBU8
M8,3'$=BE_K-H@PO]ZE##%(_=LA5M?LI$?QO"(SV-FT^Y&=3$A5Z[G-L<YT6=
ML3Y.$[>EE)-?F'[5V=F'17,[&.TXX+A;4DE*5P1L*G3SCS<QUKVG/B5QC38\
M=Y0WUY"?RI+A1, >U'=E'STTK)Y'(.@GZ$_O4RU\)CY(4XW"VMR5>7"$;-)T
MG-7<*>!SW**AG<7&$(8Y>U(7%R)'")+L^J7$KTN RRO;=[1#XSK8,(LQD*A)
M;T]F'V48[2=,4G(V]@1MT@NX:SM)O(DYM"B.]<WQ49JK:IUDZ-FI=U#EDKNQ
M0O&*1""0-6R96H1]M?YMK)PD2.XJ](;_4'WE2_+>W%&#(MSO+(FH)LQ+?45B
M*F 3)U]<P>.<Q96WP$V^GEDNS)=VV;C[FU#2"?54D-6$85NW@2&!;W([VA&G
M1F:<^;;D%.N2#DA_##)S\(_]?#&=-DF?F#Q6WX<.5:Q8IN0 $ O;A.(:+7:P
M^FQEY2",/*@ZSB]@;SK;(9QFLGN?S$A#NS)36Y3:Y8&"(3>9U QVR*!LC<VH
M&SBM;8?#WQ:^[ F7Q!IR K"1@9!6Q]PH<FI[09HS=!/5TKI%;%C]HM)S!"?9
M*+GA%5,2H9B<UJ"8@!S,+4(U2\LG)1=Y"7F$I%:8TUJM!?$>W"'H'Q_43991
MC'_C%@<RWA%Q!#I).::&M%]]K<!""\#2A8_YOR#-W=1R/6-P5JQ,>35,?64%
M=<)R:ZBK1DLBT-.,!&&&G $BI90U^Q<GG_!P)Q,;E !'Z\1-J]J3$N/0&TVF
M%%P=IEX&;B'BJ5=%#5'2V$GLP%O3S,'BN2^I,D\HGL<P<I:/B!V (D:AD%N]
M$:O )O722\YKWEIDJ#(4PJU.+=30V&08P:!JT,"KL(+WK&VV82S25)VGZ&KI
M<X(T68UDS$5FEJP*=NFKF!/)<1*E;&BZJ&CF?/!M]Y?6@'L@'D#[KG[X5Q8(
M ]K>['I(S<=/0?*<QIIH/4:-'-2D5$=,$>+<H*831X=\F"5;6L:H4-9DEH,9
MT1<.:8=0>_O/U ,W*FY(M*0]31@GZUCAU6Q[<]70&D7;[]@WLMF(NZ!E8;IH
MVW@W]K\M9K[V7</C9S!<@?$[S#[,=W'[E>M[U+61N[BL-_,2YPIV\J&%2$0P
MMZ5"Q>R>$6[9O)>E$V9=^ E1?O%RP],%7#.@#[E@5P57)YGOKOI5J/!50=;;
MW</1KG+6CI:B)H-]P_9+]5VG?OH4?^(A[W[Z1YQ._SGDTH*6.Y%B[HW4K+BV
M*C(1\*.)MU8,F=ER=-)5'2.1'BQI2M2@=#C*EN6_I;OT)FTZ7PZ;SG3*OW>%
MN;$+Y#?2M+NN^C[+85I6.ZOMO^"5H$*#/C:1#D\E8S/P!.>GKR[, WK@=-AM
M!JJ'0#E_N(!,H9@9=F(ODV;#C>-$2S%! -^>RSA- "<]+=3SAC)8ZM G[0M]
MK+\O66!SG.M7FK':G.C]1+Q8S3T).7;Y(4]9D</;%%D*Y:@Z"L,S0 E[)?I*
M%IYS[_I1F+,D=@1_M#6,$PR(8#7HX[E74;MD?((\!8T<-)(B=-"POF1!(AC%
MOA^;=H<HD]E@O3:DY3QBR@>'(KLDRZY(6"&ST"REM+@V9WC#P[E<BAZ(.*GG
MAIATAH""3<=9(57P+"8INV6X=3\) +<VT)RW;0XH_.!L?/9P(.RT^I%(O*]]
MX\A7+F\!58IL1,4'_E,&9L?(3GY"%A7JOR.NC/3+A(@J;NGT[/+JXI6@\RO\
M?<U_'GV;($IM+MXE]XF#[T'22N5WDB^2)A(-.9D9W!II$T@<GZGSG+#_=5J&
MI3%(*^5VW!)9";$_,S.>(:YIE*W36=_3;H840COCG,/V"DJAB5X/X'A'J:@4
M#PF%N)*G2^HU R2:0<FCZB381+E.CDHC0FR5Q+$B32FI\A?7"FK%G@+!@#HF
M/*ZB"9A.K.R;'\. I4]*_4]'R7EXB5-MN04,2!T=J?JF6VX5,$)+4 CL4Z6H
MN9!!@$5)OD"7W6)9^K5SXB$8<DOJG]S'  KB)!,=0\'#_#*?1HI)3PY"PSLM
MOR!5I@DVG"G*5X\3153YZM&D$'RQ(2(QV$8=1+T.R'.327'MX?,:\;N2D'30
M#ET/-BK9#<?*F)T,%VAXWEIQ,E!$K$H7G([+^-X6!LI=)7@Q$<1(2POR/3&3
M7#_ %[4Q$] 4:ANA_$ 1-VPTU%BM=FR>3CG4FSR7^OOI8VZ+VC \/5(@KQNL
M>HA3\8BYUA&D.3>*&B0U+;D[\#*I#FD.-G'"7YK( +6DWE%0/?,N@P+URA,2
ME"2-6M&84NDF):R(FGH4WON6TVM@1TK8D2_5W;*%UND FSE%&$H2<$2BGPO7
M5G:QG0K%W0(P@2=?>ABP^,#<9YV")I[7P]/:CE$3Y$PB:N:N@N85W*_-YAWA
M^CY+&0\G/"\^2V:0"'6C1D7ZVW>3.>+NFD5<<8XS=)*BY(E>ZK 6V6GL *>@
MZ7BD!<Z+J@92=>8G=ZOJG/1[==23HD$Y#7A/7ID) \U4X2G:CA@[TIZ8U3<E
MM')\;P-@9*X*\ 7)RNM]\''NB<>T[2ORS*7Y:1\J[RK ;!K4= M.%**@(%JB
M2//:HN[[!OCR[?7-Q[&YR&<NU-5/J>J2F9\M53&T$?) ;I-/W#[]HGKVA=VN
M(+]S*_,/7W_:'\+3R.JV?\E%BB%]A7":VMG7UM4':KA!Q+- !&P2WL.;BQJ/
MS<'BTO^;A(YXX*DHF"37R=#[G]"'D?D)P68Y-U?[YG71_FM&H4&KCUMJ\M4-
M\ WNW1\-#],N!=?S2J"B5CL!W(/,-#YPY%XN/<6)?!?["1S24Z6S>9_,!^3%
MZ[EZ$<:Z9<]'6+'VY-3&TEXDL[BN<\(AYYK]<Y\3""[=:L7^$)FIML#Y+3 P
M[53QQWF4C537)CQ)(]#].)Q<6L^@!2&LR,6);2\@G:JNTC$3Q5M(I'A2.1:"
M*46A!#8<+T!259D>/Z<KT0E::7[QBTP<;:2*1<.I::R9<'X!73-7OM5 ^DI0
MED".+<)UNK!5Q?:4N4"7J3,EXWRI81T-T)'HPXQR0DG8R=RU;\U]HG IH3"&
MSD6D3U'@G2V,!%<HY@!N<3#6U*"0:M\67&X8AH74*SQ-7=/OQZL^*Y+\YP.B
M-!?KP_Q"R(LNSA_V%<A4&FFF1MX"V;_,JF]DI6D'90>K(K#AXB4Y_L3C)QWN
MB$6!^+NJE62!QS(V0K_TW.-XY7!_VR:PYCIIUQ\.G$%_^'Y?\8EW;)^,I]U)
MR5 ' CYPX869V!,)TR:CX+YC0R[53Z:-%Z<W]II-<80V2<$-A50>@FGD9M@\
MP^8>^$9P38)T%>-+P2PZA9,R[63H0+<0H6) CO%T]I]+FR.,U.8-%3B:3VL:
ML_&2B][4R!Q'PVK\2.O7\8W=70JTH[:OZGA7A43?D!CV(GN%C,M(^9-2(RF<
MD6'4@^(O1221-<]HV@EA:EI4T#B]<$UEG(VW@F[[?L9T2]E%2Y@;7*>(KZ'V
M,(-F@C2]67#O+I1^N7 E);W0.X'_D1<G;EWP2JEGV7:9H8Z[.\SGKLGJ8D+2
MG2!F#54Z2E[DW@RAAT9R7(,[LK>66?R67]-Y_N30O-??HGC=5=(^?H7@ZLP[
MQ/&)[6JIDL JLT^B&TD05;01O/O1LW0V7RY]&RYIW4OG8K@AV.N8Y9<\TYK8
M=NMF<]<E4L2.WT;SYJ1O#XW[UM$HT1AZ-%3W1H/Z\]=H3,,:,U+ZQ,T!*E'-
M/U17SV//?LRSP%LC[<,0>!A*>O Y3>,JKETY&AZEL:+^\G65\:\*\/7^\@>G
MU=2_VL7R!=:-+_V/:,Q1)>+G %F5WA,^;4PLZ8H/M=@AQ5J9\(RO.O5J&</[
MEKJE'?&C;\5BFSY+3E'C.3S[8D+-[YMTUBF )'*LLL\?@:7O/-=LA]G%.;T4
M@1R41^!U:HK]6^"CI,,:<*=:IWEM2V04YU*9/\T$C$BO&DI'(QY5\@[H$IOI
MJ&<,A434/_]Q<_GF-$3C)"F5UY$JU5MFM;C"]"::=-I\M^R1OO>1T\@5DOS%
MA*HF?#O( 8(*KW%R1A1_T6%C@O,/@WQ*T7ZBN>3U5DE:!X]Z_2#9V5 *]&$
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MLX_\-J#I!(D\RH"G ?D !,/C5*[M$B:4GN%Y%]!X'C"@:0?0?'A$QOPTH "
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MHU:(&)&D(#=C(X$+?:W=5*(Z#+,\8I? &]3LJZ'.ILMQRX@!K]RP8K/*JN,
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M+$MH]AFZWC^(@V0T]3=Q/-V'PE^1^L<Y:BQ[#84;9XEFXX9N(X3\FI@"])$
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M@N>Y56X#/5=ZC )FI5(HXJ^P4$SHW&'#)/F#7A65%:-=ANN4$L EY7C#;)&
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M!7T8H'8':#]7RFXGSL'N4V/V'U!+ P04    " "#@E=69E\C\,\O  !IIP
M&0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6SM?6EO&U?6YE\IZ!UTVP E
M2[*S.C$@RTZW>I*.83G)"S3F0Y&\)"LN5K%KD<S\^CG/6>Y2+%)+W"_FPP!!
M+))5=SGW[-O][K9N/K8KY[KLT[JLVN^/5EVW^?;9LW:V<NN\/:DWKJ)?%G6S
MSCOZV"R?M9O&Y7-^:5T^.S\]_?+9.B^JHU??\7?OFE??U7U7%I5[UV1MOU[G
MS?:U*^O;[X_.CNR+]\5RU>&+9Z^^V^1+=^VZ7S;O&OKTS(\R+]:N:HNZRAJW
M^/[HXNS;R_/G>(&?^+5PMVWT=X:M3.OZ(SY<S;\_.L6*7.EF'8;(Z9\;=^G*
M$B/1.OZM@Q[Y.?%B_+>-_@-OGC8SS5MW69>_%?-N]?W1UT?9W"WRONS>U[=_
M=[JA+S#>K"Y;_G]VJ\^>'F6SONWJM;Y,*U@7E?R;?U) W.>%<WWA_+XO/-<7
M&'+/9&6\K3=YE[_ZKJEOLP9/TVCX@V'#;]-NB@K'>-TU]&M![W6OKHME52R*
M65YUV<5L5O=55U3+[%U=%K/"M=E=OS^QOYY^]ZRC]6#49S.=^[7,?;YG[N?9
M3W75K=KL;35W\Y'W+P^_?W9^8(!G! @/C7.#QNOS@R.^<;.3[/G9)#L_/3\?
M6]"C7T^6\]P?SG,>[_DC#^=?%].V:X@2_L\8\&7L%^-C@SU\VV[RF?O^B.B_
M=<V-.WKUE_\Z^_+TY=C&/]-@"1A>>#"\.#3ZJY^;95X5?^2@^TEV65<M 6">
M"QNHYMD[3%EU\D6]R'XHJKR:%7F97=.7CIA.UV9OBG96UFW?N.Q?']RG+GM=
MUK./HX [N)J' N[PUMXU!:UT4])ATL+3K?W<-]G,?^/FV<+OJPW[HO?+?NZR
M;N6()S*.\%BO:^(=579-B$)80TA$HS>;N@E@JWNP\VE;S(N\(72:9/FB<PV/
MY,J"F(V':%'1#[-ZO<FK;4885[4Y<^'V)/MMY:JL;VEY146O%BTQ=YJFF_ X
M]-JZS8YNW>0H.^I;_)^F/>+YC_# I0Q*/,WEU3T67=#NYL5- 3'2\C?Q%F@Y
M!(6V=6T;34\;P%Z+ZL:U': F^Z$/]%1-3!^/T<%DQ2+#!I/G'1W-&O(4XY%\
M**K"H))G-S1K/BV='S##NKMM]N37J[=/LY.,1 T/21\)OK<NV[@&LI>^I/_R
M<ML6@S7<KAS-U/ *=H9OLR4)/0(WS4VHT35U68(C!,RP)T^R#T (FZ*8"T"=
MP&73%!#:V=15M"-ZL=G*AFB=!#]! 8Q$#[; K;S+5O3]M.Y6V=E3&:.^!;+0
MVHN&9+((9(*-H+(,Q2^NZ5"S-K"R<IL5=.BSSJ8A@/WEO[X^/_OJ99LYVE:]
MIH-70-&V'!_SN<Q:3\MB*>A 4^?3MFZF&=%U*].&$;-:,+F!',>SM$@'X,F>
M"92+IEY'+YQDKW.@,<Z68"]8)#36DWB1T?+-AG@OG\FR)[*DU?&QSHMY5M4
M$LUP^&1 LAXGL#6F%%)>ZH;&LH$BP@\/S_L&8T*ZL(PYPR;IWU->>\$02)CA
M!V4*3&-X]6Y^ EC3 @11&D> XSU-'9$Y\;M-W@BI8]B& 4 :"V%%'N33)C"U
M)0&[R4LZ<OK=;3IC$R[[A>B(/C&')C7BEY/KD^QO%Q?OGO(*>$@\5E0DX7IA
M-CA%Z&[9V>GQ_^;'WKME7\I6KX__^R2[6 O_$Q8DDZT+.@F\C3%3'I719C)
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MHZ!]Q$DQ,N<H30:L*V:\:F'1_$W,2:<](R-/Y;V]A,>LJ8$RV<V+X")H4G
MFYF"=H%68AUZ;9_]RW@0(HW]8Q+730 @-C6<R9'@BG$Y-GE2_[P=+!*>2"EH
M=S$P.!\YSLHFM(^ !N:#%R7VZH4!Q\(3 .I[6#&4&#D]@D"0.<?U+? .EISP
M+3>/J9U5$41[&@"Q(LNN!]BK[&W?U!LG(LKT-Y!,97#WL21 3YP"L? F39R]
MAD8TK+X4PJ3D9(78>>T_B*].+%TSIEHAHV.Q0*'..&#%@@R78J$QQWKFYM#-
M;A :<ZGH[$B$-7,VI3PBPAZ PC'8>+Z>(N!5-UNVVAS].^-0N&(BR_=CB166
M^11* /MZ>RS^)TT?$,^IAZU CE22DJ5<7NGQ$T-C+ XR@:4UL7*/LJ*5T<3
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M6J1#M,.)F7H3"RVI@1GB6;];%$#C9HT/0D&U^NC*8E6+%X7@7! !<U;W4M.
M)_&+7#71((51??F:"4S6GP.QP>=C*5$8+^2NI1LMXM9($3BL^Y )-6-<#5"
MS5%UNL51X#!YU%]FB&(Q8R"VIMJKED!$T!'3<Q*!PAQ[L4+0P= 0J?6LMG2Z
M%&XACI>&BXHJ&6F@QPP)^Y &&OH'GAWNLD>BX9VJ..]C%>=-6,>#;<G/VB3P
MSO5KXSEW7'+"V947QJ(X>+5&ZQ<'C^_(;M]!0:M*XJQ^<<TDFE.$D%-((6L@
MR!I@YV:KJB[KY38>=8$>4Y;1-RB-#JQC(C7"T%C::!./T?(D^R6,$66*[0XG
MRE7C?./"O9IOU-4.J8L^2V,KOK;9"@J+08"M\04*42PC,:UILMY^'&22?,0H
M:*&A3E;L/JRB)GW<VDVL9XF6F-F\=V)E5<C^#"J+.+IQSAS[.DBS(K-8]1S8
M]3$=YU72$,_!;;PA%-#Z 2V=T7AS.!H$J*N[L31#^G>I B/LA0R)*9U2744N
M]UC?W'N4;D$PA&;SRX;UU %X'C(&:PJL::<!K!%[.Y '#S9UG-<G1!87RG5M
M7( H]AY'ME1A+YK(Z<"^#MT($1.) <;5 !=9H*\^2UT6,])YQ$<3 G_I_O>3
MHN0@P(BI[\5IP-_A2X ["SUZD(44/(FDYY#V0KH5.RT6DMU,ZH+W?T&3L&Z>
M1>.S![4"@*V&P0K,\S-,Y(%B[F[ONVI.41I,)HXP6QV7X2P::4^&@JE%_*MF
M9:.^PGTJU#VG6^&6!)W2O)8MCK8 E1P&>MN25+6='/OJBF;6K^'.YU"V)H$+
M8RLX.UGKA#XZKBPA@N-4./Q^WY-KG&X)-IXD7J#J7=O-WF,BC]MJ\/!0?!H=
MTHE2VME5$W<8 @?QM($J'B!(HG6G@#*"/N/G5+(X<X]LT02^O:0G!;4U1FI6
M+JY?9Q?7EUIH\OR+TTDB?H^SOP6K6_-5&5HCP\,D=_-V[W;O.)) U&.#S\F*
MVK50)/ZCCA62Y@AP[J\>CAU,:J%Y5I#FZOF4HLAE45>I9\/7XJHD:<FJDGQ
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M+NV,G>.[*G@*&:VM)-OWCMXKH1IA(_U:RH*8VFZ+5BV-?A-:H<'7P3G9UA!
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M=ZKYD@&4AJ#!09*Z?;>?2G2\D-CG_?IU,\BE<=5-T804$_8\"Q49*XWV4O=
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M)<Y;*IJ_]CG=JCS>KY(;Z<S5(L7%B#K%H7W$T?+]N]F'Z<<#@(][P,>'M%,
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M+'$V)L<+\+ZP0**[X0#]:7O^-U!+ P04    " "#@E=6_X#>^=X'   K&0
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MT4=]M(5,\IZA0? [W")DZ[.68W2@:UYB 2Z,*A)IHQWXXSJ,-1FU2[MR_&M
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M+E$_"TT#\'RN4.GG%[1 ^5;]\C]02P,$%     @ @X)75GIX@+[W!   H0P
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M;4H!U,;\1I\E 3?S![ !N($%0M5%4!!@)VB_1=)](U6(DPC80QWZ.^S0BYL
M%9*_,_Z1?C=I@LD45E+_AZ,+OJ=<#(1Z[!0/8_SS+937I0F>H*$\!ZW[(\ D
MY%XWY(%!CCS_<J@$,VFG221GJ IXLBKII.*H%N_W9QBH51:NATTZ-0-([.-W
MA="A3]=DL)$IN.P,89* Y?UG-)+=EFSM<[:VABTS5S7#SL=3]8U82AY7,(D<
M)-U4/\!>21(W=G!F?U1 IELC[;C7_.M 1,0V5[GQ'[1Y13?7;,XC]/]@C-H,
MA5CF(XPTV?,(+"1%HK$##'!@;0V2EW]D>=77%\7+]D7^^MWWG\#IY%'Y"9R^
MTQTGN&4[3C?/$M]!ZE4,_V;)^Z-)X35FR'LH^."8$,HIW:+X[,!WN@@>DD [
M2G_<'24X>@>Y0YAI*E3/K<\F-R*]IX]#L4P##S-?4)9WRP]0Y^:SRVJY^7KU
M9Y[>XRPN$BO8.CJ;C'N&H>)")UOZ"'.1:)ULZ'0M..1E7 #/5TFBBPM$4'Z6
M>_$_4$L#!!0    ( (."5U:-LGZ 2 D  %P:   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;*U9:V_;N!+]*X2W731 XNCA5[)) "=M=W/1;HLDW6)1
MW ^T1-N\E427I/*XO_Z>&<F*G#BJ<;$?XLCB<.9PWD.?W!G[W2V5\N(^SPIW
MVEMZOSH^/'3)4N72]<U*%5B9&YM+CZ]V<>A65LF4-^79810$H\-<ZJ)W=L+O
M/MNS$U/Z3!?JLQ6NS'-I'\Y59NY.>V%O_>)*+Y:>7AR>G:SD0ETK_V7UV>+;
M8<,EU;DJG#:%L&I^VIN&Q^<A;V"*O[2Z<ZUG04>9&?.=OERFI[V $*E,)9Y8
M2/R[51<JRX@3</RHF?8:F;2Q_;SF_IX/C\/,I%,7)ONJ4[\\[4UZ(E5S66;^
MRMS]H>H##8E?8C+'G^*NI@UZ(BF=-WF]&0AR753_Y7VMB%TV1/6&B'%7@ACE
M6^GEV8DU=\(2-;C1 Q^5=P.<+L@JU]YB56.?/[LPA;=032DS\6F6Z84D93DA
MBU1<F#S7'B;P3KRYD;-,N;V30P^IM/<PJ26<5Q*B%R2$D?@((4LGWA6I2C<9
M' )N@SE:8SZ/.CF^54E?Q.&^B((HZN 7-SJ(F5_\ K_KI;'^P"N;B[=JYL6W
M#R 0EU[E[M_;SEMQ&VSG1F%T[%8R4:<]Q(E3]E;USG[])1P%OW5@'318!UW<
MSZX1EFF9*6'FXH,I%BW8EX7SMJS,]8W-)6[4O1?GF4F^;SU(MZA+YTI9)$K
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M:4*S"V>JTR9RO+1!>3"*I)STS.(#DDD:SCZQE4!]/O,-@5J1G^X E@U ] )
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M8&5-V*?2#JK9#L8.NO> YL(N1Z2#I"?\M)6EK0/:"985TOVFCRPR.8MPC%A
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MW1B_;,LR#'/W&Z;T(,<O3.A8D1)BDB3&&A,8(G8$"ED/A>S54.BUIO!?&".
M"<K"3Y+/92VMA.]?AX&C,@]CX ZVRX4L.>)0[F%2(7&K3C4@@/&M:O6.:ARY
MS$T+!G,""[Q1KT#! <M/D L/4$'I9^AC6GD=2ENU#:%D1DO@2%O,DMP&XP<&
M#<TM<,FHX C/HH0<"79I&+(,X+OM6-%#7I9ZPVO#XB!A,>H GEJ]*>U&@\V[
M3GRYY/H>)!D+$X3'RGON)P*P6&M5@:!WS?-6V3"('5K),F-7!/E'+:UX5ZE'
MPC)\Y.H!$M#SZ^2% %P8!SV<=^S<-*70%K.2"\U:&4F4ALU8 3F6-_>2 -/&
M+!YG&<2,TR1C5WPM+:_EGQ!P^Y:OUN^O&5H-RW)VH\EU]GG,UC4!@NP2?VSD
MVND<D=6?D?B:O?VIB,+H/8M3EHQG:4)KE+%/PB" #[S>M'XA2'!H2C4X")*1
MNX:XQJ *:$6_WT/!#NA/V-<&XZ'7]!ZFMMCS,05[.$4^<!K&V$(VD"/A(QQ#
MY%8.Q93/^:S5.4YZM:ELX/X_@)5#R1>/\QEJSKA V;G18LUE1>)D8X6F'.'-
M,X6;(A%E":"<OLB*%-YA\7&7Q8UG@>(R#K+(7P&&SX?S;KQ_<R\#'?R.ZLE]
MPZTW5*$)-+OE&RXMN8?/H[1+/*;<1TYX'G2":K^J9>5@.>>U"ZH;%LU^=I^P
M3RTS4N5JE^RR);OS9 ?J1-\4=VK$#P+0/=[K5&]<7-[XR*CF7=DVFO]VZS9H
M.Q4.L$PB1 ,-X*\&-1E'088U3HJ7-=B6BNN70ALFJ$>H<B_E2'_@?PC (^TM
M[]M;?KR]^3>S[T8;H(&JLD"BOKJE'95SN*5=H'X"KR5<U +1CRMS<2^;AM#L
MZEI3N>U*;9JVHA(9NN&?;1S::FN8-'L-[B_-.I>]\"X- ,\T=5"EH2?!_J*J
MVBI.KX<N7MO"WO4$JYPQ':">29D"TP^+BE<S6&N)X8Y( : \9QAV,[0\ZE_N
M*(U^^VT%_MDE&D8!35 T5H4%S57"VEKXHDLEA*B==S=VJ;1'ZC"D(8Q^N1_$
M-M:-/[5<H1^Y0&$(E;JM1,."F+LY#!/8!Q^MK>^26;3GP2.@+7K0%D=!2Q"%
M='$(AC^@=(/T]YC;*TG<^IK;=G+C[*<AAR1V0<7K(Z:0U\SBKX3D=R#\.KF;
M'%!AR]EK$X63@/W<789T'6'CA^==-<9^W%KT/+L!)9CDQ&"28@VS289+_T+F
M#8"+%NWD#=TI,0#%=!+C9#8IB"Q-)PFN'Q8+47HA[7G/8!A/"M(*8_HD=IL$
M4FES46)D\<#M)[?$\1H6D]#39/XH#8%<E\MV.@2/2>H.Q-[D8=)N?CLXTWC!
M@=-WF$3^Z-^4JAY1!IA$E97:C4[=X-@-(#_O[&+GJ]WYK]<Z<)X;XN*4R;W2
MU$\JGZQ40%NT&)Q.G#:T9M[@KR],B;F3&4XB8CO+O"?1&S1_!W6I(_GNB!N-
M05,YK'D8. :W F-RX^N*>I#N*]LP:CV=>IV'<>Z==;7$:"I8JQ'!S9"!T<CI
M,\.:ALZ?;FCS /-H:@USF(P+=S1V>(EH?RC_ISM?LU8" :!O=O0>BXKO/VSU
M=_O/@A?^:]CVN/^F^"OB1P-H+18@A4)XW=;^.YW_8]7:?1N;*VO5RFV7@B,K
MZ ">+Y2RW1\2T'\L/?\/4$L#!!0    ( (."5U:+AEDP;0D  #,;   9
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M.>TN[09.I04J4+>6RHS5[\R&6;K;QM80$ [0F,HU-AT_:O(:@48<6N@9U!G
MD5M(_EK569M"%PS(-D#R?1SF<#YD5DN'+64%*PK#X"(C5.B&K *I$_8K#73Z
M4<S\$/^!AUW0,#5=F0D9 %G4:X/)?G3HLR!B&,IABS\/F1][E"KJ4@*U#^S@
M%BH7>7.XF<(. G[(#OB<#@G!WD\(?GXTHV/(V>] >N=R6CM$E7"O=<$1I=<\
MQ4C/]0-[XO;DO3#1$ 7M;987K=FTO4)& B#J R!Z=0 ,\7XE'HWS#)<ZS*;5
MSY:['$.J%DR_3JSC]GPW;&"@?%X( !@&ULC6P"0I.2+"(,>4=28+8J=4%&E;
M$$71G*4257-D&&N;2"W=U)VE9ICE3ME%/1@9(%<F-.S@O"\BUE0WN RV]=JR
M7;(&:?XDOM4]J_?1"JK.2R/@WE18,CL2=P#Z4@[3P_-QMQ-2GW=44E@VJ[K5
MB (0=>#P),8QP20<_3D6L:-5/DB5YEIV7 R2#5V/(!;$;C2G>]^-]\S;[VJ$
M1>!&(9T]-X[M.0QW-G.(F@^;1'97P[%YD3>/C%/6X)0O>(!#/X32@UGB([P#
M'&Y<>,@BUV=("OA/V'6N?QPMJ%+(X1-%R5&1F;X;\K>(KL!-XK>(H"BB.]_E
M'MWQV-[%_.U(7,5]7,7_5UQMYQ%P5@.OT])LA'VM<M"B"3KD58"/O/&ZN!JW
MYV-E.Q[;?'0(KEF%D*+J06X2<E=GY)KJ"8M:@/%W#/MFAUD[K876VAW(;8#"
MSCJ@G(N""K3]!0H0Z?N.%Q/0L.'_[& <.)$W)\+NM![XH.#0 =<CJ<S8I:U0
MZ(?9+ 3,PW$M")2Y,T\(CABZ41(Z//3HT7Q+#45+0&2/JF6@*)HA R!_C"OR
MH2@.9R9\!JM)9A02>+ZM*$RX411M*4J\0Q:^M"(.16&0F/@TXJ@HJ%HSA/B.
M,*=9M[>@LJ+-<-\]OL^;U4HB]P(-MW(EB@7->:)"((,@JA>/IC)HFUH]FA1I
M)B)I$Y,I^4>;*ULUN",AD_0AD_P%(?-4I1D@;O5VSJ_&S*A!^VNO9P*I<VP.
M8L,#Y (\NY6;>T0(RJVJZ]S)B28K;!R^*88W:Z%\P^SB,;P?!1%@B]O6\B:5
M.20$&%L:GSU-)R+_*89?F5!N1A>R$^L<P$8YY<SBA/E.@ "[?LX:"B<W2D"Q
MN.)NX)N =^?=$_!W]R0)#=]3^:6>"NO=_H,3\KG-,V-UT+P'W_S5X/M:#10/
MT6<*6(?8L(LKVVF^$FSC!GR774M'#N_U[Q0/BY:ZLKX\I9JC(VST6HC4R@3F
MLYW@^,)V?$R<\A.77TMZ,T9*B,CHW'4\?5(^[ )S4PMA;Q.3/_:E&3\QFTY)
MP(V-QK.R;JD+Z9H:3%"RN][N8E*S%5W'^E14#7K7,4[RO:?W2=[HOGP2ZH=L
M.BH2W9N%N[[^%;]<_[Z@#SC8M,$_%YG47N-).;3I^N:KX0)Z\]&YU8:L6*//
M>C!^*1[9&[0-W>8:W! B'#SU=Y_Z1MJ;9/>Y9PK@;=OTT#K]1%GTEHS>TZ@"
MS)B75#%;SM*;)9BZ$=>FBG182X7?GS]7RULE\0Y3=<&W?;H9O%: (5MJ;&WK
MSVUM._/L"P4_8I^DT*W-9-2-[>"9HZS<_#^5EEU%&=.;#12/'KWF<)'SQXI'
M?_ 6TQ^GHV?SWTXG]HL);USMKV6\K3"WS=/>QHE13SO,1%M+>+9\'.&>"TJ$
M:)U;4;#?\H4<[M;9<JGDDC;G(V7+BCIP^PYPF]X^OT28P D/',^V^L/*E+HH
MM/X?NKXIHT+.FT>'Z'P >:R]*&0V70P*N@@_\OAEE4 15/J<V]PV4$GM6S)4
M&3KQJ,KY'"JC5ZA$,/E.:-ZJ;=7?U#>&X5 EI\(6*N/]*F<>-X7XRRJY49F8
M..2F:^/S>*/)H/BY>3[Z@C@D7X9NA$8@&;2&XZ]!6>S,@AG5RHEK?/FE;H">
M+BD1X[WVA2H9S[V!\>2X:&\-,AU\QRBE6IJO-1JI"RG.?M+HG_9?A,[L=Y"G
MX?9S$M+0$F!FA5Q@*EKKV80I^X7&WC3UVGP5N:V;IB[-Y4H*!"4-P.^+NFXV
M-Z2@_TYV^C]02P,$%     @ @X)75B8L"4\F!   (@H  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&ULG59M3^,X$/XKHZRT!Q(D35I8%MI*P+*Z.PD6
M4?96I]5]<)-)8^'$6=NA\.]OQDE#T;850FKCV/',/,^\V#->:O-@"T0'3Z6J
M["0HG*M/H\BF!9;"AKK&BK[DVI3"T=0L(EL;%)D7*E64# ;'42ED%4S'?NW6
M3,>Z<4I6>&O -F4IS/,%*KV<!'&P6KB3B\+Q0C0=UV*!,W3?ZUM#LZC7DLD2
M*RMU!0;S27 >GUX<\7Z_X1^)2[OV#LQDKO4#3_[*)L&  :'"U+$&0<,C7J)2
MK(A@_.IT!KU)%EQ_7VG_ZKD3E[FP>*G5#YFY8A*<!)!A+AKE[O3R3^SX>("I
M5M8_8=GM'020-M;ILA,F!*6LVE$\=7YXBT#2"20>=VO(H_PBG)B.C5Z"X=VD
MC5\\52]-X&3%09DY0U\ER;GI#P\;,SA_1$-1@%DA#%KXUCCK1)7):@%[]V*N
MT.Z/(T<662Y*.^T7K?9DB_8X@6M=N<+"595A]EI!1%![O,D*[T6R4^,73$,8
MQ@>0#))DA[YASW_H]0VWZ+L2IB*.%F[1M-SAY_G<.D/I\M\FPJVZT69U7$*G
MMA8I3@*J$8OF$8/IQP_Q\>!L!]A1#W:T2_MT1B69-0I!Y_!;X&Z:<DX<Z%,7
MPI\^;'"/3PXNE$X?-O+9:7$SGW]1F#:@0.% ;Y9#LB<K2E&EJ-KLO@\0/V)^
M#%[PB@ZO;5'JM40[Y *3*<0'H^$@/.(Q2<(AC_%Q^ ENZ)#"/*>"9IJI+DNJ
M:RJ1] 'P5R,?A<+*6?@<)A#')/_QPTD2)V=OM"TLG4S\FDG5^".#<7PFNSP.
MPY,>QXY0'O6A/'IS*,\K)UN;CU1_F#9&.DGPKIY2U;"7<Z-+N-1EW3CA@9'0
M[XF[*;J[0=P7"+E6=# S;?MB>8E4!_C*O*.]J5!IHWH(RW>Z=8ZI:"RR2FE6
M :7<81,U&JDS"S[;*E8^YXN#SO9&95"0)5I .LW7?'8*[\K(RVWYLQ?O0Q4)
M_X]',/,;=,W87Y/;2_;A&(;TO[Z\G<'>D&R,^$=2K.0..QIV>[+6C;$-L0&G
M23>YHZR5?D9LMQ[RC9.Q--W"MO5\K41E#V!9R+0 /K#8%X=] A%E3R]K<*63
MZT9I2\:TE5Z'][:TG;M#SV0-K=U*^9UPZ59S!644FE12Y&LC4TH45PC7YMJ"
M&@I'0:.5-@]6*94+2A%J%QZ( KFL\07#AE\YE)H3+V60LI, =%D4^I!LBX*D
MQ/0G9%/KUFBJ*S)KN_3FF(8DG3,N#3?:(?S=GBGQ69L5A589"?P!5Q11]^QQ
MB"SS/A:*O-QV330+-YT9T=J]7:)9^.Z$43:5:Z_P?K5O@,[;>_]E>]L]70NS
MD.1GA3F)#L)/5/FF[4C:B=.U[P+FVE%/X5\+:N+0\ ;ZGFOBUTW80-\63O\'
M4$L#!!0    ( (."5U9Q7PXCG0<  #04   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;*U8:6_CMA;]*X0[K[ !Q=8N>9H$R-(EP*0)DID61=$/M$3;
M1"11%:DX[J_ON93L+&.[Z7OOBZF%O/?<]5SK>*6:![T4PK"GLJCTR6!I3/UQ
M,M'94I1<CU4M*KR9JZ;D!K?-8J+K1O#<'BJ+B>^Z\:3DLAJ<'MMGM\WIL6I-
M(2MQVS#=EB5OUN>B4*N3@3?8/+B3BZ6A!Y/3XYHOQ+TP7^K;!G>3K91<EJ+2
M4E6L$?.3P9GW\3RE_7;#+U*L](MK1I;,E'J@FZO\9. 2(%&(S) $CN517(BB
M($& \6<O<[!520=?7F^D_V!MARTSKL6%*GZ5N5F>#-(!R\6<MX6Y4ZN?1&]/
M1/(R56C[RU;]7G? LE8;5?:'@:"45;?RI]X/[SG@]P=\B[M39%%><L-/CQNU
M8@WMAC2ZL*;:TP G*PK*O6GP5N*<.;T7"[C8L#M1J\;(:L&&G_FL$'IT/#&0
M3[LF62_KO)/E[Y'E^>Q:56:IV?=5+O+7 B8 MD7G;]"=^P<E7HILS +/8;[K
M^P?D!5MK RLO>+>UOY_-M&F0&W_LLK>3%NZ61O7R4=<\$R<#%(06S:,8G'[[
MC1>[WQW &FZQAH>DG]Z)3%69+"2WZ:OF0/THJE:P>:-*UINBF5'L0E5:%3+G
M1N3L=QL_]ED\&79>J.QAIV4'=>^V[ Q%^!:260H ,+S0>$D^!0!T"ON\>V#!
MZ!=@Z16OZT)F]A6I9M*(4B/SS5)";-N@6#-5UKQ:4XRRE^9I@Z43!OUH3HT%
MHYG4C&LH+]!G-!M"4"F+@EXY3#QEHC8,FS.<1+/1HS'[5; E?R2<CU)#<MU(
M(,<>J7*+%'JIZVU 9VW34/*L!<<V<@M$D>XQ^XT>V:1G2%E1SD1CT_9G=%7-
M44TV@>G'HQ^778O\OFT6[ .+'#=*L(9.[,58 R<-0W;!FURJ1ZZSMH#HU/%B
MCR6.CQ*+G*D7L,_D=%9MY<,7N_SM!3B3,L]S4C]E4R>)8G8#8QHV]$9L&+LC
M;&&^-V57<'=F2 YL1B^K>GNS-9L7;6;:WLW#,(E'+$QP.!H!K^<[<>K3!72D
M*2ZF%N"!"HBV%1#]RPJXZ<*-G+AMU%P:-ORDM![]7RKB,)9]$;ZJD*B"#0N+
M8R;(>4QV#PU_.A1YSXG]R*Z1']K50W3>1-YW/#BS<ZWGN.$F\FKKB5[9G@0(
MG"1(\!LB<R!KFK(O%4>)9-8SO%0M=GV$OQJ<Q3.4"OA>"Q0-!!=M3BJ6(E_0
M:BE4&@FK>)4S^<Z4H=B]$^XP#)!=P]"UOWXX@H,-KQ:2=G&MD>^D53:VC6=+
MWBP(*L_^;*66I&Z2@^6UD:9MQ%$C"FLGU4F_F0VS1N32Z)$#!.C]!+2QUL&D
M5T_^Z7@F !]]IH#BA;7U\ FKX?LO[/KRCJPH;!OK<CM3FJQ/TBGL1IP3UZZ^
MFX[864E<]5>WL0\/&Z9N@"U)2&5LC[TIZY!Y2):;MW[O$Q6Y%TXIXZ93$K4Y
MO=G4:X&-9,@P(AA#SX=&[QT9;U,Y].SJ)M34AHFUBZ)IZ\'99![-=32@]5VL
MYQK-$ 8DAL1<T_')%7)>\HHMU*-H*AO\FJ]G/'M )U;HWUV?7RUEMF0<@&:"
MC,ZEKEN*!Z)$+7PC)@/'0.=:@TK&[/,2:K>(5@+'*V78<YF@H1 I[4I88"-Z
MDCE.Y6RVMALO;BZO+6S8@_M,;&39.11)D(O,0CXJ^0/AK%N4'XINW#O(L[NH
M7[ST%*76!LM]#1&\,&MVBS0K0=6M :."AV>M1N_2D'53L6O>P"'= (7?%5A,
M4>99J^"0%\6RH?/W2+ZU5-GSX@L95D-/C;V&?Q9'M,V)UZN<%PK3P'.SZ-W,
MZ/F"G+PO#N,#=!-OZ28^V.(WP^%7O0KXGB<'<M,S[;Z/6@[JW3UL?56X>QJF
M]=T^='O.[..R/4P5^&./_8<%P=BEQ;5W;VDJ&D_QU(_'/A8O&<=8]NFY%+ S
MDZ\;VEZ:[&8*ZB93]RNU802=.!*Z/2_FNV3OX\8@8$'D8W5?=,]OOTDQ9GVW
M78/7P\1.!1^LK ]66G=](!^3;3XF_W+\.2,"U*^FG?]RV#FH><_X;_/I52 [
ME_,.U7, GV/G.Y'KV=5+TK?!BT!O$>;>T$M>2]H3KL1)W)C%3C2-V(]*Y2N,
M]S1^3I$N&#ZG2)0-B[T>&71'8QB<71_G/4 \PU%E-V?;R:?7CFTAS=J1'<X"
MWPGC:7?A^]-#<4VW<4T/]YD,K-86-BTOI<Y I+;]5NQ'H18-KT%B[*P1'+@_
MH>\=?4*#S3?!!Y-=56BY,F_AL1_ZP>N".**AP0P4U-VLWYD*!\&^.Q4LT,("
M_2H?OHSOQW88\/NAP$,E7Q&?@>1") :&/H & [ [4 .J.69>&O71S+:FA:G'
M0E0Z9G]T/+-V6 T1QG*EP !84YYTL4;4( 0A0T'^K[GRW(H+Q 3_%^E#SY&:
M'[5ZFS2(2B>/B.K("/QK[-\$:0S[*)5 P'%$70*LGB"'=Z72Y,67G%)@?*3O
M5;KS0?=19_MT^TGLK/L2]+R]^YX&ZL?0K@%ZCJ/N.,$?G*;[1M7=&%7;[T(S
M98PJ[>52< PRM 'OYTJ9S0TIV'XH//T;4$L#!!0    ( (."5U9((/G_H <
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M?BHCBHBFI4:N<#2<YOBX-./GY_C@=.\_^9;:H8/V4Z05R@5OP/N51DKN'EC
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M/4\+$M=;H=T_IQ5!APRZE\>J,"8[G0#E>0W*\Q>#\BUDSK=PZ"/DK30Q+%?
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MJ*903:.:0;48U>Q.J_Y5WG@]/FEX:?,L?(INHJ.T:BP4S<".MROT.+7WW),
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M-,F:J,U&%K7>*B"S[(T($@<6HQ3PZ[3ACJ<_FE]-T&8C"UJ/X&#1G4#"VHS
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M<)P,SN@9F@PO3G#80T&[0)\4CM'"<3(XPV6:G"^^6\Z/E#DIH/#.0.;$8E2
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MRS:#E#+9WI0[PN9!S%$(,REIG0WD5,6R[1[9@:#+= /$A I!H_3C L@46-)
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M0WU7M&.8"#,:GKHLP:Q&IKHPH0NJ&PA)EB9-EJU _)%F/\O$R7V6B@'AR$A
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MN$=,$W(]>$AW3Y36!*A/;WY?WKJ1E 3IO#-#N.U!;^V$,QI4#^;%P8$DS @
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M0/Q]D:;%]DMY@]U;5:_^"U!+ P04    " "#@E=6CK _U"@%  #*%@  &0
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M0'+=I$#GX8$W\]OJ ,,@/SKTJ-GX@&;.'J=VZ/<PR@&CHR2R@_\::7&@\^+
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M<]XH _G[75V+YP_J!)OWT)[]'U!+ P04    " "#@E=6Q;/AP44$  !B%0
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M:C8I_UV.'X_E<&Y#'SF\  334CT[I'KV3:E^+T36G68CKV^:D3!WULJ>I1:
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M7MZ#K7PBTWUQ"["[5,HT+A[N&-TRGC=0[]^GJ7QYDG=PN!/>ZG]02P,$%
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M =:,@$#Q!+9BLK9B8G]/]:,83_KJOT<YKR$;)N:3J:?U@"D PD0SE)D@#!N
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M=A=F=Q_JXJF]0OJ^J.MBV?[YR),Y+QN ^/]#4=2O'YH'K*\M/_L_4$L#!!0
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M^+)8Y]E_=3-]H(Z8AQ>$FM3M!S.:$20TE3HJJ*-6ZFX_?OA\R9R;SQ>?+V]
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MQ%Q%;\Y %QZ@T$1ZN6N(CB:++ )=I@!%BZ'0Q%'@MB4:T+:8L7OSJOH;V=U
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ @X)75I'YN5$A!0  \2H
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M?!8"  "J)@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[;MM
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M<' N>&UL4$L! A0#%     @ @X)75GAG:!CN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @X)75IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "#@E=6@V&Q Y,(  "C/0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @X)75L+)^MD[
M @  O04  !@              ("!UA   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( (."5U:4#4(7G@8  *T=   8              "
M@4<3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "#@E=6
M>HP#J&<#  #C"@  &               @($;&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ @X)75G()D:FA!@  #1P  !@
M     ("!N!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M (."5U9^/54OV0(  &L)   8              " @8\D  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " "#@E=6-[)L#',,  !KB   &
M            @(&>)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ @X)75@36RY%&"P  1CD  !@              ("!1S0  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (."5U9#R7T^U@(  ( )
M   8              " @<,_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " "#@E=6.7V-,%4J  !HA0  &0              @('/0@
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (."5U;('EZA
MPA4   5$   9              " @5MM  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ @X)75B"X2Z%["0  XQ<  !D
M ("!5(,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "#
M@E=6[$$H0:8;   #90  &0              @($&C0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (."5U9W6B;TUQ   .PO   9
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M970Q."YX;6Q02P$"% ,4    " "#@E=6_LI,<V\*  "G&P  &0
M    @(%H]0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M (."5U:SX51>9Q,  .,X   9              " @0X  0!X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ @X)75IU\OC=Z!0  1 T  !D
M             ("!K!,! 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " "#@E=6Q!5H4%@)  #*%P  &0              @(%=&0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (."5U:A5Z/3?0L
M -<:   9              " @>PB 0!X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ @X)75A8V(^E!!   0 L  !D              ("!
MH"X! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "#@E=6
M8SB2OG\)  !7'   &0              @($8,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( (."5U9RL3' ] P  &(D   9
M      " @<X\ 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ @X)75@3[K2FR P  =@@  !D              ("!^4D! 'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "#@E=69E\C\,\O  !IIP
M&0              @('B30$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( (."5U;?Y?C C 0  'P+   9              " @>A] 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ @X)75FBPVO2V
M!0  >0\  !D              ("!JX(! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " "#@E=6_X#>^=X'   K&0  &0
M@(&8B $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (."
M5U8 !F7_S0(  $L&   9              " @:V0 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ @X)75ALJ*B05"0  81\  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( (."5U:CE=4)#08  !$2   9
M  " @5"\ 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M@X)75I[64?WA!P  .!4  !D              ("!E,(! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " "#@E=6BX99,&T)   S&P  &0
M            @(&LR@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( (."5U8F+ E/)@0  "(*   9              " @5#4 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ @X)75G%?#B.=!P
M-!0  !D              ("!K=@! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " "#@E=62"#Y_Z '   /$   &0              @(&!
MX $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( (."5U;%
M:-O:C0,  &X)   9              " @5CH 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ @X)75D&0\DFX"0  ;1T  !D
M     ("!'.P! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M" "#@E=6,KTIBS,#  "H#   &0              @($+]@$ >&PO=V]R:W-H
M965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( (."5U8TAGB.<RT  "1& P 9
M              " @77Y 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L!
M A0#%     @ @X)75M?3&%QA"   8U$  !D              ("!'R<" 'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "#@E=6L^A64$(#
M  #Y"0  &0              @(&W+P( >&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;%!+ 0(4 Q0    ( (."5U:1'YU5IP<  $PX   9              "
M@3 S @!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ @X)7
M5OI<L9RT&@  0RL! !D              ("!#CL" 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " "#@E=6$K9 1(\A  #V4P( &0
M        @('Y50( >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( (."5U:;KT-=IP4  ( C   9              " @;]W @!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ @X)75OW$)59S#   854
M !D              ("!G7T" 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " "#@E=6CK _U"@%  #*%@  &0              @(%'B@(
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( (."5U84_8'^
M=PX  )-V   9              " @::/ @!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ @X)75L6SX<%%!   8A4  !D
M ("!5)X" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "#
M@E=6F\^Q&&((   53P  &0              @('0H@( >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( (."5U:G$ ,8IA4  +G\   9
M          " @6FK @!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#
M%     @ @X)75J4%ZGGS P  NA0  !D              ("!1L$" 'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "#@E=6A5)JNT(,  #"
M7   &0              @(%PQ0( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+ 0(4 Q0    ( (."5U8(UP);RP\  #FC   9              " @>G1
M @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ @X)75M Z
MHG(9!0  P!<  !D              ("!Z^$" 'AL+W=O<FMS:&5E=',O<VAE
M970V,RYX;6Q02P$"% ,4    " "#@E=6@@T:,S0,  !'<0  &0
M    @($[YP( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M (."5U8C+6A4LP,  "4.   9              " @:;S @!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ @X)75OIT\_MB P  T!4   T
M             ( !D/<" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "#@E=6
MEXJ[',     3 @  "P              @ $=^P( 7W)E;',O+G)E;'-02P$"
M% ,4    " "#@E=6D?FY42$%  #Q*@  #P              @ $&_ ( >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ @X)75K5Q8'P6 @  JB8  !H
M         ( !5 $# 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ @X)75M(T9!3L 0  !R8  !,              ( !H@,# %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $D 20#V$P  OP4#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>498</ContextCount>
  <ElementCount>641</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>137</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheet Paranthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical</Role>
      <ShortName>Consolidated Balance Sheet Paranthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure</Role>
      <ShortName>Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisitions and Strategic Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments</Role>
      <ShortName>Acquisitions and Strategic Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Hedging Activities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements</Role>
      <ShortName>Hedging Activities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Contractual Obligations and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ContractualObligationsandCommitments</Role>
      <ShortName>Contractual Obligations and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock Inventive and Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StockInventiveandPurchasePlans</Role>
      <ShortName>Stock Inventive and Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Weighted Average Shares Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding</Role>
      <ShortName>Weighted Average Shares Outstanding</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Changes in Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome</Role>
      <ShortName>Changes in Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Employee Retirement Plans (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes</Role>
      <ShortName>Employee Retirement Plans (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Schedule II</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ScheduleII</Role>
      <ShortName>Schedule II</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measures and Disclosures (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies</Role>
      <ShortName>Fair Value Measures and Disclosures (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Commitment and Contingencies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies</Role>
      <ShortName>Commitment and Contingencies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - New Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies</Role>
      <ShortName>New Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies</Role>
      <ShortName>Employee Retirement Plans Employee Retirement Plans (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Acquisitions and Strategic Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables</Role>
      <ShortName>Acquisitions and Strategic Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables</Role>
      <ShortName>Hedging Activities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Contractual Obligations and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables</Role>
      <ShortName>Contractual Obligations and Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/ContractualObligationsandCommitments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables</Role>
      <ShortName>Stock Incentive and Purchase Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Weighted Average Shares Outstanding (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables</Role>
      <ShortName>Weighted Average Shares Outstanding (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SegmentReporting</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/Revenue</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Changes in Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables</Role>
      <ShortName>Changes in Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Employee Retirement Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/EmployeeRetirementPlansTables</Role>
      <ShortName>Employee Retirement Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Acquisitions and Strategic Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails</Role>
      <ShortName>Acquisitions and Strategic Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ContingentConsiderationDetails</Role>
      <ShortName>Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Strategic Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StrategicInvestmentsDetails</Role>
      <ShortName>Strategic Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Contractual Obligations and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails</Role>
      <ShortName>Contractual Obligations and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes (Details - Rate Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable</Role>
      <ShortName>Income Taxes (Details - Rate Table)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails</Role>
      <ShortName>Income Taxes Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/CommitmentsandContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/StockholdersEquity</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock Incentive and Purchase Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails</Role>
      <ShortName>Stock Incentive and Purchase Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/SegmentReportingTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/RevenueTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Changes in Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails</Role>
      <ShortName>Changes in Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Employee Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails</Role>
      <ShortName>Employee Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/EmployeeRetirementPlansTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="bsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Schedule II (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/ScheduleIIDetails</Role>
      <ShortName>Schedule II (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bostonscientific.com/role/ScheduleII</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  bsx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="bsx-20221231.htm">bsx-20221231.htm</File>
    <File>bsx-20221231.xsd</File>
    <File>bsx-20221231_cal.xml</File>
    <File>bsx-20221231_def.xml</File>
    <File>bsx-20221231_lab.xml</File>
    <File>bsx-20221231_pre.xml</File>
    <File>ex1055-2020grantxnqagreeme.htm</File>
    <File>ex1056-2020grantxrsuagreem.htm</File>
    <File>ex1057-2020grantxrsabodawa.htm</File>
    <File>ex1058-2020grantxdsubodawa.htm</File>
    <File>ex1065-2021grantxnqagreeme.htm</File>
    <File>ex1066-2021grantxrsuagreem.htm</File>
    <File>ex1067-2021grantxtsragreem.htm</File>
    <File>ex1068-2021grantxfcfagreem.htm</File>
    <File>ex1069-2021grantxrsabodawa.htm</File>
    <File>ex1070-2021grantxrsubodawa.htm</File>
    <File>ex1072-amendmentto2021revo.htm</File>
    <File>ex1076-2022grantxnqagreeme.htm</File>
    <File>ex1077-2022grantxrsuagreem.htm</File>
    <File>ex1078-2022grantxtsragreem.htm</File>
    <File>ex1079-2022grantxfcfagreem.htm</File>
    <File>ex1080-2022grantxrsabodawa.htm</File>
    <File>ex1081-2022grantxrsubodawa.htm</File>
    <File>ex1083-offerletterartbutch.htm</File>
    <File>ex1084-offerletterjeffmirv.htm</File>
    <File>ex1085-arnonxemployeedirec.htm</File>
    <File>exhibit21-listofsubsidiari.htm</File>
    <File>exhibit23-2022eyconsent.htm</File>
    <File>exhibit311-ceo302202210xk.htm</File>
    <File>exhibit312-cfo302202210xk.htm</File>
    <File>exhibit321-ceo906202210xk.htm</File>
    <File>exhibit322-cfo906202210xk.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bsx-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="1793">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bsx-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/srt/2021-01-31": 2,
    "http://fasb.org/us-gaap/2021-01-31": 1793,
    "http://xbrl.sec.gov/dei/2021q4": 43
   },
   "contextCount": 498,
   "dts": {
    "calculationLink": {
     "local": [
      "bsx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bsx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bsx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bsx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bsx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bsx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 970,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 11
   },
   "keyCustom": 102,
   "keyStandard": 539,
   "memberCustom": 80,
   "memberStandard": 51,
   "nsprefix": "bsx",
   "nsuri": "http://www.bostonscientific.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bostonscientific.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.bostonscientific.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Acquisitions and Strategic Investments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments",
     "shortName": "Acquisitions and Strategic Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Goodwill and Other Intangible Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Hedging Activities and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements",
     "shortName": "Hedging Activities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Contractual Obligations and Commitments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments",
     "shortName": "Contractual Obligations and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.bostonscientific.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Supplemental Balance Sheet Information",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.bostonscientific.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.bostonscientific.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.bostonscientific.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock Inventive and Purchase Plans",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans",
     "shortName": "Stock Inventive and Purchase Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Weighted Average Shares Outstanding",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding",
     "shortName": "Weighted Average Shares Outstanding",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.bostonscientific.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.bostonscientific.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Changes in Other Comprehensive Income",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome",
     "shortName": "Changes in Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:NewAccountingPronouncementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - New Accounting Pronouncements",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements",
     "shortName": "New Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:NewAccountingPronouncementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Employee Retirement Plans (Notes)",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes",
     "shortName": "Employee Retirement Plans (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i63c80cf97e92455e89254f71abde961e_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Schedule II",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.bostonscientific.com/role/ScheduleII",
     "shortName": "Schedule II",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i63c80cf97e92455e89254f71abde961e_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measures and Disclosures (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies",
     "shortName": "Fair Value Measures and Disclosures (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalCostsPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Commitment and Contingencies (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies",
     "shortName": "Commitment and Contingencies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "bsx:NewAccountingPronouncementsPolicyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - New Accounting Pronouncements (Policies)",
     "menuCat": "Policies",
     "order": "31",
     "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies",
     "shortName": "New Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bsx:NewAccountingPronouncementsPolicyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies)",
     "menuCat": "Policies",
     "order": "32",
     "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies",
     "shortName": "Employee Retirement Plans Employee Retirement Plans (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Acquisitions and Strategic Investments (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
     "shortName": "Acquisitions and Strategic Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables",
     "shortName": "Hedging Activities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Contractual Obligations and Commitments (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables",
     "shortName": "Contractual Obligations and Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.bostonscientific.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.bostonscientific.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables",
     "shortName": "Stock Incentive and Purchase Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Weighted Average Shares Outstanding (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables",
     "shortName": "Weighted Average Shares Outstanding (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.bostonscientific.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.bostonscientific.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Changes in Other Comprehensive Income (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables",
     "shortName": "Changes in Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Employee Retirement Plans (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables",
     "shortName": "Employee Retirement Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProductionRelatedImpairmentsOrCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Acquisitions and Strategic Investments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
     "shortName": "Acquisitions and Strategic Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "ib279fd9ff9e24cabbeea019d2dce793a_I20210301",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
     "shortName": "Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "ibc9e93fb57d049aba15e55858f4ab28e_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Strategic Investments (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.bostonscientific.com/role/StrategicInvestmentsDetails",
     "shortName": "Strategic Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Goodwill and Other Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Contractual Obligations and Commitments (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
     "shortName": "Contractual Obligations and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i8722c1d4d5cd4a7f9e485658e623e39d_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.bostonscientific.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails",
     "shortName": "Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes (Details - Rate Table)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable",
     "shortName": "Income Taxes (Details - Rate Table)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes Income Taxes (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails",
     "shortName": "Income Taxes Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i182a1036891e4f75bb208c20f52223a2_I20201214",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bsx:Fairvalueofmarketbasedawards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock Incentive and Purchase Plans (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
     "shortName": "Stock Incentive and Purchase Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bsx:Fairvalueofmarketbasedawards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheet Paranthetical",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
     "shortName": "Consolidated Balance Sheet Paranthetical",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Weighted Average Shares Outstanding (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails",
     "shortName": "Weighted Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reportablesegments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Segment Reporting (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.bostonscientific.com/role/SegmentReportingDetails",
     "shortName": "Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reportablesegments",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "bsx:EmergingMarketsTotalNumberOfCountries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "countries",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Revenue (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.bostonscientific.com/role/RevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "bsx:EmergingMarketsTotalNumberOfCountries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "countries",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Changes in Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
     "shortName": "Changes in Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Employee Retirement Plans (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
     "shortName": "Employee Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i8722c1d4d5cd4a7f9e485658e623e39d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Schedule II (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.bostonscientific.com/role/ScheduleIIDetails",
     "shortName": "Schedule II (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i87a7639e46664d8fa457ee6d81350081_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i5b0b26deeb85428db3cd49a32a784be2_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i5b0b26deeb85428db3cd49a32a784be2_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure",
     "shortName": "Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20221231.htm",
      "contextRef": "i87a7639e46664d8fa457ee6d81350081_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 137,
   "tag": {
    "bsx_A2011LtipPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2011 LTIP Plan [Member]",
        "label": "2011 LTIP Plan [Member]",
        "terseLabel": "2011 LTIP Plan [Member]"
       }
      }
     },
     "localname": "A2011LtipPlanMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_A2021AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Acquisitions",
        "label": "2021 Acquisitions [Member]",
        "terseLabel": "2021 Acquisitions"
       }
      }
     },
     "localname": "A2021AcquisitionsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_A550MCPSSeriesAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% MCPS, Series A",
        "label": "5.50% MCPS, Series A [Member]",
        "terseLabel": "5.50% MCPS, Series A [Member]"
       }
      }
     },
     "localname": "A550MCPSSeriesAMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/Cover",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails",
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2020-10 Codification Improvements",
        "label": "ASC Update No. 2020-10 Codification Improvements [Policy Text Block]",
        "terseLabel": "ASC Update No. 2020-10 Codification Improvements"
       }
      }
     },
     "localname": "ASCUpdateNo202010CodificationImprovementsPolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method",
        "label": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block]",
        "terseLabel": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method"
       }
      }
     },
     "localname": "ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)",
        "label": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block]",
        "terseLabel": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)"
       }
      }
     },
     "localname": "ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.",
        "label": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block]",
        "terseLabel": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions."
       }
      }
     },
     "localname": "ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)",
        "label": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block]",
        "terseLabel": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)"
       }
      }
     },
     "localname": "ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848",
        "label": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 [Policy Text Block]",
        "terseLabel": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848"
       }
      }
     },
     "localname": "ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_AccruedRebatesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates, Current",
        "label": "Accrued Rebates, Current",
        "terseLabel": "Accrued Rebates, Current"
       }
      }
     },
     "localname": "AccruedRebatesCurrent",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_AcotecScientificHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acotec Scientific Holdings Limited",
        "label": "Acotec Scientific Holdings Limited [Member]",
        "terseLabel": "Acotec Scientific Holdings Limited"
       }
      }
     },
     "localname": "AcotecScientificHoldingsLimitedMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ActualCovenantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Covenant.",
        "label": "Actual, Covenant [Member]",
        "terseLabel": "Actual, Covenant [Member]"
       }
      }
     },
     "localname": "ActualCovenantMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_AllOther2021AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other 2021 Acquisitions",
        "label": "All Other 2021 Acquisitions [Member]",
        "terseLabel": "All Other 2021 Acquisitions"
       }
      }
     },
     "localname": "AllOther2021AcquisitionsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of employees total compensation eligible for GESOP purchase",
        "label": "Amount of employees total compensation eligible for GESOP purchase",
        "terseLabel": "Amount of employees total compensation eligible for GESOP purchase"
       }
      }
     },
     "localname": "AmountOfEmployeesTotalCompensationEligibleForGesopPurchase",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_Annualweightedaverageforfeiturerate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends",
        "label": "annualweightedaverageforfeiturerate",
        "terseLabel": "annualweightedaverageforfeiturerate"
       }
      }
     },
     "localname": "Annualweightedaverageforfeiturerate",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_ApolloEndosurgeryIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo Endosurgery, Inc.",
        "label": "Apollo Endosurgery, Inc. [Member]",
        "terseLabel": "Apollo Endosurgery, Inc."
       }
      }
     },
     "localname": "ApolloEndosurgeryIncMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_BSXReportableSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSX Reportable Segments",
        "label": "BSX Reportable Segments [Member]",
        "terseLabel": "BSX Reportable Segments"
       }
      }
     },
     "localname": "BSXReportableSegmentsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_BaylisMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baylis Medical",
        "label": "Baylis Medical [Member]",
        "terseLabel": "Baylis Medical"
       }
      }
     },
     "localname": "BaylisMedicalMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brazil CADE - # of individuals for alleged anti-competitive behavior",
        "label": "Brazil CADE - # of individuals for alleged anti-competitive behavior",
        "terseLabel": "Brazil CADE - # of individuals for alleged anti-competitive behavior"
       }
      }
     },
     "localname": "BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]",
        "label": "Business Combination, Consideration Transferred, Additional Revenue Payment, period",
        "terseLabel": "Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest",
        "label": "Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest",
        "terseLabel": "Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_CardiacRhythmManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiac Rhythm Management",
        "label": "Cardiac Rhythm Management [Member]",
        "terseLabel": "Cardiac Rhythm Management"
       }
      }
     },
     "localname": "CardiacRhythmManagementMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_CardiovascularMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular [Member]",
        "label": "Cardiovascular [Member]",
        "terseLabel": "Cardiovascular [Member]"
       }
      }
     },
     "localname": "CardiovascularMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flow impact of deferred income tax expense (benefit)",
        "label": "Cash flow impact of deferred income tax expense (benefit)",
        "terseLabel": "Deferred and prepaid income taxes"
       }
      }
     },
     "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_CompensationExpensePerShareBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "compensation expense, per share - basic",
        "label": "compensation expense, per share - basic",
        "terseLabel": "compensation expense, per share - basic"
       }
      }
     },
     "localname": "CompensationExpensePerShareBasic",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_CompensationExpensePerShareDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "compensation expense, per share - diluted",
        "label": "compensation expense, per share - diluted",
        "terseLabel": "compensation expense, per share - diluted"
       }
      }
     },
     "localname": "CompensationExpensePerShareDiluted",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_ConsolidatedBSXDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated BSX",
        "label": "Consolidated BSX [Domain]",
        "terseLabel": "Consolidated BSX [Domain]"
       }
      }
     },
     "localname": "ConsolidatedBSXDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ConsolidatedBalanceSheetParentheticalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheet (Parenthetical)",
        "label": "Consolidated Balance Sheet (Parenthetical) [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetParentheticalAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Cash Flow Supplemental Disclosure [Abstract]",
        "label": "Consolidated Cash Flow Supplemental Disclosure [Abstract]",
        "terseLabel": "Consolidated Cash Flow Supplemental Disclosure [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedCashFlowSupplementalDisclosureAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "contingent consideration liability, probability of payment",
        "label": "contingent consideration liability, probability of payment",
        "terseLabel": "contingent consideration liability, probability of payment"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityProbabilityOfPayment",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_CorporateExpensesincludinghedgingactivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Expenses including hedging activities [Member]",
        "label": "Corporate Expenses including hedging activities [Member]",
        "terseLabel": "Corporate Expenses including hedging activities [Member]"
       }
      }
     },
     "localname": "CorporateExpensesincludinghedgingactivitiesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_CovenantAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covenant.",
        "label": "Covenant [Axis]",
        "terseLabel": "Covenant [Axis]"
       }
      }
     },
     "localname": "CovenantAxis",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_CovenantDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covenant.",
        "label": "Covenant [Domain]",
        "terseLabel": "Covenant [Domain]"
       }
      }
     },
     "localname": "CovenantDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_December2027NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2027 Notes",
        "label": "December 2027 Notes [Member]",
        "terseLabel": "December 2027 Notes [Member]"
       }
      }
     },
     "localname": "December2027NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_DeemedConsolidatedEBITDA": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed Consolidated EBITDA",
        "label": "Deemed Consolidated EBITDA",
        "terseLabel": "Deemed Consolidated EBITDA [Member]"
       }
      }
     },
     "localname": "DeemedConsolidatedEBITDA",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DeferredTaxAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets",
        "label": "Deferred tax assets [Domain]",
        "terseLabel": "Deferred tax assets [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetsDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Prepaid on Intercompany Profit",
        "label": "Deferred Tax Assets, Prepaid on Intercompany Profit",
        "terseLabel": "Deferred Tax Assets, Prepaid on Intercompany Profit"
       }
      }
     },
     "localname": "DeferredTaxAssetsPrepaidonIntercompanyProfit",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DeferredTaxLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities",
        "label": "Deferred tax liabilities [Domain]",
        "terseLabel": "Deferred tax liabilities [Domain]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO",
        "label": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO",
        "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets",
        "label": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets",
        "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan, plan assets, actuarial gain loss",
        "label": "Defined benefit plan, plan assets, actuarial gain loss",
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsActuarialGainLoss",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return",
        "label": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]",
        "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net"
       }
      }
     },
     "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_DevoroMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Devoro Medical, Inc.",
        "label": "Devoro Medical, Inc. [Member]",
        "terseLabel": "Devoro Medical, Inc."
       }
      }
     },
     "localname": "DevoroMedicalIncMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_DivestitureAgreementTransferOfFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestiture, agreement, transfer of facilities",
        "label": "Divestiture, agreement, transfer of facilities",
        "terseLabel": "Divestiture, agreement, transfer of facilities"
       }
      }
     },
     "localname": "DivestitureAgreementTransferOfFacilities",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bsx_DivestitureAgreementTransferOfGlobalEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestiture, agreement, transfer of global employees",
        "label": "Divestiture, agreement, transfer of global employees",
        "terseLabel": "Divestiture, agreement, transfer of global employees"
       }
      }
     },
     "localname": "DivestitureAgreementTransferOfGlobalEmployees",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers",
        "label": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return to provision",
        "label": "Effective Income Tax Rate Reconciliation, Return to provision",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Return to provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_ElectrophysiologyEPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electrophysiology (EP)",
        "label": "Electrophysiology (EP) [Member]",
        "terseLabel": "Electrophysiology (EP)"
       }
      }
     },
     "localname": "ElectrophysiologyEPMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_EmergingMarketsTotalNumberOfCountries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Markets total number of countries",
        "label": "Emerging Markets total number of countries",
        "terseLabel": "Emerging Markets total number of countries"
       }
      }
     },
     "localname": "EmergingMarketsTotalNumberOfCountries",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bsx_EquipmentFurnitureAndFixturesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment, furniture and fixtures Gross.",
        "label": "Equipment, furniture and fixtures Gross",
        "terseLabel": "Equipment, furniture and fixtures"
       }
      }
     },
     "localname": "EquipmentFurnitureAndFixturesGross",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_EuroDenominatedFactoringArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro Denominated Factoring Arrangements [Member]",
        "label": "Euro Denominated Factoring Arrangements [Member]",
        "terseLabel": "Euro Denominated Factoring Arrangements [Member]"
       }
      }
     },
     "localname": "EuroDenominatedFactoringArrangementsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ExclusionFromEbitdaForRestructuringCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusion from EBITDA for Restructuring Charges",
        "label": "Exclusion from EBITDA for Restructuring Charges",
        "verboseLabel": "Exclusion from EBITDA for Restructuring Charges"
       }
      }
     },
     "localname": "ExclusionFromEbitdaForRestructuringCharges",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_ExecutiveRetirementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive retirement plan [Member]",
        "label": "Executive retirement plan [Member]",
        "terseLabel": "Executive retirement plan [Member]"
       }
      }
     },
     "localname": "ExecutiveRetirementPlanMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of the fair market value of our common stock on the date of grant",
        "label": "Exercise price of the fair market value of our common stock on the date of grant",
        "terseLabel": "Exercise price of the fair market value of our common stock on the date of grant"
       }
      }
     },
     "localname": "Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_ExpenseRelatedToMatchingContributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to matching contributions",
        "label": "Expense related to matching contributions",
        "terseLabel": "Expense related to matching contributions"
       }
      }
     },
     "localname": "ExpenseRelatedToMatchingContributions",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_FairValueOfFreeCashFlowFcfPerformanceAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the Free Cash Flow (FCF) performance awards",
        "label": "Fair value of the Free Cash Flow (FCF) performance awards",
        "terseLabel": "Fair value of the Free Cash Flow (FCF) performance awards"
       }
      }
     },
     "localname": "FairValueOfFreeCashFlowFcfPerformanceAwards",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_Fairvalueofmarketbasedawards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of market based awards",
        "label": "Fair value of market based awards",
        "terseLabel": "Fair value of market based awards"
       }
      }
     },
     "localname": "Fairvalueofmarketbasedawards",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_FarapulseIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Farapulse, Inc.",
        "label": "Farapulse, Inc. [Member]",
        "terseLabel": "Farapulse, Inc."
       }
      }
     },
     "localname": "FarapulseIncMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_FarapulseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Farapulse",
        "label": "Farapulse [Member]",
        "terseLabel": "Farapulse"
       }
      }
     },
     "localname": "FarapulseMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_FederalBenefitOfUncertainTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal benefit of uncertain tax positions",
        "label": "Federal benefit of uncertain tax positions",
        "terseLabel": "Federal benefit of uncertain tax positions"
       }
      }
     },
     "localname": "FederalBenefitOfUncertainTaxPositions",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_ForeignCurrencyDenominatedInDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency denominated in debt",
        "label": "Foreign currency denominated in debt [Member]",
        "terseLabel": "Foreign currency denominated in debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedInDebtMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ForwardCurrencyContractsTimetoMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Currency Contracts, Time to Maturity in Months",
        "label": "Forward Currency Contracts, Time to Maturity",
        "terseLabel": "Forward Currency Contracts, Time to Maturity"
       }
      }
     },
     "localname": "ForwardCurrencyContractsTimetoMaturity",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]",
        "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]",
        "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]"
       }
      }
     },
     "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]",
        "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]",
        "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]"
       }
      }
     },
     "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]",
        "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]",
        "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]"
       }
      }
     },
     "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]",
        "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]",
        "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]"
       }
      }
     },
     "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]",
        "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]",
        "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_FreeTradeZoneRegimeTaxIncentive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Trade Zone Regime Tax Incentive",
        "label": "Free Trade Zone Regime Tax Incentive",
        "terseLabel": "Free Trade Zone Regime Tax Incentive"
       }
      }
     },
     "localname": "FreeTradeZoneRegimeTaxIncentive",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution",
        "label": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution",
        "terseLabel": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution"
       }
      }
     },
     "localname": "FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_GlobalCardiologyReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Cardiology Reporting Unit [Member]",
        "label": "Global Cardiology Reporting Unit [Member]",
        "terseLabel": "Global Cardiology Reporting Unit"
       }
      }
     },
     "localname": "GlobalCardiologyReportingUnitMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)",
        "label": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)",
        "terseLabel": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)"
       }
      }
     },
     "localname": "GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_GlobalEndoscopyEndoReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]",
        "label": "Global Endoscopy (Endo) Reporting Unit [Member]",
        "terseLabel": "Global Endoscopy (Endo) Reporting Unit [Member]"
       }
      }
     },
     "localname": "GlobalEndoscopyEndoReportingUnitMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_GlobalNeuromodulationNmReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]",
        "label": "Global Neuromodulation (NM) Reporting Unit [Member]",
        "terseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]"
       }
      }
     },
     "localname": "GlobalNeuromodulationNmReportingUnitMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]",
        "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]",
        "terseLabel": "Global Peripheral Interventions (PI) Reporting Unit [Member]"
       }
      }
     },
     "localname": "GlobalPeripheralInterventionsPiReportingUnitMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]",
        "label": "Global Urology and Pelvic Health Reporting Unit [Member]",
        "terseLabel": "Global Urology and Pelvic Health Reporting Unit [Member]"
       }
      }
     },
     "localname": "GlobalUrologyandPelvicHealthReportingUnitMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_GoodwillTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill (Textuals) [Abstract]",
        "label": "Goodwill (Textuals) [Abstract]",
        "terseLabel": "Goodwill (Roll Forward)"
       }
      }
     },
     "localname": "GoodwillTextualsAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of foreign currency fluctuations on net sales",
        "label": "Impact of foreign currency fluctuations on net sales",
        "terseLabel": "Impact of foreign currency fluctuations on net sales"
       }
      }
     },
     "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_IncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Abstract]",
        "label": "Income Taxes [Abstract]",
        "terseLabel": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_IndemnificationAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification asset",
        "label": "Indemnification asset",
        "terseLabel": "Indemnification asset"
       }
      }
     },
     "localname": "IndemnificationAsset",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_InternationalRetirementPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International retirement plans [Member]",
        "label": "International retirement plans [Member]",
        "terseLabel": "International retirement plans [Member]"
       }
      }
     },
     "localname": "InternationalRetirementPlansMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_InterventionalCardiologyTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Cardiology Therapies",
        "label": "Interventional Cardiology Therapies [Member]",
        "terseLabel": "Interventional Cardiology Therapies"
       }
      }
     },
     "localname": "InterventionalCardiologyTherapiesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_InventoryStepUpAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Step Up Amortization",
        "label": "InventoryStepUpAmortization",
        "terseLabel": "Inventory step-up amortization"
       }
      }
     },
     "localname": "InventoryStepUpAmortization",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_January2040NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2040 Notes [Member]",
        "label": "January 2040 Notes [Member]",
        "terseLabel": "January 2040 Notes [Member]"
       }
      }
     },
     "localname": "January2040NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_June2025NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2025 Notes",
        "label": "June 2025 Notes [Member]",
        "terseLabel": "June 2025 Notes [Member]"
       }
      }
     },
     "localname": "June2025NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_June2030NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2030 Notes",
        "label": "June 2030 Notes [Member]",
        "terseLabel": "June 2030 Notes [Member]"
       }
      }
     },
     "localname": "June2030NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_LatinAmericaandCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latin America and Canada [Member]",
        "label": "Latin America and Canada [Member]",
        "terseLabel": "Latin America and Canada [Member]"
       }
      }
     },
     "localname": "LatinAmericaandCanadaMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA",
        "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA",
        "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA"
       }
      }
     },
     "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_LesseeOperatingAndFinanceLeasesOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Leases, Option to Extend",
        "label": "Lessee, Operating and Finance Leases, Option to Extend",
        "terseLabel": "Lessee, Operating and Finance Leases, Option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesOptionToExtend",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bsx_LicensingArrangementAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangement assets",
        "label": "Licensing arrangement assets [Member]",
        "terseLabel": "Licensing arrangement assets (Member)"
       }
      }
     },
     "localname": "LicensingArrangementAssetsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_LicensingArrangementLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangement liabilities",
        "label": "Licensing arrangement liabilities [Member]",
        "terseLabel": "Licensing arrangement liabilities (Member)"
       }
      }
     },
     "localname": "LicensingArrangementLiabilitiesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_LicensingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangements",
        "label": "Licensing arrangements",
        "terseLabel": "Licensing arrangements"
       }
      }
     },
     "localname": "LicensingArrangements",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_LicensingArrangementsAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangements, asset",
        "label": "Licensing arrangements, asset",
        "terseLabel": "Licensing arrangements, asset"
       }
      }
     },
     "localname": "LicensingArrangementsAsset",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_LicensingArrangementsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangements, liability",
        "label": "Licensing arrangements, liability",
        "terseLabel": "Licensing arrangements, liability"
       }
      }
     },
     "localname": "LicensingArrangementsLiability",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_LitigationAndDebtExclusionFromEbitda": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments",
        "label": "Litigation and Debt Exclusion from EBITDA",
        "terseLabel": "Litigation and Debt Exclusion from EBITDA"
       }
      }
     },
     "localname": "LitigationAndDebtExclusionFromEbitda",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_LumenisLTDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumenis LTD",
        "label": "Lumenis LTD [Member]",
        "terseLabel": "Lumenis LTD"
       }
      }
     },
     "localname": "LumenisLTDMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_MITechCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "M.I. Tech Co., Ltd",
        "label": "M.I. Tech Co., Ltd [Member]",
        "terseLabel": "M.I. Tech Co., Ltd"
       }
      }
     },
     "localname": "MITechCoLtdMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2024NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2024 Notes",
        "label": "March 2024 Notes [Member]",
        "terseLabel": "March 2024 Notes [Member]"
       }
      }
     },
     "localname": "March2024NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2025NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2025 Notes",
        "label": "March 2025 Notes [Member]",
        "terseLabel": "March 2025 Notes"
       }
      }
     },
     "localname": "March2025NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2026NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2026 Notes",
        "label": "March 2026 Notes [Member]",
        "terseLabel": "March 2026 Notes [Member]"
       }
      }
     },
     "localname": "March2026NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2028NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2028 Notes [Member]",
        "label": "March 2028 Notes [Member]",
        "terseLabel": "March 2028 Notes [Member]"
       }
      }
     },
     "localname": "March2028NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2028SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2028 Senior Notes",
        "label": "March 2028 Senior Notes [Member]",
        "terseLabel": "March 2028 Senior Notes"
       }
      }
     },
     "localname": "March2028SeniorNotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2029NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2029 Notes",
        "label": "March 2029 Notes [Member]",
        "terseLabel": "March 2029 Notes [Member]"
       }
      }
     },
     "localname": "March2029NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2031NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2031 Notes",
        "label": "March 2031 Notes [Member]",
        "terseLabel": "March 2031 Notes"
       }
      }
     },
     "localname": "March2031NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2034NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2034 Notes",
        "label": "March 2034 Notes [Member]",
        "terseLabel": "March 2034 Notes"
       }
      }
     },
     "localname": "March2034NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2039NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2039 Notes",
        "label": "March 2039 Notes [Member]",
        "terseLabel": "March 2039 Notes [Member]"
       }
      }
     },
     "localname": "March2039NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_March2049NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2049 Notes",
        "label": "March 2049 Notes [Member]",
        "terseLabel": "March 2049 Notes [Member]"
       }
      }
     },
     "localname": "March2049NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market-based awards, valuation assumptions [Table Text Block]",
        "label": "Market-based awards, valuation assumptions [Table Text Block]",
        "terseLabel": "Market-based awards, valuation assumptions [Table Text Block]"
       }
      }
     },
     "localname": "MarketBasedAwardsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturities of Lease Liabilities",
        "label": "Maturities of Lease Liabilities [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "MaturitiesOfLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_MaximumLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement.",
        "label": "Maximum Leverage Ratio",
        "terseLabel": "Maximum Leverage Ratio"
       }
      }
     },
     "localname": "MaximumLeverageRatio",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bsx_May2022NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 Notes [Member]",
        "label": "May 2022 Notes [Member]",
        "terseLabel": "May 2022 Notes [Member]",
        "verboseLabel": "May 2022 Notes [Member]"
       }
      }
     },
     "localname": "May2022NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_May2025NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2025 Notes [Member]",
        "label": "May 2025 Notes [Member]",
        "terseLabel": "May 2025 Notes [Member]"
       }
      }
     },
     "localname": "May2025NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_Measurementperiodmarketbasedaward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement period - market based awards",
        "label": "Measurement period - market based award",
        "terseLabel": "Measurement period - market based awards"
       }
      }
     },
     "localname": "Measurementperiodmarketbasedaward",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bsx_MedsurgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedSurg [Member]",
        "label": "MedSurg [Member]",
        "terseLabel": "MedSurg [Member]"
       }
      }
     },
     "localname": "MedsurgMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_NetCurrencyExchangeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net currency exchange gain (loss)",
        "label": "Net currency exchange gain (loss)",
        "negatedTerseLabel": "Debt extinguishment costs",
        "terseLabel": "Net currency exchange gain (loss)"
       }
      }
     },
     "localname": "NetCurrencyExchangeGainLoss",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Deferred Tax Assets and Prepaid on Intercompany Profit",
        "label": "Net Deferred Tax Assets and Prepaid on Intercompany Profit",
        "terseLabel": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_NewAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Accounting Pronouncements, Policy",
        "label": "New Accounting Pronouncements, Policy [Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/NewAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_NonCashImpactOfTransferredRoyaltyRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash impact of transferred royalty rights",
        "label": "Non-cash impact of transferred royalty rights",
        "terseLabel": "Non-cash impact of transferred royalty rights"
       }
      }
     },
     "localname": "NonCashImpactOfTransferredRoyaltyRights",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_Nonvestedstockawardsexerciseprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-vested stock awards exercise price",
        "label": "Non-vested stock awards exercise price",
        "terseLabel": "Qualified options exercise price"
       }
      }
     },
     "localname": "Nonvestedstockawardsexerciseprice",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_November2019AggregateOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Aggregate Offering",
        "label": "November 2019 Aggregate Offering [Member]",
        "terseLabel": "November 2019 Aggregate Offering [Member]"
       }
      }
     },
     "localname": "November2019AggregateOfferingMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_November2035NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2035 Notes [Member]",
        "label": "November 2035 Notes [Member]",
        "terseLabel": "November 2035 Notes [Member]"
       }
      }
     },
     "localname": "November2035NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_October2023NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2023 Notes [Member]",
        "label": "October 2023 Notes [Member]",
        "terseLabel": "October 2023 Notes [Member]"
       }
      }
     },
     "localname": "October2023NotesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_Onetimetransactiontaxpost1986EPnetpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-time transaction tax post-1986 E&amp;P - net payment",
        "label": "One-time transaction tax post-1986 E&amp;P - net payment",
        "terseLabel": "One-time transaction tax post-1986 E&amp;P - net payment"
       }
      }
     },
     "localname": "Onetimetransactiontaxpost1986EPnetpayment",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_OperatingIncomeLossAllocatedToReportableSegments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income (Loss) Allocated to Reportable Segments",
        "label": "Operating Income (Loss) Allocated to Reportable Segments",
        "terseLabel": "Operating Income (Loss) Allocated to Reportable Segments"
       }
      }
     },
     "localname": "OperatingIncomeLossAllocatedToReportableSegments",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_OperatingIncomeUnallocatedToSegment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income Unallocated to Segment",
        "label": "Operating Income Unallocated to Segment",
        "terseLabel": "Operating Income Unallocated to Segment"
       }
      }
     },
     "localname": "OperatingIncomeUnallocatedToSegment",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_OptionsExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options expected to vest",
        "label": "Options expected to vest",
        "terseLabel": "Options expected to vest"
       }
      }
     },
     "localname": "OptionsExpectedToVest",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bsx_OptionsExpectedToVestWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options expected to vest, weighted average exercise price",
        "label": "Options expected to vest, weighted average exercise price",
        "terseLabel": "Options expected to vest, weighted average exercise price"
       }
      }
     },
     "localname": "OptionsExpectedToVestWeightedAverageExercisePrice",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options expected to vest, weighted average remaining contractual life",
        "label": "Options expected to vest, weighted average remaining contractual life",
        "terseLabel": "Options expected to vest, weighted average remaining contractual life"
       }
      }
     },
     "localname": "OptionsExpectedToVestWeightedAverageRemainingContractualLife",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other countries [Member]",
        "label": "Other countries [Member]",
        "terseLabel": "Other countries [Member]"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_OtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Current Assets",
        "label": "Other Current Assets [Abstract]",
        "terseLabel": "Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "OtherCurrentAssetsAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_OtherIntangibleAssetsTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Intangible Assets (Textuals) [Abstract]",
        "label": "Other Intangible Assets (Textuals) [Abstract]",
        "terseLabel": "Other Intangible Assets (Textuals) [Abstract]"
       }
      }
     },
     "localname": "OtherIntangibleAssetsTextualsAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_OtherInternationalPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International Plans",
        "label": "Other International Plans [Member]",
        "terseLabel": "Other International Plans"
       }
      }
     },
     "localname": "OtherInternationalPlansMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_OtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other, net",
        "label": "Other, net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNet",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_OtherOtherLongTermAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other, Other Long-term Assets",
        "label": "Other, Other Long-term Assets",
        "terseLabel": "Other, Other Long-term Assets"
       }
      }
     },
     "localname": "OtherOtherLongTermAssets",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration",
        "label": "Payment of contingent consideration",
        "terseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_PaymentsForRoyaltyRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for royalty rights",
        "label": "Payments for royalty rights",
        "negatedTerseLabel": "Payments for royalty rights"
       }
      }
     },
     "localname": "PaymentsForRoyaltyRights",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_Paymenttonetsharesettleemployeeequityawards": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to net share settle employee equity awards",
        "label": "Payment to net share settle employee equity awards",
        "negatedTerseLabel": "Cash used to net share settle employee equity awards"
       }
      }
     },
     "localname": "Paymenttonetsharesettleemployeeequityawards",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_Pensionbenefitobligationbenefitspaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "pension benefit obligation, benefits paid",
        "label": "pension benefit obligation, benefits paid",
        "negatedTerseLabel": "pension benefit obligation, benefits paid"
       }
      }
     },
     "localname": "Pensionbenefitobligationbenefitspaid",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_PercentOfFinishedGoodsAtConsignment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of finished goods at consignment",
        "label": "Percent of finished goods at consignment",
        "terseLabel": "Percent of finished goods at consignment"
       }
      }
     },
     "localname": "PercentOfFinishedGoodsAtConsignment",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_PreventiceSolutionsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preventice Solutions, Inc.",
        "label": "Preventice Solutions, Inc. [Member]",
        "terseLabel": "Preventice Solutions, Inc. [Member]"
       }
      }
     },
     "localname": "PreventiceSolutionsIncMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies",
        "label": "Proceeds from (payments for) investments and acquisitions of certain technologies",
        "negatedLabel": "Proceeds from (payments for) investments and acquisitions of certain technologies"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_RDRegulatoryandCommercializationbasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D, Regulatory and Commercialization-based Milestone [Member]",
        "label": "R&amp;D, Regulatory and Commercialization-based Milestone [Member]",
        "terseLabel": "R&amp;D, Regulatory and Commercialization-based Milestone [Member]"
       }
      }
     },
     "localname": "RDRegulatoryandCommercializationbasedMilestoneMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RangeofthetargetnumberofmarketbasedDSUsawarded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of the target number of market-based DSUs awarded",
        "label": "Range of the target number of market-based DSUs awarded",
        "terseLabel": "Range of the target number of market-based DSUs awarded"
       }
      }
     },
     "localname": "RangeofthetargetnumberofmarketbasedDSUsawarded",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_RangeofthetargetnumberofperformancebasedDSUsawarded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of the target number of performance-based DSUs awarded",
        "label": "Range of the target number of performance-based DSUs awarded",
        "terseLabel": "Range of the target number of performance-based DSUs awarded"
       }
      }
     },
     "localname": "RangeofthetargetnumberofperformancebasedDSUsawarded",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_RenminbiDenominatedFactoringArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renminbi Denominated Factoring Arrangements",
        "label": "Renminbi Denominated Factoring Arrangements [Member]",
        "terseLabel": "Renminbi Denominated Factoring Arrangements [Member]"
       }
      }
     },
     "localname": "RenminbiDenominatedFactoringArrangementsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility",
        "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]",
        "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility"
       }
      }
     },
     "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementAsOfMarch312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, as of March 31, 2021",
        "label": "Requirement, as of March 31, 2021 [Member]",
        "terseLabel": "Requirement, as of March 31, 2021"
       }
      }
     },
     "localname": "RequirementAsOfMarch312021Member",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, eighth quarter and thereafter following qualified acquisition",
        "label": "Requirement, eighth quarter and thereafter following qualified acquisition [Member]",
        "terseLabel": "Requirement, eighth quarter and thereafter following qualified acquisition"
       }
      }
     },
     "localname": "RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, four quarters following qualified acquisition",
        "label": "Requirement, four quarters following material acquisition [Member]",
        "terseLabel": "Requirement, four quarters following material acquisition"
       }
      }
     },
     "localname": "RequirementFourQuartersFollowingMaterialAcquisitionMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, seventh quarter following qualified acquisition",
        "label": "Requirement, seventh quarter following qualified acquisition [Member]",
        "terseLabel": "Requirement, seventh quarter following qualified acquisition"
       }
      }
     },
     "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, sixth quarter following qualified acquisition [Member]",
        "label": "Requirement, sixth quarter following qualified acquisition [Member]",
        "terseLabel": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]"
       }
      }
     },
     "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Requirement, fifth quarter following qualified acquisition [Member]",
        "label": "Requirement, fifth quarter following qualified acquisition [Member]",
        "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]"
       }
      }
     },
     "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.",
        "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA",
        "verboseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA"
       }
      }
     },
     "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_RevenueBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "revenue-based payments [Member]",
        "label": "revenue-based payments [Member]",
        "terseLabel": "revenue-based payments [Member]"
       }
      }
     },
     "localname": "RevenueBasedPaymentsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from contracts with customers, disaggregated - performance measurement",
        "label": "Revenues from contracts with customers, disaggregated - performance measurement",
        "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement"
       }
      }
     },
     "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_ScheduleofIncomeTaxRateReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]",
        "label": "Schedule of Income Tax Rate Reconciliation [Line Items]",
        "terseLabel": "Schedule of Income Tax Rate Reconciliation [Line Items]"
       }
      }
     },
     "localname": "ScheduleofIncomeTaxRateReconciliationLineItems",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_ScheduleofIncomeTaxRateReconciliationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Income Tax Rate Reconciliation [Table]",
        "label": "Schedule of Income Tax Rate Reconciliation [Table]",
        "terseLabel": "Schedule of Income Tax Rate Reconciliation [Table]"
       }
      }
     },
     "localname": "ScheduleofIncomeTaxRateReconciliationTable",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_Segmentoperatingincomeaspercentageofnetsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment operating income as percentage of net sales",
        "label": "Segment operating income as percentage of net sales",
        "terseLabel": "Segment operating income as percentage of net sales"
       }
      }
     },
     "localname": "Segmentoperatingincomeaspercentageofnetsales",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment operating income as percentage of net sales",
        "label": "Segment operating income as percentage of net sales [Table Text Block]",
        "terseLabel": "Segment operating income as percentage of net sales [Table Text Block]"
       }
      }
     },
     "localname": "SegmentoperatingincomeaspercentageofnetsalesTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_SeniorNotedue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Note due 2027 [Member]",
        "label": "Senior Note due 2027 [Member]",
        "terseLabel": "Senior Note due 2027 [Member]"
       }
      }
     },
     "localname": "SeniorNotedue2027Member",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_ShareBasedCompensationNetOfTaxBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation, net of tax benefit",
        "label": "Share-based compensation, net of tax benefit",
        "terseLabel": "Share-based compensation, net of tax benefit"
       }
      }
     },
     "localname": "ShareBasedCompensationNetOfTaxBenefit",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Abstract]",
        "label": "Significant Accounting Policies [Abstract]",
        "terseLabel": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_SpecialChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Charges [Member]",
        "label": "Special Charges [Member]",
        "terseLabel": "Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs"
       }
      }
     },
     "localname": "SpecialChargesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_SpecialtyPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Pharmaceuticals",
        "label": "Specialty Pharmaceuticals [Member]",
        "terseLabel": "Specialty Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "SpecialtyPharmaceuticalsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_StatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "statement [Axis]",
        "label": "statement [Axis]",
        "terseLabel": "statement [Axis]"
       }
      }
     },
     "localname": "StatementAxis",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_StatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for statement [Axis]",
        "label": "statement [Domain]",
        "terseLabel": "statement [Domain]"
       }
      }
     },
     "localname": "StatementDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_StockIncentiveAndPurchasePlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive and Purchase Plans [Abstract]",
        "label": "Stock Incentive and Purchase Plans [Abstract]",
        "terseLabel": "Stock Incentive and Ownership Plans [Abstract]"
       }
      }
     },
     "localname": "StockIncentiveAndPurchasePlansAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, New Issues (Common stock)",
        "label": "Stock Issued During Period, Value, New Issues (Common stock)",
        "terseLabel": "Common stock issuance (Value in excess of par)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, New Issues (Preferred stock)",
        "label": "Stock Issued During Period, Value, New Issues (Preferred stock)",
        "terseLabel": "Preferred stock issuance (Value in excess of par)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesPreferredStock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants.",
        "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]",
        "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information.",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information Related to Leases",
        "label": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_SupplementalBalanceSheetInformationTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information (Textuals)",
        "label": "Supplemental Balance Sheet Information (Textuals) [Abstract]",
        "verboseLabel": "Supplemental Balance Sheet Information (Textuals)"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationTextualsAbstract",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Information Related to Leases",
        "label": "Supplemental Cash Flow Information Related to Leases [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Target payout of Free Cash Flows (FCF) performance awards",
        "label": "Target payout of Free Cash Flows (FCF) performance awards",
        "terseLabel": "Target payout of Free Cash Flows (FCF) performance awards"
       }
      }
     },
     "localname": "TargetPayoutOfFreeCashFlowsFcfPerformanceAwards",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense",
        "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense"
       }
      }
     },
     "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_TaxIncentivesInMalaysia": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax incentives in Malaysia",
        "label": "Tax incentives in Malaysia",
        "terseLabel": "Tax incentives in Malaysia"
       }
      }
     },
     "localname": "TaxIncentivesInMalaysia",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution",
        "label": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution",
        "terseLabel": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution"
       }
      }
     },
     "localname": "TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_TaxIncentivesInPuertoRico": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Incentives in Puerto Rico",
        "label": "Tax Incentives in Puerto Rico",
        "terseLabel": "Tax Incentives in Puerto Rico"
       }
      }
     },
     "localname": "TaxIncentivesInPuertoRico",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution",
        "label": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution",
        "terseLabel": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution"
       }
      }
     },
     "localname": "TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bsx_TaxRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rate [Axis]",
        "label": "Tax Rate [Axis]",
        "terseLabel": "Tax Rate [Axis]"
       }
      }
     },
     "localname": "TaxRateAxis",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bsx_TaxRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rate [Domain]",
        "label": "Tax Rate [Domain]",
        "terseLabel": "Tax Rate [Domain]"
       }
      }
     },
     "localname": "TaxRateDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_The2018FacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "the 2018 Facility",
        "label": "the 2018 Facility [Domain]",
        "terseLabel": "the 2018 Facility [Domain]"
       }
      }
     },
     "localname": "The2018FacilityDomain",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_TheOfferingAggregatePrincipalAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "the Offering - aggregate principal amount",
        "label": "the Offering - aggregate principal amount [Member]",
        "terseLabel": "the Offering - aggregate principal amount"
       }
      }
     },
     "localname": "TheOfferingAggregatePrincipalAmountMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "the Offering - early redemption of combined aggregate principal SN",
        "label": "the Offering - early redemption of combined aggregate principal SN [Member]",
        "terseLabel": "the Offering - early redemption of combined aggregate principal SN"
       }
      }
     },
     "localname": "TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_TotalAllocatedToReportableSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total allocated to reportable segments [Member]",
        "label": "Total allocated to reportable segments [Member]",
        "terseLabel": "Total allocated to reportable segments [Member]"
       }
      }
     },
     "localname": "TotalAllocatedToReportableSegmentsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_TransitionTaxPaymentRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Tax Payment Remaining",
        "label": "Transition Tax Payment Remaining",
        "terseLabel": "transition tax payment remaining"
       }
      }
     },
     "localname": "TransitionTaxPaymentRemaining",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_UKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.K. Plan",
        "label": "U.K. Plan [Member]",
        "terseLabel": "U.K. Plan"
       }
      }
     },
     "localname": "UKPlanMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_USExcludingOtherNetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US excluding Other Net Sales",
        "label": "US excluding Other Net Sales [Member]",
        "terseLabel": "country_US excluding Other Net Sales"
       }
      }
     },
     "localname": "USExcludingOtherNetSalesMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_UnrecognizedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Compensation Cost",
        "label": "Unrecognized Compensation Cost",
        "terseLabel": "Unrecognized Compensation Cost"
       }
      }
     },
     "localname": "UnrecognizedCompensationCost",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_UnrecognizedCompensationCostNonVestedStockAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Compensation Cost - Non-vested stock awards",
        "label": "Unrecognized Compensation Cost - Non-vested stock awards",
        "terseLabel": "Unrecognized Compensation Cost - Non-vested stock awards"
       }
      }
     },
     "localname": "UnrecognizedCompensationCostNonVestedStockAwards",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_UnrecognizedCompensationCostStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Compensation Cost - Stock Options",
        "label": "Unrecognized Compensation Cost - Stock Options",
        "terseLabel": "Unrecognized Compensation Cost - Stock Options"
       }
      }
     },
     "localname": "UnrecognizedCompensationCostStockOptions",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bsx_VotingPowerOfAllClassesOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting power of all classes of stock",
        "label": "Voting power of all classes of stock",
        "verboseLabel": "Voting power of all classes of stock"
       }
      }
     },
     "localname": "VotingPowerOfAllClassesOfStock",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bsx_WatchmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watchman",
        "label": "Watchman [Member]",
        "terseLabel": "Watchman"
       }
      }
     },
     "localname": "WatchmanMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_WeightedAverageRemainingVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted average remaining vesting period",
        "label": "weighted average remaining vesting period",
        "terseLabel": "weighted average remaining vesting period"
       }
      }
     },
     "localname": "WeightedAverageRemainingVestingPeriod",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bsx_YenDenominatedFactoringArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yen denominated factoring arrangements.",
        "label": "Yen Denominated Factoring Arrangements [Member]",
        "terseLabel": "Yen Denominated Factoring Arrangements [Member]"
       }
      }
     },
     "localname": "YenDenominatedFactoringArrangementsMember",
     "nsuri": "http://www.bostonscientific.com/20221231",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COSTA RICA",
        "terseLabel": "COSTA RICA"
       }
      }
     },
     "localname": "CR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "IRELAND"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]",
        "verboseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r973",
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r973",
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r973",
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r973",
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.",
        "label": "Entity Listing, Par Value Per Share",
        "terseLabel": "Entity Listing, Par Value Per Share"
       }
      }
     },
     "localname": "EntityListingParValuePerShare",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r973",
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bostonscientific.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Asia Pacific.",
        "label": "Asia Pacific [Member]",
        "terseLabel": "APAC [Member]"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r1126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Contractual Obligation, Fiscal Year Maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r687",
      "r854",
      "r875",
      "r906",
      "r907",
      "r940",
      "r959",
      "r969",
      "r1020",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "High end of range [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r687",
      "r854",
      "r875",
      "r906",
      "r907",
      "r940",
      "r959",
      "r969",
      "r1020",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r488",
      "r856",
      "r942",
      "r967",
      "r1022",
      "r1118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r488",
      "r856",
      "r942",
      "r967",
      "r1022",
      "r1118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r642",
      "r687",
      "r830",
      "r854",
      "r875",
      "r906",
      "r907",
      "r940",
      "r959",
      "r969",
      "r1020",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r642",
      "r687",
      "r830",
      "r854",
      "r875",
      "r906",
      "r907",
      "r940",
      "r959",
      "r969",
      "r1020",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r437",
      "r692",
      "r1004"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]",
        "verboseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r421",
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ScheduleII"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r489",
      "r490",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r943",
      "r968",
      "r1022"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r890",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r909",
      "r910",
      "r943",
      "r968",
      "r1022"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r437",
      "r692",
      "r981",
      "r982",
      "r1004"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]",
        "verboseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r906",
      "r907",
      "r1111",
      "r1113",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average (Member)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r60",
      "r373",
      "r494",
      "r869",
      "r925",
      "r932"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Trade accounts receivable, net",
        "verboseLabel": "Trade accounts receivable, net"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]",
        "verboseLabel": "Trade accounts receivable, net"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology.",
        "label": "Accounts Receivable, Change in Method, Credit Loss Expense (Reversal)",
        "terseLabel": "Cumulative effect adjustment for adoption of ASC 2016-13"
       }
      }
     },
     "localname": "AccountsReceivableChangeInMethodCreditLossExpenseReversal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.bostonscientific.com/role/ScheduleIIDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r22",
      "r339",
      "r353"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued Income Taxes, Noncurrent"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities, current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued Royalties, Current"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r156"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r69",
      "r74",
      "r1064"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "negatedLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r380",
      "r384",
      "r386",
      "r387",
      "r781"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r374",
      "r870",
      "r883",
      "r887"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r74",
      "r290",
      "r878",
      "r879",
      "r924",
      "r985",
      "r986",
      "r987",
      "r1001",
      "r1002",
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted Average Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r1001",
      "r1002",
      "r1003",
      "r1101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r425",
      "r426",
      "r427",
      "r428",
      "r437",
      "r497",
      "r498",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r548",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r726",
      "r727",
      "r728",
      "r729",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r822",
      "r858",
      "r859",
      "r860",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r496",
      "r511",
      "r514",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss (ending balance)",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss (beginning balance)"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ScheduleIIDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r375",
      "r496",
      "r511"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedLabel": "Utilization of allowances",
        "negatedTerseLabel": "Utilization of allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ScheduleIIDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r102",
      "r139",
      "r147"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization expense",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r337",
      "r352",
      "r413",
      "r472",
      "r478",
      "r484",
      "r504",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r746",
      "r751",
      "r783",
      "r966",
      "r1018",
      "r1019",
      "r1109"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r64",
      "r413",
      "r504",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r746",
      "r751",
      "r783",
      "r966",
      "r1018",
      "r1019",
      "r1109"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r124",
      "r499",
      "r522",
      "r863"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Notes receivable"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails",
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r8",
      "r155"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r953",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r953",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "verboseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r269",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "verboseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements [Abstract]",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r744",
      "r992"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration net expense (benefit)",
        "verboseLabel": "Contingent consideration net expense (benefit)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r280",
      "r281",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Fair value of contingent consideration",
        "terseLabel": "Business Combination, Contingent Consideration, Liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r280",
      "r282"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r280",
      "r282"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination.",
        "label": "Business Combination, Indemnification Assets, Amount as of Acquisition Date",
        "terseLabel": "Business Combination, Indemnification Assets, Amount as of Acquisition Date"
       }
      }
     },
     "localname": "BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "verboseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance Lease Obligation"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r39",
      "r888",
      "r889",
      "r966"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r39",
      "r104"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r105",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r104",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r326"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Change in Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]",
        "terseLabel": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r413",
      "r441",
      "r442",
      "r444",
      "r446",
      "r454",
      "r455",
      "r504",
      "r549",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r587",
      "r588",
      "r591",
      "r595",
      "r783",
      "r908",
      "r980",
      "r996",
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/Cover",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r163",
      "r344",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r172",
      "r546",
      "r547",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.bostonscientific.com/role/Cover",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r198",
      "r201",
      "r216",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Compensation and Employee Benefit Plans [Text Block]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r289",
      "r292",
      "r392",
      "r394",
      "r401",
      "r865",
      "r872"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r86",
      "r400",
      "r864",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Comprehensive Income (Loss) Note [Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration Risk Disclosure [Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Capital in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r603",
      "r604",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r941"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r616"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r25",
      "r26",
      "r186",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred Stock, Convertible, Terms",
        "terseLabel": "Convertible Preferred Stock, Terms of Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate Segment"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r856"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r999",
      "r1094"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current Federal Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r999",
      "r1094"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current Foreign Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r723",
      "r733",
      "r999"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r999",
      "r1094"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current State and Local Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r343",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Debt, Current",
        "verboseLabel": "Current debt obligations"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r410",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r574",
      "r581",
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r338",
      "r341",
      "r350",
      "r418",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r810",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r572",
      "r782",
      "r936",
      "r937"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "negatedTerseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r53",
      "r418",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r810",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r53",
      "r186",
      "r189",
      "r190",
      "r191",
      "r327",
      "r328",
      "r330",
      "r348",
      "r418",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r810",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r329",
      "r570",
      "r585",
      "r936",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r999",
      "r1095"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Federal Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r999",
      "r1095"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r705",
      "r706"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r265",
      "r724",
      "r732",
      "r733",
      "r999"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r340",
      "r349",
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "terseLabel": "Deferred Tax Liabilities, Gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r705",
      "r706"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred Revenue, Current"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r999",
      "r1095"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Deferred Tax Assets, in Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Deferred Tax Assets, Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r1092"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1092"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred Tax Assets, Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Deferred Tax Assets, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r255",
      "r1092"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "terseLabel": "Deferred Tax Liabilities, Derivatives"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r263",
      "r1093"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Defined Benefit Plan, Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r633",
      "r951"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "terseLabel": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Executive Retirement Plan Discount Rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Executive Retirement Plan Rate of Compensation Increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "terseLabel": "Defined Benefit Plan, Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r628",
      "r680"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r667",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r635",
      "r644",
      "r678",
      "r949",
      "r950",
      "r951",
      "r952"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year One"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r632",
      "r643",
      "r644",
      "r645",
      "r949",
      "r950",
      "r951"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Amount"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "verboseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r620",
      "r624",
      "r655",
      "r672",
      "r951",
      "r952"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Defined Benefit Plan, Interest Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r637",
      "r1084"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r622",
      "r654",
      "r671",
      "r951",
      "r952"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Defined Benefit Plan, Service Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r102",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r102",
      "r467"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r378",
      "r379",
      "r782",
      "r926"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative Asset, Current"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]",
        "verboseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r65",
      "r304",
      "r332",
      "r377",
      "r926"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative Asset, Fair Value, Gross Asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r65",
      "r304",
      "r332",
      "r377",
      "r926"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative Liability, Fair Value, Gross Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r303",
      "r305",
      "r311",
      "r313",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r300",
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r300",
      "r303",
      "r311",
      "r313",
      "r317",
      "r318",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r378",
      "r379",
      "r782",
      "r926"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1098",
      "r1099"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r294",
      "r296",
      "r297",
      "r300",
      "r301",
      "r308",
      "r311",
      "r314",
      "r316",
      "r318",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r294",
      "r296",
      "r300",
      "r301",
      "r315",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r614",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r1022"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r538",
      "r993",
      "r1016"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Loss (gain) on disposal of businesses and assets"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r953",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r192",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "terseLabel": "Dividends, Cash"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r192",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "terseLabel": "Preferred stock dividends"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockStock": {
     "auth_ref": [
      "r192",
      "r347"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Preferred Stock, Stock",
        "terseLabel": "Preferred stock dividends"
       }
      }
     },
     "localname": "DividendsPreferredStockStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "EMEA [Member]"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r402",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438",
      "r441",
      "r444",
      "r445",
      "r446",
      "r450",
      "r771",
      "r772",
      "r866",
      "r873",
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income (loss) per common share \u2014 basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r402",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r441",
      "r444",
      "r445",
      "r446",
      "r450",
      "r771",
      "r772",
      "r866",
      "r873",
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income (loss) per common share \u2014 assuming dilution"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Reported tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r415",
      "r708",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r735",
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r1089",
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "effective income tax reconciliation, compensation-related"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r1090",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credits, Research"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r1088"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Compensation Expense"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r185",
      "r367",
      "r396",
      "r397",
      "r398",
      "r422",
      "r423",
      "r424",
      "r426",
      "r434",
      "r436",
      "r453",
      "r508",
      "r602",
      "r698",
      "r699",
      "r700",
      "r728",
      "r729",
      "r770",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r878",
      "r879",
      "r880",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r40",
      "r125",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r780"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity Securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Measurement alternative investments (1)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r321",
      "r773",
      "r774",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r572",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r774",
      "r827",
      "r828",
      "r829",
      "r936",
      "r937",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r572",
      "r644",
      "r649",
      "r774",
      "r827",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r572",
      "r644",
      "r649",
      "r774",
      "r828",
      "r936",
      "r937",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r572",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r774",
      "r829",
      "r936",
      "r937",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r323",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "verboseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r572",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r827",
      "r828",
      "r829",
      "r936",
      "r937",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r777",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r500",
      "r501",
      "r513",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r583",
      "r600",
      "r761",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r933",
      "r1010",
      "r1011",
      "r1012",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Future Amortization Expense, Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Future Amortization Expense, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Future Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Future Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Future Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r532",
      "r534",
      "r535",
      "r537",
      "r857",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r146",
      "r861"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r140",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r792",
      "r794",
      "r796",
      "r797"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Net gain (loss) from foreign currency transaction exposures",
        "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r926",
      "r949",
      "r963"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract (Member)"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.",
        "label": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net",
        "terseLabel": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net"
       }
      }
     },
     "localname": "GainLossOnCashFlowHedgeIneffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r83",
      "r123",
      "r979"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Net loss (gain) on investments and notes receivable"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r750",
      "r993"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r102",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r128",
      "r130",
      "r862",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Acquired During Period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r529",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, Gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r529",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r102",
      "r129",
      "r132",
      "r136"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r133",
      "r134",
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Translation and Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, Translation and Purchase Accounting Adjustments"
       }
      }
     },
     "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r78",
      "r413",
      "r472",
      "r477",
      "r483",
      "r486",
      "r504",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r783",
      "r931",
      "r1018"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r300",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r102",
      "r150"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r993",
      "r1015"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Goodwill and other intangible asset impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r44",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "In Process Research and Development, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r414",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r334",
      "r345",
      "r362",
      "r472",
      "r477",
      "r483",
      "r486",
      "r867",
      "r931"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SegmentReportingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r414",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r953",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r415",
      "r709",
      "r716",
      "r722",
      "r730",
      "r736",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r1091"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income Tax Examination, Penalties and Interest Accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r416",
      "r435",
      "r436",
      "r470",
      "r707",
      "r731",
      "r738",
      "r874"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "verboseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r395",
      "r703",
      "r704",
      "r716",
      "r717",
      "r721",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r98",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).",
        "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option",
        "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Increase (decrease) in operating assets and liabilities, excluding purchase accounting:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r142",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite Lived Intangible Assets Major Class Name [Domain]",
        "verboseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r138",
      "r144"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r329",
      "r346",
      "r399",
      "r466",
      "r809"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense [Member]"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r404",
      "r407",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r926",
      "r949",
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Unamortized Gain on Fair Value Hedges"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Inventory, Finished Goods, Net of Reserves"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r61",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory, Net [Abstract]"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r62",
      "r452",
      "r526",
      "r527",
      "r528",
      "r855",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Inventory, Raw Materials, Net of Reserves"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r32",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Inventory, Work in Process, Net of Reserves"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.",
        "label": "Investment Holdings, Schedule of Investments [Table Text Block]",
        "terseLabel": "Investment [Table Text Block]"
       }
      }
     },
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r503",
      "r1117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment, Policy"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r7",
      "r42"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r820"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r820"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lessee, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit Outstanding, Amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r342",
      "r357",
      "r966",
      "r998",
      "r1013",
      "r1103"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r413",
      "r504",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r747",
      "r751",
      "r752",
      "r783",
      "r966",
      "r1018",
      "r1109",
      "r1110"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r47",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r47",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r55",
      "r163",
      "r170"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Legal reserves"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r55",
      "r163"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Estimated Litigation Liability, Noncurrent",
        "terseLabel": "Estimated Litigation Liability, Noncurrent"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation Settlement, Amount Awarded to Other Party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation-related net charges (credits)",
        "verboseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r341",
      "r355",
      "r571",
      "r586",
      "r936",
      "r937"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Capital Lease Obligations",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "auth_ref": [
      "r1000"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table Text Block]",
        "terseLabel": "Long-term Purchase Commitment"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r53",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "verboseLabel": "Accrual for legal matters that are probable and estimable"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money Market Funds, at Carrying Value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "verboseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by (used for) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by (used for) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash provided by (used for) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r438",
      "r439",
      "r443",
      "r446",
      "r472",
      "r477",
      "r483",
      "r486",
      "r931"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SegmentReportingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "verboseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r472",
      "r477",
      "r483",
      "r486",
      "r931"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SegmentReportingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)",
        "verboseLabel": "Operating income allocated to reportable segments"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r815",
      "r965"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r812"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r812"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r812"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r814",
      "r816"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r819",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r818",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r50"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Other Accrued Liabilities, Noncurrent"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r17",
      "r336",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "verboseLabel": "Assets (segment reporting)"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r63",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "totalLabel": "Other Assets, Current"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other Assets, Miscellaneous, Current"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other long-term assets (total)",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent [Abstract]",
        "terseLabel": "Other Assets, Noncurrent [Abstract]"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r793",
      "r795",
      "r799"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r397",
      "r800",
      "r802",
      "r806",
      "r985"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net change in derivative financial instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r382",
      "r384",
      "r753",
      "r754",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r384",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r384",
      "r388",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r383",
      "r384",
      "r755",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": {
     "auth_ref": [
      "r383",
      "r384",
      "r755",
      "r760"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r757"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r758"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r76",
      "r185",
      "r391",
      "r394",
      "r400",
      "r800",
      "r805",
      "r806",
      "r864",
      "r871",
      "r985",
      "r986"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income (loss)",
        "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Net change in defined benefit pensions and other items",
        "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax",
        "verboseLabel": "Net change in defined benefit pensions and other items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "auth_ref": [
      "r71",
      "r75",
      "r389",
      "r661"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r72",
      "r396",
      "r400",
      "r707",
      "r737",
      "r739",
      "r800",
      "r803",
      "r806",
      "r864",
      "r871"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r926",
      "r949",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Other Contract"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other Current Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets [Member]"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r50",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]",
        "terseLabel": "Other Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "verboseLabel": "Other long-term liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other Operating Income (Expense), Net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other Sundry Liabilities, Current"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration previously established in purchase accounting"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "negatedTerseLabel": "Proceeds from (payments for) settlements of hedge contracts"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r988",
      "r989"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Proceeds from royalty rights"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Payments for repurchase of common stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedTerseLabel": "Payments for Royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Cash dividends paid on preferred stock",
        "terseLabel": "Payments of Dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired",
        "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment and internal use software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "auth_ref": [
      "r207",
      "r212",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "terseLabel": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r207",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Pension and Other Postretirement Plans, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r667",
      "r949",
      "r950",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r219",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred Stock, Dividend Rate, Percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareCashPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Preferred Stock, Dividends, Per Share, Cash Paid"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r26",
      "r186",
      "r187",
      "r996",
      "r1021"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Preferred Stock, Liquidation Preference Per Share"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r411",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Preferred Stock, Liquidation Preference, Value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails",
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r3",
      "r5",
      "r934",
      "r1014"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid income taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from disposal of certain businesses and assets"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock in connection with public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Net proceeds from issuance of preferred stock in connection with public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from borrowings on credit facilities"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": {
     "auth_ref": [
      "r990",
      "r991",
      "r994"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.",
        "label": "Proceeds from (Repayments of) Commercial Paper",
        "terseLabel": "Net increase (decrease) in commercial paper"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfCommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "negatedTerseLabel": "Proceeds from Royalties Received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments or Charges",
        "terseLabel": "Production Related Impairments or Charges"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r372",
      "r390",
      "r393",
      "r405",
      "r413",
      "r425",
      "r435",
      "r436",
      "r472",
      "r477",
      "r483",
      "r486",
      "r504",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r745",
      "r748",
      "r749",
      "r772",
      "r783",
      "r867",
      "r931",
      "r960",
      "r961",
      "r987",
      "r1018"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r43",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r42",
      "r155"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r157",
      "r358",
      "r868",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/SegmentReportingDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r157",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment, net [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r403",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Net (credits) charges to expenses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ScheduleIIDetails",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Purchase Obligations, Future Minimum Payments Due"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, after Year Five",
        "terseLabel": "Purchase Obligations, Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "PurchaseObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Five Years"
       }
      }
     },
     "localname": "PurchaseObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Four Years"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase Obligations, Future Minimum Payments Due, Current"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Two Years"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Three Years"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": {
     "auth_ref": [
      "r328",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.",
        "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)",
        "verboseLabel": "Average interest rate of de-recognized receivables"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r397",
      "r800",
      "r804",
      "r806",
      "r985"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r117",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Payments on borrowings from credit facilities"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Payments on long-term borrowings and debt extinguishment costs"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r14",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and restricted cash equivalents included in Other current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r891",
      "r892",
      "r893",
      "r983",
      "r984",
      "r995"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in Other long-term assets",
        "verboseLabel": "Restricted Cash Equivalents included in Other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r102",
      "r543",
      "r544",
      "r1017"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "verboseLabel": "Restructuring net charges (credits)"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r192",
      "r356",
      "r701",
      "r882",
      "r887",
      "r966"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r367",
      "r422",
      "r423",
      "r424",
      "r426",
      "r434",
      "r436",
      "r508",
      "r698",
      "r699",
      "r700",
      "r728",
      "r729",
      "r770",
      "r878",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r959",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r959",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails",
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r682",
      "r683",
      "r693",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r682",
      "r683",
      "r693",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r463",
      "r464",
      "r476",
      "r481",
      "r482",
      "r488",
      "r489",
      "r492",
      "r613",
      "r614",
      "r856"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r817",
      "r965"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "verboseLabel": "Trade accounts receivable, net [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r951",
      "r1072",
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r74",
      "r1104",
      "r1105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r53",
      "r186",
      "r189",
      "r190",
      "r191",
      "r327",
      "r328",
      "r330",
      "r348",
      "r936",
      "r938",
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting pension and other postretirement benefit arrangements with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r303",
      "r311",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r218",
      "r242",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.",
        "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]",
        "terseLabel": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r135",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r135",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block)"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r310",
      "r1100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments (Table Text Block)"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r120",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r219",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r221",
      "r232",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Stock Options, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Debt [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r56",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r454",
      "r587",
      "r588",
      "r589",
      "r591",
      "r595",
      "r600",
      "r940",
      "r980",
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Number of Shares [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Expected Amortization Expense [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r492",
      "r542",
      "r545",
      "r1118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segment [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r472",
      "r475",
      "r480",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "SEGMENT REPORTING"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r223",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r238",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending Balance (Shares Issued)",
        "periodStartLabel": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r18",
      "r338",
      "r354",
      "r966"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term Debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Standard Product Warranty, Policy"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r370",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r492",
      "r531",
      "r540",
      "r542",
      "r545",
      "r1118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails",
      "http://www.bostonscientific.com/role/RevenueDetails",
      "http://www.bostonscientific.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r185",
      "r413",
      "r441",
      "r442",
      "r444",
      "r446",
      "r454",
      "r455",
      "r504",
      "r549",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r587",
      "r588",
      "r591",
      "r595",
      "r783",
      "r908",
      "r980",
      "r996",
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables",
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails",
      "http://www.bostonscientific.com/role/Cover",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r59",
      "r185",
      "r367",
      "r396",
      "r397",
      "r398",
      "r422",
      "r423",
      "r424",
      "r426",
      "r434",
      "r436",
      "r453",
      "r508",
      "r602",
      "r698",
      "r699",
      "r700",
      "r728",
      "r729",
      "r770",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r878",
      "r879",
      "r880",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r422",
      "r423",
      "r424",
      "r453",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r217",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issuance (Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the number of shares issued.",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease)",
        "terseLabel": "Stock-based compensation (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r192",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r287",
      "r288",
      "r291",
      "r367",
      "r368",
      "r397",
      "r422",
      "r423",
      "r424",
      "r426",
      "r434",
      "r508",
      "r602",
      "r698",
      "r699",
      "r700",
      "r728",
      "r729",
      "r770",
      "r800",
      "r801",
      "r806",
      "r879",
      "r880",
      "r924",
      "r998",
      "r1013",
      "r1103"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodStartLabel": "Total Stockholders' Equity",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r195",
      "r412",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDER'S EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r185",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in stockholders' equity during the period.",
        "label": "Stockholders' Equity, Period Increase (Decrease)",
        "terseLabel": "Stock Issuance (Par value)"
       }
      }
     },
     "localname": "StockholdersEquityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r807",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails",
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r807",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails",
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r807",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails",
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r257",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "terseLabel": "Tax Adjustments, Settlements, and Unusual Provisions"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r1097"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes Payable, Current"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets [Member]"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails",
      "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.",
        "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]",
        "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r500",
      "r501",
      "r583",
      "r600",
      "r761",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r1010",
      "r1011",
      "r1012",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": {
     "auth_ref": [
      "r381",
      "r758"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.",
        "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax",
        "negatedTerseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax",
        "terseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails",
      "http://www.bostonscientific.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r58",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r58",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical",
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets",
      "http://www.bostonscientific.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r58",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r185",
      "r192",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r425",
      "r426",
      "r427",
      "r428",
      "r437",
      "r497",
      "r498",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r548",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r726",
      "r727",
      "r728",
      "r729",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r822",
      "r858",
      "r859",
      "r860",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/StrategicInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r702",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r713"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r712"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r456",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ScheduleIIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r1102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r1006"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r440",
      "r446"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Assuming dilution"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r438",
      "r446"
     ],
     "calculation": {
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations",
      "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1081": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1082": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1083": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1084": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1085": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1086": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1087": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1088": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1089": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1090": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1091": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1092": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1093": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1094": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1095": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1096": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1097": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1098": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1099": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1119": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1120": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1121": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1122": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1123": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1124": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1125": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1126": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r908": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r909": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r911": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r912": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r913": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r914": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r915": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r916": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r917": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r918": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r919": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r971": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r972": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r973": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r974": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r975": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r976": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r977": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r978": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0000885725-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885725-23-000008-xbrl.zip
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M5CAG;QL:GTU80Z[9E8!TCV;T\F0\EVO1L>O/?:ML(1BAGMH*QO>L*.^+CTI
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MFXU17#=-"2&#:@6%2L4:$C:>/&U%?!6'I"!.W;@!H.28(%%"RU)";OVS)F4
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M [2>VR/*D((/Z)$L]X2MG=P,QYNL18!\\PB!#+(S4 R0JZ7T6D[6,S>P7[L
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M<GX9OWEGQV]_SSZ8V67X<3HY&L7PG/[GXS>#R0">-QB=P6_>?3S_<N8<OSG
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M 7B$B<.\B'&=11ZR=U6Q:#RO^&Q6K83!;P^CW04\'OK/)RU6)V"N6?8AG8I
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M]W?U;GP?O2N67ZM27KWX!3JRM;&XKU)E/CT=:?T%^I ;(: [A]L<<)[I=_Q
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MZN=Q6H'-1X9^ 5S37JS,4(D4S):+'M3.89:MY(J/>@UOG&5 PHHJS0XP?3P
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M-_*%>9%W4%-A4%Q=GF"-8B93!%B 1UFSF1 "5'MI%8WY!*1'B,-N_1[J'?
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M\T.D<2&2MLQ;DX.0FUT))ZDEKVBCJ*Z6V%.8=.P@N1 "I/@)Y 2/O,&9R#)
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M *(U50/C>&K>D1AB(]8N50ZYG7V<?>CO:@?UA</F0BH;05^0_HVZ89_-F 2
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MFP+;)AHOFI5K ++4<*EV](X\I)P0F65+\JS"-FVA:DTQ$<FM,:<Y!%H"+[$
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ML89E%&M9M%H*3/ER26VD((@2P;_>N)-"57=Q+A!G5MZ=R@;N\A5IUDBR8?#
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M,"8B-K*',[<C^WK4K<08< Z;9B5W( 03BO(1NL;=VEQ\B7"T;250+_('B?,
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M"4*!]5/S>:+8^[L<E*OYD[?%U8'']N<NKO (5UE<GK]3=<U4A5Q8+RB]J#2
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M_G<5?($BG I_62M^DS=([]06>"E!0H5M:QO;BJUD[@7D-=&#A1^F&<D;991
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M9 U=0$KM/;P+((U73D1?I6Q[8T_E7\K$XW)39G <M;AK)W?B(.I2=4_.+.-
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MKK'SQ,E]J2/E</839:O,#*0EIQYV-?K(OB:RYG27?G',%,L;V)Z-.$+0787
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M ]0/'[;PFE*Y'SS ? 6&!(RGN*,\(R'8@R/!4Q(MO"PV=Q*'&\ O.;?;J$A
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M):Y,YW0NA4""4W24'RY)6]72B%T)(M>S4L#N%VD-_C'M(;=AQJX)<57TZA3
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M.(),FGA7P@3E,)Z?C(TU38?$9F<"L\+!,0@4D3=(;46@3=R(#D5(0A2B:5@
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M&H_[N@%KG:"02U X*E)C^PD*%4\$F"U6<5D=@-IP" PB%]$NS]U?33'1#4,
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MP!6027P_N51?_?XP#(.Q\/9+3WT30-X)R"R^PZCUTA_55S.+?9;>\D5.<TW
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M/XV#DA9Z:8-9ZLTK0!1A1_5I@C]PJ0]N^C(G2$*8&36:5AU23>JWA^TU\FN
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MQ\_4V23QNUPG+%8"]<Z^7[>>XH?Q]=.E<8[5.;C%?")."T&U.I+A45%_EH3
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MQ^ADK6ZK09?&-NE2L12ILWLWQH+#3V"J!!%H,[J:^CZ X[?U&O5H5E(ORG#
M#$^K,YL)VC#>MONS69\-64(U6UK5FBD5N5MT]C/,*BD#T!ZH'#H:[2*0)86A
M :-\V##6:2O94$E-RSMA;%7(X,;W9S-[<>/-]BP[J)WOSW[1FB_@6B.[IEK;
MOL/9)]_GDVW:3T\^0XBF90EH34R#S"<_NAEL1R-#&<',4JOU >=2PAOTK?DA
MQT0WPB:+\HO[[\0=J@RI4WN*.XPC4&Y8A&!1P=W\9JZ0&/FZ7^YSF5=G)A:W
MEV5>:\JG+]^O?URAK9%/,-]IF94ES!XU)/C6'>:7^D'B8Q:HRH-MS)6\4GT
M_$_BR\HN+-(*PK3<BFEY-AP+54=[@G7'CO$'E8-R42T+0'P\7ZX;BAA$)4DD
M+ .&/VDP-0X/,(6CBS*/(/06^$$RH[7$.LJ7TY3E_"F_MZ38X*TU5][.JKL[
M6^PC@3!FYC23+#J;"&JJ6:?Y@3&E!:E,Q:>L$+>JF(MXE,YUAW7R@N+J5L%Z
MSL-$*L@X9N3Z6=!;=1S9?,V3LEH4JSJFQAIBJ-YG=EVE# >8G?W2HI6#TU#
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MG&T-,+O&<<+MDC- PBO%:_.7@/JB!AJIM<#&-Y,5Q#9*B0)C0&(;LY3#XP3
M#<4Z!1227HBS^@ZU%#7TFT:G-2X< 99@S1#M&.TNTB_^-%_8@.P$*X+4/M;)
MN_7^:=T+M(N+<GOXNC*^S=(3^,,K(;#PU,5_$>22S(.]&CCY(Y1/5 0 \Q\V
MFM4L:D_(P,E)#HZVK>8&;S?7=+N%F_M!@:$/C/=%D>*:Z_$&!NF ,,)':6O4
M#X"8*,4%HQ?HH)++#8^U94EKB@BQ56MT1V*/$ U'G&"'?.YUNBM;W.B6.\$8
M=LMRM92&1NH"Q8:*FV>1X!^?%+X,1:*#]3SH_;J>HPQ\8,MW]R;X3Y>/]/"L
M84?U^Y(']71M\R^@78#B)RQTY4AM^G<@P%O=_$RJ2804![H)*>(3#5.>5&^L
M.Q0#*N]9 3W;RA]Y4L/!$YX1+PDW6L*8H@*!8'0IOG>&($0L_<$DEALP#J$8
M(,,1?Q(*E9R(,"E&X&+@^ Y47YFJ"E5O;B:)U<ZX*K4D!:,VFV2S428D-$_U
M%^D+)/5"PF(3LZP'^2'1"10?5*]6RLQ[/L%RZ@N: ?7%P4TL8O@NUC)RA':C
M!:.Y!&V6V*B8T#+)XPFCSG';I<NM7A,6GU@-QQ=KN+SS8Q*6$Y5/D]&&B )G
MHUF%"%' ::E:EB6GJ-"*Y12)&@S]IBR1,'S-@/6F0%QFZ8+(QB.=;T:-)]A(
M:*,3>FY>"6WJ?YFFJLH6 ^)9=2QT?]GH"9=W'TH[285!-$-)]MI1D14HRB^D
M]WV>L.<][Q^VCO>./^_L"@W)"YW7QD=Q#K#%^XTY>'11@98!%">;EFVS,LU9
M8GPZO9B>CO7OOMC^M/]2"^*!(D$UX.K]Q  4XGQ-3@Q "$[X'#DU7<LDV1,K
MH2E"+R+QU^D%&6I+]T9'"KER.S[__^;.3[49>\)&+*GZ6"UYOQ"B'$RIO6VQ
MT JW9D#OT#?HT_X];D*]<-R.624>64I0NA5))$6!64*9IO'Q_9=,\)HQMN>C
M.OQ'M31K68%/E_4($7"BQ!H*@W/2[Z6 KPBI08BF"1(8PJ0/C)2-V0DA5PW0
M^R9=%(FXSH(JA/1!?X=4("HDDT3\)9^BT$$4$AW) +]0L1&OY,LJPB 1XEE0
M)%H4TY(K="VI\4SK9DP*+45!&.&<Z;:?ZRH&/$&X"R,UMTUL+"GM(12OZ/W"
MC>C:A#,Q<%[,*K%;"G%S;IT3.%K:4RE(I18%(@ZB(YM@C2EX^4;B5BV]IC8L
M=%$HU1S8**5><"9L$O%$QPN)M^ ^@D:@MEH^V A:]7T%6P'KA. \[!RVD^I>
M$(FFZC0_.VN8K-JR3>-S[;=J.H4LVQK"G1.<=B!;"I+_I,&EDL#\AD+1@$NF
M/A)[)8Z+;@8^C4-KS\ZF8C@)J05@.-*UV4;2T(1%^QY28!FX*_4^J9V&]+'X
M_F4^PR?-.% TXK6N]RRNO<IU^V4=EKFAJ#8=5WR>A+5;CR<P$M(.L,[PDA4E
M]&PH"!^HZ5;(ZLX0[?X5:EH(5:TN+^45H68-(K&:22"SJ<YT=.]( WE-\8DT
MEZ+V1S&:29>LTKJE,B]?+'A,[0N>3=00FK.UI='7@\BGD2W41EZ[-R-\?\Q^
MYN/96'Y=X>&"KH%'<YF,O^TE?([I$?:ZID<\*O7JHS!'S;WQV0C<M$>D"S_A
MU(DO-8P3M7C4[!AI"%0-/+14-! M5!KW+)/]53.I>BD[0#'4G+82TZ1P..1\
M@C4 +K=L\R5YILR-4O,AKEO/0@\N$3RW_#O(^&*$T5\5<9(>@4:#P*>J,V">
MLME .Y>S4MX8^6CKQ13<RTNT;<7BI2.*&O84LGF),H_R#'EGRJ>(4Z%\(&13
MP1HW99H:1J4JY5RI,1?/8/O1OT+,<P5^"M5+#=_^I-S<7<&TQ[8^I,':WCBK
MUT&IRC\3M.*5O8+1#1!(T,NJZ<&J);9.%@'8P"\G[!Z@P0F?DB:T:6P9E1:0
MDD%2U3)6*L306_D''Y$O!\"#ZU[,C8I=(5DP&2C5WJ5BX&"N-%>4] 1T C8Q
MGMNM6B%ZHBHC;!:"SQU((RH59TI?JAL#B%G6")1"HP*H(4%LG!J+"+Y0LK.\
MMI7:;;M@Z1#TA5\ 2E)]*1?\4@'35H_9IKC>GC^ZN/!EW&,E0??'MB$-NT':
M84*L(20W[ '$!:!AB^Q?4V^(RJ-1O?-0TM022^M'HZ?6U WV!N0]A&H-GN++
M5'=@2-T ^=8R8N;R?52S&@*!;!*PB:CK;)>.1(P8VH:V&&$^.9M-EZ04,874
M6C,)<>;G*%_%%#7N0E8-=-=@90E,D^+=.(CJHM=TT%/(H45WTV/==)*^$Y5L
MU.IYK%E5@@F!LZGH.#\TSFH,.HV_MH/ATH44US$<X@!G;(&E8O#.' L[D!0^
MP32UB3#TV;83EW2S.9$JCAJTF:MJ=LB$9B3V&U8,]Q2;N.JN[%8^@I:% *$Z
M!?$-QNL$ 'TAI0JCB>J7Q??*/5K:@KI9G!"*2FBAVT1;B_(;8*,H8,F4L358
M[%\G?5??E+4L?62E+E\ABRD_+8J4SAQ0MN&CDI] 7Z4"NL!H#T*[ V$^YTSQ
M=I-\:()-B(,O)@JJM4-KK E/O_LZP38W1[U0SIV^*%%AY:(1"A>[7PX6-D2\
M/)N-2!4FAT:LMK6UQD2<.3@Q!MIJX0'Y^H6E+:B[C;);]Q:B0)^,&=:]5[1X
MAS@9<5^E8)2I>*HC0O>E4%\2,Y-X<^A0)C\.:09$Y"IU[U&*!/ :B\$6N;[6
M)*BU=Q)"'5+P=',GS["/&$M_"&N1ZWTF^,^\PE ]T[3-)"^3V1@BMF!JG4+.
M94(@F;(7!86-Q" 8 X;X45Y23U+($H)MP]_J6A[5^56[A,J[I4T2<P&PWTR3
M1CC!:'F33X@5/-#1 -_)M5 8L";@POFTCG,)0:@ZI6ISE//&3G;GT*JUFDKM
MM+W+*%3@DD(,CD@%)XW,2HB9"UA1BX4MC)!7S?I27$D]WHBO5U[<X$$;6YS+
MM%"LS>K:X;0XQP"-)C>D)%'9HZ>MBPA71"I.$HI;\+2$NN*U90_<FPZUJI*]
M@]$=T7R[X<<Z_#AU'&[@^<5$I6W!FS[$="5DKH51YM5WDVB%IVUN?9W0;;>,
M6"X 2 !V^"O2+O+\<2E?5SN)#*1%6X^0R\['\9 =T)V0O>:X.<+DI(Y+(JQ!
MH=5,)<C\B+SKVBTD,4><2+FK*"2ABA]8M?@B&AVSL) ;*AL7&E=G&OLBYDWY
M./0*G?]!6Y>"?(,-CST_Y5A\21$#\;3*.0+I+K7P-O>ON3SITE?PZ.MN7,EK
M#JX$@1!*E)%QK1=U"@,Z0 A MCU]B\KF J?&-!+R-N(7Q$Y"MU3:2NU$\7K$
M%]*]4O?Q:UY0X^;/,;".6HMW6T=OC:VC;>.X.,L3P_6M>V?"-Q0*C?U=&6:3
MR Z;A6A*#RHS7BSNW_V4/M]Z^S8?='^Z515P*?&T6DH75] NDM@-I/1OMWQ:
M460I^Y:+,FT'M(J=QR;%+O.G+5:?7'(GL^R>:R&?<HLF+2L6C"WRW<X;P75F
MWR+M01B@(3;HQGU7SQ_JH?+\44VHE1OU5V$^C92<7])_%SU*%YR5LO9N2RQD
M9-ASJLY2;:7+[I+9J:1:@P.E\>.TE8]J=G+"4;_2!P(_&:D^3_LVD4Y7']6\
M;JF76:+V+M@VA8:TSG_(SE&GQ)1]\L\!/ \_408[I&131"GFD+_6]3WP!LD\
M67 Y5%@W,#X3CT+6S#L9?X).RZKADC[3VA(?Z.V*</)%><(FRGLAK3&]46#=
M[_*R5G$.2J7&WJ,OUF]J;Y%,Z)F5D!'=5*72K.O-GE/Y7D$H@I>@)-.\,/M7
MW 5HL[B0]#PP/HI3/SN%_,C6@T)282OII#@3SWTN<0"D]3YI1DN:<=8U:69M
MV,,!GY7%N$BE&;YIO%5N,-3*0#\K<X8\5OP2DY#HLC<@O^SDI.0RX'#*EU]T
MT.0@&"N="5_8-#D5"VD804U,VC.+' =[M#,#W""CR]XVQ]C0?]&>Z?*B T15
M +R!LC@[O:CDB-I$VY-8'*#]\B<L9_8F>I+-9;R[DA5@K&T;HTJ1UZDZR@B_
M.(,@ K2'!-5_,KJ0Y@56,ZM2HD&-$H=?A6_L2,U='/$VZ/3O0")1B=" 7!DE
MOG5!@T(UI:[L;S-\C,!S::^WU)_NE1+>1)W/*:9&Z!5X[\ M@?,!,1AS)<K&
M4#$UY@P<:>!$6_Y.[47B>4H//H?"^A$V<^W8)QH<?SN#K )PA\CX7Y<A1TX8
M'($2#_!H46ELD#2T4OJF6DM&6^OW*GBLYB_Q;%I[:I *+U"9 [^,-C]8/4Q'
MK7W^0$[$&1*K&K'D.V7M"A6$H7*'4Y#^E0J#174*+58AMZ%#EDV;ME&%N#!Q
MEIZC'6YIWC56X90GIQ-D%C+.)55M+?K9I4QT3*FU:T^Y,^T>5@:.+M056B!Q
M#&QWHE?HE1AP8G5RCG2M-]6(FEN;_'J"2=$)ZFX A2Q3W\*V&X!<$9>]4/?E
M-R?>R9*$J!@)P5(!ZVN%H)!4H: 5E&M-D8UGZ0EZ=:%6R\ <!:/I[GF&Z)F8
MWH-^-<T9 9->OFC0RX$U592PV,ZNP/(8K%;#@/@9QQ12^70WKT0&,=.+$>"+
M1&"FGH71CE_0%0&"D05K>/\AXU0H#-"%#TT&L5$YS4KY9]6MF7/8@'#&]N8R
M$7-NDC*;Y))[\H0E]M9("!_(TSBG@TH(2!,-8Y1+P+]RF15!V7)UZJU.@I ?
M7)\Q.8QJ(M;D22O8,ZM(DT0)T[:0JL%\%<L<#DU\84P8GA=*%082HKR@\%@;
M4N<Q^@Q7=M\>"*Q/4M*/)FU*P_QAQ@34;A4*2:;*T$"W044U+.CMTA41\'0M
MQLF[]3/4)P:H72AU0K4XGQ:#MCW_:O72=#V08:]Y5L#]G.#UPX467K=K1SSH
M7['QII7BU1"BU,U@=,P$D[^WY#9@/H"K$AO ER9$^LR:J8MQ"8>5\F@3GL[
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M4X&8:>I:T=B0<+ZMP2A" MZ7@K#!*8%%RYQ1IC,:)1H2N93153>[J!F^QH]
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M:?XC3_DDO5/''^V$7+$/:3&+1_S1VET/6I6^H\ZC/J@C."?\IV=:-V):'8V
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M#;^%9)*(0 !Y5X!(Q(%/+('Q',E9"):#W-D3N[13,-X:M\7I</ 6)FET5BM
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M?7'/UA:-K5/1G.8E,@7!%)H+4=L HM09F]+F76K"B% Y4QI*ER3:6EO6#KE
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M"J0-V< <C"[;%U^U9&W)*[+1M/1@?5EO"*)I5\=*.0M0SKS^'T(P+Z6'*%@
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M%SI$_V@J3RE4("8Y0)D10;#BG[8B0J2,A.2-SR;,[[=<"XPW ;;M=Q.KL'T
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M5=_E)J#[X0,/%=VK0O>LY(C9$J:2!:U4!&&%!.,5!R(T,9I&DFW>V6.[;,[
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M(8:*_86PWYQ4JK+GW F@N'Z :QK QR"!AFA5"MH0$W;V1/=-@BH&MR\"=^E
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M4&06ON%:BZCE^_:34PDUO"_\:UY8'<H)'N!;?7Z_S=[#X>V/WIB#VVG.;2/
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MYP<G?\T.AQ^^ST<S/W[^^PNLBQU\_C#[\/W#]\.]U[/#?]X,CTYVOA]^?E?
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M[" %>U<XL1<")<VI:YDEC 5>P)(@AK,(TSC+,L[2)(QBGC'^4&/X72I175_
M!N! (L4\:#/SXC:93I<$UHHK^Y^"=$W)'MKYT_0S1B&GI#O$PEX)M5<4YZ2
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MHU&RI&8UI;IZ<!49V H"BRFZXWVD:.M%U,,O#XQOZASGZAR#]:]SO+1N<;Z
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M%MNPN[Z=<!G92>QG:9#*R'?EO)H5*<_<,$GS.':9D^6QDX;,]7,W#4,A6?I
M#>N6-,AJ>CM-X7M@<9U4/-,E%F^KXBMAF=C_0J2<U]@Q@,S_>"UPE?U0.]&#
M!U*Q%'K[=L0\9G=*RC=0,RK%.4V.!"%"$9D!ZRDZ2:MBE(.]#I:IFL"MD4;
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MJW3L635,8VBU%T]MH%],"5.ID5B6UF9)/9YC%?):NYYMZ_4WCJUY)#CK*<8
MEP9^KUDE1J]8E ;G;-1*Z@YDV19)211]2K!BY T!>,B6JF0V%3V,X<LKT52$
ML(5L:TKWRVH.=4:.OA95BS5!)>5*81@;JO,NY11%&A5H="YLL(D[MI!Q857
M4^$&80<ZV)*F,$T''6=SH?%FJ]L2HM[LVXL.44^CI;DY6.Z&!0@X";A7>*20
MAO0]=>RT<U/39UIWM-R*XH:N>K7X5^!^@[TZ[679.^C0336=/G""4; 1G7G6
M JSV[,_N0]IX<?>BGF%ZJ16_9:K7+MQ(1)YL9K<M[N'6DNN;BD$\A#Z&9N^
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MC]L:>R/3:HJ;YSE;>F\)R]/$?^>-<:K=F0OS@?K9$>5$"NM8%(2F"CKS7^6
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M!OV5I6^?^[3*L]7?*:T?*!$\R_;Q/CMP%G-+J$2)AMQSEX/>$$\08\FYR%F
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MI,Y@>$)JT&P!;P."!I/7:39ZK2<'-.L8!K\%."B0KF# S'M#P8<APD@>E*T
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M9+DWB$;L8(44"<&N%!$(Y4D6![#,"QJL #?"-F$E2TRSX(MTQ^,*)X.N/[*
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M2Y,F7G'J$V=$&1)9'2!?*B]-S J0>V=R> \9&G-?/0I>FE$:G#9,@HV$.)/
M2Y-U.M7R!7QGIE/E-=511<E"X!X+AR6/@4C.9'0>NSJ=:L%5>"J=2DLO%$D)
M,4$4XEYAI#&7*( >"VVY2%+/[7C&:]>IVQ[/",2SR*0S^92&"B:$LHFL89I9
MJF<G+=:;*$^@/E.;*,HS(Y1B2(CR=)/6R CCD7.,$X4UTX&#^LB?;**\:.%'
MK^=1[Z;GEMC L*-8)\6="<XSZW(ZNB!!Y$XJM9X_DY[[23T7-)HD#4=8&8NX
MD0IIP3QB6GA!O98,9SV?KA55'\-:A*-=BS?@9?GD:PC-UHF^]3U>:7RV3O3]
M>;\[!29?D\18/MS"O(FYV++ 3C,<F*S+S"P5N]N:=2K4"X.QY 9)I<"+,\(A
MG;1' 5.=6(C<:KNRSED=QEP>5ZQ.]'U4WY5)IRE)WMG@N O,6I\$#EHQPUU4
M=4.S9T.WJ1B5<<00XS&R-D3$O=7(DJ01F#+LL8^$&?9PW[5.]*T3?1]RFBIX
M&WQNZJ,X]U%C*E7 TI% 7(RZ3O1] >"$9U&OQ*4G+""1%,[]%AVR $K()8)S
MTR=-@E]9%WBZPE^=Z%LG^B[#/89V<W3Q2(YX^8EGH/%UTNS+N$<I5[_VLS&#
M?T/C^_K4'CV\.+KW&)8<#WI@!<^&I&#]?UWWU\OM_/(^Y8\GQE5Z<\(XF']2
M;#:^1QA[?]"-4P.^[X/^]+JGG8.5]=UVL6V[_J@@JT5^ZM7B-(*TM$Z:L1]#
M 22D")?S4'12^=*G$V!%MMD_*_X^LMV6]7%0FHI>X8:4J.AWBD]]V_U6;&7?
MLR)'MEG\-?A1?%K;6/NX]M?::F';H?CT]N/OQ:>-3_!72L")P"WKY>_)K\-K
MQ=M!MW,2\\Q<?.G)E2\MLA2?K.9L'?CXR0">QO9B<0)"60[8GIQT.S^ Q/5C
M\ZSXKSOP1$>52<&D9"+EN6AEC!83$VCP41EF2YY(,,,_X8G@<IYT>K;Y/@]T
MJ^V;@ZQ@I2,*%+$]B&'W)%92^$>GW6N$X1]7,I#>@&>,0J<4V?Q-2\\'O_[[
M"/O6/VW[Q0QV6SO'V^?;)/.YG7)\'[_M[FWPG>,_X9U#X(1;>)M^/()_<[,Z
MX'Z'!TPP&;WSR"=F$%>*(!>SIVFHEDJ'Y$)86==XND%= 8K4A%]6B][ '4??
MS]+J@>[81KNP(6MD"\A[KVB,UJKPMG=4@+0<99&U_5(+?+/3R^\-E:+?!3VL
MOF&MV(,7[&$WQGRCX7V&^E1^+L5NON[1A7%KY]W5X,>%+F^,1K<W',]N>F?]
MT"F9SGT#Z3L%6]Z+[0O!PZ]/\,3.YMN#2#UQ1%/$@B.Y*3!'FA")L,:.&!4H
M-6!#$DSUM.2EBRDNP>\J-BV6-+QO=IQMO@53T#F+8Z'_5[GLY]L'TF&2L+,H
M4&T1%S(@HV5"DC-/+;Q#\RE1JF?@31Q-8G%83FKS;*VX S>HJ$JCG2,*;Y@L
M6=DRD8RM=N86N.06W4RX,A0^LD==WO%-HP_/[V\QQ%&4I6BT3FRC6Z(V\(CN
M8>P]D^M?#BO;B+LPEAS,,MPP3%/@PE*=-Q-!;@/8Q"  %G*@'(\"Y?CG(:[1
MO&Q=3,M?G5ZO)B:S@>+MZ>[>-_CL6[IS_AG^W3\0-F<UPW0[(2/B,7#DP$(@
M2H/67B:IE5M95]=M]@V)2C$\SI1Y2F?0O0W_SM;%-VVOUTB-(?'HQA80G,Q8
MJCR3\C/-RT@DO%P<Q68HF330U9R/D@5P,_J8-V4*5CD)>!*\\MB'5-96T;+'
M=)$>Z;JAWG%:Y5$ 86^4;F$Y]6 H?SMMA/[1*-@\=F$5&'N#+R^QKM=I#OK7
M7S(9:WLF7-9D8AW'?AY=Q)!.[&%$KAOM-V03^')O;//4GO56?KWR2*U&&TU,
MX>337[\,U<\)*:K P_E(A _.)T4Y%=HZRQP.2D1KI1"B L#2B=KHE_U52>))
M4L4UX=A[YY13(F#CM0W8TI6%##C\43[#8;8Z5SS :R(EUX91;FIVXC#'2BJE
M6.3)<(NY#*E,]?<X<GV+TS07VZ5CVQ?;T?: /X;=O/4QZ';A*7ZWO4;O<[OC
M8)J^YXA1N;N:=T;:OG3PX<'V8%R_-SO^V^NS$73[>!L?B.0]5PPL@58)<>XI
M OFDB =NL#>4"A97B@BF]"0#1G<0GPDD_@"7%U@0^+"E$4D@ \7W+ 39-&1C
MY"]EUX_+[H5I.0/>URV-2>HTFYW3RP3',IYXB:-EJ!B>JVE/>O'-Z)??1IFB
MC78YNO*BWUK S0!RAN";X69BOZ+4MNKM(1(9LZ8%RV TW%@>?O$0I]9*G)K8
M7JG>TWQ-<W[MVWB-7/O>3;<E=,T(>:O;_F0_?,$28&]/ODOC\ O(UI#I]/YU
MBSR:N>927KM/-F.K[+GG]<8-\-]MT[;]M:1M;EV<7WI2Q)V?_\7D16AEE60F
M<BDE#SJ!ZZ)BE$$3)C#6I PJW<)IG)$7<4EPKO";$9$X6WJGL<INZ)QN[VVQ
M;?H9',&/WW;.]_'7XZ^-_>,_F_O',":Z=;[=VN=?OVR1G3\FLAN.-WYL'_OS
MKWL;8N?]![9S_!'&^V=CN_5/ X@%VS_>AN\]@OM\QD BICO,,R:H93HAKY-"
MW+B$X)>(2"12<9RT9V9EG9CITX%+E-MP#\R^5WK#RSJ(,GOJ-UHY#?(R(#<6
M8\A$/O.Y?-J]L#EMJ?)L[]?.:<;<O+S$?8R3-((!IR>4IY@KD1 NA!0J&,=9
M=8R:C-PK\G,0O7"VAAY6CKU]:?2/IARKWE7/ZJH;=@&P?P_W15]*"O]3(>W6
M&-)^$+N;G\\/K.-),!)0,L0A+I-!)CF!@F4R@.LF><R%2/CT1L#S]8E]604
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MZL M2]SR;U"6&6VDZJ)2(]CBAD4MK!4@SCQA;RTUTF.KI?&&,#R_&%V-0W?
MH1E5\(4A3JB<4&821IPYBXPT$5'/+0&$\@;6:)WKN@K^LJGK76C&$^CKM32C
MUN"[:? DDPA<QQBD0UYY\*@,9LCH&! C3%E))-/6KZPS\Q >42OOXMI:X;$C
M)B>T>\T)]8YRQZ/%/GG%DC'S"XS4FGHG39V*?0C%C0E<(BEI0-Q3B:SD 6E!
M*3.6.<("V-H9FEK;VL56U[O8VB?0U]K6SDF#)VVMQ3)B&2027A#$I0K(6F61
M U?>&:ZLT2G;VH=LU2Q09=4E<\MW9Y\4N9>;_CKZ05"3A#(R>LZY3,&: ,R?
M4I_+YV$BZU2:Q4.E&9U=L-:*,8,1F!) )145TEX:I*23W"<N> !>05:-7*3>
M$75WEWDSBR=0YWJSX"D4?))V,,T":#1X]TG #Z<U<CAR1+CV B<BB#59P4&$
M'KY94.OV EIJXX37P7HOJ.%11P<+SQ,E(0;@HXK7V0^+J,A3$0#05VE=,@C,
MLT/<<HZT9 E)$!#*?> NL-)2SU#DVE(OMC;?Q5(_@3K7EOHI%'S24H-MEMZ$
MB%RPH."8"&2QQ\A[Q6,N4B5"SFI?950LAJ5^61W<KCFK=5-%HKO&998V"^NA
MW0?N_/R+ M<+T_NE)E]/A\TSFMT9%83VUB!PIP";*4](8\N1=5@$B26SW.=&
MX:N:LV7N2'!717WFK:$:<%\'X-Z%'S\!XM;\^"DP>*K'L321R(B1"5YD!Y@B
MG51 2@OM3)!"4\!@LTK4- 3?>0NM1L : 1?IP9^AGU5-.9\2[J;C?3[GYBF+
M?"*Y7*-SR!J)$:5< =PQ[EU%.9F8;K)<4\X:<&O ?2K*^02(6U/.I\#@J9RM
M'&(7 +K8^XAX]$ ^,1<H<L,,5I1;$E?6]2I7TV<<%H]R#N.UHX%<U-0M\6W>
M&S5W*TLUH^GA/+ZA'N72C_(U;#*,RI3/#3%>-=%8)I;Q#'&MD;#5/MR<^8.?
MWC:@GE%M'$'>6H,X5@Q93SB2-!'&!5>"AI5U2E<UG4[:>$$^W(MPX&I071)0
M?8[=@A&J;I6='L!)N_37MBZ:/_Q5(^Z\$7?28Q.2*ZZ91)2;?";=B-Q!7J,D
MC("7:##.YDV"65ER\_/8:KRK\6XA2>2\(E4UB7PT2)L^^DN(TL[F@SE>(<X9
M1MJ8@")C4E/BE<@; 92L:CU]=K FD36HUJ"Z)/'_FD0^#^).DDA*I-:&4J0D
MMXA[F9#)NP!6!J,C<XEHOR0D<GEB_DL0I*Z'^'A#?&5E "]:&=>% *^SJLP[
M:23S(EG*-5& MCX)+*VC47.B;AN:V6J'F*[?67_[PS<'>1I'UK>VGW>RG]]F
MA+U93%0JAZ*W&''G)+(I621U8%(Z@:E)N5#S=&_PEU.L:%'N4<.(L=%SAS76
MD3-*K3?16BU4)$82$V]+SFL8>608F0I\,.P,%E*A*(5'G B!C/8.*28P5LEK
MEE1N\_.2ZXO>]QZOK'S3S[O!O? 3Y'<I(F>Q22I0[93E06@#WBP&;4H!X]PA
MON95"P&(;T]+,*Q $<9W>+Y]>B Y#X8Z@:RU/F]O.8!$8H%C&2:-!IZ,=8;$
MEUP"8E'N\>J!) D7A6+:<.$X\=YX:UGT,0&KBLRQFEDM#)!\G@22R'T"?I50
MP%(C[BUP*P%_1@L>MU546BIK('F]*:F7.HF:62GG5ORB>JI9Z;_UR9FY3="B
MF)B%27JM3<SCFI@?,[@J!C?#*2U1,/D HU,".2GR61KCL761X7QXAK+I*.#2
M)BW,07>7/?#PM D6M36IK<G3YVG4UN31K<F4PZ*3-C)1CWCBN8XMQ<AH\%HT
M%AK(NI=*$+ F?#H87%N3Y;4FI:OU:S^7WX-_0^/[^FAY=P8M6!*__K_PXNC>
M8\]X/.CU&^ELB$GK_^NZOUX(0G6?VUSWA.)"RS#V4:XRZ+O1]O(O16?0+9QM
MVK:/12<5AT,\*6P[%/:FRH1%HU<, ^'%21> K N#+?J=\H[6_V?0Z#5*M(2[
M_F[/FO#Q[1BR.,":M4Z:L5^Z?$4?!I0:W5Z_^,_ =ONQFR_(E'MM:C(7;J;+
M.[YI].'K_"WF?FMB#HO&1<I=X8]L]S#VG@E)RN$5I[$;B_^Z@[4C#G.LI%**
M19X,MYC+D*C#DG@,EN]@,R\D)IB@6SI1%Q.RFVYA\UYRBN+7?Q]AW_JG;;^8
MP6[KSZ/]\W^.=H[?\NWW;^G7S8_'NWO[8F?S[8^=+_L_=HX_PSW_.=JG?Q[_
M^]R3W8V#1(FQP7$D'#&(!QJ1TY(CPH3%Q/#$9"[U.L,U*D"TFGGA03GSJJW>
M220P3M((YKDBE*=(81"$"Z! *AC'F2A%@HQ$XC9,J!:).8@$!9&@P0<"QA&1
M9!/BBAJ@-B A7B>!@Z=!*;NRSM1T0'9")$AI'>XB%=Q';;AAF*; A:7:6 W@
M08*A.@AF2ZG (ZG M50\C53P[0\'1&B*([8H<,6 ]6*/3(:,))F4RGA,HUM9
MYS.:LTQ(!5XK2G(Q9=. )OC,)L,(42I#<TD:P!AV?*-D$J>-_M$5WM&?VG:?
M047Z1[9?W32[3 W;A)O&7N9TC=X17)$ZS6;G%"1B%CGY)[/4U(P_5HNMME];
M+4Z/&OXHTYMVY[0X 4Z2/Y4OW(F#;J?5"3E?/E_L!CTPHKW>*CQA;]#LYR](
M\(D"O@QX3#=^C^U!?M#.<2RGK%<$^!LX4C<V6F[0[<71/#6;L0U3==LI) LV
MA6]WMO:V?CI_?P,O.3F*7:" H+.Q"]-3S<IH(LO'!UYZ^=1Y6O.WYUD%@F,/
MRQG[G_^G*5&_]4J(Z.5!7*6#-Q#X(>/AM,HX.>E43_&FG!EPM7\[;83^T<CQ
M'[MPZ"KARTNL Z]HT+_^DDF'Z)DHOV83LS/V\^@B;_\$YA8Y\ N^(9M@<=[8
MYJD]ZZW\>N616HTVFIC"R:>_GJ57/V%MLFUHM >5%I6@RS6-3 EF& =NHG+_
M0:-#2EY$CRVUE3V!:V+8R#@>200" U8+K!CWW%EMK;=8DZBCEC9=NQ#/ZWV!
MZH=&;_0HV1$""06];0Z+;65-R0[1/UM_;&6MVOW\J?BT]W9G#R0>INBWXM-9
MKQ];8]IHB^\@A*#.W;,,$J"WJR.0\1UPJDJP:8'C!7I?FNT^/$_U:G_0;>??
M $*^Q?X:Z&21'>0\CGR/;KY]QAK0Z!$F@2KFX5VDEH_08QPI *'@ =L5XE5H
M- ,RMK/M.(DA5JAQ/6C\8;NA4:+759BX!B3R\'SV9IO-*S/::O0S[GRWS>_C
MXP=L/NS:UFC*^B/O.*,,?+R<K#QKY5QV(SQ".0>="Q^VO&1TE_Q)5\Y;?O42
M=\=G^78 CW\&\-,(?K<UZ.6)^61#UX[<\A%\;YS8UL6+U>+DYVK_4R'MZ(T_
M.MV33K>:XU^&;_YKK7AK81FK.>_-?-#RN2Z>]E*0;T+W/-_EFH[/=F]\T;+Y
M[%=?#$NV6HX85M&",8-[CS3A8M&J);U4OCBQ8*N5'$TIT'\&\.G^&<AI;P#/
MTNFN%KT3&&5J^/S!X32LEI,]:(?8A35IA])J5F+H 1/*Z8O?&R'FH LL$HAT
M5M__G[TO;VHCR?;]*A6\);HC2";WQ7V#"+>7OLP;8-K&[<'_=.0*LH7$E80Q
M_O3O9)4$VE@$ I6@8F+<@%1562?S_,Y^3K7 :]>TB#]D0OXMP6:?5+X_>CAC
M9^VXGT8:]@'<_O=VUW][<3KTSL7NSS__3EI*&\&J4N6,0\P3<DI$1 ,34G))
MJ1,;P*'>GF9QU#N+-150&9VN>+(73P%=@27[Y8F^= Z.'(8NRQQ @=)[6O3C
M46;?V7-ZXUL.KQTI6:77&=ZV;4_[\=7HA]] :IZV[<6K5J=<<WG1;P"-1Z"/
M##6SK(M,>9S+!U8?#]448[8X$5E3&6;7#!\\5&*V2B5FRHE>?2;(%L'BVH_Q
M%KGVLYMN2_@6X]=?>M-M;_Z,:?TL%SO'X3\Z' !Y\5[?7(0 DJD[+?66%*Z:
M96K=W9-=E:Z#@C&T_OLSY<B+O:V/V12L5;P75)R/9[VC!=[K#E&I]2)!I75_
MMWU_UK:]Y5+BP>RZ]M0]Z *C31#UOL4TBX1I5XTQ-Y+D]Z%*84O#Y"THQ2<N
M]@H&UF<VAQ9-!GZQN3D+O_^S2;UQDBM)A2)"2\XYT4R)1!.5."82C"]3;^X0
M6G@948,JW^84+)TOK;V3W1^[7X]^[)X<XOV#UWC_\Z>?A_03^_+YK^,O)Y\N
MOISL7.Q-Y]N<O/^Z=[)##W^^NX U7<![B=VW?XHO!WM?OQR$]I?/[T^^'/SS
MY/#K#OW/SW=S*KB="EP(CU*( G'A!-*,8H2Y)UB%)&T.4+)-A=4ZY]O< Z=7
M6;G0X&J#JU.X:KDRCI H# U<66THDRE1EZ*S2C#7X.HJ<76FI-UPZ3 6 0FJ
M.>(*<V0UT4A(:K@VBCEG-K;E)EWO,9)KAJN/Z+5HL+K!ZJOT<ZLD,Y%+*7G0
MR7*A8I1!D]S00I,&JU>)U?O36$U"9#X8"IHOIXA3YP&KI44Z.*&DX0;+JI7T
M>L]?>RJLOL6)\AA^IY?QS>=5CCS_3/]QF?GNJRA_TS;OVJX,CLAH&#$1I(RW
MWE@C$U,<AZ"]87CA'-\1[5\/2?^V3#[)Z6+=T$B9A:3,[JRG12A!L&8:>6U!
MRB@CD&&6(YFD8#I08J/>V!:</^,F5R^>9Z-W)CFPW;7E'(,MF*S%A@-OJCS0
M(BV99QNU<7D,/6/BYV:E+ F%DE$&\6@TLM0P9 FSVGK'A D;VV13/+RW2HU9
M^C'4H!</$TLOWVE@XJE@8L:Z=)I%X0A!*>71<)8Y@ GED;#:J<1"2I%M;---
M+.LD^1LC;C5&7/T6O"[?7%(CU%I;Q^^[/?BU4_BS7B]V_$61VF=^4%5P],MT
MZN[@./9REG=GK(SYA70T7&22RQ*,YSZ\,/QTG:@]Z,&K5-4/KSOAWV<]V)1^
M?.T]$#O7J+T..?LVI^KV&R&[D) ]G#6N99!)!2T1=90@KIU!.B:'N$]8$+"O
M6>YR*!XPQ*7&[0T;;EZ"6=UP\\JX>39X+J0+''1D:1E&/(6 =)(,:::U)8%+
MIE0>A/<\V?FI+>J7 1%+,*D;B%@91,Q8U1(G@JT2*"9I$1>&(A,$09XERHD4
MB5H'$#&;M+@2B&B,OKH8?;4.B=XG)Y\\TM#.9Y:,M-C+UT7L/3P;WU/)4IZ.
M+GF>EVY<PM@'(QS/>=]NT8&EC:]X>5+M:$Z,F#)FK'=(!"P0!UL&61$4XCAX
M;4"RL0B*+]]\5MTOFP'0=0&6!DYO,R*LB&!(.,P=X2XH%Y7C5&-C7!"&\09.
M5PFGLQ%Z1E2RDB%II 0X)1AI3@B*4?% <GZN(AO;:E/QM4[L7"<X?=(,_ :B
M7QY$+ZOU>P/1CP'1,WX<3Y+S4JH\]3/!/U0APT-$Q'DF;+0V\'*"\*;1NL'H
MQLU42S=3_1:\+M]\"4D;RREIN*UZ9QWC-XL,][9,8,,<IL)S3J,AD;%$3'*"
M8^7\PCWN[YX1F5H_8D _8Z_;B/O%2NWF#0OC+A'"!0<)+P/BGDBD<S=TIGU@
M3 ?8W9"EJX8]_&U),RGK81DM,9WCI:* C<X1G80U07 GE;9.X4!EGC^7E,>/
MB *-YO]0*)B9]"2I""DP@@+'N8"",J0#I4@GC&,4D:9RQO4F9LL:3KM>0+"B
M1)"7"BY+'Z/3@,O3@<NW:7#QF')&#$?8>8PX%A$9Y1-*P3 A3.*2T74"E\8$
MK8L)6NL4DM75#:QO8=XB:81+L$.;-,)5R8F?\X97$\T)F)[()D,1AW^1]8&@
M1)D1@;G<9@WDQ*R0N'LB88VK=QN&7H))V3#T"AEZQJJ,0E/@6HL8CQ;Q/&W1
M$D&0]#011P--.:(T)YKT+!BZ*<=_#)!8@FG8@,0*06+&.C1$<DM= EF/>4ZT
M5$A++) 06 4I3*3*;6R;FH!$8_O5Q?:K=?CQ/N4#])Y>CODCZU]HJM4R25,7
MH?GPAM4@,R6.B@3A.-%.$\:%MC;F-M96TS(1:P$O:N,Q7:),)',L8<&DC,)&
MI(G))76*Y'Y6&!EJ/'4!C&1!RN(#]HQ& 3R(6==C2D #U0U4W](^07-EB>%@
M-K-<2FN]$5I%AJD)SH<&JE<,U3,^#N:"$1Y;)(72B!L=LH]#H0AFJHS11,/8
MQK;>E'JVIU@#U<\DIM_ ?P/_2X%_)77RAG-CB.)")BMM8,%CY;BV*L0&_E<+
M_S/>*Q6$]S)%E$C" /^@KCM!&+*,*AZH(R+DW :Z:>:TGFWP?V'7VS_*0<?;
MPU'*_Y@8ZWVW =+SIH/7<?#T3J<<=YY:O?X@CUGO#6(ONXTR &P6YWED?+=W
M9#MPRU .H^Z>QFKZO&W#6GLYJZ 7\^#[<E?R,'7X:SD5/G;*"[P=Q*-N[Z)H
M1YLGLQ^W3O/7\U-/;.];'.39] 4L_WLY'WXS?WAJ\P[E$:B;A8N=F%J#\E[5
M>-0\E;WP0+8N;$B5S7 *2\JN\JWB_>44[?R$R]672RY?Z-CF!QT=]>(1K*QZ
M*=^%=W!G?2!/OP_$;77R?/OS[IPQV_U7Q7!.;?G@R8&MFT6T_CC3[_RX!3\<
MP=J!6G#'7OP>.WEV?>IU3\JE]0$4\S?SC/L\F3[$[RT?X0T^#]<(E[3ZL,#3
M7JO;*T[+++)^-:V^D_$V_UC.MB]S/ ;%1;3PM6IP>/FZ6\7!<807.[?]HM,M
M6B>G@ BCJZHWRW3*@@)>.<!EK=2"!Z;\N+/>:3>3 E:8*60[G3-8Y.4H\GRS
M5B\3I(#7R_=9</[X&C))/P+EPUPN@=W)6S(\3K<0JS@;M-JMGYGV@#W'Y;WA
MINU6WK:*"_+OL!VC/YR>]KKY8(78][V6@\< D[Q__?'WXO7'-\5!][3E"R9P
MN>&3MQI=F<_ 67^XN<,=FSD#Y^5Q2;#6XKMMG^5SV"^.6\!HO7Q$VQ=%_ $(
M'> VWO9Z%_G*ZHONH@"&LIDL@V/8($#_3),\ WBS?!^X>IAR-//0_,R\(KAK
MYL"C$3UFW[_DC1#A*2>P1R$_:E#!U]6285=*'IQ\S-7"\R.G%I_7!SOKVV=A
M=-/+K:MX9S#<PKR_L+V#HM?J?\N/NMK99WS\06FLD/V1-8GRCG<:AEXN:Z\[
MB,7KHJP<(;\5'X%0@%\>SDUQ%48M_@WJ@6]=I;BM@H ETZ6S7GG^P;@#V=7/
M*OH06R\/6SZ(('ILYZB5)8X%631X/*2=T&J6$/Z>M T^^N,8SMJQF]ZW@ 'C
MOX"1P\[ER[W.[]9_?Y:UA]<GF5,K$?WNQVGL].-!%KD'L)[?VUW_;4T-AR__
M.<;^Y*^._6S.]D_^"0;$7\=[7]_QW3_>T2]O/WS=/S@4>V_?_=C[?/AC[^LG
MN.=?QX?TGU__\W/G8O?GSM^!,DR\DDABZQ G 2-CE4+.*AMT<HJ(M%& 2+"G
M>>][9]E94$< >0<//RF5K7HAR/C! PE1GKR5X\1(@ZS4<I!^_;-L%F7#!G[/
MMG2IZ?4+9[,\/SOM5GJV';Y,1HX9$,FR, $2=C<SH_=;E?S/ FSJF_W+HM6L
M8MA+I1@N.W&M3D6J+ /+VY;?[;<JW=IF69Y1K-2?8Z]3:@R@UL8V& VECI[U
MY\VIP'1E(HZBTT6KGS]/I1;?+WZ!10"AVSEM^==7B^'>4&T?VIJ5T0@[V;:G
M_?AJ],-O(U];JU/N1WG1;V"8'+4Z(P-4G,[8C.4#JX]_.V^%P?$K8[:T8-D/
M,TPO&#ZX^I1LE2Z:*0.X^DRS+:G8M1_C+7+M9S?=EO M0M6=;ONHZ2;/*]U^
MON_M?<67A\"7UZ;2WS?9[[XI*XN,?:P)<>?[D  6V./-H*V9OWL^"5[ #-X'
M5_,MRZE]@[HZ1U'=@^<?@-C['G=A,<?/)5>SR_8.CO#AP?N3O9^[8O>/7;Q_
M\.7;X<'N.3R+'AZ\*Q76/?I7:\;;#>O9?_LAKX_M_OQV?OCS3[%W K___!W>
MZ\OQ[L$[NG?PCGWYG+W=.[,M,3EQB3%KD%.!(4XQ1CH:@K2D@0EJ-=-V8UOI
MV0YNZSD>=\T$X+48S5]8$5GMH2EK(P?GSZ6'R5,ATIQ!KBPP[XRA*!@J )$L
M(!)6$<F A:(&BV0Q(-*<GI*U'>>V9HG.UX*.>&$3K]8#=(Y[,3:PLQ#L_#D+
M.T%3[N#_2 B>$(^>(Q-T0LH$;W5@$2>YL2TU6Y(BU.@Z=X8=V>@Z]8.=]]VS
M7H,Z"Z'.IUG4P<;AQ(3,]0 ><>X=,DH:I,$0,["#7%(.J"-G1^LURLXCHXYJ
ME)T:H@Y\MT&=A5!GSCA/SCC1,E&DL+.(RVB0LP8C"[\2SASLJ0'4H0]&G67K
M.C=G"N;?\SEM=:K6.\\K+^2_IMZN.ON11"8C#AY,8^ZYL]I:;[$F44<M;=K8
M/CB._5C$85"X7X1NE6)39>!<!C+'H[(YWMCUK3*&?-X:'!>IS!P8#T#VJ\R=
M,G7.Q=C)65BP\QZN<&>#\@D7<9#CF*?MF.]S4QAR:W;KBFLW9$@43K=4#A6>
M=JL%O>K%=IF_-(P0#D%M[,)A?!%?76)=O]L^&UQ_R?017='6:SY)C?%_\VK+
MDX 5QE8G&2U)G"CBE(@:#@*6VG)!W=\$FXW15<>]T3N<VJ.(7"_:;\BF0>R]
MLNUS>]'?^,<$(4Y:'31%^&F:7<]-EPM=57;,>]OJ_963S]ZV^K[=[<-9[M<G
MW>7;2(BT#T_^V?KRQR'^<M!N?SG8Q5^^_O[U\.3]R9>O[[_N?MUK[_W<@;^U
MO^Z_F4YW^:L%UW[[\O5#>__S7^W=GQ].=O\ 8?/YR\GNY]V+7?J)[7[]<++_
M>9?_Y^<[L?OV]<^_:?+1T;*J*>>[2&Z0U<(B*E.*UA(@LJWD/C!E#*]SO8'7
M2CM/L9%$\)B892GIQ(C.H8)DX[S\F">/$5?I:OL'[XJWE^EJ__WN[1\[>W\4
MK]\<[/RU<[#S[F/Q>N]M\?[USH?BK]?_^O2NV'WW^N.G#^]VW^T=?)P%G]J)
MBFMS;^:3XRW<Z'N5WKG3R8GD97)UF0+WWS$<Y?24UR#AOP,NCO6GJ^W;WXB6
MGT%0A=#+:315RGN5/UJF@@\[\.5LFS3=M"_^J#XMJASR87I@[.4<XNI/@V/0
M;HZ.J_O!.@$ZRTS!TU[WJ&=/^L,\])%HS3E%9_TR239<T3_?%[!N["^IU;$=
M$+=MN/)R;\KLVRK]O[P3W.?R,:=GO7[.V,U9HJ'KRPMREG"W=]HMOS^SP&%:
M9OGPH0*0K^E5N?=C:QGD1CF5LM<O$Z3ZIS$GVY<?CM+4MXK]L][X56/K'MV^
M?^:^1E\5$H#BWH$C5J;39R6DE]\UK[',3LID.K)PBYSI!.A<YL%WAN]\]9#^
M,+\_ISEU4\H)4:,O]X;7]Z+O'@V+)ZHD\F,XW&4:<CQYQBG#G^-PL\O$:MB%
MWC!S+!5E9F[LY1*/B\+W8F@-V<%=%.W62:O,3+.@IY]6"5QCW\_GI=RPKSF?
M=N*,M@9GU0DIM<-6!W:G;)Y4P/F$@S]ZCLUW[V]>/2AO"2B<\(AR;=770.DL
M17)^6*L#]&V%G,\_M9)\<F'-^6A^CW $3KI@.W9SQ]_Y[U@]N[QL\JGCCYA<
M0,ER8*IVBPA::Q>>8?N91SIQ4)&IU\OX4!WS4OTM7ZPJ\!BFJ$^L!=@<G=J+
MDC+=G-]W56E3P/D=M"ON#"6+5X4B\*SR,%?W/^^>M4.E9)?I_.>M_E#=AJ,>
ML]U\5>$R_N2MXG5[<%QB5>;%D1:>2PKRDCM9LR\K*8;,6F8IE@5%U[U*B,F>
MM4O$<;'LMC7*_@8.MK"<?OZT2J2LH&H0*Q39*MY7N=B;F1YQE(9]#7K87KR$
MCK+XIMW.@ &;!8>P*FGH R#U6K"F\?W(-^_EUX&O7)1:2R8B+.-[JW]EKN2[
MAP@V3AAN25F.-'EB2H+:SM1)*H"[0$@\6Q"IK/$  %IAQZNS+*'RMS:VWXPD
MY$A5&%,AKGVO85)GF>B!)WU?JU..KJFXR =^]TI:?LSX&8\N:OEN-[Y)%LMS
ME9WKE)QA>G(_E[W!6[5*V9JQ-0YL[^(R21E M-VRKM4N]</?2MW)V[*(J%21
M,L!DEJG0MM4+J$*-<6WBMQ+;KF1%M:[8*QD56!X J 4KR+<O"Q-#V<Z]2E.N
MBO( #\K4ZRLO1%[L[M;.5G$0_?%FB5ZGP]Y^^1H?I[Y0Z6>YR@@ H#L$PBKU
M^I)"%<B4=57Y?I^V/FX!K@ ,]4KY,!*T<PE:$3\#34G9G-Q4/J&=T[+S^@%2
MSGP<XG6_!,SC(5.!<!O8;R74A.\ K/DI&2M+5:>2GF/4+-<R%%,W*I=CX+HY
MMLNP@^>V%Z[>(T-F]O+!MR;76;[2D/27BEQ9Q&7[QT4J$\>G_46WG[RMZQT\
M:XZDI<>M*B/H7Q9T7E+A&M-A*)7ZE_6XFUDZC=AL4BL?/[I7&PK7Q;->=[/X
M'61C"W;F-#MBBZS P J/-HN/H#QDZ09JW&;Q3PMTR8+Z(G8VBS?'K?(76"+<
MV+7*[7T-- 2YVP+Z31S_B])+"(R:N]Z==7+AH&^=EJN9W>MIO7ZHY<!.E156
M63'+C=+;E5Z7A7H+7K"54NQ57["=,;#9 LF3;;MA"<0=\*UT"N8RPVXITL\Z
M0X-@@J#YG8;ENC<<\O46_0N*Q"SI8_$V9D5OK(W]AUCU4,UEY=>+_G6@QXUO
M_V8HE::9]P:=-0Q)57FZ+T]-98#VBU*;FJXAUN0RH:H>N[Y9O!TSM\><0RLM
MT_IEEFR_#LN<RUX(@ZS.ERP^M#JFY?95K?*8WC(I3 ^&/H@15%7FVMS]GMIJ
M.[W9&<&R(Z(7*M4B+Z9>V[R7 S,52L+Z;G-$K73OLV()RFAEN=>+BOO52 ]8
M8"\>1U"CRU,"O\?BEWR$X(QFA3>;Q/9'\<O^FYU?5TK*K)BUAA;ON&[:'\!_
M*B KC?YKWZ?(-=[MRJM9&H<7E4MGKKI?=#W 9E93<V>2A:X9-D(9NO(NW8.7
MK)DUG9&('KY4O4[&FZ%F#W $6C30%8@=5KKWM^_[9:.9?JEDE4K:]Y&.-C)1
M>F/B/\-<IPL[ C ".A-H;*5G;C-O4ZNJIRVWLU?JB<,*VZ'V-4^O+5S,9VW\
MID _EYV2HP/1!C,#E(*Y#N-:'H37P/0KW7>0B5?:[&#8P0.>4 F\,0-N3$_.
MU+W.M7^SDI/%<=4(9!COK\Y4Z6 >Q9;N<!1O4KG72X\<N9,OZ7;I[[C>_,Z$
MFW24C,@+>U,I&+8L,!]K:7&#8V7XC=QMJ"3_,)VCXX=-I88+R!]-N43R.;C!
M9KS6S.R>P1/^'W XT/L\JU'P\8%MG8_9D>^[O9GPSJ2C A@^M@%1JB.9@VAE
M2Z#3[J XB8/C;F719<[O#XERB4"Y?G[,DW]U%S -+\-R^4YHM DC>],#TO1R
M]Y7>T&+L#XW58:^:2V5D\\KK7JWA9*BAS%G*I:(Z3+09RK_^*"+1CR ';?;-
M;U9,U2[#;9F#*O MHP-E"/'2&-NLU--LG^?3AO+)RPT*X*[=[T,O?F[;,X+=
MJ[EDHV,W.FU;Q>M^]E4<5]& LO7,4/2.#MA,G+2"WM(G.(&]\*1ZP6\Q,Y=M
M<#4&I+"7(S^*7]X<O%ZM<E9G/7>U,JRR]"85@(F<M>$9G^72BDGK1<PZ: 2C
M#G95C[N:Z]([HPR,.C2,64B-?K[NL<]QCD:3G<]H7(4(T0UJI<R\@Q66\N[Z
M=C@9:N ',I2&DWZ>>2]2KN?__B_-)/_MV@3ZF"ME)G(:C16462V3")'3A"UU
M,H6DL(:?L1=E CV^/8'^7V H'8"@?PNT7I>VP$^=[O@GO,^GOY.CT7HF@"#,
M(RXUS^U\*<(DD& D=CQ7%1L\V]!WU!&I#!..&IGFP$LGASW:8YDEUQX V PX
M:U-G0"2>&%9$X4AX2M9HSYB14<D@'&9\?A&%F#X">>NOXO$CN/P :_R8D2G\
MN^H+:8^NZB80?9&'X-O?,6#AHC6(A_*?%!!P(D><>A.Y]%SEA'F\-:_RX?^
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M>.)BKV!DLP!.)!-;LWBNR.2&+4RLVB62O._VSFTO7+:(>& "R2+D68*3K7E
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M2!,GC/):)\ BO:R.7C5JVO4BM>U5MNFJ@;;=[G:.4$XY?(B^_;([A2P@%(0
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MK_;NSP\GNW_LM0X_?SG9_;Q[L4L_L=VO'T[V/^_R__Q\=[%W<,3_3HY&ZYD
MBC"/N-0<1!VE")- @I'8<8LWM@W&,X*N@./6SAM:[OEIK]7QK5/;AE\O,Q8
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MP'=9H%P*T9%,Z5Z2CLWV&.BS(.MJ9^U^$Z11-S^X(JI,:GDXEW+N2K;9WH0
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M!%N@:=F@J3X.33$X#<HOJ$M&&L1IDDC[Q)'3UE BE0^4%6@JT+04<YL!FF3
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M2%]4 YSB*7\F-)]("62YLBW7S3NL ^+:!:2K"ER@!6PBIF!5%4]YP?."Y^N
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M=VEU:?^:U?&F6HXY&6&,])M3FYF_&?)+_GNU-S"\#$)]VZQ5WH9\.PP@-G[
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M=;.V-Y&3:D=OJHP?VX1;6X/VI8W6CSBTB8:-1>%7P.S<5[11]1[-V:E5$U3
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M%1%:<VJC#56].)T\[75U.'?E])$9<W3G$JFEX=(S,NX4(S<&+%RT!O%0?:2
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MF=.1W+K%6XLM%YHZ3 +1R5F=\A]4,06?-T7WBCEY$OD@X^0BJ),2.Y2;HB$
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M;80W&1A/+<S -BM0SG_,>YU)P6<DR3+(Q3>9$D#+;,6!&7\&\%I=,VKX D0
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MI51W#VM0UE,E+U5U7=?80+X9#+D-W'*>Z_ZJHJYNE?E<I=MWW]2Z?7><BS>
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M:&Y7/P"G6AG)(U[$R/(A_3R@Y4T.6UF$+[0(%Z%KWHLVF<HAOZO.T.2*F]M
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MH">Y#=7"F$ P"EXSX#92(1MU0C'"]UA;P@S-<B_S.NQY]=RFP,F<J8'WGN
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MMGXL5$'<\X, !Q (V$D774")!@>TR%ID/"-(Z)!4,H$SYR9!@!KN8"MR-D@
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M1,:1,<;B9(56T2TMJT5**"^5(0M*$XJ1SLE()WE"\M9[3S1*C -/8"KG99N
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M-[.Z6Q*2P%P$".C=$QY;:G575V7^\IZ9)I1R#5P\.UKMQKFA3?.?6X22FD9
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M2>J#89X$KA+"C4^)Y-029X, '<<D$AN?ITWC\Y<4*GW;/4*.TTTIXA*;AY_
M;/=O=-^[R>-Z]]/Z?A]^\*8<XO'>]W#>:8.5-\3*LSGVH*&YY4H&H+B$$\#+
MG"CA O&)"9)[SGTB,(9QY][+S\6MV,0PEC+7]0XQC 9T[AET9LQ 3W,#*IHC
MN>&4<&X"D8FGQ%+)>!*< X5\/NB\O#!&@S?/+6;:X,T]X\V,09@IK5S&&9&"
MHT'()9'6"51WC%<@<91E*^MY4]'X0B*&.V "CETQ+5_Z8IIHX;*9@_,\9KN#
M0UQ;@XHW0L7S.:9?,#S7F7*$^@Q0D>N4&,D"CFQF@CF=!<%0"[MS7YKGXB9K
M'/'/-PS8P,HM864VQB>U27R6$\%U;&,< %;2A!BG;>I=;A05#:PTL/(BXGL-
MK-P25F9L.#BLS&;6DLQH1CAF#1B0!T2JG$M&%3?&K:QG"VBC]UQPY25$]3YW
M+*Q&%W& 1.NX6[8:;48#/H0E9_H_KX6+HS.J1SK"5>_KDVJP\8;8F,RQY!15
M1DO+2>:L(=Q:4+G AB,T$]8J 3JV#//]6TT0KW&J+YDEU\#*(\'*C"67LJ"]
M48JD,GC">2:(24-"M B88"4RDV GP#76P$H#*T\G5M< S",!S(Q-Y[EB2DD%
MB&)3PC.?$Y4;3[Q)<_C">HKUC&K>W-$F,/<< W-;G4%/$QS',CAK:2PD;L$'
MG7[PO28ZMTPV73RH=_&<X*^Z<X ^KUCYO5>?5U-(LR#DI',L/JND!OT+>PK"
MD?(,,93)0#CU+I566"=94TC3.-J?G=77 ,^# L^,39@9EF=&.*+ .B0\. SL
MI1XT.&>92W.EF6F IP&>)Q/A6RCP- !S4X"9L0D%MRH3&O09[)',TS0ATC!.
M4I9ACQOGDSQ96:?)W;U.SP5=7D*<[Z,?#'N=UJ#;.NYU3XH^'/<+B_$]=J/3
MZ^)D>5)[W??U.36H>$-49'/LO31+5)8 #)HL "IRB8T3N,6$=NN,IY9+L;+.
MFDE?C1?^B53H-7CR@'@RFZ3ID\1:9HD1/B7<2XV=Y"T8=%;F"?/H?E]9%TU%
M3(,GSRRJU^#) O!DQFIC.A<)M91H@8/?<TJ)T8DF6>ZXS+T77H!^DN9-M_47
M$LDK&P.WJL3,'K#A2PO@/;;!=ILVSN\ZL-;8Q1FO:9#QALB8SK'<M,Y-"#BC
MF?*,<.5S(G.;$2\I2Y01PE*/Y3"S[JR7-[*G\9,O;X"N@9/'@),9PXWZ3+LL
MRTC(', )<PD!?=D2&2P("RVU-AGF9*K&.]Y@RK+'WAI,>0Q,F3'>%.>I<GE.
M /\#8 H+1+DT)TSFG+-<"Y;QE75![S[(YKF RDL(N<72U=56Q]]NXOO3]60M
M?U^4>#0;[ONP/\#6P4WBP4U1D,\QU&2>@4(<)%&6<QS3K(A, ]AM5J6.RL"\
MC$WIFB*ZQB_^K*RU!DWNCB8S=IK*,Y[+-"4AT9IP(Q7@BD^(L=IQHVQBN5E(
M%Y0&31HT628[K4&3NZ/);'@MN%3DC!&19"GAH)P0DUCX)V.293XS@"<KZ]F<
MN7\O%$WN&F*[B_O'='O.]\B@>_P*]Z[?;1>N56_ 4F-._F3LH;?PR*(SA)W<
M/?8]W93DW@9IQ!PK2$@0$L(!R+B,$>X31Z3,*3$^$X$;'S+#5]93.<?!7#/@
M8W#_[?Q0U^;4I</ ^9SZZ)[OEPU]#V.\-="W&.B;-=DRYIR0@'4\@,F6XB@4
M30/Q5FBK++,F83@V:C:%J4&^QV;4!OD>%?D>QM!LD&\QR#<['\$;IT.&R*<H
MX3;31 <!R!=2G6=!2U#HL;JDT?F6CU'GVKWU(NHK1<2U^;#X2_2;0-#QWJ6P
M.ZX[Q/$)TYMWC1L]OV?&C?_70,.%\%]7G*S7O+(S/(*3M>6_;0EANF2>>%EY
M>J;WKQ$SE3^'/Z:.D;.U'$[R==WF]%4<8P@H^?JT<(/#&KDG?EA2YJMD_!-M
M@.*'@\M_,DWL#^_.8;@D6-C%[9C\\[ W/M0#3TS/ZQ^ 6 /?>Z7;I_JLO_*O
M"^]T5'3(U!Y.O_[EYU#^.75VI:@Q*?,JT9G7VO$L321.3M )Y6 #:&624DK"
M;[S;P'84G@MF1 Y?R\"9RZ51Z!71$F W&,]'8K>BF05X5B[*U4_VT+MAV^^&
M31]\KQ?S:&(1>W^CX_XNM"G:0">^OX>$O >/?M/NVA]/5+)^^_=A8H_^Z>@O
M:KC[O7VX^^6/[]M[6_3;YCOX[8=D>_,0/OOGQ_;WKW3[R\<?L*;DZ]X6^_>Y
M%=O?-_:IRVD0F2)6^4!XH@*.#;(DR;1W--=@$60K+0\*R#$R3F_H+V4E=(<7
MX>R1F.D3+*$((+$Z R"IH^-N!SWSK6YH=8<]T,-*4HB9^K'I5K^E.Z[5'I-#
M2_<\?-4*W7:[>]I_=2E2S7WEB(I3V JOWM;'??^J_LMK5_2/V_KL5=&)+Q!_
M]/I(]PZ >2L<0\:=DKWQ@>77%4^K;(TJB6Q=^7^K!U<<OQ8Y?DI;*+_+DS4N
M+_\Z6:.7?G?5;2E #E.WNNW5WPEQN[O^:K$IN]9M?^%C?TJY3O-5R=%+J>N\
M%$YK\[VET@TW(H]O>NO19FNE=/4F09+;'N!(FC[N*=[3"N(=7Q4#>&E[G2J@
MHM."![715OU]2K&XE@+Z2R-ER6D059'K.&>N\\8W4]V?P<[1A62=WG9/7C"7
M7WDPM>[< N6Y56K/KZ[/V@]Z2H]_0/>2W+.H[9PUX>]>EEOZ=]62'])6YP00
MK]L[@U?M5PI_="=X_"_<]&2V8/?.=2]+MPO_=:=77!;'X U3Q89]-^6^SS,9
MK.)<*9KCP#:=:9<ZF^2&2YT[O[\U+U6#9-/NA1FGPHC*1F[Z[(GZ$BHO_=GV
MGW]\WT'?P9>_?FRSK\G.GY^3W<T#]NU[N[W]_0.L>>OGSM[VV?:G:2_]UNG7
M+]MT9_/#SZ]''\[AO9)O>Q_X[N:WH]TOG\]V-K^UOWY_1[?/MW[^^WP4FQS
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M4X:)VH'DB?4^L50$#5"9S\:B:O![QBS\1ZFE1QT=)]-/C6]&'TL>_1BG@*O
M3_\9%HB48&?Z\H=[;__:0%X!$K/#=G2BM;HX ;Y ';8'2XLM&4H.J]OP(BL.
MN@-@9T", :%*9B-G&;K1"E?H'C#T_[1@63C2M%\">J\;&?2W=_^MCXY?O_^]
MPAD/W_B3HCOL P8Y'WP/UQBMGN@CG%2XUUH;_8@,"!3(ZB?P)/@EX(@K0&[
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M6W#PO6+0C4$0/-;^67_@CZ8<;*MX!I5*7=YCI&?$^551'(QZSL."_FQW0<<
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MMD J*"TWHKH6UU86>)0U4;#A8.P#?!9E&D&%[:4L+@GTN,I1CO?Y5\0SL)I
M"IP]XXR."Y)N+).JK4:I 5*Z-.,CS(#9X'MQ$Z,\[]=1&(^N25C#E&H0\Z]
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M^+^PUUCT!7_P(S5NB LIX3]6^+0NJ![("J5]5+L&5EM.'P&Z _B ^81Z#/H
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MBKZJZ<UDZ?=?\8CBR20[X!_?UHUW^I=NO&^V^BD-8SCM.]7Y5]'#J>G;NHP
MY0'QA=>^</TGECA.,^FZ_<(7G(3"1F,G45Q)N\5"RWK\A.HYLRJ7Q$UDY)4*
M2+SS3M.EN?;^/.?(I=8N4TE_N4_$J.RE2$Q(B4Q%AOAPC\8R=P;M<AU5$Y2)
MV4N-T9RNLWDM7Z[K\5*P0TL7;SP>BXG/C10TD>93^MW(^K36EJHZ=*-WDGX^
MCEL>39)K>KC,<LSB\Z%?90X OSH'("TW,S44$&H9N-<H4"20$<S+R,R02TT9
M-D>(D+5GS!RX]BO7S&N_UV2?21OQRU@.3YHQU[](X\*BJ+11!@VZ?GGFM^]4
MAA_<N7S_\^!D]_C@Y"O<Q9]@-/1^['W;B4;:^Y.=OSZ<[?[U_D=<2VOGR[3A
M]^ERY]OGY@%^WSS<_T0.MSY'0V^''5R^O8C//SOX\18>I/O\]?7\OY=?SZ.!
M>02M=@:&  RQ&%!-') 64N ]=D2&((-6TSD<P0<=Y4C S#$J=/P?)-X1G$8#
M8FC0S+CW9<SHV-W;WV[\/9H:M[_W[O_\>^\_6]N?O_ROQO:GKQ_V#V81;.DT
M@"M#5E=U _1E_#CSQ<M-5OE6C&_0@_YQIYM%7@IBYUZI5WJL<BIH;R&5VG :
MAH8;G_?]2W[2V^'B5L4W]>00A8ZL3EU;/098!PXHAPHHE'[E\8^>(FZ57-MD
MU\R0*HXU=T494G_.[,SMJ=JY"5YNT)1(S5<^CZ@LG1=61:HY[*V7'0&K_,GB
M5LD3TAOE0^;N!\D(28.#DJ::<BZK($W1:"+K$CF8G9IU370<3'4T*1.Z^$J:
M^-'.S;Q34GGYIU^=8@1*^6M\DYQ-D#QNJ=!CO>RX5*C[TTM,+Q-)RQ1:<;DK
M2=_M-_N#4J^^*#=A?:*-7MGC(CV^:!E8,$XT"I,J/YXE^Y);P96A6RRJTH>S
MTICV1:Y'T:0C&SCACB"#B0Z6T@0UE%K+M+3$.,9LB+C"-<T@ R'#XHIV$-?!
MS(=<4G [B'G^CA!/#3&?R,ZG(\()=(1:H(*@@#K'0323":!6*"8@\IZXI(NO
M0X[7&9P#-B.0N?+D"]Z;.GD>CQ=AZDT4+=11'C5<B[$+@1.*/'7EH+IX\N!>
M)+!5HLKG:-!^'':3&)XWP*_OP.GNVR,2V0PQQ "*$AU0HR P%D( #18<,B\0
M8U&J;,R1*_\SHD#J?)!*T=YEB.XWD]]J2K5J_+;S[N.7W]<;7PJI\K:A^[G5
M1O((E(DT14.>LO_A/."^,<(6CS0S^4+P!%]/2O\9+?'C<(6O&#F^LMVS(X0L
MQ9(S( (.@'IK@"9$@."AQ''_*35IRND\R#A-[IOCW/(_N=S2 -PR;6ZLR4 B
MHI%@*4;OI0+.\]Q0LW5QIP#L \%F-@!;5M[WWL?E)C&36MGLA3&NF*2@6LV=
M3TGQ[=X>6<6-8($ QZ  -,H=H+7$@ 1-(%<JT@!<VU3BFK!K=N+$ ZN*(W.;
MX;-4F9GURUX.(8VJ?9IE!]5<]U>1F"^&FL[X(R=FP>/UK/EEXLQNS_9H5-U]
MH6R:5K&QS'/LF#/482(Y]S"BF6;<,H[E?+MK'HG>B&'_Z-;@EE-<U:NCS>_G
M.V='.#CGJ6= D:0?66B!Q X!(Q2/>I-*OJ"(<ALP>2NGJ+,@'%.0Z ON9//O
M49U@YHMJNF;.,6_YJMPU10;6<^5![EZ7BW93$V?;TMTBJIQ;&\Y4F:YGPZL]
M[M'(/-SO>S\R)Y/%EB)X@U3OG0<KIMRH7[K9RK&U%"DLLWBB?3DH@G2__-#V
M[#7*JE?=;J>.5JE@N-9IEY])M\]V+K\_3*DM0V.+U4/O!^*U'GK'P]^]_'0D
M(Q1K+R1(8XU2TE941(,6@%,F?%3_G8;H)D5T/8%#!HI4V92FPW:ZZZDL_,=4
M5]+4+;!?N<),ZB4Q&I VLH03/B7_6S:',GJE/@0GIMD>5AODA^1BDKE7K3?*
MA!;?*HJL_A@F@Z\WCJM>@3GM)=U\T,YCAD=HUFF/E.B,QQ/CE6V)@+FV890/
M4 :2\Q2OD$?<%GK0R/WW@J78E]G#]N?6GY9GW>Z,_)0I\SYGG)A!6?]6"+RA
M+,O"IIF#S:/C3:<Y=<3M%"F?I);A:.JJ(J!P=OJ3XK:C*<3:EBUI0C'A(W?9
MTY5[<M"KZ*Y\\K#);#+)!WGF<4ZE*B9WZM0")K>%&I*&*]MV3Q%6V>\S0:3U
MD^[;R$W-CNN-S=@9;D@U"+N0Y7$QJ<=#,\?N<];JD"/BQS.>VFF&&E8%]E+%
M2,Y@J!*!JD3=:H[W<-WKY1R=I"?T^F4;@M']$Y_DPKW<4^)7>8NT;Z,V)'G\
MR.C7,7F1?,;YCF!P6A)'-8B@))PQ8BGOFS*K^\.!X;FK1:2\L98+T^12CFRM
M4B+RL4Q]/;U%V6MAE/UPM3*6&H?,%WK5$.[AV=0B<$E%X(?SO:T/"Q&!C=-6
M&LYR _^_8 %0#H+WNMMJYBJ\[,M) )PYJMBD"1LG6B2=5"U=C+@O+RC2<MN^
M,1P/.:9&G'9Z_=-.NTA;RL!=BIHBQ2LA16KDF3@LHU#1&+8S3!J_+F4D8&*Q
MBD>N$*4RY:HC*3R!7C&L$#.W2!FYTG^UGX)LE7\K^4Y>'Z-=[NW_/()(8:]"
M9"\I J L4& HX0#18+7F G)GUC;Q!I&$5KQ6'M;F>*OT^0>HG<8VHJ6T@AH8
M%!**,N_B?94PGM<'^* #A#M;!T<$8>X)#<!)YT$22PDS!;!.Z4"T==$H3P>H
MD!(S!WB5JCYN)T0(Z^0QYKD9NFN6\XBT2^ V-HCL1BTGI6QDBV1PFOL&#$/B
M(VTSA;YSO_3AI, LM=-XA^\^:RXGOL2\!.?EWXM S CW9^R5:A06AEFOK/IR
MI?J(K.]%E:50]>(JOC?;>=Y7TG2*-FQE5+_(Q,0H==<:SCL?OT7S) V=*%SY
M(V5R'#E?L*S9KVRS9M$[?(R"B@9?57I#)*YF^V=NX#IHCRR 89?08=7N> OY
MTG3LE'<X\UG-K"R*=!-?-2H<&HE%W"6^8P[1I?^62F#GU%?B*5N\U5R.L9MD
M%_J$=3+*HBA*5MJ]0J7.^G^9'-SOK(\KL(4*GC9FJN_82-Z.JH3C'DUEA.2J
MG%99Y3TRW%XP#94=VT=5 &\CX_6+UI/9-UH-BYGMV_=;6<=0?/'WR7K(TL_:
MS\Z-'-@HFN$E>VKD>+W&73MA]9V5IDJ9EMZZ*.R\,4_%W:(C]TJ,O2Y,4OE4
M>^_BNNHXW17"D^QN?2>[ES^3QPVG[-FH6&JI!07Q(""@5CH@(6; ,PZM42RJ
M,<GDH%?&[#(4W,>NM(Q8+2%AQ 6J%3,>RR"P-\XHZRFZ@0+H[5SLO>KIB2P^
M1@I^Q4;FSF5\]A&7UD8Q[0%W3@**J ;&60^DX)XQH34B-(7"B)B7DYCTC8SD
MA=(Q\G6LCX:XS?4F57.<QJOD\43;E[*_-!F6B980-<*A2<RYKT-#<PF3566<
MP)2@:%1C18,T*@@IL(29\ A$D1^J'VK">QCAP;W][2,$H33"62"#$H!Z*($V
M3@/%("0P?D(INP?AC7O-\LRT,-:EF%4D-4&<>IH\"[5IK+,UQD."'>^=14;C
MJ\O;I2CF, RY/NMG3?I,U,"6J^_3VS3KU[MAJL2S-H J=ZCPDX[5KAG=RC/I
M>L<^%W)?D\RQXDF[=RR!>%=8>77]PY/6/Q2[_H#BA]>7>;-#=G]\/Q+>&\TY
M!4G" DJ2JA$U?H"]HD8K!2&3R54#Y[FUS4P)Q*3+YC[R_WX$,1/0&".(C[J[
MU\VE[2ZG8HT>_'I%/MG;_WID6%3M"8XVA9(VBGQD@!)4 1L,$T0@K5-R*=R
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M/ZX3;PMV[/+G"E/MIZT:$VFWL8[XBLJ[P_\>0WOR3UM_4X.\QI.O^.!RY_(
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M?H5\$0;[S0BN$5\2,#H?]9*H@<0OF(N&ML=-_ZN [?)FXR!FN\WX[:8>?E9
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M@?M>V8<CO 4DC*'2:9WH8[]O>Q<5E42V".)_AM=49_W\&7 O*OJD&_<*K90
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MXJ U$9D[_?VX20_X ?U =T\/3YHG']N'6^&X^?[C\1[<+\?T#O=_/=W=:K?
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M!3?2)UU<LV4!D"G7S$KLK31@=RCL$:<5W2"/*#@OC71)&XG7-HG:F"X5>*,
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M9T9(SA77QB6,?3  =BIPX2IXF^/@JL#;4\';9"L=C6WPGDMD@DBY.E4AC9E
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M@#<G 3P&0:/*)1:<,L2CB4A'F1#3+FJ+74H85P!.:0'PQ;-E3?)DC4FNYF+
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MC^-PZ]WEP>7'5G/KX[>]K;]:S9,F:\)[AUO;#.X)SWC 9W;-"I31I*E$GH6
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MJJIA$>86"K.40EO""%;$\1@L6,LYG<1+)ZVWI@AS.X79SPNSI*"!.?!J:;Q
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M%SB3)WN"AY@,9RAH$Q&W5"(;K41$:D%\!%C(M>;YFB&+MEY!IH),#X5,T5+
M((&E%9S'Z!36DE$GG6!)FWNJ7U*0Z0Z1:88S;;_8.MU+D5$B<[/8P!3BC%*D
M$XD(#'G*,6%"&I>M.2P6LQP*,A5D>B!DDL)Y*D2,V8.:%-$1!Q\9X=@XY^@]
M19H49+H[9)J)* -D>DOVL,?:.EA [W% 7.40;P88!;:[5P%@"_ZNK3FUF/)=
MD*D@TP,A4W)$1L.(B5)RGR/2C4Q,<1R"]H;A@DRKADRS 7(P!K'S:L]RS#3/
M^: N9X8R%9#Q0B&59"+>@7T7>+;G)%L,72_85+#I@;#)\8 UQ_7),J?,.Z5
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M22B3<*=G>-]M-%]6@8>0=2KNOL+.=VJNG?%!'/Z06A-R_9L5?F $EU?XN;+
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ML(_OG:D?49#^IYG]',0=JM]C'UZ-JY>9G]1G _U0-<1E:QP/?^K]6H>17YB
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MK!UND:5Q9W\,A@!>6_W/L?EW;2+!6@^C'<47L?F[P-N-X*VSS.N!HXJ4(\'
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MA&& F,\P$L15"%;4)2QDH9^$K]Y[HZ',D=13&U=81_%=@-5@Q??EQ'>$J(*
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M=9YB8=BPQ0H+\0),#"O$2[,JJG@%CF08Z8QK&22(!3A!(@E]%,L@BJ*$X20
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M#S$6C#$,Z,@33[(@ IA,X _Q EJY%@MS9M;EI&$Q<DZ,/!S%2!&X+ @2H;O
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MN<_ 'DRPIX/P9/3P;V@?$(-JLVP%%BDNF' Q36+F2<J%Y  3)!:4QYXKS5;
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M0XMS&$0&*@YN=W 7F4(M74>F/R;"93OZ(6 8-6(5UYS]*=XIT^ZFKN4J*G+
MD-*7@[_9UJZ@,IQ:::.PG?1\9^J?#GC95?E..6Q=-'?O=+J=.#+5:F;MO+C/
MK?:4P?T$#S/OA#=I&RS#6&6SCF?'27.X<:1S6N$7,X@\US_FG1O8QK"WBHJW
MXN'PB]XRY0NU86MJ[SAMQKF3M\#L2]*BC,^\Q<&>J1L-?H,GP.07TZ0'7?S4
M/RMY)[H>/S7P>C**.C<=8X=657HW8 9'LBQX:@YMZK01U3MQ54$(>[78C1]/
MBH&W8) M>$Y;Z2]+7;1D1E*_-\9P;ESS3%W)S-RCNS:]S5AS/O05,Z99M95-
MU>#0,_4FT:]CMCF,]*']NC/MIC>-5KH2,ZJ 5@B'QF/K47>YNEMDM]'HF.HR
MO<_TU)959_4*?9WF3]C?/3@IKH0E6N7ACX?A,<.7Q?"S[O#U5DBK*8CZIR#I
M3D%638$6$WV--#%G$,##MKHI-E=0H%PZ9H8_@I0Y!*/_K.$.JD:1P#XIRGJU
MVCE35VD.<P:3<-H)ZVD$N!<U.PTS1Q]3&.YF;ZR+KIK0,W.0-?*V\V]YT_K-
MN819N'(^?SZU>^O1O=57J[W!>V6_5Q_\3P?,/QB7,0DF*B=]ZJ(*W=-H.E%O
MDF;;3D8-7LN?JJOP0?-*H\RTW:&/(3*]BV7>;,@0/JNG/[1R!F4]\H6=V9Y=
M<]9VF8HEN-5E_U>Z*X8#%E$[1;J@6_,$%(S$7>M=.@UX^E6]&>K3"#T]8/'D
M>E9SF+"H.',P) NO#\Y.WSCY/:#F#=S_.@5#S' EP*35)5RI)UC= :J:XQ!S
M7<W1.#/TU'2P"KT)1IM>&:=U#;927BQ)MQ8]5YI H5[4H]><W;QP0JZ-634\
M''TGS:^@C>=[/008N;YSM0-+$["R74>M)3.H![\[O(/R![80O*PQ5ZM;F/<S
M2V/FK7)K*J&"O7I[K4P=/?QS/[J'9]S"<P<4 CHNH+!&I\X/!1X^U)R3B]\/
MSIS#XX\G9T>[%X<GQYMZTEY@4ZR=-B,A[XSGIZ\J:I]!*>7M3',5&N38[*2#
M$S U5)AU])&U1D@] 856^- $#\XX6^"^%20KQO?[J;6,AHA;<W@+KG,!63N#
MJ)D-3")\[RJ3-\YKC5,3)OE-@8L3/M4 J:7<J%B G7'<21,S?EYJ-F^4:@."
M->OZI+^:"5"-/^#/L8+;QWGI@C<*IIM<ARB,)]]5[3"M6H%7X^_&#PK-8\:>
M=UJ%G=C18778Q6"V1QKW56;.)(J'Q*J>:A3,88.!\6D(/DPCT@?4^+/MYZ4O
MS4-;RRB>I),9+1-VTKJ)32R)G<N\K5[93\7V.8?%!F4'1C7HW9-6.[U)?Q6:
MO5SZ^\KN&)*07!L"L!)5@*>CN9**49OM 39)-[.JH=JWS>R'WHUM3?VI<SU,
MPH72/30:6G[C3G&"JE]6Q[^:\#'<,:T7D3(3DKIK&>:;8A\:MANE@Y:I BU<
M7J-#G'7]A_N:\Q_0Y_K([F=QBUX$[L&%,BDW19!*K28,-(M5ZI_ I-.(RBF)
M9$N&U;29B&6[;<2T$.JPDZ<FB M#N&U?%WQ9T74*)A_@!CBD^7U#@;&M\MHR
M=ZC&:K"(^Y;/\)4-$BFE#?C(Q!FK;L@F.ZGRET"Y%/I&CS'OA(!3C79AV^FT
MH+IJ%S%<$^!NQ.7UWC+PZZ6F]>]K'96^K682I T4+,P"V+3:_2B%T,3M966/
M=\G0!G5N;VF,=:VGUIQ0E#%CC0I-XT;4>VE9FF6N\E]N]+ZMCKEA26 '&Y,]
M=CHMP(%RA4J/Z2&IA7?5AL'W9EALDL@DD)D](;6?JK_?M]DK55<=!)2\<7UZ
M#^Y90(TQ+> O2;.>-LV7]7U&=6]#J3B?'$FQ;>5GR UP)^<&+/>4?V5D>(QW
M_XB$:.>_RT\(&[WG:+=-0F0KTV1K=]IGSHS/G!2V^)WY"LCF_S /=[->X ;_
MX_5^-XF7A84P]"5WZ$O]-QF*1_3>J*1/C&1^#1C2KL.R%H9[06!G[%AC:VI?
M(8VU&)>'8??5N60U5C.0\2.4>=Z,"M71/62=-'NAC@I\U_FO]RVE;ZG5Y+N7
MT1'KPIL7D)I'GX$WC]2(X'/=]J'/:,WC\WWSD9>E>+K;/A/)WPLDVHQGOKLH
M)6-/&Y#/;#9.7^GQ .5@ ?'#93-B38D'B[3V@R[$[][H0S7G8-!:/FR87AF#
MK7JVB(YP_-P- GZI']X-S-%S3 W6$_-PZ=8Z/>"EJV>7D5)8B)KAORZLKG"(
MWW.A[^/7O"E>:(Q3H%<-N;4Q"E][7T4<^C5Y# J?MG9+Q<@)G)NZ-^4<0KV6
M@T7;,]3_X7@A"FWMD,B46:XA]-"G0,_CB[6"6Y3-ASQK.=;YD&<MA^H_$7A6
MFD!D"F,9947U655/.Z?5/#0-<]FMSWV/;:"DNB@/YDQX:W('Q8T38^HM!)Z?
MXF^MV81Q["P5^:S)-:/)Y6Z=MP?_;H\+M$7>'G&?BCWS:680LR6->#P'U1S1
MO*<VU5N9G3&A92A;C!Y?C]$^R<UZ<$,\N"?6<%OHD^I1Q.BRGPV?PI:C0QH$
MWKG^V%*#XD^IJ6EZAPAO+3Q;PJOQ1^T!^I ]0*8-_R[TM<54^0L%HHW^6[2K
MBU5;IG53S5"4K$:]]*&BXV+9+5)7XJJ?JMYLJ;C@NY(Z!:&L5-$EHA7W5)7R
MMN/H)$1]:W/FW[UMIEJ9RHMDBI_*"9MQ:NH2E"ET*>M+B^S!>A/FTZG+VP?2
M?29LH77>+W05]\M>LY&GX*HZK2S5M=#U^R(YHZ%32?0J)TI5^=#ZLN&<#U/+
M(8N&I)'NTUTO.M+/OK0;A@[N:J[VC2F2,FF:1??68EEC4S]0OW>J<%3)VS:V
M0J"__+PJ&N@O3I>@(NLZO5A7E&M8T!O&)#F9MM9Z#ZFV<YNE;86:29+O].TO
M_=PJAE(F-$_(9GXF3I+ >S5RR^74^^S5^IABG+.#3[MG^YI,YN/)V<'AIV/G
MCR]GA^?[AWNZ#NC<N?A]]\(Y/3OXZ^#XPCD\/C\]*#Y8#XJ9MDY[JX,D@4$Q
M&3FV,I>3#84=YN-Y"OB*\#R-6+I+JJD[W3T#.3D\?!X4X63]F(T(UH!S!KAQ
M<G:^XQS\]V#OR\7A7P?.R<>/AWL'9P7=T=[)V>G)V>[%@?/IY*^#,\UI-4IC
MM4(#?B#]=QP[C:ED2'-# *#S:[6F@LO TBF+P$^SYMV]<PYF;L$86W&ZFL37
MDB+@2"EC.X&2/6\WHQ_7S3K8O64AB>&TZ<N8/3_8JPAGX-T*/1V#%#[ ^:/5
MI2DDBII9JYF5B?I&93_(4Z!'EVF.6 6&VC/I3\[6<.>36M]VWSLY.CTX/G^X
MOG8%!F1W]@OO[& -=S:MZ64 2_'BTCGY^QA0_/?#4T!T!P#]8O?PV/EP<'P
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M8K.0M/J01)=;OV A::4@J23XH@ GQ"?>V_8-I=PG--:@Q- C-0PZ9L2K_A>
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MS"<WC33LY/IPJ1$;HI[^0ZE!AC_:I: =<SKUH9FW->%/E,)-TB2-G(\P$-A
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M.OMIIB+ IDSW*RM^_ONZ6:_?HY/;AM(MS<(\C5/0 $HWJY!MYW> 0'/Z['R
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M!\MJ9L]#[X_43!LSMY&:5<2##09Z6WIO@7XM@=ZDE+ ^!A:6Y?)YBRZQ:UR
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MD^!6_\24[TR -8MK*XEKME3+XMHCN.8A&?W328OSKKM,U<?@VF[O"G2F#]$
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M6X_+771?/MV:S1ELM'0FC]*94$MG8NE,!M_5TIFLHN%@BQJLX?"(X>!JC9V
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M5U/7!<1T0^S=/S]$M$=!91D1#50<4''JI>+ %3DP"HRJBE&@XE0345!QZDU
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M<D:D-"S)+@U+:B. JGBB9A!J<E6"F+,3:<0JM1'%[:"CA@NOF(L2I;P%9SN
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M5(*NZ"1*!1EMJ\'KUFJ&84'Z'E);D?#[9:]KIP*!-"IA_ Z( 4 ?\?,S[F+
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M/O,?FD?EER,8I!"VP3GY\M/_ 5!+ P04    " "#@E=6A _J^@<C  #*4@$
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M](]R@<BG&8+BGB96<@3ON$FF>*Y2G]7:Q@-IF-J 02FC. -12W)4,9H"Z62
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MMB1,(=9BSDZQPAF(D<8%^TC^:B2PWU2WZWV04FW;L7P?CJL!/\5"3PTFBC[
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M+P@E!0/*L@ ^:P4FT$OEF,JV5QG[/GAWHMU/MJ;] ))MQL(;IF2[HO7]E-B
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M'LTB/TWQP'@YF@VGX^\O1PEZ.43T/K@D7*=$I(F9.,'+46*M88X:S]H?QEL
M.1'E=R?L^US0[;GPV7][FQ9>:@-QL0?ATFAT7!.7$B<R@2:!<4=29CIR4)JI
MKCS!#1!.1/]="/B^YDU[S9^E-(;)9/&?LES6"S)+QWPD4NN =,1=R2=.28S<
M21&%X=#5 ;[F\2>B\;:"O:]MVYFV7^*7[\>?1U^'/2[!R&#1"P2@1/+DB+=2
M$W#< 8L"=Q_1K:YO'GY:FMY3J/?U[#K3<W/0O!]_&(^^](<1;8X C$M!\6!Q
M:'-DFTBPT9*8D^0:-+H-LEMEWT%P6AIO(]XU$956$;-;P#Z,)E,_^'_]J\:Z
M\#$;K2$0;7PHEB:NVG%+J ^<:6$4I:9;K=]Z_FGI?'_1KM%XJR!:V6_.QN ;
M((G19%PL/H1G!0A'(,H0!3E3+ZDPFK;6\>H3G[U6]Q;?&CVV"I652^C!AXO1
M<.GX,R.%STX3D84A,FA&'&0@4=+(4]*.1=5:EW>?^NSUV4J,:W3:*B;V">)L
MC"MD/'SN3P?0 \43-2$3:8U BT JI)KP1$6M([.)=:'3NT]]]CIM)<8U.FT5
M%/L\]B5WY]/WRS :]*2QB:*+1L 64UX[(,Y(1BACTJDLG/?MXR.W'OGLM;F_
M ->HLE4 ;,FKU]_BA1^>0Q.04R"X2ISC?H$PI,=C//!("2C0%+Q2QO/.7M'5
M)S][Q;86YQK]=A#4^@<,!O][B/[8)_ 3/!?2V\ED5@X&92)C0I&$&P8>#*")
MS4D1S9@U/C(E.@MO;(#P[#7>G8#7J+Z#J-;?1X/9<.K'S7W*>-(3RKOLLB0@
M$CKD5 BT[SP"#)%Y9;CDW':D\CN//A%5MQ'H&A5W$,IZ.1N/83B=WW^68P6=
M\=FDQV/,TE)#J'9H)B2'EKRDE!A 8,(B_UA7FEZ/X$04WH%XU^B]@]#6V^$4
MQCY.^U_@E9_Z!<Z>H4I':B,!20$M0Y>(4T$1QXVWVFJ1?%=!CO4(3D3O'8AW
M32I)!Z&M9N-YZ:=P/AI_[R43DTP4?8!@'%H7D)"'0I*LRR)IX#2E#G,,KA]\
M(EK>7YAKE-LJBC7'\^G2#P8O9A-<WF127(/ N38DBE*Y$&(FP7M)E&%6F& $
M:-V1<F\]^$24N[\PURBW56AKCN?U)8S/\0CY93SZ.KUX.;J\\D,DG=!& 9J&
M6N'Y(:/TQ"L1B,4?TQAL4+2]N_4 @!-1=GOAKE%ZJ]C7VYC'9[/4Q]\XFTYA
M,FW6^V;@SWM.<? T6H)^0<ES4)%X;B21TMFHDX\BMM^U-S__V:N\(]&NT7@'
MZ6*?+M =7!(P1Y:=8N7>DY6;[BR(#\(0R,%QY=%:%.WCG?>?^^PUW%*4:S3;
M0:;8AUD8]..;P<BC(6B%PZ49HE3&G06/#^(@X1^960XT!Y:[R@M;>>R)Z'5?
M0:Y1:P?QL7?]2?'L/OCQW_U@!A]@_.G"CZ$7%3)+64JXD+F8@P@JH<7@.*#7
MKUDVM'W9S(,03D3=70AXC>H[B(_AWG)9\A!'\9\-I,G[V;14TI;X?$\$P1.@
MAX>VORV%(9)8FP)1C!INN 8ONHJ//H3C1$C0F:C7,*&+,!IZ]V,_>#M,\.U_
MP_>>=,$DRSBA3N"VQ"+#Q>+A$R.W^#] BG9EEM]Y]*GHNX5 UZBX5<1L$;UY
MTY]$/_B_X,?+RJ#L9:0T4K0I2J:21W@.3R-B&3H()F6I0_LJG$U/?_:*[D2L
M:ZIP.BF9O$'U!G^"B]1&!@J!<.\8D0XD"> R<063M;[D*K96]8:'/WM-=R'4
M-8KNI'ARCFE>\3='I8$+J@5'-U\[]/HI>OTR2Z(C92E(XUP'AMO&QY^8LO<5
M[!IUMXJAG2&DU, J;G[R @W'*(BC:#!*L+ID32B2@P$IHF3 VF?PWGKDLU?K
M_@)<H\KVE9)]F'SV80 ]D9,MS1U(T*EX =XBO10C0H24O>,T=E4FN7QDAZI<
M:4MS&+MJ+[&M*UO_8=YCY*]Q,)I ^OG'Z7@&-S\<#:?P;?IZ (4P/_\X@?/+
M>W=[VRM]-B'GWE_UFD3Q\D$O!WXR>9\;;^#L6W_2,V@N@!*"4!EC*=Y%5]!9
M_#9)Q62BW.2'XF393T*CG\63&B;\!(/I9/F3AA"$LD5#HG]_%%*')'F@3] :
MTNRGX5$-27?8[F );!7/JV8?W I1[TZWHDXY<!]3EYO]IH9+-ZKO6&FC*A(_
M#!<\&,MSPL.()T&DI6A+AIQ)]$H'3:7*Z:%"RZ?/@5M-K(Y(@5T$74/U-]&@
M7V&>INX-",7P+%2RQ(&=(-:H3%3V45OJDX,Z)\ ]*(>S]+K2SUUUMQ)NARV,
MPN1;[Q,,^Z/Q;Z,II!F@"LP"4M8FYA@-"0S=",G+?;QUAE!O<XJ2<SSJ;NO[
M7CNR!S[^V>JP*Y%U^,X62&=*T5]??OCT";U!F)PM "7<BVQ("9U^4TI+1";>
MBX2T4F"Y89&'O(4.UW[XL]9@>W%M[$/T'S_=$0@Z%O]LWQ!P.!D-^JGT6[T^
M@B:C_!X-U\9[F=S&M66WP$<_M--6@KLMX4Z?04FMHT;D+(23N P?K#<BL<"X
M,5J5/H./?GY'SM&-IVA<=(X+16S*Q4E7@@3J!<G&!&=C8"P^5)3>@5=TC:7M
M@?\1OL!P!F_PK4-)3DMJY3_ZTXN7,]3G)8Q??XN#6;D*.IM, /^7/OMOO:C!
M.J$X22IJ7#Z^+\XF3BR:0BP&JKU^*#J___+W 'OX[:HE7^X:#;45U*%9<6/G
M3*;O\R^C49J<#1/NM5_Z$2:?1H/4DTX[ZA(EY:4F,AI-+#A':) BZ&B,"P_%
M!]M8DYLP/7N&="3N"M[$+^/19/)A/,K]:0^48S8%-)(4C24!K/24T98$GT2D
MWEMCZO@1*R">O:KW%6B'W1.74!;GZ_#\];<K=*+1F@J39G?J*6>U]U+B[E.2
M.]&X0L,8T*DI]U!,(>OD0X'C_36]$=*SUWLWPNZPL>+U.F$P*-F],$2  ]Q^
MSM(E"K> *R4:"[B]<C_%LD)R4E7JHH-$/Q<]WDP-S5)!U+0.);;#=WA^=*30
MN]'E[K51X53X"!/ #[Q ?*_0N!F,KLJ+L@!W8\_$?\WZ8TAOA[C?Q=*_"(^Y
M'F6>.>5+NCBS1'KTMZUQDO@$'++((O*'^HBT,3WW!GTJ[#J4WBH<5A]'W_V@
M%(#/7P F,@W14J)\=$2F$!!-2$2;E!GP$D1X*.>D!8MNX3@98NPOW0I'TMEE
MJ0C][\;W?Y_?#J=^>-X/ R@.TG32RRI+%U,FULI$I/*(+C-%A)11!0-.P4-)
M*/OK_F%<I\*%#J7?8=/@:_L9G:2O_<'@[>65[X\;^PP-:D0EK>&,(A9N"#I-
MB3C/!1'*QG*#DR1[J.ZGA6^R%L^I<*$#:7?867B)Z@;-?7Y>GV)+Z#V0$=&6
M-LC-9D8Y)SX*(%[8D$.97Q7K6*X[P3P5QM3338=MB9=@ER6L+T>7H3]L=KP2
MH4.$Y9YX-)STTR($?38>E[XS363Z9=."YNT0-\I96>:&?_*N[T-_4'I+]12H
MJ!POO?.#*M$\3:QGI9.?XH%G,-G5L58.M,!3(>]3Y$.'/9E7W(#I>!:GLS'"
M1/3C<YCT$(3W+DD"RJ)]#RZ@W%@)1H4,6FA@K(Y5M0[-J1"JM:0[[-&\Q/0.
M)7D^[Q(/T^D\#W%I^(<$@1L9"/-&H^%/+;$,/-'X\V9DCU*Y"@D> '4J7.A*
M[AVV<[XV\U JQ;![/_SD!_ ^7[=VX&"4%&CG,Q48D=)KXDM;'A;+F!^'UA^K
MPX=-B$Z%#)U(O,L.SQN7VV,Y =76$V]13WA8>6*U343+8&-FQ@3^4#UVAY<!
MIZ+\=C+NLLOS/41EBL@E-$Y>8F!SS(D8WW0LEKKD1 EB 3'R7+IKUDD870/F
M=*Y_]A1PA4C*^^D%C'\;#4>WH2TX>4WT:'0&;RSQ95*49+&TB<@&CZ8D1.":
M>UWI+G K?,^?&=VKH4;(I31M0V/VVF 1-L7(*#%EUY*<)>)HCB278)#*%L51
MQUNX ^0(1T(%?=V-H;00=H7;OH=7W(M)&V$@$N8TVJY.V)+%((CP+@8G!9JT
ME<Z)!W&=)#,Z5$6%.[J;LVV9Z]8?SA#D32+G"\BC,<Q_[[/_!I/7WU H^/S^
MT(^_-YLIKJ[4R*'@!\WZYJ]"ST0P02='J(VEV7/I493++"M.T5*.B=8J8JBX
MJ&=_=CT5A5<(#5]#7KQ;+V (3<Y6$ @* BE=S\H?@K@<!>$V)916"D#KI"]L
M '0B'&HGZ HQTGF*7F.G^P1)Q)1(YHZ7GAOHZ@4+A(ML?0S*2/-0L]#]57Z#
MX=EK>4]Q5@A_ONI_Z2<8ILD'5!6,QZ7FH'1.*G^4))<4%96$)LW+/&N)V)@E
MAK+HJ?.<5LIR>PC5LU=^9R*O$/K\#:8WI]C9%]\?E KQSZ.52K^+T0"?-7GA
M)_W8DTEFX2F0H#W:XL8KXM#H*H$;+P,-*8N'NE?MSY =@3Y[TM143(W Z6L_
M'J+],EGVX)NCRB8PRA4C/.50LN8,L<:4JQ_*K Y6HXBJT&4MG&=/BO9"KA$]
MO8OJ57\PFT+J<4U3L$F6L=NXM7%/B:<(4^?LA<'SCJG#*'\!Z.34OX^@NQRN
MM\3U#^B?7R"0LR_H]YPOQL.]S_>Z,5[' +0%%G&C(M0I2J05F814!LD!@QQ1
M$J#J>+.[(GWVE*FJFBZ'^NT*>''JN6B4+=W"> ;TDC(RGU-!(#@>/0-#*^7"
M[@3S\"RJJ_8].;:[RBI$<S> 76RE]QO()E!@+.(+W.#AJDKF+T414:.T%)9I
ME@ZZ56T"^L?D6"=JJQ *OM[%YPVWHN2@H[8D:FW0."^MMQS/1!E*T4I/*?I*
MU6.W<-1N3U?I#&LAS&/WIYN,IS?P/T48^G%_U'1=LBQ+F6P@FDI3$B$3L<&S
M,A<H!HC.^.WZTN$35NB W]VEPD8(A^Y#UX4Z1UV*M</3I0&TP/'[<'(%L9_[
MD!;-7K8!M4L?NNUTO@G.85O0=:2J42TY'XP$P3FJ Y4$L3 B=6G.R8,FX$UD
M"0\K^V WTB>M_ V]YPZI^UW$NU'G!VV!5,;/C.&BR/ +K.1ZW0+9JA_2IB<<
MH#G25HN[TRF),FNC,DRX9&5)!\R>2^MIC$)&*?G&3DF;'M9YVR0OJ?+>*<)8
MR5.&9-%W89R 5.C"\.PBK9,/W'W;I)4;J3),UB9P)(HRHM!01X)6G@C%I32.
MATSKE.<\L0N^7;3[P 7?+N*LT+NHR9'9\$;\!M/W^;/_-F^]CC\?@Y_ *YC_
M]]I1$]0%9RQZ9D;G<O>L41!HL1O!?(C2"6[K= =KC_W9$^G ZJN5+[=A!6]&
M8W3DA_/Y'O'[Y[$?3LHL7%30,#7?#>;U9>F_9I-ID>IRS3V=O?!.:.2.1Z$&
M7)"5PI"(QWY0@7O%Z]P\UEG/D?+S#LBL'8A](%H<F.PO_>3BS6#T]6^0SF%9
M\7*6IS#^"+&T!"VFE%^N$M>"_"M=!221*$@B8^G$;)(BPJ*4N0=/0\5<\XY6
M\2>Q#T6!&CW1'EC+A[FWAT";W_J /L$8IOUQ<_@MTM8^#/!=7?>66NXCTYIH
M4X+^IHS+%5*@D"&"1).(09VTP4H+^I/D1R!&A58[VTBU!T9%M.0<\5+B$2/0
MG',J-E7++#L RN3QS.$_F=A6915JR]; 6T+#[^9-0#Z4-D.HI^ETW ^SZ3R[
M:T,RN%-:.ZXE$8Z5P@:JB8L\$LLL4!^RD[;.-7?'"WGVWMDQ%5O_FE*Z8$6Y
MB@&:/$I&-I=TD4 "59JQ.GEW<L*I75.VX48+83[=:TKIC?<F>))MQ)U:"48L
MY6B/ZF2%,]YEMY77_>RO*7=2YZ/7E+N(]6 W5-N ^N-=4^ZDJJVNJO:1\\%(
MP $<58T#:II)G)E8G2B)+@:IFTS3K4R-IZC\G:\IN]?]+N*M$*ZZ7N;K?\WF
MH].O1L-RB=8LES/*(05!9 !?DJ98F1"82 Q:TF2HX[3R^;\.UC,^ +H7>P4C
M\ ZF)5&W %5U=N):6$<>G]A>?7<S^CN3?87-8CTX3]&!ELJ01$NU"7.X@T6'
M+X.T20)+BNHZ]S '),2VLQ0/Q(==1%Z!![?+%A<CQYP1'$'@_A=Y6:H,Q)?3
MC.G(3)2&ITI][->A.7Q<H0-%W<L@:"GEC;D$U;.:7OB!'T;X= &E#WB[_*7;
MGU4I4^D!P'>GMQD198Q2!0'2*UXJ*9O>5%Q'8.9V3M+MC^U^:%OPFJ/%211"
M(;+TA7# ->%@E59<N>CK-/GN/OMHWA#Y.AXL'>>2EE"P*I>XU%)B!03BRE1#
MD536J4Z+@=LXGD1X<A<MW^M=O[]8*V0BS=',+_6GUZ XE9F6^A_K+8+*@*!"
M+G,U<*L#SYBKU%-S+9S#J[R-CM:JNXV :PQ@]I,R8*7\IQR27_R@L8RF+_UX
M_+T_//^['\R@)QB>7TPEXJ3 D]((0X)A0-"MDC8P:F*E 91;P3L6*UJI\NY5
M1>=ZJ$"6LQA+T_!)&4E<9O^]&_GAY"-$0+SH=/\&TX5(>A9-:LF$)EHU(XH!
MB#?-G-O$&;I"VL4Z=7A;0SP%TM311Y5>:U\0Q6C\'2'UA*#&^*2)H87$O"01
MF$R)L2 #5SIE7L=\6$5Q"NK?6ZH54C/0'[KR_=1T3>LY$94)I0<6*V/FH]+$
MTBP)5SDSJP0P46?JZBJ*4]#PWE*MD"6QP+)L$+E('[JUYAYE: -%KIK,#80(
MFC@?&#')"AYIS+E2[LT6X$Z(#YWIH$+OW=M@HM,4,J"9DA)RMC0\<<DS LH%
MZZ1,4*DVX>14O[]<*_2;_# N/5VGWTN>X!1I6$S6JT6F(!*PU(0%0S*5%AVE
MC+9&Z6U%0>-&12D/H5H'PHVHGK7GV)FX*YAVU].Q EB3N4CHC/B$^TX9N.:8
M(CEXW',4%U"I\>3QAI)UJ.*]Q%C!CKL[!0T9=G\0FG9>,BX#26AUXFJM)3XK
MA4LV('+6 7BM]L:/HWO6-.A<_!4,P5>+FX_K7KC74'O6)N.D5B2I(,ND9T9"
MF;PH*$64SB26;15B;,;TK.G0D:@KF'DKAF=)EEV8)<I8"BDFDD+DN'FE@+:-
M2R52)2$IIJ.L4YN\%LZS5GU[ 5>P^Q93=0-ZFH$AXZ+UN %E!. BFK7*<1V9
MI5*Z.D,4CC6[N/-;@)U$6*%A^'*\8[^)&Z[VIYU?E=_,?V F\A)12H:7L!+Z
M+5:DC"9F\A2=2YX<5%'UM@B?_2U@%554"/ZOX+SKUZI$G8?H29"Z)%)06LA<
M\O"#LLH[[2H5>V_&='A:U-'C9K*T44(%>KR"<'W;($VD04 D5'G S8V7. <%
M @R4%>BB1ELGVV@%Q%$)T$HW]VS _01;\?[O@_]>[I>N47E0#CPG@GLT11./
MQ+,L"$]HK'C!C*G4=',]GI/1? ?BKA#P053C&:3[:^Y%HX J;4E6$6V:D(#8
MC+8J=5(&:T76E<K&-T(Z)2IT(/1:)=EK8'%OG4UE:S("'16'QC):QXFP3+.S
MU"1I*S;'.&$F="'P"D&A-8@";D><!8]*$DUUIB/!"4-X-L5[1=+2.L&@$]9^
M2S%7" 2]&PW//\/XLI@I30+357_J!^]* X'W8;"8(3[IZ92=@3(T-ENT7$(&
MXI(,N$UI!<&#@50G)6 [?*?J+G2OG H6Q;THYXIL2JA3*>ND#98$AG](ZLK
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MA!ZY=$QD5N>\N(OD9+3>2L05?-//I17B;/Q]Y9CJ!1><YTX0XRQN;(%[8FG
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M*:>2(9)'04H B4C!?(&I3*49ZK=Q=$@'/Q@<SJ+=7YCK3)<?RJ+2]*]Q,)I
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M"$2?E*1!&5,G?^ A5*VO*.,%I-E@9?;JJJQ??%_Y[MJ-[-$@O:>,$:-*J]:
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MDIU*P@66\5TZ!=9L&>'PJ$BSBTX:D.7ZO3<"7/52CQ0,,PRWW* RD8GKTFP
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M<BBM,REQ/N%!G*7*H4VX]@@TV1(K.1)+=E! BXY D]G\0_[D1Y>&F&#)6 Y
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M\73#=QI4:J"+!MDF-U>^'@51NLLLY@BD/V"*KL'<?X$!Y2JBV>B(HE*AHVB
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M;%0 TQ'@T^932VUL8,W>$=HM.#^A93Y._P(_'7!F)'"9T>^/M@R,*?/2@)$
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MNB%0$L*E(H$AY:RS(B>7E-5M:J@?A/6DJ5!?\!5-\^56,XUGJ!9YG:716,T
MN9D-E(H4QDD0-I*4C7=9)^V@R[&[Z=E/6IM5!%9Q=,;56:&NH\G,)<9$(LF
M*AF#Z.=S&XA(6NN@D6NBF_IN/_D$E-=+6)4G6?Q_%V.X#0=BQ-T CW@!1I5B
M,%ZR/16ARB4-7N9N$=$-CW[RRNLKKLI3+-8;@;[!)IMH8FA7JX10I,(]P#'O
MB/**206<ITQWV#GU*>FOM\ J#ZYX!7'E,7%S'9(3WB;K+2XME$ZO)5,_<$&B
M0Q\[H@6G;1>_Y)['/WDUUA!;Y?$3:V;9ZWBX%=)&88AG$L_DG-'MC2X2(T%'
M!LQHW674\Z9G/WD=]A98Y:D.:SSN.AZ%AZ^-AA.:?=D:4JF805!<B)"%QZU"
MN1T4Z$Y1@7L+K.:0AJO#6= ;.P(-1F662>8\XN$<T,&A@I'DE5;:RR!WL&5N
M//K)ZZ^ON&H..K@9/10W["NGJ(X2-W7.N2-22$F"1'/+!Z:$R6@N\]A!A?<\
M_LFKL8;8:DX3N+8UB!M;0V#,6+2IT*TI.2!"!^)$=(1I21737)JTPUXJ3G$O
MW5]@-=O]+S8'/[[P4_14Y8W]@?H0F852.N_1P'(.3^K +>+2%L]H%77LM)UN
M?/J3UV(%H=7NZ+\BEKQ)+"L<1)&(BJ6<$PPEUD(B0@L)GG.J88<W49[BF[B_
MP%ITS[\Q,_>[_[J"E:CE7F9+=,IH;+E8IG-;W" "95E;D7-H$RS?C.=)Z[ZB
MJ%MTPK]GW/;Z4M6(%#7#\T'G0"3+"L_Z! 0Y2[T3'%PC(CP(ZR3X4$_P+9K?
M+VOU;UP#6&842$%$MB7!+G%2$NM(-L*$%%.XL[?7*F2]#>4DU-]/P#7;V=^(
MF=R%!9XQ$:4FCGM#I'26>!X<R93YK#.HG+MX2?=_PI-69T7AU6P_?]WT9]<!
MH8'O:-*,&!X\DBP[XD5IDY:<--18(UBW6>)WGWTJ>MQ?8#7[PU\'=.,Z5@9!
M'</5!;48BQ(,;A,42/36\9!E4'F'^VMQBO?7^PNL9M_V NCSV66:VF7>VF4S
MI>7PO;4=R$7DV7BB!"N[?Y3$:XX;AW4I2&>2-UW*!#I_X)/7=1O1UNS@?OUL
MN!%!4\;39)4A-NJ,2U82ORH5+,Y:H]'HAT[999N>_>35VEM@&S38*V!UC6>O
M_73T\R,D./^ZGH=W'H9C2'<)^.GWM060@I>V5#FXXM\I)TG@"HV\P*GG^)?!
MPF[O]1XHGCPK#JB$#?SIWX1]PZR 1=:[Y<(8FI')O-C\#BP)#K<FJC(S+$7F
M;D^T;#BOX:2JA&I(O&(VVT.XWL$8'[YZ0[K@:ULSM 7AD:J'JNBS TEZ*Z-%
M+=$VG"X"4[%40;O2*4521P+EE!B9LS LH^MRN&VD/5FVU1<=A2N[Z*!R$0.>
MCIPRNX:U I1-<E090XRRN'T:JPANJ'CR%:.7"AM"I\+CC0\_@D%15?Z3FL)K
MT'MH WFI3& ,#R0+7;)!@1+O*'Z+]HM.*7+EV@P*/%TCH:>4*V9,;T:TXF(7
M3&V;!VY =1PSH*_&'B1 #W&WZ!RX"9MQZ,8(:@A0@?Y3CH$XFB3A8*+P5&L>
MVASTAZ/ EL/]$ S81<H--/]P/177+ CG!>&RC$['TXAX'PWA J3)3'OFVLQ!
M>F2%;/TUMU,9VRYBKUQ>_'+R#<9^U50K@0)EA,4E.3SE%$4<*7#"'8C 8^*>
M=HDG77_F4S_.>\FH<N',&L>*CUV0;#ZZ']3:,8[@?E+>H*H>(JKL/]U"5 9'
MF>PL,2;B>1),))9[CPX !<.1B)#R(U'6/8=E*UWM(IG:'77C_,*/UG@N*^2X
MMUSC8D*P>/+'3+Q(GM!RL>Y"V4FZN+B;GGVX ZVOG"<5A53YY/H(_[X83A=]
MNE[,/N3%W8Y@Q;Y85\C1)*PWC&A-2R:RM<0Q*DD*"$T''T/H4E*X[7.>I#*K
M"J]Z#[P;V-9E<TMX+\;I\]ET<O'E[",4"0R7 U\^Y%LF50C)L'*-IUU(1'II
M""X'V2FS-6BI11FZY'S7P'(*!&FOA(I-.V[A+^/S_L^%G\YA.GLS&8T6PY/?
M>_QVZ$<O(O[>;*&/=;,_R9RA2'5J#8*V 3<W#KBE9<&DH>66N$OYX]X GCI=
M&HJ[<@N/:Z#S,,_/_KU$G=>@\?O1, \A^3NH0T#,GF7B *%+H8!8Q2+1,F>3
MHK+9Z-U(LB."I\Z2E@*OW"CD&NI/PQ_SLQ6Y+[G]?]:H[Y([\!2C3(ZHJ-$T
M7G000\F10)GCUN+W?L=3:$<$3YTF+05>N2G)==2 <M@)=V9*!2L%83ZCN64A
MD" ,)12_=(Q1']B.MNK.&)X\59H*O7(HYQKNU\,O9Y>P%Y853,'GCFO0"8]/
M;Q:7AY3(T@O9E71$XSU(G6RR,NU&G%YXGCJ)#J>,BCU9+LL^SB;3^6>XU?S4
M*&Y2.2^EU<7 2H:X*#T!+ZBR2=&8VL3T-\)YZO'@>K(^! '6-Q<=8#6]Y+T'
MV)'&Q/57W38R])![@SN_^^!Q#BHF&8G15)=2_3(&U5%B78Z)2B[ M)F-?5 Z
M;)L8=S V["+N%G?^D_-SW"_1"?_#X\:Y.K*$ "NMU_C:"%'B?!F/2RB@:**:
M*9>,:L*!C7 .?]-;15FW[_U[2[IRJ'Q#6V0/.B.<2%AFADB: [%).F(E,Q9,
M-#1U;W5YW![2-55805KWOKK_^?=;(GF'WR[^8O'SLN2/D/]2_OOGQ[>7XOG^
M_?O?PF0VGXQG<8BV"]J>\6]Q<O[WA8P6)=ZS5S#WP]'L)H39\/SK:-M]_<U_
M__<K.#=AKAYR0V][ X,?\Y)<B:;P,/WCKT.>@A/*6&5IEDY:)W3BW'@>4'T0
M]>#FH_KM@A_PA?1E$/CBH>G%; ;SV;O+>=-*HD7H#!#%R\"?T@G,\M*5#ZSF
M$4\%!6U&*#R,JW>2-^#SX.9G+"/V+R?C^=3'^8!1%:-.FK@@\<23#)TG*BQ)
M/.#_T*$)M$T)_G9LA]]2*K+D3JYW7554/BENH4,/^,T0/>P(RW?PPZ(LZO/D
M]>(-'B@K5+1<EOL=3R0K704$RP1M),THEU'I+E'PG3[T),C05M0-C,>;,G@W
M]&%QS_?R8CK%G1_/1TZCR'C4*A%+(9PD+J.5$XW61BB9*+3Q)![&=1)<::""
MBG>M6]#]/AG'%4 FO1 *K5X1;.G2F%@IFM?$2!JH]]*8V\6J;3ER!>TYT&1/
M152\<=T,\+^A1%Q1!-_PIU_@,I_@\EQD PH^4(-XHRW,+N55-F<4#I,R\,BX
M8OP Q-F.](1Y5%E-#8I?'\3[:CB+I6E#Z8_V![KFY340C#E)O<%S%"R15B7B
MLXM$H<!TDCI1UL;@W17I\Z%57S4U*)JZB?<ENKL#$1PS0)'HWI?E^T1<I)9H
M4)9YIQEC;2Y4[F(Y86KL+.J*-[2;$?WA?RZ&P@Z\D1RD#00H*[DHQA%'N2%:
M<# 6+7%J#V'MKO&<, GV$GF#B[6/99OZD/^<P6*M'\+<EZX@;\>O?\2S,BWX
MS61ZC^$UH#QE1X,DH#A%SZU,JO=H;DGJ2L#+RRQT$[;T 'U2E#J4\N[R;N^V
MB0\%BR[!K5^.5Q?P._R8?YR,1B41]SN,OL'[R7A^-D/X D(.Z 4JB"4=RA.+
MFR91BN82,6")MSFJ>@(_*?X=4HEW.;AWF\==X;\=K\#_"_ST\_?)("6N+*=
M1"YO3/"9!"C.9I3<* D2:#HJ^6XC?I:LZZ6VFL-0^@%' L' IBQC1NC,H)N
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M7II# R<.E4/PT3GK[!-/LLGV5 '\84=V-V34[6WMT(IM<"1V6<+"XWPQ3N5
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MGFDYD'Z'C'7O-Y3;[M)QC&, 974H)0.=<@JG&S7$19E)\$8:995+JDXS@ '
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M%#WDWI(.W:ND><M!#7SUX]14QX8YDO>KGWY_/Y^5,&&J3$K1:**A^.:>"1+
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M;V6EI#$#[U%HIR;9Q9;7JZRO%HKU/K]MSGU*4-\</I?*OC?%[0M@',:HG/P
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MV0J[^L?KL(#_NBZ7,=_PCP*L&:> X(-TDD!S[6LA$Y\AD3)XKD$IS>I$ANX
M= &K_9 BKW 4W0)K3=$NP*I:_3NAG<;P'T2!CY.BA_2/LU#<^"="9Z\X$.V-
M(M($3@)8G!!2>A$\FL&ASF7%D6GQB!-P7%;L(_3Z;%A')5N6;,B1D9@X;HY1
M>6)5-,2:9(+0AN.?QV#"J>+"!U+7PR0X0-8[X[*JA)5^7,[B?WZ>3?!%BQ((
MM/Q^>#3I[F<-&$3:$?!6[&B4PGFGC<F:HOB5-S&4O$1?PDEYC*/=C^TW]UY.
M_&+Q+C>/?WM[00H\!&&9()HF0:1B#NU(M$B"86"HXH&&.C> K7 &R%!9A50W
MCVT2RQ?K L'_#6D4&*52<$E"SE!R0_&K9#7)C$)P5 @F>:VLE =P'7_%Z<^%
MEB24H21?(1RT#=V;Q:+4K\0W,Q%2:1)L:&EE4Y987:)5%6,H#\6X.1HG5I@N
ME0\'2+Q.%ML&LE<EY@?7Y]+6Z#WZ=[C*^RL8H6\=@Y66:%:JFBKIB-/6D9BY
M"SK&X&(Z BO:T5T>/P;00H7;K+L8WXYQ,TZK>KC-#]"Q1X\^*C2I0B0T@T0S
M'3UZ3U,BR@7'D-4IT&,0I17<Y?&DOPX&//C^ 7$6 =*B5'@O2UQ)$WN77\ZF
MWV"^+'5K[XYAY(!Z$-R6;&!<_SB5:'T[M/&-UC9:R96NX_CN"?0RZ%-/-Q4.
MTSJP?94.$:2 Q(,FK/3>D]XKXIU HTHS*6B*)NDZ_4RZ(KP,\E301DO=H+ZL
MV4GG3S#_LKBA^Z*I_PE..LD"8:4Z@01T_[UT@A@?N>1>9./J>$#=,5X"<RII
MY#YW>C?[:+?#2G&VQF8O65GO_3B-K':  X\D1(K2" #$-@D3.2=O-:6&RR,:
MQ/< 7@)K:NCB/F5Z5RE;U_S$L=]"'%$E<T9[G/ 42K%/$8AE7!!@47%F ^>U
MS.#[8"Z""CUE?%_MO1MMK(LUMA[OH(VME(V&@,FA-(O+Q/H$1 26%$M9!:AC
MCCP ZA)H,)3,[].A=R^,#6CO_?S=O$2<06KLH9L%:Q1PA+[44S1<LY(EA1 3
M6!) L1Q-9-[DVK38!>["Z#&(#EI.VWH?O3;H5B=_KZ[GX^G5JM?DBLZ_PY_-
MCQ8E,B(I;DJ1/5FN.P40%P-''UX+:7@0?KL,T%!W@)WP70);*FBBA3#][X@W
MSHK?S\?Q!Y6E\<D[M'N2*U7D':Y]#H0BVGII-: QM%WS?RB.[()T$;081-XM
M3!C@_+7]\.9VT1MQ]*Z3D)Z8Q$T9-R/66%WR:DIZIT!/O,X&\RBT2V#&L/)O
M84COH]<&Q0?X>CV/G_T"?>W9U=Q_^6$DK3+^V4A9C8N7BL2#QS5-6""AW$ E
M!UX;3H/-=6HB=01X"6RIH8L6SO0/6&S%^?MUD1<*9,O,_C3[!7[\<AH9+I@+
M61.?!4J(<R">*4^435Q;YH.1=>(E>L&^7'[5T%L+ZWJ?T=XX]+_.YC]@W5U,
MP3NC0&LB:+GMU+ET-]2! #<V1QF2R94B$1[%=@G\&5@#+23I?1A[>]93COK0
M$'>!9>"DG.@1B>!(X D-<<,"$RZ"B'4RJN_ N 35'R[7%BWW/C_]5#J?7L^_
M;QSKC'B,WB:1B4RNU)/QE%CI!1&*YDRI-+%2O>06,)>@\;XR;M%[[P/4C_$S
MI.L)K ?ZR_=FV*O$$,ETA! TL24=1 ;MB:4V$6I-#()+:6KES>P&=:SR/15,
MA8$D?2[E>YISO?*@35&ML@2"ELJ (;0)$&>0B;69$VZ9]3A0-*?K[!$[(9TJ
MXVHPG=\S.X>0?84XQDT\-SD_'1!5S;BZC^E$J5;#*&W[N'T8B1^'"U91+J2.
MQ A5BF.BO>.I9$2#U1YHU))6NI([$@<>RZLZ%@7V$?3 5?A?*$5_>_G^XT>8
MC]'Y7:?X1&&B8+A?&O1@2GB )-:'C'I2B5HO1>);\86MA2%;'WY:V_ 0B<^&
M%%>%U(0-_W,-2'*>O:&:T!"0G\X *<E>).00?4C625KG'. >E)]6V\,(]XAY
M\R$Z)9-'6,*A3^I"*24J#4D9T864HY5'28$\==Y\-2MN +E7R##8G?G9!=AS
M\OR>"NR<)GV(](^:/*]]<C0ZA"44 BRAHX$+2\H-?4DD]38_Y>3Y.JS81^A'
M2YYW20*C61(.K,2>*TE<HJ[4F(F*HR&C5:7 F7-/GM]+79V2Y_>1]8"F8BD$
M],%/K]:EA!*/"FU3XGCA-EL%=$4B?&81]T.)U.^B\$XUE6Y?>RD&P>&R'+AD
M6@-BS:LN, :ODK8!X/B%T0Y4P;82>\AOX!)HFW!T=#PP7!S "N0E,[A,,*1I
M9,$@&DB6=DJR.0\U/E#H;%@M[B.V@;7W&TKJR_67-9 4DK1-U15<2(C,95@R
M>L),]HE+KGBW1F*=]'?GU<?;/GL)?S:$Y ;>('_S?VT D3H:!)Z(49J7/$Z.
M!B!^A:Y_T)(!,-VIZ'0W%6Z^^B=4X<&2JWR2_?;V,C#Y9"AX2Y*GMD076N(=
M?BM28IRJF#K.R%Z'V6_K5*G9G>>EG :5DR"AE(F7V5$2@#G"I!&.)ZN#\Y6B
M6P_(N1OV0IQR:6G@D>12+%_*DHC-)2 7(23C!76QSB%HYPOQX0[_&'HJTHM(
M:!*2R*@=\8D"L9%G%936SM6)8NYT^#?DL467D9[#J=:08_84E'#"(']#(A)
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M#JOT]A'S8+)C&AT8)*0TSI7L=4Y$RLHP$:T1=:HO'FV(3VX>G"=Y*E08/<)
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MMP5<E2_Z$O[-%#URW)W0#2^/>UO^01GT7^/%*$6CA?**).%0M+&$:'/\5OB
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M$_,L*6U-)VOYIPN;&]PP'D3$=53>$ES2!=23BX_;2U.=@J0.$?/1XN.XI*X
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MD2,:C8P9Z06LR7[+. O1C"!!)^50MMZD+@4[A\#R!,EX$C6V\+!75? "9;J
M#]!DZGR:_5:*[(VG5W>LV)'GW&JM).*2Y3!2*A*R,(198))ZYMEV5G][?G"7
MESU1)@VOB!:JU+AT^,'R/Y#E+_TD-O7/IU?W%MQ7XT53<:8LRJ.<#$#"0?@B
M'1D B'/1$\A9YN298*I36;8AKB8.&\(3).II:=!"Z(.O.089R8>FL?*F-MY,
MXQS\ D8\F.RC583I<B--(1-G+!!6VH0I'ACKUDGKN/3>/:!GLI^4(BW4KW 9
M<V.7_'J-=@G<_&!UE[3X'?Y:?OH3)M_@-]R2/N->%'%W5RA$ZLMI*S!5TN 4
MR<EZ12%IPX_E/>T%_)G*1U%Y"V4KW.@\B/__!3__].=LA"*!E$2ITU*2E0IL
MIZTC3(F4$#A'D_L<F+K&^TS0F@INX66%BY_'82/18"2HITX@=[Q6"8&'2)SP
MEDC+@BXFD-WNKW-"9A;$S]RLJ^06=E9(&GD4^*^SZ_DHFI+<204!0WGI@BB)
M+:8*\R8Q+V7BVVU_3D?. OB9FU55W$+-"E=)C^,>?X.1-S3@4@]$@RP9H@$7
M?*\+>*F%52H'=C[41,#/U*RJXA9J5KAB>A!WP?SK>!']I(Q@4;I @<_+TA;!
M:@W!19*!X_(O@T.C&02QAF7+E9$^'2OQY; 1/)/WN"1HJ=#1.QGF8_P,Z7H"
M[_( LEUUCS#!.Z6")]J[DG2A,W$I1B*D3DEG7FJ<5N'U\&,9D.%^,OD)>'UB
M.K15W?J7(M*T_+<XF2T@_>-OR_DU_/AP-EW"7\O7JU#F?_QML:H(VG=6W"T7
M^;O_LFK_S:*W0D,BHI0TD<$K$ES0)"(AA?8\VTKAH.UX3M4[YM0DF0VNK K5
MWNZC6I>F[8)KGZXS Y#I% UHAM3>HX3H(?IC4H.;4EV8X7KM>3FS2H)XXP*!
M%#FG1KDHZW2X."XE=K2D.04C]I'XP'W77_\%\7J)AN%=<.M*TS9J'%"VA#:!
M=." .*H$.N R*R<CU:%+:^4'7W)\^WT8/<QJ"'' <K*W78"GS8;89(EN5I^^
M:53)E7<I9V(%X)BMU\0"M20%YQ50YYCITI#U\3==@)X'%N? 4_F/_WN#=,XS
MY<$JU%0,1$8(I;"4)< L>*=%9JQ+"XS-9UZ  @\6487RJ+]<+]!96BR:FG.+
ME23+#L,MM4K9A(.1N,,(=,AMBH HC<E22S"BSO:[ ]"S?3^8NH[$HE41P]NY
MT@%@54O_48BG,?D'46@'DO371@7C_W&@S!HE>.GJ))H"$KB1>5NJEGL5O8M6
MZESG_.Q$='G$'3@-6_91PE%JQ:\R!IL(\I=^"5>S^1@6C2 $2.&]HX2*7'KX
MF5)R5WL2N"W5[DT(.5?ARQX@G[>RJFH=L';W#=066.NIT058U6UM)[33;&?5
ME#JKJ9$*B]9N@!0]F\!Q#:5HWZ/!S]'@Y]F3J'W&>2F5-?$2J/+(5G9ZINRC
MB H,:7JJ-9DK/B[7SJ 18+EDJ#H 6CKFE2RGP D.MK2A3@HJU<UN 7-\1WL@
M5<V&E7.%WDJWC5)^^7[[Y?\>PQQ?\OG[6_@&J\[C/#$6'(X:&"VG.)P21S4G
MW'IAJ10VI3I7;-WP/=LQM90Y8#.(>RA_ [^X7LE@<1_OC7_8 6Q5LV8ON*<Q
M=6KH?1>UJBFMPKZV'VB5)</U/!,N99EY,A''$3Y+.D;/O&:J3@NY,V#8(Q;2
MV1%L'UW5)-:;Z=?KY:*1 +NYW0)AI6"<!.LB&@@YD0">E^9.47/-512^+HWN
M@SJ^ 551G;N(TU,7-8VK#6A\#<U[4-$+3S('0:2G#J$E01)3V22G==1U[.L'
M0#TUFARBBR.M)N+F^I1*T#F4WDK%WTS>E!*@BD0C4XJ>4\_JG"(^ .JIT>00
M752XV;I[^?L)_U6SZ2($87DNW0.+0QH<^HX9_0?CM$\^YFQ%G86D'<^S*S:4
MLBJT2KN/:CUENN Z8O3C#V3G$/UXF/8>)40/T5>/?MS QZ*E5$146I"J;(Z:
MN R&>*YE$I!\K=(8QZ7$7M&/=1FQC\1K7'+.OL!B.8Z;$7M2X&*82N\B')P4
M@C55UX@T*2J6O7"I4GWO>UA.'71UJ)ZVKQS["7G@L,B[86#@?39,$!M<*5K%
M(@F:9@+9F@@>_R^V>M*=?:1<3Z7U$M' 08W-'<*=N,O-:$M#65!:.,*8XNCP
M1D,<18=7HF/C?% V,]%!=P^^Y *4.9P0![3S%_/EZ$.Q4IN=Q:/OZ2V^6BGP
MI1&J+B "<9Y'K[,3WG0JN(9/W5AN\;OMI?;.:Y^X]7ZX"@;L17L+XN9TH@.,
M?6SS[HP8?KX_;H+W4,&V$GO(;\!%>QN.XC2Z$!()7%DT&85?G4GZTHE*!&Y2
MZ-1#^#S4N,-L'EZ+^XAM8.W]YO\:?[G^<F.FF6"%5$"X";BN,-Q]@L553N/.
M$%22SG<[;^FDOSNO/M[&VTOXLR$D-Z"!VP!!4?T 0FW0BC%+K-2 ?"S#H1"(
M@J 8C2E)WJG$0S<5;K[Z)U3AP9+;.0O_Y]^W1O\6O_U?_V/]<?DC^ 7\K__Q
M_P-02P,$%     @ @X)75F:V$SRRRP, +%\% !,   !B<W@M,C R,C$R,S%?
M9S$N:G!G[+QY/)3?_S=^C;&O*41DA.S[3A@M0I(M6Y:1?<E.EC B1)80BD(A
M),DN9+*GLLN^C;%DG[$.QLQO]'DOW_W^?'_WX[[_^-Y>7&?.=>:<\SROY7J]
M7N>ZN @CA!G@U(WK6M<!$)%N@&X   $I%JL>X.P  #HZ@!   )0 .4 #D!!K
M?,03&]!I $RL@X@_ $CRK_;'(*G?=29B_4.T,T#ZNP] V;S, 5 0/VF)Y\8
MP'B=8_GWG"=T0B=T0B=T0B?T_RB9.+O;>?C[<.DY>?AZ<*G;.?MZ>'-)2HA)
MB$E*2$A*BDG*22O(_).]I"2DI)4D))4D);DD%)1D))5DI0" _"GXSZR$D>,I
MZ5]UB>2DWW6PA 0 )"?_7<\!_9W=_)VY4)TZ7NU)YG)")W1")W1")_3_-OWK
M;$-:3DE&XC]L(Q(Y"/Q'3D%.+,X!9+_K .,S$/M?]9<@@3_Z$#,1$M"?=T\8
M\TA(_JQS3/X!;?V/\W]\$D8(X\!5@)*<G(*<C)*"@H**BI*:EHF.EH:&ENWT
M&0:F\^<@G.?/<7!P\8KQ<W&+\'!P",@+BDA(RLC(0/@5512DE,6D9:2.)P%1
M45'1TM"RTM&Q2EW@N"#UWR;"%X"1$M@D9E"@"P )(PC,""*T A#B*LE O^E/
MX8%(P*1DY!245-0TQ Y5IX@<@\$DI& R,E(BLZ 0XO< *2/9Z0N2E\G/Z-^E
MX/9BDGJ8])J2YTI9$[-!'YI7VL8[G(J:Y2PKV[F+?/P"@D(RLG+R"HI*5Z^I
M7]?0U+IA>-O(V,34[(ZMG;V#HY.SBX^OWWW_@,"@B$>14=&/8V*34YZEIJ4_
M?Y'Q)C<O_VU!8=&[\HK*JNJ:VD]US2VM;>T=7SN_]0\,_AP:'AD=0\ZBYN87
M%G\M+6,VM[9W=O>P^P?'?!WS^2?]AWPQ$ODB(24%DU(<\P4B\3_NP$A*=D&2
M_/1E?8J[7F>XI1Y2,EU)>EW61,4C;8!FMO'NHV;AE4%>Q!RS]INS?XZQ\/]?
MG/W%V-]\C0&T8*(1,H(9 2BP=R  O FC%@ G?<(\PUA87$N['V#V@W&_)I)-
M,R0_GYV^3>4RZ6+BG=;,V?=E%5R]%A\?+K"]G(FL<=:]="EU3.5R3Q5@7HN-
M]W&5-N]YK>Q/(A9EW/2LAFI/WCM;_N9NFPB$,3]MH5F^WS;>W>KB?7G>9U/C
M >Q2NF7@WMDP'NCI^00%NW0-VF3QYUUD37#!&W,4^]=93X/I[R\JRN:68L=T
M3L\B36YI)=-X*$0HFG$\\V<W<?X6_UPT2WH@%JB"QFR(<O5SHF[&<QYXB.DY
MW)V+;[H,O%W@_8@"K\3F%F'']G0;,J8/.:$3$T\<T\R3"TV+/*^?>GEO1!><
MUJ' %R;L CFM4S4_6?4AS5'BYJ_W=M:\UXQ%4"[RH-3T@49U%Y=&T73=^F36
MU1R_V#YW\Q^?1M9-%6E8J:_:.O+S%.;0AFC/.I<W.''UAP[FQ[8)Z6XVRK$L
M.K>#? @ T!$JLTT SE_V+S0?[R(UQGRC7\KP>F1='[O-L9M#NX.-\5$VD3;_
MA7F^UA^HF3:?.LHHGPN:SVY06&DB]4F B;>R1WZ*(NMG-/M 5UDBVB*@ 7J.
MHO26BU1IW*L"G)>G^! #LF8EU[.=T._UE6[MW<O=BS-9.!JE!AEVZWI824]W
MI"?=T?;A2P'%WZ5C35AZD?_T6Q\9;'(SK^@2HCXB81 4.MW^U"K@_N'MJH><
MYC;WQP,1TO02MT \*;^"C$,S4?5KMW;<>/K=WCQKXYDU+X!(I;-VI":]>O6%
M1T4AARRE8ZNE@+=\R2NDJ%^195),ZUN##E_H@J=D)69P\#[\U+K[!]&2A*CF
M!^%?G[]<FSJG/J:E=CM;7/GA\/A3^JG)^>0Q_JP+3#_"&N[6N*FT/QBL!/35
MR)C^+!@S TS+G&POXG=O!T_?47ZL:YKR5O77@1XXSJMF2EUY,6EZJ%PLYR>T
MTL>5+'VTO/[FDS3#[!>U'44;XU-APO6N9=>ZZ_QB.B'UEY.]0VV'!R!SAG:6
M(8ZU]\/;KXD8GY'D$.0'ARFT3]$'=@&ZKGQE,N^&)4UE!%;]BSK!RK99](HX
M8<6-*G'>]1 ^ZULS S>SY;3 "JB/X'V,VIFORFI[-/-\V8<-+/%>O8DO;GFK
M=>*\-HP_G#OZD)IC;F+W!,3Z@6FK7H4 U!.-7+A)K%3Y04F);R<WF'KIVZ)3
MMT0@Z E#RU2N\1!O?0!==?*/]V9O2$_GH&@U+#( A,1/2[>X4Z,;>BSSK)X!
M;, N1T;1 Y;ZBPVT3T>I;D D;TV&7WU*^967 - !6O,K4J85RD,],N7QCZ^D
MCE"A%.9L.0M*E=%7Z>O2DM?-;956-\%D7T#[W0 >@J\"9 UA"<YL]WS7WFMN
M\WHEKIB_H?2/47Z.Z]EP8\/] @4_UB:7Y)N1BZCT5!$,+FSZ&N_S<M$C" AA
M^E?:^5U0?CO/IGM%PLL4'0#3J0F89+'LZUP@@2G/0;XG+JK1>"#CY?H7%)%:
MS /W@5!%RP*>I9NZU$M%4M^NK5]9&^M/INSVU'BKA2K@"^.M1T^]"O3=DQ()
M-['^87!%2@V "]DC(GWK'6F3/EG'A57,(>NVU&B@43*'13=37LQYUTO9K?44
M#/9!H]X7F) M6C9I,!S]'&,89@*:D#KR:P[(UO)DO;6D<JD":&)_-D/D]LCY
M\RP&G=Q?V?)XY[5X2N\1@ M+:HQ:2#H^HS$#/56/>CXIK4[HG:&*BMAVOH3S
MXV;?7W7P\Z>HL0CDD,0"_X<*ZI["D3:>CHOS=4H<2I7OJ+=7>FIQ;3H<95VL
MR?PF5_N>S9W[#R7_[PI0I#]25.A@83FPWUB>7TK\Q69*)!NX;%^#)[N_\MZJ
MZ/9WUP?F1L*G3S.Q\)?ET#S3 ZD#3/^KXB8< 3F<[NT%__IG>*'=K^KBFS+C
MSC:HC)E52+*R)],][PT?@[PRC5V@J45F3#DMQ#Q?"QB14.:<#1/Y3[GI?!L[
MQ9?F?%J@U_[5"$#Q21;XO,6OB0PWX[&G6XP+#.#A>;F%=0AC18P97.5#N9$^
MBG\$YJ,(3A"B7*NRR_2Q4D.]FFGUG, \K)__@FH,ZB7+5L)<3/]1;1)S6:!/
MU?30&I7=GNT1R/PM_#7*1G-4B.E>0@,G0K\-,/T=!+D76\ZIS+=N39C%\-8J
MIHB-N -+V>K,WE/?III91=?>,+;&W2]<:\JA\?V7DM+?QP1.F3QO=-SSZ0*T
M_FB_ZN-'EF=EMTEJ,>/X:9N9,F/=-9*QN6PL=<+^*6Z1)^P,QX/%S1RR)[HQ
M>H&KP[<@ 8%?;-@'[T,B=61_R*V\R+_=<S.K 740"T2LE7<F5HS>G"$ ',_C
M-71AF8B[8\7J?B7*6\)+0^]RU\_XCD 3NA?'\P$S>7_&E,61[Y40! T5N>(B
MA_S=+^</!^SP/8-?8O4YXNB-+.X^VY2Z%-$TIP<>NU1HG^8TOY4K=&/\(["^
M%K6J^BD_%G\V_ISU4/?HT036&%5:=A 7"]S+J,X^]=WJ,E8!^BVSP*7Z(.=^
M]821A#^']5Q2.\,A7YBX(62C [^W+0/\D4P0"V'+998A=19G:  !\+[(_@H?
MJRAKWCVXCAB\?#[/$;NN>I\ -#(E#O8"=4I0^?3T]'MPA*#Z@9O..XW!<T_P
MC*_XUS@]1GGFU@7+O%[:JD@?])*6Y 6:NK)_SS2&M"!^Q!TR!\_ ZRL/^W;'
MO^MB\=73K"LJ'T6@3,M0VEZR7V(7ZAXZU*1>C&E<R;6#M+\)N=*OF 7V8GMU
MYL&5 M_,D/L)\!M W%2/"(FVN2!'VI?3V>*)5H$=*WHE'_(.<K5%9T6S!@Z?
M#R_P/L1=0U.H "J*.33WA^1V8Z])OBS[+EWF8+ML.I>BFS7+;C<M\Q"DP/D^
M:(8^#].K1Q:RYV]QG:X2-FU-D_69XO)XZ;Q!DST90N#1IQ6>Y!^A>5MJM)\&
M5]_/,>IZ/Y&F?:^VGA1=GJ [(ZPZ;96V/JM9LCTZ[7R/Y8(2AS<##X8)Y/KC
MY]QA]>[3B"DMMJ\X ,#[T;6G/@C-%-NY:-0.[2O1U\5?FSZP";N@1%I6C2R<
MMJ3']'@O7]K>_/:P6RE< <5$)W\MD.52EQ3K?,\W1[7QQ K.@L02P"+AF[F@
M8QI)"D]P)\WU=[</R%E1RPQ#K]Y.A938\?65O+C%9L[6K<OACX(^SB'7G:43
M&M/*S=B5"6"_%^N3"A4G $R(5V;AZU.[ F*B^68V]R^9!7'2 69_:G\29FY6
M*/V-*;LNYW37MGXG3BC'34./C?J>:(_.B//S$$6:@^R"&T"5\UT/^\]O=*>@
M!YVFZ_X'97,_,P"A_/8B>Y=YQ]IK7#.+"MW2<0>HFCN ;O77K38..1,&]D);
MQ;''.0?A_H[C;ER)>JF\I[MH>5%W8VB8=SK=$4]SJ VQ[E/&9@:SLY>>^BO'
M8D]G[PY:RQ?P?"SBJ0^1*8>9O=<OFW O&9 LV[%6-%SW5OD%OB7XYA6XA5NS
MH.YEK%W-??3IBR].A5&1?6I2X AQ(@%Y^?@1 $[T<UL"D%5!>UI"T6AEXFC5
M]Y>+W(/S*@TK]7G2*'(M4_<#T/@O 1!B3-Y$I[J]62=[:VIQ3PLKN-\S!]HI
M@#M:6/@\"!$&#RE ?1'/]Q%W@"I7>U>;2%$W5*3I?+4 >V+1CNI"P;$[%?P0
MP\V4Q#RX8\Q&'B9$P__0R_G2]=P\CZW" W_(*]'(ML%F?3_*^*1&@YR9Q%8_
MU-+7A3!VN?BW$S)KLL_$'!6?E2_" 9]]AF]O8\=H-)%14[RQLK95MZWIZ?[A
MYTCBQDK>&U1*IM6^"I!4DT\]0#W$_J1Z/;3Q(37B*'Q:>(]#^7D/=#4NT0$G
M +XU?*NZT@;3\4)W*K73$6JL_/,=D&"6&ZFM.>-YZ])3I1G_=V]W V<8[%TL
MTKC8.A_;#K]6P F "(!=ZOK-"LNO?2@2,I">5T26E"XJT<4\1*G[9\UECW/R
MA1R]9._"7<?-[X^+MFH2@ D1><[/=;O05$#C*"?.BTFZ,R+NO1TM7B%OJS3O
M,*VL77+(3+'G_#..O74E/3(^-,[G!U_6?2U0YR&K!'B@B+3&8F_C=DDP1W50
MQ?35=U-%=@(@H;6(&NQ+2>C],%EXV:S'SK!\2M!&K37#H!C%DK'HJJ@HO75U
M@O313 />%^3P+^.98.(>B@ \."#&7]E)GBN;4N\2\A. '%H"L&;HW>8[[O^I
MPRRQD_) \G :?4JC-F=I^"P,0P "5J/?R\VU%RQK_(!+JIVUK@D?8HZ:8IV-
M"5V^_EH-1Z:AFNOHJNS9XYG4\(B,UI-*A3S(KI?4YNAM8&YUU:L,B5!GO=;(
MBEX6-J@>Y5Z>A-7$M7#ST@HYK;ONH /:C_AG()G[<A\GM7R?<M6F1*>SV:A(
M#W/^%*E0)_%(NQ:O<=^:## ZNR:/"S+7EC^\IUR)Z^%'D[^6=-F<(AEHHJN>
ML)%,ZRGE62*ZTD6=*-V=31U5;\KDJY416=1Q@C-[S,IRO>9\7R\D7%QYI):[
MG4/E]!\$^O9ZS*T4>]$?_F=IX^^-V^TS< @2@-'HE24]6$"+>GE5=4/64AJ5
MECU<-)$C(2"'$H'D/[O90I]=+IO)[O!"FP-RC11R^"O.JZE8_TY>*6_*G<FI
M!NO49&2*ZTL"0$V\3MH 2RD7#Y)]XZ$^32U2+4GKW+(O5KK5&D-YFQYTO??K
M+U-"EOLY3GM-QJCLSU #U@-ZK9@>E5;D5]$%K:5?Y !.<.GM:%Z99G7??I+8
MR$1<*N0.D&;^V+KCE9!&_=L%,/1&Q*&: @'0J,D(?2Y4K[$PDD.Z65J@F.;[
M$/J)<@*^\0;ZE)G76 ZCBLZ<P^.B?4(=PD3Z_K.\RW)59$[J;.7#N&B?M+CS
M'0FZI9?WJ:/<Q'63UKZ/C-6DM?+=-:Q!<'A]I4#GT#BP/K^;>[4[4-^H.[5@
MMZR&XJ<-L+NN&K&90WZ>;V21X?ZGU1KO,-4P>2:4S9?D]!JMY%OR41VP#?#*
M 34 *_L1M"Q_S?8M#Z33Y7T=A_?45<\]DWLVJXY>65F/Z#VEVP"KJ&]#TT<Z
ME?J'[P!=%)8ZZQ^^^#\IWD*G$X\V?CF!MO^9;)!<M6)6FXX,93XMOW@%9>,8
MI@;M@:JY_$S(]7AW9WQRG$52L\,=&=';2[;\7V#^58 2F;Q/6<G8*+'H>6D:
MW6YG N1]P2.]I/\G,E/J<^W%+/%O/V_W-23E<J<FLNT_%X/3+B2W&"0:EM5\
M3A#4Y^6-]-N/)O6)ZR6;E@V!X+%0I$9&8R(!"(:@<\!=, UBJL* U5\HS24
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MTOHEC(2/T>"ID>@*I&J17V[ E6^+L]?+[MU1=!A8- ]1Y.!P.]2B0ZR<DR(
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MEW2/\J'V*>T7YH>%L6:)<W2A(8E8T?3F[BDR#)'?L#$"@%D^L-W=Q-3@A G
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M70+0-XL0@MZ%/.1D/\HE $[QXDV<P@]^;;L6"Q=-5BZE"?IK,-JW2'U<5A$
MK^MB0_FBH M)RQ"L,M%<XO0) $-K+P'X]5>+R3LBPYEXDNS]8$PTGHZ;",B4
MC5X@FGUN_G0<%.U\EGA]YC $'"7"781A8]-(MXVX-66H?-1L]4_[?GRG;&^M
MB(% GG@M-SIXPA;2LF$UG[&)&$7L>J*S5^MG+F53!<A97K?DF\7K:(T;UIKE
M;5DI]")3F=Q:M=M57 >GPI1-=FN/"F4\1J61IIBTX@*M$AW9;6.6( OIQU:S
M&M\A+XNMA7AJKO;2[VSJ$K=DE9QG,?X),N=I#+"!#W),74QZ1[O>?2_.*W(H
M5]"53?_&9M2MJP(Z,.F!HDVS$R#H5\$!_3B0K=>"<RA#95=S<7#) T\6C1[E
MM<=75&*\5HC)5&:3TG2$V[9PO$.S.>G0]OS/>^<N1ZA4-#Q.9K#I:U2)<@(?
M/+9*-31I..>>Z1]@^(,%W= F';=&BMHN)3T*#U5B((JQ@N%1U7@,[LA#]\DA
MQ(AW/OX'('A_+TGY$\.1;ZDGQA$76]=S%*A# '+. ;AA&%:,)29QG_<O;PI%
M8C,@1Z=5KA( BB2BMXG%O4>GI=-7S<9#=&LGN!H^1TWI/"(?6W_G2237W5P\
MQS2:N6XJH(4 D#\][@]LZ<CC:4*0@1^2/!I97':K]_>SQHUB'9>E(R5SE!T1
M%B8CD J-M5?$U+JPHA9&X>+35')'8]'2Z4[>%?81VPDFU=X;=7:)+]C")D!-
M"J5/0U7A31PXJK?!BD,[B=&<%X;7@J\6F'7ZT264RIC(#5^7%;'=M[U^W5J"
MG=<1(FX(RX!5(-IT=&=*VWO(L=^U7Y7,#\BR6MD;J&5,?#1[<\^/@<V>9SJ!
M*$D8A4SE"!;6_DJ-RDC6S:9#K7]]1_36)AU4MS*FH+;NTU,-#OW"[Y<D%0!
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MOG_Z_#VX0T]$W72KJ+9V[9#(=DV-1D65GQ:DZ]4%5@=4!!<TTK_Q+(8S&\5
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MHE72)X_3W+.MY%Y,%]\HC>."/T;Y;@W-:RUBZ2;->/+%HE.$S0?*0X8P\M)
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MHUD<:)":P<SV[]Z%SEJ[\KG7IW"Y6";LJ#FI>K^P6__>5*U+/ <9Y1S;2FP
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M+'+0$)Y.,B$/Q0<XWR#42$D5>*B\6SO9W*'V>LPTY!.^%Z_(T@GUI-@NZ5#
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M<B;N3Y-O'N.J-E!:282;E)!9:9[O/2L?;F/>N N.C3F,MLK&B??ON78=V ,
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M3X[?NZ[W1-XQY_/?-()<MR1D]+6D[$YTU^#RT,1%$@2W]I_@'?P30ELFO-7
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M&K*'85=!=&)P+I+A"2#B$BQ9EJ3%W@'<O_/OSP!/6-=V.Y\&"/LR&/ZG\02
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MN1H)>3A+Q&AZ53-15(1T&JI K8$IL;*O8>H488@&#K%CADMGX[YAGNS7HWV
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M]["+8D.MTM(O$U;4A[R(F0W0?R_?@+#"IP+&E7(V%A5S L@Y!:PS+TGN_P>
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M[ZIV/S-QK\BX:X8?O.DT-M\?B*#A2M KT!&XR G )7_^;O<)0%B?\?<6^@3
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M+62D6]>"H9(I+*F=U<_AG&UVT/,\?V/C=&=? 3TZ!D)T=(=>?<A?WMW[U@B
MQFKHNJ1\F!E$UB*W4ZLH@]I[W<E&UKA2DG0MH6YS&7TVNKX'KR*\6"OH+JSS
M:FL"Z+>1XD=A0J+SDRU60-P$98Q^;+5)^$IEAT\Q(=:N^<V58B9WWM@<E&"3
MZIDZ&)=I6UYI%PR5UOJK.T^57%0ZZ;.6/C]-Z2 -Q N^\I":-.=,?WX)9&@
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MITM>O+CW*_D1;0X!*YHDDW(GHPK/VY?5FO@XO@9=2L9X7GYF^>;E7YI,NAP
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M6C1?IFN<E_+GW9VG :D"CF8ZUR\ _/[NZK6(W'$#82V1R?D-Z]T6&CW@AA-
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MN#(A994-_U^R6$=Y?(W.BJ@@N.$#QG))]>_+UC'AWLM9-6!]P@!1?)8B15D
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M"ZSM3C*!!H_H2@;?1#7!N%I&&]J\M9ZR75>XFR^\^O)^LO$G6?VT1_J?Y'(
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M@C?M PO1 !=02K[R]W:#@*K@^FXT%1%6;#?KK3[)-X.Q_5I@)&6E<=)"<.>
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M+GK5Y-<7Z5]2CZ>AVU9/)1L&%W"S4FJIO,%PPC.BY*(ORZRC?0J?@X,)_,W
MZIM9>TQOU.(]'9N@V;O@"$-"!:8NI6\3F0RO!X5#7<LO9EBWUZD=C/)^R>(Q
MQIF>VIL?.4$#GMFL@K<]#[_[ -ZH1Q04"^=O!,=I"F!BL#EA%K#RM9+]09-3
MYWB[E1HJ=\JXMOCT?QN9PSO!N.LT 'UMJ4M3,*Y=N6+*TW*#<,.YK[2ORM%N
M[G)Z.%;Z<KQ 74.JT%+R4CCWK'S/1-:C/Y.+DV3EE&W*@J4(RAI?TM>:^,Q]
MR7;M>D8&Z6W+6>V &4R5(=PC968&JRC2D;<D6B'T]$DYT5KKD[G&R:^UQ[^!
MEM;S\SSH"47!)36HFA@DSF8X2<U9<=1?\42PH.$D=/-5U4I]75U+PUC);%=@
M/T=)4,9KSM?YE[9);!^I#4##K2>.1CZB)G*5?N\RW5VC+)E,SM960[K!)]JY
M\73Q1$B_,P@OR1'1:EC..+)4P]NRKB?NQI\;4R5<P/BWI>-_-O_HV@/^!SE?
M0/^/SOW0Y!_U_']^@=$1_T#Q$"#//S>/^OG6T>F*^\-?P[(]'%Y.RVD1[\J$
MI3*^W0V7&CJ#A:A G6E 1"*4D:BUIO]TR5;;J!R5ZK_+\0Q^QLCRWI65<\-"
MGG0U<=3S\"ZO=HN*:P0P!YG1O5BRSGAW_[?]#K9K02!"YUW2EKV^'JB*%,-?
ML%8"93R\\=>(A20+LB6^-+81G##Q)X9\\LGZ?,#+_JKBOCL&TVEJ[ &W#(._
MW'=",1J.+TL@88K7+9D_(YL.MI?>PE"0J1-GNYMU92<#/KCES_/ZR_LL)BOQ
MUP_4#4@US[%_$TM+0SQ3A1!EF;>U\*U4)W7L<$S5WN195NZH/0U5N0+N@QP+
M%??\PA-(B/937%$7@K^H-J5?EW^D_:;X\VAOV_T$H>I,04F&LH!+7YG"'NG(
M/3'ZMJ6M58IR*9E"KS==P M4O9;C-]8Y5@98,B]N4#_!FYJW%:##PI!-:WNW
M+N%#YU[O1-)I74,0]PSOFR-_?;(I"Q:DLD26?2E73(3)V*/3#K;]=2Z^'1[U
M=+I( V##6$BEJ <_'?[LL[_/,($?YL-UC:%.\'X^NE^<#K<\4A$N#^IX=.)4
M]S'A,! Q" N/.@]5Q9I)3%[^5GFKZF-2CH_!P,#9MHM2Z:B_SZWXY<3)#TPP
MC#3 T\S?A(LV4/E]=N?S#(#3B;>=;$P;)E5F/FI9-D43NG<$FS\T?=###XJ6
M6QO>[+)B99 H&&^5H<>&<D?1 %&P2YX] 1PEHD1V(BH&/#JX0=0-19Z]/<)>
MY^[@*0124C*_C'V%P#(_Z?@%[[K:R%IT(A!>'].OT7[9!++U&ZKM&@NZ<F91
M[ZO2=2B7]U:ZQI"ZYSX*&0(0<XV(G'AWPD=\?]PB$GVL?[@+PZUB^K)CM$-H
MVES!?A7[I,G[-_-G(O/. 4/UV* OR>TF&Q.S1.2QUXS\0*Z%2F[8Q;W2$3V!
MU??1B\;W,H66TX^_FOMVXK(A*\/>8JDSHSP_W1#4!">?TL<=0Y7$19?*]XH$
MMI0.ESJ:>IX9*#*Q++QWZ>2%KX;Z8H]9%I$RY*>',_(FGI#D)T5E(T86;L8^
M'Q#QJC4K'4*=/);OE;%C/-P(ZQSES0'(QA" .H=\W_9P=#BQ>N^3[J)GLUR-
MW?;^B=]9=Y;*#;1M;!8LB.=+^R",\WGJB]S/]E)X==H87EV5&MVE$P]:UJ3?
M7JF"]6U70U 0-K(X7G-P*U\!5YVT&'JGS5K'OELN-9*2MQ&(\(L'?DMB@\@"
MNPM!2<\M@Y,::^CFF^C%S;_,.CS4R316?QWZ7F:I,<P31P,6)R,ZY#QKX L8
M 4\)F<84">]U];19H?K7S&PFEQ\%W^&$UN"O4%DE<9*H>?\_\ID5"]YK##$C
MOG;8N5W^KDZ)3S:E0N\@=1CR<1.D&RC1ID/%-S:#&#\U;>+NZ\KYK)Y+K/P,
M?/[#H[9@>K&%95=^N@-.^=/+7$]5EVA  WC;!;=&<&H<.8/?J5#-V.1K#\PD
M9 [YR3T'VJ-L4A-:]'4K@2$@E%-@%<.*].2.!HMM9T*.$6=,\!Q1ZKF7SDX'
M)B2N;&,>Q&I0I076&>O0X2?BS<8LCXW\+].V9S8 =:X7N=%^PRL0!+()2>;_
M^1W+'1^ C(9PJVAHFRRQG YU&+IET<2I&VC1)E)P/_/65PM9@6B-D\^60>^9
MR0+)OZZD],#8B2A7OR#O ,D"_.#7ZQ_2@]"_^F\Q);'*.'%_EB051^J!*K6B
M_>:S IZNH123G?DI^3"1#6<U?-B,P[K:LQNGFNE66[/K5WK8^.BU[N!3+[#S
M\?.!-1HMB/+)]6HE.E\S<-'JWTZE5NA,5*Y:%8>79+N@$\-T'QH+7UJFWW\D
M]LU!X!<-V(HAW0\&$]IQ>2N$&%_=I)KU*,&;WVK$G4T?+VS[^SV3NAI-ARN5
M?.FL/ R;1C0W/X??N_3 ?WUOO?WVDL[E4WX^A0Y?3[(R+7;XCV[[Q%^KM11(
M$) $[H5SEP59^8H^R=?Q_J6(/4L^D7!M FKG^19J@&,G0HQ;,ZA7[ ,VY]C=
M'MXH?MXOG"5N9W))F"W$YL=\U>*0Z&5<U5J<[[Y<L#^[J?K8F3'3G2B?E^P-
MS[(TG"(##1_+T'NH>7K_W$0A<?:;WF !)X?@L]A<;QBHX14-Z$59C26U-]_@
M8H_-//-37X==68PWE9M^<W>*1!C#!6V'8G-GDB3F?=A[6VVOE/]0MV*5X/G-
M+O488*C+*W[8>3)1*;%:3S?F3:K8Z+>CY9W_S;!RY\^_4\!L=;^E1@)Z'8?H
MGN/<1P@%IUS'3;Q"_/SUSDF*#46J^$ >HGY>SA_'(?O!Q//#/;XL&TR#G<["
M8^W0'\3T/T_-L[ULM'^[+3VUI;@ZMPRLZX$*WW6U6MLD:)N5!BOV:")C Q)2
MWGMJFKV>/,AB-'WZJ#=J^0%@TEU^B5[[-G=TQZ5F8C;NH,=9OJ&QM:YQ4F4S
M[)J<PQB[BMQY+ZP8EQ*]:V)D,NNF0VM45$>YNT[)+.\L>M9PQ(SADX0&;[2P
MG04'BQ1/R*%[> $_5 H+#>CJ0JD_OMT(!J/[B?V7&GUYD7G*O\*MT:<%+"XK
M;>E8M^=@%BRV,TA^3D8!BRW[%3[' CFD\"IKIM]3W6-,#2R-48:VR7H;WOM%
M6/A6/2YW8>@7)EB]4_-,7)ER%LD_D.K3O59F=V]V [E53H_^:.'9KZP'RD6P
MP!<2)#A'K@K">:&>9<2<!9=<\Y$W#G*.!]9/.HPD-E<0FP1$-V(:CK7I)"Y)
ML.(44@IG"]"*F9BA=LEOLR:M-XF-(?%)1?P-P%R+]E[);?3%B<S_N0[Z<OU(
M3XMI=>S!MAV6Q*F,.J'.Y*.1MZ6JH^O".5?^B'[KKK"QUJV7;F[2^JAC'P\/
M0HXC5AU&[#OXK&@%KG)<,\HZ9S)]_H&U?7=C$IHGF%7IH>'#WZ>U;?*GJ6.8
M)NXMB[ 3N4MM9C8W1I9\Y4_AH]H@Z($97HCD0RFN9VXGX8%(G]BSZ[?W.=5F
MK.OSO_Z9%QW4&"MNFN2-DTRSL/P\S1!JR=P)9H0OU&$XH.[+=E"]D49%.DB'
MP,X2LV7M\/4= [YJ"]_S2VTVL_F,Q!2L;QR:S=N9#\^5NVAV[@/).=L_H^"!
MN[? 66_7LDN2'Z$#^'HJJS=.??%'2^MW?Q-M^BIC5H=ASMIH\;EF![&^Q'V6
M,HN#"NRN( WH4H%[T(#IFMXB"-%H\1S40$1M:K== ^J_N7]]+U/P$5O&^.UE
M\<<7]4#U>XW]4%&(4&DWDEVQ5[ QH[_'XKG7MGOSH/HI/:C/[R?Y;3#'-;&[
M;:>[/.@\WN[PM_S')YAO3?(Q@RI_D@W9?TE<Q)!I0+X,/2[2$5](>8'TJ4GB
M"UZZBK@9=B-@D*6:_USF*9CX]BX/']UL<HLPP_F4V3L47Q(;69*"0'H.3R=@
M R.7/%1\CP<O===MI,'OY9F;A@[ZYUKFNW3(%!NFJ;UT^:"4-)3H5C&NJ[,!
MJ5?<+L2F"$SKE_^@*N%KHJ%:H>5VCNN[YVT"Z_J?+U\KO!HK)?=JP.67NZ]&
MS: 3G "?@/'#AD!L8 \+;F+^(MH);M7ZWF/[%V-_7@#'@1Q[GZR:K=*,LC^C
M\0XW 'H/;D1MN;^ECL,8<:BH8KS!6I3*QV.&.4+;/GV?/\W;QNO,S!ZO"TIN
MT?IJ]B X"(OI04Z#"#=S>T)(:+.%*O9K623GQ9UI'B_I9[_LEJ2BG]HU10U(
MO;0,L8[I0B9GHA%;%5A0/$RS(\8HVH);OWSCX#MG6L53UR^/BEXK/RY3,E^A
MU[99R>KW340<1RZ4T0"Q\V3&!5'A/>0QV\$U![O9ID]W8L6KX-#!M#;FE1MY
MA4W5J^>_T(W NP3(X/)Y*!S?U.8C-N(1"!/W-LV<:=$>J'8)=I5/9)KA* [9
M5AV$FOWLT()WV3-E5,MBUDV7V'TN;C]D^I$___UN@T.(C\OQ8UJ[9S_"JF&#
MF'I(--(-$47(Y\:M>Y>;4DJMQL\XFH8]UN.4Y(K_ ,ARMQ9PF=M2+>W0*<R'
M\Q>2K8A\)$T,_ZFP-+FM8*^+G/^5!;('_CA0V5T6S#0MGM, [G;[S+0S1:Z5
M3>D*?!>$>N3;TY]+P5G4?M,WK:)NYH,6S_9S7MNEL@QAF4.S=2?+9J]@L^_-
M_7JJ=I#!X/CGJ5K9A[U+-;<.L]1)KS0CD@91V?Q\AP\J?BGOUIJ4D;M_,87N
M)5SS]^8B<^2NZZ&5"EFW)7@:BCBN=BAKH\^VMD=9+*V>H@'/+)E',3BCFIA6
M'>165>7&]W5"LXWSZ8GJ-^V>;[C<FI,DDUR@R98@E84UBFO(Y"=$;5(/5.SP
M'V;/!X,M B/-PFXZXF;C7M\7:E]+LB!SH14_V<Q <$:4R^PU4W]8BAZ-VF].
M?OM,]W5"UV'A#[2Z%&%/C"$X1+5[T@#&^^UC/BSITV2G1?FKGQ%!@WU+D7M2
M960/>L)V2,CH*)L]<'U2$6\20Y8#"[JG$%_\R\I+A;,2KITJ]_UN8_-$(R?K
MJ(LBVG_ZF'$GDZC)2?Q7.)VSZQ+F>6MT[@*$=PZ9 C4+3O6<Y&O\V/?YU0J[
MJ'BB&N5[(J@*"%'\[Q+(X!\E$,N1!/IGP$2/W>"43T-4>'_H:TOZ<G:Z/K:@
M)Q )>)>Q+C?Y,7%P <%Q&"68&XVB>V>_Y!"R?<ODGS??J-4_WI#X642*LD,\
M>/+1?*(333<+A5(Z.CBHPPB/QHGVFQ)U-=W7\KCU9H("JY5_=K 8IS0DOT7J
M=LC N^PZ+D+O32"QHD0=K#XVNM55#'2O2;.Z1MWWQ0.9%O'G#XSN+ZEN@(!#
M%8$.2)EN!"?,G_,QA[3[<W/5Q?,.FRC8^KHD%PI<,.(R@#V'*A E%RPB<BY]
MU^;$FLGUJ!73G:IK9C\_]>->ZLJR[D[O-^9E5#AR(1O2<'9;NKHTCJH0G.S+
M:?3X\0'L=*N/T4TWG4Q@2G]R)<BL'=IX$-2)))ZQZ.*.0-[_F*6GJS[YI@?N
M&9SK\SEZWS3LC?0: U])M.Y^&*0A\>#/]W#41T#*>Z7L1CC0"=PL^P]<0?-6
ML!4)X ?BU2:,$JH:O3'LFR?0G,OV@2VJ+T:FG"U V6*"C$(&DHIXQL?%B4_B
MI]ZF/ND#8&<V("#D@Y2IR+X,TZ7<)'?[T3,?-'3/N(_[MU6'7'DL>A'_Z6J:
M\:?/A)I:I/LN4:ZY>S@N&F.&'V^G 9S[S=V_)RT(29J&"WZ:X2-K&:0^-G"'
M]XZ/J4G]1.7#\P'LMKY;#WE0JHU?[AHOWQRWL^4QJJN)HP$>W$2IFFY(/,)K
M#"J^!E6;7!Z$]]9IS^G,4"KN&@Z3[G]B+BS@;O1W"C+#G\GR*5]7)Z#?YOKG
MWQ-L>G+^V^?2(LERV9Y9D;8/-MB=>A*8.@'"6<Q9K3G@\B:*GF![GYR?G!=U
M#2N]5D2LEG<R<>2JQ"\$/MS? V_1@$/OEC^JJECOB1!L5T)KK[% ]0OD3!_"
MT>ES<?[B X:P$)D"[N]?UDKD'R.Y=&6(%HN[T:?P@I&J)!#OC_?I;W:Z+3<J
M 6FQ ",@L0+HD93,V3@4,/]1#V^J+-Z[5'I##Y1" QICR,</%A&=-"!>0H:(
MP%D;MN :9VVRLJP)-A?[ M[VR%YLB2I*?:;"H+R@L#K3!<GR^X69;B88$%=(
M=Z&JQ* 2K]8<#S!]@]W#&;/V-.S9M987LPV6I;O2J9_OZ8UB];YR*7%O5S<6
MH8,C33Y^5V4QZ(O:XG-PO-S[3.IAB9V)V$_6]2%7J ;1%XM\#N/X3CZ+%5?0
M$>QIA6<3'(3RYEQ_27E"& <>.DW]M+ 'B#54-CF2%MF:&(5#8(>[:R+FCX?2
M "9/&4:RR;L9^VV'X%&Y2Q8()4$Z:+\V[\LK8S;]""[D7<2,+U9,?81X]O(X
M63;K2U4 )6,Q3Q,S+,LUU_<PVN_#4NU S>SIW&=#&L&;>J!\3&U6#P0]V0T1
M/=M.G E89&T7\X];,AAK-_*!"Z(3^FI_^WW=?LVJT:_YZS9\H1")L\"<@-KB
M]YO[,,\?)BVIV#(27JZ5--2;<#'87+C6=\OX71G+?6&68K%$T,CIMA257(N:
MT7"PZ#YDVH* I#1J>V)G((F7G8[KCQQT!OB8G,<FCYM 5)>:PRO,)+?$ECP[
M&5_<19I#74CJ1(L^1'T5J@MQQE21+>^TSIDI5'0ZYC.;RXOCX^-+1@.D+QJ;
MSC7UJT,<;6W?F)=L8L#WD3.FA*L=>,4HF*#4GY@8U?(F3E.C4 V7UR_1]>^^
M0 <]U<@EM>W/!M!5D!N'VD4-?B<OB."'L,8?]"J>TO:K<!"549DJL:,!]0ON
MG*>>WGKIZ?@NK/MR% GE1[\K7]I"KC>_$0\PRA]5EOR7)UM<YOR)]J*ETFT3
M'(KP9'1B%P4[USBZ<R]EJ'ET\8SWYLOE8ZEG;*OU13^Q<%OSTVV0HOWF6Q3C
MX"?:17%!>F'>_1W2W]M5WR9&95(?15LQ7>M'AAC2 #=]W?'?KO@>*COC$AP$
MH0'=8)QK-ZIGX-'\=9&H/?;0\J\6^OST_AX69LB/9^L$!LFJAPK3FQQ&*8->
M[CA/;*N>#[X[O\9D.LQG?!!2&?<Z/).$#&0V>Z_DLU5\-UPGBQ!Q:/]U/02.
M]D=&4D5]K!]=X^;Q_G$W$CP?/V<<)-[U^)7.K8-2$MLL;((&".GJ>,)YR3Y5
MQ(A![(R1'*2GLGGZ@>_I>Z?XT(/ \0\5K+<!.@<%$S3&@3J,P5FD1$+JT3/.
MGC!Q"&]PLI@ZX2!6;<Z1:;-5M3/YO$04O[IV!L1$8#@$N#T<8F@58E6&!HO8
M WH73?^]B[0F)NV6]&7%7ST]_FV)9UK.822>^QBVN3J,9J:R;N.\"=$DLYU2
M;"]N-W9U$.X;#)6OZKFX,5K&I&&R)#W6I'FAIL2C@#L;?!<^E8PBJ(Z2;7Q]
M%V>0 K.;!SS&/TV]Y%TB+MWN]:J+ RF2^F=_K[$=J];XX_Y<8FS#F^,; ^1A
M,^FF VOJK.SNA6C1[C5AE&/H6%N,^?YO,Y(WM1LLUK";;$\#^N%1]O.%BZR*
M]TEW>]Y"M$4Z\A_1Q9]*6[UZ\>=SGZGNK4NS3^'/X#@;BU@X^_Y%+"())HKH
M3;-#IOF%"GQX/[X=NR$5&Y5L2#BMMF%Z7 ]4>ZMQ!4F/]$1$8QJLDWW)K(L)
M9LY7G0Y$0D&RA)D"RC)G#+WVPZZ;4SG[G-WAX@;2_^NZ.AV5=?Y7)'M;C]W$
M>)3!ZDM@N)+)-D2:^@V#NPF.A!_K^%YJMX%"P<XFR%&RL)-VKDDHSX?@\5(-
MAG.!0BL>])N.I%N6<ST![3VRUWCC-9(B?5S&S35!7N3K^*SM0I(Y=59S'Q5%
M%5VWCTXJ-OFIFX45<',S_,2TL;?P+NT#*$=%\ET.J8;*BB2)$%$$:QPFKD;;
MO:;GR;O@N(+4'YG'528F8+:^>:_#15R1GK(7CG%GUW<R3\>LUD12=>!=L@T(
M-#TA?AQV:A/$TVBJPWW[9W';Z*E&FQ:N6,EI_JV9&Q<*$OM['^N@YF59Q'Z9
MZDF8X< $&R*$I+F^R$T?;#YXO4VNR<GZ]J_=M^(]7W]#X>]9;DRQ[?N\6E^W
M>!/.:WC.X]^A_,^QTQG;TOVMSLN-$BVC\Z@^BT*(=DB0%;+OX&.2M;6PH3$I
M0Z9AD%L1:!MSF)O1G2^7=.C6G6^_@W==H0'N9J>I6AI464]%.62F"/K<6J)8
MVB!*5$98W 05 OPYA2SU(K)M4MF8%UG@#RRV5AI3J/S\FM]P5]%KZ1T0PL#E
M>=^\R6/Z]<(S*Q'[V^!FQ/9%YJT#DNK&_*E1Q44?N&.B9PY#ZB=1Y>O/*84L
M&W6H5KW9B,O<BS7#4S3 "S+]'D,0SE@(G2:^];F]Q3GCY;=^@P?]%8II..;.
M4)-S[%?D2E+I1P V6(;^4&KS"8PS1\XHFU%*8,)VQ"<W<]:H)T#1E:=3;$B7
MW7SY+R8IW.CZG<!HM1!^Y6*G)%,)\?>AWM<BFI"TR=?'H*Q5ZU29B8"/JI+J
M26_L]*4NM!7X"7NZ)V:B/YM_,_K"])@% #F.0+ALX5UW=>GFG:[PUP6_'Y"Z
M(^*Y5RP'*K^37G\G])CWIH40U!$7$PX3-UL:@CLU?8=*<C8$^;SKL%?FSX4V
M61;4GSA?P,B0WDFG)QXF\,O\4,LSGJ;D-GX)RUU,>OYTF RS<YKQIP'5M56A
MX!Y,PCP+L<[UR=,%Y F/^7/-C7>RN(LQ1G[+=0SA)!.T,4/B4@D0L&?UD#^J
M$V5_>(WGEH2WKXGB_C^72^DJ6VJDB+](YZ!*E.*&[[Y+*1PS$&?9!Y'6S1(&
M^Q^VW[O]KN76<G@LL>$]>1AZ4(K)(-PU4#R(H3&%:*K+2HS>[<797<QG\5DE
M231ZINPHO;0S%EYAN_CUF ABP8(L4+&HV.UTD\H+2>H0;\6+J3T\F?_K$TFB
MSCMYM+_+VHKITIVDL4Q5$HO->>Z2IS8HQ>D@;.FV<(EJ:7*[O/L[Q\.!W$J"
MYF["E@;S'BW0?QV]EK_A<0S^#-G0W)."5KP29MH)DVX<1TMS!MQ!?6YO'*8?
MBJH='!:MO976I;J^L-JA3'F)7,@)X=ZJP2-NX.>SEI(<')YMK;RO&]V13S_.
M9FRXJWOU@<6!(7 5^!6A5_.>NLN\J<?U)B/@#':R$=",O[Z:^1]?QK)"/0<?
M4,8'42(.I?:>Z>2-?Q3>@.X)&C"@A$NA/#M,1O>NV1Q:_(/P_L^OLOH_@M0F
MM-E?47(G^#MJ7I3XI'"PDECJ_+U=J\3PT61.WJA#+[?;[/(QB]*;-MKJBSYG
M^^TY,YL+O:Q;^]/"A'+0?S[?SA1.W7-SNW0Z7*79I@?2$$06R,4&=8LF;(MV
MX8;P@KU-6]^:IS #WPO33)@#NIAAW.2?ULS,JP*$_?T7]DG%A&;6U9EA40.I
M>ZG"MCQ&$@4YQ$TL@LP7M&#3@Q%PW S*"2Q:XL8(^ZALAV#OU3<*?Z[)C'UC
MR0SZ.,^E(;P:KLLPUB$%FP#A;GPT#%,T;.ZP8#6F.DZ$6&K"$M@.CE]''10'
M3'W=1K&C.\HI^31@(:F#!]<ZXX4\H3J@[5+.H3'2T!3JH\/]:-3O?/N!A.W^
M3<B;D/L9[F_6"03-L)*/42];61::&N-<XZ7%!6YQR*#NR*(3+9D$(Z'L6!H0
MD\/8$8<-.VZ!(Z0]! >XO9VIY%4L1Q<\#LTO+:\:%RKY=P6PN^4;K7W)4:7#
M\')G_=)IO;:2EM:7=Y,O;GSI!< B0$MKZ@7M^*X.?'4*=\0.^;9/Z(F*PIEI
MDS!"GLX$]DP<3]W%EUH.49>ZE@]J!H;C$#@[Q3@)E3&,,=%IH4*<54'J GHH
MI*;<B^]>:F5=]=1X+&J@28];6(6.=,R68S(;>I?RMD.03)=\?&E7V),JD1_\
M9<1NH,.[7)(A:9/!:U3@D^0IOZZ]FD3P'=$4]&X?7+@$K][W='_0EV[83::M
M":\BY^%L!7[L4Q58GA3YV/9T=6=G^K7)6NHXZ&\_2&;J.(*_85?4:UYF0D4N
M]D%1;5OC]U'UXRC1BX:&CZ!-HI^T+UP2HT_7T\:@#H=. YZ'"$Q.DY6Q2#YB
MJ7?XI+R8M:7 L+1IRV._?#;%AV&Z.<0T?$*O/6*K(@BOC#6/4HQMG-EFXX08
MC.[<<4\WR':%"J6NS+D&^L2;+[X2'M;F[DDAG@%O'>!67.#$RS%QNW<E*8J]
M01:!#LS$-Y^>TP!,ZY_HB7Y1]DL^/B[):#0#;Q^'C "O7O>[\ N $!!JR;S8
M3);&--, U)G3:$60;<_%4R+S?2HLG82,!]I<N<UA)JH$&_+Q(@*<4D#EW726
MF]"]0$S?6#(;KTIS&0G@O+,1=.R'$D*[8^W6;_53;,O-PJ0$R&-&2:1*6^A!
M 7<$TLN7*/T U%"*TK%9Y(?SN>/V0BH?L5?I.IW=CA*123^U GZ=>_NE<@27
MJ(Y^9R=NF,QK@<U$J%C4$-?Z1#I&V8WNR6^-4_2_/.;AUC[&Q>VL#'G3N(II
M")M,EM=E)@YTB*ROW<(/3JEH.K5^J5,:D&10JM!@;U6]GZ:O_8+^(P -*B*?
MPTUN#Y&N!\?WW*I51]+#^-:'L/*G^\_-2;:-V1TS.]WZFKI]BR.2S'-APWOB
M 7+A)0VHO_T.F;UP;C?(7UUDA3BSI6:.K ZQ28,-P2X0]TDJ9/%O9-9BV(!]
M<B%!]>G#?<DEK4OYA)49I>N#RTU*P4!==Y3PR?L?3:DB;80T&E"D/P;'?6B@
M 4O\=&N"$ [H8:[-@*=4:7,O<K-Y8J8P+!VG]+05R_ND>YO9WVYH-<]\=LO.
MCFBAK[C#^(IP V)$MJ=$4UF@C_'/YV7QI>';^Q >"Q$CU3V;2>LD&0.VDEZ^
M@D"V8SMWS/FYPFV&X TQ21TZL%$XL[;^@KPKP7CLO.N8)*</3-O=76YZMG".
M_W/'M1UTYSTFT1?OEYEJJN%NFP@)1R@C[A$Q]VU3UE+L^;ZF$HZ,XF%)PSX^
M]WOWG7Z>+DZDP[[^QIS0<SCR4DHNMC7>EWA%48KW@Z^"F1>NXLZ:)V77?'P7
M+*3+2+RY!.^N,L*NQ6Y+0;B<#?B=G1)B[T4.NGGD*$?P%QITGDSDX-$_^4>
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M_MS 7>_]E2RP>71[T-+!5@H.2<C\_L59#3>KKIG^]I-JA?(R9&:_?_J%6_A
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MW*74T*\N\==82@F<[BCARA/AF,/7B3.>8WKD9FD6RY@_EL>N,I,POX98A_:
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M'2*0<NIJO''QD)'<!1K7MAFH03/VV ,>9!*+X]>+<]9GS&YD[RBRIOX1N[P
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MT\$QU.@ >L 0JG07+>*ED;7$+,GPD5P:IT"/1X15.E%[.]8A*(7#U(6'F@:
MTB1^XGFP]@^)GOW=$N3ACP%!; ;(:SKY-P.Z=;/F/Q8DK6[^*R6ZINQED"5;
MKM:SW?H@V$0+(^#;IPPPQ)-I]>,J$>)7\6*8NQD=/Y21I_XQEK:0OO[IB#'E
M)?8%WA,!JA8EE$>_, >[7\.@T]2X+ET%/ZW\T&E5R3.*8QK'+8A&E2/:=M,J
M<[.3ZBR>/FKD=KRXTX-)...HG%*.&K.>N.4H9<;:'"3WY2B6'CZWU& #&73;
M!\81*Q/=8'$NU**F8A!KCEMS6ZKGU0\GG[B8&2\I"4F?%1U<DP7_C)/,TO"W
M9B<1V](T;I8:B"SSD9K!0@>.EQ-=N[_Z?COY[C*I+R7CM,*->^:5?LR7;!U2
M?>B27PTRA073SHB5-U08O*6*6[?RW4FXYW0F@LK&6[M2WTP027-FRSOQYG-B
M302\X!)+8;B@C7[A 7'[-"QD?%T>4]4&\UEN_Q_\:/*_WL$(YHX'=6PX+!H<
M<%&N().Z0;B6K<X()TWK=*:?$4^2+@USN<RQ(L+[3&$/B"FM')A-0U"=?'D1
M-4NS/%&PXZ]/7JRH)YUW3S8XDSU4-P\I45V,OA8#MUZK//RA+H-$NA)[8+0Y
MP[S]J@A?AL6BP<HO3!J.>@49"X-$T=7T'#&/I'Z%<_9U1MZ)T?';4=AU''!]
M^ ,3BC>@H$59XWM /7,T+&+U8Q7*B1C7&UAA'MQ_5.O;57+]5;D[NO[FTRU6
MT8%4==:!*>I&.^O"'M"5ZK_1ZQ1+J,/Y./59VX]#O#=NMZ^W<*S5<&Q8I\()
M1;@:!$6VW)(X^] -AA$H6.#Q)+Y0UI+]I^?RF8VLLUSTQ73RV#L&G(T85Q@A
MX,([]4=H5; PZLRX3+_AA]#)BK>$WQQ&<Z9!0X7[@G8B'59Z[[-D07=B48)<
M*A$.]<Z5'L[$?5@*+>6^398\8O2SMTDF<^:C;/%8C*$!J+<'<)>!@M2:]I"2
MQ7I#_>_RNZU#)(L'CQ=:U095;T>>Q91'>[X&,9>H8SG[7Q1XCSV_AN.D) WW
M[(M7ZGWS)@9"=.)*<@+\1R:?!/[;WY7^HSVXDYT$?*$I/MQD:RSA):?M+/?R
MI: 42X^2J0+JY]5/A#APO!LC@R>D(PX8*H3OM/)G;!![JH\[\LI,.VK(+(0T
MIV;],5UD:Z$1*Y5,(]BCR?'58KHCJU.WL*>1H-)O:3LDNO,YG,CCM#9CHRNY
M^BQ,AN.SUX0#_?LJCN.O8V^8:+5FT1(Z3&(%MV8%BB3-SW[-KIBUNR[C7B67
M]:>LYL_X T84,]%0$#TTU*^3Q%#AEOH50T8,!_JB"]+*CZ98IG5<#3!0XFH
M36@K;";=ZR=,MV_+51UI-N-,'>[U.SY!^$RPY.50\&3.25;L 2%H'<;?LN?V
M40A0M!PFRI"D:;(4T_I3!J-C0T=J7V!V0M]?/Z67'V^040AJL)'U!EA*=7#$
M'(SRI4X/).97!_+][@?>C_F=3I.]^" G)>!+RCV+H!]<VR>SFS$$.,6;6K^-
M'>EJY:%9U<[GE7WTDUMARK$$SH2=GSW-1>]KC%X9_Y?8>U+S/^"1EY5UH(6
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M!Q4>:[,K<M/=OVM)F:X/ZVOR7]- 9&'XV Y:.BO-X@!S$?R,.]1?K8KFM_<
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MZ. @5Y) UJ#<(FPGV?<VS"DT$-1J#V'AWM3F#Z=K1S]6L\?-PD<DSU6TLUR
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M(%P0T^UH:)SV*>:>\2=D6VWJS74=YML0]];,Y?P;U-ST+TOWZ+*E#.=8=P2
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MP/673--+)\L>[A.V46\8#VQX"')]<V(MI("%,HFIVH&2S.O-5U,O?YU^G:P
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MNIF0*:4M4Y\G24EQ2DUIP:Q+I55<;F^F1C?^>!$::*SE9 T2TH1:62>D;;6
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M$>N1.U6;:147KQY\3G/9/0G/&!!,O_Z)HU2B?/$45)GB^X^'0" 2>DH@!"X
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M&@]Y>K&38VJ@RF2!W?[W&:57!@I*OI*Q,C#^4Y>O!F,U3^M3':AQB(>0Z".
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M2,])+?*MFN1-XQ;OHK:I?J;BT4<>D+E=49LV"IUD1:-(/KO?X_L+..L4SY)
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M6OA";"%*^+P'CU/./Z G*E WV'#45Q^6V]D_:8=#MCQ5)6]U-5H^4IGI=9/
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MS+)1M J(\C:-Q*6B!MEBVYSJX9%]D>)ON:"/]T&-5C,T5@(D 2'B?OLGYO1
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MN8:,/W7G"MY0,*# (\9""(< [60[(:-]2:#9?$&>D]P8V$7.L5[W1HW]T%,
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MD\XUGXYC/"C%F]2<MAY7N7CFNE"TZ[WNSX$38];&:&2@=\Y)/;J.,),39CP
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M0Q$GSER]Z;.:W6CQ_5<D])YQJ!#]UD 6(1?SL!+I5R4!J_G0C1BXN[RP8MN
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MG).0 MVVJJZBCBS^K&Y@7Z:2V&%7^72=ZJ1XU3TS\Z+;'YW3U6I8@#%3G1I
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MO<5H3YQ$)UAJW8 G-P[Q(5RKN'?U%]45#^2Z'N\6?OQ6+F8B@<Y@8-$S3T_
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M:2I)=/^9L-*XS,KZHSO.]^#%MDZ3O@?>*PO*_D[A2GH%ODIO]BE Y\#ED =
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M;68[KBJC%3\F:U9;[Q>=X7*0W+A*746>V<DS^<B)<MAG+!J"^'3TGJ5" [<
MS6*V=(Q&1"=7=FWA1)&Z(#:N,KZEN"ZF)-=QRME<_.P;;P7--FY@=S8@GLH"
M=N- 8V;<(@8&9I3]LWTP@_[S,$5>75"G.H8%2"'#?(@A#4>0 J^SHA,6?ONB
M!E5;M<YQ\-;?([_;>)$NWH9NED;)OQ2:44]H\+Q72,H^.)QHJ7KKN1HI]7:5
M-4,G'?VEB1TA8@*I<*&HP%*!:T@8.)U&)-TQU5'3LQS<7YZPX>9KK7VVJ![R
M^J%UR7T4%S6,N!9C*%X&CD179/D(G2W;,.R[Z57@A@VK2$H.*]>"!IR!8O'@
M5>QXZ17R=OLC7%2=R80147VW.<[7/![JBS\B]3N[2(*44$.;Z.KK3B2,*3'Y
MQ4$"Q8J*S#R!!6.V;<F"LZH(!<54AR2/IL>>&/W4CSI=XQCRT'S*]YV)8E0/
MC!=I4>1RNP[?4KKK5V;!?(E!#VDQMN1@9HC4CY=3^4>_6BBGW+-X!_\G/J%_
M)B-A+*#E/_$)HTL7<^UT9#Q"VI.;NEM]\ES&"(:/7GOK9NR?L0H^YWKBZ+M:
MVP6)(WJFD_,C\[JMN$=U_'1?-)3NW+_6=+ XM7&K%W?@9R0IPR3\LI;XG8Y3
MA@Z W!'&9"2#E]U(!-6=K2*>@=5TU5*VKFG1HI16HUU9@*LC(]'99V(QQ-"E
M3\M/EOS"/[/CS]X0=$<))\0.I/\Q[KI*,YRJ6A5/=IN-C=+G\P;KELV8DT-J
MFY_?7WR7<J")PK^GF?>S B:!(00?:0SI2*)IT_>#TR6>[WZR 'ZZ:,'M]'O%
ME)$J%_GR&*];E]/N!R9J?C#@/26^!+AB)/Z_5P3]B[_XB[_XB[_XB[_XB[_X
MB[_XB[_XB[_XB[_XB[_XB[_XB[_XB[_XB[_XB[_XO^'LZ*NI+6W@UV&.'FY,
M#G?>$Z? _ZUPY/."8H+(;=PH"CJTI;'WV=AXM_^/U"3:WBJM9"WL,$;;J$>V
ML6C=B0F-?\\"OBD/L@ P1(4%2!6:L0#NEN%J3A; NTEQIC<'CNS"7OC-@X%=
M:^Y10Q;0%%E \SDD'^W:[<O!H;(".%YJKQ2J7SML:>!*K=%V3T.KPDW;KDOO
M1D\!F+:']C6!B]#S0*!8%IY?US\;?01P/%P??8QX1L BTZJEK.'FG)4 D07$
MK"&-9J^[]!E_NY/ZM::IZ;EK@D:_>_PO"V#/J\>0@Y@3;\3G\.5XDLG,VG@H
MH5URFD\W=4E&(:?.OZDAJN78LYR'Y%R]B!MSB_QCD 2*N%\Z1MY$]ZM8SF+V
M$%!Q28(SB?UR.8C?YI[6&0'SBX<\)N '4&-PT%8=@NH:CW*1?W0AJYVIFR[^
M8NGJ8/'><=.Q\<$O=E7E>^PX4\YTC?.G<&SE^C9XBN4LX!5*6,!,%7SOR"5U
MW=9208N;V8H6JQ(V^*W^,GF]E=)*M!N.>B@H H\0Z$+J:].P?-1I*<%N;\E+
MQ67.>7,!3E\ ]8H;:>Y7@7E.#D6N99G#NOQ6+1AY<R<Q7W%R(6F$AH(S.U''
MP ZLYTP]6NQ8F=N!"<L3.<,=^S_Z\ -)Y=FULQC#;HA!F:6S?3,Z3IUL3X1&
MZGOJ9"Z5!T>:5PY-]RAK'E73/O^#Z\8MSM%>/7OO.HQ$@N]:;U++GSFY2_>:
MU/ACAL"#WB6:'=&C)#OIHQ<!.J)%7Y;FC=2D9I!'D4?!!^^F#P[O+\]>7;OT
M@:-8C9Z7DY,!:W"KIW(=:N[V3 "V7T[.8L9*,UB +WY"8H.B!Y9&;V7!!%IG
M8X?5;U5X>38@;NXUW_;=I>1YJD.U'W:+@!5E#J YZ 9D_F4S[)FL*RE+,BVJ
MD:<[YR<MA/;8!>#4#?3Z(1_8EB)$HT)08U#0SI,J0#:^1$7/H/G'@R/M!LZ;
MO;GM^*JW:DGKD)N(Z3//<5[N1WON'?=/+07A3/[#<UAYI!BU<@XK@M2H_K8
M'GR)"'WRZ'FN)>49_C-7[B'.G#L1D\>W<H0:@SC.[T',6X_J47XV,3Z6ZB,$
MUZ)\Z,?T]=-]8P0HM1OTC>.*$8\20Y1>A[X8&3G2NGQ&*"^K)I!T?H\7A[>
M:_H'_<"YAQ B/EI'7308=[GZ6X6:IJC!]ZW!FTHNS[:44P#;E#8,AS(G1V.-
M;2;] [62[5#O:0?+_+U!PB=AEZ5O5:.5<.')T]*?])_X0:<@TKNZ7BA<43B2
MT<("J&II&XC'S60AXE:>]R7S71G3LK6!Z=RKR.<6(@]U"^?.0(N>5O8@]:B1
MQ+4$%X&!!GNBSWDUN-'WFQLDOWV?]S3R*F+LPG>)WY V5\08B7];$V/'A_IH
MV<X_/CC5NKR9']Q[&G?[CT.&OYK4- %.)YP)&/CGK+NZU+M+9_;DI=Y]-7F(
M8XCM+;I"2 ;[W=.L6*(SMEW]4;80596HAQ6A$N 5X&J2T!??8UD+3T!S\W[.
M@5, T4;BI+X-!,Z^3*DV X<R\()6Q+96D$MC2M;4*JZ5'E-3I(6^LU1)H0F0
M=LV(\'&=:I8&0,-+C#+\S.NZPI5R\KOE3^E-'!5D,9O1YB#*6*5NM>O 8;T'
MO!.O#4)Z@(<;EG8KJ]SMK[3<%%PAGQ:EI3O,''%!Q#\']*UJ]?TP_<4.+;H<
M0W,O;.O_'.#'E>GX+]1C[3FX.I?)GKVG%?_;,QK[[MAP9$\MZ>ZIG(55>I+\
M9_!CZLU5XWT)^C2&F<V#6*MO=\XS\LA#G)T+)QU&5&O[K%J!% [ZZC!LIFI:
M/^NJ>@'R)+B5G='@$['^*V1A(CO@R%/G.4;R(:XM%G!W)6"S *(#0E>JV>O(
M$\1UX*6\FX3(A;&X3SNK!9H3#M-F@90LOA^^XM)Q5^.?)W__?#.%AYA)(SF-
ME #'?EFU-&DRJM SKUR@C+3 G_1]K[QBVYMTO$1FPQ[4K/O<L?UMK8/Q\'3_
M'75#Z&F$PRW/1=P>=H1WU?<G7D=?M(XG\)IFY4XSR0<&Z30GG HV6Z?F2T\X
M<X#K%[M[-G+]3N*Q,V@9+Q8@W+#O53"N=?O;+\=C17<R'F38>@K))B9&?LEN
MMU:,$-K?=(_1 /-1)8P2SH,/?^"B;Y!/C;RNC4X/&ZY:1Q8D1CY.>O$;5P \
MO/RBWV%/@_U\/;KY;N4W%J"=:LWUIK?V#S>]+R6.T"4FS(8J)Q#6LDB=FF_:
M7<ZJOT)-7Q\;WWN7XWB#1<T>BWT;R0G6-D*#XX[=8&>\-EXJ..SBR'W+T4 U
MZ*5JRWK+[H"GF2HV7V9V]AJ5G ?.^IL&N(C3;J&&KA(^PEH<&A"&T2R 3WE$
MYNEI]Z9,=537@EYQLO7S'TW'GYSJF/:'[V4!K1O\+*!'M#>$!3PI90$U;[BV
M+B9])[. E3_<R06KLD]HL,P7XD"W*-YW.KE*GRMF5/=._SA!HNF'^2^G7N\D
M!=+N!*M3S/J+<=>2?0+:QE,R!AM@'L0#SSE:S5>-A#M?8-I$S#]!!#%">;HV
M>U;3?GO.]%'5VG2SCR1 Q>@:S!Z07LX=5J)KIRLI49:B>5[[O+)2=K3J9O6G
M[-/]30>"C<^3S6("#U4^%+B"<79T,7KY4>5BU*V]1MS_6 *CN[U[KO$@D3K2
MA:^"T<4LFW$?4;F0V$&KC X%G72=EYL(Q!/?]++C!UR\$TY>FCK+[1990^*V
M^+TQPP+H$ADF9,@CGPI\G"&$!42YF=6EWARNF%BHDZA5\4X1E7+-<3OZZDG$
MV1>S&)C5V]OO,]XZ+I_V>9_K%B#^(VW24E]R[\G@'TF86X$W[AI=XE5ZHW/[
M?[A2Q:M)K>3-?_A>%^LRE@.QM:BQ*30H^S]NT.64:#](=-&CV:"&IG<SGM(%
M)>,:G(Z.B$Y]OC%8D:7V>H%BP[&/:R_G>R-/%7[>7^:0C:P_SZ]/!,\^=&C"
M@G.ME-,>:^FRM*[5@YW2W:7I6BR @_Z3:VLC$%C Z[, #QQ5M3.Z236XWAJL
MQC;HLL64:2Y:TVG\=OHVW*O,6Q8X6I#F*)?-\3M6/VT9GHL8P(A]<*GPA9ZG
MTBCC?RK$48,H%YLJP>F7^=6/D'Z!D'&K.+:[%N<I1X6\X+0\P7?%-H7' IX!
MT_K)5FX.Z#@%R>\5$[@X&&2@NS4T7,18!S>NYA$<L#VKQ9GRA%2A>R$!8%R#
M:$M,.(^TPN+JA-KQ'#^S-<">F:;^RBSWNJHL*3UK;H<'@3?L,LH/RQ<U_T/M
M(G^HO3!ZZQ%,H'GVP3_4[M%P8MK&?'N53>W:')LD:1(\A0#2U8*J6Z[#6  D
M!4U.6&K@9OM![:!?97V8GS12 V<Q,']7>4@[Z8IS%_^+W;^%1'P[E8G-G6>\
MN+9$$MI Z\1-Z[ALT8$&2V+/67E[X^^*3EF6G[6JS$?OWCVC2&$3V:Z]O"5U
MP(5O+T8Z<-6>) ::)D\M;]G1P46JT6WJVA,SDK3'(YVD$BS*O3A/]*+Y=Z"4
M8.I;]8ZUB.R]Y,F=>]XBRU66#X8UOK@[W&OSV7VFS]KHC$*,P^'FG8&1/GS5
M&LDXD*:,5/I +BB,)9*/5LNTG;Y6GOESXEUL@K?N*N\D5E6JDWP%_F&1=#F0
MYH)4^4YW"R&.(K4.)->>2%%3K-/E)RI69Z!FBR*0ZQI8XG:.4-ZA5QX"PVS1
M]:?>\Q_Y^3P_\%9PJ[.A-)A=6?QJ/W%S^?#[-I.JM?4YSXD7<IZ^A[B<@C^S
M12#8^4\441C"(["/,IB[&T"UTIC<JF\+0^V3,JF36IJ6_'?&W6PX1%)?L #!
ML$42E'8#J<W(N/\$EAB8$QCBNN%S7U"?KW353%%8P;1=6;CQR]OF124Q#E+6
M6_U/")CQ=_OK_9ND\]I> ^O3>M&F^F_N"T:N]:H2U<-QX.62RW-")(N;8(I?
M+*7N>F5O_D/70(>MJT_ZG=JU8M:_GI'[K>@&:_/B6OOEZ/K!12.9?CG\SYFY
MER0$AC&"H_EW2_O@XY>9_+]G"#&&^QO M=82WF":346 8$?I@9$GA4J1 YKO
M>DY"%)^46=MYB!-1<O\XU0+A:A);)<4J0/&#]W8]7AK1FKCPL+7V"5JP8:<?
ML@R>*BB59SQ'W\9RH;Z[\*>Z@ ^_=AGD%Y].3@W.]2V^=<-\#X=BT8VT0&4Y
MA:B]!I%WV3YO-;65_\_KI"'^O"[_/^HGV6O:P(MCZ-*E?DZ)"1-D.RV0.9J!
M*R-$ZZL77Z.Z"(E6E84=R#?6(5:M1YCA[^Z3/56:R *(U,R9)3##FDV*\SBZ
M*P;F*,"]O%50VO6G1@81D?0/0_WGG_@S+. 6##L"K1CYU"@[R]W[2"+\1*[!
MUX,=LI&G"].T.O:L%[T@]5W<Y%@9NN21BB[[IZ<_^0JF_DF("([6C9LYW).'
M$3-^$[),?N]WJ&Z8S'LD'V)&UEK86#!1TG7'QXHT^ESL9?TYGWZL2P \Y-JD
MP"-SCP[]-J'$R,3$.8.?G.UB4T.^_]%]T6R!9S7DR\X.LVIL:QYZ_1%V0H[7
M_V1%OF)9L0J%.3D0=D>"RG06\&Q;>/7%LH!R7 Q/]1Q^;W-^ZT$BP@L6$AC\
MR?..QK%K=1CKJ>NM_IP8@V/I-6M1,)$5U'&D)DA(NM_M]$@-=KW":2(LK+'I
MMM+#?IJ%=(=6A%GC V#A_^GNZUTJ8EG1@O 7\&K[CK7QC6:T['MM;)2+W(A9
MA%M%=<J(3;_^L;H/=1X7/M]Z$'$]$7J/)$6\P@+$ 1261_"SM@=>G&VH O1,
M[L,*+)3]MH8]CL=L41*3SC92#+I?:1;"E(U#_TEC;VN9(LAPIHP3DU^:!9S!
MQD&IOOM8P+P,C%B G\G%;?)2P]E?G(4RC7*$QCVV2L/OX#VPL= * JF+=KZP
MK4^H:_8^N!/L:J !MZVKEGA[(K/GR)N8*Y\]3$Z>:NZ2ZNK[$DE)8S<;?4MB
M0/_ADV5P09@%5.E\"E:?BR5A"Y .U/@B:L!%<AAU^S*SETVA[_70W)TZ+2$/
M5M)=[D-O[=_=XN0K'I2,\JW@V&%KC#UUC&=9J6 ?"U#=*60!R@-0Z@'"2D>Q
M!C@HS^ZWP3OTNA62'7$%#[/CA@ TR)S,A*V\,&8!G[7S*7_&'QTTH(_&T538
MTF5=$'@XP0)V38,,;"12B5S?*G/.&I'[$R9>.:5N5>&=;>OG(S)QU#_FG@-&
M+\5".;5+9VL8 7H2H9U"$RJM9AUXL/3^FI05A06(NA"HL318L^TT:1CN.9[N
M/ Y+/=06EBM[EKS^'M'T/S#WB=]J[I>VHZG>?M1#G@Q.0T7T?]G5V_Z?846]
M[?XY;>C_),TO5F/WQB!3WXN+\D)N&-*F_GLOTHH%W.C&,<2^=Z*^&AXD$Q)1
M7%1C!^KS5RS@)G7VUUC6I3*OW;NCSB_+:GL^]4PT76GP.6K*<UP/&@=?5Z1F
M,9LS8#N'WW"!14R^V(=$*QCE35E6A[V,P?LX[:Q/ XA2$:?8T?J0C!]32_"2
M:2VRY$IM"/&ED;[1&[IJS3=ZGJ]2NH]!L\L+(* ^^P1]3$EN9!:Z\I)VVIDY
MA),LH0L@WK<3Q]S+LS=(@T[/OR,K(;)<ZLY;?>*4F *V=<Z1M4]\U(EMM]H_
M^W/WJR"9"V7[##YV*SUA <A, (2.9K7<"\YG\G,3-\ %O2IP.JMTZO;>2?$;
M-P=LYUO/6T]-B1Y%;FER_T)LV[=/'__6P$5\>+DM>]_0S8'[5II3[TO5C_$)
MB-W6M)!+"0-X+!2!B]RH_<P>6(5Z$FSF)0Y:Z1?+5!_4IGS;4R!?&C>3/'WB
MI5CT1(#@9YN5=XD?C]YY<-RMI5P""F<'/>^&P+=>^%WZXL2B4XYZ@F$.(:72
M1FWQ?E*W$G%GUU7=AG4V<_:(SE;3)6HF$*GCR--4M/A"AH!FY]O@&&+:8O.G
MF[MNW(':*R_F=*A6,5ZR@)DR!2EJ].PC=2&D&?B%>M!R[-QQQ(,,C[ ##T[:
M:GXL.MO( SK?FB<Y/QEB-Z^$X@_V;,65N\>V[1KT>:]O-ZM7C]>U3=<)R8V0
MGN:.=I(V84R<DA.!O\#4_%YC"IP"G5I=A,F2X<B@/&_*N$=1J6R1E:W:$S>G
M]#C3;U^O<&1PFE[UG?,L %!Y=#OJ6R(A$KVG$B\;G$U;"=V3ZK?8HXGY^GN?
M[5[_VJF$=XGK#@'PK+I"NH1JIZ'J=S\8T84N?3HF;5>.7UUZV-L$SXAE_NBD
M.$ABU9Y3)]_/F8#6C_!WU*G*^)C-ER>N-I!]*ILF'&X]?=,H(8D5.>=4KZT!
MZ,I)"J2<QB; /-$3B-F1%1V_-U3I!G4WQHN1GI# /.HCZ_3I7X>?VTJGA9OM
M*KYM>/>3&T;K##2$V0T#[4A"<[IMLD*<U.46 AB%&(]BD]''QH3Y'H1.E]Y5
MR:MV7M>R?CBGL[-O07\"Z( =UT0+4A],S S\]'=VHB9T$.P?7G]_OH%'M:J%
MMXH8OEZ7<GH8\LF:+4<ICE0B.5/0<Q;28@!K)@A79M5((>S;;LL@JV_D=8PI
M\CI_N%S3F3A?OJC,8 <[;I>R*O1H9[N]U2[KNQFAH:^^8C[PK!HF#7'U63L"
M]!VV\SY 3>CBRWOS_<#UB18;Q%TJONU!W/8Z05O-9T'[[MV($U.8H$#QG66:
M&6K 18"100>8A\A)DX_D4D(D3C_,\ZMMQ'G?%$,\/LUIJ<%_LFN>B^Q'%[Y\
MOJR)"IL;6SV:D^W08 3-.%JFJHG.SY52]N\K0'YG=RR*W%$PJSY>H"WP7):F
MV[JC4W'UL1NOS,V%+L7EC1/SE\R\.@N 4)=&]D>KR5?JZIL>@=UFU0-VO:-K
M6WSN+U/EW)_8&O4*31EF;VWA5X+^"#70GF3W#KK;>:D\6+=C]F"FP;&%&6O!
MV3?=4@<Y@HYS^9O:*=Z?Y!(FH;G^A* 9?(L!M#GT6-)-BGAYLM[2[D.+-ADW
M-@X\F]N.3@Z=Y\ <![C(]I1NL+%T)9_F?_LCE?=8FL\KPC7$N'N%RFW'^E<!
M4AAHH&XZ1^@=Q0<Y0M_7)HHH;0V,9+H*,<FCKP6DOJS,6CHZ+KTF,WI.PH 6
MSCNVV8XDS)92CZ9%XS%(7948)!^C<2Z,=K5V:'.K#EVVA&YPOW),:4HKS<X5
ML)/M['E\%4M5BUKV!['$Q"^\UW1")@_+;0 G2ZW_5':DZWVCZ](.C09GCUA'
M&"#:[+=3I@@AB$5+N<O:PKFH>C%3<Y?G'B>[#F+T:11W]C<:QY!7J/&Y5+U.
M%Z'85BV$))^[3_'2=HRE>TU E4Z*+I!7[E^C=^/#YPXK%+8$Q8MN-D/"W&;0
M$_7M;L;56*MKA8-;\NE?A*^&*$;/WX4\>-AK_< 5L5T;:@.,D>#AT*H+?RK%
MT,64VAT+DS>?5S)DU$6<;I>/6CREH5Y<N'?T?-OZ:^$?M^20K_S[4;1*9#7-
M!"G+R(;=L;*T @EQ#?:Y%G-1(D:OG;TRIS[^^KQ76D$'&Q#R+D=+[)8/7D,V
M1)O#C(@G6=$.T>^ KPP5*H:0^PH=G,^HX5I=]@\2!UM*I>+,CL1ER?E+WQSD
M:7 C0NDB"7[1Z J):+)2*UK4)[?_?B."=K[;RDKCQ^.QWXDF95E]K1+QB1X7
M%&J;?R*=9C/HPO8=XQK9BY\43@P@+7WQFM<0P@9)O7J'W*<3'W89;9:*,9[]
MD6;QA _;G3_UY6>]*P7D^07/&\#:#"4;,[[&B'EP+,3=>E=7Q"?>3[K+8ZGJ
M@8'=,=1!>H.%GX1B0[%)^NZH84>U[.]MML\/9%\]:9YG/?O   +L3CESR6RA
M+QX]4V6XK^&["EN*V!.O9WH_SG =S\Y5'M2_SO4A2<QLZ)9[[,F^4#A5C9#H
MYP2GNA'-?Z1ICY)\MZ[MW_7[WOG>)TK"_6D"!PUVQ0XW?6.;_"%2NU^?FZ9$
MUV=^&23EX9P'7+]7RD8;-?T*&0F3EI5VY8J2_OF.&_#'E>'H8K$MZ,JK-=-B
M30/0YFG=O16@]_IU/M+:$QYX5^KME"\<KM&F8B("P.@/V$P>OA+'%@"><)E@
MXXO#*.'@@-ESF>DX;?(4(L* \D69WS:H5052>GNS#X)N/HG:$RP[)XNT'%BI
M# X<&IJPJZA,IG65?WQ:YE-F(E*X^EO)34+V(J]2 C65*< 6\P<N$PL9X>]A
MF\$Y0H/J43@1[9=.E" P WNLY&C#OEQK8KV/JY/Y,[6JE[X^PY<PT5RNZM#[
M=T_;-T/%8#/E/_1M_Q=K;QX.Y1N&#3^1[/N^CJ+LD5UD2+8DK78FR1Z2;608
M%+*'HH@AI(3)OAN[2K)E&\O,F$JRS5#CR8SQ3K_W_8[OG_<[CN\]ON_?V9[[
MOJ[K/J_SO.]K[BN\ J$&1N@LG14=./NZQBAU5OEL_8)%F_EZ DQ_Z*:=<"2E
MF5RTS4!E? Z.74VU]F0+?7FJD?MT**>PFNC<YXWR+ +4!_@]=AF$:M,9 KQ%
M(1[J>0BPK9/\BYFZ9VG7W[E'Y02(A%Y(#!3FLPS2"XVC>[Z\)3""ZC"!!/]W
M-=E-7B[ZN(Q6'<DRK1$"GC>Z^@::ZZ&Y^'?&(6?U<21?C5#&Q(T$L?2@Q9MV
MW?0Y7&/@[$8#Z=KJ<%Z[E/N)/,F%:+OWH_<#O_Y-M]CL=21G/D</H+%4(H.1
M&1O1[L,>%[.1EF83MA2:$[?E<JQ&1F(DZZ@FBAKL,)7%IPHYH; *'.D:1M":
M& PJ9&:L*.6.%#KD6F#"AS0F2^Y#N;\>&?JG;)]/?@,= M]:XG6[P(?1T3J=
MQI(-79$)DF$W%HP:Q!KR5.<RA'*_OWQV5*(7O,[X_!MJ<)KJ[[''2%[\I/;;
MK:/7?A68$QN<WMX-@KO%WFL;\>C%XP4' Y"]@G3I?WLA:$04,7F*D.^6:^]V
M0F5-[IA522;;]SL,H>NIH9;N<WO5T,)(A<ZI0XA1-SVH,#)\.^<T&!#^#AZA
MA'87XES]E"_(4*?3S<JG8_C-&?(B=A':^!35X--S?87*+0$1K"V-$GGZOK",
MXVZQ$MLS5Q6?+2ZNT.(F$$4]&3N9#ZM'#982T]R.J?./4-@W8H=U)EJN_Q Z
MV<(29/'E^:H.M8:4MZSF2;$DR>$&I=>01^<N+C]@9:'W)$?P(@IH_VCMA7D7
M?TA3WV!DL/!GR)QHY<@+9O2QT_=\F3<QV"S*Q)21'%6'!@&ST C%<80OPD-@
M,4/!,=LKRRXBSBI"JV\A2_^+$-DM^.$A$+ >R$EG9U!UJ4:[Y';W9)87N9](
MM2C]A&GHBA?E>M/D\?1O'^Z]?)GY%_WO;M-Y,VE,'RSIC)G$H$" *$?=J\2;
M,B;X(^,.;<A>M0U"]T$B@IUEX,P8Y^C;8YDWN2KIIT2/WI'I'&<E9HP-K^GP
M8E.Z-=U]-5P_+Y^4D3NKLBC([_7RTG'-P.^F@$]PT+-](FF;\@TJB;R-24&)
M_$$E[P?T$T;:-F#]D7I(O^8N1T)S_JIW6JF>M"ZJ565WRK:A&0DJ3V'%Y'0Q
MI,:361\5=0.IT=P=#SRQ&/M#(&C3>-;V(#U6S=(OD+LZL*SC:2(34Z3L%V"]
MA_:&^1-CD;U$-9U*IEK!X/1S$()#,EWB$/ <OCW9G"2HEW#=F'DS%=KQ_64X
M=;4BC"'/+&E"EKV8^L#?[C)9MH6#=/T"H5;Z< MJ@^QR81Z[>_EF<V[">>4&
M_H2(!/:_+G2V>] 5/W(N>K^(@9KG.]$OC84<L;&3$-*UY]<'QP\!?[_]L31T
M4)!:L+%7CN*ER6%FI5_Q'E84&=UT"6!?U/*?N>&O%VXF$5W!FY7=R88Y"6-7
M\@PZWYO<KOWYZ9L4Y>I+'I7?:7C(,)J=/H'A;CP$Q$'CM=6I6J?2@N5PSG,O
MUS-(%TM>GOW^0(#-ZY:5[%>8%!V 0RF)H&<X'BGL5+\F((85KWXFL#):=NMF
MB;<%VQP+'-8^$%F-G!^FV),4-AI*?SV Q9=]+6OY6IX9,/Q5W1G_X6>%V2W"
MC2>7(]Y\82TIX?7D8AN-M4/V^G?K,,A^'X.\).8Y:)J]KJBD4"HDSG :9<D-
M,K50$Y0*(9L/YQQ^,5;?PZ\.*WHT$</+;0T'U=6UWKS?W,"@22NQ3-T4G_-'
M]M_2#GXR;Z) !=X-'SSJ"(*5-)SQ!\?KU[Z=87352Z9J=H^DUMO<_)1=;>6Q
M_G%HQ-7G;XXV\%ESM.(.6J%XE(ST07GGB?Q8GJDP&"?-K+G5(NW&F4+?H-+3
M1G-;EZP&P9//FG/$33YP36]AZNEO_:IC1S&<ZJJIA7Y&ZJ\#.=-/JWFRP(FR
M"5".=404F;D?PX50B5JQ$_I%P<H\]/44Q"UUSY4MKTO<H38HTGR9>Y$>D'F[
M 50]M+_(L__L:GI@IQWWP2]<;T" ]X2EYW&3^L2(^W?L%\2'IGNO12WZ)V\F
M,@#K*,ER(U_^K/Q,*/S=4 M?RI19P_,+[RUZFSMWGBP[RDLI<BWQ +*HLDX5
M8C OG&IM:]?OO%6XPJUKUQ'UVFTXE'U?4P#J3#L!VI594AW_G;;7U'3ZVRZ]
M[EH)&.GX>3*P%!]_ZD7@EP>G/MBKAB_T&)3PEC1B0+79-,_I9W_4D\ZJ?7GQ
M[+,(]M'$)5:# Z(*[R5$41=XP'?P'.H_=I0^O<R>ZTYZN>NR--^:=FUBV\3E
MG3C;!ZXCLF6W-L/Q^-_'GX9#^8R/@0HK=OV&&,"?+CVUT'_=N:E:]]["";62
M(6$\<%O7+.E::^]56#K#XS:'@) _E!<:I";9G[<GN?''ZZMV&D'\[TDK?,Z=
MN]'608\BO^V_C(OIIUY&]MK68GR"L>>)A)?=[/5?PQ:\ZW>;WO[1??3*3BKH
MBR<_I%5J[QO/](\,AAG3IQ%7R86729CX6 F7=6=A2J7,B]NS+=O"W\DY-S/U
MCERI=FG8N]BM:; )4V48R4'_H-G(U4!AXT$D/<<25H=A/P2\D<D83AHOX9S(
M<&\[7_MX27Q9=\Q9P7M!V4  2LM[6^>Y ,Q@E53"^P+CCP25$E<WEJAF>OWQ
M^.ASSGW:#3ENSL0;OAS5G\0SQQ3C&R'N(=C.#B*$)A(5!A.'K1T"/$;\@2N\
M/(ZCWY&!OV8U+2GC/'J6 F_.O.T/5+66.UKUQ!PQ^N_03NR@T<BT&#/?CH12
M>@,HG@14+Y25H86A%33CJ3"ULW;<_;?S6G3103GF#R*.R.=R!6:7&Z@Z(N9+
M>$4.TI#XDF+!@UKCV5?-+Q0>T8(].5U'RVR@*"E2@M (5X?#/9:D&W$.T $#
M=!382T;VX9B-(;]B-<E)Y=JC H,.H8GJ\O5G^LPE,MWF2,"> B  Y>^67$NC
M&C&L9JM=Q-I?/W:LJ!+^V[=Y72JQ<"-W\:^,"V1EX#Y^G]@5P_Z?$OI2OJP,
MAN"GGPR7FWL9UY)Y<B_O1%VT>VMN.5SY?/E5'(3(D Q#[[%?R_H@W*JW)X7C
M,MWN_UE>N?G%6H6/XU&FAC@IZN.:^Q_JO_N[;AK)D:F#><8\Y* 4!KM13]E^
M;NZIV+Z[$>RESZ3Q3<5<3D;8D<]J:'. >0U%LH,E&(N"+E0U4()J,Z5F@5YQ
M.\$-N_&UL\FOUCU,X%'DT,57K29=QWC%OR!U,?AJ&.MOR$-,X^O"*OCE+]("
MZGQK?E6C ;=?R:=N>F7+6$W#;7OY,Z%I4=LFD#<,W,_?U NEGJ)!DH=FVH\:
MR^?87N/6GQ\-"QR2MQ;KQF=\V-GW[$($KD!!-:,(''=86I=Z3T0]B-VWID]X
MZE";*AY=7+CM?2ONPW:2X;&E$N:.)RK1= YIH@KN,9)D"TVD*WY]'&CCE'\!
MT^XQ/GHR'7U<9C"%MLY+9YLGJ?>YRX.!Q&#I]6+(5-.H;5-\V8+U&^PP=+XL
M==G U4)*NB*CYVAF*; ?%W.&E$]9JYO!W/'K-D!838CV[H=%"KKT!G@9M 6:
ME#T>[Q%W^!'%7'+-2I)39"ADYU0;PVV5Y,RW[UPA' CEJ4.@X7C,@/NR;:A>
M?NZ(V/3YG#-SFZLU,6M4<S@OWCV%I#U/NS;Q.U"=4)MT"/@E]9IA%_K/\ B9
M2K'8/8]LO6F:V_7>0(>L$(_$EZ/88]E^*O1 &X9[[?C6=6M"5<D+HP89E<\6
M7K!#? NN'!O7PV]RZ/>4\-XZR,3@WTKH;4*(5!@3'-6WVF=\$L-[@ H)B A2
M.[UTH\/B?M6$\;1\#'Y.3O8)[RCRW_U$9U<'BO5A#^U*S;A;DH,VP\-G1+[E
M%Y4W&F2-+"0RCQIM*7Q'%W>SK+?G_3L0YR$EU;P%8Q#'JW#@#Y6T&NY;<);T
M'-?OA#GB_<U%BTG62N&]8)I(\]"R>GPW>[OC"9=*LJS%2UF>'N?1WJ#*$B(V
MSBB-SAY-#70'D5=)ZCTG2<\Z*06)!PO-790? I9M\B@9^\]2PL/+T@%?,4&H
MA8!^*%/LN270X08H3;"3<1NNQ"Y*>SKP1VW4EC\R+ E-W!R+G?X%)5D7G?ID
M-[?;WY+A$Q0L>OVK[J+8TP]01'_2T(,0&,!8!FZ'P#?R'PB5:0[YD]L$TNQ^
M@OPZ#1_,L@RB!D1)OEB1(N_@TUNOH?)G6#X:<:%,@(_Z@& \[,4A((S!-PTM
MN!9/$6;[0;1VJU/>.9L!/2ZT,0\SFQSSK?TVA7/'SKCETT2N#Y_-2Z9":5#2
M:'F&<&;'VZB6BG^[<VQ>&5FE4<)UZQ+[H3/_A]MHP'>,#Q)4M4PR/@Y_-=*/
MXZ=I=K/G4*YR22Q5S!=_=,L4NE1=-8XV[105-S!TD(]Y2S5%..;B&8@G"M]?
ML,MRS#6KTTOQWOD;8,PF&1EWSV#](:P 0G(:2UB6(&4][N0D=@G:-4_IN,&7
MG/U3[J9)+#:>U\V\7<+5*J#9$"EY3F4^S$[J%Y0/@\^(W"]^IV(7PYJT%3;S
M[(M-1=."RX#U%J)U2GYO%/  S>B<!J]P<%;8=/@V4Q,FI;0U:=:"1"]\HUV#
M['+M^*ARP:C\_!M-YC.G-2I9I2(3_Q5V.4^C4HS'5@Z!Q.:)M5A?)VB#^M+I
MFO&]A1.W+2A_M39=*VG\,,)RUHIZJOLY\N72RO[H-_#8OAE#=F\3AC"-^I:+
M2$&U4SVP8J%)'HNS@8P([29UOP@R%H:G&EH1I[<DK]05?^=C+1#>D='Q_G4^
M#\&S['F%=6TL >%1@3 E)66L!/*L!8?%N$^JK%OW#('E5SY9;=R+8GURGSMP
M]C,#4\2_M1XDTT4[:]T2NU:8D.TMLP!O#P#EV+____WH_/Q<!1HX:.D,)'OV
M0)FVFF /G56QN+3NA:.7\YIA@<7+\RW!>8H:RP''V%JQ<SRCF8K,N!8./8>5
M89IV"TU(@1YW"/"Q&6-X//[MZ5-;Z.S?R>K$O8$L#GA=]UE?YZ3\$*_0H +;
M'S5E&:=_?-.$OGS-]YBC]L3Q/JY\C]P6@'F]!K<J%"3\UX5Z%8%D# 1*7AC$
MPN(16BL!ZFSSRYW.+C_=>6PO+T=[T&MAYVJ^+WYI]9;LOG81SV=^KYO]X#44
M7^(Y^.#B$MQA2*)3/53B7/$[_(7&YJ<B$-5<M6IOG3\QZ_&Y*!/>N2YB@5M?
M-^,11O]SKK6,N9Y5Q:[^F^NEYG]SY?1>ZG8LZ=UUN6<^---S?ZX'/9H%^L%
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M8];(2#LE<;8@]83)B<=6U4D6"G[*5Z,DWYL8D[[XJJ6:$T)@_S9XS(SE$0_
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MMS3C?2.$T42G']7.WSFOSI.;"D>>SZ,/>KN-"$\4B^6YALG+?3KV0.3H_2.
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M=,LFL77EK,74,^I0X>8%2\]]_P]=:C=BQ-BJN[3U4A00.8,H\X$(_=.@ <7
MGMZ/=@$ODC9,]LJU;AP"5XF5/<*1<[<F/PG'/WH]K7^35,!^KZES=<]]GT>
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M^B==>>!6!75?BD"+TSE RLI.S\[)GR=9X^&6^*&K%KQ@,+'-Z\.'7Y8N+K5
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MH\&;#\!3>,V1DP)/<P33!S3=XL0B9\DO%Q\P;X<^_!90J\M3< BXF&/',8=
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MX^MS G2(]X?Z"U20O@%M&U1RPXAXR^!Y'VP+H_?$PEC<T)Y8U%",QAZB$4U
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MXA'UF#X,9WCAC>QK\XW++/&[HV;VWLB)S(_7LGB8'\O6A.>E=9T MO\MII;
M=(&WOKBM<J)D?O&83]B'I/N\ _*-:,,RR\!+/B7B\F =>IQ[2@*M=_%EH.!C
M$#^5H9QJ3R<W:]:'VV]T7&>_SWZ_>"+#/,X81;EF?N^'H=:?W_04(AREP>4
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M1T[=C382\*?^8#IPQ]-]^@W:VFE]=%]UX/,6\ D83U"0V'9;.?J)1Y:=/;<
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MBR:B>Y8\J<J!"/<2IV77*^;GI<UYW8*Y+RJ8A$J?UJ8]9B"9]5A'PW6):*I
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MW2!+L 53U4 DE_0(9Z!TBE0JPX,'%T'<I92;S"\=QFG2=*W(@D]("LZ#+3J
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MD$MZ27T)T2'0@L^D!N-HY9Z?A-T_3>(:<VB/%S-X%SV^<3T\*6RT%#,G-JM
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MSQ=4G$7/-YWH@E]=]&7P4S7R*VN^FP8;!NF$!^T'">S%?R'; /5FQZ"8:"
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MPK(A& ,W0:L0$,]1YPM&WK26O=0H'ME33X-!>KA_#E0SV#IC8TZR;CB%K:^
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MGZ$_OOA[._Q_VZU987KA#5;9S&OH TUTQ^I:W_NCKWOZG(>=$/JK34(\NVV
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MKI^#IPI?I<36GN0#>+;EB&$$0Z[63<-\(VBS<\B@ZROP+O7V2(.2U^DQ;<*
M%#[$#_IX8)\\ST27#)!R]_[XI$UAZ_B2+DL&UJ'D; ^J>-YMH;Y!6QH<>W._
M2N D-/.Y6.^<Z#BU<-X^Z88T'9?:("II =YZ7><VBPJXV:@_Z2*7;_TX1B[O
M>E8RY^W;H<'BP*_IZM03]%Y&&]A P0EC!C=-=&-8HN2(@>JE-,.K,BO4K(78
MH\4JE:(U216GPJ+Z^YJU(]OH0J:C();B.-S+.H^M72-\EKJY1;CLO\P9T]K
M<@3;:?/SX\D<H95PK"!,[R=GU]?L&_FFWW5^6S:V/IZ)+.)=W,HZO>1[*@JP
MV*V05L^S[M)$%6:>PG1QCM.^P94;S!4HZIVB]]?,CZ/J;)M<??\L"ZK?2\HL
MLSY?XU!^]X4F,X;W%Y</9:G7N-YUB4R*YNR;7AZ?A8,QF"/U?0/6<0T-I^A6
MJF91MF:?ZI]5\"3R1Z&=Y[G(D\RT9#G0Y+X0-#E?.>(%G1(WSAXL>_%R^FKY
MU![JTR<'4YON=O*\^T1I\V-$L;/0!^C,N=Z.(3Y4+F5W3N(\F]>^,?G,^.L?
M*065K8]L]AV7'RU)LQ0(KH]3D(IIY^,=XASP@3?QMT-W(U!DF ;*FW)T1$6V
MB:.0?BI1V"I*GD]M?^H,(';EF-Y%ZZTTK66(,&=DC)=QI0G\.J]]:*FCIKVT
M8?%%J9O55UO%7^<QYV];E&QE 2I#LV+Q9HL$BU&6%O,>Y[.)VUC5+0I5=U[V
M4?V$2T3 .HEZ.6&O9U[7"W5U'V;-YZ6B)4-^ZB7F>5TJU^/P]8VB?4M]ATKL
MQ%H\R_W&%%*2^2J/^)\RVK.@K=VR"]N6]C+*A!3'T6._)?J1(,1TM#H%)X:6
MHSFN/OK9*#EQ-B(X9%\6;XN-<%9IG/$M8_<#1IE%)$8(NPJF^A,.+0?YF197
MEW,X^CF3^'I[<5^4;8#3@7?1L8#($QNAMX*<RB>/CR[%@,(T=P9^%"8 [OG-
M!;EZV,,RE$ODGL]V.NVM>KXJKJY/]_9*FKIF]1<+=6797,ZZX'N(G073N8.K
M;^*VDP+K(KA)AN[UXRBU->6/V$?"%!1:DD_"/)(,$MUG79<N6L/UG@L0?9'3
M^O/JG:1IJ MH/Z>%,MPRM#LT-MZY?3ZGYK;VJ=#4U*XL1;W3]B<(7E-'C6^=
M?&V?4+2?W<S9S9*DXU/1;O.1,NM,"3_3!(<ANYIWQZ8_KV7/^VM>.3T@^,-Z
MRI5?V"7W/MJ8"^0NKB?4W ;\R.LP72^3D#*LNN$V_[R]P#+!G);61"[T@M;[
MNG0_'I,-YHVF?XR5@UA&1U"[@9 =@!>C<8WE"\+)$,6KJ^)^^?><D8K>!^63
M*%<)E?M#=X"H\7ZL\ YP)UV&=8%="].>.-3F6XZ&@'ZWYR]E5KL?6+MT3B\B
MX8B46?B%HQ%[(9=OJ#-5.5]D2;6XU75N8</HYMQD=9RDE:V1_S3D'O REC X
M^L@!.UI0C?_SCC__"VA'"W$ W;E%40QFOOE8"Y5"35N_I^]FU2Y\'*L%]DK.
M* 1Y,/0-@7M%NT$R\SQGQB6NZ0U:Y=L?[".$R)' &SU#5T;]AS<8[-SUHQ"%
ME+F4.<TW87%A#G[A'^#UFSWIDTOSXW$$&<S7]&*_?.]DZ.<OK<A2J[=6(T$O
M5,^<OISK\RTUX<IGL7-%9CC&0? 2\QR8S?"BQ;V@#<V7)9+A OV!G+YB>W*?
M:V+ ,[=S:A"5#_U=A,5/ZG$7CQ[5>C"/7PVEDR@>'"FX%-?"<M%\IC'W?N"?
M6]A2UPFH6<"1BSV9N61G%?4&X($WM8UY U5,AB29*='PY O9 =4L)WK,X7K7
MTN_2CT4/I*IJ90CK:\W53+TT]OJ(UZ4O8!N=5YE<MKI"QZ>@W<E#R3#9N)[+
M>!3F\["6#?66S^?6+^=RZ M6S;?O!UWH_"35L&CTKQ9T(4IN*;[J\>F,2QD9
M)]X^5?38 1Y0>5>F#3?7TXMKLS\0#KJ=?EA>:+1P749>V?GQ]#;72N4#8!-'
M@,M'AXJK-Z&T'#<N-O$$:*V;@%H<@9X)]N-0PB/N2+J&CW#:N(>/<L6_"1 J
M5?AOG5Z2QO^/_XQ7^];B;U$"%"X.&[I:X_^TG9JUM:VR&;]K)_QORYS.P_O9
M=]A2/%N]D%5'YDG.)YC.*'X'\"+)+V_CH_^:Q@2K/V)9S6M,7]ASW=^=!;O=
M&FAA,5V3']\#Y=T! N!31?VHRQ08D8R+5Q9X=]-0XT^8C6ISRLUY_\#5>7:,
MYN'U*:+U5:]L9!L0,?X!$<618Q=BY'PQ_+3"IMSRJ5V_9\[SY&^$\?87.9C4
M[36/XK':]1"A0L)\A')%EB<NB:!"QZZ.OO(Q28]EG5%Q0Z!4NJZER7GPU;X^
M<RZZ."3VP/S^O>5!BP2.B]7U+_Q+::5,570DNZ852V;;,U*_&4"%49*6!4/I
M[1SYS&<S,*N[TS,Z<T>O?^P2B77\GO^+.(>7^7J-TRN(Y/,5$?<;$^]5O"/M
M>.KSKB@38'?DIZ:14O06,P0SN&^):D<S;!7GGM5^&#E]N:F-:57BL='8 U59
M<#IA&G\'V"HG\S\B^ML_W &$6<;DH;CY?SJU53JR;'K6UWG[MX'Q_?,A5FFW
M;BT=^G&*VL3V!MP!?ZZ_E>?T; ^U0_>"Y5RWF+ZWDVO(DV%:ZM1-QMR63$T=
M/ZI858?27W&5>I'OSBN #U>"@:+N8@5 X<[[TOV9 R&ERSEC#C8R8?IG)5YH
M93[SO*#UP'?5A_<S]@Z>Y]]O!#N -S3A_9X6L[#[]Z;4^JGA1[<"2F)%OO9'
M9GZ]/L]LH)-8XIUD[048#_UL=VIP:?.WT-[D4R/JS:9Y_MKB%U?A,T>JY)1B
MWRI5?2'>29\,9R2!;#JOZY=Z8O(^1#Q!T&\7:6#X]%EJC6:O1'^\/T^)<VCX
MQ C5-,$L&'&5I0TB7[(.@!'/4?J=;PT)J2^G2DO?O^M[>^--;XN^1/^#' .>
MWSBJ.%,'[*.D4V-I[I2P=)V<(D5:6F=%Z6BG6GO7X%+?Q4?&?*$'"5E@YO,9
ML(Y,2C*P59%K_?:GJDI#I+J!+^OTQY8TL3U7O9-^+AM]X>_!U<6OMGG3;!G:
M=/Y.2)I)7(QO\:_PW%T,*G)4N]BFWT90\ER%Q*7]#O&*L'X/2NL.0!Y:)3&O
MH06_7OXG2SF:H&X73K3,72<YE+([0JTNVK+MFE'7O"__?BV3N]:. Y%X>@%9
M)Y'>1TY/:!6EJ&4LFXPV3?Y 75 V$E$^(=NX$.HD__'S>$^1)#L?ZT^,-A&!
M"=/XN]=W_^) ZBP#2F?\&(&Y3L%WKP0PS9IYUV)U]U^/ G9%F3F3U=O9?N1X
MEG3,AQR3S>0W9@\H/<,Z#>GB*_J'^*?*1MZ,W-: 'KE3O>M-<,]1*>E+?_%4
M"#=UO91<:LR_U*7JY! 4:&E#5.GWS1[-_N?7T T"ED%GG:3]&+;LI'6,(#C>
MA96$[0<;6B/IB"[KVZVCK;49KE;G<JP?\JJNGFR.Y;GDZ&@5'NG85 U<&G]-
M<OCR5]CZW%;=]">)P./RGON]?^/SB'.%\+JSR41/7+0)Z1'+6Z= ISR"<OBO
M=8%MX6+RIP=^/G&V!S.F7V#TOB1MXY!$J7J>K<D*3A^\/OX#:2J9HIZ.$;V!
M"G&@+:4BN2)'-^"O\>G'R*?]]">AY"=%%]^4+!C9FT%*L;[VD[JV(#WR)5AE
M-8Y'\].-+2ZS4RG?U?,.7L_^<2YOU]5$KZV[ C,1[9[(2*W\79D64"57,(8Q
M0;OG;H/KP(ER]AM$I)ECM";]4XI!C_R#'_737DB)H9:S74@,2Q#'M$)EVXWM
M +[V<LN;14HCB[)A6#'TP=HS91'/6=4A6K=^[/=.L^\/FI-06*42_KPR2@(\
MVUK#WIX5T7M]L>>%A(&<X\6C@%*4=#L:^Y7E2]&-*3HRC%%V<YD !SG=U'LK
M59_R->:\#[C8_1)TNJ)S)0ISL^&GP6.>+3<:E*'/KB%Z#>A>J:&)M7#I])R=
MPRWSA=_2_U90Q8JJYG0WIF3)'M_]=#X;YT[;C-D!D!4-;,,&K (HX:86>-LX
MN%OD9/[>SG[AY(MWG8\O$M86LZ5X*,0&_&IO,6:4Q+_&@E:Z%6HR#N=LVHXZ
MF"\._N#A25H(='+R]/Q(KCT!I.<6<Z]*W2P'#\'C@^'1;U[N35:CDZ;MI[,4
MI6>NOPT@!__>4F,N-!ENRS=F!P HX]40IM8RMA;9<87VO6%N]._T<BJCKBI@
M2B=00$A:_V.JA=!S[F#.R!C2SV-KC*G(4LR7H@-@9ZF?\FYEG6]KZEE:+5L#
MXY/N&60GM9SOT0'IXM$GA)\,"@[]PHRL6,W<HT3!>&"B7)<7>V\'>+1"YF!7
M'L%9B0A[?(>;*V5]=<R,EY[C%W#Y^FC]4)U?^+X;$G SHQ\YBII1CH_\B3K'
MBI/^L@FM7QNCX*8<1;0&NP[NJ22!X$'M1LO2C=O#-HP9CHQW6IV&S_QMIIL&
M4UXMY$SF 69:[DE_H),XQF%Z;'I/,C$-J]1JXTW!)X:HG+WE?A/W\_Y5K;?'
MGFD<J7SB*"0=KJ<VL0;UIFYN#S],^;(K )]/#$!.-)UC5[?JE]H@7S7%F04\
MK^LK\0M^X>G6)9-T44!-6#/CP]JI8^_ZM")UK?OR =;LUS]P4".^LR_\Z\UO
M9OKS?M8J5Y^/ZNIH*]%,]J[_L%Z8SWDLX5<.JC"%6?;TI9Y4Z#P_56M>&"F^
MDJ^O^MX^;M7:[X'OWK@4PNC5+RJBTP<=Y*.\0J(A)%/[:HWGD (B$C^)<V*_
M@O%\(MOMVA@;N5'S[<7HZIFUT_K6B:H!"L?YRAR\V]L7>#Z<4+9',@U8P>R7
M<"^<+.L82,6^7-Y^AKA5T+FO\:F#6^VIZI8A@1.#TC:\QS,3EI.8)?C[I]X-
MP<\!()2<ELN\BS:@P0II&Z1.DEBH@OG!T7ML>/>^)ZLI,@(?K#<JR 5W !X]
MWBCC72'/\/$[P%MX-X[[U+#Y$&;P"Z,W@HZHR,G'2KO-FKHTY_N4-=X*D#LE
MXBN2&<N'WVX%B@%,'+7WW/5]P)8Z1SZ\1X4CI,+EU9:!$3A9E-/#Y,]EY# 1
M>0RD%NS&0/-WSKC]Y[9.1BI-N91^>0Z>CE8J-A"L6LG7'DVM?'\W4U UY=7:
M34%>]3>B]S6NA\Q&MR8!-.BD @/[#2;!^811 IWG*^ZQK1:%(ZV&+C<U9)8V
M%FDE5R4*!6J6Q"A^4.:_O]72CJU#4$\P95?>CZ733%8ZX7MA"G=R T("2L&7
M7FD!YA/ M;?TWU&OSIGR"XEU&V[O/UZRG_$<,L!,GT#,#Z41?=)C<?)H+*60
M_RI=#/?FY(-J7\:P@=&49VI;U]V32)]=$DM[[H:+]^D>N=L[00S$34*Z$8I_
MAWC1IT&_UU-<&2_>*GLT?T!W<"+0T>/:Q<"IB7NA'T6,&C?$3,;')PP"S(0
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M,322TJ=D3]:>,7;OW#8[=CA_<HHB$]6\MU+AMD3EUG3.^A@A56G9J*AM^0R
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M6)$CC<CR8$URV;.82'ZC+]QL >?43=&Z01V)X* + .@@ .@WT+VN00%4,"Q
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M<YNM6QW 1H)6"]!58Z'C*)U?@%]O"5776[/X(-,91L)&-LC84:TQ;6$?GQH
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M]0I476??=E^!O;+U'_4K\/QW3VZH00#7N]>MQ>'[JN9*#<7^O+4& ]1H..P
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MI]6&DM4O2MO-G4[S^2A67S+V%T%6Y?TG\;C)=:7(7]99V02X(S_V)2(>1'Z
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MDNVKMQ&M'RA;!2V:&3NR\N75T0O8;N3)ZI_ ;!8-JJ<WWU3=JR<SHUU[:[>
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MV"2%S^WEF&C/?_>2O.Z^)'O-P1/5P=63E^13^Y+<[%Z2IGG07ZJ79(<"J&
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M$T\.H$6' [= 3M7?H)(:_*T1&US5<H-W.\'K$-7MO0"M;J!13H>X15%F#_J
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M$$L2W^H8RT1RSVUM4>D$ZZ*U7<6[9=T!_0:ZUS7:@TK]1;/3IS[L#@0+T((
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MW)S-1O@%:,2O/JJG"K3?FVT><S_K&(8&Q\)\[/B@4[CMPX-]8',;([228-I
M81]P#J*%O1[2,TN;L7PKNE7XV]D?!Y)QRAGT([7D1IPA2!*:P"")"(_"-/0"
MRP*6)\>:GX/5B I$@[5E%O9)4.,$>S1 ,0RXQR B1/FO*$8PQ22B&#.:$+DL
M-R5930CI?KSQ 5WM)5VT#JPK<,UHWPED(U-\B];[+EK.'=.+2+C-83\YVK3)
MZY>4/LA:OWA#/^;])+Z(]594G0^;+N=_R\K[U]NBW#R(O.Z,J*8![>2J_\]O
MR=<EEBRBH1 0<Z&6OQZ+(1:40RS]D,4LII(@&[>SAPQS<S[U_D)!5K84W0=]
M,WX9&=.1F:>1OF[6VLH/?E,*@%:#!=CI %HE]!:U.V(: *%3RNHCQZ1D-@"H
MYS0WY%'#C@KHAHC50E[]T/ZN\7&?E$I<\R;GMSA>2_'UIBB7(8DB*CT.?:'L
MB:*$0>J)0#$D35+/#V,>RSX'"UP*.3<*W67+5ZU'FS"8_GGWAT;3Q=,JL'K=
MV6J[ ">+Q6J5^QU></IFF+'W2]M[9'I_25/W/DXQABU&.7SA5- 7.:HQ!M2G
M#G:,,E;?Q*G=X1+RT.R"?11KLJK:$JYYN_G5K 667L04R$$*$<-4^>&>7L;C
M"'(B?>9[GL^853\OR_'G-H$\.5VU4V !=BI4_+';EVZTL,VMLC.1&=V/"/S(
M3.X8\Q[I5[V0<YR*92?#Q&E9O0 Z3-'J]QC[JD0-]WX2*U(J=M[\3$IVKSS^
M:CF0T6U5&F3I)YY$"4+0YU$,42A#B#'FT$MB1'P9!L(WKE%D-.+<R*[=.<YK
MJ4&Y 0^-W(!U!3>OU&.&_'E&&P7/D3GLQ: T+X'D'-*)"B(-A]:J4)(53&?*
M)ID]9[(B2E9J=4LJV=TX,-O_G=X<O!=<'YM\EFV.N PY1D+W9.#*6XT22%A"
M(0F3Q*>4X22Q:M1D,.;<^+J3G-X*#2JI727[GX'?U EU"NKHCN=@//OG^E]&
M:)Q<_S/CODRN_V4@3N;Z&]QJ[SQ^%G=Z5MNT?2*RRFTEA?HWT[/=G=C(M5KK
MZYV:92A\PGR40!S(0/F080I3'JI_TA '7AI1'OJF/J3-P'.CID9VL!,>U-+K
MUI5[^?4GM;;;Y;*VR&7?<BR<1V:K^4!L[G..!?5$KJ=+R*V<T#ZXG?%%K1XW
MF4O:1\FN9]KK_GX.ZMN'Q]7FFQ"=NLI-@B9+0R]):0*E4A^B)(P@I03!,"88
M>9[D(K8ZR75RI-DQ_K$:Y_L><(NFQGG/+-G3@)LYHDY@')O072%H[81>1,>I
MZWEZM$D=SHM*/W<S+]_0CTRJA'^][9.+>[6TSKZ(.C+Z?E,4GP33E4$RF;%Z
MRXC_GVU1ZM=!IS-<W;R^_JAOJ?:2JN=\W!1E+LJL/KO4;"]]5.]9\6Z3*Y=8
MGV;2#ZZ\8YWZPU"*!?9BY:?J-C^A0) $+(6^6D#'29H$H;3*]W]1;>9&BO7Y
MFR=HM)4OOM-R?[_0V]/96NSVH/]?]MYM.6Y<2QM\%41,S/RNB,1N'L #>JYD
M6ZKM"9>MMEU[1T==9. H\>]44I5,R:5^^@%XR*2D3!(@08J[9VZJ9(DDUOI
M?EC .@&MW:K,8CQ<\A(V<,2MBF;2R*T D4JESG"E!;Y^9O3]+_-23;Q$+.Q]
MLEYH%C&/3A>SM]5HU@5S$9/W<E%>AE##%OY#]^+W3X<?_YZIW<N.W3Y]%H]J
M-G7-.1[Z@JCM ^0Q8A"I)1F2U"/0#Q$+1<P$B:PZ:ID-N[2E]-@@'1R$+0,!
MOES\8U"1/T/TS18H]YA.O)*,@=.:]NW0<<K/AD//2J1V<+QD/,N['44P7^_T
MN<K^2;/A7O&E+IUPKUER'05AC'C"H8A8 !'5+8PQEY!RZ7/U!R2X5>:&^=!+
MHZB3(:B-]*O2$MN7W]A!@Y'!P^<GQ8RUIH%Z8N9RB/+XN-U>P*:-QCT__-O&
MV/;"TALYV_\$>T^>;IV</VSWW\A>'*CST_;^09$83R7S0T^WIE,DE@8)I#[F
M$ ?4B]* A"(UZMC4/<SB"*N6%&A15Z!E$Y3BFKN+.I#M][^YP6MJUID!*G,_
MFAO(9O*:#87.RD/6CTB'/ZSCYMF\7_T*M'U=!E</+BB_Y63'%?_R![;_)]$.
M"$7#^29C3VN":4IQY,%81%1M1:F .!$4A@A1WY<B"J55T%7G:$MCRT984$L+
M&G&5T5$*;%UDO@-I,P/.&7Y3N[;ZH -_U/^?INZS"4RN"])WC#AW4?I^Y4\4
MIC>X::"_JW'0ZZ.T#^K)3S+?Z2[%51OBM<^)[V'-*F%*(/(EAVDB$AA[$8\Y
M#66<6&TH>\9;&LT<Q 5:7O!,X+HZNN5)5Q_@ACX8=S!.[249@Z"]3\,,%[=>
MAYXQY_4+F 'PZN3>\#;W3O4O8J]#1BM7P-\%OQ'-P?Y[H600K_P&V[)(1B)D
M&(D8ZUX9B=HCT@#2U$]@*AB*8L9E@HUB.Z<3<7%4UN^NU('51TU!J>H+=R4M
M-7[MM=1G/$Z]W0/?B_$N[.EG^^W]TA-.M%,W]+BYF,VW/%#,Q3B,Q\%LXP4>
M.=*(Y>=+OCT$HU;R-%5>:5&6H5FSU(]]G_LP$<A3^^F8J?UT+&"(N> D((0'
MD5TE0K.!;:ACSKK/=3CUN[HXX2__/H#<^U&W(&RG2,Y"PFV)#QQ<"_T+^*.1
MVZ4!; 64>X;L'WI^UC.&XR23F=\]M")T&2G_3=SG.SV&/DW<Y+K@_;$)F2\\
M(2DA4*2QLG9CQ4K8)R$D7BPC'(B )=B.F@Q&71XO?;_\];?++S_ M\OKK]]^
M?/KRJVUUYWZD#8_ZW*(W]8%?G2ES$!<<Y55;\$D.^<P!<ERSN7_<F2LU&P/Q
MNCZS^:W#J.>S+K$GCGM_0=0G7!<@?:JS'HJ/VI?Q+2]K1?^G(+LK]5ZN$4I1
M1'D"28(11,0GD(2*E6C(4QRE(?%\JV/!P9(L;9==*:+30P['7EJ7U:'&KCYE
MK_59 :61;I]3ZP2T4D!K9<=KPZ?1C.UFF9R).7#B>;$FR-&8.J7-X=+,2J:C
M07M)L>,?.+@0W$Z/]5%4__^T+?.8;O.->D91=4+2(UY5A[#KB(4DX7X$?80Q
M1![BD&+B0QZ2(, LB'%BV4W3:ORED6PC/GC7*/"+_ES;.OROIDW9'UH/4"MB
MZ:NQG28S.IT0_(E)= +<AQ2$&X*>ZX)P5C+,71!N"$ G"L(->HP=(7*1K3_6
MD4]7RKXEFXIAV4.QIHKU$-9%.V+D0R0#37H4P<CSA23JGY%Z@ 'I=8RQ-&)K
MQ 25G(WAH20U(ZXN.+O)R1%($Q/0 'R,"<8 @1,D4@CVMYO\\=_4W25__(GT
MC[#ZL22-KN?.0@P&BC4?O\FE QL <5YV>22;:Y+Q3]L/Y#[;DTU=-R E 1(!
M"B%/90K5WC*&:<H"B)'TO81ZJ1"1C7W3.=K2/OJCL$!+"]6*6LL[L#Y#-]9F
M1HHS!"=FA#'@V7>R,0'%;3>;SA'G[6ACHORKKC9&-]EG#_RX%5^E%#NU);LD
MN\W3-\'%75D%XJNL6LP*?G%SLQ,W9"^NU64LNR>;[U_J;X"2**!1A& B:021
M2 G$.IA$L# 1221\)(WV4^-%61H9[6\%:-0!$ BM$=@=5-+EE%BM%""-5N"^
M40M\_V(>?3]R$KN);-ZIF9CEQL^*Y5+B8'K,$RCFFZ:9DBPF_(BL\C#< -N1
MJS%R@-GR.=P T<[Y</3$P0G!^OFMF@C:)<WV@E\][!]VHOE#?8!YE3V*HS5?
M*-'5CE[7$UG+B)!(AA[T":%0.W4@X9Z$0GI4>BBAA!MML5T+MK15\70=ET8W
M4"EW_&NE7E.TI=JDZB@\F>_ %^UN+?]5ZFR==.QFXLTV 6\QG5.?(,P_DT,2
MFYW"[CKMV8UP<R=%.X7T1,JTV^</=.CGVQOUE+N/@NY_J$=\S.](METS)!,:
M"PP3S*2B>2HA14S-+DM03&+B):&5^^CT,$LC;2TEU&("+><*:$G!'Y6LEB<J
M9W U=)^/1FMJW_@@H.Q=WITXN/5GGQYJ7F=UI[JO/-'=5T\;WZ-7LMK!_>.G
MV#R*W_+M_K98$Y^%/$8<QIP)B"2.8(JD!R."PA11$@2AU;'L2'D61S#6,26E
MR=!$E52J@4JW:2)^SDVL(7'--UU3,]P<,S59#% /OF\2"71.ID7& _4 .#0J
MJ.^Q]L?:W\2?#W7!P\OLYG9_^Q\/9*>H3*?!'&S$*S5D_E,-JOZXR60F^ 53
MMQ59JQ W#B.2TIBHZ4UU>F3$(1$XAC1$,98T2)*0F1YPNQ)J:?3=TFL%1*D9
M^+-2K<QRVQ^44]N]6CM]0:4>($?]S,]4G4UP_^'W6TS;Q#3N;L8&'(<[FSKS
M@_&WF,*9CLAG^/BLCLI=0]UQ:.YLJ-F.SUV#TSY(=_[L :7H7AW>E$_?":[>
MQ,MB3^BF[&2E__+A5K> *,J+RMIXZR3B"4$14TLM)A %0:([E1)()4FY#(E'
MJ6=<K6Z,)$M;7T\?M38*554ACRJ5?P:U4E7ER+J@I$4YMU$3V;^DSC8];W((
MOMR9L:C%-]<,S56N;^J9LJOKYP+=KM)_HYX_7W5 %S \*R#HY('#S@C?/Q1J
M[**HG-;EZZR[QZJU5KW=ZJ<BX^4^.-^VVA\5A_1]BGPI?)1")G3!5AX@M<>D
M A*)11(&2'A(VAP1CA-G:4M@HPUHJ;,"1X7 ,XW:#:8*D^H 4TRHV='@?-,T
M\5(X\0Q9GPFZ =;ID>!(D68]$70#W\L#04=/M4^-N52#[)\^;66^NRN?_UG)
M\6DO[I1-Q#T18YI"CWH(HB@-81H* ;TXC!B.2!2;%4#K'F9IA%I)"EJB@C^T
ML*"4UI I>Y#M9D!W>$W,;$.ALDJ8Z4=B<,Y,QZ-G2YOI5Z^=.6-PM?WAQ,7W
M#[_?<[(77W)M+WO^1['+'M7C'T5QL>6ZAI;V/^3W&4O]Z.H?]2^N\]U>YILL
M_TR>Q.XWL;_->54P]ECKQ*-21!Y&D"0Z"C[P=,-+0J!/@C3Q$\)C;%1 >EHQ
MET9!2E-0J0J^Y'\#6ENU:.I>;P>%RWU9K2%X5RH-E-:__#NX^L?A]_"@.RB5
M!Y7VYGOJ"=^,_J.09<SWQ!0Z\51;U=F><_K-SUN6\1K,=!CS5E^^U1G-]#/2
M<8 SX>"SG>Y,#V#[Z&>&T:8HFKFFNDVQP#YD6'*U_9 $4DYBR+F,XXCB- V=
M%LNTH8,9BV2NP%98-@[K =;L_,4=6!,OH09U,.<J?CG)X4C/D LJ=GGN<,/P
MKD%NU>=MQ.JHZ2"2S,-^"&/?1Q"%C*MM!XX@8<Q'*,$HE$8M5#O&6-J>X= F
M;T_^ J04U#(2O0M0(\?E6)BF=TE.B)"5 W$L4O.Y!E\BYLS+UP5!M__NY)US
M>N:Z1'_A<^N\=)C5=$CPR7?7NYP)P0O=WKKDV*KPN2+8"Z;,NVR?B6)-<4(0
MI2&D"4\AHCB&F"4>#&+"N(<)"?QHO2V32/D/<R^:I1A&;S>NWNY7PDSWAC>B
M SW)8)<_D<W^">QTE)!EO+SMM)@985.@/ _;-I*7>8SOGN'\"ZA,MH,"X*B!
M.TMM('1.33=;&6:UY08"]-*X&_J8H64MRT&*XILHA&Z!K7:P'W43[+SL%EMW
MTQ.2>!Z7 4QE$D(4J/TCC4,&&<<)"I$(19C:%;,T&'5I%N&G+:BE!HW8Y=E1
M2_!![?A&S(L9Z3E'>V*JFPKH 84K+8!S7*[29.29BU1:@/&Z-*7-S<.H["K;
M9GOQ.7L47#W]TY;K$*WF-Y^4<;^]R>A&5*9C$ZUU45R3W?ZK/!$O4+91.YZP
M*YY+?>EAB/3.%X4!@Y@G'(;$#SE11B$-C5I<SR/NTLBSTA:6RI4?\U'A^I='
ME>L R%;,9 &TVKH(SZG@G[HGX7"RG?C-,6/IY;P/$]/[4EX%Z^5@GAERNHY,
M+/*L"] \\+]<N68:U555*>V!*K<*UWFQWXE]G:?3ON+8E*3N7TL)8B(F&$9^
MA'4I5P%)XC,8>Q[U&,-(IB-+2@V0:FD+V*FP_LIW7&V^GVOVXK*6<L-:$+N9
M:+.%:/;IF_Z<>IZ9<U U:@32$Y>,&B+9&]>+&@%F?[&H,0]WEO9QS %(I>)M
M$B(82U^WFTM2B%'B0<KC@'O8%\@?F]3Q+Y6RX309PT&JQ;]*(L5L*1*S)T L
M)[UA2/+"V-2$8K=?_T;^RNX>[NJ:!I*&?NBG#$9("H@P]R&->02CE(:!1Q-?
M&8,FC/'JR4NCAUHXR_H1KP'SDQ#)P",PI7$ D:<L9")]"5/&D> 4BT@&9O%3
MHR";)U3J[]G-+1#*1E(;[3(_9C1\W=0Y"I*)>=+X!3+FQ;/:=I&@NJE%@.I?
M+\GO]5-G8;JSRC2T=OZ"H3ZK1V5IY;NG;^3G;T112$8VNDWY5ZE/EW>/HECC
M6'!)/0H]Z1.(J-K2T@ CB"4*DCA.?!2&=@ZKOB&7QGH'B5= R0P.0J^ $EM_
MU8W@MGZI7NQ-G5(N$9W<(S46S &^)U-\'#N>>H>=V>MD"L-KEY/QG0.[@+-;
MP1\VXJN\8&SW('A3<"ZK]WNM9N">LAU$%$ _(LK68HF$A"$,XY1R3J1,(V1D
M:]D/O31::B37'TTM.V@)/]J58S$I9CPU#=03\Y5#E.W[B%L#YK:=N/GP\W85
MMX;E57-Q^R<,(S9%DA](<7N]RQ\S+OC[I]\+[>JX4EO1+7L6?'0X%PFP'T>I
MVAOYH0Z*9%CMC;A(( YP*F202A%9YI;8"[&\3=1!6). /%=3849KT\([,;UI
MHTM+#QKQ 7T"[[0&(-O^ D[!/LFQUG 0G5+> #%FI;[A,+VDP!%/LD^&^72G
M7C]E+E[E.Y'=;#\\['9BRYZN-@]L_U =RGW=*HF^DXW><0K.>11@-3EA")&.
MCL0"<ZA-/^GSU$?(*#S(>N2E67B5\-KRD)7X@-7R ]E2 .1;G8@'"JV#>;J(
MW:1T<^&D4$^](UT0RN:I.I.A/5,"CU/4K3)\!B'7D?=C][S9LH$&J=G.$1KV
M /O%X==-3LGF\NY^DS\)4?99OU9OV2TI1-5*2.Q85HB+N_QAN]?U<A_5@-O]
M/D^C7%Z1;/<;V?V7V/^#;!Y$KMO/W>55MW:RI^(FVV[5:J94V/)<"L)N\[IQ
MW;WZ;\Y_WF9J+Z!LV*Q06A1K%&,:$65X^X$G(5(&-\2A1V$0(IF@,&(6Z9E+
M4FQI2UN%#6C  :5>H(&G*MX)00,1J# "1Y# /@=I]']J_M!(@0HJ4&*E?UFA
M53^6[,$!,/5:-LX8#1IH4 ,5;.#= 3B0%4!#=SY%>]FO<O^*O21Q%V00_/_O
MYN3OIKF=LR2Q%VA&_8]X5ZW,MR6^$!W6X:+$G<WX7)36)VS;1<IG7R'U0[9_
MNM@)\B'G8NT+*6-?(.B3D$ 42@)Q0B1,D6!)R$G":&):$[7]X*69CEHVH(4#
M6CKSHJ?/P.HVCL9 ,+%Q8JB]51W34ZH.KESZ[&&SU2H]I4*[.NG)OP^-F6$[
MW13MHZC^_VE[P9CFB>*:/&GGT<66OW8KK7GB,=^3 @8R9A"AA$(JU(>:J"\S
M3ABAW.SS'"?&TC[F1F9P7PF] J1VLHJJ!%.57I"7Z06;HQZVH3:#ILPT_&;J
MB9@\)*<2'+QK5/@%9%MPF)I:C7(B3KC 70;JC$'2<?#.(%%F#N@9 ]?K()]1
M3QM0V[DTKK[*Q@HK?N1[LE&VE/[NRVW3Y28K,P*O\MVOZGV_;TRT=4II[.OD
M.AYX(43,4USJ>P2*-(DY38G V(A+QXFQ."ZM-G=Z1];HHK9W2AG 6MH 4:M3
MEK_Y]?+[UVMP7VMD47]W^.3UGTO-,R43L^J_R&Q85#N>95;FJF8\W>S8%2P>
M#6I70>+A#Y^OX/!H )X5%![_M&&;@E])MOV<%\77K8ZJN-KD/W6M8K6(JDVY
MT*$40F<A?1'[=2 %\G5S8HE3'R*=)X2#B,$H2B-&8A(1WZ@YL?7(2UNNM.#@
MG1;]%^WE+:.0M/AEI7 !7BA0QH?;6?WF<V)FZ$^"]-2^#(<@6]OSUH Y->'-
M1Y_5:K<&Y:6A;O^ 893V313[7<;V@NMQE/6O_W=Y. LM+O8?R&[WE&UORF/0
MM0C3A/F"0U\RK'LRZ<A\99DG?I(&(1*^)ZP.."S'7QJ]'<4'3']U>O>\>_&[
MX\ERH7;<;// R[C+NII"%1"S[RMOZV3RS!APPBF9F =;L_&AF8WRAY;T*U#%
MN#ADP(& .>5!6QEF9<.! +WDQ*&/&9BN=$MV@BJCD;<MRU;WN_=/QTOJ(J07
M/\F.?[TOPZ9J]Y(^5/FT57)OBXR5<OEKBH@7LH1#0I$'49 &ZJ<XA8E,11@(
M%@<BL$IOFDS4I?%MJ08L]0!M7=M=*W5P>_NZ6F%0:KP"M<XKT-)Z!0YZ5UYQ
MRR2JZ5X5,\I>Q@LP,;N_^=S;IW9-/BUN4\&F$W?>U+')87^5:C;]B(,+WI4M
M ,Z(]<]L?_MIR[/'C#^0S<G*3,7G0]=0]852EO@>]'%"(1($0\PEA9$0,N!!
MZ*G%R[+NG3/AEK90'5I7G&6JGTH]<-1O=::N6C&@^^LDLV^V$KW5G$Z\]LP]
MG4-*XSG'W76%/'<"SETHSSFT)^KEN1]CZ))19#=;W0#EHJA;\7W:J@%+ATU3
M"RO@@OBAA'$411 A&L'4QVHK0^.$QA'VD(SL5H+>,9='\(W(NL9RT_?R*+5E
M_2<;]$V9V"FFDQ/L6#@'4*8Q0(Z9L'_<F0G.&(C7O&5^ZT"?6Y[SG]EF4Q:3
M?EX]^E@O])#,CVDHHD"D,$UB'R)&$,1>$,$X\9(X\7GH1U9-!ZQ&7QI%-<+7
M1>-?UH@_*C"X]J?=Y!@ZX*:"?&HGG$NT[;UP0U!SZXFSDF!>;]P0<%YYY 8]
MQ([TRE"\W=/ZT^7:$RF)$T0A]HEBLC -8(IC#Z9()C$C7AA@8<)DQT<NC9X^
M?;O\?/'EHQGCM)#III%A^D[,#7VJ&G_NK[7K".&O+ZX^X?H?Y==;?K>M1\WR
M,;X6O?G"3OQEJ#/[OFX&]U5^%]LLWWT4=+].A/I68JQ(RXL3W:\!P90EZGL*
MB:1AR@(?TZ8#I:G7^M1 1B_<\QZ3$W]BAR:(^19L\NT-5-_U':#Y;I?_5*9:
M%7;/E>A _*7;Y#UDQ6UI;3.UQ;1V1I\$W]3G/!C0N5S+]P<L):A$!%I&EV[D
M+@P<>XM/#C6S4[A+W=>^W\ZK1[7N;D6ZU\V44T18Q'$ 94I"B&1$84HPAPE-
M*4L2RG%L=+[1-]#2EN1G#9<W[0*(8_I4O\:WFQ1<HC;7N?#$@ WJ[CT*N+=H
M\6V2^C6TS_=9,,R:?;^^_2TZ?I]5XDS;[_/7C^[]K0BY#JK^VDZ-7A-$TX@'
M'.(P$1 )+U5VEOHI\L,D]F-.$U^.:_=]9N0!UM<L';[;?:AW!]&U%<&JL@N%
MEGYPL^]S\\"#A NA-HP"Q1(BA *(/:ZF!9$H1&GH"V)5T=W1!,RXF+T5\F86
MKUL\)U[FGD'Y[1F4[=HADS1/[T%GJG[IYX9]JQ;I/3!T=$7ONW-@>*1^QFV^
M47<4.@9S_W0XYXT%X7X:",B(IY> 6%G/44"A2"+B^S2AL;"KWGYVJ*513EO2
M_^O_2 ,_^;_+\._]T[];1A2>1]>,7MQ@-C&MM(7\7Z 2$USL][N,/NS+;/1]
MKMO7EOZ_"0[-^T%R&U]W?KAYX^-ZU7X5W]9_Q\!@@ZRXSPNR^767/]Q_R??Z
M)#W?[K/M@^!?[\6NW'T<<V&:R]=Q$B11@!6[T"2&*.)4GXY+F*8R\5,11206
M ZS,@>(LU/340H)W-T37^%9+-*^EU:LVK3NFU94WAB2?#)TZ,_Z:<B9F.AIH
MX"Y56 &E!&AK 0YJK,"+!+[F5H>Q#N/@=!O_,%"6>6,BQ@'V*DYBY..&L>MG
M]6VO,2$L"8(88LZ0SM@3,*4LA@$B+)2AYV/DVUAC^J%+L[NT3';L54)C1D6V
M"D_,*YVZ6A-#6SFG7WGYX%D_V;8J+[^_9W\;]C'5G^GVYK,NG-.<K#U]4<)5
M"85K%OA>2*AV$WCJ2PND#VF4)!"S*$"8"Q&8>0V,1US:9W@0&)02KPX%I)[T
M\M=(;?>A]L-N]A4[!7/B3WPDCM8D8(R-4X;H'W56^C &X26WF-\XC'@N^/]^
M*/;-:<X7\;,NV:5&O-[E6_4C*P/!BXN_LF*=8$D"$@60(!]#Q)&$6%>Y3R,O
M3;D7!#*U2M"W&GUIA-02OCRZ5.*#H_S@N0+@#ZV"902DW>284=5DD$],6RUD
MO^_5@DMVO "_WW.UW^W#UIJR!F'DE+[L))B5R@:!\Y+6ACW$/A#C6JC73Y=S
MNLJV67$KN ZTU+G\^5;'ENLAUI(Q%H:ZUDA )40D(1!3X<- !))A%B<L-7)F
M&8ZW-!JK12[[Z-1"@QLMM2[6SHYRFP<;F(#>35830#FU$^M-4#2/W'",YDP!
M'*-1M0KHL,"H(Z[#Y"FSA7=8J-2.\K"Y;9C=6=?)^;1E^9WX0?ZZK&HUU_F&
MZX0%<4ID!#V=_H="%$),_!C&28P23TB&[ S-[N&61LFUM* 2%RAY02TP>%>+
M;-BVQ1!N,]/1'8@3D_$H_*RM13-8G)J'/4/.:@^:J?_2 #2\:^"FEJG5Z6&C
M76%E'32=^+P3MVJ [%%40^JC\(]JJ*W@]9C7^L_Y]F);W?,\#UJW]*CZU2M9
MUWX2A %&:AN,$\5.L9= 0BF&,I$D]KU(^"FRB_F?6.(!/L2I-\]'A>M:=<]4
M!N\JI7\!6NT5J!4'M>9E5Z(5(%*QL?Z\+;?5$[\>AAOQ!4SY;%OW.>;:?IL_
MSPRX/1B86.9YCQ+FF8!7AP\S#3LP#'J7,R%X<:7@^GZ;[_8_Q.ZNS';B88A8
M%(20(Y0HHY@+B$.!8$B%8F^!I?JC5=3MN9&69@\W@@+]"H%"B_HRV6Q5]OA5
M^\0RX2PKB@>B7L$AJ6;G\3?C=2>H3GU:\0S0[T= W2:=]4+A-K[V[&CSAM7V
M*?TJFK;WAF%$<NA-)W:/&1-EC;CW+\O(*;ZJ"4X/_ZS,?661KP,9!Y'4P?V^
MWHJC$$,2\11R0D-$_%0D"1H0#>=&NH4&QQV;:5;:@7/E)5?EYK2Q=,JO\5D1
ML%I-.P9S-/%F=#?C/,Y?"?10X?-8+6O5S,FSJ7/'F6[Q=$JPCD2;E8W=POF2
MNAT_?40MZ>N=&G^-2.@+C#PH1!Q E+ 4XL!/(?6$1W! 2.!9=08Y/GII)F$I
M&2A%&U!.N4++C."&83 '2?6H/ZRB\#--W5< KAX_?\7>9VJ=K+#[_(H1>4OM
M+UQO#.O">HR2-/;B&$JL4PL$BB&FA,$T#KD7LU#ZTK-.7#H]UB(_UO-+ZL!J
MAEU@&W[:;B!\6X-D@N*%!KBXSUTZ,][\R4O=BI_,7NJY96" O4ZA$<\# /76
M4"=:;JMTO2#R>4I%"CW&%:=$.A]>V0!J^9<^#F))4R&MPN][AUP:M502K\"K
MJ%8M=I5"7 EN&<'?C[T9Q;A%=&*F&0^F?8J ,3YN$PCZAYTWO< 8AE?)!^9W
MVH?/?7^XO]^4JPS9O"<;?:3Z_5:(_:>MS'=W52'I)G4X)!Z5D9? P-?-NX00
M,/45-;&0Q'[ 0QDB(_O&<MRE$5);=%#+#DKA04MZ\S PFRGHIJ0)@9W: C+"
MU+K0K"V\YM%V$\$\4]2=&=Q_<Q-T-P"JCN [FZ?-%H0W0,5V,-Z0V^VI_K/:
M_6X+M8*TMA;%6@8TE-A/=1:\)G5)(<5,P"#BB8]8&G-JY'(\.\+2Z/L@)" M
M*<WYY#2,_<0\&IRI3<-)<#%GU-'XS,2=ECA9464G!AVD>/J^V>BO4^PVT75?
M:$]IWW1UG"I X[MX5/^]_8\'LE,L<I5O-F78@/KW)I.9X!=,75ID^MVH3Y#B
M,$Q"$3(HO)CIK36"./(%]&,6$()8@JAQE<XQ@BR-(%NZK$!1:0/^K-0!LM%'
M_Z92")"C1N9T,6KJ^MEVK@F9F)3'S(7EH>OH23&G^KDF9Z8589(/QFK=< %H
MQ_(RZO&SK4(N0&@O5DZ>-]#+Q&X%?]B(K_*;8/G--OMOP3]Q)4(U6EENJ1QS
MI_ZUY:TZK>IOZI7G/W3YLQ_BK_W[C:XIB1GR NX1Z*7"AT@&/L18,LAQC'P2
M>I0$Q,HSY5:^I:V C7KZ0/2H(#AJV'1E:70LJV"UM 2UFN"/4E&@-06EJK8>
M,,<O@J'7[.VF=^ISIK>867OOW#3XN_7H.99Q7B_@- "_\AQ.-,RX9KZ'C*S6
M>&M._=A/N0])X".(/)Q K'X'@RB-N9^BB#$TI#GOJ<&61O>'(O(ZW*\EYTK7
MWBMLZQIVH6Q&OZZPFYA+A\(VN#EM%QZ3-)L].>";-(_M4OU<,]C.>X91R/NZ
M[F?+WOU\Z/ <,(DH\Q1Q)"G7_;U32$(6P(B%?NQ%?I#&J0V%= VV- II9 47
M[?WWYZ&=MSMQ-B,15^A-3"+#@;.F$1-$G-)(YX"STHB)ZB]IQ.B>H8W6F,@>
MM6U3=J:^NW_8:[I2'ZHH]I=2"K;/'L5_9F)S^.TWLA?K$/E>*JEN11%X:AN+
M.20D\2&//!D2#W$AHO6CV-'<E&,&2F+S ;7EF>X[NE##D!L!LEI*L--EL\IL
M.;@[;G1V!WVMV[,-FS(SLIIA&B8_J&TT #^5"J#6 33BKL!!#5#JH7.BZZG2
MJCBL5C$23,>=XH;),G,KN5& O>XU-^YQ W,!R[KZOXG];:X>^RCJVFOKD*"8
MA5AM[!!F$&&.82I#!A./JYT>CB0V\W+UC+,T@ZSN!E')"5J"6B;:G4'5C-8<
M8#4Q;=G#9)_NU@V"V_RU,V/-FY#6K?"K#+.>RX?1P3_(YJ'*31/L=IO]^2#*
MFO$/BG#X!U+<7FWRG[7?+HF\U&.(04J)@"CUI-JW11YDQ*=)1"41Q*H2E_G0
M2R.-@^3@(/H*'(4'6GJ@Q1^8SV(Q*68$,PW4$W..0Y2MR<@>,*?\9#'\K)1E
M#\M+%AOPA&'$5IUJ?=\KBTGSY"%T-TAQZDM.8,!0 %%$(TA8XL&88L*IC#$2
M5GTJSHRS-,JJ"^ =Y+0.D>[#U8R('* U,>L, <J:7GI@<,HEY\::E3AZ%'[)
M$GV7VU$"%]GZ<KM7UM,W<9/I1VWW7]0KL.81IBD.)%1V30P19QRF@0PA"[Q$
M(%]M>3QAP@7G!E@:"50R@J.00$MI]OV?!;'[PW<!S=1[&SM4C#_V/M5/?.6%
M8'^[R1__3=U:?N!_(OTCK'XLO^JS#YWE<^Y3J?F.>Z^S#^&]N-?15)=;GA</
MNQNQ>U(<4=O .(YE2'T)D>]%:DEG1"WI*88^X2)DU,><&#F4NH=9VL=<20I:
MHJYTF=OSR3@VD'9_U.Z FOC3/H?1@)#7#K#, UK=@#93N*KU"V85BMH/14>@
M:<?-LX61]BO0#A(UN'J<J_U#?D>S;?E*E+79>=WM[X?BWN+@Z-\\\&Q[4QTE
M-8?*G[9U;)'XN]CPZUV6[W[DK<?Y:QP@'!/*(..>!Q$)*:0)5ELH'P42,2XE
M"NS\:3-(O3S?V\&'W1)S!9[I#5J*EU];I7K3M/C@"LJV3>2A %I_4 *@^QBW
MGCTLEF#*%\ELD[BPEV/B-6HQ;\7@0(D9YFF2>(LIY7Z3L(T9)N)<],<<0P^H
M6G$X0=!MT7Q.&/&D@)S':K,01!'$,A50O26)VB0@)(EY78KVDY>V-2A:AU?F
MO>9> ]:_"Q@,P\2DZ@H!BT(/0Y&8R9HW1L2N9L,IK;NJ,CR[?KZZ"Z?$?%99
MX>0%SBSR3ULN[K:9S%A5I*&*Z+_3;H^+XJMLA<Y]U,%04E+)I: P2$L?!::0
M$&5O1UX:8LQB@KA5&M9HB99&<*=MIA<ZU2DZ*U"I!4BAX]S:\:-:M=%&LN7<
M#C:!IYNQ-S%PW4Z6"]MU&,!36Z:64KVUW3D,1 .K<N"#AW;>J',CRIJ.'[-'
M9<]N>7$M=F4)3NVHOB897R=1S$,_YFH^(WTPXE%(191"&1*$I>"1KQYJU8?#
M:-RET?%!;%#*K:,T:LE70,E>U;Q?50$;6G[;-AQFDV'&K!- /#%_.D-W0-<.
M*ZP<]_ P&WOFCAY6@+SN[V%W^YC(E]>M';FR)L,XD9 &F$.4,@RI%Z2044(]
M[@=8AE81OO\B+33K@(X]^0N(IO4C'=0Z\QRP$>$L0B2"#(<A1#B*(8VQ#V,9
M^W%,$Q)'ENDF#J"=YTC;75_2<0U)E]^)=)X.I'.V'EU$SU'+9J/3=!E]T1].
MS;M^/-L+?O6P?]@UH]0EVXO_%&3W0TV%6#/!:.Q%",9^Z$,4JY]2B2.H. ,I
MZS$.8]_*?APJR-(X^W3CQT874"ES_&NES@IH?4"ID'4N_K#Y,R.G.69E8O::
M;D*&9/F/0M-U!8!APLQ='6 49"<J!XQ[GAW-%KO]^J+(R#5A>O]?1]V(E :A
MYQ&(HT1 %.B"M%$0P32.)0Y\$F+/Z)#TY-.71H@7UQ<?+(.63J/6S5BCL9B8
MAK1LH!;.8=9'I]I=?*%N;'&%^M=+GCC]Y%D^_DZEFB^Z^Z)Q]8.4E56=TNEL
MM:U"_FF=QIP%B"J$I-HD(1D&D"0QA4C[97T>2)Q:)5^<'VII'_"S(CC-6?=!
MVF&E@TX ;&R0.(!M>I-C"&*#JP:=!V.2FD$GAGN3BD'GU3Y7+ZCC#OL(C=^W
MQZH3[=Y)'_)B_R7?_D,4^_JX[.(GV?%B'0>,!DS$4!)=A][' A(/(8@B1,,X
M2$D<QZ9!'+:#+XU4VO(_[Q:K-0 0*"7@8ZD%*+0:@)1ZF$=#6$]/-P%-#?K$
ME+1 O,T#5*;$?:88%N?X6\6Z# 6P(QS&^I&S1<P,5;8=5#/X&4/3^]3*U)3-
MK+S$7Q[*38]$U,,HC2%EV(,(QZ':*E)E>Z)8!((CXGM&O4MZ1UK: E&GMFD+
MZKFXH)+7-O7O',#=K.\4MHDI?C!B ](">] 8F1]X[NDS)PKV*/DZ8[#O!GMR
M^%BO3E=9P<CF6NRRG%^IWQ5K+^4H\CP)T\0/($*A!W'B*[/=\Q*,O92BQ*A+
M=N<H2R.%1E!020HJ44$IJSDAG >UGPR<0#7U]G,(2E8DT(O"8 (X_^39/OY>
MY=H??O_%PTZBJFWJAP>U:]WNUYAA$D="0DZX[N,3JYUCZA$H$A$3(1!3.\CU
M/M^3C=GAT[.G6WWDAS&F>WU_Z#$ JX0#I!35[I3I.7AF!TN#(9G\W+@Z/JHE
M<W=X=%)AI^=%ST>8]8CHI'(O3X5.7^2NSW53E/JI\29]?!!K&7A2^IQ +Q81
M1%P*9=H3 1/F!S04,8JEU3FRZ<!+6\K/MFD^"+_2V7]4# B[-)X,,VJ8 N*)
M6<,1NDXZ87=!-7D_[).#OWE7["Y(3'IC=][O*A"HN-CRK_M;L;O.B_U.[.M&
M4>TKGC?O^'RHWXYCRD7L(TBC-(9()"$D<8PA#U*>)+X(_$"."PX:+MS2B/!4
M?$I1]N0I]0//%7QQV<L./2,*\CM] 8R=>6\RK=.[_^:>40>A2..AGS@\:82
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MPJQEU'RU6_KC9?F/P0D'-I-GN!V=>D*FWI!.-1,C4A@&(#E1<H.-)&^4]C
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M@X?,9L"9*]2VSBSN&F9Z'9((=F1;;*IZUEO>U#$\)L=='*(%BC7U<$P)3V'
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M[?4N?\RXX.^??B\$_[2]4GN9+=.;&+;/'JL,LD!9$D%*0^C[ 85(I#[$89)
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M$42Z*B7BPM/V<PII$,6)EP8^BXQ;N;D4;&F$K70#1^6T'5:I![1^*Y"5&NK
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M"8=$YA@RFJ,\Q2R3$;);5IYO;'S+S<9>\&P,-JHX=#H%O+'9_%@9J^VC.<Y
M?9H/PL+7,RT,BIM]+$PX_ :*B+D(1Z?8&#MH3D3(G'G 8'$R=HYL1\M8WN$W
MA]*3MJ?YK'[2#7TNEW3:[(]^DY5<_)#BTWSQ:;5<+:39,#6[\Y,4,9R+5$+!
M&((8X1A2S!B,2!P)%&5Y&EO5!/:V8&SSK\8!4'M@=&IK'T![AM%Y48?E-GZ
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M6;L7;K\R-.!!-S*#&3?H#F=H2'>W/H,_W[,^DF;;Q4(*O<SHJC#IIKCF'E/
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MPA06(J8P95&6X(P(SJWK,MLU.;:AHRDPMS:[GGO>_3G3+>N.JX63W*MZ.G3
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M5&\(]\Q5&[O-.G O AF\6QL/.NL#5@OW0BULEH63!</F7?B LY>)X?40SWH
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M4\ZO]GN#NF?&'Q/*]OL&O:$]T'Y"4-2=MAR\D#NQ%>'VO,&V*+S<W-ZZ\'N
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M7)B]/CGA5!8Q5PG,,U./.5<(TC@14)KM-DXY8<)I+O0V;HR.P2_/S&CP %N
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M*5>IPC)WJOMHT^C8:+"SV23(KZUN L%$5_WZC]IRUPI1-CU@N3H(C&O?$_<
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M&>:IC*5;6(N; >,+>_GU[N[#/VX_?P;77SZ N_N_??P&;K_<7W_Y]?;]YX_
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MS#$W]R<D1Z_TU$B</SV5RWKI>CT3Z]4J+^7!(,<H4P33-(6<%49JED60%*F
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M>I9?;N>[=[/OU&SB=H9,:*)(1',&*4UBB-,40\:0B6"22$] B=1L.IG)!Q,
M>V_/F<?:L_I B^8#W6NUOX]U>UTYKY7.G^=MA/A<M;$QCL65CP%N1X$7X3=0
M?OM)S#J# Q9(/@-)V%+(QQH;MNCQ&9?WRAN?N]YW#U,8G?!R*3_K&>!>Y>3?
MZ#_GBQNSA/ZB7Y</\R=MQ00S%&M*81 K)$T\)(44&Q7OA&<X(TS(/'4[E/&P
M8GSG,QLGX-1XL5]I_ K4GH#:%6!\ 7\TWC@>U_CT6AQEM!"QIO\8FU1VDD"2
M8?UU$"49S0E5A9/V<<]]-LR><N<"^'RXQ]ZRPVQWB7OMAMZWA/OX9CPV?KU!
M#+S+ZV['P%NZWD#M[]_Z/^J"J -3,7 A'Z6>CYL=#Y/G98;5K^87\]GU3-17
M?9U7R\6Z1LY6#8WJ6OQS5=7!95_D\D[=TY\3R85$!1<PP2R'F+%",VLJH$KR
MF*6,1I$LNGFV0Y!">$L]9N@],["V#/!UW331EL%A;6V;Y\;5)DAS7A_0ET9R
MS".VH8=N5WE6I(*F4/*,F;VH&!8493"2<8&B J.,<H_8E#?J]D&G2G_E;L\+
ME"DE(QBE")GH30P))13&5)(T32.<1T[']2/H].%DFE_YV>5>-PO-*]!Z6W=[
M<_EKA\%V>2P],=@X79\#FZ6I=GP<;XG=Y&T$?=_S!.]0M[]KG/P%&#>OP.'B
M9U3IMW(K!("W)3>W^KRYY%27^P5C]=<AX6.W>K!U^%"O_@ _&!G68W/NTCXW
M\\7S?*&G6JW40%7.^'1E2E,_2O&@_T/YLOS1*K76&H\(14DN$F).OBC$>1)#
MIF@,A?Z=U'\I\C2U%?!Q;GULP\K:@4Z]PYQ9MRZ U@>P<<)#A=.]@TYS?^^P
M]\SH8T3<7A2G5^0'DKX)W@-.PC;>")Z0KW%_YF B-=[N;DO1^#_$0U1[/A=_
MEM.IB7)>T6FUSNE$)"\RGE%(96H. 0L):<2Y*=<0%2C'<<RLQXUCC8QM>.CL
M!.^^S?7_?YHO_J0+\8N#!O,Q-,^3? B,^C[G6\/3&?F+<X+Q290<]*@#H#64
MZK0?:FZZTF?@.*4>?>S6X32BSQC_2@GZW+7N#+@M)DVG-_J#+^?3^</+O9&:
M?M[,&@HD",ID GD4ZXDTX1DL<(QA&LNX2&62%9E5(*Y#FV/CQ]=F@XW=8&VX
M/0O8XGZ>.GM L_>#K+- >LR$;1&UI]D>D!V(=2]Y59VHUQ&B$TQL^Z3!B-G1
MM6V>=KW5,Y^BK.C#PT(V5>COU#>IFUS)G214G&4RTY-6:&J^0*Q24U ^SB"+
MN$0QT7]SBP*V:G5LU/W::+/YW9I]<3*P72?8[7 'A[9G'@^"JGO>@PM*83,=
MK%H>-K?!!8R]; :GFSUJB2SU_;=5M>KRR4P-D[FHTR*^R#_KOY@0X*?YK+YT
M0AA%BB$%HR+%$&="0*IGF3#-2!2K6#%J5Q71I_&Q459C&JB,;:#4UE+]0H!W
MM?WF(%C^Y":J7G]TSW3AL$AW[I3S,] ^H>Z9PFI[0&-[ES;;6'_5U1_4'C07
M5.#==J?TB;E#W8\>L1^JVD<??>!6]L,3Q%/%/EP?.5R)#T]G7Q7V\'V&WTSW
MJW[5'FDE[]BT; :K#RMY.[M_+!?B/R5=3 @2:9ZQ2$]R90YQFNB!(U4"9D+/
M;K,()YER4@D[U^#8!HO.7K QN+H"GU9+(\SW6SDKGU9/X"M]J?,5K_1'5@\A
M]_K]E<#XXQ@N=+8_[.:[(5'N>9PX /!5J[SPE9::J(R]#:#A9KJV^ 2=Y)YM
M=-#YK2T$NU-;Z_N"9>6:BJ\/L_+?4MP*L_)7)5W'YU[S?ZW*A12OY63UW_3P
MNA7,6TTDRH1**(5YD6D>PWENZ@U%4":"<Z6XHKG5L5//=HZ-_@[GF&X\!=NN
M=MD*G;-[6L^MOYH_FV#[W70'1[+LZUVQX]@1O $]4_-8.C]$-G+(KND[53F(
MK6^=QQP2<(LDYZ#->8KP/M*%?*^'1F%"^^2LJ@V[7BQ,A'D=O?>RN:2=,EZ;
M0( O*[-G?:?JOU;7J^7C?&$\F<1%CCD2$10%*2".J(!$8CT#3V012YQ)E+B5
M? AMX=B&J]H^R(SY8-M%L.5C+1R[=5WK)Z@=U0OBVM5:?[9V%FR\=93X#?XZ
MV(U+;]K)?6\JO4W_NNL']]4'8=6%@ULYK/9P7R#O*1/WUI!G!N&KND3=YL,D
M3E(1$X1@1@L.,4L5I"+-H,(TXXE2*29.-=H.-S,VRM^IVW6UWHQQS, YC*D=
MY5Z.5,^\Z0Z2>\[*20S"IIP<;FK8C)&3[NXE?)R^VOT \.-//EV9/)%/VK*/
MK%P*^FF^^":-=!I?UAO'-YIT'O1J%BLF."Y2F JD(,XP@Y0C GE>%(H2/;-,
M"[L$4;>&75[_8?(]U[8#TY_@X_O;^P_7=?&_5_:#U@'[4RB'WCA_YM</PCT3
MS!B@M3_:ZP?B@0[U0D'M=([GCMB)$SR'APUV=N?NX/:IG<?=H8I''IF2_J-<
M/M[.1/FC%"LZ/9A%V,C03S*:9%RD' J$4XA%;DI**@(+SI4DB"*"\65U)2\U
M<6Q3SH,E#H\N1__4;H*-GU='TLFK2PL)!7LA++<9WK2;^]YG>)L>#E#@,E0G
M]%S[\F(SW[@L9BB8SU?,#-:2;S'-69T(8]J[657+^9-<;"F'UH7KRQ_RAB[Y
MX^_/FYST^WD;\WA3"ZS<SCY6R_*)+K5G]]J)RJ0:SF=?%R67$Y;'.)81ABBF
M'&)%$62$2\ACGD@J5):X;5P,8//8AJ3.Y8:+.J=W-'\[QT'M.5P];^E8F)"+
MUOLK<+,6Q>D0J%5--AB &@37TI_]OTEV0]?(WH^>Q[)QO1H>A4H'ZZS Y4W[
MMWO@HJB#=<1^*=7AFO8(QC]X/-")LK2#\81A*IA($LBDB/0@EV4F E_!+$LQ
MYS1!">76$?@V+8YMB-H^D^-;9E^!6:.:M:0_._$UAP!P*_#/[[H%AW3 D]"A
MT72(H0^-ZE"!\R'0=0N4=T'J5'2\U7.&"XEW<>M5'+S3C7YKFX]*2;Y<JV_I
MYYHJ7B:2:,;UT%*W>-B.CW6*T,:0KU*_>+/E1 J"XT@5L,AC C&A":0L0E!*
MC'C!:(;<:FH'MW!L@X+L'#3:04:%T7Q8BU?^7;WZ N%"3HTBK-O:(WQ/VZTT
MWK3_^C[R67==*Z"IC6UJ*G[;Z3_SAU9R"+QK_?GEZG"0SF:'PRAQUCZ'6TOT
MUAU!5P[AK1QTG= ;R+NK@OX:\LRE6K1;=G5BU@>S-2=GPMC4/I\^R G'9J8?
M":A(CB#.$8(DSQ)(>)8F7&))J9-H@$VC8R/]M<V@-OH*=&;7]+'^[K7ECLE3
M-AU@1]RA8>V9BP,@ZIY#Y0!1V#PJFX:'S:5R@&(OG\KE7C]B^B8KJ6]ZO)Z)
M#_*'G,Z?S?C:CLA?Y].2OTQHDN*XR%(]:1448IX7FI=(#/7B@J&H0#*SVYYP
M:'-LM-297&>N;!G=S5W,N9ZQ&_S1_M=;VL2F0^QX*C#,/=-4+P@[$Y<#9D%Y
MRZ;=06G+ 8A=UG*YU7<V-?]1UB$U\\6'^8HMU6IZS?E\9<)R281HGN 8TDA&
M$-,B@TSS%!1Z]I1$0NG_.<6LG&IL;#1E:@R\XWK *)?5+Z9^A0DK,F<TLE5U
M=9TTG<#9=K(4!KV>V:<SR:Q/9?G#'(Y?@9L:R+H&P&:-:DX-%A6=!A#!<,$H
M\"SI1(,#SX[.N[X_*[*XQT>3TVC'S1<OWY?R^??GZZ?Y8EG^N]G'SG#">9IA
M2&**]0Q(4D@(SV$A5(IDDI HL:I,=Z:=L=')VE10:5O-R2_=LM9%)/(XM.>/
M7P(!UC.#G+ R#% N"II! !M,-;-[R8RYX/=G8(6=HV#F641.BF0>OWM 8<RS
M+KP6PSQ_N>?)R-/S=/XB9;TFO?MSIGGHL7PV94<^?K_[^@]9/CPNI;C6HZ1>
MG7:*(/4Y>I?LUOU23&(N69%S!+,BCR'.B)ZK21Y#@>-$1!%%R$U!**!M8^/B
MSK5F%P>LG:N+$8%WQK]?KD#G(FA]!&L)G=K+K=36M:..IR4!>]_RG.1M^K3O
M$Y+!N]/]1"0\\&'/0@+:-^PI2'A@]\X_>FC";[BH@ZF4R73^5,[HC)=TVBEO
MU%-V*?0T_KHR)<.K'?U>@?2 4&0,\BPUV2<I@Y299)24)RSC**>%D\2%OREC
M&PPZ3PP!K'W9J.RTWM2)7[0"M4,7:RY?T)%V1#],]_3,ZSWWC#.)7PYJ4,Z^
MP)Q!*?IRV'89.< 3O;,T-,TOC8K1Z_.D>[EXJNY4\W>SGS))L"0\R_4D'$D,
ML>1&"*\0,$(\9HG$^F].!SWV38^-8+<L!WL'J+7UY@/?V.^<[F#;)7;4V0_0
M0Q],;WG1@APT5< 1H= 1_[;-#QVX[PC+@?A[UR?X\5C#EI]HN:@%CS^4%9_.
MJ]5"3F2<ICPO$IAE20(QB7(]3R04XE10)3*%TB)SH:VC+8V-I1I#KX QM1'M
M!AMCW2CI.+IV#!0$L[X/>;S@<J::LU $99;CK0U*)&>=WN6-\S?XT<2VBN.L
M8:+'^53?7WW\UZI<ODR*2"0)DP+&')F,TIA#FG$*B5Y;)BEGN4!LLIPOZ=2.
M+<XUZ$0:ZV9[7*'<W5]_!I]OK]_??KZ]O_WX'5Q_^0"^W]_=_#]_N_O\X>.W
M[_\7^/C__GY[_Y]N#'(6>#LB"0EGSWRRK6!KHE8: \,1B2T40?GD;*.#THHM
M!+OL8GU??]DA=8GV3;YA-8FB."5(I9 BD\K.> 1I4J0P3UF6,(H3D@9/ -DU
M8FPS&/M$@=J3K<QCQU 6KQZS/*#HN1_Z/HGP[X(W2L,X!N;@F19[AHPNF>(8
M5#[Y$D>?Y:E46C^.\\7J_^?NW9K<QKELP;^"B(F8J2\BT8<7D 1ZGM*W:I_C
MLCUV5I]SIAX4N&:R6RGEIXOM[%\_ "\2,R51  12K'DH5]I)$GLOD L;P,;:
MLBN]_7:K9Y#FN)S2D5DA8J@G;WI2EQ8%9%'$(&&1_DN&HPP[K47U-S<U7JRL
M=50I[<?3CLO"H30P:S5<5%O:K25@%"LJ8P/*EUJ!$E;&M+_)<>5,K=P_D#6U
MN^L"[C"GME;R02[6.]XRJ9IOZ?KAPWSY\]^DN)>_TW)A_O%6Z:]6T]F<KM>E
M*GDMF;00FNAF(L)QPC"')"\BB'C"(%,RAWDB.8UQD<6(.C--(..FQDLFP9CO
M9%YTAY4_:FT8M=OK*A=&V=!'9CEDISK0W16Z:A1R?.%7&]S]9KSXAR9)[1TP
M[H'*OQM@/-S]EAHWP6L_JTFN]C0PLP;&/SP/AS)P?-8.#.U1C@_=AG=9[J?E
MFLY_7RVW3_\FYV8WU>RE?EG5OY'BBWKS;/[E\W)C%AN7BTVYT&-3([^]7+25
MZCF3A21"0!U@,HBBB$,:,0)3*G(E4TIPXE0-+)AE4QL+6L= Y=D-,+Y!M5Q!
M_6]2=QYH_3-;I:;P!C7[>MI)T/42[-UTK@$>J,?MQHJK]./  T7P+@1_U3Z&
MK3P>%O?0U<D#63=V!?.PH!ZI<AZX@8$*;ZU/%6CY\E19\?Z77/%R+=<?%W6Y
MW5?)D^WO:Y%)PC.6881A5FU%%VD&,36I[5SA/,OT+ZG50:'KF#^U$29 2:<&
MAANP \),7-I"UP?YU>U5/B*F([]J=J/6=%^@@8<VFW=G?967)WS%L$'Z<-QR
M8F%=F%:ML4&ZQ[D0V3!6>,[6I"H74K022_K#-?_5*2&M0KFI\#U+%$8HU:-H
MGB:9GHRE"21Q9HK-BSQA,>4J2V8+>6]DW^X<YF26[5OQ&:GY[,"* </VVGS0
MF%J=&;JI3PZU.4Z[N@+&#<>)E6WG6,Z;0F(]TK0H%+[NDQU'L,+.96P;'W>J
MX@C)P4S$]7YWZ8#?YTM&YV\UEY;+^?+^^9M\,L=M%_=_+LI-L\A "L+2/*<P
M)CR""/$$TJ+ 4#)!68PTF67"5D+ HKVIA?*UR6!O,]@9#8S5]F?D;<#N9Z8!
M(!R8D,ZA=W[9Q0M&>\F!P'".)#UP.:Q.*@0.(/6H$=@\9315 @>7NNH$+K=Y
M2T0]R=7FV7#]YG8A3-I?I4/U66YNV;HJ&3!3$16Q) ARA'1,F>0I))E@.MAD
M"1-%EF52V)6_=&G6Y4,8I_AE:_4->#)V5_M\LK6\TC5WUHTZ#[Y=]!@:T(&)
M>H_DUQV2[_=(FNWSOUJS ZZ1NZ 46DGJ?,-C*TI90W%$6<K^7M^9;YLR\4E'
MI1\W\G$]TW-9(I(LAC)BN:$A!'%$%%0YD1CG2$>&3N>7CK0QM7!P;R+XRQ@)
M*BL=3Z0?P])V3GH10H-//]W \9AEGG0_\(3RL)V1YXXG'3V<)IZ^]-)ZK'6>
M1)WY5D\\7PDDY)*GA8H4)$EDZG!G#.),")@3A*(DXT7!E5^=U7--3XT8NM4U
MFS2FVOA60^%2&0N'7K'<81D$ZZ%W1P+"?$%E4EO$!JHX>K;Y*U42M87E=(50
MZR?X[JKKZ9HYX/U.LLV=?L:[Y2,M%S.>RTQ/G"24RN1.2?T3$[R G!29S#-1
MT,*M7O3Q=B9'6L9,J%MZ!,;0&V!,!7_5QKKRTPEH;;=[+P9L\'U9+ZP\-DU[
MD0B\NWF\K9&W(7L=/MPO[+_<\V D72W*Q?WZJUQ5FXW[P50IBDB<9S C5$)$
MF="3G#R'2C'".9(J$:G;6LO)MJ:WP/+^]MOGCY]__PZ^OO\&OO_;[;?WCJ<7
M3\)J1PM!H!J8&%H;37Y%G92A@Y APH^S8(0]1WBRM7$/"YYS^N!$X-D;?/4
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MWYQ1,!(TS:F%&1,J3W$A8(00AXAB"1F1 B*L.,82YR*.G/04K)J=&CTU5M^
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M9P JBT''Y)MF<=%1L>H<YG:4&Q+)@8GT,A#=9:4LD0DK'76NT7'EH2PA.)"
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M^U;W.2C"[G2?;&W<C>YS3A_L<Y^]P?_(T4)WT/-GN:M#/XMP'A<TIQ"GJ0Y
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M7D"14P(1DAPR57"89+G,$JIRC*Q$#ZQ;G!JE=HP&>ZM!:[9S16M[Z,\3;7!
M!^;;ZV%I3[[!,1V)@P-@ZT3)3CCU,+/=<T8C:">WNCSM=J,[71]J1K:EA^E"
MO%]O=&Q=KA^D,+]I)"._OODR4X6*,YH@R*32L;#BRO!W#IE(A% BRU!LI67@
M;\+4"/WX,<I=>>U*97#O2_5KT'AS4__M=KV6+C4#/+ON//\/WR&#;YI<TA=O
MO@S>!_;CQO!],=) ,EB?. TOE\'9,]YX/GBT >@RQ[LCTH5/\EL[_B0U.<HO
M3W)%S0#X25)-Z.U>U)\+4:ZKL5&*][^XOO3VT?QMQA+&BSP64. \A2C)$,2<
MFM+4^A]D(0L628?Z/1<98_5)CE_@I_;E!NR\ 94[+[:.NRZ!VB=0.^6V]NS7
MB79KT</UR3A#UD#]X+Q:?1&.05>O_2P9=37[(K!>KVY?]K!0)3IT$+I]?*J6
M@OY<2_&6SGDEHKFX/U"*-^F>7U17;OGC@IM=0SEC,44T$9'A7$V\&<DA3I"$
M"8E2(6@DN!1NF5J#V#FU.<3[7Y)OJUR?;WMQGRH2JE*CEPJ\4"YOW;BT3D>8
M/K?CZ0GTY'4F'WLO@7$3=/S<7=HM].'7XP&J>P3MCX'K?82Q]<H50(("?KXF
M2-CF/*N$T/7#C.><)U%10)9&!")*"62)1+!@*&(%SQA/$J?J'_JA4V-T8Y-C
ME0X#C1V7NCH\,/'U^NI>):/C7-CJ%^;!XU:UZ+AR4*VB^SOWY=MO<O%8+ECY
M3BZ6^@<S:_Q N496?\ZWJY69?5=YF\UF<9;0%"4J@RPC.BXK%(&41SFDR A,
MQ6E"E'7Y;K>FI_9AMM:#COE@9S_H.N"Q9^_8+>>79(<#>V!2F!3.]LNNP^$]
MTG*K ^YA5E;]$.M9475\X&@KJ7Z.=E=0/9_@%VI]T TL>$GG^RS^6HT\04CE
M>0P9,@?THSB!E*8YS'.6<,J4_KW38:H3[4R-]W=F=@[*>(F/G\+5+G0+@-;
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M"*(<Y9#1.(52I)'*>(88MCZJ=>3Y4XN0C(7@T]W'K]7WY)%S<0S#?BH*@,S
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M(+R>P-G?Z#[M^KS\484G291FGY<;V0:\N<@YB7($,Y0KB)*80VJR?9*,1;+
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M$C$^0;,O!(Q7-V#OUPW8>V8"VIUO)K?'> <:]T#M'Z@==..?(/ULQUAC]][
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M&&'<E+%SRITDBYV]J-O7:IF@.O>YUS:^RN:@?2P69H.HWZZ4+#8S*!G/,4J
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M.!%$ D1X"C!#J:T>R0%,E>28""F3W+5U4F]IIL:K[@=H>[6BG5[EM7O-W%L
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M78_'/$^EAK:KAXH)P)F$@"&S@]1$Y$KE$",F_!CS_$#3X\*=G-%3):@?)UZ
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MDH@-)MM6AN^]?L]6BV+QL/ZL5E^_LY7Z:"CE;J,>US.A%=$2IT#S7 )L/GW
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M:\J?3;6]>M-@]4^_J+5:_5!K0VZW0JRV;+Z^>WQBQ:J,JUC:=NBS7#"<<:Z
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M],O<%KSS[D>[PRPWX#!(,,A)CHP1ERM F2&PE$ F$ZPH5\2S]6\7S,;K[AL
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MHAY.+!\6Q3^5O)-&K$(7=L#J5/E6_&-;K,H2BHTS(?,W\R4T?S/C<:HA4SE
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MFQ+^P2CYD3VM#4_>/CW-"V&)TZ9/;2UU?BP>B^JD83V#4K&80P5$@H0]GZ.
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M-FI?/G.6)DBEF@J "$L YEH #E$,%*9:*)E#EF*OE*:I:#8U"@S0L:PNPM7
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M8=$SGH%8Y]#(,9&(Q5.=>!<A90-!QCI1R%-4]=P\C>:(J"\-4%1"'GD4)(2
M3K9@Z,J@"V,J/<=NM'G::2CX0<^T0X0]8!RSF"_O*/\48>KQ$.QZ-QFPPIE
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M15R.OZY&SMWX==0H[3/3)+(B2A. .(D[CJ;LJ>-@5-CKI#J\OJL"-XU8L'Z
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M0=RPA> #&LD^E-60<7PSFV]RUV6S=HAQI+0+8)0@EFJ/["5*K-4HP\@R%1!
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M(VRRPB:'3'.!^T9D07S6AF3AK+74@55UYA#L0=S 85X?.'D0X/6LDO:-SD?
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M:J6M=9/6 _$GC9UX?/FNO\[WNYTE07J1;21!44ZDRYHXG@31/";F=)24LQ]
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MCH<RW32R['40WNT#(?SD#?C@5]O0>;#TL![Q64S2:>)N!2<W$,_6.3R,B4B
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M1%.@NLO5>J5#+L8Y<1V(3)ZO*B2,\[*TY,9_$I6Q].Z@ L**[0QKF*+C)-T
M6.[B\-]FJR:B&*E<HQ/P/K^_7B[*_&KT ^X8_3!;%YYMUQEXKB *@^%*<&5N
M42*!"4\4-<SF&*FGM=-[)S'0BET[$DB/9E?.I]6FP+S3K_TS&O,R+._M]+8:
M_7V^G:OW >9EN$L99[0A # A.P\D4):(Y#$1KYTD29LD7)8J&E49UCVQTHK5
M[1O@0VAZX*?\3[*\_.*7E_Y[@(\0R^N(KJ2R*.3%^Y=OE[/7?CXMUZV_CY=?
MQM//O\/D*_R*+L^7![4 I4PL<4,L4$VD])H$RSAA(E&J2K?3L.4Q[.P+< Y:
MATTW]@7M)C7;E%'OKGXWI@?CV?8*%N.+*6[Q]&*QSEEL2.YV\R]V[_X7TW3W
M[?41^&[](GI+:$+@F2?0,OB</9$1RN ::4@6-'-=U VI\D$P(/O#%AW6.SR>
M"Z*:VH8[C=0C)^U:!+?)\3OV62QO\:@G8$TL"O3$_1_VWK2YK1Q)%_XK-^[W
MO(-]B;A?O)1['.&R';9K.N:3 DM"9K=$NDG*79I?_R8H:K660_) !ZK[3D^X
MM-A$+D\"F4 NGC8EIA-M4*SHK%H'#*,P,FW"X3/[54VUW '(KSBX,;_@ZK[;
M6VEE5 )TL8*"(5\@8(C@ F*6 IG,;9YF'Z.J%[?^>9\/1M-33Y@[(+5W>Y7%
MB@L^.&*WMDQ%SL&[6( G:TN]V1*.=9O9W<%CV'BH:I"]O;N*>\+VZ_,;S^+O
MEOBO,YRG\\VU/7E!)B?:!P1S=%Q)HR%XZP!E2J;H:%-L5*[V-'&=X/%Y8?,0
M>$?284^PO(^AR]XVK$0FM !)QQ39>ZCMMCRQ)'@QCJ'*KG&9S,/$=0++L0#Q
M$.!&TDY/@'M]?O7E?\YP241]/_^ /_'DHN>YK0TI?(#,O0:ER%9=Y2IPE2SG
MGO-&9>O#Z)O6U^QN-QQ+DSWA\V;RVJ_\;8U/6B\*5P@,DR/CBPI\=@RDY@)#
M$C++-NEC.Y'9S28Y&DX&[)/C**TG1!Y>#WQ],X+:.B=$ ">R!Y55 L=* J&X
MY-Q)Q4.;;EPMN)GVU:.SW7@JE'1@*==7=KOJY%H)-\I[2.!%*E)$(995$ A>
M8X!DHXOD<J%H_LXQ AN=[/V3H?+!6]WGADCOA0J7V7YGX>13/)D=7XQ3"_/\
M9G%Z.CMPT.$.'SYJ><*^3(U6F1#7]]SW<G188FW$AUG6XFT#H?H[D8OB&(])
M-SI\[Z=GO&WWZ_?%<OT-EZ=UH8LSS7@,*E!0ZFTD$_'<U4)U"XQ.-)YX%)RU
M&2GW&%53I[@=C(J'M[4#5=##*7Z+ _I'F_! 47Q E%O0J28E24-;K=,"8D(O
MO C%ZD%MS7?'T7WD]#*8\%!MWX71P:+O$3_;L$]X:4@X",+4&6>UEC;**$%G
M99V5.F)IU,'S?H(FQM#AJGX*/'O(O0/X5,\ EYO'_/ #E]MI-M'ZX(VIS9/K
M[81-&J(Q!5!S:30BLM#F:>9><CJ#SCZ*OMN^^F"I=P"=*H_KU_^-0<60(DLZ
M@[82*4P(N8X1,9"DK2E.)BELDS7]*RV]3 P:^<PZ4.C=P>9C.+TT*$TAI*28
M%J)%#LJH2+MQ(K$$E\FRF(Z\79QP'T73^\V':/I1X.PI]@[@<\N>KF]).(G
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MB!1';:J>JRZ^X$FMF/ZVN"'>&RZK4MI'%D"+39*K$."3-5"TSBZ2UG]I-_G
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M\C_.5NO-]OMNL?R(_[[!UW(QIR_3YBQ8;=K'>E>\5L: R*X^&V0+0=!7VOK
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M*8DL)M&FP]M?MOG!3H YL/G!+MKK )PU@I@O3A;'YZ_#ZAX6+\Z!S'C1)$%
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MOB\,]I?BI![KKVWDZ;13@8D S."F;+*2;BQDPW32*0<4X_52W+T9_^CA^F@
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MF13O+3F#B.[N:=4&0ETX/^.H^G$ [2'W#L#S=K;ZL5B%D[\M%V<_-D]EFYZ
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M;R+;H],(DDU12<4DPS9EOX]1-6U/E*D[0^^GG Z =LM,'[?2VT,EI/79!H^
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MXZD?^/C^0'&  A?C2G-B0+P+R_#C[&2%[^?I<G!VR=ZR0L>^";6Z++DZ.-N
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M40J<=!Z$%<F9$H0M/5G53K'#<SZL=1@[[*7C%XOH!X?-2,^9*CQ#B9R!BJQ
MT*Z C8KK:#T:^VP#!0_@XR4& /LAL.WLH5W@T($Q7,4UVY80MP8E;F.=_.E.
M&/-+T',[YKE22Q2*MB3/(6-RH +GX#)+D /S*EHA8FHS<+DE5WT<#1,82C=0
M>8G=(CR/"JV-Q% @SS2) %ZS#-FQS'R41M[-]GC>QG#-=O9^4'-H7[E=5#CY
M%(0'IY<RJX53!0$EG4K*BLU,6P'%2,F+8IG'- "(!TZ#;;8_=@FWD=31@;NP
MS[ QD;-2$0TXX0QY1$'0F1,SF)*-M2Z:X)ZM0=A3Q$Y[2=(=>)]+[5UVS!ZY
M@[@BWXN\+ _&,4F6[AT$&1,X@]PPCL4X-6#C[:9+_',V*FMR^]&EYD>SA$;=
MP;[29K+&XUEZ/Z\C?S;BV+\UV&.?-FI?L,%DC]04[,8R5QNPEE8F3Z 4]%5]
M=Z&MD7$#2:F0HI!.ES:3>^\A9KP68#<^_"*S!VWVQ*4&5S#6V:+TE<0 11NO
MO29#M6TJWA^F:=H(Z% L/-R?ZR#9=^!-?CTCS^5?9T3_;S_ICZN,:D;!E4ZB
MCBY(M1LE,11K_6Q@ADG4&$NC>Z,'".JE/==A^KX+HQ&$WR>&MJFPPO L:Q/3
MD&O)4?%D8RYGT$H)YHM"9=M4K3](TL0X&D/A3X-H#^GW!Z-MZC,SQ?&:*D$"
M4J!4K@-_+$)F4J12LL TJ,'3H1#JH5YA)%4_#J ]Y-X#>.[;H6\$)TIH4<<,
MDIV1?!2K^[4*P!1:)8P.-CRC1W1%5R^]@,8]U<9310? NACQ_#NNOR_R-3]O
M9X6HP7G"U[C^-^+\35@NSRGLW#9TG^<_*(19GM0?77S"441BC"E+>WP5:1 "
M8JBSH+VQ043FG1W4HFQG"([%08<NV)ZH6G2@XFZAO3J2VF%11@-GILZ:MAX<
MK0_>9BFL1YERFYJ$!PCJ<)=L";S=%- -CK[6*_'--7E-RE[42_"09R?G;Y%6
M.IW-Z[ER?;N^L:$C(65(5BN(Z .H.@(X&A0@:!'&<\82V[Q+[$UR+_V(&F&Q
MM1([1.N[GQ]G1T66F"(BZ%2GK5BRO<@] Z59R*ERP=OXA_=1TTOSA^88VUGT
M'<#GU<\P.]F8P6+Y-9S@-3=O,:ZOOSN23CBN1 +#$_$E% =RHQ7(PE"X4*S0
M;?:VH13V4L4Z.LR:J*@#Z-UT$82H7=U)^;ZVO5#!%=ITBX2D?*4[U_]O_9(Q
M"$#-!EDW!-"^@NX (Z/%,LDK+9R@L]R'S96D@1@Q@ ["FLQ1F48I(VW"U=TE
M^<=\B;5?!^:_A=F\SM/Z-+\)#&5,R985L#6C0WG+"&#2@HZ!BR(U2M6FK.()
MP@999;-IQPVM<DR%]/[&?SG0+<SSI_5WK(D,87X\HS/M(B]I__?^H9\\ZMO_
M7NR,E =PN39M$;\L.UNEDT5-Z;IZ%3;%R)P)H#'(6@L<:..WTD#)Y"DDSC&:
M-K=T.Y$YWFWYY;+;EB!:"*O1 Z]=:Y2J'?X\&K)6Q5#'S!5K4U/_ $'37CFV
M0\[#5^;[ZZ.'84R;QTRN62%):'*C;>V$72PXE0M(R0RW!5$-2[)YF?.[#E#@
MO?.X=I%F#Q"X?#X,]'_))ZA=RT 5$\@:M 0F4D&&R2 ;&01=#&7:764/S./:
M17Y3#V2Z-4E*6ITPUHRJ*$P=1B; >5L@,V&\#85D,-[TO@[G<>VDN ?G<>TB
MQ:G5?VN2E/(BQ4)..'GZBIQPS<%)7T"$.HO.Z#3PE?.ESN/:6_U[2[&#2X=W
MA-TU?IC]Q%\<I=?GOX=_+)9O3L)JM=D<M4TVH17 F'<7<U^\9QZ*-<X:Z3R[
MVYYFK(+4X43V\N!XN"_16D-]@^^:L8_A]#)5RN7@'9)M<5N[F'-'MH58:G:3
M3"*IJ!I-TMF1T(EK1EL!9C@P#]9>!^#<S U:G"R.SS=M77]A<3L[B+O B@B@
MM:3M7DH-3GL%A@Q=1&8U:Y0F.XB\;H%X.$ 6K;75 00_AS5>=Q+6FL(/S@0D
M17\H0^Z%*SF#X\$ZYGE&W>:&YQ89$Q<H/R.D]I=^!]"Y]Z[VJEFYS#Q0<*(C
MKW-%3*%-WSI@=!9PLHR<4QL@/4+4Q*7#SPBKL333 <C>SS.6';P-G[7*H7#(
MPM9'^QH;!9)=X+5Y&W?.ES:'Y8Z$]I(I-EX0T5)3_0/Q7AOVDC.EM(#":C,?
MHQ0$8Y%DJHE?&26%ZE. L;^ HBEX=@/JP9KL JR?EXN$J]474B-1\OW5/+_%
MGWBR^'%Z7<1#QX!PE2E;+Z(4%@9!$V>I9#+WP)@>=@N_!SP'D-<U( \'R2^@
M'%MC'<!P6,2D9%2YADA"D;.KI"*)52_8%ZX]%XJ$UR959KSXMEDP\MPP'%]C
M'<#P*^EKTQ?DLIG(5SR^J/;?'"7)&!4D JK-BTK2X",W(),R.1>;3*.![(^2
MU4N6]WC^X7A:F+3+_A4[%]1O;4XJ[2KN 5FNXT\I=/<D$[!!6^&2B$*TF4Y\
MBXR)LQS&4_!=Z.PMZXG[5OV.>76V/+X\O;7TC'9AR$'5_H2.@3<U".>IA"2<
MR&Q(@ZE;'SJQRO=7S&(,*4W=:#0L\VSQ,ZS2V4E87KWQ*N>LE?7NMU[<$"=>
MT$&LK4[<\N"B%P.T?-]G3_SR.(JR#Y;9Q#K_^@/KI,;U^>?O87D:$IZM9RF<
M7+I&@0EILV9@3)V=EEP$9Y0!'="HJ#RS=^<.W:O]QU>9^/)H%!R,*,<.7,Q+
M-^G#52Y[%L9K810448>XL,PAB&PA<9]$06FC:ILJ_&&G-A+/4,DUGBMYF+0[
M@,LCCP%_6RY6Q(]FRO@B2#KU]C_P @ZE R1F:N.5$FVC\65/4-9'SO6>BA^>
M7;"[%OI&U:N4SD[KQ&',KTX7R_5VT/"1)DY"'? 9<PIU& (";=@,I#5)BA*B
M46V"W]UIG=;Y>3;DC:&IW;'H+[ XQ^.Z\+?1S\4+>V)9R!A2!JM= I63A:!R
MA(S6!+(EPT2;[+Y;9$SK/8T+I/WEV\%^=4G\^],?84;+WX#^Q8^JFUDK^8Y2
MB5D;\B^CKD.S#9,$?N\A6?IAMLSJT.:*>#")T][7M0'5N'KI9U-ZXE+]MS^W
M3:(OY7#DB\1B9 )>QS JIB1X.O]KHW8T,7K-[\X&>9YWW%\HG=;5'Q>%3;74
MP>YW;4JU&OHIYE*TCB4ER+Y(G*JV0(G,4% <@D 77,A>MX'@+F1.V_-A9/PU
MT\_$-UA7<3C^N3X+)]<]KTO4@EO+09!\B(=8I14E",D*4R$P,^CF\J'/'P0.
MVS<X1I-?!QO0%78QQ^"$CA"ELG2*YP2!\ K>VN08ZI)Y6[=\FDN%\73Y@/^T
MDV [ L2W99BO3B[D/\^7D]#)"ZR]5&I3E?R/L\NV&C$912()X'TF#S#6)L/T
M)W CLD9MO&G4QVH/8J>Y06@.LU;JZ@B1FTDSM/S;LSI5Z3,N9XM\)),K,M<7
M9:-E?7G@X+R48%3VP@DT-K?=MNZC:IK+A>88.U@!'8'I3@PKK/*A/ENE7 >\
MA6)(/+Y.W)1):Y>$R6V:.]Y/SS07"<T!=(#0I[\XJ-*YMZ;B%U$YSD-4=-C'
M>BNB)-J:O% @)A)3YL@2Z@$N]*#%IFWE-9X_/;YD.]AL'KOAOW&M_]N?/W"^
MPH_$[;=_X\E/_'TQ7W\G6=HHR;H0K)=D']P$(.G1+E(=2ILXRZ+-Z_%A=$_G
MR#< T0YO-B-K],7A][\Q++_]>W'D1*8-/3G0GIF+K(U S@#HN)F9)66KKH=[
MD3M=/- ;6O?1W\L$*:$.CY+R5DB?07KR:I3D D(4$>I8$VT+TUFT"5KW)'BZ
MH*)+H.ZLPQ<)U7>+L^61J9?'W@LZ-:PC@TRUC[Y+8*TIZ$K(13][/YQ'Z)TN
M>.D1J#MK\&7BE/[ND13"H2D*,!H$59P&5T?4:1EDJ4D)H5&]_W[T3O-.VBU.
M=]5@[_V1KV:0;$>R'S@$^=&/&[43\G#"1VI__!:7LY]$\$]\/R?LG5W4Z\SS
M?V(^KE?'B7YU,1OAUY:V7'$GB\S@3(WWBXT0!7<@C'/!&I%E:7-Q=@#1AVZ/
M]RY]V7#\]?F6@B]X<1V_^C[[\?K\_;P.(;^JCOI0%Z%?OCZ_[\.^S%;_O$B0
MMD*)'%P&ZT( Q:0 EVRU2L^U%@J1R^<3;Q,>ITTF?B[LW]V@.\50!\['[I+9
ME!8*3(5CRI =(RY]H7,SUQ%3Q*1*/&O!VQ1?[D=OAZCO 'T'&\G.4.@ \/>P
ML2VK"D:7'&T"8VN_>&$2>%LB%*^S])$7DEX33#](TDN#[>YX6+103@<H>Q-6
MW]^=+/Z]96A;89<86FXY66?4!506!D(,]*V2,9E$SN_U5/%1$78O.=.B:R15
M+\:6>P?@^8CKZS$ZMSEA@203.$(QL9;T,PM!(H)/7L>8R+8:31E[F*9IBX3:
MP&@D#72 I2WQ;W$U.YY?:*5NTBD6C,Y+D"R010CG(11K(;-HG0H$ IU;GG5W
MZ)D60R_$/QM!E5T"<FNO*01;"^M .>9JMY)$D5Z,(%!)# 6S#VWN-AZBJ(OS
M\2!M/PF@/43? 80N&<#\:K7EZ=K6+IL9(%E:,@)BLAE4R0@A.PY>2,>T+D;:
M5@'JD\3U!JQ]4/!+[#BN2CI V<?%/%]Q==G)-PHTBJ03/3D6=/A[BFV,(@^
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MT:2+!VD:=I_/7C J1])'%[E@.UO87=NZL+AJ7(+KB&@84!3A0$E)QA4LJR-
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MR!OV*/<1H.=%^#)=A?,WM:?!C:O%5W445N9D.&V!IL3:55R3*Y01:'FPX*5
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MNI2/[YVS'5#3QRKGD=3M/I)JP'FZ>8[_LKAY68LY>E,T"W(STY?^!$Y;DHI
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MD9L.P@7:'C.8Y!76JO+^[.G&P%#&5L@HRY$U/>,7@4,>'8LUJT<(LS!IE5(
M,'>>4U!L"Z^*WRUSWIG%Z@66O38I<3ZE-65,@$HJ,ZRZW,6R&UX_'>.2H7XZ
MIL%J84$.:N $NK&LC>1.7!FRL.^XO%B _*[*4;VIB[^F->2+PTY)2'LR)8.Q
M5H>[>,?)9\W0VBI1^=SH\&QL\K,*VQO(8'63MI-F-PD;XP)O?T6'15=Y:#5
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MQ@2I(6/A>#DN\IH6V F.(^7<KWH)P$9>P_'D3$@Z<T;455<:Y9J3C*JLU^(
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M\6N>,IC[V#=3K=(.\]N3OMCYP5G?/A2JAW9JRA$Y*&\G6W^7;>_GE=(OQ)^
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M<F\20;X JVYLFCD61/?X)9F0);5]Y/;$ZXT^=$>Q=<[@(T;$T^:6ZE)S%]+
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M/*V=]](=@5DKD7H;@<"\CZ)@0Y*%3)Z J_9Q#.9R. QW<A&AJ+S GU5"O(R
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MT;$K';S-[K_P:"E2+X<[!5FN<&VDS?SI:RIX)!D A@F0%L<^L2'C .TB!B2
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M&*AE!,\B74EUW&][%U0WK81U84\5MCN-4\Z"H^SR@8;)CQ9-XH. 1V)6IK/
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M"-[N:.\F2Q*MRI+]J0#*,&4C.K%^=2>#31;L]2F5;G'"$F!6>]]+>'0\ Q,
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M;YTT#99KE KUMB+,,;HZZ7R M#+U+Q8CW(0:(.3-VU*P>3&9Z'(6"UKO/\(
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MI>A#4P7\7P'DB0_-\/<I/X'' Z\]AS_5; 9B1@T3+6_&G8 UBXB[%[A(YHX
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M.];< 3P.9GE)70*JU4"D104T)YLTG>HH9FZ#6\)G3P7%3(_ FD'J!8X/;TB
M0^&BT0*@RA"G;.+4YAILQ(:F@7ATV&V=7,17]?VF3:S*29;'Y=RI4 6<SX+X
M7EX)'\YD"X8:GC3>_ Z&Q(JI&4_63,UHQ+1(71[@G42]1(0KH((T3@X=693S
MUQ.00 TV[NG;=>H.A;R!\P/GB(N2I)IA&BE:XOA,?<4<@WY2<.+3%#BC0N6
MSQ7:^7/_?"SB"##X#\160>"-XGQ435%@D+R%8>!@2;["X*(0'WD5YV6EC?0C
M X*$_]BQE!"G-43+?9(E$9M5>$*;K(5W>$Z:EV5'&9[+ #T<P*:,BR'(>;?A
M1Y" 5S$P9'Z0_PKB2,UW;+ P-N_@=!]X:*Y'&CD('%M<R8B>?965XO&H/V4S
MA+$"&V$+!]ASG'@C)C\)REP8+HD#N'4FJEOGF(S1U/R>'C3436KY\?C3TS7C
M3P=:E9-[YD"'+,999R5!+?)5^Z(5#G"N5<$B-\)AAW0T/=6;J!#]@T+2'2KG
MF+D1W2_\RM<!%MI?EK4)?7<H^/1@8CU9+OKV=<&#+4;&A0#<JP0+J!+^M=B6
M8"V"QF.\K9[]\+3#?A#EI8@_@Q*Q\7RG9C;0X+S5]%484>KO.S#VU2COU4V$
MM[M+)QC$\>Z;@;X*=K?W=O9V[C'4LW,[7^KBR.!WC/+]N4#F#R "GJV9"!B
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M#K2TU!;7Z**-FH,2VQ 0L8:V&+@;$+AQ&FX##FRD>%%C"LSCZUO?@@TF-,V
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M:291#=$":C0*\502X35_3H_C!+2;@=I^( 7 A)JZ%C8Q8>UNQ<RZQYO;[ZP
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MM9#%I<8/SD^@<I#OC">'E;GR"'8XJ\_D")"'8.DNC/$_[88-T9VV#99NXZ.
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MYPZ(#'8H03EL991("%EEV\>+= CFXKE;[&%NP#O@*?$TP(0C8-TW[*#Q@B,
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MQU LO5H.%U>M@954<9(ORGT[Z$@G6.GH?BDGY/$)$-8AO:1T.NI^2AK B!C
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MLE5Q-WVL-QL[@81:O#:U*_7;RJYN.5NY+"%<XR"RB_RG)<J6V70SB4*4DDW
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M[5(;'_"S]90T3.*1 EG=5#UXL)1=8#;WCB56IJ@BD)7CLY.W,K.&.#@=AO,
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MW^AP]%!!#.!8#-"MFHHLF$:]<QC/8EUPX.]:1DPSQJ'"P%>1)+4;WR.C1T9
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M)8HK+8N[MI^C1>'::9-M-0NO-H[J+"WL33/N$I3K:IN8*WUP=:E'*8J^KC!
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M;>0>U")3Y3@J3W[NNBSE0S+RXZ\4AN9)>_OGY6MJQ:/C3#)S#X-LU]#!G)J
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M;*'G5H!&VKD)\ '2[$JNY234/A([,^$W!G2OG9@AU)4,?*1 H+]]8P8@TL2
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M?["XT?*55^6#MN" IU6] SWUC("FEVQF$=0$0>Y.#[;7:DD'+' N78ER0)D
MP5!&,OI>2 \P0P,/(\U?Q7F(?/R_.2C-TKSA6_$DDWI"3'CP'@R-_@WMZR&1
MPT0'_ZK%00R4?'M^]=M+Q*U1(<WII"5S]L'S?S,SZ:^6&K,@1-% DAJI>P[R
M-HF0P5@-_OC#LY]?EXD=ZQPVQ16G,6AA%N\L/$#P8ZHL[&I$=!^NOZ/,J,J
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M,M*2%Y2/SY4+I%-T(HJN<[K/QS%O/0Z\."24P9(+?&Q.B,FJ=!NXZ-)YK>R
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M*HCU".84(U%5K1%-5)H&$P5SP<>5:JJ#J589#D#!V,H2#C"3$WP_Y2?8UU[
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M^SN'NVMV#DD\(?W]"T0V\O#5.I('G_!4H&#)@;**ZZ1$:L^ODIB%T[FH.\]
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M-,#90HH3P\>]BU(,S"CXQ1*L45Y:!HPX'X7([VVN4]E_X)QZV)IMEM\T7=0
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M/*H6_UC:8G ^4L_1MZCL6*%>S+N)V"X%Q_/G4:+ 3)/GFYF*-)A@DXESZKY
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MC[KMYLE5:6)D4%E%RD9-*+6F(&Y&=1I*T9R/7-U"R)7A6S*DQ$055=*4&O$
M4X0/-ZRO><9-;U?A"CV7&,L1GP6GU:Z7*P#N9\\)#(AVD%IS-U>1461ED6_
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MT608\<#K^0%: @RLU?&EHT')8.X\+S<#![)R\+\OS@;[!X'?N_=HCXL0$3/
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MMYGKN@'QO[50:4?J>O4.($;9Q^WCM?0LL@$LQX7,>LD.0DLJ;,&/1JE*IG0
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MA@W($<YCL9F\TIK=;Y15>E#7_B%)IE,=8R)1.N?T?E!7"Y/LS\>'PVH4%_.
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MN?]]L/=;<'9P^N'MT>'>2@WXH2XY&!'O!V?_6.>LJF42]<)VPVEU;@P^(%3
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M>XBYS@ %FNS#\#8+>/D:,>!676AQ FT>\6*=K%N.$\?N"S=(-Z^H384%G%7
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M=&\\*/CF3UA_QZ?7F)<A(K5NXW&A(^1'A[7!6D!.4"A2#1V6"A]#/-@;$;,
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M,\D[0VJ@41*P'1 3;0+B!!;QDD8LE&248Y03!8GI5+\$0G<C;V1F,9"DL?=
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MUX/#X;<FVV;C !K)=Z#DG35SZ]YFO%;H4$E%$\RO57I1)%>L#''M!?D>W8R
M2^V1UMBG2I$'""-H>IN#6/9MS=:(7C;DA<ZH2V-1I_BR(["+?GKU-GC^W"9>
M4'MB"K38"K'WH,UEE$KP0167<)(WX"(0H'!\7CQ_2ZV]5*#A5UU$*L[-];H
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M#4,2>L[2>]8'3KR*+5.5MMLI2O,PI5B*H9>D _702G#H@RST,59MCRX/P<>
M0"" P,TI%"TT!@MZ%R\%]Q-]^$8HM@Z^A[=4Y%$S[[/%T S"(]D<:;MQNCS5
M) -J#]7-3#4M\SYTNMM#TED<.HM,MQ"2[K:(='<$HI-.Y$LPX!8UCN^^>3E:
M7/#[S3AGJM'6<**]JOPF[IW!E:I+8_U?"7C<N?JR=2JE<P>5GI;MKHR$E:8%
M\,)AI1$4G0%ULU!HJJ0"OLHOU!(*.*?A(=R)@& W1^;#E2C$E\:R?TP P69-
MY%-X&)DWMZ\W70H->#-UW1(B\$:"_Y8H@7!HLD50@0V"^AJ4P'U&A?%@76R2
MN@U$1;I10MJ#P%<0ZJL/!1,;ON!D W==3<:,/NLU=>WK?[X GU#J5'T,-3RZ
M4Y$4/-\I]B@EJX_:W2@?;!$;#M0+]RU?./B;H.N:W S$S%0STFZB1@@6,[?1
MQ[LL=1-*H['<3R5-:QUF>/T49G@L5=O<99I$N?7]2$%/$TDQSCFE<WF T=W4
MG&\8[+QY]7HMS+KSP6$WY_'A0I#@YMZ[B_?;XXZL[F:P:FAQX=HJ(J&B*FZV
MP'*\X?46W=S8:S-<-E8'''Y[J0U&>M^2!<&_V(X-@V,:PL+6 F&PAZV-0 V0
M.Q"SEW''P; [!7*J9^1:/LF!"<S#X*!$>Y/[W9/6$ 9G\-QR+.U9X6LP3H)C
MJ[K"8UH0.&R5[DWRA!]S*%':?^FL7JA6?&\>\?\.3@9'*\7+'JJ3[7#X;G!T
MW%WKAV$EKJ&^\'U>WD\,?W72VM*9L[MCH2KDC#A*IRB6=,<]U".5 3?TW7.X
MQ4?Y-LBYG6!C]]G.SJ;D.Z@9)K1(%ULB!1"8Q_+LCI*&]BB;\-33U":SM),K
M.EDMW38IZ\ =/@P.!Y_N&EM:(Q[ B)=6Z!H_]# 5K0C+XA4Y_& T^Z;:3=S%
M'Q3"\"*:T@'W@CO%;@NU#M[E]U^BNMQ=04YL@?ND[M/-^=//XI(F/08=99SL
M$6,2"?9I8(@AN*!BAS#=XW*)L/ KX@P1+FCTEG2F.+$TR> =FKI+6 A5_."\
M)JH 2<K01UAA)X]@-ZGZ0FX1>0B6X,$8_^@BU,=WVC98NHU/@M^*F2R@6#6G
MQBT%R(,.\Z>L&5D$=@VBIBVX<IO]+=:D-^%8)2DYW["-):/!96Z9Y)DTU=;2
M>IMG/,%WSQQX8,)\3_H;8(<'4--Y$4/,L,$>:89TS[U&-R<F26Y?56JU[+-"
MSU*%%;S6.'O9L30,S 7\"?1=S;\2)/+)7[@6_L(WZ^(O_.<_*LYE-:2 J.E;
M$:+\STK]L_GC+1;! !O^.<EHMG33VZ9+X24,C<#MP2Z78="(^&<WZNUG//(*
M!E7%YLWR\S;]]&,5=W][\7K[U8O%/S_;WEGXV]+'OMG>>76[Q_Y(0^9AP\J4
MH"C^]P_/?V@MGCE.V[ @H!E3AR1#<G))JL?5T@NJ?-;_^PS[G&47/^_.O@0[
MO2Z<SA[DLWO(,.]33Y?)@T^N]8W^@B&4I!+?3IVIZ2BYJ/,:_3N1DQM<8.)D
M!R9/D\P6H4$P0B2?BSQ#EZQ165 '"&W6K$V^CD&N2&-@QE**.=[C@[J;^# _
MB/W#+F-]).BQTYQZ;I5>-"CL&!=>_T43H]1?HK0NL>>A:"0XR&0JOC]NY"78
M26Q)<8YWIBZLVK:PP_*"]K%+1H4:%380"R+Q>=F52CP8):[Y@7>'/M+\J*[(
M'B2D>0JSBQH$FZFQNRPVHXWC@AN6P>^P3[,)*+2@&4U'N'<<:AP'HZ2H)CV8
MN7R=VU2J)K#H"O8Q#"<<6H!V4%+#X',^"L!*3778VSJ*>@6@#IH7C)-ENK=X
MBX5X#[ H*=V&:3*V;;HC#QR0*<+%U(=VJ!0U0AV'08032O$O4X,%?UY1Q@?"
MR?-?-%.O664B6O]872&(UK<A(:N#F^Q=U+7\[%U")JL4&B'DE$ZZ22F,GUSF
M^#VJS:9)ED\T<FRE\+9M*/3V.A :[J=B&I/1K?W65H9-4&<29( 4N,49EHP_
M9_!]N+F.6G:%U\ZSU#+\94U(/!@Q!2IM:;N^-#HIXA=V?TP:4K.GJMVB3F.(
M)8<:Z#>9)7[Q'2V23  ;ME3:$C42+WPB2#1:")V6^AKY<1@L>*ID91AW:K"A
MMR^VP^[3-IF/H/\^3@@\%T%'<"BS(KE2T=SU 82%KHRCGO( Q*RE%VPO,\VX
MTSN=#_QO9Q"NC;6S!%-88+<%R)=X%,*6^*126DB.N>H)Y8[WKNG(6IZ6#7-#
MG$D])>CF$KY"\P#L!/C ^WRE.?8PQ!C&;Q/@C^]R(+XL.(L2X63! *S>X$2Q
MF_H$^.%A!1SAK(:9!;O/MI[MA,$'#=)MEL-D@O/\&HCT.(,]>Q,<Y< V@W<U
M\+S@7S!3%>S#<L-/9S!&-<.4BYWGKU^^?@VC>/,V^'\V7KW<#%Z]V'D=O'[]
MYA5]:3+:^OK0"D[RLL/2D)3 B4KRMWE+Z-#+^7@TSL:&K)1!+O+.U2;OVMV9
M&CD""!PPI '!+I/6@)U.2,#YVH/=WAO4B+[J@6\DLCV)RET]_1[AZ'\@ZNMI
M,DS=[$TO<U1F\NL N$=6>6Z;25+$]&KA0]<3TU"P):8LGF)?BVH1>^T&7@OX
M4H--DU E?RR"ZF,]!P)-ELTNZ78E_67T&.+7*3UWY1JAR1!#V$L0S0GHQTP:
MEIVX[L-=Y4B."F5_"9\S3@Y81O>@1!J.N14@0#AI@97+E:12,<EUGL/07^.:
M04%Q7Q'=2S1E23)%KIXPQB:5WR""J&D,A V4PA8_PS;=Z*J_"VN#=7_/X=S^
M9G*F>IRYA3FD1K?G$6)V%Z93%)@J=I6G( 5P248*> 6W@\.G>#7>1"7(+/@7
M;II>:GW)!_\*CH.1*')QNZTWE<61_#/L#$<<P4B-9Z\IOEUAE8H1Y@%'JJ0Y
M*/-52@@D&N<+^-U ,Q(3ILV2^(C9+KO29CT2K[[)[RUGWHU\%:;(U@A.W>JB
MHH<"::%O%O5-5G/<48)/ICN?^#3IJF:+C;XMO-7(B;DS<"Q];]S$Y%,V9U:W
M3NQ['%-.Q;+N)$FJG[=\I;7@:"@J-16_PN?,H+"D;-S8\UYR[/B/;T?G)ZG&
M U2I2RH_%G<]6K%68G"60A3IF6B 35Q F]Z L&U),=7>H)PI'-HCD/Q9N[C?
M\NVKJ\8G<7<S8PC["';;P:^@<5R1H3UNH;7TG$W;,J'!M?I,<+LBI'&B^X!/
M,)7"$I&:1SY0S<OE@(M'ZJ]U-M$2?W-W%+ZVWQ>U/"E)'LG#WMW^Z:7W'8]4
MOEQA)(5!%BO0AF"_41U),-RM"A7HRQ+.,VA(B)L(/".;@<&I1PHSU0-*#Z^Q
M0S/<E_R19)<*72[913V=U:0-XH<+./88(Z/?@(O':H(_Q2I54^Q$5-67R'HN
MB?5@9KM"20A+C/^$8GC!-$<J3I KX !FN$G!7!%<*)QW^..2WH'//%3365+(
M//"U:J:VX'\@B"<\B!%ZOS+@1S"O$KZ<(L^8J)B?B.\-\E1/Z&9Z*3 Q..6-
M]\(S+C7.#([)''C<I>(U&DS2)/A%C6I:RIJF5]6?<9E@,2_1U3&&D5PDL&JI
MNH1=5)?X$#*FXU%2T%-P1>NB+F5%Y^C/8C0*A2/BB9YH$C]WR9][,*0ZU5/<
MN(0V]5JY/6BN_Q3^<YEDA'-ZH2BG K9@BGW)#4E5V!46MBG ?Q7;.[#9*$54
M65_B7Y6:P75)K"X-H5QJ6#6%3KJIDAMP2U#+@*<SY63Y%/MQH:-PC%(-)>'E
M!,@+#)G0_"KN02RM*=%@)_*7W_#T (FA(<AGX4)]3D)X-R@\,!F84$'T]QD6
MH,(_#*&7&$1FPGZ7J%+Q4^4R>BS<.3'G9\8KPS1EUI$<H@EP:_P7*']:J^YY
M"?G!YK436!\Z//!MR8/@U_,]\CJ5U1=P8B=$]?!Y!%>G]"%._ ,!KTAAY2_Q
ML:&L/EQAOJ)7S^K,G$;85?CY,QP).C1TPL9*$[?![?D6)Y$.' X,6"#8'OTN
M1[)J[#4P/WU)\V.6TN 5G^L+Q5_3P;8LQ3#B$UU\5MGG1-@GG_>GXP['G5VZ
MP-\5\?UD1G(%_^:3R5S^$O%!8%$G23P5TB?/#Y$CT+0]&C=?351FN F^+TTF
MK1VE]](S8Q@#$!+? X]6R%[<SO/FS@S1B:!DFK.2DJG.[GK0NPQP&2SS5&V9
M/\1E*N,$@E(L, 93C2]W@Z!IHT=B"_\!>@4CK0J,R,W,"YC)]+QG [78?)+-
MX6BU'[[ILUTXHG.5H $#J['%_V%':IFP<.?Y8E0M9J9MY.M(_X&_%@FMK P%
M3\J"U2CU)2[@G"_"DXN<&Z>?UJKH##.44T>[.$75I$)6!5L%:C>\*C$;B(/"
MH27$[K>(YY->01Q_2QC_@KTPDR&?+$Z9=Q^?.JE']-1K=9FD8"90> BVHT95
MGG=$9'XC]6(5 J-_?2+G';G$2II&VX9,4>$,+FOD#<*?'!'>S'M(#-FCVJ6S
M2RWG312%)K,B#MGE0AN.7<&Y886>>6&3C6TZBKV+D&1Q.Y4AAG2^TN0RH3O)
M)C"/N3#RD1\TM9R<G8>WM1-(D(MX_UK-NJ5:.R40EN@"OO<,F):81YOH0B6T
M0:+G7.J)AFLO$[/EUKT-2EV@RTOR<=.*)ZC/8-KQ!8Z!EQMHUFAROA)%Y@YN
MNH@OH!/4B":TRPU;AK0U)['$TWU)#JO%,G7"_).E:IF@ZPYCA[BX<(@4KLZ$
M=,8BK2^]?>Y=\/!F6\8W9+XU4P^9ED>@5F[A/T35.#R0W>+;#RWCMX9!I:9L
M*$Y9_4YHT+02SHQ%3#Y=6B(U#S%B&8E$95ORWX9B"_O,^K&Y$UX"VW7I/==0
M%\MHG>6IJ+OX :<)[X&S1$XH+23/"PD:D3DQCF%<8ER 3??+'#LQ="606/O
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M8XC7\VDKW&*/"H,/ $])I@&F,\ 1NV$'C4<902,UJ.#FL;&:4A?1 O/#+?*
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MOY'66MJ[I\1+#PG3D6/=9C!;V+W1R7'$W6-#LO9,IS7C5@>8ZS#VI6_!=WM
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MY?]^^7YAH"FZVM6-9#"5R1+&F"_&+@?E$V*M V5X_"9?:-66\E^WMVF?^O@
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M3BKN%T]RNX6LX)!#L@TFV" >Q7<<9<C-+1G(6*6WP]-B&$>N2(6!SK\%=:@
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M]VN?U'N%6TW@!:L?OGOV_%40?/_]SX?')Z=_' W?'GR_]CU\?C-T'^<?W@,
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M,>=LB< WM(02J8^&K*.G: N77H@^/*O]U-%'*QI&'GZ!*@-<?P+KN'(VK!P
M*6R$Z*RPBE3:>#&T!(BNN<.,E.,T.$9BJ?'P8\VY4,]W_%RHUL2L6'NS7G"[
MWL"11O=P6QNF8I!2IJTJH18^&NP=4VAL.JE2:*^LO!([,TFEZJ8'M#,"R(=D
M']X<K$*O9I*,"1+6*4=1<E"45))VX=P'5;I+UKJ!C4O=9T49-<UL2C*3"<QM
MX.%&R*' ?C-_4]V7Z:)#YYK[2$F#]6>?14MWZ=X_RBL\+)M&0F4;-I^C._O!
ME?B!35)<MEJ[<$D]-8YQC;<+QTW-<CPF1FH^2W2:L*LF%^];U6S0Y96TMK-
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M5'NA>DGX!!L=IYBY6#UZ/3 &A7_-B"/ 'V?)N,+_3RYGJ(M%IL6O-U<[*9'
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M8DK3"=$DAMXN Q,E%3HUCRB;5W$9JF3J4@P/G0V8W<Y0H+L%KK2<@-4;&P&
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M#C3JV"7#$R%Y#7LY-#KF((YW*A:@QKN1E%TUP543X%.EPR7['O 5708L&T&
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M[7UI5]Q6MNCW]RMTG94TW"4PDP?L=-8B@!/NM;$7X,[K]R7KE'2*4ELE56L
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M(+U: Q+6'T=A<="15))V0=P'4+I+UKJ%>4N-844/-3U;2K*0"<QMX.%&R)?
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M%6:*&5V(DU$F-6 <2D7J4H=^?XS_,(I>Z+NU+EH":E=U-<D+6*:C$GF3='-
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MW]$D?CK*XROX9U)-TU_^/U!+ P04    " "#@E=6\C%.W;\D  !-W   '@
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M0(K>=5%J6P[\ U%*I\:.:;%QE!*,B9J&7DU_-BO"6^SN?J="M=B2(KJWZ.B
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MK;LSI;!LE93&JWG]3=?QN%T;+"WMJLQ'7>=YI1,(8T]VKP48%C7,E7!M?X\
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M9ZK!-X%I0Y45LLX]@9TDSDF/SI=FTY%"_INA>QID((VW6X"%A$;+214>;MZ
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MQF=FP&^3")?)8O#GGYZ]?%M^!0LWUL5#)S%(86;OS#R \6/F+Z!%1(0;KGX
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M](]3]%C.)'I;2UXL8\<'& 7SY0*8)/PQB5-]-I@Y'*5*:Q;73$"F(D"*DPE
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MPI" '5&5:Z0P($< B#4 B-,4N6$;ER",')Z"O2FH$I4:%O'EOJMR(B=U$.8
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M_HR;.'LWZO +,,#O/0 IK/T8MC7LGL*.>F<#?*KAP&C>]Q=XG "#+K I^ )
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MJUY\ ,^)92*<@<";__Y3]\7NF_F?/S_'>Q][3$</&E/_ZU@.9<&ZNYVC/3-
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M4&9P?/,"SSL,7KDBM6XP41$J>^PIKXS"J@^.K-=2(?9?^$/P8).MMCKMH6?
ML9:ZNS#Z59+_8ELM1SW6(3/2"_G,)/*!%@SVP)3' :6)HM91!7=(\39J-#);
MUQUICL@"CZ)UKCTX+<Q?"AVN-84.UX1"EUOG3XB<PK4FIW!MR&G$95QFE'$!
MFB68:Q.=XFQR-VN9R=ZO_<O.P8K/<N#_(KWJ[*V6/+-U6*,#/X\P6*5^+IYK
M@JY^Z5SSEVTYYL>49_PZX]-Q[NDZ;MU(N>%@"Q9FM2OC\>G;^KK:E=%>].VZ
M?TWE6L@D3T<\HT(K*L&UR@7ZY6?W="2HP%;-MD+S'_WX9::+KZSS<5N-H1'
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M3NVS&KC&/520K5;X<QCJ6IR251Z2[:8]>+<3L4:@#9*L2,&E 3I&&Q_P8_J
M57B5@*R54CTJM2:MS#;+D!;NZMU<L2Z=Z&GJ=.M:$GW W?.MPZ3U ZY#:<N'
M0Q6:!CM&QUF4UB,5J:E7"U&]&/]MWX(CJKT6IZB8&J67U4,9Y#]3;]L@U'B:
M0W7D?P[5',M:$8.BH'66,A ]7./Y5KX^90Y0TN-=9WZ+^XV0=IXF.SA@G,25
MY0)>X*,56"!1>39TF=V8BA BX7"P;V">U+ ]=WF6P^AM.+A]<=@MUXQ/68;F
M"0HHNOF<F@[+(\-T(YO-T/X2F]+P5.2]/P+?1!J=\(QU?NB]S$FX-8P&=,O1
M <<[RL3DG\!6JH@!XLC8. (8/3>I:A6+H$6ZY$77MRPW+NKARZI@R^ J\9M4
M1@9-(4K+85&%+8BDJ7N0SC]HZQ(.M"GC>QH&6/\IA-5K:^(>R_*UDQ.KB[(R
MM(51E3TWI6JCQ?X-3YP9)FGVQ7HFS=:(> TS9Q=00;N"L0:NL35*MW4LAA^=
M>5NC2C<_ZMM2/!RNN$7I&_\NT5%TMV_["?FRMS4*'BVF2/(R$]J373"LFBW8
M_QSN[P9 7_@'A[9TZ":GN KO.%4T3:S#46NNC8DDKFEBO(<AGROWV&"]<%!%
MF%LJCG5RX 8 [+$ P/[^TZON&TRJSVXP$^?5_ING LKBT6(;**IC"ITMKFN<
M:\RI>B9N.4GB*!"4JDNR(Y(Y@E?KA-MKK/RML +Z"K?I1FPW4WOQ*8W./$_E
MB'FT[Q8TJ6\A!K2YI<.NL\6!&M@P--$('X),:>-*1R5#^6C03+/8W$@Z8Q%'
MA&+'9RJ[P1::BF@[J$G4&I'5P1Q4^2WVNXWRQ:2JM8^JT[)3U-K:^DG/'H5K
MU76Q%6^CANI#W;LY=HNE1U?=[G =SO2P8/Z]"(^$4Y>K1T5M%PF*U**C+>J$
MI[O@:NV++FT>I"=S2OQ)/;.(5?U[DR<144Z$60,P>0@Q4NY1_87S9=F-FVQY
M60)J"IYH<E38A%<"I*:\BUC<8,:].JQU_?@,CCIVBV][P%.A+H^(RZB=?G!@
MJE5$!H4>7<%I/#8-VCJQ"'4&^1[2<^TA"XC9'HWY9N'S1+8]EY;MW(1O59$[
M!P0.1]KPLFD$4UU]N90/DWYO\<];SXT.V6E[U<3^[AJ"L3_M^6U]MKTLY%.R
M 1$:CM*EJH5WSNP##NL3.:O^J$M6$ISC 3.9?0JW-S 1W]"R["0UT*<+&]_3
M4_+:8Q3EFLIE$O-U5XXIGJ[;H6T8717F,?R51)Q:.J1T(HTWH=ZJMR4-A12@
MO1?-@UVI(FWCY5JM<6-U-7VLG4W<H?>H-ZDG!Q;XY":-2Y"WF42D0GN8EA_Y
M)7)L$R1?:9#\Y9H%R3UCE?[PRNX1D>&SMY^<$&^K&D-LI@ZBN$A]L"U(9$+0
MS2J:;,L!'5W'N*?1EYQ5;0:IOKC0HA0C959NYDV;CGJOX)8JD(; H '"$\M8
MLU(#JN=4P]>15O&E>3E%GXK1&IRA/QEUVBN?QD%G=U\3GFKG8]'^ER![:G&H
M.I91R$5GH\YL()I;5_Q0%+=")-\LEDV1B!:^]3A)92RF.KBK4G+MX3#QC8;'
MS&0SWJ-9ZU8=7U*U,D+:C-RHCYUOKO71&EQF2S/D>TX_J+JQT.&Q$^:.BT59
MR=5X"-8^'\]WCGO(NJ,[TN*\?L=S]&I;I\M"Q47SKZ;5 P\;F]Y.M%?;=DF(
MR0#-&J119Q-^T/*W8>CSQHB#&@+I7""OEC*M5-N*]>+V5IG0!58W:=35!Y'V
M7>VS+2QJ?7 *&\> V*AM5H@E6U4NAXJ<AD7)XVWE3:M8N@LQVV#L!($3I62:
MI4_$NI)?O6'<->LJ$F%LX (;IPE81-7-&*4_)<-4<KQ*L%EF'5>- :R9_53$
ML4=;:KQ;YVXIG&Y1XK)[!<!)'V.?.S'G+-+N> 2GOD%&VX1WUOSO![9#T:9Z
M8O,VF@%Y_<H[>-9()D!XSLM;Y/%\Q<Q]*F5^C,_/%-#8B((M>=8BIFZ$!W7)
M9WQS6'(GB $[O'281B -\B(-OR"SUG8[UK3.J"-LF=ER/77OGV4F\TBQVW6L
MR3-I;$=KE,9V0?M73RHYXZ#P9LOPHT>CQTY7\VK[]]8N[VRO<[2T)%/STT4=
M54UN64".0HYYI)B;1J!SFILE#5;:TE14HP6Z7<M'H-WB9]V]7?A@ENN$,/N]
M;<N]@%6J\CUEY "S\K\)^G$L>++SV]2;SN=!:W:A3A>V.88ZB[C9C <^0E^D
MZLU@.K: +CZ1>1/JW3I'=-62C8Q+1&5I:P"FM_N7+"VGRF:HUX%SY]W<OKWE
MY62]VO=2@2OKWVAYJBM#*<C4L(U0!?B^,K_#@P8[P@\6L*/N8^N!/7_8T6[G
MB!9"F6<VTF51P%3/"0MBF1=BJN#"E>=!-4X$,M&7R^+[()F\VJ9W_FQ3M[-_
MB M!YT)F<.QS;53IC%T\O+@/LJBPLK"C"WR'3@LTIW0(+-(] W4YQ)R_Y?M+
M;+S:Q&/_-E&=-97R;>V!6'Y!Q S80MJ_*DQF@V1*CC]$_UJ1MGTZJIN$=8)%
MYN&"02NA8)6-FE@.5 JZ ^_3(N46R!E'RMQ/Q,R# ,'[ANE#4[<\,WE>KI')
M\ZG"!>M_Q>14+UKE6%>N4QW)9TI&RLFPS/(E,332TE5_<TF%!5:4NFYTM/Y+
M1-7;F8)-+C!3+2],]S&U$)A"IL R6OT9C?8C5G%T'/6(NS9_/YZO6]//C_(
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M=SAX*AJ0X^%3'8_],G 9*E>N87(^^C'!.J/S$,:#Z?RPISH5YPW<%M>5.,;
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M-(R1&.*G"$4EZ?#DN-7I""=K+0H\YQ+82E78-SWR1C]O3%:3-T3]MP1]2^Y
M.5IGZ.&B.)6I'*( "#>WR20F FI?S+"3I(A)1E8U?S02>LDE61ERV7VRO?,:
M%R++$3TX(114+XW+)-M;\8999%P):7"$"PS64IZ*#P/>XR)QI?&V$J35C+='
MTV8_2+^^/1(]GJO:@ZN)JLH<Q:L#%B>LM4J"D"/J9B^@&Z['-BA]&$:()JU^
MP)2S8EM)>4V]N5NRT29=Q4YAYU3VS<;6Z1N[^U:6PD/BCT^KQQ_2!]5!3M%N
MQMT>NRY.W\71_.OZ"7'.8B7%N/)4V8(1!58)A=9;"'>2+"H,9D*RIGDH==XT
M::.<5.7,YK]3NG]KFEO3\,S%RG"*53S:"G"7IF\GYHUOTA TVG,N"J/L.V+Q
MU0@SD"J,&5(1(\MX22[RF@YT"(XCX^2O9@W 1M% (N542#IS1M016)K\FI.,
M:I;7X@ *I<BC)=L<KI&%*>I68_CMB]OH,2SH9D!5>6S]8D',8,.<-VA3Q$R^
M%][A=]I%F$G*W.$MIE6.C0_03P.B^%K,8Z#$K+PBZXC?#D0>*X?>_+66]S'+
M9.VS3%ZN8);)RJ24W$1\N&R[9A"\U2/254YY(27*"17IP1TG;R>ZKSME),CA
M030;B6P$#ZQN]V#)V9KMO(X;M))LQT !7$ M%M0E(_ .2Y14HL^#P'E4Z=N*
M2KHRBHI5Z<E#8IN?>BW<N34.99!Z78E[J,)@-'2**#CC9V.P^>U-@)OZ*7,+
M-F;,:&$G2\3!QMO-( .#?J*+[N%N@VE9.YKF$&P00"G5]@5=; ;JO9+6A!B'
M@QKJZDKKS,\$Y39RD2L )!2>&/9-%9Q&ZF6[XO<-;U=#)!@+QL*S(4ZYU+&U
MX2:68@B;DH&_@L6]UC6?7Y:-^'3-LA']JC'0%>\X&_'C3)*QB9Y80UQ$<K>A
M9LYD)(6:@/79 4@8980%"&HW.C1 QVX#[H?!E2KPF$U,^95%HFPW%.+R+0L^
M:0HRL+R@B+MX)!X4;^DV@1NJ%,[GLO:UTU_&1\_6C(^.<ZS9^U /84^QG2@5
M4=TQ-QU[Y]KBK+X6"%(F@I_@YJ6H!/_FN<[[()ZO!Z3O M1AN0VM52YK18>\
MXX.OAL5S[G$HHKE1'R4"_R37"KG6O?)S:FO"3P)EB)+,:J_>!8]_;+LA,H>/
M;V_84F=(OW=<#K;*K 73L_WPX$!WGJ\=?X,!2(Z[4]MQ917R]V%<HJ5:SK->
M^M++Q\;"1AA_R3X?US7&MQC+"=6 P<$*NFO9U>";DH* P1#%@$$5L\[E27:9
MIY>:O.N:"@60B9/R LL.J/R+LCJY)B]?_-IE*&FA/_!(8;E6*D5Q:.X2M@.^
M,D!<UKP@K%E]Z3VLI6@LGW)H$@J[;\3FT+"I^#Z+ZVJ 6J[#MVW5T:*58]#!
M:<MB4WZ&G00<'EA^Y>&!4 LE!PPV2C(0WE@33H_ F0]YR;EQ4.!UFFH-[V_"
MAUA]D?1BS432H=#X>:&(A_SNI81W*+U>!D.LT5T![?Z/5BLNM&Q#+)O6#'YB
M0._S0L#OJ0[;HK+WJ@*H*I,KN\_E@)R$, I8XF)<8D/M>R(26<-*UK#1VM/#
MC9SR4BI:2M+1/62 _BI4;JP0&M,X9/S]10T9.[#EDKA'3)GW2$4!T6DDNQ.Z
MA]P(.W#AF-KY4?H?,YN 3$2?BZ13<59-:>,9'/\A>C"^HJ9+D3RA CG"B^K7
MV)J.TLUN90Z0!S&Q1A1CD5B%,8.6@!8"01V1!M7>0XO#X=\L =]),DS8A=+L
MX%ZX G=<&S+8>*J44AD;Z4F?,"P##9;?[,W4E:-/;7US1&<%.UUI  8H="/9
M)']QFI=F3;IKUP6;P<8%E>W(2;7KLO*9YMU 'C-K3E7LF^SL2N"%<FF5S&;P
M4G-5$\J&D%)K,ZBI1[*HO==SS@]/?=47)OZ;UC/<I6GB %7\ITIC[6"D";Q3
M@DYTZX#T<(_W[,%;]A,#4F"IX<GD7C/NPL0AE9IE:SS5^M*&A,>3EU89;[7X
M=9D.3=J:Y7#%?($LDQ*\OOY_;=N_/3#R+!3:/_#!]E 7#$AA3WDYS+ED/4&J
M!N7N ?8;WEFWSN('#IMEW^MIMY]']2I -9]/;@A5+OT/B(!C,_AK%=PEB"U
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M3(Q+G;H]F/18O^,#WR'HJ0M:*N-HB @Y-MQTN34 FDD\S4C<<69QH<<YW/(
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MY2GKF50H>< \W52 ?@?^&HD)$'4W8#W7-F]#\B=,0-=50SA2;K9+==538KH
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M:'RLH_'QV^#?@]]^19"'^WI,KZC.Z#<U@5]4'*-$,Z%1C.$BYC>6"+4#H9U
M]!(P+PR+H3#CB!J#%DH4O8F&$K:C; S*A(^.$"6\7YQ:("4&5CS6"8ETJ^=F
M$GYS-TQ4R6%M$=S2AB[.&4? PU9T%\A(CTVHXRW"Z<%0?E-_J@LJ-FNO9G^<
M.2]@)3F\$B6SQ(Q?2AGP*M,V)DJ*J'91;;S9A\_V7KP&2OC1P=O!\<DC?W];
M_K[+X.B=AD8YJ+_0S"4K@=HK4;))L:0YU)$>J@PXT(=$P2T^SK>#G1<[P<;N
MDYV=3<D#43/,OY+.340*H*2>R+,[!C@FS7 5(O7LL;D^7R!KUT$$O!\<#?ZX
M;9AGC60 X_CMF8/*Y(@=I&*)8%VOFJ,>#J/9-]4:<M*]5X@WBB ?A]SLX!3!
MQ6L=O,WOOO!N*?PR9[H(B&'I#FHS?_J:2FN)V^",ATWDM)<8SWLTYQGZ BZH
M&.R3[G$Y5E@5$7&N#!?D>$N*_:NY\0.\ YN_?'; D/@'@DLR1+TJ0%EF2 XL
M/Y%'<+6O^DPY9?(0K$^!,?[9A2N.;[5ML'0;?P@J)>;T@#'6G!KC3/^GQL(.
MQ8J2+ (J H_1Q+6/)NX^6:%HXHK)TN]^IIQC@^>UV9$S7(?'J< CA0[ /!AA
MMR%&X<J<'!"F(5YNR0Y/.AG$]ZS&4CUXP66>Q/<A ^FV)Y5TCB9<^SR510R#
M#UB96)9&-I\+)CMJ'Q],=NR^JM1=^Y-;7K]"SU*%-98-I_+.3M=0%#@*[$5;
MZ&K^MS2>?I3-:R.;=U9(-O_\CXJSV@TM(.[Y5H30_;-2_V1^>8.U0J!R_)1D
M-"&ZZ4TS?O <!D"(]9%*99UIR?EK-[;M)SR^"@95Q>;-\O4V??5C%7>_>_9J
M^_63Q5\_V=Y9^-U7>NR/-&0>-JQ,"4;1?W_W]+O6XAE^VH8% 2N0HD^&JN22
M5(^JI1=4^:S_^YF*L83[I]W9YV"G&:_!AW8V()\U*4;NYQ'L;K_$33.?%41(
M\N$*]XW[P_4'T9^Q+B.I)#129VHZ3,9U7F-X)'+'#=?LN",'BRWHJ)>SAO"!
MZ%@O\@S]7$:51]TXM'GUME@CAN-(.L(Q2%+,KC(?PIU-%E-JP;%Q5^<R%+#/
M:8ZV"1;PVQ*3L&-T>\Y-X\_3GZ.T+K%MM"@R.,AD*G$H,GB4@"*QAX%K0C(U
MMN;,PM9ZVXM-@)O2SXW.K/M"C,N2X5O;AR;9!/ME& ^W):EN&VC8I- 'X!_6
M%3F47-Q8U$R@>B":"9J0XDIGX@:"GDW (@;-<SI$(C=-M(9)44UZL&#Y.D?]
M5*QEL0OL8Q@F-[3 XV#EAL&G?!A4P(DZ[&U(1"T4T(C-"T8*,WUN&G[X6,.B
MI'0;1KZ;>20-3%H<6)5:)+5.#2UJWN@_CW!B*?YFPNCPZR48OOAOG?%O-..Z
MLM!MB;@/1NH2X<2^#L]98]X4)*!.ZUK9DN<0/T)O!D64D_[6)2 ]<OP<S1/3
M>LDG'I%S+)(Z'H<E$8PE[<>^*MLWU8;7WJ/65!#LOE@@"&@[C?G7ZC5%1Q*U
MP<'!4ZTU$@>,!XM"#684=W)2RZ[P6MR56G:^VYW4M;?QL.@46%VE;3%DKK:$
M8DG;=/MH=LJSU-UI.=+UW5FY:,-/UKM,BR03P.Y E;9RX6-&@HYP]6@A=%KJ
M*SS[PV#!4P64Q$2M@PV]/=X.NT_;9%&,J19Q0KBZB(JB3*_M:(Z%;BQ'8:$K
MDU,!;[2N17K!]C+O ;>3)=&"_W8&$=KF,<X;E\("NRU T<ZC,$'2TM3KSW(L
M04[\D%YS38?6^V>/?.Z^-*FGA.I<PD=HP((E"W_P/E]J3A,YP'23WR9PQ+S-
M@?BRX"Q*Y# (!F6B@@^*LP$^P)%R5($P/:MA9F"";3W9"8/W&C2I60Z3"<[S
M*R#2DPSV[#4V$(>9O:WAV C^E6#W[GU8;OCJ#,:H9GFA@YVGKYZ_>L7=%?_?
MC1?/-X,7SW9>!:]>O7[!'VH8VO;%)/_A^Q?/W@S+*-F.\JE!5N*Z\#]U\UPA
M]()E+-30U4"TEQ0)\1;6P9TSTS0X9D/6SV B>=RVR7MY^U."7+2$.QG2@"@G
MK,9<LT*3YN#KKW;3KU%D^TI"OY+2Z*DJM)25Y\8AQQG19$\[3JQ(#H9%?H&J
M!:K3^54 ,B6K/(?Z)"EB>K5(IZN)Z?O7.O<M5&>S3KXO#Z_=2FZ!T&K(<%):
M*&"&8/Q8#HM0IF4 9RSL#Z)AP&SL@OJKZ4G+:[7OKR)20@16I8U(4#M$) 6A
M$"MK8HZ8]"J?PC&%$HBRF7/2P6*Z!R72^LZM $BL+)9F;+E<22HK4U[G.8PM
M-JH9=A:W%^'##,Q"20]"D9\PBBNUZD*,6M./"OMVA2UA!]==82SU-G(/UOT=
MI^7UMS4TR! L- RO&B.31XC(NIC+7& SS\L\A2,"EV2H0&1P8T)\BH?:0%2"
M,H._P0X+!8@G?<'\?PE<88X;N;C=]I<JN.EP-%*-\E9@I,8SW3S;O<+;&"%<
M<*1*6GFR?*5T$:)QOH#?#323<88>;98$L,UVV94VZY%X);]^ET/S;A2O,$4V
MBW'J'5U?]'P@,0RBH3[/NI!C*?C+](L4WSQ=U6S1T;>5-YH!R7J&**;/33R/
M@G^&=W6+<]_AF'+"#W$<)7#+WC*6UJ5 0U&I :X0L6<&Q0WM_;WO)<M.H.]&
M]'Y#!?W%^BOH9*E_2#6*C4I=$&:(1)'1B62/2\ZQC2(]$Z6X";=HDW,1:B\I
MIMK; N>)"BWC)W_5+=7O>.H#0W%9:\8/Y:,.;@>_@A)V27ZN40M_JD<BV083
M#5G=YP&S*T)*."XVRRU*IB.6-(]\:,IHR]\NKN6_UVO,G'@G?N6>4H+[(#,&
M6:Q 0P1J0!4MP1PM5:A 7Y3 [: U(A(F2)1L!A:Z'L)70-N@QZIQC3VFX;[D
MSR2[4.CFR\;U=%:3HHQ_C$$H8&('?0<G6JPF^%6L4C7%KDY5?8&"Z8($TP7H
M<@JU UAB_!&*I0K3'*HX09F! YCA)@5S11BM( W@EPMZ!S[S2$VQ-SW/ U^K
M9FH+_@?E9,*#&*)K.H,CN)QK.%#AXRG*E(F*^9GXYB!/]81NI]>"D%-A\\WP
ME N-<P,VFH,,O%"\2H-)F@2_J&%-BUG3!*OZ$RX4+.<%.M9&,)9Q NN6J@O8
M1W6!#R'_0SQ,"GH*KFE=U*6LZ1R]J PQI7!$/-4/>KD3^SX3ZU1/<>,2VM8K
MY?:@N?Y3^.<BR0B[=JPH%1"V8(J]U0U15=BU&;8IP)^*C4'8;#QE5%E?X&^5
MFL%U2:PN#*%<:%@UA:[AJ9(;<$M0YX*G,^5D^12[FZ%[>H2G'IZ4%Q,@+[#R
M0O.M.*7+H 3K#+'2D 'D.^0?(#&TDID;QNI3$L*[0?V#R<"$"J*_3[  %?YB
M2+W$W"<F[+>)*A4_52ZCQ\*=$\-!,UX9IBFSCN2&3T!>XT^@_&FM^C@FY$>;
M%T]@A8A]X-.2A\$#X'ODA2JKQ\"U$Z)[^'L(5Z?T1YSX+ &O2&'M+_"QH:P_
M7&$^HE?/ZLSP(^PK?/T)F(+8AGALI#1)'-R@K\&+Q'(X,!"#8)/UN[C)VK/7
MP/ST!<V/A4I#6GRJQXH_)M:V0L4(XP^Z^*2R3XF(4.;X1X8'AN<0 LAX1;(_
MF='9@K\S;[*DOT"(+UC421)/A?C),4;D"%1MF>/ZJXG*C#S!]Z7)I+6C]%YZ
M9@QC $+B>^#1"@6,VWG>W)DA.CDLF>;L:<E49W<]Z%V&&58S)%.U97X1/[.,
M$PA*\9$QF&I\N1L$31L]-5OX ^@5C-<J,,=N9E[ 8J;G/1NHY^:3; ZLU7[X
MIB]X@47G*D&##E9CB_]A[W.9\ '/\\7LJ9C%MCEAA_I/_+9(:&5E*,@I"U:C
MU!>X@'.^"#D793=./ZU5T1EF*%Q'NSA%]:1"405;!8HYO"HQ&XB#PJ$E)/"W
M2.J3;D$R?TM$_X*],),A1S9.F7<?GSJIA_34*W61I&!(4%@2MJ-&99]W1$[]
M-340[@J4]6YJ)KY0KJ%"&ES4*#=$=CD"O5XNT1%EV;A+@Q=:>%'4B*8@(^G9
ME5 ;3I0!3['"SW*R*>(V'37?Y@#EHW@J0PR)]]+D(J$[R68PCQF;LY,?-+52
MGAVN-[4CZ)"7H_]+]>Z6XNU41%BB,7SN&3@M%0!MIK%*:(-$![K0$PW77B1F
MRVUD %2^0)<7%!Z@%4]0U\%:FC&.@9<;>-WH>;Z"1>80;KH<;4 GJ"U-:)<;
MEH[H<NX\D_C !;GW%I^X$Y:N?.:6"3H\,1R+RPOB1^'Z3$BG+-+ZPMOIWB4/
MK[=U?$/G:XO\D*EY"$KG%OX@NL;AP<DN$9'0'@O6<*C4E$W)*:OG"0V:5L(9
MN@C$JTM+IN8AYM!&,E'9EOS;4'MAIUE[-G?"2V##+KSG&OKB$UQG>2K*,/Z!
MTX3W #>1$TL+T?-"@KYD>,:)C N,IK!Q?Y%C]XWN^23^ !!458VGQ]+S"NCG
M##?L4UV1<J#ZMDUYLH_GYHT57NAY(8##%&;W$E%7..@*SO^SYKZS=3 T3Q&[
MI$4<* K1_&"!QT9'X\UL*$BH8:8O4/M6F=$0/0$<TT;!M^;1LFA6@/)X:$.!
MXS[I3ZKD<Q+5BRW\P7R$Q@^86@5)D64SNFZ#\1YAO[9)[(TE5JCD>>O>YP6A
MU[-=)Y8:F$N@1R36MJL]L6G^M)+:W+1E[S:"<#LX04TKJ>H%5'&A4?P3(\F:
MTW1)&^V;L%7=,EIA9I\:NW2;"^Q),T;?=$HO&B>6(42R?.2K#(NG>IB@H8XD
M[-B<-VM+]LP?JO\BN[(7&IUBBV9BOEW&'G9R-],3'YQ=>(8RF[=UAI1;)<YL
M<4*,#T3/D/8=G%9CL/L FUVRAN%O1=LA&EJI%"[UC3KVM39?KX,T;'E(^QR?
MY&>]P)@UZAU;]%/(&(,@&!))MH/?X8/:JAM@>X7!)SP Z4RQ#B(8Z'"+?CK_
M5Z_4L<-V1UIW:(Z(Q=9#C<5R'AU/'<Y]B%:0%R2A'/L?J;[@L<IEG:M<=E>J
MRN6;[>A-B](/_K_#O9,O*DG_$M2NH8HNQD5>9_&6S'!$_[VY^Z+ Q1 6O4Z2
M.Y[)=S]3<I;#X+(UVYQ#V,;S\M)?)#.U=#")G90TDX_-RS,G-*]6@ENK,+S=
M,&=,F3$Z=ED!%CGF5+ZD9[E%-QDT+FOXO?Z<1/#L!N:,R0;T[B1,/.IE(RE'
MF23W$*H%9]676.O X#'4#( ?GF,N5&83T%ROF+ G0=WE9=HV0;8595]7#"_+
MR+[8[X#B#>)\HDOM%>5PYR #1B3-MR@5:@AZCG1HD=Z<DCA=>.W/N^E6LJ&-
METAS(!DBICOD<1WQ<D7Y+)%N-QEA]TRYEPR#^U "!>T4)QTU'GLS6,TFS@CZ
M8( C)_QLN:L,) <:'D 5KB:[V[O1+5(#G@Z3'S,054E<XY"N)KEDS%%"1Q=8
MQ.(1V#UA2)(%"2X.>,P\P)"J1Y4,@L)0H89\2'$W."B4EF(7A-$8359:B2 1
MO!5>NOZM#(@UJ,,>."GE9^Y;MKOC0NNWS1PLW8(CG+<:Z)*<%<Q$2?Y5R$AS
MOR+!BE8OG<OE*S<*]TQ]A ?%R&W(MF^ W<@#I^*E?HJ]Y6!,6CO6_'P]L,A>
M?#,P0U#B8+)ZM@S&TJQ/E&H%AY1)HL=,: :A+)<7N%]G=#]]T<M%_%%";=1^
MVL*+[@@]8F-GDTO]NS__6)K8W2^B4=1))CR)*;:7[N_J[2Y<O7.?/?ISY).*
M#A2C8+3*G"CY&@Z=E$_\"#L)@0)C$K#O^\H^_5*Z!'EC<]5YD7 '[N]"/5M*
M@DN0)4V[01"I,V!AJA$RV;1PU!:48"PK>ZG2VO56;9>G&I97U=(BE=LEL:T(
M)NXRU0,!@[,\2J;HF,IAT5)$+L.*POR..ZH-4M@5.+M5$:28TA4E/WR_^^SI
M&] X/E*-<,%#YU;O$T7%8<,DSC&]FQ1W1=,ACIK3KY',3$[W.9SH.393A\-T
MQIW4$6!,AP&84=.\= \&G4'%:"0UWXSU1!H;O.\^?U.&=#D/&13O& N2$)"
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M+_<%0TRX)<PAP/?0.YU$@GV8XU5.F(_7O?:S9]EMR3I>EU,K(N<RF4S8@=O
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M7=R#[CW5"SCPOWJ?06C<,TAAT[X\/($GH!)1_IQQZI&J:EQ[VN5\416E>/Y
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MB0XB_WO_/7OY=*:RN7M+!M=FF8Z(>J^2:A+@U8J&FH_Z9U(VAX[7V@<.Y_0
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M;-2K)';=PF>AY, &2W?%_U2CDTA*-\?%0 7Q$0/<M6E"FAD*/:X7^5W.#?Z
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M$VRM(\>2F8$W;"G(H;\[9I$MQ6C!:3AFVI^*)$/V&SJ4]0S9>NDE?RP;2_>
MWX]3_&+M3C'83F0VGMK>3*N0;@WC$LEI993U]Y5>/B/6$,'X2[8G77^I:W)7
M\D+*&B*N6G*2?B&(45\#$X(,0E< H\5FW?!,=IFGEP1N%VO* 4>VD907F%%.
M-1J4@M70I1>76(32B9(,_$AA]40JM2FH:U-!-CX\0%#HO""<:WWI">W&=+O8
MYDT^&9HDH.X;"TU%4=3XV8!*&W2%%K:V2R=J5;!Q)Q=NND$[&)LR$$2@=&!
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MN)?4>EEL\3,N3EY@^1P['C!Q+S9RG;[A<GT:++_9FZFK5)[:"MB(U!=V0M(
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MK,^#@X'SV\.OO\!:Q?DT#,[@_;_K(B7)@>"?I38E B3^T=Z@;+^\2$'C)$>
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M2:!S6H!#'.@<8?H9=#R+*:=**H2L_((WH8!S&A["Q@B:>'-D/NR+0J!NA$_
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MY2%8(@]C_+W;0R:^U;;!TFW\*@#KF/D!!GMS:MSTAT*S,']2IF016)- #XX
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MPD0N9B>GAY2.%>LD^@P[HV@IC-1X]9J2V]6 J1@AF'"D2EIW,TNE("71.%_
M[P::D3PCVBR)C9CMLBMMUB/Q2H_]QJ_FW<A788ILB.#4K1HJ*BB0%OIE4=5D
M#<<=)?AD6N>*/Y.N:O:_ZMO"&XV<F#N#NM/WQD5,_F1S9G7KQ+[!,>6$8^%.
MDN2/>\M76N.-AJ)2 \8A?,X,"JN]1XT][R7'CN_X9G3^/M5X@"IU0<@@XJI'
M ]9*#,Y\BR(]$^6OB=EK4^804C4IIMH;E+."0WL$DC]J$O<;O7V0)RYKP-C
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MG8%ZBU7IJ'M\</[SP>G1X'C_[+XVW?JH0$FCDB._X?(IN:%7N-I 7&97./K
M =.GQH%.&7W]+BT,&GMN4^-C]GI->Y[R175#KD"FA8]Y-5%5F0MZ9E;F(T70
M\M4$T?IE<.;EA8"6TR>*%FRH37HZ<(N2.Q5@ -PX1VUR*A7*R,/R1BN"=H\\
M L[=&&X*?"N,4:JRN$#!J[ZA*[T+AMH\-S:.+@&:;7?A:ZXGC<U;T!LUP+I.
M<;Q##O Q^,_! %G ?>4 *]YZ<XW[IO63U$=5H&)S#^;7OW/4/XWBMU(<:2/5
M5($4-O'FJ3Q*5Z:3RE*PXFMJM0P /2@<B%%+Q9C=SBS;)JW?1L;'*$,HLH+
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MESH!*/V?+G/3[]O(-+EZLQ,87XZ2L81F'Z()JQ)-V'V()GQ%(8NB$+-RR\J
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M_ 7^N_-J6'[^ZU\>OWA%NAE]0TUA8TW?<EXH?0V,)S* 9O#+FP33<.'[,ZW
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M/N00D>>?T4L,Q0YSTS >!4;QPF@CE;*P=1H1M,>J[2I*G[!$$7S'L06]IWC
MV+9Q.D#Z55L6F5RJR$/A<EH7.DEA,G6]!6!,UD23N?3X2F%Y:W*B)I%75'[$
M>5RLA"@)1=6LTL=LO8W"> P85?4-O-:'CQM9IE(XE9F_,C*W,JQ:ENAR596#
M."D?3C!S/#^"-5/LC!*YCQ+NU#@:*+A 0_XKF_HC,\7$8W!S=-$#2&FP3 8G
M]#C/U,OWT8RM>%@N+!&K<P0-XKE,,P=6=T&>.E)0'/=#PD<MD:4=P9H67#,(
M/;&)([T20T@>PHNS-,L*[HZ@RXH=@S4 ,0?<M(%K&A8:-L2[^#8F,Y4L4W*T
MS$'&8N2)&M8Q&2#3M,AU^Y!/G+C8X"X>#VGWDV6>/B:F=):9>#FM_('/J<?$
MRC04JC);U?V.?K![*V]*V%%89S?,_:UJG^-()IC:\"'%@DHNN^(C&V\>I _>
M&LIEXRG5<=3;L% 8=MXO/!BV;4J[&KMK \@/.C*.MK >5!-7#]&4JQO4BL(9
M74V8;*:@]7RY/O:"^F%$PQ>KF))Q$(O$$]2V5>*<2;BN<V1IL+P^LMGB38!M
M8"/@]!"-TZGI8S%%U-[ 0>&=!'D9P%:JJV@K_"F@S8U5G.AAZ8!EL/5PGDBQ
M/F/?E;(]<FTE-B:-HTNS=#Q>%_G]J^9UJQ,T>\U?:R+&&P3\6NL@TQ) SW-N
M:B6.D3?=%[A"8EQ9 ]XG!NG9S7ZI'-6&EC0=AX,%K7ST?0JTZQ3K'>Q$,OHV
M@A]WU>F^;5Y>]-K;ND(N==PNS;@]\WF[?'8:[NPP6@A&*DWY[P7U]8@542]I
M7HJ6T\NCG\EIH#-25(*E?I"!.O]TO'>TOS?:-P^KH(/?%&#BD%=*"V+O["Z<
MXO1^>?JZ$;P\//PQ: \/]FUEO:LW3:^(7M^%2',]O:/$A4GU/!^G0U66] )(
M7/&!CA=VV8K<H=[.TR1B@Z$IOOZ,O>8K>MUP"FZ<:GM+45M>MF)TJM-L5*:*
M*9U^<8XS,K0W\GN4ZP"C/2Z\9!]2L8%SZY>YPL%NV5.7",)B; 6K\3%L*3VU
MW6M&+$JN1K X;!QD<:9Q+8'(VZ[LH)[\9(>3&J"%SDO];@0I5>T:E0-O<U"T
M,>4U.%,7E_-[HA'8R(7*\+//\(5WJFRS,N/+MQ?$O-Z5;Z6!0"NIO1?OJT69
MQY^#"77K7>ZB3,K79ZYH1M^E+U?7C5T79K.^1$7S?W8ZG: 5:RWBH^"JN!V:
MW_9>T8SW/'3;Z:>'^UZO?QN&:TW@E[3K7USWWP7--[W.V?)D^M8I@6X@8?J[
M->*0.^>P9NQ*>5REM)T'S1&J]R9^DF\</C:^5</5<YRLA"%-$[(#0ZDGSO*\
M^.5W47O=I0G7)4UXLFEIPHU2=MH)!3_+,;;3+EWO9;%F0L$[[=*="-I.M_#K
M^W_-)(AWTJ6[+6 +MH":R,%&[0H;)6B\4S/=K>(U3.5HM9XZ:B-P @S('J33
M.+*\Q*IPJ2=8RFHL8&"S7FGC"P1+GY(J#6<S-7#_8-'2;=$LJ2,3&=P0"BCF
MTNVVZJ*49,2X.MZ 98QJJ<5)>,^X*%N[$RPB"=FG'HL@6E1)8#+^C+Q7@5#.
MPL_2B%0*L5NR]A*Y2+YHRIFW<,Q7Y_&LD*\I#A%D!CR'GUEB-&S#&*_*)KR_
MZ+5_]V3"FLSCISBYNN6<I>.QY(L:P27P,WENF-=]+=#'JH=F!K7"V;.*[QT$
M8)KSV9&E23P(G3")$,]]7M_JN/;WX/6M64RS!-&7O+.;?D5.Y]VT/ =GWAS$
MU$,F?ACE@RR^%8BT44@[.EF02!,R(MUE%PE8YX#>PISPIH I2EXD,<1FF'2I
M:!+_O-LSA,R2EG*0<&'0_:^9,UM\XETV.]TM>+NOQN0OBOFV8IH,$8O]9G-/
MVM<87K)Q=-/@'U+BM(<'/3.[B5U:*\@#Q-!TK)B^!=F3K9K-]1W22;Y5;6;@
M;)_E[%U/#4W9.&&I\L1JI/^F=^XR-04#U@9^CG9D@-FRD,O.0Y2YB&=I 1TZ
M02 P=2Q/Q^3GVN5F5:4%++9(J:/3$676"[A0CW>I(5T*FCYR#K1I"3E %8::
MPKO30C$/:38V=8>MZQ4#S3>.)RP>8#\U#"O.<?-!00UBYH# LE@M#>6H"\4M
MEK3NY'*T26:BA;;1II2D$S54 1>#U_=(3F1P&ZO@D/<V];0[?AC]]U.*Z7X;
MYC&H>VS%,ZS-4%^62V# =S6=KV^T^DV\2[65WR#D('1! ?BQDD;(:XZE:.E%
M/9($?-P,3NZ>\A$MPO*ISI&JGOZ3=H3W]4>R_+AI2):UV9Q+A4=0+UVH-<HR
M:@"6"JO&,'.G14;3EAZ_%[.R#=9H'CW0QHVH^<"+ ^[;)<8+4$@XC[07Y"F^
M+]HPH59)6+;?T/ZI^Y\%#K.0RS R_)M;VIE-A7>W!2THAW)%D(C:.)1HJ2FE
M4M2<[2P&1R:/C01(:Q2F;#8/J'N,%AZ+UI''$-Y'";[E7S,RR&C3)O,VT<QV
M+TW./-6Z*C40><N73J#"BG8^I/'PN[$<RG4F&@*C=P>-=M5BOS4TUKF,A%?I
M?G]N"T$&GY8ACOMR(H<%;>5TQX%R[\%1-Y;?.,WS\O!92#9CX]WG5F/E01R$
MD*_CU(:S,ZD12#IQWMDU79:16)X%K=2%A52IS8&W+!)]CA[(3M\03USQ,*ND
M1/TUBMC<P;D*XXC%C)0.J:\I3A,[UPM\W,R0$(2FSL<P?7V26'ZSZ461CM(&
M+A_!6SMXZ:C!FP+ZTQAEL[3!(DN?S+6 O\X,B7R:Q:FM%C2*J>-0'0B25#FV
M/GVVP]HWV 2-(7^'O],OD)4'5G;XGX+9'D*69YN#&<!/7\$M&J2?$I9W<->C
M;_46SIC%MTVDZR'R;H=78](!/OY$EFLRS!LV-?#DP_"'RD--"B*8I$,W-MYP
MY)6!$".\B?E(MOJK(_/=CVEV3QVJ0$-E^T<8%C G/>*.7BH2F*\.G[K>/.GD
MR6\Z%X-?<IB%C_2CJAZTQ27(G$:HO?/1X<&QN7<OG2-H'0VPH(Z.3U]R"O7H
M]>G)P1)5*2N<S5D=MBTUQ>*%FJLG Y]6*H@65\7ARC6Q8C)G!V("KU@>1N^,
M<]W;>U[\>A.T/[3/^KV+;N>L^>'#3= \.VM?]CO=MT'_7><J:+[MM=OG[6Z_
M$=Q<7--?WW<O/GYHM]ZV&\%UM]7N7?6;W5; _^*K0?^"+J3_M7OG5_SQV46W
MU>EW+KI7P<4;_MOEAV:WP3_9N_,WY8&M5KO;NC[?=+;,QS:]QY;.FU7AOG[X
M.?A(N\6= !&>.VB'HW=,Y@<3=%WT3LJUV!B>BT@?+\3P_I <UIH,Y ^_?-33
MBP_^2ME BW$W$0BSY[L_6*XDN(8T%_+17 5*'MT<H".6WE0)T[ <:8Z\Z*E$
M0&<63=BDRL6JIT-5-_ 58])@<9[Z^&/9B'4:4*5@!C77-'")K56K6.EB1RK!
M:4B3;$.N$KGP^F?A[1MZ0C&UD:ZRR 2OP;[@@G_Z\DF)V)3MXO*[@2BY\,!M
M.,^6;;N=_K_:O2TNZ;.!A$1?Y,S'!2:E>(?#[DA $.O:EP\!L=>I>5;XX%;1
MG=TDL4/SX/@DH$TEC_Y[8&FXM'CSX$TT9*L6%'94*+4\\"NPP <(UB@LCOYT
M92GLPA?6D+BH/8S9-YEE,3E0XB>X+4)9^?HUQR5$ I06Z/]HU!1@Q'$B!GB4
MA+X2&W=W87<'QD3G@8:<Q\.8O2[F,U,#D1U@9CT[)^I_,E8-VT)#2X1):PWQ
MW9'BI8>$Z\C![G0XK^W>X.0HX.XQ82MSI56;L:<#MFL_/J"C8+M=M"_H91P+
MO^FN?=/IGO_^:+==*'I=0M$_[4+1WWC:]9N=C\WOT<E8VX..40(.'U^7MBLI
MR=<J2)>IYRQY#ZNY;9*PFDZ5QZBX25B2'ZH(6F-K)RLP?@P32.T-GJJ;NSD3
M9\FZ>-?L;+$)^*=5=5R_@;WNO6_?;,'K;<N&=\V!WWZ1W4LYIL>&1>I_90V(
M"A:%C&3<-9H?U$OP0T*419^Y5@3X.197@9>[2;-[_:JI9FL*2M&&R0%T7%#,
MD,K5)RW=L=7B9_UGHU[(GHP1=]X$T;;K;J??;K&T8= ^[_2:_6VN)[V>J\4I
MH $!Y;EWD1#K8LN3G1H07)R+ 2"<(S[<[6H"?<LAL\HE69I9>$L60YQ)91;[
MX(7"G[R4H%?#+%[8&=:A92\SD5HL'$AR#\-M)C3Z)B7O5Z1I2+IL',N2O)TW
M/"]?W%QID&E>56$.9:?3H?SN9-U$-(YENX' 4&$U)\RCI0 >,#ASHX'L*%XQ
MLW(2C2FZ,M@ $I9$V,_C!!W :<PV8\?FMB9!J[@-XZ 5(7UL8GQMQ9?1QTY\
M5<)RQM&VNYK>QG4^WYBQ#_DLFG*84%Y 4E4>Q!KA40759307&@XB6=\I/&#V
M]4NZ<<B;%8;/E#XFP;! 3I26-/ >9AOU[$<S[2I*RT8'6$NM5 H!JJ(=KI;4
M)'TH/[C73]W=2MK1B/, &%#6\'=Z?4K VJ!]]WVG^[9U<?[5WOC&[\6=A(&'
M2 MA9ERE/( =&E]!0)W1O>UNLS:)HUWFZ,E.*F6.9(]:F;&9.YJ)3^CT"UE0
MS]:DAK#/2:EMB,8GH<&.SZ6\66V&0Z!.4!:]<\3=A=IPC7(N!67:YL$[^ND\
M_ ]]WR7 >@#5% )T.Z->3R<N1/SNO'?F(L2ED#9S19TN:0G=1\<W)/[=W_<-
M( (5&BP?QX!\Q#J]CZ*IP_U$9?1R-4M'-PDA]<]/7>Q7@S*>\S#8*BC:M:G+
MX.%G/FBF83RT067^4KDH'%V*SOAMG; +V*Y]P/9T:P*VOW&KO0T']P(:>Z&=
M/^)_?O[SXD SK%);G9GQ>&D6,4^A'B+LU> (M=IBREM?])D,/BFR.1K% UJ>
M>[BWNA63*$R47N!V^;U[JV_+]4@].]YXW9)C&P5'KX]?R:8L>D'[C47:5#R9
M1$-P"B3@*6_AG;VE(CX'@'$ZO&-9).")%Q."#-LEV)U@_FH854&",#:YFDHF
MFQX="R*7S/WQ^C 8TE16F6%^^_=\HWD49G T)-  !X_;]BE^P(MD2 IJG+>*
MW73T2)&F2 ?4DUJBP2$^!8OJVHAGHE/\(H<&B,["%=(.A8QSY1?[TN@#0;Y)
M19C" -*=.9;;7&<XQR%]L!RPATI3$QDYDW*T/HF53X4JHN$5TRV-CU89"78_
MX!^[9IM7\HN#\DGC'!)RAT<O0@BKY@;SASI>C$SGA\>36^K1"L+%."#VR-S#
M#+75L/8M4/XA'!=1F39#Y_.3_;?Z?4Q$ZDMP'EK^$E5S;#VO0.')7+&,_4*9
MD9K)U56%E;L D%QAJ6T,\.YK/9$VQ"ASA7J>C<-XL@[U\BHTBHJ%S(O)>/D5
MR+C/'<%$'H83.G,1Z<C3$6U$H>JD^Y>%V(2X4!S7 .,MR96' XI=D_R"P&7>
MK:XR@46!#"CWL]5=. _E0-/T/=ZD@=!0?+]AD2^'V^[YF"?_:S%';F!'T)O0
M-9:GYD,M]CGD9$7>A4> 0!;=IC#8>+N$;9M-%>@2?,RA?DU$PA9YIBZD<X-6
MT4.*[6%N^^DQ%(HJB^:7>WP#<S&G7R9<=GCR\OCT^.3XQ</Q7__R^N7/W>:_
M6^>+(>6=^;YNYOOKY>;[WX#VH?_=S2;C7_X/4$L#!!0    ( (."5U9VL@:'
M,C@  #MF 0 >    97@Q,#<X+3(P,C)G<F%N='AT<W)A9W)E96TN:'1M[7UI
M5]M6N^CW^RMTTM4>.$L0AA R].U:#K@MYTT("\C;V_NE:UO:QFIDR=4 H;_^
M/M,>--A 0X()]$.#;6EKZ]G///[X7_OO]TY_/QH&DVJ:!D<?WKP]V N>K#U]
M^MOVWM.G^Z?[P:^G[]X&S]8W-H/30F5E4B5YIM*G3X>'3X(GDZJ:O7KZ].+B
M8OUB>STOSIZ>'C_%I9X]3?.\U.MQ%3_YZ4?\!OZO5?S3__GQO];6@OT\JJ<Z
MJX*HT*K2<5"72786_!;K\F.PMB97[>6SRR(YFU3!UL;6=O!;7GQ,SA7_7B55
MJG\RZ_SXE#__^)0>\N,HCR]_^C%.SH,D_M>3)-X>O=S9W=J)-N*-9]&&4CM;
MF^.MG8UH=S?:'(WT'YNPR:=P.=]35I>I_M>3:9*M330^_]5S ,"+6?7Z(HFK
MR:O-C8WOGS0NK?2G:DVER5GVBC8,OXYS>#WY.<K3O'CUW0;]]QI_61NK:9)>
MOOKOTV2JR^!07P3'^51E_QV6 .2U4A?)F"\LD[_UJ\TM>#A]O. -[<(Z:9)I
MLT'>TO#3)!DE5;"YL;[[XL>G>(/W7KPG $[Q4_.WSIM[KQ,!='7Q9.Z]WETS
M%<=PBFNI'E>OGFVN[V[/$!"5&J7:7#/*BU@7:P"05,U*_<K\\3I.REFJ+E\E
M&;T6W?1ZJHHS.(117E7Y]-4.P.!<%U42J51V1QOEG^5L7L"K;[W$XZE@JU5L
M'BPGMTXG][2*N[^]?+'^<F/^SQOKF_:WI[0VKP]O4,Y4]J\GVT]:@'BU-?L4
M;,*F/7 B;-HOP?N?BU W.(%Y=WTY/'S6BX=O\K+*L^ D2F 7R3B)@)2+65XH
M9!XMW//@:;9IUMIA_%D(XPV$\),OL\X=G._7/JDCA5M-X 6K'[[;>?$Z"+[_
M_N>#XY/3/PX'[X;?KWT/G]\.W,?YA_< @#6<SM+\4NO@8-\":_CNZ.W[WX?#
M/P[VAX>G!S\?#(]O&TS\SFU 39,X3O4=06)PH8HX.+V<:0;$D2[&>0'+1CHX
MF:A"!Q\RD$-\V>"LT)JEM$#E8:'-4:JRX%!-!5;!Z<EQ<#0\_OG]\;O!X=XP
M./EU<#P,CH[?_W(\>&=@=!?J0[#V3?/FI:6C?5"!+4-Y?W1Z\/[PC_W!Z3#\
MX;L76YN[K]_!.I-@?S\,?H?_Y$N?RWQ;YW3?Z/LTKU0:_ +6$5@R]AQ/WY\.
MWOY!M'WR!U#VX>EP?X%D>$H:[U+H='.8PXVUSG^FJ]X3#??]R>G[P^!D[X"E
M_EX7//?G=9CX8AV)AOZJSL!(PZN>_'0 >'MX&IR^#PB'O\GC7/3^74']X?#@
M-!C\-CC>#P:_' ^'[X8]8%GT\C<$S)]U"3;4Y1TA^@_?;3[?>-W]_^DD*9UF
M%P8QN7%4&>3CH)KHFPFR8 5OP<];&Z^)D8I,A"\V7Z^& 3QKI*L+K;/@,J\#
ME<7!0ALS#%2PKU-U@:IHY+YO/&@OGX)0NO2>DL&U6:8CNO0B@;WBY2RDX;WZ
MM5S8VB5=)^L%A#WTS<(]!@. 7(Q @[<YUF5%$-S:V-P,WN;9V=JI+J;!089T
MD9SK@+1(?_OXA=G[>A#LJ5D"<@B.-@Z D*9ED.55D,,-Q452ZB#68SC<.(#/
M&EZTG*@T#28*5L8UIUIEZ(%3950D(UP"KZMRA(E.\ -=1IO("_P6/[+D(U!,
M\A3?^EA7=9'U0.JHR,\*-6V^ 7]G7B* 6VC9&:!J'L.)GR49[>I_55:KXC+8
M#-$3N$40 ]CA3P#'?1WIZ0@>OLV_/VL^Q-O*$2UL@;;\U'<MH;N<#&)S?=XO
M7\?$N2FC9[:#F#6((CVK"&& Z(GZ[V[+3WX"VC[UN O2)3"<!- _ HY1!LB!
M%+$H(%?DCM5$54%6$TDLX%H^D= WE@Y+72$M OL39E$UF'WC3@*/QX:&*IJP
M\5_H6:%+N+[TN:,P_1(X[72:5+0>LIFRK+5Y@1)W:25)WXU ]<!9HX]A,%-%
M<*Y2N/G#R7ZP@7$*8!^\1+ BFSS!:QV?+^O1G\#D\7$1F!D*>1Q04C)*TJ2Z
M#'$!"S%$"&*B*!IBBGZ4'0#)$;&@ % EH,H0:X<GC'1PQJ9!,*N+LE;\PK@N
M7.EM!=^5&3?^YCV-X- X +R &&61GR>ENT@8M/E9^"OL[N9LY)ZK)UOWC/L,
M'?X!PMNCKV>H)QC] \^4*/6.V='O0*/"AE3T,<LO4AV?L1Y!F%^U2)?PG3F4
M>8,O0H/?IJ:]?<]0^02^*<>*E>BF_%E[HTK@@P[![QB13YK<UT- ']-B;91B
M0-(3L0YVNVPY#/0GU!S("K)Z-_'HN'GSBSD\?3D/=#";H;+]*7ASE\<56K%6
MMA!,3 ;++GJ9!%RZY- =W"5TF00:"!G7!1I8I$AT;*B0OI_+5&7M77SX+.>D
MD5<%&.1HRL[-HI X_X:[18W*/*VK[BVW#:6-:T%I[5B?KP>;6^M@96[.X\IS
M/288]F&-K"_]@O\_L8[WF3K3:Z-"JX]K:@QZX2N57JC+\LE-4U3^4=;'W4I"
MHS:P&ETZ]<$9!J31D^07;PM;#F#X$"//K+[415WD^ZUUV!D"FCJ9(;&/^N*+
ML!X(?-([58"1L[ECGA&I%)X(ALBEAO^-\S3-+\S]"[<2C$@> F\";E:KM*GU
MH.1!@X#<-O)FXZ0H*]2KP':J-/IM=(6/:CZT]Z6'5C@YKKA8)H5!EG=@CKXC
M754I,PE?*^V 40YE!ALHK(Q=>#0/SDYY=L^4NT:^B!CDQWAG2;B$&+($OI(6
MSH9!,B;MX6*B,X.<EG>$#F\+?9:40'*LK0'N%D&FIFR :-3B %5CX_R$S6;
M>53#O0'?7CJRA>WL=UA)@QQP,\;3U-DU$L]%8MRT0(L%0QJN4.S_$*]KR]PB
MSS4L-?-TVRY(LBBMR85J%L9+"QUI]#8##>'K O.%O9[GE>Y;A#W=Z24NHM'O
M0Y;JPR/BG7M&Q/M:H49<!/M)J=C>N6.B/6"2TN?D#D3_)1&?IH0K$C0V&F.0
M'*,0[$<HDSA11:()5P?C,;P0.T;+@.F0 BLQ^Q?C[KL'*T+#>#7>94(E0N@F
MZ.%)8U8ZTAPD?Y"JB]7P!D(N[)#1 U _'AQ/>'[/>,(Q'&31R-+[YEF!>^6
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M<&!X+,ZH<]E?-<?.6A2S(G3<-F:]4.NHR#^"7G]&_3ZF!%(-4A:3K$W?+P3
M'/O9&0GA8WE?'UT\>PR]?2[+0=K)ZRI C;\R UY*6ULMRI;%T :YMC(AD>)(
MS-^0;'&VP<\LT9J*3=N \Q4=7\<QHH5IG8ONP @#,80U< LY"2FIQ!?AU?!J
ML9'8/N:U2KR?5""CF9+ !3E\A4S+"TO>?6H@\A<!"?=XR5'M0&M.L0PTICM>
M<X[MBJPP_3R=E', @N JA],#DJ_&"=H'V-0XKOOU'I:N/2J7TV&;C5WQ01HM
MP4+L:U+:FYX-KOP$%.-:*3:#^LT;_[1'E]Q-SS.E?((B@=LU1WL=&=APO;0>
M!&,/H'NJKG(D*]"Z&R9!,U[<EL68P#7-DG%3A/;T:U%GZ.VI O,SOKAQ0"2H
MX,=J"NP:_HCR4J /2J?.2A._ON(!9*4"=+AR"T1LC7U*Z_&84^1$XAM:0M;1
M1T/6K5:TN4 O1!^>C^34T4<K]DCQ%($J UQ_TM-9Y3P&<@"DL1&BL\8J0G_C
MY< 2(#I"#S+2CM/@&(FEQL./-:>>O7CNIYZU1I3%VANN@]OU)KPTVK7;4CP5
M@Q)@VM@2:N&CP> Q==VF<RT%4LO*JV@THVNJ;C)&._^"/';VX<U)-O1J)J>;
M(&%=H)23 !)-)6D7SGU0I;MDK1MX%*C;KV@-IGE024X) G,;>+@1<M^PE]+?
M5/=ENNC0N>8^4M+F^LYGT=)=!E,.6SX/\A78[)E.8W.OHA*4Q^*RU4J'W1#4
MJ,=Y= K'3<UR/)='2FQ+=%&Q8RP77V?5;(CF51"W<V[:U.6*E801(%M/R#4E
M_7T,6Y#FM4B1K>ZUG+#40<W5*RC5:PNT^"68R)S_0]P]M!?*%_*DCP?(.-?M
MT81_U8#98PF\9+X[CXF,G':]="9)5-BI#)_8?UZ6,\Y48BO".(IOBX&9.4F-
MKRK2A&<*T.'":_-47UL(Q#X*[L0&#Z).&V7R*5AYOFKZAG"W,1VL;*Y2-;*K
M@ED,5>"\ RKQ*JH&ZA*N@<ZD+B4YVD,V$O6VP!G9G*80&Y<WP]V8K)!DHIKQ
M^$8,8H<",!(+[-#BN/NJ\[OBVCQ?K<] L*#MO[[/7^ CF O[L'.Y+U? ;)$.
M-'%<7;#$+X8F\#3']?2#QH@W!]A;1TJ);=F,:%/I+V0;FE]L5X#0$'3K!Q1G
M\W]JD:2Y$,_Q7!6)Q RM,E\VZZZ4F_30UG\P9QN0;#X+(XI!J5HEH&RC3FQY
M%;<WLP"BLL/(,BSL%8C$>DU^=4.Q,L"RR<^.S"^;+#.F$)*N_"U^OH%H>P#P
MO'"!!3",TKHD5ZPSVE)M&TNB840J$>;7@@TU#_J>(U047T,S]U'%^<SLE_LV
MB>V ZBF(6@](K5^"N8'-@8$B#,@'SR[>>6*C/ZZ,_&-,5&'?U 39G* (SA--
MJ>$QTDDRJDV.#?+$!XC&]VWFS%OT^I:H7)R*IU<R/3A7$$=G%XGTF\5IVX0Y
M_-M;?::Y[>N>+F@"-TC:.Z:"#U;SG-.)MZGSN<"P"T]+TL&</$;3B^?*%FX-
MDPBM6B=HK/'/36E"WY.(VVH0(0H<5)XJ>SRI]A(C)+T6;'0<&^<R(]#K@4$H
M_&M&' '^.$O&%?X[N9RA+A:9ELK>(/.D1 *G/D68!I1%%-MCIQ[(/_23R$/*
M/H>W)&[AIEL!]':,C*\_E1S5(]=UP5,&2U=:B$F\/</%FL.PDNPQ2M;'>G8>
MHV2?RULBQ^(H@"Q9/!QCS_./V#NQN+0)EIRSTC-+T\3 >\?N-IF3C3XS"T8W
M &F)-B(GP:51UZ/NYFG!CV65S];L7>A:QS1!-P)YWCM0O91]=DK<?J5<#=1X
MG'P2!Z.#2FDL0B[4:J;72P\W7+?4:2/NU9>ZXK& HB6 .)Q66"@\0!7CODW$
M8FQN]>SNFZ6^!+4KO%?6AZ<JUMT4F89?GBXIKWXS6=U-H+_><'D*7=#P-^$%
M)HS!C("\/#G_RWEFE!&$2>:@IG/O/VG9.T*"H^1.=M#X'EEJ4 Y<:(RMD^ I
MU045;* AJYG1.6\O.G65F]_5&;*L>N[Q7U "^O;]R$!QU.X U.:*[GZYE_/A
MN*V5@%2?JP1;<?^:7\";%31ADR#FIPWV;$-:.%I_I3AT$.:2@XE%KYB!18P,
M6%I2=))_Y]M55^#1 ^1@]VU^UV%NYG"26Y\F90 )N"$L2\"YVOHUQQI=M5T?
M?CHKPQD3R C@"Z,9\*04?!S'[LR[>\Y*6TP"%@=6HC3KQ1HC$BCK?/%X%E>C
MUAN#%7N'?*.%L<2P"9NB/!]*8N)8)^TY'R_8Q(*6LDBE<P<N7?N%$6+<0[1A
M')*'MKF>OY+$QY"M/T#><-_&,[VEPL5#JMN\ZYHW#&YQ(:74D;H<.--A85Y:
M0XPYV[WY0A&J%D(QO^@,B]3@9U;DQ<4X*T#G2&8<OFDT$RK;%"AM*KUYXO)L
M5 .T*B0KF%8%R8NU5"FU;2CBSEICF0;%E*83HDF,O5T&)DPJ=&H>43:OXJI?
MR=6E(!YZ&S"_G:% =PM<:3D!JS>G@TH,.*,7WYK8)LWYG;DT+S'0#) ?(E7?
MMP%( T!&4$ _W3%!?W;JA?,L6ISUS!5*P\#D!RPS[5.]A<(65)9=KYQ,<0Z8
M'6'64ON50-OLW[V0GZ]ESL3+V;))P]*#UGHY3*FH[-1+]O>CK @!XX3AMP C
M*=51Y>+;\M!(FV3GTMN>5+]="4+N0R./(+O%-IJ1M-_*58/UIZ[,S\9R@9YF
MT-[&@3M; I1Q@@&5C_@<)U&DQ *Q=T#1SM.RPYB%UXY5A)YU4\*@7)RT;?"U
M2B2(Y6K YU&:8$J$*VOIWZHJC>D[9\=XAA&6P.:Q5=4,%JP*Z_8PS>"0*2NT
M(7:2"%V*^G99]=S<[\W[UO/]%]O:^BT@*"+0?S )= EL,IL<*F45C=% Z*;-
MX&/D537V:V?LY'#E1]30!(MQ)8J49Q<:*&F"W[T#2T)%DQHS>\I@Q<1IN9#=
MDP_L[($;:#&KP-ETEM5V+$;Z$YA S,_HXC'18%P&"/9,549(81RI-JE?H-7A
M55QWEK(W.+.?O)Q?:<XR268V\PH'1NGR2^>,T(JO@*'!VU[C>*U[_2YQC+'!
MQYBP 3+Q!IJ"$N:K?CVF36,)_JSAA.*D$YZ<CUBM9@\D:PP*H)?>H*XT::?T
MM?32"-6%:X?&.V<P#@1G496V:+;9%,A\NY]PG*!G.1FW:@5]47&?;.J38*,M
MQIOK5\N3^TZ(]DL=]N;C*(E>6;-UWUK!_:HIE'W7/@ 4"A/9RF)W/2OD>,VY
MSA+2DXE(F\D%BFQ;HC'3+Y[XMR_9OH+>])##]\\?P_=?C,O<MX9_)QC9DA2M
M9<@X;#9\:H<U.PRGY.U+"E/"M7*8RH_5L'G16(%[>-A97I*DF+*#LY&U5&>B
M27.'UMYL?-8PL9$4]\2SCQ%6AQN#:ZAA&.;<)\;C8M5T7/P!RN'[UI;N-X6E
MKW=+&[]3$0QLB3QWCCXN:&_MC)UV"HQXW+#GI(DN7^7X<_(ZGVENYE,TXV14
MUB+/EP59(UZP+*GB<K%K&!V@"(DFG#>PX.XK\>;+T5!C9,0=3HS8NF]9[1C8
M0<T.6.;=*[(-#!<W( >87-S7]9Z)O*V'@<%0+M-J!VQ8EE B2'*69-(QECJA
MFENJ_$P3??3<2[&AS'7W+M542V+=EW8:XI1I7=PV.K^\IHAXN?F:96C,, ]0
MI914 VI>GF( <@PL(E791[A^^UK$3K'Z1S/@"C-@][/,  1'$O_K21)OCU[N
M[&[M1!OQQK-H0ZF=K<WQULY&M+L;;8Y&^H]G3S[?='CV<OWYYYD.9J@+X<:K
MM:W-YEB7+T,'GQ\W/#H:'NX?_-]@,!>%;_)B_<1P-RSYZ.W@D$MU!^_@'8?[
MP>!P/S@>GIP.3N'#UL;F9O#V_>$O:Z?#XW?!P>'>\/#TX#_# .^;\PJ+7F^9
M7IU:0WB^>ZI"D+@JA?.P1PBZV9.LV\^5VRMB$A!\M_$]RH\M6-7X69T F_<$
M;.E !<YE_V2^&X](>KFS_HQ4HHJK+ R3Q,C?&L T5;-2OS)_O$9??JHN7R49
M089N>CU5!0C.->&LV-P [:<D4JG@,:$T_RQ<8/?Y^M;F#C*""G9:Q>;!PB/6
MB4<\K>+N;\]>K&]OS_]Y8WUS[F\+EWVY_FSW>LL^I2WSM@$P)>CM_WJR_:0%
M.X+N!K9ZP#!M$@<&->7W*I_U_BRG\VIK]BEHL0-<L@W::1+'J7XR_X"WUG?Q
M1)J<1K[\#!YZH_+?W7Y*0E'E\/QZ^+J\KP.O@D_%^:_'H/"T1)H@U3_'%W[3
MST6H]<T7?8#J$&P^^]JPZV-WR,;(5A78<M?A I1Q"]T[)<A; -ZMRJ87&]4D
M\/ 0LR-&^;EN0&L)L'"YH8@2^1&_^B"ST\2O1[2Z"? V']%J#F2V']'JGP/O
MV3_"*N,%F0^:KZ2_\D:^OOYZJV?P!D>E!]L;7\1+NKO^XCJ.B*X'#$]H[=GZ
M5M<>PR92[*.H)G>:MM1#]-=4ES\?@1\"<^CC#4_):']P_M2%[M2OY$W=O05O
M*AW/K61A++O;],UUW::;UYTPO[S!00YPF83T-R99"^L29S/NM+BHJ(!:Q9"C
MD=V$U)?:MGI#U^*;O*RP9P_-4\ V#<&>%(;3S%RI)<>EL<T/E8NS%S<'.)]B
M'?=!1JSZW"3S>]48^(4=A%;EP1&FG48)<&YTBDYRJ;Z@<;_X;S=U$QLGPW54
M7F93.5K%]";56;DZ$],(,^LNN1X$>VI&:;PX9I%!1TWY1G5%T7'3#T_*XCFV
M1]U];!Q/LMS0[RJM#GDO4UL28@/<-YE#,@_K[BOVFD9V!R[PWX?*BTIC*"U"
M*OA=H9)!&*_#NG_ ]KF]#Y91S%<\6 Y2^KY&@EO49HC'=5:,'P_Z@-OLB=HA
MX*AL@3'\2_X[.@TW*$_+D%(N0@-=+L1^B#9-5+@6'0C.V<.*(Z)HJE(O7?P=
M"Z/*"74NQ5#]A>KI%3,S/(=6EU-%QF3K+]P.X64:?51=;ZFPLV?:LM>BA[@0
M_!9)G8E#5FR3SPFRBO:^KR--\1S4/!!;*3&>!M!2%6UEILEJ7E^>.R[,+'8N
M?Z]:FY?D!PPQP4.HTJG52Y@:"QD0V &#-+%G_E >*RD89@/7^;;9#;P$H&1G
MU.T22ZT ([Q6RCRT#,LZLLZ^X3?';*4G$.48EWE=<&93$XM2Y=??-IIHFL;/
M\P_] 1/K068GR(==I@C*@11N [@RA2,B0]>6%XL):ZR.YO07ZE*EBB2ON>M:
M&!1UJKL3E)E,B2MXQ8SF?. R0+\$QQQ13X-V3V[S< 5D+]-/3)J;NY]Q\:NU
MC.V/4PRHSU^"^!_Z7*G4^B./-9X5-#L6_AKKLJ0\&*I0Q"HO*AN=Y!>FPDF?
M8Q,8X@A)UJRM;8+1"B<+Q(>!W_V'\'-"R46VT)?[MT> \'_K3#J584U6M5!9
MQ)PM2@XV @:7 3%0$.L-+O+B(XW:\B=,^HWE;9L@Z:NMG-:=4[M4FOH0\W"(
MYI9:=<8T =P6U;K9A6T&Z@HXA(DBO4D/%+]ODNU_Z-18FD/!O9Y\UM":SSZ_
MKMBF7N/J%S07V14H]ZI5G<UZI<Y6UH".'R5%5$\Q-1;Y^A>N$%[M&Q=XDY2)
MKL'YM9'?JKSK<XMV<7[1GM5BW\^SN6[=NNZY[W67BRR=O^&09" 2YB](OW><
MZ7J0]8W6[$[81I6K/P7H'QW'\LN"?HBMJ-4[3)YN!BJVUG<1#K;= <@ R[N
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M!/W?!47]+.76:!A.<V6KBLUA.YJ6NV)W9TCWC^P*'8;:9KV$4I8.0C$QN4:
M^\2#(AMIS=,PJ/:=;/ J#X.SY)Q+1Q(S RSNZ$VBS&+SWT)=9*#X(*4,LS-$
M>V[SW4[0]E7H<4*EUX:ZY#XP4?G\Q&G@M0GW[-"NEX"LRXF*&\DE/)07?>OL
MHD3H8.F#%%<G6$T^EGVP67G%IM:# S8#Z''"<#K#>*]W3F;<;O.8^A4#JKGA
M[_%\ N7 Y%7QR&Y#,SZ@\L>2\$=O(9S=+;6?=ABAJP8R;RY7A7U?LGM$RD*O
MUG,?,E<Z8-="<%K0\!GJ*5"P[Z6DB4KO5/%15\%@5)<:1[7=L9[;1[RHU!(6
M(SJ)Q69&8(Z*_*,N['SMWHF81'4\6*H[;1N9 M>7A]8STYS'F0@(*P%AX8'0
M'TPU94@J@B0YO-HV(^W8XQ%<7Q(:$RX,N#2X,44#^[R"J4S&=]M<E_05HEB\
MIOUNXALD4EZEY "^ 0#_T5&Z,^[Y=KEK!A19H?TO"0>L],,Z<4WS@-DQ3*=O
MB_8:CBQB5>(_9!CZ173&B^AJU!MVORIM5PAAB=QTHFA4N[:*-4'\O25+OGUD
M7.O=*I65$,PD&<EP\@@S.-+4.BVHL,.8Y]2)B%^5\HBP !Z]#/Q-7I8\J=D\
MV7M3-Q$59ZDPED6FA-YL &XE;\M*LLKZ/=IT*1@N I@N ,VH6%]W6_&8,OH*
M#?@SS4>"=&4 /U)E4O) P94D63675LEL!@\U5[G591Q[I&JSJ:F'INBXK"]=
M=;NMXX>W_[?6)*'!O+!3-_Q5C6MZK-$39IS =.N 8LD>O?D5BWT8P>-L8&7R
M]QC_5>*J+0W8&JOZ-FPR17ISMG!#G+HX8Q/!9CE<<6G&[[25#T_;PIQ]I!)?
M47 373L;(XF.A4>H/? 9EC,PXEQ=-XWCEM+FDF(\K!4 DH#6<EO"\6N;QE>,
M)%D6:7Q%9>C!W#DC4A9ZN79B"LI/;1GMGBVCO1O-9GN98+GW_L/AZ?'!\"1X
M_^'TY&!_&)S^.@R&'X[?'PT'A\&'PX/WA\&*\*[A!]O[B(2RNVZX]_[P_;N#
MO6!P/!RXZX<#<T.(2V''_'\?'/ZR__X=M=$_^>W@]/\-C]_"W[<$OF]3R=Q7
ME0J.BN1<17<Z_HQC'L94BG/I@D*2TU/43/S"1AN-T?7!H,UPX-)'X/=_PZ'$
M.65@G0"?_AO>F[PX<\(W+##TG,$ WZ1U0BOVC>KMIVK/2:$_H7!-*AEQ66=J
M.DK.ZKS& 'UK-BX./V#>&F(#,8[32%<(\HA[[C";=H$*4VACR$Y@QHBTI&::
MCF(]TSC%H.:5O+#N%#,>$I66')2/,=J#.4?M,A$O>M5L\T!:23,/PPS-=6%J
M"9-1SL94FL]1:I,9[:X+,PT/#DF=X8=_VHWGH:-CWV X_[ :@4A4%2=YZKIE
M6:SR%70UPM90<"!AX+( 5DS3NS29)NQO6>5# \S7F->-$=8X1I]<&.!8I]1\
MY'T CL\FF,G#,TI"3AH!%!DE!6::E3FU6 ,-M9:4])DJ0>DLO%0DZH"":H<T
MA.)I)V+XV0XIH%=S,:B[!N0DAW+#@-.!%*JQ8?!G/@HH-37LC5%B-HWDMV'6
M$X[!3BW;=38?%D-K@&?*W07!CI!R#C1!6?NEED2^ \M+B25+N&/?\[VA6'?X
ME_ZDBPC5Z9!2=_#?.N._"$1U17@@-3]T-F-U#K\8O0'EG=4T#-G.)59+FL0G
M&I1KR;*G&\IC\.MA!+^^?59*ZJ%8UWX3IXX# YT!P*N /%K^()?H:TE+BFJ4
M*UDWR8E$;XVT"B0QGP=W67 P_)_3XP%8%R?6<1&\?;OG+ 7^V1*]L*"RCK"[
M45XT>9+ODND($[C2/ R;+%$0WRRSRGV6LC-TL"-X"!A>\6KS;;W7DP1^[#N(
MRA+\*\Z(5B0#F' R2[1T"<!O_-/!/!AI!N'[U4(_N['1*E:GI2;?JLD=DI=U
MCQ'7K/7,DNA4E(-G?/^DB<W8?'"N.E"G*^W\,QU/7Q^F&0>N22M0Y-IU\$,1
M*TX5%JDL*2@E*:=QB2 YYX"(8[X5Y@(:-8O3AB8U8!Q*3>J>B($4#*@QBI[K
M1:S]H3,*55>3O(!E.MJ6-P@W!QI UYMW+%Z30R80__85@7YZ*=G'KI)JE3'A
MVKJT"[[;(']H?+UD@:"R1/J?;XE8E+G")#&* Z7P? %5OY]$")=-UCFI891E
M"(8+)KOBOV !N:9M&/\P^_$WXW':*_;A,U[V;_Y5@YE<.5E@TY_WQ203;D17
M&D$AD1X'1)_)TK%>@.IL.0"!G;.@2 .Z1NH<:H!>Q))4S\5\)FQV<3I/@%CX
MX"T#$J]SKV5 AP\JL0DZ4U2\+&4/;J&DX+1M=RHV,D$J+X&-_.!CM(HQW 7P
MP-BX6,UD1)?2_R\T0WHC57)?!-Q+E)=PODT>YXII;L3N)-C!@8X^R#5367NV
MR+$+( G,N7:]DRABL=[V[\B]7'G#OW ]0J'/ 6.,V)"+VHGDV&&]+OV6#598
M6&O/3\97,<:@<5\<T].Q2SPG0O*ZXW(4<LSQ$N]4+$"->R,INVJ"R]S'ITH[
M278^X"NZ;%.V@@!+@ Y,]_G"IU0*37(2$),97\7=F L*8O6?U;7VOB"\.2>5
M"5$$]X3!,Y\HI%-Q;WMAV@HV#L_M@[U-J91'3;LSGJL9"'K? *$?G?">$_ZW
M@]-?#P[%!^][2Q=[SV^@ MVF^_R.@/AMN,_[_>9+YC/_#&Q98MWXR$MX\X+/
M3=>ULX^D(?A"CZ5XVS$5;WQI&GLWSR(QK=XY2$X<\L@\DG!TQ:1DC'#,UJI]
MBN^7]Y28AE*\0!6V^E_S::W]5/VMSZ[N?"9C!ZZS22-N6AOQ%6*CM:?Z#%2C
M*;48=[K[HC.P24H+K/BKWR9TU\0Z2[B'I*'0G)*6/(!=\Z6;[]L6Z8L@.R#O
MQ814QV:[7.K&W=<NMQ/'N<'6&O$:&0=R<PJ_MXSAQH&*WB %%I5) (#XRIR8
MA>EUSRW>YX0H;A23D*R@2SM>W:JODO+SZ 7_=KS@2TQ&O>&O+QG9ZHUJS0MC
M?>$H5M@7L;I&C,KZPAL<V7C$N4*M*T=L-3.7DZ T@->CAFLD W#;G)P+2LRX
M3D/3B<:+"8@ ]QSH#1Y'O044#_N1G/ 44S6-7&T*$%-<+R*GYQ*3!H!K 0[W
MQ.7[9?\M^>WX6JTKSC7FG'DNF\A'0$XFT;$DIFJ;.'%*I&*'^4.2B8@:GO[
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MQ)2F$Z))C+U=!29,*G1J'E$VK^(B7TG3I2 >>AM<;VVZ6^!*RPE8O4$&5%O
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M1:V<+RKNBDW]$?RA-N2G\ZODR7LG1/NM#GO]:6I$KZS9>&B-WW[7%,F^;Q<
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MA<QZ"S)/N'0M&3[AT@!DUIYPZ8X0>\(E@<SN$RK=#F OGS"I'S!MT?^$2=<
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M9(Z\KCI<U8@&"%?JMBZ5R4B673%>/M+ V_PBI%M'WJZ/=MUSA&U!S  F"JO
MX0<[QMIO.-MJND$HCKWS7%=9J?EOM<#L+HD"VB[+HT^M[1U>V];6T$RC%],2
M,^KE)]&[I!>)ZY+H-:XAWV[P&*WKIOJDI],)CA?G!+=6US:-W'0CD@W]FUF!
MA9ZE*F+-&\=;4T@ ER2E&L,F\"41Z]/I+ITOSNGZ6I$HO/@G^X&N:&!F>^"G
M"2+@ (>IECF39CJHDB$/B!^F5V6&SE<RPG#T.?59\Q&"7+=^E[Y(I5&=NC9]
MW(Z%QID6T@:97:_>>$SX)89-PU4@;4 MGR9EB68C(.A*/EXQ$D/FP<);CO*L
M)@=QBGD,YG<.<8;!!///%/*HJ]#B,SG%S1!/2DS0Z1A?UMJ,*)L2.#)E)\^6
M3^B^-%E,=!>#KS&I=ACOT2%19^AHS-##;WSYMDM0I#*)(H#2'_,P(E*+)%0N
MH^H>-2(DBX,(6ZLO=A$061Y$J4JF/$:N2LSL:.DL;'D4_!RK*5@'IA43M0OE
MMJ# O\8Z,=YR)R<[<U-U>Y;NX,B&?@W73&X%^Z3$60X3594YSY"YG'!C$+@"
MT1#N@@_CO,YL2ZH,$#V)I=N4:X[C/=V$0W&CC6:;W(;2SI5E/3XV'3#MP(CV
MVWBCA9]T<T,#_UH\&J@SZB?FTNOHX.+NK! W>L!KV7Z=PM#6%X@6AI4&XTQ5
M+O9KM810L#?">0N1G6<2BI; )(-HB@$&F4K/+:6XCZ_I$^5,S^^%D N:&C"
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M]XZ#C\='[X^#)6$%AQ]MXQ@27.ZZP_WWQ^_?'>T'>R>'>^[ZPSUS0XA+X6"
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M;G1X<G-A8F]D87=A+FAT;>U=67<:R9)^GU^1XS[N*]V#=N_V]3D8L,T9&6D
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M92G':6-;:AX>AAX3U-KW2($>'6X99\,Q+]"KU58K>KM#_DW$8-6_?(T_LL]
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M5N'=BHAS%=B]!%]0 9.=YNXEIYNUZM:=(?!7R^8Q75VJ:[A0>.(? PQMDEV
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MWVT2?/ML@$O)+6).-[QA6QFA^F4:]++;,U-]HZ(S!*4=$79,?J.10.4KU=R
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MT-'A5H7,#D:AMX;_S9*Y__;_ 5!+ P04    " "#@E=6Q^[Y-((H  #Y[
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MDS5M"7O4\$F%(@U<"WI:@N2((F JXE3D"6)6L! =XO?P2;+9XQ Y!%2MPE-
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MPCQ134_ F<$0F::=5$UR&HMX07_#,\,T$?D"K* X\O,)?0QLHGD<P6 KWJ@
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MT?*55^6#MJR&IU6]8WKJ&=U>//WV<+FU0Z0Y';4 :1\B_C?S,OYJI@-IO.
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ME.HQ"!WB;A\&DU!$);QJ."=&-K 6Y.GCTT!V1JG4Y6;--*$@K@97P$(H0&+
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M^!,NXNSMJ,,OP "_]6!+8>['L*QA]Q16U#L;X%,-!T;??7>!QPE[T 4Q!;^
M+3P]M:O_IOVXU"?>M"=ON]T^#X^>"GB00!,PZ?-/ J;K'#=.>TAG9?[,\Z"N
MW_#^\!P>O1B*=[A*/3_^/LYJY[+A1,!)A>,NB(!W1N"D>OT3V"$/:?+X]&*(
M[A'M4:_?.:5].>D>F_T8P"F!*W4.QT.VN=VBSLF'7K\W'(')#@_A<Z.A.+E
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MA<;[,+K[S?"/,? _"_'R?U!+ P04    " "#@E=6LX\LR!<+   5/0  '@
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MH[%AV[7M!OLDU8VXY>Z^$2:$HZ*?PZK[?EBU@QP.9) ='0;BEHG@ERU1\S\
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M5EF]M]9^;XR*N!IA*FMDTFI6MA\;C#<C9:^Z'PS;GRX?_0]02P,$%     @
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M#Z$_EVJ/)[!.*")N]JQV>?U_O][\<G/OC0Z'Y\]>'> -=:^Z=O\^G#!/] O
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M&5L/R]-F'_\;$<%KI2O5S,;0Q15/>0)TP?H4SYXJMA66IVM<_<HM^B&)?1Z
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MDOE]K>./CM%;",OG:_OS&X+HV7F/_%L(R^?-X:_UW+\G@PZ2P?-U9%"<UNW
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M\]X65)FT!U5.AH?'#ODVC  JTC!# .C+$'SQ$B D9V)!B3\4-4?F;*1N*99
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M"VVC5=/8;*+3!]14(5T0FZ]5JY5&V+.28!F+0*GR^$"]I&,N59="9TS>P%B
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M""M4RF6KU;_983NQM=E)JS6?S[WYH:?TK#6Y;;FNCEI2*0->9*.=LU/7@K_
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M!'D]IQ^3J:BP6-L@ HU!,YIWP(JJN6:52Y)M1@0S,?"26L&",LPRBDL=1CL
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M<W@M,C R,C$R,S$N:'1M4$L! A0#%     @ @X)75FB(7ZN9'   ;4$! !
M             ( !P94% &)S>"TR,#(R,3(S,2YX<V102P$"% ,4    " "#
M@E=6A _J^@<C  #*4@$ %               @ &(L@4 8G-X+3(P,C(Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "#@E=6NSI&3 OK  "C_ D %
M    @ '!U04 8G-X+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "#@E=6
M9K83/+++ P L7P4 $P              @ '^P 8 8G-X+3(P,C(Q,C,Q7V<Q
M+FIP9U!+ 0(4 Q0    ( (."5U;>VW6ZT\L!  K.$P 4              "
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M<F%N='AR<W5A9W)E96TN:'1M4$L! A0#%     @ @X)75O6+-SU.)   8]L
M !X              ( !JW . &5X,3 U-RTR,#(P9W)A;G1X<G-A8F]D87=A
M+FAT;5!+ 0(4 Q0    ( (."5U98@^>>L2<  (WJ   >              "
M 365#@!E>#$P-3@M,C R,&=R86YT>&1S=6)O9&%W82YH=&U02P$"% ,4
M" "#@E=6=Z<Z<]""  #&2@, '@              @ $BO0X 97@Q,#8U+3(P
M,C%G<F%N='AN<6%G<F5E;64N:'1M4$L! A0#%     @ @X)75G+XD.2-@
M0QH# !X              ( !+D / &5X,3 V-BTR,#(Q9W)A;G1X<G-U86=R
M965M+FAT;5!+ 0(4 Q0    ( (."5U8&"@U+\3<  +QG 0 >
M  "  ?? #P!E>#$P-C<M,C R,6=R86YT>'1S<F%G<F5E;2YH=&U02P$"% ,4
M    " "#@E=6^]<+  0Y  "P90$ '@              @ $D^0\ 97@Q,#8X
M+3(P,C%G<F%N='AF8V9A9W)E96TN:'1M4$L! A0#%     @ @X)75O(Q3MV_
M)   3=P  !X              ( !9#(0 &5X,3 V.2TR,#(Q9W)A;G1X<G-A
M8F]D87=A+FAT;5!+ 0(4 Q0    ( (."5U:51(,,%2@  &7K   >
M      "  5]7$ !E>#$P-S M,C R,6=R86YT>')S=6)O9&%W82YH=&U02P$"
M% ,4    " "#@E=6W3^BG-8P  !NNP$ '@              @ &P?Q  97@Q
M,#<R+6%M96YD;65N='1O,C R,7)E=F\N:'1M4$L! A0#%     @ @X)75FP[
M!BK<A   T4@# !X              ( !PK 0 &5X,3 W-BTR,#(R9W)A;G1X
M;G%A9W)E96UE+FAT;5!+ 0(4 Q0    ( (."5U8HT'XD5X0  (XI P >
M          "  =HU$0!E>#$P-S<M,C R,F=R86YT>')S=6%G<F5E;2YH=&U0
M2P$"% ,4    " "#@E=6=K(&AS(X   [9@$ '@              @ %MNA$
M97@Q,#<X+3(P,C)G<F%N='AT<W)A9W)E96TN:'1M4$L! A0#%     @ @X)7
M5G@/&311.0  9F0! !X              ( !V_(1 &5X,3 W.2TR,#(R9W)A
M;G1X9F-F86=R965M+FAT;5!+ 0(4 Q0    ( (."5U80)7X:P"0  $_<   >
M              "  6@L$@!E>#$P.# M,C R,F=R86YT>')S86)O9&%W82YH
M=&U02P$"% ,4    " "#@E=6Q^[Y-((H  #Y[   '@              @ %D
M41( 97@Q,#@Q+3(P,C)G<F%N='AR<W5B;V1A=V$N:'1M4$L! A0#%     @
M@X)75@\FP-49#   <4(  !X              ( !(GH2 &5X,3 X,RUO9F9E
M<FQE='1E<F%R=&)U=&-H+FAT;5!+ 0(4 Q0    ( (."5U:SCRS(%PL  !4]
M   >              "  7>&$@!E>#$P.#0M;V9F97)L971T97)J969F;6ER
M=BYH=&U02P$"% ,4    " "#@E=61R\%8=PF  !1?0$ '@
M@ '*D1( 97@Q,#@U+6%R;F]N>&5M<&QO>65E9&ER96,N:'1M4$L! A0#%
M  @ @X)75A]W8.1#"0  .5\  !X              ( !XK@2 &5X:&EB:70R
M,2UL:7-T;V9S=6)S:61I87)I+FAT;5!+ 0(4 Q0    ( (."5U8SG&(0%00
M , 0   ;              "  6'"$@!E>&AI8FET,C,M,C R,F5Y8V]N<V5N
M="YH=&U02P$"% ,4    " "#@E=6?P[ _SH)  #!50  '0
M@ &OQA( 97AH:6)I=#,Q,2UC96\S,#(R,#(R,3!X:RYH=&U02P$"% ,4
M" "#@E=6BGD<94<)  #;50  '0              @ $DT!( 97AH:6)I=#,Q
M,BUC9F\S,#(R,#(R,3!X:RYH=&U02P$"% ,4    " "#@E=6B[O.FY0%  #2
M*   '0              @ &FV1( 97AH:6)I=#,R,2UC96\Y,#8R,#(R,3!X
M:RYH=&U02P$"% ,4    " "#@E=69= W+J$%  !@*   '0
M@ %UWQ( 97AH:6)I=#,R,BUC9F\Y,#8R,#(R,3!X:RYH=&U02P4&     "$
,(0!V"0  4>42

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
